PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Warriner, DR				Warriner, David R.			PERSONAL VIEW Patients who discharge themselves need further thought	BRITISH MEDICAL JOURNAL			English	Editorial Material												D.R.Warriner@sheffield.ac.uk							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 10	2011	343								d5054	10.1136/bmj.d5054	http://dx.doi.org/10.1136/bmj.d5054			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808DL	21831946				2023-01-03	WOS:000293956300015
J	Laurance, J				Laurance, Jeremy			On Reflection Costing lives	LANCET			English	Editorial Material												j.laurance@independent.co.uk							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 11	2011	377	9782					1996	1996		10.1016/S0140-6736(11)60852-0	http://dx.doi.org/10.1016/S0140-6736(11)60852-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	782LR	21665025	Bronze			2023-01-03	WOS:000292011700016
J	Luh, C; Gierth, K; Timaru-Kast, R; Engelhard, K; Werner, C; Thal, SC				Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.			Influence of a Brief Episode of Anesthesia during the Induction of Experimental Brain Trauma on Secondary Brain Damage and Inflammation	PLOS ONE			English	Article							INCOMPLETE CEREBRAL-ISCHEMIA; CONTROLLED CORTICAL IMPACT; CLOSED-HEAD TRAUMA; INTRACRANIAL-PRESSURE; ARTERIAL-HYPERTENSION; RATS; INJURY; ISOFLURANE; MICE; SEVOFLURANE	It is unclear whether a single, brief, 15-minute episode of background anesthesia already modulates delayed secondary processes after experimental brain injury. Therefore, this study was designed to characterize three anesthesia protocols for their effect on molecular and histological study endpoints. Mice were randomly separated into groups that received sevoflurane (sevo), isoflurane (iso) or an intraperitoneal anesthetic combination (midazolam, fentanyl and medetomidine; comb) prior to traumatic brain injury (controlled cortical impact, CCI; 8 m/s, 1 mm impact depth, 3 mm diameter). Twenty-four hours after insult, histological brain damage, neurological function (via neurological severity score), cerebral inflammation (via real-time RT-PCR for IL6, COX-2, iNOS) and microglia (via immunohistochemical staining for Iba1) were determined. Fifteen minutes after CCI, the brain contusion volume did not differ between the anesthetic regimens (sevo = 17.9 +/- 5.5 mm 3; iso = 20.5 +/- 3.7 mm(3); comb = 19.5 +/- 4.6 mm(3)). Within 24 hours after injury, lesion size increased in all groups (sevo = 45.3 +/- 9.0 mm(3); iso = 31.5 +/- 4.0 mm(3); comb = 44.2 +/- 6.2 mm(3)). Sevo and comb anesthesia resulted in a significantly larger contusion compared to iso, which was in line with the significantly better neurological function with iso (sevo = 4.6 +/- 1.3 pts.; iso = 3.9 +/- 0.8 pts.; comb = 5.1 +/- 1.6 pts.). The expression of inflammatory marker genes was not significantly different at 15 minutes and 24 hours after CCI. In contrast, significantly more Iba1-positive cells were present in the pericontusional region after sevo compared to comb anesthesia (sevo = 181 +/- 48/mm(3); iso = 150 +/- 36/mm(3); comb = 113 +/- 40/mm(3)). A brief episode of anesthesia, which is sufficient for surgical preparations of mice for procedures such as delivering traumatic brain injury, already has a significant impact on the extent of secondary brain damage.	[Luh, Clara; Gierth, Katharina; Timaru-Kast, Ralph; Engelhard, Kristin; Werner, Christian; Thal, Serge C.] Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany; [Luh, Clara] Johannes Gutenberg Univ Mainz, Inst Physiol & Pathophysiol, Med Ctr, D-6500 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Luh, C (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Dept Anesthesiol, Mainz, Germany.	thal@uni-mainz.de	Thal, Serge/D-6593-2011	Thal, Serge/0000-0002-1222-8729				Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; BICKLER PE, 1994, ANESTHESIOLOGY, V81, P1461, DOI 10.1097/00000542-199412000-00022; Brecht M, 2004, NATURE, V427, P704, DOI 10.1038/nature02266; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Engelhard K, 1999, BRIT J ANAESTH, V83, P415, DOI 10.1093/bja/83.3.415; Friedrich DH, 2000, ACTA NEUROCHIR SUPPL, V76, P257; Goren S, 2001, J NEUROSURG ANESTH, V13, P113, DOI 10.1097/00008506-200104000-00008; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HATASHITA S, 1986, J NEUROSURG, V64, P643, DOI 10.3171/jns.1986.64.4.0643; Hendrich KS, 2001, MAGNET RESON MED, V46, P202, DOI 10.1002/mrm.1178; JANSSEN BJ, 2004, AM J PHYSL HEART CIR; Khosrovani S, 2007, P NATL ACAD SCI USA, V104, P15911, DOI 10.1073/pnas.0702727104; Kongstad L, 2001, J TRAUMA, V51, P490, DOI 10.1097/00005373-200109000-00011; Li L, 2009, NEUROSCIENCE, V164, P497, DOI 10.1016/j.neuroscience.2009.08.011; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matchett GA, 2009, NEUROL RES, V31, P128, DOI 10.1179/174313209X393546; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Ozsuer H, 2005, NEUROSURG REV, V28, P143, DOI 10.1007/s10143-004-0374-1; PATEL PM, 1995, ANESTHESIOLOGY, V82, P996, DOI 10.1097/00000542-199504000-00024; Solt K, 2006, ANESTH ANALG, V102, P1407, DOI 10.1213/01.ane.0000204252.07406.9f; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Thal SC, 2008, J NEUROTRAUM, V25, P785, DOI 10.1089/neu.2007.0497; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wen YS, 2007, ENDOCRINOLOGY, V148, P1313, DOI 10.1210/en.2006-0665; WERNER C, 1995, BRIT J ANAESTH, V75, P756, DOI 10.1093/bja/75.6.756; Yurdakoc A, 2008, ACTA ANAESTH SCAND, V52, P658, DOI 10.1111/j.1399-6576.2008.01635.x; ZORNOW MH, 1992, ANESTH ANALG, V75, P232; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	31	36	37	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2011	6	5							e19948	10.1371/journal.pone.0019948	http://dx.doi.org/10.1371/journal.pone.0019948			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766HI	21625505	Green Published, gold, Green Submitted			2023-01-03	WOS:000290771200032
J	Wee, CC; Huskey, KW; Ngo, LH; Fowler-Brown, A; Leveille, SG; Mittlemen, MA; McCarthy, EP				Wee, Christina C.; Huskey, Karen W.; Ngo, Long H.; Fowler-Brown, Angela; Leveille, Suzanne G.; Mittlemen, Murray A.; McCarthy, Ellen P.			Obesity, Race, and Risk for Death or Functional Decline Among Medicare Beneficiaries A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							BODY-MASS INDEX; OLDER-ADULTS; WEIGHT-LOSS; US ADULTS; MORTALITY; OVERWEIGHT; DISABILITY; AMERICANS; PREVALENCE; MORBIDITY	Background: The adverse effect of obesity on health outcomes may be lower in older and African American adults than in the general U. S. population. Objective: To examine and compare the relationship between obesity and all-cause mortality and functional decline among older U. S. adults. Design: Longitudinal cohort study. Setting: Secondary analysis of data from the 1994 to 2000 Medicare Current Beneficiary Surveys, linked to Medicare enrollment files through 22 April 2008. Participants: 20 975 community-dwelling participants in the 1994 to 2000 Medicare Current Beneficiary Surveys who were aged 65 years or older. Measurements: All-cause mortality through 22 April 2008; new or worsening disability in performing activities of daily living (ADLs) and instrumental activities of daily living (IADLs) in 2 years. Results: 37% of the study sample were overweight (body mass index [BMI] of 25 to <30 kg/m(2)), 18% were obese (BMI >= 30 kg/m(2)), 48% died during the 14-year follow-up, and 27% had ADL and 43% had IADL disability at baseline. Among those without severe disability at baseline, 17% developed new or worsening ADL disability and 26% developed new or worsening IADL disabilor greater were the only group above the normal BMI range who had a higher risk for mortality (hazard ratio, 1.49 [95% CI, 1.20 to 1.85] in men and 1.21 [CI, 1.06 to 1.39] in women, compared with the reference group [BMI of 22.0 to 24.9 kg/m(2)]; P for BMI-sex interaction = 0.003). In contrast, both overweight and obesity were associated with new or progressive ADL and IADL disability in a dose-dependent manner, particularly for white men and women. Significant interactions were detected between BMI and sex but not between BMI and race for any outcome, although risk estimates for ADL disability seemed attenuated in African American relative to white respondents. Limitation: This was an observational study, baseline data were self-reported, and the study had limited power to detect differences between white and African American respondents. Conclusion: Among older U. S. adults, obesity was not associated with mortality, except for those with at least moderately severe obesity. However, lower levels of obesity were associated with new or worsening disability within 2 years. Efforts to prevent disability in older adults should target those who are overweight or obese.	[Wee, Christina C.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Univ Massachusetts, Boston, MA 02125 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Massachusetts System; University of Massachusetts Boston	Wee, CC (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.	cwee@bidmc.harvard.edu	Leveille, Suzanne G/ACS-6588-2022	Leveille, Suzanne G/0000-0003-0427-1580; Mittleman, Murray/0000-0001-9788-7274	National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK071083]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK087932, R01DK071083] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant Support: By the National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK071083).	Adams KF, 2006, NEW ENGL J MED, V355, P763, DOI 10.1056/NEJMoa055643; Al Snih S, 2007, ARCH INTERN MED, V167, P774, DOI 10.1001/archinte.167.8.774; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen HL, 2008, J AM GERIATR SOC, V56, P689, DOI 10.1111/j.1532-5415.2007.01624.x; Department of Health and Human Services. National Heart Lung and Blood Institute, 1998, CLIN GUID ID EV TREA; Doshi JA, 2007, HEALTH AFFAIR, V26, P1111, DOI 10.1377/hlthaff.26.4.1111; Janssen I, 2007, OBES REV, V8, P41, DOI 10.1111/j.1467-789X.2006.00248.x; Jensen GL, 2002, J AM GERIATR SOC, V50, P918, DOI 10.1046/j.1532-5415.2002.50220.x; Jensen GL, 2010, CURR OPIN CLIN NUTR, V13, P46, DOI 10.1097/MCO.0b013e32833309cf; Kuk JL, 2009, J AM GERIATR SOC, V57, P2077, DOI 10.1111/j.1532-5415.2009.02486.x; Lang IA, 2008, J AM GERIATR SOC, V56, P1474, DOI 10.1111/j.1532-5415.2008.01813.x; Lenz M, 2009, DTSCH ARZTEBL INT, V106, P641, DOI 10.3238/arztebl.2009.0641; Liou TH, 2005, NUTR REV, V63, P321, DOI [10.1111/j.1753-4887.2005.tb00110.x, 10.1301/nr.2005.oct.321.331]; Manini TM, 2010, OBESITY, V18, P1168, DOI 10.1038/oby.2009.317; McTigue K, 2006, JAMA-J AM MED ASSOC, V296, P79, DOI 10.1001/jama.296.1.79; McTigue KM, 2006, OBESITY, V14, P1485, DOI 10.1038/oby.2006.171; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Moore SC, 2009, AM J CLIN NUTR, V89, P1003, DOI 10.3945/ajcn.2009.27598; Ogden CL, 2006, JAMA-J AM MED ASSOC, V295, P1549, DOI 10.1001/jama.295.13.1549; Peeters A, 2004, OBES RES, V12, P1145, DOI 10.1038/oby.2004.143; Rothman KJ, 2008, INT J OBESITY, V32, pS56, DOI 10.1038/ijo.2008.87; Shea MK, 2010, J GERONTOL A-BIOL, V65, P519, DOI 10.1093/gerona/glp217; Stevens J, 2000, NUTR REV, V58, P346, DOI 10.1111/j.1753-4887.2000.tb01832.x; Villanueva EV, 2001, BMC PUBLIC HEALTH, V1, DOI 10.1186/1471-2458-1-11; Walter S, 2009, INT J OBESITY, V33, P1410, DOI 10.1038/ijo.2009.176; Zamboni M, 2003, AGING CLIN EXP RES, V15, P321, DOI 10.1007/BF03324517; Zamboni M, 2005, INT J OBESITY, V29, P1011, DOI 10.1038/sj.ijo.0803005	28	51	53	1	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					645	+		10.7326/0003-4819-154-10-201105170-00003	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00003			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	764HK	21576532	Green Accepted			2023-01-03	WOS:000290620300013
J	McGowan, CC; Weinstein, DD; Samenow, CP; Stinnette, SE; Barkanic, G; Rebeiro, PF; Sterling, TR; Moore, RD; Hulgan, T				McGowan, Catherine C.; Weinstein, David D.; Samenow, Charles P.; Stinnette, Samuel E.; Barkanic, Gema; Rebeiro, Peter F.; Sterling, Timothy R.; Moore, Richard D.; Hulgan, Todd			Drug Use and Receipt of Highly Active Antiretroviral Therapy among HIV-Infected Persons in Two US Clinic Cohorts	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; DISEASE PROGRESSION; TREATMENT INTERRUPTIONS; VIROLOGICAL RESPONSE; PROTEASE INHIBITORS; GENDER-DIFFERENCES; CRACK-COCAINE; INJECTION; ADHERENCE; MORTALITY	Objective: Drug use and receipt of highly active antiretroviral therapy (HAART) were assessed in HIV-infected persons from the Comprehensive Care Center (CCC; Nashville, TN) and Johns Hopkins University HIV Clinic (JHU; Baltimore, MD) between 1999 and 2005. Methods: Participants with and without injection drug use (IDU) history in the CCC and JHU cohorts were evaluated. Additional analysis of persons with history of IDU, non-injection drug use (NIDU), and no drug use from CCC were performed. Activity of IDU and NIDU also was assessed for the CCC cohort. HAART use and time on HAART were analyzed according to drug use category and site of care. Results: 1745 persons were included from CCC: 268 (15%) with IDU history and 796 (46%) with NIDU history. 1977 persons were included from JHU: 731 (35%) with IDU history. Overall, the cohorts differed in IDU risk factor rates, age, race, sex, and time in follow-up. In multivariate analyses, IDU was associated with decreased HAART receipt overall (OR = 0.61, 95% CI: [0.45-0.84] and OR = 0.58, 95% CI: [0.46-0.73], respectively for CCC and JHU) and less time on HAART at JHU (0.70, [0.55-0.88]), but not statistically associated with time on HAART at CCC (0.78, [0.56-1.09]). NIDU was independently associated with decreased HAART receipt (0.62, [0.47-0.81]) and less time on HAART (0.66, [0.52-0.85]) at CCC. These associations were not altered significantly whether patients at CCC were categorized according to historical drug use or drug use during the study period. Conclusions: Persons with IDU history from both clinic populations were less likely to receive HAART and tended to have less cumulative time on HAART. Effects of NIDU were similar to IDU at CCC. NIDU without IDU is an important contributor to HAART utilization.	[McGowan, Catherine C.; Stinnette, Samuel E.; Barkanic, Gema; Rebeiro, Peter F.; Sterling, Timothy R.; Hulgan, Todd] Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37212 USA; [Weinstein, David D.; Samenow, Charles P.] Vanderbilt Univ, Sch Med, Dept Psychiat, Nashville, TN 37212 USA; [Sterling, Timothy R.; Hulgan, Todd] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37212 USA; [Moore, Richard D.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Johns Hopkins University	McGowan, CC (corresponding author), Vanderbilt Univ, Sch Med, Div Infect Dis, Dept Med, Nashville, TN 37212 USA.	c.mcgowan@Vanderbilt.Edu	Hulgan, Todd/B-3947-2014; Hulgan, Todd/AAG-7491-2019	Hulgan, Todd/0000-0002-3339-067X; Rebeiro, Peter/0000-0003-1951-9104	National Institutes of Health: the Vanderbilt-Meharry Center for AIDS Research [P30 AI54999, K24 A1065298, R01 DA11602, R01 AA16893, K24 DA00432]; Tennessee Valley VA Clinical Research Center of Excellence; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI054999, K24AI065298, U01AI069918] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA016893] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011602, K24DA000432] Funding Source: NIH RePORTER	National Institutes of Health: the Vanderbilt-Meharry Center for AIDS Research; Tennessee Valley VA Clinical Research Center of Excellence; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Funding for this work was provided by the National Institutes of Health: the Vanderbilt-Meharry Center for AIDS Research (P30 AI54999 [SES, GB, PFR, CCM, TRS]); K24 A1065298 (TRS, GB, SES, RA, KX, DC); R01 DA11602, R01 AA16893, K24 DA00432 (RDM), and by the Tennessee Valley VA Clinical Research Center of Excellence (TH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arnsten JH, 2002, J GEN INTERN MED, V17, P377, DOI 10.1007/s11606-002-0044-3; Bae JW, 2011, AIDS, V25, P279, DOI 10.1097/QAD.0b013e328340feb0; Baeten JM, 2008, J INFECT DIS, V198, P1804, DOI 10.1086/593214; Baldwin GC, 1998, J NEUROIMMUNOL, V83, P133, DOI 10.1016/S0165-5728(97)00229-4; Baum MK, 2009, JAIDS-J ACQ IMM DEF, V50, P93, DOI 10.1097/QAI.0b013e3181900129; BOOTH RE, 1993, AM J PUBLIC HEALTH, V83, P1144, DOI 10.2105/AJPH.83.8.1144; Braitstein P, 2006, AIDS, V20, P323, DOI 10.1097/01.aids.0000198091.70325.f4; BRYANT HU, 1988, J PHARMACOL EXP THER, V245, P913; Cabral GA, 2006, J NEUROIMMUNE PHARM, V1, P280, DOI 10.1007/s11481-006-9023-5; CARR DJJ, 1993, J PHARMACOL EXP THER, V264, P1179; Cavazos-Rehg PA, 2009, AIDS PATIENT CARE ST, V23, P727, DOI 10.1089/apc.2008.0272; *CDCP, 2007, HIV AIDS SURV REP, V19; *CDCP, 2008, HIV AIDS SURV S REP; Celentano DD, 2001, AIDS, V15, P1707, DOI 10.1097/00002030-200109070-00015; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; Chander G, 2006, DRUGS, V66, P769, DOI 10.2165/00003495-200666060-00004; Cofrancesco J, 2008, AIDS, V22, P357, DOI 10.1097/QAD.0b013e3282f3cc21; Cook JA, 2008, AIDS, V22, P1355, DOI 10.1097/QAD.0b013e32830507f2; Ding L, 2005, ARCH INTERN MED, V165, P618, DOI 10.1001/archinte.165.6.618; Freeman EE, 2006, AIDS, V20, P73, DOI 10.1097/01.aids.0000198081.09337.a7; Galai N, 2003, AM J EPIDEMIOL, V158, P695, DOI 10.1093/aje/kwg209; Galvan FH, 2002, J STUD ALCOHOL, V63, P179, DOI 10.15288/jsa.2002.63.179; Golin CE, 2002, J GEN INTERN MED, V17, P756, DOI 10.1046/j.1525-1497.2002.11214.x; Grigoryan A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004445; Hinkin CH, 2007, AIDS BEHAV, V11, P185, DOI 10.1007/s10461-006-9152-0; Hogg RS, 2002, AIDS, V16, P1051, DOI 10.1097/00002030-200205030-00012; Junghans C, 1999, AIDS, V13, P2547, DOI 10.1097/00002030-199912240-00008; Kavasery R, 2009, JAIDS-J ACQ IMM DEF, V50, P360, DOI 10.1097/QAI.0b013e318198a800; Kempf MC, 2009, JAIDS-J ACQ IMM DEF, V52, P336, DOI 10.1097/QAI.0b013e3181b628be; Knowlton AR, 2010, AIDS PATIENT CARE ST, V24, P421, DOI 10.1089/apc.2009.0240; Lopez E, 2007, AM J INFECT DIS, V3, P240, DOI 10.3844/ajidsp.2007.240.247; Lori F, 2001, JAMA-J AM MED ASSOC, V286, P2981, DOI 10.1001/jama.286.23.2981; Lucas GM, 2006, AM J EPIDEMIOL, V163, P412, DOI 10.1093/aje/kwj059; Lucas GM, 2003, JAIDS-J ACQ IMM DEF, V33, P321, DOI 10.1097/00126334-200307010-00005; Lucas GM, 2001, J ACQ IMMUN DEF SYND, V27, P251, DOI 10.1097/00126334-200107010-00006; Mitty JA, 2005, JAIDS-J ACQ IMM DEF, V39, P545; Mocroft A, 1999, J ACQ IMMUN DEF SYND, V22, P369; Mocroft A, 2000, J ACQ IMMUN DEF SYND, V24, P475, DOI 10.1097/00126334-200008150-00013; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Moore RD, 1998, J ACQ IMMUN DEF SYND, V17, pS38, DOI 10.1097/00042560-199801001-00011; Moore RD, 2004, JAIDS-J ACQ IMM DEF, V35, P46, DOI 10.1097/00126334-200401010-00006; Murri R, 1999, J ACQ IMMUN DEF SYND, V22, P461; *NAT I DRUG AB COM, 2006, EP TRENDS DRUG AB; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Palepu A, 2003, JAIDS-J ACQ IMM DEF, V32, P522, DOI 10.1097/00126334-200304150-00009; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Poundstone KE, 2001, AIDS, V15, P1115, DOI 10.1097/00002030-200106150-00006; Rodriguez-Arenas MA, 2006, AIDS RES HUM RETROV, V22, P715, DOI 10.1089/aid.2006.22.715; Roth MD, 2002, J INFECT DIS, V185, P701, DOI 10.1086/339012; Sackoff JE, 2006, ANN INTERN MED, V145, P397, DOI 10.7326/0003-4819-145-6-200609190-00003; Shepherd BE, 2009, J CLIN EPIDEMIOL, V62, P729, DOI 10.1016/j.jclinepi.2008.09.002; Silverberg MJ, 2009, J PAIN SYMPTOM MANAG, V38, P197, DOI 10.1016/j.jpainsymman.2008.08.007; Strathdee SA, 2003, J URBAN HEALTH, V80, P7; Strathdee SA, 1998, JAMA-J AM MED ASSOC, V280, P547, DOI 10.1001/jama.280.6.547; Tucker JS, 2003, AM J MED, V114, P573, DOI 10.1016/S0002-9343(03)00093-7; UNAIDS, 2008, REP GLOB AIDS EP; Xu W, 1999, INT J IMMUNOPHARMACO, V21, P463, DOI 10.1016/S0192-0561(99)00023-5	57	35	35	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 25	2011	6	4							e18462	10.1371/journal.pone.0018462	http://dx.doi.org/10.1371/journal.pone.0018462			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	756MU	21541016	gold, Green Published			2023-01-03	WOS:000290016800010
J	Hopson, J; Holmes, J				Hopson, Jackie; Holmes, Jeremy			Through the wasteland: chronic depression	BRITISH MEDICAL JOURNAL			English	Editorial Material												jh@byfleet.org							0	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 11	2011	342								d93	10.1136/bmj.d93	http://dx.doi.org/10.1136/bmj.d93			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	752UT	21482596	Bronze			2023-01-03	WOS:000289721100016
J	Volkow, ND; McLellan, TA; Cotto, JH; Karithanom, M; Weiss, SRB				Volkow, Nora D.; McLellan, Thomas A.; Cotto, Jessica H.; Karithanom, Meena; Weiss, Susan R. B.			Characteristics of Opioid Prescriptions in 2009	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							ADOLESCENTS; DEPENDENCE; ADULTS; ABUSE		[Volkow, Nora D.; Cotto, Jessica H.; Karithanom, Meena; Weiss, Susan R. B.] NIDA, NIH, Bethesda, MD 20892 USA; [McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Pennsylvania	Volkow, ND (corresponding author), NIDA, NIH, Bethesda, MD 20892 USA.	nvolkow@nida.nih.gov			Intramural NIH HHS [Z99 DA999999] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		[Anonymous], CDCS ISS BRIEF UN DR; [Anonymous], VECT ON NAT VONA; Fortuna RJ, 2010, PEDIATRICS, V126, P1108, DOI 10.1542/peds.2010-0791; Grant BF, 1998, J SUBST ABUSE, V10, P163, DOI 10.1016/S0899-3289(99)80131-X; Schramm-Sapyta NL, 2009, PSYCHOPHARMACOLOGY, V206, P1, DOI 10.1007/s00213-009-1585-5; Zacny J, 2003, DRUG ALCOHOL DEPEN, V69, P215, DOI 10.1016/S0376-8716(03)00003-6	6	551	554	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2011	305	13					1299	1301		10.1001/jama.2011.401	http://dx.doi.org/10.1001/jama.2011.401			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	745JT	21467282	Green Accepted, Bronze			2023-01-03	WOS:000289162400016
J	Volkow, ND; McLellan, TA				Volkow, Nora D.; McLellan, Thomas A.			Curtailing Diversion and Abuse of Opioid Analgesics Without Jeopardizing Pain Treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC NONCANCER PAIN		[Volkow, Nora D.] NIDA, NIH, Bethesda, MD 20892 USA; [McLellan, Thomas A.] Univ Penn, Sch Med, Ctr Subst Abuse Solut, Philadelphia, PA 19104 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of Pennsylvania	Volkow, ND (corresponding author), NIDA, NIH, 6001 Execut Blvd,Room 5274,MSC 9581, Bethesda, MD 20892 USA.	nvolkow@nida.nih.gov			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [ZIAAA000550] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		*AM MED ASS, 2011, ASS TREAT PAIN PAT S; Centers for Disease Control and Prevention, 2010, UN DRUG POIS US; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Halperin EC, 2010, ACAD MED, V85, P203, DOI 10.1097/ACM.0b013e3181c88506; Inciardi JA, 2007, PAIN MED, V8, P171, DOI 10.1111/j.1526-4637.2006.00255.x; JOHNSTON LD, NIH PUBLICATION, V1; Manchikanti L, 2010, PAIN PHYSICIAN, V13, P401; Reid MC, 2002, J GEN INTERN MED, V17, P173, DOI 10.1046/j.1525-1497.2002.10435.x; *SAMHSA, TRENDS EM DEP VIS IN; *SAMHSA DRUG ALC S, 2008, SUBST AB TREATM ADM	10	160	162	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2011	305	13					1346	1347		10.1001/jama.2011.369	http://dx.doi.org/10.1001/jama.2011.369			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	745JT	21467287				2023-01-03	WOS:000289162400024
J	Bichsel, C; Neeld, DK; Hamazaki, T; Wu, DH; Chang, LJ; Yang, LJ; Terada, N; Jin, SG				Bichsel, Candace; Neeld, Dennis K.; Hamazaki, Takashi; Wu, Donghai; Chang, Lung-Ji; Yang, Lijun; Terada, Naohiro; Jin, Shouguang			Bacterial Delivery of Nuclear Proteins into Pluripotent and Differentiated Cells	PLOS ONE			English	Article							III SECRETION SYSTEM; PSEUDOMONAS-AERUGINOSA; LENTIVIRAL VECTOR; CRE RECOMBINASE; STEM-CELLS; INDUCTION; FIBROBLASTS; EXCISION	Numerous Gram negative pathogens possess a type III secretion system (T3SS) which allows them to inject virulent proteins directly into the eukaryotic cell cytoplasm. Injection of these proteins is dependent on a variable secretion signal sequence. In this study, we utilized the N-terminal secretion signal sequence of Pseudomonas aeruginosa exotoxin ExoS to translocate Cre recombinase containing a nuclear localization sequence (Cre-NLS). Transient exposure of human sarcoma cell line, containing Cre-dependent lacZ reporter, resulted in efficient recombination in the host chromosome, indicating that the bacterially delivered protein was not only efficiently localized to the nucleus but also retained its biological function. Using this system, we also illustrate the ability of P. aeruginosa to infect mouse embryonic stem cells (mESC) and the susceptibility of these cells to bacterially delivered Cre-NLS. A single two-hour infection caused as high as 30% of the mESC reporter cells to undergo loxP mediated chromosomal DNA recombination. A simple antibiotic treatment completely eliminated the bacterial cells following the delivery, while the use of an engineered mutant strain greatly reduced cytotoxicity. Utility of the system was demonstrated by delivery of the Cre-NLS to induced pluripotent stem cells to excise the floxed oncogenic nuclear reprogramming cassette. These results validate the use of T3SS for the delivery of transcription factors for the purpose of cellular reprogramming.	[Bichsel, Candace; Neeld, Dennis K.; Chang, Lung-Ji; Jin, Shouguang] Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA; [Hamazaki, Takashi; Yang, Lijun; Terada, Naohiro] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA; [Wu, Donghai] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, Guangzhou, Guangdong, Peoples R China	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Bichsel, C (corresponding author), Univ Florida, Coll Med, Dept Mol Genet & Microbiol, Gainesville, FL 32610 USA.	sjin@mgm.ufl.edu	Jin, Shouguang/N-5548-2016		National Institutes of Health [RC1GM091238]; UF Opportunity Fund [UF-RGP80830]; Bankhead-Coley Cancer Research Program [FLDH 09BW-12]; National Basic Research Program of China (973 Program) [2011CB504004, 2010CB945500]; National Natural Science Foundation of China [90813033]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [RC1GM091238] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); UF Opportunity Fund; Bankhead-Coley Cancer Research Program; National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health (RC1GM091238), UF Opportunity Fund (UF-RGP80830), Bankhead-Coley Cancer Research Program (FLDH 09BW-12), National Basic Research Program of China (973 Program) (2011CB504004 and 2010CB945500) and the National Natural Science Foundation of China (90813033). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barbieri JT, 2005, REV PHYSIOL BIOCH P, V152, P79, DOI 10.1007/s10254-004-0031-7; Chang CW, 2009, STEM CELLS, V27, P1042, DOI 10.1002/stem.39; Cornelis GR, 2006, NAT REV MICROBIOL, V4, P811, DOI 10.1038/nrmicro1526; Dasgupta N, 2006, INFECT IMMUN, V74, P3334, DOI 10.1128/IAI.00090-06; Epaulard O, 2006, MOL THER, V14, P656, DOI 10.1016/j.ymthe.2006.06.011; Galan JE, 2006, NATURE, V444, P567, DOI 10.1038/nature05272; Ha U, 2001, INFECT IMMUN, V69, P4398, DOI 10.1128/IAI.69.7.4398-4406.2001; Hamazaki T, 2006, MOL CELL BIOL, V26, P7539, DOI 10.1128/MCB.00508-06; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hauser AR, 2009, NAT REV MICROBIOL, V7, P654, DOI 10.1038/nrmicro2199; Hoang TT, 1998, GENE, V212, P77, DOI 10.1016/S0378-1119(98)00130-9; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73, DOI 10.1128/MMBR.43.1.73-102.1979; Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864; Kim D, 2009, CELL STEM CELL, V4, P472, DOI 10.1016/j.stem.2009.05.005; Kim J, 2005, MICROBIOL-SGM, V151, P3575, DOI 10.1099/mic.0.28277-0; Lee VT, 2005, INFECT IMMUN, V73, P1695, DOI 10.1128/IAI.73.3.1695-1705.2005; Marx Christopher J, 2008, BMC Res Notes, V1, P1, DOI 10.1186/1756-0500-1-1; Nagy A, 2000, GENESIS, V26, P99, DOI 10.1002/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B; Oka Masahiro, 2006, V329, P273; Polack B, 2000, BIOCHEM BIOPH RES CO, V275, P854, DOI 10.1006/bbrc.2000.3399; Rabin SDP, 2005, INFECT IMMUN, V73, P573, DOI 10.1128/IAI.73.1.573-582.2005; Russmann H, 1998, SCIENCE, V281, P565, DOI 10.1126/science.281.5376.565; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; Sundin C, 2002, MICROB PATHOGENESIS, V33, P265, DOI 10.1006/mpat.2002.0534; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tampakaki AP, 2004, CELL MICROBIOL, V6, P805, DOI 10.1111/j.1462-5822.2004.00432.x; WEST SEH, 1994, GENE, V148, P81, DOI 10.1016/0378-1119(94)90237-2; Yahr TL, 1998, P NATL ACAD SCI USA, V95, P13899, DOI 10.1073/pnas.95.23.13899; Yu J, 2009, INFECT IMMUN, V77, P585, DOI 10.1128/IAI.01003-08; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zaiss AK, 2002, J VIROL, V76, P7209, DOI 10.1128/JVI.76.14.7209-7219.2002; Zhou HY, 2009, CELL STEM CELL, V4, P381, DOI 10.1016/j.stem.2009.04.005	35	29	36	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2011	6	1							e16465	10.1371/journal.pone.0016465	http://dx.doi.org/10.1371/journal.pone.0016465			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	712JV	21304583	gold, Green Published			2023-01-03	WOS:000286663900053
J	Narita, K; Hisamoto, M; Okuda, T; Takeda, S				Narita, Keishi; Hisamoto, Masashi; Okuda, Tohru; Takeda, Sen			Differential Neuroprotective Activity of Two Different Grape Seed Extracts	PLOS ONE			English	Article							HIPPOCAMPAL-NEURONS; RESVERATROL; GLUTAMATE; POLYPHENOLS; BRAIN; PROLIFERATION; MECHANISMS; VARIETIES; INJURY; EGCG	Glutamate excitotoxicity is one of the major events that takes place during various neurotoxic injuries such as brain ischemia. We prepared grape seed extracts, from two different varieties, containing high amounts of polyphenols but little resveratrol. Their neuroprotective effects were investigated using primary culture of neonatal mouse hippocampal neurons treated with an excitotoxic concentration of glutamate. Koshu, a white, local variety of V. vinifera, alleviated the acute inactivation of Erk1/2 and dendrite retraction in cultured hippocampal neurons exposed to a toxic concentration of glutamate (1.0 ng/ml). By contrast, Muscat Bailey A, a red, hybrid variety (Muscat Humburg x Bailey), failed to show any neuroprotective effect. Unlike brain-derived neurotrophic factor and other neuroprotective cytokines, Koshu extract did not induce Akt phosphorylation. Koshu extract also augmented neuron survival rate 24 hours after glutamate toxicity. The comparison of polyphenols between the two samples by liquid chromatography/time-of-flight mass spectrometry demonstrated that Koshu had higher amounts of low molecular weight polyphenols along with several Koshu-specific procyanidin oligomers. These data suggest the presence of high affinity molecular targets for polyphenols in hippocampal neurons, which induce neuroprotective effects in a manner different from BDNF, and the importance of low molecular weight polyphenols and/or procyanidin oligomers for neuroprotection.	[Narita, Keishi; Takeda, Sen] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Anat & Cell Biol, Yamanashi, Japan; [Hisamoto, Masashi; Okuda, Tohru] Univ Yamanashi, Inst Enol & Viticulture, Yamanashi, Japan	University of Yamanashi; University of Yamanashi	Narita, K (corresponding author), Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Anat & Cell Biol, Yamanashi, Japan.	stakeda@yamanashi.ac.jp	Narita, Keishi/E-3539-2010; Takeda, Sen/I-8462-2012	Narita, Keishi/0000-0002-7602-8523; Takeda, Sen/0000-0001-7090-2139	Ministry of Education, Culture, Sports, Science Technology	Ministry of Education, Culture, Sports, Science Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported by a University Yamanashi Grape Polyphenols project from the Ministry of Education, Culture, Sports, Science & Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; Arts ICW, 2005, AM J CLIN NUTR, V81, p317S, DOI 10.1093/ajcn/81.1.317S; Balasubramanian S, 2007, TOXICOL APPL PHARM, V224, P214, DOI 10.1016/j.taap.2007.03.020; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Berbari NF, 2007, J NEUROSCI RES, V85, P1095, DOI 10.1002/jnr.21209; Brown L, 2009, ALCOHOL CLIN EXP RES, V33, P1513, DOI 10.1111/j.1530-0277.2009.00989.x; Choi BH, 2006, J CELL SCI, V119, P1329, DOI 10.1242/jcs.02837; Constant J, 1997, CLIN CARDIOL, V20, P420, DOI 10.1002/clc.4960200504; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dore S, 2005, NEUROSIGNALS, V14, P61, DOI 10.1159/000085386; Fujishita K, 2009, CELL MOL NEUROBIOL, V29, P1121, DOI 10.1007/s10571-009-9403-5; Fujji H, 2006, BIOSCI BIOTECH BIOCH, V70, P2104, DOI 10.1271/bbb.60053; Gao ZB, 2006, BRAIN RES, V1111, P41, DOI 10.1016/j.brainres.2006.06.096; Guendez R, 2005, PHYTOCHEM ANALYSIS, V16, P17, DOI 10.1002/pca.804; Han YS, 2006, J PHARMACOL EXP THER, V318, P238, DOI 10.1124/jpet.106.102319; Harikumar KB, 2008, CELL CYCLE, V7, P1020, DOI 10.4161/cc.7.8.5740; Hwang IK, 2004, LIFE SCI, V75, P1989, DOI 10.1016/j.lfs.2004.05.013; Kammerer D, 2004, J AGR FOOD CHEM, V52, P4360, DOI 10.1021/jf049613b; Levinthal DJ, 2005, J BIOL CHEM, V280, P5875, DOI 10.1074/jbc.M410771200; Limatola C, 2005, J NEUROIMMUNOL, V166, P19, DOI 10.1016/j.jneuroim.2005.03.023; Lotito SB, 2000, BIOCHEM BIOPH RES CO, V276, P945, DOI 10.1006/bbrc.2000.3571; Namura S, 2001, P NATL ACAD SCI USA, V98, P11569, DOI 10.1073/pnas.181213498; Okuda Tohru, 2002, Journal of Wine Research, V13, P93, DOI 10.1080/0957126022000017963; Patra SK, 2008, J PHYSIOL PHARMACOL, V59, P217; Reed JD, 2005, PHYTOCHEMISTRY, V66, P2248, DOI 10.1016/j.phytochem.2005.05.015; Campos-Esparza MR, 2009, CELL CALCIUM, V45, P358, DOI 10.1016/j.ceca.2008.12.007; Suenaga F, 2008, FEBS LETT, V582, P586, DOI 10.1016/j.febslet.2008.01.024; Takahashi T, 1999, J INVEST DERMATOL, V112, P310, DOI 10.1046/j.1523-1747.1999.00532.x; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Yanagida F, 2008, LETT APPL MICROBIOL, V47, P134, DOI 10.1111/j.1472-765X.2008.02398.x; Yazawa K, 2006, FEBS LETT, V580, P6623, DOI 10.1016/j.febslet.2006.11.011	32	31	31	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 24	2011	6	1							e14575	10.1371/journal.pone.0014575	http://dx.doi.org/10.1371/journal.pone.0014575			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710PJ	21283677	Green Submitted, Green Published, gold			2023-01-03	WOS:000286523400001
J	Kavalier, F				Kavalier, Fred			Personal View Why do pharmacists sell homoeopathic remedies?	BRITISH MEDICAL JOURNAL			English	Editorial Material												kavalier@btinternet.com							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 19	2011	342								d349	10.1136/bmj.d349	http://dx.doi.org/10.1136/bmj.d349			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	711OX	21248013				2023-01-03	WOS:000286602400025
J	Mor, V; Besdine, RW				Mor, Vincent; Besdine, Richard W.			Policy Options to Improve Discharge Planning and Reduce Rehospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CONTROLLED-TRIAL; CARE; HOSPITALISTS		[Mor, Vincent; Besdine, Richard W.] Brown Univ, Sch Med, Dept Community Hlth, Providence, RI 02912 USA; [Mor, Vincent; Besdine, Richard W.] Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; [Besdine, Richard W.] Brown Univ, Sch Med, Dept Med, Div Geriatr, Providence, RI 02912 USA	Brown University; Brown University; Brown University	Mor, V (corresponding author), Brown Univ, Sch Med, Dept Community Hlth, Box G-S121, Providence, RI 02912 USA.	vincent_mor@brown.edu			NIA NIH HHS [P0-1 AG027296, P01 AG027296] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG027296] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; *COMM MP, 2008, DAT BOOK HEALTHC SPE; Fisher ES, 2007, HEALTH AFFAIR, V26, pW44, DOI 10.1377/hlthaff.26.1.w44; Hamel MB, 2009, NEW ENGL J MED, V360, P1141, DOI 10.1056/NEJMe0900796; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kane RL, 2011, JAMA-J AM MED ASSOC, V305, P284, DOI 10.1001/jama.2010.2015; Mor V, 2010, HEALTH AFFAIR, V29, P57, DOI 10.1377/hlthaff.2009.0629; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Peterson MC, 2009, MAYO CLIN PROC, V84, P248, DOI 10.1016/S0025-6196(11)61142-7	9	28	28	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2011	305	3					302	303		10.1001/jama.2010.2006	http://dx.doi.org/10.1001/jama.2010.2006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	707YY	21245187	Green Accepted			2023-01-03	WOS:000286328700029
J	Bhutta, ZA; Soofi, S; Cousens, S; Mohammad, S; Memon, ZA; Ali, I; Feroze, A; Raza, F; Khan, A; Wall, S; Martines, J				Bhutta, Zulfiqar A.; Soofi, Sajid; Cousens, Simon; Mohammad, Shah; Memon, Zahid A.; Ali, Imran; Feroze, Asher; Raza, Farrukh; Khan, Amanullah; Wall, Steve; Martines, Jose			Improvement of perinatal and newborn care in rural Pakistan through community-based strategies: a cluster-randomised effectiveness trial	LANCET			English	Article							NEONATAL DEATHS; DEVELOPING-COUNTRIES; MORTALITY; INDIA; INTERVENTIONS; STILLBIRTHS; MANAGEMENT; PROGRAM; IMPACT	Background Newborn deaths account for 57% of deaths in children younger than 5 years in Pakistan. Although a large programme of trained lady health workers (LHWs) exists, the effectiveness of this training on newborn outcomes has not been studied. We aimed to evaluate the effectiveness of a community-based intervention package, principally delivered through LHWs working with traditional birth attendants and community health committees, for reduction of perinatal and neonatal mortality in a rural district of Pakistan. Methods We undertook a cluster randomised trial between February, 2006, and March, 2008, in Hala and Matiari subdistricts, Pakistan. Catchment areas of primary care facilities and all affiliated LHWs were used to define clusters, which were allocated to intervention and control groups by restricted, stratified randomisation. The intervention package delivered by LHWs through group sessions consisted of promotion of antenatal care and maternal health education, use of clean delivery kits, facility births, immediate newborn care, identification of danger signs, and promotion of careseeking; control clusters received routine care. Independent data collectors undertook quarterly household surveillance to capture data for births, deaths, and household practices related to maternal and newborn care. Data collectors were masked to cluster allocation; those analysing data were not. The primary outcome was perinatal and all-cause neonatal mortality. Analysis was by intention to treat. This trial is registered, ISRCTN16247511. Findings 16 clusters were assigned to intervention (23 353 households, 12 391 total births) and control groups (23 768 households, 11 443 total births). LHWs in the intervention clusters were able to undertake 4428 (63%) of 7084 planned group sessions, but were only able to visit 2943 neonates (24%) of a total 12 028 livebirths in their catchment villages. Stillbirths were reduced in intervention clusters (39.1 stillbirths per 1000 total births) compared with control (48.7 per 1000; risk ratio [RR] 0.79, 95% CI 0.68-0.92; p=0.006). The neonatal mortality rate was 43.0 deaths per 1000 livebirths in intervention clusters compared with 49.1 per 1000 in control groups (RR 0.85, 0.76-0.96; p=0.02). Interpretation Our results support the scale-up of preventive and promotive maternal and newborn interventions through community health workers and emphasise the need for attention to issues of programme management and coverage for such initiatives to achieve maximum potential.	[Bhutta, Zulfiqar A.; Soofi, Sajid; Mohammad, Shah; Memon, Zahid A.; Ali, Imran; Feroze, Asher; Raza, Farrukh] Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan; [Cousens, Simon] London Sch Hyg & Trop Med, London WC1, England; [Khan, Amanullah; Wall, Steve] Save Children USA, Saving Newborn Lives, Washington, DC USA; [Martines, Jose] WHO, Dept Child & Adolescent Hlth, CH-1211 Geneva, Switzerland	Aga Khan University; University of London; London School of Hygiene & Tropical Medicine; Save the Children; World Health Organization	Bhutta, ZA (corresponding author), Aga Khan Univ, Div Women & Child Hlth, Karachi 74800, Pakistan.	zulfiqar.bhutta@aku.edu	Memon, Zahid Ali/GRE-8118-2022	Memon, Zahid Ali/0000-0002-5321-8885	WHO; Bill & Melinda Gates Foundation	WHO(World Health Organization); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR)	The Hala trial was funded by grants from WHO and the Saving Newborn Lives programme funded by the Bill & Melinda Gates Foundation. We thank Department of Health, Sindh Government, and the National Program for Family Planning and Primary Health Care for their encouragement and support towards undertaking this trial, all staff of the Hala project office for their hard work and support, and notably, the excellent support provided by Usman Chachar, the district coordinating officer, and Hasan Murad Shah, the executive district officer for health for Matiari district.	[Anonymous], NAT PROGR FAM PLANN; Bang AT, 1999, LANCET, V354, P1955, DOI 10.1016/S0140-6736(99)03046-9; Baqui AH, 2006, Bull World Health Organ, V84, P706, DOI 10.2471/BLT.05.026443; Baqui AH, 2008, HEALTH POLICY PLANN, V23, P234, DOI 10.1093/heapol/czn012; Baqui AH, 2008, LANCET, V371, P1936, DOI 10.1016/S0140-6736(08)60835-1; Baqui AH, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2826; Bhutta Z.A., 2010, GLOB HLTH WORKFORCE, V1, P61; Bhutta ZA, 2005, PEDIATRICS, V115, P519, DOI 10.1542/peds.2004-1441; Bhutta ZA, 2004, MATERNAL CHILD HLTH, V1st; Bhutta ZA, 2008, PAKISTAN DEMOGRAPHIC; Bhutta ZA, 2008, B WORLD HEALTH ORGAN, V86, P452, DOI 10.2471/BLT.07.045849; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; Bhutta ZA, 2010, LANCET, V375, P1142, DOI 10.1016/S0140-6736(10)60324-8; Carlo WA, 2010, NEW ENGL J MED, V362, P614, DOI 10.1056/NEJMsa0806033; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Douthwaite M, 2005, HEALTH POLICY PLANN, V20, P117, DOI 10.1093/heapol/czi014; Edmond KM, 2008, PAEDIATR PERINAT EP, V22, P417, DOI 10.1111/j.1365-3016.2008.00962.x; Gogia S, 2010, B WORLD HEALTH ORGAN, V88, P658, DOI 10.2471/BLT.09.069369; Haq Zaeem, 2008, Int J Ment Health Syst, V2, P15, DOI 10.1186/1752-4458-2-15; Hayes RJ, 2009, INTERD STAT, P3; Hayes RJ, 1999, INT J EPIDEMIOL, V28, P319, DOI 10.1093/ije/28.2.319; Jafarey S N, 1981, J Pak Med Assoc, V31, P288; Kalter HD, 2008, PAEDIATR PERINAT EP, V22, P321, DOI 10.1111/j.1365-3016.2008.00943.x; Kumar V, 2008, LANCET, V372, P1151, DOI 10.1016/S0140-6736(08)61483-X; Lassi ZS, 2010, COMMUNITY BASED INTE; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lewin S, 2010, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004015.PUB3; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; Mavalankar D, 2009, INT J GYNECOL OBSTET, V107, P271, DOI 10.1016/j.ijgo.2009.09.008; Midhet F, 2010, REPROD HEALTH, V7, DOI 10.1186/1742-4755-7-30; Moulton Lawrence H, 2004, Clin Trials, V1, P297, DOI 10.1191/1740774504cn024oa; Oxford Policy Management, 2003, EV PRIM MIN LAD HLTH; Oxford Policy Management, 2009, EXT EV LAD HLTH WORK; Rajaratnam JK, 2010, LANCET, V375, P1988, DOI 10.1016/S0140-6736(10)60703-9; Sibley LM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005460; Tripathy P, 2010, LANCET, V375, P1182, DOI 10.1016/S0140-6736(09)62042-0; Tugwell P, 2006, BMJ-BRIT MED J, V332, P358, DOI 10.1136/bmj.332.7537.358; World Health Organization, 2003, STAND NEON VERB AUT	39	185	188	0	27	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN-FEB	2011	377	9763					403	412		10.1016/S0140-6736(10)62274-X	http://dx.doi.org/10.1016/S0140-6736(10)62274-X			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721ES	21239052	Green Accepted			2023-01-03	WOS:000287337000030
J	Harris, JB; LaRocque, RC; Charles, RC; Mazumder, RN; Khan, AI; Bardhan, PK				Harris, Jason B.; LaRocque, Regina C.; Charles, Richelle C.; Mazumder, Ramendra N.; Khan, Azharul I.; Bardhan, Pradip K.			Cholera's western front	LANCET			English	Editorial Material							TETRACYCLINE; VACCINES		[Harris, Jason B.; LaRocque, Regina C.; Charles, Richelle C.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [LaRocque, Regina C.; Charles, Richelle C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Mazumder, Ramendra N.; Khan, Azharul I.; Bardhan, Pradip K.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; International Centre for Diarrhoeal Disease Research (ICDDR)	Harris, JB (corresponding author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.	jbharris@partners.org	Harris, Jason/ABF-2684-2020; Charles, Richelle/W-4342-2019	Harris, Jason/0000-0003-3642-5126; Charles, Richelle/0000-0002-8881-1849	FOGARTY INTERNATIONAL CENTER [K01TW007409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI089721] Funding Source: NIH RePORTER; FIC NIH HHS [K01 TW007409] Funding Source: Medline; NIAID NIH HHS [K08 AI089721] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ali M, 2005, LANCET, V366, P44, DOI 10.1016/S0140-6736(05)66550-6; Anonymous, 2010, Morbidity and Mortality Weekly Report, V59, P1473; [Anonymous], 2010, WORLD HLTH STAT 2010; Hossain MS, 2002, J HEALTH POPUL NUTR, V20, P18; Jeuland M, 2009, VALUE HEALTH, V12, P899, DOI 10.1111/j.1524-4733.2009.00562.x; *PAN AM HLTH ORG, 2010, EP AL UPD SIT HAIT; RABBANI GH, 1989, ANTIMICROB AGENTS CH, V33, P1447, DOI 10.1128/AAC.33.9.1447; Ryan ET, 2000, AM J TROP MED HYG, V63, P12, DOI 10.4269/ajtmh.2000.63.12; Sack DA, 2006, NEW ENGL J MED, V355, P649, DOI 10.1056/NEJMp068144; Saha D, 2006, NEW ENGL J MED, V354, P2452, DOI 10.1056/NEJMoa054493; *VACC RES LIB, 2010, CHOL OUTBR TRAIN SHI; *WHO, 2004, 1 STEPS MAN OUTBR AC; WHO/UNICEF Joint Water Supply and Sanitation Monitoring Programme, 2015, PROGR SAN DRINK WAT; World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P117; World Health Organization, 2005, TREATM DIARRH MAN PH	15	36	39	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	2010	376	9757					1961	1965		10.1016/S0140-6736(10)62172-1	http://dx.doi.org/10.1016/S0140-6736(10)62172-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	701GZ	21112083	Green Accepted			2023-01-03	WOS:000285807700004
J	Vassar, R				Vassar, Robert			Alzheimer's therapy: a BACE in the hand?	NATURE MEDICINE			English	Editorial Material							AMYLOID PRECURSOR PROTEIN; CLEAVAGE; DISEASE		Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Vassar, R (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.							Alzheimer Research Forum, 2011, UPPS IS TAU IMMU TAK; Atwal JK, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002254; De Strooper B, 2010, NAT REV NEUROL, V6, P99, DOI 10.1038/nrneurol.2009.218; DeMattos RB, 2001, P NATL ACAD SCI USA, V98, P8850, DOI 10.1073/pnas.151261398; Kim SH, 2010, J NEUROSCI, V30, P3870, DOI 10.1523/JNEUROSCI.4717-09.2010; Lilly E., 2010, LILLY HALTS DEV SEMA; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Yamakawa H, 2010, J BIOL CHEM, V285, P1634, DOI 10.1074/jbc.M109.066753; Yoshimizu T, 2004, BIOCHEM BIOPH RES CO, V315, P493, DOI 10.1016/j.bbrc.2004.01.073; Yu YJ, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002230	11	3	3	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	2011	17	8					932	933		10.1038/nm0811-932	http://dx.doi.org/10.1038/nm0811-932			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	802JW	21818090				2023-01-03	WOS:000293507400023
J	Gravitz, L				Gravitz, Lauren			DRUGS A tangled web of targets	NATURE			English	Editorial Material							ALZHEIMERS-DISEASE											Golde TE, 2011, NEURON, V69, P203, DOI 10.1016/j.neuron.2011.01.002; Mangialasche F, 2010, LANCET NEUROL, V9, P702, DOI 10.1016/S1474-4422(10)70119-8; Mazanetz MP, 2007, NAT REV DRUG DISCOV, V6, P464, DOI 10.1038/nrd2111; Medina DX, 2011, BRAIN PATHOL, V21, P140, DOI 10.1111/j.1750-3639.2010.00430.x; Rinne JO, 2010, LANCET NEUROL, V9, P363, DOI 10.1016/S1474-4422(10)70043-0	5	62	64	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 14	2011	475	7355					S9	S11		10.1038/475S9a	http://dx.doi.org/10.1038/475S9a			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	791UA	21760583				2023-01-03	WOS:000292690500005
J	Cherkin, DC; Sherman, KJ; Kahn, J; Wellman, R; Cook, AJ; Johnson, E; Erro, J; Delaney, K; Deyo, RA				Cherkin, Daniel C.; Sherman, Karen J.; Kahn, Janet; Wellman, Robert; Cook, Andrea J.; Johnson, Eric; Erro, Janet; Delaney, Kristin; Deyo, Richard A.			A Comparison of the Effects of 2 Types of Massage and Usual Care on Chronic Low Back Pain A Randomized, Controlled Trial	ANNALS OF INTERNAL MEDICINE			English	Article							NATIONAL-SURVEY; THERAPY	Background: Few studies have evaluated the effectiveness of massage for chronic low back pain. Objective: To compare the effectiveness of 2 types of massage and usual care for chronic back pain. Design: Parallel-group randomized, controlled trial. Randomization was computer-generated, with centralized allocation concealment. Participants were blinded to massage type but not to assignment to massage versus usual care. Massage therapists were unblinded. The study personnel who assessed outcomes were blinded to treatment assignment. (ClinicalTrials. gov registration number: NCT00371384) Setting: An integrated health care delivery system in the Seattle area. Patients: 401 persons 20 to 65 years of age with nonspecific chronic low back pain. Intervention: Structural massage (n = 132), relaxation massage (n = 136), or usual care (n = 133). Measurements: Roland Disability Questionnaire (RDQ) and symptom bothersomeness scores at 10 weeks (primary outcome) and at 26 and 52 weeks (secondary outcomes). Mean group differences of at least 2 points on the RDQ and at least 1.5 points on the symptom bothersomeness scale were considered clinically meaningful. Results: The massage groups had similar functional outcomes at 10 weeks. The adjusted mean RDQ score was 2.9 points (95% CI, 1.8 to 4.0 points) lower in the relaxation group and 2.5 points (CI, 1.4 to 3.5 points) lower in the structural massage group than in the usual care group, and adjusted mean symptom bothersomeness scores were 1.7 points (CI, 1.2 to 2.2 points) lower with relaxation massage and 1.4 points (CI, 0.8 to 1.9 points) lower with structural massage. The beneficial effects of relaxation massage on function (but not on symptom reduction) persisted at 52 weeks but were small. Limitation: Participants were not blinded to treatment. Conclusion: Massage therapy may be effective for treatment of chronic back pain, with benefits lasting at least 6 months. No clinically meaningful difference between relaxation and structural massage was observed in terms of relieving disability or symptoms.	[Cherkin, Daniel C.] Grp Hlth Res Inst, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; Univ Vermont, Burlington, VT USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA	University of Washington; University of Washington Seattle; University of Vermont; Oregon Health & Science University	Cherkin, DC (corresponding author), Grp Hlth Res Inst, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.				National Center for Complementary and Alternative Medicine [R01 AT 001927]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT001927] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)	Primary Funding Source: National Center for Complementary and Alternative Medicine.r Grant Support: By the NCCAM (grant R01 AT 001927).	Bombardier C, 2000, SPINE, V25, P3100, DOI 10.1097/00007632-200012150-00003; Cherkin Daniel C, 2002, J Am Board Fam Pract, V15, P463; Cherkin DC, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-96; Cherkin DC, 2001, ARCH INTERN MED, V161, P1081, DOI 10.1001/archinte.161.8.1081; Chou R, 2007, ANN INTERN MED, V147, P478, DOI 10.7326/0003-4819-147-7-200710020-00006; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Field T, 2007, J BODYW MOV THER, V11, P141, DOI 10.1016/j.jbmt.2006.03.001; Furlan AD, 2009, SPINE, V34, P1669, DOI 10.1097/BRS.0b013e3181ad7bd6; Hagg O, 2003, EUR SPINE J, V12, P12, DOI 10.1007/s00586-002-0464-0; Hernandez-Reif M, 2001, INT J NEUROSCI, V106, P131, DOI 10.3109/00207450109149744; Kumnerddee Wipoo, 2009, J Med Assoc Thai, V92 Suppl 1, pS117; LI KH, 1991, J AM STAT ASSOC, V86, P1065, DOI 10.2307/2290525; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Little P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a884; PATRICK DL, 1995, SPINE, V20, P1899, DOI 10.1097/00007632-199509000-00011; Preyde M, 2000, CAN MED ASSOC J, V162, P1815; Riess PW, 1986, VITAL HLTH STAT; Rubin D., 1987, MULTIPLE IMPUTATION, DOI [10.1002/9780470316696, DOI 10.1002/9780470316696]; Van Buuren S, 1999, STAT MED, V18, P681, DOI 10.1002/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.3.CO;2-I; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wolsko PM, 2003, SPINE, V28, P292, DOI 10.1097/00007632-200302010-00018; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	22	82	85	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 5	2011	155	1					1	+		10.7326/0003-4819-155-1-201107050-00002	http://dx.doi.org/10.7326/0003-4819-155-1-201107050-00002			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	788MA	21727288				2023-01-03	WOS:000292447800001
J	Maughan, TS; Adams, RA; Smith, CG; Meade, AM; Seymour, MT; Wilson, RH; Idziaszczyk, S; Harris, R; Fisher, D; Kenny, SL; Kay, E; Mitchell, JK; Madi, A; Jasani, B; James, MD; Bridgewater, J; Kennedy, MJ; Claes, B; Lambrechts, D; Kaplan, R; Cheadle, JP				Maughan, Timothy S.; Adams, Richard A.; Smith, Christopher G.; Meade, Angela M.; Seymour, Matthew T.; Wilson, Richard H.; Idziaszczyk, Shelley; Harris, Rebecca; Fisher, David; Kenny, Sarah L.; Kay, Edward; Mitchell, Jenna K.; Madi, Ayman; Jasani, Bharat; James, Michelle D.; Bridgewater, John; Kennedy, M. John; Claes, Bart; Lambrechts, Diether; Kaplan, Richard; Cheadle, Jeremy P.		MRC COIN Trial Investigators	Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; MUTATION STATUS; LUNG-CANCER; PANITUMUMAB; KRAS; FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN; GEFITINIB; SURVIVAL	Background In the Medical Research Council (MRC) COIN trial, the epidermal growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard chemotherapy in first-line treatment of advanced colorectal cancer with the aim of assessing effect on overall survival. Methods In this randomised controlled trial, patients who were fit for but had not received previous chemotherapy for advanced colorectal cancer were randomly assigned to oxaliplatin and fluoropyrimidine chemotherapy (arm A), the same combination plus cetuximab (arm B), or intermittent chemotherapy (arm C). The choice of fluoropyrimidine therapy (capecitabine or infused fluouroracil plus leucovorin) was decided before randomisation. Randomisation was done centrally (via telephone) by the MRC Clinical Trials Unit using minimisation. Treatment allocation was not masked. The comparison of arms A and C is described in a companion paper. Here, we present the comparison of arm A and B, for which the primary outcome was overall survival in patients with KRAS wild-type tumours. Analysis was by intention to treat. Further analyses with respect to NRAS, BRAF, and EGFR status were done. The trial is registered, ISRCTN27286448. Findings 1630 patients were randomly assigned to treatment groups (815 to standard therapy and 815 to addition of cetuximab). Tumour samples from 1316 (81%) patients were used for somatic molecular analyses; 565 (43%) had KRAS mutations. In patients with KRAS wild-type tumours (arm A, n=367; arm B, n=362), overall survival did not differ between treatment groups (median survival 17.9 months [IQR 10-3-29.2] in the control group vs 17.0 months [9.4-30.1] in the cetuximab group; HR 1.04, 95% CI 0.87-1.23, p=0.67). Similarly, there was no effect on progression-free survival (8.6 months [IQR 5.0-12.5] in the control group vs 8.6 months [5.1-13-8] in the cetuximab group; HR 0-96, 0.82-1.12, p=0-60). Overall response rate increased from 57% (n=209) with chemotherapy alone to 64% (n=232) with addition of cetuximab (p=0.049). Grade 3 and higher skin and gastrointestinal toxic effects were increased with cetuximab (14 vs 114 and 67 vs 97 patients in the control group vs the cetuximab group with KRAS wild-type tumours, respectively). Overall survival differs by somatic mutation status irrespective of treatment received: BRAF mutant, 8.8 months (IQR 4.5-27.4); KRAS mutant, 14.4 months (8.5-24.0); all wild-type, 20.1 months (11.5-31.7). Interpretation This trial has not confirmed a benefit of addition of cetuximab to oxaliplatin-based chemotherapy in first-line treatment of patients with advanced colorectal cancer. Cetuximab increases response rate, with no evidence of benefit in progression-free or overall survival in KRAS wild-type patients or even in patients selected by additional mutational analysis of their tumours. The use of cetuximab in combination with oxaliplatin and capecitabine in first-fine chemotherapy in patients with widespread metastases cannot be recommended.	[Meade, Angela M.; Fisher, David; Kenny, Sarah L.; Kay, Edward; Mitchell, Jenna K.; Kaplan, Richard] MRC Clin Trials Unit, London NW1 2DA, England; [Maughan, Timothy S.; Adams, Richard A.; Smith, Christopher G.; Idziaszczyk, Shelley; Harris, Rebecca; Madi, Ayman; Jasani, Bharat; James, Michelle D.; Cheadle, Jeremy P.] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales; [Seymour, Matthew T.] St James Univ Hosp, Leeds, W Yorkshire, England; [Seymour, Matthew T.] Univ Leeds, Leeds, W Yorkshire, England; [Bridgewater, John] UCL, Inst Canc, London, England; [Kennedy, M. John] All Ireland Cooperat Oncol Res Grp, ICORG, Dublin, Ireland; [Claes, Bart; Lambrechts, Diether] Univ Louvain, VIB, Vesalius Res Ctr, Louvain, Belgium; [Wilson, Richard H.] Queens Univ Belfast, Belfast, Antrim, North Ireland	Medical Research Council Clinical Trials Unit; Cardiff University; Saint James's University Hospital; University of Leeds; University of London; University College London; All-Ireland Cooperative Oncology Research Group; Flanders Institute for Biotechnology (VIB); Queens University Belfast	Kaplan, R (corresponding author), MRC Clin Trials Unit, London NW1 2DA, England.	rk@ctu.mrc.ac.uk	Verdrengh, Evelien/H-4571-2012; Kay, Elaine/D-8539-2013; Bridgewater, John/J-5957-2018; Lambrechts, Diether/AAJ-3167-2020; Maughan, Tim/AAV-7636-2021	Lambrechts, Diether/0000-0002-3429-302X; Atherton, Philip/0000-0002-7286-046X; McDermott, Ray/0000-0002-8952-4315; Adams, Richard/0000-0003-3915-7243; Fisher, David/0000-0002-2512-2296; Tan, Li Tee/0000-0001-9333-9190; Kaplan, Richard S./0000-0002-0189-8348; Hickish, Tamas/0000-0001-6770-7279; Samuel, Leslie/0000-0002-8402-8670; Cunningham, David/0000-0001-5158-1069; Seymour, Matthew/0000-0002-2441-9629; Sebag-Montefiore, David/0000-0002-5978-9259; Azzabi, Ashraf/0000-0003-4801-9109	Cancer Research UK; Cancer Research Wales; UK Medical Research Council; Merck KGgA; UK MRC; Roche; Dako Ltd; AstraZeneca; MRC; National Cancer Research Networks; Merck; Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen); University College London Hospitals; University College London Comprehensive Biomedical Research Centre; Irish Health Research Board; Medical Research Council [MC_U122861325] Funding Source: researchfish; MRC [MC_U122861325] Funding Source: UKRI	Cancer Research UK(Cancer Research UK); Cancer Research Wales; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Merck KGgA; UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Roche(Roche Holding); Dako Ltd; AstraZeneca(AstraZeneca); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Cancer Research Networks; Merck(Merck & Company); Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen)(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT)); University College London Hospitals; University College London Comprehensive Biomedical Research Centre; Irish Health Research Board; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Funding Cancer Research UK, Cancer Research Wales, UK Medical Research Council, Merck KGgA.; TSM and RAA have received travel, accommodation, and lecture fees from Roche and Merck Serono. AMM, DE, SLK, JKM, ER, and RK are employed by the UK MRC, which is also the trial sponsor. MTS has received travel expenses and an educational grant from Roche. JB has received an honorarium payment and travel expenses for attendance at educational meetings from Merck. 131 has received consultancy fees from Dako Ltd, Roche, and AstraZeneca. MJK has received travel expenses from Amgen. CGS, SI, RH, MDJ, BC, DL, RHW, AM, and JPC all declare that they have no conflicts of interest.; We thank the 2445 patients and their families who participated in COIN; Tony Lai for use of laboratory space in the Wales Heart Research Institute, Cardiff University for the somatic mutation profiling; and Natacha Lays and Gilian Peuteman for technical support. The trial was funded through the peer-reviewed Cancer Research UK Clinical Trials Advisory and Awards Committee, the MRC, and an unrestricted educational grant from Merck kGaA. Additional support in the form of discounted products was provided by Sanofi, Wyeth, and Baxter. Data collection at UK sites was supported by staff funding from the National Cancer Research Networks. The somatic profiling was co-supported by Cancer Research Wales (CGS, PhD studentship) and Merck. BC was supported by a PhD grant of the Institute for the Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen). B was supported in part by the University College London Hospitals and University College London Comprehensive Biomedical Research Centre. MJK has received a grant from the Irish Health Research Board. In addition to the individuals named in the list of COIN Trial Investigators, we acknowledge the contributions of a large number of clinicians, research nurses, data managers, and other clinical and support staff at the participating centres.	Adams RA, 2009, BRIT J CANCER, V100, P251, DOI 10.1038/sj.bjc.6604877; Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; BOKEMEYER C, 2008, P AM SOC CLIN ONCO S, V26; Borner M, 2008, ANN ONCOL, V19, P1288, DOI 10.1093/annonc/mdn058; Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860; Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437; Kohne CH, 2002, ANN ONCOL, V13, P308, DOI 10.1093/annonc/mdf034; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; National Cancer Institute, NAT CANC I COMM TOX; National Institute for Health and Clinical Excellence, 2009, CET 1 LIN TREATM MET; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268; TVEIT K, 2011, P AM SOC CLIN ONCOL, V29; Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019	24	753	796	1	58	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 18	2011	377	9783					2103	2114		10.1016/S0140-6736(11)60613-2	http://dx.doi.org/10.1016/S0140-6736(11)60613-2			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	783XI	21641636	Green Published			2023-01-03	WOS:000292117800032
J	Tayo, BO; Teil, M; Tong, LP; Qin, HZ; Khitrov, G; Zhang, WJ; Song, QB; Gottesman, O; Zhu, XF; Pereira, AC; Cooper, RS; Bottinger, EP				Tayo, Bamidele O.; Teil, Marie; Tong, Liping; Qin, Huaizhen; Khitrov, Gregory; Zhang, Weijia; Song, Quinbin; Gottesman, Omri; Zhu, Xiaofeng; Pereira, Alexandre C.; Cooper, Richard S.; Bottinger, Erwin P.			Genetic Background of Patients from a University Medical Center in Manhattan: Implications for Personalized Medicine	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; AFRICAN-DERIVED POPULATIONS; CORONARY-ARTERY-DISEASE; PRAVASTATIN PHARMACOKINETICS; GENOTYPING ALGORITHM; SUSCEPTIBILITY LOCI; WEST AFRICANS; HAPLOTYPE MAP; AMERICANS; GWAS	Background: The rapid progress currently being made in genomic science has created interest in potential clinical applications; however, formal translational research has been limited thus far. Studies of population genetics have demonstrated substantial variation in allele frequencies and haplotype structure at loci of medical relevance and the genetic background of patient cohorts may often be complex. Methods and Findings: To describe the heterogeneity in an unselected clinical sample we used the Affymetrix 6.0 gene array chip to genotype self-identified European Americans (N = 326), African Americans (N = 324) and Hispanics (N = 327) from the medical practice of Mount Sinai Medical Center in Manhattan, NY. Additional data from US minority groups and Brazil were used for external comparison. Substantial variation in ancestral origin was observed for both African Americans and Hispanics; data from the latter group overlapped with both Mexican Americans and Brazilians in the external data sets. A pooled analysis of the African Americans and Hispanics from NY demonstrated a broad continuum of ancestral origin making classification by race/ethnicity uninformative. Selected loci harboring variants associated with medical traits and drug response confirmed substantial within-and between-group heterogeneity. Conclusion: As a consequence of these complementary levels of heterogeneity group labels offered no guidance at the individual level. These findings demonstrate the complexity involved in clinical translation of the results from genome-wide association studies and suggest that in the genomic era conventional racial/ethnic labels are of little value.	[Tayo, Bamidele O.; Tong, Liping; Cooper, Richard S.] Loyola Univ Chicago, Stritch Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL USA; [Teil, Marie; Khitrov, Gregory; Zhang, Weijia; Song, Quinbin; Gottesman, Omri; Bottinger, Erwin P.] Mt Sinai Sch Med, Charles R Bronfman Inst Personalized Med, New York, NY USA; [Qin, Huaizhen; Zhu, Xiaofeng] Case Western Univ, Dept Biostat & Epidemiol, Cleveland, OH USA; [Pereira, Alexandre C.] Univ Sao Paulo, Sch Med, Sao Paulo, Brazil	Loyola University Chicago; Icahn School of Medicine at Mount Sinai; Case Western Reserve University; Universidade de Sao Paulo	Tayo, BO (corresponding author), Loyola Univ Chicago, Stritch Sch Med, Dept Prevent Med & Epidemiol, Maywood, IL USA.	btayo@lumc.edu; erwin.bottinger@mssm.edu	Pereira, Alexandre/HHN-1038-2022; Zhu, Xiaofeng/O-6874-2019	Zhu, Xiaofeng/0000-0003-0037-411X	National Heart Lung and Blood Institute [RO1 HL53353]; Andrea and Charles Bronfman Philantropies; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053353] Funding Source: NIH RePORTER	National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Andrea and Charles Bronfman Philantropies; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	The Andrea and Charles Bronfman Philantropies (to EPB); NIH grant National Heart Lung and Blood Institute RO1 HL53353 (to RC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adeyemo A, 2010, PUBLIC HEALTH GENOMI, V13, P72, DOI 10.1159/000218711; Adeyemo A, 2010, DIABETES, V59, P1549, DOI 10.2337/db09-1252; Ashley EA, 2010, LANCET, V375, P1525, DOI 10.1016/S0140-6736(10)60452-7; Atzmon G, 2010, AM J HUM GENET, V86, P850, DOI 10.1016/j.ajhg.2010.04.015; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Behar DM, 2010, HUM MOL GENET, V19, P1816, DOI 10.1093/hmg/ddq040; Bryc K, 2010, P NATL ACAD SCI USA, V107, P8954, DOI 10.1073/pnas.0914618107; Bryc K, 2010, P NATL ACAD SCI USA, V107, P786, DOI 10.1073/pnas.0909559107; Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107; Chierici M, 2010, PHARMACOGENOMICS J, V10, P355, DOI 10.1038/tpj.2010.47; Collins F, 2010, NATURE, V464, P674, DOI 10.1038/464674a; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Falush D, 2003, GENETICS, V164, P1567; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Hamburg MA, 2010, NEW ENGL J MED, V363, P301, DOI 10.1056/NEJMp1006304; Hassanein MT, 2010, HUM MOL GENET, V19, P2907, DOI 10.1093/hmg/ddq178; Hawken SJ, 2010, HUM GENET, V128, P89, DOI 10.1007/s00439-010-0828-1; Hong H, 2010, PHARMACOGENOMICS J, V10, P364, DOI 10.1038/tpj.2010.24; Hong HX, 2010, J GENET, V89, P55, DOI 10.1007/s12041-010-0011-4; Kang SJ, 2010, HUM MOL GENET, V19, P2725, DOI 10.1093/hmg/ddq154; Kivisto KT, 2007, PHARM RES-DORDR, V24, P239, DOI 10.1007/s11095-006-9159-2; Leek JT, 2010, NAT REV GENET, V11, P733, DOI 10.1038/nrg2825; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Miclaus K, 2010, PHARMACOGENOMICS J, V10, P324, DOI 10.1038/tpj.2010.46; Miclaus K, 2010, PHARMACOGENOMICS J, V10, P336, DOI 10.1038/tpj.2010.36; Musunuru K, 2010, NATURE, V466, P714, DOI 10.1038/nature09266; *NEW YORK CIT DEP, 2004, NEW NEW YORK 2000 IM; Nishizato Y, 2003, CLIN PHARMACOL THER, V73, P554, DOI 10.1016/S0009-9236(03)00060-2; Ormond KE, 2010, LANCET, V375, P1749, DOI 10.1016/S0140-6736(10)60599-5; Perez-Andreu V, 2009, BLOOD, V113, P4977, DOI 10.1182/blood-2008-09-176222; Price AL, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0030236; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Purcell SM, 2009, NATURE, V460, P748, DOI 10.1038/nature08185; QIN H, 2010, BIOINFORMATICS; Qin HZ, 2010, BIOINFORMATICS, V26, P2961, DOI 10.1093/bioinformatics/btq560; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Rosenberg NA, 2004, MOL ECOL NOTES, V4, P137, DOI 10.1046/j.1471-8286.2003.00566.x; Rosenwaike I., 1972, POPULATION HIST NEW; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Shurin SB, 2008, NEW ENGL J MED, V358, P1061, DOI 10.1056/NEJMe0800801; Stahl EA, 2010, NAT GENET, V42, P508, DOI 10.1038/ng.582; The International HapMap Consortium, 2005, NATURE, V437, P1299, DOI DOI 10.1038/NATURE04226; Tian C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040004; Tian C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003862; Tishkoff SA, 2009, SCIENCE, V324, P1035, DOI 10.1126/science.1172257; Urban TJ, 2010, MT SINAI J MED, V77, P133, DOI 10.1002/msj.20168; Voight BF, 2010, NAT GENET, V42, P579, DOI 10.1038/ng.609; Wang S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000037; Weiss KM, 2010, EVOL ANTHROPOL, V19, P92, DOI 10.1002/evan.20261; Zhang L, 2010, PHARMACOGENOMICS J, V10, P347, DOI 10.1038/tpj.2010.27	56	42	44	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 4	2011	6	5							e19166	10.1371/journal.pone.0019166	http://dx.doi.org/10.1371/journal.pone.0019166			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	759EZ	21573225	Green Published, gold, Green Submitted			2023-01-03	WOS:000290224800016
J	[Anonymous]				[Anonymous]			PERSONAL VIEW Private alcohol detox clinics should be regulated	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2011	342								d2399	10.1136/bmj.d2399	http://dx.doi.org/10.1136/bmj.d2399			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755ON	21508046				2023-01-03	WOS:000289942900007
J	Gooren, LJ				Gooren, Louis J.			Care of Transsexual Persons	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENDER IDENTITY DISORDER; CROSS-SEX HORMONES; DSM DIAGNOSTIC-CRITERIA; TO-MALE TRANSSEXUALS; FOLLOW-UP; ADOLESCENT TRANSSEXUALS; ENDOCRINE TREATMENT; DYSPHORIC CHILDREN; REASSIGNMENT; THERAPY	A healthy and successful 40-year-old man finds it increasingly difficult to live as a male. In childhood he preferred playing with girls and recalls feeling that he should have been one. Over time he has come to regard himself more and more as a female personality inhabiting a male body. After much agonizing, he has concluded that only sex reassignment can offer the peace of mind he craves. What would you advise?	[Gooren, Louis J.] Vrije Univ Amsterdam, Med Ctr, Dept Endocrinol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam	Gooren, LJ (corresponding author), 72-1 Mool, Chiang Mai 50220, Thailand.	louisjgooren@gmail.com			Bayer Schering Pharma	Bayer Schering Pharma(Bayer AG)	Dr. Gooren reports receiving consulting fees and compensation for travel from Bayer Schering Pharma. No other potential conflict of interest relevant to this article was reported.	Allen NE, 2008, ENDOCR-RELAT CANCER, V15, P485, DOI 10.1677/ERC-07-0064; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson GL, 2004, JAMA-J AM MED ASSOC, V291, P1701, DOI 10.1001/jama.291.14.1701; ASSCHEMAN H, 2011, EUR J ENDOCRINO 0125; Bentz EK, 2010, FERTIL STERIL, V94, P2688, DOI 10.1016/j.fertnstert.2010.04.024; Cohen-Kettenis PT, 2008, J SEX MED, V5, P1892, DOI 10.1111/j.1743-6109.2008.00870.x; Cohen-Kettenis PT, 2010, ARCH SEX BEHAV, V39, P499, DOI 10.1007/s10508-009-9562-y; Cohen-Kettenis PT, 1999, J PSYCHOSOM RES, V46, P315, DOI 10.1016/S0022-3999(98)00085-3; Cohen-Kettenis PT, 1998, EUR CHILD ADOLES PSY, V7, P246, DOI 10.1007/s007870050073; CohenKettenis PT, 1997, J AM ACAD CHILD PSY, V36, P263, DOI 10.1097/00004583-199702000-00017; de Vries ALC, 2010, J AUTISM DEV DISORD, V40, P930, DOI 10.1007/s10803-010-0935-9; Delemarre-van de Waal HA, 2006, EUR J ENDOCRINOL, V155, pS131, DOI 10.1530/eje.1.02231; DEVRIES AL, 2010, J SEX MED       0714; DEVRIES AL, 2010, PSYCHIAT RES    0827; Dittrich R, 2005, EXP CLIN ENDOCR DIAB, V113, P586, DOI 10.1055/s-2005-865900; Elamin MB, 2010, CLIN ENDOCRINOL, V72, P1, DOI 10.1111/j.1365-2265.2009.03632.x; Elbers JMH, 1999, AM J PHYSIOL-ENDOC M, V276, pE317, DOI 10.1152/ajpendo.1999.276.2.E317; Elbers JMH, 2003, CLIN ENDOCRINOL, V58, P562, DOI 10.1046/j.1365-2265.2003.01753.x; Giltay EJ, 2000, J CLIN ENDOCR METAB, V85, P2913, DOI 10.1210/jc.85.8.2913; Gooren L, 2006, HORM BEHAV, V50, P589, DOI 10.1016/j.yhbeh.2006.06.011; Gooren LJ, 2008, J CLIN ENDOCR METAB, V93, P19, DOI 10.1210/jc.2007-1809; Gooren LJG, 2008, J SEX MED, V5, P765, DOI 10.1111/j.1743-6109.2007.00646.x; *H BENJ INT GEN DY, 2001, H BENJ INT GEND DYSP; Hage JJ, 2006, ANN PLAS SURG, V57, P312, DOI 10.1097/01.sap.0000221625.38212.2e; Hakimian P, 2008, BJU INT, V102, P1509, DOI 10.1111/j.1464-410X.2008.07933.x; Hembree WC, 2009, J CLIN ENDOCR METAB, V94, P3132, DOI 10.1210/jc.2009-0345; Ito K, 2007, TOHOKU J EXP MED, V212, P1, DOI 10.1620/tjem.212.1; Lawrence AA, 2003, ARCH SEX BEHAV, V32, P299, DOI 10.1023/A:1024086814364; Meyer-Bahlburg HFL, 2010, ARCH SEX BEHAV, V39, P461, DOI 10.1007/s10508-009-9532-4; Mieszczak Jakub, 2007, Pediatr Endocrinol Rev, V4 Suppl 4, P419; Monstrey S, 2009, PLAST RECONSTR SURG, V124, P510, DOI 10.1097/PRS.0b013e3181aeeb06; Mueller A, 2008, EUR J ENDOCRINOL, V159, P197, DOI 10.1530/EJE-08-0289; Murad MH, 2010, CLIN ENDOCRINOL, V72, P214, DOI 10.1111/j.1365-2265.2009.03625.x; Okabe N, 2008, PSYCHIAT RES, V157, P315, DOI 10.1016/j.psychres.2007.07.022; Perovic S, 2009, CURR OPIN UROL, V19, P571, DOI 10.1097/MOU.0b013e3283312eb3; Savic I, 2010, PROG BRAIN RES, V186, P41, DOI 10.1016/B978-0-444-53630-3.00004-X; Smith YLS, 2005, PSYCHOL MED, V35, P89, DOI 10.1017/S0033291704002776; Toorians AWFT, 2003, J CLIN ENDOCR METAB, V88, P5723, DOI 10.1210/jc.2003-030520; van Kesteren P, 1998, CLIN ENDOCRINOL, V48, P347, DOI 10.1046/j.1365-2265.1998.00396.x; vanKesteren PJ, 1996, ARCH SEX BEHAV, V25, P589, DOI 10.1007/BF02437841; vanKesteren PJM, 1997, CLIN ENDOCRINOL, V47, P337, DOI 10.1046/j.1365-2265.1997.2601068.x; Vujovic S, 2009, J SEX MED, V6, P1018, DOI 10.1111/j.1743-6109.2008.00799.x; Wallien MSC, 2008, J AM ACAD CHILD PSY, V47, P1413, DOI 10.1097/CHI.0b013e31818956b9; WENNINK JMB, 1989, CLIN ENDOCRINOL, V31, P551, DOI 10.1111/j.1365-2265.1989.tb01279.x; Weyers S, 2009, J SEX MED, V6, P752, DOI 10.1111/j.1743-6109.2008.01082.x; Zitzmann M, 2005, J CLIN ENDOCR METAB, V90, P6603, DOI 10.1210/jc.2005-0847; Zucker KJ, 2009, INT J TRANSGENDERISM, V11, P8, DOI 10.1080/15532730902799946; Zucker KJ, 2010, ARCH SEX BEHAV, V39, P477, DOI 10.1007/s10508-009-9540-4; Zucker KJ, 2004, CHILD ADOL PSYCH CL, V13, P551, DOI 10.1016/j.chc.2004.02.006	49	149	153	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2011	364	13					1251	1257		10.1056/NEJMcp1008161	http://dx.doi.org/10.1056/NEJMcp1008161			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742NO	21449788				2023-01-03	WOS:000288951300009
J	Wielinga, PY; Yakala, GK; Heeringa, P; Kleemann, R; Kooistra, T				Wielinga, Peter Y.; Yakala, Gopala K.; Heeringa, Peter; Kleemann, Robert; Kooistra, Teake			Beneficial Effects of Alternate Dietary Regimen on Liver Inflammation, Atherosclerosis and Renal Activation	PLOS ONE			English	Article							CALORIE RESTRICTION; TRANSGENIC MICE; CHOLESTEROL; DISEASE	Background: Alternate day calorie restriction (CR) has been shown to be almost as beneficial as daily CR. The question arises whether this concept is also applicable to alternating dietary composition. Objective: To seek evidence that alternating high cholesterol (HC) - cholesterol-free (CON) Western diet can effectively diminish hepatic and renal inflammation and cardiovascular risk factors as compared with daily HC-supplemented Western diet. Design: Four groups of ApoE*3Leiden mice, a humanized model for atherosclerosis, were subjected to different feeding treatments for 16 weeks. Mice were fed CON diet; CON diet with 1% w/w cholesterol (HC); alternate (ALT) diet regimen of CON (4 days) and HC (3 days); or CON diet supplemented with 0.43% (w/w) cholesterol (MC), with overall dietary cholesterol intake equal to ALT. Plasma was analyzed for cardiovascular risk factors, aorta for atherosclerotic lesion formation, and liver and kidney for inflammation. Results: ALT diet but not MC was almost as effective as daily CON feeding in preventing disease development. Compared to HC, the ALT group showed 62% lower hepatic nuclear factor kappa B (NF-kappa B) activity (P < 0.001), a reduction of the circulating inflammatory markers E-selectin (-20%; P < 0.05), vascular cell adhesion molecule 1 (VCAM-1; -15%; P < 0.05) and Serum Amyloid A (SAA; -31%; P < 0.05), smaller atherosclerotic lesion sizes (-51%; 46497 +/- 10791 mu m(2) vs. 94664 +/- 16470 mu m(2); P < 0.05) and diminished renal expression of specific inflammation and activation markers (VCAM-1, -27%; P < 0.05; monocyte chemotactic protein-1 (MCP-1); -37%; P < 0.01). Conclusion: Alternate HC-CON feeding reproduced most of the beneficial effects of daily cholesterol-free diet, including strongly diminished hepatic, vascular and renal activation and inflammation; also atherosclerosis was reduced by half as compared to HC, albeit still higher compared to the CON group.	[Wielinga, Peter Y.; Kleemann, Robert; Kooistra, Teake] TNO Metab Hlth Res, Leiden, Netherlands; [Yakala, Gopala K.; Heeringa, Peter] Univ Groningen, Med Biol Sect, Dept Pathol & Med Biol, Univ Med Ctr Groningen, Groningen, Netherlands; [Wielinga, Peter Y.; Yakala, Gopala K.; Heeringa, Peter; Kleemann, Robert] Top Inst Food & Nutr, Wageningen, Netherlands	Netherlands Organization Applied Science Research; University of Groningen; Top Institute Food & Nutrition	Wielinga, PY (corresponding author), TNO Metab Hlth Res, Leiden, Netherlands.	Peter.Wielinga@tno.nl	Heeringa, Peter/A-6008-2009	Heeringa, Peter/0000-0001-8684-763X	Top Institute Food and Nutrition [A1004]; TNO	Top Institute Food and Nutrition; TNO	The study was funded by the Top Institute Food and Nutrition (www.tifn.nl), research program A1004 and the TNO (www.tno.nl), research program Personalized Health. PYW, GKY, PH and RK are employed by Top Institute Food and Nutrition and PYW, RK and TK by TNO-BioSciences. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Fontana L, 2008, EUR J CARDIOV PREV R, V15, P3, DOI 10.1097/HJR.0b013e3282f17bd4; Hotamisligil GS, 2010, NAT MED, V16, P396, DOI 10.1038/nm0410-396; Hu FB, 2002, JAMA-J AM MED ASSOC, V288, P2569, DOI 10.1001/jama.288.20.2569; Jiang T, 2005, J AM SOC NEPHROL, V16, P2385, DOI 10.1681/ASN.2004080701; Kleemann R, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r200; Kleemann R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008817; Kooistra T, 2006, ARTERIOSCL THROM VAS, V26, P2322, DOI 10.1161/01.ATV.0000238348.05028.14; Li YK, 2005, J BIOL CHEM, V280, P21763, DOI 10.1074/jbc.M501759200; Rein D, 2006, J NUTR, V136, P2331, DOI 10.1093/jn/136.9.2331; Turk MW, 2009, J CARDIOVASC NURS, V24, P58, DOI 10.1097/01.JCN.0000317471.58048.32; VANLIEW JB, 1992, AM J PHYSIOL, V263, pF554, DOI 10.1152/ajprenal.1992.263.3.F554; Varady KA, 2008, FASEB J, V22, P2090, DOI 10.1096/fj.07-098178; Varady KA, 2010, J NUTR BIOCHEM, V21, P188, DOI 10.1016/j.jnutbio.2008.11.001; Varady KA, 2009, AM J CLIN NUTR, V90, P1138, DOI 10.3945/ajcn.2009.28380; Verschuren L, 2005, ARTERIOSCL THROM VAS, V25, P161, DOI 10.1161/01.ATV.0000148866.29829.19; Wiggins JE, 2010, J AM SOC NEPHROL, V21, P587, DOI 10.1681/ASN.2009060663; Zadelaar S, 2007, ARTERIOSCL THROM VAS, V27, P1706, DOI 10.1161/ATVBAHA.107.142570	17	24	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2011	6	3							e18432	10.1371/journal.pone.0018432	http://dx.doi.org/10.1371/journal.pone.0018432			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	743YU	21483792	Green Published, Green Submitted, gold			2023-01-03	WOS:000289057200077
J	Schulzke, JD; Andres, S; Amasheh, M; Fromm, A; Gunzel, D				Schulzke, Joerg D.; Andres, Susanne; Amasheh, Maren; Fromm, Anja; Guenzel, Dorothee			Anti-Diarrheal Mechanism of the Traditional Remedy Uzara via Reduction of Active Chloride Secretion	PLOS ONE			English	Article							EPITHELIAL-CELL LINE; CL-SECRETION; COLON; TRANSPORT; BARRIER; STIMULATION; CARBACHOL; CHANNEL; CHOLERA; CONDUCTANCE	Background and Purpose: The root extract of the African Uzara plant is used in traditional medicine as anti-diarrheal drug. It is known to act via inhibition of intestinal motility, but malabsorptive or antisecretory mechanisms are unknown yet. Experimental Approach: HT-29/B6 cells and human colonic biopsies were studied in Ussing experiments in vitro. Uzara was tested on basal as well as on forskolin- or cholera toxin-induced Cl(-) secretion by measuring short-circuit current (I(SC)) and tracer fluxes of (22)Na(+) and (36)Cl(-). Para- and transcellular resistances were determined by two-path impedance spectroscopy. Enzymatic activity of the Na(+)/K(+)-ATPase and intracellular cAMP levels (ELISA) were measured. Key Results: In HT-29/B6 cells, Uzara inhibited forskolin- as well as cholera toxin-induced I(SC) within 60 minutes indicating reduced active chloride secretion. Similar results were obtained in human colonic biopsies pre-stimulated with forskolin. In HT-29/B6, the effect of Uzara on the forskolin- induced I(SC) was time- and dose-dependent. Analyses of the cellular mechanisms of this Uzara effect revealed inhibition of the Na(+)/K(+)-ATPase, a decrease in forskolin-induced cAMP production and a decrease in paracellular resistance. Tracer flux experiments indicate that the dominant effect is the inhibition of the Na(+)/K(+)-ATPase. Conclusion and Implications: Uzara exerts anti-diarrheal effects via inhibition of active chloride secretion. This inhibition is mainly due to an inhibition of the Na(+)/K(+)-ATPase and to a lesser extent to a decrease in intracellular cAMP responses and paracellular resistance. The results imply that Uzara is suitable for treating acute secretory diarrhea.	[Schulzke, Joerg D.; Andres, Susanne; Amasheh, Maren] Free Univ Berlin, Charite, Sect Gen Med & Nutr, Dept Gastroenterol, D-1000 Berlin, Germany; [Schulzke, Joerg D.; Andres, Susanne; Amasheh, Maren; Fromm, Anja; Guenzel, Dorothee] Humboldt Univ, Berlin, Germany; [Fromm, Anja; Guenzel, Dorothee] Free Univ Berlin, Charite, Inst Clin Physiol, D-1000 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schulzke, JD (corresponding author), Free Univ Berlin, Charite, Sect Gen Med & Nutr, Dept Gastroenterol, D-1000 Berlin, Germany.	joerg.schulzke@charite.de		Gunzel, Dorothee/0000-0002-7998-7164; Fromm, Anja/0000-0003-4091-9612	German Research Foundation; DFG Research Unit [FOR 721/2]	German Research Foundation(German Research Foundation (DFG)); DFG Research Unit(German Research Foundation (DFG))	This study was funded by the German Research Foundation, DFG Research Unit FOR 721/2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbott AJ, 1998, BIOCHEM BIOPH RES CO, V251, P256, DOI 10.1006/bbrc.1998.9453; BAJNATH RB, 1991, J MEMBRANE BIOL, V122, P239, DOI 10.1007/BF01871424; BRAYDEN DJ, 1993, AM J PHYSIOL, V264, pG325, DOI 10.1152/ajpgi.1993.264.2.G325; BRIDGES RJ, 1983, N-S ARCH PHARMACOL, V323, P355, DOI 10.1007/BF00512476; BROWN L, 1983, BIOCHEM PHARMACOL, V32, P2767, DOI 10.1016/0006-2952(83)90090-4; Desjeux JF, 1997, BAILLIERE CLIN GASTR, V11, P509, DOI 10.1016/S0950-3528(97)90029-4; DHARMSATHAPHORN K, 1986, J CLIN INVEST, V77, P348, DOI 10.1172/JCI112311; Epple HJ, 1997, PFLUG ARCH EUR J PHY, V433, P638, DOI 10.1007/s004240050325; Flores CA, 2007, J PHYSIOL-LONDON, V583, P705, DOI 10.1113/jphysiol.2007.134387; Gessner O, 1930, N-S ARCH EX PATH PH, V148, P353; Ghorbani M, 1997, PLANTA MED, V63, P343, DOI 10.1055/s-2006-957697; KIMBERG DV, 1971, J CLIN INVEST, V50, P1218, DOI 10.1172/JCI106599; KREUSEL KM, 1991, AM J PHYSIOL, V261, pC574, DOI 10.1152/ajpcell.1991.261.4.C574; Krug SM, 2009, BIOPHYS J, V97, P2202, DOI 10.1016/j.bpj.2009.08.003; Kunzelmann K, 2002, PHYSIOL REV, V82, P245, DOI 10.1152/physrev.00026.2001; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; Mall M, 1998, AM J PHYSIOL-GASTR L, V275, pG1274, DOI 10.1152/ajpgi.1998.275.6.G1274; Mandal A, 2008, AM J PHYSIOL-CELL PH, V295, pC100, DOI 10.1152/ajpcell.90636.2007; Preston P, 2010, J BIOL CHEM, V285, P7165, DOI 10.1074/jbc.M109.047829; Raymond-Hamet, 1930, CR HEBD ACAD SCI, V190, P821; RITTER A, 2006, INT J CLIN PHARM TH, V44, P529; Rosenthal R, 2010, J CELL SCI, V123, P1913, DOI 10.1242/jcs.060665; SADRZADEH SMH, 1993, J PHARMACOL TOXICOL, V30, P103, DOI 10.1016/1056-8719(93)90013-5; SCHMIEDL S, 2006, INT J CLIN PHARM TH, V44, P526; Schmitz H, 2002, AIDS, V16, P983, DOI 10.1097/00002030-200205030-00004; Schulz V., 2004, RATIONAL PHYTOTHERAP, P1; SMITH PL, 1986, AM J PHYSIOL, V250, pG44, DOI 10.1152/ajpgi.1986.250.1.G44; Stockmann M, 1998, AIDS, V12, P43, DOI 10.1097/00002030-199801000-00006; STRABEL D, 1995, EUR J PHARMACOL, V274, P181, DOI 10.1016/0014-2999(94)00728-P; Thurmann PA, 2004, INT J CLIN PHARM TH, V42, P281; van Wyk BE, 2008, J ETHNOPHARMACOL, V119, P342, DOI 10.1016/j.jep.2008.05.029; WEYMER A, 1985, J CLIN INVEST, V76, P1828, DOI 10.1172/JCI112175; Zeissig S, 2004, GUT, V53, P1295, DOI 10.1136/gut.2003.036632	33	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2011	6	3							e18107	10.1371/journal.pone.0018107	http://dx.doi.org/10.1371/journal.pone.0018107			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	743YK	21479205	Green Published, Green Submitted, gold			2023-01-03	WOS:000289055700026
J	Chougule, MB; Patel, AR; Jackson, T; Singh, M				Chougule, Mahavir B.; Patel, Apurva R.; Jackson, Tanise; Singh, Mandip			Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer	PLOS ONE			English	Article							CELL LUNG-CANCER; ANTICANCER ACTIVITY; LEUKEMIC-CELLS; MOUSE MODEL; APOPTOSIS; AGENTS; TUMORS; PROLIFERATION; FORMULATION; PROGRESSION	Background: The aim of this study was to investigate the anticancer activity and mechanism of action of Noscapine alone and in combination with Doxorubicin against triple negative breast cancer (TNBC). Methods: TNBC cells were pretreated with Noscapine or Doxorubicin or combination and combination index values were calculated using isobolographic method. Apoptosis was assessed by TUNEL staining. Female athymic Nu/nu mice were xenografted with MDA-MB-231 cells and the efficacy of Noscapine, Doxorubicin and combination was determined. Protein expression, immunohistochemical staining were evaluated in harvested tumor tissues. Results: Noscapine inhibited growth of MDA-MB-231 and MDA-MB-468 cells with the IC50 values of 36.16 +/- 3.76 and 42.7 +/- 4.3 mu M respectively. The CI values (<0.59) were suggestive of strong synergistic interaction between Noscapine and Doxorubicin and combination treatment showed significant increase in apoptotic cells. Noscapine showed dose dependent reduction in the tumor volumes at a dose of 150-550 mg/kg/day compared to controls. Noscapine (300 mg/kg), Doxorubicin (1.5 mg/kg) and combination treatment reduced tumor volume by 39.4 +/- 5.8, 34.2 +/- 5.7 and 82.9 +/- 4.5 percent respectively and showed decreased expression of NF-KB pathway proteins, VEGF, cell survival, and increased expression of apoptotic and growth inhibitory proteins compared to single-agent treatment and control groups. Conclusions: Noscapine potentiated the anticancer activity of Doxorubicin in a synergistic manner against TNBC tumors via inactivation of NF-KB and anti-angiogenic pathways while stimulating apoptosis. These findings suggest potential benefit for use of oral Noscapine and Doxorubicin combination therapy for treatment of more aggressive TNBC.	[Chougule, Mahavir B.] Univ Hawaii, Coll Pharm, Hilo, HI 96720 USA; [Patel, Apurva R.; Jackson, Tanise; Singh, Mandip] Florida A&M Univ, Coll Pharm, Tallahassee, FL 32307 USA	University of Hawaii System; University Hawaii Hilo; State University System of Florida; Florida A&M University	Chougule, MB (corresponding author), Univ Hawaii, Coll Pharm, Hilo, HI 96720 USA.	mandip.sachdeva@famu.edu			NIH [G12RR03020-11, 5S06GM008111-36]; NATIONAL CANCER INSTITUTE [SC1CA161676] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM008111] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors acknowledge the financial support provided by RCMI grant (G12RR03020-11) and NIGMS/MBRS award (5S06GM008111-36) from NIH. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JT, 2005, J MED CHEM, V48, P7096, DOI 10.1021/jm050674q; Anderson JT, 2005, J MED CHEM, V48, P2756, DOI 10.1021/jm0494220; Aneja R, 2006, CANCER RES, V66, P3782, DOI 10.1158/0008-5472.CAN-05-2962; Aneja R, 2006, BLOOD, V107, P2486, DOI 10.1182/blood-2005-08-3516; Aneja R, 2007, CANCER CHEMOTH PHARM, V60, P831, DOI 10.1007/s00280-007-0430-y; Aneja R, 2007, CANCER RES, V67, P3862, DOI 10.1158/0008-5472.CAN-06-4282; Aneja R, 2006, MOL CANCER THER, V5, P2366, DOI 10.1158/1535-7163.MCT-06-0205; Bandyopadhyay A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010365; Barken I, 2008, ANTICANCER RES, V28, P3701; Buzdar AU, 2003, ONCOLOGIST, V8, P335, DOI 10.1634/theoncologist.8-4-335; Chougule M, 2010, LUNG CANC; DAHLSTROM B, 1982, EUR J CLIN PHARMACOL, V22, P535, DOI 10.1007/BF00609627; Ewens A, 2006, CANCER RES, V66, P5419, DOI 10.1158/0008-5472.CAN-05-3963; Hardenbergh PH, 1999, INT J RADIAT ONCOL, V45, P69, DOI 10.1016/S0360-3016(99)00127-3; Heidari N, 2007, ANTI-CANCER DRUG, V18, P1139, DOI 10.1097/CAD.0b013e3282eea257; Hiser L, 2008, LEUKEMIA LYMPHOMA, V49, P1603, DOI 10.1080/10428190802213480; Ichite N, 2009, CLIN CANCER RES, V15, P543, DOI 10.1158/1078-0432.CCR-08-1558; Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034; Jackson T, 2008, CANCER CHEMOTH PHARM, V63, P117, DOI 10.1007/s00280-008-0720-z; Karna P, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-93; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Kawasaki H, 2001, CANCER, V91, P2026, DOI 10.1002/1097-0142(20010601)91:11<2026::AID-CNCR1228>3.0.CO;2-E; Keam B, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-203; Landen JW, 2004, CLIN CANCER RES, V10, P5187, DOI 10.1158/1078-0432.CCR-04-0360; Landen JW, 2002, CANCER RES, V62, P4109; Liu M, 2010, CANC CHEMOTHER PHARM; Mahmoudian M, 2009, RECENT PAT ANTI-CANC, V4, P92, DOI 10.2174/157489209787002524; Markman M, 2003, SUPPORT CARE CANCER, V11, P144, DOI 10.1007/s00520-002-0405-9; Menendez JA, 2001, EUR J CANCER, V37, P402, DOI 10.1016/S0959-8049(00)00408-1; Moulder S, 2008, CLIN PHARMACOL THER, V83, P26, DOI 10.1038/sj.clpt.6100449; Newcomb EW, 2008, INT J RADIAT ONCOL, V71, P1477, DOI 10.1016/j.ijrobp.2008.04.020; Ottewell PD, 2008, JNCI-J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240; Pan Q, 2003, MOL CANCER THER, V2, P617; Patlolla RR, 2010, J CONTROL RELEASE, V144, P233, DOI 10.1016/j.jconrel.2010.02.006; Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535-7163.MCT-09-0366; Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381; Stockmans G, 2008, CURR OPIN ONCOL, V20, P614, DOI 10.1097/CCO.0b013e328312efba; Sung B, 2010, CANCER RES, V70, P3259, DOI 10.1158/0008-5472.CAN-09-4230; van Zuylen L, 2001, INVEST NEW DRUG, V19, P125, DOI 10.1023/A:1010618632738; Wang SJ, 2010, CANCER LETT, V293, P99, DOI 10.1016/j.canlet.2010.01.001; Yamamoto Y, 2010, INT J CLIN ONCOL; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601; Zamorano J, 2001, INT IMMUNOL, V13, P1479, DOI 10.1093/intimm/13.12.1479; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zhou J, 2002, J BIOL CHEM, V277, P39777, DOI 10.1074/jbc.M203927200	45	82	86	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 15	2011	6	3							e17733	10.1371/journal.pone.0017733	http://dx.doi.org/10.1371/journal.pone.0017733			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	736SH	21423660	Green Published, Green Submitted, gold			2023-01-03	WOS:000288513900018
J	Pandit, B; Gartel, AL				Pandit, Bulbul; Gartel, Andrei L.			Thiazole Antibiotic Thiostrepton Synergize with Bortezomib to Induce Apoptosis in Cancer Cells	PLOS ONE			English	Article							ANTICANCER; COMBINATION; INHIBITORS; CURCUMIN	Thiazole antibiotic, thiostrepton was recently identified as proteasome inhibitor. We investigated the therapeutic potential of the combination of thiostrepton and proteasome inhibitor bortezomib (Velcade) on various human tumor cell lines. Combination of sub-lethal concentrations of thiostrepton and bortezomib induced potent apoptosis and inhibition of long-term colony formation in a wide variety of human cancer cell lines. The synergistic relationship between thiostrepton and bortezomib combination was also quantitatively demonstrated by calculating their combination index values that were much lower than 1 in all studied cell lines. The synergy between these drugs was based on their proteasome inhibitory activities, because thiostrepton modification, thiostrepton methyl ester, which did not have intact quinaldic acid ring and did not inhibit proteasome activity failed to demonstrate any synergy in combination with bortezomib.	[Pandit, Bulbul; Gartel, Andrei L.] Univ Illinois, Dept Med, Chicago, IL 60607 USA; [Gartel, Andrei L.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL USA; [Gartel, Andrei L.] Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Pandit, B (corresponding author), Univ Illinois, Dept Med, Chicago, IL 60607 USA.	agartel@uic.edu			National Institutes of Health [1RO1CA1294414, 1R21CA134615]; NATIONAL CANCER INSTITUTE [R21CA134615] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Funding was provided by National Institutes of Health grants 1RO1CA1294414 and 1R21CA134615 (A. L. Gartel). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams BK, 2004, BIOORGAN MED CHEM, V12, P3871, DOI 10.1016/j.bmc.2004.05.006; Bhat UG, 2008, CELL CYCLE, V7, P1851, DOI 10.4161/cc.7.12.6032; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005592; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Pandit B, 2011, CANCER BIOL THER, V11, P43, DOI 10.4161/cbt.11.1.13854; Pandit B, 2010, PROSTATE, V70, P825, DOI 10.1002/pros.21116; Park J, 2008, MOL ONCOL, V2, P317, DOI 10.1016/j.molonc.2008.09.006; Schoof S, 2010, ANGEW CHEM INT EDIT, V49, P3317, DOI 10.1002/anie.200906988; Shirley RB, 2005, NEOPLASIA, V7, P1104, DOI 10.1593/neo.05520	9	24	24	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2011	6	2							e17110	10.1371/journal.pone.0017110	http://dx.doi.org/10.1371/journal.pone.0017110			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	723CC	21365012	Green Published, Green Submitted, gold			2023-01-03	WOS:000287482800026
J	MacTavish, H; Diallo, JS; Huang, BC; Stanford, M; Le Boeuf, F; De Silva, N; Cox, J; Simmons, JG; Guimond, T; Falls, T; McCart, AJ; Atkins, H; Breitbach, C; Kirn, D; Thorne, S; Bell, JC				MacTavish, Heather; Diallo, Jean-Simon; Huang, Baocheng; Stanford, Marianne; Le Boeuf, Fabrice; De Silva, Naomi; Cox, Julie; Simmons, John Graydon; Guimond, Tanya; Falls, Theresa; McCart, Andrea J.; Atkins, Harry; Breitbach, Caroline; Kirn, David; Thorne, Stephen; Bell, John C.			Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors	PLOS ONE			English	Article							INNATE ANTIVIRAL RESPONSE; TUMOR-SPECIFIC DEFECTS; T-CELL LYMPHOMA; TRICHOSTATIN-A; GENE-EXPRESSION; IN-VITRO; CANCER; PROTEIN; AGENTS; POXVIRUS	Histone deacetylase inhibitors (HDI) dampen cellular innate immune response by decreasing interferon production and have been shown to increase the growth of vesicular stomatitis virus and HSV. As attenuated tumour-selective oncolytic vaccinia viruses (VV) are already undergoing clinical evaluation, the goal of this study is to determine whether HDI can also enhance the potency of these poxviruses in infection-resistant cancer cell lines. Multiple HDIs were tested and Trichostatin A (TSA) was found to potently enhance the spread and replication of a tumour selective vaccinia virus in several infection-resistant cancer cell lines. TSA significantly decreased the number of lung metastases in a syngeneic B16F10LacZ lung metastasis model yet did not increase the replication of vaccinia in normal tissues. The combination of TSA and VV increased survival of mice harbouring human HCT116 colon tumour xenografts as compared to mice treated with either agent alone. We conclude that TSA can selectively and effectively enhance the replication and spread of oncolytic vaccinia virus in cancer cells.	[MacTavish, Heather; Diallo, Jean-Simon; Stanford, Marianne; Le Boeuf, Fabrice; De Silva, Naomi; Cox, Julie; Simmons, John Graydon; Guimond, Tanya; Falls, Theresa; Atkins, Harry; Bell, John C.] Ottawa Hosp, Ctr Canc Therapeut, Res Inst, Ottawa, ON, Canada; [MacTavish, Heather; Diallo, Jean-Simon; Stanford, Marianne; Le Boeuf, Fabrice; De Silva, Naomi; Cox, Julie; Simmons, John Graydon; Atkins, Harry; Bell, John C.] Univ Ottawa, Ottawa, ON, Canada; [Huang, Baocheng; Thorne, Stephen] Univ Pittsburgh, Dept Surg, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA USA; [Huang, Baocheng; Thorne, Stephen] Univ Pittsburgh, Dept Immunol, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA USA; [Breitbach, Caroline; Kirn, David; Thorne, Stephen; Bell, John C.] Jennerex Biotherapeut Ltd, San Francisco, CA USA; [McCart, Andrea J.] Toronto Gen Res Inst, Div Expt Therapeut, Toronto, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	MacTavish, H (corresponding author), Ottawa Hosp, Ctr Canc Therapeut, Res Inst, Ottawa, ON, Canada.	jbell@ohri.ca	Falls, Theresa/GWZ-9829-2022; Diallo, Jean-Simon/G-4465-2017	Falls, Theresa/0000-0001-5995-9118; Diallo, Jean-Simon/0000-0002-4862-2795; Stanford, Marianne/0000-0003-0432-3707	Terry Fox Foundation; Ottawa Regional Cancer Foundation; FRSQ; CIHR; OGSST; Ontario Institute for Cancer Research; Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the Fonds de la recherche en sante du Quebec (FRSQ)	Terry Fox Foundation; Ottawa Regional Cancer Foundation; FRSQ(Fonds de la Recherche en Sante du Quebec); CIHR(Canadian Institutes of Health Research (CIHR)); OGSST; Ontario Institute for Cancer Research; Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec)	This study was supported by grants to JB and HA from the Terry Fox Foundation and the Ottawa Regional Cancer Foundation; JSD is a recipient of an FRSQ post-doctoral fellowship. FB is a recipient of a CIHR post-doctoral fellowship. HM is supported by an OGSST studentship. JB is supported by the Ontario Institute for Cancer Research. JB, DK, ST, and CB are affiliated with or employed by Jennerex Biotherapeutics. With the exception of JB and ST who are affiliated with Jennerex Biotherapeutics, the funders had no role in study design, data collection and analysis, or decision to publish.; We would like to thank Dr. Anne-Marie Mes-Masson for kindly providing the normal ovarian cell lines. To this end, tumor banking was supported by the Banque de tissus et de donnees of the Reseau de recherche sur le cancer of the Fonds de la recherche en sante du Quebec (FRSQ), affiliated to the Canadian Tumor Repository Network (CTRNet). We would also like to thank Dominique Vaillant and Stefanie Reid for their technical assistance.	Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166; Alcami A, 2000, J VIROL, V74, P11230, DOI 10.1128/JVI.74.23.11230-11239.2000; Arsenio J, 2008, VIROLOGY, V377, P124, DOI 10.1016/j.virol.2008.04.014; Batty N, 2009, CANCER LETT, V280, P192, DOI 10.1016/j.canlet.2009.03.013; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Chang HM, 2004, P NATL ACAD SCI USA, V101, P9578, DOI 10.1073/pnas.0400567101; CHOU TC, 1977, J BIOL CHEM, V252, P6438; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67; Dunn GP, 2006, NAT REV IMMUNOL, V6, P836, DOI 10.1038/nri1961; Genin P, 2003, J VIROL, V77, P7113, DOI 10.1128/JVI.77.12.7113-7119.2003; Kirn DH, 2007, PLOS MED, V4, P2001, DOI 10.1371/journal.pmed.0040353; Kirn DH, 2009, NAT REV CANCER, V9, P64, DOI 10.1038/nrc2545; Kirstein JM, 2009, CLIN EXP METASTAS, V26, P121, DOI 10.1007/s10585-008-9221-z; Liu TC, 2008, MOL THER, V16, P1637, DOI 10.1038/mt.2008.143; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; McCart JA, 2001, CANCER RES, V61, P8751; Mehnert JM, 2007, CANCER J, V13, P23, DOI 10.1097/PPO.0b013e31803c72ba; Meng XZ, 2009, J VIROL, V83, P10627, DOI 10.1128/JVI.01260-09; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moreira JMA, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-30; Naik S, 2009, EXPERT OPIN BIOL TH, V9, P1163, DOI 10.1517/14712590903170653; Nguyen TLA, 2008, P NATL ACAD SCI USA, V105, P14981, DOI 10.1073/pnas.0803988105; Nusinzon I, 2006, MOL CELL BIOL, V26, P3106, DOI 10.1128/MCB.26.8.3106-3113.2006; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155; Parato KA, 2005, NAT REV CANCER, V5, P965, DOI 10.1038/nrc1750; Park BH, 2008, LANCET ONCOL, V9, P533, DOI 10.1016/S1470-2045(08)70107-4; Shen YQ, 2005, MOL THER, V11, P180, DOI 10.1016/j.ymthe.2004.10.015; Stanford MM, 2008, MOL THER, V16, P52, DOI 10.1038/sj.mt.6300348; Stojdl DF, 2003, CANCER CELL, V4, P263, DOI 10.1016/S1535-6108(03)00241-1; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Sun WH, 1998, BLOOD, V91, P570, DOI 10.1182/blood.V91.2.570.570_570_576; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; Thorne SH, 2007, J CLIN INVEST, V117, P3350, DOI 10.1172/JCI32727; Vanhaecke T, 2004, CURR MED CHEM, V11, P1629, DOI 10.2174/0929867043365099; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vlasakova J, 2007, BLOOD, V109, P1373, DOI 10.1182/blood-2006-02-003418; Wang LQ, 2009, NAT REV DRUG DISCOV, V8, P969, DOI 10.1038/nrd3031; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; XU B, 1994, BLOOD, V84, P1942; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang ZN, 2005, ANN NY ACAD SCI, V1056, P69, DOI 10.1196/annals.1352.005	43	48	51	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 30	2010	5	12							e14462	10.1371/journal.pone.0014462	http://dx.doi.org/10.1371/journal.pone.0014462			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	701DD	21283510	Green Accepted, gold, Green Published, Green Submitted			2023-01-03	WOS:000285793600005
J	Pipeling, MR; Fan, E				Pipeling, Matthew R.; Fan, Eddy			Therapies for Refractory Hypoxemia in Acute Respiratory Distress Syndrome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE LUNG INJURY; FREQUENCY OSCILLATORY VENTILATION; INHALED NITRIC-OXIDE; EXTRACORPOREAL MEMBRANE-OXYGENATION; END-EXPIRATORY PRESSURE; MECHANICAL VENTILATION; RECRUITMENT MANEUVERS; CLINICAL-TRIAL; TIDAL VOLUME; OUTCOMES	Acute respiratory distress syndrome (ARDS) is a common and severe form of acute lung injury, resulting from both direct (eg, pneumonia) and indirect (eg, sepsis) pulmonary insults. It is a common cause of admission to the intensive care unit due to hypoxemic respiratory failure requiring mechanical ventilation, and is associated with significant morbidity and mortality. In some patients, ARDS leads to the development of life-threatening refractory hypoxemia. In these patients, physicians may consider a number of therapies (eg, recruitment maneuvers, prone positioning, inhaled nitric oxide, high-frequency oscillatory ventilation, extracorporeal membrane oxygenation) to alleviate hypoxemia in patients unable to maintain reasonable oxygenation while being supported with conventional mechanical ventilation. Although these strategies have demonstrated improved oxygenation with their use, their impact on patient-important outcomes (eg, mortality) remains unproven. However, in the minority of patients with ARDS and refractory hypoxemia, institution of these therapies may be considered on a case-by-case basis. Future studies are needed to elucidate the efficacy of these therapies on outcomes in patients with severe ARDS and refractory hypoxemia. JAMA. 2010; 304(22): 2521-2527	[Pipeling, Matthew R.; Fan, Eddy] Johns Hopkins Univ, Johns Hopkins Med Inst, Div Pulm & Crit Care Med, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine	Fan, E (corresponding author), Toronto Western Hosp, 399 Bathurst St,2MCL-411H, Toronto, ON M5T 2S8, Canada.	eddy.fan@uhn.on.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr Fan is supported by a fellowship award from the Canadian Institutes of Health Research.	Adhikari NKJ, 2007, BMJ-BRIT MED J, V334, P779, DOI 10.1136/bmj.39139.716794.55; ARDS Clinical Trials Network, 2003, CRIT CARE MED, V31, P2592, DOI 10.1097/01.CCM.0000090001.91640.45; ASHBAUGH DG, 1967, LANCET, V2, P319; Bartlett RH, 2000, JAMA-J AM MED ASSOC, V283, P904, DOI 10.1001/jama.283.7.904; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bollen CW, 2005, CRIT CARE, V9, pR430, DOI 10.1186/cc3737; Briel M, 2010, JAMA-J AM MED ASSOC, V303, P865, DOI 10.1001/jama.2010.218; Broome M, 2008, ANN THORAC SURG, V86, P1357, DOI 10.1016/j.athoracsur.2008.03.053; Brower RG, 2004, NEW ENGL J MED, V351, P327; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Christie JD, 2009, J HEART LUNG TRANSPL, V28, P1031, DOI 10.1016/j.healun.2009.08.004; Davies A, 2009, JAMA-J AM MED ASSOC, V302, P1888, DOI 10.1001/jama.2009.1535; Dellinger RP, 1998, CRIT CARE MED, V26, P15, DOI 10.1097/00003246-199801000-00011; Derdak S, 2002, AM J RESP CRIT CARE, V166, P801, DOI 10.1164/rccm.2108052; Diaz JV, 2010, CRIT CARE MED, V38, P1644, DOI 10.1097/CCM.0b013e3181e795ee; DRAZEN JM, 1984, PHYSIOL REV, V64, P505, DOI 10.1152/physrev.1984.64.2.505; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fan E, 2005, JAMA-J AM MED ASSOC, V294, P2889, DOI 10.1001/jama.294.22.2889; Fan E, 2006, CLIN CHEST MED, V27, P615, DOI 10.1016/j.ccm.2006.06.008; Fan E, 2008, AM J RESP CRIT CARE, V178, P1156, DOI 10.1164/rccm.200802-335OC; Ferguson ND, 2005, CRIT CARE MED, V33, P479, DOI 10.1097/01.CCM.0000155785.23200.9E; Fischer S, 2006, J THORAC CARDIOV SUR, V131, P719, DOI 10.1016/j.jtcvs.2005.10.050; Fort P, 1997, CRIT CARE MED, V25, P937, DOI 10.1097/00003246-199706000-00008; Gattinoni L, 2001, NEW ENGL J MED, V345, P568, DOI 10.1056/NEJMoa010043; Gerlach H, 2003, AM J RESP CRIT CARE, V167, P1008, DOI 10.1164/rccm.2108121; Griffiths MJD, 2005, NEW ENGL J MED, V353, P2683, DOI 10.1056/NEJMra051884; Guerin C, 2004, JAMA-J AM MED ASSOC, V292, P2379, DOI 10.1001/jama.292.19.2379; Hager DN, 2007, CRIT CARE MED, V35, P1522, DOI 10.1097/01.CCM.0000266586.04676.55; Jackson A, 2008, J HEART LUNG TRANSPL, V27, P348, DOI 10.1016/j.healun.2007.12.006; Kahn JM, 2006, NEW ENGL J MED, V355, P41, DOI 10.1056/NEJMsa053993; Lundin S, 1999, INTENS CARE MED, V25, P911, DOI 10.1007/s001340050982; Mancebo J, 2006, AM J RESP CRIT CARE, V173, P1233, DOI 10.1164/rccm.200503-353OC; Meade MO, 2008, RESP CARE, V53, P1441; Meade MO, 2008, JAMA-J AM MED ASSOC, V299, P637, DOI 10.1001/jama.299.6.637; Mehta S, 2001, CRIT CARE MED, V29, P1360, DOI 10.1097/00003246-200107000-00011; Mercat A, 2008, JAMA-J AM MED ASSOC, V299, P646, DOI 10.1001/jama.299.6.646; Michael JR, 1998, AM J RESP CRIT CARE, V157, P1372, DOI 10.1164/ajrccm.157.5.96-10089; MORRIS AH, 1994, AM J RESP CRIT CARE, V149, P295, DOI 10.1164/ajrccm.149.2.8306022; MUSCEDERE JG, 1994, AM J RESP CRIT CARE, V149, P1327, DOI 10.1164/ajrccm.149.5.8173774; Oczenski W, 2004, ANESTHESIOLOGY, V101, P620, DOI 10.1097/00000542-200409000-00010; Papazian L, 2010, NEW ENGL J MED, V363, P1107, DOI 10.1056/NEJMoa1005372; Peek GJ, 2009, LANCET, V374, P1351, DOI 10.1016/S0140-6736(09)61069-2; Richard JC, 2001, AM J RESP CRIT CARE, V163, P1609, DOI 10.1164/ajrccm.163.7.2004215; Richman PS, 2006, CRIT CARE MED, V34, P1395, DOI 10.1097/01.CCM.0000215454.50964.F8; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Rubenfeld GD, 2007, CHEST, V131, P554, DOI 10.1378/chest.06-1976; Slutsky AS, 1999, CHEST, V116, p9S, DOI 10.1378/chest.116.suppl_1.9S-a; Stapleton RD, 2005, CHEST, V128, P525, DOI 10.1378/chest.128.2.525; Sud S, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2327; Sud S, 2010, INTENS CARE MED, V36, P585, DOI 10.1007/s00134-009-1748-1; Taccone P, 2009, JAMA-J AM MED ASSOC, V302, P1977, DOI 10.1001/jama.2009.1614; Taylor RW, 2004, JAMA-J AM MED ASSOC, V291, P1603, DOI 10.1001/jama.291.13.1603; Thompson BT, 2001, CHEST, V120, P1622, DOI 10.1378/chest.120.5.1622; Troncy E, 1998, AM J RESP CRIT CARE, V157, P1483, DOI 10.1164/ajrccm.157.5.9707090; Ware Lorraine B, 2005, Crit Care Med, V33, pS217, DOI 10.1097/01.CCM.0000155788.39101.7E; White DB, 2009, JAMA-J AM MED ASSOC, V302, P1905, DOI 10.1001/jama.2009.1539; ZAPOL WM, 1979, JAMA-J AM MED ASSOC, V242, P2193, DOI 10.1001/jama.242.20.2193	57	85	94	2	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	2010	304	22					2521	2527		10.1001/jama.2010.1752	http://dx.doi.org/10.1001/jama.2010.1752			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691AS	21139113				2023-01-03	WOS:000285053300026
J	Lin, JS; O'Connor, E; Whitlock, EP; Beil, TL				Lin, Jennifer S.; O'Connor, Elizabeth; Whitlock, Evelyn P.; Beil, Tracy L.			Behavioral Counseling to Promote Physical Activity and a Healthful Diet to Prevent Cardiovascular Disease in Adults: A Systematic Review for the U.S. Preventive Services Task Force	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; LIFE-STYLE INTERVENTION; CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; PRIMARY-CARE; OLDER-ADULTS; LOW-FAT; BLOOD-PRESSURE; HYPERTENSION PREVENTION; RISK-FACTORS	Background: Poor diet and lack of physical activity can worsen cardiovascular health, yet most Americans do not meet diet and physical activity recommendations. Purpose: To assist the U.S. Preventive Services Task Force in updating its previous recommendations by systematically reviewing trials of physical activity or dietary counseling to prevent cardiovascular disease. Data Sources: MEDLINE, PsycINFO, Cochrane Central Register of Controlled Trials (2001 to January 2010), experts, and existing systematic reviews. Study Selection: Two investigators independently reviewed 13 562 abstracts and 481 articles against a set of a priori inclusion criteria and critically appraised each study by using design-specific quality criteria. Data Extraction and Analysis: Data from 73 studies (109 articles) were abstracted by one reviewer and checked by a second reviewer. Random-effects meta-analyses were conducted for multiple intermediate health and behavioral outcomes. Data Synthesis: Long-term observational follow-up of intensive sodium reduction counseling showed a decrease in the incidence of cardiovascular disease; however, other direct evidence for reduction in disease morbidity is lacking. High-intensity dietary counseling, with or without physical activity counseling, resulted in changes of -0.3 to -0.7 kg/m(2) in body mass index (adiposity), -1.5 mm Hg (95% CI, -0.9 to -2.1 mm Hg) in systolic blood pressure, -0.7 mm Hg (CI, -0.6 to -0.9 mm Hg) in diastolic pressure, -0.17 mmol/L (CI, -0.09 to -0.25 mmol/L) (-6.56 mg/dL [CI, -3.47 to -9.65 mg/dL]) in total cholesterol level, and -0.13 mmol/L (CI, -0.06 to -0.21 mmol/L) (-5.02 mg/dL [CI, -2.32 to -8.11 mg/dL]) in low-density lipoprotein cholesterol level. Medium-and high-intensity counseling resulted in moderate to large changes in self-reported dietary and physical activity behaviors. Limitations: Meta-analyses for some outcomes had large statistical heterogeneity or evidence for publication bias. Only 11 trials followed outcomes beyond 12 months. Conclusion: Counseling to improve diet or increase physical activity changed health behaviors and was associated with small improvements in adiposity, blood pressure, and lipid levels.	[Lin, Jennifer S.; O'Connor, Elizabeth; Whitlock, Evelyn P.; Beil, Tracy L.] Kaiser Permanente NW, Ctr Hlth Res, Portland, OR 97227 USA	Kaiser Permanente	Lin, JS (corresponding author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA.				Agency for Healthcare Research and Quality, Rockville, Maryland [HHS-290-2007-10057-I]; Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality, Rockville, Maryland(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By the Agency for Healthcare Research and Quality, Rockville, Maryland (contract HHS-290-2007-10057-I, task order 3).; Primary Funding Source: Agency for Healthcare Research and Quality.	Aittasalo M, 2006, PREV MED, V42, P40, DOI 10.1016/j.ypmed.2005.10.003; Albert CM, 2000, NEW ENGL J MED, V343, P1355, DOI 10.1056/NEJM200011093431902; Aldana SG, 2005, J AM DIET ASSOC, V105, P371, DOI 10.1016/j.jada.2004.12.007; Aldana Steven G, 2006, Prev Chronic Dis, V3, pA05; Allen Peg, 2008, Prev Chronic Dis, V5, pA76; AMMERMAN A, 2003, COUNSELING PROMOTE H, P145; Ammerman AS, 2002, PREV MED, V35, P25, DOI 10.1006/pmed.2002.1028; Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61; ANDERSON JW, 1992, AM J CLIN NUTR, V56, P887, DOI 10.1093/ajcn/56.5.887; [Anonymous], 1990, Arch Intern Med, V150, P153, DOI 10.1001/archinte.150.1.153; Babazono A, 2007, DIS MANAG HEALTH OUT, V15, P119, DOI 10.2165/00115677-200715020-00007; BARON JA, 1990, BRIT J GEN PRACT, V40, P137; Beresford SAA, 1997, AM J PUBLIC HEALTH, V87, P610, DOI 10.2105/AJPH.87.4.610; Bernstein MA, 2002, J AM DIET ASSOC, V102, P1421, DOI 10.1016/S0002-8223(02)90315-9; Bowen D, 1996, ANN EPIDEMIOL, V6, P507, DOI 10.1016/S1047-2797(96)00072-5; Brekke HK, 2005, DIABETES RES CLIN PR, V70, P225, DOI 10.1016/j.diabres.2005.03.027; Brekke HK, 2004, J HUM NUTR DIET, V17, P513, DOI 10.1111/j.1365-277X.2004.00566.x; Carpenter RA, 2004, J NUTR EDUC BEHAV, V36, P20, DOI 10.1016/S1499-4046(06)60124-3; Castro CM, 2002, PSYCHOSOM MED, V64, P458, DOI 10.1097/00006842-200205000-00010; *CDCP PRES COUNC P, 2006, MIDC REV HLTH PEOPL; Coates RJ, 1999, AM J EPIDEMIOL, V149, P1104, DOI 10.1093/oxfordjournals.aje.a009764; Cohen J., 2013, STAT POWER ANAL BEHA; Connell CM, 2009, J APPL GERONTOL, V28, P171, DOI 10.1177/0733464808326951; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; De Vet E, 2009, INT J BEHAV NUTR PHY, V6, DOI 10.1186/1479-5868-6-11; Delichatsios HK, 2001, AM J HEALTH PROMOT, V15, P215, DOI 10.4278/0890-1171-15.4.215; Dutton GR, 2008, PREV MED, V46, P216, DOI 10.1016/j.ypmed.2007.12.012; Eakin EG, 2007, HEALTH PSYCHOL, V26, P392, DOI 10.1037/0278-6133.26.4.392; Eakin EG, 2007, AM J PREV MED, V32, P419, DOI 10.1016/j.amepre.2007.01.004; Edelman D, 2006, J GEN INTERN MED, V21, P728, DOI 10.1111/j.1525-1497.2006.00495.x; EDEN KB, 2002, CLIN COUNSELING PROM, P34; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elley CR, 2003, BRIT MED J, V326, P793, DOI 10.1136/bmj.326.7393.793; Fowles ER, 2007, CAN J NURS RES, V39, P146; Franko DL, 2008, PREV MED, V47, P369, DOI 10.1016/j.ypmed.2008.06.013; Fries E, 2005, AM J PREV MED, V28, P162, DOI 10.1016/j.amepre.2004.10.017; Giri S, 1999, JAMA-J AM MED ASSOC, V282, P1731, DOI 10.1001/jama.282.18.1731; Goldstein MG, 1999, ANN BEHAV MED, V21, P40, DOI 10.1007/BF02895032; Grandes G, 2009, ARCH INTERN MED, V169, P694, DOI 10.1001/archinternmed.2009.23; Greaney ML, 2008, GERONTOLOGIST, V48, P358, DOI 10.1093/geront/48.3.358; Green BB, 2002, AM J PREV MED, V22, P177, DOI 10.1016/S0749-3797(01)00428-7; Greene GW, 2008, GERONTOLOGIST, V48, P378, DOI 10.1093/geront/48.3.378; Halbert JA, 2000, MED J AUSTRALIA, V173, P84, DOI 10.5694/j.1326-5377.2000.tb139250.x; Halbert JA, 1999, J AM GERIATR SOC, V47, P477, DOI 10.1111/j.1532-5415.1999.tb07242.x; Hall WD, 2003, ETHNIC DIS, V13, P337; Hallqvist J, 2000, AM J EPIDEMIOL, V151, P459, DOI 10.1093/oxfordjournals.aje.a010231; Hardcastle S, 2008, PATIENT EDUC COUNS, V70, P31, DOI 10.1016/j.pec.2007.09.014; Harland J, 1999, BRIT MED J, V319, P828, DOI 10.1136/bmj.319.7213.828; Hebert Patricia R., 1995, Annals of Epidemiology, V5, P130, DOI 10.1016/1047-2797(94)00057-Z; HELLENIUS ML, 1995, QUAL LIFE RES, V4, P13, DOI 10.1007/BF00434378; HELLENIUS ML, 1993, ATHEROSCLEROSIS, V103, P81, DOI 10.1016/0021-9150(93)90042-S; HERMAN C, 2006, AM PUBL HLTH ASS 134; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hillsdon M, 2005, Cochrane Database Syst Rev, pCD003180; Hivert MF, 2007, INT J OBESITY, V31, P1262, DOI 10.1038/sj.ijo.0803572; HOLTZMAN J, 2004, EFFECTIVENESS BEHAV, P336; Hooper L, 2004, Cochrane Database Syst Rev, pCD003656; Howard BV, 2010, AM J CLIN NUTR, V91, P860, DOI 10.3945/ajcn.2009.28034; Howard BV, 2006, JAMA-J AM MED ASSOC, V295, P655, DOI 10.1001/jama.295.6.655; Institute of Medicine, 2006, DRI DIET REF INT ESS; Jeffery RW, 1999, AM J PUBLIC HEALTH, V89, P747, DOI 10.2105/AJPH.89.5.747; John JH, 2002, LANCET, V359, P1969, DOI 10.1016/S0140-6736(02)98858-6; Joint WHO/FAO Expert Consultation, 2003, WHO TECHN REP SER; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kallings LV, 2009, EUR J CARDIOV PREV R, V16, P80, DOI 10.1097/HJR.0b013e32831e953a; Kallings LV, 2008, PHYS ACTIVITY PRESCR; Katz DL, 2008, J EVAL CLIN PRACT, V14, P294, DOI 10.1111/j.1365-2753.2007.00853.x; Kerse N, 2005, J AM GERIATR SOC, V53, P1951, DOI 10.1111/j.1532-5415.2005.00466.x; Keyserling TC, 2008, PREV MED, V46, P499, DOI 10.1016/j.ypmed.2008.02.011; King AC, 2007, HEALTH PSYCHOL, V26, P718, DOI 10.1037/0278-6133.26.6.718; King AC, 2002, J GERONTOL A-BIOL, V57, pM26, DOI 10.1093/gerona/57.1.M26; Kinmonth AL, 2008, LANCET, V371, P41, DOI 10.1016/S0140-6736(08)60070-7; Kolt GS, 2007, J AM GERIATR SOC, V55, P986, DOI 10.1111/j.1532-5415.2007.01203.x; Kristal AR, 2000, PREV MED, V31, P380, DOI 10.1006/pmed.2000.0711; Kumanyika SK, 2005, J HUM HYPERTENS, V19, P33, DOI 10.1038/sj.jhh.1001774; KUMANYIKA SK, 1993, HYPERTENSION, V22, P502, DOI 10.1161/01.HYP.22.4.502; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Lawton BA, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2509; Lemmens VEPP, 2008, OBES REV, V9, P446, DOI 10.1111/j.1467-789X.2008.00468.x; Lin JS, 2010, BEHAV COUNSELING PRO; Lutz SF, 1999, J AM DIET ASSOC, V99, P705, DOI 10.1016/S0002-8223(99)00169-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; Marcus BH, 2007, HEALTH PSYCHOL, V26, P401, DOI 10.1037/0278-6133.26.4.401; Marshall AL, 2003, ANN BEHAV MED, V25, P194, DOI 10.1207/S15324796ABM2503_05; Martinson BC, 2008, PREV MED, V46, P111, DOI 10.1016/j.ypmed.2007.08.007; Martinson BC, 2010, PREV MED, V51, P37, DOI 10.1016/j.ypmed.2010.04.002; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MEINERT CL, 1989, CONTROL CLIN TRIALS, V10, pS1, DOI 10.1016/0197-2456(89)90040-8; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Moore TJ, 1999, HYPERTENSION, V34, P472, DOI 10.1161/01.HYP.34.3.472; Morey MC, 2008, J REHABIL RES DEV, V45, P31, DOI 10.1682/JRRD.2007.03.0044; Morey MC, 2009, J AM GERIATR SOC, V57, P1166, DOI 10.1111/j.1532-5415.2009.02301.x; Mosca L, 2008, CIRC-CARDIOVASC QUAL, V1, P98, DOI 10.1161/CIRCOUTCOMES.108.825786; Napolitano MA, 2006, PREV MED, V43, P447, DOI 10.1016/j.ypmed.2006.06.011; Naslund GK, 1996, J EPIDEMIOL COMMUN H, V50, P131, DOI 10.1136/jech.50.2.131; Norris SL, 2000, PREV MED, V30, P513, DOI 10.1006/pmed.2000.0673; Oldroyd JC, 2006, DIABETES RES CLIN PR, V72, P117, DOI 10.1016/j.diabres.2005.09.018; Oldroyd JC, 2001, DIABETES RES CLIN PR, V52, P29, DOI 10.1016/S0168-8227(00)00244-8; Pekmezi DW, 2009, AM J PREV MED, V37, P495, DOI 10.1016/j.amepre.2009.08.023; Physical Activity Guidelines Advisory Committee, 2008, PHYS ACT GUID ADV CO; Pinto BM, 2002, AM J PREV MED, V23, P113, DOI 10.1016/S0749-3797(02)00441-5; Pinto BM, 1998, AM J PREV MED, V15, P95, DOI 10.1016/S0749-3797(98)00043-9; Pinto BM, 2005, AM J PREV MED, V29, P247, DOI 10.1016/j.amepre.2005.06.016; Prentice RL, 2006, JAMA-J AM MED ASSOC, V295, P629, DOI 10.1001/jama.295.6.629; Prochaska JO, 2005, PREV MED, V41, P406, DOI 10.1016/j.ypmed.2004.09.050; Roderick P, 1997, BRIT J GEN PRACT, V47, P7; Sacerdote C, 2006, INT J EPIDEMIOL, V35, P409, DOI 10.1093/ije/dyi170; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Satterfield S, 1991, Ann Epidemiol, V1, P455; SHAH M, 1990, J AM DIET ASSOC, V90, P69; Sherwood Nancy E, 2008, BMC Geriatr, V8, P17, DOI 10.1186/1471-2318-8-17; Simkin-Silverman L R, 1998, Womens Health, V4, P255; Simkin-Silverman LR, 2003, ANN BEHAV MED, V26, P212, DOI 10.1207/S15324796ABM2603_06; SIMKINSILVERMAN L, 1995, PREV MED, V24, P509, DOI 10.1006/pmed.1995.1081; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; Stefanick ML, 1998, NEW ENGL J MED, V339, P12, DOI 10.1056/NEJM199807023390103; STENSEL DJ, 1994, EUR J APPL PHYSIOL O, V68, P531, DOI 10.1007/BF00599525; Stevens VJ, 2003, PREV MED, V36, P594, DOI 10.1016/S0091-7435(03)00019-7; Stewart AL, 2001, J GERONTOL A-BIOL, V56, pM465, DOI 10.1093/gerona/56.8.M465; Terrin N, 2005, J CLIN EPIDEMIOL, V58, P894, DOI 10.1016/j.jclinepi.2005.01.006; Thompson JL, 2008, AM J PREV MED, V34, P192, DOI 10.1016/j.amepre.2007.11.014; Thompson RL., 2003, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001366, 10.1002/14651858.CD001366]; Tinker LF, 2008, ARCH INTERN MED, V168, P1500, DOI 10.1001/archinte.168.14.1500; US Department of Health and Human Services, 2008, PHYS ACT GUID AM; US Department of Health and Human Services and US Department of Agriculture, 2005, DIET GUID AM; US Preventive Services Task Force, 2008, AHRQ PUBL; van der Bij AK, 2002, AM J PREV MED, V22, P120, DOI 10.1016/S0749-3797(01)00413-5; Vandelanotte C, 2005, ANN BEHAV MED, V29, P138, DOI 10.1207/s15324796abm2902_8; von Klot S, 2008, EUR HEART J, V29, P1881, DOI 10.1093/eurheartj/ehn235; Watanabe M, 2003, DIABETES CARE, V26, P3209, DOI 10.2337/diacare.26.12.3209; Wells H. F., 2008, Economic Information Bulletin - USDA Economic Research Service; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657; Williams K, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-48; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; Wister A, 2007, CAN MED ASSOC J, V177, P859, DOI 10.1503/cmaj.061059; YATES T, 2009, DIABETIC MED, V26, P17; Yates T, 2008, PATIENT EDUC COUNS, V73, P264, DOI 10.1016/j.pec.2008.06.010; Yates T, 2009, DIABETES CARE, V32, P1404, DOI 10.2337/dc09-0130; Zaza S, 2000, AM J PREV MED, V18, P27, DOI 10.1016/S0749-3797(99)00123-3	141	150	153	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	2010	153	11					736	750		10.7326/0003-4819-153-11-201012070-00007	http://dx.doi.org/10.7326/0003-4819-153-11-201012070-00007			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690KN	21135297				2023-01-03	WOS:000285003800006
J	Swartz, K				Swartz, Katherine			Sharing the Financial Responsibility of Caring for Parents	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LONG-TERM-CARE		Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Swartz, K (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	kswartz@hsph.harvard.edu						Campbell JC, 2010, HEALTH AFFAIR, V29, P87, DOI 10.1377/hlthaff.2009.0548; Commission on funding of care and support, FAIR CAR FUND REP CO; Feinberg L, AARP PUBLIC POLICY I; Kaiser Commission on Medicaid and the Uninsured, MED LONG TERM CAR SE; Karlsson M, 2010, 20102 U OSL HLTH EC; Kemper P, 2005, INQUIRY-J HEALTH CAR, V42, P335, DOI 10.5034/inquiryjrnl_42.4.335; Ritchie CS, 2011, JAMA-J AM MED ASSOC, V306, P746, DOI 10.1001/jama.2011.1163; United States Census Bureau, INT DAT BAS; Vincent GK, 2010, P251138 US DEP COMM	9	2	2	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	2011	306	7					760	761		10.1001/jama.2011.1173	http://dx.doi.org/10.1001/jama.2011.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	807LP	21846859				2023-01-03	WOS:000293900000028
J	Martel, CJM; Agger, EM; Poulsen, JJ; Jensen, TH; Andresen, L; Christensen, D; Nielsen, LP; Blixenkrone-Moller, M; Andersen, P; Aasted, B				Martel, Cyril Jean-Marie; Agger, Else Marie; Poulsen, Julie Juul; Jensen, Trine Hammer; Andresen, Lars; Christensen, Dennis; Nielsen, Lars Peter; Blixenkrone-Moller, Merete; Andersen, Peter; Aasted, Bent			CAF01 Potentiates Immune Responses and Efficacy of an Inactivated Influenza Vaccine in Ferrets	PLOS ONE			English	Article							T-CELL RESPONSES; VIRUS-INFECTION; MONOCLONAL-ANTIBODIES; PROTECTION; LIPOSOMES; ADJUVANT; DIMETHYLDIOCTADECYLAMMONIUM; LYMPHOCYTES; ACTIVATION; CHALLENGE	Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated immune responses is negligible. Recently, a cationic liposomal adjuvant (dimethyldioctadecylammonium/trehalose 6,6'-dibehenate, CAF01) was developed. CAF01 has proven to enhance both humoral and cell-mediated immune responses to a number of different experimental vaccine candidates. In this study, we compared the immune responses in ferrets to a commercially available TIV with the responses to the same vaccine mixed with the CAF01 adjuvant. Two recently circulating H1N1 viruses were used as challenge to test the vaccine efficacy. CAF01 improved the immunogenicity of the vaccine, with increased influenza-specific IgA and IgG levels. Additionally, CAF01 promoted cellular-mediated immunity as indicated by interferon-gamma expressing lymphocytes, measured by flow cytometry. CAF01 also enhanced the protection conferred by the vaccine by reducing the viral load measured in nasal washes by RT-PCR. Finally, CAF01 allowed for dose-reduction and led to higher levels of protection compared to TIV adjuvanted with a squalene emulsion. The data obtained in this human-relevant challenge model supports the potential of CAF01 in future influenza vaccines.	[Martel, Cyril Jean-Marie; Poulsen, Julie Juul; Jensen, Trine Hammer; Andresen, Lars; Blixenkrone-Moller, Merete; Aasted, Bent] Univ Copenhagen, Dept Vet Dis Biol, Fac Life Sci, Copenhagen, Denmark; [Agger, Else Marie; Christensen, Dennis; Andersen, Peter] Statens Serum Inst, Dept Infect Dis Immunol, DK-2300 Copenhagen, Denmark; [Nielsen, Lars Peter] Statens Serum Inst, Natl Influenza Lab, DK-2300 Copenhagen, Denmark	University of Copenhagen; Statens Serum Institut; Statens Serum Institut	Martel, CJM (corresponding author), Univ Copenhagen, Dept Vet Dis Biol, Fac Life Sci, Copenhagen, Denmark.	PA@ssi.dk; bas@life.ku.dk	Andresen, Lars/K-1287-2012; Christensen, Dennis/C-6378-2008; Andresen, Lars/O-2271-2019	Christensen, Dennis/0000-0003-2382-8639; Andresen, Lars/0000-0002-6362-7973; Andersen, Peter/0000-0002-5869-2551	Danish Graduate School of Immunology; Danish National Advanced Technology Foundation; FluSecure; European Commission DG SANCO [2005207]; Danish Fur Breeders' Association	Danish Graduate School of Immunology; Danish National Advanced Technology Foundation; FluSecure; European Commission DG SANCO(European CommissionEuropean Commission Joint Research Centre); Danish Fur Breeders' Association	This work has been financially supported by the Danish Graduate School of Immunology, the Danish National Advanced Technology Foundation and FluSecure. FluSecure has been made possible by contributions from the European Commission DG SANCO (Contract no. 2005207) and the 10 participating members. BA has been supported by a grant from the Danish Fur Breeders' Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aasted B, 2007, VET IMMUNOL IMMUNOP, V119, P27, DOI 10.1016/j.vetimm.2007.06.025; Agger EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003116; [Anonymous], 2005, HHS PAND INFL PLAN; Bodewes R, 2011, J VIROL, V85, P2695, DOI 10.1128/JVI.02371-10; Boni MF, 2008, VACCINE, V26, pC8, DOI 10.1016/j.vaccine.2008.04.011; Bungener L, 2008, VACCINE, V26, P2350, DOI 10.1016/j.vaccine.2008.02.063; COATES DM, 1986, J GEN VIROL, V67, P419, DOI 10.1099/0022-1317-67-3-419; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; Davidsen J, 2005, BBA-BIOMEMBRANES, V1718, P22, DOI 10.1016/j.bbamem.2005.10.011; Doherty PC, 2006, NAT IMMUNOL, V7, P449, DOI 10.1038/ni1343; Doherty PC, 2000, ANNU REV IMMUNOL, V18, P561, DOI 10.1146/annurev.immunol.18.1.561; Ellebedy AH, 2010, CLIN VACCINE IMMUNOL, V17, P1998, DOI 10.1128/CVI.00247-10; *EUR MED AG, 2009, PREP EUR PUBL ASS RE, P11601; Fedson DS, 2008, BIOLOGICALS, V36, P346, DOI 10.1016/j.biologicals.2008.07.001; Gerdil C, 2003, VACCINE, V21, P1776, DOI 10.1016/S0264-410X(03)00071-9; Guo HL, 2011, J LEUKOCYTE BIOL, V89, P189, DOI 10.1189/jlb.0610319; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; Hamada H, 2009, J IMMUNOL, V182, P3469, DOI 10.4049/jimmunol.0801814; Hehme N, 2004, VIRUS RES, V103, P163, DOI 10.1016/j.virusres.2004.02.029; Henriksen-Lacey M, 2010, J CONTROL RELEASE, V142, P180, DOI 10.1016/j.jconrel.2009.10.022; HINSHAW VS, 1981, INFECT IMMUN, V34, P354, DOI 10.1128/IAI.34.2.354-361.1981; Jones T, 2009, CURR OPIN MOL THER, V11, P337; Kistner O, 2007, VACCINE, V25, P6028, DOI 10.1016/j.vaccine.2007.05.013; Korsholm KS, 2007, IMMUNOLOGY, V121, P216, DOI 10.1111/j.1365-2567.2007.02560.x; KORSMAN S, 2006, VACCINES, P11601; Kugel D, 2009, J VIROL, V83, P3843, DOI 10.1128/JVI.02453-08; Launay O, 2008, VACCINE, V26, P4073, DOI 10.1016/j.vaccine.2008.05.035; Lindenstrom T, 2009, J IMMUNOL, V182, P8047, DOI 10.4049/jimmunol.0801592; Long BR, 2008, CLIN VACCINE IMMUNOL, V15, P120, DOI 10.1128/CVI.00357-07; Mann JFS, 2009, EXPERT REV VACCINES, V8, P103, DOI 10.1586/14760584.8.1.103; Mann JFS, 2009, VACCINE, V27, P3643, DOI 10.1016/j.vaccine.2009.03.040; Martel CJM, 2009, VET IMMUNOL IMMUNOP, V132, P109, DOI 10.1016/j.vetimm.2009.05.011; Mukherjee S, 2002, J LEUKOCYTE BIOL, V72, P921; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; Orenstein WA, 2008, AM J MED, V121, pS22, DOI 10.1016/j.amjmed.2008.05.004; Pedersen LG, 2002, VET IMMUNOL IMMUNOP, V88, P111, DOI 10.1016/S0165-2427(02)00139-3; PILLET S, 2011, VACCINE IN PRESS, P11601; Pinnamaneni S, 2003, PHARMAZIE, V58, P554; REUMAN PD, 1989, J VIROL METHODS, V24, P27, DOI 10.1016/0166-0934(89)90004-9; Rimmelzwaan GF, 2007, CURR OPIN BIOTECH, V18, P529, DOI 10.1016/j.copbio.2007.11.002; Sant AJ, 2007, EXPERT REV VACCINES, V6, P357, DOI 10.1586/14760584.6.3.357; STEBBING N, 1982, J VIROL METHODS, V5, P343, DOI 10.1016/0166-0934(82)90026-X; Subbarao K, 2007, NAT REV IMMUNOL, V7, P267, DOI 10.1038/nri2054; Tambyah PA, 2008, RESPIROLOGY, V13, pS41, DOI 10.1111/j.1440-1843.2008.01257.x; Tamura SI, 2004, JPN J INFECT DIS, V57, P236; Thomas PG, 2006, EMERG INFECT DIS, V12, P48, DOI 10.3201/eid1201.051237; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; Wack A, 2008, VACCINE, V26, P552, DOI 10.1016/j.vaccine.2007.11.054; Werninghaus K, 2009, J EXP MED, V206, P89, DOI 10.1084/jem.20081445; *WHO, 2002, RESP CDSA, P11601; Wood JM, 2002, VACCINE, V20, pB40, DOI 10.1016/S0264-410X(02)00509-1	51	23	24	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2011	6	8							e22891	10.1371/journal.pone.0022891	http://dx.doi.org/10.1371/journal.pone.0022891			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803EC	21850242	Green Published, gold, Green Submitted			2023-01-03	WOS:000293563300027
J	Geng, EH; Glidden, DV; Bwana, MB; Musinguzi, N; Emenyonu, N; Muyindike, W; Christopoulos, KA; Neilands, TB; Yiannoutsos, CT; Deeks, SG; Bangsberg, DR; Martin, JN				Geng, Elvin H.; Glidden, David V.; Bwana, Mwebesa Bosco; Musinguzi, Nicolas; Emenyonu, Nneka; Muyindike, Winnie; Christopoulos, Katerina A.; Neilands, Torsten B.; Yiannoutsos, Constantin T.; Deeks, Steven G.; Bangsberg, David R.; Martin, Jeffrey N.			Retention in Care and Connection to Care among HIV-Infected Patients on Antiretroviral Therapy in Africa: Estimation via a Sampling-Based Approach	PLOS ONE			English	Article							PATIENTS LOST; FOLLOW-UP; PROGRAMS; MORTALITY; OUTCOMES	Introduction: Current estimates of retention among HIV-infected patients on antiretroviral therapy (ART) in Africa consider patients who are lost to follow-up (LTF) as well as those who die shortly after their last clinic visit to be no longer in care and to represent limitations in access to care. Yet many lost patients may have "silently" transferred and deaths shortly after the last clinic visit more likely represent limitations in clinical care rather than access to care after initial linkage. Methods: We evaluated HIV-infected adults initiating ART from 1/1/2004 to 9/30/2007 at a clinic in rural Uganda. A representative sample of lost patients was tracked in the community to obtain updated information about care at other ART sites. Updated outcomes were incorporated with probability weights to obtain "corrected" estimates of retention for the entire clinic population. We used the competing risks approach to estimate "connection to care"-the percentage of patients accessing care over time (including those who died while in care). Results: Among 3,628 patients, 829 became lost, 128 were tracked and in 111, updated information was obtained. Of 111, 79 (71%) were alive and 35/48 (73%) of patients interviewed in person were in care and on ART. Patient retention for the clinic population assuming lost patients were not in care was 82.3%, 68.9%, and 60.1% at 1, 2 and 3 years. Incorporating updated care information from the sample of lost patients increased estimates of patient retention to 85.8% to 90.9%, 78.9% to 86.2% and 75.8% to 84.7% at the same time points. Conclusions: Accounting for "silent transfers" and early deaths increased estimates of patient retention and connection to care substantially. Deaths soon after the last clinic visit (potentially reflecting limitations in clinical effectiveness) and disconnection from care among patient who were alive each accounted for approximately half of failures of retention.	[Geng, Elvin H.; Christopoulos, Katerina A.; Deeks, Steven G.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA; [Glidden, David V.; Martin, Jeffrey N.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Bwana, Mwebesa Bosco; Musinguzi, Nicolas; Emenyonu, Nneka; Muyindike, Winnie] Mbarara Univ Sci & Technol, Dept Med, Mbarara, Uganda; [Neilands, Torsten B.] Univ Calif San Francisco, Ctr AIDS Prevent Studies, Dept Med, San Francisco, CA USA; [Yiannoutsos, Constantin T.] Indiana Univ, Dept Med, Div Biostat, Indianapolis, IN USA; [Emenyonu, Nneka; Bangsberg, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Geng, Elvin H.; Glidden, David V.; Bwana, Mwebesa Bosco; Musinguzi, Nicolas; Emenyonu, Nneka; Muyindike, Winnie; Yiannoutsos, Constantin T.; Bangsberg, David R.; Martin, Jeffrey N.] E Africa Int Epidemiol Databases Evaluate AIDS Ie, Eldoret, Kenya	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Mbarara University of Science & Technology; University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Harvard University; Harvard Medical School; Massachusetts General Hospital	Geng, EH (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, Div HIV AIDS, San Francisco, CA 94143 USA.	genge@php.ucsf.edu	Muyindike, Winnie/W-2892-2019; Glidden, David/AAD-4730-2020	Glidden, David/0000-0001-5888-1419	National Institutes of Health [K23 AI084544, U01 AI069911, R01 MH054907, P30 AI027763]; United States President's Emergency Plan for AIDS Relief (PEPFAR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027763, U01AI069911, K23AI084544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH087227, K23MH092220, R01MH054907] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); United States President's Emergency Plan for AIDS Relief (PEPFAR)(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Funding was provided by the National Institutes of Health (K23 AI084544, U01 AI069911, R01 MH054907, P30 AI027763) and the United States President's Emergency Plan for AIDS Relief (PEPFAR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Brinkhof MWG, 2008, B WORLD HEALTH ORGAN, V86, P559, DOI 10.2471/BLT.07.044248; Coviello V, 2004, STATA J, V4, P103, DOI 10.1177/1536867X0400400201; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Frangakis CE, 2001, BIOMETRICS, V57, P333, DOI 10.1111/j.0006-341X.2001.00333.x; Geng EH, 2008, JAMA-J AM MED ASSOC, V300, P506, DOI 10.1001/jama.300.5.506; Geng EH, 2010, JAIDS-J ACQ IMM DEF, V53, P405, DOI 10.1097/QAI.0b013e3181b843f0; Hare CB, 2008, CLIN INFECT DIS, V47, P421, DOI 10.1086/589867; *ICAP, 2009, ICAP NEWS        OCT; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Liechty CA, 2007, TROP MED INT HEALTH, V12, P929, DOI 10.1111/j.1365-3156.2007.01874.x; Longley N, 2008, CLIN INFECT DIS, V47, P1556, DOI 10.1086/593194; Losina E, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000173; MAKADZANGE A, 2009, E EARLY VS DELAYED A; Moore D, 2007, AIDS, V21, P713, DOI 10.1097/QAD.0b013e328013f632; Navario P, 2009, LANCET, V374, P184, DOI 10.1016/S0140-6736(09)61312-X; PRENTICE RL, 1978, BIOMETRICS, V34, P541, DOI 10.2307/2530374; Rosen S, 2007, PLOS MED, V4, P1691, DOI 10.1371/journal.pmed.0040298; Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102; van Oosterhout JJ, 2005, TROP MED INT HEALTH, V10, P464, DOI 10.1111/j.1365-3156.2005.01409.x; Wools-Kaloustian K, 2006, AIDS, V20, P41, DOI 10.1097/01.aids.0000196177.65551.ea; UGANDA DISTRICTS INF	22	72	72	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 26	2011	6	7							e21797	10.1371/journal.pone.0021797	http://dx.doi.org/10.1371/journal.pone.0021797			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	798BE	21818265	Green Published, gold, Green Submitted			2023-01-03	WOS:000293175100008
J	Gheorghiade, M; Peterson, ED				Gheorghiade, Mihai; Peterson, Eric D.			Improving Postdischarge Outcomes in Patients Hospitalized for Acute Heart Failure Syndromes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MANAGEMENT		[Gheorghiade, Mihai] Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, Chicago, IL 60611 USA; [Peterson, Eric D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA	Northwestern University; Feinberg School of Medicine; Duke University	Gheorghiade, M (corresponding author), Northwestern Univ, Feinberg Sch Med, Ctr Cardiovasc Innovat, 645 N Michigan Ave,Ste 1006, Chicago, IL 60611 USA.	m-gheorghiade@northwestern.edu	Peterson, Eric David/ABF-5033-2021					Albert NM, 2009, JAMA-J AM MED ASSOC, V302, P1658, DOI 10.1001/jama.2009.1493; Dunlay SM, 2010, EUR J HEART FAIL, V12, P367, DOI 10.1093/eurjhf/hfq019; Felker GM, 2011, NEW ENGL J MED, V364, P797, DOI 10.1056/NEJMoa1005419; Fonarow GC, 2011, CIRCULATION, V123, P1601, DOI 10.1161/CIRCULATIONAHA.110.989632; Gheorghiade M, 2006, JAMA-J AM MED ASSOC, V296, P2217, DOI 10.1001/jama.296.18.2217; Gheorghiade M, 2010, EUR J HEART FAIL, V12, P423, DOI 10.1093/eurjhf/hfq045; Gheorghiade M, 2009, JAMA-J AM MED ASSOC, V302, P2146, DOI 10.1001/jama.2009.1657; Metra M, 2010, CIRCULATION, V122, P1782, DOI 10.1161/CIRCULATIONAHA.110.982207; Pang PS, 2010, EUR HEART J, V31, P784, DOI 10.1093/eurheartj/ehq040; Shah SJ, 2008, JAMA-J AM MED ASSOC, V300, P431, DOI 10.1001/jama.300.4.431	10	35	36	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2011	305	23					2456	2457		10.1001/jama.2011.836	http://dx.doi.org/10.1001/jama.2011.836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777EB	21673297				2023-01-03	WOS:000291597300026
J	Huffman, MD; Rao, KD; Pichon-Riviere, A; Zhao, D; Harikrishnan, S; Ramaiya, K; Ajay, VS; Goenka, S; Calcagno, JI; Caporale, JE; Niu, SL; Li, Y; Liu, J; Thankappan, KR; Daivadanam, M; van Esch, J; Murphy, A; Moran, AE; Gaziano, TA; Suhrcke, M; Reddy, KS; Leeder, S; Prabhakaran, D				Huffman, Mark D.; Rao, Krishna D.; Pichon-Riviere, Andres; Zhao, Dong; Harikrishnan, S.; Ramaiya, Kaushik; Ajay, V. S.; Goenka, Shifalika; Calcagno, Juan I.; Caporale, Joaquin E.; Niu, Shaoli; Li, Yan; Liu, Jing; Thankappan, K. R.; Daivadanam, Meena; van Esch, Jan; Murphy, Adrianna; Moran, Andrew E.; Gaziano, Thomas A.; Suhrcke, Marc; Reddy, K. Srinath; Leeder, Stephen; Prabhakaran, Dorairaj			A Cross-Sectional Study of the Microeconomic Impact of Cardiovascular Disease Hospitalization in Four Low- and Middle-Income Countries	PLOS ONE			English	Article							CATASTROPHIC HEALTH EXPENDITURE; PROTECTION; CHINA	Objective: To estimate individual and household economic impact of cardiovascular disease (CVD) in selected low-and middle-income countries (LMIC). Background: Empirical evidence on the microeconomic consequences of CVD in LMIC is scarce. Methods and Findings: We surveyed 1,657 recently hospitalized CVD patients (66% male; mean age 55.8 years) from Argentina, China, India, and Tanzania to evaluate the microeconomic and functional/productivity impact of CVD hospitalization. Respondents were stratified into three income groups. Median out-of-pocket expenditures for CVD treatment over 15 month follow-up ranged from 354 international dollars (2007 INT$, Tanzania, low-income) to INT$2,917 (India, high-income). Catastrophic health spending (CHS) was present in >50% of respondents in China, India, and Tanzania. Distress financing (DF) and lost income were more common in low-income respondents. After adjustment, lack of health insurance was associated with CHS in Argentina (OR 4.73 [2.56, 8.76], India (OR 3.93 [2.23, 6.90], and Tanzania (OR 3.68 [1.86, 7.26] with a marginal association in China (OR 2.05 [0.82, 5.11]). These economic effects were accompanied by substantial decreases in individual functional health and productivity. Conclusions: Individuals in selected LMIC bear significant financial burdens following CVD hospitalization, yet with substantial variation across and within countries. Lack of insurance may drive much of the financial stress of CVD in LMIC patients and their families.	[Huffman, Mark D.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; [Huffman, Mark D.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Huffman, Mark D.; Ajay, V. S.; Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India; [Rao, Krishna D.; Ajay, V. S.; Goenka, Shifalika; Reddy, K. Srinath; Prabhakaran, Dorairaj] Publ Hlth Fdn India, New Delhi, India; [Pichon-Riviere, Andres; Calcagno, Juan I.; Caporale, Joaquin E.] Inst Clin Effectiveness Res & Hlth Policy, Buenos Aires, DF, Argentina; [Pichon-Riviere, Andres; Zhao, Dong; Ajay, V. S.; Goenka, Shifalika; Reddy, K. Srinath; Leeder, Stephen; Prabhakaran, Dorairaj] Initiat Cardiovasc Hlth Res Developing Countries, New Delhi, India; [Zhao, Dong; Li, Yan; Liu, Jing] Capital Med Univ, Dept Epidemiol, Beijing Anzhen Hosp, Beijing, Peoples R China; [Zhao, Dong; Li, Yan; Liu, Jing] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China; [Harikrishnan, S.; Thankappan, K. R.; Daivadanam, Meena] Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India; [Ramaiya, Kaushik; van Esch, Jan] Muhimbili Univ Hlth & Allied Sci, Shree Hindu Mandal Hosp, Dept Internal Med, Dar Es Salaam, Tanzania; [Niu, Shaoli] Navy Gen Hosp, Cadre Ward, Beijing, Peoples R China; [Murphy, Adrianna] Harvard Univ, Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA; [Moran, Andrew E.] Columbia Univ, Med Ctr, Div Gen Med, New York, NY USA; [Gaziano, Thomas A.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Suhrcke, Marc] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; [Leeder, Stephen] Univ Sydney, Menzies Ctr Hlth Policy, Sydney, NSW 2006, Australia	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Public Health Foundation of India; Capital Medical University; Department of Science & Technology (India); Sree Chitra Tirunal Institute for Medical Sciences Technology (SCTIMST); Muhimbili University of Health & Allied Sciences; Sixth Medical Center of Chinese PLA General Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Columbia University; Harvard University; Brigham & Women's Hospital; University of East Anglia; University of Sydney	Huffman, MD (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA.	dprabhakaran@ccdcindia.org	Daivadanam, Meena/F-1747-2018; Zhao, D/AAX-5040-2021; S, Harikrishnan/AAT-8083-2021; Thankappan, Kr/ABC-9551-2021; Suhrcke, Marc/AAE-9024-2019; Liu, Jing/AAH-8079-2021; Prabhakaran, Dorairaj/B-4147-2011	Daivadanam, Meena/0000-0002-9532-6059; Liu, Jing/0000-0002-3311-0818; Prabhakaran, Dorairaj/0000-0002-3172-834X; Huffman, Mark/0000-0001-7412-2519; Pichon-Riviere, Andres/0000-0001-6052-025X; Ajay, Vamadevan S/0000-0002-4102-0505; , KR/0000-0002-4536-2684; S, Harikrishnan/0000-0002-7509-0712; Suhrcke, Marc/0000-0001-7263-8626; Reddy, K Srinath/0000-0003-3416-3548; Goenka, Shifalika/0000-0001-6993-2883	Global Forum for Health Research; World Bank; International Union for Health Promotion and Education; NIH FICR-F [R24TW007988]; NHLBI [5T32HL069771]; World Bank via the Global Forum for Health Research; FOGARTY INTERNATIONAL CENTER [R24TW007988] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL089675, T32HL069771] Funding Source: NIH RePORTER	Global Forum for Health Research; World Bank(The World Bank India); International Union for Health Promotion and Education; NIH FICR-F(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); World Bank via the Global Forum for Health Research; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Global Forum for Health Research, World Bank, and International Union for Health Promotion and Education. MDH was supported by the NIH FICR-F program (R24TW007988) and is supported by an NHLBI training grant in cardiovascular epidemiology (5T32HL069771). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was partially funded by the World Bank via the Global Forum for Health Research. Otherwise, the authors have no other relevant declarations relating to employment, consultancy, patents, products in development or marketed products related to this manuscript. The authors confirm that the inclusion of the World Bank as a partial funder does not not alter their adherence to all the PLoS ONE policies on sharing data and materials.	*AG HEALTHC RES QU, 2006, MED EXP PAN SURV; [Anonymous], GLOB BURD DIS 2004 U; Flores G, 2008, HEALTH ECON, V17, P1393, DOI 10.1002/hec.1338; Kawabata K, 2002, B WORLD HEALTH ORGAN, V80, P612; Knaul FM, 2006, LANCET, V368, P1828, DOI 10.1016/S0140-6736(06)69565-2; Leeder S, 2004, RACE TIME CHALLENGE; Makinen M, 2000, B WORLD HEALTH ORGAN, V78, P55; WAGSTAFF A, 2007, WORLD BANK IMPACT EV, V12; Wagstaff A., 2009, 4821 WPS WORLD BANK; Wagstaff A, 2008, J HEALTH ECON, V27, P990, DOI 10.1016/j.jhealeco.2008.02.002; Wagstaff A, 2007, J HEALTH ECON, V26, P505, DOI 10.1016/j.jhealeco.2006.10.006; Wagstaff A, 2009, J HEALTH ECON, V28, P322, DOI 10.1016/j.jhealeco.2008.10.011; Waters HR, 2004, HEALTH POLICY, V69, P339, DOI 10.1016/j.healthpol.2004.01.003; *WHO, 2003, COP HEALTHC COSTS IM; World Health Organization, 2001, WORLD HLTH REP 2000; World Health Organization, 2005, PREVENTING CHRONIC D; Xu K, 2003, LANCET, V362, P111, DOI 10.1016/S0140-6736(03)13861-5; Xu K, 2007, HEALTH AFFAIR, V26, P972, DOI 10.1377/hlthaff.26.4.972	18	119	119	0	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2011	6	6							e20821	10.1371/journal.pone.0020821	http://dx.doi.org/10.1371/journal.pone.0020821			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	778EB	21695127	Green Submitted, gold, Green Published, Green Accepted			2023-01-03	WOS:000291682300013
J	Ejim, L; Farha, MA; Falconer, SB; Wildenhain, J; Coombes, BK; Tyers, M; Brown, ED; Wright, GD				Ejim, Linda; Farha, Maya A.; Falconer, Shannon B.; Wildenhain, Jan; Coombes, Brian K.; Tyers, Mike; Brown, Eric D.; Wright, Gerard D.			Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy	NATURE CHEMICAL BIOLOGY			English	Article							ESCHERICHIA-COLI; RESISTANCE; DISEASES; MICE	Combinations of antibiotics are commonly used in medicine to broaden antimicrobial spectrum and generate synergistic effects. Alternatively, combination of nonantibiotic drugs with antibiotics offers an opportunity to sample a previously untapped expanse of bioactive chemical space. We screened a collection of drugs to identify compounds that augment the activity of the antibiotic minocycline. Unexpected synergistic drug combinations exhibited in vitro and in vivo activity against bacterial pathogens, including multidrug-resistant isolates.	[Ejim, Linda; Farha, Maya A.; Falconer, Shannon B.; Coombes, Brian K.; Brown, Eric D.; Wright, Gerard D.] McMaster Univ, MG DeGroote Inst Infect Dis Res, Hamilton, ON, Canada; [Ejim, Linda; Farha, Maya A.; Falconer, Shannon B.; Coombes, Brian K.; Brown, Eric D.; Wright, Gerard D.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [Wildenhain, Jan; Tyers, Mike] Univ Edinburgh, Sch Biol Sci, Wellcome Trust Ctr Cell Biol, Edinburgh, Midlothian, Scotland	McMaster University; McMaster University; University of Edinburgh	Ejim, L (corresponding author), McMaster Univ, MG DeGroote Inst Infect Dis Res, Hamilton, ON, Canada.	ebrown@mcmaster.ca; wrightge@mcmaster.ca	Tyers, Michael/ABE-3194-2021; Coombes, Brian K/A-1727-2009; Wright, G/ABB-7666-2021; Wildenhain, Jan/Q-6596-2019; Wildenhain, Jan/E-5597-2011	Wildenhain, Jan/0000-0002-5461-3828; Wildenhain, Jan/0000-0002-5461-3828; Wright, Gerard/0000-0002-9129-7131; Coombes, Brian/0000-0001-9883-1010	Canada Research Chairs; Canadian Cystic Fibrosis Foundation; Canadian Institutes of Health Research [MOP-81330, XNE-8705, FRN-79488]; European Research Council	Canada Research Chairs(Canada Research ChairsCGIAR); Canadian Cystic Fibrosis Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); European Research Council(European Research Council (ERC)European Commission)	The authors thank the staff of the McMaster High Throughput Screening Laboratory for technical assistance. The work was supported by Canada Research Chairs to E.D.B., M.T., G.D.W., the Canadian Cystic Fibrosis Foundation, Canadian Institutes of Health Research operating grants to E.D.B. (MOP-81330), G.D.W. (XNE-8705, FRN-79488) and the European Research Council to M.T.	Barthel M, 2003, INFECT IMMUN, V71, P2839, DOI 10.1128/IAI.71.5.2839-2858.2003; Borisy AA, 2003, P NATL ACAD SCI USA, V100, P7977, DOI 10.1073/pnas.1337088100; Boucher HW, 2009, CLIN INFECT DIS, V48, P1, DOI 10.1086/595011; Cascales E, 2000, MOL MICROBIOL, V38, P904, DOI 10.1046/j.1365-2958.2000.02190.x; Chong CR, 2007, NATURE, V448, P645, DOI 10.1038/448645a; CHOPRA I, 1989, FEMS MICROBIOL LETT, V60, P21, DOI 10.1016/0378-1097(89)90070-0; Christianson S, 2007, J CLIN MICROBIOL, V45, P1904, DOI 10.1128/JCM.02500-06; Costanzo M, 2010, SCIENCE, V327, P425, DOI 10.1126/science.1180823; HURWITZ A, 1994, LIFE SCI, V54, P1687, DOI 10.1016/0024-3205(94)00609-1; Kristiansen JE, 2007, J ANTIMICROB CHEMOTH, V59, P1271, DOI 10.1093/jac/dkm071; Kruszewska Hanna, 2004, Acta Pol Pharm, V61 Suppl, P18; Lehar J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100116; Lehtinen J, 2007, INT J ANTIMICROB AG, V30, P44, DOI 10.1016/j.ijantimicag.2007.02.019; Liu A, 2010, ANTIMICROB AGENTS CH, V54, P1393, DOI 10.1128/AAC.00906-09; Mazumdar K, 2009, EUR J CLIN MICROBIOL, V28, P881, DOI 10.1007/s10096-009-0739-z; Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Paul K, 2008, NATURE, V451, P489, DOI 10.1038/nature06497; Pillai SK, 2005, ANTIBIOTICS LAB MED, P365; Sharom JR, 2004, CURR OPIN CHEM BIOL, V8, P81, DOI 10.1016/j.cbpa.2003.12.007; Stolk P, 2006, B WORLD HEALTH ORGAN, V84, P745, DOI 10.2471/BLT.06.031518; TABER HW, 1987, MICROBIOL REV, V51, P439, DOI 10.1128/MMBR.51.4.439-457.1987; Walsh C, 2000, NATURE, V406, P775, DOI 10.1038/35021219; YAMAGUCHI A, 1991, ANTIMICROB AGENTS CH, V35, P53, DOI 10.1128/AAC.35.1.53	24	342	355	7	134	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	JUN	2011	7	6					348	350		10.1038/NCHEMBIO.559	http://dx.doi.org/10.1038/NCHEMBIO.559			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	765BH	21516114				2023-01-03	WOS:000290677900009
J	McCannon, J; Berwick, DM				McCannon, Joseph; Berwick, Donald M.			A New Frontier in Patient Safety	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Berwick, Donald M.] US Dept HHS, Ctr Medicare Serv, Washington, DC 20201 USA; US Dept HHS, Ctr Medicaid Serv, Washington, DC 20201 USA	Centers for Medicare & Medicaid Services; Centers for Medicare & Medicaid Services	Berwick, DM (corresponding author), US Dept HHS, Ctr Medicare Serv, 200 Independence Ave SW,Ste 314, Washington, DC 20201 USA.	donald.berwick@cms.hhs.gov						[Anonymous], 2010, OEI06Y0900090; Berenholtz SM, 2011, INFECT CONT HOSP EP, V32, P305, DOI 10.1086/658938; Haynes Alex B, 2009, N Engl J Med, V360, P491, DOI 10.1056/NEJMsa0810119; Interagency Working Group on Health Care Quality for the National Quality Strategy, NAT QUAL STRAT; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Pronovost PJ, 2011, HEALTH AFFAIR, V30, P628, DOI 10.1377/hlthaff.2011.0047; Srinivasan A., 2011, Morbidity and Mortality Weekly Report, V60, P243	8	32	32	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 1	2011	305	21					2221	2222		10.1001/jama.2011.742	http://dx.doi.org/10.1001/jama.2011.742			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	770RN	21632485				2023-01-03	WOS:000291106300025
J	Komori, T; Nakamura, T; Matsunaga, I; Morita, D; Hattori, Y; Kuwata, H; Fujiwara, N; Hiromatsu, K; Harashima, H; Sugita, M				Komori, Takaya; Nakamura, Takashi; Matsunaga, Isamu; Morita, Daisuke; Hattori, Yuki; Kuwata, Hirotaka; Fujiwara, Nagatoshi; Hiromatsu, Kenji; Harashima, Hideyoshi; Sugita, Masahiko			A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS INFECTION; OCTAARGININE-MODIFIED LIPOSOMES; T-CELL RECOGNITION; LIPID ANTIGENS; INTRACELLULAR TRAFFICKING; ENDOPLASMIC-RETICULUM; PRESENTING MOLECULES; IMMUNE-RESPONSES; CD1 MOLECULES; GUINEA-PIGS	Delayed-type hypersensitivity (DTH) is marked by high levels of protein antigen-specific T cell responses in sensitized individuals. Recent evidence has revealed a distinct pathway for T cell immunity directed against glycolipid antigens, but DTH to this class of antigen has been undetermined and difficult to prove due to their insolubility in aqueous solutions. Here, glucose monomycolate (GMM), a highly hydrophobic glycolipid of the cell wall of mycobacteria, was dispersed in aqueous solutions in the form of octaarginine-modified liposomes and tested for its ability to elicit cutaneous DTH responses in bacillus Calmette-Guerin (BCG)-immunized guinea pigs. After an intradermal challenge with the GMM liposome, a significant skin induration was observed in BCG-immunized, but not mock-treated, animals. The skin reaction peaked at around 2 days with local infiltration by mononuclear cells, and therefore, the response shared basic features with the classical DTH to protein antigens. Lymph node T cells from BCG-immunized guinea pigs specifically increased IFN-gamma transcription in response to the GMM liposome, and this response was completely blocked by antibodies to CD1 lipid antigen-presenting molecules. Finally, whereas the T cells increased transcription of both T helper (Th) 1-type (IFN-gamma and TNF-alpha) and Th2-type (IL-5 and IL-10) cytokines in response to the purified protein derivative or tuberculin, their GMM-specific response was skewed to Th1-type cytokine production known to be critical for protection against tuberculosis. Thus, our study reveals a novel form of DTH with medical implications.	[Komori, Takaya; Matsunaga, Isamu; Morita, Daisuke; Hattori, Yuki; Kuwata, Hirotaka; Sugita, Masahiko] Kyoto Univ, Inst Virus Res, Lab Cell Regulat, Kyoto 6068507, Japan; [Komori, Takaya; Matsunaga, Isamu; Morita, Daisuke; Hattori, Yuki; Sugita, Masahiko] Grad Sch Biostudies, Lab Cell Regulat & Mol Network, Kyoto 6068507, Japan; [Nakamura, Takashi; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Sapporo, Hokkaido 0600812, Japan; [Fujiwara, Nagatoshi] Osaka City Univ, Grad Sch Med, Dept Bacteriol, Osaka 5458585, Japan; [Hiromatsu, Kenji] Fukuoka Univ, Fac Med, Dept Microbiol & Immunol, Fukuoka 8140180, Japan	Kyoto University; Hokkaido University; Osaka Metropolitan University; Fukuoka University	Sugita, M (corresponding author), 53 Kawahara Cho,Sakyo Ku, Kyoto 6068507, Japan.	msugita@virus.kyoto-u.ac.jp	Komori, Takaya/AAW-7731-2021; Nakamura, Takashi/F-4419-2016; Hattori, Yuki/AAW-2061-2021; Harashima, Hideyoshi/D-8390-2012; Kuwata, Hiro/N-2023-2019	Nakamura, Takashi/0000-0001-9019-1426; Kuwata, Hiro/0000-0002-5023-1777; Hattori, Yuki/0000-0001-6576-0121; Sugita, Masahiko/0000-0001-5511-1304	Ministry of Education, Culture, Sports, Science, and Technology; Japan Society for the Promotion of Science	Ministry of Education, Culture, Sports, Science, and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology (grant-in-aid for Scientific Research on Priority Areas) and from the Japan Society for the Promotion of Science (grant-in-aid for Scientific Research (B) (to M. S.)).	Batuwangala T, 2004, J IMMUNOL, V172, P2382, DOI 10.4049/jimmunol.172.4.2382; Behar SM, 2007, CURR TOP MICROBIOL, V314, P215; Dascher CC, 2003, INT IMMUNOL, V15, P915, DOI 10.1093/intimm/dxg091; Grant EP, 1999, J EXP MED, V189, P195, DOI 10.1084/jem.189.1.195; Hiromatsu K, 2002, J IMMUNOL, V169, P330, DOI 10.4049/jimmunol.169.1.330; Hiromatsu K, 2002, IMMUNOLOGY, V106, P159, DOI 10.1046/j.1365-2567.2002.01422.x; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; Homhuan A, 2009, J CONTROL RELEASE, V136, P79, DOI 10.1016/j.jconrel.2009.01.004; Ishikawa E, 2009, J EXP MED, V206, P2879, DOI 10.1084/jem.20091750; Kawashima T, 2003, J IMMUNOL, V170, P5345, DOI 10.4049/jimmunol.170.11.5345; Khalil IA, 2006, J BIOL CHEM, V281, P3544, DOI 10.1074/jbc.M503202200; Kobayashi K, 2001, MICROSC RES TECHNIQ, V53, P241, DOI 10.1002/jemt.1090; Matsunaga I, 2004, J EXP MED, V200, P1559, DOI 10.1084/jem.20041429; Matsunaga I, 2008, J BIOL CHEM, V283, P28835, DOI 10.1074/jbc.M805776200; Moody DB, 2000, J EXP MED, V192, P965, DOI 10.1084/jem.192.7.965; Moody DB, 2000, NATURE, V404, P884, DOI 10.1038/35009119; Moody DB, 1997, SCIENCE, V278, P283, DOI 10.1126/science.278.5336.283; Morita D, 2008, BIOCHEM BIOPH RES CO, V377, P889, DOI 10.1016/j.bbrc.2008.10.075; Nakamura T, 2008, MOL THER, V16, P1507, DOI 10.1038/mt.2008.122; Nakao H, 2009, J BIOCHEM, V146, P659, DOI 10.1093/jb/mvp113; North RJ, 2004, ANNU REV IMMUNOL, V22, P599, DOI 10.1146/annurev.immunol.22.012703.104635; Orme IM, 1999, IMMUNOL TODAY, V20, P307, DOI 10.1016/S0167-5699(98)01438-8; Otsuka A, 2008, J IMMUNOL, V181, P8528, DOI 10.4049/jimmunol.181.12.8528; PORCELLI SA, 1995, ADV IMMUNOL, V59, P1, DOI 10.1016/S0065-2776(08)60629-X; Rosat JP, 1999, J IMMUNOL, V162, P366; Ryll R, 2001, MICROBIOL IMMUNOL, V45, P801, DOI 10.1111/j.1348-0421.2001.tb01319.x; Stenger S, 1998, SCIENCE, V282, P121, DOI 10.1126/science.282.5386.121; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; Sugita M, 2000, P NATL ACAD SCI USA, V97, P8445, DOI 10.1073/pnas.150236797; Sugita M, 1999, IMMUNITY, V11, P743, DOI 10.1016/S1074-7613(00)80148-X; Sugita M, 1997, J IMMUNOL, V159, P2358; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; Sugita M, 2002, IMMUNITY, V16, P697, DOI 10.1016/S1074-7613(02)00311-4; Ulrichs T, 2003, INFECT IMMUN, V71, P3076, DOI 10.1128/IAI.71.6.3076-3087.2003; Van Rhijn I, 2009, EUR J IMMUNOL, V39, P3031, DOI 10.1002/eji.200939619; Watanabe Y, 2006, VACCINE, V24, P5700, DOI 10.1016/j.vaccine.2006.04.049	36	28	31	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 13	2011	286	19					16800	16806		10.1074/jbc.M110.217224	http://dx.doi.org/10.1074/jbc.M110.217224			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	760CZ	21454504	Green Published, hybrid			2023-01-03	WOS:000290301900029
J	Rettig, RA				Rettig, Richard A.			Special Treatment - The Story of Medicare's ESRD Entitlement	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									RAND Washington, Washington, DC USA		Rettig, RA (corresponding author), RAND Washington, Washington, DC USA.							Alexander S, 1962, LIFE, P124; Alexander S, 1962, LIFE, P118; Alexander S., 1962, LIFE, P102; Alexander Shana, 1962, LIFE, P110; Alexander Shana, 1962, LIFE, P106; Alexander Shana, 1962, LIFE, P108; Alexander Shana, 1962, LIFE, P123; Alexander Shana, 1962, LIFE, P115; Alexander Shana, 1962, LIFE, P117; Bobbitt P., 1978, TRAGIC CHOICES; Knauf F, 2009, J AM SOC NEPHROL, V20, P2093, DOI 10.1681/ASN.2009070715; Moss AH, 2010, CLIN J AM SOC NEPHRO, V5, P2380, DOI 10.2215/CJN.07170810; *NIH, 2010, USRDS 2010 ANN DAT R, V2	13	56	56	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2011	364	7					596	598		10.1056/NEJMp1014193	http://dx.doi.org/10.1056/NEJMp1014193			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722BW	21323539				2023-01-03	WOS:000287406000002
J	Pandeeti, EVP; Pitchika, GK; Jotshi, J; Nilegaonkar, SS; Kanekar, PP; Siddavattam, D				Pandeeti, Emmanuel Vijay Paul; Pitchika, Gopi Krishna; Jotshi, Jyotsna; Nilegaonkar, Smita S.; Kanekar, Pradnya P.; Siddavattam, Dayananda			Enzymatic Depilation of Animal Hide: Identification of Elastase (LasB) from Pseudomonas aeruginosa MCM B-327 as a Depilating Protease	PLOS ONE			English	Article							ALKALINE PROTEASE; EXTRACELLULAR PROTEINS; ESCHERICHIA-COLI; KERATINASE; EXPRESSION; PURIFICATION; ACTIVATION; CLONING; OPTIMIZATION; MUTAGENESIS	Conventional leather processing involving depilation of animal hide by lime and sulphide treatment generates considerable amounts of chemical waste causing severe environmental pollution. Enzymatic depilation is an environmentally friendly process and has been considered to be a viable alternative to the chemical depilation process. We isolated an extracellular protease from Pseudomonas aeruginosa strain MCM B-327 with high depilation activity using buffalo hide as a substrate. This 33 kDa protease generated a peptide mass fingerprint and de novo sequence that matched perfectly with LasB (elastase), of Pseudomonas aeruginosa. In support of this data a lasB mutant of MCM B-327 strain lacked depilatory activity and failed to produce LasB. LasB heterologously over-produced and purified from Escherichia coli also exhibited high depilating activity. Moreover, reintroduction of the lasB gene to the P. aeruginosa lasB mutant via a knock-in strategy also successfully restored depilation activity thus confirming the role of LasB as the depilating enzyme.	[Pandeeti, Emmanuel Vijay Paul; Pitchika, Gopi Krishna; Siddavattam, Dayananda] Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India; [Jotshi, Jyotsna; Nilegaonkar, Smita S.; Kanekar, Pradnya P.] MACS Agharkar Res Inst, Microbial Sci Div, Pune, Maharashtra, India	University of Hyderabad; Department of Science & Technology (India); Agharkar Research Institute (ARI)	Pandeeti, EVP (corresponding author), Univ Hyderabad, Sch Life Sci, Dept Anim Sci, Hyderabad 500134, Andhra Pradesh, India.	sdsl@uohyd.ernet.in		Pandeeti, Emmanuel/0000-0001-8244-7401	CSIR-NMITLI, New Delhi [5/258/13A/2005-NMITLI]	CSIR-NMITLI, New Delhi(Council of Scientific & Industrial Research (CSIR) - India)	This work was funded by CSIR-NMITLI, New Delhi through the grant 5/258/13A/2005-NMITLI to DS. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anbu P, 2005, ENZYME MICROB TECH, V36, P639, DOI 10.1016/j.enzmictec.2004.07.019; Anderson RM, 1999, J BACTERIOL, V181, P6264, DOI 10.1128/JB.181.20.6264-6270.1999; Bayoudh A, 2000, J IND MICROBIOL BIOT, V24, P291, DOI 10.1038/sj.jim.2900822; Brandelli A, 2008, FOOD BIOPROCESS TECH, V1, P105, DOI 10.1007/s11947-007-0025-y; Braun P, 2000, MICROBIOL-UK, V146, P2565, DOI 10.1099/00221287-146-10-2565; Braun P, 2001, J BIOL CHEM, V276, P26030, DOI 10.1074/jbc.M007122200; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Friedrich J, 2005, ENZYME MICROB TECH, V36, P455, DOI 10.1016/j.enzmictec.2004.09.015; Germann H.P., 1999, P 25 IULTCS C CHENN; Giongo JL, 2007, WORLD J MICROB BIOT, V23, P375, DOI 10.1007/s11274-006-9234-1; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; Hauser AR, 1998, INFECT IMMUN, V66, P1413, DOI 10.1128/IAI.66.4.1413-1420.1998; HOLDER IA, 1989, INFECT IMMUN, V57, P3345, DOI 10.1128/IAI.57.11.3345-3348.1989; Kanekar PP, 2002, BIORESOURCE TECHNOL, V85, P87, DOI 10.1016/S0960-8524(02)00018-4; KUNITZ M, 1947, J GEN PHYSIOL, V30, P291, DOI 10.1085/jgp.30.4.291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lewenza S, 2005, GENOME RES, V15, P321, DOI 10.1101/gr.3257305; Lin HH, 2009, J AGR FOOD CHEM, V57, P5321, DOI 10.1021/jf900417t; Lin HH, 2009, J AGR FOOD CHEM, V57, P3506, DOI 10.1021/jf803752j; Lin XJ, 2009, PROTEIN EXPRES PURIF, V63, P69, DOI 10.1016/j.pep.2007.12.011; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDVIK J, 2000, USRAS921201151 UN NA; Macedo AJ, 2005, APPL ENVIRON MICROB, V71, P594, DOI 10.1128/AEM.71.1.594-596.2005; Marsal A, 1999, J SOC LEATH TECH CH, V83, P310; MORALES VM, 1991, GENE, V97, P39, DOI 10.1016/0378-1119(91)90007-X; Mukhopadhyay R. P., 1993, Indian Journal of Experimental Biology, V31, P557; Najafi MF, 2006, ENZYME MICROB TECH, V39, P1433, DOI 10.1016/j.enzmictec.2006.03.031; Nilegaonkar SS, 2007, BIORESOURCE TECHNOL, V98, P1238, DOI 10.1016/j.biortech.2006.05.003; Nouwens AS, 2003, MICROBIOL-SGM, V149, P1311, DOI 10.1099/mic.0.25967-0; Nouwens AS, 2002, PROTEOMICS, V2, P1325, DOI 10.1002/1615-9861(200209)2:9<1325::AID-PROT1325>3.0.CO;2-4; Pandeeti EVP, 2009, LETT APPL MICROBIOL, V48, P566, DOI 10.1111/j.1472-765X.2009.02564.x; PANDEY JP, 2009, MOL BIOL REP, V34, P13; Puvanakrishnan R., 1988, ENZYMES DEHAIRING; Ramasami T, 1999, J SOC LEATH TECH CH, V83, P39; RAMASAMI T, 1998, BACKGROUND INFORMATI, P183; RUST L, 1996, J BACTERIOL, V179, P557; Sambrook J., 1989, MOL CLONING LAB MANU; Sandkvist M, 2001, INFECT IMMUN, V69, P3523, DOI 10.1128/IAI.69.6.3523-3535.2001; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Sharma R, 2010, BIOTECHNOL LETT, V32, P1863, DOI 10.1007/s10529-010-0361-2; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; Wang HY, 2007, LETT APPL MICROBIOL, V44, P1, DOI 10.1111/j.1472-765X.2006.02039.x; Yahr TL, 1996, MOL MICROBIOL, V22, P991, DOI 10.1046/j.1365-2958.1996.01554.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YATES JR, 1968, AUST J BIOL SCI, V21, P361, DOI 10.1071/BI9680361; Yates JR, 1972, J SOC LEATHER TRADES, V56, P158; Zambare VP, 2007, WORLD J MICROB BIOT, V23, P1569, DOI 10.1007/s11274-007-9402-y; ZAMBARE VP, 2010, NEW BIOTECH IN PRESS	48	12	16	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 11	2011	6	2							e16742	10.1371/journal.pone.0016742	http://dx.doi.org/10.1371/journal.pone.0016742			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721OO	21347249	gold, Green Published, Green Submitted			2023-01-03	WOS:000287364500004
J	Voisin, SN; Krakovska, O; Matta, A; DeSouza, LV; Romaschin, AD; Colgan, TJ; Siu, KWM				Voisin, Sebastien N.; Krakovska, Olga; Matta, Ajay; DeSouza, Leroi V.; Romaschin, Alexander D.; Colgan, Terence J.; Siu, K. W. Michael			Identification of Novel Molecular Targets for Endometrial Cancer Using a Drill-Down LC-MS/MS Approach with iTRAQ	PLOS ONE			English	Article							MULTIDIMENSIONAL LIQUID-CHROMATOGRAPHY; PYRUVATE-KINASE M2; MASS-SPECTROMETRY; BIOMARKER DISCOVERY; OXIDATIVE STRESS; S100 PROTEINS; CATHEPSIN-B; PROTEOMICS; SURVIVAL; ROLES	Background: The number of patients with endometrial carcinoma (EmCa) with advanced stage or high histological grade is increasing and prognosis has not improved for over the last decade. There is an urgent need for the discovery of novel molecular targets for diagnosis, prognosis and treatment of EmCa, which will have the potential to improve the clinical strategy and outcome of this disease. Methodology and Results: We used a "drill-down'' proteomics approach to facilitate the identification of novel molecular targets for diagnosis, prognosis and/or therapeutic intervention for EmCa. Based on peptide ions identified and their retention times in the first LC-MS/MS analysis, an exclusion list was generated for subsequent iterations. A total of 1529 proteins have been identified below the Proteinpilot (R) 5% error threshold from the seven sets of iTRAQ experiments performed. On average, the second iteration added 78% new peptides to those identified after the first run, while the third iteration added 36% additional peptides. Of the 1529 proteins identified, only 40 satisfied our criteria for significant differential expression in EmCa in comparison to normal proliferative tissues. These proteins included metabolic enzymes (pyruvate kinase M2 and lactate dehydrogenase A); calcium binding proteins (S100A6, calcyphosine and calumenin), and proteins involved in regulating inflammation, proliferation and invasion (annexin A1, interleukin enhancer-binding factor 3, alpha-1-antitrypsin, macrophage capping protein and cathepsin B). Network analyses revealed regulation of these molecular targets by c-myc, Her2/neu and TNF alpha, suggesting intervention with these pathways may be a promising strategy for the development of novel molecular targeted therapies for EmCa. Conclusions: Our analyses revealed the significance of drill-down proteomics approach in combination with iTRAQ to overcome some of the limitations of current proteomics strategies. This study led to the identification of a number of novel molecular targets having therapeutic potential for targeted molecular therapies for endometrial carcinoma.	[Voisin, Sebastien N.; Krakovska, Olga; Matta, Ajay; DeSouza, Leroi V.; Siu, K. W. Michael] York Univ, Dept Chem, Toronto, ON M3J 2R7, Canada; [Voisin, Sebastien N.; Krakovska, Olga; Matta, Ajay; DeSouza, Leroi V.] York Univ, Ctr Res Mass Spectrometry, Toronto, ON M3J 2R7, Canada; [Romaschin, Alexander D.] St Michaels Hosp, Div Clin Biochem, Toronto, ON M5B 1W8, Canada; [Romaschin, Alexander D.; Colgan, Terence J.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Colgan, Terence J.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada	York University - Canada; York University - Canada; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto	Voisin, SN (corresponding author), York Univ, Dept Chem, Toronto, ON M3J 2R7, Canada.	kwmsiu@yorku.ca	Colgan, Terence J/J-2339-2016; MATTA, AJAY/AFT-2977-2022; DeSouza, Leroi V/H-3831-2013	Voisin, Sebastien/0000-0001-5897-333X	Canadian Cancer Society Research Institute (formerly the National Cancer Institute of Canada); MITACS, Ontario, Canada	Canadian Cancer Society Research Institute (formerly the National Cancer Institute of Canada); MITACS, Ontario, Canada	The support of the Canadian Cancer Society Research Institute (formerly the National Cancer Institute of Canada) is gratefully acknowledged. AB SCIEX provided infrastructural and reagent support of this research; Ajay Matta is the recipient of a MITACS Accelerate Fellowship, Ontario, Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelmohsen K, 2008, BIOL CHEM, V389, P243, DOI 10.1515/BC.2008.022; Carpenter B, 2006, BBA-REV CANCER, V1765, P85, DOI 10.1016/j.bbcan.2005.10.002; Chen HS, 2005, ANAL CHEM, V77, P7816, DOI 10.1021/ac050956y; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Clarke BA, 2010, J CLIN PATHOL, V63, P410, DOI 10.1136/jcp.2009.071225; Curto M, 2004, CANCER CELL, V5, P113, DOI 10.1016/S1535-6108(04)00031-5; De Petris L, 2009, LUNG CANCER, V63, P410, DOI 10.1016/j.lungcan.2008.06.003; DeSouza L, 2005, J PROTEOME RES, V4, P377, DOI 10.1021/pr049821j; DeSouza LV, 2007, MOL CELL PROTEOMICS, V6, P1170, DOI 10.1074/mcp.M600378-MCP200; DeSouza LV, 2009, ANAL CHEM, V81, P3462, DOI 10.1021/ac802726a; Di Cristofano A, 2007, ANNU REV PATHOL-MECH, V2, P57, DOI 10.1146/annurev.pathol.2.010506.091905; Diamandis EP, 2004, MOL CELL PROTEOMICS, V3, P367, DOI 10.1074/mcp.R400007-MCP200; Dizon DS, 2010, GYNECOL ONCOL, V117, P373, DOI 10.1016/j.ygyno.2010.02.007; Dube V, 2007, J PROTEOME RES, V6, P2648, DOI 10.1021/pr070087o; Eckert RL, 2004, J INVEST DERMATOL, V123, P23, DOI 10.1111/j.0022-202X.2004.22719.x; Eigenbrodt E., 1992, Critical Reviews in Oncogenesis, V3, P91; Emberley ED, 2004, BIOCHEM CELL BIOL, V82, P508, DOI 10.1139/O04-052; Fais S, 2004, TRENDS MOL MED, V10, P249, DOI 10.1016/j.molmed.2004.04.005; Ferguson EC, 2008, TRENDS BIOCHEM SCI, V33, P359, DOI 10.1016/j.tibs.2008.05.006; Filipek A, 2006, CHEMOTHERAPY, V52, P32, DOI 10.1159/000090240; Guo WH, 2011, J CANCER RES CLIN, V137, P65, DOI 10.1007/s00432-010-0860-5; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hung KE, 2010, GASTROENTEROLOGY, V138, P46, DOI 10.1053/j.gastro.2009.11.020; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kaiserman Dion, 2006, Expert Reviews in Molecular Medicine, V8, P1, DOI 10.1017/S1462399406000184; Kulasingam V, 2008, NAT CLIN PRACT ONCOL, V5, P588, DOI 10.1038/ncponc1187; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107; Lesniak W, 2009, BIOCHEM BIOPH RES CO, V390, P1087, DOI 10.1016/j.bbrc.2009.10.150; Li ZY, 2008, INT J CANCER, V123, P2377, DOI 10.1002/ijc.23808; Li ZY, 2010, INT J GYNECOL CANCER, V20, P9, DOI 10.1111/IGC.0b013e3181a9026d; Lim LHK, 2007, FASEB J, V21, P968, DOI 10.1096/fj.06-7464rev; Makawita S, 2010, CLIN CHEM, V56, P212, DOI 10.1373/clinchem.2009.127019; Mazurek S, 2008, ERNST SCHERING FOUND, V4, P99, DOI 10.1007/2789_2008_091; Negishi A, 2009, CANCER SCI, V100, P514, DOI 10.1111/j.1349-7006.2008.01055.x; Podgorski I, 2003, BIOCHEM SOC SYMP, V70, P263, DOI 10.1042/bss0700263; Ralhan R, 2009, J PROTEOME RES, V8, P300, DOI 10.1021/pr800501j; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Scherl A, 2004, PROTEOMICS, V4, P917, DOI 10.1002/pmic.200300673; Shi HS, 2010, CANCER SCI, V101, P1447, DOI 10.1111/j.1349-7006.2010.01562.x; Shilov IV, 2007, MOL CELL PROTEOMICS, V6, P1638, DOI 10.1074/mcp.T600050-MCP200; Simpson RJ, 2008, CURR OPIN CHEM BIOL, V12, P72, DOI 10.1016/j.cbpa.2008.02.010; Spoden GA, 2009, EXP CELL RES, V315, P2765, DOI 10.1016/j.yexcr.2009.06.024; Street JM, 2010, BRIT J CLIN PHARMACO, V69, P367, DOI 10.1111/j.1365-2125.2009.03610.x; Tomoo K, 2010, CURR TOP MED CHEM, V10, P696, DOI 10.2174/156802610791113441; van der Merwe DE, 2007, ADV CANCER RES, V96, P23, DOI 10.1016/S0065-230X(06)96002-3; Vander Heiden MG, 2010, BIOCHEM PHARMACOL, V79, P1118, DOI 10.1016/j.bcp.2009.12.003; Vimalachandran D, 2005, CANCER RES, V65, P3218, DOI 10.1158/0008-5472.CAN-04-4311; Wang N, 2008, ANAL CHEM, V80, P4696, DOI 10.1021/ac800260w; Wang XH, 2010, AM J PATHOL, V177, P586, DOI 10.2353/ajpath.2010.091217	50	37	39	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16352	10.1371/journal.pone.0016352	http://dx.doi.org/10.1371/journal.pone.0016352			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	21305022	Green Published, Green Submitted, gold			2023-01-03	WOS:000286834300054
J	Aufderheide, TP; Frascone, RJ; Wayne, MA; Mahoney, BD; Swor, RA; Domeier, RM; Olinger, ML; Holcomb, RG; Tupper, DE; Yannopoulos, D; Lurie, KG				Aufderheide, Tom P.; Frascone, Ralph J.; Wayne, Marvin A.; Mahoney, Brian D.; Swor, Robert A.; Domeier, Robert M.; Olinger, Michael L.; Holcomb, Richard G.; Tupper, David E.; Yannopoulos, Demetris; Lurie, Keith G.			Standard cardiopulmonary resuscitation versus active compression-decompression cardiopulmonary resuscitation with augmentation of negative intrathoracic pressure for out-of-hospital cardiac arrest: a randomised trial	LANCET			English	Article							IMPEDANCE THRESHOLD DEVICE; CHEST-WALL DECOMPRESSION; INSPIRATORY IMPEDANCE; PORCINE MODEL; VALVE; INSTRUCTOR; SURVIVAL; STUDENT; CPR	Background Active compression-decompression cardiopulmonary resuscitation (CPR) with decreased intrathoracic pressure in the decompression phase can lead to improved haemodynamics compared with standard CPR. We aimed to assess effectiveness and safety of this intervention on survival with favourable neurological function after out-of-hospital cardiac arrest. Methods In our randomised trial of 46 emergency medical service agencies (serving 2.3 million people) in urban, suburban, and rural areas of the USA, we assessed outcomes for patients with out-of-hospital cardiac arrest according to Utstein guidelines. We provisionally enrolled patients to receive standard CPR or active compression-decompression CPR with augmented negative intrathoracic pressure (via an impedance-threshold device) with a computer-generated block randomisation weekly schedule in a one-to-one ratio. Adults (presumed age or age a:18 years) who had a nontraumatic arrest of presumed cardiac cause and met initial and final selection criteria received designated CPR and were included in the final analyses. The primary endpoint was survival to hospital discharge with favourable neurological function (modified Rankin scale score of <= 3). All investigators apart from initial rescuers were masked to treatment group assignment. This trial is registered with ClinicalTrials.gov, number NCT00189423. Findings 2470 provisionally enrolled patients were randomly allocated to treatment groups. 813 (68%) of 1201 patients assigned to the standard CPR group (controls) and 840 (66%) of 1269 assigned to intervention CPR received designated CPR and were included in the final analyses. 47 (6%) of 813 controls survived to hospital discharge with favourable neurological function compared with 75 (9%) of 840 patients in the intervention group (odds ratio 1.58, 95% CI 1.07-2.36; p=0.019]. 74 (9%) of 840 patients survived to 1 year in the intervention group compared with 48 (6%) of 813 controls (p=0.03), with equivalent cognitive skills, disability ratings, and emotional-psychological statuses in both groups. The overall major adverse event rate did not differ between groups, but more patients had pulmonary oedema in the intervention group (94 [11%] of 840) than did controls (62 [7%] of 813; p=0.015). Interpretation On the basis of our findings showing increased effectiveness and generalisability of the study intervention, active compression-decompression CPR with augmentation of negative intrathoracic pressure should be considered as an alternative to standard CPR to increase long-term survival after cardiac arrest.	[Aufderheide, Tom P.] Med Coll Wisconsin, Dept Emergency Med, Milwaukee, WI 53226 USA; [Frascone, Ralph J.] Reg Hosp, Dept Emergency Med, St Paul, MN USA; [Wayne, Marvin A.] St Joseph Med Ctr, Dept Emergency Med, Whatcom Cty Emergency Med Serv, Bellingham, WA USA; [Mahoney, Brian D.; Lurie, Keith G.] Hennepin Cty Med Ctr, Dept Emergency Med, Minneapolis, MN 55415 USA; [Swor, Robert A.] William Beaumont Hosp, Dept Emergency Med, Royal Oak, MI 48072 USA; [Domeier, Robert M.] St Joseph Mercy Hosp, Dept Emergency Med, Ann Arbor, MI 48104 USA; [Olinger, Michael L.] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN USA; [Holcomb, Richard G.] Quintiles Consulting, Rockville, MD USA; [Tupper, David E.; Yannopoulos, Demetris; Lurie, Keith G.] Univ Minnesota, Med Ctr, Div Cardiovasc, Dept Neurol, Minneapolis, MN 55455 USA; [Tupper, David E.; Yannopoulos, Demetris; Lurie, Keith G.] Univ Minnesota, Med Ctr, Div Cardiovasc, Dept Med, Minneapolis, MN 55455 USA	Medical College of Wisconsin; Hennepin County Medical Center; Beaumont Health; Saint Joseph Mercy Health System (SJMHS); Indiana University System; Indiana University Bloomington; IQVIA; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Aufderheide, TP (corresponding author), Med Coll Wisconsin, Dept Emergency Med, 9200 W Wisconsin Ave,Pavil 1P, Milwaukee, WI 53226 USA.	taufderh@mcw.edu			US National Institutes of Health; federal grant [R44-HL065851-03]; NIH Immediate Trial; NIH Resuscitation Outcomes Consortium; NIH Neurological Emergency Treatment Trials Network; NIH Medical College of Wisconsin; Predict HD study [NINDS-6375, NINDS-40068, NIMH-01579]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R44HL065851] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); federal grant; NIH Immediate Trial(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Resuscitation Outcomes Consortium(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH Neurological Emergency Treatment Trials Network; NIH Medical College of Wisconsin; Predict HD study; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank the many first responders, firefighters, emergency medical technicians, and paramedics at all sites who took care of the patients, and without whom survival from out-of-hospital cardiac arrest would not be possible (see webappendix pp 5-9). The study was funded by the US National Institutes of Health and the federal grant (R44-HL065851-03) was used by Advanced Circulatory Systems to fund the study.; TPA, RJF, MAW, BDM, RAS, RMD, and MLO all received grant funds to their respective institutions for services related to patient enrolment, follow-up and data management for this clinical study; RGH received consulting fees for statistical analyses (US National Institutes of Health [NIH] R44-HL065851-03). KGL was co-inventor of the impedance-threshold device and active compression-decompression cardiopulmonary resuscitation device, and founded Advanced Circulatory Systems in 1997 after the University of Minnesota (MN, USA) declined the opportunity to apply for patent protection on the impedance threshold device. All investigators feel KGL contributed substantially to this study and therefore should be listed as an author rather than incorporating his role within the activities of the sponsor, Advanced Circulatory Systems. In his role as the Chief Medical Officer of Advanced Circulatory Systems, KGL participated with the other investigators in obtaining the NIH grant funding (KG L was the principal investigator on the Small Business Innovation Research grant), the study design, data interpretation, writing and the decision to submit the paper for publication. KGL was not involved in any patient care or assessment of patient neurological status during the 1-year follow-up. Outside the present study, TPA has board membership for Take Heart America and Citizen CPR Foundation, has consulted for JoLife Medical and Medtronic Foundation, and has received grants/grants pending from the NIH Immediate Trial, NIH Resuscitation Outcomes Consortium, NIH Neurological Emergency Treatment Trials Network, and NIH Medical College of Wisconsin K12 Research Career Development Program. RJF has received payment for one lecture from Advanced Circulatory Systems. MAW has consulted for Baxter and Vitacare, has received grants/grants pending from the NIH Immediate Trial, payment for lectures or speakers' bureau membership from Vitacare and Sub Zero, and royalties from Cook Critical Care. BDM has board membership for Take Heart Minnesota and has received grants/grants pending from the NIH Neurological Emergency Treatment Trials Network. DET has received grants/grants pending from the Predict HD study, NINDS-6375, NINDS-40068 and NIMH-01579, and royalties as a textbook editor.	Andreka P, 2006, CURR OPIN CRIT CARE, V12, P198, DOI 10.1097/01.ccx.0000224861.70958.59; [Anonymous], 2005, CIRCULATION, V112, pIV1, DOI 10.1161/CIRCULATIONAHA.105.166550; Aufderheide TP, 2008, CRIT CARE MED, V36, pS397, DOI 10.1097/CCM.0b013e31818a7e56; Aufderheide TP, 2005, RESUSCITATION, V64, P353, DOI 10.1016/j.resuscitation.2004.10.007; Bahlmann L, 2003, RESUSCITATION, V59, P255, DOI 10.1016/S0300-9572(03)00211-9; Cabrini L, 2008, CRIT CARE MED, V36, P1625, DOI 10.1097/CCM.0b013e318170ba80; CRAVEN JL, 1988, INT J PSYCHIAT MED, V18, P365; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; Hollenberg J, 2008, CIRCULATION, V118, P389, DOI 10.1161/CIRCULATIONAHA.107.734137; Lai SM, 2001, NEUROEPIDEMIOLOGY, V20, P26, DOI 10.1159/000054754; Langhelle A, 2002, RESUSCITATION, V52, P39, DOI 10.1016/S0300-9572(01)00442-7; Lurie K, 2000, RESUSCITATION, V44, P219, DOI 10.1016/S0300-9572(00)00160-X; LURIE KG, 1995, CIRCULATION, V91, P1629, DOI 10.1161/01.CIR.91.6.1629; Lurie KG, 1997, J CARDIOVASC ELECTR, V8, P584, DOI 10.1111/j.1540-8167.1997.tb00827.x; McCurry SM, 1999, INT J GERIATR PSYCH, V14, P882, DOI 10.1002/(SICI)1099-1166(199910)14:10<882::AID-GPS42>3.0.CO;2-D; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Plaisance P, 2000, CIRCULATION, V101, P989, DOI 10.1161/01.CIR.101.9.989; Plaisance P, 2005, CRIT CARE MED, V33, P990, DOI 10.1097/01.CCM.0000163235.18990.F6; Plaisance P, 2004, RESUSCITATION, V61, P265, DOI 10.1016/j.resuscitation.2004.01.032; Raedler C, 2002, ANESTH ANALG, V95, P1496, DOI 10.1097/00000539-200212000-00007; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schneider T, 1996, RESUSCITATION, V32, P203, DOI 10.1016/0300-9572(96)00946-X; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; Srinivasan V, 2006, J AM COLL CARDIOL, V47, P835, DOI 10.1016/j.jacc.2005.09.062; Voelckel WG, 2002, PEDIATR RES, V51, P523, DOI 10.1203/00006450-200204000-00020; Wik L, 1996, RESUSCITATION, V32, P206, DOI 10.1016/0300-9572(96)82051-X; Wolcke BB, 2003, CIRCULATION, V108, P2201, DOI 10.1161/01.CIR.0000095787.99180.B5; Yannopoulos D, 2005, RESUSCITATION, V64, P363, DOI 10.1016/j.resuscitation.2004.10.009; Yannopoulos D, 2006, CRIT CARE MED, V34, pS495, DOI 10.1097/01.CCM.0000246082.10422.7E	31	178	201	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 22	2011	377	9762					301	311		10.1016/S0140-6736(10)62103-4	http://dx.doi.org/10.1016/S0140-6736(10)62103-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714ZO	21251705	Green Accepted			2023-01-03	WOS:000286850400027
J	Someya, S; Yu, W; Hallows, WC; Xu, JZ; Vann, JM; Leeuwenburgh, C; Tanokura, M; Denu, JM; Prolla, TA				Someya, Shinichi; Yu, Wei; Hallows, William C.; Xu, Jinze; Vann, James M.; Leeuwenburgh, Christiaan; Tanokura, Masaru; Denu, John M.; Prolla, Tomas A.			Sirt3 Mediates Reduction of Oxidative Damage and Prevention of Age-Related Hearing Loss under Caloric Restriction	CELL			English	Article							GLUTATHIONE REDOX STATE; DIETARY RESTRICTION; CELL-DEATH; RAT-LIVER; LIFE-SPAN; MICE; DISEASE; STRESS; MITOCHONDRIA; DEACETYLASE	Caloric restriction (CR) extends the life span and health span of a variety of species and slows the progression of age-related hearing loss (AHL), a common age-related disorder associated with oxidative stress. Here, we report that CR reduces oxidative DNA damage in multiple tissues and prevents AHL in wild-type mice but fails to modify these phenotypes in mice lacking the mitochondrial deacetylase Sirt3, a member of the sirtuin family. In response to CR, Sirt3 directly deacetylates and activates mitochondrial isocitrate dehydrogenase 2 (Idh2), leading to increased NADPH levels and an increased ratio of reduced-to-oxidized glutathione in mitochondria. In cultured cells, overexpression of Sirt3 and/or Idh2 increases NADPH levels and protects from oxidative stress-induced cell death. Therefore, our findings identify Sirt3 as an essential player in enhancing the mitochondrial glutathione antioxidant defense system during CR and suggest that Sirt3-dependent mitochondrial adaptations may be a central mechanism of aging retardation in mammals.	[Yu, Wei; Hallows, William C.; Denu, John M.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; [Someya, Shinichi; Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; [Someya, Shinichi; Vann, James M.; Prolla, Tomas A.] Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA; [Someya, Shinichi; Tanokura, Masaru] Univ Tokyo, Dept Appl Biol Chem, Tokyo 1138657, Japan; [Xu, Jinze; Leeuwenburgh, Christiaan] Univ Florida, Dept Aging & Geriatr, Gainesville, FL 32611 USA; [Xu, Jinze; Leeuwenburgh, Christiaan] Univ Florida, Inst Aging, Gainesville, FL 32611 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Tokyo; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Denu, JM (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.	jmdenu@wisc.edu; taprolla@wisc.edu	Xu, Jinze/G-7868-2011; YU, WEI/G-4128-2013; YU, WEI/C-3822-2012	YU, WEI/0000-0001-9898-4607; Tanokura, Masaru/0000-0001-5072-2480; Leeuwenburgh, Christiaan/0000-0003-0826-4257	NIH [AG021905, GM065386]; Ministry of Education, Culture, Sports, Science, and Technologies of Japan; Marine Bio Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021905, P30AG028740] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Education, Culture, Sports, Science, and Technologies of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Marine Bio Foundation; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank S. Kinoshita for histological processing. This research was supported by NIH grants AG021905 (T.A.P.) and GM065386 (J.M.D.), the National Projects on Protein Structural and Functional Analyses from the Ministry of Education, Culture, Sports, Science, and Technologies of Japan, and Marine Bio Foundation.	Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Anderson ME, 1998, CHEM-BIOL INTERACT, V112, P1; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Barger JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002264; Bordone L, 2007, AGING CELL, V6, P759, DOI 10.1111/j.1474-9726.2007.00335.x; Chen D, 2005, SCIENCE, V310, P1641, DOI 10.1126/science.1118357; Chen D, 2008, GENE DEV, V22, P1753, DOI 10.1101/gad.1650608; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Donmez G, 2010, AGING CELL, V9, P285, DOI 10.1111/j.1474-9726.2010.00548.x; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197; Halliwell B.G.J.M.C., 2007, FREE RADICALS BIOL M; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hofer T, 2006, BIOL CHEM, V387, P103, DOI 10.1515/BC.2006.014; HUNTER KP, 1987, HEARING RES, V30, P207, DOI 10.1016/0378-5955(87)90137-7; Jiang H, 2007, NEUROBIOL AGING, V28, P1605, DOI 10.1016/j.neurobiolaging.2006.06.025; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Johnson KR, 2010, HEARING RES, V268, P85, DOI 10.1016/j.heares.2010.05.002; Keithley EM, 2004, HEARING RES, V188, P21, DOI 10.1016/S0378-5955(03)00365-4; KORNBERG A, 1955, METHOD ENZYMOL, V1, P705, DOI 10.1016/0076-6879(55)01122-1; Koubova J, 2003, GENE DEV, V17, P313, DOI 10.1101/gad.1052903; KUBO K, 1992, BIOCHEMISTRY-US, V31, P3703, DOI 10.1021/bi00129a020; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Liu XZ, 2007, J PATHOL, V211, P188, DOI 10.1002/path.2102; Mari M, 2009, ANTIOXID REDOX SIGN, V11, P2685, DOI [10.1089/ars.2009.2695, 10.1089/ARS.2009.2695]; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McFadden SL, 1999, NEUROBIOL AGING, V20, P1, DOI 10.1016/S0197-4580(99)00018-4; McNeill DR, 2007, MOL CANCER RES, V5, P61, DOI 10.1158/1541-7786.MCR-06-0329; Meira LB, 2009, P NATL ACAD SCI USA, V106, P888, DOI 10.1073/pnas.0807030106; Noben-Trauth K, 2003, NAT GENET, V35, P21, DOI 10.1038/ng1226; Ohlemiller KK, 1999, AUDIOL NEURO-OTOL, V4, P237, DOI 10.1159/000013847; OLAFSDOTTIR K, 1988, BIOCHIM BIOPHYS ACTA, V964, P377, DOI 10.1016/0304-4165(88)90038-4; Paeratakul S, 2002, INT J OBESITY, V26, P1205, DOI 10.1038/sj.ijo.0802026; Poirier P, 2006, ARTERIOSCL THROM VAS, V26, P968, DOI 10.1161/01.ATV.0000216787.85457.f3; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Rahman I, 2006, NAT PROTOC, V1, P3159, DOI 10.1038/nprot.2006.378; Rebrin I, 2003, FREE RADICAL BIO MED, V35, P626, DOI 10.1016/S0891-5849(03)00388-5; Rebrin I, 2008, ADV DRUG DELIVER REV, V60, P1545, DOI 10.1016/j.addr.2008.06.001; Rebrin I, 2007, BRAIN RES, V1127, P10, DOI 10.1016/j.brainres.2006.10.040; Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4; Schlicker C, 2008, J MOL BIOL, V382, P790, DOI 10.1016/j.jmb.2008.07.048; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Smith BC, 2009, ANAL BIOCHEM, V394, P101, DOI 10.1016/j.ab.2009.07.019; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Someya S, 2007, NEUROBIOL AGING, V28, P1613, DOI 10.1016/j.neurobiolaging.2006.06.024; Someya S, 2010, MECH AGEING DEV, V131, P480, DOI 10.1016/j.mad.2010.04.006; Someya S, 2009, P NATL ACAD SCI USA, V106, P19432, DOI 10.1073/pnas.0908786106; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1996, HEARING RES, V28, P227; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; SWEET RJ, 1988, AUDIOLOGY, V27, P305; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Weindruch R., 1988, RETARDATION AGING DI; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9; Zhu HY, 1999, BRAIN RES, V842, P224, DOI 10.1016/S0006-8993(99)01827-2	63	844	888	7	141	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	2010	143	5					802	812		10.1016/j.cell.2010.10.002	http://dx.doi.org/10.1016/j.cell.2010.10.002			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	684VX	21094524	Green Accepted, Bronze			2023-01-03	WOS:000284583500021
J	Graham, WJ; Varghese, B				Graham, Wendy J.; Varghese, Beena			Quality, quality, quality: gaps in the continuum of care	LANCET			English	Editorial Material							HEALTH		[Graham, Wendy J.] Univ Aberdeen, Sch Med & Dent, Aberdeen AB25 2ZD, Scotland; [Varghese, Beena] Publ Hlth Fdn India, New Delhi, India	University of Aberdeen; Public Health Foundation of India	Graham, WJ (corresponding author), Univ Aberdeen, Sch Med & Dent, Aberdeen AB25 2ZD, Scotland.	w.graham@abdn.ac.uk		Graham, Wendy/0000-0003-1473-5342				Bell JS., 2003, TRENDS DELIVERY CARE; Bradshaw D, 2008, LANCET, V371, P1294, DOI 10.1016/S0140-6736(08)60564-4; Godlee F, 2009, BMJ-BRIT MED J, V339, pb4346, DOI DOI 10.1136/bmj.b4346; Institute of Medicine, 2001, CROSS QUAL CHASM; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Neal S, 2010, WHITE RIBBON ALLIANC; Nehru, 1962, GLIMPSES WORLD HIST; Pan American Health Organization/WHO, 2003, MON RED MAT MORB MOR; The Earth Institute Columbia University, 2010, BARR GAPS AFF MHEALT; United Nations, 2010, GLOB STRAT WOM CHILD; United Nations Population Fund, 2009, CONC ASS JAN SUR YOJ; van den Broek NR, 2009, BJOG-INT J OBSTET GY, V116, P18, DOI 10.1111/j.1471-0528.2009.02333.x; WHO, 2010, WOR HEALT REP, P1; WHO, 2008, FACTSH SKILL ATT; COUNTDOWN 2015 MATER; 2010, PARTNERSHIP MATERNAL	16	56	56	1	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 14	2012	379	9811					E5	E6		10.1016/S0140-6736(10)62267-2	http://dx.doi.org/10.1016/S0140-6736(10)62267-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	879GM	21474173				2023-01-03	WOS:000299317700001
J	Abou-Setta, AM; Beaupre, LA; Rashiq, S; Dryden, DM; Hamm, MP; Sadowski, CA; Menon, MRG; Majumdar, SR; Wilson, DM; Karkhaneh, M; Mousavi, SS; Wong, K; Tjosvold, L; Jones, CA				Abou-Setta, Ahmed M.; Beaupre, Lauren A.; Rashiq, Saifee; Dryden, Donna M.; Hamm, Michele P.; Sadowski, Cheryl A.; Menon, Matthew R. G.; Majumdar, Sumit R.; Wilson, Donna M.; Karkhaneh, Mohammad; Mousavi, Shima S.; Wong, Kai; Tjosvold, Lisa; Jones, C. Allyson			Comparative Effectiveness of Pain Management Interventions for Hip Fracture: A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							FEMORAL NERVE BLOCK; PREOPERATIVE SKIN TRACTION; PSOAS COMPARTMENT BLOCK; PERIOPERATIVE MYOCARDIAL-ISCHEMIA; SPINAL-ANESTHESIA; ELDERLY-PATIENTS; POSTOPERATIVE ANALGESIA; EMERGENCY-DEPARTMENT; ONSET TIME; DOSE BUPIVACAINE	Background: Pain management is integral to the management of hip fracture. Purpose: To review the benefits and harms of pharmacologic and nonpharmacologic interventions for managing pain after hip fracture. Data Sources: 25 electronic databases (January 1990 to December 2010), gray literature, trial registries, and reference lists, with no language restrictions. Study Selection: Multiple reviewers independently and in duplicate screened 9357 citations to identify randomized, controlled trials (RCTs); nonrandomized, controlled trials (non-RCTs); and cohort studies of pain management techniques in older adults after acute hip fracture. Data Extraction: Independent, duplicate data extraction and quality assessment were conducted, with discrepancies resolved by consensus or a third reviewer. Data extracted included study characteristics, inclusion and exclusion criteria, participant characteristics, interventions, and outcomes. Data Synthesis: 83 unique studies (64 RCTs, 5 non-RCTs, and 14 cohort studies) were included that addressed nerve blockade (n = 32), spinal anesthesia (n = 30), systemic analgesia (n = 3), traction (n = 11), multimodal pain management (n = 2), neurostimulation (n = 2), rehabilitation (n = 1), and complementary and alternative medicine (n = 2). Overall, moderate evidence suggests that nerve blockades are effective for relieving acute pain and reducing delirium. Low-level evidence suggests that preoperative traction does not reduce acute pain. Evidence was insufficient on the benefits and harms of most interventions, including spinal anesthesia, systemic analgesia, multimodal pain management, acupressure, relaxation therapy, transcutaneous electrical neurostimulation, and physical therapy regimens, in managing acute pain. Limitations: No studies evaluated outcomes of chronic pain or exclusively examined participants from nursing homes or with cognitive impairment. Systemic analgesics (narcotics, nonsteroidal anti-inflammatory drugs) were understudied during the search period. Conclusion: Nerve blockade seems to be effective in reducing acute pain after hip fracture. Sparse data preclude firm conclusions about the relative benefits or harms of many other pain management interventions for patients with hip fracture.	[Abou-Setta, Ahmed M.] Univ Alberta, Fac Med & Dent, Dept Pediat, Alberta Res Ctr Hlth Evidence,Univ Alberta Eviden, Edmonton, AB T6G 2J3, Canada	University of Alberta	Abou-Setta, AM (corresponding author), Univ Alberta, Fac Med & Dent, Dept Pediat, Alberta Res Ctr Hlth Evidence,Univ Alberta Eviden, Aberhart Ctr 1,Room 8412,11402 Univ Ave, Edmonton, AB T6G 2J3, Canada.	ahmedabou-setta@med.ualberta.ca	Sadowski, Cheryl/X-4663-2019	Tjosvold, Lisa/0000-0002-5667-6312	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [HHSA 290 2007 10021 I]; Alberta Innovates-Health Solutions (formerly Alberta Heritage Foundation for Medical Research); Canadian Institutes of Health Research; Agency for Healthcare Research and Quality; University of Alberta Evidence-based Practice Center; Edmonton Civic Employees Charitable Fund	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); Alberta Innovates-Health Solutions (formerly Alberta Heritage Foundation for Medical Research); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); University of Alberta Evidence-based Practice Center; Edmonton Civic Employees Charitable Fund	This project was funded under contract HHSA 290 2007 10021 I from the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services. Drs. Beaupre, Jones, and Majumdar receive salary support from Alberta Innovates-Health Solutions (formerly Alberta Heritage Foundation for Medical Research), and Dr. Jones receives new investigator salary support from the Canadian Institutes of Health Research.r Drs. Abou-Setta, Rashiq, and Dryden: Grant (money to institution): Agency for Healthcare Research and Quality. Drs. Beaupre and Jones: Grant (money to institution): Agency for Healthcare Research and Quality; Other (money to institution): University of Alberta Evidence-based Practice Center. Dr. Sadowski: Grants/grants pending (money to institution): Pfizer Canada; Payment for lectures including service on speakers bureaus: Pfizer Canada. Dr. Menon: Employment: University of Alberta; Grants/grants pending: Edmonton Civic Employees Charitable Fund. Dr. Karkhaneh: Grant (money to institution): Agency for Healthcare Research and Quality. Mr. Wong: Grant (money to institution): Agency for Healthcare Research and Quality. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M11-0328.	Abbey Jennifer, 2004, Int J Palliat Nurs, V10, P6; Abou-Setta AM, 2011, AHRQ PUBLICATION; Adams H A, 1990, Anasth Intensivther Notfallmed, V25, P263, DOI 10.1055/s-2007-1001062; Alonso Chico A, 2003, Rev Esp Anestesiol Reanim, V50, P17; Amador LF, 2005, J AM COLL SURGEONS, V200, P767, DOI 10.1016/j.jamcollsurg.2004.08.031; ANDERSON GH, 1993, J BONE JOINT SURG BR, V75, P794, DOI 10.1302/0301-620X.75B5.8376442; Antonopoulo E, 2006, REGIONAL ANESTHES S1, V31, P92; Apostolopoulos A, 2006, J BONE JOINT SURG S1, p[88, 186]; Baker A, 2004, ANESTH ANALG, V99, P128, DOI 10.1213/01.ANE.0000114549.17864.36; Barker R, 2006, ACAD EMERG MED, V13, P19, DOI 10.1197/j.aem.2005.07.014; Beaupre LA, 2007, J GERONTOL A-BIOL, V62, P1127, DOI 10.1093/gerona/62.10.1127; Ben-David B, 2000, ANESTHESIOLOGY, V92, P6, DOI 10.1097/00000542-200001000-00007; Bitsch MS, 2004, ACTA ORTHOP SCAND, V75, P378, DOI 10.1080/00016470410001123; Bradburn MJ, 2007, STAT MED, V26, P53, DOI 10.1002/sim.2528; BREDAHL C, 1991, ACTA ANAESTH SCAND, V35, P548, DOI 10.1111/j.1399-6576.1991.tb03346.x; Casati A, 2003, EUR J ANAESTH, V20, P640, DOI 10.1097/00003643-200308000-00009; Chudinov A, 1999, REGION ANESTH PAIN M, V24, P563, DOI 10.1016/S1098-7339(99)90050-0; Cleeland CS, 1998, JAMA-J AM MED ASSOC, V279, P1914, DOI 10.1001/jama.279.23.1914; CLOSS SJ, 1990, J ADV NURS, V15, P42, DOI 10.1111/j.1365-2648.1990.tb01671.x; COAD NR, 1991, EUR J ANAESTH, V8, P287; Cuvillon P, 2007, ANN FR ANESTH, V26, P2, DOI 10.1016/j.annfar.2006.06.025; Danelli G, 2008, CAN J ANAESTH, V55, P501, DOI 10.1007/BF03016669; de Visme V, 2000, REGION ANESTH PAIN M, V25, P158, DOI 10.1053/rapm.2000.0250158; Del Rosario E., 2008, ACUTE PAIN, V10, P59, DOI [10.1016/j.acpain.2008.02.001, DOI 10.1016/J.ACPAIN.2008.02.001]; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Lorenzo L, 2007, Eura Medicophys, V43, P349; Ehret B, 2006, J EUROPEEN URGENCES, V19, P9; Eyrolle L, 1998, BRIT J ANAESTHESI S1, V80, P112; FavarelGarrigues JF, 1996, ANESTH ANALG, V82, P312, DOI 10.1097/00000539-199602000-00017; Ferrell BA, 1998, J AM GERIATR SOC, V46, P635, DOI 10.1111/j.1532-5415.1998.tb01084.x; FERRELL BA, 1991, J AM GERIATR SOC, V39, P64, DOI 10.1111/j.1532-5415.1991.tb05908.x; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; FINSEN V, 1992, INJURY, V23, P242, DOI 10.1016/S0020-1383(05)80007-5; Fletcher AK, 2003, ANN EMERG MED, V41, P227, DOI 10.1067/mem.2003.51; Foss NB, 2005, ANESTHESIOLOGY, V102, P1197, DOI 10.1097/00000542-200506000-00020; Foss NB, 2007, ANESTHESIOLOGY, V106, P773, DOI 10.1097/01.anes.0000264764.56544.d2; Fuchs-Lacelle S, 2004, PAIN MANAG NURS, V5, P37, DOI 10.1016/j.pmn.2003.10.001; Ghnaimat M, 2005, J BAHRAIN MED SOC, V17, P240; Gille J, 2006, ANAESTHESIST, V55, P414, DOI 10.1007/s00101-005-0949-4; Monzon DG, 2010, INT J EMERG MED, V3, P321, DOI 10.1007/s12245-010-0234-4; Gorodetskyi IG, 2007, J BONE JOINT SURG BR, V89B, P1488, DOI 10.1302/0301-620X.89B11.19352; Gotzsche PC, 2007, JAMA-J AM MED ASSOC, V298, P430, DOI 10.1001/jama.298.4.430; Graham CA, 2008, HONG KONG J EMERG ME, V15, P205, DOI 10.1177/102490790801500403; HADDAD FS, 1995, J BONE JOINT SURG BR, V77B, P922, DOI 10.1302/0301-620X.77B6.7593107; Henderson K, 2008, ANN EMERG MED, V52, pS164, DOI 10.1016/j.annemergmed.2008.06.426; Herrick C, 2004, J AM GERIATR SOC, V52, P2062, DOI 10.1111/j.1532-5415.2004.52566.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Hoda Mohammad Qamarul, 2007, J Pak Med Assoc, V57, P245; HOOD G, 1991, ANAESTHESIA, V46, P138, DOI 10.1111/j.1365-2044.1991.tb09361.x; Hooda S, 2006, J ANAESTHESIOLOGY CL, V22, P267; Jerre R, 2000, CLIN ORTHOP RELAT R, P169; Juelsgaard P, 1998, EUR J ANAESTH, V15, P656, DOI 10.1097/00003643-199811000-00006; KLIMSCHA W, 1995, ANESTH ANALG, V80, P322, DOI 10.1097/00000539-199502000-00020; Kocum A, 2007, ANAESTH INTENS CARE, V35, P510, DOI 10.1177/0310057X0703500408; Koval KJ, 1999, ORTHOPEDICS, V22, P31; Krobot R, 2006, REG ANESTH PAIN M S1, V31, P33; Kwan A. S. K., 1997, Hong Kong Medical Journal, V3, P250; LABAILLE T, 1992, REGION ANESTH, V17, P193; Lane A, 2008, CAN J ANAESTH, V55, P190, DOI 10.1007/BF03016097; Lang T, 2007, J TRAUMA, V62, P184, DOI 10.1097/01.ta.0000197176.75598.fc; Mak JCS, 2010, MED J AUSTRALIA, V192, P37, DOI 10.5694/j.1326-5377.2010.tb03400.x; Malchow RJ, 2008, CRIT CARE MED, V36, pS346, DOI 10.1097/CCM.0b013e31817e2fc9; Malcolmson SE, 2009, CRITICAL CARE SHOCK, V12, P144; Malek J, 2004, ACUTE PAIN, V6, P53; Mannion S, 2005, ANESTH ANALG, V100, P873, DOI 10.1213/01.ANE.0000143950.13939.7A; Marhofer P, 1997, ANESTH ANALG, V85, P854, DOI 10.1097/00000539-199710000-00026; Marhofer P, 1998, REGION ANESTH PAIN M, V23, P584, DOI 10.1016/S1098-7339(98)90086-4; Marhofer P, 2000, ANESTH ANALG, V90, P125, DOI 10.1097/00000539-200001000-00028; Martin KR, 1991, RELAXATION POSTOPERA; Martyr JW, 2005, ANAESTH INTENS CARE, V33, P64, DOI 10.1177/0310057X0503300110; Martyr JW, 2001, ANAESTH INTENS CARE, V29, P501, DOI 10.1177/0310057X0102900509; Matot I, 2003, ANESTHESIOLOGY, V98, P156, DOI 10.1097/00000542-200301000-00025; MAURETTE P, 1993, REGION ANESTH, V18, P290; Milisen K, 2001, J AM GERIATR SOC, V49, P523, DOI 10.1046/j.1532-5415.2001.49109.x; MILLER K, 1990, ANAESTHESIST, V39, P83; Minville V, 2006, ANESTH ANALG, V102, P1559, DOI 10.1213/01.ane.0000218421.18723.cf; Minville V, 2008, MINERVA ANESTESIOL, V74, P691; Morrison RS, 2003, J GERONTOL A-BIOL, V58, P76; Morrison RS, 2003, PAIN, V103, P303, DOI 10.1016/S0304-3959(02)00458-X; Mouzopoulos G, 2009, J ORTHOP TRAUMATOL, V10, P127, DOI 10.1007/s10195-009-0062-6; Navas Martinez A, 2008, REG ANESTH PAIN M S1, V33, pe30; NEEDOFF M, 1993, INJURY, V24, P317, DOI 10.1016/0020-1383(93)90054-A; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Olofsson C, 2004, ACTA ANAESTH SCAND, V48, P1240, DOI 10.1111/j.1399-6576.2004.00504.x; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Parker MJ, 2006, COCHRANE DB SYST REV, V3; Pasero CL, 1997, AM J NURS, V97, P20; Pedersen SJ, 2008, J AM GERIATR SOC, V56, P1831, DOI 10.1111/j.1532-5415.2008.01945.x; Penrod JD, 2004, J AM GERIATR SOC, V52, P1114, DOI 10.1111/j.1532-5415.2004.52309.x; Pergolizzi Joseph, 2008, Pain Pract, V8, P287, DOI 10.1111/j.1533-2500.2008.00204.x; Poitevin Luciano Augusto, 1999, Prensa Medica Argentina, V86, P913; Rais K, 2008, EUR 2008 EUR SOC AN; Resch S, 2005, DISABIL REHABIL, V27, P1191, DOI 10.1080/09638280500055800; Resch S, 1998, ACTA ORTHOP SCAND, V69, P277; Ronald LA, 2008, CAN J AGING, V27, P109, DOI 10.3138/cja.27.1.109; Roofthooft E, 2008, CURR OPIN ANESTHESIO, V21, P259, DOI 10.1097/ACO.0b013e3282ff5e41; Rosen JE, 2001, J ORTHOP TRAUMA, V15, P81, DOI 10.1097/00005131-200102000-00001; Said-Ahmed HA, 2006, ACTA ANAESTHESIOL IT, V57, P198; Saygi B, 2010, BULL HOSP JT DIS, V68, P15; Scheinin H, 2000, ACTA ANAESTH SCAND, V44, P1061, DOI 10.1034/j.1399-6576.2000.440905.x; Jimenez MIS, 2009, REV ESP ANEST REANIM, V56, P590, DOI 10.1016/S0034-9356(09)70474-8; Segado Jimnez MI., 2010, REV SOC ESPA OLA DOL, V17, P259; Sen Selda, 2007, J Clin Monit Comput, V21, P103, DOI 10.1007/s10877-006-9062-8; Shih YJ, 2010, INT J GERONTOL, V4, P37, DOI 10.1016/S1873-9598(10)70020-X; Spansberg NLM, 1996, EUR J ANAESTH, V13, P410, DOI 10.1046/j.1365-2346.1996.00958.x; SUTCLIFFE AJ, 1994, ANAESTHESIA, V49, P237; Tuncer S, 2003, ACUTE PAIN, V4, P105; Turker G, 2003, ACTA ANAESTH SCAND, V47, P30, DOI 10.1034/j.1399-6576.2003.470106.x; Van Balen R, 2003, DISABIL REHABIL, V25, P507, DOI 10.1080/0963828031000090443; Vermeiren J, 1995, Acta Orthop Belg, V61, P122; Warden Victoria, 2003, J Am Med Dir Assoc, V4, P9, DOI 10.1097/00130535-200301000-00002; Wells G., 2009, VIS COMMUN Q; Yip DKH, 2002, INT ORTHOP, V26, P361, DOI 10.1007/s00264-002-0387-8; Yun MJ, 2009, ACTA ANAESTH SCAND, V53, P1282, DOI 10.1111/j.1399-6576.2009.02052.x	115	125	134	5	55	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2011	155	4					234	+		10.7326/0003-4819-155-4-201108160-00346	http://dx.doi.org/10.7326/0003-4819-155-4-201108160-00346			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807KN	21844549				2023-01-03	WOS:000293896400004
J	Luther, S; Fenton, FH; Kornreich, BG; Squires, A; Bittihn, P; Hornung, D; Zabel, M; Flanders, J; Gladuli, A; Campoy, L; Cherry, EM; Luther, G; Hasenfuss, G; Krinsky, VI; Pumir, A; Gilmour, RF; Bodenschatz, E				Luther, Stefan; Fenton, Flavio H.; Kornreich, Bruce G.; Squires, Amgad; Bittihn, Philip; Hornung, Daniel; Zabel, Markus; Flanders, James; Gladuli, Andrea; Campoy, Luis; Cherry, Elizabeth M.; Luther, Gisa; Hasenfuss, Gerd; Krinsky, Valentin I.; Pumir, Alain; Gilmour, Robert F., Jr.; Bodenschatz, Eberhard			Low-energy control of electrical turbulence in the heart	NATURE			English	Article							CARDIAC TISSUE; SPIRAL WAVES; DEFIBRILLATION; FIBRILLATION; TERMINATION; FIELD; PROPAGATION; ACTIVATION; MECHANISMS; SHOCKS	Controlling the complex spatio-temporal dynamics underlying life-threatening cardiac arrhythmias such as fibrillation is extremely difficult, because of the nonlinear interaction of excitation waves in a heterogeneous anatomical substrate(1-4). In the absence of a better strategy, strong, globally resetting electrical shocks remain the only reliable treatment for cardiac fibrillation(5-7). Here we establish the relationship between the response of the tissue to an electric field and the spatial distribution of heterogeneities in the scale-free coronary vascular structure. We show that in response to a pulsed electric field, E, these heterogeneities serve as nucleation sites for the generation of intramural electrical waves with a source density rho(E) and a characteristic time, tau, for tissue depolarization that obeys the power law tau proportional to E-alpha. These intramural wave sources permit targeting of electrical turbulence near the cores of the vortices of electrical activity that drive complex fibrillatory dynamics. Weshow in vitro that simultaneous and direct access to multiple vortex cores results in rapid synchronization of cardiac tissue and therefore, efficient termination of fibrillation. Using this control strategy, we demonstrate low-energy termination of fibrillation in vivo. Our results give new insights into the mechanisms and dynamics underlying the control of spatio-temporal chaos in heterogeneous excitable media and provide new research perspectives towards alternative, life-saving low-energy defibrillation techniques.	[Luther, Stefan; Fenton, Flavio H.; Squires, Amgad; Bittihn, Philip; Hornung, Daniel; Cherry, Elizabeth M.; Luther, Gisa; Krinsky, Valentin I.; Bodenschatz, Eberhard] Max Planck Inst Dynam & Self Org, D-37077 Gottingen, Germany; [Luther, Stefan; Fenton, Flavio H.; Cherry, Elizabeth M.; Gilmour, Robert F., Jr.] Cornell Univ, Dept Biomed Sci, Ithaca, NY 14853 USA; [Luther, Stefan; Bittihn, Philip; Hornung, Daniel; Luther, Gisa; Bodenschatz, Eberhard] Georg August Univ, Inst Nonlinear Dynam, D-37077 Gottingen, Germany; [Luther, Stefan; Zabel, Markus; Hasenfuss, Gerd; Bodenschatz, Eberhard] Heart Res Ctr Gottingen HRCG, D-37075 Gottingen, Germany; [Kornreich, Bruce G.; Flanders, James; Gladuli, Andrea; Campoy, Luis] Cornell Univ, Dept Clin Sci, Ithaca, NY 14853 USA; [Squires, Amgad; Bodenschatz, Eberhard] Cornell Univ, Lab Atom & Solid State Phys, Ithaca, NY 14853 USA; [Zabel, Markus; Hasenfuss, Gerd] Univ Med Ctr UMG, Dept Cardiol & Pneumol, D-37075 Gottingen, Germany; [Cherry, Elizabeth M.] Rochester Inst Technol, Sch Math Sci, Rochester, NY 14623 USA; [Krinsky, Valentin I.] Inst Nonlineaire Nice, F-06560 Valbonne, France; [Pumir, Alain] Univ Lyon 1, Lab Phys, Ecole Normale Super Lyon, F-69007 Lyon, France; [Pumir, Alain] CNRS, F-69007 Lyon, France; [Bodenschatz, Eberhard] Cornell Univ, Dept Mech & Aerosp Engn, Ithaca, NY 14853 USA	Max Planck Society; Cornell University; University of Gottingen; Cornell University; Cornell University; Rochester Institute of Technology; Ecole Normale Superieure de Lyon (ENS de LYON); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique (CNRS); Cornell University	Luther, S (corresponding author), Max Planck Inst Dynam & Self Org, Fassberg 17, D-37077 Gottingen, Germany.	stefan.luther@ds.mpg.de; flavio.h.fenton@cornell.edu	Luther, Stefan/C-7226-2009; Squires, Amgad Andrew/E-7414-2010; Bittihn, Philip/E-2078-2011; Pumir, Alain/AAH-6566-2020	Bittihn, Philip/0000-0002-1276-9381; Bodenschatz, Eberhard/0000-0002-2901-0144; Hornung, Daniel/0000-0002-7846-6375	National Science Foundation (NSF) [0800793, 0926190]; National Institutes of Health (NIH) [HL075515-S04, HL075515, HL073644]; IFCPAR Project [3404-4]; German Ministry for Education and Research [FKZ 01EZ0905/6]; Kavli Institute for Theoretical Physics [NSFPHY05-51164]; Pittsburgh Supercomputing Center (NSF TeraGrid); Pittsburgh NMR Center for Biomedical Research [NIH P41-EB001977]; European Community [HEALTH-F2-2009-241526]; Max Planck Society; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073644, R01HL075515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB001977] Funding Source: NIH RePORTER	National Science Foundation (NSF)(National Science Foundation (NSF)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); IFCPAR Project; German Ministry for Education and Research(Federal Ministry of Education & Research (BMBF)); Kavli Institute for Theoretical Physics; Pittsburgh Supercomputing Center (NSF TeraGrid)(National Science Foundation (NSF)); Pittsburgh NMR Center for Biomedical Research; European Community(European Commission); Max Planck Society(Max Planck SocietyFoundation CELLEX); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank M. L. Riccio and the Cornell University mu CT Facility for Imaging and Preclinical Research for performing the micro-CT scanning, and T. K. Hitchens for technical assistance with cardiac structural imaging. M. W. Enyeart and J. Boesch assisted with the experiments and N. F. Otani provided insights from computer simulations. G. Hooker conducted the statistical analysis. This work was supported by National Science Foundation (NSF) grants 0800793 (F.H.F. and E.M.C.) and 0926190 (F.H.F.); by National Institutes of Health (NIH) grants HL075515-S04 (F.H.F.), HL075515 (R.F.G.) and HL073644 (R.F.G. and E.B.); by IFCPAR Project no. 3404-4 (A.P.); by the German Ministry for Education and Research through FKZ 01EZ0905/6 (S.L., M.Z., E.B. and G.H.); by the Kavli Institute for Theoretical Physics through NSFPHY05-51164; by the Pittsburgh Supercomputing Center (NSF TeraGrid); by the Pittsburgh NMR Center for Biomedical Research (NIH P41-EB001977); by the European Community's Seventh Framework Programme FP7/2007-2013 agreement HEALTH-F2-2009-241526 (EUTrigTreat) and by the Max Planck Society.	BABBS CF, 1980, AM HEART J, V99, P734, DOI 10.1016/0002-8703(80)90623-7; BIKTASHEV VN, 1994, PHILOS T R SOC A, V347, P611, DOI 10.1098/rsta.1994.0070; Cherry EM, 2008, NEW J PHYS, V10, DOI 10.1088/1367-2630/10/12/125016; DAVIDENKO JM, 1992, NATURE, V355, P349, DOI 10.1038/355349a0; Fast VG, 1998, CIRC RES, V82, P375, DOI 10.1161/01.RES.82.3.375; Fenton F, 1998, CHAOS, V8, P20, DOI 10.1063/1.166311; Fenton FH, 2002, CHAOS, V12, P852, DOI 10.1063/1.1504242; Fenton FH, 2009, CIRCULATION, V120, P467, DOI 10.1161/CIRCULATIONAHA.108.825091; Gray RA, 2005, P NATL ACAD SCI USA, V102, P4672, DOI 10.1073/pnas.0407860102; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; Hooks DA, 2002, CIRC RES, V91, P331, DOI 10.1161/01.RES.0000031957.70034.89; Kassab GS, 2006, AM J PHYSIOL-HEART C, V290, pH894, DOI 10.1152/ajpheart.00579.2005; KIRCHHOF C, 1993, CIRCULATION, V88, P736, DOI 10.1161/01.CIR.88.2.736; Koster RW, 2004, AM HEART J, V147, DOI 10.1016/j.ahj.2003.10.049; Mackenzie D, 2004, SCIENCE, V303, P786, DOI 10.1126/science.303.5659.786; Maleckar MM, 2008, AM J PHYSIOL-HEART C, V295, pH1626, DOI 10.1152/ajpheart.00706.2008; Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207; PLONSEY R, 1982, BIOPHYS J, V39, P309, DOI 10.1016/S0006-3495(82)84521-9; Pumir A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.208101; Pumir A, 1999, J THEOR BIOL, V199, P311, DOI 10.1006/jtbi.1999.0957; Rappel WJ, 1999, PHYS REV LETT, V83, P456, DOI 10.1103/PhysRevLett.83.456; Ripplinger CM, 2006, AM J PHYSIOL-HEART C, V291, pH184, DOI 10.1152/ajpheart.01300.2005; ROTH BJ, 1986, IEEE T BIO-MED ENG, V33, P467, DOI 10.1109/TBME.1986.325804; Sakurai T, 2002, SCIENCE, V296, P2009, DOI 10.1126/science.1071265; Sambelashvili AT, 2004, AM J PHYSIOL-HEART C, V286, pH2183, DOI 10.1152/ajpheart.00637.2003; Santini M, 1999, J INTERV CARD ELECTR, V3, P45, DOI 10.1023/A:1009871422517; Takagi S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.058101; Trayanova N, 1998, J ELECTROCARDIOL, V31, P23, DOI 10.1016/S0022-0736(98)90274-6; Walcott GP, 2003, RESUSCITATION, V59, P59, DOI 10.1016/S0300-9572(03)00161-8; Witkowski FX, 1998, NATURE, V392, P78, DOI 10.1038/32170	30	219	222	3	87	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2011	475	7355					235	U152		10.1038/nature10216	http://dx.doi.org/10.1038/nature10216			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	791UA	21753855	Green Accepted			2023-01-03	WOS:000292690500052
J	Gentschev, I; Muller, M; Adelfinger, M; Weibel, S; Grummt, F; Zimmermann, M; Bitzer, M; Heisig, M; Zhang, Q; Yu, YA; Chen, NG; Stritzker, J; Lauer, UM; Szalay, AA				Gentschev, Ivaylo; Mueller, Meike; Adelfinger, Marion; Weibel, Stephanie; Grummt, Friedrich; Zimmermann, Martina; Bitzer, Michael; Heisig, Martin; Zhang, Qian; Yu, Yong A.; Chen, Nanhai G.; Stritzker, Jochen; Lauer, Ulrich M.; Szalay, Aladar A.			Efficient Colonization and Therapy of Human Hepatocellular Carcinoma (HCC) Using the Oncolytic Vaccinia Virus Strain GLV-1h68	PLOS ONE			English	Article							BREAST-TUMORS; NUDE-MICE; IN-VIVO; CANCER; ANGIOGENESIS; INHIBITOR; TISSUE; AGENT; COX-2	Virotherapy using oncolytic vaccinia virus strains is one of the most promising new strategies for cancer therapy. In this study, we analyzed for the first time the therapeutic efficacy of the oncolytic vaccinia virus GLV-1h68 in two human hepatocellular carcinoma cell lines HuH7 and PLC/PRF/5 (PLC) in cell culture and in tumor xenograft models. By viral proliferation assays and cell survival tests, we demonstrated that GLV-1h68 efficiently colonized, replicated in, and did lyse these cancer cells in culture. Experiments with HuH7 and PLC xenografts have revealed that a single intravenous injection (i.v.) of mice with GLV-1h68 resulted in a significant reduction of primary tumor sizes compared to uninjected controls. In addition, replication of GLV-1h68 in tumor cells led to strong inflammatory and oncolytic effects resulting in intense infiltration of MHC class II-positive cells like neutrophils, macrophages, B cells and dendritic cells and in up-regulation of 13 pro-inflammatory cytokines. Furthermore, GLV-1h68 infection of PLC tumors inhibited the formation of hemorrhagic structures which occur naturally in PLC tumors. Interestingly, we found a strongly reduced vascular density in infected PLC tumors only, but not in the non-hemorrhagic HuH7 tumor model. These data demonstrate that the GLV-1h68 vaccinia virus may have an enormous potential for treatment of human hepatocellular carcinoma in man.	[Gentschev, Ivaylo; Zhang, Qian; Yu, Yong A.; Chen, Nanhai G.; Stritzker, Jochen; Szalay, Aladar A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Gentschev, Ivaylo; Mueller, Meike; Adelfinger, Marion; Weibel, Stephanie; Grummt, Friedrich; Stritzker, Jochen; Szalay, Aladar A.] Univ Wurzburg, Dept Biochem, Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Rudolf Virchow Ctr Expt Biomed, Wurzburg, Germany; [Szalay, Aladar A.] Univ Wurzburg, Inst Mol Infect Biol, Wurzburg, Germany; [Zimmermann, Martina; Bitzer, Michael; Lauer, Ulrich M.] Med Univ Hosp, Dept Gastroenterol & Hepatol, Tubingen, Germany; [Heisig, Martin] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Zhang, Qian; Yu, Yong A.; Chen, Nanhai G.; Szalay, Aladar A.] Univ Calif San Diego, Dept Radiat Oncol, Rebecca & John Moores Comprehens Canc Ctr, La Jolla, CA 92093 USA	University of Wurzburg; University of Wurzburg; University of Wurzburg; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; University of Hamburg; University Medical Center Hamburg-Eppendorf; Yale University; University of California System; University of California San Diego	Gentschev, I (corresponding author), Genelux Corp, San Diego Sci Ctr, San Diego, CA USA.	aaszalay@genelux.com	Stritzker, Jochen/E-9094-2011; Gentschev, Ivaylo/F-9454-2011; Gentschev, Ivaylo/AAJ-5819-2021	Gentschev, Ivaylo/0000-0003-3743-6329; Muller, Meike/0000-0003-3119-2327	Research and Development Division of Genelux Corporation, San Diego, USA; Genelux Corp., San Diego, USA; Genelux Corporation; German Research Council (DFG) [SFB 773, C3]	Research and Development Division of Genelux Corporation, San Diego, USA; Genelux Corp., San Diego, USA; Genelux Corporation; German Research Council (DFG)(German Research Foundation (DFG))	The research was supported by the Research and Development Division of Genelux Corporation, San Diego, USA, and a Service Grant to the University of Wurzburg, Germany also funded by Genelux Corp., San Diego, USA. IG QZ YAY NGC JS and AAS are employees and shareholders of Genelux. MA and SW were supported by grants of Genelux Corporation. This work also was supported in part by grants from the German Research Council (DFG) SFB 773 (project C3). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANGIOLILLO AL, 1995, J EXP MED, V182, P155, DOI 10.1084/jem.182.1.155; Brader P, 2009, CLIN CANCER RES, V15, P3791, DOI 10.1158/1078-0432.CCR-08-3236; Chen NH, 2009, MOL MED, V15, P144, DOI 10.2119/molmed.2009.00014; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gentschev I, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/489759; Gentschev I, 2010, J ONCOL, V2010, DOI 10.1155/2010/736907; Hu KQ, 2003, INT J ONCOL, V22, P757; Hu KQ, 2002, J LAB CLIN MED, V139, P234, DOI 10.1067/mlc.2002.122281; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Kelly KJ, 2009, INT J CANCER, V124, P911, DOI 10.1002/ijc.24037; Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697; Kondo M, 1999, CLIN CANCER RES, V5, P4005; Lee JC, 2002, CANCER RES, V62, P747; Lin SF, 2007, SURGERY, V142, P976, DOI 10.1016/j.surg.2007.09.017; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; Llovet JM, 2003, LANCET, V362, P1907, DOI 10.1016/S0140-6736(03)14964-1; Schonbeck U, 2001, CELL MOL LIFE SCI, V58, P4, DOI 10.1007/PL00000776; ten Hagen TLM, 2003, TECHNOL CANCER RES T, V2, P195; Thomas MB, 2005, J CLIN ONCOL, V23, P2892, DOI 10.1200/JCO.2005.03.196; Weibel S, 2008, CELL MICROBIOL, V10, P1235, DOI 10.1111/j.1462-5822.2008.01122.x; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Yu ZJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-45; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146; Zhang Q, 2009, MOL GENET GENOMICS, V282, P417, DOI 10.1007/s00438-009-0475-1	26	34	36	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 11	2011	6	7							e22069	10.1371/journal.pone.0022069	http://dx.doi.org/10.1371/journal.pone.0022069			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	791QY	21779374	Green Published, gold, Green Submitted			2023-01-03	WOS:000292680900027
J	Caplan, AI; Correa, D				Caplan, Arnold I.; Correa, Diego			The MSC: An Injury Drugstore	CELL STEM CELL			English	Article							MESENCHYMAL STEM-CELLS; MARROW STROMAL CELLS; PROGENITOR CELLS; ADIPOSE-TISSUE; ADULT; CULTURES; THERAPY; DIFFERENTIATION; TRANSPLANTATION; MECHANISMS	Now that mesenchymal stem cells (MSCs) have been shown to be perivascular in vivo, the existing traditional view that focuses on the multipotent differentiation capacity of these cells should be expanded to include their equally interesting role as cellular modulators that brings them into a broader therapeutic scenario. We discuss existing evidence that leads us to propose that during local injury, MSCs are released from their perivascular location, become activated, and establish a regenerative microenvironment by secreting bioactive molecules and regulating the local immune response. These trophic and immunomodulatory activities suggest that MSCs may serve as site-regulated "drugstores" in vivo.	[Caplan, Arnold I.; Correa, Diego] Case Western Reserve Univ, Skeletal Res Ctr, Dept Biol, Cleveland, OH 44106 USA	Case Western Reserve University	Caplan, AI (corresponding author), Case Western Reserve Univ, Skeletal Res Ctr, Dept Biol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	arnold.caplan@case.edu		Caplan, Arnold/0000-0002-8677-6621	E. Virginia and L. David Baldwin Research Fund; NIH [PO1-AR053622]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR053622] Funding Source: NIH RePORTER	E. Virginia and L. David Baldwin Research Fund; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Support for this article was provided by the E. Virginia and L. David Baldwin Research Fund and the NIH (PO1-AR053622).	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Bai LH, 2009, GLIA, V57, P1192, DOI 10.1002/glia.20841; Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582-4934.2004.tb00320.x; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Bonfield TL, 2010, AM J PHYSIOL-LUNG C, V299, pL760, DOI 10.1152/ajplung.00182.2009; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Caplan AI, 2008, CELL STEM CELL, V3, P229, DOI 10.1016/j.stem.2008.08.008; Caplan AI, 2006, J CELL BIOCHEM, V98, P1076, DOI 10.1002/jcb.20886; Caplan AI, 2010, TISSUE ENG PT A, V16, P2415, DOI [10.1089/ten.tea.2010.0216, 10.1089/ten.TEA.2010.0216]; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003; Daquinag AC, 2011, CELL STEM CELL, V9, P74, DOI 10.1016/j.stem.2011.05.017; Dennis JE, 1999, J BONE MINER RES, V14, P700, DOI 10.1359/jbmr.1999.14.5.700; Diaz-Flores L, 2009, HISTOL HISTOPATHOL, V24, P909, DOI 10.14670/HH-24.909; FRIEDENS.AJ, 1966, J EMBRYOL EXP MORPH, V16, P381; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; Giordano A, 2007, J CELL PHYSIOL, V211, P27, DOI 10.1002/jcp.20959; Gonzalez-Rey E, 2009, GUT, V58, P929, DOI 10.1136/gut.2008.168534; Guilak F, 2010, CLIN ORTHOP RELAT R, V468, P2530, DOI 10.1007/s11999-010-1410-9; Hall BK, 2008, J BIOSCIENCES, V33, P781, DOI 10.1007/s12038-008-0098-4; Hass R, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-12; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234; Itescu S, 2003, J MOL MED, V81, P288, DOI 10.1007/s00109-003-0432-0; Iyer SS, 2008, EXPERT OPIN BIOL TH, V8, P569, DOI 10.1517/14712598.8.5.569 ; Jones BJ, 2008, EXP HEMATOL, V36, P733, DOI 10.1016/j.exphem.2008.03.006; Koc ON, 2002, BONE MARROW TRANSPL, V30, P215, DOI 10.1038/sj.bmt.1703650; Krasnodembskaya A, 2010, STEM CELLS, V28, P2229, DOI 10.1002/stem.544; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Le Blanc K, 2003, SCAND J IMMUNOL, V57, P11, DOI 10.1046/j.1365-3083.2003.01176.x; LeBlanc K, 2008, LANCET, V371, P1579, DOI 10.1016/S0140-6736(08)60690-X; Mackay AM, 1998, TISSUE ENG, V4, P415, DOI 10.1089/ten.1998.4.415; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Miller RH, 2010, DISCOV MED, V9, P236; Minguell JJ, 2006, EXP BIOL MED, V231, P39; Moretti P, 2010, ADV BIOCHEM ENG BIOT, V123, P29, DOI 10.1007/10_2009_15; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; OWEN M, 1988, CIBA F SYMP, V136, P42; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rehman J, 2004, CIRCULATION, V109, P1292, DOI 10.1161/01.CIR.0000121425.42966.F1; Ringden O, 2006, TRANSPLANTATION, V81, P1390, DOI 10.1097/01.tp.0000214462.63943.14; Rodeheffer MS, 2008, CELL, V135, P240, DOI 10.1016/j.cell.2008.09.036; Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025; Schuster MD, 2004, AM J PHYSIOL-HEART C, V287, pH525, DOI 10.1152/ajpheart.00058.2004; Singer NG, 2011, ANNU REV PATHOL-MECH, V6, P457, DOI 10.1146/annurev-pathol-011110-130230; Sorrell JM, 2009, TISSUE ENG PT A, V15, P1751, DOI 10.1089/ten.tea.2008.0254; Tang W, 2008, SCIENCE, V322, P583, DOI 10.1126/science.1156232; TAVASSOLI M, 1968, SCIENCE, V161, P54, DOI 10.1126/science.161.3836.54; Traktuev DO, 2008, CIRC RES, V102, P77, DOI 10.1161/CIRCRESAHA.107.159475; Wagner J, 2009, CURR OPIN BIOTECH, V20, P531, DOI 10.1016/j.copbio.2009.08.009	53	1073	1113	2	115	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	JUL 8	2011	9	1					11	15		10.1016/j.stem.2011.06.008	http://dx.doi.org/10.1016/j.stem.2011.06.008			5	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	797VA	21726829	Bronze, Green Accepted			2023-01-03	WOS:000293157000005
J	Cuijpers, P; Donker, T; Johansson, R; Mohr, DC; van Straten, A; Andersson, G				Cuijpers, Pim; Donker, Tara; Johansson, Robert; Mohr, David C.; van Straten, Annemieke; Andersson, Gerhard			Self-Guided Psychological Treatment for Depressive Symptoms: A Meta-Analysis	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; PRIMARY-CARE; STEPPED-CARE; OVERCOMING DEPRESSION; HELP INTERVENTIONS; INTERNET ODIN; HEALTH-CARE; ANXIETY; PROGRAM	Background: A number of trials have examined the effects of self-guided psychological intervention, without any contact between the participants and a therapist or coach. The results and sizes of these trials have been mixed. This is the first quantitative meta-analysis, aimed at organizing and evaluating the literature, and estimating effect size. Method: We conducted systematic literature searches in PubMed, PsycINFO and Embase up to January 2010, and identified additional studies through earlier meta-analyses, and the references of included studies. We identified seven randomized controlled trials that met our inclusion criteria, with a total of 1,362 respondents. The overall quality of the studies was high. A post-hoc power calculation showed that the studies had sufficient statistical power to detect an effect size of d = 0.19. Results: The overall mean effect size indicating the difference between self-guided psychological treatment and control groups at post-test was d = 0.28 (p<0.001), which corresponds to a NNT of 6.41. At 4 to 12 months follow-up the effect size was d = 0.23. There was no indication for significant publication bias. Conclusions: We found evidence that self-guided psychological treatment has a small but significant effect on participants with increased levels of depressive symptomatology.	[Cuijpers, Pim; Donker, Tara; van Straten, Annemieke] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Johansson, Robert; Andersson, Gerhard] Linkoping Univ, Dept Behav Sci & Learning, Swedish Inst Disabil Res, Linkoping, Sweden; [Mohr, David C.] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; [Andersson, Gerhard] Karolinska Inst, Psychiat Sect, Dept Clin Neurosci, Stockholm, Sweden	Vrije Universiteit Amsterdam; Linkoping University; Northwestern University; Karolinska Institutet	Cuijpers, P (corresponding author), Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands.	p.cuijpers@psy.vu.nl	van Straten, Annemieke/P-8495-2019; Cuijpers, Pim/G-1703-2013; Andersson, Gerhard/J-8529-2012	van Straten, Annemieke/0000-0001-6875-2215; Andersson, Gerhard/0000-0003-4753-6745; Johansson, Robert/0000-0001-5547-3866; Cuijpers, Pim/0000-0001-5497-2743; Donker, Tara/0000-0002-7470-8234; Mohr, David/0000-0002-5443-7596	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [RL1HD058295] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025741] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960; Borenstein M., 2009, INTRO META ANAL; Christensen H, 2006, PSYCHOL MED, V36, P1737, DOI 10.1017/S0033291706008695; Christensen H, 2004, BRIT MED J, V328, P265, DOI 10.1136/bmj.37945.566632.EE; Clarke G, 2005, J MED INTERNET RES, V7, DOI 10.2196/jmir.7.2.e16; Clarke G, 2002, J MED INTERNET RES, V4, DOI 10.2196/jmir.4.3.e14; Clarke Greg, 2009, Cognitive Behaviour Therapy, V38, P222, DOI 10.1080/16506070802675353; Cohen J., 2013, STAT POWER ANAL BEHA; Cuijpers P, 1997, J BEHAV THER EXP PSY, V28, P139, DOI 10.1016/S0005-7916(97)00005-0; Cuijpers P, 2010, PSYCHOL MED, V40, P1943, DOI 10.1017/S0033291710000772; Cuijpers P, 2010, PSYCHOL MED, V40, P211, DOI 10.1017/S0033291709006114; Cuijpers P, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-36; de Graaf LE, 2009, BRIT J PSYCHIAT, V195, P73, DOI 10.1192/bjp.bp.108.054429; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Fletcher J, 2005, BEHAV COGN PSYCHOTH, V33, P319, DOI 10.1017/S1352465805002079; Gellatly J, 2007, PSYCHOL MED, V37, P1217, DOI 10.1017/S0033291707000062; Gregory RJ, 2004, PROF PSYCHOL-RES PR, V35, P275, DOI 10.1037/0735-7028.35.3.275; Grime PR, 2004, OCCUP MED-OXFORD, V54, P353, DOI 10.1093/occmed/kqh077; Haddock CK, 1997, CEPHALALGIA, V17, P113, DOI 10.1046/j.1468-2982.1997.1702113.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hirai M, 2006, BEHAV THER, V37, P99, DOI 10.1016/j.beth.2005.05.002; Holdsworth N, 1996, J MENTAL HLTH, V5, P195, DOI DOI 10.1080/09638239650037081; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; LITTLE P, BMJ, V328, P441; Marrs RW, 1995, AM J COMMUN PSYCHOL, V23, P843, DOI 10.1007/BF02507018; Menchola M, 2007, PROF PSYCHOL-RES PR, V38, P421, DOI 10.1037/0735-7028.38.4.421; Meyer B, 2009, J MED INTERNET RES, V11, DOI 10.2196/jmir.1151; Patten SB, 2003, PSYCHIAT SERV, V54, P396, DOI 10.1176/appi.ps.54.3.396; Rahe RH, 2002, PSYCHOSOM MED, V64, P278, DOI 10.1097/00006842-200203000-00011; Sackett D.L., 2000, EVIDENCE BASED MED P, DOI DOI 10.1016/S1031-170X(97)80036-0; Salkovskis P, 2006, PSYCHOL MED, V36, P325, DOI 10.1017/S0033291705006422; Scogin F, 1996, J CONSULT CLIN PSYCH, V64, P1086, DOI 10.1037/0022-006X.64.5.1086; Seekles W, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-90; Spek V, 2007, PSYCHOL MED, V37, P1797, DOI 10.1017/S0033291707000542; Spek V, 2007, PSYCHOL MED, V37, P319, DOI 10.1017/S0033291706008944; van Straten A, 2010, MED J AUSTRALIA, V192, pS36, DOI 10.5694/j.1326-5377.2010.tb03691.x; van Straten A, 2009, SLEEP MED REV, V13, P61, DOI 10.1016/j.smrv.2008.04.006; van't Veer-Tazelaar PJ, 2009, ARCH GEN PSYCHIAT, V66, P297, DOI 10.1001/archgenpsychiatry.2008.555; Webster J, 2003, BJOG-INT J OBSTET GY, V110, P842, DOI 10.1016/S1470-0328(03)02977-X; Zetterqvist Kristofer, 2003, Cognitive Behaviour Therapy, V32, P151, DOI 10.1080/16506070302316	41	177	180	0	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 21	2011	6	6							e21274	10.1371/journal.pone.0021274	http://dx.doi.org/10.1371/journal.pone.0021274			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	782CL	21712998	Green Published, Green Submitted, gold			2023-01-03	WOS:000291985100023
J	Manchanda, S; Saikia, B; Gupta, N; Chowdhary, S; Puliyel, JM				Manchanda, Samiksha; Saikia, Bedangshu; Gupta, Neeraj; Chowdhary, Sona; Puliyel, Jacob M.			Sex Ratio at Birth in India, Its Relation to Birth Order, Sex of Previous Children and Use of Indigenous Medicine	PLOS ONE			English	Article							SELECTIVE ABORTIONS; INFANTICIDE; MORTALITY	Objective: Sex-ratio at birth in families with previous girls is worse than those with a boy. Our aim was to prospectively study in a large maternal and child unit sex-ratio against previous birth sex and use of traditional medicines for sex selection. Main Outcome Measures: Sex-ratio among mothers in families with a previous girl and in those with a previous boy, prevalence of indigenous medicine use and sex-ratio in those using medicines for sex selection. Results: Overall there were 806 girls to 1000 boys. The sex-ratio was 720:1000 if there was one previous girl and 178:1000 if there were two previous girls. In second children of families with a previous boy 1017 girls were born per 1000 boys. Sex-ratio in those with one previous girl, who were taking traditional medicines for sex selection, was 928:1000. Conclusion: Evidence from the second children clearly shows the sex-ratio is being manipulated by human interventions. More mothers with previous girls tend to use traditional medicines for sex selection, in their subsequent pregnancies. Those taking such medication do not seem to be helped according to expectations. They seem to rely on this method and so are less likely use more definitive methods like sex selective abortions. This is the first such prospective investigation of sex ratio in second children looked at against the sex of previous children. More studies are needed to confirm the findings.	[Manchanda, Samiksha; Saikia, Bedangshu; Gupta, Neeraj; Chowdhary, Sona; Puliyel, Jacob M.] St Stephen Hosp, Dept Neonatol & Pediat, Delhi, India	St. Stephen's Hospital	Manchanda, S (corresponding author), St Stephen Hosp, Dept Neonatol & Pediat, Delhi, India.	manchandasami@yahoo.com						Bandyopadhyay S, 2007, IND J COMMUN MED, V32, P32; Biggar RJ, 1999, AM J EPIDEMIOL, V150, P957; Census of India, 2001, PROV POP TOT; Chatterjee M, 1990, REPORT INDIAN WOMEN; GANGADHARAN S, 1991, EC TIMES        0418; GEORGE S, 1998, SEARCH B, V12, P18; GEORGE S, 1997, FEMALE INFANTICIDE T; George SM, 2002, REPROD HEALTH MATTER, V10, P190, DOI 10.1016/S0968-8080(02)00034-4; GHOSH S, 1987, B NUTR FDN INDIA, V8, P4; Grover A, 2006, LANCET, V367, P1726, DOI 10.1016/S0140-6736(06)68760-6; GUPTA MD, 1997, POPULATION STUDIES, V51, P307; HESKETH T, 2006, ABNORMAL SEX RATIO H; Jha P, 2006, LANCET, V367, P211, DOI 10.1016/S0140-6736(06)67930-0; Khanna R, 2003, BRIT MED J, V327, P126, DOI 10.1136/bmj.327.7407.126; LEIDL P, 2005, SILENT SPRINGS TRAGE; Levy N, 2007, SOUTH MED J, V100, P107, DOI 10.1097/SMJ.0b013e31802e6138; Sahni M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002224; Sen A, 2003, BMJ-BRIT MED J, V327, P1297, DOI 10.1136/bmj.327.7427.1297; Sen Amartya, 2001, FRONTLINE, V18, P4; Sudha S, 1999, DEV CHANGE, V30, P585, DOI 10.1111/1467-7660.00130; VISARIA P, 1991, EC TIMES        0418; ZENG Y, 1993, POPUL DEV REV, V19, P283	22	17	18	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2011	6	6							e20097	10.1371/journal.pone.0020097	http://dx.doi.org/10.1371/journal.pone.0020097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778TS	21697990	gold, Green Published			2023-01-03	WOS:000291730000008
J	Santos, JL; De la Cruz, R; Holst, C; Grau, K; Naranjo, C; Maiz, A; Astrup, A; Saris, WHM; MacDonald, I; Oppert, JM; Hansen, T; Pedersen, O; Sorensen, TIA; Martinez, JA				Santos, Jose L.; De la Cruz, Rolando; Holst, Claus; Grau, Katrine; Naranjo, Carolina; Maiz, Alberto; Astrup, Arne; Saris, Wim H. M.; MacDonald, Ian; Oppert, Jean-Michel; Hansen, Torben; Pedersen, Oluf; Sorensen, Thorkild I. A.; Alfredo Martinez, J.		NUGENOB Consortium	Allelic Variants of Melanocortin 3 Receptor Gene (MC3R) and Weight Loss in Obesity: A Randomised Trial of Hypo-Energetic High- versus Low-Fat Diets	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; CHILDHOOD OBESITY; EATING BEHAVIOR; FOOD-INTAKE; BODY-FAT; POLYMORPHISMS; INSULIN; MOUSE; INDIVIDUALS; MUTATIONS	Introduction: The melanocortin system plays an important role in energy homeostasis. Mice genetically deficient in the melanocortin-3 receptor gene have a normal body weight with increased body fat, mild hypophagia compared to wild-type mice. In humans, Thr6Lys and Val81Ile variants of the melanocortin-3 receptor gene (MC3R) have been associated with childhood obesity, higher BMI Z-score and elevated body fat percentage compared to non-carriers. The aim of this study is to assess the association in adults between allelic variants of MC3R with weight loss induced by energy-restricted diets. Subjects and Methods: This research is based on the NUGENOB study, a trial conducted to assess weight loss during a 10-week dietary intervention involving two different hypo-energetic (high-fat and low-fat) diets. A total of 760 obese patients were genotyped for 10 single nucleotide polymorphisms covering the single exon of MC3R gene and its flanking regions, including the missense variants Thr6Lys and Val81Ile. Linear mixed models and haplotype-based analysis were carried out to assess the potential association between genetic polymorphisms and differential weight loss, fat mass loss, waist change and resting energy expenditure changes. Results: No differences in drop-out rate were found by MC3R genotypes. The rs6014646 polymorphism was significantly associated with weight loss using co-dominant (p = 0.04) and dominant models (p = 0.03). These p-values were not statistically significant after strict control for multiple testing. Haplotype-based multivariate analysis using permutations showed that rs3827103-rs1543873 (p = 0.06), rs6014646-rs6024730 (p = 0.05) and rs3746619-rs3827103 (p = 0.10) displayed near-statistical significant results in relation to weight loss. No other significant associations or gene*diet interactions were detected for weight loss, fat mass loss, waist change and resting energy expenditure changes. Conclusion: The study provided overall sufficient evidence to support that there is no major effect of genetic variants of MC3R and differential weight loss after a 10-week dietary intervention with hypo-energetic diets in obese Europeans.	[Santos, Jose L.; Maiz, Alberto] Pontificia Univ Catolica Chile, Dept Nutr Diabet & Metab, Santiago, Chile; [Santos, Jose L.; Alfredo Martinez, J.] Univ Navarra, Dept Nutr & Food Sci, E-31080 Pamplona, Spain; [De la Cruz, Rolando; Naranjo, Carolina] Pontificia Univ Catolica Chile, Dept Publ Hlth, Santiago, Chile; [De la Cruz, Rolando; Naranjo, Carolina] Pontificia Univ Catolica Chile, Dept Stat, Santiago, Chile; [Holst, Claus; Grau, Katrine; Sorensen, Thorkild I. A.] Copenhagen Univ Hosp, Inst Prevent Med, Ctr Hlth & Soc, Copenhagen, Denmark; [Astrup, Arne] Univ Copenhagen, Fac Life Sci, Dept Human Nutr, Copenhagen, Denmark; [Saris, Wim H. M.] Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht, Maastricht, Netherlands; [Oppert, Jean-Michel] Univ Paris 06, Hotel Dieu Hosp, Dept Nutr, Human Nutr Res Ctr Ile de France, Paris, France; [MacDonald, Ian] Univ Nottingham, Sch Med, Queens Med Ctr, Sch Biomed Sci, Nottingham, England; [Hansen, Torben; Pedersen, Oluf] Hagedorn Res Inst, Gentofte, Denmark; [Pedersen, Oluf] Univ Copenhagen, Inst Biomed Sci, Copenhagen, Denmark	Pontificia Universidad Catolica de Chile; University of Navarra; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; University of Copenhagen; University of Copenhagen; Maastricht University; Maastricht University Medical Centre (MUMC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; University of Nottingham; Novo Nordisk; Hagedorn Research Institute; University of Copenhagen	Santos, JL (corresponding author), Pontificia Univ Catolica Chile, Dept Nutr Diabet & Metab, Santiago, Chile.	jalfmtz@unav.es	Oppert, Jean-Michel/F-2810-2017; Pedersen, Oluf/AAG-8015-2020; Pedersen, Oluf/Z-1731-2019; de la Cruz, Rolando/C-1905-2016; Astrup, Arne/B-1407-2015; Martinez Hernandez, J Alfredo/K-8709-2014; Santos, Jose Luis/D-1818-2017	Pedersen, Oluf/0000-0002-3321-3972; de la Cruz, Rolando/0000-0002-1415-1809; Astrup, Arne/0000-0001-8968-8996; Macdonald, Ian/0000-0002-7540-9850; Martinez Hernandez, J Alfredo/0000-0001-5218-6941; Santos, Jose Luis/0000-0003-2895-0369	EU [QLK1-CT-2000-00618]; Linea Especial de la Universidad de Navarra; Chilean FONDECYT [1061096]; European Community	EU(European Commission); Linea Especial de la Universidad de Navarra; Chilean FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); European Community(European Commission)	This work was funded by the 5th Framework Program (EU grant QLK1-CT-2000-00618). This study was carried out with the support of the "Linea Especial de la Universidad de Navarra" and Chilean FONDECYT 1061096. The study is also part of the research in the Danish Obesity Research Centre (DanORC, see www.danorc.dk). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The dietician core group and all other co-workers from the twelve participating centers are gratefully acknowledged. NUGENOB ('Nutrient-Gene interactions in human obesity-implications for dietary guidelines') was supported by the European Community. Trial ISRCTN25867281 (Contract QLK1-CT-2000-00618). See www.nugenob.org for a complete list of NUGENOB contributors.	Adan RAH, 2006, BRIT J PHARMACOL, V149, P815, DOI 10.1038/sj.bjp.0706929; Butler AA, 2000, ENDOCRINOLOGY, V141, P3518, DOI 10.1210/en.141.9.3518; Butler AA, 2006, PEPTIDES, V27, P281, DOI 10.1016/j.peptides.2005.02.029; Calton MA, 2009, HUM MOL GENET, V18, P1140, DOI 10.1093/hmg/ddn431; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Feng NP, 2005, DIABETES, V54, P2663, DOI 10.2337/diabetes.54.9.2663; Fox CS, 2005, J CLIN ENDOCR METAB, V90, P3197, DOI 10.1210/jc.2004-1752; Garfield AS, 2009, TRENDS ENDOCRIN MET, V20, P203, DOI 10.1016/j.tem.2009.02.002; Grau K, 2009, INT J OBESITY, V33, P1227, DOI 10.1038/ijo.2009.159; Grau K, 2010, AM J CLIN NUTR, V91, P472, DOI 10.3945/ajcn.2009.27947; Hainer V, 2000, INT J OBESITY, V24, P1051, DOI 10.1038/sj.ijo.0801358; Haupt A, 2009, OBESITY, V17, P1942, DOI 10.1038/oby.2009.233; Hjelmborg JVB, 2008, OBESITY, V16, P847, DOI 10.1038/oby.2007.135; Lee M, 2008, PEPTIDES, V29, P440, DOI 10.1016/j.peptides.2007.11.005; Lee YS, 2007, DIABETES, V56, P2622, DOI 10.2337/db07-0225; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; Li SX, 2010, AM J CLIN NUTR, V91, P184, DOI 10.3945/ajcn.2009.28403; Marks DL, 2006, PEPTIDES, V27, P259, DOI 10.1016/j.peptides.2005.01.025; Martinez JA, 2008, ASIA PAC J CLIN NUTR, V17, P119; Mencarelli M, 2008, EUR J HUM GENET, V16, P581, DOI 10.1038/sj.ejhg.5202005; Moreno-Aliaga MJ, 2005, OBES REV, V6, P155, DOI 10.1111/j.1467-789X.2005.00180.x; Obregon AM, 2010, NUTRITION, V26, P760, DOI 10.1016/j.nut.2009.07.005; Oswal A, 2007, OBES REV, V8, P293, DOI 10.1111/j.1467-789X.2007.00378.x; Petersen M, 2006, INT J OBESITY, V30, P552, DOI 10.1038/sj.ijo.0803186; Rutanen J, 2007, J CLIN ENDOCR METAB, V92, P1112, DOI 10.1210/jc.2006-1201; Sandholt CH, 2010, DIABETES, V59, P1667, DOI 10.2337/db09-1042; Santoro N, 2007, AM J CLIN NUTR, V85, P950, DOI 10.1093/ajcn/85.4.950; Santos JL, 2008, J PHYSIOL BIOCHEM, V64, P205, DOI 10.1007/BF03178843; SANTOS JL, 2006, EUR J NUTR, V59, P1; Savastano DM, 2009, AM J CLIN NUTR, V90, P912, DOI 10.3945/ajcn.2009.27537; Schalin-Jantti C, 2003, INT J OBESITY, V27, P70, DOI 10.1038/sj.ijo.0802184; Seeley RJ, 2004, ANNU REV NUTR, V24, P133, DOI 10.1146/annurev.nutr.24.012003.132428; Sorensen TIA, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010012; Sutton GM, 2006, ENDOCRINOLOGY, V147, P2183, DOI 10.1210/en.2005-1209; Sutton GM, 2008, J NEUROSCI, V28, P12946, DOI 10.1523/JNEUROSCI.3615-08.2008; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; Zhao JH, 2009, OBESITY, V17, P2254, DOI 10.1038/oby.2009.159	40	21	23	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 14	2011	6	6							e19934	10.1371/journal.pone.0019934	http://dx.doi.org/10.1371/journal.pone.0019934			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778EB	21695122	gold, Green Submitted, Green Published			2023-01-03	WOS:000291682300002
J	Sturm, G; Lamina, C; Zitt, E; Lhotta, K; Haider, F; Neyer, U; Kronenberg, F				Sturm, Gisela; Lamina, Claudia; Zitt, Emanuel; Lhotta, Karl; Haider, Florian; Neyer, Ulrich; Kronenberg, Florian			Association of HbA1c Values with Mortality and Cardiovascular Events in Diabetic Dialysis Patients. The INVOR Study and Review of the Literature	PLOS ONE			English	Review							GLYCEMIC CONTROL; HEMODIALYSIS-PATIENTS; GLYCATED ALBUMIN; HEMOGLOBIN VALUES; SURVIVAL; PREDICTOR	Background: Improved glycemic control reduces complications in patients with diabetes mellitus (DM). However, it is discussed controversially whether patients with diabetes mellitus and end-stage renal disease benefit from strict glycemic control. Methods: We followed 78 patients with DM initiating dialysis treatment of the region of Vorarlberg in a prospective cohort study applying a time-dependent Cox regression analysis using all measured laboratory values for up to more than seven years. This resulted in 880 HbA(1c) measurements (with one measurement every 3.16 patient months on average) during the entire observation period. Non-linear P-splines were used to allow flexible modeling of the association with mortality and cardiovascular disease (CVD) events. Results: We observed a decreased mortality risk with increasing HbA(1c) values (HR = 0.72 per 1% increase, p = 0.024). Adjustment for age and sex and additional adjustment for other CVD risk factors only slightly attenuated the association (HR = 0.71, p = 0.044). A non-linear P-spline showed that the association did not follow a fully linear pattern with a highly significant non-linear component (p = 0.001) with an increased risk of all-cause mortality for HbA(1c) values up to 6-7%. Causes of death were associated with HbA(1c) values. The risk for CVD events, however, increased with increasing HbA(1c) values (HR = 1.24 per 1% increase, p = 0.048) but vanished after extended adjustments. Conclusions: This study considered the entire information collected on HbA(1c) over a period of more than seven years. Besides the methodological advantages our data indicate a significant inverse association between HbA(1c) levels and all-cause mortality. However, for CVD events no significant association could be found.	[Sturm, Gisela; Lamina, Claudia; Haider, Florian; Kronenberg, Florian] Innsbruck Med Univ, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, Innsbruck, Austria; [Zitt, Emanuel; Lhotta, Karl; Neyer, Ulrich] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria; [Zitt, Emanuel; Lhotta, Karl; Neyer, Ulrich] Vorarlberg Inst Vasc Invest & Treatment VIVIT, Feldkirch, Austria	Medical University of Innsbruck	Sturm, G (corresponding author), Innsbruck Med Univ, Div Genet Epidemiol, Dept Med Genet Mol & Clin Pharmacol, Innsbruck, Austria.	Florian.Kronenberg@i-med.ac.at	Lamina, Claudia/F-7608-2010; Zitt, Emanuel/ABE-1926-2020; Kronenberg, Florian/B-1736-2008	Lamina, Claudia/0000-0002-5398-5806; Zitt, Emanuel/0000-0001-6944-6041; Kronenberg, Florian/0000-0003-2229-1120	Hans Drexel; Austrian Heart Fund	Hans Drexel; Austrian Heart Fund	This study was supported by a grant from Hans Drexel to the Vorarlberg Institute for Vascular Investigation and Treatment (VIVIT) and by a grant from the Austrian Heart Fund to Florian Kronenberg. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari A, 2003, AM J KIDNEY DIS, V41, P523, DOI 10.1053/ajkd.2003.50114; Drechsler C, 2009, CIRCULATION, V120, P2421, DOI 10.1161/CIRCULATIONAHA.109.857268; Fukuoka K, 2008, NEPHROLOGY, V13, P278, DOI 10.1111/j.1440-1797.2007.00864.x; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; Gouya G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017803; Inaba M, 2007, J AM SOC NEPHROL, V18, P896, DOI 10.1681/ASN.2006070772; Ishimura E, 2009, DIABETES RES CLIN PR, V83, P320, DOI 10.1016/j.diabres.2008.11.038; Kalantar-Zadeh K, 2007, DIABETES CARE, V30, P1049, DOI 10.2337/dc06-2127; Kovesdy CP, 2008, AM J KIDNEY DIS, V52, P766, DOI 10.1053/j.ajkd.2008.04.011; Levin A, 2007, AM J KIDNEY DIS, V49, pS10, DOI 10.1053/j.ajkd.2006.12.004; McMurray SD, 2002, AM J KIDNEY DIS, V40, P566, DOI 10.1053/ajkd.2002.34915; Morioka T, 2001, DIABETES CARE, V24, P909, DOI 10.2337/diacare.24.5.909; Okada T, 2007, INTERNAL MED, V46, P807, DOI 10.2169/internalmedicine.46.6355; Oomichi T, 2006, DIABETES CARE, V29, P1496, DOI 10.2337/dc05-1887; Peacock TP, 2008, KIDNEY INT, V73, P1062, DOI 10.1038/ki.2008.25; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Shima K, 2010, NEPHROLOGY, V15, P632, DOI 10.1111/j.1440-1797.2010.01273.x; Shurraw S, 2010, AM J KIDNEY DIS, V55, P875, DOI 10.1053/j.ajkd.2009.12.038; Sturm G, 2010, NEPHROL DIAL TRANSPL, V25, P2715, DOI 10.1093/ndt/gfq101; Tsujimoto Y, 2009, THER APHER DIAL, V13, P358, DOI 10.1111/j.1744-9987.2009.00691.x; Williams ME, 2009, AM J NEPHROL, V29, P54, DOI 10.1159/000151276; Williams ME, 2006, KIDNEY INT, V70, P1503, DOI 10.1038/sj.ki.5001789; Wu MS, 1997, NEPHROL DIAL TRANSPL, V12, P2105, DOI 10.1093/ndt/12.10.2105	23	16	19	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 18	2011	6	5							e20093	10.1371/journal.pone.0020093	http://dx.doi.org/10.1371/journal.pone.0020093			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	765PE	21625600	Green Published, Green Submitted, gold			2023-01-03	WOS:000290720200061
J	Xiong, W; Cheng, KJ; Cui, TX; Godlewski, G; Rice, KC; Xu, Y; Zhang, L				Xiong, Wei; Cheng, KeJun; Cui, Tanxing; Godlewski, Grzegorz; Rice, Kenner C.; Xu, Yan; Zhang, Li			Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia	NATURE CHEMICAL BIOLOGY			English	Article							MODULATION; PAIN; SUBUNIT; DYNAMICS; MODEL; MICE; INHIBITION; ALPHA-1; TARGET; 2ND	Cannabinoids enhance the function of glycine receptors (GlyRs). However, little is known about the mechanisms and behavioral implication of cannabinoid-GlyR interaction. Using mutagenesis and NMR analysis, we have identified a serine at 296 in the GlyR protein critical for the potentiation of I-Gly by Delta(9)-tetrahydrocannabinol (THC), a major psychoactive component of marijuana. The polarity of the amino acid residue at 296 and the hydroxyl groups of THC are critical for THC potentiation. Removal of the hydroxyl groups of THC results in a compound that does not affect I-Gly when applied alone but selectively antagonizes cannabinoid-induced potentiating effect on I-Gly and analgesic effect in a tail-flick test in mice. The cannabinoid-induced analgesia is absent in mice lacking alpha 3GlyRs but not in those lacking CB1 and CB2 receptors. These findings reveal a new mechanism underlying cannabinoid potentiation of GlyRs, which could contribute to some of the cannabis-induced analgesic and therapeutic effects.	[Xiong, Wei; Zhang, Li] US Natl Inst Alcohol Abuse & Alcoholism, Lab Integrat Neurosci, US Natl Inst Hlth, Bethesda, MD USA; [Cheng, KeJun; Rice, Kenner C.] US Natl Inst Drug Abuse, Chem Biol Res Branch, US Natl Inst Hlth, Bethesda, MD USA; [Cui, Tanxing; Xu, Yan] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Cui, Tanxing; Xu, Yan] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA; [Cui, Tanxing; Xu, Yan] Univ Pittsburgh, Sch Med, Dept Biol Struct, Pittsburgh, PA 15261 USA; [Godlewski, Grzegorz] US Natl Inst Alcohol Abuse & Alcoholism, Lab Physiol Studies, US Natl Inst Hlth, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Zhang, L (corresponding author), US Natl Inst Alcohol Abuse & Alcoholism, Lab Integrat Neurosci, US Natl Inst Hlth, Bethesda, MD USA.	lzhang@mail.nih.gov	Xiong, Wei/G-9027-2018; Zhang, Li/W-2104-2019; Xiong, Wei/F-8251-2011	Xu, Yan/0000-0003-2773-8024	US National Institute on Alcohol Abuse and Alcoholism; US National Institute of General Medical Sciences of the US National Institutes of Health [R37GM049202]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM049202] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000529] Funding Source: NIH RePORTER	US National Institute on Alcohol Abuse and Alcoholism(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); US National Institute of General Medical Sciences of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	We thank C. L. Cepko for providing alpha 2<SUP>-/-</SUP> Glra mice. We especially thank D. M. Lovinger for critical comments on the manuscript. This work was supported by funds from the intramural program of the US National Institute on Alcohol Abuse and Alcoholism. We acknowledge the grant support (R37GM049202 to Y.X.) from the US National Institute of General Medical Sciences of the US National Institutes of Health.	Ahrens J, 2009, PHARMACOLOGY, V83, P217, DOI 10.1159/000201556; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; Buckley  NE, 2000, EUR J PHARMACOL, V396, P141, DOI 10.1016/S0014-2999(00)00211-9; Canlas CG, 2008, J PHYS CHEM B, V112, P14312, DOI 10.1021/jp805952w; Compton DR, 1996, J PHARMACOL EXP THER, V277, P586; Delaney AJ, 2010, NEUROSCI LETT, V469, P237, DOI 10.1016/j.neulet.2009.12.003; Demir R, 2009, PHARMACOLOGY, V83, P270, DOI 10.1159/000209291; Findlay GS, 2003, J NEUROSCI, V23, P8051; Griffon N, 1999, EMBO J, V18, P4711, DOI 10.1093/emboj/18.17.4711; GROSSMAN ML, 1982, J COMP NEUROL, V206, P9, DOI 10.1002/cne.902060103; Harris RA, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.128re7; Harvey RJ, 2004, SCIENCE, V304, P884, DOI 10.1126/science.1094925; Hejazi N, 2006, MOL PHARMACOL, V69, P991, DOI 10.1124/mol.105.019174; Hilf RJC, 2009, NATURE, V457, P115, DOI 10.1038/nature07461; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Huestis MA, 2007, CHEM BIODIVERS, V4, P1770, DOI 10.1002/cbdv.200790152; Izzo AA, 2009, TRENDS PHARMACOL SCI, V30, P515, DOI 10.1016/j.tips.2009.07.006; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Kimura T, 2009, BIOPHYS J, V96, P4916, DOI 10.1016/j.bpj.2009.03.033; Klein TW, 2007, ADV EXP MED BIOL, V601, P395; Laube B, 2002, TRENDS PHARMACOL SCI, V23, P519, DOI 10.1016/S0165-6147(02)02138-7; Ledent C, 1999, SCIENCE, V283, P401, DOI 10.1126/science.283.5400.401; Lobo IA, 2005, INT REV NEUROBIOL, V65, P53, DOI 10.1016/S0074-7742(04)65003-3; Lynch JW, 2009, NEUROPHARMACOLOGY, V56, P303, DOI 10.1016/j.neuropharm.2008.07.034; Ma DJ, 2005, BIOCHEMISTRY-US, V44, P8790, DOI 10.1021/bi050256n; Marris E, 2009, NATURE, V458, P394, DOI 10.1038/458394a; Oz M, 2006, PHARMACOL THERAPEUT, V111, P114, DOI 10.1016/j.pharmthera.2005.09.009; Pacher P, 2006, PHARMACOL REV, V58, P389, DOI 10.1124/pr.58.3.2; Pernia-Andrade AJ, 2009, SCIENCE, V325, P760, DOI 10.1126/science.1171870; SHIANG R, 1995, ANN NEUROL, V38, P85, DOI 10.1002/ana.410380115; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SMITH PB, 1992, BRAIN RES, V578, P8, DOI 10.1016/0006-8993(92)90222-U; Spivak CE, 2007, MOL PHARMACOL, V72, P1024, DOI 10.1124/mol.107.036939; Tang P, 2002, BIOPHYS J, V83, P252, DOI 10.1016/S0006-3495(02)75166-7; Varvel SA, 2005, J PHARMACOL EXP THER, V314, P329, DOI 10.1124/jpet.104.080739; Welch SP, 1998, J PHARMACOL EXP THER, V286, P1301; Xiong W, 2008, MOL PHARMACOL, V73, P314, DOI 10.1124/mol.107.039149; Yang Z, 2008, BIOCHEM PHARMACOL, V76, P1014, DOI 10.1016/j.bcp.2008.07.037; Young-Pearse TL, 2006, MOL CELL BIOL, V26, P5728, DOI 10.1128/MCB.00237-06; Zeilhofer HU, 2007, BIOCHEM PHARMACOL, V73, P165, DOI 10.1016/j.bcp.2006.07.037; Zeilhofer HU, 2005, CELL MOL LIFE SCI, V62, P2027, DOI 10.1007/s00018-005-5107-2; Zhang GH, 2010, EUR J NEUROSCI, V31, P225, DOI 10.1111/j.1460-9568.2009.07075.x; Zhang L, 2009, VITAM HORM, V81, P315, DOI 10.1016/S0083-6729(09)81012-1; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	44	102	105	0	27	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	MAY	2011	7	5					296	303		10.1038/nchembio.552	http://dx.doi.org/10.1038/nchembio.552			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	751KZ	21460829	Green Accepted			2023-01-03	WOS:000289617800013
J	Beyrer, C				Beyrer, Chris			Safe injection facilities save lives	LANCET			English	Editorial Material							DRUG-USERS; COST-EFFECTIVENESS; HARM REDUCTION; MORTALITY; COHORT		Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21202 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Beyrer, C (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21202 USA.	cbeyrer@jhsph.edu						Beyrer C, 2010, LANCET, V376, P551, DOI 10.1016/S0140-6736(10)60928-2; Christie T, 2003, INT J DRUG POLICY, V16, P56; Degenhardt L, 2006, SEX TRANSM INFECT, V82, pIII56, DOI 10.1136/sti.2005.019273; Guinness L, 2010, ADDICTION, V105, P319, DOI 10.1111/j.1360-0443.2009.02755.x; HALL N, 2010, VANCOUVER SUN   0115; Marshall BDL, 2011, LANCET, V377, P1429, DOI 10.1016/S0140-6736(10)62353-7; Padian NS, 2011, JAIDS-J ACQ IMM DEF, V56, P199, DOI 10.1097/QAI.0b013e31820bb448; Palmateer N, 2010, ADDICTION, V105, P844, DOI 10.1111/j.1360-0443.2009.02888.x; Small D, 2010, HARM REDUCT J, V7, DOI 10.1186/1477-7517-7-23; Stoove MA, 2008, DRUG ALCOHOL DEPEN, V96, P281, DOI 10.1016/j.drugalcdep.2008.03.006; Vickerman P, 2006, SEX TRANSM DIS, V33, pS89, DOI 10.1097/01.olq.0000221335.80508.fa	11	4	4	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 23	2011	377	9775					1385	1386		10.1016/S0140-6736(11)60132-3	http://dx.doi.org/10.1016/S0140-6736(11)60132-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755UF	21497899				2023-01-03	WOS:000289963000006
J	Sudo, K; Harada, H				Sudo, Kazumasa; Harada, Hiroshi			Calcification of the Aorta and Common Iliac Arteries	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Sudo, Kazumasa; Harada, Hiroshi] Sapporo City Gen Hosp, Sapporo, Hokkaido, Japan	Sapporo City General Hospital	Sudo, K (corresponding author), Sapporo City Gen Hosp, Sapporo, Hokkaido, Japan.	kazumasa.sudo@doc.city.sapporo.jp							0	0	0	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2011	364	15					1449	1449		10.1056/NEJMicm1007721	http://dx.doi.org/10.1056/NEJMicm1007721			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	749LD	21488767				2023-01-03	WOS:000289467200009
J	Buiting, HM; Rurup, ML; Wijsbek, H; van Zuylen, L; den Hartogh, G				Buiting, Hilde M.; Rurup, Mette L.; Wijsbek, Henri; van Zuylen, Lia; den Hartogh, Govert			Understanding provision of chemotherapy to patients with end stage cancer: qualitative interview study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To examine health professionals' experiences of and attitudes towards the provision of chemotherapy to patients with end stage cancer. Design Purposive, qualitative design based on in-depth interviews. Setting Oncology departments at university hospitals and general hospitals in the Netherlands. Participants 14 physicians and 13 nurses who cared for patients with metastatic cancer. Results Physicians and nurses reported trying to inform patients fully about their poor prognosis and treatment options. They would carefully consider the (side) effects of chemotherapy and sometimes doubted whether further treatment would contribute to patients' quality of life. Both groups considered the patients' wellbeing to be important, and physicians seemed inclined to try to preserve this by offering further chemotherapy, often followed by the patient. Nurses were more often inclined to express their doubts about further treatment, preferring to allow patients to make the best use of the time that is left. When confronted with a treatment dilemma and a patient's wish for treatment, physicians preferred to make compromises, such as by "trying out one dose." Discussing death or dying with patients while at the same time administering chemotherapy was considered contradictory as this could diminish the patients' hope. Conclusions The trend to greater use of chemotherapy at the end of life could be explained by patients' and physicians' mutually reinforcing attitudes of "not giving up" and by physicians' broad interpretation of patients' quality of life, in which taking away patients' hope by withholding treatment is considered harmful. To rebalance the ratio of quantity of life to quality of life, input from other health professionals, notably nurses, may be necessary.	[Buiting, Hilde M.; Rurup, Mette L.; Wijsbek, Henri; den Hartogh, Govert] Univ Amsterdam, Dept Philosophy, Oude Turfmarkt 141-147, NL-1012 GC Amsterdam, Netherlands; [van Zuylen, Lia] Univ Med Ctr, Erasmus MC, Dept Med Oncol, POB 2040, NL-3000 CA Rotterdam, Netherlands	University of Amsterdam; Erasmus University Rotterdam; Erasmus MC	Buiting, HM (corresponding author), Univ Amsterdam, Dept Philosophy, Oude Turfmarkt 141-147, NL-1012 GC Amsterdam, Netherlands.	h.m.buiting@uva.nl			ZonMw, the Netherlands Organization for Health Research and Development [70-71300-98-048]	ZonMw, the Netherlands Organization for Health Research and Development(Netherlands Organization for Health Research and DevelopmentNetherlands Government)	This study was supported by a grant from ZonMw, the Netherlands Organization for Health Research and Development ( grant No 70-71300-98-048). The study sponsor had no role in the study design; collection, analysis, and interpretation of the data; or in the writing of the article and decision to submit the article for publication.	Ablin RJ, 2010, ARCH INTERN MED, V170, P1397, DOI 10.1001/archinternmed.2010.290; Barnato AE, 2004, HEALTH SERV RES, V39, P363, DOI 10.1111/j.1475-6773.2004.00232.x; Beauchamp T. L., 2012, PRINCIPLES BIOMEDICA, VVII-a; Braga S, 2007, PSYCHO-ONCOL, V16, P863, DOI 10.1002/pon.1140; Breier-Mackie S, 2001, NURS ETHICS, V8, P510, DOI 10.1191/096973301682553805; Buiting HM, 2008, EUR J PUBLIC HEALTH, V18, P681, DOI 10.1093/eurpub/ckn084; de Kort SJ, 2010, HEALTH CARE ANAL, V18, P164, DOI 10.1007/s10728-009-0121-4; Dreyer A, 2009, J MED ETHICS, V35, P672, DOI 10.1136/jme.2009.030668; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Earle CC, 2008, J CLIN ONCOL, V26, P3860, DOI 10.1200/JCO.2007.15.8253; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fishman J, 2010, ARCH INTERN MED, V170, P515, DOI 10.1001/archinternmed.2010.11; Grady D, 2010, ARCH INTERN MED, V170, P749, DOI 10.1001/archinternmed.2010.90; Grant L, 2010, BMJ-BRIT MED J, V341, pc4859; Kirk P, 2004, BMJ-BRIT MED J, V328, P1343, DOI 10.1136/bmj.38103.423576.55; LANTOS JD, 1989, AM J MED, V87, P81; Mack JW, 2010, J CLIN ONCOL, V28, P1203, DOI 10.1200/JCO.2009.25.4672; Pope C, 2000, BMJ-BRIT MED J, V320, P114, DOI 10.1136/bmj.320.7227.114; Punt CJA, 1998, CANCER-AM CANCER SOC, V83, P679, DOI 10.1002/(SICI)1097-0142(19980815)83:4<679::AID-CNCR8>3.0.CO;2-F; Ritchie J, 2007, QUALITATIVE RES PRAC; SCHNEIDERMAN LJ, 1993, ARCH INTERN MED, V153, P437, DOI 10.1001/archinte.153.4.437; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; Spencer L, 2007, QUALITATIVE RES PRAC; STEWARD WP, 1995, ANN ONCOL, V6, P49; The AM, 2000, BRIT MED J, V321, P1376, DOI 10.1136/bmj.321.7273.1376; van Leeunven AF, 2004, J PAIN SYMPTOM MANAG, V28, P351, DOI 10.1016/j.jpainsymman.2004.01.005; Vos T, 2009, THESIS U AMSTERDAM; Zanchetta Margareth S, 2006, Clin J Oncol Nurs, V10, P803, DOI 10.1188/06.CJON.803-807	28	70	70	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 4	2011	342								d1933	10.1136/bmj.d1933	http://dx.doi.org/10.1136/bmj.d1933			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	V44GZ	21464103	Green Published			2023-01-03	WOS:000209738800001
J	Cerqueira, FM; Laurindo, FRM; Kowaltowski, AJ				Cerqueira, Fernanda M.; Laurindo, Francisco R. M.; Kowaltowski, Alicia J.			Mild Mitochondrial Uncoupling and Calorie Restriction Increase Fasting eNOS, Akt and Mitochondrial Biogenesis	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; LIFE-SPAN; INSULIN SENSITIVITY; DIETARY RESTRICTION; GENE-EXPRESSION; RHESUS-MONKEYS; BLOOD-GLUCOSE; PHOSPHORYLATION; METABOLISM; MIMETICS	Enhanced mitochondrial biogenesis promoted by eNOS activation is believed to play a central role in the beneficial effects of calorie restriction (CR). Since treatment of mice with dinitrophenol (DNP) promotes health and lifespan benefits similar to those observed in CR, we hypothesized that it could also impact biogenesis. We found that DNP and CR increase citrate synthase activity, PGC-1 alpha, cytochrome c oxidase and mitofusin-2 expression, as well as fasting plasma levels of NO center dot products. In addition, eNOS and Akt phosphorylation in skeletal muscle and visceral adipose tissue was activated in fasting CR and DNP animals. Overall, our results indicate that systemic mild uncoupling activates eNOS and Akt-dependent pathways leading to mitochondrial biogenesis.	[Cerqueira, Fernanda M.; Kowaltowski, Alicia J.] Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil; [Laurindo, Francisco R. M.] Univ Sao Paulo, Inst Coracao, Fac Med, BR-01498 Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo	Cerqueira, FM (corresponding author), Univ Sao Paulo, Inst Quim, Dept Bioquim, BR-01498 Sao Paulo, Brazil.	alicia@iq.usp.br	Laurindo, Francisco R/J-6575-2015; cerqueira, fernanda/C-8326-2014; Kowaltowski, Alicia J/H-8698-2012		Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (INCT Redoxoma); The John Simon Guggenhein Memorial Foundation	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (INCT Redoxoma); The John Simon Guggenhein Memorial Foundation	This work was supported by grants from the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP), Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq), Instituto Nacional de Ciencia e Tecnologia de Processos Redox em Biomedicina (INCT Redoxoma) and The John Simon Guggenhein Memorial Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews ZB, 2009, AM J PHYSIOL-ENDOC M, V296, pE621, DOI 10.1152/ajpendo.90903.2008; Barros MH, 2004, J BIOL CHEM, V279, P49883, DOI 10.1074/jbc.M408918200; Baylis C, 1998, CURR OPIN NEPHROL HY, V7, P59, DOI 10.1097/00041552-199801000-00010; Benard G, 2006, AM J PHYSIOL-CELL PH, V291, pC1172, DOI 10.1152/ajpcell.00195.2006; Boden G, 2005, ANN INTERN MED, V142, P403, DOI 10.7326/0003-4819-142-6-200503150-00006; BODKIN NL, 1995, J GERONTOL A-BIOL, V50, pB142, DOI 10.1093/gerona/50A.3.B142; Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2; Cerqueira FM, 2010, AGEING RES REV, V9, P424, DOI 10.1016/j.arr.2010.05.002; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; da Silva CCC, 2008, AGING CELL, V7, P552, DOI 10.1111/j.1474-9726.2008.00407.x; Escriva F, 2007, J ENDOCRINOL, V194, P131, DOI 10.1677/joe.1.07043; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Hu ZL, 2008, J BIOL CHEM, V283, P25256, DOI 10.1074/jbc.M802455200; Humphrey DM, 2009, EXP GERONTOL, V44, P316, DOI 10.1016/j.exger.2009.02.001; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Katic M, 2007, AGING CELL, V6, P827, DOI 10.1111/j.1474-9726.2007.00346.x; KEMNITZ JW, 1994, AM J PHYSIOL, V266, pE540, DOI 10.1152/ajpendo.1994.266.4.E540; Lambert AJ, 2004, AM J PHYSIOL-REG I, V286, pR71, DOI 10.1152/ajpregu.00341.2003; LANE MA, 1995, AM J PHYSIOL-ENDOC M, V268, pE941, DOI 10.1152/ajpendo.1995.268.5.E941; Lanza IR, 2010, PFLUG ARCH EUR J PHY, V459, P277, DOI 10.1007/s00424-009-0724-5; Lemire BD, 2009, MECH AGEING DEV, V130, P461, DOI 10.1016/j.mad.2009.05.001; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lopez-Lluch G, 2006, P NATL ACAD SCI USA, V103, P1768, DOI 10.1073/pnas.0510452103; Masoro EJ, 2009, BBA-GEN SUBJECTS, V1790, P1040, DOI 10.1016/j.bbagen.2009.02.011; Molina AJA, 2009, DIABETES, V58, P2303, DOI 10.2337/db07-1781; MONTAGNANI M, 2001, J BIOL CHEM, V12, P597; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Padalko VI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P986, DOI 10.1007/s10541-005-0213-1; Rashid G, 2007, NEPHROL DIAL TRANSPL, V22, P2831, DOI 10.1093/ndt/gfm269; Ritchie SA, 2010, BIOCHEM J, V426, P85, DOI 10.1042/BJ20091580; Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3; Scarpulla RC, 2006, J CELL BIOCHEM, V97, P673, DOI 10.1002/jcb.20743; Severin FF, 2010, P NATL ACAD SCI USA, V107, P663, DOI 10.1073/pnas.0910216107; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Speakman JR, 2004, AGING CELL, V3, P87, DOI 10.1111/j.1474-9728.2004.00097.x; Tahara EB, 2009, FREE RADICAL BIO MED, V46, P1283, DOI 10.1016/j.freeradbiomed.2009.02.008; Tainter ML, 1938, J PHARMACOL EXP THER, V63, P51; van Diepeningen AD, 2010, EXP GERONTOL, V45, P516, DOI 10.1016/j.exger.2010.01.002; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zheng YB, 2009, J ENDOCRINOL, V203, P337, DOI 10.1677/JOE-09-0181; Zhou XS, 2009, AM J PHYSIOL-HEART C, V297, pH2227, DOI 10.1152/ajpheart.00325.2009; Zorzano A, 2009, CURR OPIN DRUG DISC, V12, P597	46	58	61	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 31	2011	6	3							e18433	10.1371/journal.pone.0018433	http://dx.doi.org/10.1371/journal.pone.0018433			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	743YU	21483800	Green Submitted, Green Published, gold			2023-01-03	WOS:000289057200078
J	Mulrooney, TJ; Marsh, J; Urits, I; Seyfried, TN; Mukherjee, P				Mulrooney, Tiernan J.; Marsh, Jeremy; Urits, Ivan; Seyfried, Thomas N.; Mukherjee, Purna			Influence of Caloric Restriction on Constitutive Expression of NF-kappa B in an Experimental Mouse Astrocytoma	PLOS ONE			English	Article							INFLAMMATORY FACTOR-I; ENDOTHELIAL-GROWTH-FACTOR; DIETARY RESTRICTION; MALIGNANT GLIOMAS; GENE-EXPRESSION; KETOGENIC DIET; MESSENGER-RNA; KETONE-BODIES; UP-REGULATION; BRAIN-TUMORS	Background: Many of the current standard therapies employed for the management of primary malignant brain cancers are largely viewed as palliative, ultimately because these conventional strategies have been shown, in many instances, to decrease patient quality of life while only offering a modest increase in the length of survival. We propose that caloric restriction (CR) is an alternative metabolic therapy for brain cancer management that will not only improve survival but also reduce the morbidity associated with disease. Although we have shown that CR manages tumor growth and improves survival through multiple molecular and biochemical mechanisms, little information is known about the role that CR plays in modulating inflammation in brain tumor tissue. Methodology/Principal Findings: Phosphorylation and activation of nuclear factor kappa B (NF-kappa B) results in the transactivation of many genes including those encoding cycloxygenase-2 (COX-2) and allograft inflammatory factor-1 (AIF-1), both of which are proteins that are primarily expressed by inflammatory and malignant cancer cells. COX-2 has been shown to enhance inflammation and promote tumor cell survival in both in vitro and in vivo studies. In the current report, we demonstrate that the p65 subunit of NF-kappa B was expressed constitutively in the CT-2A tumor compared with contra-lateral normal brain tissue, and we also show that CR reduces (i) the phosphorylation and degree of transcriptional activation of the NF-kappa B-dependent genes COX-2 and AIF-1 in tumor tissue, as well as (ii) the expression of proinflammatory markers lying downstream of NF-kappa B in the CT-2A malignant mouse astrocytoma, [e. g. macrophage inflammatory protein-2 (MIP-2)]. On the whole, our date indicate that the NF-kappa B inflammatory pathway is constitutively activated in the CT-2A astrocytoma and that CR targets this pathway and inflammation. Conclusion: CR could be effective in reducing malignant brain tumor growth in part by inhibiting inflammation in the primary brain tumor.	[Mulrooney, Tiernan J.] Georgetown Univ, Med Ctr, Tumor Biol Program, Washington, DC 20007 USA; [Marsh, Jeremy] Albert Einstein Coll Med, Bronx, NY 10467 USA; [Urits, Ivan; Seyfried, Thomas N.; Mukherjee, Purna] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA	Georgetown University; Yeshiva University; Albert Einstein College of Medicine; Boston College	Mulrooney, TJ (corresponding author), Georgetown Univ, Med Ctr, Tumor Biol Program, Washington, DC 20007 USA.	mukherjp@bc.edu		Seyfried, Thomas/0000-0003-1491-3989	National Institutes of Health [NS 055195, CA102135]; Boston College; NATIONAL CANCER INSTITUTE [R01CA102135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS055195, R01NS055195] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Boston College; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by National Institutes of Health grants NS 055195 and CA102135 and the Boston College research expense fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albini A, 2007, NAT REV CANCER, V7, P139, DOI 10.1038/nrc2067; Angileri FF, 2008, CANCER-AM CANCER SOC, V112, P2258, DOI 10.1002/cncr.23407; Annabi B, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-8; Armstrong DA, 2004, J LEUKOCYTE BIOL, V75, P641, DOI 10.1189/jlb.0803370; Atkinson GP, 2009, ONCOGENE, V28, P3735, DOI 10.1038/onc.2009.232; Autieri MV, 1996, BIOCHEM BIOPH RES CO, V228, P29, DOI 10.1006/bbrc.1996.1612; Badie B, 2003, CLIN CANCER RES, V9, P872; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408; Carlson MRJ, 2007, CLIN CANCER RES, V13, P2592, DOI 10.1158/1078-0432.CCR-06-2772; Chung HY, 2006, ANTIOXID REDOX SIGN, V8, P572, DOI 10.1089/ars.2006.8.572; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; Clement K, 2004, FASEB J, V18, P1657, DOI 10.1096/fj.04-2204com; Csiszar A, 2009, MECH AGEING DEV, V130, P518, DOI 10.1016/j.mad.2009.06.004; Derr RL, 2009, J CLIN ONCOL, V27, P1082, DOI 10.1200/JCO.2008.19.1098; Dixit VD, 2008, J LEUKOCYTE BIOL, V84, P882, DOI 10.1189/jlb.0108028; Dong WM, 1998, AM J RESP CELL MOL, V19, P462, DOI 10.1165/ajrcmb.19.3.3114; Fenton JI, 2009, DIABETES OBES METAB, V11, P343, DOI 10.1111/j.1463-1326.2008.00974.x; Fiedler U, 2006, TRENDS IMMUNOL, V27, P552, DOI 10.1016/j.it.2006.10.004; Fisher PG, 2005, JAMA-J AM MED ASSOC, V293, P615, DOI 10.1001/jama.293.5.615; FLAVIN HJ, 1991, J NEUROCHEM, V56, P1007, DOI 10.1111/j.1471-4159.1991.tb02021.x; GUSTAFSON MP, NEURO ONCOL; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; HARVEY AE, 2010, CANC PREVENTION RE S, V3, pB54; Hayashi S, 2001, NEUROL MED-CHIR, V41, P187, DOI 10.2176/nmc.41.187; Heilbronn LK, 2003, AM J CLIN NUTR, V78, P361, DOI 10.1093/ajcn/78.3.361; HOLNESS CL, 1993, BLOOD, V81, P1607; HUANG S, 1992, AM J PATHOL, V141, P981; Hursting SD, 2007, CANCER RES, V67, P2391, DOI 10.1158/0008-5472.CAN-06-4237; Hursting SD, 2010, CARCINOGENESIS, V31, P83, DOI 10.1093/carcin/bgp280; Huysentruyt LC, 2008, INT J CANCER, V123, P73, DOI 10.1002/ijc.23492; Ikeda S, 2001, ARCH SURG-CHICAGO, V136, P297, DOI 10.1001/archsurg.136.3.297; Jackson JR, 1997, FASEB J, V11, P457, DOI 10.1096/fasebj.11.6.9194526; JENKS S, J NATL CANC I, V102, P519; Jia J, 2010, PEDIATR RES, V67, P29, DOI 10.1203/PDR.0b013e3181bf572b; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Jukich PJ, 2001, NEURO-ONCOLOGY, V3, P141, DOI 10.1093/neuonc/3.3.141; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kim DS, 2003, MOL IMMUNOL, V40, P633, DOI 10.1016/j.molimm.2003.07.001; Kimura M, 2007, J IMMUNOL, V178, P3316, DOI 10.4049/jimmunol.178.5.3316; Kobayashi Hanako, 2009, V511, P185, DOI 10.1007/978-1-59745-447-6_8; Korkolopoulou P, 2008, HUM PATHOL, V39, P1143, DOI 10.1016/j.humpath.2008.01.020; Krebs H.A., 1971, ADV ENZYME REGUL, V9, P387, DOI [10.1016/S0065-2571(71)80055-9, DOI 10.1016/S0065-2571(71)80055-9]; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu S, 2008, CANCER SCI, V99, P952, DOI 10.1111/j.1349-7006.2008.00787.x; Lowry JK, 1998, ARCH NEUROL-CHICAGO, V55, P922, DOI 10.1001/archneur.55.7.922; Lu S, 2004, RADIOLOGY, V232, P221, DOI 10.1148/radiol.2321030653; Ludwig HC, 2000, ANTICANCER RES, V20, P299; Lukins MB, 2005, ANESTH ANALG, V100, P1129, DOI 10.1213/01.ANE.0000146943.45445.55; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; MANCINO A, CLIN CANC RES, V16, P784; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Marsh J, 2008, CLIN CANCER RES, V14, P7751, DOI 10.1158/1078-0432.CCR-08-0213; Martinez-Murillo R, 2007, HISTOL HISTOPATHOL, V22, P1309, DOI 10.14670/HH-22.1309; Matzer SP, 2004, INT IMMUNOL, V16, P1675, DOI 10.1093/intimm/dxh169; McMillan DC, 2006, BRIT MED J, V333, P1109, DOI 10.1136/bmj.39042.565035.BE1; Mitchell JR, 2010, AGING CELL, V9, P40, DOI 10.1111/j.1474-9726.2009.00532.x; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Mukherjee P, 1999, JNCI-J NATL CANCER I, V91, P512, DOI 10.1093/jnci/91.6.512; Mukherjee P, 2004, CLIN CANCER RES, V10, P5622, DOI 10.1158/1078-0432.CCR-04-0308; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Mukherjee P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-37; NABEL GJ, 1993, GENE DEV, V7, P2063, DOI 10.1101/gad.7.11.2063; Nicholson HS, 2007, CANCER, V110, P1542, DOI 10.1002/cncr.22961; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337; Ohsawa K, 2004, J NEUROCHEM, V88, P844, DOI 10.1046/j.1471-4159.2003.02213.x; Pashenkov M, 2000, SCAND J IMMUNOL, V52, P117; Pope WB, 2005, AM J NEURORADIOL, V26, P2466; Portnow J, 2002, NEURO-ONCOLOGY, V4, P22, DOI 10.1093/neuonc/4.1.22; Ranes MK, 2001, BRIT J CANCER, V84, P1107, DOI 10.1054/bjoc.2000.1713; Ruskin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008349; Rutz HP, 2005, CANCER BIOL THER, V4, P1186, DOI 10.4161/cbt.4.11.2232; Rutz HP, 2005, CANCER, V103, P2656, DOI 10.1002/cncr.21067; Seyfried Thomas N, 2005, Nutr Metab (Lond), V2, P30, DOI 10.1186/1743-7075-2-30; Seyfried TN, 2003, BRIT J CANCER, V89, P1375, DOI 10.1038/sj.bjc.6601269; Seyfried TN, 2001, PERSPECT BIOL MED, V44, P263, DOI 10.1353/pbm.2001.0035; SEYFRIED TN, 1992, MOL CHEM NEUROPATHOL, V17, P147, DOI 10.1007/BF03159989; SEYFRIED TN, NUTR METAB LOND, V7, P7; SEYFRIED TN, BIOCH BIOPHYS ACTA; Shelton LM, 2010, ASN NEURO, V2, DOI 10.1042/AN20100002; SHELTON LM, J NEUROONCOL; Shono T, 2001, CANCER RES, V61, P4375; Smith JS, 2000, FRONT BIOSCI-LANDMRK, V5, pD213, DOI 10.2741/Smith; STAUDT LM, COLD SPRING HARB PER, V2; Temel SG, 2009, J MOL HISTOL, V40, P369, DOI 10.1007/s10735-009-9250-1; Tsunoda Keishi, 2005, Brain Tumor Pathol, V22, P79, DOI 10.1007/s10014-005-0186-1; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; WANG H, CURR CANC DRUG TARGE; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; WILLIAMSON DH, 1962, BIOCHEM J, V82, P90, DOI 10.1042/bj0820090; WOLPE SD, 1989, P NATL ACAD SCI USA, V86, P612, DOI 10.1073/pnas.86.2.612; Xie TX, 2010, ONCOL REP, V23, P725, DOI 10.3892/or_00000690; Yang ZF, 2005, INT IMMUNOL, V17, P1391, DOI 10.1093/intimm/dxh316; Zampetaki A, 2004, FASEB J, V18, P1090, DOI 10.1096/fj.03-0991fje; Zhou WH, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-5	103	46	49	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 30	2011	6	3							e18085	10.1371/journal.pone.0018085	http://dx.doi.org/10.1371/journal.pone.0018085			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	743YK	21479220	Green Published, Green Submitted, gold			2023-01-03	WOS:000289055700024
J	Ravva, SV; Sarreal, CZ; Mandrell, RE				Ravva, Subbarao V.; Sarreal, Chester Z.; Mandrell, Robert E.			Bacterial Communities in Aerosols and Manure Samples from Two Different Dairies in Central and Sonoma Valleys of California	PLOS ONE			English	Article							ESCHERICHIA-COLI O157-H7; AVIUM SUBSP PARATUBERCULOSIS; FECAL POLLUTION; GENETIC-MARKERS; WASTE; IDENTIFICATION; ENVIRONMENT; SURVIVAL; 16S; TRANSMISSION	Aerosols have been suspected to transport food pathogens and contaminate fruits and vegetables grown in close proximity to concentrated animal feeding operations, but studies are lacking that substantiate such transport. To monitor the potential transport of bacteria originated from fresh or dry manure through aerosols on a dairy, we identified by 16S rRNA sequencing, bacteria in aerosols collected within 2 to 3 meters from dairy cows at two dairies. Gram-positive Firmicutes were predominant in aerosols from a dairy in Sonoma, California, and surrounded by vineyards, in contrast to sequences of Gram-negative Proteobacteria predominant in aerosols from a dairy in Modesto, California, also surrounded by other dairies. Although Firmicutes represented approximately 50% of the 10 most abundant sequences, aerosols from the Sonoma dairy also contained sequences of Bacteriodetes and Actinobacteria, identified previously with animal feces. While none of the top 10 sequences from fresh or dry manure from Modesto dairy were detected in aerosols, two of the sequences from the phylum Bacteriodetes and one from class Clostridia from fresh manure were detected in aerosols from Sonoma. Interestingly, none of the sequences from dry manure were in the top 10 sequences in aerosols from both dairies. The 10 most abundant sequences in aerosols from the Modesto dairy were all from Proteobacteria and nearly half of them were from genus Massilia, which have been isolated previously from immune-compromised people and aerosols. We conclude that the predominant bacteria in aerosols are diverse among locations and that they do not reflect the predominant species of bacteria present in cow feces and/or in close proximity to cows. These results suggest that the aerosol sequences did not originate from manure. Large volumes of aerosols would be required to determine if bacterial sequences from aerosols could be used to track bacteria in manure to crops grown in proximity.	[Ravva, Subbarao V.; Sarreal, Chester Z.; Mandrell, Robert E.] ARS, Produce Safety & Microbiol Res Unit, Western Reg Res Ctr, USDA, Albany, CA USA	United States Department of Agriculture (USDA)	Ravva, SV (corresponding author), ARS, Produce Safety & Microbiol Res Unit, Western Reg Res Ctr, USDA, Albany, CA USA.	subbarao.ravva@ars.usda.gov	Mandrell, Robert E/O-9814-2018		U.S. Department of Agriculture, Agricultural Research Service [5325-42000-044]	U.S. Department of Agriculture, Agricultural Research Service(United States Department of Agriculture (USDA)USDA Agricultural Research Service)	The work was funded by the U.S. Department of Agriculture, Agricultural Research Service under CRIS project 5325-42000-044. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baertsch C, 2007, APPL ENVIRON MICROB, V73, P4522, DOI 10.1128/AEM.02387-06; Bergman W, 2005, J AEROSOL SCI, V36, P619, DOI 10.1016/j.jaerosci.2004.12.010; Bernhard AE, 2000, APPL ENVIRON MICROB, V66, P1587, DOI 10.1128/AEM.66.4.1587-1594.2000; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Brooks JP, 2010, SCI TOTAL ENVIRON, V408, P4770, DOI 10.1016/j.scitotenv.2010.06.038; Cole DJ, 1999, OCCUP MED-STATE ART, V14, P423; Cooley M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001159; Cornick NA, 2008, APPL ENVIRON MICROB, V74, P2488, DOI 10.1128/AEM.02897-07; DURSO LM, 2011, FOODBORNE P IN PRESS; Harbaugh E, 2006, POULTRY SCI, V85, P1693, DOI 10.1093/ps/85.10.1693; Hernlem BJ, 2007, J ENVIRON MONITOR, V9, P1317, DOI 10.1039/b710512f; Holmes A, 1998, EMERG INFECT DIS, V4, P221, DOI 10.3201/eid0402.980209; Hutchison ML, 2008, J APPL MICROBIOL, V105, P848, DOI 10.1111/j.1365-2672.2008.03811.x; Ibekwe AM, 2004, FEMS MICROBIOL ECOL, V48, P239, DOI 10.1016/j.femsec.2004.01.012; Kudva IT, 1998, APPL ENVIRON MICROB, V64, P3166; La Scola B, 1998, J CLIN MICROBIOL, V36, P2847, DOI 10.1128/JCM.36.10.2847-2852.1998; Le Goff O, 2010, J APPL MICROBIOL, V108, P325, DOI 10.1111/j.1365-2672.2009.04427.x; Leclerc MC, 2000, RES MICROBIOL, V151, P629, DOI 10.1016/S0923-2508(00)90129-3; McBride MT, 2003, ANAL CHEM, V75, P5293, DOI 10.1021/ac034722v; McGarvey JA, 2004, APPL ENVIRON MICROB, V70, P4267, DOI 10.1128/AEM.70.7.4267-4275.2004; McGarvey JA, 2007, APPL ENVIRON MICROB, V73, P193, DOI 10.1128/AEM.01422-06; McGarvey JA, 2010, APPL MICROBIOL BIOT, V85, P1947, DOI 10.1007/s00253-009-2229-8; Nehme B, 2008, ENVIRON MICROBIOL, V10, P665, DOI 10.1111/j.1462-2920.2007.01489.x; Patton TG, 2009, VET MICROBIOL, V136, P285, DOI 10.1016/j.vetmic.2008.10.032; Pillai SD, 2002, CAN J MICROBIOL, V48, P681, DOI [10.1139/w02-070, 10.1139/W02-070]; Radosevich JL, 2002, LETT APPL MICROBIOL, V34, P162, DOI 10.1046/j.1472-765x.2002.01048.x; Raizman EA, 2004, J DAIRY SCI, V87, P2959, DOI 10.3168/jds.S0022-0302(04)73427-X; Ravva SV, 2006, J APPL MICROBIOL, V101, P891, DOI 10.1111/j.1365-2672.2006.02956.x; Ravva SV, 2005, J MICROBIOL METH, V63, P305, DOI 10.1016/j.mimet.2005.04.004; Savichtcheva O, 2006, WATER RES, V40, P2463, DOI 10.1016/j.watres.2006.04.040; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Whittington RJ, 2004, APPL ENVIRON MICROB, V70, P2989, DOI 10.1128/AEM.70.5.2989-3004.2004; Wu CH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011285	33	25	25	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2011	6	2							e17281	10.1371/journal.pone.0017281	http://dx.doi.org/10.1371/journal.pone.0017281			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	723CC	21364996	Green Submitted, Green Published, gold			2023-01-03	WOS:000287482800045
J	Vijayan, S; Chase, A				Vijayan, Sethumadhavan; Chase, Alexander			Lingual Hematoma after Thrombolytic Therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Vijayan, Sethumadhavan; Chase, Alexander] Morriston Hosp, Swansea, W Glam, Wales	Morriston Hospital	Vijayan, S (corresponding author), Morriston Hosp, Swansea, W Glam, Wales.	sethu@doctors.org.uk							0	1	1	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2011	364	7					E13	E13		10.1056/NEJMicm1005647	http://dx.doi.org/10.1056/NEJMicm1005647			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722BW	21323537				2023-01-03	WOS:000287406000013
J	Kroon, AA; Wang, JX; Kavanagh, B; Huang, Z; Kuliszewski, M; van Goudoever, JB; Post, M				Kroon, Andreas A.; Wang, Jinxia; Kavanagh, Brian; Huang, Zhen; Kuliszewski, Maciej; van Goudoever, Johannes B.; Post, Martin			Prolonged Mechanical Ventilation Induces Cell Cycle Arrest in Newborn Rat Lung	PLOS ONE			English	Article							GENE-EXPRESSION; GROWTH; P27(KIP1); DISEASE; SIMILARITIES; INHIBITOR; COMPLEXES; APOPTOSIS; PATHWAYS; MEDIATOR	Rationale: The molecular mechanism(s) by which mechanical ventilation disrupts alveolar development, a hallmark of bronchopulmonary dysplasia, is unknown. Objective: To determine the effect of 24 h of mechanical ventilation on lung cell cycle regulators, cell proliferation and alveolar formation in newborn rats. Methods: Seven-day old rats were ventilated with room air for 8, 12 and 24 h using relatively moderate tidal volumes (8.5 mL. kg(-1)). Measurement and Main Results: Ventilation for 24 h (h) decreased the number of elastin-positive secondary crests and increased the mean linear intercept, indicating arrest of alveolar development. Proliferation (assessed by BrdU incorporation) was halved after 12 h of ventilation and completely arrested after 24 h. Cyclin D1 and E1 mRNA and protein levels were decreased after 8-24 h of ventilation, while that of p27(Kip1) was significantly increased. Mechanical ventilation for 24 h also increased levels of p57(Kip2), decreased that of p16(INK4a), while the levels of p21(Waf/Cip1) and p15(INK4b) were unchanged. Increased p27(Kip1) expression coincided with reduced phosphorylation of p27(Kip1) at Thr(157), Thr(187) and Thr(198) (p<0.05), thereby promoting its nuclear localization. Similar -but more rapid-changes in cell cycle regulators were noted when 7-day rats were ventilated with high tidal volume (40 mL.kg(-1)) and when fetal lung epithelial cells were subjected to a continuous (17% elongation) cyclic stretch. Conclusion: This is the first demonstration that prolonged (24 h) of mechanical ventilation causes cell cycle arrest in newborn rat lungs; the arrest occurs in G(1) and is caused by increased expression and nuclear localization of Cdk inhibitor proteins (p27(Kip)1, p57(Kip2)) from the Kip family.	[Kroon, Andreas A.; Wang, Jinxia; Kavanagh, Brian; Huang, Zhen; Kuliszewski, Maciej; Post, Martin] Hosp Sick Children, Res Inst, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada; [Post, Martin] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Kavanagh, Brian; Post, Martin] Univ Toronto, Dept Physiol, Toronto, ON, Canada; [Kavanagh, Brian] Univ Toronto, Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Kavanagh, Brian] Univ Toronto, Hosp Sick Children, Dept Anesthesia, Toronto, ON M5G 1X8, Canada; [Kroon, Andreas A.; van Goudoever, Johannes B.] Erasmus MC Sophia, Dept Pediat, Rotterdam, Netherlands; [van Goudoever, Johannes B.] Emmas Childrens Hosp, Dept Pediat, Amsterdam Med Ctr, Amsterdam, Netherlands; [van Goudoever, Johannes B.] Free Univ Amsterdam Hosp, Dept Pediat, NL-1081 HV Amsterdam, Netherlands	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Erasmus University Rotterdam; Erasmus MC; Emma Children's Hospital; University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Kroon, AA (corresponding author), Hosp Sick Children, Res Inst, Physiol & Expt Med Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	martin.post@sickkids.ca	van Goudoever, Johannes Bernard/Y-4520-2018	van Goudoever, Johannes (Hans)/0000-0003-3960-1703	Canadian Institute of Health Research [MOP-15272]; Canadian Foundation for Innovation; Sophia Children's Hospital	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation(Canada Foundation for Innovation); Sophia Children's Hospital	The study was supported by operating grants (MOP-15272) from the Canadian Institute of Health Research and the Sophia Children's Hospital Fund (SSWO) and infrastructure grants (CCURE, CSCCD) from the Canadian Foundation for Innovation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Mohanna MA, 2004, ONCOGENE, V23, P201, DOI 10.1038/sj.onc.1206927; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burri P.H., 1999, LUNG DEV, P122; CANIGGIA I, 1991, AM J PHYSIOL, V261, pL424, DOI 10.1152/ajplung.1991.261.6.L424; Clement A, 2001, AM J RESP CRIT CARE, V164, pS81, DOI 10.1164/ajrccm.164.supplement_2.2106069; Coalson JJ, 1999, AM J RESP CRIT CARE, V160, P1333, DOI 10.1164/ajrccm.160.4.9810071; Copland IB, 2007, J CELL PHYSIOL, V210, P133, DOI 10.1002/jcp.20840; Copland IB, 2006, AM J PHYSIOL-LUNG C, V291, pL487, DOI 10.1152/ajplung.00510.2005; Corroyer S, 1996, J BIOL CHEM, V271, P25117, DOI 10.1074/jbc.271.41.25117; Cutz E, 2008, NEW ENGL J MED, V358, P743, DOI 10.1056/NEJMc073362; Das KC, 2004, ANTIOXID REDOX SIGN, V6, P117, DOI 10.1089/152308604771978426; De Paepe ME, 1999, AM J RESP CELL MOL, V21, P65, DOI 10.1165/ajrcmb.21.1.3511; DUNNILL M. S., 1964, THORAX, V19, P443, DOI 10.1136/thx.19.5.443; Edwards YS, 1999, FEBS LETT, V448, P127, DOI 10.1016/S0014-5793(99)00357-9; Fanaroff Avroy A, 2007, Am J Obstet Gynecol, V196, DOI 10.1016/j.ajog.2006.09.014; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Helt CE, 2004, AM J PHYSIOL-LUNG C, V286, pL506, DOI 10.1152/ajplung.00243.2003; Husain AN, 1998, HUM PATHOL, V29, P710, DOI 10.1016/S0046-8177(98)90280-5; Jobe AJ, 1999, PEDIATR RES, V46, P641, DOI 10.1203/00006450-199912000-00001; KAUFFMAN SL, 1974, ANAT RECORD, V180, P63, DOI 10.1002/ar.1091800108; Kinsella JP, 2006, LANCET, V367, P1421, DOI 10.1016/S0140-6736(06)68615-7; Kroon AA, 2010, PEDIATR RES, V68, P63, DOI 10.1203/00006450-201011001-00120; Larrea MD, 2008, MOL CELL BIOL, V28, P6462, DOI 10.1128/MCB.02300-07; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003; Maniscalco WM, 2005, PEDIATR RES, V58, P549, DOI 10.1203/01.pdr.0000176923.79584.f7; McAdams RM, 2006, AM J PHYSIOL-LUNG C, V291, pL166, DOI 10.1152/ajplung.00160.2005; McConnell BB, 1999, MOL CELL BIOL, V19, P1981; McGrath SA, 1998, AM J RESP CELL MOL, V18, P179, DOI 10.1165/ajrcmb.18.2.2964m; Mokres LM, 2010, AM J PHYSIOL-LUNG C, V298, pL23, DOI 10.1152/ajplung.00251.2009; Nardo L, 2000, EXP LUNG RES, V26, P105, DOI 10.1080/019021400269907; Ngiam N, 2010, AM J RESP CRIT CARE, V181, P947, DOI 10.1164/rccm.200908-1297OC; Park MT, 2003, J BIOCHEM MOL BIOL, V36, P60; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rancourt RC, 2001, AM J PHYSIOL-LUNG C, V280, pL617, DOI 10.1152/ajplung.2001.280.4.L617; Roth-Kleiner M, 2005, PEDIATR PULM, V40, P113, DOI 10.1002/ppul.20252; Roth-Kleiner M, 2007, PEDIATR RES, V61, P191, DOI 10.1203/01.pdr.0000252437.51779.21; Sanchez-Esteban J, 2002, AM J PHYSIOL-LUNG C, V282, pL448, DOI 10.1152/ajplung.00399.2000; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Staversky RJ, 2006, FREE RADICAL BIO MED, V41, P601, DOI 10.1016/j.freeradbiomed.2006.04.029; Susaki E, 2007, CELL CYCLE, V6, P3015, DOI 10.4161/cc.6.24.5087; Susaki E, 2009, CELL CYCLE, V8, P2497, DOI 10.4161/cc.8.16.9330; Vermeulen K, 2003, CELL PROLIFERAT, V36, P131, DOI 10.1046/j.1365-2184.2003.00266.x; Xu J, 1998, AM J PHYSIOL-LUNG C, V275, pL545, DOI 10.1152/ajplung.1998.275.3.L545; Yi M, 2004, AM J RESP CRIT CARE, V170, P1188, DOI 10.1164/rccm.200402-215OC	49	18	18	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2011	6	2							e16910	10.1371/journal.pone.0016910	http://dx.doi.org/10.1371/journal.pone.0016910			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721YC	21359218	Green Published, gold			2023-01-03	WOS:000287392700029
J	Espinosa, N; Marino, J; de Labra, C; Cudeiro, J				Espinosa, Nelson; Marino, Jorge; de Labra, Carmen; Cudeiro, Javier			Cortical Modulation of the Transient Visual Response at Thalamic Level: A TMS Study	PLOS ONE			English	Article							LATERAL GENICULATE-NUCLEUS; TRANSCRANIAL MAGNETIC STIMULATION; RECEPTIVE-FIELD ORGANIZATION; RETINAL GANGLION-CELLS; CATS STRIATE CORTEX; SPATIAL SUMMATION; X-CELLS; SPATIOTEMPORAL ORGANIZATION; RELAY CELLS; LGN BURSTS	The transient visual response of feline dorsal lateral geniculate nucleus (dLGN) cells was studied under control conditions and during the application of repetitive transcranial magnetic stimulation at 1 Hz (rTMS@1Hz) on the primary visual cortex (V1). The results show that rTMS@1Hz modulates the firing mode of Y cells, inducing an increase in burst spikes and a decrease in tonic firing. On the other hand, rTMS@1Hz modifies the spatiotemporal characteristics of receptive fields of X cells, inducing a delay and a decrease of the peak response, and a change of the surround/center amplitude ratio of RF profiles. These results indicate that V1 controls the activity of the visual thalamus in a different way in the X and Y pathways, and that this feedback control is consistent with functional roles associated with each cell type.	[Espinosa, Nelson] Univ A Coruna, Neurosci & Motor Control Grp NEUROcom, La Coruna, Spain; Univ A Coruna, Biomed Inst Coruna INIBIC, La Coruna, Spain	Universidade da Coruna; Universidade da Coruna; Instituto de Investigacion Biomedica de A Coruna (INIBIC)	Espinosa, N (corresponding author), Univ A Coruna, Neurosci & Motor Control Grp NEUROcom, La Coruna, Spain.	jcud@udc.es	de Labra, Carmen/C-9992-2017	de Labra, Carmen/0000-0002-5306-0475; Cudeiro, Javier/0000-0002-6597-6077; , Gerontology Research Group/0000-0001-7207-9481	MICINN, Spain [BFU2009-08169]; Xunta de Galicia (Conselleria de Educacion) [2007/000140-0]	MICINN, Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Xunta de Galicia (Conselleria de Educacion)(Xunta de Galicia)	The work was supported by grants BFU2009-08169-MICINN, Spain and Xunta de Galicia (Conselleria de Educacion-2007/000140-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADELSON EH, 1985, J OPT SOC AM A, V2, P284, DOI 10.1364/JOSAA.2.000284; Alitto HJ, 2005, J NEUROSCI, V25, P514, DOI 10.1523/JNEUROSCI.3369-04.2005; Aydin-Abidin S, 2006, J PHYSIOL-LONDON, V574, P443, DOI 10.1113/jphysiol.2006.108464; BERARDI N, 1984, J PHYSIOL-LONDON, V357, P525, DOI 10.1113/jphysiol.1984.sp015515; Briggs F, 2009, NEURON, V62, P135, DOI 10.1016/j.neuron.2009.02.024; Cai DQ, 1997, J NEUROPHYSIOL, V78, P1045, DOI 10.1152/jn.1997.78.2.1045; Chen R, 1997, NEUROLOGY, V48, P1398, DOI 10.1212/WNL.48.5.1398; CLELAND BG, 1985, J PHYSIOL-LONDON, V369, P249, DOI 10.1113/jphysiol.1985.sp015899; CLELAND BG, 1971, J PHYSIOL-LONDON, V217, P473, DOI 10.1113/jphysiol.1971.sp009581; DAWIS S, 1984, VISION RES, V24, P549, DOI 10.1016/0042-6989(84)90109-3; de Labra C, 2007, CEREB CORTEX, V17, P1376, DOI 10.1093/cercor/bhl048; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1118, DOI 10.1152/jn.1993.69.4.1118; DEANGELIS GC, 1993, J NEUROPHYSIOL, V69, P1091, DOI 10.1152/jn.1993.69.4.1091; DERRINGTON AM, 1979, J PHYSIOL-LONDON, V293, P347, DOI 10.1113/jphysiol.1979.sp012893; ENROTHCUGELL C, 1983, J PHYSIOL-LONDON, V341, P279, DOI 10.1113/jphysiol.1983.sp014806; ENROTHCUGELL C, 1966, J PHYSIOL-LONDON, V187, P517, DOI 10.1113/jphysiol.1966.sp008107; Fanselow EE, 2001, P NATL ACAD SCI USA, V98, P15330, DOI 10.1073/pnas.261273898; FUKUDA Y, 1976, BRAIN RES, V113, P188, DOI 10.1016/0006-8993(76)90018-4; FUNKE K, 1995, J PHYSIOL-LONDON, V485, P715, DOI 10.1113/jphysiol.1995.sp020764; Funke K, 1996, NEUROREPORT, V7, P2130, DOI 10.1097/00001756-199609020-00013; Funke K, 1997, PROG NEUROBIOL, V53, P67, DOI 10.1016/S0301-0082(97)00032-4; GEISERT EE, 1981, BRAIN RES, V208, P409, DOI 10.1016/0006-8993(81)90568-0; Godwin DW, 1996, J NEUROPHYSIOL, V76, P1800, DOI 10.1152/jn.1996.76.3.1800; Grieve KL, 2009, BRAIN RES, V1273, P48, DOI 10.1016/j.brainres.2009.03.053; Grubb MS, 2005, J NEUROPHYSIOL, V93, P3224, DOI 10.1152/jn.00445.2004; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; JONES JP, 1987, J NEUROPHYSIOL, V58, P1187, DOI 10.1152/jn.1987.58.6.1187; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; Lesica NA, 2006, PLOS BIOL, V4, P1201, DOI 10.1371/journal.pbio.0040209; LINDSTROM S, 1990, J PHYSIOL-LONDON, V429, P259, DOI 10.1113/jphysiol.1990.sp018255; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; LU SM, 1992, J NEUROPHYSIOL, V68, P2185, DOI 10.1152/jn.1992.68.6.2185; Maeda F, 2000, CLIN NEUROPHYSIOL, V111, P800, DOI 10.1016/S1388-2457(99)00323-5; MCCLURKIN JW, 1984, J PHYSIOL-LONDON, V348, P135, DOI 10.1113/jphysiol.1984.sp015103; Mix A, 2010, EUR J NEUROSCI, V32, P1575, DOI 10.1111/j.1460-9568.2010.07425.x; Moliadze V, 2003, J PHYSIOL-LONDON, V553, P665, DOI 10.1113/jphysiol.2003.050153; MONTERO VM, 1985, EXP BRAIN RES, V60, P603; MUKHERJEE P, 1995, J NEUROPHYSIOL, V74, P1222, DOI 10.1152/jn.1995.74.3.1222; MURPHY PC, 1987, NATURE, V329, P727, DOI 10.1038/329727a0; Murphy PC, 1996, J NEUROSCI, V16, P1180; Murphy PC, 2000, J NEUROSCI, V20, P845, DOI 10.1523/JNEUROSCI.20-02-00845.2000; Nassi JJ, 2009, NAT REV NEUROSCI, V10, P360, DOI 10.1038/nrn2619; PALMER LA, 1991, NEURAL BASIS VISUAL, P246; Pasley BN, 2009, NEURON, V62, P291, DOI 10.1016/j.neuron.2009.03.012; Reinagel P, 1999, J NEUROPHYSIOL, V81, P2558, DOI 10.1152/jn.1999.81.5.2558; Rivadulla C, 2003, J PHYSIOL-LONDON, V553, P601, DOI 10.1113/jphysiol.2003.048561; Rivadulla C, 2002, J NEUROSCI, V22, P2956, DOI 10.1523/JNEUROSCI.22-07-02956.2002; RODIECK R. W., 1965, VISION RES, V5, P583, DOI 10.1016/0042-6989(65)90033-7; Sack AT, 2006, CURR OPIN NEUROBIOL, V16, P593, DOI 10.1016/j.conb.2006.06.016; SHAPLEY R, 1975, NATURE, V256, P411, DOI 10.1038/256411a0; Sillito AM, 2006, TRENDS NEUROSCI, V29, P307, DOI 10.1016/j.tins.2006.05.001; SILLITO AM, 1983, BRAIN RES, V277, P63, DOI 10.1016/0006-8993(83)90908-3; SINGER W, 1977, PHYSIOL REV, V57, P386, DOI 10.1152/physrev.1977.57.3.386; Smith GD, 2002, J NEUROSCI, V22, P10242; VIDNYANSZKY Z, 1994, J COMP NEUROL, V349, P259, DOI 10.1002/cne.903490208; Waleszczyk WJ, 2005, EXP NEUROL, V196, P54, DOI 10.1016/j.expneurol.2005.07.006; Wang W, 2006, NAT NEUROSCI, V9, P1330, DOI 10.1038/nn1768; Wang X, 2007, NEURON, V55, P465, DOI 10.1016/j.neuron.2007.06.039; Wassermann EM, 1996, LANCET, V347, P825, DOI 10.1016/S0140-6736(96)90898-3; WATSON AB, 1985, J OPT SOC AM A, V2, P322, DOI 10.1364/JOSAA.2.000322; Weyand TG, 2001, J NEUROPHYSIOL, V85, P1107, DOI 10.1152/jn.2001.85.3.1107; Worgotter F, 1998, NATURE, V396, P165, DOI 10.1038/24157; Zhan XJ, 1999, J NEUROPHYSIOL, V81, P2360, DOI 10.1152/jn.1999.81.5.2360	63	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 10	2011	6	2							e17041	10.1371/journal.pone.0017041	http://dx.doi.org/10.1371/journal.pone.0017041			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721NZ	21347322	Green Published, gold, Green Submitted			2023-01-03	WOS:000287363000033
J	Clark, AL; Johnson, MJ; Squire, I				Clark, Andrew L.; Johnson, Miriam J.; Squire, Iain			Uncertainties Page Does home oxygen benefit people with chronic heart failure?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							EXERCISE CAPACITY; BREATHLESSNESS; THERAPY; DYSPNEA					a.l.clark@hull.ac.uk		Johnson, Miriam/0000-0001-6204-9158	National Institute for Health Research [06/80/01] Funding Source: researchfish; Department of Health [06/80/01] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		Abernethy AP, 2010, LANCET, V376, P784, DOI 10.1016/S0140-6736(10)61115-4; Booth S, 2004, RESP MED, V98, P66, DOI 10.1016/j.rmed.2003.08.008; Bradley TD, 2005, NEW ENGL J MED, V353, P2025, DOI 10.1056/NEJMoa051001; CLARK A, 1994, BRIT HEART J, V71, P528; Cranston JM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001744.pub2; Cranston JM, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004769.pub2; Currow DC, 2009, PALLIATIVE MED, V23, P309, DOI 10.1177/0269216309104058; Mak S, 2001, CHEST, V120, P467, DOI 10.1378/chest.120.2.467; MOORE DP, 1992, LANCET, V339, P850, DOI 10.1016/0140-6736(92)90288-E; Oldenburg O, 2007, EUR J HEART FAIL, V9, P251, DOI 10.1016/j.ejheart.2006.08.003; RUBIN SA, 1982, CIRCULATION, V66, P143, DOI 10.1161/01.CIR.66.1.143; Russell SD, 1999, AM J CARDIOL, V84, P1412, DOI 10.1016/S0002-9149(99)00587-1; Sasayama S, 2009, CIRC J, V73, P1255, DOI 10.1253/circj.CJ-08-1210; Scottish Intercollegiate Guidelines Network, 2003, 73 SCOTT INT GUID NE; THOMAS M, 1965, BRIT HEART J, V27, P401; Toyama T, 2009, CIRC J, V73, P299, DOI 10.1253/circj.CJ-07-0297	16	15	15	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 4	2011	342								d234	10.1136/bmj.d234	http://dx.doi.org/10.1136/bmj.d234			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	718PX	21296836				2023-01-03	WOS:000287138600005
J	Hoberman, A; Paradise, JL; Rockette, HE; Shaikh, N; Wald, ER; Kearney, DH; Colborn, DK; Kurs-Lasky, M; Bhatnagar, S; Haralam, MA; Zoffel, LM; Jenkins, C; Pope, MA; Balentine, TL; Barbadora, KA				Hoberman, Alejandro; Paradise, Jack L.; Rockette, Howard E.; Shaikh, Nader; Wald, Ellen R.; Kearney, Diana H.; Colborn, D. Kathleen; Kurs-Lasky, Marcia; Bhatnagar, Sonika; Haralam, Mary Ann; Zoffel, Lisa M.; Jenkins, Carly; Pope, Marcia A.; Balentine, Tracy L.; Barbadora, Karen A.			Treatment of Acute Otitis Media in Children under 2 Years of Age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							YOUNG-CHILDREN; MANAGEMENT; INFANTS; TRIALS	BACKGROUND Recommendations vary regarding immediate antimicrobial treatment versus watchful waiting for children younger than 2 years of age with acute otitis media. METHODS We randomly assigned 291 children 6 to 23 months of age, with acute otitis media diagnosed with the use of stringent criteria, to receive amoxicillin-clavulanate or placebo for 10 days. We measured symptomatic response and rates of clinical failure. RESULTS Among the children who received amoxicillin-clavulanate, 35% had initial resolution of symptoms by day 2, 61% by day 4, and 80% by day 7; among children who received placebo, 28% had initial resolution of symptoms by day 2, 54% by day 4, and 74% by day 7 (P = 0.14 for the overall comparison). For sustained resolution of symptoms, the corresponding values were 20%, 41%, and 67% with amoxicillin-clavulanate, as compared with 14%, 36%, and 53% with placebo (P = 0.04 for the overall comparison). Mean symptom scores over the first 7 days were lower for the children treated with amoxicillin-clavulanate than for those who received placebo (P = 0.02). The rate of clinical failure - defined as the persistence of signs of acute infection on otoscopic examination - was also lower among the children treated with amoxicillin-clavulanate than among those who received placebo: 4% versus 23% at or before the visit on day 4 or 5 (P<0.001) and 16% versus 51% at or before the visit on day 10 to 12 (P<0.001). Mastoiditis developed in one child who received placebo. Diarrhea and diaper-area dermatitis were more common among children who received amoxicillin-clavulanate. There were no significant changes in either group in the rates of nasopharyngeal colonization with nonsusceptible Streptococcus pneumoniae. CONCLUSIONS Among children 6 to 23 months of age with acute otitis media, treatment with amoxicillin-clavulanate for 10 days tended to reduce the time to resolution of symptoms and reduced the overall symptom burden and the rate of persistent signs of acute infection on otoscopic examination.	[Hoberman, Alejandro] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Pediat,Div Gen Acad Pediat,Sch Med, Pittsburgh, PA 15224 USA; [Rockette, Howard E.; Kurs-Lasky, Marcia] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15224 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hoberman, A (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Dept Pediat,Div Gen Acad Pediat,Sch Med, Childrens Hosp Off Bldg,3rd Fl,4401 Penn Ave, Pittsburgh, PA 15224 USA.	hoberman@chp.edu			National Institute of Allergy and Infectious Diseases [3U01AI066007-02S1]; Merck; GlaxoSmithKline; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI066007] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Merck(Merck & Company); GlaxoSmithKline(GlaxoSmithKline); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by a grant (3U01AI066007-02S1) from the National Institute of Allergy and Infectious Diseases.; Dr. Hoberman reports receiving honoraria and travel-expense reimbursement from GlaxoSmithKline, and Dr. Wald, grant support from Merck and GlaxoSmithKline. No other potential conflict of interest relevant to this article was reported.	APPELMAN CL, 1999, HUISARTS WET, V42, P362; Finkelstein JA, 2000, ARCH PEDIAT ADOL MED, V154, P395, DOI 10.1001/archpedi.154.4.395; *FOOD DRUG ADM CTR, 2008, GUID IND AC BACT OT; Forgie S, 2009, PAED CHILD HEALT-CAN, V14, P457, DOI 10.1093/pch/14.7.457; Freid V M, 1998, Vital Health Stat 13, P1; HAYDEN GF, 1985, AM J DIS CHILD, V139, P721, DOI 10.1001/archpedi.1985.02140090083037; Hoberman A, 1997, PEDIATR INFECT DIS J, V16, pS25, DOI 10.1097/00006454-199702001-00007; Hoberman A, 2005, PEDIATR INFECT DIS J, V24, P525, DOI 10.1097/01.inf.0000164794.50281.1a; KALEIDA PH, 1992, AM J DIS CHILD, V146, P433, DOI 10.1001/archpedi.1992.02160160053013; KALEIDA PH, 1991, PEDIATRICS, V87, P466; Laine MK, 2010, PEDIATRICS, V125, pE1154, DOI 10.1542/peds.2009-2689; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; NIEMELA M, 1994, PEDIATR INFECT DIS J, V13, P765, DOI 10.1097/00006454-199409000-00002; Paradise Jack L., 1993, Pediatric Research, V33, p121A; PARADISE JL, 1987, J PEDIATR-US, V111, P948, DOI 10.1016/S0022-3476(87)80226-3; Paradise JL, 1997, JAMA-J AM MED ASSOC, V278, P1640, DOI 10.1001/jama.278.20.1640; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; *SCOTT INT GUID NE, 2003, DIAGN MAN CHILDH OT, V66; Shaikh N, 2009, PEDIATR INFECT DIS J, V28, P9, DOI 10.1097/INF.0b013e318185a3a0; Shaikh N, 2009, PEDIATR INFECT DIS J, V28, P5, DOI 10.1097/INF.0b013e318185a387	20	157	166	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2011	364	2					105	115		10.1056/NEJMoa0912254	http://dx.doi.org/10.1056/NEJMoa0912254			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	705NJ	21226576	Green Accepted, Bronze			2023-01-03	WOS:000286142900004
J	Tahtinen, PA; Laine, MK; Huovinen, P; Jalava, J; Ruuskanen, O; Ruohola, A				Tahtinen, Paula A.; Laine, Miia K.; Huovinen, Pentti; Jalava, Jari; Ruuskanen, Olli; Ruohola, Aino			A Placebo-Controlled Trial of Antimicrobial Treatment for Acute Otitis Media	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; ANTIBIOTIC-TREATMENT; CLINICAL-TRIALS; CHILDREN; AMOXICILLIN; METAANALYSIS; MYRINGOTOMY; MICROBIOLOGY; DIAGNOSIS; THERAPY	BACKGROUND The efficacy of antimicrobial treatment in children with acute otitis media remains controversial. METHODS In this randomized, double-blind trial, children 6 to 35 months of age with acute otitis media, diagnosed with the use of strict criteria, received amoxicillin-clavulanate (161 children) or placebo (158 children) for 7 days. The primary outcome was the time to treatment failure from the first dose until the end-of-treatment visit on day 8. The definition of treatment failure was based on the overall condition of the child (including adverse events) and otoscopic signs of acute otitis media. RESULTS Treatment failure occurred in 18.6% of the children who received amoxicillin-clavulanate, as compared with 44.9% of the children who received placebo (P<0.001). The difference between the groups was already apparent at the first scheduled visit (day 3), at which time 13.7% of the children who received amoxicillin-clavulanate, as compared with 25.3% of those who received placebo, had treatment failure. Overall, amoxicillin-clavulanate reduced the progression to treatment failure by 62% (hazard ratio, 0.38; 95% confidence interval [CI], 0.25 to 0.59; P<0.001) and the need for rescue treatment by 81% (6.8% vs. 33.5%; hazard ratio, 0.19; 95% CI, 0.10 to 0.36; P<0.001). Analgesic or antipyretic agents were given to 84.2% and 85.9% of the children in the amoxicillin-clavulanate and placebo groups, respectively. Adverse events were significantly more common in the amoxicillin-clavulanate group than in the placebo group. A total of 47.8% of the children in the amoxicillin-clavulanate group had diarrhea, as compared with 26.6% in the placebo group (P<0.001); 8.7% and 3.2% of the children in the respective groups had eczema (P = 0.04). CONCLUSIONS Children with acute otitis media benefit from antimicrobial treatment as compared with placebo, although they have more side effects. Future studies should identify patients who may derive the greatest benefit, in order to minimize unnecessary antimicrobial treatment and the development of bacterial resistance. (Funded by the Foundation for Paediatric Research and others;	[Tahtinen, Paula A.; Laine, Miia K.; Ruuskanen, Olli; Ruohola, Aino] Turku Univ Hosp, Dept Pediat, FIN-20521 Turku, Finland; [Huovinen, Pentti; Jalava, Jari] Natl Inst Hlth & Welf, Div Hlth Protect, Turku, Finland; [Huovinen, Pentti] Univ Turku, Dept Med Microbiol & Immunol, Turku, Finland	University of Turku; Finland National Institute for Health & Welfare; University of Turku	Ruohola, A (corresponding author), Turku Univ Hosp, Dept Pediat, PL 52, FIN-20521 Turku, Finland.	aino.ruohola@utu.fi	Huovinen, Pentti/C-9121-2019	Huovinen, Pentti/0000-0003-0003-1539	European Society for Paediatric Infectious Diseases; Foundation for Paediatric Research; Specified Government Transfers; Jenny and Antti Wihuri Foundation; Paulo Foundation; Maud Kuistila Memorial Foundation; Emil Aaltonen Foundation; Finnish Cultural Foundation; Turku University Hospital Research Foundation; Finnish-Norwegian Medical Foundation	European Society for Paediatric Infectious Diseases; Foundation for Paediatric Research; Specified Government Transfers; Jenny and Antti Wihuri Foundation; Paulo Foundation; Maud Kuistila Memorial Foundation; Emil Aaltonen Foundation; Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Turku University Hospital Research Foundation; Finnish-Norwegian Medical Foundation	Supported by the Fellowship Award of the European Society for Paediatric Infectious Diseases (to Dr. Ruohola) and by grants from the Foundation for Paediatric Research; Research Funds from Specified Government Transfers; the Jenny and Antti Wihuri Foundation; the Paulo Foundation; the Maud Kuistila Memorial Foundation; the Emil Aaltonen Foundation; the Finnish Cultural Foundation, Varsinais-Suomi Regional Fund; the Turku University Hospital Research Foundation; and the Finnish-Norwegian Medical Foundation.	APPELMAN CLM, 1991, BMJ-BRIT MED J, V303, P1450, DOI 10.1136/bmj.303.6815.1450; Appelman CLM, 1990, HUISARTS WET, V33, P242; Bain J, 2001, BRIT J GEN PRACT, V51, P132; Bain J, 2003, DIAGNOSIS MANAGEMENT; BURKE P, 1991, BRIT MED J, V303, P558, DOI 10.1136/bmj.303.6802.558; Coker TR, 2010, JAMA-J AM MED ASSOC, V304, P2161, DOI 10.1001/jama.2010.1651; Dagan R, 2002, PEDIATR INFECT DIS J, V21, P894, DOI 10.1097/00006454-200210000-00003; Damoiseaux RAMJ, 2000, BRIT MED J, V320, P350, DOI 10.1136/bmj.320.7231.350; DELBECCARO MA, 1992, J PEDIATR-US, V120, P81, DOI 10.1016/S0022-3476(05)80605-5; DelMar C, 1997, BRIT MED J, V314, P1526, DOI 10.1136/bmj.314.7093.1526; Dowell SF, 1998, PEDIATRICS, V101, P165; ENGELHARD D, 1989, LANCET, V2, P141; Forgie S, 2009, PAED CHILD HEALT-CAN, V14, P457, DOI 10.1093/pch/14.7.457; HALSTED C, 1968, AM J DIS CHILD, V115, P542, DOI 10.1001/archpedi.1968.02100010544003; Hendley JO, 2002, NEW ENGL J MED, V347, P1169, DOI 10.1056/NEJMcp010944; Johann-Liang R, 2003, PEDIATR INFECT DIS J, V22, P936, DOI 10.1097/01.inf.0000092637.66762.c6; Juven T, 2004, EUR J PEDIATR, V163, P140, DOI 10.1007/s00431-003-1397-2; KALEIDA PH, 1991, PEDIATRICS, V87, P466; Lahikainen E, 1953, ACTA OTO-LARYNGOL, V107, P1; Laine MK, 2010, PEDIATRICS, V125, pE1154, DOI 10.1542/peds.2009-2689; Le Saux N, 2005, CAN MED ASSOC J, V172, P335, DOI 10.1503/cmaj.1040771; Lieberthal AS, 2004, PEDIATRICS, V113, P1451, DOI 10.1542/peds.113.5.1451; Marchant CD, 2002, PEDIATR INFECT DIS J, V21, P891, DOI 10.1097/00006454-200210000-00002; Marchisio P, 2010, INT J PEDIATR OTORHI, V74, P1209, DOI 10.1016/j.ijporl.2010.08.016; Marcy M, 2000, Evid Rep Technol Assess (Summ), P1; MYGIND N, 1981, CLIN OTOLARYNGOL, V6, P5, DOI 10.1111/j.1365-2273.1981.tb01781.x; Pichichero ME, 2008, PEDIATR INFECT DIS J, V27, P958, DOI 10.1097/INF.0b013e318179a2ac; Pichichero ME, 2008, INT J PEDIATR OTORHI, V72, P737, DOI 10.1016/j.ijporl.2008.02.020; Rautakorpi UM, 2001, SCAND J INFECT DIS, V33, P920, DOI 10.1080/00365540110077056; ROSENFELD RM, 1994, J PEDIATR-US, V124, P355, DOI 10.1016/S0022-3476(94)70356-6; Rovers MM, 2006, LANCET, V368, P1429, DOI 10.1016/S0140-6736(06)69606-2; Rovers MM, 2004, LANCET, V363, P1080; Rovers MM, 2004, LANCET, V363, P465, DOI 10.1016/S0140-6736(04)15495-0; RUDBERG R. D., 1954, ACTA OTO LARYNGOL, V113, P1; Ruohola A, 2003, PEDIATRICS, V111, P1061, DOI 10.1542/peds.111.5.1061; Ruohola A, 2006, CLIN INFECT DIS, V43, P1417, DOI 10.1086/509332; Sanders S, 2010, COCHRANE DB SYST REV, V1; Schaad UB, 2004, PEDIATR INFECT DIS J, V23, pS101, DOI 10.1097/01.inf.0000112522.34408.cc; Shaikh N, 2010, NEW ENGL J MED, V362; Thalin A, 1985, P INT C AC SECR OT 1, P441; Toikka P, 1999, CLIN INFECT DIS, V29, P568, DOI 10.1086/598635; VANBUCHEM FL, 1981, LANCET, V2, P883; Vergison A, 2010, LANCET INFECT DIS, V10, P195, DOI 10.1016/S1473-3099(10)70012-8; Vouloumanou EK, 2009, J ANTIMICROB CHEMOTH, V64, P16, DOI 10.1093/jac/dkp166	44	132	137	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2011	364	2					116	126		10.1056/NEJMoa1007174	http://dx.doi.org/10.1056/NEJMoa1007174			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	705NJ	21226577	Bronze			2023-01-03	WOS:000286142900005
J	Church, TS; Blair, SN; Cocreham, S; Johannsen, N; Johnson, W; Kramer, K; Mikus, CR; Myers, V; Nauta, M; Rodarte, RQ; Sparks, L; Thompson, A; Earnest, CP				Church, Timothy S.; Blair, Steven N.; Cocreham, Shannon; Johannsen, Neil; Johnson, William; Kramer, Kimberly; Mikus, Catherine R.; Myers, Valerie; Nauta, Melissa; Rodarte, Ruben Q.; Sparks, Lauren; Thompson, Angela; Earnest, Conrad P.			Effects of Aerobic and Resistance Training on Hemoglobin A(1c) Levels in Patients With Type 2 Diabetes A Randomized Controlled Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIORESPIRATORY FITNESS; CARDIOVASCULAR-DISEASE; PHYSICAL-ACTIVITY; GLYCEMIC CONTROL; BODY-MASS; EXERCISE; MORTALITY; RISK; MEN; COMPLICATIONS	Context Exercise guidelines for individuals with diabetes include both aerobic and resistance training although few studies have directly examined this exercise combination. Objective To examine the benefits of aerobic training alone, resistance training alone, and a combination of both on hemoglobin A(1c) (HbA(1c)) in individuals with type 2 diabetes. Design, Setting, and Participants A randomized controlled trial in which 262 sedentary men and women in Louisiana with type 2 diabetes and HbA(1c) levels of 6.5% or higher were enrolled in the 9-month exercise program between April 2007 and August 2009. Intervention Forty-one participants were assigned to the nonexercise control group, 73 to resistance training 3 days a week, 72 to aerobic exercise in which they expended 12 kcal/kg per week; and 76 to combined aerobic and resistance training in which they expended 10 kcal/kg per week and engaged in resistance training twice a week. Main Outcome Change in HbA(1c) level. Secondary outcomes included measures of anthropometry and fitness. Results The study included 63.0% women and 47.3% nonwhite participants who were a mean (SD) age of 55.8 years (8.7 years) with a baseline HbA(1c) level of 7.7% (1.0%). Compared with the control group, the absolute mean change in HbA(1c) in the combination training exercise group was -0.34% (95% confidence interval [CI], -0.64% to -0.03%; P=.03). The mean changes in HbA(1c) were not statistically significant in either the resistance training (-0.16%; 95% CI, -0.46% to 0.15%; P=.32) or the aerobic (-0.24%; 95% CI, -0.55% to 0.07%; P=.14) groups compared with the control group. Only the combination exercise group improved maximum oxygen consumption (mean, 1.0 mL/kg per min; 95% CI, 0.5-1.5, P<.05) compared with the control group. All exercise groups reduced waist circumference from -1.9 to -2.8 cm compared with the control group. The resistance training group lost a mean of -1.4 kg fat mass (95% CI, -2.0 to -0.7 kg; P<.05) and combination training group lost a mean of -1.7 (-2.3 to -1.1 kg; P<.05) compared with the control group. Conclusions Among patients with type 2 diabetes mellitus, a combination of aerobic and resistance training compared with the nonexercise control group improved HbA(1c) levels. This was not achieved by aerobic or resistance training alone.	[Church, Timothy S.; Cocreham, Shannon; Johannsen, Neil; Johnson, William; Kramer, Kimberly; Myers, Valerie; Nauta, Melissa; Rodarte, Ruben Q.; Thompson, Angela; Earnest, Conrad P.] Louisiana State Univ Syst, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; [Blair, Steven N.] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA; [Mikus, Catherine R.] Univ Missouri, Dept Nutr & Exercise Physiol, Columbia, MO USA; [Sparks, Lauren] Maastricht Univ, Med Ctr, Dept Human Biol, NUTRIM Sch Nutr Toxicol & Metab, Maastricht, Netherlands	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of Missouri System; University of Missouri Columbia; Maastricht University; Maastricht University Medical Centre (MUMC)	Church, TS (corresponding author), Louisiana State Univ Syst, Pennington Biomed Res Ctr, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.	tim.church@pbrc.edu	Thompson-Paul, Angela/N-7067-2016; Earnest, Conrad P/A-7860-2009; Earnest, Conrad P./M-6849-2017; Hug, Balthasar L./G-1568-2010	Thompson-Paul, Angela/0000-0003-1186-9150; Earnest, Conrad P./0000-0002-6546-1268; 	American Heart Association; National Institutes of Health [DK068298]; Sanofi Aventis; Orexigen; Arena; Amylin; Human Kinetics; Department of Defense; Body Media; Coca-Cola; HART-D grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068298] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Sanofi Aventis(Sanofi-Aventis); Orexigen; Arena(Australian Renewable Energy Agency (ARENA)); Amylin; Human Kinetics; Department of Defense(United States Department of Defense); Body Media; Coca-Cola; HART-D grant; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Dr Church reported that he receives honoraria for lectures from scientific, educational, and lay groups; has received research funding from the American Heart Association and the National Institutes of Health, oversaw study sites for large pharmaceutical trials funded by Sanofi Aventis, Orexigen, Arena, and Amylin; is a member of the Jenny Craig medical advisory board; has served as a consultant to Technogym, Trestle Tree, Neuliven Health, and Coca-Cola; and serves as a paid expert for EverydayHealth.com. Dr Blair reported that he receives book royalties (<$5000 annually) from publisher Human Kinetics; honoraria for service on the scientific/medical advisory Boards for Alere, Technogym, Santech, and Jenny Craig; and honoraria for lectures and consultations from scientific, educational, and lay groups. During the past 5-year period he reported that he has received research grants from the National Institutes of Health, Department of Defense, Body Media, and Coca-Cola. Dr Earnest reported that he receives honoraria for lectures from scientific, educational, and lay groups. No other disclosures were reported.; This work was supported by grant DK068298 from the National Institutes of Health.; Contributions: We thank all HART-D participants and the Pennington Biomedical Research Center staff members Gina Billiot, Sheletta Donatto, RD, and Ronald Monce, PA-C, for their hard work and commitment. In addition we thank the HART-D data and safety monitoring board and Scientific Advisory Board, and Pennington Biomedical Research Center faculty members William Cefalu, MD, Steve Smith, MD (now at Burnham Institute in Orlando, Florida), and Jennifer Rood, PhD, for their scientific guidance both in planning and conducting the study. Part of Ms Donatto and Mr Monce's salaries were supported through the HART-D grant, and Dr. Rood's laboratory was reimbursed for clinical laboratory measures. Members of the data and safety monitoring board were provided modest honorariums for their time. Drs Cefalu and Dr Smith and the Scientific Advisory Board received no compensation for their contributions.	Agel J, 2005, AM J SPORT MED, V33, P524, DOI 10.1177/0363546504269937; American College., 2006, ACSMS GUID EX TEST P; [Anonymous], 2007, DIABETES CARE, V30, pS4, DOI [10.2337/dc07-S004, DOI 10.2337/DC07-S004]; BLOCK G, 1992, J AM DIET ASSOC, V92, P686; Boule NG, 2001, JAMA-J AM MED ASSOC, V286, P1218, DOI 10.1001/jama.286.10.1218; Church TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004515; Church TS, 2005, ARCH INTERN MED, V165, P2114, DOI 10.1001/archinte.165.18.2114; Church TS, 2004, DIABETES CARE, V27, P83, DOI 10.2337/diacare.27.1.83; Goldberg PA, 2004, DIABETES CARE, V27, P461, DOI 10.2337/diacare.27.2.461; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI [10.1249/mss.0b013e3180616b27, 10.1161/CIRCULATIONAHA.107.185649]; King NA, 2008, INT J OBESITY, V32, P177, DOI 10.1038/sj.ijo.0803712; Kodama S, 2009, JAMA-J AM MED ASSOC, V301, P2024, DOI 10.1001/jama.2009.681; Marwick TH, 2009, CIRCULATION, V119, P3244, DOI 10.1161/CIRCULATIONAHA.109.192521; Pischon T, 2008, NEW ENGL J MED, V359, P2105, DOI 10.1056/NEJMoa0801891; Ross R, 2001, MED SCI SPORT EXER, V33, pS521, DOI 10.1097/00005768-200106001-00023; Selvin E, 2004, ANN INTERN MED, V141, P421, DOI 10.7326/0003-4819-141-6-200409210-00007; Sigal RJ, 2007, ANN INTERN MED, V147, P357, DOI 10.7326/0003-4819-147-6-200709180-00005; Snowling NJ, 2006, DIABETES CARE, V29, P2518, DOI 10.2337/dc06-1317; Stratton IM, 2000, BMJ-BRIT MED J, V321, P405, DOI 10.1136/bmj.321.7258.405; US Department of Health and Human Services, 2008, 2008 PHYS ACT GUID A	20	541	564	1	101	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	2010	304	20					2253	2262		10.1001/jama.2010.1710	http://dx.doi.org/10.1001/jama.2010.1710			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	684KI	21098771	Bronze, Green Accepted			2023-01-03	WOS:000284548400024
J	Gill, TM; Allore, HG; Gahbauer, EA; Murphy, TE				Gill, Thomas M.; Allore, Heather G.; Gahbauer, Evelyne A.; Murphy, Terrence E.			Change in Disability After Hospitalization or Restricted Activity in Older Persons	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PHYSICAL PERFORMANCE; CONTROLLED-TRIAL; LIFE EXPECTANCY; ELDERLY-PEOPLE; GAIT SPEED; ADULTS; RISK; CARE; REHABILITATION; FORECASTS	Context Disability among older persons is a complex and highly dynamic process, with high rates of recovery and frequent transitions between states of disability. The role of intervening illnesses and injuries (ie, events) on these transitions is uncertain. Objectives To evaluate the relationship between intervening events and transitions among states of no disability, mild disability, severe disability, and death and to determine the association of physical frailty with these transitions. Design, Setting, and Participants Prospective cohort study conducted in greater New Haven, Connecticut, from March 1998 to December 2008 of 754 community-living persons aged 70 years or older who were nondisabled at baseline in 4 essential activities of daily living: bathing, dressing, walking, and transferring. Telephone interviews were completed monthly for more than 10 years to assess disability and ascertain exposure to intervening events, which included illnesses and injuries leading to either hospitalization or restricted activity. Physical frailty (defined as gait speed > 10 seconds on the rapid gait test) was assessed every 18 months through 108 months. Main Outcome Measure Transitions between no disability, mild disability, and severe disability and 3 transitions from each of these states to death, evaluated each month. Results Hospitalization was strongly associated with 8 of the 9 possible transitions, with increased multivariable hazard ratios (HRs) as high as 168 (95% confidence interval [CI], 118-239) for the transition from no disability to severe disability and decreased HRs as low as 0.41 (95% CI, 0.30-0.54) for the transition from mild disability to no disability. Restricted activity also increased the likelihood of transitioning from no disability to both mild and severe disability (HR, 2.59; 95% CI, 2.23-3.02; and HR, 8.03; 95% CI, 5.28-12.21), respectively, and from mild disability to severe disability (HR, 1.45; 95% CI, 1.14-1.84), but was not associated with recovery from mild or severe disability. For all 9 transitions, the presence of physical frailty accentuated the associations of the intervening events. For example, the absolute risk of transitioning from no disability to mild disability within 1 month after hospitalization for frail individuals was 34.9% (95% CI, 34.5%-35.3%) vs 4.9% (95% CI, 4.7%-5.1%) for non-frail individuals. Among the possible reasons for hospitalization, fall-related injury conferred the highest likelihood of developing new or worsening disability. Conclusions Among older persons, particularly those who were physically frail, intervening illnesses and injuries greatly increased the likelihood of developing new or worsening disability. Only the most potent events, ie, those leading to hospitalization, reduced the likelihood of recovery from disability. JAMA. 2010; 304(17): 1919-1928	[Gill, Thomas M.] Yale Univ, Sch Med, Dept Internal Med, Adler Geriatr Ctr, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Adler Geriatr Ctr, 20 York St, New Haven, CT 06504 USA.	thomas.gill@yale.edu	Gill, Thomas M./H-7043-2019; Murphy, Terrence E/A-9394-2009	Gill, Thomas M./0000-0002-6450-0368; Allore, Heather/0000-0001-7685-8175	National Institute on Aging [R37AG17560, R01AG022993, K24AG021507]; NATIONAL INSTITUTE ON AGING [K24AG021507, R01AG022993, R37AG017560, P30AG021342] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The work for this report was funded by grants from the National Institute on Aging (R37AG17560, R01AG022993). The study was conducted at the Yale Claude D. Pepper Older Americans Independence Center (P30AG21342). Dr Gill is the recipient of a Midcareer Investigator Award in Patient-Oriented Research (K24AG021507) from the National Institute on Aging.	Allison P.D., 2010, SURVIVAL ANAL USING; Baker CJ, 2010, ANN INTERN MED, V152, P36, DOI 10.7326/0003-4819-152-1-201001050-00008; Barry LC, 2008, ARCH GEN PSYCHIAT, V65, P172, DOI 10.1001/archgenpsychiatry.2007.17; BENICHOU J, 1990, BIOMETRICS, V46, P813, DOI 10.2307/2532098; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Beswick AD, 2008, LANCET, V371, P725, DOI 10.1016/S0140-6736(08)60342-6; Binder EF, 2004, JAMA-J AM MED ASSOC, V292, P837, DOI 10.1001/jama.292.7.837; Campbell AJ, 1997, AGE AGEING, V26, P315, DOI 10.1093/ageing/26.4.315; Cohen HJ, 2002, NEW ENGL J MED, V346, P905, DOI 10.1056/NEJMsa010285; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; Ferrucci Luigi, 1997, JAMA (Journal of the American Medical Association), V277, P728, DOI 10.1001/jama.277.9.728; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fried LP, 1997, J AM GERIATR SOC, V45, P92, DOI 10.1111/j.1532-5415.1997.tb00986.x; Gill TM, 2008, J AM GERIATR SOC, V56, P436, DOI 10.1111/j.1532-5415.2007.01603.x; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 2002, J AM GERIATR SOC, V50, P1492, DOI 10.1046/j.1532-5415.2002.50403.x; Gill TM, 2001, ANN INTERN MED, V135, P313, DOI 10.7326/0003-4819-135-5-200109040-00007; Gill TM, 2001, J AM GERIATR SOC, V49, P1039, DOI 10.1046/j.1532-5415.2001.49206.x; Goodwin James S, 2002, Lancet, V359, P1358, DOI 10.1016/S0140-6736(02)08318-6; Guralnik JM, 2000, J GERONTOL A-BIOL, V55, pM221, DOI 10.1093/gerona/55.4.M221; Hardy SE, 2005, AM J EPIDEMIOL, V161, P575, DOI 10.1093/aje/kwi083; Hardy SE, 2004, JAMA-J AM MED ASSOC, V291, P1596, DOI 10.1001/jama.291.13.1596; Hoenig H, 1997, J AM GERIATR SOC, V45, P1371, DOI 10.1111/j.1532-5415.1997.tb02939.x; Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; Kohout F J, 1993, J Aging Health, V5, P179, DOI 10.1177/089826439300500202; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; Lin HQ, 2008, BIOMETRICS, V64, P1032, DOI 10.1111/j.1541-0420.2008.01011.x; Manton KG, 2006, P NATL ACAD SCI USA, V103, P18374, DOI 10.1073/pnas.0608483103; MANTON KG, 1993, J GERONTOL, V48, P11, DOI 10.1093/geronj/48.Special_Issue.11; Olshansky SJ, 2009, MILBANK Q, V87, P842, DOI 10.1111/j.1468-0009.2009.00581.x; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88, DOI 10.1093/gerona/56.2.M88; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Straus SE, 2002, JAMA-J AM MED ASSOC, V288, P1396, DOI 10.1001/jama.288.11.1396; Tinetti ME, 2008, NEW ENGL J MED, V359, P252, DOI 10.1056/NEJMoa0801748; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; US Census Bureau, AM FACTFINDER; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881	40	336	341	1	28	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1919	1928		10.1001/jama.2010.1568	http://dx.doi.org/10.1001/jama.2010.1568			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	674GT	21045098	Bronze, Green Accepted			2023-01-03	WOS:000283725900022
J	Sasahara, A; Nanatani, K; Enomoto, M; Kuwahara, S; Abe, K				Sasahara, Ayako; Nanatani, Kei; Enomoto, Masaru; Kuwahara, Shigefumi; Abe, Keietsu			Substrate Specificity of the Aspartate:Alanine Antiporter (AspT) of Tetragenococcus halophilus in Reconstituted Liposomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSPORTER CLASSIFICATION DATABASE; BACTERIAL ANION-EXCHANGE; AMINO-ACID ANTIPORTER; OXALOBACTER-FORMIGENES; ALANINE ANTIPORTER; ESCHERICHIA-COLI; AGMATINE ANTIPORTER; MEMBRANE TOPOLOGY; OXLT; MECHANISM	The aspartate: alanine antiporter (AspT) of the lactic acid bacterium Tetragenococcus halophilus is a member of the aspartate: alanine exchanger (AAEx) transporter family. T. halophilus AspT catalyzes the electrogenic exchange of L-aspartate(1-) with L-alanine(0). Although physiological functions of AspT were well studied, L-aspartate(1-) : L-alanine(0) antiport mechanisms are still unsolved. Here we report that the binding sites of L-aspartate and L-alanine are independently present in AspT by means of the kinetic studies. We purified His(6)-tagged T. halophilus AspT and characterized its kinetic properties when reconstituted in liposomes (K-m = 0.35 +/- 0.03 mM for L-aspartate, K-m = 0.098 +/- 0 mM for D-aspartate, K-m = 26 +/- 2 mM for L-alanine, K-m = 3.3 +/- 0.2 mM for D-alanine). Competitive inhibition by various amino acids of L-aspartate or L-alanine in self-exchange reactions revealed that L-cysteine selectively inhibited L-aspartate self-exchange but only weakly inhibited L-alanine self-exchange. Additionally, L-serine selectively inhibited L-alanine self-exchange but barely inhibited L-aspartate self-exchange. The aspartate analogs L-cysteine sulfinic acid, L-cysteic acid, and D-cysteic acid competitively and strongly inhibited L-aspartate self-exchange compared with L-alanine self-exchange. Taken together, these kinetic data suggest that the putative binding sites of L-aspartate and L-alanine are independently located in the substrate translocation pathway of AspT.	[Sasahara, Ayako; Abe, Keietsu] Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab, Sendai, Miyagi 9818555, Japan; [Enomoto, Masaru; Kuwahara, Shigefumi] Tohoku Univ, Grad Sch Agr Sci, Dept Appl Bioorgan Chem, Lab Appl Bioorgan Chem, Sendai, Miyagi 9818555, Japan; [Nanatani, Kei] Tohoku Univ, Grad Sch Engn, Lab Appl Biophys Chem, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan; [Abe, Keietsu] Tohoku Univ, New Ind Creat Hatchery Ctr, Microbial Genom Lab, Sendai, Miyagi 9808579, Japan	Tohoku University; Tohoku University; Tohoku University; Tohoku University	Abe, K (corresponding author), Tohoku Univ, Grad Sch Agr Sci, Dept Microbial Biotechnol, Appl Microbiol Lab, Sendai, Miyagi 9818555, Japan.	kabe@biochem.tohoku.ac.jp	Enomoto, Masaru/T-6967-2019	Enomoto, Masaru/0000-0001-6342-217X	Japan Society for the Promotion of Science (JSPS) [2265108]; Kato Memorial Bioscience Foundation; NISR (Noda Institute for Scientific Research); Grants-in-Aid for Scientific Research [23780073] Funding Source: KAKEN	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Kato Memorial Bioscience Foundation; NISR (Noda Institute for Scientific Research); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by a Grant-in-aid for challenging exploratory research from Japan Society for the Promotion of Science (JSPS) Grant 2265108 (to K. A.), the Kato Memorial Bioscience Foundation (to K. N.), and a NISR (Noda Institute for Scientific Research) Research grant (to K. A.).	Abe K, 1996, J BIOL CHEM, V271, P6789, DOI 10.1074/jbc.271.12.6789; Abe K, 2002, J BACTERIOL, V184, P2906, DOI 10.1128/JB.184.11.2906-2913.2002; Abe K, 1996, J BIOL CHEM, V271, P3079, DOI 10.1074/jbc.271.6.3079; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMBUDKAR SV, 1986, J BIOL CHEM, V261, P79; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; Barabote RD, 2006, BBA-BIOMEMBRANES, V1758, P1557, DOI 10.1016/j.bbamem.2006.06.018; CLARKE HT, 1955, ORGANIC SYNTHESES CO, P226; CORNISHB.A, 1974, BIOCHEM J, V139, P721, DOI 10.1042/bj1390721; DIXON M, 1953, BIOCHEM J, V55, P170, DOI 10.1042/bj0550170; Fujiki T, 2007, J BIOCHEM, V141, P85, DOI 10.1093/jb/mvm010; Fukui K, 2011, J BIOTECHNOL, V154, P25, DOI 10.1016/j.jbiotec.2011.03.010; Gao X, 2010, NATURE, V463, P828, DOI 10.1038/nature08741; Gao X, 2009, SCIENCE, V324, P1565, DOI 10.1126/science.1173654; Gong S, 2003, J BACTERIOL, V185, P4402, DOI 10.1128/JB.185.15.4402-4409.2003; Iyer R, 2003, J BACTERIOL, V185, P6556, DOI 10.1128/JB.185.22.6556-6561.2003; MALONEY PC, 1992, J BIOL CHEM, V267, P10531; MALONEY PC, 1994, J EXP BIOL, V196, P471; Nanatani K, 2005, BIOCHEM BIOPH RES CO, V328, P20, DOI 10.1016/j.bbrc.2004.12.133; Nanatani K, 2007, J BACTERIOL, V189, P7089, DOI 10.1128/JB.00088-07; Nanatani K, 2009, J BACTERIOL, V191, P2122, DOI 10.1128/JB.00830-08; Saier MH, 2006, NUCLEIC ACIDS RES, V34, pD181, DOI 10.1093/nar/gkj001; Saier MH, 2009, NUCLEIC ACIDS RES, V37, pD274, DOI 10.1093/nar/gkn862; Wang XC, 2006, BIOCHEMISTRY-US, V45, P10344, DOI 10.1021/bi060746v; Ye LW, 2002, J BIOL CHEM, V277, P20372, DOI 10.1074/jbc.M111140200	25	6	6	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 19	2011	286	33					29044	29052		10.1074/jbc.M111.260224	http://dx.doi.org/10.1074/jbc.M111.260224			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	806TY	21719707	hybrid, Green Published			2023-01-03	WOS:000293837000041
J	Mattern, S				Mattern, Susan			The art of medicine Galen and his patients	LANCET			English	Editorial Material									[Mattern, Susan] Univ Georgia, Dept Hist, Athens, GA 30602 USA	University System of Georgia; University of Georgia	Mattern, S (corresponding author), Univ Georgia, Dept Hist, Athens, GA 30602 USA.	smattern@uga.edu						Flemming R., 2000, MED MAKING ROMAN WOM; Hankinson RJ, 2008, CAMBR COMPANION PHIL, P1, DOI 10.1017/CCOL9780521819541; Littman R J, 1973, Am J Philol, V94, P243, DOI 10.2307/293979; Mattern S. P., 2008, GALEN RHETORIC HEALI; Nutton V., 2004, ANCIENT MED; Temkin Owsei, 1973, GALENISM RISE DECLIN	6	10	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 6	2011	378	9790					478	479		10.1016/S0140-6736(11)61240-3	http://dx.doi.org/10.1016/S0140-6736(11)61240-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	809SO	21826808				2023-01-03	WOS:000294077200015
J	Enblom, A; Lekander, M; Hammar, M; Johnsson, A; Onelov, E; Ingvar, M; Steineck, G; Borjeson, S				Enblom, Anna; Lekander, Mats; Hammar, Mats; Johnsson, Anna; Onelov, Erik; Ingvar, Martin; Steineck, Gunnar; Borjeson, Sussanne			Getting the Grip on Nonspecific Treatment Effects: Emesis in Patients Randomized to Acupuncture or Sham Compared to Patients Receiving Standard Care	PLOS ONE			English	Article							CHEMOTHERAPY-INDUCED NAUSEA; CANCER-PATIENTS; CONTROLLED-TRIAL; PAIN; PROPHYLAXIS; MULTICENTER; ACUPRESSURE; SICKNESS; P6	Background: It is not known whether or not delivering acupuncture triggers mechanisms cited as placebo and if acupuncture or sham reduces radiotherapy-induced emesis more than standard care. Methodology/Principal Findings: Cancer patients receiving radiotherapy over abdominal/pelvic regions were randomized to verum (penetrating) acupuncture (n = 109; 99 provided data) in the alleged antiemetic acupuncture point PC6 or sham acupuncture (n = 106; 101 provided data) performed with a telescopic non-penetrating needle at a sham point 2-3 times/week during the whole radiotherapy period. The acupuncture cohort was compared to a reference cohort receiving standard care (n = 62; 62 provided data). The occurrence of emesis in each group was compared after a mean dose of 27 Gray. Nausea and vomiting were experienced during the preceding week by 37 and 8% in the verum acupuncture group, 38 and 7% in the sham acupuncture group and 63 and 15% in the standard care group, respectively. The lower occurrence of nausea in the acupuncture cohort (verum and sham) compared to patients receiving standard care (37% versus 63%, relative risk (RR) 0.6, 95 % confidence interval (CI) 0.5-0.8) was also true after adjustment for potential confounding factors for nausea (RR 0.8, CI 0.6 to 0.9). Nausea intensity was lower in the acupuncture cohort (78% no nausea, 13% a little, 8% moderate, 1% much) compared to the standard care cohort (52% no nausea, 32% a little, 15% moderate, 2% much) (p = 0.002). The acupuncture cohort expected antiemetic effects from their treatment (95%). Patients who expected nausea had increased risk for nausea compared to patients who expected low risk for nausea (RR 1.6; Cl 1.2-2.4). Conclusions/Significance: Patients treated with verum or sham acupuncture experienced less nausea and vomiting compared to patients receiving standard care, possibly through a general care effect or due to the high level of patient expectancy.	[Enblom, Anna; Borjeson, Sussanne] Linkoping Univ, Div Nursing Sci, Dept Med & Hlth Sci, Linkoping, Sweden; [Enblom, Anna] Vardal Inst, Lund, Sweden; [Enblom, Anna; Lekander, Mats; Ingvar, Martin] Karolinska Inst, Dept Clin Neurosci, Osher Ctr Integrat Med, Stockholm, Sweden; [Lekander, Mats] Stockholm Univ, Stress Res Inst, S-10691 Stockholm, Sweden; [Hammar, Mats] Linkoping Univ, Dept Clin & Expt Med Obstet & Gynecol, Linkoping, Sweden; [Johnsson, Anna] Univ Lund Hosp, Dept Oncol, Div Physiotherapy, S-22185 Lund, Sweden; [Onelov, Erik; Steineck, Gunnar] Karolinska Inst, Dept Oncol, Div Clin Canc Epidemiol, Stockholm, Sweden; [Steineck, Gunnar] Sahlgrens Acad, Dept Oncol, Div Clin Canc Epidemiol, Gothenburg, Sweden; [Borjeson, Sussanne] Linkoping Univ Hosp, Ctr Surg & Oncol, S-58185 Linkoping, Sweden	Linkoping University; Karolinska Institutet; Stockholm University; Linkoping University; Lund University; Skane University Hospital; Karolinska Institutet; University of Gothenburg; Linkoping University	Enblom, A (corresponding author), Linkoping Univ, Div Nursing Sci, Dept Med & Hlth Sci, Linkoping, Sweden.	anna.enblom@ki.se	Hammar, Mats/R-7908-2019; Steineck, Gunnar/W-1515-2019	Hammar, Mats/0000-0002-4593-7273; Steineck, Gunnar/0000-0002-0787-3969; Ingvar, Martin/0000-0002-9041-5714; Johnsson, Anna/0000-0001-9347-5336	Swedish Cancer Society; Vardal Institute; County Council of Ostergotland; University of Linkoping; Cancer and Traffic Injury Fund; Vardal Foundation for Health Care Sciences and Allergy Research; Vinnova; Swedish Strategic Research Foundation	Swedish Cancer Society(Swedish Cancer Society); Vardal Institute; County Council of Ostergotland; University of Linkoping; Cancer and Traffic Injury Fund; Vardal Foundation for Health Care Sciences and Allergy Research; Vinnova(Vinnova); Swedish Strategic Research Foundation(Swedish Foundation for Strategic Research)	This study was supported by The Swedish Cancer Society, The Vardal Institute, The County Council of Ostergotland, The University of Linkoping, Cancer and Traffic Injury Fund and The Vardal Foundation for Health Care Sciences and Allergy Research. Mats Lekander and Martin Ingvar are members of Stockholm Brain Institute funded by Vinnova and The Swedish Strategic Research Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGLIETTI L, 1990, CANCER CHEMOTH PHARM, V26, P239, DOI 10.1007/BF02897209; Arving Cecilia, 2007, Cancer Nurs, V30, pE10, DOI 10.1097/01.NCC.0000270709.64790.05; Borjeson S, 2002, J PAIN SYMPTOM MANAG, V24, P345, DOI 10.1016/S0885-3924(02)00543-2; Borjeson S, 1997, CANCER NURS, V20, P260; Dibble S L, 2000, Oncol Nurs Forum, V27, P41; DUNDEE JW, 1989, J ROY SOC MED, V82, P268, DOI 10.1177/014107688908200508; ENBLOM A, 2008, 1088 LINK U MED DISS; Enblom A, 2009, SUPPORT CARE CANCER, V17, P23, DOI 10.1007/s00520-008-0445-x; Ezzo JM, 2006, COCHRANE DB SYST REV, V19, P2285, DOI DOI 10.1002/14651858.CD002285.PUB2; FEYER PC, 2009, SUPPORT CAR IN PRESS; Goldman RH, 2008, CLIN J PAIN, V24, P211, DOI 10.1097/AJP.0b013e31815ec20f; Haake M, 2007, ARCH INTERN MED, V167, P1892, DOI 10.1001/archinte.167.17.1892; Higgins SC, 2007, SUPPORT CARE CANCER, V15, P171, DOI 10.1007/s00520-006-0113-y; Hui KKS, 2005, NEUROIMAGE, V27, P479, DOI 10.1016/j.neuroimage.2005.04.037; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Lu Weidong, 2005, Semin Oncol Nurs, V21, P190, DOI 10.1016/j.soncn.2005.04.008; Luebbert K, 2001, PSYCHO-ONCOLOGY, V10, P490, DOI 10.1002/pon.537; Maranzano E, 1999, INT J RADIAT ONCOL, V44, P619, DOI 10.1016/S0360-3016(99)00055-3; Molassiotis A, 2007, COMPLEMENT THER MED, V15, P3, DOI 10.1016/j.ctim.2006.07.005; Myers Cynthia D, 2008, J Soc Integr Oncol, V6, P19; Mystakidou K, 2006, MED ONCOL, V23, P251, DOI 10.1385/MO:23:2:251; Pariente J, 2005, NEUROIMAGE, V25, P1161, DOI 10.1016/j.neuroimage.2005.01.016; Park J, 1999, ACUPUNCT MED, V17, P110, DOI DOI 10.1136/AIM.17.2.110; Price DD, 2008, ANNU REV PSYCHOL, V59, P565, DOI 10.1146/annurev.psych.59.113006.095941; Roscoe JA, 2003, J PAIN SYMPTOM MANAG, V26, P731, DOI 10.1016/S0885-3924(03)00254-9; Shen JN, 2000, JAMA-J AM MED ASSOC, V284, P2755, DOI 10.1001/jama.284.21.2755; Shin YH, 2004, CANCER NURS, V27, P267, DOI 10.1097/00002820-200407000-00002; Shun SC, 2008, SUPPORT CARE CANCER, V16, P1059, DOI 10.1007/s00520-007-0384-y; Steineck G, 2006, ACTA ONCOL, V45, P421, DOI 10.1080/02841860600649293; Streitberger K, 2003, CLIN CANCER RES, V9, P2538; Xia Y. S., 2000, INT J CLIN ACUPUNCTU, V11, P145; Young SD, 2007, IEEE T VIS COMPUT GR, V13, P422, DOI 10.1109/TVCG.2007.1029; Zachariae R, 2007, PSYCHOTHER PSYCHOSOM, V76, P376, DOI 10.1159/000107566	34	26	26	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2011	6	3							e14766	10.1371/journal.pone.0014766	http://dx.doi.org/10.1371/journal.pone.0014766			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740QW	21448267	Green Published, Green Submitted, gold			2023-01-03	WOS:000288810500001
J	Healey, F; Darowski, A; Lamont, T; Panesar, S; Poulton, S; Treml, J; Wiese, M				Healey, Frances; Darowski, Adam; Lamont, Tara; Panesar, Sukhmeet; Poulton, Susan; Treml, Jonathan; Wiese, Martin			Safety Alerts Essential care after an inpatient fall: summary of a safety report from the National Patient Safety Agency	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HOSPITALS		[Healey, Frances; Lamont, Tara; Panesar, Sukhmeet] Natl Patient Safety Agcy, London W1T 5HD, England; [Darowski, Adam] John Radcliffe Hosp, Oxford OX3 9DU, England; [Poulton, Susan] Queen Alexandra Hosp, Portsmouth PO6 3LY, Hants, England; [Treml, Jonathan] Queen Elizabeth Hosp, Univ Hosp Birmingham NHS Fdn Trust, Birmingham B15 2WB, W Midlands, England; [Wiese, Martin] Leicester Royal Infirm, Leicester LE1 5WW, Leics, England	University of Oxford; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; University of Birmingham; University of Leicester	Healey, F (corresponding author), Natl Patient Safety Agcy, London W1T 5HD, England.							British Orthopaedic Association British Geriatric Society, 2007, BLUE BOOK GUID TREAT; National Institute for Health and Clinical Excellence, 2007, 56 NAT I HLTH CLIN E; National Patient Safety Agency, 2010, SLIPS TRIPS FALLS DA; National Patient Safety Agency, 2010, NPSA2011RRR001; Oliver D, 2010, CLIN GERIATR MED, V26, P645, DOI 10.1016/j.cger.2010.06.005; Patient Safety First, 2009, GUID RED HARM FALLS; Sari ABA, 2007, BMJ-BRIT MED J, V334, P79, DOI 10.1136/bmj.39031.507153.AE; Wiese MF, 2003, BMJ-BRIT MED J, V327, P782, DOI 10.1136/bmj.327.7418.782; Youde J, 2009, INJURY, V40, P1226, DOI 10.1016/j.injury.2009.06.167	9	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 28	2011	342								d329	10.1136/bmj.d329	http://dx.doi.org/10.1136/bmj.d329			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715MR	21278215				2023-01-03	WOS:000286889100002
J	Zhang, HT; Zhou, R; Li, L; Chen, J; Chen, LL; Li, CJ; Ding, H; Yu, LA; Hu, LH; Jiang, HL; Shen, X				Zhang, Haitao; Zhou, Rong; Li, Li; Chen, Jing; Chen, Lili; Li, Chenjing; Ding, Hong; Yu, Liang; Hu, Lihong; Jiang, Hualiang; Shen, Xu			Danthron Functions as a Retinoic X Receptor Antagonist by Stabilizing Tetramers of the Receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RXR; RAR; MODULATION; ACTIVATION; COMPLEX; CANCER; ACID	Retinoic X receptor (RXR) is a promising target for drug discovery against cancer and metabolic syndromes. Here, we identified a specific RXR alpha antagonist, danthron, from the traditional Chinese medicine rhubarb. Danthron repressed all tested RXR alpha-involved response element transcription, including the RXRE, PPRE, FXRE, and LXRE. Results from native PAGE and isothermal titration calorimetry (ITC)-based assays indicated that danthron bound to the tetrameric RXR alpha-LBD in a specific stoichimetric ratio, and such a binding could influence the corepressor SMRT affinity to the receptor. Additionally, a unique tetrameric structure of the apo-RXR alpha ligand-binding domain (LBD) was determined, which exhibited a larger tetramer interface and different ligand-binding pocket size compared with the one previously reported. Together with the biochemical and biophysical results, the determined crystal structure of danthron-soaked RXR alpha-LBD suggested a new mechanism for danthron antagonism to tetrameric RXR alpha. Moreover, the in vivo efficient improvement of insulin sensitivity by danthron was observed in diet-induced obese (DIO) mice. Thus, our findings were expected to supply new insights into the structural basis of RXR alpha antagonist for its further potential therapeutic application.	[Jiang, Hualiang; Shen, Xu] Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China; [Zhou, Rong; Li, Li; Shen, Xu] E China Univ Sci & Technol, Shanghai 200237, Peoples R China; [Shen, Xu] Shanghai Jiao Tong Univ, Sch Med, E Inst Shanghai Municipal Educ Commiss, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Institute of Materia Medica, CAS; East China University of Science & Technology; Shanghai Jiao Tong University		simmhulh@mail.shcnc.ac.cn; xshen@mail.shcnc.ac.cn	Zhang, Haitao/L-7612-2015	Zhang, Haitao/0000-0003-4879-2951	State Key Program of Basic Research of China [2010CB912501, 2007CB914304, 2009CB918502]; National Natural Science Foundation of China [30925040, 30890044, 10979072]; Key New Drug Creation and Manufacturing Program [2009ZX09301-001]; Science Foundation of Shanghai [08431902900]; E-Institutes of Shanghai Municipal Education Commission [E09013]; Foundation of Chinese Academy of Sciences [KSCX2-YW-R-168, SCX1-YW-02-2]	State Key Program of Basic Research of China(State Key Development Program for Basic Research of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key New Drug Creation and Manufacturing Program; Science Foundation of Shanghai(Natural Science Foundation of Shanghai); E-Institutes of Shanghai Municipal Education Commission; Foundation of Chinese Academy of Sciences(Chinese Academy of Sciences)	This work was supported by the State Key Program of Basic Research of China (Grants 2010CB912501, 2007CB914304, and 2009CB918502), the National Natural Science Foundation of China (Grants 30925040, 30890044, and 10979072), Key New Drug Creation and Manufacturing Program (2009ZX09301-001), the Science Foundation of Shanghai (Grant 08431902900), the E-Institutes of Shanghai Municipal Education Commission (Grant E09013), and the Foundation of Chinese Academy of Sciences (Grants KSCX2-YW-R-168 and SCX1-YW-02-2).	Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bourguet W, 2000, MOL CELL, V5, P289, DOI 10.1016/S1097-2765(00)80424-4; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; de Lera AR, 2007, NAT REV DRUG DISCOV, V6, P811, DOI 10.1038/nrd2398; Delano W.L, 2002, DELANO SCI; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Egea PF, 2002, MOL ENDOCRINOL, V16, P987, DOI 10.1210/me.16.5.987; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gampe RT, 2000, GENE DEV, V14, P2229, DOI 10.1101/gad.802300; Gao Q, 2010, PLANTA MED, V76, P27, DOI 10.1055/s-0029-1185948; Germain P, 2006, PHARMACOL REV, V58, P760, DOI 10.1124/pr.58.4.7; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Gronemeyer H, 2004, NAT REV DRUG DISCOV, V3, P950, DOI 10.1038/nrd1551; Huang Q, 2007, MED RES REV, V27, P609, DOI 10.1002/med.20094; Jackson TA, 1997, MOL ENDOCRINOL, V11, P693, DOI 10.1210/me.11.6.693; KERSTEN S, 1995, BIOCHEMISTRY-US, V34, P14263, DOI 10.1021/bi00043a034; Kersten S, 1998, J MOL BIOL, V284, P21, DOI 10.1006/jmbi.1998.2168; KERSTEN S, 1995, P NATL ACAD SCI USA, V92, P8645, DOI 10.1073/pnas.92.19.8645; Kersten S, 1997, J BIOL CHEM, V272, P29759, DOI 10.1074/jbc.272.47.29759; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu Y, 2009, EXP MOL MED, V41, P648, DOI 10.3858/emm.2009.41.9.071; MANGELSDORF DJ, 1993, RECENT PROG HORM RES, V48, P99; Nahoum V, 2007, P NATL ACAD SCI USA, V104, P17323, DOI 10.1073/pnas.0705356104; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pinaire JA, 2007, PPAR RES, V2007, DOI 10.1155/2007/94156; Sakaki J, 2007, BIOORG MED CHEM LETT, V17, P4804, DOI 10.1016/j.bmcl.2007.06.080; Schoch GA, 2010, J MOL BIOL, V395, P568, DOI 10.1016/j.jmb.2009.11.011; Tanaka T, 2009, CANCER RES, V69, P4945, DOI 10.1158/0008-5472.CAN-08-4407; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Xue JF, 2010, FITOTERAPIA, V81, P173, DOI 10.1016/j.fitote.2009.08.020; Yotsumoto T, 2005, METABOLISM, V54, P573, DOI 10.1016/j.metabol.2004.11.013; Zhang L, 2008, J BIOL CHEM, V283, P5370, DOI 10.1074/jbc.M705566200	36	46	48	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 21	2011	286	3					1868	1875		10.1074/jbc.M110.166215	http://dx.doi.org/10.1074/jbc.M110.166215			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	706BV	21084305	hybrid, Green Published			2023-01-03	WOS:000286191500027
J	Carone, BR; Fauquier, L; Habib, N; Shea, JM; Hart, CE; Li, RW; Bock, C; Li, CJ; Gu, HC; Zamore, PD; Meissner, A; Weng, ZP; Hofmann, HA; Friedman, N; Rando, OJ				Carone, Benjamin R.; Fauquier, Lucas; Habib, Naomi; Shea, Jeremy M.; Hart, Caroline E.; Li, Ruowang; Bock, Christoph; Li, Chengjian; Gu, Hongcang; Zamore, Phillip D.; Meissner, Alexander; Weng, Zhiping; Hofmann, Hans A.; Friedman, Nir; Rando, Oliver J.			Paternally Induced Transgenerational Environmental Reprogramming of Metabolic Gene Expression in Mammals	CELL			English	Article							DNA METHYLATION; EPIGENETIC INHERITANCE; HUMAN GENOME; MOUSE; MICE; DROSOPHILA; CHROMATIN; PROMOTER; ALLELE; CELLS	Epigenetic information can be inherited through the mammalian germline and represents a plausible transgenerational carrier of environmental information. To test whether transgenerational inheritance of environmental information occurs in mammals, we carried out an expression profiling screen for genes in mice that responded to paternal diet. Offspring of males fed a low-protein diet exhibited elevated hepatic expression of many genes involved in lipid and cholesterol biosynthesis and decreased levels of cholesterol esters, relative to the offspring of males fed a control diet. Epigenomic profiling of offspring livers revealed numerous modest (similar to 20%) changes in cytosine methylation depending on paternal diet, including reproducible changes in methylation over a likely enhancer for the key lipid regulator Ppara. These results, in conjunction with recent human epidemiological data, indicate that parental diet can affect cholesterol and lipid metabolism in offspring and define a model system to study environmental reprogramming of the heritable epigenome.	[Carone, Benjamin R.; Fauquier, Lucas; Shea, Jeremy M.; Hart, Caroline E.; Li, Chengjian; Zamore, Phillip D.; Rando, Oliver J.] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA; [Li, Ruowang; Weng, Zhiping] Univ Massachusetts, Sch Med, Program Bioinformat & Integrat Biol, Worcester, MA 01605 USA; [Zamore, Phillip D.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; [Habib, Naomi; Friedman, Nir] Hebrew Univ Jerusalem, Sch Comp Sci & Engn, IL-91904 Jerusalem, Israel; [Habib, Naomi] Hebrew Univ Jerusalem, Dept Mol Genet & Biotechnol, Fac Med, IL-91120 Jerusalem, Israel; [Bock, Christoph; Gu, Hongcang; Meissner, Alexander] Broad Inst, Cambridge, MA 02142 USA; [Bock, Christoph; Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA; [Hofmann, Hans A.] Univ Texas Austin, Inst Neurosci, Sect Integrat Biol, Inst Cellular & Mol Biol, Austin, TX 78712 USA; [Friedman, Nir] Hebrew Univ Jerusalem, Inst Life Sci, IL-91904 Jerusalem, Israel	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; University of Texas System; University of Texas Austin; Hebrew University of Jerusalem	Rando, OJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA.	oliver.rando@umassmed.edu	Zamore, Phillip D/A-8941-2013; Friedman, Nir/H-9692-2012; Habib, Naomi/AAA-8937-2020; Hofmann, Hans A/E-4538-2016; Bock, Christoph/AAE-7618-2019	Friedman, Nir/0000-0002-9678-3550; Hofmann, Hans A/0000-0002-3335-330X; Bock, Christoph/0000-0001-6091-3088; Rando, Oliver/0000-0003-1516-9397; Carone, Benjamin/0000-0002-9822-4218; Zamore, Phillip/0000-0002-4505-9618; Gu, Hongcang/0000-0002-1439-7606	Burroughs Wellcome Fund; NIGMS [GM088618, GM62862, GM65236]; NIH; US-Israel Binational Science Foundation (BSF); NSF; Alfred P. Sloan Foundation; Meidan fellowship; Dwight W. and Blanche Faye Reeder Centennial Fellowship in Systematic and Evolutionary Biology; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088618, R37GM062862, R01GM065236, R01GM062862] Funding Source: NIH RePORTER	Burroughs Wellcome Fund(Burroughs Wellcome Fund); NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US-Israel Binational Science Foundation (BSF)(US-Israel Binational Science Foundation); NSF(National Science Foundation (NSF)); Alfred P. Sloan Foundation(Alfred P. Sloan Foundation); Meidan fellowship; Dwight W. and Blanche Faye Reeder Centennial Fellowship in Systematic and Evolutionary Biology; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank D. Haig for initial discussions motivating this experiment and K. Ahmad, P. Kaufman, C. Meiklejohn, Y. Nahmias, and members of the Rando lab for critical reading of the manuscript. O.J.R. is supported in part by a Career Award in Biomedical Sciences from the Burroughs Wellcome Fund, by grant GM088618 from NIGMS, and by the Mathers Foundation and is a member of the UMass Diabetes Endocrinology Research Center (DK32520). N.F. is supported by grants from the NIH and the US-Israel Binational Science Foundation (BSF). H. A. H. is supported by NSF, an Alfred P. Sloan Foundation Fellowship and a Dwight W. and Blanche Faye Reeder Centennial Fellowship in Systematic and Evolutionary Biology. P.D.Z. is supported by grants GM62862 and GM65236 from the NIGMS. N.H. is supported by the Meidan fellowship. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Anderson LM, 2006, NUTRITION, V22, P327, DOI 10.1016/j.nut.2005.09.006; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arpanahi A, 2009, GENOME RES, V19, P1338, DOI 10.1101/gr.094953.109; Avital Eytan, 2000, ANIMAL TRADITIONS BE, DOI 10-1017/CBO9780511542251; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Blewitt ME, 2006, PLOS GENET, V2, P399, DOI 10.1371/journal.pgen.0020049; Boylston WH, 2004, AGING CELL, V3, P283, DOI 10.1111/j.1474-9728.2004.00115.x; Brykczynska U, 2010, NAT STRUCT MOL BIOL, V17, P679, DOI 10.1038/nsmb.1821; Champagne F, 2001, Prog Brain Res, V133, P287; Chong SY, 2007, NAT GENET, V39, P614, DOI 10.1038/ng2031; Crews D, 2007, P NATL ACAD SCI USA, V104, P5942, DOI 10.1073/pnas.0610410104; Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; Fricke C, 2008, EVOLUTION, V62, P3170, DOI 10.1111/j.1558-5646.2008.00515.x; Ghildiyal M, 2008, SCIENCE, V320, P1077, DOI 10.1126/science.1157396; Gray S, 2007, CELL METAB, V5, P305, DOI 10.1016/j.cmet.2007.03.002; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hammoud SS, 2009, NATURE, V460, P473, DOI 10.1038/nature08162; Harris A, 2011, HORM BEHAV, V59, P279, DOI 10.1016/j.yhbeh.2010.06.007; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Hendrickson DG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002126; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; Horton JD, 2003, P NATL ACAD SCI USA, V100, P12027, DOI 10.1073/pnas.1534923100; Horton TH, 2005, AM J HUM BIOL, V17, P34, DOI 10.1002/ajhb.20092; Jablonka E., 1995, EPIGENETIC INHERITAN; Jablonka E., 2005, EVOLUTION 4 DIMENSIO; Jacinto FV, 2008, BIOTECHNIQUES, V44, P35, DOI 10.2144/000112708; Jiang J, 2008, CLIN CANCER RES, V14, P419, DOI 10.1158/1078-0432.CCR-07-0523; Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859; Lumey LH, 2007, INT J EPIDEMIOL, V36, P1196, DOI 10.1093/ije/dym126; Madsen MA, 2004, BIOCHEM BIOPH RES CO, V318, P998, DOI 10.1016/j.bbrc.2004.04.126; Meaney MJ, 2007, TRENDS MOL MED, V13, P269, DOI 10.1016/j.molmed.2007.05.003; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491; Ooi SL, 2007, CURR OPIN CELL BIOL, V19, P257, DOI 10.1016/j.ceb.2007.04.015; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5201538; Pryke SR, 2009, SCIENCE, V323, P1605, DOI 10.1126/science.1168928; Rakhshandehroo M, 2007, PPAR RES, V2007, DOI 10.1155/2007/26839; Rakyan VK, 2003, P NATL ACAD SCI USA, V100, P2538, DOI 10.1073/pnas.0436776100; Rando OJ, 2007, CELL, V128, P655, DOI 10.1016/j.cell.2007.01.023; Rassoulzadegan M, 2006, NATURE, V441, P469, DOI 10.1038/nature04674; Symonds ME, 2009, NAT REV ENDOCRINOL, V5, P604, DOI 10.1038/nrendo.2009.195; Torrisani J, 2007, CURR GENOMICS, V8, P229; Tsuchiya T, 2004, PHYSIOL GENOMICS, V17, P307, DOI 10.1152/physiolgenomics.00039.2004; Wagner KD, 2008, DEV CELL, V14, P962, DOI 10.1016/j.devcel.2008.03.009; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990; Whitelaw NC, 2008, CURR OPIN GENET DEV, V18, P273, DOI 10.1016/j.gde.2008.07.001; Wolfner MF, 2002, HEREDITY, V88, P85, DOI 10.1038/sj.hdy.6800017; Yamaguchi R, 2010, HORM METAB RES, V42, P821, DOI 10.1055/s-0030-1261954; Yang X, 2009, NAT GENET, V41, P415, DOI 10.1038/ng.325; Youngson NA, 2008, ANNU REV GENOM HUM G, V9, P233, DOI 10.1146/annurev.genom.9.081307.164445	56	770	811	5	178	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 23	2010	143	7					1084	1096		10.1016/j.cell.2010.12.008	http://dx.doi.org/10.1016/j.cell.2010.12.008			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	698WO	21183072	Green Accepted, Bronze			2023-01-03	WOS:000285625400007
J	McBride, D; Hardoon, S; Walters, K; Gilmour, S; Raine, R				McBride, Dulcie; Hardoon, Sarah; Walters, Kate; Gilmour, Stuart; Raine, Rosalind			Explaining variation in referral from primary to secondary care: cohort study	BRITISH MEDICAL JOURNAL			English	Article							PRACTICE RESEARCH DATABASE; JOINT ARTHROPLASTY; HEALTH; HIP; OSTEOARTHRITIS; EXPLORATION; PEOPLE; EQUITY; SCORES; WOMEN	Objectives To determine the extent to which referral for defined symptoms from primary care varies by age, sex, and social deprivation and whether any sociodemographic variations in referral differ according to the presence of national referral guidance and the potential of the symptoms to be life threatening. Design Cohort study using individual patient data from the health improvement network database in primary care. Setting United Kingdom. Participants 5492 patients with postmenopausal bleeding, 23 121 with hip pain, and 101 212 with dyspepsia from 326 general practices, 2001-7. Main outcome measures Multivariable associations between odds of immediate referral for postmenopausal bleeding and age and social deprivation; hazard rates of referral for hip pain or dyspepsia and age, sex, and social deprivation. Analyses for dyspepsia were stratified for people aged less than and more than 55 years because referral guidance differs by age. Results 61.4% (3374/5492) of patients with postmenopausal bleeding, 17.4% (4019/23 121) with hip pain, and 13.8% (13 944/101 212) with dyspepsia were referred. The likelihood of referral for postmenopausal bleeding declined with increasing age: the adjusted odds ratio for patients aged 85 or more compared with those aged 55-64 was 0.39 (95% confidence interval 0.31 to 0.49). Patients aged 85 or more with hip pain were also less likely to be referred than those aged 55-64 (0.68, 0.57 to 0.81). Women were less likely than men to be referred for hip pain (hazard ratio 0.90, 95% confidence interval 0.84 to 0.96). More deprived patients with hip pain or dyspepsia (if aged <55) were less likely to be referred. Adjusted hazard ratios for those in the most deprived Townsend fifth compared with the least deprived were 0.72 (95% confidence interval 0.62 to 0.82) and 0.76 (0.68 to 0.85), respectively. No socioeconomic gradient was evident in referral for postmenopausal bleeding. Conclusions Inequalities in referral associated with socioeconomic circumstances were more likely to occur in the absence of both explicit guidance and potentially life threatening conditions, whereas inequalities with age were evident for all conditions.	[McBride, Dulcie; Raine, Rosalind] UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England; [Hardoon, Sarah; Walters, Kate] UCL, Royal Free & Univ Med Sch, Dept Primary Care & Populat Hlth, London WC1E 6BT, England; [Gilmour, Stuart] Kings Fund, London, England	University of London; University College London; University of London; University College London	McBride, D (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	dulciemcbride@googlemail.com		Walters, Kate/0000-0003-2173-2430; Raine, Rosalind/0000-0003-0904-749X	King's Fund; National Institute for Health Research; National Institute for Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre	King's Fund; National Institute for Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre	The King's Fund provided support for access to the data. RR is partly funded by a National Institute for Health Research public health career scientist award and by the National Institute for Health Research University College London Hospitals/University College London Comprehensive Biomedical Research Centre. The opinions stated in this paper are those of the authors as individuals, independent from the funding sources. The funding sources had no role in the study design, analysis, interpretation, writing the report or decision to submit the paper for publication.	Adams J, 2005, J PUBLIC HEALTH, V27, P101, DOI 10.1093/pubmed/fdh193; Bowling A, 1999, BRIT MED J, V319, P1353, DOI 10.1136/bmj.319.7221.1353; *BRIT SOC GASTR, 2002, DYSP MAN GUID; Campbell S., 2000, GYNAECOLOGY 10 TEACH; Campbell SM, 1996, FAM PRACT, V13, P75, DOI 10.1093/fampra/13.1.75; COULTHARD M, 2004, FOCUS SOCIAL INEQUAL; D'Ambrosia RD, 2005, ORTHOPEDICS, V28, pS201; *DEP HLTH, 2008, NEW GMS CONTR QOF IM; *DEP HLTH, 2000, REF GUID SUSP CANC; Department of Health, 2001, NAT SERV FRAM OLD PE; Department of Health, 2000, NHS CANC PLAN; DIEPPE P, 1995, BRIT MED J, V311, P853, DOI 10.1136/bmj.311.7009.853; Dixon Anna, 2007, J Health Serv Res Policy, V12, P104, DOI 10.1258/135581907780279549; Goddard M, 2001, SOC SCI MED, V53, P1149, DOI 10.1016/S0277-9536(00)00415-9; GREDMARK T, 1995, BRIT J OBSTET GYNAEC, V102, P133, DOI 10.1111/j.1471-0528.1995.tb09066.x; Grundy E, 2001, J EPIDEMIOL COMMUN H, V55, P895, DOI 10.1136/jech.55.12.895; Hawker GA, 2000, NEW ENGL J MED, V342, P1016, DOI 10.1056/NEJM200004063421405; Hawker GA, 2002, ARTHRITIS RHEUM-US, V46, P3331, DOI 10.1002/art.10682; Karlsen E., 1997, AM J MED, V102, P534; Katz JN, 2001, JAMA-J AM MED ASSOC, V286, P1506, DOI 10.1001/jama.286.12.1506; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Maguire A, 2009, PHARMACOEPIDEM DR S, V18, P76, DOI 10.1002/pds.1688; MAJEED A, 2001, AC HLTH SERV RES HLT, V18, P89; Mercer SW, 2007, ANN FAM MED, V5, P503, DOI 10.1370/afm.778; Miller P, 1999, BRIT J GEN PRACT, V49, P541; Moller AM, 2003, J BONE JOINT SURG BR, V85B, P178, DOI 10.1302/0301-620X.85B2.13717; MORRIS S, 2003, INEQUITY INEQUALITY; North of England Dyspepsia Guideline Development G. National Institute for Health and Clinical Excellence: Guidance, 2004, DYSP MAN DYSP AD PRI; O'Donnell CA, 2000, FAM PRACT, V17, P462, DOI 10.1093/fampra/17.6.462; Parker C, 2007, BRIT J GEN PRACT, V57, P371; Raine R, 2000, J Health Serv Res Policy, V5, P237; Raine R, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1279; Santaguida PL, 2008, CAN J SURG, V51, P428; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; STEWARD A, 2005, CANC ATLAS UK IRELAN; SURENDER R, 1995, BRIT MED J, V311, P1205, DOI 10.1136/bmj.311.7014.1205; Tate AR, 2010, BRIT J CANCER, V102, P947, DOI 10.1038/sj.bjc.6605593; Townsend P., 1986, INEQUALITIES HLTH NO; Walters K, 2001, FAM PRACT, V18, P277, DOI 10.1093/fampra/18.3.277; Walters K, 2008, EUR HEART J, V29, P2981, DOI 10.1093/eurheartj/ehn477; Williams A, 1997, HEALTH ECON, V6, P117, DOI 10.1002/(SICI)1099-1050(199703)6:2<117::AID-HEC256>3.0.CO;2-B; 2008, HLTH EPISODE STAT	42	60	60	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2010	341								c6267	10.1136/bmj.c6267	http://dx.doi.org/10.1136/bmj.c6267			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	691OG	21118873	Green Published, hybrid			2023-01-03	WOS:000285090100004
J	Walter, S; Kostpopoulos, P; Haass, A; Helwig, S; Keller, I; Licina, T; Schlechtriemen, T; Roth, C; Papanagiotou, P; Zimmer, A; Vierra, J; Korner, H; Schmidt, K; Romann, MS; Alexandrou, M; Yilmaz, U; Grunwald, I; Kubulus, D; Lesmeister, M; Ziegeler, S; Pattar, A; Golinski, M; Liu, Y; Volk, T; Bertsch, T; Reith, W; Fassbender, K				Walter, Silke; Kostpopoulos, Panagiotis; Haass, Anton; Helwig, Stefan; Keller, Isabel; Licina, Tamara; Schlechtriemen, Thomas; Roth, Christian; Papanagiotou, Panagiotis; Zimmer, Anna; Vierra, Julio; Koerner, Heiko; Schmidt, Kathrin; Romann, Marie-Sophie; Alexandrou, Maria; Yilmaz, Umut; Grunwald, Iris; Kubulus, Darius; Lesmeister, Martin; Ziegeler, Stephan; Pattar, Alexander; Golinski, Martin; Liu, Yang; Volk, Thomas; Bertsch, Thomas; Reith, Wolfgang; Fassbender, Klaus			Bringing the Hospital to the Patient: First Treatment of Stroke Patients at the Emergency Site	PLOS ONE			English	Article							GUIDELINES; MANAGEMENT; HEMORRHAGE; MORTALITY; PENUMBRA; OUTCOMES; COUNCIL; EVENTS; ADULTS	Background: Early treatment with rt-PA is critical for favorable outcome of acute stroke. However, only a very small proportion of stroke patients receive this treatment, as most arrive at hospital too late to be eligible for rt-PA therapy. Methods and Findings: We developed a "Mobile Stroke Unit'', consisting of an ambulance equipped with computed tomography, a point-of-care laboratory system for complete stroke laboratory work-up, and telemedicine capabilities for contact with hospital experts, to achieve delivery of etiology-specific and guideline-adherent stroke treatment at the site of the emergency, well before arrival at the hospital. In a departure from current practice, stroke patients could be differentially treated according to their ischemic or hemorrhagic etiology even in the prehospital phase of stroke management. Immediate diagnosis of cerebral ischemia and exclusion of thrombolysis contraindications enabled us to perform prehospital rt-PA thrombolysis as bridging to later intra-arterial recanalization in one patient. In a complementary patient with cerebral hemorrhage, prehospital diagnosis allowed immediate initiation of hemorrhage-specific blood pressure management and telemedicine consultation regarding surgery. Call-to-therapy-decision times were 35 minutes. Conclusion: This preliminary study proves the feasibility of guideline-adherent, etiology-specific and causal treatment of acute stroke directly at the emergency site.	[Walter, Silke; Kostpopoulos, Panagiotis; Haass, Anton; Helwig, Stefan; Keller, Isabel; Licina, Tamara; Lesmeister, Martin; Liu, Yang; Fassbender, Klaus] Univ Hosp Saarland, Dept Neurol, Homburg, Germany; [Schlechtriemen, Thomas] Zweckverband Rettungsdienst & Feuerwehralarmierun, Saarland, Germany; [Roth, Christian; Papanagiotou, Panagiotis; Zimmer, Anna; Vierra, Julio; Koerner, Heiko; Schmidt, Kathrin; Romann, Marie-Sophie; Alexandrou, Maria; Yilmaz, Umut; Grunwald, Iris; Reith, Wolfgang] Univ Hosp Saarland, Dept Neuroradiol, Homburg, Germany; [Kubulus, Darius; Ziegeler, Stephan; Pattar, Alexander; Golinski, Martin; Volk, Thomas] Univ Hosp Saarland, Dept Anaesthesiol & Intens Care, Homburg, Germany; [Bertsch, Thomas] Nurnberg Hosp, Dept Clin Chem, Nurnberg, Germany	Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes	Walter, S (corresponding author), Univ Hosp Saarland, Dept Neurol, Homburg, Germany.	Klaus.Fassbender@uks.eu	Papanagiotou, Panagiotis/B-1434-2012; Roth, Christian/B-6952-2015; Yilmaz, Umut/A-9508-2012; Liu, Yang/GSD-5476-2022; Grunwald, Iris/AAY-2521-2021; Romann, Michael/H-3571-2019	Roth, Christian/0000-0001-5147-2241; Yilmaz, Umut/0000-0003-4940-3575; Grunwald, Iris/0000-0002-3404-7590; Romann, Michael/0000-0003-4139-2955; Fassbender, Klaus/0000-0003-3596-868X; Lesmeister, Martin/0000-0001-5228-6483; Liu, Yang/0000-0002-7614-4233; Walter, Silke/0000-0002-1176-2911	Ministry of Health of the Saarland, Germany; Jackstaedt-Foundation, Germany; Else Kroener-Fresenius Foundation, Germany; "Zweckverband fur Rettungsdienst und Feuerwehralarmierung Saar", Germany; German Red Cross, Saarland, Germany	Ministry of Health of the Saarland, Germany; Jackstaedt-Foundation, Germany; Else Kroener-Fresenius Foundation, Germany; "Zweckverband fur Rettungsdienst und Feuerwehralarmierung Saar", Germany; German Red Cross, Saarland, Germany	This study was funded by grants from the Ministry of Health of the Saarland, Germany; Jackstaedt-Foundation, Germany; Else Kroener-Fresenius Foundation, Germany; "Zweckverband fur Rettungsdienst und Feuerwehralarmierung Saar", Germany, and German Red Cross, Saarland, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams HP, 2007, CIRCULATION, V115, pE478, DOI 10.1161/CIRCULATIONAHA.107.181486; BOEHRINGER, 2009, SUMMARY PRODUCT CHAR; Bose A, 2008, AM J NEURORADIOL, V29, P1409, DOI 10.3174/ajnr.A1110; Broderick J, 2007, CIRCULATION, V116, pE391, DOI 10.1161/CIRCULATIONAHA.107.183689; *EUR STROK IN WORK, 2008, CEREBROVASC DIS, V22, P294; Fassbender K, 2003, STROKE, V34, pE44, DOI 10.1161/01.STR.0000075573.22885.3B; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Howells DW, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000224; Katzan IL, 2004, ARCH NEUROL-CHICAGO, V61, P346, DOI 10.1001/archneur.61.3.346; Kleindorfer DO, 2008, STROKE, V39, pE43, DOI 10.1161/STROKEAHA.107.509109; Lichtman JH, 2009, STROKE, V40, pE127; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marler JR, 2000, NEUROLOGY, V55, P1649, DOI 10.1212/WNL.55.11.1649; Mazighi M, 2009, LANCET NEUROL, V8, P802, DOI 10.1016/S1474-4422(09)70182-6; Nor AM, 2005, LANCET NEUROL, V4, P727, DOI 10.1016/S1474-4422(05)70201-5; Price CI, 2009, EXPERT REV NEUROTHER, V9, P211, DOI 10.1586/14737175.9.2.211; Qureshi AI, 2005, NEUROSURGERY, V57, P647, DOI 10.1227/01.NEU.0000175546.62088.D6; Rothwell PM, 2005, LANCET, V366, P1773, DOI 10.1016/S0140-6736(05)67702-1; van der Worp HB, 2007, NEW ENGL J MED, V357, P572, DOI 10.1056/NEJMcp072057; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WEIR CJ, 1994, LANCET, V344, P999, DOI 10.1016/S0140-6736(94)91648-9	22	86	91	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 29	2010	5	10							e13758	10.1371/journal.pone.0013758	http://dx.doi.org/10.1371/journal.pone.0013758			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	673FU	21060800	Green Published, gold			2023-01-03	WOS:000283645300037
J	Shen, H; Harris, G; Chen, WX; Sjostedt, A; Ryden, P; Conlan, W				Shen, Hua; Harris, Gregory; Chen, Wangxue; Sjostedt, Anders; Ryden, Patrik; Conlan, Wayne			Molecular Immune Responses to Aerosol Challenge with Francisella tularensis in Mice Inoculated with Live Vaccine Candidates of Varying Efficacy	PLOS ONE			English	Article							DELTA-T-CELLS; INTERFERON-GAMMA; PROTECTIVE IMMUNITY; TULAREMIA VACCINE; RESPIRATORY CHALLENGE; NATURAL INFECTION; IL-17 PRODUCTION; STRAIN; PATHOGEN; IMMUNIZATION	Background: Francisella tularensis is a facultative intracellular bacterial pathogen and the etiological agent of tularemia. The subspecies F. tularensis tularensis is especially virulent for humans when inhaled and respiratory tularemia is associated with high mortality if not promptly treated. A live vaccine strain (LVS) derived from the less virulent holarctica subspecies confers incomplete protection against aerosol challenge with subsp. tularensis. Moreover, correlates of protection have not been established for LVS. Methodology/Principal Findings: In the present study we compare molecular immune responses elicited by LVS and two defined deletion mutants of clinical subsp. tularensis strain, SCHU S4, that confer enhanced protection in a mouse model. BALB/c mice were immunized intradermally then challenged with an aerosol of SCHU S4 six weeks later. Changes in the levels of a selected panel of cytokines and chemokines were examined in the lungs, spleens, and sera of vaccinated and challenged mice. Mostly, increased cytokine and chemokine levels correlated with increased bacterial burden. However, after adjusting for this variable, immunization with either of the two Schu S4 mutants resulted in higher levels of several pulmonary cytokines, versus those resulting after LVS immunization, including IL-17. Moreover, treatment of mice immunized with Delta clpB with anti-IL-17 antibodies post-challenge enhanced lung infection. Conclusions/Significance: This is the first report characterizing local and systemic cytokine and chemokine responses in mice immunized with vaccines with different efficacies against aerosol challenge with virulent F. tularensis subsp. tularensis. It shows that increases in the levels of most of these immunomodulators, including those known to be critical for protective immunity, do not superficially correlate with protection unless adjusted for the effects of bacterial burden. Additionally, several cytokines were selectively suppressed in the lungs of naive mice, suggesting that one mechanism of vaccine action is to overcome this pathogen-induced immunosuppression.	[Shen, Hua; Harris, Gregory; Chen, Wangxue; Conlan, Wayne] Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada; [Sjostedt, Anders] Umea Univ, Dept Clin Microbiol, Umea, Sweden; [Ryden, Patrik] Umea Univ, Dept Stat, Computat Life Sci Cluster, Dept Math & Math Stat,Dept Stat, Umea, Sweden	National Research Council Canada; Umea University; Umea University	Shen, H (corresponding author), Natl Res Council Canada, Inst Biol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.	wayne.conlan@nrc-cnrc.gc.ca	Rydén, Patrik/I-4201-2016; Sjöstedt, Anders/AAC-6575-2020	Rydén, Patrik/0000-0002-0577-123X; Sjöstedt, Anders/0000-0002-0768-8405	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [AI60689]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060689] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This project has been funded with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services under grant No. AI60689. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bakshi CS, 2008, VACCINE, V26, P5276, DOI 10.1016/j.vaccine.2008.07.051; Bosio CM, 2007, J IMMUNOL, V178, P4538, DOI 10.4049/jimmunol.178.7.4538; Chen WX, 2004, MICROB PATHOGENESIS, V36, P311, DOI 10.1016/j.micpath.2004.02.003; Chen WX, 2003, VACCINE, V21, P3690, DOI 10.1016/S0264-410X(03)00386-4; Conlan JW, 2008, MOL IMMUNOL, V45, P2962, DOI 10.1016/j.molimm.2008.01.022; Conlan JW, 2010, VACCINE, V28, P1824, DOI 10.1016/j.vaccine.2009.12.001; Conlan JW, 2005, VACCINE, V23, P2477, DOI 10.1016/j.vaccine.2004.10.034; Cowley SC, 2010, J IMMUNOL, V184, P5791, DOI 10.4049/jimmunol.1000362; Elkins KL, 2007, ANN NY ACAD SCI, V1105, P284, DOI 10.1196/annals.1409.014; ERICSSON M, 1994, J INFECT DIS, V170, P110, DOI 10.1093/infdis/170.1.110; Fuller CL, 2006, J ALLERGY CLIN IMMUN, V117, P1186, DOI 10.1016/j.jaci.2006.01.044; Fuller CL, 2007, MOL IMMUNOL, V44, P3173, DOI 10.1016/j.molimm.2007.01.037; Green M, 2005, VACCINE, V23, P2680, DOI 10.1016/j.vaccine.2004.03.071; Higgins SC, 2006, J IMMUNOL, V177, P7980, DOI 10.4049/jimmunol.177.11.7980; HORNICK RB, 1966, BACTERIOL REV, V30, P532, DOI 10.1128/MMBR.30.3.532-538.1966; KARTTUNEN R, 1987, J CLIN MICROBIOL, V25, P1074, DOI 10.1128/JCM.25.6.1074-1078.1987; Kelchtermans H, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2787; Khader SA, 2007, NAT IMMUNOL, V8, P369, DOI 10.1038/ni1449; Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025; Lyons CR, 2007, ANN NY ACAD SCI, V1105, P238, DOI 10.1196/annals.1409.003; Markel G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011176; MCCRUMB FR, 1961, BACTERIOL REV, V25, P262, DOI 10.1128/MMBR.25.3.262-267.1961; McMurry JA, 2007, VACCINE, V25, P3179, DOI 10.1016/j.vaccine.2007.01.039; Paranavitana C, 2010, J INTERF CYTOK RES, V30, P471, DOI 10.1089/jir.2009.0108; Peck A, 2010, INFECT IMMUN, V78, P32, DOI 10.1128/IAI.00929-09; Salerno-Goncalves R, 2009, VACCINE, V28, P195, DOI 10.1016/j.vaccine.2009.09.100; SASLAW S, 1961, ARCH INTERN MED, V107, P702, DOI 10.1001/archinte.1961.03620050068007; SASLAW S, 1961, AM J MED SCI, V241, P689, DOI 10.1097/00000441-196106000-00001; Schulz SM, 2008, INT IMMUNOL, V20, P1129, DOI 10.1093/intimm/dxn069; Shibata K, 2007, J IMMUNOL, V178, P4466, DOI 10.4049/jimmunol.178.7.4466; SJOSTEDT A, 1992, IMMUNOLOGY, V76, P584; Sjostedt A, 1996, MICROBIOL-UK, V142, P1369, DOI 10.1099/13500872-142-6-1369; SJOSTEDT A, 1994, INFECT IMMUN, V62, P2779; Sjostedt A, 2007, ANN NY ACAD SCI, V1105, P1, DOI 10.1196/annals.1409.009; TARNVIK A, 1989, REV INFECT DIS, V11, P440; Velin D, 2009, GASTROENTEROLOGY, V136, P2237, DOI 10.1053/j.gastro.2009.02.077; Woolard MD, 2008, INFECT IMMUN, V76, P2651, DOI 10.1128/IAI.01412-07; Wu TH, 2009, VACCINE, V27, P4684, DOI 10.1016/j.vaccine.2009.05.060; Wu TH, 2005, INFECT IMMUN, V73, P2644, DOI 10.1128/IAI.73.5.2644-2654.2005; Zhang XY, 2009, J IMMUNOL, V183, P1291, DOI 10.4049/jimmunol.0803075	40	48	49	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2010	5	10							e13349	10.1371/journal.pone.0013349	http://dx.doi.org/10.1371/journal.pone.0013349			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662KX	20967278	gold, Green Published, Green Submitted			2023-01-03	WOS:000282807300027
J	McCartney, M				McCartney, Margaret			The scam of integrative medicine	BRITISH MEDICAL JOURNAL			English	Editorial Material												margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358					0	1	1	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2011	343								d4446	10.1136/bmj.d4446	http://dx.doi.org/10.1136/bmj.d4446			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	794OE	21752859				2023-01-03	WOS:000292908900017
J	Howard, L; Salooja, N				Howard, Luke; Salooja, Nina			Outpatient management of pulmonary embolism	LANCET			English	Editorial Material							DEEP-VEIN THROMBOSIS		[Howard, Luke] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Natl Pulm Hypertens Serv, London W12 0HS, England; [Salooja, Nina] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London W12 0HS, England	Imperial College London; Imperial College London	Howard, L (corresponding author), Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Natl Pulm Hypertens Serv, London W12 0HS, England.	L.howard@imperial.ac.uk		Howard, Luke/0000-0003-2822-210X				Aujesky D, 2005, AM J RESP CRIT CARE, V172, P1041, DOI 10.1164/rccm.200506-862OC; Aujesky D, 2011, LANCET, V378, P41, DOI 10.1016/S0140-6736(11)60824-6; Dolovich LR, 2000, ARCH INTERN MED, V160, P181, DOI 10.1001/archinte.160.2.181; Heit JA, 1999, ARCH INTERN MED, V159, P445, DOI 10.1001/archinte.159.5.445; Jimenez D, 2010, AM J RESP CRIT CARE, V181, P983, DOI 10.1164/rccm.200908-1204OC; Otero R, 2010, THROMB RES, V126, pE1, DOI 10.1016/j.thromres.2009.09.026	6	6	6	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 2	2011	378	9785					5	6		10.1016/S0140-6736(11)60932-X	http://dx.doi.org/10.1016/S0140-6736(11)60932-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	791IU	21703675				2023-01-03	WOS:000292659700005
J	Hewish, M; Cunningham, D				Hewish, Madeleine; Cunningham, David			First-line treatment of advanced colorectal cancer	LANCET			English	Editorial Material							CETUXIMAB; KRAS; CHEMOTHERAPY; MUTATION		[Cunningham, David] Royal Marsden Hosp NHS Trust, London SM2 5PT, Surrey, England; Royal Marsden Hosp NHS Trust, Sutton 5M2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust	Cunningham, D (corresponding author), Royal Marsden Hosp NHS Trust, London SM2 5PT, Surrey, England.	david.cunningham@rmh.nhs.uk		Cunningham, David/0000-0001-5158-1069	Medical Research Council [G0802325] Funding Source: Medline; MRC [G0802325] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4; Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dahan L, 2009, BRIT J PHARMACOL, V158, P610, DOI 10.1111/j.1476-5381.2009.00341.x; De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; DEWDNEY A, 2011, J CLIN ONCOL S, V29, P360; Hawkes E, 2010, J CLIN ONCOL, V28, pE529, DOI 10.1200/JCO.2010.29.5626; Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2; Mekenkamp L, 2011, AACR ANN M ORL FLOR, P235; Oden-Gangloff A, 2009, BRIT J CANCER, V100, P1330, DOI 10.1038/sj.bjc.6605008; Pander J, 2010, EUR J CANCER, V46, P1829, DOI 10.1016/j.ejca.2010.03.017; Scartozzi M, 2011, BRIT J CANCER, V104, P1786, DOI 10.1038/bjc.2011.161; TA176, 2009, TA176 CET 1 LIN TREA; Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091	15	12	12	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 18	2011	377	9783					2060	2062		10.1016/S0140-6736(11)60788-5	http://dx.doi.org/10.1016/S0140-6736(11)60788-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	783XI	21641637				2023-01-03	WOS:000292117800006
J	Harkema, S; Gerasimenko, Y; Hodes, J; Burdick, J; Angeli, C; Chen, YS; Ferreira, C; Willhite, A; Rejc, E; Grossman, RG; Edgerton, VR				Harkema, Susan; Gerasimenko, Yury; Hodes, Jonathan; Burdick, Joel; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea; Rejc, Enrico; Grossman, Robert G.; Edgerton, V. Reggie			Effect of epidural stimulation of the lumbosacral spinal cord on voluntary movement, standing, and assisted stepping after motor complete paraplegia: a case study	LANCET			English	Article							LUMBAR CORD; LOCOMOTION; INJURY; HUMANS; CAT; SPINALIZATION; VERTEBRATES; PLASTICITY; NETWORKS; GENERATE	Background Repeated periods of stimulation of the spinal cord and training increased the ability to control movement in animal models of spinal cord injury. We hypothesised that tonic epidural spinal cord stimulation can modulate spinal circuitry in human beings into a physiological state that enables sensory input from standing and stepping movements to serve as a source of neural control to undertake these tasks. Methods A 23-year-old man who had paraplegia from a C7-T1 sublimation as a result of a motor vehicle accident in July 2006, presented with complete loss of clinically detectable voluntary motor function and partial preservation of sensation below the T1 cord segment. After 170 locomotor training sessions over 26 months, a 16-electrode array was surgically placed on the dura (L1-S1 cord segments) in December 2009, to allow for chronic electrical stimulation. Spinal cord stimulation was done during sessions that lasted up to 250 min. We did 29 experiments and tested several stimulation combinations and parameters with the aim of the patient achieving standing and stepping. Findings Epidural stimulation enabled the man to achieve full weight-bearing standing with assistance provided only for balance for 4.25 min. The patient achieved this standing during stimulation using parameters identified as specific for standing while providing bilateral load-bearing proprioceptive input. We also noted locomotor-like patterns when stimulation parameters were optimised for stepping. Additionally, 7 months after implantation, the patient recovered supraspinal control of some leg movements, but only during epidural stimulation. Interpretation Task-specific training with epidural stimulation might reactivate previously silent spared neural circuits or promote plasticity. These interventions could be a viable clinical approach for functional recovery after severe paralysis.	[Edgerton, V. Reggie] Univ Calif Los Angeles, Dept Neurobiol, Dept Integrat Biol & Comparat Physiol, Los Angeles, CA 90095 USA; [Harkema, Susan; Hodes, Jonathan; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea] Univ Louisville, Kentucky Spinal Cord Res Ctr, Dept Neurol Surg, Louisville, KY 40292 USA; [Harkema, Susan; Angeli, Claudia; Chen, Yangsheng; Ferreira, Christie; Willhite, Andrea] Frazier Rehab Inst, Louisville, KY USA; [Gerasimenko, Yury] IP Pavlov Physiol Inst, St Petersburg 199034, Russia; [Burdick, Joel] CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; [Rejc, Enrico] Univ Udine, Dept Biomed Sci & Technol, I-33100 Udine, Italy; [Grossman, Robert G.] Methodist Hosp, Neurol Inst, Dept Neurosurg, Houston, TX 77030 USA	University of California System; University of California Los Angeles; University of Louisville; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences; California Institute of Technology; University of Udine; The Methodist Hospital System; The Methodist Hospital - Houston	Edgerton, VR (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Dept Integrat Biol & Comparat Physiol, Los Angeles, CA 90095 USA.	vre@ucla.edu	Gerasimenko, Yury/A-3655-2017	Angeli, Claudia/0000-0003-4127-7121	National Institutes of Health; Christopher and Dana Reeve Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB007615] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS062009] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Christopher and Dana Reeve Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Funding National Institutes of Health and Christopher and Dana Reeve Foundation.	BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; Beres-Jones JA, 2003, EXP BRAIN RES, V149, P222, DOI 10.1007/s00221-002-1349-5; Calancie B, 2006, J SPINAL CORD MED, V29, P413, DOI 10.1080/10790268.2006.11753891; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; de Leon RD, 1998, J NEUROPHYSIOL, V79, P1329, DOI 10.1152/jn.1998.79.3.1329; de Leon RD, 1998, J NEUROPHYSIOL, V80, P83; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dimitrijevic MR, 1998, ANN NY ACAD SCI, V860, P360, DOI 10.1111/j.1749-6632.1998.tb09062.x; Fuentes R, 2009, SCIENCE, V323, P1578, DOI 10.1126/science.1164901; Gerasimenko Y, 2001, NATO SCI SER I LIFE, V326, P164; Gerasimenko Y, 2008, EXP NEUROL, V209, P417, DOI 10.1016/j.expneurol.2007.07.015; GRILLNER S, 1979, EXP BRAIN RES, V34, P241; GRILLNER S, 1985, SCIENCE, V228, P143, DOI 10.1126/science.3975635; Grillner S, 2003, NAT REV NEUROSCI, V4, P573, DOI 10.1038/nrn1137; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; Harkema S. J., ARCH PHYS M IN PRESS; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797, DOI 10.1152/jn.1997.77.2.797; Harkema SJ, 2008, BRAIN RES REV, V57, P255, DOI 10.1016/j.brainresrev.2007.07.012; Ichiyama RM, 2008, J NEUROSCI, V28, P7370, DOI 10.1523/JNEUROSCI.1881-08.2008; Jankowska E, 2001, J PHYSIOL-LONDON, V533, P31, DOI 10.1111/j.1469-7793.2001.0031b.x; Jilge B, 2004, EXP BRAIN RES, V154, P308, DOI 10.1007/s00221-003-1666-3; KUHN RA, 1950, BRAIN, V73, P1, DOI 10.1093/brain/73.1.1; Maegele M, 2002, J NEUROTRAUM, V19, P1217, DOI 10.1089/08977150260338010; Marino RJ, 2003, J SPINAL CORD MED, V26, pS50, DOI [DOI 10.1080/10790268.2003.11754575, 10.1080/10790268.2003.11754575]; Minassian K, 2007, HUM MOVEMENT SCI, V26, P275, DOI 10.1016/j.humov.2007.01.005; Minassian K, 2004, SPINAL CORD, V42, P401, DOI 10.1038/sj.sc.3101615; Nadeau S, 2010, NEUROREHAB NEURAL RE, V24, P377, DOI 10.1177/1545968309349945; Rossignol S, 2008, BRAIN RES REV, V57, P228, DOI 10.1016/j.brainresrev.2007.06.019; Wernig A, 1998, SPINAL CORD, V36, P744, DOI 10.1038/sj.sc.3100670; WERNIG A, 1992, PARAPLEGIA, V30, P229, DOI 10.1038/sc.1992.61	30	630	689	11	136	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 4	2011	377	9781					1938	1947		10.1016/S0140-6736(11)60547-3	http://dx.doi.org/10.1016/S0140-6736(11)60547-3			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21601270	Green Accepted			2023-01-03	WOS:000291623200030
J	Matthews, LT; Giddy, J; Ghebremichael, M; Hampton, J; Guarino, AJ; Ewusi, A; Carver, E; Axten, K; Geary, MC; Gandhi, RT; Bangsberg, DR				Matthews, Lynn T.; Giddy, Janet; Ghebremichael, Musie; Hampton, Jane; Guarino, Anthony J.; Ewusi, Aba; Carver, Emma; Axten, Karen; Geary, Meghan C.; Gandhi, Rajesh T.; Bangsberg, David R.			A Risk-Factor Guided Approach to Reducing Lactic Acidosis and Hyperlactatemia in Patients on Antiretroviral Therapy	PLOS ONE			English	Article							HIV-INFECTED PATIENTS; SYMPTOMATIC HYPERLACTATEMIA; COMPLICATIONS; MANAGEMENT; STAVUDINE; LACTATE; WOMEN	Background: Stavudine continues to be used in antiretroviral treatment (ART) regimens in many resource-limited settings. The use of zidovudine instead of stavudine in higher-risk patients to reduce the likelihood of lactic acidosis and hyperlactatemia (LAHL) has not been examined. Methods: Antiretroviral-naive, HIV-infected adults initiating ART between 2004 and 2007 were divided into cohorts of those initiated on stavudine- or zidovudine-containing therapy. We evaluated stavudine or zidovudine use, age, sex, body mass index (BMI), baseline CD4 cell count, creatinine, hemoglobin, alanine aminotransferase, and albumin as predictors of time to LAHL with Cox Proportional Hazards (PH) regression models. Results: Among 2062 patients contributing 2747 patient years (PY), the combined incidence of LAHL was 3.2/100 PY in those initiating stavudine- and 0.34/100 PY in those initiating zidovudine-containing ART (RR 9.26, 95% CI: 1.28-66.93). In multivariable Cox PH analysis, stavudine exposure (HR 14.31, 95% CI: 5.79-35.30), female sex (HR 3.41, 95% CI: 1.89-6.19), higher BMI (HR 3.21, 95% CI: 2.16-4.77), higher creatinine (1.63, 95% CI: 1.12-2.36), higher albumin (HR 1.04, 95% CI: 1.011.07), and lower CD4 cell count (HR 0.96, 95% CI: 0.92-1.0) at baseline were associated with higher LAHL rates. Among participants who started on stavudine, switching to zidovudine was associated with lower LAHL rates (HR 0.15, 95% CI: 0.06-0.35). Subgroup analysis limited to women with higher BMI >= 25 kg/m(2) initiated on stavudine also showed that switch to zidovudine was protective when controlling for other risk factors (HR 0.21, 95% CI.07-0.64). Conclusions: Stavudine exposure, female sex, and higher BMI are strong, independent predictors for developing LAHL. Patients with risk factors for lactic acidosis have less LAHL while on zidovudine-rather than stavudine-containing ART. Switching patients from stavudine to zidovudine is protective. Countries continuing to use stavudine should avoid this drug in women and patients with higher BMI.	[Matthews, Lynn T.] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA; [Giddy, Janet; Hampton, Jane] McCord Hosp, HIV Program, Durban, South Africa; [Ghebremichael, Musie; Axten, Karen; Gandhi, Rajesh T.; Bangsberg, David R.] Ragon Inst Massachusetts Gen Hosp Massachusetts I, Boston, MA USA; [Guarino, Anthony J.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA; [Ewusi, Aba] Harvard Vanguard Med Associates, Div Internal Med, Boston, MA USA; [Carver, Emma] Univ Wales Hosp, Dept Emergency Med, Cardiff CF4 4XW, S Glam, Wales; [Geary, Meghan C.] Albany Med Coll, Albany, NY 12208 USA; [Gandhi, Rajesh T.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; [Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda; [Bangsberg, David R.] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Massachusetts General Hospital; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Massachusetts General Hospital; Harvard Vanguard Medical Associates; Cardiff University; Albany Medical College; Harvard University; Massachusetts General Hospital; Mbarara University of Science & Technology; Harvard University; Massachusetts General Hospital	Matthews, LT (corresponding author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.	ltmatthe@bidmc.harvard.edu			Mark and Lisa Schwartz Family Foundation; Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene; NIH [R01 AI066992-04A1, NIH G08LM008830-01, MH K-24 87227]; Harvard University Center for AIDS Research [NIH 2P30 AI06035406];  [NIH U01 AI 694722]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066992, P30AI060354] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [K24MH087227] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [G08LM008830] Funding Source: NIH RePORTER	Mark and Lisa Schwartz Family Foundation; Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene(Burroughs Wellcome Fund); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard University Center for AIDS Research; ; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	Dr. Matthews' work was supported by the Mark and Lisa Schwartz Family Foundation and by a postdoctoral fellowship in tropical infectious diseases from the Burroughs Wellcome Fund/American Society for Tropical Medicine and Hygiene. Dr. Gandhi is supported by NIH R01 AI066992-04A1 and NIH G08LM008830-01 and by grants to the AIDS Clinical Trials Group (NIH U01 AI 694722) and the Harvard University Center for AIDS Research (NIH 2P30 AI06035406). Dr. Bangsberg was supported by NIH grant MH K-24 87227. The authors are also grateful to Dr. Heather Ribaudo of the Harvard University Center for AIDS Research Biostatistical Core (NIH #AI060354). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AD AIDS CLIN TRIA, 2003, AACTG TOX EV GROUP C; Arenas-Pinto A, 2007, AIDS, V21, P2455, DOI 10.1097/QAD.0b013e3282f08cdc; Bellomo R, 2002, CRIT CARE, V6, P322; Bolhaar MG, 2007, CLIN INFECT DIS, V45, P254, DOI 10.1086/518976; Bonnet F, 2003, CLIN INFECT DIS, V36, P1324, DOI 10.1086/374601; Boubaker K, 2001, CLIN INFECT DIS, V33, P1931, DOI 10.1086/324353; Boulle A, 2007, ANTIVIR THER, V12, P753; Cox DR., 1989, ANAL BINARY DATA, V2nd; Fabian J, 2008, SAMJ S AFR MED J, V98, P795; Geddes R, 2006, SAMJ S AFR MED J, V96, P722; Harrell Frank E., 2001, REGRESSION MODELING; HILL A, 2007, EXPERT OPINION PHAMA, V8; Ivers LC, 2006, AIDS, V20, P779, DOI 10.1097/01.aids.0000216382.37679.b2; Kiragga AK, 2008, JAIDS-J ACQ IMM DEF, V49, P564, DOI 10.1097/QAI.0b013e31817e6391; Kumarasamy N, 2008, J WOMENS HEALTH, V17, P1471, DOI 10.1089/jwh.2007.0670; Lonergan JT, 2003, AIDS, V17, P2495, DOI 10.1097/00002030-200311210-00012; Moyle GJ, 2002, AIDS, V16, P1341, DOI 10.1097/00002030-200207050-00005; Murphy RA, 2007, J INFECT DIS, V196, pS449, DOI 10.1086/521112; Osler M, 2010, HIV MED, V11, P121, DOI 10.1111/j.1468-1293.2009.00754.x; Rosen S, 2008, JAIDS-J ACQ IMM DEF, V48, P334, DOI 10.1097/QAI.0b013e31817ae5ef; Shibuyama S, 2006, CURR PHARM DESIGN, V12, P1075, DOI 10.2174/138161206776055796; South Africa National AIDS Council, 2010, S AFR ANT TREATM GUI; SPAULDING A, COCHRANE DATABASE SY; Stead D, 2008, ANTIVIR THER, V13, P937; Stenzel MS, 2000, INFECT DIS CLIN N AM, V14, P851, DOI 10.1016/S0891-5520(05)70137-9; VANGRIENSVEN J, T R SOC TROP MED HYG, V104, P148; Wester CW, 2007, JAIDS-J ACQ IMM DEF, V46, P318, DOI 10.1097/QAI.0b013e3181568e3f; WHO, 2010, ANT THER HIV INF AD; Wohl DA, 2006, CLIN INFECT DIS, V43, P645, DOI 10.1086/507333	29	13	13	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2011	6	4							e18736	10.1371/journal.pone.0018736	http://dx.doi.org/10.1371/journal.pone.0018736			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747XH	21494566	Green Submitted, gold, Green Published			2023-01-03	WOS:000289354100037
J	Joynt, KE; Orav, EJ; Jha, AK				Joynt, Karen E.; Orav, E. John; Jha, Ashish K.			Thirty-Day Readmission Rates for Medicare Beneficiaries by Race and Site of Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-CARE; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; CONGESTIVE-HEART-FAILURE; SAFETY-NET HOSPITALS; DUTY HOUR REFORM; BLACK PATIENTS; TRANSITIONS INTERVENTION; ADMINISTRATIVE DATA; RACIAL DISPARITIES	Context Understanding whether and why there are racial disparities in readmissions has implications for efforts to reduce readmissions. Objective To determine whether black patients have higher odds of readmission than white patients and whether these disparities are related to where black patients receive care. Design Using national Medicare data, we examined 30-day readmissions after hospitalization for acute myocardial infarction (MI), congestive heart failure (CHF), and pneumonia. We categorized hospitals in the top decile of proportion of black patients as minority-serving. We determined the odds of readmission for black patients compared with white patients at minority-serving vs non-minority-serving hospitals. Setting and Participants Medicare Provider Analysis Review files of more than 3.1 million Medicare fee-for-service recipients who were discharged from US hospitals in 2006-2008. Main Outcome Measure Risk-adjusted odds of 30-day readmission. Results Overall, black patients had higher readmission rates than white patients (24.8% vs 22.6%, odds ratio [OR], 1.13; 95% confidence interval [CI], 1.11-1.14; P<.001); patients from minority-serving hospitals had higher readmission rates than those from non-minority-serving hospitals (25.5% vs 22.0%, OR, 1.23; 95% CI, 1.20-1.27; P<.001). Among patients with acute MI and using white patients from non-minority-serving hospitals as the reference group (readmission rate 20.9%), black patients from minority-serving hospitals had the highest readmission rate (26.4%; OR, 1.35; 95% CI, 1.28-1.42), while white patients from minority-serving hospitals had a 24.6% readmission rate (OR, 1.23; 95% CI, 1.18-1.29) and black patients from non-minority-serving hospitals had a 23.3% readmission rate (OR, 1.20; 95% CI, 1.16-1.23; P<.001 for each); patterns were similar for CHF and pneumonia. The results were unchanged after adjusting for hospital characteristics including markers of caring for poor patients. Conclusion Among elderly Medicare recipients, black patients were more likely to be readmitted after hospitalization for 3 common conditions, a gap that was related to both race and to the site where care was received. JAMA. 2011;305(7):675-681 www.jama.com	[Joynt, Karen E.] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Joynt, KE (corresponding author), Brigham & Womens Hosp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.	kjoynt@partners.org			National Institutes of Health, Brigham and Women's Hospital, Division of Cardiovascular Medicine [T32HL007604-24]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007604] Funding Source: NIH RePORTER	National Institutes of Health, Brigham and Women's Hospital, Division of Cardiovascular Medicine; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Joynt was supported by National Institutes of Health Training Grant T32HL007604-24, Brigham and Women's Hospital, Division of Cardiovascular Medicine.	Ayanian JZ, 1999, MED CARE, V37, P1260, DOI 10.1097/00005650-199912000-00009; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Baicker K, 2004, HLTH AFF MILLWOOD S, pVAR33; Benatar D, 2003, ARCH INTERN MED, V163, P347, DOI 10.1001/archinte.163.3.347; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; Breslin TM, 2009, J CLIN ONCOL, V27, P3945, DOI 10.1200/JCO.2008.20.8546; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Culler SD, 2010, MED CARE, V48, P273, DOI 10.1097/MLR.0b013e3181c161ba; Deswal A, 2004, J AM COLL CARDIOL, V43, P778, DOI 10.1016/j.jacc.2003.10.033; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Gaskin DJ, 2008, HEALTH AFFAIR, V27, P518, DOI 10.1377/hlthaff.27.2.518; Givens JL, 2010, ARCH INTERN MED, V170, P427, DOI 10.1001/archinternmed.2009.547; Halm EA, 2009, STROKE, V40, P2493, DOI 10.1161/STROKEAHA.108.544866; Han B, 2006, MED CARE, V44, P731, DOI 10.1097/01.mlr.0000215858.37118.65; Hasnain-Wynia R, 2007, ARCH INTERN MED, V167, P1233, DOI 10.1001/archinte.167.12.1233; Healthcare Cost and Utilization Project (HCUP), COM SOFTW VERS 3 6; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; *I MED, 2002, UN TREATM CONFR RAC; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Jha AK, 2005, NEW ENGL J MED, V353, P683, DOI 10.1056/NEJMsa050672; Jha AK, 2007, HEALTH AFFAIR, V26, P1104, DOI 10.1377/hlthaff.26.4.1104; Jha AK, 2007, ARCH INTERN MED, V167, P1177, DOI 10.1001/archinte.167.11.1177; Jha AK, 2007, AM HEART J, V153, P785, DOI 10.1016/j.ahj.2007.02.014; Kahn CN, 2006, HEALTH AFFAIR, V25, P148, DOI 10.1377/hlthaff.25.1.148; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Lucas FL, 2006, ANN SURG, V243, P281, DOI 10.1097/01.sla.0000197560.92456.32; Mayr FB, 2010, CRIT CARE MED, V38, P759, DOI 10.1097/CCM.0b013e3181c8fd58; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; Parry Carla, 2009, Home Health Care Serv Q, V28, P84, DOI 10.1080/01621420903155924; Pine M, 2007, JAMA-J AM MED ASSOC, V297, P71, DOI 10.1001/jama.297.1.71; Polsky D, 2008, HEALTH SERV RES, V43, P1388, DOI 10.1111/j.1475-6773.2008.00837.x; Sisk JE, 2006, ANN INTERN MED, V145, P273, DOI 10.7326/0003-4819-145-4-200608150-00007; Skinner J, 2005, CIRCULATION, V112, P2634, DOI 10.1161/CIRCULATIONAHA.105.543231; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Tan EJ, 2003, J AM GERIATR SOC, V51, P246, DOI 10.1046/j.1532-5415.2003.51065.x; Trivedi AN, 2006, J AM COLL CARDIOL, V47, P417, DOI 10.1016/j.jacc.2005.08.068; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P984, DOI 10.1001/jama.298.9.984; Volpp KG, 2007, JAMA-J AM MED ASSOC, V298, P975, DOI 10.1001/jama.298.9.975; Weller WE, 2007, J AM COLL SURGEONS, V204, P383, DOI 10.1016/j.jamcollsurg.2006.12.031; Werner RM, 2008, JAMA-J AM MED ASSOC, V299, P2180, DOI 10.1001/jama.299.18.2180; Zwanziger J, 2008, MED CARE RES REV, V65, P478, DOI 10.1177/1077558708315440	45	559	562	0	36	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2011	305	7					675	681		10.1001/jama.2011.123	http://dx.doi.org/10.1001/jama.2011.123			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	721NH	21325183	Green Accepted, Bronze			2023-01-03	WOS:000287361100018
J	Stalder, D; Barelli, H; Gautier, R; Macia, E; Jackson, CL; Antonny, B				Stalder, Daniele; Barelli, Helene; Gautier, Romain; Macia, Eric; Jackson, Catherine L.; Antonny, Bruno			Kinetic Studies of the Arf Activator Arno on Model Membranes in the Presence of Arf Effectors Suggest Control by a Positive Feedback Loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; PLECKSTRIN-HOMOLOGY DOMAINS; ADP-RIBOSYLATION FACTOR-1; COILED-COIL DOMAIN; SMALL G-PROTEINS; STRUCTURAL BASIS; PH DOMAIN; FAMILY; BINDING; SEC7	Proteins of the cytohesin/Arno/Grp1 family of Arf activators are positive regulators of the insulin-signaling pathway and control various remodeling events at the plasma membrane. Arno has a catalytic Sec7 domain, which promotes GDP to GTP exchange on Arf, followed by a pleckstrin homology (PH) domain. Previous studies have revealed two functions of the PH domain: inhibition of the Sec7 domain and membrane targeting. Interestingly, the Arno PH domain interacts not only with a phosphoinositide (phosphatidylinositol 4,5-bisphosphate or phosphatidylinositol 3,4,5-trisphosphate) but also with an activating Arf family member, such as Arf6 or Arl4. Using the full-length membrane-bound forms of Arf1 and Arf6 instead of soluble forms, we show here that the membrane environment dramatically affects the mechanism of Arno activation. First, Arf6-GTP stimulates Arno at nanomolar concentrations on liposomes compared with micromolar concentrations in solution. Second, mutations in the PH domain that abolish interaction with Arf6-GTP render Arno completely inactive when exchange reactions are reconstituted on liposomes but have no effect on Arno activity in solution. Third, Arno is activated by its own product Arf1-GTP in addition to a distinct activating Arf isoform. Consequently, Arno activity is strongly modulated by competition with Arf effectors. These results show that Arno behaves as a bistable switch, having an absolute requirement for activation by an Arf protein but, once triggered, becoming highly active through the positive feedback effect of Arf1-GTP. This property of Arno might provide an explanation for its function in signaling pathways that, once triggered, must move forward decisively.	[Stalder, Daniele; Barelli, Helene; Gautier, Romain; Macia, Eric; Antonny, Bruno] Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, F-06560 Valbonne, France; [Jackson, Catherine L.] CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Antonny, B (corresponding author), Univ Nice Sophia Antipolis, Inst Pharmacol Mol & Cellulaire, CNRS, 660 Route Lucioles, F-06560 Valbonne, France.	antonny@ipmc.cnrs.fr	Jackson, Catherine/T-5688-2019; Antonny, Bruno/ABH-7434-2020; Jackson, Catherine/A-3421-2013; Macia, Eric/AAW-2964-2021	Antonny, Bruno/0000-0002-9166-8668; Jackson, Catherine/0000-0002-0843-145X; BARELLI, Helene/0000-0001-6376-863X; macia, eric/0000-0003-3686-2000; GAUTIER, Romain/0000-0001-6678-132X	Agence Nationale de la Recherche [ANR-08-BLAN-0060-01]; Ministere de l'Enseignement Superieur et de la Recherche	Agence Nationale de la Recherche(French National Research Agency (ANR)); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission)	This work was supported by Agence Nationale de la Recherche Grant ANR-08-BLAN-0060-01.; Supported by a fellowship from the Ministere de l'Enseignement Superieur et de la Recherche.	ALBERTY RA, 1953, J AM CHEM SOC, V75, P1928, DOI 10.1021/ja01104a045; Beemiller P, 2006, PLOS BIOL, V4, P987, DOI 10.1371/journal.pbio.0040162; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; Bigay J, 2005, EMBO J, V24, P2244, DOI 10.1038/sj.emboj.7600714; Boehm T, 2003, EMBO J, V22, P1014, DOI 10.1093/emboj/cdg101; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Boulay PL, 2008, J BIOL CHEM, V283, P36425, DOI 10.1074/jbc.M803603200; Boykevisch S, 2006, CURR BIOL, V16, P2173, DOI 10.1016/j.cub.2006.09.033; Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617; Canagarajah B, 2004, CELL, V119, P407, DOI 10.1016/j.cell.2004.10.012; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Chavrier P, 2001, METHOD ENZYMOL, V329, P272; Cohen LA, 2007, MOL BIOL CELL, V18, P2244, DOI 10.1091/mbc.E06-11-0998; Cronin TC, 2004, EMBO J, V23, P3711, DOI 10.1038/sj.emboj.7600388; DiNitto JP, 2007, MOL CELL, V28, P569, DOI 10.1016/j.molcel.2007.09.017; Drin G, 2008, SCIENCE, V320, P670, DOI 10.1126/science.1155821; El Annan J, 2004, AM J PHYSIOL-CELL PH, V286, pC768, DOI 10.1152/ajpcell.00250.2003; Franco M, 1998, P NATL ACAD SCI USA, V95, P9926, DOI 10.1073/pnas.95.17.9926; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Frank S, 1998, J BIOL CHEM, V273, P23, DOI 10.1074/jbc.273.1.23; Fuss B, 2006, NATURE, V444, P945, DOI 10.1038/nature05412; Garcia-Mata R, 2003, MOL BIOL CELL, V14, P2250, DOI 10.1091/mbc.E02-11-0730; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Grosshans BL, 2006, P NATL ACAD SCI USA, V103, P11821, DOI 10.1073/pnas.0601617103; Groves JT, 2010, NAT STRUCT MOL BIOL, V17, P659, DOI 10.1038/nsmb.1844; Gureasko J, 2008, NAT STRUCT MOL BIOL, V15, P452, DOI 10.1038/nsmb.1418; Hofmann I, 2007, CURR BIOL, V17, P711, DOI 10.1016/j.cub.2007.03.007; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Kam JL, 2000, J BIOL CHEM, V275, P9653, DOI 10.1074/jbc.275.13.9653; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Kumari S, 2008, NAT CELL BIOL, V10, P30, DOI 10.1038/ncb1666; Lebensohn AM, 2009, MOL CELL, V36, P512, DOI 10.1016/j.molcel.2009.10.024; Li CC, 2007, MOL BIOL CELL, V18, P4420, DOI 10.1091/mbc.E07-02-0149; Li HS, 2003, BMC CELL BIOL, V4, P1, DOI 10.1186/1471-2121-4-13; Li PL, 2008, NAT STRUCT MOL BIOL, V15, P613, DOI 10.1038/nsmb.1428; Lim J, 2010, GENE DEV, V24, P1496, DOI 10.1101/gad.1904610; Macia E, 2000, BIOCHEMISTRY-US, V39, P5893, DOI 10.1021/bi992795w; Macia E, 2001, J BIOL CHEM, V276, P24925, DOI 10.1074/jbc.M103284200; Mansour M, 2002, J BIOL CHEM, V277, P32302, DOI 10.1074/jbc.M202898200; Menetrey J, 2007, EMBO J, V26, P1953, DOI 10.1038/sj.emboj.7601634; Moss J, 2002, ARCH BIOCHEM BIOPHYS, V397, P156, DOI 10.1006/abbi.2001.2661; Nagel WG, 1998, MOL BIOL CELL, V9, P1981, DOI 10.1091/mbc.9.8.1981; Nevrivy DJ, 2000, J BIOL CHEM, V275, P16827, DOI 10.1074/jbc.275.22.16827; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Renault L, 2003, NATURE, V426, P525, DOI 10.1038/nature02197; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Santy LC, 2001, J CELL BIOL, V154, P599, DOI 10.1083/jcb.200104019; Santy LC, 1999, CURR BIOL, V9, P1173, DOI 10.1016/S0960-9822(00)80019-6; Shmuel M, 2006, J BIOL CHEM, V281, P13300, DOI 10.1074/jbc.M513723200; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Venkateswarlu K, 2003, J BIOL CHEM, V278, P43460, DOI 10.1074/jbc.M304078200; Viaud J, 2007, P NATL ACAD SCI USA, V104, P10370, DOI 10.1073/pnas.0700773104; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Wang JY, 2002, J BIOL CHEM, V277, P34401, DOI 10.1074/jbc.M203954200; White DT, 2010, MOL BIOL CELL, V21, P562, DOI 10.1091/mbc.E09-03-0217	58	57	57	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2011	286	5					3873	3883		10.1074/jbc.M110.145532	http://dx.doi.org/10.1074/jbc.M110.145532			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712GE	21118813	Green Published, hybrid			2023-01-03	WOS:000286653200068
J	Reed, DA; Fletcher, KE; Arora, VM				Reed, Darcy A.; Fletcher, Kathlyn E.; Arora, Vineet M.			Systematic Review: Association of Shift Length, Protected Sleep Time, and Night Float With Patient Care, Residents' Health, and Education	ANNALS OF INTERNAL MEDICINE			English	Review							WORK HOUR RESTRICTIONS; INTERNAL-MEDICINE RESIDENTS; BLOOD-PRESSURE; CALL STRUCTURE; IMPACT; DEPRIVATION; PERFORMANCE; QUALITY; ERRORS; STAFF	Background: The Accreditation Council for Graduate Medical Education's new duty-hour standards limit interns' shifts to 16 hours and night float to 6 consecutive nights. Protected sleep time (that is, "nap") is strongly encouraged. As duty-hour reforms are implemented, examination of the quality and outcomes of the relevant literature is important. Purpose: To systematically review the literature examining shift length, protected sleep time, and night float. Data Sources: MEDLINE, PREMEDLINE, and EMBASE from January 1989 through May 2010. Study Selection: Studies examined the associations of shift length, protected sleep time, or night float with patient care, resident health, and education outcomes among residents in practice settings. Data Extraction: Study quality was measured by using the validated Medical Education Research Study Quality Instrument and the U.S. Preventive Services Task Force criteria. Two investigators independently rated study quality, and interrater agreement was calculated. Data Synthesis: Sixty-four studies met inclusion criteria. Most studies used single-group cross-sectional (19 studies [29.7%]) or prepost (41 studies [64.1%]) designs, and 4 (6.3%) were randomized, controlled trials. Five studies (7.8%) were multi-institutional. Twenty-four of 33 (72.7%) studies examining shift length reported that shorter shifts were associated with decreased medical errors, motor vehicle crashes, and percutaneous injuries. Only 2 studies assessed protected sleep time and reported that residents' adherence to naps was poor. Night floats described in 33 studies involved 5 to 7 consecutive nights. Limitations: Most studies used single-institution, observational designs. Publication bias is likely but difficult to assess in this methodologically weak and heterogeneous body of evidence. Conclusion: For the limited outcomes measured, most studies supported reducing shift length but did not adequately address the optimal shift duration. Studies had numerous methodological limitations and unclear generalizability for most outcomes. Specific recommendations about shift length, protected sleep time, and night float should acknowledge the limitations of this evidence.	[Reed, Darcy A.] Mayo Clin, Div Primary Care Internal Med, Coll Med, Rochester, MN 55905 USA; Med Coll Wisconsin, Milwaukee Vet Affairs Med Ctr, Milwaukee, WI 53226 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	Mayo Clinic; Medical College of Wisconsin; University of Chicago	Reed, DA (corresponding author), Mayo Clin, Div Primary Care Internal Med, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.			Arora, Vineet/0000-0002-4745-7599	Accreditation Council for Graduate Medical Education; ACGME	Accreditation Council for Graduate Medical Education; ACGME	Accreditation Council for Graduate Medical Education.; The authors thank Lisa Bellini, MD, at the University of Pennsylvania for expert review of the reference list. They also thank Jessica Schmidt and Andrea Bruckbauer at the Milwaukee Veterans Affairs Medical Center; Alexis Dye, MS, and Mark Oium at the Medical College of Wisconsin; Katya Papatla at Duke University; Patricia Erwin, MLS, and Kate Featherstone at the Mayo Clinic College of Medicine; Meryl Prochaska, BA, and Diane Daviera, BS, at the University of Chicago; and Emily Chiu at the University of Michigan for their excellent research assistance. Finally, they thank Jack Littrell, MS, for his assistance with database creation and management and DeWitt Baldwin, MD, at the ACGME for his assistance with obtaining funding.	Afessa B, 2005, CHEST, V128, P3910, DOI 10.1378/chest.128.6.3910; Akl EA, 2006, J GEN INTERN MED, V21, P494, DOI 10.1111/j.1525-1497.2006.00434.x; Amir O, 2004, AM J CARDIOL, V93, P947, DOI 10.1016/j.amjcard.2003.12.032; Antiel RM, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMp1008305; Arora V, 2006, ANN INTERN MED, V144, P792, DOI 10.7326/0003-4819-144-11-200606060-00005; Ayas NT, 2006, JAMA-J AM MED ASSOC, V296, P1055, DOI 10.1001/jama.296.9.1055; Bailit JL, 2004, OBSTET GYNECOL, V103, P613, DOI 10.1097/01.AOG.0000119225.57285.c1; Barden CB, 2002, J AM COLL SURGEONS, V195, P531, DOI 10.1016/S1072-7515(02)01242-5; Barger LK, 2006, PLOS MED, V3, P2440, DOI 10.1371/journal.pmed.0030487; Barger LK, 2005, NEW ENGL J MED, V352, P125, DOI 10.1056/NEJMoa041401; BENBARKA MM, 1995, HORM METAB RES, V27, P332, DOI 10.1055/s-2007-979972; BERKOFF K, 1991, J DEV BEHAV PEDIATR, V12, P6; Bhavsar J, 2007, AM J MED, V120, P968, DOI 10.1016/j.amjmed.2007.07.026; Blanchard MH, 2004, AM J OBSTET GYNECOL, V191, P1746, DOI 10.1016/j.ajog.2004.07.060; Brater DC, 2010, COMMUNICATION   0806; BUFF DD, 1995, J GEN INTERN MED, V10, P400, DOI 10.1007/BF02599842; Busowski JD, 1997, AM J PERINAT, V14, P177, DOI 10.1055/s-2007-994122; Cao CGL, 2008, HUM FACTORS, V50, P276, DOI 10.1518/001872008X288303; CAREY JC, 1989, OBSTET GYNECOL, V74, P668; Cavallo A, 2003, ERGONOMICS, V46, P653, DOI 10.1080/0014013031000085671; Cavallo A, 2002, CHRONOBIOL INT, V19, P893, DOI 10.1081/CBI-120014106; Cedfeldt Andrea S, 2009, J Grad Med Educ, V1, P178, DOI 10.4300/JGME-D-09-00031.1; Charap M, 2004, ANN INTERN MED, V140, P814, DOI 10.7326/0003-4819-140-10-200405180-00011; Chatterton RT, 1999, J SOC GYNECOL INVEST, V6, P50, DOI 10.1016/S1071-5576(98)00045-8; Chow KM, 2005, QJM-INT J MED, V98, P753, DOI 10.1093/qjmed/hci116; Druss BJ, 1996, ACAD PSYCHIATR, V20, P26, DOI 10.1007/BF03341958; Eastridge BJ, 2003, AM J SURG, V186, P169, DOI 10.1016/S0002-9610(03)00183-1; Ferguson Charles M, 2005, Curr Surg, V62, P535, DOI 10.1016/j.cursur.2005.04.001; Fialho G, 2006, AM J HYPERTENS, V19, P1005, DOI 10.1016/j.amjhyper.2006.03.007; Fletcher KE, 2005, JAMA-J AM MED ASSOC, V294, P1088, DOI 10.1001/jama.294.9.1088; Fletcher KE, 2004, ANN INTERN MED, V141, P851, DOI 10.7326/0003-4819-141-11-200412070-00009; Goldstein Michael J, 2005, Curr Surg, V62, P132, DOI 10.1016/j.cursur.2004.10.013; GOTTLIEB DJ, 1993, J GEN INTERN MED, V8, P146, DOI 10.1007/BF02599762; GOTTLIEB DJ, 1991, ARCH INTERN MED, V151, P2065, DOI 10.1001/archinte.151.10.2065; Griffith CH, 1997, J GEN INTERN MED, V12, P308, DOI 10.1046/j.1525-1497.1997.012005308.x; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hatala R, 2005, CAN MED ASSOC J, V172, P661, DOI 10.1503/cmaj.1031920; HAYNES DF, 1995, SOUTHERN MED J, V88, P283, DOI 10.1097/00007611-199503000-00007; Hendey GW, 2005, ACAD EMERG MED, V12, P629, DOI 10.1197/j.aem.2005.02.009; Horwitz LI, 2006, ARCH INTERN MED, V166, P1173, DOI 10.1001/archinte.166.11.1173; Institute of Medicine, 2008, RES DUT HOURS ENH SL; Izu Brent S, 2007, J Surg Educ, V64, P361, DOI 10.1016/j.jsurg.2007.08.006; Jarman Benjamin T, 2004, Curr Surg, V61, P612, DOI 10.1016/j.cursur.2004.06.016; Jasti H, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-52; Jeanmonod R, 2008, AM J EMERG MED, V26, P789, DOI 10.1016/j.ajem.2007.10.037; Kelly Robert J Jr, 2009, J Surg Educ, V66, P314, DOI 10.1016/j.jsurg.2009.07.009; Kiernan Michael, 2006, Curr Surg, V63, P237, DOI 10.1016/j.cursur.2006.03.002; Kirch DG, 2010, COMMUNICATION   0809; Kirkpatrick D. L., 1976, TRAINING DEV HDB, V2nd, P301; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Leff DR, 2008, ANN SURG, V247, P530, DOI 10.1097/SLA.0b013e3181661a99; Lefrak S, 2005, AM J SURG, V189, P639, DOI 10.1016/j.amjsurg.2004.11.034; Lehmann KS, 2010, SURGERY, V147, P246, DOI 10.1016/j.surg.2009.08.007; LIEU TA, 1992, AM J DIS CHILD, V146, P307, DOI 10.1001/archpedi.1992.02160150047018; Lockley SW, 2004, NEW ENGL J MED, V351, P1829, DOI 10.1056/NEJMoa041404; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mann F A, 1993, Invest Radiol, V28, P92, DOI 10.1097/00004424-199301000-00032; Mautone SG, 2009, 2009 ACCR COUNC GRAD; Mcelearney ST, 2005, AM SURGEON, V71, P552; Moher D, 2009, ANN INTERN MED, V151, P264, DOI 10.7326/0003-4819-151-4-200908180-00135; Nakayama DK, 2009, AM SURGEON, V75, P1234; Nasca TJ, 2010, NEW ENGL J MED, V363, DOI 10.1056/NEJMsb1005800; Nasca TJ, 2009, ACCREDITATION COUNCI; Nuckols TK, 2009, NEW ENGL J MED, V360, P2202, DOI 10.1056/NEJMsa0810251; Parks DK, 2000, CHRONOBIOL INT, V17, P61, DOI 10.1081/CBI-100101032; Parthasarathy S, 2007, CHEST, V131, P1685, DOI 10.1378/chest.06-1398; Petzel RA, 2010, COMMUNICATION   0805; Philibert I, 2005, SLEEP, V28, P1392, DOI 10.1093/sleep/28.11.1392; Pollack R, 2010, COMMUNICATION   0806; Privette AR, 2009, ANN SURG, V250, P316, DOI 10.1097/SLA.0b013e3181ae332a; Reader Douglas W, 2002, Emerg Radiol, V9, P82; Reed DA, 2008, J GEN INTERN MED, V23, P903, DOI 10.1007/s11606-008-0664-3; Reed DA, 2007, JAMA-J AM MED ASSOC, V298, P1002, DOI 10.1001/jama.298.9.1002; Richardson GS, 1996, SLEEP, V19, P718; ROSENBERG M, 1995, J GEN INTERN MED, V10, P95, DOI 10.1007/BF02600236; Roses Robert E, 2009, J Surg Educ, V66, P357, DOI 10.1016/j.jsurg.2009.07.005; Schenarts P, 2005, AM J SURG, V190, P147, DOI 10.1016/j.amjsurg.2005.03.026; SEELIG CB, 1992, SOUTH MED J, V85, P972, DOI 10.1097/00007611-199210000-00010; SEELIG CB, 1993, J GEN INTERN MED, V8, P610, DOI 10.1007/BF02599716; Short Amy C, 2006, J Matern Fetal Neonatal Med, V19, P801; Sim DJ, 2004, ANAESTHESIA, V59, P781, DOI 10.1111/j.1365-2044.2004.03808.x; STORER JS, 1989, ACAD MED, V64, P29, DOI 10.1097/00001888-198901000-00013; Suryadevara AC, 2008, LARYNGOSCOPE, V118, P1257, DOI 10.1097/MLG.0b013e31816bf52f; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; TRONTELL MC, 1991, J GEN INTERN MED, V6, P445, DOI 10.1007/BF02598169; U.S. Preventive Services Task Force Evidence Syntheses, 2010, USP STF QUAL RAT CRI; van Dongen HP, 2005, PRINCIPLES PRACTICE, P435; Vaughn DM, 2008, AM SURGEON, V74, P542; Wallach SL, 2006, SOUTH MED J, V99, P919, DOI 10.1097/01.smj.0000235501.62397.ef; Ware J Catesby, 2006, Behav Sleep Med, V4, P1, DOI 10.1207/s15402010bsm0401_1; Wayne DB, 2009, J GEN INTERN MED, V24, P1169, DOI 10.1007/s11606-009-1093-7; Welling Richard E, 2004, Curr Surg, V61, P241, DOI 10.1016/j.cursur.2003.10.009; YETMAN RJ, 1994, CHRONOBIOL INT, V11, P54, DOI 10.3109/07420529409057231; Zheng HY, 2006, JAMA-J AM MED ASSOC, V296, P1049, DOI 10.1001/jama.296.9.1049; Zucherman M, 1965, MULTIPLE AFFECT ADJE	95	103	105	2	16	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2010	153	12					829	+		10.7326/0003-4819-153-12-201012210-00010	http://dx.doi.org/10.7326/0003-4819-153-12-201012210-00010			26	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	696PL	21173417				2023-01-03	WOS:000285453700007
J	Choi, HS; Ashitate, Y; Lee, JH; Kim, SH; Matsui, A; Insin, N; Bawendi, MG; Semmler-Behnke, M; Frangioni, JV; Tsuda, A				Choi, Hak Soo; Ashitate, Yoshitomo; Lee, Jeong Heon; Kim, Soon Hee; Matsui, Aya; Insin, Numpon; Bawendi, Moungi G.; Semmler-Behnke, Manuela; Frangioni, John V.; Tsuda, Akira			Rapid translocation of nanoparticles from the lung airspaces to the body	NATURE BIOTECHNOLOGY			English	Article							INSOLUBLE IRIDIUM PARTICLES; QUANTUM DOTS; ULTRAFINE PARTICLES; CLEARANCE; BIODISTRIBUTION; MACROPHAGES; ORGANS	Nano-size particles show promise for pulmonary drug delivery, yet their behavior after deposition in the lung remains poorly understood. In this study, a series of near-infrared (NIR) fluorescent nanoparticles were systematically varied in chemical composition, shape, size and surface charge, and their biodistribution and elimination were quantified in rat models after lung instillation. We demonstrate that nanoparticles with hydrodynamic diameter (HD) less than approximate to 34 nm and a noncationic surface charge translocate rapidly from the lung to mediastinal lymph nodes. Nanoparticles of HD <6 nm can traffic rapidly from the lungs to lymph nodes and the bloodstream, and then be subsequently cleared by the kidneys. We discuss the importance of these findings for drug delivery, air pollution and carcinogenesis.	[Choi, Hak Soo; Ashitate, Yoshitomo; Lee, Jeong Heon; Kim, Soon Hee; Matsui, Aya; Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA; [Insin, Numpon; Bawendi, Moungi G.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Semmler-Behnke, Manuela] German Res Ctr Environm Hlth, Helmholtz Ctr Munchen, Inst Lung Biol & Dis, Neuherberg, Germany; [Frangioni, John V.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; [Tsuda, Akira] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard T.H. Chan School of Public Health	Frangioni, JV (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Hematol Oncol, Boston, MA 02215 USA.	jfrangio@bidmc.harvard.edu; atsuda@hsph.harvard.edu	Kim, Soon Hee/GXF-6736-2022; Choi, Hak Soo/C-9954-2011		NIH [HL054885, HL070542, HL074022, R01-CA-115296]; NATIONAL CANCER INSTITUTE [R01CA115296] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054885, R01HL074022, R01HL070542] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM068762] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank R. Oketokoun and S. Gioux for help with developing the FLARE imaging system and E.P. Lunsford of the Longwood Small Animal Imaging Facility for assistance with SPECT/CT imaging. The Biophysical Instrumentation Facility for the Study of Complex Macromolecular Systems (National Science Foundation-0070319 and US National Institutes of Health (NIH) GM68762) is gratefully acknowledged. We thank W. Liu and B.I. Ipe for providing quantum dots, L. Moffitt for editing, and L. Keys and E. Trabucchi for administrative support. This work was supported in part by NIH grant HL054885 (A.T.), HL070542 (A.T.), HL074022 (A.T.) and R01-CA-115296 (J.V.F.).	Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Burns AA, 2009, NANO LETT, V9, P442, DOI 10.1021/nl803405h; Choi HS, 2007, NAT BIOTECHNOL, V25, P1165, DOI 10.1038/nbt1340; Choi HS, 2010, MOL IMAGING, V9, P291, DOI 10.2310/7290.2010.00031; Choi HS, 2010, NAT NANOTECHNOL, V5, P42, DOI [10.1038/NNANO.2009.314, 10.1038/nnano.2009.314]; Choi HS, 2009, NANO LETT, V9, P2354, DOI 10.1021/nl900872r; Courrier HM, 2002, CRIT REV THER DRUG, V19, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v19.i45.40; Duncan R, 2006, NAT REV CANCER, V6, P688, DOI 10.1038/nrc1958; Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007; Geiser M, 2008, AM J RESP CELL MOL, V38, P371, DOI 10.1165/rcmb.2007-0138OC; Gioux S, 2009, MOL IMAGING, V8, P156, DOI 10.2310/7290.2009.00009; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; Insin N, 2008, ACS NANO, V2, P197, DOI 10.1021/nn700344x; Janib S. M., 2010, ADV DRUG DELIV REV, V3, P1; Kim S, 2004, NAT BIOTECHNOL, V22, P93, DOI 10.1038/nbt920; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; Liu WH, 2007, J AM CHEM SOC, V129, P14530, DOI 10.1021/ja073790m; Mills NL, 2009, NAT CLIN PRACT CARD, V6, P36, DOI 10.1038/ncpcardio1399; Moller W, 2008, AM J RESP CRIT CARE, V177, P426, DOI 10.1164/rccm.200602-301OC; Nemmar A, 2002, AM J RESP CRIT CARE, V166, P998, DOI 10.1164/rccm.200110-026OC; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Semmler M, 2004, INHAL TOXICOL, V16, P453, DOI 10.1080/08958370490439650; Semmler-Behnke M, 2008, SMALL, V4, P2108, DOI 10.1002/smll.200800922; Troyan SL, 2009, ANN SURG ONCOL, V16, P2943, DOI 10.1245/s10434-009-0594-2; Tsuda A, 2002, P NATL ACAD SCI USA, V99, P10173, DOI 10.1073/pnas.102318299; Wichmann H E, 2000, Res Rep Health Eff Inst, P5; WICHMANN HE, 2000, RES REP HLTH EFF I, P87; Zhang LW, 2009, TOXICOL SCI, V110, P138, DOI 10.1093/toxsci/kfp087; Zrazhevskiy P., 2010, CHEM SOC REV, V3, P1	29	440	449	7	180	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2010	28	12					1300	U113		10.1038/nbt.1696	http://dx.doi.org/10.1038/nbt.1696			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	691NP	21057497	Green Submitted, Green Accepted			2023-01-03	WOS:000285088400025
J	Wichmann, J; Andersen, Z; Ketzel, M; Ellermann, T; Loft, S				Wichmann, Janine; Andersen, Zorana; Ketzel, Matthias; Ellermann, Thomas; Loft, Steffen			Apparent Temperature and Cause-Specific Emergency Hospital Admissions in Greater Copenhagen, Denmark	PLOS ONE			English	Article							CASE-CROSSOVER ANALYSES; AIR-POLLUTION; EUROPEAN CITIES; CARDIOVASCULAR-DISEASES; MORTALITY; WEATHER; HEALTH; COLD; SELECTION; WAVES	One of the key climate change factors, temperature, has potentially grave implications for human health. We report the first attempt to investigate the association between the daily 3-hour maximum apparent temperature (Tapp(max)) and respiratory (RD), cardiovascular (CVD), and cerebrovascular (CBD) emergency hospital admissions in Copenhagen, controlling for air pollution. The study period covered 1 January 2002231 December 2006, stratified in warm and cold periods. A case-crossover design was applied. Susceptibility (effect modification) by age, sex, and socio-economic status was investigated. For an IQR (8 degrees C) increase in the 5-day cumulative average of Tapp(max), a 7% (95% CI: 1%, 13%) increase in the RD admission rate was observed in the warm period whereas an inverse association was found with CVD (-8%, -5% CI: -13%, -4%), and none with CBD. There was no association between the 5-day cumulative average of Tapp(max) during the cold period and any of the cause-specific admissions, except in some susceptible groups: a negative association for RD in the oldest age group and a positive association for CVD in men and the second highest SES group. In conclusion, an increase in Tapp(max) is associated with a slight increase in RD and decrease in CVD admissions during the warmer months.	[Wichmann, Janine; Loft, Steffen] Univ Copenhagen, Environm Hlth Sect, Copenhagen, Denmark; [Andersen, Zorana] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark; [Ketzel, Matthias; Ellermann, Thomas] Aarhus Univ, Dept Environm Sci, Aarhus, Denmark	University of Copenhagen; Danish Cancer Society; Aarhus University	Wichmann, J (corresponding author), Univ Copenhagen, Environm Hlth Sect, Copenhagen, Denmark.	jawic@sund.ku.dk	Andersen, Zorana Jovanovic/P-4983-2014; Ketzel, Matthias/K-4246-2015	Andersen, Zorana Jovanovic/0000-0003-4138-9828; Ketzel, Matthias/0000-0001-9519-1935; Loft, Steffen/0000-0001-9552-8518	Danish National Board of Health; Danish Research Councils; Danish Environmental Protection Agency	Danish National Board of Health; Danish Research Councils(Det Frie Forskningsrad (DFF)); Danish Environmental Protection Agency	This work was commissioned and partially funded by the Danish National Board of Health and the Danish Research Councils. The Danish Environmental Protection Agency is funding the air pollution and meteorological measurements as part of the Danish Air Quality Monitoring Programme. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Analitis A, 2008, AM J EPIDEMIOL, V168, P1397, DOI 10.1093/aje/kwn266; Andersen ZJ, 2007, J EXPO SCI ENV EPID, V17, P625, DOI 10.1038/sj.jes.7500546; Basu R, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-40; Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; Bateson TF, 2001, EPIDEMIOLOGY, V12, P654, DOI 10.1097/00001648-200111000-00013; Ebi KL, 2004, INT J BIOMETEOROL, V49, P48, DOI 10.1007/s00484-004-0207-5; Ellermann T, 2011, 836 AARH U NAT ENV R; Falagas ME, 2010, ENFERM INFEC MICR CL, V28, P716, DOI 10.1016/j.eimc.2009.11.013; *FORSKN FOR SUNDH, DAN HLTH REV REG COM; Green RS, 2010, INT J PUBLIC HEALTH, V55, P113, DOI 10.1007/s00038-009-0076-0; HEI (Health Effects Institute), 2003, REV AN TIM SER STUD; Keatinge WR, 2000, BRIT MED J, V321, P670, DOI 10.1136/bmj.321.7262.670; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; Lee JT, 2000, ENVIRON HEALTH PERSP, V108, P1107, DOI 10.2307/3434821; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Lucas RM, 2005, B WORLD HEALTH ORGAN, V83, P792; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Matthies F., 2008, HEAT HLTH ACTION PLA; Mercer JB, 2003, ENVIRON RES, V92, P8, DOI 10.1016/S0013-9351(02)00009-9; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC; Nafstad P, 2001, EUR J EPIDEMIOL, V17, P621, DOI 10.1023/A:1015547012242; Nayha S, 2007, INT J CIRCUMPOL HEAL, V66, P418; Nayha Simo, 2005, Int J Circumpolar Health, V64, P451; Reichert TA, 2004, AM J EPIDEMIOL, V160, P492, DOI 10.1093/aje/kwh227; Rocklov J, 2008, SCAND J PUBLIC HEALT, V36, P516, DOI 10.1177/1403494807088458; Schwartz J, 2004, EPIDEMIOLOGY, V15, P755, DOI 10.1097/01.ede.0000134875.15919.0f; WHO (World Health Organization), 2004, MET TIM SER STUD PAN; Wilkinson P, 2004, BMJ-BRIT MED J, V329, P647, DOI 10.1136/bmj.38167.589907.55; World Health Organization, AIR QUAL GUID GLOB U; *WORLD MET ORG, UN ENV PROGR	33	55	55	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2011	6	7							e22904	10.1371/journal.pone.0022904	http://dx.doi.org/10.1371/journal.pone.0022904			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KV	21829550	Green Published, Green Submitted, gold			2023-01-03	WOS:000293286500048
J	Tu, CY; Chen, TJ; Chou, LF				Tu, Chun-Yi; Chen, Tzeng-Ji; Chou, Li-Fang			Application of Frequent Itemsets Mining to Analyze Patterns of One-Stop Visits in Taiwan	PLOS ONE			English	Article							CHINESE HERBAL MEDICINE; CHRONIC DISEASE; PRESCRIPTIONS; PREVALENCE; CARE	Background: The free choice of health care facilities without limitations on frequency of visits within the National Health Insurance in Taiwan gives rise to not only a high number of annual ambulatory visits per capita but also a unique "one-stop shopping'' phenomenon, which refers to a patient' visits to several specialties of the same healthcare facility in one day. The visits to multiple physicians would increase the potential risk of polypharmacy. The aim of this study was to analyze the frequency and patterns of one-stop visits in Taiwan. Methodology/Principal Findings: The claims datasets of 1 million nationally representative people within Taiwan's National Health Insurance in 2005 were used to calculate the number of patients with one-stop visits. The frequent itemsets mining was applied to compute the combination patterns of specialties in the one-stop visits. Among the total 13,682,469 ambulatory care visits in 2005, one-stop visits occurred 144,132 times and involved 296,822 visits (2.2% of all visits) by 66,294 (6.6%) persons. People tended to have this behavior with age and the percentage reached 27.5% (5,662 in 20,579) in the age group >= 80 years. In general, women were more likely to have one-stop visits than men (7.2% vs. 6.0%). Internal medicine plus ophthalmology was the most frequent combination with a visited frequency of 3,552 times (2.5%), followed by cardiology plus neurology with 3,183 times (2.2%). The most frequent three-specialty combination, cardiology plus neurology and gastroenterology, occurred only 111 times. Conclusions/Significance: Without the novel computational technique, it would be hardly possible to analyze the extremely diverse combination patterns of specialties in one-stop visits. The results of the study could provide useful information either for the hospital manager to set up integrated services or for the policymaker to rebuild the health care system.	[Tu, Chun-Yi; Chen, Tzeng-Ji] Natl Yang Ming Univ, Sch Med, Inst Hosp & Hlth Care Adm, Taipei 112, Taiwan; [Tu, Chun-Yi] Taoyuan Vet Hosp, Dept Family Med, Tao Yuan, Taiwan; [Chen, Tzeng-Ji] Taipei Vet Gen Hosp, Dept Family Med, Taipei, Taiwan; [Chou, Li-Fang] Natl Chengchi Univ, Dept Publ Finance, Taipei 11623, Taiwan	National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Chengchi University	Tu, CY (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Hosp & Hlth Care Adm, Taipei 112, Taiwan.	tjchen@vghtpe.gov.tw	Chen, TJ/AAH-8430-2021		National Science Council [NSC 96-2416-H-004-007-MY2]; Taipei Veterans General Hospital [V98S2-006]	National Science Council(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital)	This study was supported by grants from the National Science Council (NSC 96-2416-H-004-007-MY2) and the Taipei Veterans General Hospital (V98S2-006). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal R., 1993, ACM SIGMOD RECORD, V22, P207, DOI DOI 10.1145/170035.170072; Berry MJA., 1997, DATA MINING TECHNIQU; Birns J, 2006, AGE AGEING, V35, P306, DOI 10.1093/ageing/afj057; Chen FP, 2008, J ETHNOPHARMACOL, V117, P84, DOI 10.1016/j.jep.2008.01.018; Chen TJ, 2003, CLIN THER, V25, P2453, DOI 10.1016/S0149-2918(03)80287-4; Chen TJ, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-54; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x; Han J., 2006, DATA MINING CONCEPTS; Jackson Jane, 2009, Nurs Manag (Harrow), V15, P24; Kung YY, 2006, ALLERGY, V61, P1316, DOI 10.1111/j.1398-9995.2006.01152.x; Liu ZR, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-394; Marengoni A, 2009, J AM GERIATR SOC, V57, P225, DOI 10.1111/j.1532-5415.2008.02109.x; Naughton C, 2006, AGE AGEING, V35, P633, DOI 10.1093/ageing/afl106; Nguyen Thach, 2005, J Interv Cardiol, V18, P107, DOI 10.1111/j.1540-8183.2005.4046a.x; Reid MJ, 2009, ANN ROY COLL SURG, V91, P301, DOI 10.1308/003588409X391910; ROMANO M, 2002, MODERN HEALTHCARE, V32, P32; Tamblyn RM, 1996, CAN MED ASSOC J, V154, P1177; 1996, ED MANAG, V8, P40	19	10	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2011	6	7							e14824	10.1371/journal.pone.0014824	http://dx.doi.org/10.1371/journal.pone.0014824			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	786HC	21747926	gold, Green Submitted, Green Published			2023-01-03	WOS:000292293400001
J	Lee, SH; Jaganath, IB; Wang, SM; Sekaran, SD				Lee, Sau Har; Jaganath, Indu Bala; Wang, Seok Mui; Sekaran, Shamala Devi			Antimetastatic Effects of Phyllanthus on Human Lung (A549) and Breast (MCF-7) Cancer Cell Lines	PLOS ONE			English	Article							NF-KAPPA-B; DOWN-REGULATION; CYCLE ARREST; DIETARY PHYTOCHEMICALS; GALLIC ACID; INHIBITION; APOPTOSIS; MIGRATION; INVASION; METASTASIS	Background: Current chemotherapeutic drugs kill cancer cells mainly by inducing apoptosis. However, they become ineffective once cancer cell has the ability to metastasize, hence the poor prognosis and high mortality rate. Therefore, the purpose of this study was to evaluate the antimetastatic potential of Phyllanthus (P. niruri, P. urinaria, P. watsonii, and P. amarus) on lung and breast carcinoma cells. Methodology/Principal Findings: Cytotoxicity of Phyllanthus plant extracts were first screened using the MTS reduction assay. They were shown to inhibit MCF-7 (breast carcinoma) and A549 (lung carcinoma) cells growth with IC50 values ranging from 50-180 mu g/ml and 65-470 mu g/ml for methanolic and aqueous extracts respectively. In comparison, they have lower toxicity on normal cells with the cell viability percentage remaining above 50% when treated up to 1000 mu g/ml for both extracts. After determining the non-toxic effective dose, several antimetastasis assays were carried out and Phyllanthus extracts were shown to effectively reduce invasion, migration, and adhesion of both MCF-7 and A549 cells in a dose-dependent manner, at concentrations ranging from 20-200 mu g/ml for methanolic extracts and 50-500 mu g/ml for aqueous extracts. This was followed by an evaluation of the possible modes of cell death that occurred along with the antimetastatic activity. Phyllanthus was shown to be capable of inducing apoptosis in conjunction with its antimetastastic action, with more than three fold increase of caspases-3 and -7, the presence of DNA-fragmentation and TUNEL-positive cells. The ability of Phyllanthus to exert antimetastatic activities is mostly associated to the presence of polyphenol compounds in its extracts. Conclusions/Significance: The presence of polyphenol compounds in the Phyllanthus plant is critically important in the inhibition of the invasion, migration, and adhesion of cancer cells, along with the involvement of apoptosis induction. Hence, Phyllanthus could be a valuable candidate in the treatment of metastatic cancers.	[Lee, Sau Har; Wang, Seok Mui; Sekaran, Shamala Devi] Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia; [Jaganath, Indu Bala] MARDI, Ctr Biotechnol, Serdang, Malaysia	Universiti Malaya; Institute Penyelidikan Dan Kemajuan Pertanian	Lee, SH (corresponding author), Univ Malaya, Fac Med, Dept Med Microbiol, Kuala Lumpur, Malaysia.	shamalamy@yahoo.com	Sekaran, Shamala Devi/B-8482-2008; Lee, Sau Har/L-2230-2013; Devi, Shamala Devi/B-9735-2010; wang, seok mui/C-3205-2011; Wang, Seok Mui/X-5856-2019	Sekaran, Shamala Devi/0000-0002-0478-0425; Devi, Shamala Devi/0000-0002-0478-0425; Wang, Seok Mui/0000-0002-3631-6504; , Sau Har/0000-0002-9803-8677; Jaganath, Indu/0000-0002-3272-9598	Malaysian Agriculture and Research Development Institute [53-02-03-1002]; UM [PS180/2010A]	Malaysian Agriculture and Research Development Institute; UM	This study was supported by the Malaysian Agriculture and Research Development Institute Grant (53-02-03-1002; www.mardi.gov.my) and the Postgraduate Research Fund, UM (PS180/2010A; www.um.edu.my). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barros ME, 2003, UROL RES, V30, P374, DOI 10.1007/s00240-002-0285-y; Budzinski JW, 2000, PHYTOMEDICINE, V7, P273, DOI 10.1016/S0944-7113(00)80044-6; Chen CN, 2004, BIOCHEM PHARMACOL, V67, P53, DOI 10.1016/j.bcp.2003.07.020; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Gopalakrishnan A, 2008, FOOD CHEM TOXICOL, V46, P1257, DOI 10.1016/j.fct.2007.09.082; Ha KT, 2004, VASC PHARMACOL, V41, P83, DOI 10.1016/j.vph.2004.05.003; Harikumar KB, 2009, INTEGR CANCER THER, V8, P190, DOI 10.1177/1534735408330713; Ho HH, 2010, FOOD CHEM TOXICOL, V48, P2508, DOI 10.1016/j.fct.2010.06.024; Issa AY, 2006, J FOOD COMPOS ANAL, V19, P405, DOI 10.1016/j.jfca.2006.02.009; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jin UH, 2005, LIFE SCI, V77, P2760, DOI 10.1016/j.lfs.2005.02.028; Kim SC, 2010, FOOD CHEM TOXICOL, V48, P1478, DOI 10.1016/j.fct.2010.03.014; Lee JC, 2008, MOL NUTR FOOD RES, V52, P655, DOI 10.1002/mnfr.200700381; Lee M, 2010, INT J RADIAT ONCOL, V76, P1528, DOI 10.1016/j.ijrobp.2009.11.022; Lee YC, 2010, EUR J PHARMACOL, V632, P23, DOI 10.1016/j.ejphar.2010.01.009; Lin J, 2003, WORLD J GASTROENTERO, V9, P670, DOI 10.3748/wjg.v9.i4.670; Lin SY, 2008, FOOD CHEM TOXICOL, V46, P2485, DOI 10.1016/j.fct.2008.04.007; Lu Y, 2010, EUR J PHARMACOL, V641, P102, DOI 10.1016/j.ejphar.2010.05.043; Mollah ML, 2009, ONCOL RES, V18, P259, DOI 10.3727/096504009X12596189659321; Montague R, 2004, EUR UROL, V46, P389, DOI 10.1016/j.eururo.2004.04.022; Naik A D, 2003, Indian J Med Sci, V57, P387; PARANJAPE P, 2001, INDIAN MED PLANTS FO; Pinmai K, 2008, WORLD J GASTROENTERO, V14, P1491, DOI 10.3748/wjg.14.1491; Pojarova M, 2007, BIOORGAN MED CHEM, V15, P7368, DOI 10.1016/j.bmc.2007.07.046; Puente XS, 2003, NAT REV GENET, V4, P544, DOI 10.1038/nrg1111; Qiu XB, 1998, FREE RADICAL BIO MED, V24, P848, DOI 10.1016/S0891-5849(97)00368-7; Rajkapoor B, 2007, BIOSCI BIOTECH BIOCH, V71, P2177, DOI 10.1271/bbb.70149; Rendon BE, 2007, J BIOL CHEM, V282, P29910, DOI 10.1074/jbc.M704898200; Russo GL, 2007, BIOCHEM PHARMACOL, V74, P533, DOI 10.1016/j.bcp.2007.02.014; Sabir SM, 2008, FOOD CHEM, V111, P845, DOI 10.1016/j.foodchem.2008.04.060; SALVATORE DB, 2004, MOL CANCER THER, V9, P1079; Song TY, 2008, J ETHNOPHARMACOL, V115, P50, DOI 10.1016/j.jep.2007.09.001; Sun J, 2006, CANCER LETT, V241, P124, DOI 10.1016/j.canlet.2005.10.027; TANG YQ, 2010, PLOS ONE, V9, P1; Tanimura S, 2005, BIOCHEM BIOPH RES CO, V330, P1306, DOI 10.1016/j.bbrc.2005.03.116; VASILIS A, 2008, BREAST CANCER RES, V3, P1; Vinatier D, 1996, EUR J OBSTET GYN R B, V67, P85, DOI 10.1016/0301-2115(96)02467-0; WANG YY, 2009, BMC CANCER, V174, P1; Woo HD, 2008, TOXICOL IN VITRO, V22, P1840, DOI 10.1016/j.tiv.2008.09.019; Wu CC, 2006, MUTAT RES-FUND MOL M, V601, P71, DOI 10.1016/j.mrfmmm.2006.06.015; Wu SJ, 2009, FOOD CHEM TOXICOL, V47, P1132, DOI 10.1016/j.fct.2009.01.044; Xia SH, 2005, CARCINOGENESIS, V26, P779, DOI 10.1093/carcin/bgi019; Xie KP, 2003, FREE RADICAL BIO MED, V34, P969, DOI 10.1016/S0891-5849(02)01364-3; Yang HL, 2006, CANCER LETT, V231, P215, DOI 10.1016/j.canlet.2005.02.004; Yang SF, 2008, ARCH ORAL BIOL, V53, P287, DOI 10.1016/j.archoralbio.2007.09.001; Yang YW, 2004, VACCINE, V22, P2316, DOI 10.1016/j.vaccine.2003.10.036	46	52	55	1	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 16	2011	6	6							e20994	10.1371/journal.pone.0020994	http://dx.doi.org/10.1371/journal.pone.0020994			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778UW	21698198	Green Submitted, Green Published, gold			2023-01-03	WOS:000291734100042
J	Kistler, AD; Siwy, J; Breunig, F; Jeevaratnam, P; Scherl, A; Mullen, W; Warnock, DG; Wanner, C; Hughes, DA; Mischak, H; Wuthrich, RP; Serra, AL				Kistler, Andreas D.; Siwy, Justyna; Breunig, Frank; Jeevaratnam, Praveen; Scherl, Alexander; Mullen, William; Warnock, David G.; Wanner, Christoph; Hughes, Derralynn A.; Mischak, Harald; Wuethrich, Rudolf P.; Serra, Andreas L.			A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; ONSET HYPERTROPHIC CARDIOMYOPATHY; MASS-SPECTROMETRY; ALPHA-GALACTOSIDASE; HEMODIALYSIS-PATIENTS; CLINICAL PROTEOMICS; YOUNG-PATIENTS; DISCOVERY; GLOBOTRIAOSYLCERAMIDE; PREVALENCE	Female patients affected by Fabry disease, an X-linked lysosomal storage disorder, exhibit a wide spectrum of symptoms, which renders diagnosis, and treatment decisions challenging. No diagnostic test, other than sequencing of the alpha-galactosidase A gene, is available and no biomarker has been proven useful to screen for the disease, predict disease course and monitor response to enzyme replacement therapy. Here, we used urine proteomic analysis based on capillary electrophoresis coupled to mass spectrometry and identified a biomarker profile in adult female Fabry patients. Urine samples were taken from 35 treatment-naive female Fabry patients and were compared to 89 age-matched healthy controls. We found a diagnostic biomarker pattern that exhibited 88.2% sensitivity and 97.8% specificity when tested in an independent validation cohort consisting of 17 treatment-naive Fabry patients and 45 controls. The model remained highly specific when applied to additional control patients with a variety of other renal, metabolic and cardiovascular diseases. Several of the 64 identified diagnostic biomarkers showed correlations with measures of disease severity. Notably, most biomarkers responded to enzyme replacement therapy, and 8 of 11 treated patients scored negative for Fabry disease in the diagnostic model. In conclusion, we defined a urinary biomarker model that seems to be of diagnostic use for Fabry disease in female patients and may be used to monitor response to enzyme replacement therapy.	[Kistler, Andreas D.; Wuethrich, Rudolf P.; Serra, Andreas L.] Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland; [Kistler, Andreas D.] Univ Miami, Miller Sch Med, Div Nephrol & Hypertens, Miami, FL 33136 USA; [Siwy, Justyna; Mischak, Harald] Mosaiques Diagnost & Therapeut AG, Hannover, Germany; [Breunig, Frank; Wanner, Christoph] Univ Hosp, Div Nephrol, Wurzburg, Germany; [Jeevaratnam, Praveen; Hughes, Derralynn A.] UCL, Sch Med, Dept Haematol, London W1N 8AA, England; [Scherl, Alexander] Univ Geneva, Fac Med, Prote Core Facil, Geneva, Switzerland; [Mullen, William] Univ Glasgow, Sch Life Sci, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Warnock, David G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Mischak, Harald] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland	University of Zurich; University Zurich Hospital; University of Miami; University of Wurzburg; University of London; University College London; UCL Medical School; University of Geneva; University of Glasgow; University of Alabama System; University of Alabama Birmingham; University of Glasgow	Kistler, AD (corresponding author), Univ Zurich Hosp, Div Nephrol, CH-8091 Zurich, Switzerland.	akistler@med.miami.edu	Mullen, William/GWC-8078-2022; Scherl, Alexander/B-8910-2012; Mischak, Harald/E-8685-2011; Hughes, Derralynn/J-8012-2013	Hughes, Derralynn/0000-0003-4531-9173; Kistler, Andreas/0000-0002-4114-9560; Mullen, William/0000-0002-5685-1563; Siwy, Justyna/0000-0003-1407-2534; Mischak, Harald/0000-0003-0323-0306	Genzyme; Shire; Amgen; European Community [HEALTH-F2-2009-241544]; Genzyme Inc.; Shire HGT; Amicus therapeutics; Genzyme Corporation	Genzyme(Sanofi-AventisGenzyme Corporation); Shire; Amgen(Amgen); European Community(European Commission); Genzyme Inc.(Sanofi-AventisGenzyme Corporation); Shire HGT; Amicus therapeutics; Genzyme Corporation(Sanofi-AventisGenzyme Corporation)	Funding for this study was supported by unrestricted research grants provided by Genzyme (to ADK, RPW and ALS), Shire (to ADK, RPW and ALS) and Amgen (to RPW) and a European Community's 7th Framework Programme grant (to HM; grant agreement HEALTH-F2-2009-241544 (SysKID)). The funders had no role in study design, data collection and analysis, or preparation of the manuscript.; ADK has received travel grants from Shire HGT and honoraria from Genzyme Inc. HM is the founder and co-owner of Mosaiques Diagnostics, who developed the CE-MS technology. JS is an employee of Mosaiques Diagnostics. DAH has received research support, travel grants and honoraria for meetings and advisory boards from Genzyme Inc, Shire HGT and Amicus therapeutics. DGW is a consultant for Genzyme Corporation on Fabry disease, and has received research support from Genzyme Corporation and Amicus therapeutics. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.	Andrade J, 2008, CLIN J AM SOC NEPHRO, V3, P139, DOI 10.2215/CJN.02490607; Auray-Blais C, 2010, CLIN CHIM ACTA, V411, P1906, DOI 10.1016/j.cca.2010.07.038; Baptista MV, 2010, STROKE, V41, P431, DOI 10.1161/STROKEAHA.109.570499; Brouns R, 2010, STROKE, V41, P863, DOI 10.1161/STROKEAHA.110.579409; Chimenti C, 2004, CIRCULATION, V110, P1047, DOI 10.1161/01.CIR.0000139847.74101.03; Coon JJ, 2008, PROTEOM CLIN APPL, V2, P964, DOI 10.1002/prca.200800024; Decramer S, 2006, NAT MED, V12, P398, DOI 10.1038/nm1384; DeLeo J. M., 1993, RECEIVER OPERATING C, P318; Delles C, 2010, J HYPERTENS, V28, P2316, DOI 10.1097/HJH.0b013e32833d81b7; Desnick RJ, 2003, ANN INTERN MED, V138, P338, DOI 10.7326/0003-4819-138-4-200302180-00014; Dobyns WB, 2004, AM J MED GENET A, V129A, P136, DOI 10.1002/ajmg.20004.a.30123; El Dib R.P., 2010, COCHRANE DB SYST REV, V5; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Gaspar P, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-19; Good DM, 2010, MOL CELL PROTEOMICS, V9, P2424, DOI 10.1074/mcp.M110.001917; Guffon N, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.4.e38; Haubitz M, 2009, MOL CELL PROTEOMICS, V8, P2296, DOI 10.1074/mcp.M800529-MCP200; Jantos-Siwy J, 2009, J PROTEOME RES, V8, P268, DOI 10.1021/pr800401m; Kistler AD, 2009, KIDNEY INT, V76, P89, DOI 10.1038/ki.2009.93; Kitagawa T, 2005, MOL GENET METAB, V85, P196, DOI 10.1016/j.ymgme.2005.01.007; Kotanko P, 2004, J AM SOC NEPHROL, V15, P1323, DOI 10.1097/01.ASN.0000124671.61963.1E; Linthorst GE, 2005, CLIN CHIM ACTA, V353, P201, DOI 10.1016/j.cccn.2004.10.019; Mehta A, 2004, EUR J CLIN INVEST, V34, P236, DOI 10.1111/j.1365-2362.2004.01309.x; Merta M, 2007, NEPHROL DIAL TRANSPL, V22, P179, DOI 10.1093/ndt/gfl528; Metzger J, 2009, CRIT REV CL LAB SCI, V46, P129, DOI 10.1080/10408360902805261; Mischak H, 2007, PROTEOM CLIN APPL, V1, P148, DOI 10.1002/prca.200600771; Mischak H, 2009, MASS SPECTROM REV, V28, P703, DOI 10.1002/mas.20205; Moore DF, 2007, P NATL ACAD SCI USA, V104, P2873, DOI 10.1073/pnas.0611315104; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; Neuhoff NV, 2004, RAPID COMMUN MASS SP, V18, P149, DOI 10.1002/rcm.1294; PASCHKE E, 2010, AM J KIDNEY DIS; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Rolfs A, 2005, LANCET, V366, P1794, DOI 10.1016/S0140-6736(05)67635-0; Rossing K, 2008, J AM SOC NEPHROL, V19, P1283, DOI 10.1681/ASN.2007091025; Rozenfeld PA, 2009, CLIN CHIM ACTA, V403, P194, DOI 10.1016/j.cca.2009.02.016; Sachdev B, 2002, CIRCULATION, V105, P1407, DOI 10.1161/01.CIR.0000012626.81324.38; Schiffer E, 2009, CLIN CANCER RES, V15, P4935, DOI 10.1158/1078-0432.CCR-09-0226; Schiffmann R, 2001, JAMA-J AM MED ASSOC, V285, P2743, DOI 10.1001/jama.285.21.2743; Tanaka M, 2005, CLIN NEPHROL, V64, P281; Theodorescu D, 2006, LANCET ONCOL, V7, P230, DOI 10.1016/S1470-2045(06)70584-8; Theodorescu D, 2005, ELECTROPHORESIS, V26, P2797, DOI 10.1002/elps.200400208; Thongboonkerd V, 2007, J PROTEOME RES, V6, P3881, DOI 10.1021/pr070328s; Vojtova L, 2010, RENAL FAILURE, V32, P1202, DOI 10.3109/0886022X.2010.516859; Vylet'al P, 2008, J INHERIT METAB DIS, V31, P508, DOI 10.1007/s10545-008-0900-3; Whitfield PD, 2005, J INHERIT METAB DIS, V28, P21, DOI 10.1007/s10545-005-4415-x; Whybra C, 2004, CLIN GENET, V65, P299, DOI 10.1111/j.1399-0004.2004.00219.x; Wilcox WR, 2008, MOL GENET METAB, V93, P112, DOI 10.1016/j.ymgme.2007.09.013; Wittke S, 2005, ELECTROPHORESIS, V26, P1476, DOI 10.1002/elps.200410140; Young E, 2005, ACTA PAEDIATR, V94, P51, DOI 10.1080/08035320510028111; Zurbig P, 2006, ELECTROPHORESIS, V27, P2111, DOI 10.1002/elps.200500827	50	19	19	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2011	6	6							e20534	10.1371/journal.pone.0020534	http://dx.doi.org/10.1371/journal.pone.0020534			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778TS	21698285	gold, Green Accepted, Green Published, Green Submitted			2023-01-03	WOS:000291730000013
J	Iwai, Y; Murakami, K; Gomi, Y; Hashimoto, T; Asakawa, Y; Okuno, Y; Ishikawa, T; Hatakeyama, D; Echigo, N; Kuzuhara, T				Iwai, Yuma; Murakami, Kouki; Gomi, Yasuyuki; Hashimoto, Toshihiro; Asakawa, Yoshinori; Okuno, Yoshinobu; Ishikawa, Toyokazu; Hatakeyama, Dai; Echigo, Noriko; Kuzuhara, Takashi			Anti-Influenza Activity of Marchantins, Macrocyclic Bisbibenzyls Contained in Liverworts	PLOS ONE			English	Article							INFLUENZA-A VIRUSES; RNA-POLYMERASE; CHEMICAL-CONSTITUENTS; PA SUBUNIT; ENDONUCLEASE; GENES; CHEMOSYSTEMATICS; BIS(BIBENZYLS); OSELTAMIVIR; BRYOPHYTES	The H1N1 influenza A virus of swine-origin caused pandemics throughout the world in 2009 and the highly pathogenic H5N1 avian influenza virus has also caused epidemics in Southeast Asia in recent years. The threat of influenza A thus remains a serious global health issue and novel drugs that target these viruses are highly desirable. Influenza A possesses an endonuclease within its RNA polymerase which comprises PA, PB1 and PB2 subunits. To identify potential new anti-influenza compounds in our current study, we screened 33 different types of phytochemicals using a PA endonuclease inhibition assay in vitro and an anti-influenza A virus assay. The marchantins are macrocyclic bisbibenzyls found in liverworts, and plagiochin A and perrottetin F are marchantin-related phytochemicals. We found from our screen that marchantin A, B, E, plagiochin A and perrottetin F inhibit influenza PA endonuclease activity in vitro. These compounds have a 3,4-dihydroxyphenethyl group in common, indicating the importance of this moiety for the inhibition of PA endonuclease. Docking simulations of marchantin E with PA endonuclease suggest a putative "fitting and chelating model" as the mechanism underlying PA endonuclease inhibition. The docking amino acids are well conserved between influenza A and B. In a cultured cell system, marchantin E was further found to inhibit the growth of both H3N2 and H1N1 influenza A viruses, and marchantin A, E and perrotein F showed inhibitory properties towards the growth of influenza B. These marchantins also decreased the viral infectivity titer, with marchantin E showing the strongest activity in this assay. We additionally identified a chemical group that is conserved among different anti-influenza chemicals including marchantins, green tea catechins and dihydroxy phenethylphenylphthalimides. Our present results indicate that marchantins are candidate anti-influenza drugs and demonstrate the utility of the PA endonuclease assay in the screening of phytochemicals for anti-influenza characteristics.	[Iwai, Yuma; Hatakeyama, Dai; Echigo, Noriko; Kuzuhara, Takashi] Tokushima Bunri Univ, Fac Pharmaceut Sci, Biochem Lab, Tokushima 770, Japan; [Murakami, Kouki; Gomi, Yasuyuki; Okuno, Yoshinobu; Ishikawa, Toyokazu] Osaka Univ, Res Fdn Microbial Dis, Kanonji Inst, Res Grp,Res & Prod Technol Div, Kagawa, Japan; [Hashimoto, Toshihiro] Tokushima Bunri Univ, Fac Pharmaceut Sci, Lab Pharmacognosy, Tokushima 770, Japan; [Asakawa, Yoshinori] Tokushima Bunri Univ, Fac Pharmaceut Sci, Lab Pharmacognosy, Tokushima 770, Japan	Tokushima Bunri University; Osaka University; Tokushima Bunri University; Tokushima Bunri University	Iwai, Y (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Biochem Lab, Yamashiro Cho, Tokushima 770, Japan.	kuzuhara@ph.bunri-u.ac.jp	ハタケヤマ, ダイ/HHS-5095-2022	ハタケヤマ, ダイ/0000-0001-6047-7124; Kuzuhara, Takashi/0000-0003-0565-6060	Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan Society for the Promotion of Science (JSPS); Tokushima Bunri University	Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Tokushima Bunri University	The influenza virus (A/PR/8/34) RNA polymerase PA plasmid, pBMSA-PA, was provided by the DNA Bank, RIKEN BioResource Center (Tsukuba, Japan; originally deposited by Dr. Susumu Nakada) with the support of National Bio-Resources Project of the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT).; This work was supported in part by a Grant-in-Aid from the Japan Society for the Promotion of Science (JSPS), and funding from Tokushima Bunri University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Asakawa Y, 2008, CURR PHARM DESIGN, V14, P3067, DOI 10.2174/138161208786404272; Asakawa Y, 2004, PHYTOCHEMISTRY, V65, P623, DOI 10.1016/j.phytochem.2004.01.003; Asakawa Y., 1999, Phytochemicals in human health protection, nutrition, and plant defense., P319; ASAKAWA Y, 1982, PROG CH ORG NAT PROD, V42, P1; Asakawa Y., 1990, BRYOPHYTES THEIR CHE, P369; Asakawa Y, 1995, PROG CH ORG NAT PROD, V65, P1; Asakawa Y, 2009, HETEROCYCLES, V77, P99, DOI 10.3987/REV-08-SR(F)3; BUCHANAN MS, 1995, PHYTOCHEMISTRY, V40, P1251, DOI 10.1016/0031-9422(95)00467-L; *CHEM COMP GROUP C, 2004, MOL OP ENV MOE; Collins PJ, 2008, NATURE, V453, P1258, DOI 10.1038/nature06956; De Clercq E, 2006, NAT REV DRUG DISCOV, V5, P1015, DOI 10.1038/nrd2175; Dias A, 2009, NATURE, V458, P914, DOI 10.1038/nature07745; Goto J, 2008, J CHEM INF MODEL, V48, P583, DOI 10.1021/ci700352q; Harinantenaina L, 2005, J NAT PROD, V68, P1779, DOI 10.1021/np0502589; HASHIMOTO T, 1994, CHEM PHARM BULL, V42, P1376; Hashimoto T, 2003, PHYTOMEDICINE, V10, P309, DOI 10.1078/094471103322004802; HASHIMOTO T, 1994, CHEM PHARM BULL, V42, P2397; HASHIMOTO T, 1994, TETRAHEDRON LETT, V35, P2559, DOI 10.1016/S0040-4039(00)77170-X; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Hayden FG, 1999, NEW ENGL J MED, V341, P1336, DOI 10.1056/NEJM199910283411802; Honda A, 1997, BIOL CHEM, V378, P483; Honda A, 2002, P NATL ACAD SCI USA, V99, P13166, DOI 10.1073/pnas.152456799; Horimoto T, 2005, NAT REV MICROBIOL, V3, P591, DOI 10.1038/nrmicro1208; Itoh Y, 2009, NATURE, V460, P1021, DOI 10.1038/nature08260; Iwai Y, 2010, BIOORGAN MED CHEM, V18, P5379, DOI 10.1016/j.bmc.2010.05.035; Izumi Y, 2007, NEUROSCI LETT, V426, P54, DOI 10.1016/j.neulet.2007.08.054; Kuzuhara T., 2009, PLOS CURR INFLUENZA; Kuzuhara T, 2009, J BIOL CHEM, V284, P6855, DOI 10.1074/jbc.C800224200; MAHY BWJ, VIROLOGY METHODS MAN, P35; Morita H, 2009, BIOORG MED CHEM LETT, V19, P493, DOI 10.1016/j.bmcl.2008.11.036; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Morse SS, 2007, NAT MED, V13, P681, DOI 10.1038/nm1597; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NAKAMURA Y, 1991, J BIOCHEM-TOKYO, V110, P395, DOI 10.1093/oxfordjournals.jbchem.a123592; Neumann G, 2009, NATURE, V459, P931, DOI 10.1038/nature08157; OKUNO Y, 1990, J CLIN MICROBIOL, V28, P1308, DOI 10.1128/JCM.28.6.1308-1313.1990; Reece PA, 2007, J MED VIROL, V79, P1577, DOI 10.1002/jmv.20951; Song JM, 2005, ANTIVIR RES, V68, P66, DOI 10.1016/j.antiviral.2005.06.010; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Suzuki T, 2008, J PHARMACOL SCI, V107, P285, DOI 10.1254/jphs.08006FP; TAIRA Z, 1994, CHEM PHARM BULL, V42, P52; Taub M, 1979, Methods Enzymol, V58, P552; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; THOMPSON, 1997, NUCLEIC ACIDS RES, V24, P4876, DOI DOI 10.1093/NAR/25.24.4876; Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641; Yuan PW, 2009, NATURE, V458, P909, DOI 10.1038/nature07720; Zhao C, 2009, J VIROL, V83, P9024, DOI 10.1128/JVI.00911-09	47	66	73	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2011	6	5							e19825	10.1371/journal.pone.0019825	http://dx.doi.org/10.1371/journal.pone.0019825			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766OI	21625478	gold, Green Published, Green Submitted			2023-01-03	WOS:000290793400014
J	Huang, TT; Liu, FG; Wei, CF; Lu, CC; Chen, CC; Lin, HC; Ojcius, DM; Lai, HC				Huang, Tsung-Teng; Liu, Fu-Guo; Wei, Chia-Fong; Lu, Chia-Chen; Chen, Chang-Chieh; Lin, Hung-Chi; Ojcius, David M.; Lai, Hsin-Chih			Activation of Multiple Apoptotic Pathways in Human Nasopharyngeal Carcinoma Cells by the Prenylated Isoflavone, Osajin	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; MACLURA-POMIFERA; CANCER; DEATH; BCL-2; TUMOR; FLAVONOIDS; INDUCTION; LINES; BAX	Osajin is a prenylated isoflavone showing antitumor activity in different tumor cell lines. The underlying mechanism of osajin-induced cancer cell death is not clearly understood. In the present study, the mechanisms of osajin-induced cell death of human nasopharyngeal carcinoma (NPC) cells were explored. Osajin was found to significantly induce apoptosis of NPC cells in a dose-and time-dependent manner. Multiple molecular effects were observed during osajin treatment including a significant loss of mitochondrial transmembrane potential, release of cytochrome c into the cytosol, enhanced expression of Fas ligand (FasL), suppression of glucose-regulated protein 78 kDa (GRP78), and activation of caspases-9, -8, -4 and -3. In addition, up-regulation of proapoptotic Bax protein and down-regulation of antiapoptotic Bcl-2 protein were also observed. Taken together, osajin induces apoptosis in human NPC cells through multiple apoptotic pathways, including the extrinsic death receptor pathway, and intrinsic pathways relying on mitochondria and endoplasmic reticulum stress. Thus, osajin could be developed as a new effective and chemopreventive compound for human NPC.	[Huang, Tsung-Teng; Liu, Fu-Guo] Natl Cent Univ, Dept Life Sci, Tao Yuan, Taiwan; [Wei, Chia-Fong; Chen, Chang-Chieh; Lin, Hung-Chi; Lai, Hsin-Chih] Chang Gung Univ, Dept Med Biotechnol & Lab Sci, Tao Yuan, Taiwan; [Lu, Chia-Chen] Fu Jen Catholic Univ, Dept Resp Therapy, Taipei, Taiwan; [Ojcius, David M.] Univ Calif Merced, Sch Nat Sci, Merced, CA USA; [Ojcius, David M.] Univ Calif Merced, Hlth Sci Res Inst, Merced, CA USA; [Ojcius, David M.; Lai, Hsin-Chih] Chang Gung Univ, Ctr Mol & Clin Immunol, Tao Yuan, Taiwan	National Central University; Chang Gung University; Fu Jen Catholic University; University of California System; University of California Merced; University of California System; University of California Merced; Chang Gung University	Huang, TT (corresponding author), Natl Cent Univ, Dept Life Sci, Tao Yuan, Taiwan.	liur@cc.ncu.edu.tw; dojcius@ucmerced.edu; hclai@mail.cgu.edu.tw	Ojcius, David/ABE-6557-2020	Ojcius, David/0000-0003-1461-4495; LAI, HSIN-CHIH/0000-0002-0605-5040	National Science Council [NSC96-2628-B-033-MY3]; Chang Gung Memorial Hospital [CMRPD160273]	National Science Council(Ministry of Science and Technology, Taiwan); Chang Gung Memorial Hospital(Chang Gung Memorial Hospital)	This work was supported by grants from the National Science Council (NSC96-2628-B-033-MY3) and Chang Gung Memorial Hospital (CMRPD160273). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Aggarwal BB, 2006, BIOCHEM PHARMACOL, V71, P1397, DOI 10.1016/j.bcp.2006.02.009; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Bellosillo B, 2002, BLOOD, V100, P1810, DOI 10.1182/blood-2001-12-0327; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CHANG YS, 1989, CANCER RES, V49, P6752; Chen GG, 2002, CLIN EXP METASTAS, V19, P457, DOI 10.1023/A:1016336724463; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Erkal HS, 2001, RADIOTHER ONCOL, V61, P247, DOI 10.1016/S0167-8140(01)00448-0; Fadeel B, 1997, INT IMMUNOL, V9, P201, DOI 10.1093/intimm/9.2.201; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fischer H, 2002, BIOCHEM BIOPH RES CO, V293, P722, DOI 10.1016/S0006-291X(02)00289-9; Florian Tomas, 2006, Biomedical Papers (Olomouc), V150, P93; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Havsteen BH, 2002, PHARMACOL THERAPEUT, V96, P67, DOI 10.1016/S0163-7258(02)00298-X; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawaii S, 1999, BIOSCI BIOTECH BIOCH, V63, P896, DOI 10.1271/bbb.63.896; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Khan N, 2007, CARCINOGENESIS, V28, P233, DOI 10.1093/carcin/bgl243; Kim SJ, 2006, HUM MOL GENET, V15, P1826, DOI 10.1093/hmg/ddl105; Konopleva M, 2002, LEUKEMIA, V16, P1713, DOI 10.1038/sj.leu.2402608; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Licitra L, 2003, CRIT REV ONCOL HEMAT, V45, P199, DOI 10.1016/S1040-8428(01)00210-4; LIN CT, 1990, LAB INVEST, V62, P713; LIN CT, 1993, LAB INVEST, V68, P716; Lo KW, 2004, CANCER CELL, V5, P423, DOI 10.1016/S1535-6108(04)00119-9; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; METHA U, 2002, GEN PHYSL BIOPHYS, V21, P15; Michels G, 2005, TOXICOLOGY, V206, P337, DOI 10.1016/j.tox.2004.07.022; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nishino H, 2004, BIOFACTORS, V22, P57, DOI 10.1002/biof.5520220110; O'Sullivan B, 2007, INT J RADIAT ONCOL, V69, pS118, DOI 10.1016/j.ijrobp.2007.04.085; Raff M, 1998, NATURE, V396, P119, DOI 10.1038/24055; Rao RV, 2004, CELL DEATH DIFFER, V11, P372, DOI 10.1038/sj.cdd.4401378; Roy S, 2000, J EXP MED, V192, pF21, DOI 10.1084/jem.192.8.F21; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Son IH, 2007, BIOORG MED CHEM LETT, V17, P4753, DOI 10.1016/j.bmcl.2007.06.060; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Tombal B, 2000, PROSTATE, V43, P303; Tsao R, 2003, J AGR FOOD CHEM, V51, P6445, DOI 10.1021/jf0342369; Van Hoorn DEC, 2002, EUR J PHARMACOL, V451, P111, DOI 10.1016/S0014-2999(02)02192-1; Vesela D, 2004, FITOTERAPIA, V75, P209, DOI 10.1016/j.fitote.2003.12.005; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhang ZJ, 2006, HUM MOL GENET, V15, P337, DOI 10.1093/hmg/ddi451	52	25	26	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2011	6	4							e18308	10.1371/journal.pone.0018308	http://dx.doi.org/10.1371/journal.pone.0018308			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	748QE	21532751	Green Published, gold, Green Submitted			2023-01-03	WOS:000289404700010
J	Sare, J				Sare, Jeremy			Medicine and the Media How the media helped ban mephedrone	BRITISH MEDICAL JOURNAL			English	Editorial Material												jeremysare@btinternet.com							0	4	4	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 24	2011	342								d1138	10.1136/bmj.d1138	http://dx.doi.org/10.1136/bmj.d1138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729BE	21349891				2023-01-03	WOS:000287920900004
J	Peinemann, F; Kroger, N; Bartel, C; Grouven, U; Pittler, M; Erttmann, R; Kulig, M				Peinemann, Frank; Kroeger, Nicolaus; Bartel, Carmen; Grouven, Ulrich; Pittler, Max; Erttmann, Rudolf; Kulig, Michael			High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation for Metastatic Rhabdomyosarcoma-A Systematic Review	PLOS ONE			English	Review							BONE-MARROW-TRANSPLANTATION; SOFT-TISSUE SARCOMA; RISK SOLID TUMORS; SMALL ROUND-CELL; INTENSIVE CHEMOTHERAPY; ALVEOLAR RHABDOMYOSARCOMA; MULTIAGENT CHEMOTHERAPY; COMPLETE REMISSION; PEDIATRIC BONE; EWINGS-SARCOMA	Introduction: Patients with metastatic rhabdomyosarcoma (RMS) have a poor prognosis. The aim of this systematic review is to investigate whether high-dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (HSCT) in patients with metastatic RMS has additional benefit or harm compared to standard chemotherapy. Methods: Systematic literature searches were performed in MEDLINE, EMBASE, and The Cochrane Library. All databases were searched from inception to February 2010. PubMed was searched in June 2010 for a last update. In addition to randomized and non-randomized controlled trials, case series and case reports were included to complement results from scant data. The primary outcome was overall survival. A meta-analysis was performed using the hazard ratio as primary effect measure, which was estimated from Cox proportional hazard models or from summary statistics of Kaplan Meier product-limit estimations. Results: A total of 40 studies with 287 transplant patients with metastatic RMS (age range 0 to 32 years) were included in the assessment. We identified 3 non-randomized controlled trials. The 3-year overall survival ranged from 22% to 53% in the transplant groups vs. 18% to 55% in the control groups. Meta-analysis on overall survival in controlled trials showed no difference between treatments. Result of meta-analysis of pooled individual survival data of case series and case reports, and results from uncontrolled studies with aggregate data were in the range of those from controlled data. The risk of bias was high in all studies due to methodological flaws. Conclusions: HDCT followed by autologous HSCT in patients with RMS remains an experimental treatment. At present, it does not appear justifiable to use this treatment except in appropriately designed controlled trials.	[Peinemann, Frank; Bartel, Carmen; Grouven, Ulrich; Kulig, Michael] Inst Qual & Efficiency Hlth Care IQWiG, Cologne, Germany; [Kroeger, Nicolaus] Univ Hosp Hamburg Eppendorf, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany; [Grouven, Ulrich] Hannover Med Sch, D-3000 Hannover, Germany; [Pittler, Max] Univ Freiburg, German Cochrane Ctr, Freiburg, Germany; [Erttmann, Rudolf] Univ Hosp Hamburg Eppendorf, Dept Pediat Hematol & Oncol, Hamburg, Germany; [Kulig, Michael] German Hlth Care Syst G BA, Fed Joint Comm, Berlin, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf; Hannover Medical School; University of Freiburg; University of Hamburg; University Medical Center Hamburg-Eppendorf	Peinemann, F (corresponding author), Inst Qual & Efficiency Hlth Care IQWiG, Cologne, Germany.	frank.peinemann@iqwig.de	Peinemann, Frank/H-2800-2019	Peinemann, Frank/0000-0002-4727-1313				ADMIRAAL R, 2007, COCHRANE DB SYST REV; BADER JL, 1989, RADIOTHER ONCOL, V16, P189, DOI 10.1016/0167-8140(89)90019-4; BAGNULO S, 1985, EUR PAEDIATR HAEMAT, V2, P129, DOI 10.3109/08880018509141221; Banna Giuseppe Luigi, 2007, Curr Stem Cell Res Ther, V2, P65; Bernbeck B, 2007, KLIN PADIATR, V219, P318, DOI 10.1055/s-2007-985896; BIEN E, 2007, CHILDS NERVOUS SYS, P1147; Bisogno G, 2009, EUR J CANCER, V45, P3035, DOI 10.1016/j.ejca.2009.08.019; Blay JY, 2000, J CLIN ONCOL, V18, P3643, DOI 10.1200/JCO.2000.18.21.3643; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Carli M, 2004, J CLIN ONCOL, V22, P4787, DOI 10.1200/JCO.2004.04.083; Carli M, 1999, J CLIN ONCOL, V17, P2796, DOI 10.1200/JCO.1999.17.9.2796; Carvajal R, 2005, HEMATOL ONCOL CLIN N, V19, P501, DOI 10.1016/j.hoc.2005.03.004; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; CHAN KW, 1991, BONE MARROW TRANSPL, V7, P171; Cochrane Collaboration, 2005, GLOSS TERMS COCHR CO; *CTEP, 2009, COMM TERM CRIT ADV E; Deeks J J, 2003, Health Technol Assess, V7, piii; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUMONTET C, 1992, BONE MARROW TRANSPL, V10, P405; *EBMT, 2010, ONG STUD STWP SOL TU; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ek ETH, 2006, EXPERT REV ANTICANC, V6, P225, DOI 10.1586/14737140.6.2.225; EKERT H, 1984, AUST PAEDIATR J, V20, P195; Elias AD, 1998, SEMIN ONCOL, V25, P19; EMMINGER W, 1991, BONE MARROW TRANSPL, V8, P119; Endo M, 1996, ONCOL REP, V3, P519; Engelhardt M, 2007, J CANCER RES CLIN, V133, P1, DOI 10.1007/s00432-006-0137-1; FEKRAT S, 1993, ARCH OPHTHALMOL-CHIC, V111, P1662, DOI 10.1001/archopht.1993.01090120084026; Fraser CJ, 2006, BONE MARROW TRANSPL, V37, P175, DOI 10.1038/sj.bmt.1705224; Galandi Daniel, 2006, BMC Med Res Methodol, V6, P30, DOI 10.1186/1471-2288-6-30; Goodenough JB, 2001, STRUCT BOND, V98, P1; Gratwohl A, 2007, BONE MARROW TRANSPL, V39, P71, DOI 10.1038/sj.bmt.1705555; GURNEY JG, 1999, NIH PUB, P111; Hale GA, 2005, EXPERT REV ANTICANC, V5, P835, DOI 10.1586/14737140.5.5.835; Hara J, 1998, BONE MARROW TRANSPL, V22, P7, DOI 10.1038/sj.bmt.1701283; Hawkins DS, 2002, CANCER, V95, P1354, DOI 10.1002/cncr.10801; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hosoi H, 2007, INT J CLIN ONCOL, V12, P137, DOI 10.1007/s10147-006-0638-6; Juni P, 2002, INT J EPIDEMIOL, V31, P115, DOI 10.1093/ije/31.1.115; KAIZER H, 1979, EXP HEMATOL, V7, P309; KANABAR DJ, 1995, PEDIATR HEMAT ONCOL, V12, P29, DOI 10.3109/08880019509029525; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kasper B, 2004, BONE MARROW TRANSPL, V34, P37, DOI 10.1038/sj.bmt.1704520; Kasper B, 2010, BONE MARROW TRANSPL, V45, P1234, DOI 10.1038/bmt.2009.333; Kasper B, 2007, ONCOLOGY-BASEL, V73, P58, DOI 10.1159/000120629; KAVAN P, 1997, KLIN ONKOLOGIE, V10, P148; Kirkham JJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c365; Klingebiel T, 2008, PEDIATR BLOOD CANCER, V50, P739, DOI 10.1002/pbc.21494; Korfel A, 2001, BONE MARROW TRANSPL, V28, P787, DOI 10.1038/sj.bmt.1703212; Koscielniak E, 1997, BONE MARROW TRANSPL, V19, P227, DOI 10.1038/sj.bmt.1700628; Kuroiwa Minoru, 2009, J Pediatr Surg, V44, pe31, DOI 10.1016/j.jpedsurg.2008.12.010; Kwan WH, 1996, PEDIATR HEMAT ONCOL, V13, P277, DOI 10.3109/08880019609030828; Kwon SY, 2010, PEDIATR HEMAT ONCOL, V27, P1, DOI 10.3109/14992020903352226; Ladenstein Ruth, 1997, Current Opinion in Pediatrics, V9, P55, DOI 10.1097/00008480-199702000-00013; Lafay-Cousin L, 2000, BONE MARROW TRANSPL, V26, P627, DOI 10.1038/sj.bmt.1702573; Lashkari A, 2009, ANTICANCER RES, V29, P3281; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Lucidarme N, 1998, BONE MARROW TRANSPL, V22, P535, DOI 10.1038/sj.bmt.1701395; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mackall CL, 2001, J PEDIAT HEMATOL ONC, V23, P266, DOI 10.1097/00043426-200106000-00005; Matsubara H, 2003, PEDIATR HEMAT ONCOL, V20, P201, DOI 10.1080/08880010390158829; McDowell HP, 2010, EUR J CANCER, V46, P1588, DOI 10.1016/j.ejca.2010.02.051; Meyers PA, 2004, CURR OPIN ONCOL, V16, P120, DOI 10.1097/00001622-200403000-00006; Michon J, 1999, BEST PRACT RES CL HA, V12, P247, DOI 10.1053/beha.1999.0021; MILLER RW, 1995, CANCER, V75, P395, DOI 10.1002/1097-0142(19950101)75:1+<395::AID-CNCR2820751321>3.0.CO;2-W; MITCHELL PLR, 1994, ARCH DIS CHILD, V70, P237, DOI 10.1136/adc.70.3.237; Moher D, 2003, Health Technol Assess, V7, P1; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MUNOZ LL, 1983, INT J RADIAT ONCOL, V9, P1951, DOI 10.1016/0360-3016(83)90367-X; *NAT LIB MED, 2006, MESH TREE NUMB CHANG; Navid F, 2006, CANCER-AM CANCER SOC, V106, P1846, DOI 10.1002/cncr.21810; *NCI, 2010, CLIN TRIALS PHYS DAT; *NIHR, 2010, UK CLIN RES NETW UKC; Oue T, 2003, J PEDIATR SURG, V38, P130, DOI 10.1053/jpsu.2003.50026; Parham DM, 2006, ARCH PATHOL LAB MED, V130, P1454; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Pedrazzoli P, 2006, ANN ONCOL, V17, P1479, DOI 10.1093/annonc/mdl044; Perentesis JP, 1999, BONE MARROW TRANSPL, V24, P609, DOI 10.1038/sj.bmt.1701950; PINKERTON R, 1986, CLIN HAEMATOL, V15, P187, DOI 10.1016/S0308-2261(86)80011-X; Reichardt P, 2002, CRIT REV ONCOL HEMAT, V41, P157, DOI 10.1016/S1040-8428(01)00153-6; Ritchie DS, 2004, INTERN MED J, V34, P431, DOI 10.1111/j.1444-0903.2004.00630.x; Rossbach HC, 1999, J PEDIAT HEMATOL ONC, V21, P528, DOI 10.1097/00043426-199911000-00015; Rosti G, 2002, CRIT REV ONCOL HEMAT, V41, P129, DOI 10.1016/S1040-8428(01)00150-0; Saikawa Y, 2006, J CLIN ONCOL, V24, P5783, DOI 10.1200/JCO.2006.08.4673; Sakayama K, 2008, ANTICANCER RES, V28, P2361; Sanchez-Garcia I, 2007, BIOESSAYS, V29, P1269, DOI 10.1002/bies.20679; Sanz N, 1997, PEDIATR SURG INT, V12, P200, DOI 10.1007/BF01350002; Schlemmer M, 2006, ONCOLOGY-BASEL, V71, P32, DOI 10.1159/000100447; SEEGER RC, 1991, PEDIATR CLIN N AM, V38, P393; Shaw PJ, 1996, BONE MARROW TRANSPL, V18, P1043; Sobin L, 2009, UICC TNM CLASSIFICAT; Song, 2000, HEALTH TECHNOL ASSES, V4, P1, DOI DOI 10.3310/HTA4100; Stiff PJ, 2010, BIOL BLOOD MARROW TR, V16, P525, DOI 10.1016/j.bbmt.2009.11.020; Suita S, 2005, EUR J PEDIATR SURG, V15, P409, DOI 10.1055/s-2005-872927; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; TYBAERT S, 2007, NLM TECH B, pE6; Verma S, 2008, CANCER-AM CANCER SOC, V112, P1197, DOI 10.1002/cncr.23302; Walterhouse DO, 1999, MED PEDIATR ONCOL, V32, P88, DOI 10.1002/(SICI)1096-911X(199902)32:2<88::AID-MPO3>3.0.CO;2-N; Weigel BJ, 2001, J PEDIAT HEMATOL ONC, V23, P272, DOI 10.1097/00043426-200106000-00007; Williams BA, 2004, J PEDIAT HEMATOL ONC, V26, P243, DOI 10.1097/00043426-200404000-00006; WOODS WG, 1999, CANC RES THERAPY CON, V9, P95; Yamada K, 2007, BONE MARROW TRANSPL, V39, P471, DOI 10.1038/sj.bmt.1705625	103	12	12	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2011	6	2							e17127	10.1371/journal.pone.0017127	http://dx.doi.org/10.1371/journal.pone.0017127			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725PJ	21373200	Green Published, Green Submitted, gold			2023-01-03	WOS:000287657500034
J	Qaseem, A; Humphrey, LL; Chou, R; Snow, V; Shekelle, P				Qaseem, Amir; Humphrey, Linda L.; Chou, Roger; Snow, Vincenza; Shekelle, Paul		Amer Coll Phys	Use of Intensive Insulin Therapy for the Management of Glycemic Control in Hospitalized Patients: A Clinical Practice Guideline From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; GLUCOSE-INSULIN; DIABETES-MELLITUS; CARDIAC-SURGERY; ISCHEMIC-STROKE; HYPERGLYCEMIA; HYPOGLYCEMIA; MORTALITY; INFUSION	Description: The American College of Physicians (ACP) developed this guideline to present the evidence for the link between the use of intensive insulin therapy to achieve different glycemic targets and health outcomes in hospitalized patients with or without diabetes mellitus. Methods: Published literature on this topic was identified by using MEDLINE and the Cochrane Library. Additional articles were obtained from systematic reviews and the reference lists of pertinent studies, reviews, and editorials, as well as by consulting experts; unpublished studies on ClinicalTrials.gov were also identified. The literature search included studies published from 1950 through March 2009. Searches were limited to English-language publications. The primary outcomes of interest were short-term mortality and hypoglycemia. This guideline grades the evidence and recommendations by using the ACP clinical practice guidelines grading system. Recommendation 1: ACP recommends not using intensive insulin therapy to strictly control blood glucose in non-surgical intensive care unit (SICU)/medical intensive care unit (MICU) patients with or without diabetes mellitus (Grade: strong recommendation, moderate-quality evidence). Recommendation 2: ACP recommends not using intensive insulin therapy to normalize blood glucose in SICU/MICU patients with or without diabetes mellitus (Grade: strong recommendation, high-quality evidence). Recommendation 3: ACP recommends a target blood glucose level of 7.8 to 11.1 mmol/L (140 to 200 mg/dL) if insulin therapy is used in SICU/MICU patients (Grade: weak recommendation, moderate-quality evidence).	[Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA; Pfizer, Collegeville, PA USA; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Portland VA Med Ctr, Portland, OR USA; W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA	American College of Physicians; Pfizer; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center	Qaseem, A (corresponding author), Amer Coll Physicians, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	aqaseem@acponline.org		Chou, Roger/0000-0001-9889-8610	ACP operating budget; Agency for Healthcare Research and Quality	ACP operating budget; Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Financial support for the development of this guideline comes exclusively from the ACP operating budget.; Any financial and nonfinancial conflicts of interest of the group members were declared, discussed, and resolved. Dr. Vincenza Snow was an employee of the American College of Physicians at the time of the writing of this guideline. Dr. Snow: Employment: American College of Physicians, Pfizer. Dr. Shekelle: Grants/grants pending (money to institution): Agency for Healthcare Research and Quality; Royalties: UpToDate. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2725.	Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; BARCELLOS DS, 2007, REV BRAS CIR CARDIOV, V22, P275; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bruno A, 2008, STROKE, V39, P384, DOI 10.1161/STROKEAHA.107.493544; Butterworth J, 2005, J THORAC CARDIOV SUR, V130, P1319, DOI 10.1016/j.jtcvs.2005.02.049; Cheung NW, 2006, DIABETES CARE, V29, P765, DOI 10.2337/diacare.29.04.06.dc05-1894; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Datta Swati, 2007, Endocr Pract, V13, P225; de Azevedo JRA, 2007, ARQ NEURO-PSIQUIAT, V65, P733, DOI 10.1590/S0004-282X2007000500001; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Desouza C, 2003, DIABETES CARE, V26, P1485, DOI 10.2337/diacare.26.5.1485; Dickerson Lori M, 2003, Ann Fam Med, V1, P29, DOI 10.1370/afm.2; Farah R, 2007, ISRAEL MED ASSOC J, V9, P140; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Garber AJ, 2006, DIABETES CARE, V29, P1955, DOI 10.2337/dc06-9913; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; Ingels C, 2006, EUR HEART J, V27, P2716, DOI 10.1093/eurheartj/ehi855; Kansagara D, 2008, MANAGEMENT INPATIENT; Kansagara D, 2011, ANN INTERN MED, V154, P268, DOI 10.7326/0003-4819-154-4-201102150-00008; Kirdemir P, 2008, J CARDIOTHOR VASC AN, V22, P383, DOI 10.1053/j.jvca.2007.09.015; Krinsley J, 2007, CHEST, V132, P1, DOI 10.1378/chest.07-0834; Krinsley JS, 2003, MAYO CLIN PROC, V78, P1471, DOI 10.4065/78.12.1471; Lazar HL, 2004, CIRCULATION, V109, P1497, DOI 10.1161/01.CIR.0000121747.71054.79; Levetan CS, 1998, DIABETES CARE, V21, P246, DOI 10.2337/diacare.21.2.246; Li JY, 2006, TEX HEART I J, V33, P445; LINDSTROM T, 1992, DIABETIC MED, V9, P536, DOI 10.1111/j.1464-5491.1992.tb01834.x; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Meijering S, 2006, CRIT CARE, V10, DOI 10.1186/cc3981; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Nazer Lama H, 2007, Endocr Pract, V13, P137; NEEDHAM P, 2008, P NUTR SOC, V67, pE152; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Rasoul S, 2007, INT J CARDIOL, V122, P52, DOI 10.1016/j.ijcard.2006.11.037; Savioli M, 2009, CRIT CARE MED, V37, P424, DOI 10.1097/CCM.0b013e31819542da; Shilo S, 1998, J AM GERIATR SOC, V46, P978, DOI 10.1111/j.1532-5415.1998.tb02752.x; Smith A, 2002, J CARDIOTHOR VASC AN, V16, P413, DOI 10.1053/jcan.2002.125151; Spyer G, 2000, LANCET, V356, P1970, DOI 10.1016/S0140-6736(00)03322-5; Subramaniam B, 2009, ANESTHESIOLOGY, V110, P970, DOI 10.1097/ALN.0b013e3181a1005b; Svensson AM, 2005, EUR HEART J, V26, P1255, DOI 10.1093/eurheartj/ehi230; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; Umpierrez GE, 2007, DIABETES CARE, V30, P2181, DOI 10.2337/dc07-0295; Van den Berghe G, 2006, CRIT CARE MED, V34, P612, DOI 10.1097/01.CCM.0000201408.15502.24; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Van den Berghe G, 2001, J CLIN ENDOCR METAB, V86, P3217, DOI 10.1210/jc.86.7.3217; Van den Berghe G, 2006, DIABETES, V55, P3151, DOI 10.2337/db06-0855; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Walters MR, 2006, CEREBROVASC DIS, V22, P116, DOI 10.1159/000093239; Whitmer RA, 2009, JAMA-J AM MED ASSOC, V301, P1565, DOI 10.1001/jama.2009.460; Wilson M, 2007, DIABETES CARE, V30, P1005, DOI 10.2337/dc06-1964; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004	59	214	235	0	24	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2011	154	4					260	W81		10.7326/0003-4819-154-4-201102150-00007	http://dx.doi.org/10.7326/0003-4819-154-4-201102150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720VF	21320941				2023-01-03	WOS:000287310000018
J	Pham, CTN; Mitchell, LM; Huang, JL; Lubniewski, CM; Schall, OF; Killgore, JK; Pan, DPJ; Wickline, SA; Lanza, GM; Hourcade, DE				Pham, Christine T. N.; Mitchell, Lynne M.; Huang, Jennifer L.; Lubniewski, Christopher M.; Schall, Otto F.; Killgore, J. Kendall; Pan, Dipanjan; Wickline, Samuel A.; Lanza, Gregory M.; Hourcade, Dennis E.			Variable Antibody-dependent Activation of Complement by Functionalized Phospholipid Nanoparticle Surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE LUNG INJURY; ALTERNATIVE PATHWAY; FUMAGILLIN NANOPARTICLES; TOXIC OXYGEN; IN-VIVO; 2 PARTS; LIPOSOMES; IMMUNOLOGY; CONVERTASE; MODEL	A wide variety of nanomaterials are currently being developed for use in the detection and treatment of human diseases. However, there is no systematic way to measure and predict the action of such materials in biological contexts. Lipid-encapsulated nanoparticles (NPs) are a class of nanomaterials that includes the liposomes, the most widely used and clinically proven type of NPs. Liposomes can, however, activate the complement system, an important branch of innate immunity, resulting in undesirable consequences. Here, we describe the complement response to lipid-encapsulated NPs that are functionalized on the surface with various lipid-anchored gadolinium chelates. We developed a quantitative approach to examine the interaction of NPs with the complement system using in vitro assays and correlating these results with those obtained in an in vivo mouse model. Our results indicate that surface functionalization of NPs with certain chemical structures elicits swift complement activation that is initiated by a natural IgM antibody and propagated via the classical pathway. The intensity of the response is dependent on the chemical structures of the lipid-anchored chelates and not zeta potential effects alone. Moreover, the extent of complement activation may be tempered by complement inhibiting regulatory proteins that bind to the surface of NPs. These findings represent a step forward in the understanding of the interactions between nanomaterials and the host innate immune response and provide the basis for a systematic structure-activity relationship study to establish guidelines that are critical to the future development of biocompatible nanotherapeutics.	[Hourcade, Dennis E.] Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA; [Pan, Dipanjan; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, Div Cardiol, Dept Med, St Louis, MO 63110 USA; [Schall, Otto F.; Killgore, J. Kendall] Kereos Inc, St Louis, MO 63108 USA	Washington University (WUSTL); Washington University (WUSTL)	Pham, CTN (corresponding author), 660 S Euclid Ave,Box 8045, St Louis, MO 63110 USA.	cpham@dom.wustl.edu; dhourcad@dom.wustl.edu		Pan, Dipanjan/0000-0003-0175-4704	National Institutes of Health [AR056468, HL073646, CA119342, NS059302, HL094470, AI051436/AI051436S1]; National Institutes of Health/Food and Drug Administration [U01NS073457]; NATIONAL CANCER INSTITUTE [U54CA119342] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073646, R01HL094470] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI051436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR056468] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059302, U01NS073457] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health/Food and Drug Administration(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported in part by National Institutes of Health Grants AR056468 (to C. T. N. P.), HL073646 (to S. A. W.), CA119342 (to G. M. L.), NS059302 (to G. M. L.), HL094470 (to G. M. L.), and AI051436/AI051436S1 (to D. E. H.) and National Institutes of Health/Food and Drug Administration Grant U01NS073457 (to D. E. H.). S. A. W. and G. M. L. are scientific founders of Kereos, Inc., and minority shareholders (less than 5%).	Andersson J, 2002, J IMMUNOL, V168, P5786, DOI 10.4049/jimmunol.168.11.5786; ATKINSON JP, 1980, J IMMUNOL METHODS, V33, P351, DOI 10.1016/0022-1759(80)90005-8; Botto M, 1998, NAT GENET, V19, P56, DOI 10.1038/ng0598-56; Caruthers SD, 2007, CURR OPIN BIOTECH, V18, P26, DOI 10.1016/j.copbio.2007.01.006; CHONN A, 1991, J IMMUNOL, V146, P4234; CUNNINGHAM CM, 1979, J IMMUNOL, V122, P1237; Dobrovolskaia MA, 2007, NAT NANOTECHNOL, V2, P469, DOI 10.1038/nnano.2007.223; Fischer HC, 2007, CURR OPIN BIOTECH, V18, P565, DOI 10.1016/j.copbio.2007.11.008; Fischer MB, 1996, J IMMUNOL, V157, P549; Gros P, 2008, NAT REV IMMUNOL, V8, P48, DOI 10.1038/nri2231; Harris TD, 2003, [No title captured], Patent No. [US6511648, 6511648]; Klos A, 2009, MOL IMMUNOL, V46, P2753, DOI 10.1016/j.molimm.2009.04.027; Kraus D, 1998, INFECT IMMUN, V66, P399, DOI 10.1128/IAI.66.2.399-405.1998; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; Lanza GM, 1996, CIRCULATION, V94, P3334, DOI 10.1161/01.CIR.94.12.3334; Liszewski M.K., 1998, HUMAN COMPLEMENT SYS, P149; LUNDBERG C, 1987, AM J PATHOL, V128, P471; Matsumoto M, 1997, P NATL ACAD SCI USA, V94, P8720, DOI 10.1073/pnas.94.16.8720; Niederbichler AD, 2006, J EXP MED, V203, P53, DOI 10.1084/jem.20051207; Nilsson B, 2010, TRENDS IMMUNOL, V31, P32, DOI 10.1016/j.it.2009.09.005; PANGBURN MK, 1981, J EXP MED, V154, P856, DOI 10.1084/jem.154.3.856; Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; Rihova B, 2002, ADV DRUG DELIVER REV, V54, P653; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; Szebeni J, 2005, TOXICOLOGY, V216, P106, DOI 10.1016/j.tox.2005.07.023; Szebeni J, 1999, CIRCULATION, V99, P2302, DOI 10.1161/01.CIR.99.17.2302; TILL GO, 1986, FASEB J, V45, P13; TILL GO, 1982, J CLIN INVEST, V69, P1126, DOI 10.1172/JCI110548; TVEDTEN HW, 1985, AM J PATHOL, V119, P92; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Whaley K, 1985, METHODS COMPLEMENT C, P77; Winter PM, 2008, FASEB J, V22, P2758, DOI 10.1096/fj.07-103929; Winter PM, 2008, JACC-CARDIOVASC IMAG, V1, P624, DOI 10.1016/j.jcmg.2008.06.003; WRIGHT SD, 1983, J EXP MED, V158, P2016, DOI 10.1084/jem.158.6.2016	37	55	58	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 7	2011	286	1					123	130		10.1074/jbc.M110.180760	http://dx.doi.org/10.1074/jbc.M110.180760			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	700YZ	21047788	hybrid, Green Published			2023-01-03	WOS:000285782800013
J	Kaptchuk, TJ; Friedlander, E; Kelley, JM; Sanchez, MN; Kokkotou, E; Singer, JP; Kowalczykowski, M; Miller, FG; Kirsch, I; Lembo, AJ				Kaptchuk, Ted J.; Friedlander, Elizabeth; Kelley, John M.; Sanchez, M. Norma; Kokkotou, Efi; Singer, Joyce P.; Kowalczykowski, Magda; Miller, Franklin G.; Kirsch, Irving; Lembo, Anthony J.			Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome	PLOS ONE			English	Article							QUALITY-OF-LIFE; CLINICAL-TRIALS; END-POINT; VALIDATION; BLIND	Background: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). Methods: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 +/- 18 with IBS diagnosed by Rome III criteria and with a score >= 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). Findings: Open-label placebo produced significantly higher mean (+/- SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 +/- 1.0 vs. 4.0 +/- 1.1, p<.001) and at 21-day endpoint (5.0 +/- 1.5 vs. 3.9 +/- 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). Conclusion: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent.	[Kaptchuk, Ted J.; Friedlander, Elizabeth; Sanchez, M. Norma; Kokkotou, Efi; Kowalczykowski, Magda; Lembo, Anthony J.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA; [Kaptchuk, Ted J.; Singer, Joyce P.] Harvard Univ, Sch Med, Osher Res Ctr, Boston, MA 02215 USA; [Kelley, John M.] Endicott Coll, Dept Psychol, Beverly, MA USA; [Kelley, John M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02215 USA; [Miller, Franklin G.] NIH, Dept Bioeth, Bethesda, MD 20892 USA; [Kirsch, Irving] Univ Hull, Dept Psychol, Kingston Upon Hull HU6 7RX, N Humberside, England	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; National Institutes of Health (NIH) - USA; University of Hull	Kaptchuk, TJ (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.	ted_kaptchuk@hms.harvard.edu	Kirsch, Irving/P-9316-2019		National Center for Complementary and Alternative Medicine-NIH [K24 AT004095, R01 AT00402-01, R01AT004662]; NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE [R01AT004662] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R01AT000402] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine-NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY & ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was partially supported by grant K24 AT004095, R01 AT00402-01 and R01AT004662 from National Center for Complementary and Alternative Medicine-NIH and in part from a gift from The Bernard Osher Foundation. The opinions expressed by the authors are their views alone and do not reflect the official views or policy of the National Center for Complementary and Alternative Medicine, National Institutes of Health, Public Health Service or the U.S. Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AM MED ASS, 2006, 2I2006 CEJA AM MED A; Brandt LJ, 2009, AM J GASTROENTEROL, V104, pS1, DOI 10.1038/ajg.2008.122; Camilleri M, 2000, LANCET, V355, P1035, DOI 10.1016/S0140-6736(00)02033-X; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Drossman DA, 2002, GASTROENTEROLOGY, V123, P2108, DOI 10.1053/gast.2002.37095; Drossman DA, 2000, AM J GASTROENTEROL, V95, P999; DROSSMAN DA, 2009, J CLINCAL GASTROENTE; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Francis CY, 1997, ALIMENT PHARM THERAP, V11, P395, DOI 10.1046/j.1365-2036.1997.142318000.x; Glaster B. G., 1967, THEORETICAL SENSITIV; Gordon S, 2003, DIGEST DIS SCI, V48, P1317, DOI 10.1023/A:1024159226274; Gralnek IM, 2000, GASTROENTEROLOGY, V119, P654, DOI 10.1053/gast.2000.16484; GRYLL SL, 1978, PSYCHOPHARMOCOLOGY, V57, P129; Hammer J, 2004, GUT, V53, P666, DOI 10.1136/gut.2003.021857; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kaptchuk TJ, 2009, CULT MED PSYCHIAT, V33, P382, DOI 10.1007/s11013-009-9141-7; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; Lembo T, 2001, AM J GASTROENTEROL, V96, P2662; Longstreth GF, 2006, GASTROENTEROLOGY, V130, P1480, DOI 10.1053/j.gastro.2005.11.061; Mangel AW, 1998, J INT MED RES, V26, P76, DOI 10.1177/030006059802600203; Miller FG, 2009, AM J BIOETHICS, V9, P39, DOI 10.1080/15265160903316263; Miller FG, 2009, PERSPECT BIOL MED, V52, P518, DOI 10.1353/pbm.0.0115; Novick J, 2002, ALIMENT PHARM THER, V16, P1877, DOI 10.1046/j.1365-2036.2002.01372.x; Pare P, 2006, CLIN THER, V28, P1726, DOI 10.1016/j.clinthera.2006.10.010; PARK LC, 1965, ARCH GEN PSYCHIAT, V12, P336; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Rahimi R, 2008, CLIN THER, V30, P884, DOI 10.1016/j.clinthera.2008.05.002; Saito YA, 2002, AM J GASTROENTEROL, V97, P1910; Sandler AD, 2008, CHILD CARE HLTH DEV, V34, P104, DOI 10.1111/j.1365-2214.2007.00797.x; Silverman D., 2003, COLLECTING INTERPRET, P821; Spiro HM, 1986, DOCTORS PATIENTS PLA; Thompson WG, 1999, GUT, V45, P43; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; VANNER SJ, 2004, GUT, V53, P666	37	519	524	0	79	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 22	2010	5	12							e15591	10.1371/journal.pone.0015591	http://dx.doi.org/10.1371/journal.pone.0015591			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	698FG	21203519	Green Published, Green Submitted, gold			2023-01-03	WOS:000285578000036
J	Duran-Cantolla, J; Aizpuru, F; Montserrat, JM; Ballester, E; Teran-Santos, J; Aguirregomoscorta, JI; Gonzalez, M; Lloberes, P; Masa, JF; De la Pena, M; Carrizo, S; Mayos, M; Barbe, F				Duran-Cantolla, Joaquin; Aizpuru, Felipe; Montserrat, Jose Maria; Ballester, Eugeni; Teran-Santos, Joaquin; Aguirregomoscorta, Jose Ignacio; Gonzalez, Monica; Lloberes, Patricia; Masa, Juan Fernando; De la Pena, Monica; Carrizo, Santiago; Mayos, Mercedes; Barbe, Ferran		Spanish Sleep Breathing Grp	Continuous positive airway pressure as treatment for systemic hypertension in people with obstructive sleep apnoea: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE; RISK-FACTOR; PLACEBO; HYPOPNEA; ASSOCIATION; STROKE; CPAP; METAANALYSIS; MORTALITY; OXYGEN	Objective To assess the effect of continuous positive airway pressure (CPAP) on 24 hour ambulatory blood pressure monitoring values in a large number of patients with untreated systemic hypertension of new onset and obstructive sleep apnoea. Design Multicentre, double blind, randomised, placebo controlled trial. Setting Eleven general hospitals in Spain between 2004 and 2007. Participants 340 patients recently diagnosed as having systemic hypertension by a general practitioner (systolic blood pressure >= 140 mm Hg, diastolic blood pressure >= 90 mm Hg, or both) and an apnoea-hypopnoea index per hour of sleep of >15 events/hour. Intervention Patients were assigned to CPAP (n=169) or sham CPAP (n=171) for three months. Main outcome measurements Net changes in the different 24 hour ambulatory blood pressure monitoring values from baseline to three months of optimal or sham CPAP. Results 277 (81%) of the 340 patients randomised were men; the patients had a mean age of 52.4 (SD 10.5) years, a body mass index of 31.9 (5.7), an Epworth sleepiness scale score of 10.1 (4.3), an apnoea-hypopnoea index of 43.5 (24.5). No differences between groups were seen at baseline. Compared with placebo and analysed by intention to treat, the mean 24 hour ambulatory blood pressure of the CPAP group decreased by 1.5 (95% confidence interval: 0.4 to 2.7) mm Hg (P=0.01). The mean 24 hour ambulatory blood pressure monitoring measures decreased by 2.1 mm Hg (0.4 to 3.7) mm Hg (P=0.01) for systolic pressure and 1.3 (0.2 to 2.3) mm Hg (P=0.02) for diastolic blood pressure. Mean nocturnal blood pressure decreased by 2.1 (0.5 to 3.6) mm Hg (P=0.01). Conclusions CPAP produced a statistically significant reduction in blood pressure in patients with systemic hypertension and obstructive sleep apnoea. This reduction is small and did not achieve the 3 mm Hg drop in mean 24 hour ambulatory blood pressure that the trial was powered to detect. Consequently, these results may have uncertain clinical relevance. However, taking into account the prevalence of hypertension and the likelihood of comorbidities, the decrease in blood pressure, although minimal, may be beneficial.	[Duran-Cantolla, Joaquin] Univ Basque Country, Fac Med, Hosp Univ Txagorritxu, Sleep Unit, Vitoria 01009, Spain; [Duran-Cantolla, Joaquin; Barbe, Ferran] IRBlleida, Dept Resp Med, Lleida 25198, Spain; [Aizpuru, Felipe] Hosp Univ Txagorritxu, Araba Res Unit, Vitoria, Spain; [Aizpuru, Felipe; Montserrat, Jose Maria; Ballester, Eugeni; Teran-Santos, Joaquin; Lloberes, Patricia; Masa, Juan Fernando; De la Pena, Monica; Carrizo, Santiago; Barbe, Ferran] Inst Salud Carlos III, Madrid, Spain; [Montserrat, Jose Maria; Ballester, Eugeni] Hosp Clin Barcelona, Dept Resp Med, Sleep Unit, E-08036 Barcelona, Spain; [Teran-Santos, Joaquin] Hosp Gen Yague, Dept Resp & Sleep Med, Burgos 09005, Spain; [Aguirregomoscorta, Jose Ignacio] Hosp Galdakano, Dept Resp Med, Sleep Unit, Vizcaya 48960, Spain; [Gonzalez, Monica] Hosp Univ Marques Valdecilla, Dept Resp & Sleep Med, Santander 39008, Spain; [Lloberes, Patricia] Hosp Valle De Hebron, Dept Resp Med, Sleep Unit, Barcelona 08035, Spain; [Masa, Juan Fernando] Hosp San Pedro de Alcantara, Dept Resp Med, Sleep Unit, Caceres 10003, Spain; [De la Pena, Monica] Hosp Son Dureta, Dept Resp Med, Sleep Unit, Palma de Mallorca 07014, Spain; [Carrizo, Santiago] Hosp Univ Miguel Server, Dept Resp Med, Sleep Unit, Zaragoza 50009, Spain; [Mayos, Mercedes] Hosp San Pablo, Dept Resp Med, Sleep Unit, Barcelona 08030, Spain	University Hospital of Araba; University of Basque Country; Institut de Recerca Biomedica - IRB Lleida; University Hospital of Araba; Instituto de Salud Carlos III; University of Barcelona; Hospital Clinic de Barcelona; Hospital General Yague; Galdakao Hospital; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitari Vall d'Hebron; Hospital Universitari Son Espases; Hospital Universitari Son Dureta; Miguel Servet University Hospital	Duran-Cantolla, J (corresponding author), Univ Basque Country, Fac Med, Hosp Univ Txagorritxu, Sleep Unit, Vitoria 01009, Spain.	joaquin.durancantolla@gmail.com	LOPEZ-PICADO, AMANDA/AAF-3948-2019; GONZALEZ, MONICA/AAM-4033-2021; CARRIZO SIERRA, SANTIAGO/AAO-1780-2021; Lloberes Canadell, Patricia/F-9707-2014; Garin, Intza/J-4500-2012; Cantolla, Joaquin Duran/B-6996-2015; Barbé, Ferran/A-5988-2010	LOPEZ-PICADO, AMANDA/0000-0002-5649-296X; GONZALEZ, MONICA/0000-0003-1516-0181; Lloberes Canadell, Patricia/0000-0002-1595-8225; Barbé, Ferran/0000-0002-2340-8928; MONTSERRAT, Josep Maria/0000-0003-3098-4605; de la Pena, Monica/0000-0003-3276-776X	Spanish Ministry of Health [PI041110]; Basque Government's Department of Health [20031103]; Spanish Respiratory Society	Spanish Ministry of Health(Instituto de Salud Carlos IIISpanish Government); Basque Government's Department of Health; Spanish Respiratory Society	The study was sponsored by the Spanish Ministry of Health (PI041110), the Basque Government's Department of Health (20031103), and the Spanish Respiratory Society (SEPAR 2005). The sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, and approval of the manuscript. The opinions, results, and conclusions are those of the authors.	Alajmi M, 2007, LUNG, V185, P67, DOI 10.1007/s00408-006-0117-x; Arias MA, 2006, EUR HEART J, V27, P1106, DOI 10.1093/eurheartj/ehi807; Arias MA, 2005, CIRCULATION, V112, P375, DOI 10.1161/CIRCULATIONAHA.104.501841; Barbe F, 2001, ANN INTERN MED, V134, P1015, DOI 10.7326/0003-4819-134-11-200106050-00007; Barbe F, 2010, AM J RESP CRIT CARE, V181, P718, DOI 10.1164/rccm.200901-0050OC; Barnes M, 2004, AM J RESP CRIT CARE, V170, P656, DOI 10.1164/rccm.200311-1571OC; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Campos-Rodriguez F, 2006, CHEST, V129, P1459, DOI 10.1378/chest.129.6.1459; *CHMP, 2009, GUID MISS DAT CONF C; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Duran J, 2001, AM J RESP CRIT CARE, V163, P685, DOI 10.1164/ajrccm.163.3.2005065; Ellen RLB, 2006, J CLIN SLEEP MED, V2, P193; Faccenda JF, 2001, AM J RESP CRIT CARE, V163, P344, DOI 10.1164/ajrccm.163.2.2005037; Farre R, 1999, LANCET, V353, P1154, DOI 10.1016/S0140-6736(99)01056-9; Fox KM, 2003, LANCET, V362, P782; Giles TL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001106.pub3; Haentjens P, 2007, ARCH INTERN MED, V167, P757, DOI 10.1001/archinte.167.8.757; Hui DS, 2006, THORAX, V61, P1083, DOI 10.1136/thx.2006.064063; Johnson KG, 2010, J CLIN SLEEP MED, V6, P131; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kohler M, 2008, EUR RESPIR J, V32, P1488, DOI 10.1183/09031936.00026608; Kushida CA, 2005, SLEEP, V28, P499, DOI 10.1093/sleep/28.4.499; Law MR, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1665; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Mancia G, 2007, EUR HEART J, V28, P1462, DOI [10.1093/eurheartj/ehm236, 10.1093/eurheartj/eht151]; Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC; Mar J, 2003, EUR RESPIR J, V21, P515, DOI 10.1183/09031936.03.00040903; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marshall NS, 2008, SLEEP, V31, pA145; Marshall NS, 2005, THORAX, V60, P427, DOI 10.1136/thx.2004.032078; Masa JF, 2004, AM J RESP CRIT CARE, V170, P1218, DOI 10.1164/rccm.200312-1787OC; McDaid C, 2009, SLEEP MED REV, V13, P427, DOI 10.1016/j.smrv.2009.02.004; Mills PJ, 2006, J APPL PHYSIOL, V100, P343, DOI 10.1152/japplphysiol.00494.2005; Mo Li, 2007, Zhonghua Yi Xue Za Zhi, V87, P1177; Monasterio C, 2001, AM J RESP CRIT CARE, V164, P939, DOI 10.1164/ajrccm.164.6.2008010; Munoz R, 2006, STROKE, V37, P2317, DOI 10.1161/01.STR.0000236560.15735.0f; Newman AB, 2001, AM J EPIDEMIOL, V154, P50, DOI 10.1093/aje/154.1.50; Nieto FJ, 2000, JAMA-J AM MED ASSOC, V283, P1829, DOI 10.1001/jama.283.14.1829; Norman D, 2006, HYPERTENSION, V47, P840, DOI 10.1161/01.HYP.0000217128.41284.78; O'Connor GT, 2009, AM J RESP CRIT CARE, V179, P1159, DOI 10.1164/rccm.200712-1809OC; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Peppard PE, 2006, ARCH INTERN MED, V166, P1709, DOI 10.1001/archinte.166.16.1709; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Punjabi NM, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000132; Robinson GV, 2006, EUR RESPIR J, V27, P1229, DOI 10.1183/09031936.06.00062805; Rodway GW, 2010, SLEEP, V33, P260, DOI 10.1093/sleep/33.2.260; Tregear S, 2009, J CLIN SLEEP MED, V5, P573; Turnbull F, 2003, LANCET, V362, P1527; Yaggi HK, 2005, NEW ENGL J MED, V353, P2034, DOI 10.1056/NEJMoa043104; Young T, 2008, SLEEP, V31, P1071	52	166	176	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 24	2010	341								c5991	10.1136/bmj.c5991	http://dx.doi.org/10.1136/bmj.c5991			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688EA	21106625	hybrid, Green Published			2023-01-03	WOS:000284831400003
J	Adamaszek, M; Khaw, AV; Buck, U; Andresen, B; Thomasius, R				Adamaszek, Michael; Khaw, Alexander V.; Buck, Ulrike; Andresen, Burghard; Thomasius, Rainer			Evidence of Neurotoxicity of Ecstasy: Sustained Effects on Electroencephalographic Activity in Polydrug Users	PLOS ONE			English	Article							COGNITIVE PERFORMANCE; 3,4-METHYLENEDIOXYMETHAMPHETAMINE MDMA; EEG; IMPAIRMENT; MOOD	Objective: According to previous EEG reports of indicative disturbances in Alpha and Beta activities, a systematic search for distinct EEG abnormalities in a broader population of Ecstasy users may especially corroborate the presumed specific neurotoxicity of Ecstasy in humans. Methods: 105 poly-drug consumers with former Ecstasy use and 41 persons with comparable drug history without Ecstasy use, and 11 drug naives were investigated for EEG features. Conventional EEG derivations of 19 electrodes according to the 10-20-system were conducted. Besides standard EEG bands, quantitative EEG analyses of 1-Hz-subdivided power ranges of Alpha, Theta and Beta bands have been considered. Results: Ecstasy users with medium and high cumulative Ecstasy doses revealed an increase in Theta and lower Alpha activities, significant increases in Beta activities, and a reduction of background activity. Ecstasy users with low cumulative Ecstasy doses showed a significant Alpha activity at 11 Hz. Interestingly, the spectral power of low frequencies in medium and high Ecstasy users was already significantly increased in the early phase of EEG recording. Statistical analyses suggested the main effect of Ecstasy to EEG results. Conclusions: Our data from a major sample of Ecstasy users support previous data revealing alterations of EEG frequency spectrum due rather to neurotoxic effects of Ecstasy on serotonergic systems in more detail. Accordingly, our data may be in line with the observation of attentional and memory impairments in Ecstasy users with moderate to high misuse. Despite the methodological problem of polydrug use also in our approach, our EEG results may be indicative of the neuropathophysiological background of the reported memory and attentional deficits in Ecstasy abusers. Overall, our findings may suggest the usefulness of EEG in diagnostic approaches in assessing neurotoxic sequela of this common drug abuse.	[Adamaszek, Michael] Univ Leipzig, Neurol Rehabil Zentrum Leipzig, Bennewitz, Germany; [Adamaszek, Michael; Andresen, Burghard; Thomasius, Rainer] Univ Med Ctr Hamburg Eppendorf, Clin Psychiat & Psychotherapy, Hamburg, Germany; [Khaw, Alexander V.] Ernst Moritz Arndt Univ Greifswald, Dept Neurol, Greifswald, Germany; [Buck, Ulrike] Hosp Rissen, Dept Psychiat, Hamburg, Germany; [Thomasius, Rainer] Univ Med Ctr Hamburg Eppendorf, Deutsch Zentrum Suchtfragen Kindes & Jugendalter, Hamburg, Germany	Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf; Ernst Moritz Arndt Universitat Greifswald; University of Hamburg; University Medical Center Hamburg-Eppendorf	Adamaszek, M (corresponding author), Univ Leipzig, Neurol Rehabil Zentrum Leipzig, Bennewitz, Germany.	michael.adamaszek@sachsenklinik.de			Federal Institute for Drugs and Medical Devices, Germany [FZ: Z12.01-68503-206]	Federal Institute for Drugs and Medical Devices, Germany	The study was supported by the Federal Institute for Drugs and Medical Devices (FZ: Z12.01-68503-206), Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BENTE D, 1982, ORGANIC PSYCHOSYNDRO; Capela JP, 2007, NEUROTOXICOLOGY, V28, P868, DOI 10.1016/j.neuro.2007.04.005; Cowan RL, 2007, PSYCHOPHARMACOLOGY, V189, P539, DOI 10.1007/s00213-006-0467-3; Croft RJ, 2001, AM J PSYCHIAT, V158, P1687, DOI 10.1176/appi.ajp.158.10.1687; Dafters RI, 1999, PSYCHOPHARMACOLOGY, V145, P82, DOI 10.1007/s002130051035; de Sola S, 2008, PSYCHOPHARMACOLOGY, V200, P425, DOI 10.1007/s00213-008-1217-5; DOLAN RJ, 1997, HUMAN BRAIN FUNCTION, P405; FISCHER C, 1995, J NEUROSCI, V15, P5476; Gamma A, 2000, NEUROREPORT, V11, P157, DOI 10.1097/00001756-200001170-00031; Gouzoulis-Mayfrank E, 2000, J NEUROL NEUROSUR PS, V68, P719, DOI 10.1136/jnnp.68.6.719; Gouzoulis-Mayfrank E, 2006, J PSYCHOPHARMACOL, V20, P188, DOI 10.1177/0269881106059939; Hatzidimitriou G, 1999, J NEUROSCI, V19, P5096; HERRMANN WM, 1988, Z GERONTOPSYCHOL PSY, V1, P1; INSEL TR, 1989, J PHARMACOL EXP THER, V249, P713; LUCAS RA, 1992, INT J OBESITY, V16, pS49; LUU P, 2003, COGNITIVE ELECTROPHY, P199; McCann UD, 1998, LANCET, V352, P1433, DOI 10.1016/S0140-6736(98)04329-3; MCKENNA DJ, 1990, J NEUROCHEM, V54, P14, DOI 10.1111/j.1471-4159.1990.tb13277.x; Meyer JS, 2006, ANN NY ACAD SCI, V1074, P365, DOI 10.1196/annals.1369.036; Morgan MJ, 1999, PSYCHOPHARMACOLOGY, V141, P30, DOI 10.1007/s002130050803; NYSTROM C, 1988, ACTA PSYCHIAT SCAND, V77, P457, DOI 10.1111/j.1600-0447.1988.tb05151.x; OKEN BS, 1992, J CLIN NEUROPHYSIOL, V9, P480, DOI 10.1097/00004691-199210000-00003; Olbrich S, 2009, NEUROIMAGE, V45, P319, DOI 10.1016/j.neuroimage.2008.11.014; Reneman L, 2006, J PSYCHOPHARMACOL, V20, P164, DOI 10.1177/0269881106061515; RICAURTE GA, 1988, BRAIN RES, V446, P165, DOI 10.1016/0006-8993(88)91309-1; Robbins Trevor W., 1995, P703; Robertson IH, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P631; SATO N, NEUROREPORT; Struder HK, 2001, INT J SPORTS MED, V22, P482, DOI 10.1055/s-2001-17606; Thomasius R, 2006, J PSYCHOPHARMACOL, V20, P211, DOI 10.1177/0269881106059486; Thomasius R, 1997, FORTSCHR NEUROL PSYC, V65, P49, DOI 10.1055/s-2007-996309; THOMASIUS R, 2000, ECSTASY STUDY HLTH P; Tuchtenhagen F, 2000, NEUROPSYCHOPHARMACOL, V22, P608, DOI 10.1016/S0893-133X(99)00140-2; Verkes RJ, 2001, PSYCHOPHARMACOLOGY, V153, P196, DOI 10.1007/s002130000563; Zakzanis KK, 2001, NEUROLOGY, V56, P966, DOI 10.1212/WNL.56.7.966	35	14	15	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 23	2010	5	11							e14097	10.1371/journal.pone.0014097	http://dx.doi.org/10.1371/journal.pone.0014097			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	684DM	21124854	Green Published, Green Submitted, gold			2023-01-03	WOS:000284527900010
J	Himmelfarb, J; Ikizler, TA				Himmelfarb, Jonathan; Ikizler, T. Alp			MEDICAL PROGRESS Hemodialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; CENTER NOCTURNAL HEMODIALYSIS; CARDIOVASCULAR EVENTS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; MORTALITY RISK; BLOOD-PRESSURE; TREATMENT TIME; UNITED-STATES		[Himmelfarb, Jonathan] Univ Washington, Kidney Res Inst, Dept Med, Div Nephrol, Seattle, WA 98104 USA; [Ikizler, T. Alp] Vanderbilt Univ, Med Ctr, Dept Med, Div Nephrol, Nashville, TN USA	University of Washington; University of Washington Seattle; Vanderbilt University	Himmelfarb, J (corresponding author), Univ Washington, Kidney Res Inst, Dept Med, Div Nephrol, Box 359606,325 9th Ave, Seattle, WA 98104 USA.	himmej@u.washington.edu		Ikizler, Talat/0000-0002-5717-4218	KAI Pharmaceuticals; Fresenius Medical Care North America; Kidney Research Institute at the University of Washington; Amgen; Abbott Renal Care; Novo Nordisk; Renal Advantage; Eli Lilly; Medical Nutrition USA	KAI Pharmaceuticals; Fresenius Medical Care North America; Kidney Research Institute at the University of Washington; Amgen(Amgen); Abbott Renal Care; Novo Nordisk(Novo Nordisk); Renal Advantage; Eli Lilly(Eli Lilly); Medical Nutrition USA	Dr. Himmelfarb reports serving on the Shire Pharmaceuticals scientific advisory board on Outcomes Studies in Hemodialysis Patients and the CytoPherx (formerly Nephrion) medical advisory board and receiving consulting fees from KAI Pharmaceuticals, as well as receipt by his former institution, the Maine Medical Center Research Institute, of research support from Fresenius Medical Services of North America (now Fresenius Medical Care North America). All payments for board membership and consulting were donated to the Kidney Research Institute at the University of Washington. Dr. Ikizler reports serving on the boards of the American Board of Internal Medicine and Satellite Healthcare, receiving consulting fees from Amgen, Abbott Renal Care, Novo Nordisk, Renal Advantage, Eli Lilly, and Fresenius Medical Care North America, royalties from Wolter Kluwer, as well as receipt by his institution, the Vanderbilt University Medical Center, of research support from Medical Nutrition USA and Fresenius Medical Care North America. Dr. Ikizler reports having been the medical director of the Vanderbilt Dialysis Unit, which is owned by Vanderbilt University Medical Center and managed by Fresenius Medical Care North America, until June 2010. No other potential conflict of interest relevant to this article was reported.	Agarwal R, 2002, SEMIN DIALYSIS, V15, P299, DOI 10.1046/j.1525-139X.2002.00074.x; Annuk M, 2001, J AM SOC NEPHROL, V12, P2747, DOI 10.1681/ASN.V12122747; [Anonymous], 2009, USRDS 2009 ANN DAT R; Arnold RM, 2009, NEW ENGL J MED, V361, P1597, DOI 10.1056/NEJMe0907698; Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Block GA, 2007, KIDNEY INT, V71, P438, DOI 10.1038/sj.ki.5002059; Bugeja A, 2009, CLIN J AM SOC NEPHRO, V4, P778, DOI 10.2215/CJN.05221008; Charra B, 1996, AM J NEPHROL, V16, P35, DOI 10.1159/000168968; COLLINS AJ, 1994, AM J KIDNEY DIS, V23, P272, DOI 10.1016/S0272-6386(12)80984-X; CONVERSE RL, 1992, NEW ENGL J MED, V327, P1912, DOI 10.1056/NEJM199212313272704; *CTR MED MED SERV, DIAL FAC COMP DEC; *CTR MED STAT OP S, 2008, ENDST REN DIS ESRD P; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2008, SEMIN DIALYSIS, V21, P415, DOI 10.1111/j.1525-139X.2008.00482.x; DEFRONZO RA, 1981, J CLIN INVEST, V67, P563, DOI 10.1172/JCI110067; Depner TA., 1991, PRESCRIBING HEMODIAL, V2nd Ed.; Drueke TB, 2006, NEW ENGL J MED, V355, P2071, DOI 10.1056/NEJMoa062276; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; Fellstrom BC, 2010, NEW ENGL J MED, V362, P1450; Fissell WH, 2009, SEMIN DIALYSIS, V22, P665, DOI 10.1111/j.1525-139X.2009.00662.x; *FIST 1 BREAKTHR I, NAT AV FIST RAT REAC; Foley RN, 2009, J AM SOC NEPHROL, V20, P1432, DOI 10.1681/ASN.2009030282; Goodkin DA, 2004, AM J KIDNEY DIS, V44, pS16, DOI 10.1053/j.akjd.2004.08.006; Goodkin DA, 2003, J AM SOC NEPHROL, V14, P3270, DOI 10.1097/01.ASN.0000100127.54107.57; GOTCH FA, 1985, KIDNEY INT, V28, P526, DOI 10.1038/ki.1985.160; Gura V, 2009, CLIN J AM SOC NEPHRO, V4, P1441, DOI 10.2215/CJN.02790409; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Herzog CA, 2008, SEMIN DIALYSIS, V21, P300, DOI 10.1111/j.1525-139X.2008.00455.x; Himmelfarb J, 2002, KIDNEY INT, V62, P1524, DOI 10.1046/j.1523-1755.2002.00600.x; HIMMELFARB J, 2008, HEMODIALYSIS; Himmelfarb J, 2007, J AM SOC NEPHROL, V18, P2021, DOI 10.1681/ASN.2007020152; Himmelfarb J, 2007, ANNU REV MED, V58, P387, DOI 10.1146/annurev.med.58.061705.151442; HORNBERGER JC, 1992, J AM SOC NEPHROL, V3, P1227; Ikizler TA, 1999, KIDNEY INT, V55, P1945, DOI 10.1046/j.1523-1755.1999.00410.x; Jamison RL, 2008, JAMA-J AM MED ASSOC, V300, P170; Jamison RL, 2007, JAMA-J AM MED ASSOC, V298, P1163, DOI 10.1001/jama.298.10.1163; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Kliger AS, 2007, CLIN J AM SOC NEPHRO, V2, P390, DOI 10.2215/CJN.03110906; Knauf F, 2009, J AM SOC NEPHROL, V20, P2093, DOI 10.1681/ASN.2009070715; Koda Y, 1997, KIDNEY INT, V52, P1096, DOI 10.1038/ki.1997.434; Lacson E, 2007, AM J KIDNEY DIS, V50, P379, DOI 10.1053/j.ajkd.2007.06.006; Li L, 2008, KIDNEY INT, V74, P1247, DOI 10.1038/ki.2008.318; Liu YM, 2004, JAMA-J AM MED ASSOC, V291, P451, DOI 10.1001/jama.291.4.451; Locatelli F, 2005, NEPHROL DIAL TRANSPL, V20, P22, DOI 10.1093/ndt/gfh555; Locatelli F, 1996, KIDNEY INT, V50, P1293, DOI 10.1038/ki.1996.441; Locatelli Francesco, 2002, Kidney Int Suppl, P115; Lopot F, 2004, J Vasc Access, V5, P25; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; Lowrie EG, 2003, AM J KIDNEY DIS, V41, P1286, DOI 10.1016/S0272-6386(03)00361-5; Maduell F, 2008, AM J KIDNEY DIS, V52, P85, DOI 10.1053/j.ajkd.2008.03.014; Maggiore Q, 2002, AM J KIDNEY DIS, V40, P280, DOI 10.1053/ajkd.2002.34506; Marshall MR, 2006, KIDNEY INT, V69, P1229, DOI 10.1038/sj.ki.5000188; Meyer TW, 2007, NEW ENGL J MED, V357, P1316, DOI 10.1056/NEJMra071313; Middleton RJ, 2001, J AM SOC NEPHROL, V12, P1079, DOI 10.1681/ASN.V1251079; Moss AH, 2001, AM J KIDNEY DIS, V37, P1081; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Nissenson Allen R, 2005, Hemodial Int, V9, P210, DOI 10.1111/j.1492-7535.2005.01135.x; Oliver MJ, 2001, J AM SOC NEPHROL, V12, P151, DOI 10.1681/ASN.V121151; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; Paniagua R, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1351307; Passauer J, 2000, J AM SOC NEPHROL, V11, P1726, DOI 10.1681/ASN.V1191726; Pfeffer MA, 2009, NEW ENGL J MED, V361, P2019, DOI 10.1056/NEJMoa0907845; Port FK, 2004, AM J KIDNEY DIS, V43, P1014, DOI 10.1053/j.ajkd.2004.02.014; Port FK, 2001, AM J KIDNEY DIS, V37, P276, DOI 10.1053/ajkd.2001.21290; Powell JR, 2009, CLIN J AM SOC NEPHRO, V4, P1097, DOI 10.2215/CJN.06651208; QUINTON W, 1960, T AM SOC ART INT ORG, V6, P104; Raggi P, 2007, KIDNEY INT, V71, P802, DOI 10.1038/sj.ki.5002164; Rastogi A, 2009, CLIN J AM SOC NEPHRO, V4, pS132, DOI 10.2215/CJN.02860409; RETTIG RA, 1976, LAW CONTEMP PROBL, V40, P196, DOI 10.2307/1191314; Saran R, 2006, KIDNEY INT, V69, P1222, DOI 10.1038/sj.ki.5000186; Schreiner GE, 2000, AM J KIDNEY DIS, V35, pS37, DOI 10.1016/S0272-6386(00)70229-0; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P88; Singh AK, 2006, NEW ENGL J MED, V355, P2085, DOI 10.1056/NEJMoa065485; Spalding EM, 2008, KIDNEY INT, V74, P348, DOI 10.1038/ki.2008.185; Spiegel DM, 2009, CLIN J AM SOC NEPHRO, V4, P1009, DOI 10.2215/CJN.00270109; Suki WN, 2007, KIDNEY INT, V72, P1130, DOI 10.1038/sj.ki.5002466; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; Suri RS, 2006, CLIN J AM SOC NEPHRO, V1, P33, DOI 10.2215/CJN.00340705; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; Troidle L, 2007, ADV CHRONIC KIDNEY D, V14, P244, DOI 10.1053/j.ackd.2007.03.002; Unger EF, 2010, NEW ENGL J MED, V362, P189, DOI 10.1056/NEJMp0912328; VALLANCE P, 1992, LANCET, V339, P572; Vanholder R, 2008, J AM SOC NEPHROL, V19, P863, DOI 10.1681/ASN.2007121377; Wanner C, 2005, NEW ENGL J MED, V353, P1640; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Ward RA, 2004, SEMIN DIALYSIS, V17, P489, DOI 10.1111/j.0894-0959.2004.17617.x; Ward RA, 2009, BLOOD PURIFICAT, V27, P6, DOI 10.1159/000167001; Williams ME, 2006, KIDNEY INT, V70, P1503, DOI 10.1038/sj.ki.5001789; Yilmaz MI, 2009, CLIN J AM SOC NEPHRO, V4, P1716, DOI 10.2215/CJN.02760409; Yoshino M, 2006, J AM SOC NEPHROL, V17, P3510, DOI 10.1681/ASN.2006020156; Young EW, 2000, KIDNEY INT, V57, pS74, DOI 10.1046/j.1523-1755.2000.07413.x; Zoccali C, 2002, J AM SOC NEPHROL, V13, P134, DOI 10.1681/ASN.V131134	95	214	226	1	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1833	1845		10.1056/NEJMra0902710	http://dx.doi.org/10.1056/NEJMra0902710			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047227				2023-01-03	WOS:000283787800008
J	Kale, S; Yende, S; Kong, L; Perkins, A; Kellum, JA; Newman, AB; Vallejo, AN; Angus, DC				Kale, Sachin; Yende, Sachin; Kong, Lan; Perkins, Amy; Kellum, John A.; Newman, Anne B.; Vallejo, Abbe N.; Angus, Derek C.		GenIMS Investigators	The Effects of Age on Inflammatory and Coagulation-Fibrinolysis Response in Patients Hospitalized for Pneumonia	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CYTOKINE PRODUCTION; TERM MORTALITY; UNITED-STATES; OLDER-ADULTS; SEPSIS; MARKERS; FRAILTY; BACTEREMIA	Objective: To determine whether inflammatory and hemostasis response in patients hospitalized for pneumonia varies by age and whether these differences explain higher mortality in the elderly. Methods: In an observational cohort of subjects with community-acquired pneumonia (CAP) recruited from emergency departments (ED) in 28 hospitals, we divided subjects into 5 age groups (<50, 51-64, 65-74, 75-84, and >= 85). We measured circulating levels of inflammatory (TNF, IL-6, and IL-10), hemostasis (D-dimer, Factor IX, thrombin-antithrombin complex, antithrombin and plasminogen-activator inhibitor-1), and cell-surface markers (TLR-2, TLR-4, and HLA-DR) during the first week of hospitalization and at discharge and compared 90-day mortality. We used logistic regression to compare odds ratios (OR) for 90-day mortality between age groups, adjusting for differences in pre-infection factors alone and then additionally adjusting for immune markers. Results: Of 2,183 subjects, 495, 444, 403, 583, and 258 subjects were,50, 51-64, 65-74, 75-84, and >= 85 years of age, respectively. Large age-related differences were observed in 90-day mortality (0.82% vs. 3.2% vs. 6.4% vs. 12.8% vs. 13.6%, p<0.01). No age-related differences in inflammatory and cell surface markers occurred during the first week. Older subjects had higher pro-coagulant markers on ED presentation and over first week (p <= 0.03), but these differences were modest (1.0-1.7-fold differences). Odds of death for older adults changed minimally in models incorporating differences in hemostasis and inflammatory markers (for subjects >= 85 compared to those,50, OR = 4.36, when adjusted for pre-infection factors and OR = 3.49 when additionally adjusted for hemostasis markers). At discharge, despite clinical recovery as evidenced by normal vital signs in >85% subjects, older subjects had modestly increased hemostasis markers and IL-6 levels (p<0.01). Conclusions: Modest age-related increases in coagulation response occur during hospitalization for CAP; however these differences do not explain the large differences in mortality. Despite clinical recovery, immune resolution may be delayed in older adults at discharge.	[Kale, Sachin; Yende, Sachin; Kellum, John A.; Angus, Derek C.] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA; [Kale, Sachin; Yende, Sachin; Kellum, John A.; Angus, Derek C.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Kong, Lan; Perkins, Amy] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15261 USA; [Newman, Anne B.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Vallejo, Abbe N.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kale, S (corresponding author), Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Pittsburgh, PA USA.	yendes@upmc.edu	Angus, Derek C/E-9671-2012; Newman, Anne B./C-6408-2013; Kellum, John A/HCH-2944-2022; Kellum, John/AAP-3072-2020	Newman, Anne B./0000-0002-0106-1150; Kellum, John A/0000-0003-1995-2653; Kellum, John/0000-0003-1995-2653	National Institute of General Medical Sciences (NIGMS) [R01 GM61992]; NIH [T32 AG021885];  [K23 GM083215]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM083215, R01GM061992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG021885, P30AG024827] Funding Source: NIH RePORTER	National Institute of General Medical Sciences (NIGMS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	GenIMS was funded by National Institute of General Medical Sciences (NIGMS) R01 GM61992 with additional support from GlaxoSmithKline for enrollment and clinical data collection, and Diagnostic Products Corporation for the cytokine assays. Sachin Kale is supported by NIH T32 AG021885. Dr. Sachin Yende is supported by K23 GM083215. The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.	Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; Bretz WA, 2005, J AM GERIATR SOC, V53, P1532, DOI 10.1111/j.1532-5415.2005.53468.x; Bruunsgaard H, 2003, IMMUNOL ALLERGY CLIN, V23, P15, DOI 10.1016/S0889-8561(02)00056-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Christ-Crain M, 2010, CRIT CARE, V14, DOI 10.1186/cc8155; Devaraj S, 2008, J CLIN ENDOCR METAB, V93, P578, DOI 10.1210/jc.2007-2185; Dhainaut JF, 2005, CLIN INFECT DIS, V41, pS481, DOI 10.1086/432001; Epstein MP, 2003, AM J HUM GENET, V72, P611, DOI 10.1086/367924; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146; Girard TD, 2007, CLIN GERIATR MED, V23, P633, DOI 10.1016/j.cger.2007.05.003; Halm EA, 2002, NEW ENGL J MED, V347, P2039, DOI 10.1056/NEJMcp020499; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; KANE RL, 1994, ESSENTIALS CLIN GERI; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; Kaplan V, 2002, AM J RESP CRIT CARE, V165, P766, DOI 10.1164/ajrccm.165.6.2103038; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Kelly E, 2009, RESPIROLOGY, V14, P210, DOI 10.1111/j.1440-1843.2008.01423.x; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Krabbe KS, 2004, EXP GERONTOL, V39, P687, DOI 10.1016/j.exger.2004.01.009; Kumar AT, 2009, INDIAN J CRIT CARE M, V13, P74, DOI 10.4103/0972-5229.56052; Lekkou A, 2004, CLIN DIAGN LAB IMMUN, V11, P161, DOI 10.1128/CDLI.11.1.161-167.2004; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Marik PE, 2001, J AM GERIATR SOC, V49, P5, DOI 10.1046/j.1532-5415.2001.49003.x; Martin GS, 2006, CRIT CARE MED, V34, P15, DOI 10.1097/01.CCM.0000194535.82812.BA; MCDONALD AP, 2009, THROMB RES; Metersky ML, 2004, AM J RESP CRIT CARE, V169, P342, DOI 10.1164/rccm.200309-1248OC; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Nourhashemi F, 2001, J GERONTOL A-BIOL, V56, pM448, DOI 10.1093/gerona/56.7.M448; Opal SM, 2005, CLIN INFECT DIS, V41, pS504, DOI 10.1086/432007; Pajkrt D, 1997, BLOOD, V89, P2701, DOI 10.1182/blood.V89.8.2701; Pieper CF, 2000, J GERONTOL A-BIOL, V55, pM649, DOI 10.1093/gerona/55.11.M649; PRALONG G, 1989, THROMB HAEMOSTASIS, V61, P459; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; Roubenoff R, 1998, J GERONTOL A-BIOL, V53, pM20, DOI 10.1093/gerona/53A.1.M20; Samarakoon R, 2010, CELL SIGNAL, V22, P1413, DOI 10.1016/j.cellsig.2010.03.020; Saurwein-Teissl M, 2000, CYTOKINE, V12, P1160, DOI 10.1006/cyto.2000.0679; Singh M, 2008, MAYO CLIN PROC, V83, P1146, DOI 10.4065/83.10.1146; Sogaard M, 2008, J AM GERIATR SOC, V56, P1593, DOI 10.1111/j.1532-5415.2008.01855.x; Steinbach G, 2004, CLIN CHEM LAB MED, V42, P440, DOI 10.1515/CCLM.2004.077; STOWE RP, J GERONTOL A, V65, P429; Turnbull IR, 2009, CRIT CARE MED, V37, P1018, DOI 10.1097/CCM.0b013e3181968f3a; van Duin D, 2007, J AM GERIATR SOC, V55, P1438, DOI 10.1111/j.1532-5415.2007.01300.x; Vincent JL, 2006, CRIT CARE MED, V34, P344, DOI 10.1097/01.CCM.0000194725.48928.3A; Walston J, 2002, ARCH INTERN MED, V162, P2333, DOI 10.1001/archinte.162.20.2333; Waterer GW, 2004, AM J RESP CRIT CARE, V169, P910, DOI 10.1164/rccm.200310-1448OC; Yamamoto K, 2002, AM J PATHOL, V161, P1805, DOI 10.1016/S0002-9440(10)64457-4; Yende S, 2005, AM J RESP CRIT CARE, V172, P1440, DOI 10.1164/rccm.200506-888OC; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yende S, 2007, J AM GERIATR SOC, V55, P518, DOI 10.1111/j.1532-5415.2007.01100.x; Yende Sachin, 2007, Curr Infect Dis Rep, V9, P382, DOI 10.1007/s11908-007-0059-3; Zeerleder S, 2006, THROMB RES, V118, P205, DOI 10.1016/j.thromres.2005.06.007	55	24	26	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 4	2010	5	11							e13852	10.1371/journal.pone.0013852	http://dx.doi.org/10.1371/journal.pone.0013852			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	675NY	21085465	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000283838600022
J	Widodo, N; Priyandoko, D; Shah, N; Wadhwa, R; Kaul, SC				Widodo, Nashi; Priyandoko, Didik; Shah, Navjot; Wadhwa, Renu; Kaul, Sunil C.			Selective Killing of Cancer Cells by Ashwagandha Leaf Extract and Its Component Withanone Involves ROS Signaling	PLOS ONE			English	Article							FUNCTION EVOLUTION DATA; MEDIATED MECHANISM; PANCREATIC-CANCER; RIBOZYME LIBRARY; PROTEIN-SEQUENCE; IN-VITRO; DIFFERENTIATION; IDENTIFICATION; SOMNIFERA; APOPTOSIS	Background and Purpose: Ashwagandha is a popular Ayurvedic herb used in Indian traditional home medicine. It has been assigned a variety of health-promoting effects of which the mechanisms remain unknown. We previously reported the selective killing of cancer cells by leaf extract of Ashwagandha (i-Extract) and its purified component Withanone. In the present study, we investigated its mechanism by loss-of-function screening (abrogation of i-Extract induced cancer cell killing) of the cellular targets and gene pathways. Methodology/Principal Findings: Randomized ribozyme library was introduced into cancer cells prior to the treatment with i-Extract. Ribozymes were recovered from cells that survived the i-Extract treatment. Gene targets of the selected ribozymes (as predicted by database search) were analyzed by bioinformatics and pathway analyses. The targets were validated for their role in i-Extract induced selective killing of cancer cells by biochemical and molecular assays. Fifteen gene-targets were identified and were investigated for their role in specific cancer cell killing activity of i-Extract and its two major components (Withaferin A and Withanone) by undertaking the shRNA-mediated gene silencing approach. Bioinformatics on the selected gene-targets revealed the involvement of p53, apoptosis and insulin/IGF signaling pathways linked to the ROS signaling. We examined the involvement of ROS-signaling components (ROS levels, DNA damage, mitochondrial structure and membrane potential) and demonstrate that the selective killing of cancer cells is mediated by induction of oxidative stress. Conclusion: Ashwagandha leaf extract and Withanone cause selective killing of cancer cells by induction of ROS-signaling and hence are potential reagents that could be recruited for ROS-mediated cancer chemotherapy.	[Widodo, Nashi; Priyandoko, Didik; Shah, Navjot; Wadhwa, Renu; Kaul, Sunil C.] Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan; [Widodo, Nashi] Brawijaya Univ, Fac Math & Nat Sci, Dept Biol, Malang, Indonesia; [Priyandoko, Didik; Shah, Navjot] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Brawijaya University; University of Tsukuba	Widodo, N (corresponding author), Natl Inst Adv Ind Sci & Technol, Tsukuba, Ibaraki, Japan.	renu-wadhwa@aist.go.jp; s-kaul@aist.go.jp	widodo, nashi/X-4595-2019; Priyandoko, Didik/GNP-1593-2022; Kaul, Sunil C/L-8671-2018; Wadhwa, Renu/L-8898-2018	widodo, nashi/0000-0002-1126-498X; Priyandoko, Didik/0000-0001-8601-9818; Kaul, Sunil C/0000-0002-0046-3916; Wadhwa, Renu/0000-0001-8248-5192	New Energy and Industrial Technology Development Organization (Japan); MEXT, Japan	New Energy and Industrial Technology Development Organization (Japan)(New Energy and Industrial Technology Development Organization (NEDO)); MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported in part by grants from the New Energy and Industrial Technology Development Organization (Japan). N. S. is a recipient of MEXT Scholarship, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bibby RA, 2009, J BIOL CHEM, V284, P33177, DOI 10.1074/jbc.M109.032722; Breitkreutz BJ, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r23; Deocaris CC, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-14; Dietrich D, 2009, J HISTOCHEM CYTOCHEM, V57, P477, DOI 10.1369/jhc.2009.953026; Ding HM, 2009, NUTR CANCER, V61, P348, DOI 10.1080/01635580802567158; Furukawa T, 2006, ONCOGENE, V25, P4831, DOI 10.1038/sj.onc.1209494; Ge Y, 2006, BLOOD, V108, P4126, DOI 10.1182/blood-2006-04-017046; Hoye AT, 2008, ACCOUNTS CHEM RES, V41, P87, DOI 10.1021/ar700135m; Kim Y, 2003, CANCER GENE THER, V10, P707, DOI 10.1038/sj.cgt.7700623; Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08; Lebedeva IV, 2003, CANCER RES, V63, P8138; Lieber A, 1996, J VIROL, V70, P8782, DOI 10.1128/JVI.70.12.8782-8791.1996; Menendez C, 2009, CURR DRUG TARGETS, V10, P406, DOI 10.2174/138945009788185077; Mi HY, 2007, NUCLEIC ACIDS RES, V35, pD247, DOI 10.1093/nar/gkl869; Mirjalili MH, 2009, MOLECULES, V14, P2373, DOI 10.3390/molecules14072373; Mishra L C, 2000, Altern Med Rev, V5, P334; Modak M, 2007, J CLIN BIOCHEM NUTR, V40, P163, DOI 10.3164/jcbn.40.163; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Piccirillo S, 2009, J BIOL CHEM, V284, P27721, DOI 10.1074/jbc.M109.014837; Rajab A, 2008, HUM MOL GENET, V17, P2150, DOI 10.1093/hmg/ddn114; Scott WG, 2009, BBA-GENE REGUL MECH, V1789, P634, DOI 10.1016/j.bbagrm.2009.09.006; Shah N, 2009, CANCER SCI, V100, P1740, DOI 10.1111/j.1349-7006.2009.01236.x; Shah S, 2009, BIOCHEM CELL BIOL, V87, P117, DOI 10.1139/O08-107; Tanenbaum ME, 2009, CURR BIOL, V19, P1703, DOI 10.1016/j.cub.2009.08.027; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Tohda C, 2008, YAKUGAKU ZASSHI, V128, P1159, DOI 10.1248/yakushi.128.1159; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Tuschl T, 1998, EMBO J, V17, P2637, DOI 10.1093/emboj/17.9.2637; Unwalla HJ, 2008, MOL THER, V16, P1113, DOI 10.1038/mt.2008.54; Usman N, 1996, CURR OPIN STRUC BIOL, V6, P527, DOI 10.1016/S0959-440X(96)80119-9; Vlassov AV, 2004, OLIGONUCLEOTIDES, V14, P210, DOI 10.1089/oli.2004.14.210; Wadhwa R, 2004, J BIOL CHEM, V279, P51622, DOI 10.1074/jbc.M407428200; Wadhwa R, 2000, CANCER RES, V60, P6818; Warner SL, 2009, CLIN CANCER RES, V15, P6519, DOI 10.1158/1078-0432.CCR-09-0077; Welch PJ, 2000, GENOMICS, V66, P274, DOI 10.1006/geno.2000.6230; Widodo N, 2008, CANCER LETT, V262, P37, DOI 10.1016/j.canlet.2007.11.037; Widodo N, 2007, CLIN CANCER RES, V13, P2298, DOI 10.1158/1078-0432.CCR-06-0948; Widodo N, 2009, J GERONTOL A-BIOL, V64, P1031, DOI 10.1093/gerona/glp088; Winters M, 2006, ALTERN MED REV, V11, P269; Wu XJ, 2007, CANCER BIOL THER, V6, P646, DOI 10.4161/cbt.6.5.4092; Xu YM, 2009, BIOORGAN MED CHEM, V17, P2210, DOI 10.1016/j.bmc.2008.10.091; Yen Laising, 2009, V540, P335, DOI 10.1007/978-1-59745-558-9_24; Zhu Z, 2009, HEPATOLOGY, V49, P504, DOI 10.1002/hep.22675	43	101	101	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	OCT 21	2010	5	10							e13536	10.1371/journal.pone.0013536	http://dx.doi.org/10.1371/journal.pone.0013536			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	668TQ	20975835	Green Submitted, Green Published, gold			2023-01-03	WOS:000283293800010
J	Khan, JA; Kudgus, RA; Szabolcs, A; Dutta, S; Wang, EF; Cao, S; Curran, GL; Shah, V; Curley, S; Mukhopadhyay, D; Robertson, JD; Bhattacharya, R; Mukherjee, P				Khan, Jameel Ahmad; Kudgus, Rachel A.; Szabolcs, Annamaria; Dutta, Shamit; Wang, Enfeng; Cao, Sheng; Curran, Geoffry L.; Shah, Vijay; Curley, Steven; Mukhopadhyay, Debabrata; Robertson, J. David; Bhattacharya, Resham; Mukherjee, Priyabrata			Designing Nanoconjugates to Effectively Target Pancreatic Cancer Cells In Vitro and In Vivo	PLOS ONE			English	Article							GROWTH-FACTOR-RECEPTOR; FUNCTIONALIZED GOLD NANOPARTICLES; MONOCLONAL-ANTIBODY CETUXIMAB; PARTICLE-SIZE; MECHANISM; CHEMISTRY; DELIVERY; BIODISTRIBUTION; NANOTECHNOLOGY; TRAFFICKING	Background: Pancreatic cancer is the fourth leading cause of cancer related deaths in America. Monoclonal antibodies are a viable treatment option for inhibiting cancer growth. Tumor specific drug delivery could be achieved utilizing these monoclonal antibodies as targeting agents. This type of designer therapeutic is evolving and with the use of gold nanoparticles it is a promising approach to selectively deliver chemotherapeutics to malignant cells. Gold nanoparticles (GNPs) are showing extreme promise in current medicinal research. GNPs have been shown to non-invasively kill tumor cells by hyperthermia using radiofrequency. They have also been implemented as early detection agents due to their unique X-ray contrast properties; success was revealed with clear delineation of blood capillaries in a preclinical model by CT (computer tomography). The fundamental parameters for intelligent design of nanoconjugates are on the forefront. The goal of this study is to define the necessary design parameters to successfully target pancreatic cancer cells. Methodology/Principal Findings: The nanoconjugates described in this study were characterized with various physicochemical techniques. We demonstrate that the number of cetuximab molecules (targeting agent) on a GNP, the hydrodynamic size of the nanoconjugates, available reactive surface area and the ability of the nanoconjugates to sequester EGFR (epidermal growth factor receptor), all play critical roles in effectively targeting tumor cells in vitro and in vivo in an orthotopic model of pancreatic cancer. Conclusion: Our results suggest the specific targeting of tumor cells depends on a number of crucial components 1) targeting agent to nanoparticle ratio 2) availability of reactive surface area on the nanoparticle 3) ability of the nanoconjugate to bind the target and 4) hydrodynamic diameter of the nanoconjugate. We believe this study will help define the design parameters for formulating better strategies for specifically targeting tumors with nanoparticle conjugates.	[Khan, Jameel Ahmad; Kudgus, Rachel A.; Szabolcs, Annamaria; Dutta, Shamit; Wang, Enfeng; Mukhopadhyay, Debabrata; Bhattacharya, Resham; Mukherjee, Priyabrata] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Cao, Sheng; Shah, Vijay] Mayo Clin, Coll Med, Dept Med & Physiol, Rochester, MN USA; [Curley, Steven] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Mukhopadhyay, Debabrata; Mukherjee, Priyabrata] Mayo Clin, Coll Med, Ctr Canc, Rochester, MN USA; [Robertson, J. David] Univ Missouri, Dept Chem, Columbia, MO 65211 USA; [Robertson, J. David] Univ Missouri, Univ Missouri Res Reactor, Columbia, MO USA; [Mukhopadhyay, Debabrata; Mukherjee, Priyabrata] Coll Med, Dept Biomed Engn, Rochester, MN USA	Mayo Clinic; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia	Khan, JA (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.	Mukherjee.priyabrata@mayo.edu		Robertson, John/0000-0002-6675-8469	National Institutes of Health [CA135011, CA136494, CA150190]; MD Anderson Cancer Center Developmental Grant (UTMD); NATIONAL CANCER INSTITUTE [R01CA150190, R01CA136494, R01CA135011] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MD Anderson Cancer Center Developmental Grant (UTMD); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by National Institutes of Health CA135011, CA136494, CA150190 and an MD Anderson Cancer Center Developmental Grant (UTMD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartlett DW, 2007, P NATL ACAD SCI USA, V104, P15549, DOI 10.1073/pnas.0707461104; Bhattacharya R, 2008, ADV DRUG DELIVER REV, V60, P1289, DOI 10.1016/j.addr.2008.03.013; Bhattacharya R, 2007, NANOMED-NANOTECHNOL, V3, P224, DOI 10.1016/j.nano.2007.07.001; Bhattacharya R, 2007, ADV MATER, V19, P711, DOI 10.1002/adma.200602098; Bhattacharyya S, 2010, P NATL ACAD SCI USA, V107, P14541, DOI 10.1073/pnas.1006507107; Biesso A, 2009, J AM CHEM SOC, V131, P2442, DOI 10.1021/ja8088873; Burda C, 2005, CHEM REV, V105, P1025, DOI 10.1021/cr030063a; Chanda N, 2010, P NATL ACAD SCI USA, V107, P8760, DOI 10.1073/pnas.1002143107; Choi CHJ, 2010, P NATL ACAD SCI USA, V107, P1235, DOI 10.1073/pnas.0914140107; Choi HS, 2010, NAT NANOTECHNOL, V5, P42, DOI [10.1038/NNANO.2009.314, 10.1038/nnano.2009.314]; Daniel MC, 2004, CHEM REV, V104, P293, DOI 10.1021/cr030698+; De Jong WH, 2008, BIOMATERIALS, V29, P1912, DOI 10.1016/j.biomaterials.2007.12.037; Ehrenberg MS, 2009, BIOMATERIALS, V30, P603, DOI 10.1016/j.biomaterials.2008.09.050; Ferrari M, 2005, NAT REV CANCER, V5, P161, DOI 10.1038/nrc1566; Gannon Christopher J., 2008, Journal of Nanobiotechnology, V6, P2, DOI 10.1186/1477-3155-6-2; Hainfeld JF, 2006, BRIT J RADIOL, V79, P248, DOI 10.1259/bjr/13169882; Han G, 2007, NANOMEDICINE-UK, V2, P113, DOI 10.2217/17435889.2.1.113; Hirsch LR, 2003, P NATL ACAD SCI USA, V100, P13549, DOI 10.1073/pnas.2232479100; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jans H, 2009, ANAL CHEM, V81, P9425, DOI 10.1021/ac901822w; Kang B, 2010, J AM CHEM SOC, V132, P1517, DOI 10.1021/ja9102698; Khan JA, 2007, CHEMBIOCHEM, V8, P1237, DOI 10.1002/cbic.200700165; Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003; Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049; Lu Y, 2007, CANCER RES, V67, P8240, DOI 10.1158/0008-5472.CAN-07-0589; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Mangeney C, 2002, J AM CHEM SOC, V124, P5811, DOI 10.1021/ja010796h; Mirkin CA, 2000, NATURE, V405, P626, DOI 10.1038/35015190; Mukherjee P, 2005, CLIN CANCER RES, V11, P3530, DOI 10.1158/1078-0432.CCR-04-2482; Mukherjee Priyabrata, 2007, Journal of Nanobiotechnology, V5, P4, DOI 10.1186/1477-3155-5-4; Orth JD, 2006, CANCER RES, V66, P3603, DOI 10.1158/0008-5472.CAN-05-2916; Park JW, 2002, CLIN CANCER RES, V8, P1172; Patra CR, 2008, CANCER RES, V68, P1970, DOI 10.1158/0008-5472.CAN-07-6102; Patra CR, 2010, ADV DRUG DELIVER REV, V62, P346, DOI 10.1016/j.addr.2009.11.007; Perrault SD, 2009, NANO LETT, V9, P1909, DOI 10.1021/nl900031y; Rocha-Lima Caio M, 2007, Cancer Control, V14, P295; SCHREIBER AB, 1983, J BIOL CHEM, V258, P846; Slovin SF, 2009, CLIN GENITOURIN CANC, V7, pE77, DOI 10.3816/CGC.2009.n.028; Sonavane G, 2008, COLLOID SURFACE B, V66, P274, DOI 10.1016/j.colsurfb.2008.07.004; Stephan S, 2004, CLIN CANCER RES, V10, P6993, DOI 10.1158/1078-0432.CCR-04-0808; Whitesides GM, 2003, NAT BIOTECHNOL, V21, P1161, DOI 10.1038/nbt872; Xie H, 2003, ANAL CHEM, V75, P5797, DOI 10.1021/ac034578d; Yen CW, 2009, J PHYS CHEM A, V113, P4340, DOI 10.1021/jp811014u	43	54	55	0	36	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2011	6	6							e20347	10.1371/journal.pone.0020347	http://dx.doi.org/10.1371/journal.pone.0020347			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	783OD	21738572	Green Submitted, Green Published, gold			2023-01-03	WOS:000292092600001
J	Pavelko, KD; Girtman, MA; Mitsunaga, Y; Mendez-Fernandez, YV; Bell, MP; Hansen, MJ; Allen, KS; Rodriguez, M; Pease, LR				Pavelko, Kevin D.; Girtman, Megan A.; Mitsunaga, Yoshihiro; Mendez-Fernandez, Yanice V.; Bell, Michael P.; Hansen, Michael J.; Allen, Kathleen S.; Rodriguez, Moses; Pease, Larry R.			Theiler's Murine Encephalomyelitis Virus as a Vaccine Candidate for Immunotherapy	PLOS ONE			English	Article							IMMUNE-RESPONSES; LEADER PROTEIN; DANIELS STRAIN; C57BL/6 MICE; SIALIC-ACID; IN-VITRO; T-CELLS; INFECTION; BINDING; EPITOPE	The induction of sterilizing T-cell responses to tumors is a major goal in the development of T-cell vaccines for treating cancer. Although specific components of anti-viral CD8+ immunity are well characterized, we still lack the ability to mimic viral CD8+ T-cell responses in therapeutic settings for treating cancers. Infection with the picornavirus Theiler's murine encephalomyelitis virus (TMEV) induces a strong sterilizing CD8+ T-cell response. In the absence of sterilizing immunity, the virus causes a persistent infection. We capitalized on the ability of TMEV to induce strong cellular immunity even under conditions of immune deficiency by modifying the virus to evaluate its potential as a T-cell vaccine. The introduction of defined CD8+ T-cell epitopes into the leader sequence of the TMEV genome generates an attenuated vaccine strain that can efficiently drive CD8+ T-cell responses to the targeted antigen. This virus activates T-cells in a manner that is capable of inducing targeted tissue damage and glucose dysregulation in an adoptive T-cell transfer model of diabetes mellitus. As a therapeutic vaccine for the treatment of established melanoma, epitope-modified TMEV can induce strong cytotoxic T-cell responses and promote infiltration of the T-cells into established tumors, ultimately leading to a delay in tumor growth and improved survival of vaccinated animals. We propose that epitope-modified TMEV is an excellent candidate for further development as a human T-cell vaccine for use in immunotherapy.	[Pavelko, Kevin D.; Girtman, Megan A.; Mitsunaga, Yoshihiro; Mendez-Fernandez, Yanice V.; Bell, Michael P.; Hansen, Michael J.; Allen, Kathleen S.; Rodriguez, Moses; Pease, Larry R.] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Rodriguez, Moses] Mayo Clin, Dept Neurol, Rochester, MN USA	Mayo Clinic; Mayo Clinic	Pavelko, KD (corresponding author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.	pease.larry@mayo.edu	Pavelko, Kevin D/K-7072-2019	Pavelko, Kevin D/0000-0001-7555-1315; Rodriguez, Moses/0000-0001-6328-6497	Mayo Clinic, National Institutes of Health (NIH) [5R01CA104996, 5R01NS32129]; Richard M. Schulze Family Foundation; NATIONAL CANCER INSTITUTE [R01CA104996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032129] Funding Source: NIH RePORTER	Mayo Clinic, National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Richard M. Schulze Family Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work is supported by Mayo Clinic, National Institutes of Health (NIH) grants 5R01CA104996 and 5R01NS32129, and a generous gift from the Richard M. Schulze Family Foundation. The funders have no role in study design, data collection and anaylsis, decision to publish, or preparation of the manuscript.	Amato RJ, 2010, EXPERT OPIN BIOL TH, V10, P281, DOI 10.1517/14712590903586213; Au GG, 2007, BRIT J HAEMATOL, V137, P133, DOI 10.1111/j.1365-2141.2007.06550.x; Badshah C, 2000, J VIROL, V74, P875, DOI 10.1128/JVI.74.2.875-882.2000; Block MS, 2005, J IMMUNOL, V174, P2756, DOI 10.4049/jimmunol.174.5.2756; BORROW P, 1992, J GEN VIROL, V73, P1861, DOI 10.1099/0022-1317-73-7-1861; Borson ND, 1997, J VIROL, V71, P5244, DOI 10.1128/JVI.71.7.5244-5250.1997; Budhu S, 2010, J EXP MED, V207, P223, DOI 10.1084/jem.20091279; Delhaye S, 2004, J VIROL, V78, P4357, DOI 10.1128/JVI.78.8.4357-4362.2004; Dethlefs S, 1997, J VIROL, V71, P5361, DOI 10.1128/JVI.71.7.5361-5365.1997; Dunlop LR, 2003, MICROBES INFECT, V5, P1049, DOI 10.1016/S1286-4579(03)00194-1; Gallo P, 2005, GENE THER, V12, pS84, DOI 10.1038/sj.gt.3302619; Goetz C, 2010, CYTOKINE GROWTH F R, V21, P197, DOI 10.1016/j.cytogfr.2010.02.005; Hales LM, 2008, J GEN VIROL, V89, P1265, DOI 10.1099/vir.0.83570-0; HEMMI S, 1988, J EXP MED, V168, P2319, DOI 10.1084/jem.168.6.2319; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hwang C, 1999, CURR OPIN MOL THER, V1, P471; Jnaoui K, 2002, J VIROL, V76, P8138, DOI 10.1128/JVI.76.16.8138-8147.2002; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; Jones MS, 2007, J CLIN MICROBIOL, V45, P2144, DOI 10.1128/JCM.00174-07; Kang MH, 2008, GLIA, V56, P942, DOI 10.1002/glia.20668; Kumar ASM, 2003, J VIROL, V77, P2709, DOI 10.1128/JVI.77.4.2709-2716.2003; Lin XQ, 1998, J VIROL, V72, P1262, DOI 10.1128/JVI.72.2.1262-1269.1998; LINDSLEY MD, 1991, J VIROL, V65, P6612, DOI 10.1128/JVI.65.12.6612-6620.1991; Lipton HL, 2001, VIRUS RES, V76, P79, DOI 10.1016/S0168-1702(01)00256-8; Lukashev AN, 2010, REV MED VIROL, V20, P327, DOI 10.1002/rmv.660; Myoung J, 2007, VIROLOGY, V360, P159, DOI 10.1016/j.virol.2006.09.045; NITAYAPHAN S, 1985, J VIROL, V56, P887, DOI 10.1128/JVI.56.3.887-895.1985; Olson JK, 2002, J IMMUNOL, V169, P2719, DOI 10.4049/jimmunol.169.5.2719; Parish Christopher R, 2009, Curr Protoc Immunol, VChapter 4, DOI 10.1002/0471142735.im0409s84; Reddi HV, 2003, J GEN VIROL, V84, P845, DOI 10.1099/vir.0.18746-0; Reiman JM, 2007, SEMIN CANCER BIOL, V17, P275, DOI 10.1016/j.semcancer.2007.06.009; RODRIGUEZ M, 1983, LAB INVEST, V49, P672; RODRIGUEZ M, 1986, J EXP MED, V163, P620, DOI 10.1084/jem.163.3.620; RODRIGUEZ M, 1983, ANN NEUROL, V13, P426, DOI 10.1002/ana.410130409; ROOS RP, 1989, J VIROL, V63, P5492, DOI 10.1128/JVI.63.12.5492-5496.1989; Rossi CP, 1998, J VIROL, V72, P4515; Schagen FHE, 2004, CRIT REV ONCOL HEMAT, V50, P51, DOI 10.1016/S1040-8428(03)00172-0; van Pesch V, 2001, J VIROL, V75, P7811, DOI 10.1128/JVI.75.17.7811-7817.2001; Zhang G, 1999, J GEN VIROL, V80, P639, DOI 10.1099/0022-1317-80-3-639; Zoll J, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000416	40	20	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2011	6	5							e20217	10.1371/journal.pone.0020217	http://dx.doi.org/10.1371/journal.pone.0020217			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766OI	21625449	Green Published, gold, Green Submitted			2023-01-03	WOS:000290793400047
J	Webb, DJ				Webb, David J.			Value-based medicine pricing: NICE work?	LANCET			English	Editorial Material									Univ Edinburgh, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland	University of Edinburgh	Webb, DJ (corresponding author), Univ Edinburgh, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh EH16 4TJ, Midlothian, Scotland.	cpu@ed.ac.uk						*2020HEALTH ORG, 2009, IMPR PAT OUTC CAN VA; BOSELEY S, 2010, NICE LOSE POWERS DEC; Collier J, 2007, BRIT MED J, V334, P435, DOI 10.1136/bmj.39136.464421.BE; *DEP BUS INN SKILL, 2009, PHARM PRIC REG SCHEM; Hutton J, 2007, INT J TECHNOL ASSESS, V23, P425, DOI 10.1017/S0266462307070651; Martin S., 2007, LINK HEALTHCARE SPEN; Taylor D, 2009, HEALTH ECON POLICY L, V4, P515, DOI 10.1017/S1744133109990247; Webb DJ, 2007, LANCET, V369, P1415, DOI 10.1016/S0140-6736(07)60648-5; 2007, PHARM PRICE REGULATI	9	13	14	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 7	2011	377	9777					1552	1553		10.1016/S0140-6736(10)62137-X	http://dx.doi.org/10.1016/S0140-6736(10)62137-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	763IJ	21093902				2023-01-03	WOS:000290549700008
J	Joshi, D; O'Grady, J; Dieterich, D; Gazzard, B; Agarwal, K				Joshi, Deepak; O'Grady, John; Dieterich, Doug; Gazzard, Brian; Agarwal, Kosh			Increasing burden of liver disease in patients with HIV infection	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; NONCIRRHOTIC PORTAL-HYPERTENSION; NODULAR REGENERATIVE HYPERPLASIA; ACTIVE ANTIRETROVIRAL THERAPY; ALPHA-2A PLUS RIBAVIRIN; B-VIRUS; RISK-FACTORS; HEPATOCELLULAR-CARCINOMA; PEGYLATED INTERFERON	Introduction of effective combined antiretroviral therapy has made HIV infection a chronic illness. Substantial reductions in the number of AIDS-related deaths have been accompanied by an increase in liver-related morbidity and mortality due to co-infection with chronic hepatitis B and C viruses. Increases in non-alcoholic fatty liver disease and drug-induced hepatotoxicity, together with development of hepatocellular carcinoma, also potentiate the burden of liver disease in individuals with HIV infection. We provide an overview of the key causes, disease mechanisms of pathogenesis, and recommendations for treatment options including the evolving role of liver transplantation.	[Joshi, Deepak; O'Grady, John; Agarwal, Kosh] Kings Coll Hosp London, Inst Liver Studies, London SE5 9RS, England; [Dieterich, Doug] Mt Sinai Hosp, Dept Med, New York, NY 10029 USA; [Gazzard, Brian] Chelsea & Westminster Hosp, Dept HIV Med, London, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Icahn School of Medicine at Mount Sinai; Imperial College London	Agarwal, K (corresponding author), Kings Coll Hosp London, Inst Liver Studies, Denmark Hill, London SE5 9RS, England.	kosh.agarwal@nhs.net	Agarwal, Kosh/ABH-8721-2020	Agarwal, Kosh/0000-0002-4754-828X	Gilead Sciences; Merck Sharpe and Dohme; AIDS Research Trust; Bristol-Myers Squibb; Johnson and Johnson	Gilead Sciences(Gilead Sciences); Merck Sharpe and Dohme(Merck & Company); AIDS Research Trust; Bristol-Myers Squibb(Bristol-Myers Squibb); Johnson and Johnson(Johnson & JohnsonJohnson & Johnson USA)	BC and BG's institution have received consultancy fees from Gilead Sciences, and Merck Sharpe and Dohme; BG's institution has received grants from AIDS Research Trust; and BC has received payment for development of educational presentations from Bristol-Myers Squibb, and Johnson and Johnson. All other authors declare that they have no conflicts of interest.	Altavilla G, 2000, AM J PATHOL, V157, P1081, DOI 10.1016/S0002-9440(10)64622-6; Angulo P, 2007, ALIMENT PHARM THER, V25, P883, DOI 10.1111/j.1365-2036.2007.03246.x; [Anonymous], 1999, VIR NELF PRESCR INF; [Anonymous], 2001, CRIX IND SULF PRESCR; [Anonymous], 1998, FORT SAQ PRESCR INF; [Anonymous], 2003, REYAT AT SULF PRESCR; [Anonymous], 1999, NORV RIT PRESCR INF; Aranzabal L, 2005, CLIN INFECT DIS, V40, P588, DOI 10.1086/427216; Balagopal A, 2008, GASTROENTEROLOGY, V135, P226, DOI 10.1053/j.gastro.2008.03.022; Bani- Sadr F, 2005, CLIN INFECT DIS, V41, P1806, DOI 10.1086/498312; Benhamou Y, 1999, HEPATOLOGY, V30, P1054, DOI 10.1002/hep.510300409; Benhamou Y, 2004, 11 C RETR OPP INF FE; Berenguer J, 2009, HEPATOLOGY, V50, P407, DOI 10.1002/hep.23020; Blackard JT, 2006, J MED VIROL, V78, P202, DOI 10.1002/jmv.20528; Blanco F, 2011, J VIRAL HEPATITIS, V18, P11, DOI 10.1111/j.1365-2893.2009.01261.x; Bollepalli S, 2007, SEX TRANSM DIS, V34, P367, DOI 10.1097/01.olq.0000240295.35457.b1; Bonnard P, 2007, J VIRAL HEPATITIS, V14, P806, DOI 10.1111/j.1365-2893.2007.00874.x; Bossi P, 2000, CLIN INFECT DIS, V30, P227, DOI 10.1086/313629; Brau N, 2007, J HEPATOL, V47, P527, DOI 10.1016/j.jhep.2007.06.010; Brook G, 2010, HIV MED, V11, P1, DOI 10.1111/j.1468-1293.2009.00781.x; Bruno R, 2010, GUT, V59, P513, DOI 10.1136/gut.2008.163287; Cargnel A, 2005, ANTIVIR THER, V10, P309; Carrat F, 2004, JAMA-J AM MED ASSOC, V292, P2839, DOI 10.1001/jama.292.23.2839; Chander G, 2006, JAIDS-J ACQ IMM DEF, V43, P411, DOI 10.1097/01.qai.0000243121.44659.a4; Chapman Louisa E., 2008, Morbidity and Mortality Weekly Report, V57, P1; Chaudhry AA, 2009, HIV MED, V10, P133, DOI 10.1111/j.1468-1293.2008.00662.x; Chung RT, 2004, NEW ENGL J MED, V351, P451, DOI 10.1056/NEJMoa032653; Colin JF, 1999, HEPATOLOGY, V29, P1306, DOI 10.1002/hep.510290447; Cooper CL, 2002, CLIN INFECT DIS, V34, P1259, DOI 10.1086/339867; Crum-Cianflone N, 2009, JAIDS-J ACQ IMM DEF, V50, P464, DOI 10.1097/QAI.0b013e318198a88a; Danta M, 2007, AIDS, V21, P983, DOI 10.1097/QAD.0b013e3281053a0c; de Vera ME, 2006, AM J TRANSPLANT, V6, P2983, DOI 10.1111/j.1600-6143.2006.01546.x; den Brinker M, 2000, AIDS, V14, P2895, DOI 10.1097/00002030-200012220-00011; Dominguez S, 2006, AIDS, V20, P1157, DOI 10.1097/01.aids.0000226956.02719.fd; Dore GJ, 1999, J INFECT DIS, V180, P607, DOI 10.1086/314942; Dore GJ, 2010, AIDS, V24, P857, DOI 10.1097/QAD.0b013e328334bddb; DORRUCCI M, 1995, J INFECT DIS, V172, P1503, DOI 10.1093/infdis/172.6.1503; Duclos-Vallee JC, 2008, HEPATOLOGY, V47, P407, DOI 10.1002/hep.21990; Ena J, 2003, INT J STD AIDS, V14, P776, DOI 10.1258/09564620360719840; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fox J, 2008, AIDS, V22, P666, DOI 10.1097/QAD.0b013e3282f5f4cf; Garba ML, 2002, J IMMUNOL, V168, P2247, DOI 10.4049/jimmunol.168.5.2247; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Gilson RJC, 1997, AIDS, V11, P597, DOI 10.1097/00002030-199705000-00007; Gotz HM, 2005, AIDS, V19, P969, DOI 10.1097/01.aids.0000171412.61360.f8; Graham CS, 2001, CLIN INFECT DIS, V33, P562, DOI 10.1086/321909; Graham CS, 2004, HEPATOLOGY, V40, P125, DOI 10.1002/hep.20258; Greub G, 2000, LANCET, V356, P1800, DOI 10.1016/S0140-6736(00)03232-3; Guaraldi G, 2008, CLIN INFECT DIS, V47, P250, DOI 10.1086/589294; Hadziyannis SJ, 2005, NEW ENGL J MED, V352, P2673, DOI 10.1056/NEJMoa042957; Haydon GH, 1998, EUR J GASTROEN HEPAT, V10, P485, DOI 10.1097/00042737-199806000-00009; Hoffmann CJ, 2009, AIDS, V23, P1881, DOI 10.1097/QAD.0b013e32832e463a; Iloeje UH, 2006, GASTROENTEROLOGY, V130, P678, DOI 10.1053/j.gastro.2005.11.016; Ingiliz P, 2009, HEPATOLOGY, V49, P436, DOI 10.1002/hep.22665; Joint UN Programme on HIV/AIDS, 2006 REP GLOB AIDS E; Joshi D, 2008, 59 ANN M AM ASS STUD; Kamath PS, 2007, HEPATOLOGY, V45, P797, DOI 10.1002/hep.21563; Kellerman SE, 2003, J INFECT DIS, V188, P571, DOI 10.1086/377135; Kovari H, 2010, CLIN INFECT DIS, V50, P502, DOI 10.1086/649922; Kovari H, 2009, CLIN INFECT DIS, V49, P626, DOI 10.1086/603559; Koziel MJ, 2007, NEW ENGL J MED, V356, P1445, DOI 10.1056/NEJMra065142; Lafeuillade A, 2001, LANCET, V357, P280, DOI 10.1016/S0140-6736(00)03618-7; Laguno M, 2005, ANTIVIR THER, V10, P423; Laguno M, 2009, HEPATOLOGY, V49, P22, DOI 10.1002/hep.22598; Lin W, 2008, GASTROENTEROLOGY, V134, P803, DOI 10.1053/j.gastro.2008.01.005; Maida I, 2006, JAIDS-J ACQ IMM DEF, V42, P177, DOI 10.1097/01.qai.0000221683.44940.62; Mallet V, 2007, HEPATOLOGY, V46, p576A; Mallet V, 2007, AIDS, V21, P187, DOI 10.1097/QAD.0b013e3280119e47; Marcellin P, 2009, J HEPATOL, V50, P227, DOI 10.1016/j.jhep.2008.10.001; Martin-Carbonero L, 2009, J VIRAL HEPATITIS, V16, P790, DOI 10.1111/j.1365-2893.2009.01133.x; Matteoni CA, 1999, GASTROENTEROLOGY, V116, P1413, DOI 10.1016/S0016-5085(99)70506-8; Mauss S, 2004, AIDS, V18, pF21, DOI 10.1097/00002030-200409030-00002; McHutchison JG, 2009, NEW ENGL J MED, V361, P580, DOI 10.1056/NEJMoa0808010; Miailhes P, 2011, J VIRAL HEPATITIS, V18, P61, DOI 10.1111/j.1365-2893.2010.01275.x; Miller MF, 2005, CLIN INFECT DIS, V41, P713, DOI 10.1086/432618; Mindikoglu AL, 2008, TRANSPLANTATION, V85, P359, DOI 10.1097/TP.0b013e3181605fda; Mocroft A, 2002, AIDS, V16, P1663, DOI 10.1097/00002030-200208160-00012; Mohammed SS, 2007, JAIDS-J ACQ IMM DEF, V45, P432, DOI 10.1097/QAI.0b013e318074efe3; Moreno A, 2006, J VIRAL HEPATITIS, V13, P466, DOI 10.1111/j.1365-2893.2005.00710.x; Moyle Graeme, 2002, HIV Clin Trials, V3, P89; Murillas J, LIVER TRANSPL, V15, P1133; Nunez M, 2006, J HEPATOL, V44, pS132, DOI 10.1016/j.jhep.2005.11.027; Nunez M, 2007, AIDS RES HUM RETROV, V23, P972, DOI 10.1089/aid.2007.0011; O'Grady J, 2005, HIV MED, V6, P149, DOI 10.1111/j.1468-1293.2005.00303.x; Pasquier C, 2003, J MED VIROL, V69, P344, DOI 10.1002/jmv.10295; Peters MG, 2006, HEPATOLOGY, V44, P1110, DOI 10.1002/hep.21388; Pineda JA, 2005, HEPATOLOGY, V41, P779, DOI 10.1002/hep.20626; Pineda JA, 2007, HEPATOLOGY, V46, P622, DOI 10.1002/hep.21757; Puoti M, 2004, AIDS, V18, P2285, DOI 10.1097/00002030-200411190-00009; Ragni MV, 2003, J INFECT DIS, V188, P1412, DOI 10.1086/379254; Rallon NI, 2010, AIDS, V24, pF23, DOI 10.1097/QAD.0b013e3283391d6d; Rauch A, 2010, GASTROENTEROLOGY, V138, P1338, DOI 10.1053/j.gastro.2009.12.056; Rivero A, 2007, J ANTIMICROB CHEMOTH, V59, P342, DOI 10.1093/jac/dkl524; Rosenthal E, 2007, J VIRAL HEPATITIS, V14, P183, DOI 10.1111/j.1365-2893.2006.00791.x; Safadi R, 2004, GASTROENTEROLOGY, V127, P870, DOI 10.1053/j.gastro.2004.04.062; Saifee S, 2008, CLIN GASTROENTEROL H, V6, P1167, DOI 10.1016/j.cgh.2008.04.023; Salmon-Ceron D, 2005, J HEPATOL, V42, P799, DOI 10.1016/j.jhep.2005.01.022; Salmon-Ceron D, 2009, J HEPATOL, V50, P736, DOI 10.1016/j.jhep.2008.11.018; Sandrine PF, 2007, AIDS, V21, P1498, DOI 10.1097/QAD.0b013e328235a54c; Sanne I, 2005, J INFECT DIS, V191, P825, DOI 10.1086/428093; Sauleda S, 2006, HAEMOPHILIA, V12, P228, DOI 10.1111/j.1365-2516.2006.01211.x; Schiano TD, 2007, AM J GASTROENTEROL, V102, P2536, DOI 10.1111/j.1572-0241.2007.01428.x; Servoss JC, 2006, JAIDS-J ACQ IMM DEF, V43, P320, DOI 10.1097/01.qai.0000243054.58074.59; Shintani Y, 2004, GASTROENTEROLOGY, V126, P840, DOI 10.1053/j.gastro.2003.11.056; Shlay JC, 2007, JAIDS-J ACQ IMM DEF, V44, P506, DOI 10.1097/QAI.0b013e31804216cf; Soriano V, 2008, AIDS, V22, P1399, DOI 10.1097/QAD.0b013e3282f8b46f; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; Subramanian A, 2010, GASTROENTEROLOGY, V138, P159, DOI 10.1053/j.gastro.2009.09.053; Sulkowski MS, 2004, CLIN INFECT DIS, V38, pS90, DOI 10.1086/381444; Sulkowski MS, 2000, JAMA-J AM MED ASSOC, V283, P2526; Sulkowski MS, 2002, HEPATOLOGY, V35, P182, DOI 10.1053/jhep.2002.30319; Sulkowski MS, 2005, AIDS, V19, P585, DOI 10.1097/01.aids.0000163935.99401.25; Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Terrault NA, 2009, 60 ANN M AM ASS STUD; Terrault NA, 2006, LIVER TRANSPLANT, V12, P801, DOI 10.1002/lt.20776; Thio CL, 2002, LANCET, V360, P1921, DOI 10.1016/S0140-6736(02)11913-1; Torriani FJ, 2004, NEW ENGL J MED, V351, P438, DOI 10.1056/NEJMoa040842; Tricot L, 2009, AM J TRANSPLANT, V9, P1946, DOI 10.1111/j.1600-6143.2009.02684.x; Trotti R, 2001, Minerva Gastroenterol Dietol, V47, P205; Tuma P, 2010, AIDS, V24, P745, DOI 10.1097/QAD.0b013e3283366602; Vergara S, 2007, CLIN INFECT DIS, V45, P969, DOI 10.1086/521857; Vispo E, 2010, AIDS, V24, P1171, DOI 10.1097/QAD.0b013e3283389e26; Wang CC, 2007, J INFECT DIS, V196, P1474, DOI 10.1086/522608; Wasley Annemarie, 2008, Morbidity and Mortality Weekly Report, V57, P1; Weber R, 2006, ARCH INTERN MED, V166, P1632, DOI 10.1001/archinte.166.15.1632; Wolters LMM, 2002, J CLIN VIROL, V24, P173, DOI 10.1016/S1386-6532(01)00245-1; Worm SW, 2010, AIDS, V24, P427, DOI 10.1097/QAD.0b013e328334344e	127	202	210	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	2011	377	9772					1198	1209		10.1016/S0140-6736(10)62001-6	http://dx.doi.org/10.1016/S0140-6736(10)62001-6			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	750IH	21459211				2023-01-03	WOS:000289539300036
J	Adzick, NS; Thom, EA; Spong, CY; Brock, JW; Burrows, PK; Johnson, MP; Howell, LJ; Farrell, JA; Dabrowiak, ME; Sutton, LN; Gupta, N; Tulipan, NB; D'Alton, ME; Farmer, DL				Adzick, N. Scott; Thom, Elizabeth A.; Spong, Catherine Y.; Brock, John W., III; Burrows, Pamela K.; Johnson, Mark P.; Howell, Lori J.; Farrell, Jody A.; Dabrowiak, Mary E.; Sutton, Leslie N.; Gupta, Nalin; Tulipan, Noel B.; D'Alton, Mary E.; Farmer, Diana L.		MOMS Investigators	A Randomized Trial of Prenatal versus Postnatal Repair of Myelomeningocele	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL-FETAL SURGERY; IN-UTERO; HINDBRAIN HERNIATION; MODEL	BACKGROUND Prenatal repair of myelomeningocele, the most common form of spina bifida, may result in better neurologic function than repair deferred until after delivery. We compared outcomes of in utero repair with standard postnatal repair. METHODS We randomly assigned eligible women to undergo either prenatal surgery before 26 weeks of gestation or standard postnatal repair. One primary outcome was a composite of fetal or neonatal death or the need for placement of a cerebrospinal fluid shunt by the age of 12 months. Another primary outcome at 30 months was a composite of mental development and motor function. RESULTS The trial was stopped for efficacy of prenatal surgery after the recruitment of 183 of a planned 200 patients. This report is based on results in 158 patients whose children were evaluated at 12 months. The first primary outcome occurred in 68% of the infants in the prenatal-surgery group and in 98% of those in the postnatal-surgery group (relative risk, 0.70; 97.7% confidence interval [CI], 0.58 to 0.84; P<0.001). Actual rates of shunt placement were 40% in the prenatal-surgery group and 82% in the postnatal-surgery group (relative risk, 0.48; 97.7% CI, 0.36 to 0.64; P<0.001). Prenatal surgery also resulted in improvement in the composite score for mental development and motor function at 30 months (P = 0.007) and in improvement in several secondary outcomes, including hindbrain herniation by 12 months and ambulation by 30 months. However, prenatal surgery was associated with an increased risk of preterm delivery and uterine dehiscence at delivery. CONCLUSIONS Prenatal surgery for myelomeningocele reduced the need for shunting and improved motor outcomes at 30 months but was associated with maternal and fetal risks.	[Adzick, N. Scott] Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, Philadelphia, PA 19104 USA; [Adzick, N. Scott; Johnson, Mark P.; Howell, Lori J.; Sutton, Leslie N.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Thom, Elizabeth A.; Burrows, Pamela K.] George Washington Univ, Ctr Biostat, Washington, DC USA; [Spong, Catherine Y.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Brock, John W., III; Dabrowiak, Mary E.; Tulipan, Noel B.] Vanderbilt Univ, Med Ctr, Nashville, TN USA; [Farrell, Jody A.; Gupta, Nalin; Farmer, Diana L.] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Farrell, Jody A.; Gupta, Nalin; Farmer, Diana L.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; [D'Alton, Mary E.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; George Washington University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Vanderbilt University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Columbia University	Adzick, NS (corresponding author), Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	adzick@email.chop.edu	Drehmer, Jeremy/J-5873-2019	Drehmer, Jeremy/0000-0002-5022-5836; Cochrane, Douglas/0000-0002-4907-4583; Sugarman, Jeremy/0000-0001-7022-8332; Farmer, Diana/0000-0002-3530-5993	Eunice Kennedy Shriver National Institute of Child Health and Human Development [U10 HD041666, U01HD041665, U10 HD041667, U10 HD041669]; National Institutes of Health [UL1-RR-024134, UL1-RR-024131, UL1-RR-024975]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U10HD041667, U10HD041666, U10HD041669, U01HD041665] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024131, TL1RR024978, UL1RR024975, UL1RR024134, KL2RR024977] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Supported by grants (U10 HD041666, U01HD041665, U10 HD041667, and U10 HD041669) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by grants (UL1-RR-024134, UL1-RR-024131, and UL1-RR-024975) from the Clinical and Translational Science Awards, National Institutes of Health.	ADZICK NS, 1986, J PEDIATR SURG, V21, P477, DOI 10.1016/S0022-3468(86)80215-9; Bouchard S, 2003, J PEDIATR SURG, V38, P451, DOI 10.1053/jpsu.2003.50078; Boulet SL, 2008, BIRTH DEFECTS RES A, V82, P527, DOI 10.1002/bdra.20468; Caldarelli M, 1996, CHILD NERV SYST, V12, P748, DOI 10.1007/BF00261592; Danzer E, 2010, NEUROPEDIATRICS, V41, P140, DOI 10.1055/s-0030-1263164; Danzer E, 2008, NEUROPEDIATRICS, V39, P359, DOI 10.1055/s-0029-1202835; Danzer E, 2009, FETAL DIAGN THER, V25, P47, DOI 10.1159/000197359; Farrell JA, 1999, FETAL DIAGN THER, V14, P190, DOI 10.1159/000020918; HEFFEZ DS, 1993, NEUROSURGERY, V32, P1005, DOI 10.1227/00006123-199306000-00021; Hunt GM, 1997, DEV MED CHILD NEUROL, V39, P568; Johnson MP, 2006, AM J OBSTET GYNECOL, V194, P1145, DOI 10.1016/j.ajog.2006.01.072; Johnson MP, 2003, AM J OBSTET GYNECOL, V189, P482, DOI 10.1067/S0002-9378(03)00295-3; KORENROMP MJ, 1986, LANCET, V1, P917, DOI 10.1016/S0140-6736(86)91022-6; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Manning SM, 2000, MENT RETARD DEV D R, V6, P6, DOI 10.1002/(SICI)1098-2779(2000)6:1<6::AID-MRDD2>3.0.CO;2-B; MEULI M, 1995, J PEDIATR SURG, V30, P1028, DOI 10.1016/0022-3468(95)90335-6; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; Mitchell LE, 2004, LANCET, V364, P1885, DOI 10.1016/S0140-6736(04)17445-X; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Paek BW, 2000, AM J OBSTET GYNECOL, V183, P1119, DOI 10.1067/mob.2000.108867; Rintoul NE, 2002, PEDIATRICS, V109, P409, DOI 10.1542/peds.109.3.409; SHURTLEFF DB, 1994, CIBA F SYMP, V181, P270; Sival DA, 1997, EARLY HUM DEV, V50, P27, DOI 10.1016/S0378-3782(97)00090-X; Sutton LN, 1999, JAMA-J AM MED ASSOC, V282, P1826, DOI 10.1001/jama.282.19.1826; Tulipan N, 1999, PEDIATR NEUROSURG, V31, P183, DOI 10.1159/000028859; WEI LJ, 1978, J AM STAT ASSOC, V73, P559, DOI 10.2307/2286600; Wilson RD, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.03.029; Wilson RD, 2003, FETAL DIAGN THER, V18, P314, DOI 10.1159/000071972	28	1119	1144	1	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2011	364	11					993	1004		10.1056/NEJMoa1014379	http://dx.doi.org/10.1056/NEJMoa1014379			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	735SX	21306277	Green Accepted			2023-01-03	WOS:000288439000005
J	Buchowski, MS; Meade, NN; Charboneau, E; Park, S; Dietrich, MS; Cowan, RL; Martin, PR				Buchowski, Maciej S.; Meade, Natalie N.; Charboneau, Evonne; Park, Sohee; Dietrich, Mary S.; Cowan, Ronald L.; Martin, Peter R.			Aerobic Exercise Training Reduces Cannabis Craving and Use in Non-Treatment Seeking Cannabis-Dependent Adults	PLOS ONE			English	Article							PSYCHOLOGICAL STRESS; CIGARETTE CRAVINGS; PHYSICAL-ACTIVITY; RAT; ACTIVATION; DEPRESSION; RECOVERY; BINDING	Background: Cannabis dependence is a significant public health problem. Because there are no approved medications for this condition, treatment must rely on behavioral approaches empirically complemented by such lifestyle change as exercise. Aims: To examine the effects of moderate aerobic exercise on cannabis craving and use in cannabis dependent adults under normal living conditions. Design: Participants attended 10 supervised 30-min treadmill exercise sessions standardized using heart rate (HR) monitoring (60-70% HR reserve) over 2 weeks. Exercise sessions were conducted by exercise physiologists under medical oversight. Participants: Sedentary or minimally active non-treatment seeking cannabis-dependent adults (n = 12, age 25 +/- 63 years, 8 females) met criteria for primary cannabis dependence using the Substance Abuse module of the Structured Clinical Interview for DSM-IV (SCID). Measurements: Self-reported drug use was assessed for 1-week before, during, and 2-weeks after the study. Participants viewed visual cannabis cues before and after exercise in conjunction with assessment of subjective cannabis craving using the Marijuana Craving Questionnaire (MCQ-SF). Findings: Daily cannabis use within the run-in period was 5.9 joints per day (SD = 3.1, range 1.8-10.9). Average cannabis use levels within the exercise (2.8 joints, SD = 1.6, range 0.9-5.4) and follow-up (4.1 joints, SD = 2.5, range 1.1-9.5) periods were lower than during the run-in period (both P <.005). Average MCQ factor scores for the pre- and post-exercise craving assessments were reduced for compulsivity (P = .006), emotionality (P = .002), expectancy (P = .002), and purposefulness (P = .002). Conclusions: The findings of this pilot study warrant larger, adequately powered controlled trials to test the efficacy of prescribed moderate aerobic exercise as a component of cannabis dependence treatment. The neurobiological mechanisms that account for these beneficial effects on cannabis use may lead to understanding of the physical and emotional underpinnings of cannabis dependence and recovery from this disorder.	[Buchowski, Maciej S.; Meade, Natalie N.] Vanderbilt Univ, Dept Med, Div Gastroenterol Hepatol & Nutr, Energy Balance Lab, Nashville, TN 37203 USA; [Charboneau, Evonne; Dietrich, Mary S.; Cowan, Ronald L.; Martin, Peter R.] Vanderbilt Univ, Dept Psychiat, Addict Ctr, Nashville, TN USA; [Charboneau, Evonne; Dietrich, Mary S.; Cowan, Ronald L.; Martin, Peter R.] Vanderbilt Univ, Dept Psychiat, Psychiat Neuroimaging Program, Nashville, TN USA; [Park, Sohee; Cowan, Ronald L.] Vanderbilt Univ, Dept Psychol, Nashville, TN 37240 USA; [Dietrich, Mary S.] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA; [Cowan, Ronald L.] Vanderbilt Univ, Dept Radiol & Radiol Sci, Nashville, TN USA; [Cowan, Ronald L.] Vanderbilt Univ, Inst Imaging Sci, Nashville, TN USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Buchowski, MS (corresponding author), Vanderbilt Univ, Dept Med, Div Gastroenterol Hepatol & Nutr, Energy Balance Lab, Nashville, TN 37203 USA.	maciej.buchowski@vanderbilt.edu	Martin, Peter R/A-7738-2008; Buchowski, Maciej S./A-2683-2008	Buchowski, Maciej S./0000-0002-0566-1743; Park, Sohee/0000-0003-3797-4776	National Center for Research Resources (NCRR/NIH), Vanderbilt Institute for Clinical and Translational Research (VICTR) [1UL1 RR024975]; National Institute on Drug Abuse (NIDA/NIH) [R01 DA01537, R21 DA020149, 1R01 DA015713]; Vanderbilt Addiction Center;  [DK69465]; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK069465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015713, R21DA020149] Funding Source: NIH RePORTER	National Center for Research Resources (NCRR/NIH), Vanderbilt Institute for Clinical and Translational Research (VICTR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); National Institute on Drug Abuse (NIDA/NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Vanderbilt Addiction Center; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was supported in part by the Vanderbilt Institute for Clinical and Translational Research (VICTR) grant 1UL1 RR024975 from the National Center for Research Resources (NCRR/NIH), and from grants R01 DA01537 and R21 DA020149 from the National Institute on Drug Abuse (NIDA/NIH) (to RLC), 1R01 DA015713 from NIDA/NIH (to PRM), and from the Vanderbilt Addiction Center. MSB was supported in part by DK69465. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2008, DRUG ALCOHOL DEPEN, V95, P107, DOI 10.1016/j.drugalcdep.2007.12.017; American College of Sports Medicine, 2008, ACSMS GUID EX TEST P; ARPANA A, 2008, ADDICTION, V103, P1896; Brown Richard A, 2010, Ment Health Phys Act, V3, P27; Brown RA, 2009, BEHAV MODIF, V33, P220, DOI 10.1177/0145445508329112; BUDNEY A, 2007, ADDICTION SCI CLIN P, V4, P1; Cowan RL, 2006, PHARMACOL BIOCHEM BE, V84, P219, DOI 10.1016/j.pbb.2006.04.024; Cowan RL, 2008, SYNAPSE, V62, P268, DOI 10.1002/syn.20491; Cowan RL, 2007, PSYCHIAT RES-NEUROIM, V155, P179, DOI 10.1016/j.pscychresns.2007.01.008; Cowan RL, 2009, PHARMACOL BIOCHEM BE, V92, P105, DOI 10.1016/j.pbb.2008.10.022; Dunn AL, 2005, AM J PREV MED, V28, P1, DOI 10.1016/j.amepre.2004.09.003; First M.B., 1994, USERS GUIDE SCID 5 P; Fisher BE, 2004, J NEUROSCI RES, V77, P378, DOI 10.1002/jnr.20162; GILLIAM PE, 1984, PHARMACOL BIOCHEM BE, V20, P863, DOI 10.1016/0091-3057(84)90008-X; HATTORI S, 1994, BRAIN RES BULL, V35, P41, DOI 10.1016/0361-9230(94)90214-3; Heishman SJ, 2006, METH MOLEC MED, V123, P209; Heishman SJ, 2009, DRUG ALCOHOL DEPEN, V102, P35, DOI 10.1016/j.drugalcdep.2008.12.010; Johnson PL, 2008, NEUROPSYCHOPHARMACOL, V33, P2093, DOI 10.1038/sj.npp.1301621; LYNCH WJ, 2010, BIOL PSYCHI IN PRESS; MACRAE PG, 1987, PSYCHOPHARMACOLOGY, V92, P236; Martin PR, 2005, AM J ADDICTION, V14, P1, DOI 10.1080/10550490590899808; Matthews CE, 2005, MED SCI SPORT EXER, V37, P986, DOI 10.1249/01.mss.0000171615.76521.69; Meeusen R, 1997, ACTA PHYSIOL SCAND, V159, P335, DOI 10.1046/j.1365-201X.1997.00118.x; MORGAN, 1982, BEHAV MED UPDATE, V4, P25; Muller SM, 2006, PERCEPT MOTOR SKILL, V103, P717, DOI 10.2466/PMS.103.3.717-725; NORRIS R, 1992, J PSYCHOSOM RES, V36, P55, DOI 10.1016/0022-3999(92)90114-H; NORRIS R, 1990, J PSYCHOSOM RES, V34, P367, DOI 10.1016/0022-3999(90)90060-H; Parfitt G, 2006, BRIT J HEALTH PSYCH, V11, P39, DOI 10.1348/135910705X43606; Petzinger GM, 2007, J NEUROSCI, V27, P5291, DOI 10.1523/JNEUROSCI.1069-07.2007; ROESSLER K, 2010, SCAND J PUBLIC  0621; Smith MA, 2008, DRUG ALCOHOL DEPEN, V98, P129, DOI 10.1016/j.drugalcdep.2008.05.006; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; Ussher MH, 2008, COCHRANE DB SYST REV, V4; Ussher M, 2009, ADDICTION, V104, P1251, DOI 10.1111/j.1360-0443.2009.02605.x; Van Rensburg KJ, 2008, HUM PSYCHOPHARM CLIN, V23, P193, DOI 10.1002/hup.925; VEALE D, 1992, J ROY SOC MED, V85, P541; Waade NR, 2004, AUST J PHYSIOTHER, V50, P117, DOI 10.1016/S0004-9514(14)60106-9; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469	38	86	92	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 8	2011	6	3							e17465	10.1371/journal.pone.0017465	http://dx.doi.org/10.1371/journal.pone.0017465			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	732FI	21408154	Green Published, gold			2023-01-03	WOS:000288170000032
J	Li, SY; Yang, D; Yeung, CM; Yu, WY; Chang, RCC; So, KF; Wong, D; Lo, ACY				Li, Suk-Yee; Yang, Di; Yeung, Chung-Man; Yu, Wing-Yan; Chang, Raymond Chuen-Chung; So, Kwok-Fai; Wong, David; Lo, Amy C. Y.			Lycium Barbarum Polysaccharides Reduce Neuronal Damage, Blood-Retinal Barrier Disruption and Oxidative Stress in Retinal Ischemia/Reperfusion Injury	PLOS ONE			English	Article							AMYLOID PEPTIDE NEUROTOXICITY; CEREBRAL-ARTERY OCCLUSION; ISCHEMIA-REPERFUSION; MULLER CELLS; RAT RETINA; IN-VIVO; SYNCHROTRON-RADIATION; DIABETIC-NEUROPATHY; PROTEIN COMPLEX; MOUSE RETINA	Neuronal cell death, glial cell activation, retinal swelling and oxidative injury are complications in retinal ischemia/reperfusion (I/R) injuries. Lycium barbarum polysaccharides (LBP), extracts from the wolfberries, are good for "eye health'' according to Chinese medicine. The aim of our present study is to explore the use of LBP in retinal I/R injury. Retinal I/R injury was induced by surgical occlusion of the internal carotid artery. Prior to induction of ischemia, mice were treated orally with either vehicle (PBS) or LBP (1 mg/kg) once a day for 1 week. Paraffin-embedded retinal sections were prepared. Viable cells were counted; apoptosis was assessed using TUNEL assay. Expression levels of glial fibrillary acidic protein (GFAP), aquaporin-4 (AQP4), poly(ADP-ribose) (PAR) and nitrotyrosine (NT) were investigated by immunohistochemistry. The integrity of blood-retinal barrier (BRB) was examined by IgG extravasations. Apoptosis and decreased viable cell count were found in the ganglion cell layer (GCL) and the inner nuclear layer (INL) of the vehicle-treated I/R retina. Additionally, increased retinal thickness, GFAP activation, AQP4 up-regulation, IgG extravasations and PAR expression levels were observed in the vehicle-treated I/R retina. Many of these changes were diminished or abolished in the LBP-treated I/R retina. Pre-treatment with LBP for 1 week effectively protected the retina from neuronal death, apoptosis, glial cell activation, aquaporin water channel up-regulation, disruption of BRB and oxidative stress. The present study suggests that LBP may have a neuroprotective role to play in ocular diseases for which I/R is a feature.	[Li, Suk-Yee; Yang, Di; Yeung, Chung-Man; Yu, Wing-Yan; Wong, David; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai] Univ Hong Kong, Li Ka Shing Fac Med, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Chang, Raymond Chuen-Chung; So, Kwok-Fai; Wong, David; Lo, Amy C. Y.] Univ Hong Kong, Li Ka Shing Fac Med, Res Ctr Heart Brain Hormone & Healthy Aging, Hong Kong, Hong Kong, Peoples R China; [Wong, David] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England	University of Hong Kong; University of Hong Kong; University of Hong Kong; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool	Li, SY (corresponding author), Univ Hong Kong, Li Ka Shing Fac Med, Inst Eye, Hong Kong, Hong Kong, Peoples R China.	amylo@hkucc.hku.hk	Chang, Raymond Chuen-Chung/C-1107-2009; Wong, Sai Hung David/D-8482-2015; Lo, Amy C. Y./C-1195-2009	Chang, Raymond Chuen-Chung/0000-0001-8538-7993; Lo, Amy C. Y./0000-0003-4239-6851; YU, Wing Yan/0000-0003-4980-3712; So, Kwok-Fai/0000-0003-4039-4246	Small Project Funding; The University of Hong Kong	Small Project Funding; The University of Hong Kong(University of Hong Kong)	This project was supported by the Small Project Funding (C.M. Yeung) and the University Development Fund from The University of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], J HUAZHONG U SCI TEC; Aslan M, 2006, FREE RADICAL RES, V40, P147, DOI 10.1080/10715760500456219; Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351; Bringmann A, 2006, PROG RETIN EYE RES, V25, P397, DOI 10.1016/j.preteyeres.2006.05.003; Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103; Chan HC, 2007, EXP NEUROL, V203, P269, DOI 10.1016/j.expneurol.2006.05.031; Chang RCC, 2008, CELL MOL NEUROBIOL, V28, P643, DOI 10.1007/s10571-007-9181-x; Chatterjee PK, 2000, FASEB J, V14, P641, DOI 10.1096/fasebj.14.5.641; Cheung AKH, 2005, DIABETES, V54, P3119, DOI 10.2337/diabetes.54.11.3119; Cheung AKH, 2007, EXP EYE RES, V85, P608, DOI 10.1016/j.exer.2007.07.013; Chiu Kin, 2009, J Ocul Biol Dis Infor, V2, P47; Da T, 2004, INVEST OPHTH VIS SCI, V45, pU96; Dijk F, 2004, BRAIN RES, V1026, P205, DOI 10.1016/j.brainres.2004.08.014; DREIXLER JC, 2010, EXP EYE RES; Du Guang, 2004, J Huazhong Univ Sci Technolog Med Sci, V24, P518; El-Remessy AB, 2003, AM J PATHOL, V163, P1997, DOI 10.1016/S0002-9440(10)63558-4; Erdelyi K, 2005, CELL MOL LIFE SCI, V62, P751, DOI 10.1007/s00018-004-4506-0; Fernandez DC, 2009, J NEUROCHEM, V111, P488, DOI 10.1111/j.1471-4159.2009.06334.x; Fernandez DC, 2009, INVEST OPHTH VIS SCI, V50, P3922, DOI 10.1167/iovs.08-3344; Gan L, 2004, INT IMMUNOPHARMACOL, V4, P563, DOI 10.1016/j.intimp.2004.01.023; Gan L, 2003, EUR J PHARMACOL, V471, P217, DOI 10.1016/S0014-2999(03)01827-2; Gardner TW, 2002, SURV OPHTHALMOL, V47, pS253, DOI 10.1016/S0039-6257(02)00387-9; Gong HY, 2005, CANCER BIOTHER RADIO, V20, P155, DOI 10.1089/cbr.2005.20.155; Gresle MM, 2006, BRAIN RES, V1110, P13, DOI 10.1016/j.brainres.2006.06.111; Ha KT, 2005, J ETHNOPHARMACOL, V96, P529, DOI 10.1016/j.jep.2004.09.054; Hai-Yang Gong, 2004, J Exp Ther Oncol, V4, P181; Haurigot V, 2009, J BIOL CHEM, V284, P22961, DOI 10.1074/jbc.M109.014787; Haverkamp S, 2003, J COMP NEUROL, V455, P463, DOI 10.1002/cne.10491; Haverkamp S, 2000, J COMP NEUROL, V424, P1; Huang Xiaolan, 2003, Wei Sheng Yan Jiu, V32, P599; Iandiev I, 2006, NEUROSCI LETT, V408, P108, DOI 10.1016/j.neulet.2006.08.084; Jarlestedt K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010397; Ji D, 2008, NEUROCHEM INT, V52, P786, DOI 10.1016/j.neuint.2007.09.012; Kaja S, 2003, INVEST OPHTH VIS SCI, V44, P3155, DOI 10.1167/iovs.02-1204; Kalesnykas G, 2008, NEUROSCIENCE, V155, P937, DOI 10.1016/j.neuroscience.2008.06.038; Kaur C, 2007, J PATHOL, V212, P429, DOI 10.1002/path.2195; Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003; Kidoguchi K, 2006, STROKE, V37, P1856, DOI 10.1161/01.STR.0000226904.96059.a6; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Kuroki M, 1996, J CLIN INVEST, V98, P1667, DOI 10.1172/JCI118962; LEAL EC, 2010, DIABETES; Lelong DC, 2007, STROKE, V38, P3237, DOI 10.1161/STROKEAHA.107.499319; Li SY, 2010, INT J MOL SCI, V11, P2109, DOI 10.3390/ijms11052109; Li SY, 2009, INVEST OPHTH VIS SCI, V50, P836, DOI 10.1167/iovs.08-2310; Li XM, 2007, J ETHNOPHARMACOL, V111, P504, DOI 10.1016/j.jep.2006.12.024; Luo Q, 2004, LIFE SCI, V76, P137, DOI 10.1016/j.lfs.2004.04.056; Melena J, 2003, BRAIN RES, V989, P128, DOI 10.1016/S0006-8993(03)03375-4; Miranda M, 2010, FREE RADICAL BIO MED, V48, P216, DOI 10.1016/j.freeradbiomed.2009.10.042; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nakajima Y, 2009, CURR EYE RES, V34, P311, DOI 10.1080/02713680902745408; Newman E, 1996, TRENDS NEUROSCI, V19, P307, DOI 10.1016/0166-2236(96)10040-0; Obrosova IG, 2005, DIABETES, V54, P3435, DOI 10.2337/diabetes.54.12.3435; Obrosova IG, 2004, DIABETES, V53, P711, DOI 10.2337/diabetes.53.3.711; Palamalai V, 2006, MOL VIS, V12, P1543; Pannicke T, 2004, MOL CELL NEUROSCI, V26, P493, DOI 10.1016/j.mcn.2004.04.005; Sarthy V P, 2000, Arch Soc Esp Oftalmol, V75, P367; Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6; Schwartz M, 2005, J NEUROL SCI, V233, P163, DOI 10.1016/j.jns.2005.03.014; Steele EC, 2008, STROKE, V39, P2099, DOI 10.1161/STROKEAHA.107.504357; Tamaki Masahiro, 2006, Kobe Journal of Medical Sciences, V52, P111; Verkman AS, 2008, PROG RETIN EYE RES, V27, P420, DOI 10.1016/j.preteyeres.2008.04.001; Wu H, 2006, YAKUGAKU ZASSHI, V126, P365, DOI 10.1248/yakushi.126.365; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yu MS, 2007, INT J MOL MED, V20, P261; Yu MS, 2005, EXP GERONTOL, V40, P716, DOI 10.1016/j.exger.2005.06.010	66	125	141	6	58	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 26	2011	6	1							e16380	10.1371/journal.pone.0016380	http://dx.doi.org/10.1371/journal.pone.0016380			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	712JL	21298100	gold, Green Published, Green Submitted			2023-01-03	WOS:000286662800034
J	Solberg, R; Loberg, EM; Andresen, JH; Wright, MS; Charrat, E; Khrestchatisky, M; Rivera, S; Saugstad, OD				Solberg, Ronnaug; Loberg, Else Marit; Andresen, Jannicke H.; Wright, Marianne S.; Charrat, Eliane; Khrestchatisky, Michel; Rivera, Santiago; Saugstad, Ola Didrik			Resuscitation of Newborn Piglets. Short-Term Influence of FiO(2) on Matrix Metalloproteinases, Caspase-3 and BDNF	PLOS ONE			English	Article							NEONATAL HYPOXIA-ISCHEMIA; DOSE-DEPENDENT INCREASE; ROOM-AIR RESUSCITATION; NEURONAL CELL-DEATH; 100-PERCENT OXYGEN; DEVELOPING BRAIN; PATHOLOGICAL APOPTOSIS; ANIMAL-MODELS; INJURY; ACTIVATION	Background: Perinatal hypoxia-ischemia is a major cause of mortality and cerebral morbidity, and using oxygen during newborn resuscitation may further harm the brain. The aim was to examine how supplementary oxygen used for newborn resuscitation would influence early brain tissue injury, cell death and repair processes and the regulation of genes related to apoptosis, neurodegeneration and neuroprotection. Methods and Findings: Anesthetized newborn piglets were subjected to global hypoxia and then randomly assigned to resuscitation with 21%, 40% or 100% O-2 for 30 min and followed for 9 h. An additional group received 100% O-2 for 30 min without preceding hypoxia. The left hemisphere was used for histopathology and immunohistochemistry and the right hemisphere was used for in situ zymography in the corpus striatum; gene expression and the activity of various relevant biofactors were measured in the frontal cortex. There was an increase in the net matrix metalloproteinase gelatinolytic activity in the corpus striatum from piglets resuscitated with 100% oxygen vs. 21%. Hematoxylin-eosin (HE) staining revealed no significant changes. Nine hours after oxygen-assisted resuscitation, caspase-3 expression and activity was increased by 30-40% in the 100% O-2 group (n = 9/10) vs. the 21% O-2 group (n = 10; p<0.04), whereas brain-derived neurotrophic factor (BDNF) activity was decreased by 65% p<0.03. Conclusions: The use of 100% oxygen for resuscitation resulted in increased potentially harmful proteolytic activities and attenuated BDNF activity when compared with 21%. Although there were no significant changes in short term cell loss, hyperoxia seems to cause an early imbalance between neuroprotective and neurotoxic mechanisms that might compromise the final pathological outcome.	[Solberg, Ronnaug; Andresen, Jannicke H.; Wright, Marianne S.; Saugstad, Ola Didrik] Univ Oslo, Dept Paediat Res, Oslo, Norway; [Solberg, Ronnaug; Andresen, Jannicke H.; Wright, Marianne S.; Saugstad, Ola Didrik] Univ Oslo, Rikshosp, Oslo Univ Hosp, N-0027 Oslo, Norway; [Solberg, Ronnaug; Andresen, Jannicke H.] Univ Oslo, Dept Surg Res, Oslo, Norway; [Solberg, Ronnaug] Vestfold Cent Hosp, Dept Pediat, Tonsberg, Norway; [Loberg, Else Marit] Oslo Univ Hosp, Dept Pathol, Oslo, Norway; [Charrat, Eliane; Khrestchatisky, Michel; Rivera, Santiago] Univ Aix Marseille 2, Fac Med, CNRS, UMR NICN 6184, F-13284 Marseille 07, France	University of Oslo; University of Oslo; National Hospital Norway; University of Oslo; University of Oslo; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Solberg, R (corresponding author), Univ Oslo, Dept Paediat Res, Oslo, Norway.	ronnaug.solberg@medisin.uio.no	Saugstad, Ola/AAS-9041-2021	Saugstad, Ola/0000-0002-3166-5254	Health South-East Research Foundation, Norway; Norwegian Sudden Infant Death Syndrom and Stillbirth Society, Landsforeningen Uventet Barnedod	Health South-East Research Foundation, Norway; Norwegian Sudden Infant Death Syndrom and Stillbirth Society, Landsforeningen Uventet Barnedod	This work was supported by Health South-East Research Foundation, Norway and Norwegian Sudden Infant Death Syndrom and Stillbirth Society, Landsforeningen Uventet Barnedod. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almli CR, 2000, EXP NEUROL, V166, P99, DOI 10.1006/exnr.2000.7492; Amess PN, 1997, PEDIATR RES, V41, P803, DOI 10.1203/00006450-199706000-00002; Andresen JH, 2009, J MATERN-FETAL NEO M, V22, P161, DOI 10.1080/14767050802663186; Berchtold NC, 2005, NEUROSCIENCE, V133, P853, DOI 10.1016/j.neuroscience.2005.03.026; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Blomgren K, 2007, APOPTOSIS, V12, P993, DOI 10.1007/s10495-007-0754-4; CANDELARIOJALIL E, 2008, NEUROSCIENCE; Chen WQ, 2009, J NEUROCHEM, V111, P726, DOI 10.1111/j.1471-4159.2009.06362.x; Chiang MC, 2007, NEUROSCI LETT, V421, P67, DOI 10.1016/j.neulet.2007.05.024; Davis PG, 2004, LANCET, V364, P1329, DOI 10.1016/S0140-6736(04)17189-4; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Felderhoff-Mueser U, 2004, NEUROBIOL DIS, V17, P273, DOI 10.1016/j.nbd.2004.07.019; Geddes R, 2001, DEV NEUROSCI-BASEL, V23, P180, DOI 10.1159/000046140; Gerstner B, 2006, J NEUROSCI RES, V84, P306, DOI 10.1002/jnr.20880; Gill MB, 2008, J NEUROSCI RES, V86, P3584, DOI 10.1002/jnr.21795; Greenwood K, 2000, PEDIATR RES, V48, P346, DOI 10.1203/00006450-200009000-00014; Gressens P, 2008, BRAIN PATHOL, V18, P10, DOI 10.1111/j.1750-3639.2007.00095.x; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Gunn AJ, 2009, CLIN PERINATOL, V36, P579, DOI 10.1016/j.clp.2009.06.007; Han BH, 2000, NEUROBIOL DIS, V7, P38; Han BH, 2000, J NEUROSCI, V20, P5775, DOI 10.1523/jneurosci.20-15-05775.2000; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Iwata O, 2007, BRAIN RES, V1154, P173, DOI 10.1016/j.brainres.2007.03.083; Jantzie LL, 2008, RESUSCITATION, V77, P111, DOI 10.1016/j.resuscitation.2007.10.008; Jourquin J, 2003, EUR J NEUROSCI, V18, P1507, DOI 10.1046/j.1460-9568.2003.02876.x; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marini AM, 2007, AMINO ACIDS, V32, P299, DOI 10.1007/s00726-006-0414-y; Markus T, 2007, PEDIATR RES, V62, P71, DOI 10.1203/PDR.0b013e31811ead6e; Mattson MP, 2002, AGEING RES REV, V1, pIII; Mendoza-Paredes A, 2008, RESUSCITATION, V76, P261, DOI 10.1016/j.resuscitation.2007.07.022; Mukae N, 1998, P NATL ACAD SCI USA, V95, P9123, DOI 10.1073/pnas.95.16.9123; Munkeby BH, 2005, PEDIATR RES, V58, P542, DOI 10.1203/01.PDR.0000179407.46810.2D; Munkeby BH, 2004, PEDIATR RES, V56, P783, DOI 10.1203/01.PDR.0000141988.89820.E3; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nikolaou KE, 2006, ANN NY ACAD SCI, V1092, P426, DOI 10.1196/annals.1365.041; Northington FJ, 2007, NEUROSCIENCE, V149, P822, DOI 10.1016/j.neuroscience.2007.06.060; O'Brien FE, 2006, PEDIATRICS, V117, P1549, DOI 10.1542/peds.2005-1649; Presti AL, 2006, PEDIATR RES, V60, P55, DOI 10.1203/01.pdr.0000223766.98760.88; Rabi Y, 2007, RESUSCITATION, V72, P353, DOI 10.1016/j.resuscitation.2006.06.134; Ranasinghe HS, 2009, NEUROSCIENCE, V158, P732, DOI 10.1016/j.neuroscience.2008.07.069; Richards JG, 2006, RESUSCITATION, V69, P319, DOI 10.1016/j.resuscitation.2005.08.012; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; RIVERA S, 2010, J NEUROSCIE IN PRESS; Roohey T, 1997, EARLY HUM DEV, V47, P115, DOI 10.1016/S0378-3782(96)01773-2; Saugstad OD, 2003, PEDIATRICS, V112, P296, DOI 10.1542/peds.112.2.296; Saugstad OD, 2008, NEONATOLOGY, V94, P176, DOI 10.1159/000143397; Sbai O, 2010, GLIA, V58, P344, DOI 10.1002/glia.20927; Sbai O, 2008, MOL CELL NEUROSCI, V39, P549, DOI 10.1016/j.mcn.2008.08.004; Solberg R, 2007, PEDIATR RES, V62, P559, DOI 10.1203/PDR.0b013e318156e8aa; Solberg R, 2010, PEDIATR RES, V67, P250, DOI 10.1203/PDR.0b013e3181cde843; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Takizawa Y, 2006, BRAIN RES, V1095, P200, DOI 10.1016/j.brainres.2006.04.027; Tanaka H, 2004, J NEUROSCI, V24, P2750, DOI 10.1523/JNEUROSCI.5475-03.2004; Vento M, 2005, AM J RESP CRIT CARE, V172, P1393, DOI 10.1164/rccm.200412-1740OC; Webster MJ, 2006, GENE EXPR PATTERNS, V6, P941, DOI 10.1016/j.modgep.2006.03.009; Yang Y, 2010, J NEUROCHEM, V112, P134, DOI 10.1111/j.1471-4159.2009.06433.x; Zhao BQ, 2007, STROKE, V38, P748, DOI 10.1161/01.STR.0000253500.32979.d1; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387	58	15	15	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2010	5	12							e14261	10.1371/journal.pone.0014261	http://dx.doi.org/10.1371/journal.pone.0014261			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	692ES	21151608	Green Published, gold, Green Submitted			2023-01-03	WOS:000285135800003
J	Wang, C; Cao, B; Liu, QQ; Zou, ZQ; Liang, ZA; Gu, L; Dong, JP; Liang, LR; Li, XW; Hu, K; He, XS; Sun, YH; An, Y; Yang, T; Cao, ZX; Guo, YM; Wen, XM; Wang, YG; Liu, YL; Jiang, LD				Wang, Chen; Cao, Bin; Liu, Qing-Quan; Zou, Zhi-Qiang; Liang, Zong-An; Gu, Li; Dong, Jian-Ping; Liang, Li-Rong; Li, Xing-Wang; Hu, Ke; He, Xue-Song; Sun, Yan-Hua; An, Yu; Yang, Ting; Cao, Zhi-Xin; Guo, Yan-Mei; Wen, Xian-Min; Wang, Yu-Guang; Liu, Ya-Ling; Jiang, Liang-Duo			Oseltamivir Compared With the Chinese Traditional Therapy Maxingshigan-Yinqiaosan in the Treatment of H1N1 Influenza	ANNALS OF INTERNAL MEDICINE			English	Article							NEURAMINIDASE INHIBITORS; DRUG-THERAPY; EPHEDRA; SAFETY; VIRUS; EFFICACY; A(H1N1); EVENTS	Background: Observational studies from Asia suggest that maxingshigan-yinqiaosan may be effective in the treatment of acute H1N1 influenza. Objective: To compare the efficacy and safety of oseltamivir and maxingshigan-yinqiaosan in treating uncomplicated H1N1 influenza. Design: Prospective, nonblinded, randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00935194) Setting: Eleven hospitals from 4 provinces in China. Patients: 410 young adults aged 15 to 59 years with laboratory-confirmed H1N1 influenza. Intervention: Oseltamivir, 75 mg twice daily; maxingshigan-yinqiaosan decoction (composed of 12 Chinese herbal medicines, including honey-fried Herba Ephedrae), 200 mL 4 times daily; oseltamivir plus maxingshigan-yinqiaosan; or no intervention (control). Interventions and control were given for 5 days. Measurements: Primary outcome was time to fever resolution. Secondary outcomes included symptom scores and viral shedding determined by using real-time reverse transcriptase polymerase chain reaction. Results: Significant reductions in the estimated median time to fever resolution compared with the control group (26.0 hours [95% CI, 24.0 to 33.0 hours]) were seen with oseltamivir (34% [95% CI, 20% to 46%]; P < 0.001), maxingshigan-yinqiaosan (37% [CI, 23% to 49%]; P < 0.001), and oseltamivir plus maxingshigan-yinqiaosan (47% [CI, 35% to 56%]; P < 0.001). Time to fever resolution was reduced by 19% (CI, 0.3% to 34%; P = 0.05) with oseltamivir plus maxingshigan-yinqiaosan compared with oseltamivir. The interventions and control did not differ in terms of decrease in symptom scores (P = 0.38). Two patients who received maxingshigan-yinqiaosan reported nausea and vomiting. Limitations: Participants were young and had mild H1N1 influenza virus infection. Missing viral data precluded definitive conclusions about viral shedding. Conclusion: Oseltamivir and maxingshigan-yinqiaosan, alone and in combination, reduced time to fever resolution in patients with H1N1 influenza virus infection. These data suggest that maxingshigan-yinqiaosan may be used as an alternative treatment of H1N1 influenza virus infection.	[Cao, Bin] Capital Med Univ, Beijing Inst Resp Med, Beijing Chao Yang Hosp, Dept Infect Dis & Clin Microbiol, Gongti S Rd 8, Beijing 100020, Peoples R China; [Wang, Chen] Minist Hlth, Beijing Hosp, Beijing 100020, Peoples R China; Beijing Univ Chinese Med, Dongzhimen Hosp, Beijing, Peoples R China; Chengdu Infect Dis Hosp, Chengdu, Sichuan, Peoples R China; Beijing Haidian Hosp, Beijing, Peoples R China; Capital Med Univ, Inst Infect Dis, Beijing Ditan Hosp, Beijing 100020, Peoples R China; Changxindian Hosp Fengtai Dist Beijing, Beijing, Peoples R China; Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China; Second Hosp Chaoyang Dist Beijing, Beijing, Peoples R China; Second Hosp Beijing, Beijing, Peoples R China; Sichuan Univ, W China Hosp, W China Med Sch, Chengdu, Sichuan, Peoples R China	Capital Medical University; Beijing Hospital; Beijing University of Chinese Medicine; Capital Medical University; Wuhan University; Sichuan University	Cao, B (corresponding author), Capital Med Univ, Beijing Inst Resp Med, Beijing Chao Yang Hosp, Dept Infect Dis & Clin Microbiol, Gongti S Rd 8, Beijing 100020, Peoples R China.	cyh-birm@263.net; caobin1999@gmail.com			Beijing Science and Technology Project [Z08050700020801, Z09000700090903]; Beijing Nova Program [2007A037]	Beijing Science and Technology Project; Beijing Nova Program(Beijing Municipal Science & Technology Commission)	Grant Support: By the Beijing Science and Technology Project (grants Z08050700020801 and Z09000700090903) and the Beijing Nova Program (grant 2007A037).	Andraws R, 2005, PROG CARDIOVASC DIS, V47, P217, DOI 10.1016/j.pcad.2004.07.006; [Anonymous], 2007, HLTH CANADA REQUESTS; Baz M, 2009, NEW ENGL J MED, V361, P2296, DOI 10.1056/NEJMc0910060; Cao B, 2009, NEW ENGL J MED, V361, P2507, DOI 10.1056/NEJMoa0906612; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P467; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P431; Chan K, 2005, J ETHNOPHARMACOL, V96, P1, DOI 10.1016/j.jep.2004.09.019; Chen N, 2004, ACAD J GUANG DONG CO, P545; Cheng JT, 2000, J CLIN PHARMACOL, V40, P445, DOI 10.1177/00912700022009198; Chinese Pharmacopoeia Commission, 2005, PHARM PEOPL REP CHIN; Chow MS, 2008, FASEB J S, V22; Dharan NJ, 2009, JAMA-J AM MED ASSOC, V301, P1034, DOI 10.1001/jama.2009.294; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Ginsberg M., 2009, Morbidity and Mortality Weekly Report, V58, P400; Hallas J, 2008, AM J EPIDEMIOL, V168, P966, DOI 10.1093/aje/kwn191; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; Huang JM, 2003, J FUJIAN TRADITIONAL, V34, P38; Jain S, 2009, NEW ENGL J MED, V361, P1935, DOI 10.1056/NEJMoa0906695; Jefferson T, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b5106; Lu F.G., 2007, PRACTICAL PREVENTIVE, V14, P1351; Lu GF, 2008, J TRADITIONAL CHINES, V28, P5; Moscona A, 2005, NEW ENGL J MED, V353, P1363, DOI 10.1056/NEJMra050740; Nicholson KG, 2000, LANCET, V355, P1845, DOI 10.1016/S0140-6736(00)02288-1; Patel K, 2006, PHARM STAT, V5, P213, DOI 10.1002/pst.213; Poon PMK, 2006, AM J CHINESE MED, V34, P13, DOI 10.1142/S0192415X0600359X; Soni MG, 2004, TOXICOL LETT, V150, P97, DOI 10.1016/j.toxlet.2003.07.006; Treanor JJ, 2000, JAMA-J AM MED ASSOC, V283, P1016, DOI 10.1001/jama.283.8.1016; U.S. Food and Drug Administration, 2006, DIET SUPPL CONT EPH; Uyeki Tim, 2009, N Engl J Med, V361, pe110, DOI 10.1056/NEJMopv0910738; Wang J, 2007, CHINESE ARCH TRADITI, V25, P2200; WHO, 2009, WHO GUID PHARM MAN P; WHO CDC, 2009, CDC PROT REALT RTPCR; WHO (World Health Organization), 2010, PAND H1N1 2009 UPD 9; [杨金燕 YANG Jinyan], 2007, [华西药学杂志, West China Journal of Pharmaceutical Sciences], V22, P559; Zhao WN, 2007, PRACTICAL PREVENTIVE, V14, P178	35	177	246	10	90	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 16	2011	155	4					217	+		10.7326/0003-4819-155-4-201108160-00005	http://dx.doi.org/10.7326/0003-4819-155-4-201108160-00005			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	807KN	21844547				2023-01-03	WOS:000293896400002
J	McCartney, M				McCartney, Margaret			MEDICINE AND THE MEDIA Press repeats journal's hype over acupuncture	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SHAM ACUPUNCTURE					margaret@margaretmccartney.com	mccartney, margaret/AAR-4727-2020	McCartney, Margaret/0000-0002-7238-6358				[Anonymous], 2011, DAILY MASH      0531; [Anonymous], 2011, DAILY TELEGRAPH 0530; [Anonymous], 2011, DAILY MIRROR    0505; Assefi NP, 2005, ANN INTERN MED, V143, P10, DOI 10.7326/0003-4819-143-1-200507050-00005; Moffet HH, 2009, J ALTERN COMPLEM MED, V15, P213, DOI 10.1089/acm.2008.0356; Paterson C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X572689; Tulder MW VA, 2000, COCHRANE DB SYST REV, V2	7	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2011	343								d4606	10.1136/bmj.d4606	http://dx.doi.org/10.1136/bmj.d4606			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	797ZH	21775397				2023-01-03	WOS:000293168700013
J	Robert, C; Thomas, L; Bondarenko, I; O'Day, S; Weber, J; Garbe, C; Lebbe, C; Baurain, JF; Testori, A; Grob, JJ; Davidson, N; Richards, J; Maio, M; Hauschild, A; Miller, WH; Gascon, P; Lotem, M; Harmankaya, K; Ibrahim, R; Francis, S; Chen, TT; Humphrey, R; Hoos, A; Wolchok, JD				Robert, Caroline; Thomas, Luc; Bondarenko, Igor; O'Day, Steven; Weber, Jeffrey; Garbe, Claus; Lebbe, Celeste; Baurain, Jean-Francois; Testori, Alessandro; Grob, Jean-Jacques; Davidson, Neville; Richards, Jon; Maio, Michele; Hauschild, Axel; Miller, Wilson H., Jr.; Gascon, Pere; Lotem, Michal; Harmankaya, Kaan; Ibrahim, Ramy; Francis, Stephen; Chen, Tai-Tsang; Humphrey, Rachel; Hoos, Axel; Wolchok, Jedd D.			Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT INTERLEUKIN-2 THERAPY; COOPERATIVE-ONCOLOGY-GROUP; LONG-TERM SURVIVAL; MALIGNANT-MELANOMA; RESPONSE CRITERIA; DOUBLE-BLIND; PHASE-III; CHEMOTHERAPY; ANTIBODIES; TAMOXIFEN	BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved overall survival in a phase 3 study involving patients with previously treated metastatic melanoma. We conducted a phase 3 study of ipilimumab (10 mg per kilogram) plus dacarbazine in patients with previously untreated metastatic melanoma. METHODS We randomly assigned 502 patients with previously untreated metastatic melanoma, in a 1: 1 ratio, to ipilimumab (10 mg per kilogram) plus dacarbazine (850 mg per square meter of body-surface area) or dacarbazine (850 mg per square meter) plus placebo, given at weeks 1, 4, 7, and 10, followed by dacarbazine alone every 3 weeks through week 22. Patients with stable disease or an objective response and no dose-limiting toxic effects received ipilimumab or placebo every 12 weeks thereafter as maintenance therapy. The primary end point was overall survival. RESULTS Overall survival was significantly longer in the group receiving ipilimumab plus dacarbazine than in the group receiving dacarbazine plus placebo (11.2 months vs. 9.1 months, with higher survival rates in the ipilimumab-dacarbazine group at 1 year (47.3% vs. 36.3%), 2 years (28.5% vs. 17.9%), and 3 years (20.8% vs. 12.2%) (hazard ratio for death, 0.72; P < 0.001). Grade 3 or 4 adverse events occurred in 56.3% of patients treated with ipilimumab plus dacarbazine, as compared with 27.5% treated with dacarbazine and placebo (P < 0.001). No drug-related deaths or gastrointestinal perforations occurred in the ipilimumab-dacarbazine group. CONCLUSIONS Ipilimumab (at a dose of 10 mg per kilogram) in combination with dacarbazine, as compared with dacarbazine plus placebo, improved overall survival in patients with previously untreated metastatic melanoma. The types of adverse events were consistent with those seen in prior studies of ipilimumab; however, the rates of elevated liver-function values were higher and the rates of gastrointestinal events were lower than expected on the basis of prior studies. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00324155.)	[Wolchok, Jedd D.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Robert, Caroline] Inst Gustave, Villejuif, France; [Thomas, Luc] Ctr Hosp, Pierre Benite, France; [Lebbe, Celeste] Hop St Louis Univ, Paris, France; [Grob, Jean-Jacques] Hop La Timone, Marseille, France; [Bondarenko, Igor] Dnepropetrovsk State Med Ctr, Dnepropetrovsk, Ukraine; [O'Day, Steven] Angeles Clin & Res Inst, Santa Monica, CA USA; [Weber, Jeffrey] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Garbe, Claus] Univ Med Ctr, Tubingen, Germany; [Baurain, Jean-Francois] Clin Univ St Luc, B-1200 Brussels, Belgium; [Francis, Stephen] Bristol Myers Squibb, Braine Lalleud, Belgium; [Testori, Alessandro] Ist Europeo Oncol, Milan, Italy; [Maio, Michele] Univ Hosp Siena, Siena, Italy; [Richards, Jon] Oncol Specialists, Park Ridge, IL USA; [Hauschild, Axel] Univ Kiel, Kiel, Germany; [Miller, Wilson H., Jr.] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; [Miller, Wilson H., Jr.] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada; [Gascon, Pere] Hosp Clin Barcelona, Barcelona, Spain; [Lotem, Michal] Hadassah Hebrew Univ Hosp, Sharett Inst Oncol, Jerusalem, Israel; [Harmankaya, Kaan] Med Univ Vienna, Vienna, Austria; [Ibrahim, Ramy] Medimmune, Gaithersburg, MD USA; [Chen, Tai-Tsang; Hoos, Axel] Bristol Myers Squibb, Wallingford, CT USA; [Humphrey, Rachel] Bristol Myers Squibb, Lawrenceville, NJ USA	Memorial Sloan Kettering Cancer Center; UNICANCER; Gustave Roussy; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Dnipro State Medical University; Angeles Clinic & Research Institute; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Bristol-Myers Squibb; IRCCS European Institute of Oncology (IEO); University of Siena; University Hospital of Siena; University of Kiel; Lady Davis Institute; McGill University; McGill University; University of Barcelona; Hospital Clinic de Barcelona; Hebrew University of Jerusalem; Hadassah University Medical Center; Medical University of Vienna; AstraZeneca; Medimmune; Bristol-Myers Squibb; Bristol-Myers Squibb	Wolchok, JD (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	wolchokj@mskcc.org	Bondarenko, Igor/W-9412-2019; Robert, Caroline/G-6157-2018; Garbe, Claus/ABH-2128-2021; Bondarenko, Igor/U-5156-2017; Bondarenko, Igor N/GQP-1497-2022	Bondarenko, Igor/0000-0002-7071-2471; Robert, Caroline/0000-0002-9493-0238; Garbe, Claus/0000-0001-8530-780X; Bondarenko, Igor/0000-0002-7071-2471; Bondarenko, Igor N/0000-0002-7071-2471; CHEN, TAI-TSANG/0000-0003-2524-0409; Grob, Jean-Jacques/0000-0002-0667-153X; coral, sandra/0000-0002-1308-3082; Maio, Michele/0000-0002-0323-6321; TESTORI, ALESSANDRO/0000-0003-3685-0210; Weber, Jeffrey/0000-0002-4962-2957	Bristol-Myers Squibb; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER	Bristol-Myers Squibb(Bristol-Myers Squibb); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Bristol-Myers Squibb.	Agarwala SS, 2009, EXPERT REV ANTICANC, V9, P587, DOI [10.1586/era.09.25, 10.1586/ERA.09.25]; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Bedikian AY, 2008, CANCER INVEST, V26, P624, DOI 10.1080/07357900802027073; DANCYGIER H, 1983, HEPATO-GASTROENTEROL, V30, P93; Falkson CI, 1998, J CLIN ONCOL, V16, P1743, DOI 10.1200/JCO.1998.16.5.1743; Fong L, 2008, J CLIN ONCOL, V26, P5275, DOI 10.1200/JCO.2008.17.8954; FROSCH PJ, 1979, J CANCER RES CLIN, V95, P281, DOI 10.1007/BF00410649; GREENSTONE MA, 1981, BRIT MED J, V282, P1744, DOI 10.1136/bmj.282.6278.1744; Hersh EM, 2011, INVEST NEW DRUG, V29, P489, DOI 10.1007/s10637-009-9376-8; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hoos A, 2010, JNCI-J NATL CANCER I, V102, P1388, DOI 10.1093/jnci/djq310; Julia F, 2010, ANTI-CANCER AGENT ME, V10, P661, DOI 10.2174/187152010794479834; Melero I, 2007, NAT REV CANCER, V7, P95, DOI 10.1038/nrc2051; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Mokyr MB, 1998, CANCER RES, V58, P5301; O'Day SJ, 2010, ANN ONCOL, V21, P1712, DOI 10.1093/annonc/mdq013; O'Day SJ, 2007, CANCER-AM CANCER SOC, V110, P2614, DOI 10.1002/cncr.23086; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Robert C, 2009, ONCOLOGIST, V14, P848, DOI 10.1634/theoncologist.2009-0028; Rusthoven JJ, 1996, J CLIN ONCOL, V14, P2083, DOI 10.1200/JCO.1996.14.7.2083; Schmidt H, 2009, EJC SUPPL, V7, P577, DOI 10.1016/S1359-6349(09)71948-2; Weber J, 2009, CLIN CANCER RES, V15, P5591, DOI 10.1158/1078-0432.CCR-09-1024; Wolchok JD, 2010, LANCET ONCOL, V11, P155, DOI 10.1016/S1470-2045(09)70334-1; Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	27	3248	3388	7	183	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2011	364	26					2517	2526		10.1056/NEJMoa1104621	http://dx.doi.org/10.1056/NEJMoa1104621			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	785AM	21639810	Bronze			2023-01-03	WOS:000292199800007
J	Lai, KM; Bottomley, C; McNerney, R				Lai, Ka-Man; Bottomley, Christian; McNerney, Ruth			Propagation of Respiratory Aerosols by the Vuvuzela	PLOS ONE			English	Article							AIRBORNE TRANSMISSION; PULMONARY-FUNCTION; PILGRIMAGE HAJJ; TUBERCULOSIS; INFECTION; INFLUENZA; DISEASE; DISSEMINATION; PARTICLES; CONTAGION	Vuvuzelas, the plastic blowing horns used by sports fans, recently achieved international recognition during the FIFA World Cup soccer tournament in South Africa. We hypothesised that vuvuzelas might facilitate the generation and dissemination of respiratory aerosols. To investigate the quantity and size of aerosols emitted when the instrument is played, eight healthy volunteers were asked to blow a vuvuzela. For each individual the concentration of particles in expelled air was measured using a six channel laser particle counter and the duration of blowing and velocity of air leaving the vuvuzela were recorded. To allow comparison with other activities undertaken at sports events each individual was also asked to shout and the measurements were repeated while using a paper cone to confine the exhaled air. Triplicate measurements were taken for each individual. The mean peak particle counts were 658x10(3) per litre for the vuvuzela and 3.7x10(3) per litre for shouting, representing a mean log(10) difference of 2.20 (95% CI: 2.03,2.36; p<0.001). The majority (>97%) of particles captured from either the vuvuzela or shouting were between 0.5 and 5 microns in diameter. Mean peak airflows recorded for the vuvuzela and shouting were 6.1 and 1.8 litres per second respectively. We conclude that plastic blowing horns (vuvuzelas) have the capacity to propel extremely large numbers of aerosols into the atmosphere of a size able to penetrate the lower lung. Some respiratory pathogens are spread via contaminated aerosols emitted by infected persons. Further investigation is required to assess the potential of the vuvuzela to contribute to the transmission of aerosol borne diseases. We recommend, as a precautionary measure, that people with respiratory infections should be advised not to blow their vuvuzela in enclosed spaces and where there is a risk of infecting others.	[Lai, Ka-Man] UCL, Dept Civil Environm & Geomat Engn, Healthy Infrastruct Res Ctr, London, England; [Bottomley, Christian] London Sch Hyg & Trop Med, MRC, Trop Epidemiol Grp, London WC1, England; [McNerney, Ruth] London Sch Hyg & Trop Med, Dept Pathogen Mol Biol, London WC1, England	University of London; University College London; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	Lai, KM (corresponding author), UCL, Dept Civil Environm & Geomat Engn, Healthy Infrastruct Res Ctr, London, England.	ruth.mcnerney@lshtm.ac.uk	Lai, Ka Man/C-3259-2015	Lai, Ka Man/0000-0002-0037-792X; MCNERNEY, Ruth/0000-0002-1957-443X; Bottomley, Christian/0000-0002-5241-8412	Engineering and Physical Science Research Council [EPSRC EP/G029881/1]; Department for International Development, UK; Medical Research Council (UK); Engineering and Physical Sciences Research Council [EP/G029881/1] Funding Source: researchfish; Medical Research Council [G0700837] Funding Source: researchfish; EPSRC [EP/G029881/1] Funding Source: UKRI; MRC [G0700837] Funding Source: UKRI	Engineering and Physical Science Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Department for International Development, UK; Medical Research Council (UK)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This study was supported by Engineering and Physical Science Research Council grant EPSRC EP/G029881/1 (K-ML) and the Department for International Development, UK (RM). CB received salary support from the Medical Research Council (UK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed QA, 2006, LANCET, V367, P1008, DOI 10.1016/S0140-6736(06)68429-8; Al-Ghamdi SM, 2003, SAUDI MED J, V24, P1073; BATES JH, 1965, NEW ENGL J MED, V272, P714, DOI 10.1056/NEJM196504082721403; Biellik RJ, 1997, B WORLD HEALTH ORGAN, V75, P367; BLUMBERG L, 2010, 2010 FIFA SOCCER WOU, P63; Chao CYH, 2009, J AEROSOL SCI, V40, P122, DOI 10.1016/j.jaerosci.2008.10.003; DUGUID J P, 1947, Rep Dep Health Scotl, V46, P62; DUGUID JP, 1946, J HYG-CAMBRIDGE, V44, P471, DOI 10.1017/S0022172400019288; DUGUID JP, 1946, BRIT MED J, V1, P265, DOI 10.1136/bmj.1.4442.265; EHRESMANN KR, 1995, J INFECT DIS, V171, P679, DOI 10.1093/infdis/171.3.679; El-Sheikh SM, 1998, TROP MED INT HEALTH, V3, P205; Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC; Fiegel J, 2006, DRUG DISCOV TODAY, V11, P51, DOI 10.1016/S1359-6446(05)03687-1; HALL WJ, 1980, ANNU REV MED, V31, P233, DOI 10.1146/annurev.me.31.020180.001313; HATCH TF, 1961, BACTERIOL REV, V25, P237, DOI 10.1128/MMBR.25.3.237-240.1961; HENDLEY JO, 1988, EPIDEMIOL REV, V10, P242, DOI 10.1093/oxfordjournals.epirev.a036024; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; Knight V, 1980, Ann N Y Acad Sci, V353, P147, DOI 10.1111/j.1749-6632.1980.tb18917.x; LECLAIR JM, 1980, NEW ENGL J MED, V302, P450, DOI 10.1056/NEJM198002213020807; LOUDON RG, 1968, AM REV RESPIR DIS, V98, P297; Moloney A, 2009, LANCET, V373, P1591, DOI 10.1016/S0140-6736(09)60868-0; Morawska L, 2009, J AEROSOL SCI, V40, P256, DOI 10.1016/j.jaerosci.2008.11.002; National Institute for Communicable Diseases, 2011, SEV AC RESP ILLN SAR; Rashid H, 2008, LANCET INFECT DIS, V8, P526, DOI 10.1016/S1473-3099(08)70186-5; RILEY RL, 1974, AM J MED, V57, P466, DOI 10.1016/0002-9343(74)90140-5; RILEY RL, 1995, AM J EPIDEMIOL, V142, P3, DOI 10.1093/oxfordjournals.aje.a117542; ROBERTS F, 2000, RESP PHYSL UPDATE AN; Roy CJ, 2004, NEW ENGL J MED, V350, P1710, DOI 10.1056/NEJMp048051; Schwarz K, 2010, J AEROSOL MED PULM D, V23, P371, DOI 10.1089/jamp.2009.0809; Serisier DJ, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-63; Swanepoel D, 2010, SAMJ S AFR MED J, V100, P192, DOI 10.7196/SAMJ.4098; Swanepoel DW, 2010, SAMJ S AFR MED J, V100, P99, DOI 10.7196/SAMJ.3697; Tang JW, 2006, J HOSP INFECT, V64, P100, DOI 10.1016/j.jhin.2006.05.022; Tellier R, 2006, EMERG INFECT DIS, V12, P1657, DOI 10.3201/eid1211.060426; Wainwright CE, 2009, THORAX, V64, P926, DOI 10.1136/thx.2008.112466; Wells WF, 1934, AM J HYG, V20, P611, DOI 10.1093/oxfordjournals.aje.a118097; WELLS WF, 1948, AM J HYG, V47, P11, DOI 10.1093/oxfordjournals.aje.a119179; World Health Organization, 2010, GLOB TUB CONTR WHO R	38	12	12	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 23	2011	6	5							e20086	10.1371/journal.pone.0020086	http://dx.doi.org/10.1371/journal.pone.0020086			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769ID	21629778	Green Submitted, Green Accepted, Green Published, gold			2023-01-03	WOS:000291005200033
J	Donate, A; Coppola, D; Cruz, Y; Heller, R				Donate, Amy; Coppola, Domenico; Cruz, Yolmari; Heller, Richard			Evaluation of a Novel Non-Penetrating Electrode for Use in DNA Vaccination	PLOS ONE			English	Article							IN-VIVO ELECTROPORATION; INFLUENZA-VIRUS INFECTION; CELLULAR IMMUNE-RESPONSES; GENE-TRANSFER; RHESUS MACAQUES; PLASMID DNA; CUTANEOUS TRANSFECTION; SKELETAL-MUSCLES; DELIVERY; VACCINES	Current progress in the development of vaccines has decreased the incidence of fatal and non-fatal infections and increased longevity. However, new technologies need to be developed to combat an emerging generation of infectious diseases. DNA vaccination has been demonstrated to have great potential for use with a wide variety of diseases. Alone, this technology does not generate a significant immune response for vaccination, but combined with delivery by electroporation (EP), can enhance plasmid expression and immunity. Most EP systems, while effective, can be invasive and painful making them less desirable for use in vaccination. Our lab recently developed a non-invasive electrode known as the multi-electrode array (MEA), which lies flat on the surface of the skin without penetrating the tissue. In this study we evaluated the MEA for its use in DNA vaccination using Hepatitis B virus as the infectious model. We utilized the guinea pig model because their skin is similar in thickness and morphology to humans. The plasmid encoding Hepatitis B surface antigen (HBsAg) was delivered intradermally with the MEA to guinea pig skin. The results show increased protein expression resulting from plasmid delivery using the MEA as compared to injection alone. Within 48 hours of treatment, there was an influx of cellular infiltrate in experimental groups. Humoral responses were also increased significantly in both duration and intensity as compared to injection only groups. While this electrode requires further study, our results suggest that the MEA has potential for use in electrically mediated intradermal DNA vaccination.	[Donate, Amy; Coppola, Domenico] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA; [Donate, Amy; Heller, Richard] Old Dominion Univ, Ctr Bioelect, Norfolk, VA USA; [Heller, Richard] Old Dominion Univ, Coll Hlth Sci, Norfolk, VA USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; Old Dominion University; Old Dominion University	Donate, A (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.	rheller@odu.edu	Heller, Richard/I-6605-2012; Heller, Richard/ABF-1445-2020	Heller, Richard/0000-0003-1899-3859; Donate, Amy/0000-0002-0481-5675	National Institutes of Health [R01 EB005441]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005441] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This research was supported in part by a research grant from the National Institutes of Health R01 EB005441. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Abdulhaqq SA, 2008, IMMUNOL RES, V42, P219, DOI 10.1007/s12026-008-8076-3; Babiuk S, 2002, VACCINE, V20, P3399, DOI 10.1016/S0264-410X(02)00269-4; Babiuk S, 2007, BIOELECTROCHEMISTRY, V70, P269, DOI 10.1016/j.bioelechem.2006.10.003; Bachy M, 2001, VACCINE, V19, P1688, DOI 10.1016/S0264-410X(00)00406-0; Best SR, 2009, VACCINE, V27, P5450, DOI 10.1016/j.vaccine.2009.07.005; Broderick KE, 2011, GENE THER, V18, P258, DOI 10.1038/gt.2010.137; Chen JJ, 2005, VACCINE, V23, P4322, DOI 10.1016/j.vaccine.2005.03.035; Chen Z, 2000, VACCINE, V18, P3214, DOI 10.1016/S0264-410X(00)00149-3; Daud AI, 2008, J CLIN ONCOL, V26, P5896, DOI 10.1200/JCO.2007.15.6794; Dobano C, 2007, VACCINE, V25, P6635, DOI 10.1016/j.vaccine.2007.06.036; Drabick JJ, 2001, MOL THER, V3, P249, DOI 10.1006/mthe.2000.0257; Dujardin N, 2001, PHARM RES-DORDR, V18, P61, DOI 10.1023/A:1011026726938; Encke J, 1999, INTERVIROLOGY, V42, P117, DOI 10.1159/000024971; Fattori Elena, 2002, Somatic Cell and Molecular Genetics, V27, P75, DOI 10.1023/A:1022927822244; Giese M, 1998, VIRUS GENES, V17, P219, DOI 10.1023/A:1008013720032; Gilbert RA, 1997, BBA-GEN SUBJECTS, V1334, P9, DOI 10.1016/S0304-4165(96)00119-5; Glasspool-Malone J, 2000, MOL THER, V2, P140, DOI 10.1006/mthe.2000.0107; Gurunathan S, 2000, ANNU REV IMMUNOL, V18, P927, DOI 10.1146/annurev.immunol.18.1.927; Heller LC, 2006, HUM GENE THER, V17, P890, DOI 10.1089/hum.2006.17.890; Heller R, 1996, FEBS LETT, V389, P225, DOI 10.1016/0014-5793(96)00590-X; Heller R, 2001, DNA CELL BIOL, V20, P21, DOI 10.1089/10445490150504666; Heller R, 2010, HUM GENE THER, V21, P357, DOI 10.1089/hum.2009.065; Hirao LA, 2008, VACCINE, V26, P440, DOI 10.1016/j.vaccine.2007.10.041; Hu H, 2009, VACCINE, V27, P1758, DOI 10.1016/j.vaccine.2009.01.021; Kadowaki S, 2000, VACCINE, V18, P2779, DOI 10.1016/S0264-410X(00)00087-6; Kim CY, 2008, EXP MOL MED, V40, P669, DOI 10.3858/emm.2008.40.6.669; Laddy DJ, 2009, J VIROL, V83, P4624, DOI 10.1128/JVI.02335-08; Littel-van den Hurk SV, 2008, VACCINE, V26, P5503, DOI 10.1016/j.vaccine.2008.07.093; Lu BJ, 2009, CLIN VACCINE IMMUNOL, V16, P73, DOI 10.1128/CVI.00261-08; Luxembourg A, 2008, VACCINE, V26, P5216, DOI 10.1016/j.vaccine.2008.03.064; Luxembourg A, 2006, VACCINE, V24, P4490, DOI 10.1016/j.vaccine.2005.08.014; Makidon PE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002954; Martinon F, 2009, HUM GENE THER, V20, P1291, DOI 10.1089/hum.2009.044; Maruyama H, 2001, GENE THER, V8, P1808, DOI 10.1038/sj.gt.3301604; McMahon JM, 2004, BIODRUGS, V18, P155, DOI 10.2165/00063030-200418030-00002; Medi Babu M., 2008, V423, P225, DOI 10.1007/978-1-59745-194-9_16; Medi BM, 2005, INT J PHARMACEUT, V294, P53, DOI 10.1016/j.ijpharm.2004.12.014; Muller I, 2009, TRENDS IMMUNOL, V30, P522, DOI 10.1016/j.it.2009.07.007; Muthumani K, 2009, CURR HIV RES, V7, P144, DOI 10.2174/157016209787581481; Muttil P, 2010, AAPS J, V12, P699, DOI 10.1208/s12248-010-9229-6; Nishi T, 1996, CANCER RES, V56, P1050; Otten G, 2004, VACCINE, V22, P2489, DOI 10.1016/j.vaccine.2003.11.073; Otten GR, 2006, VACCINE, V24, P4503, DOI 10.1016/j.vaccine.2005.08.017; Peachman KK, 2003, METHODS, V31, P232, DOI 10.1016/S1046-2023(03)00137-3; Ramanathan MP, 2009, VACCINE, V27, P4370, DOI 10.1016/j.vaccine.2009.01.137; Rosati M, 2009, P NATL ACAD SCI USA, V106, P15831, DOI 10.1073/pnas.0902628106; Scheerlinck JPY, 2004, VACCINE, V22, P1820, DOI 10.1016/j.vaccine.2003.09.053; Seo SH, 2009, VACCINE, V27, P5906, DOI 10.1016/j.vaccine.2009.07.033; Sueki H, 2000, EUR J DERMATOL, V10, P357; Tollefsen S, 2002, VACCINE, V20, P3370, DOI 10.1016/S0264-410X(02)00289-X; Trollet C, 2009, INFECT IMMUN, V77, P2221, DOI 10.1128/IAI.01269-08; Tuting T, 1998, J INVEST DERMATOL, V111, P183, DOI 10.1046/j.1523-1747.1998.00261.x; Vandermeulen G, 2007, J CONTROL RELEASE, V124, P81, DOI 10.1016/j.jconrel.2007.08.010; Wallace M, 2009, MOL THER, V17, P922, DOI 10.1038/mt.2009.27; Widera G, 2000, J IMMUNOL, V164, P4635, DOI 10.4049/jimmunol.164.9.4635; Wu CJ, 2004, VACCINE, V22, P1457, DOI 10.1016/j.vaccine.2003.10.011; Zhang L, 2004, BIOELECTROCHEMISTRY, V63, P369, DOI 10.1016/j.bioelechem.2003.11.011; Zhang L, 2002, BBA-GEN SUBJECTS, V1572, P1, DOI 10.1016/S0304-4165(02)00270-2; Zhao YG, 2006, VACCINE, V24, P897, DOI 10.1016/j.vaccine.2005.08.093; Zheng LY, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-17; Zucchelli S, 2000, J VIROL, V74, P11598, DOI 10.1128/JVI.74.24.11598-11607.2000; 2004, DRUGS R D, V5, P293	62	41	41	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2011	6	4							e19181	10.1371/journal.pone.0019181	http://dx.doi.org/10.1371/journal.pone.0019181			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	756OZ	21559474	gold, Green Published, Green Submitted			2023-01-03	WOS:000290024700093
J	Tallis, R				Tallis, Raymond			Should the law on assisted dying be changed? Yes	BRITISH MEDICAL JOURNAL			English	Editorial Material							OF-LIFE PRACTICES; NETHERLANDS		Univ Manchester, Manchester, Lancs, England	University of Manchester	Tallis, R (corresponding author), Univ Manchester, Manchester, Lancs, England.	raymond@rtallis.wanadoo.co.uk						Battin MP, 2007, J MED ETHICS, V33, P591, DOI 10.1136/jme.2007.022335; Bilsen J, 2009, NEW ENGL J MED, V361, P1119, DOI 10.1056/NEJMc0904292; Clery E., 2007, BRIT SOCIAL ATTITUDE, P35; Jackson A., 2009, DIGN CHOIC S END OF; KMEITOVICZ Z, 2002, BRIT MED J, V324, P11; McAndrew Siobhan, 2010, BRIT SOCIAL ATTITUDE, P87; *OR HLTH AUTH, DEATH DIGN ANN REP; *OR PUBL HLTH DIV, 1998, CHAR END OF LIF CAR; Seale C, 2009, PALLIATIVE MED, V23, P198, DOI 10.1177/0269216308102042; Seale C, 2010, J PAIN SYMPTOM MANAG, V39, P44, DOI 10.1016/j.jpainsymman.2009.06.007; van der Heide A, 2007, NEW ENGL J MED, V356, P1957, DOI 10.1056/NEJMsa071143; VANBEEK K, 2010, ASSESSING ORG IMPROV, P117	12	4	4	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 21	2011	342								d2355	10.1136/bmj.d2355	http://dx.doi.org/10.1136/bmj.d2355			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755OR	21511806				2023-01-03	WOS:000289943400009
J	Jarvinen, TLN; Sievanen, H; Kannus, P; Jokihaara, J; Khan, KM				Jarvinen, Teppo L. N.; Sievanen, Harri; Kannus, Pekka; Jokihaara, Jarkko; Khan, Karim M.			The true cost of pharmacological disease prevention	BRITISH MEDICAL JOURNAL			English	Editorial Material							OSTEOPOROTIC FRACTURES; CONTROLLED-TRIAL; FALLS; RISK		[Jarvinen, Teppo L. N.] Univ Tampere, Dept Orthopaed Surg, Tampere 33014, Finland; [Sievanen, Harri] Cent Finland Cent Hosp, Dept Surg, Jyvaskyla 40620, Finland; [Sievanen, Harri] UKK Inst, Bone Res Grp, Tampere 33500, Finland; [Kannus, Pekka] Tampere Univ Hosp, Div Orthopaed & Traumatol, Tampere 33520, Finland; [Jokihaara, Jarkko; Khan, Karim M.] Univ British Columbia, Ctr Hip Hlth & Mobil, Vancouver, BC V5Z 1M9, Canada	Tampere University; Central Finland Central Hospital; UKK Institute; Tampere University; Tampere University Hospital; University of British Columbia	Jarvinen, TLN (corresponding author), Univ Tampere, Dept Orthopaed Surg, Tampere 33014, Finland.	teppo.jarvinen@uta.fi	Jokihaara, Jarkko/C-5817-2017; Järvinen, Teppo/B-8189-2013	Jokihaara, Jarkko/0000-0001-6153-2180; Järvinen, Teppo/0000-0003-3713-956X				Borgstrom F, 2010, OSTEOPOROSIS INT, V21, P495, DOI 10.1007/s00198-009-0989-8; Compston JE, 2006, LANCET, V368, P973, DOI 10.1016/S0140-6736(06)69394-X; Cooper A, 2008, CLIN GUIDELINES EVID; Dawson J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c186; Haynes B, 1999, BRIT MED J, V319, P652, DOI 10.1136/bmj.319.7211.652; Inderjeeth CA, 2009, BONE, V44, P744, DOI 10.1016/j.bone.2008.12.003; Jarvinen TLN, 2008, BRIT MED J, V336, P124, DOI 10.1136/bmj.39428.470752.AD; Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198-006-0172-4; Kannus P, 2006, J BONE MINER RES, V21, P1836, DOI 10.1359/JBMR.060815; Kuehn BM, 2008, JAMA-J AM MED ASSOC, V299, P1651, DOI 10.1001/jama.299.14.1651; Marshall D, 1996, BRIT MED J, V312, P1254, DOI 10.1136/bmj.312.7041.1254; *NAT I HLTH CLIN E, 2006, NICE CLIN GUID, V34; *NICE, 2010, NICE TECHN APPR GUID, V160; Parikh S, 2009, J AM GERIATR SOC, V57, P327, DOI 10.1111/j.1532-5415.2008.02119.x; Relton C, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1066; Robertson MC, 2001, BRIT MED J, V322, P701, DOI 10.1136/bmj.322.7288.701; Sawka AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009515; Sox HC, 2009, ANN INTERN MED, V151, P203, DOI 10.7326/0003-4819-151-3-200908040-00125; Stone KL, 2003, J BONE MINER RES, V18, P1947, DOI 10.1359/jbmr.2003.18.11.1947; van Staa TP, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000194; Yeaw J, 2009, J MANAGE CARE PHARM, V15, P728, DOI 10.18553/jmcp.2009.15.9.728	21	39	39	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 19	2011	342								d2175	10.1136/bmj.d2175	http://dx.doi.org/10.1136/bmj.d2175			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755OI	21505222				2023-01-03	WOS:000289942200004
J	Grover, A; Citro, B				Grover, Anand; Citro, Brian			India: access to affordable drugs and the right to health	LANCET			English	Editorial Material									[Grover, Anand; Citro, Brian] Lawyers Collect HIV AIDS Unit, Bombay 400001, Maharashtra, India		Grover, A (corresponding author), Lawyers Collect HIV AIDS Unit, Bombay 400001, Maharashtra, India.	anandgrover@gmail.com						[Anonymous], 2004, WHO MED STRAT COUNTR; [Anonymous], 2004, WORLD MED SIT; European Commission, 2009, ANT TRAD AGR ACTA FA; *IND DEP IND POL P, 2010, DISC PAP SUBJ COMP L; Niens LM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000333; Office of the United Nations High Commissioner for Human Rights, INT COV EC SOC CULT; Reddy KS, 2011, LANCET, V377, P760, DOI 10.1016/S0140-6736(10)61960-5; VIVASEUGUI D, 2003, REGIONAL BILATERAL A; Waning B, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-35; *WHO, 2004, EQ ACC ESS MED FRAM, V8	10	10	10	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 19	2011	377	9770					976	977		10.1016/S0140-6736(10)62042-9	http://dx.doi.org/10.1016/S0140-6736(10)62042-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	740FA	21227487				2023-01-03	WOS:000288775800008
J	Kaplan, LJ; Shaw, AD				Kaplan, Lewis J.; Shaw, Andrew D.			Standards for Education and Credentialing in Critical Care Medicine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							UNIT; ILL		[Kaplan, Lewis J.] Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, New Haven, CT 06520 USA; [Shaw, Andrew D.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA	Yale University; Duke University	Kaplan, LJ (corresponding author), Yale Univ, Sch Med, Dept Surg, Sect Trauma Surg Crit Care & Surg Emergencies, 330 Cedar St,BB-310, New Haven, CT 06520 USA.	lewis.kaplan@yale.edu		Shaw, Andrew/0000-0002-0566-8005				Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; [Anonymous], GRADUATE MED ED DATA; Kleinpell RM, 2008, CRIT CARE MED, V36, P2888, DOI 10.1097/CCM.0b013e318186ba8c; Milbrandt EB, 2008, CRIT CARE MED, V36, P2504, DOI 10.1097/CCM.0b013e318183ef84; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; *US DEP HHS, NAT HEALTHC EXP AGGR; *US DEP HHS, CRIT CAR WORKF STUD; NEUROCRITICAL CARE C	8	23	24	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2011	305	3					296	297		10.1001/jama.2010.1997	http://dx.doi.org/10.1001/jama.2010.1997			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	707YY	21239762				2023-01-03	WOS:000286328700026
J	Blackwood, B; Alderdice, F; Burns, K; Cardwell, C; Lavery, G; O'Halloran, P				Blackwood, Bronagh; Alderdice, Fiona; Burns, Karen; Cardwell, Chris; Lavery, Gavin; O'Halloran, Peter			Use of weaning protocols for reducing duration of mechanical ventilation in critically ill adult patients: Cochrane systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMPUTERIZED DECISION-SUPPORT; CONTROLLED-TRIAL; CLINICAL-OUTCOMES; RANDOMIZED-TRIAL; CARE; SEDATION; PNEUMONIA; EFFICACY; QUALITY	Objective To investigate the effects of weaning protocols on the total duration of mechanical ventilation, mortality, adverse events, quality of life, weaning duration, and length of stay in the intensive care unit and hospital. Design Systematic review. Data sources Cochrane Central Register of Controlled Trials, Medline, Embase, CINAHL, LILACS, ISI Web of Science, ISI Conference Proceedings, Cambridge Scientific Abstracts, and reference lists of articles. We did not apply language restrictions. Review methods We included randomised and quasi-randomised controlled trials of weaning from mechanical ventilation with and without protocols in critically ill adults. Data selection Three authors independently assessed trial quality and extracted data. A priori subgroup and sensitivity analyses were performed. We contacted study authors for additional information. Results Eleven trials that included 1971 patients met the inclusion criteria. Compared with usual care, the geometric mean duration of mechanical ventilation in the weaning protocol group was reduced by 25% (95% confidence interval 9% to 39%, P=0.006; 10 trials); the duration of weaning was reduced by 78% (31% to 93%, P=0.009; six trials); and stay in the intensive care unit length by 10% (2% to 19%, P=0.02; eight trials). There was significant heterogeneity among studies for total duration of mechanical ventilation (I-2=76%, P<0.01) and duration of weaning (I-2=97%, P<0.01), which could not be explained by subgroup analyses based on type of unit or type of approach. Conclusion There is evidence of a reduction in the duration of mechanical ventilation, weaning, and stay in the intensive care unit when standardised weaning protocols are used, but there is significant heterogeneity among studies and an insufficient number of studies to investigate the source of this heterogeneity. Some studies suggest that organisational context could influence outcomes, but this could not be evaluated as it was outside the scope of this review.	[Blackwood, Bronagh; Alderdice, Fiona; O'Halloran, Peter] Queens Univ Belfast, Nursing & Midwifery Res Unit, Belfast BT9 5BN, Antrim, North Ireland; [Burns, Karen] St Michaels Hosp, Interdept Div Crit Care Med, Toronto, ON M5B 1W8, Canada; [Cardwell, Chris] Queens Univ Belfast, Ctr Publ Hlth, Belfast BT9 5BN, Antrim, North Ireland; [Lavery, Gavin] Royal Victoria Hosp, Belfast Hlth & Social Care Trust, Belfast BT12 6BA, Antrim, North Ireland	Queens University Belfast; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Queens University Belfast	Blackwood, B (corresponding author), Queens Univ Belfast, Nursing & Midwifery Res Unit, Belfast BT9 5BN, Antrim, North Ireland.	b.blackwood@qub.ac.uk	Blackwood, Bronagh/GPS-9197-2022	Cardwell, Chris/0000-0002-2689-4335; Alderdice, Fiona/0000-0003-2404-5644; O'Halloran, Peter/0000-0002-0022-7331	Research and Development Office, Northern Ireland; Health Research Board, Ireland	Research and Development Office, Northern Ireland; Health Research Board, Ireland	The review was funded through a Cochrane Fellowship Award for BB from the Research and Development Office, Northern Ireland, and the Health Research Board, Ireland.	Beale R, COMP AUTOMATED WEANI; Blackwood B, 2009, COCHRANE DB SYST REV, V5; Blackwood B, 2006, J ADV NURS, V54, P612, DOI 10.1111/j.1365-2648.2006.03869.x; Bland JM, 1996, BMJ-BRIT MED J, V312, P1153; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; Burns KEA, 2008, INTENS CARE MED, V34, P1757, DOI 10.1007/s00134-008-1154-0; Burns KEA, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1574; Butler RJ, NCT00157287; Cook D, 2000, AHRQ PUBLICATION; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Dongelmans DA, 2009, ANESTH ANALG, V108, P565, DOI 10.1213/ane.0b013e318190c49f; Dries DJ, 1997, J TRAUMA, V43, P372, DOI 10.1097/00005373-199708000-00032; East TD, 1999, J AM MED INFORM ASSN, P251; Ely EW, 2001, INTENS CARE MED, V27, P1892, DOI 10.1007/s00134-001-1132-2; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; ESEN F, 1992, ADV EXP MED BIOL, V317, P371; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; Hendrix H, 2006, EUR J CARDIO-THORAC, V29, P957, DOI 10.1016/j.ejcts.2006.01.036; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Higgins JPT, 2008, STAT MED, V27, P6072, DOI 10.1002/sim.3427; Hozo Stela Pudar, 2005, BMC Med Res Methodol, V5, P13, DOI 10.1186/1471-2288-5-13; Kollef MH, 1998, CHEST, V114, P541, DOI 10.1378/chest.114.2.541; Kollef MH, 1997, CRIT CARE MED, V25, P567, DOI 10.1097/00003246-199704000-00004; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kress JP, 1996, AM J RESP CRIT CARE, V153, P1012, DOI 10.1164/ajrccm.153.3.8630539; Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-761OC; Lawton R, 1999, SOC SCI MED, V48, P353, DOI 10.1016/S0277-9536(98)00345-1; Lellouche F, 2006, AM J RESP CRIT CARE, V174, P894, DOI 10.1164/rccm.200511-1780OC; Lellouche F, 2009, BEST PRACT RES-CLIN, V23, P81, DOI 10.1016/j.bpa.2008.08.001; Mancebo J, 1996, EUR RESPIR J, V9, P1923, DOI 10.1183/09031936.96.09091923; Marelich GP, 2000, CHEST, V118, P459, DOI 10.1378/chest.118.2.459; McKinley BA, 2001, J TRAUMA, V50, P415, DOI 10.1097/00005373-200103000-00004; Meade M O, 1995, Clin Intensive Care, V6, P166, DOI 10.1080/714028896; Meade MO, 1997, CRIT CARE MED, V25, P1915, DOI 10.1097/00003246-199711000-00034; Medical Research Council, 2008, DEV EV COMPL INT NEW; Murtagh D, 2010, PROTOCOLS PUT MORE P; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Navalesi P, 2008, CRIT CARE MED, V36, P2986, DOI 10.1097/CCM.0b013e31818b35f2; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; Papirov G, 2007, COMPUTER DRIVEN MANA; Piotto RF, 2010, REV BRAS CIR CARDIOV; Polverino E, 2010, INTENS CARE MED, V36, P137, DOI 10.1007/s00134-009-1658-2; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Randolph AG, 2002, JAMA-J AM MED ASSOC, V288, P2561, DOI 10.1001/jama.288.20.2561; Reschreiter H, 2008, CRIT CARE, V12, DOI 10.1186/cc7141; Rose L, 2007, ANAESTH INTENS CARE, V35, P213, DOI 10.1177/0310057X0703500210; Rose L, 2008, INTENS CARE MED, V34, P1788, DOI 10.1007/s00134-008-1179-4; SAHN SA, 1973, CHEST, V63, P1002, DOI 10.1378/chest.63.6.1002; Scholz J, AUTOMATIC CONTROL PR; Schweickert WD, 2007, CHEST, V131, P1541, DOI 10.1378/chest.06-2065; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Simeone F, 2002, J CARDIOVASC SURG, V43, P633; Slutsky AS, 1998, AM J RESP CRIT CARE, V157, P1721, DOI 10.1164/ajrccm.157.6.9709092; Stahl C., 2009, Intensivmedizin und Notfallmedizin, V46, P441, DOI 10.1007/s00390-009-0061-0; STRICKLAND JH, 1993, CHEST, V103, P1220, DOI 10.1378/chest.103.4.1220; STROETZ RW, 1995, AM J RESP CRIT CARE, V152, P1034, DOI 10.1164/ajrccm.152.3.7663780; Strom T, 2010, LANCET, V375, P475, DOI 10.1016/S0140-6736(09)62072-9; Taniguchi C, 2009, CRIT CARE, V13, DOI 10.1186/cc7695; The Nordic Cochrane Centre The Cochrane Collaboration., 2008, REV MAN REVMAN VERS; Thompson B Taylor, 2007, Proc Am Thorac Soc, V4, P577, DOI 10.1513/pats.200706-072JK; THORENS JB, 1995, CRIT CARE MED, V23, P1807, DOI 10.1097/00003246-199511000-00004; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	66	135	147	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 13	2011	342								c7237	10.1136/bmj.c7237	http://dx.doi.org/10.1136/bmj.c7237			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	708TG	21233157	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000286386600001
J	Wake, M; Tobin, S; Girolametto, L; Ukoumunne, OC; Gold, L; Levickis, P; Sheehan, J; Goldfeld, S; Reilly, S				Wake, Melissa; Tobin, Sherryn; Girolametto, Luigi; Ukoumunne, Obioha C.; Gold, Lisa; Levickis, Penny; Sheehan, Jane; Goldfeld, Sharon; Reilly, Sheena			Outcomes of population based language promotion for slow to talk toddlers at ages 2 and 3 years: Let's Learn Language cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHILD LANGUAGE; DISORDERS; DELAY; COMMUNICATION; INTERVENTION; IMPAIRMENT; SPEECH; SKILLS	Objective To determine the benefits of a low intensity parent-toddler language promotion programme delivered to toddlers identified as slow to talk on screening in universal services. Design Cluster randomised trial nested in a population based survey. Setting Three local government areas in Melbourne, Australia. Participants Parents attending 12 month well child checks over a six month period completed a baseline questionnaire. At 18 months, children at or below the 20th centile on an expressive vocabulary checklist entered the trial. Intervention Maternal and child health centres (clusters) were randomly allocated to intervention (modified "You Make the Difference" programme over six weekly sessions) or control ("usual care") arms. Main outcome measures The primary outcome was expressive language (Preschool Language Scale-4) at 2 and 3 years; secondary outcomes were receptive language at 2 and 3 years, vocabulary checklist raw score at 2 and 3 years, Expressive Vocabulary Test at 3 years, and Child Behavior Checklist/1.5-5 raw score at 2 and 3 years. Results 1217 parents completed the baseline survey; 1138 (93.5%) completed the 18 month checklist, when 301 (26.4%) children had vocabulary scores at or below the 20th centile and were randomised (158 intervention, 143 control). 115 (73%) intervention parents attended at least one session (mean 4.5 sessions), and most reported high satisfaction with the programme. Interim outcomes at age 2 years were similar in the two groups. Similarly, at age 3 years, adjusted mean differences (intervention-control) were -2.4 (95% confidence interval -6.2 to 1.4; P=0.21) for expressive language; -0.3 (-4.2 to 3.7; P=0.90) for receptive language; 4.1 (-2.3 to 10.6; P=0.21) for vocabulary checklist; -0.5 (-4.4 to 3.4; P=0.80) for Expressive Vocabulary Test; -0.1 (-1.6 to 1.4; P=0.86) for externalising behaviour problems; and -0.1 (-1.3 to 1.2; P=0. 92) for internalising behaviour problems. Conclusion This community based programme targeting slow to talk toddlers was feasible and acceptable, but little evidence was found that it improved language or behaviour either immediately or at age 3 years.	[Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Wake, Melissa; Tobin, Sherryn; Levickis, Penny; Sheehan, Jane; Goldfeld, Sharon; Reilly, Sheena] Univ Melbourne, Parkville, Vic 3052, Australia; [Girolametto, Luigi] Univ Toronto, Dept Speech Language Pathol, Toronto, ON M5G 1V7, Canada; [Ukoumunne, Obioha C.] Univ Exeter, Peninsula Coll Med & Dent, PenCLAHRC, Exeter, Devon, England; [Gold, Lisa] Deakin Univ, Burwood, Vic 3125, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne; University of Toronto; University of Exeter; University of Plymouth; Deakin University	Wake, M (corresponding author), Royal Childrens Hosp, Ctr Community Child Hlth, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	melissa.wake@rch.org.au	Levickis, Penny/M-3579-2019; Wake, Melissa/J-1396-2012; Reilly, Sheena/A-7035-2016; Reilly, Sheena/D-5120-2012; Levickis, Penny/K-8968-2019; Levickis, Penny/N-9394-2018	Levickis, Penny/0000-0003-0534-733X; Wake, Melissa/0000-0001-7501-9257; Reilly, Sheena/0000-0001-6506-4767; Reilly, Sheena/0000-0001-6506-4767; Levickis, Penny/0000-0003-0534-733X; Goldfeld, Sharon/0000-0001-6520-7094; Gold, Lisa/0000-0002-2733-900X; Sheehan, Jane/0000-0001-8799-5108	Australian National Health and Medical Research Council (NHMRC) [384491, 546405, 425855, 436914, 491210]; Victorian government	Australian National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Victorian government	The trial was funded by the Australian National Health and Medical Research Council (NHMRC) strategic award 384491. The following authors were supported by the NHMRC during the trial: MW (population health career development grant 546405); LGold (population health capacity building grant 425855), SG and OU (population health capacity building grant 436914), and SR (practitioner research fellowship 491210). Murdoch Childrens Research Institute's research is supported by the Victorian government's Operational Infrastructure Support Program. The researchers were independent of the funders.	Achenbach T, 2000, ACHENBACH SYSTEM EMP; *AUSTR BUR STAT, 2001, SOC IND AR; Beitchman J, 1999, TRANSITIONS ADULTHOO; Buschmann A, 2008, ARCH DIS CHILD, V94, P80; Campbell MJ, 2000, STAT METHODS MED RES, V9, P81, DOI 10.1191/096228000676246354; CAULFIELD MB, 1989, J ABNORM CHILD PSYCH, V17, P187, DOI 10.1007/BF00913793; Clegg J, 2005, J CHILD PSYCHOL PSYC, V46, P128, DOI 10.1111/j.1469-7610.2004.00342.x; Dale PS, 2000, J CHILD LANG, V27, P619, DOI 10.1017/S0305000900004281; Dale PS, 2003, J SPEECH LANG HEAR R, V46, P544, DOI 10.1044/1092-4388(2003/044); de Koning HJ, 2004, J MED SCREEN, V11, P109, DOI 10.1258/0969141041732229; Desmarais C, 2007, INT J LANG COMM DIS, V1, P30; Dollaghan C. A., 2007, HDB EVIDENCE BASED P; Dowd T, 2007, NEONAT PAEDIAT CHILD, V10, P13; Feldman HM, 2005, CHILD DEV, V76, P856, DOI 10.1111/j.1467-8624.2005.00882.x; Fenson L, 2000, APPL PSYCHOLINGUIST, V21, P95, DOI 10.1017/S0142716400001053; Fenson L, 2000, CHILD DEV, V71, P323, DOI 10.1111/1467-8624.00147; Girolametto L., 1996, J CHILDRENS COMMUNIC, V17, P39, DOI [10.1177/152574019501700205, DOI 10.1177/152574019501700205]; Glogowska M, 2000, BRIT MED J, V321, P923, DOI 10.1136/bmj.321.7266.923; Goldstein H, 2003, MULTILEVEL STAT MODE; Huebner CE, 2005, J APPL DEV PSYCHOL, V26, P296, DOI 10.1016/j.appdev.2005.02.006; Landry SH, 2008, DEV PSYCHOL, V44, P1335, DOI 10.1037/a0013030; Law J, 2004, J SPEECH LANG HEAR R, V47, P924, DOI 10.1044/1092-4388(2004/069); Law J, 2003, Cochrane Database Syst Rev, pCD004110, DOI 10.1002/14651858.CD004110; Manolson HA, 1995, YOU MAKE DIFFERENCE; Miniscalco C, 2005, ACTA PAEDIATR, V94, P1798, DOI 10.1080/08035250500244242; Nelson HD, 2006, PEDIATRICS, V117, pE298, DOI 10.1542/peds.2005-1467; Perera R, 2007, BRIT MED J, V334, P127, DOI 10.1136/bmj.39045.396817.68; Reilly S, 2007, PEDIATRICS, V120, pE1441, DOI 10.1542/peds.2007-0045; Reilly S, 2006, J PAEDIATR CHILD H, V42, P764, DOI 10.1111/j.1440-1754.2006.00974.x; Rescorla L, 2009, J SPEECH LANG HEAR R, V52, P16, DOI 10.1044/1092-4388(2008/07-0171); Robertson SB, 1999, J SPEECH LANG HEAR R, V42, P1234, DOI 10.1044/jslhr.4205.1234; Robey RR, 1998, J SPEECH LANG HEAR R, V41, P1227, DOI 10.1044/jslhr.4106.1227; Roy P., 2005, SURE START LANGUAGE; Schafer J.L., 1997, ANAL INCOMPLETE MULT; Sheehan J, 2009, EARLY CHILDHOOD SERV, V3, P33; Tomblin JB, 1997, J SPEECH LANG HEAR R, V40, P1245, DOI 10.1044/jslhr.4006.1245; Tomblin JB, 2000, J CHILD PSYCHOL PSYC, V41, P473, DOI 10.1111/1469-7610.00632; van Agt HME, 2007, PEDIATRICS, V120, P1317, DOI 10.1542/peds.2006-3145; Warren SF, 2007, MENT RETARD DEV D R, V13, P70, DOI 10.1002/mrdd.20139; Wetherby AM, 2001, CSBS DEV PROFILE INF; Zimmerman I. L., 2002, PRESCHOOL LANGUAGE S, V4th	41	65	66	1	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 18	2011	343								d4741	10.1136/bmj.d4741	http://dx.doi.org/10.1136/bmj.d4741			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811LE	21852344	hybrid, Green Published, Green Submitted			2023-01-03	WOS:000294210800001
J	Podolsky, SH; Greene, JA				Podolsky, Scott H.; Greene, Jeremy A.			HISTORY OF MEDICINE Combination Drugs - Hype, Harm, and Hope	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Podolsky, Scott H.] Brigham & Womens Hosp, Ctr Hist Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Podolsky, SH (corresponding author), Brigham & Womens Hosp, Ctr Hist Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.							Avorn J, 2005, NEW ENGL J MED, V352, P2573, DOI 10.1056/NEJMp058075; FINLAND M, 1974, NEW ENGL J MED, V291, P624, DOI 10.1056/NEJM197409192911209; Podolsky SH, 2010, J HIST MED ALL SCI, V65, P327, DOI 10.1093/jhmas/jrq003; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Woodcock J, 2011, NEW ENGL J MED, V364, P985, DOI 10.1056/NEJMp1101548	5	40	43	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2011	365	6					488	491		10.1056/NEJMp1106161	http://dx.doi.org/10.1056/NEJMp1106161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805MW	21830965				2023-01-03	WOS:000293732100004
J	Kong, MYF; Li, Y; Oster, R; Gaggar, A; Clancy, JP				Kong, Michele Y. F.; Li, Yao; Oster, Robert; Gaggar, Amit; Clancy, J. P.			Early Elevation of Matrix Metalloproteinase-8 and-9 in Pediatric ARDS Is Associated with an Increased Risk of Prolonged Mechanical Ventilation	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; NEUTROPHIL MIGRATION; PREVENTS; INHIBITION; OUTCOMES	Background: Matrix metalloproteinases (MMP) -8 and -9 may play key roles in the modulation of neutrophilic lung inflammation seen in pediatric Acute Respiratory Distress Syndrome (ARDS). We aimed to perform a comprehensive analysis of MMP-8 and MMP-9 activity in tracheal aspirates of pediatric ARDS patients compared with non-ARDS controls, testing whether increased MMP-8 and -9 activities were associated with clinical outcomes. Methods: Tracheal aspirates were collected from 33 pediatric ARDS patients and 21 non-ARDS controls at 48 hours of intubation, and serially for those who remained intubated greater than five days. MMPs, tissue inhibitor of metalloproteinases (TIMPs), human neutrophil elastase (HNE) and myeloperoxidase (MPO) activity were measured by ELISA, and correlated with clinical indicators of disease severity such as PRISM (Pediatric Risk of Mortality) scores, oxygen index (OI), multi-organ system failure (MOSF) and clinical outcome measures including length of intubation, ventilator-free days (VFDs) and mortality in the Pediatric Intensive Care Unit (PICU). Results: Active MMP-9 was elevated early in pediatric ARDS subjects compared to non-ARDS controls. Higher MMP-8 and active MMP-9 levels at 48 hours correlated with a longer course of mechanical ventilation (r = 0.41, p = 0.018 and r = 0.75, p<0.001; respectively) and fewer number of VFDs (r = -0.43, p = 0.013 and r = -0.76, p<0.001; respectively), independent of age, gender and severity of illness. Patients with the highest number of ventilator days had the highest levels of active MMP-9. MMP-9 and to a lesser extent MMP-8 activities in tracheal aspirates from ARDS subjects were sensitive to blockade by small molecule inhibitors. Conclusions: Higher MMP-8 and active MMP-9 levels at 48 hours of disease onset are associated with a longer duration of mechanical ventilation and fewer ventilator-free days among pediatric patients with ARDS. Together, these results identify early biomarkers predictive of disease course and potential therapeutic targets for this life threatening disease.	[Kong, Michele Y. F.; Li, Yao] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA; [Oster, Robert; Gaggar, Amit] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Clancy, J. P.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Cincinnati Children's Hospital Medical Center	Kong, MYF (corresponding author), Univ Alabama Birmingham, Dept Pediat, Birmingham, AL 35294 USA.	mkong@peds.uab.edu		Oster, Robert/0000-0002-2247-8596	Kaul Pediatric Research Institute	Kaul Pediatric Research Institute	This study is funded by the Kaul Pediatric Research Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albaiceta GM, 2008, AM J PHYSIOL-LUNG C, V294, pL535, DOI 10.1152/ajplung.00334.2007; Bendeck MP, 2002, AM J PATHOL, V160, P1089, DOI 10.1016/S0002-9440(10)64929-2; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Carney DE, 1999, CIRCULATION, V100, P400, DOI 10.1161/01.CIR.100.4.400; Carney DE, 2001, J SURG RES, V99, P245, DOI 10.1006/jsre.2001.6180; Cederqvist K, 2006, PEDIATR RES, V60, P395, DOI 10.1203/01.pdr.0000238342.16081.f9; Dahlem P, 2007, PAEDIATR RESPIR REV, V8, P348, DOI 10.1016/j.prrv.2007.03.001; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288, DOI 10.1165/ajrcmb.14.3.8845180; Fligiel SEG, 2006, HUM PATHOL, V37, P422, DOI 10.1016/j.humpath.2005.11.023; Flori HR, 2007, PEDIATR CRIT CARE ME, V8, P96, DOI 10.1097/01.PCC.0000257097.42640.6F; Gaggar A, 2008, J IMMUNOL, V180, P5662, DOI 10.4049/jimmunol.180.8.5662; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Golub L M, 1998, Adv Dent Res, V12, P12; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; Keck T, 2002, GASTROENTEROLOGY, V122, P188, DOI 10.1053/gast.2002.30348; Kim JH, 2006, AM J PHYSIOL-LUNG C, V291, pL580, DOI 10.1152/ajplung.00270.2005; Kim JH, 2004, AM J PHYSIOL-LUNG C, V287, pL127, DOI 10.1152/ajplung.00047.2003; Kong MYF, 2009, INT J MED SCI, V6, P9; Lanchou J, 2003, CRIT CARE MED, V31, P536, DOI 10.1097/01.CCM.0000048626.02184.F8; Lukkarinen H, 2009, AM J RESP CELL MOL, V41, P59, DOI 10.1165/rcmb.2008-0179OC; Pugin J, 1999, CRIT CARE MED, V27, P304, DOI 10.1097/00003246-199902000-00036; Reel B, 2009, PEDIATR PULM, V44, P1118, DOI 10.1002/ppul.21111; Ricou B, 1996, AM J RESP CRIT CARE, V154, P346, DOI 10.1164/ajrccm.154.2.8756805; Sapru A, 2010, INTENS CARE MED, V36, P157, DOI 10.1007/s00134-009-1690-2; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Steinberg J, 2005, SHOCK, V24, P348, DOI 10.1097/01.shk.0000180619.06317.2c; Torii K, 1997, AM J RESP CRIT CARE, V155, P43, DOI 10.1164/ajrccm.155.1.9001287; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Yeo SJ, 2002, ARCH VIROL, V147, P229, DOI 10.1007/s705-002-8316-1	29	33	33	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2011	6	8							e22596	10.1371/journal.pone.0022596	http://dx.doi.org/10.1371/journal.pone.0022596			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	803CQ	21857935	Green Published, Green Submitted, gold			2023-01-03	WOS:000293558900019
J	McWilliams, JM; Zaslavsky, AM; Huskamp, HA				McWilliams, J. Michael; Zaslavsky, Alan M.; Huskamp, Haiden A.			Implementation of Medicare Part D and Nondrug Medical Spending for Elderly Adults With Limited Prior Drug Coverage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE CORONARY SYNDROMES; OLDER-ADULTS; COST; BENEFICIARIES; ADHERENCE; BENEFITS; IMPACT; GAP; INFARCTION; INSURANCE	Context Implementation of Medicare Part D was followed by increased use of prescription medications, reduced out-of-pocket costs, and improved medication adherence. Its effects on nondrug medical spending remain unclear. Objective To assess differential changes in nondrug medical spending following the implementation of Part D for traditional Medicare beneficiaries with limited prior drug coverage. Design, Setting, and Participants Nationally representative longitudinal survey data and linked Medicare claims from 2004-2007 were used to compare nondrug medical spending before and after the implementation of Part D by self-reported generosity of prescription drug coverage before 2006. Participants included 6001 elderly Medicare beneficiaries from the Health and Retirement Study, including 2538 with generous and 3463 with limited drug coverage before 2006. Comparisons were adjusted for sociodemographic and health characteristics and checked for residual confounding by conducting similar comparisons for a control cohort from 2002-2005. Main Outcome Measure Nondrug medical spending assessed from claims, in total and by type of service (inpatient and skilled nursing facility vs physician services). Results Total nondrug medical spending was differentially reduced after January 1, 2006, for beneficiaries with limited prior drug coverage (-$306/quarter [95% confidence interval {CI}, -$586 to -$51]; P=.02), relative to beneficiaries with generous prior drug coverage. This differential reduction was explained mostly by differential changes in spending on inpatient and skilled nursing facility care (-$204/quarter [95% CI, -$447 to $2]; P=.05). Differential reductions in spending on physician services (-$67/quarter [95% CI, -$134 to -$5]; P=.03) were not associated with differential changes in outpatient visits (-0.06 visits/quarter [95% CI, -0.21 to 0.08]; P=.37), suggesting reduced spending on inpatient physician services for beneficiaries with limited prior drug coverage. In contrast, nondrug medical spending in the control cohort did not differentially change after January 1, 2004, for beneficiaries with limited prior drug coverage in 2002 ($14/quarter [95% CI, -$338 to $324]; P=.93), relative to beneficiaries with generous prior coverage. Conclusion Implementation of Part D was associated with significant differential reductions in nondrug medical spending for Medicare beneficiaries with limited prior drug coverage. JAMA. 2011; 306(4): 402-409	[McWilliams, J. Michael; Zaslavsky, Alan M.; Huskamp, Haiden A.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [McWilliams, J. Michael] Brigham & Womens Hosp, Dept Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	McWilliams, JM (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	mcwilliams@hcp.med.harvard.edu			Doris Duke Charitable Foundation [2010053]; William F. Milton Fund; Robert Wood Johnson Foundation	Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); William F. Milton Fund; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF))	This study was supported by grants from the Doris Duke Charitable Foundation (Clinical Scientist Development Award 2010053, Dr McWilliams), the William F. Milton Fund (Dr McWilliams), and a Robert Wood Johnson Foundation Investigator Award in Health Policy Research (Dr Huskamp).	Afendulis CC, 2011, HEALTH SERV RES, V46, P1022, DOI 10.1111/j.1475-6773.2011.01244.x; [Anonymous], 2011 EC REPORT PRESI; BINDER DA, 1983, INT STAT REV, V51, P279, DOI 10.2307/1402588; Chandra A, 2010, AM ECON REV, V100, P193, DOI 10.1257/aer.100.1.193; Chernew ME, 2007, HEALTH AFFAIR, V26, pW195, DOI 10.1377/hlthaff.26.2.w195; Choudhry NK, 2008, CIRCULATION, V117, P1261, DOI 10.1161/CIRCULATIONAHA.107.735605; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; Donohue JM, 2010, AM HEART J, V160, P159, DOI 10.1016/j.ahj.2010.04.023; Duggan M, 2010, AM ECON REV, V100, P590, DOI 10.1257/aer.100.1.590; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Fisher ES, 2009, HEALTH AFFAIR, V28, pW219, DOI 10.1377/hlthaff.28.2.w219; Fortess EE, 2001, J AM GERIATR SOC, V49, P793, DOI 10.1046/j.1532-5415.2001.49158.x; Fung V, 2010, HEALTH SERV RES, V45, P355, DOI 10.1111/j.1475-6773.2009.01071.x; Gu QA, 2010, AM J MANAG CARE, V16, P911; Hales John W, 2010, Manag Care, V19, P36; Health and Retirement Study, 2008, SAMPL SIZ RESP RAT 2; Health and Retirement Study (HRS), HRS 1992 2008 PUBL U; Heeringa S.G., 1995, TECHNICAL DESCRIPTIO; Heisler M, 2004, MED CARE, V42, P626, DOI 10.1097/01.mlr.0000129352.36733.cc; Hsu J, 2008, JAMA-J AM MED ASSOC, V299, P1929, DOI 10.1001/jama.299.16.1929; Hsu J, 2006, NEW ENGL J MED, V354, P2349, DOI 10.1056/NEJMsa054436; Huskamp HA, 2009, PSYCHIAT SERV, V60, P1168, DOI 10.1176/ps.2009.60.9.1169; Ingber M, 2010, MEDICARE PART D PROG; Ketcham JD, 2008, AM J MANAG CARE, V14, pSP14; Lichtenberg FR, 2007, HEALTH AFFAIR, V26, P1735, DOI 10.1377/hlthaff.26.6.1735; Madden JM, 2009, JAMA-J AM MED ASSOC, V302, P1755, DOI 10.1001/jama.2009.1516; Raebel MA, 2008, MED CARE, V46, P1116, DOI 10.1097/MLR.0b013e318185cddd; Ray KK, 2005, J AM COLL CARDIOL, V46, P1405, DOI 10.1016/j.jacc.2005.03.077; Safran DG, 2010, J GEN INTERN MED, V25, P10, DOI 10.1007/s11606-009-1134-2; Schneeweiss S, 2009, HEALTH AFFAIR, V28, pW305, DOI 10.1377/hlthaff.28.2.w305; Shrank WH, 2011, NEW ENGL J MED, V364, P598, DOI 10.1056/NEJMp1011625; Stuart BC, 2009, DIABETES CARE, V32, P647, DOI 10.2337/dc08-1311; Stuart BC, 2009, HEALTH SERV RES, V44, P128, DOI 10.1111/j.1475-6773.2008.00897.x; Tamblyn R, 2001, JAMA-J AM MED ASSOC, V285, P421, DOI 10.1001/jama.285.4.421; Yin W, 2008, ANN INTERN MED, V148, P169, DOI 10.7326/0003-4819-148-3-200802050-00200; Yusuf S, 2001, NEW ENGL J MED, V345, P494; Zhang YT, 2011, HEALTH SERV RES, V46, P185, DOI 10.1111/j.1475-6773.2010.01183.x; Zhang YT, 2010, ARCH INTERN MED, V170, P1308, DOI 10.1001/archinternmed.2010.235; Zhang YT, 2010, MED CARE, V48, P409, DOI 10.1097/MLR.0b013e3181d68978; Zhang Y, 2009, NEW ENGL J MED, V361, P52, DOI 10.1056/NEJMsa0807998; Zhang Y, 2009, HEALTH AFFAIR, V28, pW317, DOI 10.1377/hlthaff.28.2.w317	41	53	53	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	2011	306	4					402	409		10.1001/jama.2011.1026	http://dx.doi.org/10.1001/jama.2011.1026			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	797KL	21791689	Bronze			2023-01-03	WOS:000293125800026
J	Black, ME				Black, Mary E.			THE BIGGER PICTURE Choice: a tale of two hospitals	BRITISH MEDICAL JOURNAL			English	Editorial Material												drmaryblack@gmail.com							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 13	2011	343								d4421	10.1136/bmj.d4421	http://dx.doi.org/10.1136/bmj.d4421			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	794OE	21752858				2023-01-03	WOS:000292908900010
J	Saul, ME; Thomas, PA; Dosen, PJ; Isbister, GK; O'Leary, MA; Whyte, IM; McFadden, SA; van Helden, DF				Saul, Megan E.; Thomas, Paul A.; Dosen, Peter J.; Isbister, Geoffrey K.; O'Leary, Margaret A.; Whyte, Ian M.; McFadden, Sally A.; van Helden, Dirk F.			A pharmacological approach to first aid treatment for snakebite	NATURE MEDICINE			English	Article							LYMPH-FLOW; ABSORPTION; VENOM	Snake venom toxins first transit the lymphatic system before entering the bloodstream. Ointment containing a nitric oxide donor, which impedes the intrinsic lymphatic pump, prolonged lymph transit time in rats and humans and also increased rat survival time after injection of venom. This pharmacological approach should give snakebite victims more time to obtain medical care and antivenom treatment.	[Dosen, Peter J.; van Helden, Dirk F.] Univ Newcastle, Sch Pharm & Biomed Sci, Callaghan, NSW 2308, Australia; [Saul, Megan E.] John Hunter Hosp, Dept Nucl Med, New Lambton, NSW, Australia; [Thomas, Paul A.] Royal Brisbane & Womens Hosp, Dept Nucl Med, Herston, Qld, Australia; [Isbister, Geoffrey K.; Whyte, Ian M.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Isbister, Geoffrey K.; O'Leary, Margaret A.; Whyte, Ian M.] Calvary Mater Newcastle, Dept Clin Toxicol & Pharmacol, Waratah, NSW, Australia; [McFadden, Sally A.] Univ Newcastle, Sch Psychol, Callaghan, NSW 2308, Australia	University of Newcastle; John Hunter Hospital; Royal Brisbane & Women's Hospital; University of Newcastle; Calvary Mater Newcastle Hospital; University of Newcastle	van Helden, DF (corresponding author), Univ Newcastle, Sch Pharm & Biomed Sci, Callaghan, NSW 2308, Australia.	dirk.vanhelden@newcastle.edu.au	Thomas, Paul A/K-7463-2012; Isbister, Geoffrey K/G-8052-2015; MCFADDEN, SALLY/G-7164-2013; Whyte, Ian/A-1621-2010	Thomas, Paul A/0000-0002-2420-0950; Isbister, Geoffrey K/0000-0003-1519-7419; Whyte, Ian/0000-0001-7693-3948; McFadden, Sally/0000-0001-6761-1592; O'Leary, Margaret/0000-0003-2579-2334	National Health and Medical Research Council of Australia; Hunter Medical Research Institute	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Hunter Medical Research Institute	We sincerely thank L. Milward and D. Laver for critical evaluation of the manuscript, the National Health and Medical Research Council of Australia and Hunter Medical Research Institute for funding support and J. Weigel from The Australian Reptile Park for the donation of snake venom.	ANKER RL, 1982, MED J AUSTRALIA, V1, P103, DOI 10.5694/j.1326-5377.1982.tb132180.x; Aukland K, 2005, ACTA PHYSIOL SCAND, V185, P171, DOI 10.1111/j.1365-201X.2005.01470.x; Barnes JM, 1941, LANCET, V1, P623; Canale E, 2009, EMERG MED AUSTRALAS, V21, P184, DOI 10.1111/j.1742-6723.2009.01180.x; Chippaux JP, 1998, B WORLD HEALTH ORGAN, V76, P515; Gilchrist J., 2008, WORLD REPORT CHILD I; Hack JB, 2010, J MED TOXICOL, V6, P207, DOI 10.1007/s13181-010-0050-5; HOWARTH DM, 1994, MED J AUSTRALIA, V161, P695, DOI 10.5694/j.1326-5377.1994.tb126923.x; Kasturiratne A, 2008, PLOS MED, V5, P1591, DOI 10.1371/journal.pmed.0050218; Krifi MN, 2005, TOXICON, V45, P187, DOI 10.1016/j.toxicon.2004.10.007; MARCO AJ, 1992, LAB ANIM, V26, P200, DOI 10.1258/002367792780740549; Meggs WJ, 2010, CLIN TOXICOL, V48, P61, DOI 10.3109/15563650903376071; OLSZEWSKI WL, 1980, AM J PHYSIOL, V239, pH775, DOI 10.1152/ajpheart.1980.239.6.H775; Riviere G, 1998, J PHARMACOL EXP THER, V285, P490; SCHMIDSCHONBEIN GW, 1990, PHYSIOL REV, V70, P987, DOI 10.1152/physrev.1990.70.4.987; Sutherland SK, 2005, WILD ENVIRON MED, V16, P164, DOI 10.1580/1080-6032(2005)16[164:ROFMFE]2.0.CO;2; YOKOYAMA S, 1993, AM J PHYSIOL, V264, pH1460, DOI 10.1152/ajpheart.1993.264.5.H1460	17	33	33	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUL	2011	17	7					809	811		10.1038/nm.2382	http://dx.doi.org/10.1038/nm.2382			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	789FT	21706027	Green Published			2023-01-03	WOS:000292500800033
J	Alves, E; Faustino, MAF; Tome, JPC; Neves, MGPMS; Tome, AC; Cavaleiro, JAS; Cunha, A; Gomes, NCM; Almeida, A				Alves, Eliana; Faustino, Maria A. F.; Tome, Joao P. C.; Neves, Maria G. P. M. S.; Tome, Augusto C.; Cavaleiro, Jose A. S.; Cunha, Angela; Gomes, Newton C. M.; Almeida, Adelaide			Photodynamic Antimicrobial Chemotherapy in Aquaculture: Photoinactivation Studies of Vibrio fischeri	PLOS ONE			English	Article							GNOTOBIOTIC ARTEMIA-FRANCISCANA; PORPHYRIN DERIVATIVES; ESCHERICHIA-COLI; WASTE-WATER; THERAPY; BACTERIA; FISH; PHOTOSENSITIZERS; DISINFECTION; INACTIVATION	fischeri Background: Photodynamic antimicrobial chemotherapy (PACT) combines light, a light-absorbing molecule that initiates a photochemical or photophysical reaction, and oxygen. The combined action of these three components originates reactive oxygen species that lead to microorganisms' destruction. The aim was to evaluate the efficiency of PACT on Vibrio fischeri: 1) with buffer solution, varying temperature, pH, salinity and oxygen concentration values; 2) with aquaculture water, to reproduce photoinactivation (PI) conditions in situ. Methodology/Principal Findings: To monitor the PI kinetics, the bioluminescence of V. fischeri was measured during the experiments. A tricationic meso-substituted porphyrin (Tri-Py+-Me-PF) was used as photosensitizer (5 mu M in the studies with buffer solution and 10-50 mu M in the studies with aquaculture water); artificial white light (4 mW cm(-2)) and solar irradiation (40 mW cm(-2)) were used as light sources; and the bacterial concentration used for all experiments was approximate to 10(7) CFU mL(-1) (corresponding to a bioluminescence level of 10(5) relative light units - RLU). The variations in pH (6.5-8.5), temperature (10-25 degrees C), salinity (20-40 g L-1) and oxygen concentration did not significantly affect the PI of V. fischeri, once in all tested conditions the bioluminescent signal decreased to the detection limit of the method (approximate to 7 log reduction). The assays using aquaculture water showed that the efficiency of the process is affected by the suspended matter. Total PI of V. fischeri in aquaculture water was achieved under solar light in the presence of 20 mu M of Tri-Py+-Me-PF. Conclusions/Significance: If PACT is to be used in environmental applications, the matrix containing target microbial communities should be previously characterized in order to establish an efficient protocol having into account the photosensitizer concentration, the light source and the total light dose delivered. The possibility of using solar light in PACT to treat aquaculture water makes this technology cost-effective and attractive.	[Alves, Eliana; Cunha, Angela; Gomes, Newton C. M.; Almeida, Adelaide] Univ Aveiro, Ctr Environm & Marine Studies, Dept Biol, P-3800 Aveiro, Portugal; [Faustino, Maria A. F.; Tome, Joao P. C.; Neves, Maria G. P. M. S.; Tome, Augusto C.; Cavaleiro, Jose A. S.] Univ Aveiro, Dept Chem, P-3800 Aveiro, Portugal	Universidade de Aveiro; Universidade de Aveiro	Alves, E (corresponding author), Univ Aveiro, Ctr Environm & Marine Studies, Dept Biol, P-3800 Aveiro, Portugal.	aalmeida@ua.pt	Almeida, Adelaide/D-9899-2011; Gomes, Newton CM/F-7430-2012; Gomes, Newton Carlos Marcial/K-3211-2015; Cunha, Angela/AAC-3830-2019; Alves, Eliana/K-3158-2013; Faustino, Maria Amparo/J-5787-2012; Tomé, Augusto C./K-7184-2014; Neves, Maria/M-1560-2014; Cunha, Angela/E-9537-2011; Alves, Eliana/AAD-3520-2019; Tome, Joao P. C./K-6782-2014; Gomes, Newton Carlos Marcial/AAV-4603-2021	Almeida, Adelaide/0000-0002-8422-8664; Gomes, Newton CM/0000-0003-1934-0091; Gomes, Newton Carlos Marcial/0000-0003-1934-0091; Cunha, Angela/0000-0002-9118-3521; Alves, Eliana/0000-0001-5396-6536; Faustino, Maria Amparo/0000-0003-4423-3802; Tomé, Augusto C./0000-0003-4331-714X; Neves, Maria/0000-0002-7953-8166; Cunha, Angela/0000-0002-9118-3521; Tome, Joao P. C./0000-0001-6057-4936; Gomes, Newton Carlos Marcial/0000-0003-1934-0091; Cavaleiro, Jose/0000-0001-5495-5126; Tome Saraiva, Joao/0000-0001-7672-3369	University of Aveiro; Fundacao para a Ciencia e a Tecnologia (FCT) [SFRH/BD/41806/2007]; FEDER; CESAM (Centro de Estudos do Ambiente e do Mar)	University of Aveiro(European Commission); Fundacao para a Ciencia e a Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); FEDER(European Commission); CESAM (Centro de Estudos do Ambiente e do Mar)	The authors are thankful to University of Aveiro, Fundacao para a Ciencia e a Tecnologia (FCT) and FEDER for funding the Organic Chemistry Research Unit (QOPNA) and to CESAM (Centro de Estudos do Ambiente e do Mar) for funding the Microbiology Research Group. Eliana Alves is also grateful to FCT for her PhD grant (SFRH/BD/41806/2007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ACHER AJ, 1994, WATER RES, V28, P1153, DOI 10.1016/0043-1354(94)90202-X; Alouini Z, 2001, J ENVIRON MONITOR, V3, P548, DOI 10.1039/b103471p; Alves E, 2008, J IND MICROBIOL BIOT, V35, P1447, DOI 10.1007/s10295-008-0446-2; Arijo S, 2005, J FISH DIS, V28, P33, DOI 10.1111/j.1365-2761.2004.00597.x; BERTOLONI G, 1989, J GEN MICROBIOL, V135, P957; Bonnett R, 2006, WATER RES, V40, P1269, DOI 10.1016/j.watres.2006.01.014; Cabello FC, 2006, ENVIRON MICROBIOL, V8, P1137, DOI 10.1111/j.1462-2920.2006.01054.x; Carvalho CMB, 2010, ACS NANO, V4, P7133, DOI 10.1021/nn1026092; Carvalho CMB, 2009, J PORPHYR PHTHALOCYA, V13, P574, DOI 10.1142/S1088424609000528; Carvalho GG, 2009, J MICROBIOL, V47, P619, DOI 10.1007/s12275-009-0059-0; Costa L, 2010, PHOTOCH PHOTOBIO SCI, V9, P1126, DOI 10.1039/c0pp00051e; Defoirdt T, 2007, TRENDS BIOTECHNOL, V25, P472, DOI 10.1016/j.tibtech.2007.08.001; Defoirdt T, 2006, AQUACULTURE, V261, P804, DOI 10.1016/j.aquaculture.2006.06.038; Defoirdt T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000989; Gabor F, 2001, RADIAT ENVIRON BIOPH, V40, P145, DOI 10.1007/s004110100092; Halet D, 2007, FEMS MICROBIOL ECOL, V60, P363, DOI 10.1111/j.1574-6941.2007.00305.x; Jemli M, 2002, J ENVIRON MONITOR, V4, P511, DOI 10.1039/b204637g; Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361; Klein G, 1998, MOL GEN GENET, V259, P179, DOI 10.1007/s004380050803; Lio-Po GD, 2005, AQUACULTURE, V250, P1, DOI 10.1016/j.aquaculture.2005.01.029; Maestrin APJ, 2004, J BRAZIL CHEM SOC, V15, P923, DOI 10.1590/S0103-50532004000600021; Magaraggia M, 2006, J ENVIRON MONITOR, V8, P923, DOI 10.1039/b606975d; Maisch T, 2009, MINI-REV MED CHEM, V9, P974, DOI 10.2174/138955709788681582; Moriarty DJW, 1998, AQUACULTURE, V164, P351, DOI 10.1016/S0044-8486(98)00199-9; Moriarty DJW, 1999, P 8 INT S MICR EC; Muroga K, 2001, AQUACULTURE, V202, P23, DOI 10.1016/S0044-8486(01)00597-X; O'Connor AE, 2009, PHOTOCHEM PHOTOBIOL, V85, P1053, DOI 10.1111/j.1751-1097.2009.00585.x; Olafsen JA, 2001, AQUACULTURE, V200, P223, DOI 10.1016/S0044-8486(01)00702-5; Ortner MA, 2009, CURR OPIN GASTROEN, V25, P472, DOI 10.1097/MOG.0b013e32832e6e1f; Prates RA, 2009, LASER PHYS, V19, P1038, DOI 10.1134/S1054660X09050284; REED PA, 1996, FA31 U FLOR I FOOD A; Romalde Jesus L., 2002, International Microbiology, V5, P3, DOI 10.1007/s10123-002-0051-6; Rotomskis R, 1997, J PHOTOCH PHOTOBIO B, V39, P172, DOI 10.1016/S1011-1344(96)00014-0; Shao ZZJ, 2001, ADV DRUG DELIVER REV, V50, P229, DOI 10.1016/S0169-409X(01)00159-4; Shivu MM, 2007, ENVIRON MICROBIOL, V9, P322, DOI 10.1111/j.1462-2920.2006.01140.x; Smits T, 2009, J PHOTOCH PHOTOBIO B, V96, P159, DOI 10.1016/j.jphotobiol.2009.06.003; Tavares A, 2010, MAR DRUGS, V8, P91, DOI 10.3390/md8010091; Tome JPC, 2004, J MED CHEM, V47, P6649, DOI 10.1021/jm040802v; Toranzo AE, 2005, AQUACULTURE, V246, P37, DOI 10.1016/j.aquaculture.2005.01.002; Vadstein O, 1997, AQUACULTURE, V155, P401, DOI 10.1016/S0044-8486(97)00114-2; WATTS RJ, 1995, WATER RES, V29, P95, DOI 10.1016/0043-1354(94)E0122-M; WEST CML, 1988, INT J RADIAT BIOL, V54, P621, DOI 10.1080/09553008814552061	42	59	60	1	41	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2011	6	6							e20970	10.1371/journal.pone.0020970	http://dx.doi.org/10.1371/journal.pone.0020970			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778VR	21698119	gold, Green Published, Green Submitted			2023-01-03	WOS:000291737600035
J	Maa, J				Maa, John			The Waits That Matter	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Calif San Francisco, Sch Med, Div Gen Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Maa, J (corresponding author), Univ Calif San Francisco, Sch Med, Div Gen Surg, San Francisco, CA 94143 USA.							*AM COLL SURG DIV, 2006, GROW CRIS PAT ACC EM; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; *HOSP EM DEP, CROWD CONT OCC SOM P; *HOSP EM DEP, 2003, CROWD COND VAR HOSP; Institute of Medicine Committee on the Future of Emergency Care in the United States Health System, 2006, HOSP BAS EM CAR BREA	5	10	10	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	2011	364	24					2279	2281		10.1056/NEJMp1101882	http://dx.doi.org/10.1056/NEJMp1101882			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777RZ	21675887				2023-01-03	WOS:000291643800004
J	Inacio, AS; Mesquita, KA; Baptista, M; Ramalho-Santos, J; Vaz, WLC; Vieira, OV				Inacio, Angela S.; Mesquita, Katia A.; Baptista, Marta; Ramalho-Santos, Joao; Vaz, Winchil L. C.; Vieira, Otilia V.			In Vitro Surfactant Structure-Toxicity Relationships: Implications for Surfactant Use in Sexually Transmitted Infection Prophylaxis and Contraception	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CATIONIC SURFACTANTS; HIV-INFECTION; CONTROLLED-TRIAL; LIPID-BILAYERS; DOSE-RESPONSE; NONOXYNOL 9; THERMODYNAMICS; MICROBICIDES; CELLS	Background: The need for woman-controlled, cheap, safe, effective, easy-to-use and easy-to-store topical applications for prophylaxis against sexually transmitted infections (STIs) makes surfactant-containing formulations an interesting option that requires a more fundamental knowledge concerning surfactant toxicology and structure-activity relationships. Methodology/Principal Findings: We report in vitro effects of surfactant concentration, exposure time and structure on the viability of mammalian cell types typically encountered in the vagina, namely, fully polarized and confluent epithelial cells, confluent but non-polarized epithelial-like cells, dendritic cells, and human sperm. Representatives of the different families of commercially available surfactants - nonionic (Triton X-100 and monolaurin), zwitterionic (DDPS), anionic (SDS), and cationic (C(n)TAB (n = 10 to 16), C12PB, and C(12)BZK) - were examined. Triton X-100, monolaurin, DDPS and SDS were toxic to all cell types at concentrations around their critical micelle concentration (CMC) suggesting a non-selective mode of action involving cell membrane destabilization and/or destruction. All cationic surfactants were toxic at concentrations far below their CMC and showed significant differences in their toxicity toward polarized as compared with non-polarized cells. Their toxicity was also dependent on the chemical nature of the polar head group. Our results suggest an intracellular locus of action for cationic surfactants and show that their structure-activity relationships could be profitably exploited for STI prophylaxis in vaginal gel formulations. The therapeutic indices comparing polarized epithelial cell toxicity to sperm toxicity for all surfactants examined, except C12PB and C(12)BZK, does not justify their use as contraceptive agents. C12PB and C(12)BZK are shown to have a narrow therapeutic index recommending caution in their use in contraceptive formulations. Conclusions/Significance: Our results contribute to understanding the mechanisms involved in surfactant toxicity, have a predictive value with regard to their safety, and may be used to design more effective and less harmful surfactants for use in topical applications for STI prophylaxis.	[Inacio, Angela S.; Mesquita, Katia A.; Baptista, Marta; Ramalho-Santos, Joao; Vieira, Otilia V.] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal; [Ramalho-Santos, Joao] Univ Coimbra, Dept Life Sci, Coimbra, Portugal; [Ramalho-Santos, Joao] Univ Hosp Coimbra, Human Reprod Serv, Coimbra, Portugal; [Vaz, Winchil L. C.] Univ Coimbra, Dept Chem, Coimbra, Portugal	Universidade de Coimbra; Universidade de Coimbra; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Universidade de Coimbra	Inacio, AS (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal.	vieira@cnc.cj.uc.pt	Mesquita, Katia/AAD-1225-2019; Vieira, Otilia V/O-8660-2017; Vaz, Winchil/N-4320-2013; Inácio, Ângela S./AAE-1653-2020; Ramalho-Santos, João/F-8641-2012; Vieira, O V/C-4860-2013; Santos, João/HHZ-5595-2022	Mesquita, Katia/0000-0001-9832-5548; Vieira, Otilia V/0000-0003-4924-1780; Vaz, Winchil/0000-0002-3797-4330; Inácio, Ângela S./0000-0002-5401-8455; Ramalho-Santos, João/0000-0002-1172-4018; 	Foundation for Science and Technology of the Portuguese Ministry of Science and Higher Education (FCT) [PTDC/SAU-MII/66285/2006, PTDC/BIA-BCM/112138/2009]; FCT [SFRH/BD/38397/2007, SFRH/BD/46078/2008]	Foundation for Science and Technology of the Portuguese Ministry of Science and Higher Education (FCT)(Portuguese Foundation for Science and Technology); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	This work was supported by the research grants PTDC/SAU-MII/66285/2006 and PTDC/BIA-BCM/112138/2009 from the Foundation for Science and Technology of the Portuguese Ministry of Science and Higher Education (FCT). ASI is a holder of a doctoral fellowship (ref. SFRH/BD/38397/2007) from the FCT. MB is a holder of a doctoral fellowship (ref. SFRH/BD/46078/2008) from the FCT. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu MSC, 2004, BIOPHYS J, V87, P353, DOI 10.1529/biophysi.104.040576; Ackermann Leane, 2002, Health Care Women Int, V23, P163, DOI 10.1080/073993302753429031; Ayotte N, 2002, ADV THER, V19, P219, DOI 10.1007/BF02850362; Bercoff DP, 2010, RETROVIROLOGY, V7, DOI 10.1186/1742-4690-7-98; BRITO RMM, 1986, ANAL BIOCHEM, V152, P250, DOI 10.1016/0003-2697(86)90406-9; Burns M, 1999, J THROMB THROMBOLYS, V7, P137, DOI 10.1023/A:1008829403320; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; Carpo Beatriz G, 2007, J Drugs Dermatol, V6, P991; Catalone BJ, 2005, ANTIMICROB AGENTS CH, V49, P1509, DOI 10.1128/AAC.49.4.1509-1520.2005; Cone RA, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-90; Dias RS, 2005, J PHYS CHEM B, V109, P10458, DOI 10.1021/jp0444464; Dymond MK, 2008, LANGMUIR, V24, P11743, DOI 10.1021/la8017612; Ekelund K, 2005, J PHARM SCI-US, V94, P730, DOI 10.1002/jps.20283; Enomoto R, 2007, ANN NY ACAD SCI, V1095, P1, DOI 10.1196/annals.1397.001; Estronca LMBB, 2007, BIOPHYS J, V93, P4244, DOI 10.1529/biophysj.107.112847; Feldblum PJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001474; Fichorova RN, 2001, J INFECT DIS, V184, P418, DOI 10.1086/322047; Finkel R, 2009, PHARMACOLOGY, P33; Gennis R.B., 1989, BIOMEMBRANES MOL STR, DOI DOI 10.1007/978-1-4757-2065-5; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; Hitchcock PJ, 2000, SEXUALLY TRANSMITTED, P149; Hladik Florian, 2009, Curr HIV/AIDS Rep, V6, P20, DOI 10.1007/s11904-009-0004-1; Hladik F, 2007, IMMUNITY, V26, P257, DOI 10.1016/j.immuni.2007.01.007; HONIG BH, 1986, ANNU REV BIOPHYS BIO, V15, P163; Irvine JD, 1999, J PHARM SCI, V88, P28, DOI 10.1021/js9803205; Knezevic SZ, 2007, WEED TECHNOL, V21, P840, DOI 10.1614/WT-06-161.1; Kopecky F, 1996, PHARMAZIE, V51, P135; Krebs FC, 1999, ANTIVIR RES, V43, P157, DOI 10.1016/S0166-3542(99)00044-3; Krebs FC, 2000, ANTIMICROB AGENTS CH, V44, P1954, DOI 10.1128/AAC.44.7.1954-1960.2000; KREISS J, 1992, JAMA-J AM MED ASSOC, V268, P477, DOI 10.1001/jama.268.4.477; Lin YC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007499; Liu BS, 2009, J LEUKOCYTE BIOL, V85, P205, DOI 10.1189/jlb.0408241; Masurier C, 1998, J VIROL, V72, P7822, DOI 10.1128/JVI.72.10.7822-7829.1998; Mesquita PMM, 2009, J INFECT DIS, V200, P599, DOI 10.1086/600867; Miller V, 1998, ANTIMICROB AGENTS CH, V42, P3123, DOI 10.1128/AAC.42.12.3123; Moreno MJ, 2006, BIOPHYS J, V91, P873, DOI 10.1529/biophysj.106.082115; Neves BM, 2008, TOXICOL LETT, V177, P74, DOI 10.1016/j.toxlet.2007.12.006; Nuttall J, 2010, DRUGS, V70, P1231, DOI 10.2165/10898650-000000000-00000; PARTEARROYO MA, 1990, BIOCHEM PHARMACOL, V40, P1323, DOI 10.1016/0006-2952(90)90399-6; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; Perani A, 2001, AMINO ACIDS, V21, P185, DOI 10.1007/s007260170025; Peterson L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001312; Phillips DM, 2000, CONTRACEPTION, V62, P149, DOI 10.1016/S0010-7824(00)00156-6; Piao J, 2006, COLLOID SURFACE A, V277, P15, DOI 10.1016/j.colsurfa.2005.10.053; Ramalho-Santos J, 2007, MODERN RES ED TOPICS, V1, P394; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Roddy RE, 1998, NEW ENGL J MED, V339, P504, DOI 10.1056/NEJM199808203390803; Sampaio JL, 2005, BIOPHYS J, V88, P4064, DOI 10.1529/biophysj.104.054007; SEEFELDT SS, 1995, WEED TECHNOL, V9, P218, DOI 10.1017/S0890037X00023253; Simoncic B, 1998, ACTA CHIM SLOV, V45, P143; Simons K, 2004, ANNU REV BIOPH BIOM, V33, P269, DOI 10.1146/annurev.biophys.32.110601.141803; Spink CH, 1997, J AM CHEM SOC, V119, P10920, DOI 10.1021/ja964324s; Stephenson J, 2000, JAMA-J AM MED ASSOC, V284, P949, DOI 10.1001/jama.284.8.949; Stone A, 2006, LANCET, V368, P431, DOI 10.1016/S0140-6736(06)69131-9; Tanford C., 1991, HYDROPHOBIC EFFECT F, pix; Terris-Prestholt F, 2006, SEX TRANSM DIS, V33, pS153, DOI 10.1097/01.olq.0000235177.30718.84; VED HS, 1990, LIPIDS, V25, P119, DOI 10.1007/BF02562216; Velarde G, 1999, TOXICOL IN VITRO, V13, P719, DOI 10.1016/S0887-2333(99)00055-7; Vieira DB, 2006, J ANTIMICROB CHEMOTH, V58, P760, DOI 10.1093/jac/dkl312; Vieira OV, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002913; Wilson DP, 2008, P NATL ACAD SCI USA, V105, P9835, DOI 10.1073/pnas.0711813105; World Health Organization, 2007, GLOB STRAT PREV CONT; World Health Organization, 1999, WHO LAB MANUAL EXAMI, V4; Zhu DM, 2006, LANGMUIR, V22, P3735, DOI 10.1021/la052161s	64	90	93	2	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2011	6	5							e19850	10.1371/journal.pone.0019850	http://dx.doi.org/10.1371/journal.pone.0019850			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	764TP	21603626	Green Published, gold, Green Submitted			2023-01-03	WOS:000290656300031
J	Pattinson, R; Kerber, K; Buchmann, E; Friberg, IK; Belizan, M; Lansky, S; Weissman, E; Mathai, M; Rudan, I; Walker, N; Lawn, JE				Pattinson, Robert; Kerber, Kate; Buchmann, Eckhart; Friberg, Ingrid K.; Belizan, Maria; Lansky, Sonia; Weissman, Eva; Mathai, Matthews; Rudan, Igor; Walker, Neff; Lawn, Joy E.		Lancet's Stillbirths Series Steeri	Stillbirths 4 Stillbirths: how can health systems deliver for mothers and babies?	LANCET			English	Article							MATERNAL MORTALITY; CHILD HEALTH; OBSTETRIC CARE; GLOBAL HEALTH; PRETERM BIRTH; NEWBORN; INTERVENTIONS; CHALLENGES; FACILITIES; CONTINUUM	The causes of stillbirths are inseparable from the causes of maternal and neonatal deaths. This report focuses on prevention of stillbirths by scale-up of care for mothers and babies at the health-system level, with consideration for effects and cost. In countries with high mortality rates, emergency obstetric care has the greatest effect on maternal and neonatal deaths, and on stillbirths. Syphilis detection and treatment is of moderate effect but of lower cost and is highly feasible. Advanced antenatal care, including induction for post-term pregnancies, and detection and management of hypertensive disease, fetal growth restriction, and gestational diabetes, will further reduce mortality, but at higher cost. These interventions are best packaged and provided through linked service delivery methods tailored to suit existing health-care systems. If 99% coverage is reached in 68 priority countries by 2015, up to 1.1 million (45%) third-trimester stillbirths, 201000 (54%) maternal deaths, and 1.4 million (43%) neonatal deaths could be saved per year at an additional total cost of US$10.9 billion or $2.32 per person, which is in the range of $0.96-2.32 for other ingredients-based intervention packages with only recurrent costs.	[Pattinson, Robert; Belizan, Maria] Univ Pretoria, Dept Obstet & Gynaecol, Med Res Council Maternal & Infant Hlth Care Strat, ZA-0001 Pretoria, South Africa; [Kerber, Kate; Lawn, Joy E.] Saving Newborn Lives Save Children, Cape Town, South Africa; [Buchmann, Eckhart] Chris Hani Baragwanath Hosp, Dept Obstet & Gynaecol, Johannesburg, South Africa; [Buchmann, Eckhart] Univ Witwatersrand, Johannesburg, South Africa; [Friberg, Ingrid K.; Walker, Neff] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Belizan, Maria] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina; [Lansky, Sonia] Univ Fed Minas Gerais, Belo Horizonte Hlth Dept, Belo Horizonte, MG, Brazil; [Weissman, Eva] Futures Inst, New York, NY USA; [Mathai, Matthews] WHO, Dept Maternal Newborn Child & Adolescent Hlth, CH-1211 Geneva, Switzerland; [Rudan, Igor] Univ Split, Sch Med, Croatian Ctr Global Hlth, Split, Croatia; [Rudan, Igor] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Lawn, Joy E.] MRC, Hlth Syst Res Unit, Cape Town, South Africa; [Lawn, Joy E.] Inst Child Hlth, London, England	University of Pretoria; Save the Children; University of Witwatersrand; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Universidade Federal de Minas Gerais; World Health Organization; University of Split; University of Edinburgh; University of London; University College London	Pattinson, R (corresponding author), Univ Pretoria, Dept Obstet & Gynaecol, Med Res Council Maternal & Infant Hlth Care Strat, POB 667, ZA-0001 Pretoria, South Africa.	robert.pattinson@up.ac.za	Rudan, Igor/I-1467-2012; Lawn, Joy/ABE-6382-2020; Flenady, Vicki Jane/O-9609-2014	Rudan, Igor/0000-0001-6993-6884; Lawn, Joy/0000-0002-4573-1443; Flenady, Vicki Jane/0000-0001-8114-7677; Belizan, Maria/0000-0002-8739-5249; Froen Froen, Jahn Frederik/0000-0001-9390-8509	Bill & Melinda Gates Foundation; Global Alliance to Prevent Prematurity and Stillbirth; Partnership for Maternal, Newborn and Child Health	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Global Alliance to Prevent Prematurity and Stillbirth; Partnership for Maternal, Newborn and Child Health	Some technical work and travel for this report during 2010 were funded through a grant for The Lancet's Series from the Bill & Melinda Gates Foundation to the International Stillbirth Alliance secretariat. JEL and KK are funded by the Bill & Melinda Gates Foundation through Saving Newborn Lives/Save the Children. Some meetings and travel were partially funded by the Global Alliance to Prevent Prematurity and Stillbirth and the Partnership for Maternal, Newborn and Child Health. The funding organisations had no role in the drafting or direction of this report. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of their employers. We thank Robert Goldenberg for helpful insights and thoughtful review of this paper; and scorers for the Child Health and Nutrition Research Initiative research priority setting exercise (in alphabetical order): Hassan Baaqeel, Zulfiqar A Bhutta, Betty Chacko, Evita Fernandez, Rajshree Jha, Ruby Jose, James Machoki M'Imunya, Suneeta Mittal, Nafissa Bique Osman, Zahida Qureshi, Gary L Darmstadt, Louise Day, Nighat Shah, Nilofer Babar, Shabnam Khowaja, and Sidrah Nausheen for low-income countries; and Hany Abdel-Aleem, Jose M Belizan, Jackie Ho, Ravindran Jegasothy, Tippawan Liabsuetrakul, Deepika Attygalle, Eckhart Buchmann, Jose Guilherme Cecatti, Yolanda Contreras Garcia, Glen Mola, Neil Moran, Metin Gulmezoglu, Matthews Mathai, Jose Ortiz-Segarra, Robert Pattinson, Alejandro Vargas, Paulino Vigil-De Gracia, and Juan Carlos Vazquez for middle-income countries.	Althabe F, 2008, PAEDIATR PERINAT EP, V22, P42, DOI 10.1111/j.1365-3016.2007.00912.x; Amiel S, 2002, BRIT MED J, V325, P746, DOI 10.1136/bmj.325.7367.746; [Anonymous], INT DRUG PRIC IND GU; Bala M, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004704.pub2; Barros FC, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S3; BHUTTA ZA, 2011, LANCET, DOI DOI 10.1016/S0140-6736(10)62050-8; Bhutta ZA, 2008, B WORLD HEALTH ORGAN, V86, P452, DOI 10.2471/BLT.07.045849; Bhutta ZA, 2008, LANCET, V371, P417, DOI 10.1016/S0140-6736(07)61693-6; Bhutta ZA, 2010, LANCET, V375, P2032, DOI 10.1016/S0140-6736(10)60678-2; BLENCOWE H, INT J EPIDEMIOL S1, V39, P110; Blencowe H, 2010, INT J EPIDEMIOL, V39, P102, DOI 10.1093/ije/dyq027; Bryce J, 2005, LANCET, V365, P2193, DOI 10.1016/S0140-6736(05)66777-3; Bryce J, 2003, LANCET, V362, P159, DOI 10.1016/S0140-6736(03)13870-6; Chivu CM, 2008, AM J HEALTH PROMOT, V22, P237, DOI 10.4278/06051566R2.1; Darmstadt GL, 2008, HEALTH POLICY PLANN, V23, P101, DOI 10.1093/heapol/czn001; Darmstadt GL, 2009, INT J GYNECOL OBSTET, V107, pS89, DOI 10.1016/j.ijgo.2009.07.010; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Davies MJ, 2008, BMJ-BRIT MED J, V336, P491, DOI 10.1136/bmj.39474.922025.BE; Flenady V, 2011, LANCET, V377, P1703, DOI 10.1016/S0140-6736(11)60064-0; Froen JF, 2011, LANCET, V377, P1353, DOI 10.1016/S0140-6736(10)62232-5; *GUTTM I, FACTS INV FAM PLANN; Hodnett ED, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003766.pub2; Hofmeyr GJ, 2009, INT J GYNECOL OBSTET, V107, pS21, DOI 10.1016/j.ijgo.2009.07.017; Hounton S, 2009, GLOBAL HEALTH ACTION, V2, DOI 10.3402/gha.v2i0.1947; *INT HLTH PARTN, 2009, TASKF INN INT FIN HL; Jokhio AH, 2005, NEW ENGL J MED, V352, P2091, DOI 10.1056/NEJMsa042830; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Lagarde M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008137; Lassi ZS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007754.pub3; LAWN J, 2005, TRACKING PROGR CHILD; LAWN J, 2005, DIS CONTROL PRIORITI; Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3; Lawn JE, 2009, INT J GYNECOL OBSTET, V107, pS123, DOI 10.1016/j.ijgo.2009.07.021; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Lee ACC, 2009, INT J GYNECOL OBSTET, V107, pS65, DOI 10.1016/j.ijgo.2009.07.012; Lim SS, 2010, LANCET, V375, P2009, DOI 10.1016/S0140-6736(10)60744-1; Manandhar DS, 2004, LANCET, V364, P970, DOI 10.1016/S0140-6736(04)17021-9; McClure EM, 2007, INT J GYNECOL OBSTET, V96, P139, DOI 10.1016/j.ijgo.2006.10.010; MEADS CA, 2008, HEALTH TECHNOL ASSES, V12, pR3, DOI DOI 10.3310/hta12060; Mwansa-Kambafwile J, 2010, INT J EPIDEMIOL, V39, P122, DOI 10.1093/ije/dyq029; OPIYO N, 2010, COCHRANE DB SYST REV, V4; Pattinson R, 2009, INT J GYNECOL OBSTET, V107, pS113, DOI 10.1016/j.ijgo.2009.07.011; Plsek PE, 2001, BRIT MED J, V323, P625, DOI 10.1136/bmj.323.7313.625; Rudan I, 2008, CROAT MED J, V49, P720, DOI 10.3325/cmj.2008.49.720; Shiffman J, 2007, AM J PUBLIC HEALTH, V97, P796, DOI 10.2105/AJPH.2006.095455; Shiffman J, 2010, LANCET, V375, P2045, DOI 10.1016/S0140-6736(10)60710-6; Shiffman J, 2009, B WORLD HEALTH ORGAN, V87, P608, DOI 10.2471/BLT.08.060749; Singh S, 2009, ADDING IT COSTS BENE; *SKILL CAR IN, 2007, TEST APPR INCR SKILL; SOWDEN A, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001291; Stover J, 2010, INT J EPIDEMIOL, V39, P7, DOI 10.1093/ije/dyq016; UNICEF, SUPPL CAT; Victora CG, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-S1-S4; Vidanapathirana J, 2005, COCHRANE DB SYST REV, V3; Villar J, 2001, LANCET, V357, P1551, DOI 10.1016/S0140-6736(00)04722-X; Walker N, 2010, INT J EPIDEMIOL, V39, P21, DOI 10.1093/ije/dyq036; *WHO, 2009, REC INT IMPR MAT NEW; *WHO, 2010, CHOOSING INT AR COST; WHO, 2010, TRENDS MAT MORT 1990; *WHO COMM MACR HLT, 2002, IMPR HLTH OUTC POOR; World Health Organization, 2005, WORLD HLTH REPORT 20	62	123	123	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	2011	377	9777					1610	1623		10.1016/S0140-6736(10)62306-9	http://dx.doi.org/10.1016/S0140-6736(10)62306-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	763IJ	21496910	Green Submitted			2023-01-03	WOS:000290549700035
J	Jeong, HJ; Choi, Y; Kim, KY; Kim, MH; Kim, HM				Jeong, Hyun-Ja; Choi, Youngjin; Kim, Kyu-Yeob; Kim, Min-Ho; Kim, Hyung-Min			C-Kit Binding Properties of Hesperidin (a Major Component of KMP6) as a Potential Anti-Allergic Agent	PLOS ONE			English	Article							STEM-CELL FACTOR; FACTOR-INDUCED MIGRATION; MAST-CELLS; TNF-ALPHA; ACTIVATION; EXPRESSION; DIFFERENTIATION; INFLAMMATION; PATHWAYS; RECEPTOR	Accumulation of mast cells can be causally related to several allergic inflammations. Stem cell factor (SCF) as a mast cell chemotaxin induces mast cell migration. To clarify a new effect of Pyeongwee-San extract (KMP6, a drug for indigestion) for the treatment of allergy, we investigated the effects of KMP6 on SCF-induced migration of rat peritoneal mast cells (RPMCs). A molecular docking simulation showed that hesperidin, a major component of KMP6, controls the SCF and c-kit binding by interaction with the active site of the c-kit. KMP6 and hesperidin significantly inhibited SCF-induced migration of RPMCs (P<0.05). The ability of the SCF to enhance morphological alteration and F-actin formation was also abolished by treatment with KMP6 or hesperidin. KMP6 and hesperidin inhibited SCF-induced p38 MAPK activation. In addition, SCF-induced inflammatory cytokine production was significantly inhibited by treatment with KMP6 or hesperidin (P<0.05). Our results show for the first time that KMP6 potently regulates SCF-induced migration, p38 MAPK activation and inflammatory cytokines production through hindrance of SCF and c-kit binding in RPMCs. Such modulation may have functional consequences during KMP6 treatment, especially mast cell-mediated allergic inflammation disorders.	[Jeong, Hyun-Ja; Choi, Youngjin] Hoseo Univ, Biochip Res Ctr, Asan, South Korea; [Kim, Kyu-Yeob; Kim, Hyung-Min] Kyung Hee Univ, Dept Pharmacol, Seoul, South Korea; [Kim, Min-Ho] Chonbuk Natl Univ, High Enthalpy Plasma Res Ctr, Jeonju, South Korea	Hoseo University; Kyung Hee University; Jeonbuk National University	Jeong, HJ (corresponding author), Hoseo Univ, Biochip Res Ctr, Asan, South Korea.	hmkim@khu.ac.kr			Ministry for Health and Welfare and Family Affairs, Republic of Korea [B100037]	Ministry for Health and Welfare and Family Affairs, Republic of Korea(Ministry of Health & Welfare (MOHW), Republic of Korea)	This study was supported by a grant of the Traditional Korean Medicine R&D Project, Ministry for Health and Welfare and Family Affairs, Republic of Korea (No. B100037). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arafa HMM, 2009, TOXICOL IND HEALTH, V25, P417, DOI 10.1177/0748233709106624; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brunet A, 1996, SCIENCE, V272, P1652, DOI 10.1126/science.272.5268.1652; Chai OH, 2011, EXP MOL MED, V43, P35, DOI 10.3858/emm.2011.43.1.004; Chang YL, 2010, ACTA PHARMACOL SIN, V31, P546, DOI 10.1038/aps.2010.34; Choi IY, 2007, MOL CELL BIOCHEM, V305, P153, DOI 10.1007/s11010-007-9539-x; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44, DOI 10.1159/000234024; Farooqi IS, 1998, THORAX, V53, P927, DOI 10.1136/thx.53.11.927; Grzelewska-Rzymowska Iwona, 2004, Pol Merkur Lekarski, V16, P179; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Imhof BA, 1997, HORM METAB RES, V29, P614, DOI 10.1055/s-2007-979112; IRANI AMA, 1992, BLOOD, V80, P3009; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Jeong HJ, 2003, ENDOCRINOLOGY, V144, P4080, DOI 10.1210/en.2003-0115; Jeong HJ, 2002, CELL SIGNAL, V14, P633, DOI 10.1016/S0898-6568(02)00005-0; Kuo DH, 2010, J AGR FOOD CHEM, V58, P5777, DOI 10.1021/jf100601r; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697, DOI 10.1164/ajrccm/147.3.697; Lorentz A, 2001, IMMUNOL REV, V179, P57, DOI 10.1034/j.1600-065X.2001.790106.x; MEININGER CJ, 1992, BLOOD, V79, P958; NILSSON G, 1994, J IMMUNOL, V153, P3717; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; PTEIFFER JR, 1994, J IMMUNOL, V152, P270; Seo MJ, 2011, IMMUNOPHARM IMMUNOT, V33, P178, DOI 10.3109/08923973.2010.491082; Sundstrom M, 2001, EXP CELL RES, V267, P144, DOI 10.1006/excr.2001.5239; Thong BYH, 2010, ALLERGY ASTHMA IMMUN, V2, P77, DOI 10.4168/aair.2010.2.2.77; WASSERMAN SI, 1984, ARTHRITIS RHEUM, V27, P841, DOI 10.1002/art.1780270801; Yeh MH, 2009, TOXICOL LETT, V184, P204, DOI 10.1016/j.toxlet.2008.11.018	30	8	9	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2011	6	4							e19528	10.1371/journal.pone.0019528	http://dx.doi.org/10.1371/journal.pone.0019528			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	756OZ	21559359	gold, Green Published, Green Submitted			2023-01-03	WOS:000290024700202
J	Zwarenstein, M; Fairall, LR; Lombard, C; Mayers, P; Bheekie, A; English, RG; Lewin, S; Bachmann, MO; Bateman, E				Zwarenstein, Merrick; Fairall, Lara R.; Lombard, Carl; Mayers, Pat; Bheekie, Angeni; English, Rene G.; Lewin, Simon; Bachmann, Max O.; Bateman, Eric			Outreach education for integration of HIV/AIDS care, antiretroviral treatment, and tuberculosis care in primary care clinics in South Africa: PALSA PLUS pragmatic cluster randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SUB-SAHARAN AFRICA; RESOURCE-POOR SETTINGS; EXPANDING ACCESS; HIV TREATMENT; HEALTH; THERAPY; DELIVERY; SERVICES; WILL; AIDS	Objective To investigate whether PALSA PLUS, an on-site educational outreach programme of non-didactic, case based, iterative clinical education of staff, led by a trainer, can increase access to and comprehensiveness of care for patients with HIV/AIDS. Design Cluster randomised trial. Setting Public primary care clinics offering HIV/AIDS care, antiretroviral treatment (ART), tuberculosis care, and ambulatory primary care in Free State province, South Africa. Participants Fifteen clinics all implementing decentralisation and task shifting were randomised. The clinics cared for 400 000 general primary care patients and 10 136 patients in an HIV/AIDS/ART programme. There were 150 nurses. Intervention On-site outreach education in eight clinics; no such education in seven (control). Main outcome measures Provision of co-trimoxazole prophylaxis among patients referred to the HIV/AIDS/ART programme, and detection of cases of tuberculosis among those in the programme. Proportion of patients in the programme enrolled through general primary care consultations. Results Patients referred to the HIV/AIDS programme through general primary care at intervention clinics were more likely than those at control clinics to receive co-trimoxazole prophylaxis (41%, (2253/5523) v 32% (1340/4210); odds ratio 1.95, 95% confidence interval 1.11 to 3.40), and tuberculosis was more likely to be diagnosed among patients with HIV/AIDS/ART (7% (417/5793) v 6% (245/4343); 1.25, 1.01 to 1.55). Enrolment in the HIV/AIDS and ART programme through HIV testing in general primary care was not significantly increased (53% v 50%; 1.19, 0.51 to 2.77). Secondary outcomes were similar, except for weight gain, which was higher in the intervention group (2.3 kg v 1.9 kg, P<0.001). Conclusion Though outreach education is an effective and feasible strategy for improving comprehensiveness of care and wellbeing of patients with HIV/AIDS, there is no evidence that it increases access to the ART programme. It is now being widely implemented in South Africa.	[Zwarenstein, Merrick] Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Zwarenstein, Merrick; Fairall, Lara R.; Mayers, Pat; English, Rene G.; Lewin, Simon; Bachmann, Max O.] Univ Cape Town, Lung Inst, Knowledge Translat Unit, ZA-7925 Cape Town, South Africa; [Lombard, Carl] MRC, Biostat Unit, Cape Town, South Africa; [Fairall, Lara R.; Bateman, Eric] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa; [Mayers, Pat] Univ Cape Town, Div Nursing & Midwifery, ZA-7925 Cape Town, South Africa; [Bheekie, Angeni] Univ Western Cape, Sch Pharm, ZA-7535 Bellville, South Africa; [Lewin, Simon] Norwegian Knowledge Ctr Hlth Serv, Oslo, Norway; [Zwarenstein, Merrick] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Bachmann, Max O.] Univ E Anglia, Sch Med Hlth Policy & Practice, Norwich NR4 7TJ, Norfolk, England; [Zwarenstein, Merrick] Karolinska Inst, IHCAR, Stockholm, Sweden; [Lewin, Simon] MRC, Hlth Syst Res Unit, Cape Town, South Africa	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Cape Town; University of Cape Town; University of Cape Town; University of the Western Cape; Norwegian Knowledge Centre for Health Services; University of Toronto; University of East Anglia; Karolinska Institutet	Zwarenstein, M (corresponding author), Sunnybrook Res Inst, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	merrick.zwarenstein@ices.on.ca	Zwarenstein, Merrick F/P-5210-2014; Mayers, Pat M/B-7224-2016	Zwarenstein, Merrick F/0000-0003-0162-7027; Mayers, Pat M/0000-0002-2622-1624; Bachmann, Max Oscar/0000-0003-1770-3506; Lombard, Carl/0000-0002-2136-6533; Fairall, Lara/0000-0002-7460-4670	International Development Research Centre (IDRC) of Canada	International Development Research Centre (IDRC) of Canada	The study was funded by the International Development Research Centre (IDRC) of Canada, who had no role in study design, in the collection, analysis, and interpretation of data, in the writing of the article, or in the decision to submit it for publication. The researchers were completely independent of IDRC.	Assefa Y, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000056; Bedelu M, 2007, J INFECT DIS, V196, pS464, DOI 10.1086/521114; Bendavid E, 2009, ANN INTERN MED, V150, P688, DOI 10.7326/0003-4819-150-10-200905190-00117; Bheekie A, 2006, INT NURS REV, V53, P261, DOI 10.1111/j.1466-7657.2006.00520.x; Calmy A, 2004, AIDS, V18, P2353; CAMPBELL M, 1999, CLUSTER SAMPLE SIZE; Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702; Chaisson RE, 2008, NEW ENGL J MED, V358, P1089, DOI 10.1056/NEJMp0800809; CHAPMAN R, 2003, PROPOSED PLAN IMPLEM; Coetzee D, 2004, TROP MED INT HEALTH, V9, pA11, DOI 10.1111/j.1365-3156.2004.01259.x; Colvin CJ, 2010, SAMJ S AFR MED J, V100, P210, DOI 10.7196/SAMJ.4124; *DEP HLTH, 2010, TUB HIV AIDS CLIN GU; Dong K, 2007, J INFECT DIS, V196, pS491, DOI 10.1086/521111; Fairall LR, 2008, ARCH INTERN MED, V168, P86, DOI 10.1001/archinternmed.2007.10; Fairall LR, 2008, TRIALS, V9, DOI 10.1186/1745-6215-9-21; Fairall LR, 2005, BMJ-BRIT MED J, V331, P750, DOI 10.1136/bmj.331.7519.750; Frenk J, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000089; *GLOB FUND, GLOB FUND GRANTS PRO; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; Groenewald P, 2005, AIDS, V19, P193, DOI 10.1097/00002030-200501280-00012; Harries AD, 2008, T ROY SOC TROP MED H, V102, P310, DOI 10.1016/j.trstmh.2008.01.005; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Kurowski C, 2007, HEALTH POLICY PLANN, V22, P113, DOI 10.1093/heapol/czm012; McCoy D, 2005, AM J PUBLIC HEALTH, V95, P18, DOI 10.2105/AJPH.2004.040121; O'Brien MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000409.pub2; Ovretveit J, 2009, DIR DEV, P35; Oxman AD, 2010, LANCET, V375, P427, DOI 10.1016/S0140-6736(09)61251-4; Pfeiffer J, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-3; Philips M, 2008, LANCET, V371, P682, DOI 10.1016/S0140-6736(08)60307-4; Rowe AK, 2005, LANCET, V366, P1026, DOI 10.1016/S0140-6736(05)67028-6; *S AFR GOV INF, 2003, OP PLAN COMPR HIV AI; Samb B, 2007, NEW ENGL J MED, V357, P2510, DOI 10.1056/NEJMsb071889; SCHULL M, 2010, STRENGTHENING HUMAN; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; Statistics South Africa, 2005, MORT CAUS DEATH S AF; Stein J, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-240; Steinbrook R, 2007, NEW ENGL J MED, V357, P1996, DOI 10.1056/NEJMp0706918; Topp SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011522; *UNAIDS, 2006, ASS REP SCAL UN ACC; Van Damme W, 2008, SOC SCI MED, V66, P2108, DOI 10.1016/j.socscimed.2008.01.043; WEI LJ, 1988, CONTROL CLIN TRIALS, V9, P345, DOI 10.1016/0197-2456(88)90048-7; *WHO, 2006, HLTH SYST SERV TAK S; *WHO, 2008, TASK SHIFT RAT RED T, V1; *WHO, 2010, PROGR GLOB AIDS ACC; Wood R, 2007, J INFECT DIS, V196, pS497, DOI 10.1086/521118	46	60	61	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2011	342								d2022	10.1136/bmj.d2022	http://dx.doi.org/10.1136/bmj.d2022			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755OR	21511783	hybrid, Green Published			2023-01-03	WOS:000289943400003
J	Ramgolam, K; Lauriol, J; Lalou, C; Lauden, L; Michel, L; de la Grange, P; Khatib, AM; Aoudjit, F; Charron, D; Alcaide-Loridan, C; Al-Daccak, R				Ramgolam, Kiran; Lauriol, Jessica; Lalou, Claude; Lauden, Laura; Michel, Laurence; de la Grange, Pierre; Khatib, Abdel-Majid; Aoudjit, Fawzi; Charron, Dominique; Alcaide-Loridan, Catherine; Al-Daccak, Reem			Melanoma Spheroids Grown Under Neural Crest Cell Conditions Are Highly Plastic Migratory/Invasive Tumor Cells Endowed with Immunomodulator Function	PLOS ONE			English	Article							CANCER STEM-CELLS; MHC CLASS-II; IN-VITRO; INITIATING CELLS; B-16 MELANOMA; EXPRESSION; METASTASIS; ACTIVATION; PHENOTYPE; LIGAND	Background: The aggressiveness of melanoma tumors is likely to rely on their well-recognized heterogeneity and plasticity. Melanoma comprises multi-subpopulations of cancer cells some of which may possess stem cell-like properties. Although useful, the sphere-formation assay to identify stem cell-like or tumor initiating cell subpopulations in melanoma has been challenged, and it is unclear if this model can predict a functional phenotype associated with aggressive tumor cells. Methodology/Principal Findings: We analyzed the molecular and functional phenotypes of melanoma spheroids formed in neural crest cell medium. Whether from metastatic or advanced primary tumors, spheroid cells expressed melanoma-associated markers. They displayed higher capacity to differentiate along mesenchymal lineages and enhanced expression of SOX2, NANOG, KLF4, and/or OCT4 transcription factors, but not enhanced self-renewal or tumorigenicity when compared to their adherent counterparts. Gene expression profiling attributed a neural crest cell signature to these spheroids and indicated that a migratory/invasive and immune-function modulating program could be associated with these cells. In vitro assays confirmed that spheroids display enhanced migratory/invasive capacities. In immune activation assays, spheroid cells elicited a poorer allogenic response from immune cells and inhibited mitogen-dependent T cells activation and proliferation more efficiently than their adherent counterparts. Our findings reveal a novel immune-modulator function of melanoma spheroids and suggest specific roles for spheroids in invasion and in evasion of antitumor immunity. Conclusion/Significance: The association of a more plastic, invasive and evasive, thus a more aggressive tumor phenotype with melanoma spheroids reveals a previously unrecognized aspect of tumor cells expanded as spheroid cultures. While of limited efficiency for melanoma initiating cell identification, our melanoma spheroid model predicted aggressive phenotype and suggested that aggressiveness and heterogeneity of melanoma tumors can be supported by subpopulations other than cancer stem cells. Therefore, it could be constructive to investigate melanoma aggressiveness, relevant to patients and clinical transferability.	[Ramgolam, Kiran; Lalou, Claude; Lauden, Laura; Khatib, Abdel-Majid; Charron, Dominique; Al-Daccak, Reem] Univ Paris 07, INSERM, Hop St Louis, Inst Univ Hematol,UMRS 940, Paris, France; [Lauriol, Jessica; Alcaide-Loridan, Catherine] Univ Paris 07, Inst Jacques Monod, UMRS 7592, CNRS, F-75251 Paris, France; [Michel, Laurence] Univ Paris 07, INSERM, Hop St Louis, UMRS976, Paris, France; [Aoudjit, Fawzi] Univ Laval, CRCHUQ, Ctr Rech Rhumatol & Immunol, Quebec City, PQ G1K 7P4, Canada; [Charron, Dominique] Hop St Louis, AP HP, CIB HOG, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Laval University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Ramgolam, K (corresponding author), Univ Paris 07, INSERM, Hop St Louis, Inst Univ Hematol,UMRS 940, Paris, France.	reem.al-daccak@inserm.fr	Michel, Laurence/E-8605-2017; Al-Daccak, Reem/L-8804-2018; KHATIB, Abdel-Majid/A-9948-2015	KHATIB, Abdel-Majid/0000-0001-6957-0384; de la Grange, Pierre/0000-0001-6361-1878; Al-Daccak, Reem/0000-0002-6146-2845; LALOU, Claude/0000-0002-5271-7439	Association de la Recherche sur le Cancer; Institut National du Cancer (Reseau des cellules souches) - France; La Ligue contre le Cancer, France; Conseil Regional d'Ile-de-France; Ministere de la Recherche	Association de la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Institut National du Cancer (Reseau des cellules souches) - France(Institut National du Cancer (INCA) France); La Ligue contre le Cancer, France; Conseil Regional d'Ile-de-France(Region Ile-de-France); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France)	This work was supported by grants to R. D. from Association de la Recherche sur le Cancer and Institut National du Cancer (Reseau des cellules souches) - France. K. R. is supported by a postdoctoral fellowship from La Ligue contre le Cancer, France. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank Dr. Didier Auboeuf for microarray platform, Dr. Ryad Tamouza and Wahid Boukouaci (UMRS 940) for effective discussions, and Carine Deruyfellaere and Stephanie Ghislin (Institut Jacques Monod) for technical support. Particular thanks for Dr M. Pla (UMRS 940 and Departement d'experimentation animale, Hopital Saint-Louis) and Martine Chopin (Departement d'experimentation animale, Hopital Saint-Louis) for their help in conducting animal studies. We also thank the Imagery Department of the Institut Universitaire d'Hematologie. The imagery department is supported by grants from the Conseil Regional d'Ile-de-France and the Ministere de la Recherche.	Aoudjit F, 2004, EXP CELL RES, V299, P79, DOI 10.1016/j.yexcr.2004.05.011; Balemans W, 2002, DEV BIOL, V250, P231, DOI 10.1006/dbio.2002.0779; Banerjee SS, 2000, HISTOPATHOLOGY, V36, P387; Byrne SN, 2003, CANCER IMMUNOL IMMUN, V52, P396, DOI 10.1007/s00262-003-0380-0; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Clark TA, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r64; Coucke Paul H. A., 1994, In Vivo (Attiki), V8, P333; de la Grange P, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-180; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; Flammiger A, 2009, J INVEST DERMATOL, V129, P945, DOI 10.1038/jid.2008.316; Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008-5472.CAN-04-3327; French PJ, 2007, CANCER RES, V67, P5635, DOI 10.1158/0008-5472.CAN-06-2869; Fukunaga-Kalabis M, 2010, ONCOGENE, V29, P6115, DOI 10.1038/onc.2010.350; Gardina PJ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-325; Ghosh S, 2005, J CELL PHYSIOL, V204, P522, DOI 10.1002/jcp.20320; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Huls M, 2009, J PHARMACOL EXP THER, V328, P3, DOI 10.1124/jpet.107.132225; Jeffs AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008461; JIANG X, 2008, STEM CELLS DEV; Klarmann GJ, 2009, CLIN EXP METASTAS, V26, P433, DOI 10.1007/s10585-009-9242-2; Klein WM, 2007, MODERN PATHOL, V20, P102, DOI 10.1038/modpathol.3800720; Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373-004-8183-7; Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103; Kuriyama S, 2008, PHILOS T R SOC B, V363, P1349, DOI 10.1098/rstb.2007.2252; Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471; LEVENE A, 1980, J CLIN PATHOL, V33, P101, DOI 10.1136/jcp.33.2.101; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lunter PC, 2005, CANCER RES, V65, P8801, DOI 10.1158/0008-5472.CAN-05-0378; Martins I, 2007, EUR J IMMUNOL, V37, P788, DOI 10.1002/eji.200636620; Martins I, 2009, MELANOMA RES, V19, P226, DOI 10.1097/CMR.0b013e32832e0bc3; Matsumoto Y, 2009, BURNS, V35, P383, DOI 10.1016/j.burns.2008.06.017; McFadden C, 2007, J IMMUNOL, V179, P6439, DOI 10.4049/jimmunol.179.10.6439; Mills L, 2002, CANCER RES, V62, P5106; Monzani E, 2007, EUR J CANCER, V43, P935, DOI 10.1016/j.ejca.2007.01.017; Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404; Ostmeier H, 2001, BRIT J DERMATOL, V145, P203, DOI 10.1046/j.1365-2133.2001.04335.x; Palacios R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001222; Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]; Perego M, 2010, J INVEST DERMATOL, V130, P1877, DOI 10.1038/jid.2010.69; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567; Quintana E, 2010, CANCER CELL, V18, P510, DOI 10.1016/j.ccr.2010.10.012; Rappa G, 2008, EXP CELL RES, V314, P2110, DOI 10.1016/j.yexcr.2008.03.008; RAZ A, 1983, SCIENCE, V221, P1307, DOI 10.1126/science.6612347; REFAELI Y, 2009, EMBO REP; Rutz S, 2005, EUR J IMMUNOL, V35, P2443, DOI 10.1002/eji.200526294; Schatton T, 2008, PIGM CELL MELANOMA R, V21, P39, DOI 10.1111/j.1755-148X.2007.00427.x; Schatton T, 2010, J INVEST DERMATOL, V130, P1769, DOI 10.1038/jid.2010.135; Schatton T, 2010, CANCER RES, V70, P697, DOI 10.1158/0008-5472.CAN-09-1592; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; STACKPOLE CW, 1985, INT J CANCER, V35, P667, DOI 10.1002/ijc.2910350516; Strizzi L, 2008, CELL CYCLE, V7, P1931, DOI 10.4161/cc.7.13.6236; Suva ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008-5472.CAN-08-2242; Suzuki K, 2008, NAT IMMUNOL, V9, P17, DOI 10.1038/ni1553; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Vigouroux S, 2003, J VIROL, V77, P10872, DOI 10.1128/JVI.77.20.10872-10880.2003; Wang HY, 2005, J IMMUNOL, V174, P2661, DOI 10.4049/jimmunol.174.5.2661; Wei J, 2010, CLIN CANCER RES, V16, P461, DOI 10.1158/1078-0432.CCR-09-1983; WIDERA D, 2009, STEM CELLS; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Xi LQ, 2008, NUCLEIC ACIDS RES, V36, P6535, DOI 10.1093/nar/gkn697; Yu SC, 2009, STEM CELL REV REP, V5, P66, DOI 10.1007/s12015-008-9047-8	71	72	74	2	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2011	6	4							e18784	10.1371/journal.pone.0018784	http://dx.doi.org/10.1371/journal.pone.0018784			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	750WK	21526207	gold, Green Submitted, Green Published			2023-01-03	WOS:000289578600033
J	Pardoll, D				Pardoll, Drew			Timeline: a decade of advances in immunotherapy	NATURE MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA	Johns Hopkins University	Pardoll, D (corresponding author), Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21218 USA.	dpardol1@jhmi.edu			NATIONAL CANCER INSTITUTE [P30CA006973, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA006973, P30 CA021765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))			0	3	3	1	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAR	2011	17	3					296	296		10.1038/nm0311-296	http://dx.doi.org/10.1038/nm0311-296			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	730XF	21383743	Bronze, Green Accepted			2023-01-03	WOS:000288070000039
J	Kaufman, DS; Zietman, AL; Dahl, DM; Harisinghani, MG; Wu, CL				Kaufman, Donald S.; Zietman, Anthony L.; Dahl, Douglas M.; Harisinghani, Mukesh G.; Wu, Chin-Lee			Case 5-2011: A 65-Year-Old Man with Hematuria after Treatment for Prostate Cancer ANATOMICAL DIAGNOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADENOCARCINOMA; BRACHYTHERAPY; RADIOTHERAPY; OUTCOMES		[Kaufman, Donald S.] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA; [Zietman, Anthony L.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA; [Dahl, Douglas M.] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA; [Harisinghani, Mukesh G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; [Wu, Chin-Lee] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Kaufman, Donald S.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Zietman, Anthony L.] Harvard Univ, Sch Med, Dept Radiat Oncol, Boston, MA USA; [Dahl, Douglas M.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Harisinghani, Mukesh G.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA; [Wu, Chin-Lee] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Kaufman, DS (corresponding author), Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA.		Harisinghani, Mukesh/G-1347-2010; Harisinghani, Mukesh/D-7590-2011					Adley Brian P., 2006, Int. braz j urol., V32, P681, DOI 10.1590/S1677-55382006000600009; AJCC, 2009, AJCC CANC STAG MAN; Aronowitz JN, 2002, INT J RADIAT ONCOL, V54, P712, DOI 10.1016/S0360-3016(02)02987-5; Brenner DJ, 2000, CANCER, V88, P398, DOI 10.1002/(SICI)1097-0142(20000115)88:2<398::AID-CNCR22>3.0.CO;2-V; Curtis MW, 2005, MODERN PATHOL, V18, P585, DOI 10.1038/modpathol.3800317; Potosky AL, 2000, JNCI-J NATL CANCER I, V92, P1582, DOI 10.1093/jnci/92.19.1582; Potters L, 2005, J UROLOGY, V173, P1562, DOI 10.1097/01.ju.0000154633.73092.8e; Sanda MG, 2008, NEW ENGL J MED, V358, P1250, DOI 10.1056/NEJMoa074311; Sunkoya AO, 2007, AM J SURG PATHOL, V31, P1323, DOI 10.1097/PAS.0b013e31802ff7c4; Tran KP, 1996, AM J SURG PATHOL, V20, P1346, DOI 10.1097/00000478-199611000-00005; Zelefsky MJ, 2007, INT J RADIAT ONCOL, V67, P327, DOI 10.1016/j.ijrobp.2006.08.056	11	4	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2011	364	7					667	675		10.1056/NEJMcpc1005310	http://dx.doi.org/10.1056/NEJMcpc1005310			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	722BW	21323545				2023-01-03	WOS:000287406000014
J	Spiegel, D				Spiegel, David			Mind Matters in Cancer Survival	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							METASTATIC BREAST-CANCER; TRIAL		Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA	Stanford University	Spiegel, D (corresponding author), Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, 401 Quarry Rd,Off 2325, Stanford, CA 94305 USA.	dspiegel@stanford.edu		Spiegel, David/0000-0002-9476-9173	NATIONAL CANCER INSTITUTE [R01CA118567] Funding Source: NIH RePORTER; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [P30AT005886] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047226] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG018784] Funding Source: NIH RePORTER; NCCIH NIH HHS [1 P30 AT00 5886] Funding Source: Medline; NCI NIH HHS [1 R01 CA118567] Funding Source: Medline; NIA NIH HHS [P01 AG18784] Funding Source: Medline; NIMH NIH HHS [R01 MH47226] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCCIH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Andersen BL, 2008, CANCER-AM CANCER SOC, V113, P3450, DOI 10.1002/cncr.23969; Giese-Davis J, 2011, J CLIN ONCOL, V29, P413, DOI 10.1200/JCO.2010.28.4455; Goodwin PJ, 2001, NEW ENGL J MED, V345, P1719, DOI 10.1056/NEJMoa011871; HOUSE JS, 1988, SCIENCE, V241, P540, DOI 10.1037/0003-066X.59.8.676; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; Sephton SE, 2000, J NATL CANCER I, V92, P994, DOI 10.1093/jnci/92.12.994; SPIEGEL D, 1989, LANCET, V2, P888; Spiegel D, 2007, CANCER-AM CANCER SOC, V110, P1130, DOI 10.1002/cncr.22890; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	10	44	44	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2011	305	5					502	503		10.1001/jama.2011.69	http://dx.doi.org/10.1001/jama.2011.69			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714LI	21285429	Green Accepted			2023-01-03	WOS:000286810700025
J	Morgan, SG; Cunningham, CM; Hanley, GE				Morgan, Steven G.; Cunningham, Colleen M.; Hanley, Gillian E.			Individual and Contextual Determinants of Regional Variation in Prescription Drug Use: An Analysis of Administrative Data from British Columbia	PLOS ONE			English	Article							HEALTH-CARE; GEOGRAPHIC-VARIATION; BEHAVIORAL-MODEL; UNITED-STATES; MEDICAL-CARE; CANADA	Background: Increasing attention is being paid to variations in the use of prescription drugs because their role in health care has grown to the point where their use can be considered a proxy for health system performance. Studies have shown that prescription drug use varies across regions in the US, UK, and Canada by more than would be predicted based on age and health status alone. In this paper, we explore the determinants of variations in the use of prescription drugs, drawing on health services theories of access to care. Methods: We conducted a cross-sectional analysis using population-based administrative health care data for British Columbia (BC), Canada. We used logistic and hierarchical regressions to analyze the effects of individual-and area-level determinants of use of prescriptions overall and rates of purchase of prescriptions from five therapeutic categories representing a range of indications: antihypertensives, statins, acid reducing drugs, opioid drugs, and antidepressants. To indicate the relative scale of regional variations and the importance of individual-and area-level variables in explaining them, we computed standardized rates of utilization for 49 local health areas in BC. Results: We found that characteristics of individuals and the areas in which they live affect likelihood of prescription drug purchase. Individual-level factors influenced prescription drug purchases in ways generally consistent with behavioral models of health services use. Contextual variables exerted influences that differed by type of drug studied. Population health, education levels, and ethnic composition of local areas were associated with significant differences in the likelihood of purchasing medications. Relatively modest regional variations remained after both individual-level and area-level determinants were taken into account. Conclusions: The results of this study suggest that individual-and area-level factors should be considered when studying variations in the use of prescription drugs. Some sources of such variations, including individual-and area-level socioeconomic status, warrant further investigation and possible intervention to address inequities.	[Morgan, Steven G.; Cunningham, Colleen M.; Hanley, Gillian E.] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada; [Morgan, Steven G.; Hanley, Gillian E.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada	University of British Columbia; University of British Columbia	Morgan, SG (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V5Z 1M9, Canada.	morgan@chspr.ubc.ca	Cunningham, Colleen/AAY-4357-2021; Morgan, Steven/J-8814-2015	Hanley, Gillian/0000-0001-9594-0545; Morgan, Steven/0000-0002-7529-0028	British Columbia Ministry of Health Services; Canadian Institutes of Health Research	British Columbia Ministry of Health Services; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This project was made possible through the financial support of the British Columbia Ministry of Health Services and an operating research grant from the Canadian Institutes of Health Research (www.CIHR.ca). The construction of the research database was supported, in part, by contributions of the Ministry of Health Services to the University of British Columbia Centre for Health Services and Policy Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aday L A, 1974, Health Serv Res, V9, P208; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; *BC STATS, 2010, BC GDP IND; *BC STATS, 2009, PROF IMM; Birch S, 1993, Health Econ, V2, P87, DOI 10.1002/hec.4730020203; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; *CIHI, 2010, DRUG EXP CAN 1985 20; Cox ER, 2003, PEDIATRICS, V111, P237, DOI 10.1542/peds.111.2.237; Dubois RW, 2002, HEALTH AFFAIR, V21, P240, DOI 10.1377/hlthaff.21.1.240; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Goyder Elizabeth, 2006, Int J Equity Health, V5, P4, DOI 10.1186/1475-9276-5-4; Hanley GE, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-79; LIPSITZ SR, 1994, BIOMETRICS, V50, P270, DOI 10.2307/2533218; Morgan S, 2004, CAN MED ASSOC J, V170, P329; Morgan S., 2005, CANADIAN RX ATLAS; MORGAN S, 2008, CANADIAN RX ATLAS; MORGAN S, 2005, BC RX ATLAS; MORGAN S, 2009, BC RX ATLAS; NEWBOLD KB, 1995, SOC SCI MED, V40, P1181, DOI 10.1016/0277-9536(94)00229-M; Phillips KA, 1998, HEALTH SERV RES, V33, P571; ROOS NP, 1986, AM J PUBLIC HEALTH, V76, P45, DOI 10.2105/AJPH.76.1.45; Sutherland JM, 2009, NEW ENGL J MED, V361, P1227, DOI 10.1056/NEJMp0907172; Ward Paul R, 2007, Int J Equity Health, V6, P2, DOI 10.1186/1475-9276-6-2; Watson D, 2009, ROAD RENEWAL MAPPING; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; ZHANG Y, 2010, NEW ENGLAND J MED	29	13	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2010	5	12							e15883	10.1371/journal.pone.0015883	http://dx.doi.org/10.1371/journal.pone.0015883			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	701CZ	21209960	Green Published, gold, Green Submitted			2023-01-03	WOS:000285793200064
J	Yin, HS; Wolf, MS; Dreyer, BP; Sanders, LM; Parker, RM				Yin, H. Shonna; Wolf, Michael S.; Dreyer, Benard P.; Sanders, Lee M.; Parker, Ruth M.			Evaluation of Consistency in Dosing Directions and Measuring Devices for Pediatric Nonprescription Liquid Medications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH LITERACY; ACETAMINOPHEN; PARENTS; ERRORS; VARIABILITY; ASSOCIATION; INSTRUMENTS; ACCURACY; LABELS	Context In response to reports of unintentional drug overdoses among children given over-the-counter (OTC) liquid medications, in November 2009 the US Food and Drug Administration (FDA) released new voluntary industry guidelines that recommend greater consistency and clarity in OTC medication dosing directions and their accompanying measuring devices. Objective To determine the prevalence of inconsistent dosing directions and measuring devices among popular pediatric OTC medications at the time the FDA's guidance was released. Design and Setting Descriptive study of 200 top-selling pediatric oral liquid OTC medications during the 52 weeks ending October 30, 2009. Sample represents 99% of the US market of analgesic, cough/cold, allergy, and gastrointestinal OTC oral liquid products with dosing information for children younger than 12 years. Main Outcome Measures Inclusion of measuring device, within-product inconsistency between dosing directions on the bottle's label and dose markings on enclosed measuring device, across-product use of nonstandard units and abbreviations, and presence of abbreviation definitions. Results Measuring devices were packaged with 148 of 200 products (74.0%). Within this subset of 148 products, inconsistencies between the medication's dosing directions and markings on the device were found in 146 cases (98.6%). These included missing markings (n=36, 24.3%) and superfluous markings (n=120, 81.1%). Across all products, 11 (5.5%) used atypical units of measurement (eg, drams, cc) for doses listed. Milliliter, teaspoon, and tablespoon units were used for doses in 143 (71.5%), 155 (77.5%), and 37 (18.5%) products, respectively. A nonstandard abbreviation for milliliter (not mL) was used by 97 products. Of the products that included an abbreviation, 163 did not define at least 1 abbreviation. Conclusion At the time the FDA released its new guidance, top-selling pediatric OTC liquid medications contained highly variable and inconsistent dosing directions and measuring devices. JAMA. 2010;304(23):2595-2602 www.jama.com	[Yin, H. Shonna; Dreyer, Benard P.] NYU, Sch Med, Dept Pediat, New York, NY 10016 USA; [Yin, H. Shonna; Dreyer, Benard P.] Bellevue Hosp Ctr, New York, NY 10016 USA; [Wolf, Michael S.] Northwestern Univ, Feinberg Sch Med, Hlth Literacy & Learning Program, Ctr Commun Healthcare,Div Gen Internal Med, Chicago, IL 60611 USA; [Wolf, Michael S.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA; [Sanders, Lee M.] Univ Miami, Miller Sch Med, Dept Pediat, Miami, FL 33136 USA; [Parker, Ruth M.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA	New York University; Bellevue Hospital Center; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; University of Miami; Emory University	Yin, HS (corresponding author), NYU, Sch Med, Dept Pediat, 550 1st Ave,NBV 8S4-11, New York, NY 10016 USA.	yinh02@med.nyu.edu	Wolf, Michael/V-3351-2018; Parker, Ruth M/S-4583-2017	Wolf, Michael/0000-0002-4342-6517; Parker, Ruth M/0000-0001-9685-6396; Yin, Hsiang Shonna/0000-0003-3287-0011; Dreyer, Benard/0000-0001-5299-5634	Pfizer; McNeil Consumer Healthcare; Abbott Foundation; McNeil ConsumerHealth	Pfizer(Pfizer); McNeil Consumer Healthcare; Abbott Foundation; McNeil ConsumerHealth	Dr Yin reported receiving funds from Pfizer as part of its Fellowship in Health Literacy/Clear Health Communication and having served as a paid consultant to McKing Consulting Corporation. Dr Wolf reported receiving unrestricted research grant funding from McNeil Consumer Healthcare and Abbott Foundation and having served as a paid consultant to McNeil Consumer Healthcare and Abbott Laboratories. Dr Sanders reported receiving unrestricted research grant funding from Pfizer as part of its Fellowship in Health Literacy/Clear Health Communication and having served as a paid consultant to Pfizer's Clear Health Communication program. Dr Parker reported receiving unrestricted research grant funding from McNeil ConsumerHealth and Abbott Foundation and having served as a paid consultant to Johnson & Johnson and McKing Consulting Corporation. No other disclosures were reported.	*AM AC PED, PAR COM Q A MED; *AM COLL PHYS FDN, IMPR PRESCR DRUG CON; [Anonymous], 2002, FDA Consum, V36, P35; BACIU A, 2007, FUTURE DRUG SAFETY P; Brunetti L, 2007, JT COMM J QUAL PATIE, V33, P576, DOI 10.1016/S1553-7250(07)33062-6; Budnitz DS, 2007, PHARMACOEPIDEM DR S, V16, P160, DOI 10.1002/pds.1242; *CHAIN DRUG REV, TOP 100 CHAINS PHARM; *CONS HEALTHC PROD, VOL MEAS DOS OV THE; Dart RC, 2009, ANN EMERG MED, V53, P411, DOI 10.1016/j.annemergmed.2008.09.015; Davis TC, 2006, J GEN INTERN MED, V21, P847, DOI 10.1111/j.1525-1497.2006.00529.x; Davis TC, 2006, ANN INTERN MED, V145, P887, DOI 10.7326/0003-4819-145-12-200612190-00144; Frush KS, 2004, ARCH PEDIAT ADOL MED, V158, P620, DOI 10.1001/archpedi.158.7.620; GRIBETZ B, 1987, PEDIATRICS, V80, P630; Hahn Robert, 2007, MMWR Recomm Rep, V56, P1; HERNANDEZ LM, 2007, STANDARDIZING MEDICA; HYAM E, 1989, FAM PRACT, V6, P221, DOI 10.1093/fampra/6.3.221; *I MED, 2010, SAF US IN HLTH LIT W; Institute of Medicine, 2007, PREV MED ERR QUAL CH; *JOINT COMM, OFF DO NOT US LIST; Kutner M, HLTH LITERACY AM ADU; Li SF, 2000, PEDIATR EMERG CARE, V16, P394, DOI 10.1097/00006565-200012000-00003; LITOVITZ T, 1992, ANN PHARMACOTHER, V26, P917, DOI 10.1177/106002809202600710; Madlon-Kay DJ, 2000, J FAM PRACTICE, V49, P741; MCKENZIE MW, 1981, US PHARM, V6, P55; McMahon SR, 1997, PEDIATRICS, V100, P330, DOI 10.1542/peds.100.3.330; Nielson-Bohlman L, 2004, HLTH LITERACY PRESCR; Persell SD, 2007, J GEN INTERN MED, V22, P1523, DOI 10.1007/s11606-007-0334-x; Schillie SF, 2009, AM J PREV MED, V37, P181, DOI 10.1016/j.amepre.2009.05.018; Sharif I, 2010, PEDIATRICS, V125, P960, DOI 10.1542/peds.2009-2530; Shrank W, 2007, ANN PHARMACOTHER, V41, P783, DOI 10.1345/aph.1H582; Shrank WH, 2007, ARCH INTERN MED, V167, P1760, DOI 10.1001/archinte.167.16.1760; Simon HK, 1997, ARCH PEDIAT ADOL MED, V151, P654, DOI 10.1001/archpedi.1997.02170440016003; Sobhani P, 2008, ANN PHARMACOTHER, V42, P46, DOI 10.1345/aph.1K420; *US DEP HHS, GUID IND DOS DEL DEV; *US PHARM, 32 USP; *USP CTR ADV PAT S, ABB CAN LEAD MED ERR; Vernacchio L, 2009, PEDIATRICS, V124, P446, DOI 10.1542/peds.2008-2869; Wolf MS, 2007, PATIENT EDUC COUNS, V67, P293, DOI 10.1016/j.pec.2007.03.024; Wolf MS, 2006, AM J HEALTH-SYST PH, V63, P1048, DOI 10.2146/ajhp050469; Wolf MS, 2006, PATIENT EDUC COUNS, V62, P316, DOI 10.1016/j.pec.2006.06.010; Wolf MS, 2009, MED CARE, V47, P370, DOI 10.1097/MLR.0b013e31818af91a; YAFFE SJ, 1975, PEDIATRICS, V56, P327; Yin HS, 2008, ARCH PEDIAT ADOL MED, V162, P814, DOI 10.1001/archpedi.162.9.814; Yin HS, 2007, AMBUL PEDIATR, V7, P292, DOI 10.1016/j.ambp.2007.04.004; Yin H Shonna, 2009, Pediatrics, V124 Suppl 3, pS289, DOI 10.1542/peds.2009-1162E; Yin HS, 2010, ARCH PEDIAT ADOL MED, V164, P181, DOI 10.1001/archpediatrics.2009.269; 2009, DRUG STORE NEWS, V31	47	50	52	0	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 15	2010	304	23					2595	2602		10.1001/jama.2010.1797	http://dx.doi.org/10.1001/jama.2010.1797			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	694MX	21119074	Bronze			2023-01-03	WOS:000285303400022
J	Teschke, R; Schulze, J				Teschke, Rolf; Schulze, Johannes			Risk of Kava Hepatotoxicity and the FDA Consumer Advisory	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Teschke, Rolf] Goethe Univ Frankfurt, Teaching Hosp, Dept Internal Med 2, Div Gastroenterol & Hepatol,Klinikum Hanau, D-63450 Hanau, Germany; [Schulze, Johannes] Goethe Univ Frankfurt, Fac Med, Off Dean, D-63450 Hanau, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Teschke, R (corresponding author), Goethe Univ Frankfurt, Teaching Hosp, Dept Internal Med 2, Div Gastroenterol & Hepatol,Klinikum Hanau, Leimenstr 20, D-63450 Hanau, Germany.	rolf.teschke@gmx.de						*AUSTR GOV DEP HLT, 2005, KAV FACT SHEET; Lasme P, 2008, J AGR FOOD CHEM, V56, P4976, DOI 10.1021/jf800439g; Sarris J, 2009, PSYCHOPHARMACOLOGY, V205, P399, DOI 10.1007/s00213-009-1549-9; Schmidt M., 2007, HERBALGRAM, V73, P45; Teschke R, 2010, LIVER INT, V30, P1270, DOI 10.1111/j.1478-3231.2010.02308.x; Teschke R, 2010, ANN HEPATOL, V9, P251, DOI 10.1016/S1665-2681(19)31634-5; U.S. Food and Drug Administration, CONS ADV KAV CONT DI; *WHO, 2007, ASS RISK HEP KAV PRO; Zhou P, 2010, FASEB J, V24, P4722, DOI 10.1096/fj.10-163311	9	32	33	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2174	2175		10.1001/jama.2010.1689	http://dx.doi.org/10.1001/jama.2010.1689			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081732				2023-01-03	WOS:000284269800030
J	Ouslander, JG				Ouslander, Joseph G.			A Murmur of Music	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												joseph.ouslander@fau.edu							0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	2010	304	17					1875	1875		10.1001/jama.2010.1141	http://dx.doi.org/10.1001/jama.2010.1141			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674GT	21045087				2023-01-03	WOS:000283725900001
J	Jilkova, A; Rezacova, P; Lepsik, M; Horn, M; Vachova, J; Fanfrlik, J; Brynda, J; McKerrow, JH; Caffrey, CR; Mares, M				Jilkova, Adela; Rezacova, Pavlina; Lepsik, Martin; Horn, Martin; Vachova, Jana; Fanfrlik, Jindrich; Brynda, Jiri; McKerrow, James H.; Caffrey, Conor R.; Mares, Michael			Structural Basis for Inhibition of Cathepsin B Drug Target from the Human Blood Fluke, Schistosoma mansoni	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEASE INHIBITORS; RAY CRYSTAL-STRUCTURE; H-BONDING CORRECTION; OCCLUDING LOOP; SUBSTRATE-SPECIFICITY; SELECTIVE INHIBITORS; RNA INTERFERENCE; VINYL SULFONES; POTENT; IDENTIFICATION	Schistosomiasis caused by a parasitic blood fluke of the genus Schistosoma afflicts over 200 million people worldwide. Schistosoma mansoni cathepsin B1 (SmCB1) is a gut-associated peptidase that digests host blood proteins as a source of nutrients. It is under investigation as a drug target. To further this goal, we report three crystal structures of SmCB1 complexed with peptidomimetic inhibitors as follows: the epoxide CA074 at 1.3 angstrom resolution and the vinyl sulfones K11017 and K11777 at 1.8 and 2.5 angstrom resolutions, respectively. Interactions of the inhibitors with the subsites of the active-site cleft were evaluated by quantum chemical calculations. These data and inhibition profiling with a panel of vinyl sulfone derivatives identify key binding interactions and provide insight into the specificity of SmCB1 inhibition. Furthermore, hydrolysis profiling of SmCB1 using synthetic peptides and the natural substrate hemoglobin revealed that carboxydipeptidase activity predominates over endopeptidolysis, thereby demonstrating the contribution of the occluding loop that restricts access to the active-site cleft. Critically, the severity of phenotypes induced in the parasite by vinyl sulfone inhibitors correlated with enzyme inhibition, providing support that SmCB1 is a valuable drug target. The present structure and inhibitor interaction data provide a footing for the rational design of anti-schistosomal inhibitors.	[Jilkova, Adela; Rezacova, Pavlina; Lepsik, Martin; Horn, Martin; Vachova, Jana; Fanfrlik, Jindrich; Brynda, Jiri; Mares, Michael] Acad Sci Czech Republ, Inst Organ Chem & Biochem, CR-16610 Prague, Czech Republic; [Jilkova, Adela] Charles Univ Prague, Dept Biochem, Fac Sci, Prague 12843, Czech Republic; [Rezacova, Pavlina; Brynda, Jiri] Acad Sci Czech Republ, Inst Mol Genet, Dept Biol Struct, Prague 16610, Czech Republic; [McKerrow, James H.; Caffrey, Conor R.] Univ Calif San Francisco, Sandler Ctr Drug Discovery, Calif Inst Quantitat Biosci, San Francisco, CA 94158 USA; [McKerrow, James H.; Caffrey, Conor R.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94158 USA	Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Mares, M (corresponding author), Flemingovo 2, Prague 16610, Czech Republic.	mares@uochb.cas.cz	Lepšík, Martin/X-8603-2019; Rezacova, Pavlina/G-3600-2014; Brynda, Jiri/G-2760-2014; Lepsik, Martin/C-6614-2012; Mares, Michael/B-2413-2009; Jilkova, Adela/G-5809-2014; Horn, Martin/A-8701-2008	Lepšík, Martin/0000-0003-2607-8132; Rezacova, Pavlina/0000-0001-9626-346X; Brynda, Jiri/0000-0003-3675-6769; Lepsik, Martin/0000-0003-2607-8132; Mares, Michael/0000-0002-0847-5022; Jilkova, Adela/0000-0002-3158-9626; Horn, Martin/0000-0001-9110-2018; Fanfrlik, Jindrich/0000-0002-1257-1201	Grant Agency of the Czech Republic [203/09/1585, P208/11/0295]; Academy of Sciences of the Czech Republic; Sandler Center for Drug Discovery; Ministry of Education, Youth and Sports of the Czech Repulic [OC09007]; United States Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-AC02-06CH11357];  [Z40550506];  [Z50520514]	Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Sandler Center for Drug Discovery; Ministry of Education, Youth and Sports of the Czech Repulic; United States Department of Energy, Office of Science, Office of Basic Energy Sciences(United States Department of Energy (DOE)); ; 	This work was supported, in whole or in part, by Grant 203/09/1585 from the Grant Agency of the Czech Republic, Institutional Research Projects Z40550506 and Z50520514, the Academy of Sciences of the Czech Republic, and by the Sandler Center for Drug Discovery. Additional support was by Grant P208/11/0295 (to M. L. and J. F.) from the Grant Agency of the Czech Republic and by Grant OC09007 (to M. M.) from the Ministry of Education, Youth and Sports of the Czech Repulic. Use of the Advanced Photon Source was supported by the United States Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357.	Abdulla MH, 2007, PLOS MED, V4, P130, DOI 10.1371/journal.pmed.0040014; Abdulla MH, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000478; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Betts MJ, 1999, PROTEIN ENG, V12, P271, DOI 10.1093/protein/12.4.271; Brady CP, 1999, INFECT IMMUN, V67, P368, DOI 10.1128/IAI.67.1.368-374.1999; Brindley PJ, 1997, MOL BIOCHEM PARASIT, V89, P1, DOI 10.1016/S0166-6851(97)00098-4; Brinen LS, 2000, STRUCT FOLD DES, V8, P831, DOI 10.1016/S0969-2126(00)00173-8; Bromme D, 1996, BIOCHEM J, V315, P85; Caffrey CR, 2007, CURR OPIN CHEM BIOL, V11, P433, DOI 10.1016/j.cbpa.2007.05.031; Caffrey CR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004413; Caffrey CR, 1997, PARASITOL RES, V83, P37, DOI 10.1007/s004360050204; Caffrey CR, 2002, MOL BIOCHEM PARASIT, V121, P49, DOI 10.1016/S0166-6851(02)00022-1; Caffrey CR, 2004, TRENDS PARASITOL, V20, P241, DOI 10.1016/j.pt.2004.03.004; Caffrey CR, 1997, PARASITOL RES, V83, P632, DOI 10.1007/s004360050310; Caffrey CR, 2000, FEBS LETT, V466, P244, DOI 10.1016/S0014-5793(99)01798-6; Case D. A., 2008, AMBER 10; Cezari MHS, 2002, BIOCHEM J, V368, P365, DOI 10.1042/BJ20020840; Chen YT, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000825; Choe Y, 2006, J BIOL CHEM, V281, P12824, DOI 10.1074/jbc.M513331200; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Delano W.L, 2002, DELANO SCI; Delcroix M, 2006, J BIOL CHEM, V281, P39316, DOI 10.1074/jbc.M607128200; Dvorak J, 2005, INT J PARASITOL, V35, P895, DOI 10.1016/j.ijpara.2005.02.018; Dvorak J, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000449; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Engel JC, 1998, J EXP MED, V188, P725, DOI 10.1084/jem.188.4.725; Greenspan PD, 2001, J MED CHEM, V44, P4524, DOI 10.1021/jm010206q; Gryseels B, 2006, LANCET, V368, P1106, DOI 10.1016/S0140-6736(06)69440-3; HASNAIN S, 1993, J BIOL CHEM, V268, P235; Horn M, 2011, ACS CHEM BIOL, V6, P609, DOI 10.1021/cb100411v; Horn M, 2009, CHEM BIOL, V16, P1053, DOI 10.1016/j.chembiol.2009.09.009; Illy C, 1997, J BIOL CHEM, V272, P1197, DOI 10.1074/jbc.272.2.1197; Jaishankar P, 2008, BIOORG MED CHEM LETT, V18, P624, DOI 10.1016/j.bmcl.2007.11.070; JIA ZC, 1995, J BIOL CHEM, V270, P5527, DOI 10.1074/jbc.270.10.5527; Kerr ID, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000701; Kerr ID, 2009, J BIOL CHEM, V284, P25697, DOI 10.1074/jbc.M109.014340; Korth M, 2010, J CHEM THEORY COMPUT, V6, P344, DOI 10.1021/ct900541n; Krissinel E., 2005, DETECTION PROTEIN AS, P163; Krupa JC, 2002, BIOCHEM J, V361, P613, DOI 10.1042/0264-6021:3610613; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Lowther J, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000369; Masa M, 2006, BIOCHEMISTRY-US, V45, P15474, DOI 10.1021/bi0614986; McCarthy E, 2004, INT J PARASITOL, V34, P703, DOI 10.1016/j.ijpara.2004.01.008; McKerrow JH, 2009, MEM I OSWALDO CRUZ, V104, P263, DOI 10.1590/S0074-02762009000900034; McKerrow JH, 2008, CURR OPIN INFECT DIS, V21, P668, DOI 10.1097/QCO.0b013e328315cca9; Minor W, 2006, ACTA CRYSTALLOGR D, V62, P859, DOI 10.1107/S0907444906019949; MURATA M, 1991, FEBS LETT, V280, P307, DOI 10.1016/0014-5793(91)80318-W; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MUSIL D, 1991, EMBO J, V10, P2321, DOI 10.1002/j.1460-2075.1991.tb07771.x; Nagler DK, 1997, BIOCHEMISTRY-US, V36, P12608, DOI 10.1021/bi971264+; Olson JE, 1999, BIOORGAN MED CHEM, V7, P633, DOI 10.1016/S0968-0896(99)00004-8; PALMER JT, 1995, J MED CHEM, V38, P3193, DOI 10.1021/jm00017a002; Quraishi O, 1999, BIOCHEMISTRY-US, V38, P5017, DOI 10.1021/bi981950o; Rai G, 2009, J MED CHEM, V52, P6474, DOI 10.1021/jm901021k; Ranjit N, 2008, MOL BIOCHEM PARASIT, V160, P90, DOI 10.1016/j.molbiopara.2008.04.008; Renslo AR, 2006, NAT CHEM BIOL, V2, P701, DOI 10.1038/nchembio837; Rezac J, 2009, J CHEM THEORY COMPUT, V5, P1749, DOI 10.1021/ct9000922; Roush WR, 2001, BIOORG MED CHEM LETT, V11, P2759, DOI 10.1016/S0960-894X(01)00566-2; Roush WR, 1998, J AM CHEM SOC, V120, P10994, DOI 10.1021/ja981792o; Sajid M, 2003, MOL BIOCHEM PARASIT, V131, P65, DOI 10.1016/S0166-6851(03)00194-4; Schagger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4; Scheidt KA, 1998, BIOORGAN MED CHEM, V6, P2477, DOI 10.1016/S0968-0896(98)80022-9; Somoza JR, 2000, BIOCHEMISTRY-US, V39, P12543, DOI 10.1021/bi000951p; Sorgine MHF, 2000, J BIOL CHEM, V275, P28659, DOI 10.1074/jbc.M005675200; Sripa J, 2010, CELL MICROBIOL, V12, P781, DOI 10.1111/j.1462-5822.2010.01433.x; Stefanic S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000850; Steverding D, 2006, MINI-REV MED CHEM, V6, P1025, DOI 10.2174/138955706778195207; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; UTZINGER J, 2011, ACTA TROP IN PRESS; Vagin A, 2000, ACTA CRYSTALLOGR D, V56, P1622, DOI 10.1107/S0907444900013780; Watanabe D, 2006, J MOL BIOL, V362, P979, DOI 10.1016/j.jmb.2006.07.070; Williamson AL, 2004, J BIOL CHEM, V279, P35950, DOI 10.1074/jbc.M405842200; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Yamamoto A, 2000, J BIOCHEM-TOKYO, V127, P635, DOI 10.1093/oxfordjournals.jbchem.a022651	75	57	57	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 14	2011	286	41					35770	35781		10.1074/jbc.M111.271304	http://dx.doi.org/10.1074/jbc.M111.271304			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	834AG	21832058	Green Published, hybrid			2023-01-03	WOS:000295927100050
J	Cohen, D				Cohen, David			PROFILE Edzard Ernst: the prince and me	BRITISH MEDICAL JOURNAL			English	Biographical-Item												mail@davidcohen.net							0	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 3	2011	343								d4937	10.1136/bmj.d4937	http://dx.doi.org/10.1136/bmj.d4937			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805NN	21816747				2023-01-03	WOS:000293734700010
J	Kesavelu, D; Dalzell, M; Eaton, V				Kesavelu, Dhanasekhar; Dalzell, Mark; Eaton, Vicki			CASE REPORT Abdominal distension in a 4 year old	BRITISH MEDICAL JOURNAL			English	Editorial Material							CELIAC-DISEASE; DIAGNOSIS; SENSITIVITY; CHILDREN		[Kesavelu, Dhanasekhar; Dalzell, Mark] Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; [Eaton, Vicki] Mersey Deanery, Liverpool L3 4BL, Merseyside, England	Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital	Kesavelu, D (corresponding author), Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England.	dkesavelu@doctors.org.uk	KESAVELU, DHANASEKHAR/AAV-8310-2020	KESAVELU, DHANASEKHAR/0000-0003-4051-3102				Cataldo F, 1997, J PEDIATR-US, V131, P306, DOI 10.1016/S0022-3476(97)70172-0; Hill ID, 2005, GASTROENTEROLOGY, V128, pS25, DOI 10.1053/j.gastro.2005.02.012; Hill ID, 2005, J PEDIATR GASTR NUTR, V40, P1, DOI 10.1097/00005176-200501000-00001; Hopper AD, 2007, BMJ-BRIT MED J, V334, P729, DOI 10.1136/bmj.39133.668681.BE; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; *NAT I HLTH CLIN E, 2009, CG86 NAT I HLTH CLIN; Report of Working Group of European Society of Paediatric Gastroenterology and Nutrition, 1990, ARCH DIS CHILD, V65, P909; Tumer L, 2001, PEDIATR INT, V43, P71, DOI 10.1046/j.1442-200x.2001.01327.x	8	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 3	2011	343								d3614	10.1136/bmj.d3614	http://dx.doi.org/10.1136/bmj.d3614			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	805NN	21816738				2023-01-03	WOS:000293734700001
J	Kuo, YF; Goodwin, JS				Kuo, Yong-Fang; Goodwin, James S.			Association of Hospitalist Care With Medical Utilization After Discharge: Evidence of Cost Shift From a Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT SAFETY; OUTPATIENT; SERVICE; CONTINUITY; PHYSICIANS; INPATIENT; OUTCOMES; COMMUNICATION; TRANSITIONS; RISK	Background: Hospitalist care has grown rapidly, in part because it is associated with decreased length of stay and hospital costs. No national studies examining the effect of hospitalist care on hospital costs or on medical utilization and costs after discharge have been done. Objective: To assess the relationship of hospitalist care with hospital length of stay, hospital charges, and medical utilization and Medicare costs after discharge. Design: Population-based national cohort study. Setting: Hospital care of Medicare patients. Patients: A 5% national sample of enrollees in Medicare parts A and B with a primary care physician who were cared for by their primary care physician or a hospitalist during medical hospitalizations from 2001 to 2006. Measurements: Length of stay, hospital charges, discharge location and physician visits, emergency department visits, rehospitalization, and Medicare spending within 30 days after discharge. Results: In propensity score analysis, hospital length of stay was 0.64 day less among patients receiving hospitalist care. Hospital charges were $282 lower, whereas Medicare costs in the 30 days after discharge were $332 higher (P < 0.001 for both). Patients cared for by hospitalists were less likely to be discharged to home (odds ratio, 0.82 [95% CI, 0.78 to 0.86]) and were more likely to have emergency department visits (odds ratio, 1.18 [CI, 1.12 to 1.24]) and readmissions (odds ratio, 1.08 [CI, 1.02 to 1.14]) after discharge. They also had fewer visits with their primary care physician and more nursing facility visits after discharge. Limitation: Observational studies are subject to selection bias. Conclusion: Decreased length of stay and hospital costs associated with hospitalist care are offset by higher medical utilization and costs after discharge.	[Kuo, Yong-Fang] Univ Texas Med Branch, Dept Internal Med, Sealy Ctr Aging, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Kuo, YF (corresponding author), Univ Texas Med Branch, Dept Internal Med, Sealy Ctr Aging, 301 Univ Blvd, Galveston, TX 77555 USA.	yokuo@utmb.edu			National Institute on Aging [1R01-AG033134, P30AG024832]; National Cancer Institute [K05-CA134923]; NATIONAL CANCER INSTITUTE [K05CA134923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG033134, P30AG024832] Funding Source: NIH RePORTER	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the National Institute on Aging (grants 1R01-AG033134 and P30AG024832) and the National Cancer Institute (grant K05-CA134923).	Anderson GF, 1999, ARCH FAM MED, V8, P149, DOI 10.1001/archfami.8.2.149; Centers for Medicare & Medicaid Services, 100 MEDPAR INP HOSP; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Donini-Lenhoff F, 2005, GUIDEBOOK GME PROGRA, P59; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Finkelstein EA, 2009, HEALTH AFFAIR, V28, pW822, DOI 10.1377/hlthaff.28.5.w822; Forster AJ, 2005, J GEN INTERN MED, V20, P317, DOI 10.1111/j.1525-1497.2005.30390.x; Frakt AB, 2005, HEALTH CARE FINANC R, V26, P21; Fried TR, 2002, NEW ENGL J MED, V346, P1061, DOI 10.1056/NEJMsa012528; Go JT, 2010, J HOSP MED, V5, P133, DOI 10.1002/jhm.612; Griswold ME, 2010, ANN INTERN MED, V152, P393, DOI 10.7326/0003-4819-152-6-201003160-00010; Hinami K, 2009, J HOSP MED, V4, P535, DOI 10.1002/jhm.523; Howrey B, MED CARE IN PRESS; Kearns PJ, 2001, ARCH INTERN MED, V161, P235, DOI 10.1001/archinte.161.2.235; Koroukian SM, 2008, MED CARE, V46, P1184, DOI 10.1097/MLR.0b013e31817925d2; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Kuo YF, 2010, J AM GERIATR SOC, V58, P1649, DOI 10.1111/j.1532-5415.2010.03007.x; Kuo Y, 2009, NEW ENGL J MED, V360, P1102, DOI 10.1056/NEJMsa0802381; Lin DY, 1998, BIOMETRICS, V54, P948, DOI 10.2307/2533848; Lindenauer PK, 2007, NEW ENGL J MED, V357, P2589, DOI 10.1056/NEJMsa067735; McWilliams JM, 2009, ANN INTERN MED, V151, P757, DOI 10.7326/0003-4819-151-11-200912010-00149; Meltzer D, 2002, ANN INTERN MED, V137, P866, DOI 10.7326/0003-4819-137-11-200212030-00007; Moore C, 2003, J GEN INTERN MED, V18, P646, DOI 10.1046/j.1525-1497.2003.20722.x; Mullahy J, 1998, J HEALTH ECON, V17, P247, DOI 10.1016/S0167-6296(98)00030-7; Palmer HC, 2001, AM J MED, V111, P627, DOI 10.1016/S0002-9343(01)00976-7; Pham HH, 2008, HEALTH AFFAIR, V27, P1315, DOI 10.1377/hlthaff.27.5.1315; Rabe-Hesketh S., 2005, MULTILEVEL LONGITUDI; Roy CL, 2005, ANN INTERN MED, V143, P121, DOI 10.7326/0003-4819-143-2-200507190-00011; Shah BR, 2007, HEALTH SERV RES, V42, P1783, DOI 10.1111/j.1475-6773.2006.00681.x; Sharma G, 2010, ARCH INTERN MED, V170, P1664, DOI 10.1001/archinternmed.2010.345; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Sharma G, 2009, ARCH INTERN MED, V169, P81, DOI 10.1001/archinternmed.2008.514; Wachter RM, 1998, JAMA-J AM MED ASSOC, V279, P1560, DOI 10.1001/jama.279.19.1560; Yabroff KR, 2008, JNCI-J NATL CANCER I, V100, P630, DOI 10.1093/jnci/djn103	35	81	82	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 2	2011	155	3					152	+		10.7326/0003-4819-155-3-201108020-00005	http://dx.doi.org/10.7326/0003-4819-155-3-201108020-00005			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800DJ	21810708	Green Accepted			2023-01-03	WOS:000293339600003
J	Detsky, AS; Baerlocher, MO				Detsky, Allan S.; Baerlocher, Mark O.			Do Nice Patients Receive Better Care?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PHYSICIANS		[Detsky, Allan S.] Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; [Detsky, Allan S.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Detsky, Allan S.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Detsky, Allan S.] Univ Hlth Network, Toronto, ON, Canada; [Baerlocher, Mark O.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of California System; University of California San Diego	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Room 429, Toronto, ON M5G 1X5, Canada.	adetsky@mtsinai.on.ca						Atzema CL, 2011, CAN MED ASSOC J, V183, P663, DOI 10.1503/cmaj.100685; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; Bach PB, 1999, NEW ENGL J MED, V341, P1198, DOI 10.1056/NEJM199910143411606; Cain DM, 2008, JAMA-J AM MED ASSOC, V299, P2893, DOI 10.1001/jama.299.24.2893; Chapman KR, 2001, CHEST, V119, P1691, DOI 10.1378/chest.119.6.1691; GORLIN R, 1983, NEW ENGL J MED, V308, P1059, DOI 10.1056/NEJM198305053081804; Hahn SR, 1996, J GEN INTERN MED, V11, P1, DOI 10.1007/BF02603477; LEVINSON W, 1993, MED CARE, V31, P285, DOI 10.1097/00005650-199304000-00001; Lutfey K, 2005, AM J SOCIOL, V110, P1326, DOI 10.1086/428914; Pomm HA, 2004, FAM MED, V36, P467	10	6	6	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2011	306	1					94	95		10.1001/jama.2011.883	http://dx.doi.org/10.1001/jama.2011.883			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	787LV	21730247				2023-01-03	WOS:000292378700028
J	Spence, D				Spence, Des			FROM THE FRONTLINE Assisted dying: are doctors in denial?	BRITISH MEDICAL JOURNAL			English	Editorial Material												destwo@yahoo.co.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 22	2011	342								d3891	10.1136/bmj.d3891	http://dx.doi.org/10.1136/bmj.d3891			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	785AT	21697230				2023-01-03	WOS:000292200500012
J	Zeytinoglu, M				Zeytinoglu, Meltem			Talking It Out: Helping Our Patients Live Better While Dying	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							PALLIATIVE CARE; LIFE; ASSOCIATIONS; CANCER; HEALTH; COSTS; DEATH	Although dying is an inevitable part of the life cycle, there has been extensive political debate over end-of-life care. Participating in end-of-life care conversations can be emotionally challenging for everyone involved. Messages about serious or terminal illnesses can be very hard for patients and their families to hear, and physicians frequently struggle with the burden of delivering these messages. Still, evidence shows that conversations about end-of-life care options between physicians and patients can improve the quality of life of dying patients and help to relieve the emotional burden on surviving loved ones. Legislation to support these discussions by consistently reimbursing physicians for their time spent performing this service has been blocked on multiple occasions. More research on how to improve end-of-life care will enable health care providers to optimize treatment of their patients. Overcoming political divides to support end-of-life care conversations is needed to promote care that is consistent with patients' values and needs and is a key step in encouraging better quality of life for dying patients.	[Zeytinoglu, Meltem] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Zeytinoglu, M (corresponding author), Univ Chicago, NorthShore Programs, Dept Internal Med, 2650 Ridge Ave,Room 5319, Evanston, IL 60201 USA.	meltemz@gmail.com			American Cancer Society	American Cancer Society(American Cancer Society)	Grant Support: By the American Cancer Society Physician Training Award in Cancer Prevention and Control.	Billings ME, 2010, J PALLIAT MED, V13, P319, DOI 10.1089/jpm.2009.0293; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Field MJ, 1997, APPROACHING DEATH IM; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Meier DE, 2009, J PALLIAT MED, V12, P291, DOI 10.1089/jpm.2009.9648; Morrison RS, 2004, NEW ENGL J MED, V350, P2582, DOI 10.1056/NEJMcp035232; Pear R., 2010, NY TIMES        1225; Peppercorn JM, 2011, J CLIN ONCOL, V29, P755, DOI 10.1200/JCO.2010.33.1744; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Wright AA, 2008, JAMA-J AM MED ASSOC, V300, P1665, DOI 10.1001/jama.300.14.1665; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	13	3	4	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 21	2011	154	12					830	832		10.7326/0003-4819-154-12-201106210-00011	http://dx.doi.org/10.7326/0003-4819-154-12-201106210-00011			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	779SA	21690597				2023-01-03	WOS:000291800500019
J	Portenoy, RK				Portenoy, Russell K.			Treatment of cancer pain	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; QUALITY-OF-LIFE; CELL LUNG-CANCER; NEUROPATHIC PAIN; OPIOID ROTATION; PALLIATIVE CARE; ORAL METHADONE; MANAGEMENT; MORPHINE; RECOMMENDATIONS	In patients with active cancer, the management of chronic pain is an essential element in a comprehensive strategy for palliative care. This strategy emphasises multidimensional assessment and the coordinated use of treatments that together mitigate suffering and provide support to the patient and family. This review describes this framework, an approach to pain assessment, and widely accepted techniques to optimise the safety and effectiveness of opioid drugs and other treatments. The advances of recent decades suggest a future that includes increased evidence-based targeting of specific analgesic interventions within an individualised plan of care that is appropriate throughout the course of illness.	[Portenoy, Russell K.] Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA; [Portenoy, Russell K.] Albert Einstein Coll Med, New York, NY USA; [Portenoy, Russell K.] MJHS Hosp & Palliat Care, New York, NY USA	Harvard University; Beth Israel Deaconess Medical Center; Yeshiva University	Portenoy, RK (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pain Med & Palliat Care, New York, NY 10003 USA.	rporteno@chpnet.org			CNSBio; Covidien Mallinckrodt; Grupo Ferrer; King Pharmaceuticals; ProStrakan Pharmaceuticals; Purdue Pharrna; Abbott Laboratories; Ameritox; Archimedes Pharmaceuticals; Cephalon; Endo Pharmaceuticals; Forest Laboratories; GW Pharma; Meda Pharmaceuticals; Ortho-McNeil Janssen; Otsuka Pharma; Purdue Pharma; Tempur-Pedic Corp.	CNSBio; Covidien Mallinckrodt; Grupo Ferrer; King Pharmaceuticals; ProStrakan Pharmaceuticals; Purdue Pharrna; Abbott Laboratories(Abbott Laboratories); Ameritox; Archimedes Pharmaceuticals; Cephalon; Endo Pharmaceuticals; Forest Laboratories; GW Pharma; Meda Pharmaceuticals; Ortho-McNeil Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Otsuka Pharma(Otsuka Pharmaceutical); Purdue Pharma; Tempur-Pedic Corp.	I have received consultancy fees from CNSBio, Covidien Mallinckrodt, Grupo Ferrer, King Pharmaceuticals, ProStrakan Pharmaceuticals, and Purdue Pharrna, speakers' fees from Grupo Ferrer, and grants from Abbott Laboratories, Ameritox, Archimedes Pharmaceuticals, Cephalon, Covidien Mallinckrodt, Endo Pharmaceuticals, Forest Laboratories, GW Pharma, King Pharmaceuticals, Meda Pharmaceuticals, Ortho-McNeil Janssen, Otsuka Pharma, Purdue Pharma, and Tempur-Pedic Corp.	American Pain Society, 2008, PRINC AN US TREATM A; Bannister Kirsty, 2010, Curr Opin Support Palliat Care, V4, P1, DOI 10.1097/SPC.0b013e328335ddfe; Bardia A, 2006, J CLIN ONCOL, V24, P5457, DOI 10.1200/JCO.2006.08.3725; Becker G, 2007, J PAIN SYMPTOM MANAG, V34, P547, DOI 10.1016/j.jpainsymman.2006.12.018; Bennett GJ, 2010, ONCOLOGIST, V15, P9, DOI 10.1634/theoncologist.2009-S503; Brogan Shane, 2010, J Support Oncol, V8, P52; Bruera E, 2004, J CLIN ONCOL, V22, P185, DOI 10.1200/JCO.2004.03.172; Bryson John, 2006, Curr Oncol Rep, V8, P282, DOI 10.1007/s11912-006-0034-4; Caraceni A, 1999, PAIN, V82, P263, DOI 10.1016/S0304-3959(99)00073-1; Cassileth BR, 2010, ONCOLOGIST, V15, P19, DOI 10.1634/theoncologist.2009-S504; Chan FKL, 2008, AM J GASTROENTEROL, V103, P2908, DOI 10.1111/j.1572-0241.2008.02200.x; Chen YF, 2008, HEALTH TECHNOL ASSES, V12, P1, DOI 10.3310/hta12110; Cherny NI, 2010, ANN ONCOL, V21, P615, DOI 10.1093/annonc/mdp581; Chu LF, 2008, CLIN J PAIN, V24, P479, DOI 10.1097/AJP.0b013e31816b2f43; Coluzzi PH, 2001, PAIN, V91, P123, DOI 10.1016/S0304-3959(00)00427-9; Cormie PJ, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2154; Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323; Cruciani RA, 2005, J PAIN SYMPTOM MANAG, V29, P385, DOI 10.1016/j.jpainsymman.2004.06.012; De Lima MHAL, 2001, HEALTH POLICY, V56, P99, DOI 10.1016/S0168-8510(00)00130-5; Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419; Dy SM, 2008, J CLIN ONCOL, V26, P3879, DOI 10.1200/JCO.2007.15.9517; Fainsinger RL, 2005, J PAIN SYMPTOM MANAG, V29, P224, DOI 10.1016/j.jpainsymman.2004.05.008; Falkmer U, 2003, ACTA ONCOL, V42, P620, DOI 10.1080/02841860310014895; Ferris FD, 2009, J CLIN ONCOL, V27, P3052, DOI 10.1200/JCO.2008.20.1558; Fine PG, 2009, J PAIN SYMPTOM MANAG, V38, P418, DOI 10.1016/j.jpainsymman.2009.06.002; Goudas LC, 2005, CANCER INVEST, V23, P182, DOI 10.1081/CNV-200050482; Green E, 2010, CLIN J PAIN, V26, P449, DOI 10.1097/AJP.0b013e3181dacd62; Grossman SA, 2000, ONCOLOGY-NY, V14, P135; Hjermstad Marianne J, 2009, Curr Opin Support Palliat Care, V3, P24, DOI 10.1097/SPC.0b013e3283260644; Holzer Peter, 2009, J Opioid Manag, V5, P145; Jimenez-Andrade JM, 2010, ANN NY ACAD SCI, V1198, P173, DOI 10.1111/j.1749-6632.2009.05429.x; Johnson C, 2010, EUR J CANCER, V46, P2242, DOI 10.1016/j.ejca.2010.04.014; Jost L, 2008, ANN ONCOL, V19, P119, DOI 10.1093/annonc/mdn108; Katz NP, 2007, CLIN J PAIN, V23, P103, DOI 10.1097/01.ajp.0000210953.86255.8f; Klepstad P, 2003, ACTA ANAESTH SCAND, V47, P725, DOI 10.1034/j.1399-6576.2003.00138.x; Knotkova H, 2009, J PAIN SYMPTOM MANAG, V38, P426, DOI 10.1016/j.jpainsymman.2009.06.001; Krakowski I, 2003, BRIT J CANCER, V89, pS67, DOI 10.1038/sj.bjc.6601086; Kwekkeboom KL, 2010, J PAIN SYMPTOM MANAG, V39, P126, DOI 10.1016/j.jpainsymman.2009.05.022; Lotsch J, 2009, PAIN, V144, P119, DOI 10.1016/j.pain.2009.03.023; Lussier D, 2010, OXFORD TXB PALLIATIV, P706; Maltoni M, 2005, SUPPORT CARE CANCER, V13, P888, DOI 10.1007/s00520-005-0807-6; McNicol E, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005180; Mercadante S, 2008, EUR J PAIN, V12, P1040, DOI 10.1016/j.ejpain.2008.01.013; Mercadante S, 2007, J PAIN SYMPTOM MANAG, V33, P217, DOI 10.1016/j.jpainsymman.2006.06.014; Modesto-Lowe V, 2010, J GEN INTERN MED, V25, P305, DOI 10.1007/s11606-009-1225-0; Moore RA, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471-2474-8-73; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Oldenmenger WH, 2009, EUR J CANCER, V45, P1370, DOI 10.1016/j.ejca.2009.01.007; Portenoy RK, 2011, SUBSTANCE ABUSE COMP, P695; Rhodin A, 2010, CLIN J PAIN, V26, P374, DOI 10.1097/AJP.0b013e3181d1059d; Sandoval JA, 2005, CLIN J PAIN, V21, P503, DOI 10.1097/01.ajp.0000146165.15529.50; Ferreira KAS, 2006, SUPPORT CARE CANCER, V14, P1086, DOI 10.1007/s00520-006-0086-x; Savage SR, 2003, J PAIN SYMPTOM MANAG, V26, P655, DOI 10.1016/S0885-3924(03)00219-7; Schneider JP, 2010, CNS DRUGS, V24, P805, DOI 10.2165/11584260-000000000-00000; Sloan Paul A, 2007, Curr Pain Headache Rep, V11, P283, DOI 10.1007/s11916-007-0205-5; Smith TJ, 2002, J CLIN ONCOL, V20, P4040, DOI 10.1200/JCO.2002.02.118; Stone P, 2011, PALLIATIVE MED, V25, P431, DOI 10.1177/0269216310380763; Tanvetyanon T, 2007, J THORAC ONCOL, V2, P1091, DOI 10.1097/JTO.0b013e31815cff64; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678; Trescot AM, 2010, J NATL COMPR CANC NE, V8, P1087, DOI 10.6004/jnccn.2010.0077; Walker JM, 2007, J CLIN SLEEP MED, V3, P455; Wilcock A, 2006, PALLIATIVE MED, V20, P661, DOI 10.1177/0269216306070755; World Health Organization, 1996, CANC PAIN REL; Zeppetella Giovambattista, 2009, Curr Opin Support Palliat Care, V3, P1, DOI 10.1097/SPC.0b013e3283260658	64	308	324	2	54	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN-JUL	2011	377	9784					2236	2247		10.1016/S0140-6736(11)60236-5	http://dx.doi.org/10.1016/S0140-6736(11)60236-5			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	786XI	21704873				2023-01-03	WOS:000292340800036
J	Sestak, K; Conroy, L; Aye, PP; Mehra, S; Doxiadis, GG; Kaushal, D				Sestak, Karol; Conroy, Lauren; Aye, Pyone P.; Mehra, Smriti; Doxiadis, Gaby G.; Kaushal, Deepak			Improved Xenobiotic Metabolism and Reduced Susceptibility to Cancer in Gluten-Sensitive Macaques upon Introduction of a Gluten-Free Diet	PLOS ONE			English	Article							CELIAC-DISEASE; TISSUE TRANSGLUTAMINASE; RHESUS MACAQUES; SPRUE; NOMENCLATURE; ANTIBODIES; SPECTRUM; HUMANS	Background: A non-human primate (NHP) model of gluten sensitivity was employed to study the gene perturbations associated with dietary gluten changes in small intestinal tissues from gluten-sensitive rhesus macaques (Macacamulatta). Methodology: Stages of remission and relapse were accomplished in gluten-sensitive animals by administration of glutenfree (GFD) and gluten-containing (GD) diets, as described previously. Pin-head-sized biopsies, obtained non-invasively by pediatric endoscope from duodenum while on GFD or GD, were used for preparation of total RNA and gene profiling, using the commercialRhesus Macaque Microarray (Agilent Technologies), targetingexpression of over 20,000 genes. Principal Findings: When compared with normal healthy control, gluten-sensitive macaques showed differential gene expressions induced by GD. While observed gene perturbations were classified into one of 12 overlapping categories cancer, metabolism, digestive tract function, immune response, cell growth, signal transduction, autoimmunity, detoxification of xenobiotics, apoptosis, actin-collagen deposition, neuronal and unknown function - this study focused on cancer-related gene networks such as cytochrome P450 family (detoxification function) and actin-collagen-matrix metalloproteinases (MMP) genes. Conclusions/Significance: A loss of detoxification function paralleled with necessity to metabolize carcinogens was revealed in gluten sensitive animals while on GD. An increase in cancer-promoting factors and a simultaneous decrease in cancer-preventing factors associated with altered expression of actin-collagen-MMP gene network were noted. In addition, gluten-sensitive macaques showed reduced number of differentially expressed genes including the cancer-associated ones upon withdrawal of dietary gluten. Taken together, these findings indicate potentially expanded utility of gluten-sensitive rhesus macaques in cancer research.	[Sestak, Karol; Conroy, Lauren] Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA; [Sestak, Karol; Kaushal, Deepak] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA; [Aye, Pyone P.] Tulane Natl Primate Res Ctr, Div Comparat Pathol, Covington, LA USA; [Mehra, Smriti] Tulane Natl Primate Res Ctr, Div Bacteriol & Parasitol, DNA Microarray & Express Core, Covington, LA USA; [Doxiadis, Gaby G.] Biomed Primate Res Ctr, Rijswijk, Netherlands	Tulane University; Tulane University; Tulane University; Tulane University	Sestak, K (corresponding author), Tulane Natl Primate Res Ctr, Div Microbiol, Covington, LA 70433 USA.	ksestak@tulane.edu			National Institutes of Health [R01DK076653, 3R01DK076653]; TNPRC [RR000164]; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076653] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); TNPRC; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by National Institutes of Health grants R01DK076653 and 3R01DK076653 to KS and the base operating grant of the TNPRC RR000164. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barcia G, 2008, J AUTISM DEV DISORD, V38, P407, DOI 10.1007/s10803-007-0480-3; Bethune MT, 2009, CHEM BIOL, V16, P868, DOI 10.1016/j.chembiol.2009.07.009; Bethune MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001614; Bethune MT, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001857; Bontrop RE, 2006, HUM IMMUNOL, V67, P388, DOI 10.1016/j.humimm.2006.03.007; Brandtzaeg P, 2006, IMMUNOL LETT, V105, P127, DOI 10.1016/j.imlet.2006.03.004; Cerqueira RM, 2010, EUR J GASTROEN HEPAT, V22, P868, DOI 10.1097/MEG.0b013e3283328341; Doxiadis GGM, 2007, P NATL ACAD SCI USA, V104, P8907, DOI 10.1073/pnas.0702964104; Doxiadis GGM, 2003, IMMUNOGENETICS, V55, P540, DOI 10.1007/s00251-003-0590-9; Doxiadis GGM, 2001, IMMUNOL REV, V183, P76, DOI 10.1034/j.1600-065x.2001.1830106.x; Ellis SA, 2006, IMMUNOGENETICS, V57, P953, DOI 10.1007/s00251-005-0071-4; FERRERI AJ, 2010, CRIT REV ON IN PRESS; Green PHR, 2007, NEW ENGL J MED, V357, P1731, DOI 10.1056/NEJMra071600; Guillen-Ahlers H, 2008, CARCINOGENESIS, V29, P1421, DOI 10.1093/carcin/bgn123; Jabri B, 2005, IMMUNOL REV, V206, P219, DOI 10.1111/j.0105-2896.2005.00294.x; Johnson TN, 2001, BRIT J CLIN PHARMACO, V51, P451, DOI 10.1046/j.1365-2125.2001.01370.x; Korponay-Szabo IR, 2000, J PEDIATR GASTR NUTR, V31, P520, DOI 10.1097/00005176-200011000-00013; Lang CC, 1996, CLIN PHARMACOL THER, V59, P41, DOI 10.1016/S0009-9236(96)90022-3; Lombardo Mauro, 2008, Cases J, V1, P159, DOI 10.1186/1757-1626-1-159; MARSH MN, 1992, GASTROENTEROLOGY, V102, P330, DOI 10.1016/0016-5085(92)91819-P; Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291, DOI 10.1111/j.1399-0039.2010.01466.x; Mazumdar K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010228; Mehra S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012266; MULDER CJJ, 1993, GUT, V34, P1740, DOI 10.1136/gut.34.12.1740; Myers TA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000659; Rubio-Tapia A, 2010, CURR OPIN GASTROEN, V26, P116, DOI 10.1097/MOG.0b013e3283365263; Schumann M, 2008, GUT, V57, P747, DOI 10.1136/gut.2007.136366; Schuppan D, 2009, GASTROENTEROLOGY, V137, P1912, DOI 10.1053/j.gastro.2009.09.008; Shamaly H, 2007, J PEDIATR GASTR NUTR, V44, P583, DOI 10.1097/MPG.0b013e3180320679; Simell S, 2010, DIABETES CARE, V33, P774, DOI 10.2337/dc09-1217; Sollid LM, 2006, NAT MED, V12, P611, DOI 10.1038/nm0606-611; Tjon JML, 2010, IMMUNOGENETICS, V62, P641, DOI 10.1007/s00251-010-0465-9	32	10	10	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 12	2011	6	4							e18648	10.1371/journal.pone.0018648	http://dx.doi.org/10.1371/journal.pone.0018648			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	748QE	21533263	gold, Green Published, Green Submitted			2023-01-03	WOS:000289404700025
J	Gott, M; Ingleton, C; Bennett, MI; Gardiner, C				Gott, Merryn; Ingleton, Christine; Bennett, Michael I.; Gardiner, Clare			Transitions to palliative care in acute hospitals in England: qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OF-LIFE CARE; HEART-FAILURE; CANCER; END; SPOTLIGHT; PEOPLE	Objective To explore how transitions to a palliative care approach are perceived to be managed in acute hospital settings in England. Design Qualitative study. Setting Secondary or primary care settings in two contrasting areas of England. Participants 58 health professionals involved in the provision of palliative care in secondary or primary care. Results Participants identified that a structured transition to a palliative care approach of the type advocated in UK policy guidance is seldom evident in acute hospital settings. In particular they reported that prognosis is not routinely discussed with inpatients. Achieving consensus among the clinical team about transition to palliative care was seen as fundamental to the transition being effected; however, this was thought to be insufficiently achieved in practice. Secondary care professionals reported that discussions about adopting a palliative care approach to patient management were not often held with patients; primary care professionals confirmed that patients were often discharged from hospital with "false hope" of cure because this information had not been conveyed. Key barriers to ensuring a smooth transition to palliative care included the difficulty of "standing back" in an acute hospital situation, professional hierarchies that limited the ability of junior medical and nursing staff to input into decisions on care, and poor communication. Conclusion Significant barriers to implementing a policy of structured transitions to palliative care in acute hospitals were identified by health professionals in both primary and secondary care. These need to be addressed if current UK policy on management of palliative care in acute hospitals is to be established.	[Gott, Merryn] Univ Auckland, Fac Med & Hlth Sci, Sch Nursing, Auckland 1, New Zealand; [Ingleton, Christine] Univ Sheffield, No Gen Hosp, Sch Nursing & Midwifery, Sheffield S10 2TN, S Yorkshire, England; [Bennett, Michael I.] Univ Lancaster, Sch Hlth & Med, Int Observ End Life Care, Lancaster LA1 4YW, England; [Gardiner, Clare] Univ Sheffield, St Lukes Hosp, Sch Nursing & Midwifery, Sheffield S10 2TN, S Yorkshire, England	University of Auckland; Northern General Hospital; University of Sheffield; Lancaster University; University of Sheffield	Gott, M (corresponding author), Univ Auckland, Fac Med & Hlth Sci, Sch Nursing, Auckland 1, New Zealand.	m.gott@auckland.ac.nz	Harding, Richard/G-9729-2012; Bennett, Michael I/A-1620-2009	Bennett, Michael I/0000-0002-8369-8349; Gott, Merryn/0000-0003-4399-962X; Gardiner, Clare/0000-0003-1785-7054	National Institute of Health Research; National Institute for Health Research [08/1809/233] Funding Source: researchfish	National Institute of Health Research(National Institute for Health Research (NIHR)); National Institute for Health Research(National Institute for Health Research (NIHR))	The study was funded by the National Institute of Health Research under the Service Delivery and Organisation programme. The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the Department of Health. All authors declare independence from the study funders.	Barclay S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4862; Barnes S, 2006, HEALTH SOC CARE COMM, V14, P482, DOI 10.1111/j.1365-2524.2006.00636.x; Bell D, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c3231; Bennett MI, 2010, PALLIATIVE MED, V24, P456, DOI 10.1177/0269216310366064; Boyd K, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4863; Burt R. S., 2005, BROKERAGE CLOSURE IN; Department of Health, 2008, END LIF CAR STRAT EN; Department of Health, 2010, ROUT SUCC END LIF CA; Doug M, 2009, ARCH DIS CHILD; General Medical Council, 2010, TREATM CAR END LIF G; Gold Standards Framework, 2010, GSF AC HOSP; Gomes B, 2008, PALLIATIVE MED, V22, P33, DOI 10.1177/0269216307084606; Gott M, 2009, PALLIATIVE MED, V23, P642, DOI 10.1177/0269216309106790; Gott M, 2007, PALLIATIVE MED, V21, P95, DOI 10.1177/0269216307076348; Grande G, 2009, PALLIATIVE MED, V23, P187, DOI 10.1177/0269216309102697; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Morgan D. L., 1997, FOCUS GROUPS QUALITA, V16; Murray SA, 2008, BRIT MED J, V336, P958, DOI 10.1136/bmj.39535.491238.94; National Audit Office, 2008, END LIF CAR; O'Leary N, 2009, EUR J HEART FAIL, V11, P406, DOI 10.1093/eurjhf/hfp007; Schofield P, 2006, PALLIATIVE MED, V20, P397, DOI 10.1191/0269216306pm1156oa; Selman L, 2007, HEART, V93, P963, DOI 10.1136/hrt.2006.106518; Seymour J, 2011, LIVING AGEING DYING; The Gold Standards Framework, 2010, GSF PROGN IND GUID; van Walraven C, 2004, J GEN INTERN MED, V19, P624, DOI 10.1111/j.1525-1497.2004.30082.x	25	91	91	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2011	342								d1773	10.1136/bmj.d1773	http://dx.doi.org/10.1136/bmj.d1773			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	745WE	21447572	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000289200800004
J	Tan, T; Shaw, EJ; Siddiqui, F; Kandaswamy, P; Barry, PW; Baker, M				Tan, T.; Shaw, E. J.; Siddiqui, F.; Kandaswamy, P.; Barry, P. W.; Baker, M.		Guideline Dev Grp	Guidelines Inpatient management of diabetic foot problems: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material												pwb1@leicester.ac.uk						Diabetes UK, 2009, PUTT FEET 1 COMM SPE; *NAT I HLTH CLIN E, 2011, CLIN GUID NAT I HLTH, V114; *NAT I HLTH CLIN E, 2011, CLIN GUID NAT I HLTH, V119; *NAT I HLTH CLIN E, 2008, CLIN GUID NAT I HLTH, V73; *NAT I HLTH CLIN E, 2004, CLIN GUID NAT I HLTH, V10; Reiber GE, 1999, DIABETES CARE, V22, P157, DOI 10.2337/diacare.22.1.157	6	19	25	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2011	342								d1280	10.1136/bmj.d1280	http://dx.doi.org/10.1136/bmj.d1280			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742MJ	21430002				2023-01-03	WOS:000288948000014
J	Hancock, CR; Han, DH; Higashida, K; Kim, SH; Holloszy, JO				Hancock, Chad R.; Han, Dong-Ho; Higashida, Kazuhiko; Kim, Sang Hyun; Holloszy, John O.			Does calorie restriction induce mitochondrial biogenesis? A reevaluation	FASEB JOURNAL			English	Article						aging; citrate synthase; cytochrome c; PGC-1 alpha	TRANSCRIPTIONAL COACTIVATOR PGC-1; RAT SKELETAL-MUSCLE; OXIDATIVE DAMAGE; GLUCOSE-TRANSPORT; GENE-EXPRESSION; PPAR-DELTA; AGE; METABOLISM; SARCOPENIA; INCREASE	It has been reported that 30% calorie restriction (CR) for 3 mo results in large increases in mitochondrial biogenesis in heart, brain, liver, and adipose tissue, with concomitant increases in respiration and ATP synthesis. We found these results surprising, and performed this study to determine whether 30% CR does induce an increase in mitochondria in heart, brain, liver, adipose tissue, and/or skeletal muscle. To this end, we measured the levels of a range of mitochondrial proteins, and mRNAs. With the exception of long-chain acyl-CoA dehydrogenase protein level, which was increased similar to 60% in adipose tissue, none of the mitochondrial proteins or mRNAs that we measured were increased in rats subjected to 30% CR for 14 wk. There was also no increase in citrate synthase activity. Because it is not possible to have an increase in mitochondria without any increase in key mitochondrial proteins, we conclude that 30% CR does not induce an increase in mitochondria in heart, brain, liver, adipose tissue, or skeletal muscle in laboratory rodents.-Hancock, C. R., Han, D.-H., Higashida, K., Kim, S. H., Holloszy, J. O. Does calorie restriction induce mitochondrial biogenesis? A reevaluation. FASEB J. 25, 785-791 (2011). www.fasebj.org	[Hancock, Chad R.; Han, Dong-Ho; Higashida, Kazuhiko; Kim, Sang Hyun; Holloszy, John O.] Washington Univ, Sch Med, Div Geriatr & Nutr Sci, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Div Geriatr & Nutr Sci, Dept Med, 4566 Scott Ave,Campus Box 8113, St Louis, MO 63110 USA.	jhollosz@dom.wustl.edu	Hancock, Chad R./X-4803-2018	Hancock, Chad R./0000-0002-1578-5301	U.S. National Institutes of Health [AG00425]; American Diabetes Association; Individual National Research Service Award [DK076410]; Japan Society for the Promotion of Science; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK076410, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG000425, R56AG000425, R37AG000425, Z01AG000425] Funding Source: NIH RePORTER	U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); Individual National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	The authors thank Iheoma Nwaogu and Jamie Votava for their technical assistance. This research was supported by U.S. National Institutes of Health grant AG00425. C. R. H. was supported by an American Diabetes Association-based post-doctoral fellowship initially and then by Individual National Research Service Award DK076410. K. H. was supported by a Research Fellow of the Japan Society for the Promotion of Science grant.	Baar K, 2003, FASEB J, V17, P1666, DOI 10.1096/fj.03-0049com; Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Baker DJ, 2006, J GERONTOL A-BIOL, V61, P675, DOI 10.1093/gerona/61.7.675; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; Barish GD, 2006, J CLIN INVEST, V116, P590, DOI 10.1172/JCI27955; BOOTH FW, 1997, HDB PHYSL 12, P1075; Cao WH, 2004, MOL CELL BIOL, V24, P3057, DOI 10.1128/MCB.24.7.3057-3067.2004; CARTIER LJ, 1986, J BIOL CHEM, V261, P3827; Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076; CONSTABLE SH, 1987, AM J PHYSIOL, V253, pC316, DOI 10.1152/ajpcell.1987.253.2.C316; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Garcia-Roves P, 2007, P NATL ACAD SCI USA, V104, P10709, DOI 10.1073/pnas.0704024104; Guarente L, 2008, CELL, V132, P171, DOI 10.1016/j.cell.2008.01.007; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831; Huang JH, 2009, IUBMB LIFE, V61, P201, DOI 10.1002/iub.164; Judge S, 2007, AM J PHYSIOL-CELL PH, V292, pC1983, DOI 10.1152/ajpcell.00285.2006; Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604; Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778; Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marzetti E, 2010, BBA-GEN SUBJECTS, V1800, P235, DOI 10.1016/j.bbagen.2009.05.007; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; McKiernan SH, 2007, AM J PHYSIOL-RENAL, V292, pF1751, DOI 10.1152/ajprenal.00307.2006; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Mulligan JD, 2008, EXP GERONTOL, V43, P146, DOI 10.1016/j.exger.2007.10.011; Nisoli E, 2005, SCIENCE, V310, P314, DOI 10.1126/science.1117728; Otani K, 2004, J BIOL CHEM, V279, P20915, DOI 10.1074/jbc.M400213200; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rabol R, 2009, METABOLISM, V58, P1145, DOI 10.1016/j.metabol.2009.03.014; Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB; Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Srere P.A., 1969, METHODS ENZYMOLOGY, V13, P3, DOI [10.1016/0076-6879(69)13005-0, DOI 10.1016/0076-6879(69)13005-0]; Taffet GE, 1997, J GERONTOL A-BIOL, V52, pB285, DOI 10.1093/gerona/52A.6.B285; Terada S, 2006, AM J PHYSIOL-ENDOC M, V290, pE607, DOI 10.1152/ajpendo.00430.2005; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Wang YX, 2003, CELL, V113, P159, DOI 10.1016/S0092-8674(03)00269-1; Ward WF, 2005, J GERONTOL A-BIOL, V60, P847, DOI 10.1093/gerona/60.7.847; WINDER WW, 1979, AM J PHYSIOL, V236, pC132, DOI 10.1152/ajpcell.1979.236.3.C132	45	101	104	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2011	25	2					785	791		10.1096/fj.10-170415	http://dx.doi.org/10.1096/fj.10-170415			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	713GZ	21048043	Green Published			2023-01-03	WOS:000286724800035
J	Vann, RD; Butler, FK; Mitchell, SJ; Moon, RE				Vann, Richard D.; Butler, Frank K.; Mitchell, Simon J.; Moon, Richard E.			Decompression illness	LANCET			English	Article							PATENT FORAMEN OVALE; ARTERIAL GAS EMBOLISM; TO-LEFT SHUNT; HYPERBARIC-OXYGEN THERAPY; INNER-EAR; BUBBLE FORMATION; PULMONARY-EDEMA; AIR-EMBOLISM; SCUBA-DIVERS; CEREBRAL PROTECTION	Decompression illness is caused by intravascular or extravascular bubbles that are formed as a result of reduction in environmental pressure (decompression). The term covers both arterial gas embolism, in which alveolar gas or venous gas emboli (via cardiac shunts or via pulmonary vessels) are introduced into the arterial circulation, and decompression sickness, which is caused by in-situ bubble formation from dissolved inert gas. Both syndromes can occur in divers, compressed air workers, aviators, and astronauts, but arterial gas embolism also arises from iatrogenic causes unrelated to decompression. Risk of decompression illness is affected by immersion, exercise, and heat or cold. Manifestations range From itching and minor pain to neurological symptoms, cardiac collapse, and death. First-aid treatment is 100% oxygen and definitive treatment is recompression to increased pressure, breathing 100% oxygen. Adjunctive treatment, including fluid administration and prophylaxis against venous thromboembolism in paralysed patients, is also recommended. Treatment is, in most cases, effective although residual deficits can remain in serious cases, even after several recompressions.	[Vann, Richard D.; Moon, Richard E.] Duke Univ, Med Ctr, Ctr Hyperbar Med & Environm Physiol, Durham, NC 27710 USA; [Vann, Richard D.; Moon, Richard E.] Duke Univ, Med Ctr, Dept Anesthesiol, Durham, NC 27710 USA; [Butler, Frank K.] USA, Inst Surg Res, San Antonio, TX USA; [Mitchell, Simon J.] Univ Auckland, Dept Anaesthesiol, Auckland 1, New Zealand	Duke University; Duke University; University of Auckland	Vann, RD (corresponding author), Duke Univ, Med Ctr, Ctr Hyperbar Med & Environm Physiol, Box 3823, Durham, NC 27710 USA.	richard.vann@duke.edu	Moon, Richard/AAF-2170-2019	Moon, Richard/0000-0003-4432-0332; Mitchell, Simon/0000-0002-5149-6371	US Navy; Divers Alert Network	US Navy(United States Department of Defense); Divers Alert Network	The authors received no revenue in support for this manuscript. RDV and REM received research grant funding from the US Navy. A portion of RDV's salary is paid by the Divers Alert Network. All other authors declare that they have no conflicts of interest.	ACOTT CJ, 1992, ANAESTH INTENS CARE, V20, P249; Adir Y, 2004, CHEST, V126, P394, DOI 10.1378/chest.126.2.394; BALL R, 1993, UNDERSEA HYPERBAR M, V20, P133; BALLDIN UI, 1972, AEROSPACE MED, V43, P1101; BALLDIN UI, 1971, AEROSPACE MED, V42, P489; BARRY PD, 1984, UNDERSEA BIOMED RES, V11, P387; BASON R, 1991, AVIAT SPACE ENVIR MD, V62, P994; BASON R, 1991, AVIAT SPACE ENVIR MD, V62, P1180; Bendrick GA, 1996, AVIAT SPACE ENVIR MD, V67, P199; Bennell P., 1989, Proceedings of the SACCAR/ISNAR regional workshop on human resource management in National Agricultural Research Systems., P29; Bennett M, 2003, UNDERSEA HYPERBAR M, V30, P195; Bennett M., 2005, MANAGEMENT MIND MARG, P125; Bennett MH, 2007, COCHRANE DB SYST REV, V2; Benson J, 2003, UNDERSEA HYPERBAR M, V30, P117; Benton PJ, 1996, AVIAT SPACE ENVIR MD, V67, P63; Berghage T.E.D., 1980, US NAVY AIR DECOMPRE; Blatteau JE, 2005, AVIAT SPACE ENVIR MD, V76, P666; Blatteau JE, 2007, BRIT J SPORT MED, V41, P375, DOI 10.1136/bjsm.2006.032359; BOND JG, 1990, AVIAT SPACE ENVIR MD, V61, P738; Bosco G, 2001, UNDERSEA HYPERBAR M, V28, P207; Boussuges A, 1996, INT J SPORTS MED, V17, P351, DOI 10.1055/s-2007-972859; Boussuges A, 1996, UNDERSEA HYPERBAR M, V23, P151; Bove AA, 1998, UNDERSEA HYPERBAR M, V25, P175; Boycott AE, 1908, J HYG-CAMBRIDGE, V8, P342, DOI 10.1017/S0022172400003399; Brouns R, 2009, CLIN NEUROL NEUROSUR, V111, P483, DOI 10.1016/j.clineuro.2009.04.001; BRUNNER FP, 1964, LANCET, V1, P1071; BUTLER FK, 1986, ANN EMERG MED, V15, P738, DOI 10.1016/S0196-0644(86)80439-5; BUTLER FK, 1991, AVIAT SPACE ENVIR MD, V62, P346; Butler FK, 1999, UNDERSEA HYPERBAR M, V26, P257; Butler FK, 2001, UNDERSEA HYPERBAR M, V28, P31; Cantais E, 2003, CRIT CARE MED, V31, P84, DOI 10.1097/00003246-200301000-00013; Cianci P, 2006, AVIAT SPACE ENVIR MD, V77, P1003; Cooper PD, 2009, DIVING HYPERB MED, V39, P71; Dainer H, 2007, J APPL PHYSIOL, V102, P1099, DOI 10.1152/japplphysiol.01539.2005; DICK APK, 1985, NEUROLOGY, V35, P667, DOI 10.1212/WNL.35.5.667; Doolette DJ, 2004, SPUMS J, V34, P63; Doolette DJ, 2005, MANAGEMENT MILD MARG, P10; Dowse MS, 2002, AVIAT SPACE ENVIR MD, V73, P743; Dromsky DM, 2003, AVIAT SPACE ENVIR MD, V74, P21; Dujic E, 2004, J PHYSIOL-LONDON, V555, P637, DOI 10.1113/jphysiol.2003.059360; Dujic Z, 2006, AVIAT SPACE ENVIR MD, V77, P592; Dujic Z, 2008, EXERC SPORT SCI REV, V36, P38, DOI 10.1097/jes.0b013e31815ddb02; Dunford RG, 2002, UNDERSEA HYPERBAR M, V29, P247; EASTAUGH J, 1989, ARCH INTERN MED, V149, P1735, DOI 10.1001/archinte.149.8.1735; ECKENHOFF RG, 1990, J APPL PHYSIOL, V69, P914, DOI 10.1152/jappl.1990.69.3.914; Fahlman A, 2006, AVIAT SPACE ENVIR MD, V77, P102; FARMER JC, 1977, ANN OTO RHINOL LARYN, V86, P1; Flynn ET, 2004, BOVE DAVIS DIVING ME, P343; FRANCIS TJR, 1988, UNDERSEA BIOMED RES, V15, P403; Francis TJR, 1991, DESCRIBING DECOMPRES; Francis TJR, 2003, BENNETT ELLIOTTS PHY, V5th, P578; Freiberger JJ, 2004, AVIAT SPACE ENVIR MD, V75, P1023; Freiberger JJ, 2002, AVIAT SPACE ENVIR MD, V73, P980; Gempp E, 2009, BRIT J SPORT MED, V43, P224, DOI 10.1136/bjsm.2007.043240; Gempp E, 2009, INT J SPORTS MED, V30, P150, DOI 10.1055/s-2008-1038844; Gempp E, 2010, J CRIT CARE, V25, P236, DOI 10.1016/j.jcrc.2009.05.011; Gempp E, 2009, CLIN J SPORT MED, V19, P512, DOI 10.1097/JSM.0b013e3181bd1df9; Gempp E, 2008, AVIAT SPACE ENVIR MD, V79, P1112, DOI 10.3357/ASEM.2376.2008; Germonpre P, 1998, J APPL PHYSIOL, V84, P1622, DOI 10.1152/jappl.1998.84.5.1622; Gerth WA, 2007, TR0607 NEDU; GOLDING F C, 1960, Br J Ind Med, V17, P167; Gorman DF, 1987, UNDERWAWTER HYPERBAR, P1031; Grover I, 2007, UNDERSEA HYPERBAR M, V34, P199; HAGEN PT, 1984, MAYO CLIN PROC, V59, P17, DOI 10.1016/S0025-6196(12)60336-X; Hampson NB, 1997, UNDERSEA HYPERBAR M, V24, P29; Harrah JD, 2008, UNDERSEA HYPERBAR M, V35, P207; Holley T., 2000, SPUMS J, V30, P75; Howle LE, 2009, J APPL PHYSIOL, V107, P1539, DOI 10.1152/japplphysiol.00185.2009; HYLDEGAARD O, 1991, UNDERSEA BIOMED RES, V18, P361; Ito M, 1999, AVIAT SPACE ENVIR MD, V70, P141; Jallul S, 2007, SPINAL CORD, V45, P116, DOI 10.1038/sj.sc.3101923; Jersey SL, 2010, AVIAT SPACE ENVIR MD, V81, P64, DOI 10.3357/ASEM.2303.2010; Kelleher PC, 1996, AVIAT SPACE ENVIR MD, V67, P654; Kerut EK, 2001, J AM COLL CARDIOL, V38, P613, DOI 10.1016/S0735-1097(01)01427-9; KIZER KW, 1982, JAMA-J AM MED ASSOC, V247, P2555, DOI 10.1001/jama.247.18.2555; Klingmann C, 2003, LARYNGOSCOPE, V113, P1356, DOI 10.1097/00005537-200308000-00017; Klingmann C, 2007, OTOL NEUROTOL, V28, P447, DOI 10.1097/MAO.0b013e318030d356; Krause KM, 2000, AVIAT SPACE ENVIR MD, V71, P115; Ladd G, 2002, S PACIFIC UNDERW MED, V32, P124; LEITCH DR, 1985, UNDERSEA BIOMED RES, V12, P291; LEITCH DR, 1984, UNDERSEA BIOMED RES, V11, P221; Longphre JM, 2007, UNDERSEA HYPERBAR M, V34, P43; LOWE VJ, 1994, UNDERSEA HYPERBAR M, V21, P103; Martin JD, 2002, AVIAT SPACE ENVIR MD, V73, P565; Mathew JP, 2009, STROKE, V40, P880, DOI 10.1161/STROKEAHA.108.531236; MELLEM H, 1990, AVIAT SPACE ENVIR MD, V61, P559; Mitchell SJ, 2009, ANN THORAC SURG, V87, P820, DOI 10.1016/j.athoracsur.2008.12.042; Mitchell SJ, 2009, J APPL PHYSIOL, V106, P298, DOI 10.1152/japplphysiol.90915.2008; Mitchell SJ, 1999, ANN THORAC SURG, V67, P1117, DOI 10.1016/S0003-4975(99)00057-0; Mitchell SJ, 2001, UNDERSEA HYPERBAR M, V28, P165; Mitchell SJ, 2009, TECHN DIV P DIV AL N, P178; Mitchell SJ, 1998, SPUMS J, V28, P89; Mitchell SJ., 2005, MANAGEMENT MILD MARG; MOLVAER OI, 1988, UNDERSEA BIOMED RES, V15, P271; MOON RE, 1989, LANCET, V1, P513; Moon RE, 2004, UNDERSEA HYPERBAR M, V31, P271; Moon RE, 1997, AVIAT SPACE ENVIR MD, V68, P234; Moon RE., 2003, ADJUNCTIVE THERAPY D; Navy Department, 2008, US NAV DIV MAN REV 6; NEUMAN TS, 1990, UNDERSEA BIOMED RES, V17, P429; Newton HB, 2007, UNDERSEA HYPERBAR M, V34, P349; Nossum V, 2002, EUR J APPL PHYSIOL, V86, P209, DOI 10.1007/s00421-001-0531-y; Ozyigit T, 2010, AVIAT SPACE ENVIR MD, V81, P3, DOI 10.3357/ASEM.2495.2010; Pickard BJ, 2003, AVIAT SPACE ENVIR MD, V74, P357; Pitkin AD, 1999, AVIAT SPACE ENVIR MD, V70, P517; Pollock NW, 2008, DAN ANN DIVING REPOR; Randsoe T, 2009, J APPL PHYSIOL, V107, P1857, DOI 10.1152/japplphysiol.00785.2009; RIVERA JC, 1964, MIL MED, V129, P314, DOI 10.1093/milmed/129.4.314; Ross JAS., 2000, CLIN AUDIT OUTCOME M; Schoen SP, 2008, HEART, V94, P844, DOI 10.1136/hrt.2007.132662; SHUPAK A, 1991, LARYNGOSCOPE, V101, P173; Slade JB, 2001, CHEST, V120, P1686, DOI 10.1378/chest.120.5.1686; Smerz RW, 2005, UNDERSEA HYPERBAR M, V32, P363; SMITH RM, 1994, NEW ENGL J MED, V330, P19, DOI 10.1056/NEJM199401063300104; Soliman OII, 2007, EUR J ECHOCARDIOGR, V8, pS2, DOI 10.1016/j.euje.2007.03.006; SPENCER MP, 1976, J APPL PHYSIOL, V40, P229, DOI 10.1152/jappl.1976.40.2.229; Spiess BD, 2009, J APPL PHYSIOL, V106, P1444, DOI 10.1152/japplphysiol.90995.2008; Steigleman A, 2003, AVIAT SPACE ENVIR MD, V74, P985; Temple DJ, 1999, DIVE PROFILES MANIFE, VI; Thalmann E, 1996, TREATMENT DECOMPRESS; Thalmann ED, 1990, DIVING ACCIDENT MANA, P194; TOko B, 2005, SPUMS J, V35, P23; Torti SR, 2004, EUR HEART J, V25, P1014, DOI 10.1016/j.ehj.2004.04.028; Van der Aue OE, 1949, EFFECT EXERCISE DURI, P8; Van Liew HD, 2005, UNDERSEA HYPERBAR M, V32, P409; Van Liew HD, 2005, UNDERSEA HYPERBAR M, V32, P187; Vann R., 2004, BOVE DAVIS DIVING ME, P53, DOI 10.1016/b978-0-7216-9424-5.50010-1; Vann RD, 2007, UNDERSEA HYPERBAR M, V34, P211; Vann R.D., 2004, BOVE DAVIS DIVING ME, V4th ed., P127, DOI DOI 10.1016/B978-0-7216-9424-5.X5001-1; Vann RD, 2004, UNDERSEA HYPERBAR M, V31, P431; Vann RD, 2000, DANS ANN REV RECREAT; Vann RD, 2008, AVIAT SPACE ENVIR MD, V79, P797, DOI 10.3357/ASEM.2316.2008; Vann RD, 2007, UNDERSEA HYPERBAR M, V34, P311; VIK A, 1990, J APPL PHYSIOL, V69, P237, DOI 10.1152/jappl.1990.69.1.237; Weaver LK, 2006, UNDERSEA HYPERBAR M, V33, P85; Webb JT, 2003, AVIAT SPACE ENVIR MD, V74, P2; WEIEN RW, 1990, AVIAT SPACE ENVIR MD, V61, P833; Weisher DD, 2008, UNDERSEA HYPERBAR M, V35, P159; WEISS LD, 1995, CHEST, V107, P1653, DOI 10.1378/chest.107.6.1653; Williams STB, 2007, WILD ENVIRON MED, V18, P48, DOI 10.1580/06-WEME-BR-009R.1; Wilmshurst P, 2000, CLIN SCI, V99, P65, DOI 10.1042/CS19990338; WILMSHURST PT, 1989, LANCET, V2, P1302; WILMSHURST PT, 1986, BRIT MED J, V293, P1277, DOI 10.1136/bmj.293.6557.1277; Zhu J, 2007, UNDERSEA HYPERBAR M, V34, P7; ZWIREWICH CV, 1987, RADIOLOGY, V163, P81, DOI 10.1148/radiology.163.1.3823462	145	368	391	1	76	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2011	377	9760					153	164		10.1016/S0140-6736(10)61085-9	http://dx.doi.org/10.1016/S0140-6736(10)61085-9			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	707NH	21215883				2023-01-03	WOS:000286292800028
J	Kronik, N; Kogan, Y; Elishmereni, M; Halevi-Tobias, K; Vuk-Pavlovic, S; Agur, Z				Kronik, Natalie; Kogan, Yuri; Elishmereni, Moran; Halevi-Tobias, Karin; Vuk-Pavlovic, Stanimir; Agur, Zvia			Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models	PLOS ONE			English	Article							APOPTOTIC TUMOR-CELLS; DENDRITIC CELLS; T-CELLS; CHEMOTHERAPY; GROWTH; VACCINATION; STRATEGIES; INDUCTION; DOCETAXEL; INTERVAL	Background: Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients. We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simple mathematical models. Methodology/Principal Findings: We developed a general mathematical model encompassing the basic interactions of a vaccine, immune system and PCa cells, and validated it by the results of a clinical trial testing an allogeneic PCa whole-cell vaccine. For model validation in the absence of any other pertinent marker, we used the clinically measured changes in prostate-specific antigen (PSA) levels as a correlate of tumor burden. Up to 26 PSA levels measured per patient were divided into each patient's training set and his validation set. The training set, used for model personalization, contained the patient's initial sequence of PSA levels; the validation set contained his subsequent PSA data points. Personalized models were simulated to predict changes in tumor burden and PSA levels and predictions were compared to the validation set. The model accurately predicted PSA levels over the entire measured period in 12 of the 15 vaccination-responsive patients (the coefficient of determination between the predicted and observed PSA values was R-2 = 0.972). The model could not account for the inconsistent changes in PSA levels in 3 of the 15 responsive patients at the end of treatment. Each validated personalized model was simulated under many hypothetical immunotherapy protocols to suggest alternative vaccination regimens. Personalized regimens predicted to enhance the effects of therapy differed among the patients. Conclusions/Significance: Using a few initial measurements, we constructed robust patient-specific models of PCa immunotherapy, which were retrospectively validated by clinical trial results. Our results emphasize the potential value and feasibility of individualized model-suggested immunotherapy protocols.	[Kronik, Natalie; Kogan, Yuri; Elishmereni, Moran; Halevi-Tobias, Karin; Agur, Zvia] Inst Med BioMath, Bene Ataroth, Israel; [Vuk-Pavlovic, Stanimir] Mayo Clin, Coll Med, Rochester, MN USA	Mayo Clinic	Kronik, N (corresponding author), Holon Inst Technol, Dept Appl Math, Fac Exact Sci, Holon, Israel.	agur@imbm.org			Chai Foundation; NIH [P50CA91956]; NATIONAL CANCER INSTITUTE [P50CA091956] Funding Source: NIH RePORTER	Chai Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	N.K., Y.K., M.E., K.H.T., and Z.A. thank the Chai Foundation for support of this work. S.V.P. gratefully acknowledges the support by Mrs. Adelyn L. Luther, Mayo Clinic Cancer Center, and NIH Grant P50CA91956. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aalamian-Matheis M, 2007, ADV EXP MED BIOL, V601, P173; ACHARYA RS, 1984, INT J BIOMED COMPUT, V15, P139, DOI 10.1016/0020-7101(84)90026-6; Agur Z., 1994, Random and Computational Dynamics, V2, P279; Agur Z, 2004, DISCRETE CONT DYN-B, V4, P29; AGUR Z, 1992, EUR J CANCER, V28A, P1085, DOI 10.1016/0959-8049(92)90463-C; Agur Z, 2006, OPER RES, V54, P829, DOI 10.1287/opre.1060.0320; Arakelyan L, 2005, EUR J CANCER, V41, P159, DOI 10.1016/j.ejca.2004.09.012; Arakelyan L., 2002, Angiogenesis, V5, P203, DOI 10.1023/A:1023841921971; Bajzer Z, 2005, BIOSYSTEMS, V80, P1, DOI 10.1016/j.biosystems.2004.09.025; BAJZER Z, 1984, SCIENCE, V225, P930, DOI 10.1126/science.6382606; BAJZER Z, 1990, Critical Reviews in Oncogenesis, V2, P53; Brandacher G, 2006, CURR DRUG METAB, V7, P599, DOI 10.2174/138920006778017768; Brill TH, 2009, HUM GENE THER, V20, P1641, DOI 10.1089/hum.2009.101; Bunimovich-Mendrazitsky S, 2008, B MATH BIOL, V70, P2055, DOI 10.1007/s11538-008-9344-z; Cappuccio A, 2007, J THEOR BIOL, V248, P259, DOI 10.1016/j.jtbi.2007.05.015; Cappuccio A, 2006, CANCER RES, V66, P7293, DOI 10.1158/0008-5472.CAN-06-0241; Chen M, 2007, MOL IMMUNOL, V44, P2558, DOI 10.1016/j.molimm.2006.12.020; COJOCARU L, 1992, MATH BIOSCI, V109, P85, DOI 10.1016/0025-5564(92)90053-Y; Collins C, 2007, CANCER BIOL THER, V6, P1360; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; de Pillis LG, 2006, J THEOR BIOL, V238, P841, DOI 10.1016/j.jtbi.2005.06.037; de Pillis LG, 2005, CANCER RES, V65, P7950, DOI 10.1158/0008-5472.CAN-05-0564; De Vleeschouwer S, 2005, CANCER IMMUNOL IMMUN, V54, P372, DOI 10.1007/s00262-004-0615-8; DEPILLIS LG, 2001, COMP MATH MATH PHYS, V3, P1748; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; ELISHMERENI M, 2008, AACR INT C ADV CANC; Georger TC, 2003, EUR J IMMUNOL, V33, P502, DOI 10.1002/immu.200310026; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; Gorelik B, 2008, CANCER RES, V68, P9033, DOI 10.1158/0008-5472.CAN-08-1723; HARNEVO LE, 1992, CANCER CHEMOTH PHARM, V30, P469, DOI 10.1007/BF00685599; Harzstark AL, 2009, ONCOLOGIST, V14, P391, DOI 10.1634/theoncologist.2008-0240; Healy CG, 1998, CYTOMETRY, V32, P109, DOI 10.1002/(SICI)1097-0320(19980601)32:2<109::AID-CYTO6>3.0.CO;2-G; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; Kiessling A, 2008, EUR UROL, V53, P694, DOI 10.1016/j.eururo.2007.11.043; Kirschner D, 1998, J MATH BIOL, V37, P235, DOI 10.1007/s002850050127; Kokhaei P, 2004, LEUKEMIA, V18, P1810, DOI 10.1038/sj.leu.2403517; Kokhaei P, 2003, LEUKEMIA, V17, P894, DOI 10.1038/sj.leu.2402913; Kronik N, 2008, CANCER IMMUNOL IMMUN, V57, P425, DOI 10.1007/s00262-007-0387-z; Kulprathipanja NV, 2004, J NEUROIMMUNOL, V153, P76, DOI 10.1016/j.jneuroim.2004.04.011; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Leon K, 2007, J IMMUNOL, V179, P5659, DOI 10.4049/jimmunol.179.9.5659; Louzoun Y, 2007, IMMUNOL REV, V216, P9; Machiels JP, 2008, J CLIN ONCOL, V26, P5261, DOI 10.1200/JCO.2008.16.9524; Marrari A, 2007, CANCER IMMUNOL IMMUN, V56, P429, DOI 10.1007/s00262-006-0233-8; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Michael A, 2005, CLIN CANCER RES, V11, P4469, DOI 10.1158/1078-0432.CCR-04-2337; Min WP, 2003, J IMMUNOL, V170, P1304, DOI 10.4049/jimmunol.170.3.1304; Nani F, 2000, MATH BIOSCI, V163, P159, DOI 10.1016/S0025-5564(99)00058-9; Olson WC, 2007, REV RECENT CLIN TRIA, V2, P182, DOI 10.2174/157488707781662724; Pawelec G, 2004, FEBS LETT, V567, P63, DOI 10.1016/j.febslet.2004.02.091; Peshwa MV, 1998, PROSTATE, V36, P129, DOI 10.1002/(SICI)1097-0045(19980701)36:2<129::AID-PROS8>3.0.CO;2-D; SCHELLHAMMER PF, 2009, ANN M AM UR ASS APR; Street D, 1997, GYNECOL ONCOL, V65, P265, DOI 10.1006/gyno.1997.4667; Swanson KR, 2003, J NEUROL SCI, V216, P1, DOI 10.1016/j.jns.2003.06.001; Vuk-Pavlovic S, 2008, BLOOD CELL MOL DIS, V40, P94, DOI 10.1016/j.bcmd.2007.06.025; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Weiner LM, 2008, NEW ENGL J MED, V358, P2664, DOI 10.1056/NEJMp0803663; Willimsky G, 2008, J EXP MED, V205, P1687, DOI 10.1084/jem.20072016; YOUNGA D, 2009, SYSTEMS BIOMEDICINE, pCH15	59	78	81	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2010	5	12							e15482	10.1371/journal.pone.0015482	http://dx.doi.org/10.1371/journal.pone.0015482			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691MJ	21151630	Green Submitted, Green Published, gold			2023-01-03	WOS:000285084100037
J	Choudhry, NK; Shrank, WH				Choudhry, Niteesh K.; Shrank, William H.			Four-Dollar Generics -- Increased Accessibility, Impaired Quality Assurance.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Choudhry, NK (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 2008, US TODAY; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; *KAIS FAM FDN HLTH, EMPL HLTH BEN 2009 A; Kohl H, 2007, J AM GERIATR SOC, V55, P1106, DOI 10.1111/j.1532-5415.2007.01286.x; *NAT ASS CHAIN DRU, 2008, RX SAL	5	69	69	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 11	2010	363	20					1885	1887		10.1056/NEJMp1006189	http://dx.doi.org/10.1056/NEJMp1006189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	678CR	21067379				2023-01-03	WOS:000284047600003
J	Nutt, DJ; King, LA; Phillips, LD				Nutt, David J.; King, Leslie A.; Phillips, Lawrence D.		Independent Sci Comm Drugs	Drug harms in the UK: a multicriteria decision analysis	LANCET			English	Article							ILLICIT DRUGS; TOXICITY; MISUSE	Background Proper assessment of the harms caused by the misuse of drugs can inform policy makers in health, policing, and social care. We aimed to apply multicriteria decision analysis (MCDA) modelling to a range of drug harms in the UK. Method Members of the Independent Scientific Committee on Drugs, including two invited specialists, met in a 1-day interactive workshop to score 20 drugs on 16 criteria: nine related to the harms that a drug produces in the individual and seven to the harms to others. Drugs were scored out of 100 points, and the criteria were weighted to indicate their relative importance. Findings MCDA modelling showed that heroin, crack cocaine, and metamfetamine were the most harmful drugs to individuals (part scores 34, 37, and 32, respectively), whereas alcohol, heroin, and crack cocaine were the most harmful to others (46, 21, and 17, respectively). Overall, alcohol was the most harmful drug (overall harm score 72), with heroin (55) and crack cocaine (54) in second and third places. Interpretation These findings lend support to previous work assessing drug harms, and show how the improved scoring and weighting approach of MCDA increases the differentiation between the most and least harmful drugs. However, the findings correlate poorly with present UK drug classification, which is not based simply on considerations of harm.	[Nutt, David J.] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, London W12 0NN, England; [King, Leslie A.] EMCDDA, Lisbon, Portugal; [Phillips, Lawrence D.] Univ London London Sch Econ & Polit Sci, Dept Management, London WC2A 2AE, England	Imperial College London; University of London; London School Economics & Political Science	Nutt, DJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Neuropsychopharmacol Unit, Burlington Danes Bldg,Du Cane Rd, London W12 0NN, England.	d.nutt@imperial.ac.uk			Centre for Crime and Justice Studies (UK); Facilitations Limited	Centre for Crime and Justice Studies (UK); Facilitations Limited	This study is funded by the Centre for Crime and Justice Studies (UK). Yuji Wu assisted with some of the data analyses.; DJN and LAK received travel expenses to attend the decision conference meeting. LAK is a consultant to the Department of Health and the EMCDDA. LDP is a director of Facilitations Limited, which paid him a consulting fee because it was the company engaged by the Centre for Crime and Justice Studies to run the study and analyse the data.	Academy of Medical Sciences (AMS), 2004, CALL TIM NAT DRINK M; *ADV COUNC MIS DRU, 2010, CONS US MULT DEC AN; [Anonymous], 2010, DRUGS RES OVERVIEW E; Anthony JC, 1994, EXP CLIN PSYCHOPHARM, V2, P244, DOI 10.1037/1064-1297.2.3.244; *BRIT MED ASS, 1987, LIV RISK; Coomber R, 1999, ADDICT RES, V7, P85, DOI 10.3109/16066359909004376; DODGSON J, 2000, MULTICRITERIA ANAL M; Gable RS, 2004, ADDICTION, V99, P686, DOI 10.1111/j.1360-0443.2004.00744.x; *HC HLTH COMM, 2010, 1511 HC HLTH COMM; Horn G., 2008, BRAIN SCI ADDICTION; King LA, 2010, HUM PSYCHOPHARM CLIN, V25, P162, DOI 10.1002/hup.1090; Morton A, 2009, RISK ANAL, V29, P764, DOI 10.1111/j.1539-6924.2008.01192.x; Murphy PI, 2007, LANCET, V369, P1856, DOI 10.1016/S0140-6736(07)60841-1; NICE (National Institute of Clinical Excellence), 2010, ALCOHOL USE DISORDER; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Phillips LD, 2007, ADVANCES IN DECISION ANALYSIS: FROM FOUNDATIONS TO APPLICATIONS, P375, DOI 10.1017/CBO9780511611308.020; REGANCIRINCIONE P, 1994, ORG BEHAV HUMAN DECI, V58, P246; United Nations Office on Drugs and Crime, 2010, WORLD DRUG REP 2010; van Amsterdam J, 2010, EUR ADDICT RES, V16, P202, DOI 10.1159/000317249; Werb D., 2010, EFFECT DRUG LAW ENFO	20	870	891	6	247	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1558	1565		10.1016/S0140-6736(10)61462-6	http://dx.doi.org/10.1016/S0140-6736(10)61462-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QE	21036393				2023-01-03	WOS:000284248700033
J	Lima, ABC; Macedo, LT; Sasse, AD				Costa Lima, Andre Bacellar; Macedo, Ligia T.; Sasse, Andre Deeke			Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							PHASE-III TRIAL; PLUS CARBOPLATIN; 1ST-LINE THERAPY; PACLITAXEL; RECURRENT; NSCLC; HYPERTENSION; COMBINATION; SURVIVAL; SAFETY	Introduction: Recently, studies have demonstrated that the addition of bevacizumab to chemotherapy could be associated with better outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, the benefit seems to be dependent on the drugs used in the chemotherapy regimens. This systematic review evaluated the strength of data on efficacy of the addition of bevacizumab to chemotherapy in advanced NSCLC. Methods: PubMed, EMBASE, and Cochrane databases were searched. Eligible studies were randomized clinical trials (RCTs) that evaluated chemotherapy with or without bevacizumab in patients with advanced NSCLC. The outcomes included overall survival (OS), progression-free survival (PFS), response rate (RR), toxicities and treatment related mortality. Hazard ratios (HR) and odds ratios (OR) were used for the meta-analysis and were expressed with 95% confidence intervals (CI). Results: We included results reported from five RCTs, with a total of 2,252 patients included in the primary analysis, all of them using platinum-based chemotherapy regimens. Compared to chemotherapy alone, the addition of bevacizumab to chemotherapy resulted in a significant longer OS (HR 0.89; 95% CI 0.79 to 0.99; p = 0.04), longer PFS (HR 0.73; 95% CI 0.66 to 0.82; p<0.00001) and higher response rates (OR 2.34; 95% CI 1.89 to 2.89; p<0.00001). We found no heterogeneity between trials, in all comparisons. There was a slight increase in toxicities in bevacizumab group, as well as an increased rate of treatment-related mortality. Conclusions: The addition of bevacizumab to chemotherapy in patients with advanced NSCLC prolongs OS, PFS and RR. Considering the toxicities added, and the small absolute benefits found, bevacizumab plus platinum-based chemotherapy can be considered an option in selected patients with advanced NSCLC. However, risks and benefits should be discussed with patients before decision making.	[Costa Lima, Andre Bacellar; Macedo, Ligia T.; Sasse, Andre Deeke] Univ Estadual Campinas UNICAMP, Fac Ciencias Med, Dept Clin Med, Sao Paulo, Brazil; [Costa Lima, Andre Bacellar; Macedo, Ligia T.; Sasse, Andre Deeke] Ctr Evidencias Oncol CEVON, Sao Paulo, Brazil	Universidade Estadual de Campinas	Lima, ABC (corresponding author), Univ Estadual Campinas UNICAMP, Fac Ciencias Med, Dept Clin Med, Sao Paulo, Brazil.	sasse@cevon.com.br	Macedo, Ligia Traldi/N-5432-2019; Sasse, Andre/P-7272-2019; Sasse, Andre D/B-3375-2009; Macedo, Ligia T Traldi/P-8122-2018; Macedo, Ligia Traldi/L-8432-2019	Macedo, Ligia Traldi/0000-0003-0575-586X; Sasse, Andre D/0000-0002-3038-3933; Macedo, Ligia T Traldi/0000-0003-0575-586X; Costa Lima, Andre Bacellar/0000-0002-7726-5002				ALBERTI W, 1995, BRIT MED J, V311, P899; Besse B, 2010, CLIN CANCER RES, V16, P269, DOI 10.1158/1078-0432.CCR-09-2439; Chen F, 2007, CANCER EPIDEM BIOMAR, V16, P2724, DOI 10.1158/1055-9965.EPI-07-0455; Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713; Crino L, 2010, LANCET ONCOL, V11, P733, DOI 10.1016/S1470-2045(10)70151-0; Dahlberg SE, 2010, J CLIN ONCOL, V28, P949, DOI 10.1200/JCO.2009.25.4482; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Garrido P, 2009, EJC SUPPL, V7, P557, DOI 10.1016/S1359-6349(09)71883-X; Gressett SM, 2009, ANN PHARMACOTHER, V43, P490, DOI 10.1345/aph.1L426; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hood JD, 1998, AM J PHYSIOL-HEART C, V274, pH1054; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Lynch T, 2008, ANN ONCOL, V19, P93; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mourad JJ, 2008, ANN ONCOL, V19, P927, DOI 10.1093/annonc/mdm550; NISHIO M, 2009, J CLIN ONCOL, V27; Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8; Ramalingam SS, 2008, J CLIN ONCOL, V26, P60, DOI 10.1200/JCO.2007.13.1144; Ranpura V, 2011, JAMA-J AM MED ASSOC, V305, P487, DOI 10.1001/jama.2011.51; Reck M, 2010, ANN ONCOL, V21, P1804, DOI 10.1093/annonc/mdq020; RECK M, 2010, ANN ONCOL       0211; Reck M, 2009, J CLIN ONCOL, V27, P1227, DOI 10.1200/JCO.2007.14.5466; Sandler AB, 2006, J CLIN ONCOL, V24, p381S; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Sterne JAC, 2001, SYSTEMATIC REV HLTH, P347, DOI [DOI 10.1002/9780470693926.CH18, 10.1002/9780470693926.ch18]; Thatcher N, 2009, J THORAC ONCOL, V4, pS358; Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16; Tsai C, 2009, EJC SUPPL, V7, P557, DOI 10.1016/S1359-6349(09)71884-1; van Heeckeren WJ, 2007, J CLIN ONCOL, V25, P2993, DOI 10.1200/JCO.2007.11.5113; Yuan A, 2001, J CLIN ONCOL, V19, P432, DOI 10.1200/JCO.2001.19.2.432	35	72	75	1	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 2	2011	6	8							e22681	10.1371/journal.pone.0022681	http://dx.doi.org/10.1371/journal.pone.0022681			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	802LF	21829644	gold, Green Submitted, Green Published			2023-01-03	WOS:000293511900011
J	Mathieu, C; Gillard, P				Mathieu, Chantal; Gillard, Pieter			Arresting type 1 diabetes after diagnosis: GAD is not enough	LANCET			English	Editorial Material							BETA-CELL FUNCTION; DOUBLE-BLIND; THERAPY; CHILDREN; INSULIN; MICE		[Mathieu, Chantal] Catholic Univ Louvain, Univ Hosp Leuven, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Catholic Univ Louvain, Univ Hosp Leuven, Clin Expt Med & Endocrinol, B-3000 Louvain, Belgium	KU Leuven; University Hospital Leuven; Universite Catholique Louvain; KU Leuven; University Hospital Leuven; Universite Catholique Louvain	Mathieu, C (corresponding author), Catholic Univ Louvain, Univ Hosp Leuven, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium.	chantal.mathieu@uzleuven.be	Gillard, Pieter/AAA-9820-2020; Gillard, Pieter/GPX-1490-2022; Gillard, Pieter/AAY-1483-2020; mathieu, chantal/ABD-5505-2021	Gillard, Pieter/0000-0001-9111-4561; Gillard, Pieter/0000-0001-9111-4561; mathieu, chantal/0000-0002-4055-5233				Balasa B, 2001, CLIN IMMUNOL, V99, P241, DOI 10.1006/clim.2001.5012; Chatenoud L, 2010, NAT REV ENDOCRINOL, V6, P149, DOI 10.1038/nrendo.2009.275; *DIAB TRIALNET, TYP 1 DIAB TRIALNET; GlaxoSmithKline, GLAXOSMITHKLINE TOL; Gottlieb PA, 2010, DIABETES CARE, V33, P826, DOI 10.2337/dc09-1349; Greenbaum CJ, 2008, DIABETES CARE, V31, P1966, DOI 10.2337/dc07-2451; Keymeulen B, 2005, NEW ENGL J MED, V352, P2598, DOI 10.1056/NEJMoa043980; Mastrandrea L, 2009, DIABETES CARE, V32, P1244, DOI 10.2337/dc09-0054; Matthews JB, 2010, CLIN EXP IMMUNOL, V160, P176, DOI 10.1111/j.1365-2249.2010.04153.x; Nanto-Salonen K, 2008, LANCET, V372, P1746, DOI 10.1016/S0140-6736(08)61309-4; Pescovitz MD, 2009, NEW ENGL J MED, V361, P2143, DOI 10.1056/NEJMoa0904452; Roep BO, 2007, ANN NY ACAD SCI, V1103, P1, DOI 10.1196/annals.1394.018; Thayer TC, 2010, ENDOCRIN METAB CLIN, V39, P541, DOI 10.1016/j.ecl.2010.05.001; Vandemeulebroucke E, 2010, DIABETOLOGIA, V53, P36, DOI 10.1007/s00125-009-1569-3; Wherrett DK, 2011, LANCET, V378, P319, DOI 10.1016/S0140-6736(11)60895-7	15	10	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 23	2011	378	9788					291	292		10.1016/S0140-6736(11)60978-1	http://dx.doi.org/10.1016/S0140-6736(11)60978-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	803XL	21715000				2023-01-03	WOS:000293615800004
J	Minami, M; Ichikawa, M; Hata, N; Hasegawa, T				Minami, Masaaki; Ichikawa, Mariko; Hata, Nanako; Hasegawa, Tadao			Protective Effect of Hainosankyuto, a Traditional Japanese Medicine, on Streptococcus pyogenes Infection in Murine Model	PLOS ONE			English	Article							SKIN INFECTION; MICE; INTERLEUKIN-12; INHIBITION; ACID	Background: Streptococcus pyogenes (S. pyogenes) causes various serious diseases including necrotizing fasciitis and streptococcal toxic shock syndrome. One serious problem observed recently with S. pyogenes therapy is attenuation of the antibiotic effect, especially penicillin treatment failure and macrolide resistance. Hainosankyuto, a traditional Japanese medicine based on ancient Chinese medicine, has been used for treatment of infectious purulent diseases in Japan. In this study, we investigated the protective and therapeutic efficacy of Hainosankyuto against S. pyogenes-skin infection. Methodology/Principal Findings: A broth microdilution method revealed that Hainosankyuto did not show a direct antibacterial effect against S. pyogenes. Force-feeding Hainosankyuto to infected mice for 4 consecutive days increased the survival rate and reduced the size of local skin lesions compared with mice fed PBS. Although we did not find the significant recovery of survival rate in Hainosankyuto administration only after S. pyogenes infection, the sizes of ulcer lesion were significant smaller after Hainosankyuto administration compared with mice fed PBS. No difference was observed in the antibacterial effect of Hainosankyuto between macrolide-susceptible and -resistant strains. Blood bactericidal assay showed that the survival rate of S. pyogenes using the blood from Hainosankyuto -treated mice was lower than that using the blood from untreated mice. We also found increased levels of IL-12, IFN-gamma and a decreased level of TNF-alpha in the serum of S. pyogenes-infected mice treated with Hainosankyuto. Mouse peritoneal macrophage from Hainosankyuto-treated mice had significant phagocytic activity and increased mRNA levels of IL-12, IFN-gamma and decreased mRNA level of TNF-alpha compared with control macrophage. Conclusions/Significance: Hainosankyuto increased survival rate after S. pyogenes infection and up-regulated both blood bactericidal activity and macrophage phagocytic activity through modulation of inflammatory cytokines. Our data also suggest Hainosankyuto may be useful for the treatment of S. pyogenes infection more prophylactically than therapeutically.	[Minami, Masaaki; Ichikawa, Mariko; Hasegawa, Tadao] Nagoya City Univ, Grad Sch Med Sci, Dept Bacteriol, Nagoya, Aichi, Japan; [Hata, Nanako] Nagoya City Univ Hosp, Dept Microbiol, Nagoya, Aichi, Japan	Nagoya City University; Nagoya City University	Minami, M (corresponding author), Nagoya City Univ, Grad Sch Med Sci, Dept Bacteriol, Nagoya, Aichi, Japan.	minami@med.nagoya-cu.ac.jp			Nagoya City University; Toyo Igaku Kenkyu Association	Nagoya City University; Toyo Igaku Kenkyu Association	This study was supported by a Grant-in-Aid for Research from Nagoya City University and the research fund of the Toyo Igaku Kenkyu Association. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baltina LA, 2003, CURR MED CHEM, V10, P155, DOI 10.2174/0929867033368538; Brook I, 2001, J OTOLARYNGOL, V30, P324, DOI 10.2310/7070.2001.19359; Chung JW, 2008, BIOL PHARM BULL, V31, P2114, DOI 10.1248/bpb.31.2114; *CLSI NCCLS, 2003, M7A6 CLSI NCCLS; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Dai Y, 2002, BIOL PHARM BULL, V25, P1175, DOI 10.1248/bpb.25.1175; Diao H, 2005, INFECT IMMUN, V73, P3745, DOI 10.1128/IAI.73.6.3745-3748.2005; Hasegawa T, 2010, MICROBIOL-SGM, V156, P184, DOI 10.1099/mic.0.031955-0; Ishih A, 2007, J NAT MED-TOKYO, V61, P280, DOI 10.1007/s11418-007-0146-7; Kroes BH, 1997, IMMUNOLOGY, V90, P115, DOI 10.1046/j.1365-2567.1997.00131.x; Kuo CF, 2005, J MED MICROBIOL, V54, P795, DOI 10.1099/jmm.0.45704-0; METZGER DW, 1995, J INFECT DIS, V171, P1643, DOI 10.1093/infdis/171.6.1643; Minami M, 2010, ANTIMICROB AGENTS CH, V54, P98, DOI 10.1128/AAC.00804-09; OZAKI Y, 1995, BIOL PHARM BULL, V18, P559, DOI 10.1248/bpb.18.559; Peng XH, 2000, J LEUKOCYTE BIOL, V68, P723; Raeder RH, 2000, J INFECT DIS, V181, P639, DOI 10.1086/315281; Richter SS, 2005, CLIN INFECT DIS, V41, P599, DOI 10.1086/432473; SHIMIZU H, 1990, J TRAD MED, V7, P54; SHIMIZU S, 1997, JPN TOYO IGAKU ZASSH, V48, P369; Tanaka M, 2005, ANTIMICROB AGENTS CH, V49, P88, DOI 10.1128/AAC.49.1.88-96.2005	20	13	13	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2011	6	7							e22188	10.1371/journal.pone.0022188	http://dx.doi.org/10.1371/journal.pone.0022188			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	797BJ	21799792	gold, Green Submitted, Green Published			2023-01-03	WOS:000293097300020
J	Schleicher, SM; Thotala, DK; Linkous, AG; Hu, R; Leahy, KM; Yazlovitskaya, EM; Hallahan, DE				Schleicher, Stephen M.; Thotala, Dinesh K.; Linkous, Amanda G.; Hu, Rong; Leahy, Kathleen M.; Yazlovitskaya, Eugenia M.; Hallahan, Dennis E.			Autotaxin and LPA Receptors Represent Potential Molecular Targets for the Radiosensitization of Murine Glioma through Effects on Tumor Vasculature	PLOS ONE			English	Article							LYSOPHOSPHATIDIC ACID RECEPTORS; CANCER METASTASIS; CELL MOTILITY; AKT; PATHWAY; IDENTIFICATION; ANGIOGENESIS; MECHANISMS; INVASION; ANALOGS	Despite wide margins and high dose irradiation, unresectable malignant glioma (MG) is less responsive to radiation and is uniformly fatal. We previously found that cytosolic phospholipase A2 (cPLA(2)) is a molecular target for radiosensitizing cancer through the vascular endothelium. Autotaxin (ATX) and lysophosphatidic acid (LPA) receptors are downstream from cPLA(2) and highly expressed in MG. Using the ATX and LPA receptor inhibitor, alpha-bromomethylene phosphonate LPA (BrP-LPA), we studied ATX and LPA receptors as potential molecular targets for the radiosensitization of tumor vasculature in MG. Treatment of Human Umbilical Endothelial cells (HUVEC) and mouse brain microvascular cells bEND. 3 with 5 mu mol/L BrP-LPA and 3 Gy irradiation showed decreased clonogenic survival, tubule formation, and migration. Exogenous addition of LPA showed radioprotection that was abrogated in the presence of BrP-LPA. In co-culture experiments using bEND. 3 and mouse GL-261 glioma cells, treatment with BrP-LPA reduced Akt phosphorylation in both irradiated cell lines and decreased survival and migration of irradiated GL-261 cells. Using siRNA to knock down LPA receptors LPA1, LPA2 or LPA3 in HUVEC, we demonstrated that knockdown of LPA2 but neither LPA1 nor LPA3 led to increased viability and proliferation. However, knockdown of LPA1 and LPA3 but not LPA2 resulted in complete abrogation of tubule formation implying that LPA1 and LPA3 on endothelial cells are likely targets of BrP-LPA radiosensitizing effect. Using heterotopic tumor models of GL-261, mice treated with BrP-LPA and irradiation showed a tumor growth delay of 6.8 days compared to mice treated with irradiation alone indicating that inhibition of ATX and LPA receptors may significantly improve malignant glioma response to radiation therapy. These findings identify ATX and LPA receptors as molecular targets for the development of radiosensitizers for MG.	[Schleicher, Stephen M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Yazlovitskaya, Eugenia M.] Vanderbilt Univ, Dept Med, Div Nephrol, Vanderbilt Ingram Canc Ctr, Nashville, TN USA; [Linkous, Amanda G.] NCI, Neurooncol Branch, NIH, Bethesda, MD 20892 USA; [Thotala, Dinesh K.; Hu, Rong; Leahy, Kathleen M.; Hallahan, Dennis E.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA; [Hallahan, Dennis E.] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA; [Hallahan, Dennis E.] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA	Vanderbilt University; Vanderbilt University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL)	Schleicher, SM (corresponding author), Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.	dhallahan@radonc.wustl.edu		Linkous, Amanda/0000-0003-1663-6364	U.S. National Cancer Institute [1R01CA140220-02, 5R01CA125757-06, 7R01CA112385-0]; Siteman Cancer Research Award; Elizabeth and James McDonnell III Endowment; Howard Hughes Medical Institute-Ivy Foundation; Department of Radiation Oncology Startup Funds; NATIONAL CANCER INSTITUTE [R01CA125757, R01CA112385, R01CA140220] Funding Source: NIH RePORTER	U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Siteman Cancer Research Award; Elizabeth and James McDonnell III Endowment; Howard Hughes Medical Institute-Ivy Foundation; Department of Radiation Oncology Startup Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by U.S. National Cancer Institute grants 1R01CA140220-02, 5R01CA125757-06, 7R01CA112385-0, Siteman Cancer Research Award, Elizabeth and James McDonnell III Endowment (D. Hallahan), Howard Hughes Medical Institute-Ivy Foundation Research Training Fellowship (www.hhmi.org) (S. Schleicher), and Department of Radiation Oncology Startup Funds (D. Thotala). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker DL, 2001, ANAL BIOCHEM, V292, P287, DOI 10.1006/abio.2001.5063; Berens M E, 1990, Neurosurg Clin N Am, V1, P1; Cechin SR, 2005, NEUROCHEM RES, V30, P603, DOI 10.1007/s11064-005-2747-4; Chakravarti A, 2004, J CLIN ONCOL, V22, P1926, DOI 10.1200/JCO.2004.07.193; Chautard E, 2010, NEURO-ONCOLOGY, V12, P434, DOI 10.1093/neuonc/nop059; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; Deng W, 2007, GASTROENTEROLOGY, V132, P1834, DOI 10.1053/j.gastro.2007.03.038; FIDLER IJ, 1990, CANCER RES, V50, P6130; Gong F, 1999, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V16, P216; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hoelzinger DB, 2008, J NEURO-ONCOL, V86, P297, DOI 10.1007/s11060-007-9480-6; Hoelzinger DB, 2007, J NATL CANCER I, V99, P1583, DOI 10.1093/jnci/djm187; Jiang GW, 2007, CHEMMEDCHEM, V2, P679, DOI 10.1002/cmdc.200600280; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kishi Y, 2006, J BIOL CHEM, V281, P17492, DOI 10.1074/jbc.M601803200; Linkous A, 2009, CLIN CANCER RES, V15, P1635, DOI 10.1158/1078-0432.CCR-08-1905; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LoPiccolo J, 2007, ANTI-CANCER DRUG, V18, P861; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; Nam SW, 2001, CANCER RES, V61, P6938; Prestwich GD, 2008, BBA-MOL CELL BIOL L, V1781, P588, DOI 10.1016/j.bbalip.2008.03.008; Ptaszynska MM, 2010, MOL CANCER RES, V8, P309, DOI 10.1158/1541-7786.MCR-09-0288; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Stassar MJJG, 2001, BRIT J CANCER, V85, P1372, DOI 10.1054/bjoc.2001.2074; Stefan C, 1999, BBA-MOL CELL RES, V1450, P45, DOI 10.1016/S0167-4889(99)00031-2; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; STRACKE ML, 1992, J BIOL CHEM, V267, P2524; Tanno S, 2004, CANCER RES, V64, P3486, DOI 10.1158/0008-5472.CAN-03-1788; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; van Meeteren LA, 2007, PROG LIPID RES, V46, P145, DOI 10.1016/j.plipres.2007.02.001; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wachsberger P, 2003, CLIN CANCER RES, V9, P1957; Wen Patrick Y, 2004, Curr Neurol Neurosci Rep, V4, P218, DOI 10.1007/s11910-004-0042-4; Xia HHX, 2009, CANCER-AM CANCER SOC, V115, P5441, DOI 10.1002/cncr.24609; Xue JX, 2010, ONCOL REP, V24, P1515, DOI 10.3892/or_00001013; Yazlovitskaya EM, 2008, CELL DEATH DIFFER, V15, P1641, DOI 10.1038/cdd.2008.93; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378	39	51	53	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2011	6	7							e22182	10.1371/journal.pone.0022182	http://dx.doi.org/10.1371/journal.pone.0022182			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	794WE	21799791	Green Published, gold, Green Submitted			2023-01-03	WOS:000292931200033
J	Yonesu, K; Kubota, K; Tamura, M; Inaba, S; Honda, T; Yahara, C; Watanabe, N; Matsuoka, T; Nara, F				Yonesu, Kiyoaki; Kubota, Kazuishi; Tamura, Masakazu; Inaba, Shin-ichi; Honda, Tomohiro; Yahara, Chizuko; Watanabe, Nobuaki; Matsuoka, Tatsuji; Nara, Futoshi			Purification and Identification of Activating Enzymes of CS-0777, a Selective Sphingosine 1-Phosphate Receptor 1 Modulator, in Erythrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RELAPSING MULTIPLE-SCLEROSIS; FRUCTOSAMINE 3-KINASE-RELATED PROTEIN; FUNCTIONAL-CHARACTERIZATION; IMMUNOSUPPRESSANT FTY720; IMMUNOMODULATOR FTY720; SUBSTRATE-SPECIFICITY; LYMPHOCYTE EGRESS; MOLECULAR-CLONING; ORAL FINGOLIMOD; KINASE TYPE-2	CS-0777 is a selective sphingosine 1-phosphate (S1P) receptor 1 modulator with potential benefits in the treatment of autoimmune diseases, including multiple sclerosis. CS-0777 is a prodrug that requires phosphorylation to an active S1P analog, similar to the first-in-class S1P receptor modulator FTY720 (fingolimod). We sought to identify the kinase(s) involved in phosphorylation of CS-0777, anticipating sphingosine kinase (SPHK) 1 or 2 as likely candidates. Unlike kinase activity for FTY720, which is found predominantly in platelets, CS-0777 kinase activity was found mainly in red blood cells (RBCs). N,N-Dimethylsphingosine, an inhibitor of SPHK1 and -2, did not inhibit CS-0777 kinase activity. We purified CS-0777 kinase activity from human RBCs by more than 10,000-fold using ammonium sulfate precipitation and successive chromatography steps, and we identified fructosamine 3-kinase (FN3K) and fructosamine 3-kinase-related protein (FN3K-RP) by mass spectrometry. Incubation of human RBC lysates with 1-deoxy-1-morpholinofructose, a competitive inhibitor of FN3K, inhibited similar to 10% of the kinase activity, suggesting FN3K-RP is the principal kinase responsible for activation of CS-0777 in blood. Lysates from HEK293 cells overexpressing FN3K or FN3K-RP resulted in phosphorylation of CS-0777 and structurally related molecules but showed little kinase activity for FTY720 and no kinase activity for sphingosine. Substrate preference was highly correlated among FN3K, FN3K-RP, and rat RBC lysates. FN3K and FN3K-RP are known to phosphorylate sugar moieties on glycosylated proteins, but this is the first report that these enzymes can phosphorylate hydrophobic xenobiotics. Identification of the kinases responsible for CS-0777 activation will permit a better understanding of the pharmacokinetics and pharmacodynamics of this promising new drug.	[Yonesu, Kiyoaki; Nara, Futoshi] Daiichi Sankyo Co Ltd, Cardiovasc Metab Res Labs, Tokyo 1348630, Japan; [Kubota, Kazuishi] Daiichi Sankyo Co Ltd, Translat Med & Clin Pharmacol Dept, Tokyo 1348630, Japan; [Tamura, Masakazu; Matsuoka, Tatsuji] Daiichi Sankyo Co Ltd, Biol Res Labs, Tokyo 1348630, Japan; [Inaba, Shin-ichi; Honda, Tomohiro; Yahara, Chizuko; Watanabe, Nobuaki] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo 1348630, Japan	Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited; Daiichi Sankyo Company Limited	Kubota, K (corresponding author), 1-16-13 Kitakasai,Edogawa Ku, Tokyo 1348630, Japan.	kubota.kazuishi.ht@daiichisankyo.co.jp; nara.futoshi.fm@daiichisankyo.co.jp		Matsuoka, Tatsuji/0000-0001-5982-4248				Allende ML, 2004, J BIOL CHEM, V279, P15396, DOI 10.1074/jbc.M314291200; Anada Y, 2007, EUR J PHARMACOL, V568, P106, DOI 10.1016/j.ejphar.2007.04.053; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bohler T, 2004, NEPHROL DIAL TRANSPL, V19, P702, DOI 10.1093/ndt/gfg599; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Budde K, 2003, AM J TRANSPLANT, V3, P846, DOI 10.1034/j.1600-6143.2003.00130.x; Cohen JA, 2010, NEW ENGL J MED, V362, P402, DOI 10.1056/NEJMoa0907839; Collard F, 2004, BIOCHEM J, V382, P137, DOI 10.1042/BJ20040307; Collard FO, 2003, DIABETES, V52, P2888, DOI 10.2337/diabetes.52.12.2888; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Delpierre G, 2000, DIABETES, V49, P1627, DOI 10.2337/diabetes.49.10.1627; Delpierre G, 2000, BIOCHEM J, V352, P835, DOI 10.1042/0264-6021:3520835; Delplanque J, 2004, J BIOL CHEM, V279, P46606, DOI 10.1074/jbc.M407678200; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; Fujita T, 1996, J MED CHEM, V39, P4451, DOI 10.1021/jm960391l; Galetta SL, 2005, CNS DRUGS, V19, P239, DOI 10.2165/00023210-200519030-00005; Graler MH, 2004, FASEB J, V18, P551, DOI 10.1096/fj.03-0910fje; Hisano Y, 2011, J BIOL CHEM, V286, P1758, DOI 10.1074/jbc.M110.171116; Horga A, 2010, EXPERT OPIN PHARMACO, V11, P1183, DOI 10.1517/14656561003769866; Ishizuka T, 2010, J BIOL CHEM, V285, P11892, DOI 10.1074/jbc.M109.072629; Kappos L, 2010, NEW ENGL J MED, V362, P387, DOI 10.1056/NEJMoa0909494; Kawahara A, 2009, SCIENCE, V323, P524, DOI 10.1126/science.1167449; Kihara A, 2008, BBA-MOL CELL BIOL L, V1781, P496, DOI 10.1016/j.bbalip.2008.05.003; Kobayashi N, 2009, J BIOL CHEM, V284, P21192, DOI 10.1074/jbc.M109.006163; Kohama T, 1998, J BIOL CHEM, V273, P23722, DOI 10.1074/jbc.273.37.23722; Kovarik JM, 2009, J CLIN PHARMACOL, V49, P212, DOI 10.1177/0091270008329553; Kubota K, 2004, J BIOL CHEM, V279, P37832, DOI 10.1074/jbc.M400089200; Kubota K, 2003, PROTEOMICS, V3, P616, DOI 10.1002/pmic.200300410; Kubota K, 2002, J BONE MINER RES, V17, P257, DOI 10.1359/jbmr.2002.17.2.257; Kubota K, 2009, NAT BIOTECHNOL, V27, P933, DOI 10.1038/nbt.1566; Lee YM, 2007, PROSTAG OTH LIPID M, V84, P154, DOI 10.1016/j.prostaglandins.2007.08.001; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Marsolais D, 2009, NAT REV DRUG DISCOV, V8, P297, DOI 10.1038/nrd2356; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Moberly J., 2011, J CLIN PHAR IN PRESS; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Nava VE, 2000, FEBS LETT, V473, P81, DOI 10.1016/S0014-5793(00)01510-6; Nishi T, 2011, ACS MED CHEM LETT, V2, P368, DOI 10.1021/ml100301k; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Pappu R, 2007, SCIENCE, V316, P295, DOI 10.1126/science.1139221; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Ransohoff RM, 2007, NEW ENGL J MED, V356, P2622, DOI 10.1056/NEJMct071462; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Schwab SR, 2005, SCIENCE, V309, P1735, DOI 10.1126/science.1113640; Szwergold B, 2007, BIOCHEM BIOPH RES CO, V361, P870, DOI 10.1016/j.bbrc.2007.07.127; Szwergold BS, 2001, DIABETES, V50, P2139, DOI 10.2337/diabetes.50.9.2139; Van Schaftingen E., 2010, AMINO ACIDS IN PRESS; Van Schaftingen E, 2007, ADV ENZYME REGUL, V47, P261, DOI 10.1016/j.advenzreg.2006.12.002	51	11	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	2011	286	28					24765	24775		10.1074/jbc.M110.217299	http://dx.doi.org/10.1074/jbc.M110.217299			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	789WD	21613209	hybrid, Green Published			2023-01-03	WOS:000292547900027
J	Gay, M; Pares, A; Carrascal, M; Bosch-i-Crespo, P; Gorga, M; Mas, A; Abian, J				Gay, Marina; Pares, Albert; Carrascal, Montserrat; Bosch-i-Crespo, Pau; Gorga, Marina; Mas, Antoni; Abian, Joaquin			Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus	PLOS ONE			English	Article							ADSORBENT RECIRCULATING SYSTEM; PROTEINS; SERUM; IDENTIFICATION; PEPTIDES; SLURP-1; MARS	Albumin dialysis using the molecular adsorbent recirculating system (MARS) is a new therapeutic approach for liver diseases. To gain insight into the mechanisms involved in albumin dialysis, we analyzed the peptides and proteins absorbed into the MARS strong anion exchange (SAX) cartridges as a result of the treatment of patients with cholestasis and resistant pruritus. Proteins extracted from the SAX MARS cartridges after patient treatment were digested with two enzymes. The resulting peptides were analyzed by multidimensional liquid chromatography coupled to tandem mass spectrometry. We identified over 1,500 peptide sequences corresponding to 144 proteins. In addition to the proteins that are present in control albumin-derived samples, this collection includes 60 proteins that were specific to samples obtained after patient treatment. Five of these proteins (neutrophil defensin 1 [HNP-1], secreted Ly-6/uPAR-related protein 1 [SLURP1], serum amyloid A, fibrinogen alpha chain and pancreatic prohormone) were confirmed to be removed by the dialysis procedure using targeted selected-reaction monitoring MS/MS. Furthermore, capture of HNP-1 and SLURP1 was also validated by Western blot. Interestingly, further analyses of SLURP1 in serum indicated that this protein was 3-fold higher in cholestatic patients than in controls. Proteins captured by MARS share certain structural and biological characteristics, and some of them have important biological functions. Therefore, their removal could be related either to therapeutic or possible adverse effects associated with albumin dialysis.	[Gay, Marina; Carrascal, Montserrat; Bosch-i-Crespo, Pau; Gorga, Marina; Abian, Joaquin] IDIBAPS, CSIC, IIBB, CSIC UAB Prote Lab, Bellaterra, Spain; [Pares, Albert; Bosch-i-Crespo, Pau; Gorga, Marina; Mas, Antoni] Univ Barcelona, IDIBAPS, Hosp Clin, CIBERehd,Liver Unit, Barcelona, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Gay, M (corresponding author), IDIBAPS, CSIC, IIBB, CSIC UAB Prote Lab, Bellaterra, Spain.	Joaquim.Abian.csic@uab.cat	Pares, Albert/G-1328-2011; Gay, Marina/D-8551-2019; BARCELO, DAMIA/O-4558-2016; Carrascal, Montserrat/M-1913-2014; Abian, Joaquin/M-1965-2014; Pares, Albert/M-6268-2019	Pares, Albert/0000-0002-5413-9687; Gay, Marina/0000-0002-8827-7092; BARCELO, DAMIA/0000-0002-8873-0491; Carrascal, Montserrat/0000-0002-0205-2176; Abian, Joaquin/0000-0003-2823-5429; Pares, Albert/0000-0002-5413-9687	GAMBRO AB (Hechingen, Germany); Spanish Ministry of Education [SAF2005-03649, SAF2008-04012]; Centro de Investigaciones Biomedicas en Red de Enfermedades Hepaticas y Digestivas (CIBERehd); Instituto de Salud Carlos III, Spain; CSIC	GAMBRO AB (Hechingen, Germany); Spanish Ministry of Education(Spanish Government); Centro de Investigaciones Biomedicas en Red de Enfermedades Hepaticas y Digestivas (CIBERehd); Instituto de Salud Carlos III, Spain(Instituto de Salud Carlos III); CSIC	This study was partially funded by GAMBRO AB (Hechingen, Germany), the Spanish Ministry of Education (SAF2005-03649 and SAF2008-04012), and the Centro de Investigaciones Biomedicas en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Spain. M. Gay was supported by a CSIC JAE-doc contract. LP CSIC/UAB is a member of ProteoRed, which was founded by Genome Spain and follows the quality criteria established by ProteoRed standards. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors have the following competing interest: This study was partially funded by GAMBRO AB (Hechingen, Germany). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.	Arredondo J, 2005, J INVEST DERMATOL, V125, P1236, DOI 10.1111/j.0022-202X.2005.23973.x; AUTH MK, 2004, J PEDIAT GASTROENTER, V40, P54; Carrascal M, 2008, J PROTEOME RES, V7, P5167, DOI 10.1021/pr800500r; Catalina MV, 2003, LIVER INT, V23, P39, DOI 10.1034/j.1478-3231.23.s.3.10.x; CHEN J, 2005, INTERNET J PHARM, V3; Chimienti F, 2003, HUM MOL GENET, V12, P3017, DOI 10.1093/hmg/ddg320; Choi H, 2008, MOL CELL PROTEOMICS, V7, P2373, DOI 10.1074/mcp.M800203-MCP200; COHN EJ, 1946, J AM CHEM SOC, V68, P459, DOI 10.1021/ja01207a034; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Fischer J, 2001, HUM MOL GENET, V10, P875, DOI 10.1093/hmg/10.8.875; Gay M, 2010, PROTEOMICS, V10, P172, DOI 10.1002/pmic.200900182; Gundry RL, 2007, PROTEOM CLIN APPL, V1, P73, DOI 10.1002/prca.200600276; Heemann U, 2002, HEPATOLOGY, V36, P949, DOI 10.1053/jhep.2002.36130; Heyer Gisela, 1997, Journal of Dermatology (Tokyo), V24, P621; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jalan R, 2001, Z Gastroenterol, V39 Suppl 2, P12, DOI 10.1055/s-2001-919023; Jones EA, 1999, HEPATOLOGY, V29, P1003, DOI 10.1002/hep.510290450; Kremer AE, 2008, DRUGS, V68, P2163, DOI 10.2165/00003495-200868150-00006; Laleman W, 2006, CRIT CARE, V10, DOI 10.1186/cc4985; Lowenthal MS, 2005, CLIN CHEM, V51, P1933, DOI 10.1373/clinchem.2005.052944; Mitzner SR, 2001, J AM SOC NEPHROL, V12, pS75; Pares A, 2004, AM J GASTROENTEROL, V99, P1105, DOI 10.1111/j.1572-0241.2004.30204.x; Pares A, 2010, J HEPATOL, V53, P307, DOI 10.1016/j.jhep.2010.02.031; Patzer JF, 2008, ARTIF ORGANS, V32, P499, DOI 10.1111/j.1525-1594.2008.00581.x; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Saliba F, 2006, CRIT CARE, V10, DOI 10.1186/cc4825; Sen S, 2005, AM J GASTROENTEROL, V100, P468, DOI 10.1111/j.1572-0241.2005.40864.x; Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442; Stange J, 1999, ARTIF ORGANS, V23, P319; Tiss A, 2010, PROTEOMICS, V10, P3388, DOI 10.1002/pmic.201000100; Twycross R, 2003, QJM-INT J MED, V96, P7, DOI 10.1093/qjmed/hcg002; Williams R, 2007, ACTA GASTRO-ENT BELG, V70, P210; Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6; Zheng XY, 2006, J CHROMATOGR A, V1120, P173, DOI 10.1016/j.chroma.2006.01.098; Ziganshin R, 2011, J PROTEOMICS, V74, P595, DOI 10.1016/j.jprot.2011.01.014	35	10	10	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2011	6	7							e21850	10.1371/journal.pone.0021850	http://dx.doi.org/10.1371/journal.pone.0021850			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	793HP	21779339	Green Published, Green Submitted, gold			2023-01-03	WOS:000292811300018
J	Persson, J; Beyer, I; Yumul, R; Li, ZY; Kiem, HP; Roffler, S; Lieber, A				Persson, Jonas; Beyer, Ines; Yumul, Roma; Li, ZongYi; Kiem, Hans-Peter; Roffler, Steve; Lieber, Andre			Immuno-Therapy with Anti-CTLA4 Antibodies in Tolerized and Non-Tolerized Mouse Tumor Models	PLOS ONE			English	Article							REGULATORY T-CELLS; COMBINATION IMMUNOTHERAPY; NKT CELLS; GENE-EXPRESSION; CTLA4 BLOCKADE; INSULATOR; VECTORS; BETA; REJECTION; EFFECTOR	Monoclonal antibodies specific for cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA4) are a novel form of cancer immunotherapy. While preclinical studies in mouse tumor models have shown anti-tumor efficacy of anti-CTLA4 injection or expression, anti-CTLA4 treatment in patients with advanced cancers had disappointing therapeutic benefit. These discrepancies have to be addressed in more adequate pre-clinical models. We employed two tumor models. The first model is based on C57BI/6 mice and syngeneic TC-1 tumors expressing HPV16 E6/E7. In this model, the HPV antigens are neo-antigens, against which no central tolerance exists. The second model involves mice transgenic for the proto-oncogen neu and syngeneic mouse mammary carcinoma (MMC) cells. In this model tolerance to Neu involves both central and peripheral mechanisms. Anti-CTLA4 delivery as a protein or expression from gene-modified tumor cells were therapeutically efficacious in the non-tolerized TC-1 tumor model, but had no effect in the MMC-model. We also used the two tumor models to test an immuno-gene therapy approach for anti-CTLA4. Recently, we used an approach based on hematopoietic stem cells (HSC) to deliver the relaxin gene to tumors and showed that this approach facilitates pre-existing anti-tumor T-cells to control tumor growth in the MMC tumor model. However, unexpectedly, when used for anti-CTLA4 gene delivery in this study, the HSC-based approach was therapeutically detrimental in both the TC-1 and MMC models. Anti-CTLA4 expression in these models resulted in an increase in the number of intratumoral CD1d+ NKT cells and in the expression of TGF-beta 1. At the same time, levels of pro-inflammatory cytokines and chemokines, which potentially can support anti-tumor T-cell responses, were lower in tumors of mice that received anti-CTLA4-HSC therapy. The differences in outcomes between the tolerized and non-tolerized models also provide a potential explanation for the low efficacy of CTLA4 blockage approaches in cancer immunotherapy trials.	[Persson, Jonas; Beyer, Ines; Yumul, Roma; Li, ZongYi; Lieber, Andre] Univ Washington, Dept Med, Seattle, WA 98195 USA; [Kiem, Hans-Peter] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; [Roffler, Steve] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Lieber, Andre] Univ Washington, Dept Pathol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Academia Sinica - Taiwan; University of Washington; University of Washington Seattle	Persson, J (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	lieber00@u.washington.edu	Roffler, Steve R/N-7791-2018; Beyer, Ines/Q-3236-2017	Roffler, Steve R/0000-0003-2543-7295; Beyer, Ines/0000-0001-7468-4466; Lieber, Andre/0000-0001-6742-6266	NIH [R01CA080192]; National Science Council [NSC96-2628-B001-003-MY3]; Deutsche Krebshilfe; Swedish Research Council [524-2009-539]; NATIONAL CANCER INSTITUTE [P01CA018029, R01CA080192] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025014] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Council(Ministry of Science and Technology, Taiwan); Deutsche Krebshilfe(Deutsche Krebshilfe); Swedish Research Council(Swedish Research CouncilEuropean Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	The work was supported by NIH grant R01CA080192 (to A.L.); National Science Council Grant NSC96-2628-B001-003-MY3 (to S. R.); Deutsche Krebshilfe Postdoctoral Training Grant (to I.B.); and Swedish Research Council Postdoctoral Grant 524-2009-539 (to J.P.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agarwala SS, 2010, J IMMUNOTHER, V33, P557, DOI 10.1097/CJI.0b013e3181dcd260; Aker M, 2007, HUM GENE THER, V18, P333, DOI 10.1089/hum.2007.021; Attia P, 2005, J CLIN ONCOL, V23, P6043, DOI 10.1200/JCO.2005.06.205; BEYER I, 2010, MOL THER; Beyer I, 2011, MOL THER, V19, P479, DOI 10.1038/mt.2010.256; Camacho LH, 2009, J CLIN ONCOL, V27, P1075, DOI 10.1200/JCO.2008.19.2435; De Palma M, 2009, BBA-REV CANCER, V1796, P5, DOI 10.1016/j.bbcan.2009.04.001; Diao J, 2010, J IMMUNOL, V184, P1261, DOI 10.4049/jimmunol.0903050; Egen JG, 2002, NAT IMMUNOL, V3, P611, DOI 10.1038/ni0702-611; Emery DW, 2000, P NATL ACAD SCI USA, V97, P9150, DOI 10.1073/pnas.160159597; Godfrey DI, 2004, NAT REV IMMUNOL, V4, P231, DOI 10.1038/nri1309; Griffin MD, 2001, J IMMUNOL METHODS, V248, P77, DOI 10.1016/S0022-1759(00)00344-6; Hegde S, 2010, IMMUNOLOGY, V130, P471, DOI 10.1111/j.1365-2567.2010.03293.x; Hurwitz AA, 2000, CANCER RES, V60, P2444; Kavanagh B, 2008, BLOOD, V112, P1175, DOI 10.1182/blood-2007-11-125435; Khan S, 2011, CLIN IMMUNOL, V138, P85, DOI 10.1016/j.clim.2010.09.011; Klopp AH, 2011, STEM CELLS, V29, P11, DOI 10.1002/stem.559; Knutson KL, 2006, J IMMUNOL, V177, P1526, DOI 10.4049/jimmunol.177.3.1526; Knutson KL, 2006, J IMMUNOL, V177, P84, DOI 10.4049/jimmunol.177.1.84; Knutson KL, 2004, CANCER RES, V64, P1146, DOI 10.1158/0008-5472.CAN-03-0173; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li CL, 2008, GENE THER, V15, P49, DOI 10.1038/sj.gt.3303009; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li Z, 2009, BLOOD, V113, P5423, DOI 10.1182/blood-2008-10-187237; Lu HL, 2006, CANCER RES, V66, P9754, DOI 10.1158/0008-5472.CAN-06-1083; Malik P, 2005, ANN NY ACAD SCI, V1054, P238, DOI 10.1196/annals.1345.030; Quezada SA, 2006, J CLIN INVEST, V116, P1935, DOI 10.1172/JCI27745; Read S, 2006, J IMMUNOL, V177, P4376, DOI 10.4049/jimmunol.177.7.4376; Shieh SJ, 2009, J IMMUNOL, V183, P2277, DOI 10.4049/jimmunol.0900679; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Stearman RS, 2008, CANCER RES, V68, P34, DOI 10.1158/0008-5472.CAN-07-0988; Stone D, 2008, J VIROL, V82, P7711, DOI 10.1128/JVI.00542-08; Strauss R, 2009, CURR OPIN MOL THER, V11, P513; Strauss R, 2009, CANCER RES, V69, P5115, DOI 10.1158/0008-5472.CAN-09-0645; Szulc J, 2006, NAT METHODS, V3, P109, DOI 10.1038/NMETH846; Teige A, 2010, J IMMUNOL, V185, P345, DOI 10.4049/jimmunol.0901693; Terabe M, 2008, ADV CANCER RES, V101, P277, DOI 10.1016/S0065-230X(08)00408-9; Tuve S, 2007, CANCER RES, V67, P5929, DOI 10.1158/0008-5472.CAN-06-4296; Tuve S, 2009, VACCINE, V27, P4225, DOI 10.1016/j.vaccine.2009.03.074; van Elsas A, 1999, J EXP MED, V190, P355, DOI 10.1084/jem.190.3.355; Yamaguchi T, 2006, SEMIN CANCER BIOL, V16, P115, DOI 10.1016/j.semcancer.2005.11.005	43	10	10	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2011	6	7							e22303	10.1371/journal.pone.0022303	http://dx.doi.org/10.1371/journal.pone.0022303			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	793HP	21779410	Green Published, Green Submitted, gold			2023-01-03	WOS:000292811300063
J	Metzner, KJ; Leemann, C; Di Giallonardo, F; Grube, C; Scherrer, AU; Braun, D; Kuster, H; Weber, R; Guenthard, HF				Metzner, Karin J.; Leemann, Christine; Di Giallonardo, Francesca; Grube, Christina; Scherrer, Alexandra U.; Braun, Dominique; Kuster, Herbert; Weber, Rainer; Guenthard, Huldrych F.			Reappearance of Minority K103N HIV-1 Variants after Interruption of ART Initiated during Primary HIV-1 Infection	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; DRUG-RESISTANCE MUTATIONS; TREATMENT-NAIVE PATIENTS; ACTIVE ANTIRETROVIRAL THERAPY; SOCIETY-USA PANEL; REVERSE-TRANSCRIPTASE; PLASMA VIREMIA; IN-VIVO; TRANSMISSION; POPULATIONS	Background: In the Zurich Primary HIV infection study (ZPHI), minority drug-resistant HIV-1 variants were detected in some acutely HIV-1-infected patients prior to initiation of early antiretroviral therapy (ART). Here, we investigated the reappearance of minority K103N and M184V HIV-1 variants in these patients who interrupted efficient early ART after 8-27 months according to the study protocol. These mutations are key mutations conferring drug resistance to reverse transcriptase inhibitors and they belong to the most commonly transmitted drug resistance mutations. Methodology/Principal Findings: Early ART was offered to acutely HIV-1-infected patients enrolled in the longitudinal prospective ZPHI study. Six patients harboring and eleven patients not harboring drug-resistant viruses at low frequencies prior to ART were included in this substudy. Minority K103N and M184V HIV-1 variants were quantified in longitudinal plasma samples after treatment interruption by allele-specific real-time PCR. All 17 patients were infected with HIV-1 subtype B between 04/2003 and 09/2005 and received LPV/r+AZT+3TC during primary HIV-1 infection (PHI). Minority K103N HIV-1 variants reappeared after cessation of ART in two of four patients harboring this variant during PHI and even persisted in one of those patients at frequencies similar to the frequency observed prior to ART (< 1%). The K103N mutation did not appear during treatment interruption in any other patient. Minority M184V HIV-1 variants were detected in two patients after ART interruption, one harboring and one not harboring these variants prior to ART. Conclusion: Minority K103N HIV-1 variants, present in acutely HIV-1 infected patients prior to early ART, can reappear and persist after interruption of suppressive ART containing two nucleoside/nucleotide analogue reverse transcriptase inhibitors and a ritonavir-boosted protease inhibitor.	[Metzner, Karin J.; Leemann, Christine; Di Giallonardo, Francesca; Grube, Christina; Scherrer, Alexandra U.; Braun, Dominique; Kuster, Herbert; Weber, Rainer; Guenthard, Huldrych F.] Univ Zurich, Div Infect Dis & Hosp Epidemiol, Univ Zurich Hosp, Zurich, Switzerland	University of Zurich; University Zurich Hospital	Metzner, KJ (corresponding author), Univ Zurich, Div Infect Dis & Hosp Epidemiol, Univ Zurich Hosp, Zurich, Switzerland.	Karin.Metzner@usz.ch	Metzner, Karin J/G-5319-2011; Kuster, Herbert/A-3912-2013; Weber, Rainer/D-5175-2012; gunthard, huldrych f/F-1724-2011	Metzner, Karin J/0000-0003-4862-1503; gunthard, huldrych f/0000-0002-1142-6723; Kuster, Herbert/0000-0001-6873-0091; Braun, Dominique Laurent/0000-0003-4036-1030; Di Giallonardo, Francesca/0000-0002-8749-4095	Swiss National Science Foundation (SNF) [324700-120793, 324730-130865]; Gilead Sciences Switzerland; European Community [FP7/2007-2013, 223131]; Gilead; Roche Diagnostics; GlaxoSmithKline; Bristol-Myers Squibb; Tibotec; Abbott; Gilead Sciences; Merck Sharp Dome; Pfizer; LaRoche; TRB Chemedica; Astra-Zeneca; Boehringer Ingelheim; Roche	Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); Gilead Sciences Switzerland(Gilead Sciences); European Community(European Commission); Gilead(Gilead Sciences); Roche Diagnostics; GlaxoSmithKline(GlaxoSmithKline); Bristol-Myers Squibb(Bristol-Myers Squibb); Tibotec; Abbott(Abbott Laboratories); Gilead Sciences(Gilead Sciences); Merck Sharp Dome; Pfizer(Pfizer); LaRoche; TRB Chemedica; Astra-Zeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Roche(Roche Holding)	This study was financed by Swiss National Science Foundation (SNF) grant 324700-120793 (to H.F.G. and K.J.M.), SNF grants 324730-130865 (to H.F.G.), and an unrestricted research grant from Gilead Sciences Switzerland. The research leading to these results has received further funding from the European Community's Seventh Framework Programme (FP7/2007-2013) under the project "Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN)" - grant agreement no 223131. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; K.J.M. has received travel grants and honoraria from Gilead, Roche Diagnostics, GlaxoSmithKline, Bristol-Myers Squibb, Tibotec, and Abbott, and has received a research grant from Gilead. R.W. has received travel grants or speakers honoraria from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck Sharp & Dome, Pfizer, LaRoche, TRB Chemedica, and Tibotec. H.F.G. has been an adviser and/or consultant for the following companies: GlaxoSmithKline, Abbott, Gilead, Novartis, Boehringer Ingelheim, Roche, Tibotec, Pfizer, ViiV Healthcare, and Bristol-Myers Squibb, and has received unrestricted research and educational grants from Roche, Abbott, Bristol-Myers Squibb, Gilead, Astra-Zeneca, GlaxoSmithKline, and Merck Sharp & Dohme. All other authors declare no conflict of interest.	Allers K, 2007, JAIDS-J ACQ IMM DEF, V44, P377, DOI 10.1097/QAI.0b013e31803104c0; Bailey JR, 2006, J VIROL, V80, P6441, DOI 10.1128/JVI.00591-06; Balduin M, 2009, J CLIN VIROL, V45, P34, DOI 10.1016/j.jcv.2009.03.002; Bennett DE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004724; Bergroth T, 2009, J MED VIROL, V81, P1, DOI 10.1002/jmv.21363; Carr JM, 2009, J MED VIROL, V81, P1983, DOI 10.1002/jmv.21628; Chun TW, 2008, J INFECT DIS, V197, P714, DOI 10.1086/527324; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cozzi-Lepri A, 2010, CLIN INFECT DIS, V50, P1275, DOI 10.1086/651684; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Gianella S, 2010, J INFECT DIS, V202, P657, DOI 10.1086/655397; Gunthard HF, 1999, J VIROL, V73, P9404; Gunthard HF, 1998, AIDS RES HUM RETROV, V14, P869, DOI 10.1089/aid.1998.14.869; Hance AJ, 2001, J VIROL, V75, P6410, DOI 10.1128/JVI.75.14.6410-6417.2001; Heneine W, 2010, J INFECT DIS, V201, P647, DOI 10.1086/650545; Hirsch MS, 2008, CLIN INFECT DIS, V47, P266, DOI 10.1086/589297; Jakobsen MR, 2010, CLIN INFECT DIS, V50, P566, DOI 10.1086/650001; Johnson JA, 2008, PLOS MED, V5, P1112, DOI 10.1371/journal.pmed.0050158; Johnson Victoria A, 2008, Top HIV Med, V16, P138; Joos B, 2008, P NATL ACAD SCI USA, V105, P16725, DOI 10.1073/pnas.0804192105; Lataillade M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010952; Masquelier BND, 2005, JAIDS-J ACQ IMM DEF, V40, P505, DOI 10.1097/01.qai.0000186361.42834.61; Metzner Karin J, 2006, J HIV Ther, V11, P74; Metzner KJ, 2006, FUTURE VIROL, V1, P377, DOI 10.2217/17460794.1.3.377; Metzner KJ, 2007, AIDS, V21, P703, DOI 10.1097/QAD.0b013e3280121ac6; Metzner KJ, 2010, J INFECT DIS, V201, P1063, DOI 10.1086/651136; Metzner KJ, 2009, CLIN INFECT DIS, V48, P239, DOI 10.1086/595703; Metzner KJ, 2003, J INFECT DIS, V188, P1433, DOI 10.1086/379215; Nicastri E, 2003, J MED VIROL, V69, P1, DOI 10.1002/jmv.10269; Paredes R, 2010, J INFECT DIS, V201, P662, DOI 10.1086/650543; Peuchant O, 2008, AIDS, V22, P1417, DOI 10.1097/QAD.0b013e3283034953; Rieder P, 2010, AIDS, V24, P1177, DOI 10.1097/QAD.0b013e328338e4de; Schuurman R, 1999, J CLIN MICROBIOL, V37, P2291, DOI 10.1128/JCM.37.7.2291-2296.1999; Simen BB, 2009, J INFECT DIS, V199, P693, DOI 10.1086/596736; Sterne JAC, 2005, LANCET, V366, P378, DOI 10.1016/S0140-6736(05)67022-5; Thompson MA, 2010, JAMA-J AM MED ASSOC, V304, P321, DOI 10.1001/jama.2010.1004; Van Laethem K, 2007, J CLIN VIROL, V39, P43, DOI 10.1016/j.jcv.2007.02.003; Vignoles M, 2009, ANTIVIR THER, V14, P1175, DOI 10.3851/IMP1461; Wainberg Mark A, 2004, Expert Rev Anti Infect Ther, V2, P147, DOI 10.1586/14787210.2.1.147; Wang JO, 2010, J VIROL, V84, P9377, DOI 10.1128/JVI.00618-10; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 2007, AIDS, V21, P2223, DOI 10.1097/QAD.0b013e3282f0b685; Zaccarelli M, 2003, ANTIVIR THER, V8, P51; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565	45	9	9	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2011	6	7							e21734	10.1371/journal.pone.0021734	http://dx.doi.org/10.1371/journal.pone.0021734			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	791AK	21754996	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000292632000022
J	Benson, JM; Sachs, CW; Treacy, G; Zhou, HH; Pendley, CE; Brodmerkel, CM; Shankar, G; Mascelli, MA				Benson, Jacqueline M.; Sachs, Clifford W.; Treacy, George; Zhou, Honghui; Pendley, Charles E.; Brodmerkel, Carrie M.; Shankar, Gopi; Mascelli, Mary A.			Therapeutic targeting of the IL-12/23 pathways: generation and characterization of ustekinumab	NATURE BIOTECHNOLOGY			English	Article							INTERLEUKIN-12/23 MONOCLONAL-ANTIBODY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELL POPULATION; IFN-GAMMA; DOUBLE-BLIND; PHASE-I; MULTIPLE-SCLEROSIS; SEVERE PSORIASIS; CYTOKINE; IL-23	Preclinical and clinical studies conducted in the mid-1990s reported strong association and causality between the T-cell helper (T-H) 1 inductor cytokine interleukin (IL)-12 and numerous immune-mediated disorders, which spurred the development of therapeutic agents targeting IL-12 function. One of the first to enter the clinic, ustekinumab, is a human monoclonal antibody (mAb) that binds to the p40 subunit of IL-12. Subsequent to the generation of ustekinumab, it was discovered that IL-23 also contains the p40 subunit. Thus, although ustekinumab was designed to target IL-12, it also modulates IL-23, a cytokine important to the development and/or maintenance of T(H)17 cells. Clinical observations established that IL-12/23p40 is integral to the pathologies of psoriasis, psoriatic arthritis and Crohn's disease. The molecular and cellular evaluations conducted in ustekinumab clinical programs have provided numerous insights into the pathologic processes of these disorders, illustrating how a novel molecular entity can contribute to our understanding of disease. The individual contributions of these cytokines to specific pathologies require investigation and clinical evaluation of the role of IL-12-and IL-23-specific inhibitors.	[Benson, Jacqueline M.; Sachs, Clifford W.; Treacy, George; Zhou, Honghui; Pendley, Charles E.; Brodmerkel, Carrie M.; Shankar, Gopi] Centocor Res & Dev Inc, Malvern, PA USA; [Mascelli, Mary A.] Biopharmaceut Consultant LLC, Ambler, PA USA	Johnson & Johnson; Johnson & Johnson USA	Benson, JM (corresponding author), Centocor Res & Dev Inc, Malvern, PA USA.	jbenson4@its.jnj.com						Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Aggarwal S, 2003, J BIOL CHEM, V278, P1910, DOI 10.1074/jbc.M207577200; Airoldi I, 2005, BLOOD, V106, P3846, DOI 10.1182/blood-2005-05-2034; Berrebi D, 1998, AM J PATHOL, V152, P667; Bowman EP, 2006, CURR OPIN INFECT DIS, V19, P245, DOI 10.1097/01.qco.0000224818.42729.67; Brodmerkel C, 2010, J DRUGS DERMATOL, V9, P677; Buse E, 2003, TOXICOLOGY, V185, P221, DOI 10.1016/S0300-483X(02)00614-5; Capon F, 2007, HUM GENET, V122, P201, DOI 10.1007/s00439-007-0397-0; Cardenes M, 2010, J MED GENET, V47, P635, DOI 10.1136/jmg.2009.071910; Cargill M, 2007, AM J HUM GENET, V80, P273, DOI 10.1086/511051; Cua DJ, 2003, NATURE, V421, P744, DOI 10.1038/nature01355; Curtis MM, 2009, J IMMUNOL, V183, P381, DOI 10.4049/jimmunol.0900939; Davidson NJ, 1998, J IMMUNOL, V161, P3143; Di Meglio P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017160; DILLON SB, 2010, DRUG DISC WORLD  FAL, P87; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; Fassbender K, 1998, NEUROLOGY, V51, P753, DOI 10.1212/WNL.51.3.753; Fieschi C, 2003, EUR J IMMUNOL, V33, P1461, DOI 10.1002/eji.200324038; Filipe-Santos O, 2006, SEMIN IMMUNOL, V18, P347, DOI 10.1016/j.smim.2006.07.010; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Fishwild DM, 1996, NAT BIOTECHNOL, V14, P845, DOI 10.1038/nbt0796-845; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Ghetie V, 2002, IMMUNOL RES, V25, P97, DOI 10.1385/IR:25:2:097; Gottlieb A, 2010, LANCET, V376, P1542; Gottlieb AB, 2007, CURR MED RES OPIN, V23, P1081, DOI 10.1185/030079907X182112; Gottlieb AB, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.06.021; Gran B, 2002, J IMMUNOL, V169, P7104, DOI 10.4049/jimmunol.169.12.7104; Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652; Hong K, 1999, J IMMUNOL, V162, P7480; JUDSON M, J AM ACAD D IN PRESS; Kasper LH, 2006, CURR MED RES OPIN, V22, P1671, DOI 10.1185/030079906X120931; Kauffman CL, 2004, J INVEST DERMATOL, V123, P1037, DOI 10.1111/j.0022-202X.2004.23448.x; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; Krueger GG, 2007, NEW ENGL J MED, V356, P580, DOI 10.1056/NEJMoa062382; Langrish CL, 2005, J EXP MED, V201, P233, DOI 10.1084/jem.20041257; Laurence A, 2007, NAT IMMUNOL, V8, P903, DOI 10.1038/ni0907-903; Leonard JP, 1997, BLOOD, V90, P2541; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; Leonardi CL, 2008, LANCET, V371, P1838; Leonardi CL, 2008, LANCET, V371, P1665, DOI 10.1016/S0140-6736(08)60725-4; Looney RJ, 2007, CLIN IMMUNOL, V123, P235, DOI 10.1016/j.clim.2007.01.001; Lowes MA, 2007, NATURE, V445, P866, DOI 10.1038/nature05663; Luo JQ, 2010, J MOL BIOL, V402, P797, DOI 10.1016/j.jmb.2010.07.046; Malfait AM, 1998, CLIN EXP IMMUNOL, V111, P377; MARTIN PL, 2010, BIRTH DEFECTS RES, V83, P1; Monteleone G, 1997, GASTROENTEROLOGY, V112, P1169, DOI 10.1016/S0016-5085(97)70128-8; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Murphy CA, 2003, J EXP MED, V198, P1951, DOI 10.1084/jem.20030896; Murphy KM, 2010, NAT IMMUNOL, V11, P674, DOI 10.1038/ni.1899; Naz RK, 1998, J ANDROL, V19, P302; Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595; Nicoletti F, 1996, J NEUROIMMUNOL, V70, P87, DOI 10.1016/S0165-5728(96)00101-4; Novelli F, 2004, CYTOKINE GROWTH F R, V15, P367, DOI 10.1016/j.cytogfr.2004.03.009; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Papp KA, 2008, LANCET, V371, P1675, DOI 10.1016/S0140-6736(08)60726-6; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Portielje JEA, 1999, CLIN CANCER RES, V5, P3983; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; Reddy M, 2010, J DERMATOL, V37, P413, DOI 10.1111/j.1346-8138.2010.00802.x; SACHS C, 2008, TOXICOLOGIST, V102; Sandborn WJ, 2008, GASTROENTEROLOGY, V135, P1130, DOI 10.1053/j.gastro.2008.07.014; Schellekens H, 2002, CLIN THER, V24, P1720, DOI 10.1016/S0149-2918(02)80075-3; Segal BM, 2008, LANCET NEUROL, V7, P796, DOI 10.1016/S1474-4422(08)70173-X; Shigehara K, 2001, J IMMUNOL, V166, P642, DOI 10.4049/jimmunol.166.1.642; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Toichi E, 2006, J IMMUNOL, V177, P4917, DOI 10.4049/jimmunol.177.7.4917; Torti DC, 2007, J AM ACAD DERMATOL, V57, P1059, DOI 10.1016/j.jaad.2007.07.016; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; van Boxel-Dezaire AHH, 1999, ANN NEUROL, V45, P695, DOI 10.1002/1531-8249(199906)45:6<695::AID-ANA3>3.0.CO;2-R; van de Wetering D, 2009, INT IMMUNOL, V21, P145, DOI 10.1093/intimm/dxn132; Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985; Yawalkar N, 1998, J INVEST DERMATOL, V111, P1053, DOI 10.1046/j.1523-1747.1998.00446.x; Zhou HH, 2006, J CLIN PHARMACOL, V46, P1268, DOI 10.1177/0091270006294278; Zhou HH, 2010, J CLIN PHARMACOL, V50, P257, DOI 10.1177/0091270009343695; Zhou HH, 2009, DRUG DISCOV TODAY, V14, P891, DOI 10.1016/j.drudis.2009.05.014; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001; Zhu YW, 2010, INT J CLIN PHARM TH, V48, P830; Zhu YW, 2007, J CLIN PHARMACOL, V47, P1203; Zhu YW, 2009, J CLIN PHARMACOL, V49, P162, DOI 10.1177/0091270008329556	84	104	107	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156	1546-1696		NAT BIOTECHNOL	Nat. Biotechnol.	JUL	2011	29	7					615	624		10.1038/nbt.1903	http://dx.doi.org/10.1038/nbt.1903			10	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	790NM	21747388				2023-01-03	WOS:000292595200020
J	Harris, JB; Ivers, LC; Ferraro, MJ				Harris, Jason B.; Ivers, Louise C.; Ferraro, Mary Jane			A Boy with Vomiting and Diarrhea Vibrio cholerae O1 (toxigenic), serotype Ogawa (testing performed at the CDC).	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEVELOPING-COUNTRIES; GLOBAL BURDEN; BANGLADESH; MORTALITY; CHILDREN		[Harris, Jason B.] Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA; [Ferraro, Mary Jane] Massachusetts Gen Hosp, Dept Pathol & Microbiol, Boston, MA 02114 USA; [Ivers, Louise C.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Harris, Jason B.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; [Ivers, Louise C.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Ferraro, Mary Jane] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Harris, JB (corresponding author), Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA.		Harris, Jason/ABF-2684-2020; Ivers, Louise C/Q-4164-2018	Harris, Jason/0000-0003-3642-5126; Ivers, Louise C/0000-0003-2314-9230				[Anonymous], 2010, WORLD HLTH STAT 2010; [Anonymous], 2010, MMWR MORB MORTAL WKL, V59, P1473; Boschi-Pinto C, 2008, B WORLD HEALTH ORGAN, V86, P710, DOI 10.2471/BLT.07.050054; BUTLER T, 1987, B WORLD HEALTH ORGAN, V65, P317; Chin CS, 2011, NEW ENGL J MED, V364, P33, DOI 10.1056/NEJMoa1012928; Harris JB, 2010, LANCET, V376, P1961, DOI 10.1016/S0140-6736(10)62172-1; HUILAN S, 1991, B WORLD HEALTH ORGAN, V69, P549; Kosek M, 2003, B WORLD HEALTH ORGAN, V81, P197; Kotloff KL, 1999, B WORLD HEALTH ORGAN, V77, P651; MAHALANABIS D, 1970, PEDIATRICS, V45, P374; Nelson EJ, 2011, NEW ENGL J MED, V364, P5, DOI 10.1056/NEJMp1013771; Nelson EJ, 2009, NAT REV MICROBIOL, V7, P693, DOI 10.1038/nrmicro2204; Ryan ET, 2000, AM J TROP MED HYG, V63, P12, DOI 10.4269/ajtmh.2000.63.12; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Walton DA, 2011, NEW ENGL J MED, V364, P3, DOI 10.1056/NEJMp1012997; World Health Organisation, 2007, WHO CAS DEF HIV SURV; World Health Organization, 2005, TREAT DIARRH MAN PHY; World Health Organization, 1999, MAN SEV MALN MAN PHY; 2010, MMWR MORB MORTAL WKL, V59, P1586; 2010, MMWR MORB MORTAL WKL, V59, P1556; CHOLERA OUTBREAK TRA	21	6	6	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2011	364	25					2452	2461		10.1056/NEJMcpc1100927	http://dx.doi.org/10.1056/NEJMcpc1100927			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	781MG	21696312				2023-01-03	WOS:000291936100013
J	Sueyoshi, T; Green, WD; Vinal, K; Woodrum, TS; Moore, R; Negishi, M				Sueyoshi, Tatsuya; Green, William D.; Vinal, Kellie; Woodrum, Tyler S.; Moore, Rick; Negishi, Masahiko			Garlic Extract Diallyl Sulfide (DAS) Activates Nuclear Receptor CAR to Induce the Sult1e1 Gene in Mouse Liver	PLOS ONE			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; DRUG-METABOLIZING-ENZYMES; ORGANOSULFUR COMPOUNDS; ESTROGEN SULFOTRANSFERASE; ENHANCER MODULE; 1E1 EXPRESSION; CANCER; RISK; POLYMORPHISMS; CYP1A1	Constituent chemicals in garlic extract are known to induce phase I and phase II enzymes in rodent livers. Here we have utilized Car(+/+) and Car(-/-) mice to demonstrate that the nuclear xenobiotic receptor CAR regulated the induction of the estrogen sulfotransferase Sult1e1 gene by diallyl sulfide (DAS) treatment in mouse liver. DAS treatment caused CAR accumulation in the nucleus, resulting in a remarkable increase of SULT1E1 mRNA (3,200 fold) and protein in the livers of Car(+/+) females but not of Car(-/-) female mice. DAS also induced other CAR-regulated genes such as Cyp2b10, Cyp3a11 and Gadd45 beta. Compared with the rapid increase of these mRNA levels, which began as early as 6 hourrs after DAS treatment, the levels of SULT1E1 mRNA began increasing after 24 hours. This slow response to DAS suggested that CAR required an additional factor to activate the Sult1e1 gene or that this activation was indirect. Despite the remarkable induction of SULT1E1, there was no decrease in the serum levels of endogenous E2 or increase of estrone sulfate while the clearance of exogenously administrated E2 was accelerated in DAS treated mice.	[Sueyoshi, Tatsuya; Green, William D.; Vinal, Kellie; Woodrum, Tyler S.; Moore, Rick; Negishi, Masahiko] Natl Inst Environm Hlth Sci, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Sueyoshi, T (corresponding author), Natl Inst Environm Hlth Sci, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC USA.	sueyoshi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928; Green, William/0000-0001-7472-8756	NIH, National Institute of Environmental Health Sciences (NIEHS) [Zo1Es71005-01]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES080040] Funding Source: NIH RePORTER	NIH, National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was supported by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (NIEHS), Zo1Es71005-01. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alnouti Y, 2008, J PHARMACOL EXP THER, V324, P612, DOI 10.1124/jpet.107.129650; Berges R, 2004, CARCINOGENESIS, V25, P1953, DOI 10.1093/carcin/bgh200; Bianchini F, 2001, ENVIRON HEALTH PERSP, V109, P893; Chang TKH, 2009, AAPS J, V11, P590, DOI 10.1208/s12248-009-9135-y; Choi JY, 2005, CANCER EPIDEM BIOMAR, V14, P1090, DOI 10.1158/1055-9965.EPI-04-0688; di Masi A, 2009, MOL ASPECTS MED, V30, P297, DOI 10.1016/j.mam.2009.04.002; Dong B, 2009, P NATL ACAD SCI USA, V106, P18831, DOI 10.1073/pnas.0909731106; Falany CN, 2009, J STEROID BIOCHEM, V114, P113, DOI 10.1016/j.jsbmb.2009.02.009; FALANY CN, 1995, J STEROID BIOCHEM, V52, P529, DOI 10.1016/0960-0760(95)00015-R; Falany CN, 2005, METHOD PHARMACOL TOX, P341; Fisher CD, 2007, DRUG METAB DISPOS, V35, P995, DOI 10.1124/dmd.106.014340; Fleischauer AT, 2001, J NUTR, V131, p1032S, DOI 10.1093/jn/131.3.1032S; Gong H, 2008, CANCER RES, V68, P7386, DOI 10.1158/0008-5472.CAN-08-1545; Guyonnet D, 2002, CARCINOGENESIS, V23, P1335, DOI 10.1093/carcin/23.8.1335; Guyonnet D, 2001, MUTAT RES-GEN TOX EN, V495, P135, DOI 10.1016/S1383-5718(01)00205-4; He D, 2008, BBA-MOL CELL RES, V1783, P2391, DOI 10.1016/j.bbamcr.2008.08.012; Hirata H, 2008, CANCER-AM CANCER SOC, V112, P1964, DOI 10.1002/cncr.23392; Honkakoski P, 2003, ANN MED, V35, P172, DOI 10.1080/07853890310008224; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Huang WD, 2005, MOL ENDOCRINOL, V19, P1646, DOI 10.1210/me.2004-0520; Kakizaki S, 2008, CURR DRUG METAB, V9, P614, DOI 10.2174/138920008785821666; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kang HS, 2007, PHYSIOL GENOMICS, V31, P281, DOI 10.1152/physiolgenomics.00098.2007; Kawamoto T, 2000, MOL ENDOCRINOL, V14, P1897, DOI 10.1210/me.14.11.1897; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Konno Y, 2008, DRUG METAB PHARMACOK, V23, P8, DOI 10.2133/dmpk.23.8; Ngo SNT, 2007, J NUTR, V137, P2264, DOI 10.1093/jn/137.10.2264; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; Qatanani M, 2005, CURR DRUG METAB, V6, P329, DOI 10.2174/1389200054633899; Rebbeck TR, 2006, J NATL CANCER I, V98, P1311, DOI 10.1093/jnci/djj360; Song WC, 2001, ANN NY ACAD SCI, V948, P43; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Swales K, 2004, MOL ENDOCRINOL, V18, P1589, DOI 10.1210/me.2003-0397; Tong MH, 2005, NAT MED, V11, P153, DOI 10.1038/nm1184; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Urquhart BL, 2007, J CLIN PHARMACOL, V47, P566, DOI 10.1177/0091270007299930; Wada T, 2009, TRENDS ENDOCRIN MET, V20, P273, DOI 10.1016/j.tem.2009.03.003; Wang HB, 2004, J BIOL CHEM, V279, P29295, DOI 10.1074/jbc.M400580200; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Yamamoto Y, 2004, CANCER RES, V64, P7197, DOI 10.1158/0008-5472.CAN-04-1459; Yamazaki Y, 2007, GUT, V56, P565, DOI 10.1136/gut.2006.093260; Yoshinari K, 2003, FEBS LETT, V548, P17, DOI 10.1016/S0014-5793(03)00720-8; Yoshinari K, 2010, BIOCHEM PHARMACOL, V79, P261, DOI 10.1016/j.bcp.2009.08.008; Zhang P, 2006, CARCINOGENESIS, V27, P2090, DOI 10.1093/carcin/bgl064	47	28	29	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2011	6	6							e21229	10.1371/journal.pone.0021229	http://dx.doi.org/10.1371/journal.pone.0021229			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778TS	21698271	Green Published, gold			2023-01-03	WOS:000291730000064
J	Hernandez-Corbacho, MJ; Jenkins, RW; Clarke, CJ; Hannun, YA; Obeid, LM; Snider, AJ; Siskind, LJ				Hernandez-Corbacho, Maria Jose; Jenkins, Russell W.; Clarke, Christopher J.; Hannun, Yusuf A.; Obeid, Lina M.; Snider, Ashley J.; Siskind, Leah J.			Accumulation of Long-Chain Glycosphingolipids during Aging Is Prevented by Caloric Restriction	PLOS ONE			English	Article							RENAL-CELL CARCINOMA; MEMBRANE-ASSOCIATED SIALIDASE; OXIDATIVE STRESS; INSULIN SENSITIVITY; RAT-KIDNEY; T-CELLS; NUTRITIONAL INFLUENCES; DIABETIC-NEPHROPATHY; ALZHEIMERS-DISEASE; FISCHER-344 RATS	Background: Chronic kidney disease and end-stage renal disease are major causes of morbidity and mortality that are seen far more commonly in the aged population. Interestingly, kidney function declines during aging even in the absence of underlying renal disease. Declining renal function has been associated with age-related cellular damage and dysfunction with reports of increased levels of apoptosis, necrosis, and inflammation in the aged kidney. Bioactive sphingolipids have been shown to regulate these same cellular processes, and have also been suggested to play a role in aging and cellular senescence. Methodology/Principal Findings: We hypothesized that alterations in kidney sphingolipids play a role in the declining kidney function that occurs during aging. To begin to address this, the sphingolipid profile was measured in young (3 mo), middle aged (9 mo) and old (17 mo) C57BL/6 male mice. Interestingly, while modest changes in ceramides and sphingoid bases were evident in kidneys from older mice, the most dramatic elevations were seen in long-chain hexosylceramides (HexCer) and lactosylceramides (LacCer), with C14-and C16-lactosylceramides elevated as much as 8 and 12-fold, respectively. Increases in long-chain LacCers during aging are not exclusive to the kidney, as they also occur in the liver and brain. Importantly, caloric restriction, previously shown to prevent the declining kidney function seen in aging, inhibits accumulation of long-chain HexCer/LacCers and prevents the age-associated elevation of enzymes involved in their synthesis. Additionally, long-chain LacCers are also significantly elevated in human fibroblasts isolated from elderly individuals. Conclusion/Significance: This study demonstrates accumulation of the glycosphingolipids HexCer and LacCer in several different organs in rodents and humans during aging. In addition, data demonstrate that HexCer and LacCer metabolism is regulated by caloric restriction. Taken together, data suggest that HexCer/LacCers are important mediators of cellular processes fundamental to mammalian aging.	[Hernandez-Corbacho, Maria Jose; Obeid, Lina M.; Snider, Ashley J.; Siskind, Leah J.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; [Jenkins, Russell W.; Clarke, Christopher J.; Hannun, Yusuf A.] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Obeid, Lina M.; Snider, Ashley J.; Siskind, Leah J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA	Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center	Hernandez-Corbacho, MJ (corresponding author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.	siskind@musc.edu		Siskind, Leah/0000-0001-5026-5187; obeid, lina/0000-0002-0734-0847	VA Merit; VA; VA REAP; American Cancer Society [IRG-97-219-11]; NIH/NCRR [P30 CA138313, P20 RR17677]; American Heart Association [AHA 081509E]; NIH [GM08716, GM-43825]; MUSC Hollings Cancer Center Abney Foundation; NIH/NIA [R01 AG016583]; NATIONAL CANCER INSTITUTE [P30CA138313] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG016583] Funding Source: NIH RePORTER	VA Merit(US Department of Veterans Affairs); VA(US Department of Veterans Affairs); VA REAP; American Cancer Society(American Cancer Society); NIH/NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); American Heart Association(American Heart Association); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MUSC Hollings Cancer Center Abney Foundation; NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work is supported by: VA Merit (to L.M.O.), VA CDA-2 Awards (to L.J.S. and A.J.S.), pilot project from the VA REAP (to L.J.S., A.J.S., and L.M.O.), the American Cancer Society Institutional Research Grant # IRG-97-219-11 (subaward to L.J.S.), Lipidomics Shared Resource of the Hollings Cancer Center supported by a Cancer Center Support Grant (P30 CA138313), pilot project (to L.J.S) from the NIH/NCRR P20 RR17677 COBRE in Lipidomics and Pathobiology, American Heart Association Pre-Doctoral Fellowship (AHA 081509E - to R.W.J.), NIH MSTP Training Grant (GM08716 - to R.W.J.), MUSC Hollings Cancer Center Abney Foundation Scholarship (to R.W.J.), and NIH/NIA R01 AG016583 (L.M.O.) and NIH GM-43825 (YAH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts JM, 2007, DIABETES, V56, P1341, DOI 10.2337/db06-1619; Alessenko AV, 2004, BIOCHEM SOC T, V32, P144, DOI 10.1042/BST0320144; Bielawski J, 2006, METHODS, V39, P82, DOI 10.1016/j.ymeth.2006.05.004; Biswas K, 2006, CANCER RES, V66, P6816, DOI 10.1158/0008-5472.CAN-06-0250; Biswas S, 2009, J IMMUNOL, V183, P5050, DOI 10.4049/jimmunol.0900259; Breunig F, 2008, J NEPHROL, V21, P32; CADENAS S, 1994, EXP GERONTOL, V29, P77, DOI 10.1016/0531-5565(94)90064-7; Chatteriee S, 2008, BBA-GEN SUBJECTS, V1780, P370, DOI 10.1016/j.bbagen.2007.08.010; Chatterjee S, 2003, METHOD ENZYMOL, V363, P300; Chatterjee S, 1996, J LIPID RES, V37, P1334; Coughlan MT, 2008, ANN NY ACAD SCI, V1126, P190, DOI 10.1196/annals.1433.018; Covington MD, 2009, AM J PHYSIOL-RENAL, V296, pF478, DOI 10.1152/ajprenal.90477.2008; Csiszar A, 2007, ACTA PHYSIOL HUNG, V94, P107, DOI 10.1556/APhysiol.94.2007.1-2.10; Cutler RG, 2004, P NATL ACAD SCI USA, V101, P2070, DOI 10.1073/pnas.0305799101; Das T, 2008, CANCER RES, V68, P2014, DOI 10.1158/0008-5472.CAN-07-6037; Dave GS, 2007, CELL MOL BIOL, V53, P68, DOI 10.1170/T820; Degroote S, 2004, SEMIN CELL DEV BIOL, V15, P375, DOI 10.1016/j.semcdb.2004.03.007; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; Fernandez-Checa Jose C, 2003, Ann Hepatol, V2, P69; Forbes JM, 2008, DIABETES, V57, P1446, DOI 10.2337/db08-0057; Garcia-Ruiz C, 2003, J CLIN INVEST, V111, P197, DOI 10.1172/JCI200316010; GIUSTO NM, 1992, LIPIDS, V27, P835, DOI 10.1007/BF02535859; Gredilla R, 2004, ANN NY ACAD SCI, V1019, P333, DOI 10.1196/annals.1297.057; GRONE EF, 1994, ATHEROSCLEROSIS, V107, P1, DOI 10.1016/0021-9150(94)90136-8; Guan F, 2009, P NATL ACAD SCI USA, V106, P7461, DOI 10.1073/pnas.0902368106; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; GUPTA G, FEBS LETT, V584, P1634; Ha H, 2005, NEPHROLOGY, V10, pS7, DOI 10.1111/j.1440-1797.2005.00448.x; HAMMAD SM, J LIPID RES, V51, P3074; Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329; Hedlund M, 1998, MOL MICROBIOL, V29, P1297, DOI 10.1046/j.1365-2958.1998.01017.x; Huwiler A, 2001, BIOCHEM BIOPH RES CO, V284, P404, DOI 10.1006/bbrc.2001.4941; Jiang T, 2005, J AM SOC NEPHROL, V16, P2385, DOI 10.1681/ASN.2004080701; Jung JU, 2009, EXP MOL MED, V41, P935, DOI 10.3858/emm.2009.41.12.099; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; Kim HJ, 2002, EXP GERONTOL, V37, P1041, DOI 10.1016/S0531-5565(02)00082-7; Langeveld M, 2009, PROG LIPID RES, V48, P196, DOI 10.1016/j.plipres.2009.03.002; Lee JH, 2004, EXP GERONTOL, V39, P1361, DOI 10.1016/j.exger.2004.06.015; Lightle SA, 2000, MECH AGEING DEV, V120, P111, DOI 10.1016/S0047-6374(00)00191-3; Liu B, 2000, METHOD ENZYMOL, V311, P156; Lochhead KM, 1998, KIDNEY INT, V54, P373, DOI 10.1046/j.1523-1755.1998.00022.x; MAEDA H, 1985, J GERONTOL, V40, P671, DOI 10.1093/geronj/40.6.671; Martin JE, 2007, J PATHOL, V211, P198, DOI 10.1002/path.2111; Martin SF, 2006, GLYCOCONJUGATE J, V23, P147, DOI 10.1007/s10719-006-7920-8; Maruyama R, 2007, ANTICANCER RES, V27, P4345; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; MATHER AR, 2011, LANDES BIOS IN PRESS; Mei CL, 2009, SEMIN NEPHROL, V29, P555, DOI 10.1016/j.semnephrol.2009.07.002; Miyagi T, 2008, BBA-GEN SUBJECTS, V1780, P532, DOI 10.1016/j.bbagen.2007.09.016; Muhlberg W, 1999, GERONTOLOGY, V45, P243, DOI 10.1159/000022097; NATOLI TA, NAT MED; Nikolova-Karakashian Mariana, 2008, V49, P469, DOI 10.1007/978-1-4020-8831-5_18; Ogiso M, 1999, EXP EYE RES, V68, P229, DOI 10.1006/exer.1998.0598; Rao RP, 2007, P NATL ACAD SCI USA, V104, P11364, DOI 10.1073/pnas.0705049104; Ravussin E, 2007, Journ Annu Diabetol Hotel Dieu, P111; Razzaque MS, 2007, AGEING RES REV, V6, P211, DOI 10.1016/j.arr.2007.06.001; Razzaque MS, 1998, CELL TISSUE RES, V293, P471, DOI 10.1007/s004410051139; Ruiz-Torres MP, 1998, J AM SOC NEPHROL, V9, P782; Rutkute K, 2007, J LIPID RES, V48, P2443, DOI 10.1194/jlr.M700227-JLR200; Sa G, 2009, CANCER RES, V69, P3095, DOI 10.1158/0008-5472.CAN-08-3776; Sacket SJ, 2009, ACTA PHARMACOL SIN, V30, P1454, DOI 10.1038/aps.2009.136; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; Senda M, 2007, BIOCHEM J, V402, P459, DOI 10.1042/BJ20061118; Sessa A, 2001, J INHERIT METAB DIS, V24, P66, DOI 10.1023/A:1012423924648; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Siskind LJ, 2010, J BIOL CHEM, V285, P11818, DOI 10.1074/jbc.M109.078121; Spassieva S, 2006, J BIOL CHEM, V281, P33931, DOI 10.1074/jbc.M608092200; Summers SA, 2006, PROG LIPID RES, V45, P42, DOI 10.1016/j.plipres.2005.11.002; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894; Thornton MV, 2004, J IMMUNOL, V172, P3480, DOI 10.4049/jimmunol.172.6.3480; Ueno S, 2006, J BIOL CHEM, V281, P7756, DOI 10.1074/jbc.M509668200; van Eijk M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004723; Vasto S, 2007, MECH AGEING DEV, V128, P83, DOI 10.1016/j.mad.2006.11.015; Vogtlander NPJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005979; VOGTLANDER NP, NEPHROL DIAL TRANSPL, V25, P478; WENNEKES T, J MED CHEM, V53, P689; Wennekes T, 2009, ANGEW CHEM INT EDIT, V48, P8848, DOI 10.1002/anie.200902620; Yamashita T, 2003, P NATL ACAD SCI USA, V100, P3445, DOI 10.1073/pnas.0635898100; YANG Q, CELL MOL LIFE SCI, V67, P1477; YEW NS, PLOS ONE, V5; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; ZADOR IZ, 1993, J CLIN INVEST, V91, P797, DOI 10.1172/JCI116299; Zager RA, 1998, J AM SOC NEPHROL, V9, P1670; Zager RA, 1998, KIDNEY INT, V53, P573, DOI 10.1046/j.1523-1755.1998.00772.x; Zager RA, 1997, KIDNEY INT, V52, P60, DOI 10.1038/ki.1997.304; Zarate YA, 2008, LANCET, V372, P1427, DOI 10.1016/S0140-6736(08)61589-5; Zhang XB, 2004, ANN CLIN LAB SCI, V34, P3; Zhao HM, 2007, DIABETES, V56, P1210, DOI 10.2337/db06-0719	88	31	33	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2011	6	6							e20411	10.1371/journal.pone.0020411	http://dx.doi.org/10.1371/journal.pone.0020411			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777JJ	21687659	gold, Green Submitted, Green Published			2023-01-03	WOS:000291611500023
J	Ope, MO; Katz, MA; Aura, B; Gikunju, S; Njenga, MK; Ng'ang'a, Z; Vulule, J; Breiman, RF; Feikin, DR				Ope, Maurice O.; Katz, Mark A.; Aura, Barrack; Gikunju, Stella; Njenga, M. Kariuki; Ng'ang'a, Zipporah; Vulule, John; Breiman, Robert F.; Feikin, Daniel R.			Risk Factors for Hospitalized Seasonal Influenza in Rural Western Kenya	PLOS ONE			English	Article							RESPIRATORY-TRACT INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; TYPE-1 INFECTION; SWINE INFLUENZA; HIGH PREVALENCE; MORTALITY; MORBIDITY; HUMANS; EPIDEMIOLOGY	Background: Risk factors for influenza hospitalization in Africa are unknown, including the role of HIV. Methods: We conducted a case-control study of risk factors for hospitalized seasonal influenza among persons in rural western Kenya, a high HIV prevalence area, from March 2006-August 2008. Eligible cases were >= five years old, admitted to health facilities with respiratory symptoms, and had nasopharyngeal/oropharyngeal swab specimens that tested positive for influenza A or B by real-time reverse transcription-PCR. Three randomly selected age- ,sex-and neighborhood-matched controls were enrolled per case. A structured questionnaire was administered and home-based HIV testing was performed. Risk factors were evaluated using conditional logistic regression. Results: A total of 64 cases (38 with influenza A and 26 with influenza B) and 190 controls were enrolled. The median age was 16 years (range 5-69 years). Among cases, 24.5% were HIV-infected versus 12.5% of controls (p = 0.004). Among persons >= 18 years old, 13 (59%) of 22 tested cases were HIV-positive compared with 15 (24%) of 62 tested controls (p = 0.005). In multivariable analysis, HIV-infection was associated with hospitalization due to influenza [adjusted Odds Ratio (aOR) 3.56, 95% CI 1.25-10.1]. The mean CD4 count among HIV-infected cases and controls was similar (399 vs. 387, respectively, p = 0.89). Chronic lung disease (aOR 6.83, 95% CI 1.37-34.0) was also associated with influenza hospitalization in multivariable analysis. Active pulmonary tuberculosis was associated with influenza hospitalization in bivariate, but not multivariable, analysis. Conclusions: People with HIV infection and chronic lung disease were at increased risk of hospitalized influenza in rural Kenya. HIV infection is common in many parts of sub-Saharan Africa. Influenza vaccine might prevent severe influenza in these risk groups.	[Ope, Maurice O.] Minist Publ Hlth & Sanitat, Dept Dis Surveillance & Response, Nairobi, Kenya; [Ope, Maurice O.] Ctr Dis Control & Prevent, Field Epidemiol & Lab Management Training Program, Nairobi, Kenya; [Ope, Maurice O.; Ng'ang'a, Zipporah] Jomo Kenyatta Univ Agr & Technol, Nairobi, Kenya; [Katz, Mark A.] Ctr Dis Control & Prevent, Global Dis Detect Div, Influenza Program, Nairobi, Kenya; [Aura, Barrack; Gikunju, Stella; Njenga, M. Kariuki; Breiman, Robert F.; Feikin, Daniel R.] Ctr Dis Control & Prevent, Int Emerging Infect Program, Nairobi, Kenya; [Aura, Barrack; Gikunju, Stella; Vulule, John] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya	Jomo Kenyatta University of Agriculture & Technology; Kenya Medical Research Institute	Ope, MO (corresponding author), Minist Publ Hlth & Sanitat, Dept Dis Surveillance & Response, Nairobi, Kenya.	dfeikin@cdc.gov			U.S. Centers for Disease Control and Prevention	U.S. Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	The project was funded by funding from the U.S. Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261, DOI 10.1056/NEJMra0707279; Adazu K, 2005, AM J TROP MED HYG, V73, P1151, DOI 10.4269/ajtmh.2005.73.1151; Amornkul PN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006470; Anema A, 2008, HIV MED, V9, P57, DOI 10.1111/j.1468-1293.2008.00515.x; Bender JM, 2009, PEDIATR EMERG CARE, V25, P369, DOI 10.1097/PEC.0b013e3181a792a9; Boschini A, 2006, J MED VIROL, V78, P1218, DOI 10.1002/jmv.20684; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; Fine AD, 2001, CLIN INFECT DIS, V32, P1784, DOI 10.1086/320747; Gessner BD, 2011, LANCET INFECT DIS, V11, P223, DOI 10.1016/S1473-3099(11)70008-1; Howard AA, 2010, CLIN INFECT DIS, V50, pS238, DOI 10.1086/651497; *IFPMA, 2010, P 7 C OPT CONTR INFL; Karim SSA, 2009, LANCET, V374, P921, DOI 10.1016/S0140-6736(09)60916-8; Kunisaki KM, 2009, LANCET INFECT DIS, V9, P493, DOI 10.1016/S1473-3099(09)70175-6; Li GX, 2009, J CLIN VIROL, V46, P275, DOI 10.1016/j.jcv.2009.07.015; Lin JC, 2001, ARCH INTERN MED, V161, P441, DOI 10.1001/archinte.161.3.441; Madhi SA, 2002, PEDIATR INFECT DIS J, V21, P291, DOI 10.1097/00006454-200204000-00007; Madhi SA, 2000, J PEDIATR-US, V137, P78, DOI 10.1067/mpd.2000.105350; Madhi SA, 2007, PEDIATR INFECT DIS J, V26, P693, DOI 10.1097/INF.0b013e3180621192; Myers KP, 2007, CLIN INFECT DIS, V44, P1084, DOI 10.1086/512813; National AIDS and STI Control Programme, 2008, KEN AIDS IND SURV 20; Neuzil KM, 2003, JAIDS-J ACQ IMM DEF, V34, P304, DOI 10.1097/00126334-200311010-00008; Neuzil KM, 1999, JAMA-J AM MED ASSOC, V281, P901, DOI 10.1001/jama.281.10.901; Ortiz JR, 2009, EMERG INFECT DIS, V15, P1271, DOI 10.3201/eid1508.081422; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Shinde V, 2009, NEW ENGL J MED, V360, P2616, DOI 10.1056/NEJMoa0903812; Tasker SA, 1999, ANN INTERN MED, V131, P430, DOI 10.7326/0003-4819-131-6-199909210-00006; World Health Organization, 2008, HIV AIDS EP SURV REP; Zurovac D, 2006, TROP MED INT HEALTH, V11, P1185, DOI 10.1111/j.1365-3156.2006.01674.x; 2002, WKLY EPIDEMIOL REC, V77, P350	29	29	29	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2011	6	5							e20111	10.1371/journal.pone.0020111	http://dx.doi.org/10.1371/journal.pone.0020111			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769XS	21637856	gold, Green Published, Green Submitted			2023-01-03	WOS:000291052200033
J	Dugue, L; Marque, P; VanRullen, R				Dugue, Laura; Marque, Philippe; VanRullen, Rufin			Transcranial Magnetic Stimulation Reveals Attentional Feedback to Area V1 during Serial Visual Search	PLOS ONE			English	Article							FRONTAL EYE FIELDS; PARIETAL CORTEX; TIME-COURSE; SET-SIZE; CONJUNCTION; PERCEPTION; BRAIN; MODEL	Visual search tasks have been used to understand how, where and when attention influences visual processing. Current theories suggest the involvement of a high-level "saliency map'' that selects a candidate location to focus attentional resources. For a parallel (or "pop-out'') task, the first chosen location is systematically the target, but for a serial (or "difficult'') task, the system may cycle on a few distractors before finally focusing on the target. This implies that attentional effects upon early visual areas, involving feedback from higher areas, should be visible at longer latencies during serial search. A previous study from Juan & Walsh (2003) had used Transcranial Magnetic Stimulation (TMS) to support this conclusion; however, only a few post-stimulus delays were compared, and no control TMS location was used. Here we applied TMS double-pulses (sub-threshold) to induce a transient inhibition of area V1 at every post-stimulus delay between 100 ms and 500 ms (50 ms steps). The search array was presented either at the location affected by the TMS pulses (previously identified by applying several pulses at supra-threshold intensity to induce phosphene perception), or in the opposite hemifield, which served as a retinotopically-defined control location. Two search tasks were used: a parallel (+ among Ls) and a serial one (T among Ls). TMS specifically impaired the serial, but not the parallel search. We highlight an involvement of V1 in serial search 300 ms after the onset; conversely, V1 did not contribute to parallel search at delays beyond 100 ms. This study supports the idea that serial search differs from parallel search by the presence of additional cycles of a select-and-focus iterative loop between V1 and higher-level areas.	[Dugue, Laura; VanRullen, Rufin] Univ Toulouse 3, F-31062 Toulouse, France; [Dugue, Laura; VanRullen, Rufin] CNRS, Ctr Rech Cerveau & Cognit, UMR5549, Fac Med Purpan, Toulouse, France; [Marque, Philippe] CHU Rangueil, F-31054 Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Dugue, L (corresponding author), Univ Toulouse 3, F-31062 Toulouse, France.	laura.dugue@cerco.ups-tlse.fr	MARQUE, Philippe/AAC-4798-2019; MARQUE, PHILIPPE/F-9303-2013; VanRullen, Rufin/B-2150-2008	VanRullen, Rufin/0000-0002-3611-7716; Dugue, Laura/0000-0003-3085-1458	EURYI Award; ANR [06JCJC-0154]	EURYI Award(European Science Foundation (ESF)); ANR(French National Research Agency (ANR))	This research was funded by a EURYI Award and an ANR grant 06JCJC-0154 to RV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashbridge E, 1997, NEUROPSYCHOLOGIA, V35, P1121, DOI 10.1016/S0028-3932(97)00003-1; Barker AT, 1999, HIST BASIC PRINCIPLE; Carrasco M, 1998, J EXP PSYCHOL HUMAN, V24, P673, DOI 10.1037/0096-1523.24.2.673; Deco G, 2002, VISION RES, V42, P2925, DOI 10.1016/S0042-6989(02)00358-9; Eckstein MP, 2000, PERCEPT PSYCHOPHYS, V62, P425, DOI 10.3758/BF03212096; Green D. M., 1966, SIGNAL DETECTION THE; Itti L, 2001, NAT REV NEUROSCI, V2, P194, DOI 10.1038/35058500; Kalla R, 2008, NEUROREPORT, V19, P1067, DOI 10.1097/WNR.0b013e328304d9c4; Muggleton NG, 2008, NEUROPSYCHOLOGIA, V46, P2198, DOI 10.1016/j.neuropsychologia.2008.02.016; Muggleton NG, 2010, CORTEX, V46, P178, DOI 10.1016/j.cortex.2009.01.011; Nothdurft HC, 1999, VISION RES, V39, P2305, DOI 10.1016/S0042-6989(99)00006-1; NOWAK LG, 1995, VISUAL NEUROSCI, V12, P371, DOI 10.1017/S095252380000804X; O'Shea J, 2004, J COGNITIVE NEUROSCI, V16, P1060, DOI 10.1162/0898929041502634; PALMER J, 1993, J EXP PSYCHOL HUMAN, V19, P108, DOI 10.1037/0096-1523.19.1.108; Romei V, 2010, J NEUROSCI, V30, P8692, DOI 10.1523/JNEUROSCI.0160-10.2010; Rossi S, 2009, CLIN NEUROPHYSIOL, V120, P2008, DOI 10.1016/j.clinph.2009.08.016; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Sommer M, 2008, TMS WAVEFORM CURRENT; Thorpe SJ, 2001, SCIENCE, V291, P260, DOI 10.1126/science.1058249; Treisman A, 1998, PHILOS T ROY SOC B, V353, P1295, DOI 10.1098/rstb.1998.0284; TREISMAN A, 1985, J EXP PSYCHOL GEN, V114, P285, DOI 10.1037/0096-3445.114.3.285; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Valero-Cabre A, 2005, EXP BRAIN RES, V163, P1, DOI 10.1007/s00221-004-2140-6; VanRullen R, 2001, J COGNITIVE NEUROSCI, V13, P454, DOI 10.1162/08989290152001880; Wassermann EM, 1998, NEUROSCI LETT, V250, P141, DOI 10.1016/S0304-3940(98)00437-6; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8; Wolfe Jeremy M, 2010, Curr Biol, V20, pR346, DOI 10.1016/j.cub.2010.02.016; Wolfe JM, 2010, CURR BIOL, V20, pR346, DOI 10.1016/j.cub.2010.02.016; WOLFE JM, 1989, J EXP PSYCHOL HUMAN, V15, P419, DOI 10.1037/0096-1523.15.3.419	29	14	14	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 17	2011	6	5							e19712	10.1371/journal.pone.0019712	http://dx.doi.org/10.1371/journal.pone.0019712			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	764TX	21611188	Green Published, gold, Green Submitted			2023-01-03	WOS:000290657500016
J	White, PM; Lewis, SC; Gholkar, A; Sellar, RJ; Nahser, H; Cognard, C; Forrester, L; Wardlaw, JM				White, Philip M.; Lewis, Stephanie C.; Gholkar, Anil; Sellar, Robin J.; Nahser, Hans; Cognard, Christophe; Forrester, Lynn; Wardlaw, Joanna M.		HELPS Trial Collaborators	Hydrogel-coated coils versus bare platinum coils for the endovascular treatment of intracranial aneurysms (HELPS): a randomised controlled trial	LANCET			English	Article							CEREBRAL ANEURYSMS; EMBOLIZATION; MENINGITIS; AGREEMENT; OCCLUSION; PACKING; EDEMA; ISAT	Background Coated coils for endovascular treatment of cerebral aneurysm were developed to reduce recurrence and retreatment rates, and have been in clinical use for 8-9 years without robust evidence to determine their efficacy. We assessed the efficacy and safety of hydrogel-coated coils. Methods This randomised trial was undertaken in 24 centres in seven countries. Patients aged 18-75 years with a previously untreated ruptured or unruptured cerebral aneurysm of 2-25 mm in maximum diameter were randomly allocated (1:1) to aneurysm coiling with either hydrogel-coated coils or standard bare platinum coils (control). Randomisation was done with a computer-generated sequence, stratified by aneurysm size, shape, and dome-to-neck ratio; intention to use assist device; and by region. Participants and those assessing outcomes were masked to allocation. Analysis was by modified intention to treat (excluding missing data). Primary outcome was a composite of angiographic and clinical outcomes at 18-month follow-up. We also did prespecified subgroup analyses of characteristics likely to be relevant to angiographic outcome. This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN30531382. Findings 249 patients were allocated to the hydrogel coil group and 250 to the control group. In 44 of 467 patients for whom an 18-month composite primary outcome was unavailable, 6-month angiographic results were used. 70 (28%) patients in the hydrogel group and 90 (36%) control patients had an adverse composite primary outcome, giving an absolute reduction in the proportion of adverse composite primary outcomes with hydrogel of 7.0% (95% CI -1.6 to 15.5), odds ratio (OR) 0.73 (0.49-1.1, p=0.13). In a prespecified subgroup analysis in recently ruptured aneurysms, there were more adverse composite primary outcomes in the control group than in the hydrogel group OR 2.08 (1.24-3.46, p=0.014). There were 8.6% fewer major angiographic recurrences in patients allocated to hydrogel coils OR 0.7 (0.4-1.0, p=0.049). There were five cases of unexplained hydrocephalus in not-recently-ruptured aneurysms in the hydrogel coil group and one case in the control group. Interpretation Whether use of hydrogel coils reduces late aneurysm rupture or improves long-term clinical outcome is not dear, but our results indicate that their use lowers major recurrence.	[White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Western Gen Hosp, Dept Neuroradiol, Edinburgh EH4 2XU, Midlothian, Scotland; [White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Western Gen Hosp, Univ Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; [White, Philip M.; Sellar, Robin J.; Forrester, Lynn; Wardlaw, Joanna M.] Univ Edinburgh, SINAPSE Collaborat, Edinburgh, Midlothian, Scotland; [Lewis, Stephanie C.] Univ Edinburgh, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Gholkar, Anil] Newcastle Gen Hosp, Dept Neuroradiol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Nahser, Hans] Walton Ctr Neurosurg & Neurol, Liverpool, Merseyside, England; [Cognard, Christophe] Purpan Hosp, Dept Neuroradiol, Toulouse, France	University of Edinburgh; University of Edinburgh; University of Edinburgh; University of Edinburgh; Newcastle General Hospital; Walton Centre; CHU de Toulouse	White, PM (corresponding author), Western Gen Hosp, Dept Neuroradiol, Edinburgh EH4 2XU, Midlothian, Scotland.	pwhite1@staffmail.ed.ac.uk	Hernandez, María/GYU-3543-2022; Wardlaw, Joanna M/Y-3456-2019	Wardlaw, Joanna M/0000-0002-9812-6642; White, Philip/0000-0001-6007-6013; cognard, christophe/0000-0003-4287-2627	MicroVention Inc; Lothian University Hospitals Division (Edinburgh, UK); Scottish Funding Council [SC005336]; Micrus; Codman; Siemens Medical; MicroVention Terumo; MicroVention Terumo Inc.; MRC [G0800803] Funding Source: UKRI; Medical Research Council [G0800803] Funding Source: researchfish	MicroVention Inc; Lothian University Hospitals Division (Edinburgh, UK); Scottish Funding Council; Micrus; Codman; Siemens Medical; MicroVention Terumo; MicroVention Terumo Inc.; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The trial was funded by MicroVention Inc (the manufacturers of the hydrogel coils used in this trial) and sponsored by Lothian University Hospitals Division (Edinburgh, UK). (MW was supported by the Scottish Funding Council through the SINAPSE Collaboration (grant number SC005336). We are very grateful to all the trial participants and collaborators, and to the data monitoring committee (RB, PS, and NA). Preliminary findings from this study have been presented at the World Federation of Interventional and Therapeutic Neuroradiology Congress; Montreal, Canada; June 29 July 3, 2009.; PMW has done consultancy work for MicroVention Inc and Micrus (both companies manufacture coils for aneurysm treatment); holds an unrestricted research grant front MicroVention for HELPS as the Chief Investigator, has received financial support to attend conferences during the past 5 years from Micrus, Codman (a manufacturer of coils for aneurysm treatment), and MicroVention; had MicroVention stock options from 2001-02, which were bought out when Terumo took over Microvention in 2006; and is the co-organiser of an educational meeting (Brainstorm), which is sponsored by Siemens Medical and MicroVention Terumo. SCL had some of her salary paid from the grant from Microvention Terumo for HELPS. AG has received travel support to conferences from MicroVention Inc and Codman, and has done consultancy work for Codman. RJS has done consultancy work for MicroVention and Micrus and is the co-organiser of an annual educational meeting (Brainstorm), which is sponsored by Siemens Medical and Microvention Terumo. HN has done consultancy work for Boston Scientific (a manufacturer of coils for aneurysm treatment) and has received support to attend conferences during the past 5 years from Boston, Codman, and Microvention. CC has done consultancy work for Boston Scientific, Codman, eV3 (a manufacturer of coils for aneurysm treatment), and MicroVention Terumo Inc. LF was employed as the trial manager of HELPS, funded by MicroVention Terumo Inc. JMW declares that she has no conflicts of interest.	Adams WM, 2000, NEUROINTERVENTIONIST, V1, P74; BREIG A, 1967, LANCET, V1, P874; Brilstra EH, 1999, STROKE, V30, P470, DOI 10.1161/01.STR.30.2.470; Byrne JV, 1999, J NEUROSURG, V90, P656, DOI 10.3171/jns.1999.90.4.0656; Campi A, 2007, STROKE, V38, P1538, DOI 10.1161/STROKEAHA.106.466987; Cloft HJ, 2007, AM J NEURORADIOL, V28, P497; Cloft HJ, 2004, AM J NEURORADIOL, V25, P60; Cognard C, 1998, RADIOLOGY, V206, P499, DOI 10.1148/radiology.206.2.9457205; DRAKE CG, 1988, J NEUROSURG, V68, P985; Fanning NF, 2008, J NEUROSURG, V108, P1074, DOI 10.3171/JNS/2008/108/6/1074; Horie N, 2007, J NEUROSURG, V106, P916, DOI 10.3171/jns.2007.106.5.916; Im SH, 2007, AM J NEURORADIOL, V28, P511; Kallmes DF, 2002, AM J NEURORADIOL, V23, P1580; Meyers PM, 2004, NEUROSURGERY, V55, P1222, DOI 10.1227/01.NEU.0000140987.71791.DF; Molyneux A, 2002, LANCET, V360, P1267, DOI 10.1016/S0140-6736(02)11314-6; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Naggara ON, 2010, RADIOLOGY, V256, P887, DOI 10.1148/radiol.10091982; Plowman RS, 2011, J NEUROSURG, V114, P863, DOI 10.3171/2010.6.JNS091058; Raymond J, 2003, STROKE, V34, P1398, DOI 10.1161/01.STR.0000073841.88563.E9; Raymond J, 2007, AM J NEURORADIOL, V28, P501; ROTHWELL P, 1995, LANCET, V346, P1623, DOI 10.1016/S0140-6736(95)91953-8; White PM, 2008, AM J NEURORADIOL, V29, P217, DOI 10.3174/ajnr.A0936; White PM, 2009, AM J NEURORADIOL, V30, P219, DOI 10.3174/ajnr.A1324; Wiebers D, 2003, LANCET, V362, P103, DOI 10.1016/S0140-6736(03)13860-3	25	200	209	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1655	1662		10.1016/S0140-6736(11)60408-X	http://dx.doi.org/10.1016/S0140-6736(11)60408-X			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571149				2023-01-03	WOS:000290777700030
J	Van Allen, EM				Van Allen, Eliezer M.			Paracentesis by Moonlight	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												evanallen@partners.org		Van Allen, Eliezer/0000-0002-0201-4444					0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	2011	305	16					1635	1636		10.1001/jama.2011.472	http://dx.doi.org/10.1001/jama.2011.472			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	754XG	21521838				2023-01-03	WOS:000289890500001
J	Poplawski, MM; Mastaitis, JW; Isoda, F; Grosjean, F; Zheng, F; Mobbs, CV				Poplawski, Michal M.; Mastaitis, Jason W.; Isoda, Fumiko; Grosjean, Fabrizio; Zheng, Feng; Mobbs, Charles V.			Reversal of Diabetic Nephropathy by a Ketogenic Diet	PLOS ONE			English	Article							OXIDATIVE STRESS; ALZHEIMERS-DISEASE; MOUSE MODEL; APOPTOSIS; NEURONS; GLUCOSE; RESTRICTION; EXPRESSION; COMPLICATIONS; HYSTERESIS	Intensive insulin therapy and protein restriction delay the development of nephropathy in a variety of conditions, but few interventions are known to reverse nephropathy. Having recently observed that the ketone 3-beta-hydroxybutyric acid (3-OHB) reduces molecular responses to glucose, we hypothesized that a ketogenic diet, which produces prolonged elevation of 3-OHB, may reverse pathological processes caused by diabetes. To address this hypothesis, we assessed if prolonged maintenance on a ketogenic diet would reverse nephropathy produced by diabetes. In mouse models for both Type 1 (Akita) and Type 2 (db/db) diabetes, diabetic nephropathy (as indicated by albuminuria) was allowed to develop, then half the mice were switched to a ketogenic diet. After 8 weeks on the diet, mice were sacrificed to assess gene expression and histology. Diabetic nephropathy, as indicated by albumin/creatinine ratios as well as expression of stress-induced genes, was completely reversed by 2 months maintenance on a ketogenic diet. However, histological evidence of nephropathy was only partly reversed. These studies demonstrate that diabetic nephropathy can be reversed by a relatively simple dietary intervention. Whether reduced glucose metabolism mediates the protective effects of the ketogenic diet remains to be determined.	[Poplawski, Michal M.; Isoda, Fumiko; Mobbs, Charles V.] Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY USA; [Mastaitis, Jason W.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; [Grosjean, Fabrizio; Zheng, Feng] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY USA	Icahn School of Medicine at Mount Sinai; Yale University; Icahn School of Medicine at Mount Sinai	Poplawski, MM (corresponding author), Mt Sinai Sch Med, Fishberg Ctr Neurobiol, New York, NY USA.	charles.mobbs@mssm.edu		Mobbs, Charles/0000-0002-5815-8711	Juvenile Diabetes Foundation International; NIH/NIDDK [1R01HD060914-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD060914] Funding Source: NIH RePORTER	Juvenile Diabetes Foundation International; NIH/NIDDK(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	These studies were supported by the Juvenile Diabetes Foundation International. Grant support: NIH/NIDDK (1R01HD060914-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002; Badman MK, 2009, AM J PHYSL ENDOCRINO; Bailey EE, 2005, EPILEPSY BEHAV, V6, P4, DOI 10.1016/j.yebeh.2004.10.006; Barutta F, 2010, DIABETES, V59, P1046, DOI 10.2337/db09-1336; Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a; Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009; Cheng H, 2008, ENDOCRINOLOGY, V149, P703, DOI 10.1210/en.2007-0772; CROFFORD OB, 1995, ANNU REV MED, V46, P267; El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188; Garriga-Canut M, 2006, NAT NEUROSCI, V9, P1382, DOI 10.1038/nn1791; Ghosh S, 2009, AM J PHYSIOL-RENAL, V296, pF700, DOI 10.1152/ajprenal.90548.2008; Grant MM, 2005, PROTEOMICS, V5, P534, DOI 10.1002/pmic.200300924; Gum ET, 2004, STROKE, V35, P590, DOI 10.1161/01.STR.0000110790.05859.DA; Hamada Yasuhiro, 2007, Kobe J Med Sci, V53, P53; Ho L, 2004, FASEB J, V18, P902, DOI 10.1096/fj.03-0978fje; Kennedy AR, 2007, AM J PHYSIOL-ENDOC M, V292, pE1724, DOI 10.1152/ajpendo.00717.2006; Kojima S, 2009, PEPTIDES, V30, P962, DOI 10.1016/j.peptides.2009.01.007; Kowluru RA, 2004, J DIABETES COMPLICAT, V18, P282, DOI 10.1016/j.jdiacomp.2004.03.002; Laurent M, 2005, CELL MOL BIOL, V51, P583, DOI 10.1170/T667; Lee Y, 2004, NEUROCHEM INT, V44, P107, DOI 10.1016/S0197-0186(03)00112-8; Ma WY, 2007, J NEUROSCI, V27, P3618, DOI 10.1523/JNEUROSCI.0132-07.2007; Maalouf M, 2009, BRAIN RES REV, V59, P293, DOI 10.1016/j.brainresrev.2008.09.002; Menini S, 2007, DIABETOLOGIA, V50, P2591, DOI 10.1007/s00125-007-0821-y; Mercer LD, 2005, BIOCHEM PHARMACOL, V69, P339, DOI 10.1016/j.bcp.2004.09.018; Mobbs Charles V., 2007, V35, P39; Osakada F, 2004, J PHARMACOL EXP THER, V311, P51, DOI 10.1124/jpet.104.070334; Ozbudak EM, 2004, NATURE, V427, P737, DOI 10.1038/nature02298; Pelsman A, 2003, INT J DEV NEUROSCI, V21, P117, DOI 10.1016/S0736-5748(03)00031-5; Smith SL, 2005, CNS DRUG REV, V11, P113; Susztak K, 2006, DIABETES, V55, P225, DOI 10.2337/diabetes.55.01.06.db05-0894; Tonna S, 2010, NAT REV NEPHROL, V6, P332, DOI 10.1038/nrneph.2010.55; Wang J, 2005, FASEB J, V19, P659, DOI 10.1096/fj.04-3182fje; Zhang MH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000245	33	56	58	1	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 20	2011	6	4							e18604	10.1371/journal.pone.0018604	http://dx.doi.org/10.1371/journal.pone.0018604			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	752UE	21533091	Green Published, gold, Green Submitted			2023-01-03	WOS:000289719400016
J	Sandison, TG; Homsy, J; Arinaitwe, E; Wanzira, H; Kakuru, A; Bigira, V; Kalamya, J; Vora, N; Kublin, J; Kamya, MR; Dorsey, G; Tappero, JW				Sandison, Taylor G.; Homsy, Jaco; Arinaitwe, Emmanuel; Wanzira, Humphrey; Kakuru, Abel; Bigira, Victor; Kalamya, Julius; Vora, Neil; Kublin, James; Kamya, Moses R.; Dorsey, Grant; Tappero, Jordan W.			Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							TRIMETHOPRIM-SULFAMETHOXAZOLE PROPHYLAXIS; FALCIPARUM DIHYDROFOLATE-REDUCTASE; INSECTICIDE-TREATED BEDNETS; POLYMERASE CHAIN-REACTION; PLASMODIUM-FALCIPARUM; SULFADOXINE-PYRIMETHAMINE; DIHYDROPTEROATE SYNTHASE; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED ADULTS; MOZAMBICAN CHILDREN	Objective To evaluate the protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children (uninfected children born to HIV infected mothers) in Africa. Design Non-blinded randomised control trial Setting Tororo district, rural Uganda, an area of high malaria transmission intensity Participants 203 breastfeeding HIV exposed infants enrolled between 6 weeks and 9 months of age Intervention Co-trimoxazole prophylaxis from enrolment until cessation of breast feeding and confirmation of negative HIV status. All children who remained HIV uninfected (n=185) were then randomised to stop co-trimoxazole prophylaxis immediately or continue co-trimoxazole until 2 years old. Main outcome measure Incidence of malaria, calculated as the number of antimalarial treatments per person year. Results The incidence of malaria and prevalence of genotypic mutations associated with antifolate resistance were high throughout the study. Among the 98 infants randomised to continue co-trimoxazole, 299 malaria cases occurred in 92.28 person years (incidence 3.24 cases/person year). Among the 87 infants randomised to stop co-trimoxazole, 400 malaria cases occurred in 71.81 person years (5.57 cases/person year). Co-trimoxazole prophylaxis yielded a 39% reduction in malaria incidence, after adjustment for age at randomisation (incidence rate ratio 0.61 (95% CI 0.46 to 0.81), P=0.001). There were no significant differences in the incidence of complicated malaria, diarrhoea, pneumonia, hospitalisations, or deaths between the two treatment arms. Conclusions Co-trimoxazole prophylaxis was moderately protective against malaria in HIV exposed infants when continued beyond the period of HIV exposure despite the high prevalence of Plasmodium genotypes associated with antifolate resistance.	[Sandison, Taylor G.] Univ Washington, Dept Med, UW FHCRC Clin Res, Seattle, WA 98195 USA; [Homsy, Jaco] Univ Calif San Francisco, Inst Global Hlth, San Francisco, CA 94143 USA; [Arinaitwe, Emmanuel; Wanzira, Humphrey; Kakuru, Abel; Bigira, Victor] Infect Dis Res Collaborat, Kampala, Uganda; [Kalamya, Julius] Ctr Dis Control Uganda, PMTCT, Entebbe, Uganda; [Vora, Neil; Dorsey, Grant] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Kublin, James] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Inst, Seattle, WA 98104 USA; [Kublin, James] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA; [Kamya, Moses R.] Makerere Univ, Sch Med, Dept Med, Kampala, Uganda; [Tappero, Jordan W.] Ctr Dis Control & Prevent, Global AIDS Program, Atlanta, GA USA	University of Washington; University of Washington Seattle; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Makerere University; Centers for Disease Control & Prevention - USA	Sandison, TG (corresponding author), Univ Washington, Dept Med, UW FHCRC Clin Res, Box 358080, Seattle, WA 98195 USA.	tgsand@u.washington.edu	Vora, Neil Manhar/AAJ-7269-2021; Wanzira, Humphrey/AAF-1373-2020	Vora, Neil Manhar/0000-0002-4989-3108; Wanzira, Humphrey/0000-0003-1074-5340; Kakuru, Abel/0000-0001-9941-1309	US President's Emergency Plan for AIDS Relief; Centers for Disease Control and Prevention (CDC); National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Global AIDS Program (GAP); Doris Duke Charitable Foundation; NIH/NIAID [K23-AI082553]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI082553] Funding Source: NIH RePORTER	US President's Emergency Plan for AIDS Relief(United States Agency for International Development (USAID)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Centers for Disease Control and Prevention (CDC)(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Global AIDS Program (GAP); Doris Duke Charitable Foundation(Doris Duke Charitable Foundation (DDCF)); NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Participants in this study were enrolled in programmes supported by the US President's Emergency Plan for AIDS Relief and by Cooperative Agreement No U62P024421 from the Centers for Disease Control and Prevention (CDC); National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); and Global AIDS Program (GAP). Funding was also provided by the Doris Duke Charitable Foundation (GD is a recipient of the Clinical Scientist Development Award, and NV is a recipient of the Clinical Research Fellowship). TS was funded through the Puget Sound Partners in Global Health and NIH/NIAID K23-AI082553. The funders were not involved with study design, data analysis, or manuscript preparation. The contents of the manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or Doris Duke Charitable Foundation.	Alonso PL, 2005, LANCET, V366, P2012, DOI 10.1016/S0140-6736(05)67669-6; Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Anglaret X, 1999, LANCET, V353, P1463, DOI 10.1016/S0140-6736(98)07399-1; [Anonymous], 1994, ICH HARM TRIP GUID C; [Anonymous], 2004, MAL HIV INT THEIR IM; [Anonymous], 2005, AIDS EP UPD DEC 2005; Aponte JJ, 2007, LANCET, V370, P1543, DOI 10.1016/S0140-6736(07)61542-6; Aponte JJ, 2009, LANCET, V374, P1533, DOI 10.1016/S0140-6736(09)61258-7; Arinaitwe E, 2009, CLIN INFECT DIS, V49, P1629, DOI 10.1086/647946; Bejon P, 2008, NEW ENGL J MED, V359, P2521, DOI 10.1056/NEJMoa0807381; Brahmbhatt H, 2006, JAIDS-J ACQ IMM DEF, V41, P504, DOI 10.1097/01.qai.0000188122.15493.0a; Cairns M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009467; Chatterjee A, 2007, JAIDS-J ACQ IMM DEF, V46, P599, DOI 10.1097/QAI.0b013e31815a5703; Chintu C, 2004, LANCET, V364, P1865, DOI 10.1016/S0140-6736(04)17442-4; Crampin AC, 2003, AIDS, V17, P389, DOI 10.1097/00002030-200302140-00013; Dorsey G, 2004, AM J TROP MED HYG, V71, P758, DOI 10.4269/ajtmh.2004.71.758; Duraisingh MT, 1998, EXP PARASITOL, V89, P1, DOI 10.1006/expr.1998.4274; Faucher JF, 2002, CLIN INFECT DIS, V35, P1147, DOI 10.1086/342908; Gasasira AF, 2010, MALARIA J, V9, DOI 10.1186/1475-2875-9-177; Gill CJ, 2004, B WORLD HEALTH ORGAN, V82, P290; GREENWOOD BM, 1988, LANCET, V1, P1121; HOGH B, 1994, ACTA TROP, V57, P265, DOI 10.1016/0001-706X(94)90072-8; Iyer JK, 2001, LANCET, V358, P1066, DOI 10.1016/S0140-6736(01)06201-8; [Joint United Nations Programme on HIV/AIDS (UNAIDS) World Health Organization (WHO)], 2009, AIDS EP UPD NOV 2009; Kamya MR, 2007, AIDS, V21, P2059, DOI 10.1097/QAD.0b013e3282ef6da1; Kublin JG, 2002, J INFECT DIS, V185, P380, DOI 10.1086/338566; Kuhn L, 2005, CLIN INFECT DIS, V41, P1654, DOI 10.1086/498029; Kuhn L, 2007, JAIDS-J ACQ IMM DEF, V46, P517, DOI 10.1097/QAI.0b013e31814d6600; Kyabayinze D, 2003, AM J TROP MED HYG, V69, P247, DOI 10.4269/ajtmh.2003.69.247; Lynen L, 2007, T ROY SOC TROP MED H, V101, P1059, DOI 10.1016/j.trstmh.2007.07.001; Malamba S, 2010, AM J TROP MED HYG, V82, P766, DOI 10.4269/ajtmh.2010.08-0408; Marinda E, 2007, PEDIATR INFECT DIS J, V26, P519, DOI 10.1097/01.inf.0000264527.69954.4c; McIntyre J, 2010, CURR OPIN HIV AIDS, V5, P48, DOI 10.1097/COH.0b013e328333b8ab; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; Mermin J, 2006, LANCET, V367, P1256, DOI 10.1016/S0140-6736(06)68541-3; Mermin J, 2005, AIDS, V19, P1035, DOI 10.1097/01.aids.0000174449.32756.c7; Ministry of Health, 2005, UG NAT POL GUID HIV; Nahum A, 2009, MALARIA J, V8, DOI 10.1186/1475-2875-8-37; Newell ML, 2004, LANCET, V364, P1236, DOI 10.1016/S0140-6736(04)17140-7; Okello PE, 2006, AM J TROP MED HYG, V75, P219, DOI 10.4269/ajtmh.2006.75.219; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Sacarlal J, 2009, J INFECT DIS, V200, P329, DOI 10.1086/600119; Santmyire BR, 2001, OBSTET GYNECOL SURV, V56, P306, DOI 10.1097/00006254-200105000-00026; Sibley CH, 2001, TRENDS PARASITOL, V17, P582, DOI 10.1016/S1471-4922(01)02085-2; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V58, P283, DOI 10.1016/0166-6851(93)90050-8; Thera MA, 2005, J INFECT DIS, V192, P1823, DOI 10.1086/498249; Tinto H, 2007, AM J TROP MED HYG, V76, P608, DOI 10.4269/ajtmh.2007.76.608; Triglia T, 1997, P NATL ACAD SCI USA, V94, P13944, DOI 10.1073/pnas.94.25.13944; WATKINS WM, 1987, LANCET, V1, P125; WHO, 2006, WHO GUID TREATM MAL; Wiktor SZ, 1999, LANCET, V353, P1469, DOI 10.1016/S0140-6736(99)03465-0; Wilfert CM, 2007, J INFECT DIS, V195, P165, DOI 10.1086/510255; WOLDE B, 1994, J TROP MED HYG, V97, P215; World Health Organization, 2010, WHO GUID INF FEED PR; World Health Organization (WHO), 2006, GUID COTR PROPH HIV	55	56	56	1	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 31	2011	342								d1617	10.1136/bmj.d1617	http://dx.doi.org/10.1136/bmj.d1617			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	745WI	21454456	hybrid, Green Published			2023-01-03	WOS:000289201600003
J	Yu, H; Zhu, GY; Xu, RZ; Niu, HZ; Lu, Q; Li, GZ; Wang, ZY; Zhang, DS; Gu, N; Teng, GJ				Yu, Hui; Zhu, Guang-Yu; Xu, Rui-Zhi; Niu, Huan-Zhang; Lu, Qin; Li, Guo-Zhao; Wang, Zi-Yu; Zhang, Dong-Sheng; Gu, Ning; Teng, Gao-Jun			Arterial Embolization Hyperthermia Using As2O3 Nanoparticles in VX2 Carcinoma-Induced Liver Tumors	PLOS ONE			English	Article							UNRESECTABLE HEPATOCELLULAR-CARCINOMA; MAGNETIC FLUID HYPERTHERMIA; ENDOTHELIAL GROWTH-FACTOR; ARSENIC TRIOXIDE; TRANSARTERIAL CHEMOEMBOLIZATION; FERROMAGNETIC EMBOLIZATION; ANGIOGENESIS; METASTASIS; APOPTOSIS; MODEL	Background: Combination therapy for arterial embolization hyperthermia (AEH) with arsenic trioxide (As2O3) nanoparticles (ATONs) is a novel treatment for solid malignancies. This study was performed to evaluate the feasibility and therapeutic effect of AEH with As2O3 nanoparticles in a rabbit liver cancer model. The protocol was approved by our institutional animal use committee. Methodology/Principal Findings: In total, 60 VX2 liver-tumor-bearing rabbits were randomly assigned to five groups (n = 12/group) and received AEH with ATONs (Group 1), hepatic arterial embolization with ATONs (Group 2), lipiodol (Group 3), or saline (Group 4), on day 14 after tumor implantation. Twelve rabbits that received AEH with ATONs were prepared for temperature measurements, and were defined as Group 5. Computed tomography was used to measure the tumors' longest dimension, and evaluation was performed according to the Response Evaluation Criteria in Solid Tumors. Hepatic toxicity, tumor necrosis rate, vascular endothelial growth factor level, and microvessel density were determined. Survival rates were measured using the Kaplan-Meier method. The therapeutic temperature (42.5 degrees C) was obtained in Group 5. Hepatotoxicity reactions occurred but were transient in all groups. Tumor growth was delayed and survival was prolonged in Group 1 (treated with AEH and ATONs). Plasma and tumor vascular endothelial growth factor and microvessel density were significantly inhibited in Group 1, while tumor necrosis rates were markedly enhanced compared with those in the control groups. Conclusions: ATON-based AEH is a safe and effective treatment that can be targeted at liver tumors using the dual effects of hyperthermia and chemotherapy. This therapy can delay tumor growth and noticeably inhibit tumor angiogenesis.	[Yu, Hui; Zhu, Guang-Yu; Niu, Huan-Zhang; Lu, Qin; Li, Guo-Zhao; Teng, Gao-Jun] Southeast Univ, Jiangsu Key Lab Mol Imaging & Funct Imaging, Dept Radiol, Zhong Da Hosp,Med Sch, Nanjing, Peoples R China; [Xu, Rui-Zhi; Gu, Ning] Southeast Univ, Jiangsu Lab Biomat & Devices, State Key Lab BioElect, Sch Biol Sci & Med Engn, Nanjing, Peoples R China; [Wang, Zi-Yu; Zhang, Dong-Sheng] Southeast Univ, Sch Med, Dept Pathol & Pathophysiol, Nanjing, Peoples R China	Southeast University - China; Southeast University - China; Southeast University - China	Teng, GJ (corresponding author), Southeast Univ, Jiangsu Key Lab Mol Imaging & Funct Imaging, Dept Radiol, Zhong Da Hosp,Med Sch, Nanjing, Peoples R China.	gjteng@vip.sina.com			National Natural Science Foundation of China [30470507, 30870703]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was financially supported by National Natural Science Foundation of China (NSFC No. 30470507 and NSFC No. 30870703). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Biolato M, 2010, EUR REV MED PHARMACO, V14, P356; Gallagher RE, 1998, NEW ENGL J MED, V339, P1389, DOI 10.1056/NEJM199811053391909; Griffin RJ, 2000, NEOPLASIA, V2, P555, DOI 10.1038/sj.neo.7900123; Griffin RJ, 2003, INT J HYPERTHER, V19, P575, DOI 10.1080/0265673031000124316; Hajitou A, 2008, P NATL ACAD SCI USA, V105, P4471, DOI 10.1073/pnas.0712184105; Hamaguchi S, 2003, CANCER SCI, V94, P834, DOI 10.1111/j.1349-7006.2003.tb01527.x; Hassouneh B, 2007, MOL CANCER THER, V6, P1039, DOI 10.1158/1535-7163.MCT-06-0524; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; Hines-Peralta A, 2006, RADIOLOGY, V240, P82, DOI 10.1148/radiol.2401050788; Johannsen M, 2005, INT J HYPERTHER, V21, P637, DOI 10.1080/02656730500158360; Jones SK, 2002, INT J HYPERTHER, V18, P117, DOI 10.1080/02656730110103519; Kinjo K, 2000, LEUKEMIA, V14, P431, DOI 10.1038/sj.leu.2401646; Kito M, 2003, CANCER SCI, V94, P1010, DOI 10.1111/j.1349-7006.2003.tb01393.x; Kito M, 2002, BIOCHEM BIOPH RES CO, V291, P861, DOI 10.1006/bbrc.2002.6525; Lew YS, 1999, CANCER RES, V59, P6033; Lew YS, 2002, CANCER RES, V62, P4202; Lin CC, 2007, INVEST NEW DRUG, V25, P77, DOI 10.1007/s10637-006-9004-9; Liu B, 2006, CANCER SCI, V97, P675, DOI 10.1111/j.1349-7006.2006.00230.x; Llovet JM, 2003, HEPATOLOGY, V37, P429, DOI 10.1053/jhep.2003.50047; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Llovet JM, 2008, JNCI-J NATL CANCER I, V100, P698, DOI 10.1093/jnci/djn134; Lu Q, 2008, CANCER BIOL THER, V7, P218, DOI 10.4161/cbt.7.2.5258; Maeda H, 2001, CANCER RES, V61, P5432; Marelli L, 2007, CARDIOVASC INTER RAD, V30, P6, DOI 10.1007/s00270-006-0062-3; Monzen Hajime, 2004, Radiat Med, V22, P205; Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785; Moroz P, 2002, PHYS MED BIOL, V47, P1591, DOI 10.1088/0031-9155/47/9/312; Moroz P, 2002, INT J HYPERTHER, V18, P129, DOI 10.1080/02656730110095609; Moroz P, 2001, J SURG ONCOL, V78, P22, DOI 10.1002/jso.1118; Pacella CM, 2001, RADIOLOGY, V219, P669, DOI 10.1148/radiology.219.3.r01ma02669; Paoloni MC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004972; Park MJ, 2003, INT J ONCOL, V22, P1271; Park WH, 2003, BIOCHEM BIOPH RES CO, V300, P230, DOI 10.1016/S0006-291X(02)02831-0; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PATTERSON J, 1979, INT J RADIAT ONCOL, V5, P235, DOI 10.1016/0360-3016(79)90725-9; Roboz GJ, 2000, BLOOD, V96, P1525, DOI 10.1182/blood.V96.4.1525.h8001525_1525_1530; RUIZHI X, 2009, MAGNETICS IEEE T, V45, P3085; RUIZHI X, 2007, MAGNETICS IEEE T, V43, P1078; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vogl TJ, 2004, RADIOLOGY, V230, P450, DOI 10.1148/radiol.2302020646; Vogl TJ, 2003, RADIOLOGY, V229, P457, DOI 10.1148/radiol.2292021329; Wang ZY, 2009, WORLD J GASTROENTERO, V15, P2995, DOI 10.3748/wjg.15.2995; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Xu HY, 2004, WORLD J GASTROENTERO, V10, P3677, DOI 10.3748/wjg.v10.i24.3677; Xu HY, 2000, WORLD J GASTROENTERO, V6, P681; Yamaguchi R, 1998, HEPATOLOGY, V28, P68, DOI 10.1002/hep.510280111; Yan SY, 2005, J NANOSCI NANOTECHNO, V5, P1185, DOI 10.1166/jnn.2005.219; Yoon CJ, 2003, RADIOLOGY, V229, P126, DOI 10.1148/radiol.2291021029; Yoshiji H, 2002, HEPATOLOGY, V35, P834, DOI 10.1053/jhep.2002.32541; Zhu AL, 2004, WORLD J GASTROENTERO, V10, P1659, DOI 10.3748/wjg.v10.i11.1659	50	23	24	1	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2011	6	3							e17926	10.1371/journal.pone.0017926	http://dx.doi.org/10.1371/journal.pone.0017926			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740QW	21448278	Green Submitted, gold, Green Published			2023-01-03	WOS:000288810500023
J	El-Khatib, Z; Katzenstein, D; Marrone, G; Laher, F; Mohapi, L; Petzold, M; Morris, L; Ekstrom, AM				El-Khatib, Ziad; Katzenstein, David; Marrone, Gaetano; Laher, Fatima; Mohapi, Lerato; Petzold, Max; Morris, Lynn; Ekstrom, Anna Mia			Adherence to Drug-Refill Is a Useful Early Warning Indicator of Virologic and Immunologic Failure among HIV Patients on First-Line ART in South Africa	PLOS ONE			English	Article							SINGLE-DOSE NEVIRAPINE; ANTIRETROVIRAL THERAPY ADHERENCE; SUB-SAHARAN AFRICA; VIRAL LOAD; RESISTANCE; ADULTS; CARE; INFECTION; LEVEL	Background: Affordable strategies to prevent treatment failure on first-line regimens among HIV patients are essential for the long-term success of antiretroviral therapy (ART) in sub-Saharan Africa. WHO recommends using routinely collected data such as adherence to drug-refill visits as early warning indicators. We examined the association between adherence to drug-refill visits and long-term virologic and immunologic failure among non-nucleoside reverse transcriptase inhibitor (NNRTI) recipients in South Africa. Methods: In 2008, 456 patients on NNRTI-based ART for a median of 44 months (range 12-99 months; 1,510 person-years) were enrolled in a retrospective cohort study in Soweto. Charts were reviewed for clinical characteristics before and during ART. Multivariable logistic regression and Kaplan-Meier survival analysis assessed associations with virologic (two repeated VL>50 copies/ml) and immunologic failure (as defined by WHO). Results: After a median of 15 months on ART, 19% (n = 88) and 19% (n = 87) had failed virologically and immunologically respectively. A cumulative adherence of <95% to drug-refill visits was significantly associated with both virologic and immunologic failure (p<0.01). In the final multivariable model, risk factors for virologic failure were incomplete adherence (OR 2.8, 95% CI 1.2-6.7), and previous exposure to single-dose nevirapine or any other antiretrovirals (adj. OR 2.1, 95% CI 1.2-3.9), adjusted for age and sex. In Kaplan-Meier analysis, the virologic failure rate by month 48 was 19% vs. 37% among adherent and non-adherent patients respectively (logrank p value = 0.02). Conclusion: One in five failed virologically after a median of 15 months on ART. Adherence to drug-refill visits works as an early warning indicator for both virologic and immunologic failure.	[El-Khatib, Ziad; Marrone, Gaetano; Petzold, Max; Ekstrom, Anna Mia] Karolinska Inst, Div Global Hlth IHCAR, Stockholm, Sweden; [El-Khatib, Ziad; Morris, Lynn] NICD, AIDS Virus Res Unit, Johannesburg, South Africa; [Katzenstein, David] Stanford Univ, Div Infect Dis, Palo Alto, CA 94304 USA; [Laher, Fatima; Mohapi, Lerato] Univ Witwatersrand, PHRU, Soweto, South Africa; [Petzold, Max] Nord Sch Publ Hlth NHV, Gothenburg, Sweden	Karolinska Institutet; National Institute for Communicable Diseases (NICD); Stanford University; University of Witwatersrand	El-Khatib, Z (corresponding author), Karolinska Inst, Div Global Hlth IHCAR, Stockholm, Sweden.	ziad.khatib@gmail.com	Franzeck, Fabian C/B-5055-2011; Morris, Lynn/V-3941-2018; El-Khatib, Ziad/B-5161-2017	Morris, Lynn/0000-0003-3961-7828; El-Khatib, Ziad/0000-0003-0756-7280; Marrone, Gaetano/0000-0002-2991-1663; El-Khatib, Ziad/0000-0002-0711-5404; katzenstein, david/0000-0002-8593-4560	Swedish International Development Cooperation Agency; Karolinska Institutet; HIV/TB Research Fogarty International Center/NIH [2 U2R TW006878]; Freeman-Spogli Institute at Stanford University; FOGARTY INTERNATIONAL CENTER [U2RTW006878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066922] Funding Source: NIH RePORTER	Swedish International Development Cooperation Agency; Karolinska Institutet(Karolinska Institutet); HIV/TB Research Fogarty International Center/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); Freeman-Spogli Institute at Stanford University; FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This study was funded by the Swedish International Development Cooperation Agency to National Institute for Communicable Diseases (NICD) and Karolinska Institutet; The Karolinska Institutet (PhD student grant to ZEK and senior research grant to AME); Sven Gard's Fund for Virology Research, African Programme for Training in HIV/TB Research Fogarty International Center/NIH 2 U2R TW006878 and the Freeman-Spogli Institute at Stanford University to ZEK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badri M, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-89; Barth RE, 2010, LANCET INFECT DIS, V10, P155, DOI 10.1016/S1473-3099(09)70328-7; Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Boulle A, 2010, AIDS, V24, P563, DOI 10.1097/QAD.0b013e328333bfb7; Calmy A, 2007, CLIN INFECT DIS, V44, P128, DOI 10.1086/510073; Cambiano V, 2010, HIV MED, V11, P216, DOI 10.1111/j.1468-1293.2009.00771.x; Coovadia A, 2009, CLIN INFECT DIS, V48, P462, DOI 10.1086/596486; Datay MI, 2010, JAIDS-J ACQ IMM DEF, V54, P489, DOI 10.1097/QAI.0b013e3181d91788; EGGER M, 2007, OUTCOMES ANTIRETROVI; El-Khatib Z, 2010, AIDS, V24, P1679, DOI 10.1097/QAD.0b013e32833a097b; ELKHATIB Z, 2009, MED REV S AFRICAN AD; ELKHATIB Z, 2004, QUESTIONNAIRE DESIGN; ELKHATIB Z, 2010, DRUG RESIST IN PRESS; *EPIDATA FDN, 2008, EPIDATA DAT ENTR DOC; Eshleman SH, 2005, AIDS, V19, P2167, DOI 10.1097/01.aids.0000194800.43799.94; Ford N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010460; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Harries AD, 2010, LANCET INFECT DIS, V10, P60, DOI 10.1016/S1473-3099(09)70321-4; HATANO H, 2010, AIDS; Hedt BL, 2008, ANTIVIR THER, V13, P69; Hosseinipour MC, 2009, AIDS, V23, P1127, DOI 10.1097/QAD.0b013e32832ac34e; Jackson JB, 2000, AIDS, V14, pF111, DOI 10.1097/00002030-200007280-00001; Kagee A, 2010, GLOB PUBLIC HEALTH, V1-15; Kantor R, 2009, CLIN INFECT DIS, V49, P454, DOI 10.1086/600396; Keiser O, 2008, PLOS MED, V5, P1102, DOI 10.1371/journal.pmed.0050148; Kuritzkes DR, 2004, AIDS PATIENT CARE ST, V18, P259, DOI 10.1089/108729104323076007; Lampe FC, 2006, ARCH INTERN MED, V166, P521, DOI 10.1001/archinte.166.5.521; Low-Beer S, 2000, J ACQ IMMUN DEF SYND, V23, P360; Madge S, 2008, HIV MED, V9, P208, DOI 10.1111/j.1468-1293.2008.00548.x; Martin M, 2008, AIDS RES HUM RETROV, V24, P1263, DOI 10.1089/aid.2008.0141; Martinson NA, 2009, AIDS, V23, P809, DOI 10.1097/QAD.0b013e328323ad49; Mee P, 2008, AIDS, V22, P1971, DOI 10.1097/QAD.0b013e32830e4cd8; Nachega JB, 2007, ANN INTERN MED, V146, P564, DOI 10.7326/0003-4819-146-8-200704170-00007; Nachega JB, 2006, JAIDS-J ACQ IMM DEF, V43, P78, DOI 10.1097/01.qai.0000225015.43266.46; Nachega JB, 2010, CURR OPIN HIV AIDS, V5, P70, DOI 10.1097/COH.0b013e328333ad61; NATTRASS N, 2006, SO AFRICAN J HIV MED; Paredes R, 2004, MIL DRUG TH, P53; Parienti JJ, 2004, CLIN INFECT DIS, V38, P1311, DOI 10.1086/383572; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Phillips AN, 2001, AIDS, V15, P2385, DOI 10.1097/00002030-200112070-00006; PRISM G, 2005, VERSION 4 0C; REWARI BB, 2010, J ACQUIR IMMUNE 1001; RICHARD T, 2010, LANCET, DOI DOI 10.1016/S0140-6736(10)61997-6; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; Sanne IM, 2009, J INT AIDS SOC, V12, DOI 10.1186/1758-2652-12-38; Shuter J, 2007, JAIDS-J ACQ IMM DEF, V45, P4, DOI 10.1097/QAI.0b013e318050d8c2; Simon V, 2006, LANCET, V368, P489, DOI 10.1016/S0140-6736(06)69157-5; *STATACORP LP, 2008, STAT SE 10 1; Unge C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013613; WHO, 2010, ANT THER HIV INF AD; *WHO, 2006, HIV DRUG RES EARL WA; World Health Organization, 2008, PRIM HLTH CAR MOR NE, P1; World Health Organization, 2004, SCAL ANT THER RES LT	53	66	66	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 9	2011	6	3							e17518	10.1371/journal.pone.0017518	http://dx.doi.org/10.1371/journal.pone.0017518			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732FR	21408071	gold, Green Published, Green Submitted			2023-01-03	WOS:000288170900024
J	Sanchez-Martin, D; Cuesta, AM; Fogal, V; Ruoslahti, E; Alvarez-Vallina, L				Sanchez-Martin, David; Cuesta, Angel M.; Fogal, Valentina; Ruoslahti, Erkki; Alvarez-Vallina, Luis			The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; ENDOTHELIAL-CELLS; IN-VIVO; BINDING-PROTEIN; HOMING PEPTIDE; GLOBULAR HEADS; SURFACE; C1Q; LOCALIZATION; EXPRESSION	Tumor-associated cell surface antigens and tumor-associated vascular markers have been used as a target for cancer intervention strategies. However, both types of targets have limitations due to accessibility, low and/or heterogeneous expression, and presence of tumor-associated serum antigen. It has been previously reported that a mitochondrial/cell surface protein, p32/gC1qR, is the receptor for a tumor-homing peptide, LyP-1, which specifically recognizes an epitope in tumor cells, tumor lymphatics, and tumor-associated macrophages/myeloid cells. Using antibody phage technology, we have generated an anti-p32 human monoclonal antibody (2.15). The 2.15 antibody, expressed in single-chain fragment variable and in trimerbody format, was then characterized in vivo using mice grafted subcutaneously with MDA-MB-231 human breast cancers cells, revealing a highly selective tumor uptake. The intratumoral distribution of the antibody was consistent with the expression pattern of p32 in the surface of some clusters of cells. These results demonstrate the potential of p32 for antibody-based tumor targeting strategies and the utility of the 2.15 antibody as targeting moiety for the selective delivery of imaging and therapeutic agents to tumors.	[Alvarez-Vallina, Luis] Hosp Univ Puerta Hierro, Unidad Inmunol Mol, Madrid 28222, Spain; [Fogal, Valentina; Ruoslahti, Erkki] Sanford Burnham Med Res Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Vasc Mapping Ctr, Sanford Burnham Med Res Inst, Santa Barbara, CA 93106 USA	Hospital Puerta de Hierro-Majadahonda; Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California Santa Barbara	Alvarez-Vallina, L (corresponding author), Hosp Univ Puerta Hierro, Unidad Inmunol Mol, C Manuel Falla 1, Madrid 28222, Spain.	lalvarezv.hpth@salud.madrid.org	Cuesta, Angel/F-1668-2011; Álvarez-Vallina, Luis/A-2032-2010; AM, Cuesta/AAA-9356-2020; Alvarez-Vallina, Luis/A-2033-2010; Sánchez-Martín, David/C-9927-2013; Alvarez-Vallina, Luis/ABD-2431-2020	Cuesta, Angel/0000-0002-6596-9600; AM, Cuesta/0000-0002-6596-9600; Sánchez-Martín, David/0000-0002-2712-4762; Alvarez-Vallina, Luis/0000-0003-3053-6757	Ministerio de Ciencia e Innovacion [BIO2008-03233]; Comunidad Autonoma de Madrid [BIO-0236-2006]; European Union [SUDOE-FEDER (IMMUNONET-SOE1/P1/E014]; U.S. Department of Defense; Comunidad Autonoma de Madrid/Fondo Social Europeo Training [FPI-000531]; Susan Komen Foundation	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Comunidad Autonoma de Madrid(Comunidad de Madrid); European Union(European Commission); U.S. Department of Defense(United States Department of Defense); Comunidad Autonoma de Madrid/Fondo Social Europeo Training(Comunidad de Madrid); Susan Komen Foundation(Susan G. Komen Breast Cancer Foundation)	This work was supported by grants from the Ministerio de Ciencia e Innovacion (BIO2008-03233), the Comunidad Autonoma de Madrid (S-BIO-0236-2006), the European Union (SUDOE-FEDER (IMMUNONET-SOE1/P1/E014; to L.A.-V.), and a grant from the U.S. Department of Defense Breast Cancer Program (to E. R.).; Supported by Comunidad Autonoma de Madrid/Fondo Social Europeo Training Grant FPI-000531.; Supported a fellowship from the Susan Komen Foundation.	Begent RHJ, 1996, NAT MED, V2, P979, DOI 10.1038/nm0996-979; Birchler M, 1999, J IMMUNOL METHODS, V231, P239, DOI 10.1016/S0022-1759(99)00160-X; Birchler MT, 2007, OTOLARYNG HEAD NECK, V136, P543, DOI 10.1016/j.otohns.2006.07.027; Braun L, 2000, EMBO J, V19, P1458, DOI 10.1093/emboj/19.7.1458; Buchsbaum GM, 2004, INT UROGYNECOL J, V15, P432, DOI 10.1007/s00192-004-1181-5; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; Cuesta AM, 2010, TRENDS BIOTECHNOL, V28, P355, DOI 10.1016/j.tibtech.2010.03.007; Cuesta AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005381; Dedio J, 1996, FEBS LETT, V399, P255, DOI 10.1016/S0014-5793(96)01339-7; Eggleton P, 2000, CLIN EXP IMMUNOL, V120, P406, DOI 10.1046/j.1365-2249.2000.01218.x; EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830; Fogal V, 2008, CANCER RES, V68, P7210, DOI 10.1158/0008-5472.CAN-07-6752; GHEBREHIWET B, 1994, J EXP MED, V179, P1809, DOI 10.1084/jem.179.6.1809; Gibson T., 1984, THESIS U CAMBRIDGE C; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GUPTA S, 1991, EUR J CELL BIOL, V56, P58; Harries M, 2002, ENDOCR-RELAT CANCER, V9, DOI 10.1677/erc.0.0090075; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; JACOBSSON H, 1994, EUR J NUCL MED, V21, P582; Karmali PP, 2009, NANOMED-NANOTECHNOL, V5, P73, DOI 10.1016/j.nano.2008.07.007; Kittlesen DJ, 2000, J CLIN INVEST, V106, P1239, DOI 10.1172/JCI10323; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; Kristensen P, 1998, FOLD DES, V3, P321, DOI 10.1016/S1359-0278(98)00044-3; Kuna P, 1996, CLIN IMMUNOL IMMUNOP, V81, P48, DOI 10.1006/clin.1996.0156; Laakkonen P, 2004, P NATL ACAD SCI USA, V101, P9381, DOI 10.1073/pnas.0403317101; Laakkonen P, 2002, NAT MED, V8, P751, DOI 10.1038/nm720; Lynch NJ, 1997, FEBS LETT, V418, P111, DOI 10.1016/S0014-5793(97)01348-3; Mahdi F, 2002, BLOOD, V99, P3585, DOI 10.1182/blood.V99.10.3585; Mahdi F, 2001, BLOOD, V97, P2342, DOI 10.1182/blood.V97.8.2342; McDevitt MR, 2000, CANCER RES, V60, P6095; Neri D, 1997, NAT BIOTECHNOL, V15, P1271, DOI 10.1038/nbt1197-1271; Nguyen BD, 2009, CURR PROBL DIAGN RAD, V38, P68, DOI 10.1067/j.cpradiol.2007.10.003; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; OIKI S, 1988, J IMMUNOL, V141, P3177; Peerschke EIB, 1996, J IMMUNOL, V157, P4154; PEERSCHKE EIB, 1994, J IMMUNOL, V152, P5896; Retter I, 2005, NUCLEIC ACIDS RES, V33, pD671, DOI 10.1093/nar/gki088; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Sanz L, 2002, GENE THER, V9, P1049, DOI 10.1038/sj.gt.3301725; Sanz L, 2001, CANCER IMMUNOL IMMUN, V50, P557, DOI 10.1007/s00262-001-0235-5; Silacci M, 2006, PROTEIN ENG DES SEL, V19, P471, DOI 10.1093/protein/gzl033; Steffen AC, 2006, EUR J NUCL MED MOL I, V33, P631, DOI 10.1007/s00259-005-0012-3; Steinberger P, 2002, J LEUKOCYTE BIOL, V71, P133; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; vandenBerg RH, 1997, J IMMUNOL, V158, P3909; Vegh Z, 2003, INT IMMUNOPHARMACOL, V3, P345, DOI 10.1016/S1567-5769(02)00234-5; VOGEL CA, 1993, BRIT J CANCER, V68, P684, DOI 10.1038/bjc.1993.410; YU L, 1995, J VIROL, V69, P3017, DOI 10.1128/JVI.69.5.3017-3023.1995	48	34	35	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2011	286	7					5197	5203		10.1074/jbc.M110.161927	http://dx.doi.org/10.1074/jbc.M110.161927			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	719SY	21156793	Green Published, hybrid			2023-01-03	WOS:000287230600028
J	Andrews, G; Cuijpers, P; Craske, MG; McEvoy, P; Titov, N				Andrews, Gavin; Cuijpers, Pim; Craske, Michelle G.; McEvoy, Peter; Titov, Nickolai			Computer Therapy for the Anxiety and Depressive Disorders Is Effective, Acceptable and Practical Health Care: A Meta-Analysis	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; INTERNET-BASED TREATMENT; SOCIAL PHOBIA; SELF-HELP; PANIC DISORDER; PSYCHOTHERAPY; SEVERITY; EFFICACY; SIZE	Background: Depression and anxiety disorders are common and treatable with cognitive behavior therapy (CBT), but access to this therapy is limited. Objective: Review evidence that computerized CBT for the anxiety and depressive disorders is acceptable to patients and effective in the short and longer term. Method: Systematic reviews and data bases were searched for randomized controlled trials of computerized cognitive behavior therapy versus a treatment or control condition in people who met diagnostic criteria for major depression, panic disorder, social phobia or generalized anxiety disorder. Number randomized, superiority of treatment versus control (Hedges g) on primary outcome measure, risk of bias, length of follow up, patient adherence and satisfaction were extracted. Principal Findings: 22 studies of comparisons with a control group were identified. The mean effect size superiority was 0.88 (NNT 2.13), and the benefit was evident across all four disorders. Improvement from computerized CBT was maintained for a median of 26 weeks follow-up. Acceptability, as indicated by adherence and satisfaction, was good. Research probity was good and bias risk low. Effect sizes were non-significantly higher in comparisons with waitlist than with active treatment control conditions. Five studies comparing computerized CBT with traditional face-to-face CBT were identified, and both modes of treatment appeared equally beneficial. Conclusions: Computerized CBT for anxiety and depressive disorders, especially via the internet, has the capacity to provide effective acceptable and practical health care for those who might otherwise remain untreated.	[Andrews, Gavin; Titov, Nickolai] Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia; [Cuijpers, Pim] Vrije Univ Amsterdam, Dept Clin Psychol, Amsterdam, Netherlands; [Craske, Michelle G.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; [McEvoy, Peter] Ctr Clin Intervent, Perth, WA, Australia	University of New South Wales Sydney; Vrije Universiteit Amsterdam; University of California System; University of California Los Angeles	Andrews, G (corresponding author), Univ New S Wales, Sch Psychiat, Sydney, NSW, Australia.	gavina@unsw.edu.au	Andrews, Gavin/J-6537-2012; Cuijpers, Pim/G-1703-2013	Andrews, Gavin/0000-0002-4315-2173; Cuijpers, Pim/0000-0001-5497-2743; Titov, Nickolai/0000-0002-7268-729X; McEvoy, Peter/0000-0003-2924-6760	Australian National Health and Medical Research Council [630560]	Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	GA, NT, PM, MC hold a grant for research on Internet Treatment from the Australian National Health and Medical Research Council registration #630560. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andersson G, 2005, BRIT J PSYCHIAT, V187, P456, DOI 10.1192/bjp.187.5.456; Andersson G, 2006, J CONSULT CLIN PSYCH, V74, P677, DOI 10.1037/0022-006X.74.4.677; Andersson Gerhard, 2009, Cognitive Behaviour Therapy, V38, P196, DOI 10.1080/16506070903318960; Andrews G, 2004, BRIT J PSYCHIAT, V184, P526, DOI 10.1192/bjp.184.6.526; Berger T, 2009, J CLIN PSYCHOL, V65, P1021, DOI 10.1002/jclp.20603; BORENSTEIN M, 2007, COMPREHENSIVE META A; Botella C, 2009, BRIT J GUID COUNS, V37, P297, DOI 10.1080/03069880902957023; Butler AC, 2006, CLIN PSYCHOL REV, V26, P17, DOI 10.1016/j.cpr.2005.07.003; Carlbring P, 2005, BEHAV RES THER, V43, P1321, DOI 10.1016/j.brat.2004.10.002; Carlbring P, 2001, BEHAV THER, V32, P751, DOI 10.1016/S0005-7894(01)80019-8; Carlbring P, 2007, BRIT J PSYCHIAT, V190, P123, DOI 10.1192/bjp.bp.105.020107; Carlbring P, 2006, AM J PSYCHIAT, V163, P2119, DOI 10.1176/appi.ajp.163.12.2119; Cuijpers P, 2008, BMC PSYCHIATRY, V8, DOI 10.1186/1471-244X-8-36; Cuijpers Pim, 2009, Cognitive Behaviour Therapy, V38, P66, DOI 10.1080/16506070802694776; Duval S, 2009, J AM STAT ASSOC, V1, P1338; Fournier JC, 2010, JAMA-J AM MED ASSOC, V303, P47, DOI 10.1001/jama.2009.1943; Furmark T, 2009, BRIT J PSYCHIAT, V195, P440, DOI 10.1192/bjp.bp.108.060996; Goldberg DP, 2009, PSYCHOL MED, V39, P2043, DOI 10.1017/S0033291709990298; Haby MM, 2006, AUST NZ J PSYCHIAT, V40, P9, DOI 10.1080/j.1440-1614.2006.01736.x; Hedges LV, 1996, J EDUC BEHAV STAT, V21, P299, DOI 10.2307/1165338; Higgins J., 2009, COCHRANE HDB SYSTEMA; Issakidis C, 2004, ACTA PSYCHIAT SCAND, V109, P426, DOI 10.1111/j.1600-0047.2004.00264.x; Kay-Lambkin FJ, 2009, ADDICTION, V104, P378, DOI 10.1111/j.1360-0443.2008.02444.x; Kessler D, 2009, LANCET, V374, P628, DOI 10.1016/S0140-6736(09)61257-5; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kiropoulos LA, 2008, J ANXIETY DISORD, V22, P1273, DOI 10.1016/j.janxdis.2008.01.008; Klein B, 2006, J BEHAV THER EXP PSY, V37, P213, DOI 10.1016/j.jbtep.2005.07.001; Klein B, 2001, BEHAV COGN PSYCHOTH, V29, P113, DOI 10.1017/S1352465801001138; Kraemer HC, 2006, BIOL PSYCHIAT, V59, P990, DOI 10.1016/j.biopsych.2005.09.014; Licinio J, 2010, MOL PSYCHIATR, V15, P445, DOI 10.1038/mp.2010.58; Marks IM, 2004, PSYCHOL MED, V34, P9, DOI 10.1017/S003329170300878X; *NAT I CLIN EXC, COMP COGN BEH THER D, V97; Perini S, 2009, AUST NZ J PSYCHIAT, V43, P571, DOI 10.1080/00048670902873722; Proudfoot J, 2004, BRIT J PSYCHIAT, V185, P46, DOI 10.1192/bjp.185.1.46; Richards J. C., 2006, CLIN PSYCHOL, V10, P2, DOI DOI 10.1080/13284200500378795; Robinson E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010942; ROYBYRNE PP, 2007, GUIDE TREATMENTS WOR, P395; SELMI PM, 1990, AM J PSYCHIAT, V147, P51; Titov N, 2008, AUST NZ J PSYCHIAT, V42, P595, DOI 10.1080/00048670802119820; Titov N, 2008, AUST NZ J PSYCHIAT, V42, P585, DOI 10.1080/00048670802119762; Titov N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010939; Titov N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010885; Titov N, 2009, AUST NZ J PSYCHIAT, V43, P920, DOI 10.1080/00048670903179228; Titov N, 2009, AUST NZ J PSYCHIAT, V43, P905, DOI 10.1080/00048670903179269; Titov N, 2009, AUST NZ J PSYCHIAT, V43, P754, DOI 10.1080/00048670903001992; Titov N, 2008, AUST NZ J PSYCHIAT, V42, P1030, DOI 10.1080/00048670802512107; Weisberg RB, 2007, AM J PSYCHIAT, V164, P276, DOI 10.1176/appi.ajp.164.2.276; Weissman MM, 2006, ARCH GEN PSYCHIAT, V63, P925, DOI 10.1001/archpsyc.63.8.925; WIMS E, 2010, AUST NZ J P IN PRESS; Wright JH, 2005, AM J PSYCHIAT, V162, P1158, DOI 10.1176/appi.ajp.162.6.1158	50	689	703	2	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 13	2010	5	10							e13196	10.1371/journal.pone.0013196	http://dx.doi.org/10.1371/journal.pone.0013196			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	663FZ	20967242	Green Published, gold			2023-01-03	WOS:000282869800004
J	Jin, HJ; Lv, SQ; Yang, JH; Wang, XN; Hu, HZ; Su, CQ; Zhou, CL; Li, J; Huang, Y; Li, LF; Liu, XY; Wu, MC; Qian, QJ				Jin, Huajun; Lv, Saiqun; Yang, Jiahe; Wang, Xiaoning; Hu, Huanzhang; Su, Changqing; Zhou, Chengliang; Li, Jiang; Huang, Yao; Li, Linfang; Liu, Xinyuan; Wu, Mengchao; Qian, Qijun			Use of MicroRNA Let-7 to Control the Replication Specificity of Oncolytic Adenovirus in Hepatocellular Carcinoma Cells	PLOS ONE			English	Article							MESSENGER-RNA; CANCER; EXPRESSION; GROWTH; IDENTIFICATION; REPRESSION; GENERATION; EFFICACY; THERAPY; TARGET	Highly selective therapy for hepatocellular carcinoma (HCC) remains an unmet medical need. In present study, we found that the tumor suppressor microRNA, let-7 was significantly downregulated in a proportion of primary HCC tissues (12 of 33, 36.4%) and HCC cell lines. In line with this finding, we have engineered a chimeric Ad5/11 fiber oncolytic adenovirus, SG7011 let7T, by introducing eight copies of let-7 target sites (let7T) into the 39 untranslated region of E1A, a key gene associated with adenoviral replication. The results showed that the E1A expression (both RNA and protein levels) of the SG7011 let7T was tightly regulated according to the endogenous expression level of the let-7. As contrasted with the wild-type adenovirus and the control virus, the replication of SG7011 let7T was distinctly inhibited in normal liver cells lines (i.e. L-02 and WRL-68) expressing high level of let-7 (. 300 folds), whereas was almost not impaired in HCC cells (i.e. Hep3B and PLC/PRF/5) with low level of let-7. Consequently, the cytotoxicity of SG7011 let7T to normal liver cells was successfully decreased while was almost not attenuated in HCC cells in vitro. The antitumor ability of SG7011 let7T in vivo was maintained in mice with Hep3B xenograft tumor, whereas was greatly decreased against the SMMC-7721 xenograft tumor expressing a high level of let-7 similar with L-02 when compared to the wild-type adenovirus. These results suggested that SG7011 let7T may be a promising anticancer agent or vector to mediate the expression of therapeutic gene, broadly applicable in the treatment for HCC and other cancers where the let-7 gene is downregulated.	[Jin, Huajun; Lv, Saiqun; Yang, Jiahe; Hu, Huanzhang; Su, Changqing; Zhou, Chengliang; Li, Jiang; Huang, Yao; Li, Linfang; Wu, Mengchao; Qian, Qijun] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China; [Jin, Huajun; Wang, Xiaoning] S China Univ Technol, Sch Biosci & Bioengn, Guangzhou, Guangdong, Peoples R China; [Liu, Xinyuan; Qian, Qijun] Zhejiang Sci Tech Univ, Coll Life Sci, Hangzhou, Zhejiang, Peoples R China	Naval Medical University; South China University of Technology; Zhejiang Sci-Tech University	Jin, HJ (corresponding author), Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Shanghai, Peoples R China.	qianqj@sino-gene.cn	Liu, Xinyuan/HDM-5505-2022		National Natural Science Foundation of China [81001013, 30730104]; National Natural Science Funds for Distinguished Young Scholar [30925037]; Major State Basic Research Development Program (973 Program) [2010CB529900-G]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Funds for Distinguished Young Scholar(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Major State Basic Research Development Program (973 Program)(National Basic Research Program of China)	The work was supported by National Natural Science Foundation of China (No. 81001013), National Natural Science Funds for Distinguished Young Scholar (No. 30925037), Key Program of National Natural Science Foundation of China (No. 30730104), and Major State Basic Research Development Program (973 Program, No. 2010CB529900-G). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Barh D, 2010, CURR ONCOL, V17, P70; Bell JC, 2008, NAT BIOTECHNOL, V26, P1346, DOI 10.1038/nbt1208-1346; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Cawood R, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000440; Edge RE, 2008, MOL THER, V16, P1437, DOI 10.1038/mt.2008.130; Fukazawa T, 2010, INT J MOL MED, V25, P3, DOI 10.3892/ijmm_00000306; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hamid O, 2003, J CLIN ONCOL, V21, P1498, DOI 10.1200/JCO.2003.09.114; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Herranz H, 2010, GENE DEV, V24, P1339, DOI 10.1101/gad.1937010; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Ji JF, 2010, J HEPATOL, V52, P690, DOI 10.1016/j.jhep.2009.12.025; Kelly EJ, 2008, NAT MED, V14, P1278, DOI 10.1038/nm.1776; Kong YW, 2008, P NATL ACAD SCI USA, V105, P8866, DOI 10.1073/pnas.0800650105; Lai EC, 2002, NAT GENET, V30, P363, DOI 10.1038/ng865; Lan FF, 2011, INT J CANCER, V128, P319, DOI 10.1002/ijc.25336; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Lu L, 2007, CANCER RES, V67, P10117, DOI 10.1158/0008-5472.CAN-07-2544; Mi SL, 2007, P NATL ACAD SCI USA, V104, P19971, DOI 10.1073/pnas.0709313104; Michael MZ, 2003, MOL CANCER RES, V1, P882; Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; Poulin KL, 2010, J VIROL, V84, P10074, DOI 10.1128/JVI.02665-09; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Roberts LR, 2008, NEW ENGL J MED, V359, P420, DOI 10.1056/NEJMe0802241; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Rowan K, 2010, J NATL CANCER I, V102, P590, DOI 10.1093/jnci/djq165; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Seregin SS, 2010, BLOOD, V116, P1669, DOI 10.1182/blood-2010-03-276949; Shimizu S, 2010, J HEPATOL, V52, P698, DOI 10.1016/j.jhep.2009.12.024; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; Wakiyama M, 2007, GENE DEV, V21, P1857, DOI 10.1101/gad.1566707; Wang GH, 2009, J GENE MED, V11, P477, DOI 10.1002/jgm.1326; Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002; Wang XH, 2008, MOL CANCER THER, V7, P1598, DOI 10.1158/1535-7163.MCT-07-2429; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Ylosmaki E, 2008, J VIROL, V82, P11009, DOI 10.1128/JVI.01608-08; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhang Q, 2004, CANCER RES, V64, P5390, DOI 10.1158/0008-5472.CAN-04-1229; Zhang Q, 2006, CLIN CANCER RES, V12, P6523, DOI 10.1158/1078-0432.CCR-06-1491	45	43	48	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2011	6	7							e21307	10.1371/journal.pone.0021307	http://dx.doi.org/10.1371/journal.pone.0021307			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	795FA	21814544	Green Submitted, Green Published, gold			2023-01-03	WOS:000292956800003
J	Shetty, P				Shetty, Priya			Exhibition Arabic roots of modern medicine	LANCET			English	Editorial Material												priya4876@gmail.com							0	3	3	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 2	2011	378	9785					19	20		10.1016/S0140-6736(11)61004-0	http://dx.doi.org/10.1016/S0140-6736(11)61004-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	791IU	21739645	Bronze			2023-01-03	WOS:000292659700013
J	Koog, YH; We, SR; Min, BI				Koog, Yun Hyung; We, Seo Ryang; Min, Byung-Il			Three-Armed Trials Including Placebo and No-Treatment Groups May Be Subject to Publication Bias: Systematic Review	PLOS ONE			English	Review							ELECTRICAL NERVE-STIMULATION; ANTIDEPRESSANT TRIALS; ACUPUNCTURE TREATMENT; COMPARING PLACEBO; CLINICAL-TRIALS; FUNNEL PLOTS; PAIN RELIEF; METAANALYSIS; ACUPRESSURE; NAUSEA	Background: It has been argued that placebos may not have important clinical impacts in general. However, there is increasing evidence of a publication bias among trials published in journals. Therefore, we explored the potential for publication bias in randomized trials with active treatment, placebo, and no-treatment groups. Methods: Three-armed randomized trials of acupuncture, acupoint stimulation, and transcutaneous electrical stimulation were obtained from electronic databases. Effect sizes between treatment and placebo groups were calculated for treatment effect, and effect sizes between placebo and no-treatment groups were calculated for placebo effect. All data were then analyzed for publication bias. Results: For the treatment effect, small trials with fewer than 100 patients per arm showed more benefits than large trials with at least 100 patients per arm in acupuncture and acupoint stimulation. For the placebo effect, no differences were found between large and small trials. Further analyses showed that the treatment effect in acupuncture and acupoint stimulation may be subject to publication bias because study design and any known factors of heterogeneity were not associated with the small study effects. In the simulation, the magnitude of the placebo effect was smaller than that calculated after considering publication bias. Conclusions: Randomized three-armed trials, which are necessary for estimating the placebo effect, may be subject to publication bias. If the magnitude of the placebo effect is assessed in an intervention, the potential for publication bias should be investigated using data related to the treatment effect.	[Koog, Yun Hyung; We, Seo Ryang] Medifarm Hosp, Honam Res Ctr, Sunchon, South Korea; [Min, Byung-Il] Kyung Hee Univ, Dept EW Med, Grad Sch, Seoul, South Korea; [Min, Byung-Il] Kyung Hee Univ, Sch Med, Dept Physiol, Seoul, South Korea	Kyung Hee University; Kyung Hee University	Koog, YH (corresponding author), Medifarm Hosp, Honam Res Ctr, Sunchon, South Korea.	samlungchim@hanmail.net; mbi@khu.ac.kr						Alkaissi A, 1999, ACTA ANAESTH SCAND, V43, P270, DOI 10.1034/j.1399-6576.1999.430306.x; Alkaissi A, 2002, CAN J ANAESTH, V49, P1034, DOI 10.1007/BF03017897; ALTMAN DG, 2003, BMJ-BRIT MED J, V325, P219; Arai YCP, 2008, BRIT J ANAESTH, V100, P78, DOI 10.1093/bja/aem306; Aune A, 1998, SCAND J PRIM HEALTH, V16, P37; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; Breit R, 2004, J ARTHROPLASTY, V19, P45, DOI 10.1016/S0883-5403(03)00458-3; Brinkhaus B, 2006, ARCH INTERN MED, V166, P450; Cho HJ, 2005, PSYCHOSOM MED, V67, P301, DOI 10.1097/01.psy.0000156969.76986.e0; Defrin R, 2005, PAIN, V115, P152, DOI 10.1016/j.pain.2005.02.018; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DUNDEE JW, 1986, BRIT MED J, V293, P583, DOI 10.1136/bmj.293.6547.583; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Ernst E, 2008, J POSTGRAD MED, V54, P214, DOI 10.4103/0022-3859.41806; Facco E, 2008, HEADACHE, V48, P398, DOI 10.1111/j.1526-4610.2007.00916.x; Fanti L, 2003, AM J GASTROENTEROL, V98, P312, DOI 10.1016/S0002-9270(02)05899-9; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Freire AO, 2007, SLEEP MED, V8, P43, DOI 10.1016/j.sleep.2006.04.009; GALLOWAY DJ, 1984, SURG GYNECOL OBSTET, V159, P453; Gioia L, 2006, J CATARACT REFR SURG, V32, P1951, DOI 10.1016/j.jcrs.2006.06.027; Gosman-Hedstrom G, 1998, STROKE, V29, P2100, DOI 10.1161/01.STR.29.10.2100; GOTZSCHE PC, 1994, LANCET, V344, P925; HAUSER W, 2011, PAIN; Hrobjartsson A, 2002, J CLIN EPIDEMIOL, V55, P430, DOI 10.1016/S0895-4356(01)00496-6; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Hrobjartsson A, 2004, J INTERN MED, V256, P91, DOI 10.1111/j.1365-2796.2004.01355.x; Hrobjartsson A, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003974.pub3; Ioannidis JPA, 1998, JAMA-J AM MED ASSOC, V279, P281, DOI 10.1001/jama.279.4.281; JOHN C, 2001, NEW ENGL J MED, V344, P1630; Johnstone PAS, 2003, J UROLOGY, V169, P1037, DOI 10.1097/01.ju.0000044925.03113.ab; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kemeny ME, 2007, J ALLERGY CLIN IMMUN, V119, P1375, DOI 10.1016/j.jaci.2007.03.016; Koog YH, 2010, CLIN REHABIL, V24, P685, DOI 10.1177/0269215510367557; Kyzas PA, 2005, JNCI-J NATL CANCER I, V97, P1043, DOI 10.1093/jnci/dji184; Linde K, 2005, JAMA-J AM MED ASSOC, V293, P2118, DOI 10.1001/jama.293.17.2118; Maa SH, 2007, J CLIN NURS, V16, P794, DOI 10.1111/j.1365-2702.2005.01515.x; Macdonald GM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001930.pub2; Madsen MV, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3115; MCMILLAN CM, 1994, PHYSIOTHERAPY, V80, P5; Melchart D, 2005, BMJ-BRIT MED J, V331, P376, DOI 10.1136/bmj.38512.405440.8F; Moreno SG, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2981; NAUMANN VC, 1989, Z PHYSIOTHER, V41, P9; Nuesch E, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c3515; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Peters JL, 2008, J CLIN EPIDEMIOL, V61, P991, DOI 10.1016/j.jclinepi.2007.11.010; Presser M, 2000, PAIN CLINIC, V12, P77, DOI 10.1163/156856900750229816; Roschke J, 2000, J AFFECT DISORDERS, V57, P73, DOI 10.1016/S0165-0327(99)00061-0; Rosler A, 2003, J ALTERN COMPLEM MED, V9, P847, DOI 10.1089/107555303771952190; Rusy LM, 2002, ANESTHESIOLOGY, V96, P300, DOI 10.1097/00000542-200202000-00013; Schuler MS, 2005, J AM GERIATR SOC, V53, P549, DOI 10.1111/j.1532-5415.2005.53178_6.x; Shang AJ, 2005, LANCET, V366, P726, DOI 10.1016/S0140-6736(05)67177-2; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2004, STATA J, V4, P127, DOI 10.1177/1536867X0400400204; Tang JL, 2005, PLOS MED, V2, P1226, DOI 10.1371/journal.pmed.0020409; Tarcin Orhan, 2004, Turk J Gastroenterol, V15, P258; Tonella Rodrigo Marques, 2006, Rev. Bras. Anestesiol., V56, P630, DOI 10.1590/S0034-70942006000600007; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Turner EH, 2008, NEW ENGL J MED, V358, P252, DOI 10.1056/NEJMsa065779; Weber S, 2010, STATA J, V10, P331, DOI 10.1177/1536867X1001000302; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015; Ziaei S, 2006, INT J GYNECOL OBSTET, V92, P71, DOI 10.1016/j.ijgo.2005.09.008	64	13	13	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2011	6	5							e20679	10.1371/journal.pone.0020679	http://dx.doi.org/10.1371/journal.pone.0020679			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770OP	21655196	gold, Green Published			2023-01-03	WOS:000291097600120
J	Ma, B; Guo, JW; Qi, GQ; Li, HM; Peng, JY; Zhang, YL; Ding, YQ; Yang, KH				Ma, Bin; Guo, Jiwu; Qi, Guoqing; Li, Haimin; Peng, Jiye; Zhang, Yulong; Ding, Yanqin; Yang, Kehu			Epidemiology, Quality and Reporting Characteristics of Systematic Reviews of Traditional Chinese Medicine Interventions Published in Chinese Journals	PLOS ONE			English	Article							METAANALYSES	Background: Systematic reviews (SRs) of TCM have become increasingly popular in China and have been published in large numbers. This review provides the first examination of epidemiological characteristics of these SRs as well as compliance with the PRISMA and AMSTAR guidelines. Objectives: To examine epidemiological and reporting characteristics as well as methodological quality of SRs of TCM published in Chinese journals. Methods: Four Chinese databases were searched (CBM, CSJD, CJFD and Wanfang Database) for SRs of TCM, from inception through Dec 2009. Data were extracted into Excel spreadsheets. The PRISMA and AMSTAR checklists were used to assess reporting characteristics and methodological quality, respectively. Results: A total of 369 SRs were identified, most (97.6%) of which used the terms systematic review or meta-analysis in the title. None of the reviews had been updated. Half (49.8%) were written by clinicians and nearly half (47.7%) were reported in specialty journals. The impact factors of 45.8% of the journals published in were zero. The most commonly treated conditions were diseases of the circulatory and digestive disease. Funding sources were not reported for any reviews. Most (68.8%) reported information about quality assessment, while less than half (43.6%) reported assessing for publication bias. Statistical mistakes appeared in one-third (29.3%) of reviews and most (91.9%) did not report on conflict of interest. Conclusions: While many SRs of TCM interventions have been published in Chinese journals, the quality of these reviews is troubling. As a potential key source of information for clinicians and researchers, not only were many of these reviews incomplete, some contained mistakes or were misleading. Focusing on improving the quality of SRs of TCM, rather than continuing to publish them in great quantity, is urgently needed in order to increase the value of these studies.	[Ma, Bin; Guo, Jiwu; Qi, Guoqing; Zhang, Yulong; Ding, Yanqin; Yang, Kehu] Lanzhou Univ, Evidence Based Med Ctr, Inst Tradit Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China; [Guo, Jiwu; Zhang, Yulong] Lanzhou Univ, Sch Clin Med 2, Lanzhou 730000, Gansu, Peoples R China; [Peng, Jiye] Lib Lanzhou Univ, Lanzhou, Gansu, Peoples R China	Lanzhou University; Lanzhou University	Ma, B (corresponding author), Lanzhou Univ, Evidence Based Med Ctr, Inst Tradit Chinese & Western Med, Sch Basic Med Sci, Lanzhou 730000, Gansu, Peoples R China.	kehuyangebm2006@126.com		Guo, Jiwu/0000-0002-7496-8300				Bessa-Nogueira Ricardo V, 2008, BMC Oral Health, V8, P27, DOI 10.1186/1472-6831-8-27; CHEN ZF, 1999, TRAD CHINESE MED RES, V12, P20; Delaney A, 2005, CRIT CARE, V9, pR575, DOI 10.1186/cc3803; Jadad AR, 1996, J CLIN EPIDEMIOL, V49, P235, DOI 10.1016/0895-4356(95)00062-3; [李廷谦 LI Tingqian], 2007, [中国循证医学杂志, Chinese Journal of Evidence-Based Medicine], V7, P180; LIU JP, 2007, ZHONGGUO ZHONG XI YI, V4, P306; LIU K, 2010, J LIAO NING MED U, V3, P259; Moher D, 2006, LANCET, V367, P881, DOI 10.1016/S0140-6736(06)68358-X; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moher D, 2007, PLOS MED, V4, P447, DOI 10.1371/journal.pmed.0040078; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648, DOI 10.1136/bmj.309.6955.648; Petticrew M, 2001, BMJ-BRIT MED J, V322, P98, DOI 10.1136/bmj.322.7278.98; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Shea B, 2002, EVAL HEALTH PROF, V25, P116, DOI 10.1177/0163278702025001008; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; WANG XP, 2010, MED INFORM, V8, P2537; XIONG J, 2010, CHIN J EVID BASED ME, V9, P44; ZHZANG JH, 2007, J ALTERN COMPLEM MED, V13, P797	19	45	48	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2011	6	5							e20185	10.1371/journal.pone.0020185	http://dx.doi.org/10.1371/journal.pone.0020185			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769IQ	21633698	Green Published, Green Submitted, gold			2023-01-03	WOS:000291006500038
J	Seymour, MT; Thompson, LC; Wasan, HS; Middleton, G; Brewster, AE; Shepherd, SF; O'Mahony, MS; Maughan, TS; Parmar, M; Langley, RE				Seymour, Matthew T.; Thompson, Lindsay C.; Wasan, Harpreet S.; Middleton, Gary; Brewster, Alison E.; Shepherd, Stephen F.; O'Mahony, M. Sinend; Maughan, Timothy S.; Parmar, Mahesh; Langley, Ruth E.		FOCUS2 Investigators; Natl Canc Res Inst	Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial	LANCET			English	Article							COMBINATION CHEMOTHERAPY; 1ST-LINE TREATMENT; CLINICAL-TRIALS; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OLDER; CAPECITABINE; ONCOLOGY; COIN	Background Elderly and frail patients with cancer, although often treated with chemotherapy, are under-represented in clinical trials. We designed FOCUS2 to investigate reduced-dose chemotherapy options and to seek objective predictors of outcome in frail patients with advanced colorectal cancer. Methods We undertook an open, 2 x 2 factorial trial in 61 UK centres for patients with previously untreated advanced colorectal cancer who were considered unfit for full-dose chemotherapy. After comprehensive health assessment (CHA), patients were randomly assigned by minimisation to: 48-h intravenous fluorouracil with levofolinate (group A); oxaliplatin and fluorouracil (group B); capecitabine (group C); or oxaliplatin and capecitabine (group D). Treatment allocation was not masked. Starting doses were 80% of standard doses, with discretionary escalation to full dose after 6 weeks. The two primary outcome measures were: addition of oxaliplatin ([A vs B] + [C vs D]), assessed with progression-free survival (PFS); and substitution of fluorouracil with capecitabine ([A vs C] + [B vs D]), assessed by change from baseline to 12 weeks in global quality of life (QoL). Analysis was by intention to treat. Baseline clinical and CHA data were modelled against outcomes with a novel composite measure, overall treatment utility (OTU). This study is registered, number ISRCTN21221452. Findings 459 patients were randomly assigned (115 to each of groups A C, 114 to group D). Factorial comparison of addition of oxaliplatin versus no addition suggested some improvement in PFS, but the finding was not significant (median 5.8 months [IQR 3.3-7.5] vs 4.5 months [2.8-6.4]; hazard ratio 0.84, 95% CI 0-69-1.01, p=0.07). Replacement of fluorouracil with capecitabine did not improve global QoL: 69 of 124 (56%) patients receiving fluorouracil reported improvement in global QoL compared with 69 of 123 (56%) receiving capecitabine. The risk of having any grade 3 or worse toxic effect was not significantly increased with oxaliplatin (83/219 [38%] vs 70/221 [32%]; p=0.17), but was higher with capecitabine than with fluorouracil (88/222 [40 4] vs 65/218 [30%]; p=0.03). In multivariable analysis, fewer baseline symptoms (odds ratio 1.32, 95% CI 1.14-1.52), less widespread disease (1.51, 1.05-2-19), and use of oxaliplatin (0.57, 0.39-0.82) were predictive of better OTU. Interpretation FOCUS2 shows that with an appropriate design, including reduced starting doses of chemotherapy, frail and elderly patients can participate in a randomised controlled trial. On balance, a combination including oxaliplatin was preferable to single-agent fluoropyrimidines, although the primary endpoint of PFS was not met. Capecitabine did not improve QoL compared with fluorouracil. Comprehensive baseline assessment holds promise as an objective predictor of treatment benefit.	[Seymour, Matthew T.] St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England; [Seymour, Matthew T.] Univ Leeds, Leeds, W Yorkshire, England; [Thompson, Lindsay C.; Parmar, Mahesh; Langley, Ruth E.] MRC, Clin Trials Unit, London, England; [Wasan, Harpreet S.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England; [Middleton, Gary] Royal Surrey Cty Hosp, Guildford, Surrey, England; [Brewster, Alison E.; O'Mahony, M. Sinend; Maughan, Timothy S.] Velindre Hosp NHS Trust, Cardiff, S Glam, Wales; [Brewster, Alison E.; O'Mahony, M. Sinend; Maughan, Timothy S.] Univ Cardiff, Cardiff, S Glam, Wales; [Shepherd, Stephen F.] Cheltenham Gen Hosp, Cheltenham, Glos, England	Saint James's University Hospital; University of Leeds; Medical Research Council Clinical Trials Unit; Imperial College London; Royal Surrey County Hospital; Velindre Hospital; Cardiff University; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Seymour, MT (corresponding author), St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England.	m.seymour@ncrn.org.uk	Maughan, Tim/AAV-7636-2021	Astras, George/0000-0003-4931-8397; Samuel, Leslie/0000-0002-8402-8670; Hickish, Tamas/0000-0001-6770-7279; Sebag-Montefiore, David/0000-0002-5978-9259; Quirke, Philip/0000-0002-3597-5444; Seymour, Matthew/0000-0002-2441-9629; Middleton, Gary/0000-0001-5695-3474; Naderi, Ali/0000-0001-7142-7616; Wasan, Harpreet/0000-0002-6268-2030	UK MRC; Cancer Research UK [C6003/A3830]; National Institute of Health Research (NIHR) National Cancer Research Network	UK MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); National Institute of Health Research (NIHR) National Cancer Research Network(National Institute for Health Research (NIHR))	MTS has received travel and accommodation and departmental research funding (unconnected with FOCUS2) from Roche. HSW has received travel support, honoraria, and educational support from Roche and Sanofi-Aventis. LCT, MP, and REL are employed by the UK MRC, which is also the trial sponsor. MSO'M is the Chair the Academic and Research Committee of the British Geriatrics Society and chairs the Drugs and Prescribing section of the British Geriatrics Society. The British Geriatrics Society has a mission statement that clinical trials be inclusive of older people and frail people. GM, AEB, SFS, and TSM declare that they have no conflicts of interest.; This trial was developed by the UK National Cancer Research Institute Colorectal Clinical Studies Group, funded by Cancer Research UK (C6003/A3830), and ran within the National Health Service supported by the National Institute of Health Research (NIHR) National Cancer Research Network. Discounted levofolinate and infusors were provided, respectively, by Wyeth and Baxter; these companies did not have access to data, and were not involved in any aspect of the research. We thank the 459 participating patients and the large number of clinicians, research nurses, data managers, and other clinical and support staff at the participating centres.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Adams R, 2009, EJC SUPPL, V7, P10, DOI 10.1016/S1359-6349(09)72050-6; American Cancer Society, 2006, CANC FACTS FIG 2006; [Anonymous], 2006, MRC GOOD RES PRACT; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cheeseman SL, 2002, BRIT J CANCER, V87, P393, DOI 10.1038/sj.bjc.6600467; Cort MC, 1994, JAMA-J AM MED ASSOC, V272, P1035; de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938; Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1; Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498; Folprecht G, 2008, J CLIN ONCOL, V26, P1443, DOI 10.1200/JCO.2007.14.0509; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Kind P, 1996, QUALITY LIFE PHARMAC; Maas HAAM, 2007, EUR J CANCER, V43, P2161, DOI 10.1016/j.ejca.2007.08.002; Maughan T, 2009, EJC SUPPL, V7, P4, DOI 10.1016/S1359-6349(09)72034-8; Nonni F, 1998, CLIN REHABIL, V1, P233; Rosati G, 2010, ANN ONCOL, V21, P781, DOI 10.1093/annonc/mdp359; Saif MW, 2009, CRIT REV ONCOL HEMAT, V72, P155, DOI 10.1016/j.critrevonc.2009.02.006; Sargent DJ, 2009, J CLIN ONCOL, V27, P1948, DOI 10.1200/JCO.2008.20.2879; Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3; Seymour MT, 1996, J CLIN ONCOL, V14, P2280, DOI 10.1200/JCO.1996.14.8.2280; Simonsick EM, 2000, AGING-CLIN EXP RES, V12, P274, DOI 10.1007/BF03339847; TEBBUTT NC, 2009, J CLIN ONCOL S, V27, P4023; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113; Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141; Twelves C, 2001, EUR J CANCER, V37, P597, DOI 10.1016/S0959-8049(00)00444-5; Twelves C, 2001, EJC SUPPL, V37, P272; UK Office of National Statistics, MORT STAT 2007 REG; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	30	278	280	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1749	1759		10.1016/S0140-6736(11)60399-1	http://dx.doi.org/10.1016/S0140-6736(11)60399-1			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	771AS	21570111	Bronze, Green Published			2023-01-03	WOS:000291130200033
J	Cohen-Bearak, A				Cohen-Bearak, Adena			Entering Data	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material												adenacb@verizon.net							0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 18	2011	305	19					1944	1944		10.1001/jama.2011.621	http://dx.doi.org/10.1001/jama.2011.621			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764WO	21586704				2023-01-03	WOS:000290665500001
J	Heuser, RG; Osborne, M; Hall, J				Heuser, Rose G.; Osborne, Molly L.; Hall, Jesse			Update in Pulmonary and Critical Care Medicine: Evidence Published in 2010	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							DISEASE; RISK	This Update summarizes studies published in 2010 that the authors consider highly relevant to the practice of pulmonary and critical care medicine. Topics include anticholinergic therapy in asthma, identification of patients with chronic obstructive pulmonary disease who are at risk for exacerbations, pulmonary vasodilator therapy in idiopathic pulmonary fibrosis, tuberculosis testing, tyrosine kinase inhibitors in non-small cell lung cancer, early palliative care and cancer survival, outcomes of critical illness, sedatives and neuromuscular blockade in critically ill patients, interventions and monitoring in patients with shock, and management of acute hypoxemic respiratory failure.	Oregon Hlth & Sci Univ, Dept Med, Pulm & Crit Care, Portland, OR 97239 USA; Univ Chicago Hosp & Clin, Sect Pulm & Crit Care Med, Chicago, IL 60637 USA	Oregon Health & Science University; University of Chicago; University of Illinois System	Osborne, M (corresponding author), Oregon Hlth & Sci Univ, Dept Med, Pulm & Crit Care, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.							Au DH, 2009, J GEN INTERN MED, V24, P457, DOI 10.1007/s11606-009-0907-y; Collard HR, 2007, CHEST, V131, P897, DOI 10.1378/chest.06-2101; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418, DOI 10.1164/ajrccm.157.5.9709032; Singh S, 2008, JAMA-J AM MED ASSOC, V300, P1439, DOI 10.1001/jama.300.12.1439; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800	5	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 3	2011	154	9					614	621		10.7326/0003-4819-154-9-201105030-00339	http://dx.doi.org/10.7326/0003-4819-154-9-201105030-00339			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	757UD	21464338				2023-01-03	WOS:000290112300014
J	Kar, UK; Srivastava, MK; Andersson, A; Baratelli, F; Huang, M; Kickhoefer, VA; Dubinett, SM; Rome, LH; Sharma, S				Kar, Upendra K.; Srivastava, Minu K.; Andersson, Asa; Baratelli, Felicita; Huang, Min; Kickhoefer, Valerie A.; Dubinett, Steven M.; Rome, Leonard H.; Sharma, Sherven			Novel CCL21-Vault Nanocapsule Intratumoral Delivery Inhibits Lung Cancer Growth	PLOS ONE			English	Article							VAULT RIBONUCLEOPROTEIN-PARTICLES; BRONCHOALVEOLAR CELL-CARCINOMA; MODIFIED DENDRITIC CELLS; REGULATORY T-CELLS; TUMOR-BEARING MICE; BONE-MARROW CELLS; SUPPRESSOR-CELLS; ANTITUMOR RESPONSES; MYELOID CELLS; IMMUNITY	Background: Based on our preclinical findings, we are assessing the efficacy of intratumoral injection of dendritic cells (DC) transduced with an adenoviral vector expressing the secondary lymphoid chemokine (CCL21) gene (Ad-CCL21-DC) in a phase I trial in advanced non-small cell lung cancer (NSCLC). While this approach shows immune enhancement, the preparation of autologous DC for CCL21 genetic modification is cumbersome, expensive and time consuming. We are evaluating a non-DC based approach which utilizes vault nanoparticles for intratumoral CCL21 delivery to mediate antitumor activity in lung cancer. Principal Findings: Here we describe that vault nanocapsule platform for CCL21 delivery elicits antitumor activity with inhibition of lung cancer growth. Vault nanocapsule packaged CCL21 (CCL21-vaults) demonstrated functional activity in chemotactic and antigen presenting activity assays. Recombinant vaults impacted chemotactic migration of T cells and this effect was predominantly CCL21 dependent as CCL21 neutralization abrogated the CCL21 mediated enhancement in chemotaxis. Intratumoral administration of CCL21-vaults in mice bearing lung cancer enhanced leukocytic infiltrates (CXCR3(+)T, CCR7(+)T, IFN gamma T+ lymphocytes, DEC205(+) DC), inhibited lung cancer tumor growth and reduced the frequencies of immune suppressive cells [myeloid derived suppressor cells (MDSC), T regulatory cells (Treg), IL-10 T cells]. CCL21-vaults induced systemic antitumor responses by augmenting splenic T cell lytic activity against parental tumor cells. Significance: This study demonstrates that the vault nanocapsule can efficiently deliver CCL21 to sustain antitumor activity and inhibit lung cancer growth. The vault nanocapsule can serve as an "off the shelf" approach to deliver antitumor cytokines to treat a broad range of malignancies.	[Kar, Upendra K.; Kickhoefer, Valerie A.; Rome, Leonard H.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; [Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Lung Canc Res Program, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Srivastava, Minu K.; Andersson, Asa; Baratelli, Felicita; Huang, Min; Dubinett, Steven M.; Sharma, Sherven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; [Srivastava, Minu K.; Andersson, Asa; Huang, Min; Dubinett, Steven M.; Sharma, Sherven] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Med Lab, Los Angeles, CA USA; [Kickhoefer, Valerie A.; Dubinett, Steven M.; Rome, Leonard H.; Sharma, Sherven] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Kar, UK (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu; lrome@mednet.ucla.edu; ssharma@mednet.ucla.edu	Rome, Leonard H/E-8786-2016; Kar, Upendra K/H-5250-2012	Rome, Leonard H/0000-0002-1236-2063; Kar, Upendra K/0000-0003-4065-0860; Kickhoefer, Valerie/0000-0002-0048-0580	University of California [15RT-0207]; Jonnson Comprehensive Cancer Center; National Institutes of Health [RO1 CA95686, RO1 CAl26944]; NATIONAL CANCER INSTITUTE [R01CA126944] Funding Source: NIH RePORTER	University of California(University of California System); Jonnson Comprehensive Cancer Center; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a University of California Discovery Grant (to LHR and VAK) a Jonnson Comprehensive Cancer Center Fellowship to UKK) and by National Institutes of Health Grants (RO1 CA95686 and RO1 CAl26944), University of California Los Angeles Lung Cancer Program, Department of Veterans Affairs Medical Research Funds and Tobacco Related Disease Program Award Program of University of California (15RT-0207). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Almand B, 2001, J IMMUNOL, V166, P678, DOI 10.4049/jimmunol.166.1.678; Andersson A, 2009, J IMMUNOL, V182, P6951, DOI 10.4049/jimmunol.0803340; Baratelli F, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-38; Berger W, 2009, CELL MOL LIFE SCI, V66, P43, DOI 10.1007/s00018-008-8364-z; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Champion CI, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005409; Chen H, 2009, P NATL ACAD SCI USA, V106, P2729, DOI 10.1073/pnas.0813175106; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hiraoka K, 2006, BRIT J CANCER, V94, P275, DOI 10.1038/sj.bjc.6602934; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson SK, 2000, LUNG CANCER-J IASLC, V27, P27, DOI 10.1016/S0169-5002(99)00095-1; KEDERSHA NL, 1991, J CELL BIOL, V112, P225, DOI 10.1083/jcb.112.2.225; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; Kickhoefer VA, 2005, P NATL ACAD SCI USA, V102, P4348, DOI 10.1073/pnas.0500929102; Kickhoefer VA, 1999, J CELL BIOL, V146, P917, DOI 10.1083/jcb.146.5.917; Kickhoefer VA, 2009, ACS NANO, V3, P27, DOI 10.1021/nn800638x; Kirk CJ, 2001, CANCER RES, V61, P8794; Kong LB, 1999, STRUCT FOLD DES, V7, P371, DOI 10.1016/S0969-2126(99)80050-1; Kusmartsev SA, 1998, ADV EXP MED BIOL, V451, P189; KUSMARTSEV SA, 1989, EKSP ONKOL, V11, P23; Kusmartsev SA, 2000, J IMMUNOL, V165, P779, DOI 10.4049/jimmunol.165.2.779; Lai CY, 2009, ACS NANO, V3, P691, DOI 10.1021/nn8008504; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liang CM, 2007, J VIROL, V81, P9502, DOI 10.1128/JVI.00208-07; Liu CR, 2007, BLOOD, V109, P4336, DOI 10.1182/blood-2006-09-046201; LIU CY, 2009, J CANC RES CLIN ONCO; Liu L, 2009, CANCER BIOTHER RADIO, V24, P357, DOI 10.1089/cbr.2008.0612; Mikyas Y, 2004, J MOL BIOL, V344, P91, DOI 10.1016/j.jmb.2004.09.021; Novak L, 2007, MOL CANCER THER, V6, P1755, DOI 10.1158/1535-7163.MCT-06-0709; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sharma S, 2000, J IMMUNOL, V164, P4558, DOI 10.4049/jimmunol.164.9.4558; Sharma S, 2001, CANCER RES, V61, P6406; Sharma Sherven, 2003, Mol Cancer, V2, P22; Sinha P, 2005, J IMMUNOL, V174, P636, DOI 10.4049/jimmunol.174.2.636; Siva AC, 2001, INT J CANCER, V92, P195, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1168>3.0.CO;2-7; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; Srivastava MK, 2008, CANCER IMMUNOL IMMUN, V57, P1493, DOI 10.1007/s00262-008-0490-9; Stephen AG, 2001, J BIOL CHEM, V276, P23217, DOI 10.1074/jbc.C100226200; SUBIZA JL, 1989, INT J CANCER, V44, P307, DOI 10.1002/ijc.2910440220; Suprenant KA, 2002, BIOCHEMISTRY-US, V41, P14447, DOI 10.1021/bi026747e; Warnock RA, 2000, J EXP MED, V191, P77, DOI 10.1084/jem.191.1.77; Willimann K, 1998, EUR J IMMUNOL, V28, P2025, DOI 10.1002/(SICI)1521-4141(199806)28:06<2025::AID-IMMU2025>3.0.CO;2-C; Woo EY, 2002, J IMMUNOL, V168, P4272, DOI 10.4049/jimmunol.168.9.4272; Wu S, 2008, IMMUNOBIOLOGY, V213, P417, DOI 10.1016/j.imbio.2007.10.003; Yang SC, 2004, CLIN CANCER RES, V10, P2891, DOI 10.1158/1078-0432.CCR-03-0380; Yang SC, 2006, CANCER RES, V66, P3205, DOI 10.1158/0008-5472.CAN-05-3619; YOUNG MR, 1987, CANCER RES, V47, P100; YOUSEFIEH N, 2009, CANC MICROENVIRON, V6, P6	50	83	88	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 3	2011	6	5							e18758	10.1371/journal.pone.0018758	http://dx.doi.org/10.1371/journal.pone.0018758			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	759EM	21559281	Green Submitted, Green Published, gold			2023-01-03	WOS:000290223500003
J	Rappaport, B; Mellon, RD; Simone, A; Woodcock, J				Rappaport, Bob; Mellon, R. Daniel; Simone, Arthur; Woodcock, Janet			Defining Safe Use of Anesthesia in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COHORT		[Rappaport, Bob; Mellon, R. Daniel; Simone, Arthur] US FDA, Off New Drugs, Div Anesthesia & Analgesia Prod, Silver Spring, MD 20993 USA; [Woodcock, Janet] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Rappaport, B (corresponding author), US FDA, Off New Drugs, Div Anesthesia & Analgesia Prod, Silver Spring, MD 20993 USA.							Brambrink AM, 2010, ANESTHESIOLOGY, V112, P834, DOI 10.1097/ALN.0b013e3181d049cd; DiMaggio C, 2009, J NEUROSURG ANESTH, V21, P286, DOI 10.1097/ANA.0b013e3181a71f11; JR SW, 2007, TOXICOL SCI, V98, P145; PAULE MG, 2011, NEUROTOXICOL TE 0115; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d	5	154	157	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	2011	364	15					1387	1390		10.1056/NEJMp1102155	http://dx.doi.org/10.1056/NEJMp1102155			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	749LD	21388302	Bronze			2023-01-03	WOS:000289467200002
J	Lawrence, C				Lawrence, Christopher			Historical keyword Blood	LANCET			English	Editorial Material												c.lawrence645@btinternet.com							0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2011	377	9773					1231	1231		10.1016/S0140-6736(11)60488-1	http://dx.doi.org/10.1016/S0140-6736(11)60488-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	751DI	21481693	Bronze			2023-01-03	WOS:000289597300014
J	Jalota, L; Kalira, V; George, E; Shi, YY; Hornuss, C; Radke, O; Pace, NL; Apfel, CC				Jalota, Leena; Kalira, Vicki; George, Elizabeth; Shi, Yung-Ying; Hornuss, Cyrill; Radke, Oliver; Pace, Nathan L.; Apfel, Christian C.		Perioperative Clinical Res Core	Prevention of pain on injection of propofol: systematic review and meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							LONG-CHAIN TRIGLYCERIDE; IONTOPHORETICALLY APPLIED LIDOCAINE; PATIENT-CONTROLLED ANALGESIA; ADULT SURGICAL-PATIENTS; DOUBLE-BLIND; VENOUS OCCLUSION; REDUCES PAIN; FLURBIPROFEN AXETIL; INTRAVENOUS-INJECTION; NITROUS-OXIDE	Objective To systematically determine the most efficacious approach for preventing pain on injection of propofol. Design Systematic review and meta-analysis. Data sources PubMed, Embase, Cochrane Library, www.clinicaltrials.gov, and hand searching from the reference lists of identified papers. Study selection Randomised controlled trials comparing drug and non-drug interventions with placebo or another intervention to alleviate pain on injection of propofol in adults. Results Data were analysed from 177 randomised controlled trials totalling 25 260 adults. The overall risk of pain from propofol injection alone was about 60%. Using an antecubital vein instead of a hand vein was the most effective single intervention (relative risk 0.14, 95% confidence interval 0.07 to 0.30). Pretreatment using lidocaine (lignocaine) in conjunction with venous occlusion was similarly effective (0.29, 0.22 to 0.38). Other effective interventions were a lidocaine-propofol admixture (0.40, 0.33 to 0.48); pretreatment with lidocaine (0.47, 0.40 to 0.56), opioids (0.49, 0.41 to 0.59), ketamine (0.52, 0.46 to 0.57), or non-steroidal anti-inflammatory drugs (0.67, 0.49 to 0.91); and propofol emulsions containing medium and long chain triglycerides (0.75, 0.67 to 0.84). Statistical testing of indirect comparisons showed that use of the antecubital vein and pretreatment using lidocaine along with venous occlusion to be more efficacious than the other interventions. Conclusions The two most efficacious interventions to reduce pain on injection of propofol were use of the antecubital vein, or pretreatment using lidocaine in conjunction with venous occlusion when the hand vein was chosen. Under the assumption of independent efficacy a third practical alternative could be pretreatment of the hand vein with lidocaine or ketamine and use of a propofol emulsion containing medium and long chain triglycerides. Although not the most effective intervention on its own, a small dose of opioids before induction halved the risk of pain from the injection and thus can generally be recommended unless contraindicated.	[Jalota, Leena; Kalira, Vicki; George, Elizabeth; Shi, Yung-Ying; Hornuss, Cyrill; Radke, Oliver; Pace, Nathan L.; Apfel, Christian C.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94115 USA; [Kalira, Vicki] W Virginia Sch Med, Morgantown, WV 26506 USA; [Radke, Oliver] Tech Univ Dresden, Univ Hosp Carl Gustav Dresden, Dept Anaesthesia & Crit Care Med, Dresden, Germany; [Pace, Nathan L.] Univ Utah, Dept Anaesthesiol, Salt Lake City, UT USA	University of California System; University of California San Francisco; Technische Universitat Dresden; Utah System of Higher Education; University of Utah	Apfel, CC (corresponding author), Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94115 USA.	apfelc@anesthesia.ucsf.edu		Radke, Oliver/0000-0003-4811-6128	University of California, San Francisco; Department of Anaesthesia and Perioperative Care, University of California, San Francisco	University of California, San Francisco(University of California System); Department of Anaesthesia and Perioperative Care, University of California, San Francisco(University of California System)	This study was funded by the Perioperative Clinical Research Core, University of California, San Francisco.; All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf and declare that LJ, VK, EG, YYS, CH, OR, and CCA have support from the Perioperative Clinical Research Core, Department of Anaesthesia and Perioperative Care, University of California, San Francisco, CA for the submitted work; LJ, VK, EG, YYS, CH, NLP, OR, and CCA have no relationships that might have an interest in the submitted work in the previous 3 years; their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and LJ, VK, EG, YYS, OR, and CCA have no non-financial interests; and NLP is an unpaid statistical editor for a Cochrane Collaborative Review Group.	Aantaa R, 1997, CURR THER RES CLIN E, V58, P38, DOI 10.1016/S0011-393X(97)80076-8; Adachi Hiroshi, 2002, Masui, V51, P983; Adam S, 2004, ANESTH ANALG, V99, P1076, DOI [10.1213/01.ANE.0000130344.17898.CD, 10.1213/01.ane.0000130344.17898.cd]; Agarwal A, 2004, ANAESTH INTENS CARE, V32, P657, DOI 10.1177/0310057X0403200508; Agarwal A, 2004, ANESTH ANALG, V99, P117, DOI 10.1213/01.ANE.0000117002.03919.49; Agarwal A, 2004, ANESTH ANALG, V98, P683, DOI 10.1213/01.ANE.0000103266.73568.18; Agarwal A, 2004, CAN J ANAESTH, V51, P130, DOI 10.1007/BF03018771; Ahmad N, 2008, Med J Malaysia, V63, P431; Akcaboy ZN, 2007, SAUDI MED J, V28, P1550; Al-Refal AR, 2007, MINERVA ANESTESIOL, V73, P219; Aldrete JA, 2010, ACTA ANAESTH SCAND, V54, P442, DOI 10.1111/j.1399-6576.2009.02174.x; Allford MA, 2006, EUR J ANAESTH, V23, P971, DOI 10.1017/S0265021506001049; Alyafi Walid A., 1996, Middle East Journal of Anesthesiology, V13, P613; Ambesh SP, 1999, ANESTH ANALG, V89, P197, DOI 10.1097/00000539-199907000-00035; Angst MS, 1997, J CLIN ANESTH, V9, P462, DOI 10.1016/S0952-8180(97)00101-3; Aouad MT, 2007, ANESTH ANALG, V104, P1540, DOI 10.1213/01.ane.0000261520.34879.09; Apiliogullari S, 2007, EUR J ANAESTH, V24, P235, DOI 10.1017/S026502150600202X; ARYA A, 2008, J ANESTHESIA CLIN PH, V24, P291; Asik I, 2003, EUR J ANAESTH, V20, P487; Auerswald K, 2005, ANASTH INTENSIV NOTF, V40, P259, DOI 10.1055/s-2005-861353; AUN CST, 1992, BRIT J ANAESTH, V68, P64, DOI 10.1093/bja/68.1.64; Austin JD, 2009, J CLIN ANESTH, V21, P44, DOI 10.1016/j.jclinane.2008.06.018; Ayoglu H, 2007, EUR J ANAESTH, V24, P541, DOI 10.1017/S0265021506002250; Ayuso M A, 2004, Rev Esp Anestesiol Reanim, V51, P531; Azma Toshiharu, 2004, Hiroshima Journal of Medical Sciences, V53, P13; Bachmann-Mennenga B, 2007, EUR J ANAESTH, V24, P33, DOI 10.1017/S0265021506000974; Bachmann-Mennenga B, 2003, ARZNEIMITTEL-FORSCH, V53, P621; Baker MT, 2005, ANESTHESIOLOGY, V103, P860, DOI 10.1097/00000542-200510000-00026; Barbi E, 2003, PAEDIATR ANAESTH, V13, P764, DOI 10.1046/j.1460-9592.2003.01150.x; BARKER P, 1991, ANAESTHESIA, V46, P1069, DOI 10.1111/j.1365-2044.1991.tb09927.x; Basaranoglu G, 2005, EUR J ANAESTH, V22, P890, DOI 10.1017/S0265021505231502; Basaranoglu G, 2002, ANESTH ANALG, V94, P1040, DOI 10.1097/00000539-200204000-00053; Batra YK, 2005, EUR J ANAESTH, V22, P69, DOI 10.1017/S0265021505220148; Batra YK, 2004, CAN J ANAESTH, V51, P519, DOI 10.1007/BF03018325; Beh T, 2002, CAN J ANAESTH, V49, P1061, DOI 10.1007/BF03017903; BEST N, 1991, ANAESTH INTENS CARE, V19, P50, DOI 10.1177/0310057X9101900109; Bilotta F, 2006, PEDIATR ANESTH, V16, P1232, DOI 10.1111/j.1460-9592.2006.01970.x; Borazan H, 2010, EUR J ANAESTH, V27, P253, DOI 10.1097/EJA.0b013e328330eca2; BORGEAT A, 1990, ANESTH ANALG, V71, P511; Borgeat A, 1997, BRIT J ANAESTH, V78, P433, DOI 10.1093/bja/78.4.433; BORGEAT A, 1992, ANESTH ANALG, V74, P539; Bouvet L, 2004, CAN J ANAESTH, V51, P122, DOI 10.1007/BF03018769; BOYSEN K, 1989, ACTA ANAESTH SCAND, V33, P689, DOI 10.1111/j.1399-6576.1989.tb02993.x; BRIGGS LP, 1985, POSTGRAD MED J, V61, P35; BRIGGS LP, 1982, BRIT J ANAESTH, V54, P303, DOI 10.1093/bja/54.3.303; Brock MF, 2010, J CLIN ANESTH, V22, P505, DOI 10.1016/j.jclinane.2009.11.004; BROWNLIE GS, 1991, ANAESTHESIA, V46, P775, DOI 10.1111/j.1365-2044.1991.tb09778.x; BRYSON HM, 1995, DRUGS, V50, P513, DOI 10.2165/00003495-199550030-00008; Burimsittichai Rattanaporn, 2006, J Med Assoc Thai, V89 Suppl 3, pS86; CAMERON E, 1992, ANAESTHESIA, V47, P604, DOI 10.1111/j.1365-2044.1992.tb02335.x; CAMPBELL WI, 1989, BRIT J ANAESTH, V62, P545, DOI 10.1093/bja/62.5.545; Canbay O, 2008, BRIT J ANAESTH, V100, P95, DOI 10.1093/bja/aem301; Canessa R, 1991, J Cardiothorac Vasc Anesth, V5, P566, DOI 10.1016/1053-0770(91)90007-G; Charuluxananan S, 2001, ANESTH ANALG, V93, P162; Cheng Kuang-I, 1998, Kaohsiung Journal of Medical Sciences, V14, P480; Cheong MA, 2002, ANESTH ANALG, V95, P1293, DOI 10.1097/00000539-200211000-00035; COLLINS LM, 1997, BR J ANAESTH, V79; Davies AF, 2002, ANAESTHESIA, V57, P557, DOI 10.1046/j.1365-2044.2002.02602.x; Dedic A, 2010, MINERVA ANESTESIOL, V76, P720; DEWANDRE J, 1994, ANAESTHESIA, V49, P8, DOI 10.1111/j.1365-2044.1994.tb03303.x; DIVATIA JV, 1999, J ANESTH CLIN PHARMA, V15, P279; Doenicke AW, 1997, ANESTH ANALG, V85, P1399, DOI 10.1097/00000539-199712000-00040; Dubey PK, 2005, ANESTH ANALG, V101, P1060, DOI 10.1213/01.ane.0000166951.72702.05; Dubey PK, 2003, CLIN J PAIN, V19, P121, DOI 10.1097/00002508-200303000-00007; Egan TD, 2003, ANESTH ANALG, V97, P72, DOI 10.1213/01.ANE.0000066019.42467.7A; Erdil Feray Akgul, 2007, Pain Clinic, V19, P21, DOI 10.1179/016911107X217437; Eriksson M, 1999, EUR J ANAESTH, V16, P315, DOI 10.1046/j.1365-2346.1999.00489.x; ERIKSSON M, 1995, ACTA ANAESTH SCAND, V39, P210, DOI 10.1111/j.1399-6576.1995.tb04045.x; Eriksson M, 1997, BRIT J ANAESTH, V78, P502, DOI 10.1093/bja/78.5.502; Eti Z, 1999, J Anesth, V13, P175, DOI 10.1007/s005400050051; Fahringer DL, 2010, PEDIATR ANESTH, V20, P545, DOI 10.1111/j.1460-9592.2010.03318.x; Fletcher GC, 1996, ANAESTHESIA, V51, P498, DOI 10.1111/j.1365-2044.1996.tb07802.x; FLETCHER JE, 1994, BRIT J ANAESTH, V72, P342, DOI 10.1093/bja/72.3.342; FRAGEN RJ, 1982, BRIT J ANAESTH, V54, P913; Fujii Y, 2005, CLIN DRUG INVEST, V25, P537, DOI 10.2165/00044011-200525080-00006; Fujii Y, 2005, CLIN THER, V27, P588, DOI 10.1016/j.clinthera.2005.05.003; Fujii Y, 2005, CAN J ANAESTH, V52, P474, DOI 10.1007/BF03016525; Fujii Y, 2004, CLIN DRUG INVEST, V24, P749, DOI 10.2165/00044011-200424120-00006; Fujii Y, 2004, CAN J ANAESTH, V51, P1047, DOI 10.1007/BF03018498; Fujii Y, 2004, ANAESTH INTENS CARE, V32, P653; Fujii Y, 2002, OBSTET GYNECOL, V99, P75, DOI 10.1016/S0029-7844(01)01641-6; Fujii Y, 2008, CLIN THER, V30, P280, DOI 10.1016/j.clinthera.2008.02.018; Fujii Y, 2007, CLIN THER, V29, P856, DOI 10.1016/j.clinthera.2007.05.019; Fujii Y, 2006, J CLIN ANESTH, V18, P526, DOI 10.1016/j.jclinane.2006.03.008; Fujii Y, 2006, CLIN DRUG INVEST, V26, P639, DOI 10.2165/00044011-200626110-00003; Fujii Y, 2006, CLIN THER, V28, P1116, DOI 10.1016/j.clinthera.2006.08.015; Fujii Y, 2009, CLIN THER, V31, P2107, DOI 10.1016/j.clinthera.2009.10.012; Fujii Y, 2009, CLIN THER, V31, P721, DOI 10.1016/j.clinthera.2009.04.014; Gajraj NM, 1996, J CLIN ANESTH, V8, P575, DOI 10.1016/S0952-8180(96)00133-X; GAJRAJ NM, 1995, ANAESTHESIA, V50, P187; Galvez-Escalera L, 2004, EUR J ANAESTH, V21, P579; GANTA R, 1992, BRIT J ANAESTH, V69, P316, DOI 10.1093/bja/69.3.316; GEHAN G, 1991, BRIT J ANAESTH, V66, P324, DOI 10.1093/bja/66.3.324; Ghai B, 2010, J CLIN ANESTH, V22, P88, DOI 10.1016/j.jclinane.2009.03.011; Gill PS, 2001, EUR J ANAESTH, V18, P166, DOI 10.1046/j.0265-0215.2000.00805.x; GOEL AV, 2005, J ANAESTH CLIN PHARM, V21, P389; GOLD MI, 1987, CAN J ANAESTH, V34, P478, DOI 10.1007/BF03014354; Goldmann R, 1997, ANASTH INTENSIV NOTF, V32, P98, DOI 10.1055/s-2007-995016; Grauers A, 2002, ACTA ANAESTH SCAND, V46, P361, DOI 10.1034/j.1399-6576.2002.460405.x; Gutmann A, 2006, PEDIATR ANESTH, V16, P266, DOI 10.1111/j.1460-9592.2005.01777.x; Hampl KF, 1996, ACTA ANAESTH SCAND, V40, P53, DOI 10.1111/j.1399-6576.1996.tb04388.x; Harmon D, 2003, EUR J ANAESTH, V20, P158, DOI 10.1097/00003643-200302000-00014; HAUGEN RD, 1995, CAN J ANAESTH, V42, P1108, DOI 10.1007/BF03015097; HEIM C, 1994, ANAESTHESIST, V43, P504, DOI 10.1007/s001010050085; HELBOHANSEN S, 1988, ACTA ANAESTH SCAND, V32, P502; Hellier C, 2003, ANAESTHESIA, V58, P802, DOI 10.1046/j.1365-2044.2003.03191.x; HELMERS JHJH, 1990, CAN J ANAESTH, V37, P267, DOI 10.1007/BF03005485; HILLER A, 1992, ACTA ANAESTH SCAND, V36, P564, DOI 10.1111/j.1399-6576.1992.tb03519.x; Ho CM, 1999, J CLIN ANESTH, V11, P296, DOI 10.1016/S0952-8180(99)00040-9; HONARMAND A, 2008, ACUTE PAIN, V10, P23, DOI DOI 10.1016/J.ACPAIN.2008.01.001]; Honarmand A, 2008, CLIN DRUG INVEST, V28, P27, DOI 10.2165/00044011-200828010-00004; HUANG CL, 1995, ANESTH ANALG, V81, P1087, DOI 10.1097/00000539-199511000-00033; Huang YW, 2002, ACTA ANAESTH SCAND, V46, P1021, DOI 10.1034/j.1399-6576.2002.460816.x; Hwang I, 2010, KOREAN J ANESTHESIOL, V59, P233, DOI 10.4097/kjae.2010.59.4.233; Hwang J, 2009, ANAESTH INTENS CARE, V37, P584, DOI 10.1177/0310057X0903700404; Inoue S, 1997, Masui, V46, P543; Ishiyama T, 2006, J CLIN ANESTH, V18, P211, DOI 10.1016/j.jclinane.2005.08.005; Iwama H, 2000, J Anesth, V14, P164, DOI 10.1007/s005400070028; Iwama H, 1998, BRIT J ANAESTH, V81, P963, DOI 10.1093/bja/81.6.963; Iwata M, 2010, J ANESTH, V24, P31, DOI 10.1007/s00540-009-0833-5; Iyilikci L, 2004, J CLIN ANESTH, V16, P499, DOI 10.1016/j.jclinane.2004.01.005; JOHNSON RA, 1990, ANAESTHESIA, V45, P439, DOI 10.1111/j.1365-2044.1990.tb14328.x; Jones D, 1999, ANAESTH INTENS CARE, V27, P346, DOI 10.1177/0310057X9902700403; Jung JA, 2010, BRIT J ANAESTH, V104, P563, DOI 10.1093/bja/aeq040; Kaabachi O, 2007, PEDIATR ANESTH, V17, P734, DOI 10.1111/j.1460-9592.2007.02242.x; Kajiyama Seiji, 2009, Masui, V58, P891; KAKINOHANA M, 2004, ACUTE PAIN, V5, P75; KALLELA H, 1994, ANESTH ANALG, V79, P512; Kam E, 2004, ANAESTHESIA, V59, P1167, DOI 10.1111/j.1365-2044.2004.03964.x; Kang HJ, 2010, KOREAN J ANESTHESIOL, V58, P239, DOI 10.4097/kjae.2010.58.3.239; Karasawa F, 2000, J Anesth, V14, P135, DOI 10.1007/s005400070020; Kau Y C, 2000, Acta Anaesthesiol Sin, V38, P9; Kaya F. N., 2006, Pain Clinic, V18, P361, DOI 10.1163/156856906778704704; KAYA K, 1995, BRIT J ANAESTH, V74, P140; Kaya S, 2008, CURR THER RES CLIN E, V69, P29, DOI 10.1016/j.curtheres.2008.02.005; Kazama T, 2000, ANESTHESIOLOGY, V92, P1017, DOI 10.1097/00000542-200004000-00019; Kim KM, 2007, ANESTHESIOLOGY, V106, P924, DOI 10.1097/01.anes.0000265151.78943.af; KING SY, 1992, ANESTH ANALG, V74, P246, DOI 10.1213/00000539-199202000-00013; Kinoshita Maho, 2006, Masui, V55, P338; KLEMENT W, 1991, BRIT J ANAESTH, V66, P189, DOI 10.1093/bja/66.2.189; KLEMENT W, 1991, BRIT J ANAESTH, V67, P281, DOI 10.1093/bja/67.3.281; Knapp G, 2003, STAT MED, V22, P2693, DOI 10.1002/sim.1482; Knibbe CAJ, 1999, BRIT J CLIN PHARMACO, V47, P653, DOI 10.1046/j.1365-2125.1999.00942.x; Kobayashi Y, 1999, Masui, V48, P847; Kobayashi Y, 1999, Masui, V48, P852; Koo SW, 2006, ANESTH ANALG, V103, P1444, DOI 10.1213/01.ane.0000243334.83816.53; Kranke P, 2000, ANESTH ANALG, V90, P1004, DOI 10.1213/00000539-200004000-00053; Krobbuaban Banjong, 2005, Journal of the Medical Association of Thailand, V88, P1401; Kunitz O, 2004, ANASTH INTENSIV NOTF, V39, P10; Kwak HJ, 2009, BRIT J ANAESTH, V103, P410, DOI 10.1093/bja/aep163; Kwak K, 2007, EUR J ANAESTH, V24, P746, DOI 10.1017/S026502150600233X; Kwak KH, 2008, CLIN THER, V30, P1113, DOI 10.1016/j.clinthera.2008.05.019; LANGLEY MS, 1988, DRUGS, V35, P334, DOI 10.2165/00003495-198835040-00002; Larsen B, 2001, ANAESTHESIST, V50, P842, DOI 10.1007/s00101-001-0234-0; Larsen R, 2001, Anaesthesist, V50, P676; Lassnigg A, 2003, CAN J ANAESTH, V50, P964, DOI 10.1007/BF03018753; Lee JR, 2007, BRIT J ANAESTH, V99, P876, DOI 10.1093/bja/aem293; Lee P, 2004, ANAESTH INTENS CARE, V32, P482, DOI 10.1177/0310057X0403200432; LEE TW, 1994, ANAESTHESIA, V49, P817; LEES NW, 1985, POSTGRAD MED J, V61, P88; Leeson RM, 2007, REGION ANESTH PAIN M, V32, P303, DOI 10.1016/j.rapm.2006.07.010; Lembert N, 2002, ANN FR ANESTH, V21, P263, DOI 10.1016/S0750-7658(02)00588-9; Liaw WJ, 1999, ACTA ANAESTH SCAND, V43, P24, DOI 10.1034/j.1399-6576.1999.430106.x; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Liljeroth E, 2007, ACTA ANAESTH SCAND, V51, P456, DOI 10.1111/j.1399-6576.2006.01256.x; Liljeroth E, 2005, ACTA ANAESTH SCAND, V49, P248, DOI 10.1111/j.1399-6576.2004.00573.x; Liljeroth E, 2001, ACTA ANAESTH SCAND, V45, P839, DOI 10.1034/j.1399-6576.2001.045007839.x; Lin S S, 1994, Acta Anaesthesiol Sin, V32, P73; Lyons B, 1996, ANAESTHESIA, V51, P394, DOI 10.1111/j.1365-2044.1996.tb07756.x; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Madenoglu H, 2003, CURR THER RES CLIN E, V64, P310, DOI 10.1016/S0011-393X(03)00066-3; Mallick A, 2007, EUR J ANAESTH, V24, P403, DOI 10.1017/S0265021506002298; Mamiya H, 1998, Anesth Prog, V45, P18; Marik PE, 2004, CURR PHARM DESIGN, V10, P3639, DOI 10.2174/1381612043382846; Marret E, 2005, ANESTHESIOLOGY, V102, P1249, DOI 10.1097/00000542-200506000-00027; Masago K, 1999, Masui, V48, P256; Massad IM, 2006, SAUDI MED J, V27, P997; MATTILA MAK, 1985, POSTGRAD MED J, V61, P162; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; McCluskey A, 2003, ANESTH ANALG, V97, P713, DOI 10.1213/01.ANE.0000074791.44467.D8; MCCRIRRICK A, 1990, ANAESTHESIA, V45, P443, DOI 10.1111/j.1365-2044.1990.tb14329.x; MCCULLOCH MJ, 1985, ANAESTHESIA, V40, P1117, DOI 10.1111/j.1365-2044.1985.tb10615.x; McDonald DS, 1996, ANAESTHESIA, V51, P878, DOI 10.1111/j.1365-2044.1996.tb12624.x; MECKLEM DWJ, 1994, ANAESTH INTENS CARE, V22, P568, DOI 10.1177/0310057X9402200511; Memis D, 2002, EUR J ANAESTH, V19, P47, DOI 10.1017/S0265021502000078; Memis D, 2002, ANESTH ANALG, V95, P606, DOI 10.1213/01.ANE.0000023204.79877.7A; Minogue SC, 2005, ANESTH ANALG, V100, P683, DOI 10.1213/01.ANE.0000148617.98716.EB; Mohta M, 2004, ANAESTH INTENS CARE, V32, P765, DOI 10.1177/0310057X0403200606; MOK MS, 1999, CLIN PHARM, V15, P37; Nagao N, 2005, CAN J ANAESTH, V52, P660, DOI 10.1007/BF03015789; Nakane M, 1999, BRIT J ANAESTH, V83, P397, DOI 10.1093/bja/83.3.397; Nakayama M, 2001, Masui, V50, P1213; Nakayama S, 2007, J ANESTH, V21, P19, DOI 10.1007/s00540-006-0466-x; Nathanson MH, 1996, ANESTH ANALG, V82, P469, DOI 10.1097/00000539-199603000-00006; Nathanson MH, 1998, ANAESTHESIA, V53, P608; NEWCOMBE GN, 1990, ANAESTH INTENS CARE, V18, P105, DOI 10.1177/0310057X9001800116; Niazi A, 2005, EUR J ANAESTH, V22, P299, DOI 10.1017/S0265021505000505; NICOLME, 1991, ANAESTHESIA, V46, P67; NIEVES GB, 1997, J SOC ANEST, V20, P53; Nishiyama Tomoki, 2005, J Anesth, V19, P273, DOI 10.1007/s00540-005-0331-3; Nonaka A, 1999, Masui, V48, P862; Nonaka A, 2000, Masui, V49, P1235; Nyman Y, 2005, BRIT J ANAESTH, V95, P222, DOI 10.1093/bja/aei156; OHara JF, 1997, ANESTH ANALG, V84, P865, DOI 10.1097/00000539-199704000-00030; Ohmizo H, 2005, CAN J ANAESTH, V52, P595, DOI 10.1007/BF03015768; OKA S, 2008, J JPN DENT SOC ANEST, V36, P21; Ong LB, 2000, ANAESTH INTENS CARE, V28, P527, DOI 10.1177/0310057X0002800507; Ozkocak I, 2005, EUR J ANAESTH, V22, P44, DOI 10.1017/S0265021505000104; Ozturk E, 1998, ANESTHESIOLOGY, V89, P1041, DOI 10.1097/00000542-199810000-00039; Pang W W, 1998, Acta Anaesthesiol Sin, V36, P133; Pang Wei-Wu, 2002, Acta Anaesthesiol Sin, V40, P65; Pang WW, 1998, ANESTH ANALG, V86, P382, DOI 10.1097/00000539-199802000-00031; Pang WW, 1998, REGION ANESTH PAIN M, V23, P580, DOI 10.1016/S1098-7339(98)90085-2; Pang WW, 1999, REGION ANESTH PAIN M, V24, P246, DOI 10.1016/S1098-7339(99)90136-0; Parmar AK, 1998, ANAESTHESIA, V53, P79, DOI 10.1111/j.1365-2044.1998.00248.x; Paul M, 2003, ANAESTHESIA, V58, P1056, DOI 10.1046/j.1365-2044.2003.03345.x; Pellegrini M, 2003, BRIT J ANAESTH, V90, P375, DOI 10.1093/bja/aeg056; Picard P, 2000, ANESTH ANALG, V90, P963; Pickford A, 2000, PAEDIATR ANAESTH, V10, P129, DOI 10.1046/j.1460-9592.2000.00461.x; PIOTROWSKI R, 1990, ANAESTHESIST, V39, P398; Piper SN, 2002, ANASTH INTENSIV NOTF, V37, P528, DOI 10.1055/s-2002-33767; Pollard RC, 2002, CAN J ANAESTH, V49, P1064, DOI 10.1007/BF03017904; Rau J, 2001, ANESTH ANALG, V93, P382, DOI 10.1097/00000539-200108000-00029; Reddy MS, 2001, ANAESTHESIA, V56, P902, DOI 10.1046/j.1365-2044.2001.02059-6.x; Rochette A, 2008, BRIT J ANAESTH, V101, P390, DOI 10.1093/bja/aen169; Roehm KD, 2003, ANAESTHESIA, V58, P165, DOI 10.1046/j.1365-2044.2003.02964_2.x; Rohm KD, 2003, ANASTH INTENSIV NOTF, V38, P643; Rucker G, 2008, STAT MED, V27, P746, DOI 10.1002/sim.2971; Ryu JH, 2008, J CLIN ANESTH, V20, P328, DOI 10.1016/j.jclinane.2007.12.015; Saadawy Iman, 2007, Middle East Journal of Anesthesiology, V19, P631; SAARNIVAARA L, 1991, ACTA ANAESTH SCAND, V35, P19, DOI 10.1111/j.1399-6576.1991.tb03235.x; Sadler PJ, 1999, BRIT J ANAESTH, V82, P432, DOI 10.1093/bja/82.3.432; Salanti G, 2008, STAT METHODS MED RES, V17, P279, DOI 10.1177/0962280207080643; Schaub E, 2004, ANESTH ANALG, V99, P1699, DOI 10.1213/01.ANE.0000136848.54207.97; SCOTT RPF, 1988, ANAESTHESIA, V43, P492, DOI 10.1111/j.1365-2044.1988.tb06641.x; Seki S, 1999, Masui, V48, P62; Sethi Nitin, 2009, Middle East Journal of Anesthesiology, V20, P71; SHAH MH, 2008, J ANAESTHESIOL CLIN, V24, P197; Sharpe P, 2002, EUR J ANAESTH, V19, P170, DOI 10.1017/S0265021502000303; Siddik-Sayyid SM, 2005, ANESTH ANALG, V100, P1204, DOI 10.1213/01.ANE.0000148166.29749.3B; Sim JY, 2009, BRIT J CLIN PHARMACO, V67, P316, DOI 10.1111/j.1365-2125.2008.03358.x; Singh M, 2005, EUR J ANAESTH, V22, P888, DOI 10.1017/S0265021505221506; Sinha PK, 2005, ANAESTH INTENS CARE, V33, P235, DOI 10.1177/0310057X0503300213; Slavik VC, 2007, PHARMACOTHERAPY, V27, P1588, DOI 10.1592/phco.27.11.1588; Smith AJ, 1996, ANAESTHESIA, V51, P883, DOI 10.1111/j.1365-2044.1996.tb12626.x; SMITH I, 1993, ANESTH ANALG, V76, P1181, DOI 10.1213/00000539-199376060-00001; Soltesz S, 2007, ANESTHESIOLOGY, V106, P80, DOI 10.1097/00000542-200701000-00015; Song D, 2004, ANESTHESIOLOGY, V100, P1072, DOI 10.1097/00000542-200405000-00007; Song DJ, 2004, ANESTH ANALG, V98, P687, DOI 10.1213/01.ANE.0000103184.36451.D7; STARK RD, 1985, POSTGRAD MED J, V61, P152; Sterne JAC, 2001, BMJ-BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; STOKES DN, 1989, BRIT J ANAESTH, V62, P202, DOI 10.1093/bja/62.2.202; Sun NCH, 2005, ANESTH ANALG, V101, P675, DOI 10.1213/01.ANE.0000157564.91910.04; Sundarathiti Petchara, 2007, Journal of the Medical Association of Thailand, V90, P2683; Suzuki H, 2006, ACTA ANAESTH SCAND, V50, P568, DOI 10.1111/j.1399-6576.2006.00986.x; Suzuki Satomi, 2002, Masui, V51, P140; Tan CH, 1998, ANAESTHESIA, V53, P302, DOI 10.1046/j.1365-2044.1998.00287.x; Tan CH, 1998, ANAESTHESIA, V53, P468, DOI 10.1046/j.1365-2044.1998.00405.x; Tan HL, 2009, ANAESTH INTENS CARE, V37, P807, DOI 10.1177/0310057X0903700509; TARIQ MA, 2006, J POSTGRADUATE MED I, V20, P8; TARMIZ K, 2010, ANN FR ANESTH, V28, P171; THAM CS, 1995, ANAESTH INTENS CARE, V23, P154, DOI 10.1177/0310057X9502300204; Thompson N, 1996, BRIT J ANAESTH, V77, P213, DOI 10.1093/bja/77.2.213; Tramer MR, 2007, ANESTH ANALG, V104, P1374, DOI 10.1213/01.ane.0000263416.14948.dc; Tsubokura H, 2001, Masui, V50, P1196; Turan A, 2003, EUR J ANAESTH, V20, P170, DOI 10.1097/00003643-200302000-00020; TURAN A, 2002, TURK ANESTEZIYOLOJI, V30, P152; Uda R, 1998, Masui, V47, P843; Uda R, 1999, ANESTHESIOLOGY, V91, P591, DOI 10.1097/00000542-199908000-00058; Ueki R, 2007, J ANESTH, V21, P325, DOI 10.1007/s00540-007-0530-1; UZUN S, 2008, J ANAESTH CLIN PHARM, V24, P406; Varghese E, 2010, PEDIATR ANESTH, V20, P338, DOI 10.1111/j.1460-9592.2010.03272.x; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; VUKSANAJ D, 1992, J CLIN ANESTH, V4, P402, DOI 10.1016/0952-8180(92)90166-X; Wajima Z, 2002, ANAESTH INTENS CARE, V30, P742, DOI 10.1177/0310057X0203000604; WALL RJ, 1990, ANAESTH INTENS CARE, V18, P214, DOI 10.1177/0310057X9001800210; Wang HB, 2007, CURR OPIN ANESTHESIO, V20, P311, DOI 10.1097/ACO.0b013e3281667777; Weksler N, 2001, J CLIN ANESTH, V13, P321, DOI 10.1016/S0952-8180(01)00271-9; WILKINSON D, 1993, ANESTH ANALG, V77, P1139; Wong W. H., 2001, SMJ Singapore Medical Journal, V42, P193; Wrench IJ, 1996, BRIT J ANAESTH, V77, P162, DOI 10.1093/bja/77.2.162; Yamakage M, 2005, ANAESTH INTENS CARE, V33, P351, DOI 10.1177/0310057X0503300301; Yavascaoglu B, 2007, J CLIN ANESTH, V19, P413, DOI 10.1016/j.jclinane.2007.02.011; Yew WS, 2005, ANESTH ANALG, V100, P1693, DOI 10.1213/01.ANE.0000151718.58709.0B; Yokota S, 1997, ANESTH ANALG, V85, P672, DOI 10.1097/00000539-199709000-00034; Yoshikawa T, 2001, CAN J ANAESTH, V48, P538, DOI 10.1007/BF03016829; Yoshikawa T, 2001, BRIT J ANAESTH, V86, P874, DOI 10.1093/bja/86.6.874; Yoshimura Yasuhiro, 2003, Masui, V52, P1204; Yull DN, 2000, ANAESTHESIA, V55, P284, DOI 10.1046/j.1365-2044.2000.01320.x; Zahedi Hamid, 2009, Middle East Journal of Anesthesiology, V20, P401	290	128	136	2	40	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 15	2011	342								d1110	10.1136/bmj.d1110	http://dx.doi.org/10.1136/bmj.d1110			18	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739FA	21406529	hybrid			2023-01-03	WOS:000288698100004
J	Schmidt, SL; Hickey, MS; Koblenz, KM; Klamer, H; Botero, MF; Pfaffenbach, KT; Pagliassotti, MJ; Melby, CL				Schmidt, Stacy L.; Hickey, Matthew S.; Koblenz, Kathryn M.; Klamer, Holly; Botero, Maria F.; Pfaffenbach, Kyle T.; Pagliassotti, Michael J.; Melby, Christopher L.			Cardiometabolic Plasticity in Response to a Short-Term Diet and Exercise Intervention in Young Hispanic and NonHispanic White Adults	PLOS ONE			English	Article							HUMAN SKELETAL-MUSCLE; NUTRITION EXAMINATION SURVEY; TYPE-2 DIABETES-MELLITUS; MEXICAN-AMERICAN ADULTS; 3RD NATIONAL-HEALTH; INSULIN SENSITIVITY; CARDIOVASCULAR-DISEASE; LIFE-STYLE; METABOLIC SYNDROME; MESSENGER-RNA	Background: Young adult Mexican Americans (MA) exhibit lower insulin sensitivity (Si) than nonHispanic whites (NHW), even when controlling for fitness and adiposity. It is unclear if MA are as responsive to the same lifestyle intervention as NHW. Objective: We developed a model to examine cardiometabolic plasticity (i.e., changes in Si and plasma lipids) in MA compared to NHW adults in response to a diet-exercise intervention. Design: Sedentary subjects (20 NHW: 11F, 9M, 23.0 y, 25.5 kg/m(2); 17 MA: 13F, 4M, 22.7 y, 25.4 kg/m(2)) consumed their habitual diets and remained sedentary for 7 days, after which fasting blood samples were obtained, and a 3-h intravenous glucose tolerance test (IVGTT) was performed with the insulin area under the curve (IAUC) used to estimate Si. Subjects then completed a 7-day diet/exercise intervention (diet: low saturated fat, low added sugar, high fiber; exercise: cycling, six total sessions lasting 40-45 min/session at 65% VO2 max). Pre-intervention tests were repeated. Results: Pre intervention IAUC was 28% higher (p < 0.05) in MA (IAUC pre = 2298 mu U*180 min/mL) than in NHW (IAUC = 1795 mu U*180 min/mL). Following the intervention, there was a significant reduction in IAUC in MA (29%) and NHW (32%), however, the IAUC remained higher (p < 0.05) for MA (post = 1635 mu U*180 min/mL) than for NHW (post = 1211 mu U*180 min/mL). Pre test plasma lipids were not different in MA compared to NHW. Plasma cholesterol and TG concentrations significantly improved in both groups, but concentrations of low density lipoprotein-cholesterol and small dense LDL particles significantly improved only in the NHW. Conclusion: With a short-term diet-exercise intervention, the magnitude of improvements in Si and serum cholesterol and TG in Hispanics are similar to those in NHW. However, because at the outset MA were less insulin sensitive compared to NHW, within the short timeframe studied the ethnic gap in insulin sensitivity remained.	[Schmidt, Stacy L.; Klamer, Holly; Botero, Maria F.; Melby, Christopher L.] Colorado State Univ, Dept Food Sci & Human Nutr, Nutr & Metab Fitness Lab, Ft Collins, CO 80523 USA; [Hickey, Matthew S.; Koblenz, Kathryn M.] Colorado State Univ, Dept Hlth & Exercise Sci, Human Performance Clin Res Lab, Ft Collins, CO 80523 USA; [Pfaffenbach, Kyle T.; Pagliassotti, Michael J.] Colorado State Univ, Dept Food Sci & Human Nutr, Mol Nutr Lab, Ft Collins, CO 80523 USA	Colorado State University; Colorado State University; Colorado State University	Schmidt, SL (corresponding author), Colorado State Univ, Dept Food Sci & Human Nutr, Nutr & Metab Fitness Lab, Ft Collins, CO 80523 USA.	cmelby@cahs.colostate.edu			Agricultural Experiment Station	Agricultural Experiment Station	The funding source was The Agricultural Experiment Station. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abate N, 2003, J DIABETES COMPLICAT, V17, P39, DOI 10.1016/S1056-8727(02)00190-3; Aguirre MA, 1997, J GERONTOL A-BIOL, V52, pM56, DOI 10.1093/gerona/52A.1.M56; Alexander H, 1999, J AM COLL NUTR, V18, P127, DOI 10.1080/07315724.1999.10718840; Baier LJ, 2000, J CLIN INVEST, V106, pR69, DOI 10.1172/JCI10665; Barcenas CH, 2007, OBESITY, V15, P1043, DOI 10.1038/oby.2007.537; Black AE, 2000, EUR J CLIN NUTR, V54, P386, DOI 10.1038/sj.ejcn.1600970; BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; Borissova AM, 2005, INT J CLIN PRACT, V59, P422, DOI 10.1111/j.1368-5031.2005.00209.x; *CDC, 2004, NAT DIAB FACT SHEET; Clausen JO, 1996, J CLIN INVEST, V98, P1195, DOI 10.1172/JCI118903; CONONIE CC, 1994, J AM GERIATR SOC, V42, P394, DOI 10.1111/j.1532-5415.1994.tb07487.x; Corpeleijn E, 2006, DIABETIC MED, V23, P907, DOI 10.1111/j.1464-5491.2006.01888.x; Crespo CJ, 2001, AM J PUBLIC HEALTH, V91, P1254, DOI 10.2105/AJPH.91.8.1254; Cruz ML, 2004, J CLIN ENDOCR METAB, V89, P108, DOI 10.1210/jc.2003-031188; Dixon LB, 2000, AM J EPIDEMIOL, V152, P548, DOI 10.1093/aje/152.6.548; Donahue RP, 1996, INT J OBESITY, V20, P76; Duncan GE, 2003, DIABETES CARE, V26, P557, DOI 10.2337/diacare.26.3.557; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Frosig C, 2009, OBESITY, V17, pS15, DOI 10.1038/oby.2009.383; Garvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; Haffner SM, 1999, ARTERIOSCL THROM VAS, V19, P2234, DOI 10.1161/01.ATV.19.9.2234; Hanley AJG, 2002, DIABETES CARE, V25, P1177, DOI 10.2337/diacare.25.7.1177; Haskell W L, 1984, Exerc Sport Sci Rev, V12, P205; Ho RC, 2005, CYTOKINE, V30, P14, DOI 10.1016/j.cyto.2004.10.015; Ho RC, 2002, AM J PHYSIOL-ENDOC M, V283, pE799, DOI 10.1152/ajpendo.00105.2002; Ho RC, 2002, METABOLISM, V51, P1478, DOI 10.1053/meta.2002.35577; Houmard JA, 1995, J APPL PHYSIOL, V79, P1936, DOI 10.1152/jappl.1995.79.6.1936; Houmard JA, 1999, AM J PHYSIOL-ENDOC M, V277, pE1055, DOI 10.1152/ajpendo.1999.277.6.E1055; ISBELL JM, DIABETES CARE; Kaline K, 2007, HORM METAB RES, V39, P687, DOI 10.1055/s-2007-985811; Kishimoto H, 2002, HORM METAB RES, V34, P27, DOI 10.1055/s-2002-19963; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kraniou GN, 2004, EXP PHYSIOL, V89, P559, DOI 10.1113/expphysiol.2004.027409; LEFLOCH JP, 1990, DIABETES CARE, V13, P172, DOI 10.2337/diacare.13.2.172; Li CY, 2006, DIABETES CARE, V29, P2396, DOI 10.2337/dc06-0289; Luna MTT, 2005, ARCH MED RES, V36, P210, DOI 10.1016/j.arcmed.2005.03.004; Monda KL, 2009, J LIPID RES, V50, P1685, DOI 10.1194/jlr.P900029-JLR200; OLEFSKY JM, 1974, AM J MED, V57, P551, DOI 10.1016/0002-9343(74)90006-0; Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848; Perez-Escamilla R, 2007, J NUTR, V137, P860, DOI 10.1093/jn/137.4.860; PIATTI PM, 1994, METABOLISM, V43, P1481, DOI 10.1016/0026-0495(94)90005-1; ROGERS MA, 1988, DIABETES CARE, V11, P613, DOI 10.2337/diacare.11.8.613; Srinivasan SR, 2003, METABOLISM, V52, P443, DOI 10.1053/meta.2003.50065; WEIR JBD, 1949, J PHYSIOL-LONDON, V109, P1, DOI 10.1113/jphysiol.1949.sp004363; West DS, 2008, OBESITY, V16, P1413, DOI 10.1038/oby.2008.224	47	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 22	2011	6	2							e16987	10.1371/journal.pone.0016987	http://dx.doi.org/10.1371/journal.pone.0016987			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725PA	21364957	Green Published, gold, Green Submitted			2023-01-03	WOS:000287656600027
J	Kalhan, SC; Uppal, SO; Moorman, JL; Bennett, C; Gruca, LL; Parimi, PS; Dasarathy, S; Serre, D; Hanson, RW				Kalhan, Satish C.; Uppal, Sonal O.; Moorman, Jillian L.; Bennett, Carole; Gruca, Lourdes L.; Parimi, Prabhu S.; Dasarathy, Srinivasan; Serre, David; Hanson, Richard W.			Metabolic and Genomic Response to Dietary Isocaloric Protein Restriction in the Rat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SYNTHASE ACTIVITY; AMINO-ACID-METABOLISM; 3-PHOSPHOGLYCERATE DEHYDROGENASE; HUMAN-PREGNANCY; IN-VIVO; METHIONINE METABOLISM; TRANSCRIPTION FACTORS; SECRETORY PROTEINS; MAMMALIAN-CELLS; SKELETAL-MUSCLE	We have examined hepatic, genomic, and metabolic responses to dietary protein restriction in the non-pregnant Sprague-Dawley rat. Animals were pair-fed either a 6 or 24% casein-based diet for 7-10 days. At the end of the dietary period, a microarray analysis of the liver was performed, followed by validation of the genes of interest. The rates of appearance of phenylalanine, methionine, serine, and glucose and the contribution of pyruvate to serine and glucose were quantified using tracer methods. Plasma and tissue amino acid levels, enzyme activities, and metabolic intermediates were measured. Protein restriction resulted in significant differential expression of a number of genes involved in cell cycle, cell differentiation, transport, transcription, and metabolic processes. RTPCR showed that the expression of genes involved in serine biosynthesis and fatty acid oxidation was higher, and those involved in fatty acid synthesis and urea synthesis were lower in the liver of protein-restricted animals. Free serine and glycine levels were higher and taurine levels lower in all tissues examined. Tracer isotope studies showed an similar to 50% increase in serine de novo synthesis. Pyruvate was the primary (similar to 90%) source of serine in both groups. Transmethylation of methionine was significantly higher in the protein-restricted group. This was associated with a higher S-adenosylmethionine/S-adenosylhomocysteine ratio and lower cystathione beta-synthase and cystathionine gamma-lyase activity. Dietary isocaloric protein restriction results in profound changes in hepatic one-carbon metabolism within a short period. These may be related to high methylation demands placed on the organism and caused by possible changes in cellular osmolarity as a result of the efflux of the intracellular taurine.	Cleveland Clin, Dept Pathobiol, Cleveland, OH 44195 USA; [Dasarathy, Srinivasan] Cleveland Clin, Dept Gastroenterol, Cleveland, OH 44195 USA; [Serre, David] Cleveland Clin, Genom Med Inst, Cleveland, OH 44195 USA; [Hanson, Richard W.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Kalhan, SC (corresponding author), Cleveland Clin Fdn, 9500 Euclid Ave,NE40, Cleveland, OH 44195 USA.	sck@case.edu		Kalhan, Satish/0000-0002-8012-4171	National Institutes of Health [DK079937, DK58620]; Cleveland Clinic Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058620, R01DK079937] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cleveland Clinic Foundation; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported, in whole or in part, by National Institutes of Health Grants DK079937 (to S.C.K.) and DK58620 (to R.W.H.). This work was also supported by institutional support (to S.C.K.) from the Cleveland Clinic Foundation.	Achouri Y, 1999, BIOCHEM J, V344, P15, DOI 10.1042/0264-6021:3440015; ADIBI SA, 1973, AM J PHYSIOL, V225, P408, DOI 10.1152/ajplegacy.1973.225.2.408; Afolabi PR, 2004, AM J PHYSIOL-ENDOC M, V287, pE327, DOI 10.1152/ajpendo.00036.2004; BALLARD FJ, 1967, BIOCHEM J, V102, P952, DOI 10.1042/bj1020952; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; BROSNAN JT, 1989, CAN J PHYSIOL PHARM, V67, P1058, DOI 10.1139/y89-167; Chen JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004950; Courtney-Martin G, 2008, J NUTR, V138, P2172, DOI 10.3945/jn.108.093302; Dasarathy J, 2010, AM J CLIN NUTR, V91, P357, DOI 10.3945/ajcn.2009.28457; Dasarathy S, 2007, AM J PHYSIOL-GASTR L, V292, pG1105, DOI 10.1152/ajpgi.00529.2006; De Koning TJ, 2003, BIOCHEM J, V371, P653, DOI 10.1042/BJ20021785; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; Fernandez-Twinn DS, 2005, AM J PHYSIOL-REG I, V288, pR368, DOI 10.1152/ajpregu.00206.2004; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; FRASCA V, 1988, BIOCHEMISTRY-US, V27, P8458, DOI 10.1021/bi00422a025; Fux R, 2005, AM J PHYSIOL-RENAL, V289, pF786, DOI 10.1152/ajprenal.00465.2004; Gaine PC, 2006, METABOLISM, V55, P501, DOI 10.1016/j.metabol.2005.10.012; Garcia AJ, 2002, J CHROMATOGR B, V779, P359, DOI 10.1016/S1570-0232(02)00401-4; GLAMOUR TS, 1995, AM J PHYSIOL-ENDOC M, V268, pE789, DOI 10.1152/ajpendo.1995.268.4.E789; Hall WL, 2003, BRIT J NUTR, V89, P239, DOI 10.1079/BJN2002760; Haussinger D, 1996, BIOCHEM J, V313, P697; HEINONEN K, 1973, BIOCHEM J, V136, P1011, DOI 10.1042/bj1361011; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Ingenbleek Y, 2002, NUTRITION, V18, P40, DOI 10.1016/S0899-9007(01)00783-3; Jackson AA, 2001, AM J PHYSIOL-GASTR L, V281, pG1179, DOI 10.1152/ajpgi.2001.281.5.G1179; Jun DY, 2008, GENE, V414, P106, DOI 10.1016/j.gene.2008.02.018; Kalhan SC, 2003, AM J PHYSIOL-ENDOC M, V284, pE733, DOI 10.1152/ajpendo.00167.2002; KALHAN SC, 1995, J MASS SPECTROM, V30, P1588, DOI 10.1002/jms.1190301111; Kalhan SC, 2001, AM J PHYSIOL-ENDOC M, V281, pE991, DOI 10.1152/ajpendo.2001.281.5.E991; Kalhan SC, 1998, AM J PHYSIOL-ENDOC M, V275, pE423, DOI 10.1152/ajpendo.1998.275.3.E423; Kang J, 1999, KIDNEY INT, V56, P452, DOI 10.1046/j.1523-1755.1999.00562.x; Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145; Lambert IH, 2006, ACTA PHYSIOL, V187, P75, DOI 10.1111/j.1748-1716.2006.01557.x; Lambert IH, 2004, NEUROCHEM RES, V29, P27, DOI 10.1023/B:NERE.0000010433.08577.96; LANDAU BR, 1995, J CLIN INVEST, V95, P172, DOI 10.1172/JCI117635; LARIVIERE F, 1992, AM J PHYSIOL, V263, pE173, DOI 10.1152/ajpendo.1992.263.1.E173; LARIVIERE F, 1994, METABOLISM, V43, P462, DOI 10.1016/0026-0495(94)90077-9; Ling PR, 2004, AM J PHYSIOL-REG I, V287, pR801, DOI 10.1152/ajpregu.00715.2003; Merali S, 2000, J BIOL CHEM, V275, P14958, DOI 10.1074/jbc.275.20.14958; Mitoma J, 2004, GENE, V334, P15, DOI 10.1016/j.gene.2004.03.015; MUDD SH, 1965, J BIOL CHEM, V240, P4382; Nagao K, 2009, AMINO ACIDS, V36, P555, DOI 10.1007/s00726-008-0117-7; Noguchi Y, 2008, PHYSIOL GENOMICS, V34, P315, DOI 10.1152/physiolgenomics.00007.2008; Ohuchi S, 2009, J NUTR SCI VITAMINOL, V55, P178, DOI 10.3177/jnsv.55.178; Ozanne SE, 1999, BIOCHEM SOC T, V27, P94, DOI 10.1042/bst0270094; Parimi PS, 2004, PEDIATR RES, V56, P423, DOI 10.1203/01.PDR.0000136277.10365.84; Parimi PS, 2003, PEDIATR RES, V53, P325, DOI [10.1203/01.PDR.0000047643.26484.48, 10.1203/00006450-200302000-00020]; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rao S, 2003, EUR J CLIN NUTR, V57, P531, DOI 10.1038/sj.ejcn.1601582; Reynolds RM, 2007, J CLIN ENDOCR METAB, V92, P2208, DOI 10.1210/jc.2007-0071; Rowling MJ, 2002, J NUTR, V132, P2545, DOI 10.1093/jn/132.9.2545; Shan J., 2010, PHYSL GENOM IN PRESS; SKETCHER RD, 1974, BRIT J NUTR, V32, P615, DOI 10.1079/BJN19740114; Stipanuk MH, 2006, J NUTR, V136, p1652S, DOI 10.1093/jn/136.6.1652S; STIPANUK MH, 1979, J NUTR, V109, P2126, DOI 10.1093/jn/109.12.2126; van de Poll MCG, 2004, AM J CLIN NUTR, V79, P185; Warner MJ, 2010, BIOCHEM J, V427, P333, DOI 10.1042/BJ20091861; Yamamoto N, 1996, J NUTR SCI VITAMINOL, V42, P589, DOI 10.3177/jnsv.42.589; Yang JQ, 2009, J BIOL CHEM, V284, P27025, DOI 10.1074/jbc.R109.040543	59	52	54	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 18	2011	286	7					5266	5277		10.1074/jbc.M110.185991	http://dx.doi.org/10.1074/jbc.M110.185991			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	719SY	21147771	Green Published, hybrid			2023-01-03	WOS:000287230600035
J	Zhang, ZJ; Tan, QR; Tong, Y; Wang, XY; Wang, HH; Ho, LM; Wong, HK; Feng, YB; Wang, D; Ng, R; McAlonan, GM; Wang, CY; Wong, VT				Zhang, Zhang-Jin; Tan, Qing-Rong; Tong, Yao; Wang, Xue-Yi; Wang, Huai-Hai; Ho, Lai-Ming; Wong, Hei Kiu; Feng, Yi-Bin; Wang, Di; Ng, Roger; McAlonan, Grainne M.; Wang, Chuan-Yue; Wong, Vivian Taam			An Epidemiological Study of Concomitant Use of Chinese Medicine and Antipsychotics in Schizophrenic Patients: Implication for Herb-Drug Interaction	PLOS ONE			English	Article							ALTERNATIVE MEDICINE; UNITED-STATES; PREVALENCE; ASSOCIATION; PHENELZINE; SUBTYPES; WOMEN	Background: Herb-drug interactions are an important issue in drug safety and clinical practice. The aim of this epidemiological study was to characterize associations of clinical outcomes with concomitant herbal and antipsychotic use in patients with schizophrenia. Methods and Findings: In this retrospective, cross-sectional study, 1795 patients with schizophrenia who were randomly selected from 17 psychiatric hospitals in China were interviewed face-to-face using a structured questionnaire. Association analyses were conducted to examine correlates between Chinese medicine (CM) use and demographic, clinical variables, antipsychotic medication mode, and clinical outcomes. The prevalence of concomitant CM and antipsychotic treatment was 36.4% [95% confidence interval (95% CI) 34.2%-38.6%]. Patients using concomitant CM had a significantly greater chance of improved outcomes than non-CM use (61.1% vs. 34.3%, OR = 3.44, 95% CI 2.80-4.24). However, a small but significant number of patients treated concomitantly with CM had a greater risk of developing worse outcomes (7.2% vs. 4.4%, OR = 2.06, 95% CI 2.06-4.83). Significant predictors for concomitant CM treatment-associated outcomes were residence in urban areas, paranoid psychosis, and exceeding 3 months of CM use. Herbal medicine regimens containing Radix Bupleuri, Fructus Gardenia, Fructus Schisandrae, Radix Rehmanniae, Akebia Caulis, and Semen Plantaginis in concomitant use with quetiapine, clozapine, and olanzepine were associated with nearly 60% of the risk of adverse outcomes. Conclusions: Concomitant herbal and antipsychotic treatment could produce either beneficial or adverse clinical effects in schizophrenic population. Potential herb-drug pharmacokinetic interactions need to be further evaluated.	[Zhang, Zhang-Jin; Tong, Yao; Wong, Hei Kiu; Feng, Yi-Bin; Wang, Di] Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong, Hong Kong, Peoples R China; [Zhang, Zhang-Jin; Tan, Qing-Rong; Wang, Huai-Hai] Fourth Mil Med Univ, Dept Psychiat, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Wang, Xue-Yi] Hebei Med Univ, Mental Hlth Ctr, Shijiazhuang, Hebei, Peoples R China; [Ho, Lai-Ming] Univ Hong Kong, Sch Publ Hlth, Hong Kong, Hong Kong, Peoples R China; [Ng, Roger] Kowloon Hosp, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [McAlonan, Grainne M.] Univ Hong Kong, Dept Psychiat, Hong Kong, Hong Kong, Peoples R China; [Wang, Chuan-Yue] Capital Med Univ, Beijing Anding Hosp, Beijing, Peoples R China; [Wong, Vivian Taam] Hosp Author, Chinese Med Sect, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Air Force Military Medical University; Hebei Medical University; University of Hong Kong; University of Hong Kong; Capital Medical University	Zhang, ZJ (corresponding author), Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong, Hong Kong, Peoples R China.	zhangzj@hku.hk; tanqingr@fmmu.edu.cn	zhang, zhang/GQZ-6804-2022; zhang, zheng/HCH-9684-2022; Wang, Chuan-Yue/C-9369-2015; McAlonan, Grainne/G-1541-2011	Wang, Chuan-Yue/0000-0001-6549-3713; McAlonan, Grainne/0000-0002-4466-2343; ho, lm/0000-0002-2709-927X	University of Hong Kong; Hospital Authority of Hong Kong	University of Hong Kong(University of Hong Kong); Hospital Authority of Hong Kong	Funding: This study was supported by the intramural research fund of the University of Hong Kong and Hospital Authority of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bagnis CI, 2004, AM J KIDNEY DIS, V44, P1, DOI 10.1053/j.ajkd.2004.02.009; BERSANI G, 1989, J PSYCHIAT RES, V23, P213, DOI 10.1016/0022-3956(89)90026-5; Chen Z, 2008, J ALTERN COMPLEM MED, V14, P1049, DOI 10.1089/acm.2008.0039; Csernansky JG, 2002, CNS DRUGS, V16, P473, DOI 10.2165/00023210-200216070-00004; DEAHL M, 1989, MOVEMENT DISORD, V4, P330, DOI 10.1002/mds.870040406; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Ernst E, 2004, PHARMACOEPIDEM DR S, V13, P767, DOI 10.1002/pds.1014; Ernst E, 2002, TRENDS PHARMACOL SCI, V23, P136, DOI 10.1016/S0165-6147(00)01972-6; Fanous Ayman H, 2008, Curr Psychiatry Rep, V10, P164, DOI 10.1007/s11920-008-0028-z; Feng YB, 2009, BASIC CLIN TOXICOLOG; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Izzo AA, 2009, DRUGS, V69, P1777, DOI 10.2165/11317010-000000000-00000; Jablensky A, 2006, MOL PSYCHIATR, V11, P815, DOI 10.1038/sj.mp.4001857; JONES BD, 1987, J CLIN PSYCHOPHARM, V7, P201, DOI 10.1097/00004714-198706000-00030; Ma K, 2008, AIDS BEHAV, V12, P637, DOI 10.1007/s10461-007-9245-4; Maciocia G., 1994, PRACTICE CHINESE MED, P342; Peterson Erica, 2008, S D Med, V61, P173; Przekop P, 2009, AM J PSYCHIAT, V166, P832, DOI 10.1176/appi.ajp.2009.08121759; SHADER RI, 1985, J CLIN PSYCHOPHARM, V5, P65, DOI 10.1097/00004714-198504000-00001; Sheehan JJ, 2010, CURR DRUG METAB, V11, P516, DOI 10.2174/138920010791636202; Tanaka A, 2001, INTERNAL MED, V40, P296, DOI 10.2169/internalmedicine.40.296; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; Wang B, 2009, CURR MED CHEM, V16, P4066, DOI 10.2174/092986709789378198; World Health Organization, 1992, ICD 10 CLAS MENT BEH; Wu B, 2007, STROKE, V38, P1973, DOI 10.1161/STROKEAHA.106.473165; Xiang YT, 2007, PHARMACOPSYCHIATRY, V40, P47, DOI 10.1055/s-2007-970062; Xiang YT, 2008, SCHIZOPHR RES, V102, P270, DOI 10.1016/j.schres.2008.04.009; Yang XX, 2006, CURR PHARM DESIGN, V12, P4649, DOI 10.2174/138161206779010440; Yuan HN, 2008, J CLIN PSYCHOPHARM, V28, P264, DOI 10.1097/JCP.0b013e318172473c; Yuen MF, 2006, ALIMENT PHARM THER, V24, P1179, DOI 10.1111/j.1365-2036.2006.03111.x; Zalewski C, 1998, SCHIZOPHRENIA BULL, V24, P127, DOI 10.1093/oxfordjournals.schbul.a033305; Zhang ZJ, 2007, J PSYCHIATR RES, V41, P828, DOI 10.1016/j.jpsychires.2006.08.002; Zhang ZX, 2006, NEUROEPIDEMIOLOGY, V27, P177, DOI 10.1159/000096131; Zhang ZJ, 2010, CLIN TRIALS PSYCHOPH, V21, P311	36	31	32	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2011	6	2							e17239	10.1371/journal.pone.0017239	http://dx.doi.org/10.1371/journal.pone.0017239			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721YC	21359185	Green Published, gold, Green Submitted			2023-01-03	WOS:000287392700064
J	Preudhomme, C; Guilhot, J; Nicolini, FE; Guerci-Bresler, A; Rigal-Huguet, F; Maloisel, F; Coiteux, V; Gardembas, M; Berthou, C; Vekhoff, A; Rea, D; Jourdan, E; Allard, C; Delmer, A; Rousselot, P; Legros, L; Berger, M; Corm, S; Etienne, G; Roche-Lestienne, C; Eclache, V; Mahon, FX; Guilhot, F				Preudhomme, Claude; Guilhot, Joelle; Nicolini, Franck Emmanuel; Guerci-Bresler, Agnes; Rigal-Huguet, Francoise; Maloisel, Frederic; Coiteux, Valerie; Gardembas, Martine; Berthou, Christian; Vekhoff, Anne; Rea, Delphine; Jourdan, Eric; Allard, Christian; Delmer, Alain; Rousselot, Philippe; Legros, Laurence; Berger, Marc; Corm, Selim; Etienne, Gabriel; Roche-Lestienne, Catherine; Eclache, Virginie; Mahon, Francois-Xavier; Guilhot, Francois		SPIRIT Investigators France Interg	Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; PATIENTS RECEIVING IMATINIB; HEMATOPOIETIC STEM-CELLS; ABL TYROSINE KINASE; FOLLOW-UP; INTERFERON; CYTARABINE; QUIESCENT; CML; CHROMOSOME	Background: Imatinib (400 mg daily) is considered the best initial therapy for patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase. However, only a minority of patients treated with imatinib have a complete molecular remission. Methods: We randomly assigned 636 patients with untreated chronic-phase CML to receive imatinib alone at a dose of 400 mg daily, imatinib (400 mg daily) plus cytarabine (20 mg per square meter of body-surface area per day on days 15 through 28 of each 28-day cycle) or pegylated interferon (peginterferon) alfa-2a (90 microg weekly), or imatinib alone at a dose of 600 mg daily. Molecular and cytogenetic responses, time to treatment failure, overall and event-free survival, and adverse events were assessed. An analysis of molecular response at 12 months was planned. A superior molecular response was defined as a decrease in the ratio of transcripts of the tyrosine kinase gene BCR-ABL to transcripts of ABL of 0.01% or less, corresponding to a reduction of 4 log(sub 10) units or more from the baseline level, as assessed by means of a real-time quantitative polymerase-chain-reaction assay. Results: At 12 months, the rates of cytogenetic response were similar among the four groups. The rate of a superior molecular response was significantly higher among patients receiving imatinib and peginterferon alfa-2a (30%) than among patients receiving 400 mg of imatinib alone (14%) (P=0.001). The rate was significantly higher among patients treated for more than 12 months than among those treated for 12 months or less. Gastrointestinal events were more frequent among patients receiving cytarabine, whereas rash and depression were more frequent among patients receiving peginterferon alfa-2a. Conclusions: As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML. (Funded by the French Ministry of Health and others; ClinicalTrials.gov number, NCT00219739.) N Engl J Med 2010;363:2511-21.	[Guilhot, Joelle; Guilhot, Francois] CHU Poitiers, INSERM, U935, CIC 802, F-86021 Poitiers, France; [Preudhomme, Claude; Roche-Lestienne, Catherine] CHU Lille, Hematol Lab, F-59037 Lille, France; [Preudhomme, Claude; Roche-Lestienne, Catherine] INSERM, U837, F-59045 Lille, France; [Nicolini, Franck Emmanuel] Hop Edouard Herriot, Hematol Clin, Lyon, France; [Guerci-Bresler, Agnes] CHU Brabois, Serv Hematol, Vandoeuvre Les Nancy, France; [Rigal-Huguet, Francoise] Hop Purpan, Serv Hematol, Toulouse, France; [Maloisel, Frederic] Clin St Anne, Serv Oncohematol, Strasbourg, France; [Coiteux, Valerie] Hop Claude Huriez, Serv Malad Sang, Lille, France; [Gardembas, Martine] CHU Angers, Serv Malad Sang, Angers, France; [Berthou, Christian] CHU Brest, Serv Hematol, F-29285 Brest, France; [Vekhoff, Anne] Hop Hotel Dieu, Serv Hematol Clin, Paris, France; [Rea, Delphine] Hop St Louis, INSERM, CIC 9504, Paris, France; [Jourdan, Eric] Grp Hosp Univ Caremeau, Nimes, France; [Allard, Christian] Ctr Hosp Meaux, Serv Hematol, Meaux, France; [Delmer, Alain] CHU Reims, Serv Hematol Clin, Reims, France; [Rousselot, Philippe] Hop Versailles, Versailles, France; [Legros, Laurence] Hop Archet 1, Serv Hematol Clin, Nice, France; [Berger, Marc] CHU Estaing, Clermont Ferrand, France; [Corm, Selim] CHU, Serv Hematol Clin, Chambery, France; [Etienne, Gabriel] Inst Bergonie, Bordeaux, France; [Eclache, Virginie] Hop Avicenne, Hematol Lab, F-93009 Bobigny, France; [Mahon, Francois-Xavier] CHU Bordeaux, Hematol Lab, Bordeaux, France; [Mahon, Francois-Xavier] CHU Bordeaux, Serv Malad Sang, Bordeaux, France; [Mahon, Francois-Xavier] Univ Victor Segalen, INSERM, U876, Bordeaux, France	CHU Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Universite de Poitiers; Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU de Nancy; CHU de Toulouse; Universite de Lille - ISITE; CHU Lille; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Brest; Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; CHU de Nimes; CHU de Reims; Universite de Reims Champagne-Ardenne; Centre Hospitalier de Versailles; CHU Nice; CHU Clermont Ferrand; UNICANCER; Institut Bergonie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; CHU Bordeaux; CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Guilhot, F (corresponding author), CHU Poitiers, INSERM, U935, CIC 802, F-86021 Poitiers, France.	fr.guilhot@wanadoo.fr	Besson, Caroline/H-4648-2018; Giraudeau, Bruno/L-9003-2015; SAULNIER, Pierre-Jean/H-7218-2016; maury, sebastien/Q-6573-2018; Preudhomme, Claude/T-8553-2018; DECONINCK, ERIC/AAF-3647-2021; Vey, Norbert/AGE-3573-2022	Besson, Caroline/0000-0003-4364-7173; Giraudeau, Bruno/0000-0003-3031-8258; SAULNIER, Pierre-Jean/0000-0003-1862-4252; maury, sebastien/0000-0002-1170-8683; Preudhomme, Claude/0000-0002-1267-9546; DECONINCK, ERIC/0000-0002-6006-8088; Vey, Norbert/0000-0001-7027-040X; Kiladjian, Jean-Jacques/0000-0002-8121-438X; Guilhot, Francois/0000-0001-7222-487X; Roche-Lestienne, Catherine/0000-0002-7998-3817; Casasnovas, Rene-Olivier/0000-0002-1156-8983; Rea, Delphine/0000-0001-5379-7461; Delmer, Alain/0000-0002-1430-2574; moreau, philippe/0000-0003-1780-8746; Bouscary, Didier/0000-0003-3654-5064; Ojeda-Uribe, Mario/0000-0001-6881-6055; IFRAH, Norbert/0000-0003-3063-850X; GYAN, Emmanuel/0000-0002-7651-9189	French Ministry of Health; Novartis; Roche Pharma	French Ministry of Health; Novartis(Novartis); Roche Pharma	Supported by grants from the French Ministry of Health (Programme Hospitalier de Recherche Clinique 2003 and 2006), Novartis, and Roche Pharma.	Copland M, 2006, BLOOD, V107, P4532, DOI 10.1182/blood-2005-07-2947; Cortes JE, 2010, J CLIN ONCOL, V28, P392, DOI 10.1200/JCO.2009.25.4896; Cortes JE, 2010, J CLIN ONCOL, V28, P398, DOI 10.1200/JCO.2009.25.4920; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815; Gabert J, 2003, LEUKEMIA, V17, P2318, DOI 10.1038/sj.leu.2403135; Gardembas M, 2003, BLOOD, V102, P4298, DOI 10.1182/blood-2003-04-1010; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Guilhot F, 2009, BEST PRACT RES CL HA, V22, P315, DOI 10.1016/j.beha.2009.10.005; Hochhaus A, 2010, LEUKEMIA, V24, P1102, DOI 10.1038/leu.2010.71; Hochhaus A, 2009, LEUKEMIA, V23, P1054, DOI 10.1038/leu.2009.38; Hughes TP, 2003, NEW ENGL J MED, V349, P1423, DOI 10.1056/NEJMoa030513; Jiang X, 2007, LEUKEMIA, V21, P926, DOI 10.1038/sj.leu.2404609; Jorgensen HG, 2007, BLOOD, V109, P4016, DOI 10.1182/blood-2006-11-057521; Kantarjian H, 2010, NEW ENGL J MED, V362, P2260, DOI 10.1056/NEJMoa1002315; Lipton JH, 2007, LEUKEMIA LYMPHOMA, V48, P497, DOI 10.1080/10428190601175393; Michallet M, 2004, LEUKEMIA, V18, P309, DOI 10.1038/sj.leu.2403217; Muller MC, 2009, LEUKEMIA, V23, P1957, DOI 10.1038/leu.2009.168; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Rousselot P, 2007, BLOOD, V109, P58, DOI 10.1182/blood-2006-03-011239; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614; Sato T, 2009, NAT MED, V15, P696, DOI 10.1038/nm.1973; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SKORSKI T, 1995, BLOOD, V86, P726, DOI 10.1182/blood.V86.2.726.bloodjournal862726; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; The Criteria Committee of the New York Heart Association, 1994, NOMENCLATURE CRITERI, V9th, P253	32	293	310	2	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	2010	363	26					2511	2521		10.1056/NEJMoa1004095	http://dx.doi.org/10.1056/NEJMoa1004095			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697YL	21175313				2023-01-03	WOS:000285555600006
J	Domingo, P; Torres-Torronteras, J; Pomar, V; Giralt, M; Domingo, JC; Gutierrez, MD; Gallego-Escuredo, JM; Mateo, MG; Cano-Soldado, P; Fernandez, I; Pastor-Anglada, M; Vidal, F; Villarroya, F; Andreu, A; Marti, R				Domingo, Pere; Torres-Torronteras, Javier; Pomar, Virginia; Giralt, Marta; Carles Domingo, Joan; del Mar Gutierrez, Maria; Gallego-Escuredo, Jose M.; Gracia Mateo, Maria; Cano-Soldado, Pedro; Fernandez, Irene; Pastor-Anglada, Marcal; Vidal, Francesc; Villarroya, Francesc; Andreu, Antoni; Marti, Ramon			Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome	PLOS ONE			English	Article							MITOCHONDRIAL-DNA; TOXICITY; RAT; SUPPLEMENTATION; PHOSPHORYLASE; LIPOATROPHY; INHIBITOR; STAVUDINE; DEPLETION; DISEASE	Background: Uridine has been advocated for the treatment of HIV-1/HAART-associated lipodystrophy (HALS), although its metabolism in HIV-1-infected patients is poorly understood. Methods: Plasma uridine concentrations were measured in 35 controls and 221 HIV-1-infected patients and fat uridine in 15 controls and 19 patients. The diagnosis of HALS was performed following the criteria of the Lipodystrophy Severity Grading Scale. Uridine was measured by a binary gradient-elution HPLC method. Analysis of genes encoding uridine metabolizing enzymes in fat was performed with TaqMan RT-PCR. Results: Median plasma uridine concentrations for HIV-1-infected patients were 3.80 mmol/l (interquartile range: 1.60), and for controls 4.60 mmol/l (IQR: 1.8) (P = 0.0009). In fat, they were of 6.0 (3.67), and 2.8 (4.65) nmol/mg of protein, respectively (P = 0.0118). Patients with a mixed HALS form had a median plasma uridine level of 4.0 (IC95%: 3.40-4.80) whereas in those with isolated lipoatrophy it was 3.25 (2.55-4.15) mmol/l/l (P = 0.0066). The expression of uridine cytidine kinase and uridine phosphorylase genes was significantly decreased in all groups of patients with respect to controls. A higher expression of the mRNAs for concentrative nucleoside transporters was found in HIV-1-infected patients with respect to healthy controls. Conclusions: HIV-1 infection is associated with a decrease in plasma uridine and a shift of uridine to the adipose tissue compartment. Antiretroviral therapy was not associated with plasma uridine concentrations, but pure lipoatrophic HALS was associated with significantly lower plasma uridine concentrations.	[Domingo, Pere; Pomar, Virginia; del Mar Gutierrez, Maria; Gracia Mateo, Maria; Fernandez, Irene] Hosp Santa Crue & St Pau, Infect Dis Unit, Barcelona, Spain; [Torres-Torronteras, Javier; Andreu, Antoni; Marti, Ramon] Inst Recerca Hosp Vall dHebron, Lab Mitochondrial Disorders, Barcelona, Spain; [Torres-Torronteras, Javier; Andreu, Antoni; Marti, Ramon] CIBERER, Barcelona, Spain; [Giralt, Marta; Carles Domingo, Joan; Gallego-Escuredo, Jose M.; Cano-Soldado, Pedro; Pastor-Anglada, Marcal; Villarroya, Francesc] Univ Barcelona, Dept Bioquim & Biol Mol, Barcelona, Spain; [Giralt, Marta; Carles Domingo, Joan; Gallego-Escuredo, Jose M.; Cano-Soldado, Pedro; Pastor-Anglada, Marcal; Villarroya, Francesc] Univ Barcelona, Inst Biomed, Barcelona, Spain; [Vidal, Francesc] Hosp Univ Joan XXIII, Infect Dis Unit, Tarragona, Spain	CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of Barcelona; University of Barcelona	Domingo, P (corresponding author), Hosp Santa Crue & St Pau, Infect Dis Unit, Barcelona, Spain.	pdomingo@santpau.cat	Domingo, Pere/CAF-3577-2022; Domingo, Pere/AAP-7571-2021; Villarroya, Francesc/K-4357-2014; Torres-Torronteras, Javier/K-4974-2014; Pedrol, Joan Carles C Domingo/A-4856-2019; Martí, Ramon/Q-3442-2016; Giralt, Marta/A-4756-2013	Domingo, Pere/0000-0003-1138-5770; Torres-Torronteras, Javier/0000-0002-6092-9458; Pedrol, Joan Carles C Domingo/0000-0002-6356-0836; Martí, Ramon/0000-0002-8273-9540; Giralt, Marta/0000-0001-7968-4190; ANDREU, antonio luis/0000-0002-3936-3234; Villarroya, Francesc/0000-0003-1266-9142; GALLEGO-ESCUREDO, JOSE MIGUEL/0000-0001-7899-8585; Vidal, Francesc/0000-0002-6692-6186	Fondo de Investigaciones Sanitarias (FIS) [02/1280, 05/1591, 07/0976, EC08/00256]; Fundacion para la Prevencion del SIDA en Espana (FIPSE) [36610, 36572/06, 36621/06]; Ministerio de Ciencia e Innovacion [SAF2008-00577]; Red de Investigacion en SIDA (RIS) [RD06/006/0022, RD06/0006/1004]	Fondo de Investigaciones Sanitarias (FIS)(Instituto de Salud Carlos III); Fundacion para la Prevencion del SIDA en Espana (FIPSE); Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Red de Investigacion en SIDA (RIS)	This work was partially funded by the Fondo de Investigaciones Sanitarias (FIS 02/1280, 05/1591, 07/0976, EC08/00256), the Fundacion para la Prevencion del SIDA en Espana (FIPSE 36610, 36572/06, 36621/06), Ministerio de Ciencia e Innovacion (SAF2008-00577), and the Red de Investigacion en SIDA (RIS RD06/006/0022, RD06/0006/1004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AUSSEDAT J, 1983, CARDIOVASC RES, V17, P145, DOI 10.1093/cvr/17.3.145; BENZI G, 1984, J NEUROSCI RES, V11, P437, DOI 10.1002/jnr.490110410; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Calzolari I, 2009, CURR PHARM DESIGN, V15, P4094, DOI 10.2174/138161209789909755; CDC, 1993, MMWR-MORBID MORTAL W, V41, P1; Connolly GP, 1999, TRENDS PHARMACOL SCI, V20, P218, DOI 10.1016/S0165-6147(99)01298-5; Cote HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035; Domingo P, 2010, CLIN INFECT DIS, V50, P1033, DOI 10.1086/651117; GALLAI V, 1992, ACTA NEUROL SCAND, V86, P3, DOI 10.1111/j.1600-0404.1992.tb08045.x; GASSER T, 1981, SCIENCE, V213, P777, DOI 10.1126/science.7256279; GEIGER A, 1956, J NEUROCHEM, V1, P93, DOI 10.1111/j.1471-4159.1956.tb12059.x; Giralt M, 2006, ANTIVIR THER, V11, P729; Guggr JP, 2007, ANTIVIR THER, V12, P853; LANGMANN P, 2008, AIDS 2008 17 INT AID; LEPAGE G, 1986, J LIPID RES, V27, P114; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Loffler M, 2005, TRENDS MOL MED, V11, P430, DOI 10.1016/j.molmed.2005.07.003; Maagaard A, 2006, HIV MED, V7, P53, DOI 10.1111/j.1468-1293.2005.00336.x; McComsey G, 2010, 17 C RETR OPP INF SA; McComsey GA, 2010, AIDS, V24, P2503, DOI 10.1097/QAD.0b013e32833ea9bc; Moreno-Torres A, 2007, ANTIVIR THER, V12, P195; Mouton JW, 2008, J ANTIMICROB CHEMOTH, V61, P235, DOI 10.1093/jac/dkm476; MOYER JD, 1981, CANCER RES, V41, P3010; Pastor-Anglada M, 2004, LEUKEMIA, V18, P385, DOI 10.1038/sj.leu.2403271; Pizzorno G, 1998, CLIN CANCER RES, V4, P1165; Pizzorno G, 2002, BBA-MOL BASIS DIS, V1587, P133, DOI 10.1016/S0925-4439(02)00076-5; Setzer B, 2008, AM J PATHOL, V172, P681, DOI 10.2353/ajpath.2008.070613; Simmonds HA, 1995, BIOCHEM SOC T, V23, P877, DOI 10.1042/bst0230877; Sutinen J, 2007, ANTIVIR THER, V12, P97; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; VANGROENINGEN CJ, 1986, CANCER TREAT REP, V70, P745; Walker UA, 2006, ANTIVIR THER, V11, P25	32	10	11	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 15	2010	5	11							e13896	10.1371/journal.pone.0013896	http://dx.doi.org/10.1371/journal.pone.0013896			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	680KW	21085568	gold, Green Submitted, Green Published			2023-01-03	WOS:000284231800001
J	Kaida, A; Laher, F; Strathdee, SA; Money, D; Janssen, PA; Hogg, RS; Gray, G				Kaida, Angela; Laher, Fatima; Strathdee, Steffanie A.; Money, Deborah; Janssen, Patricia A.; Hogg, Robert S.; Gray, Glenda			Contraceptive Use and Method Preference among Women in Soweto, South Africa: The Influence of Expanding Access to HIV Care and Treatment Services	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; POSITIVE WOMEN; FERTILITY INTENTIONS; DISEASE PROGRESSION; SEXUAL-ACTIVITY; INFECTED WOMEN; TRANSMISSION; UGANDA; HAART; PREGNANCY	Objective: Preventing unintended pregnancy among HIV-positive women constitutes a critical and cost-effective approach to primary prevention of mother-to-child transmission of HIV and is a global public health priority for addressing the desperate state of maternal and child health in HIV hyper-endemic settings. We sought to investigate whether the prevalence of contraceptive use and method preferences varied by HIV status and receipt of highly active antiretroviral therapy (HAART) among women in Soweto, South Africa. Methods: We used survey data from 563 sexually active, non-pregnant women (18-44 years) recruited from the Perinatal HIV Research Unit in Soweto (May-December, 2007); 171 women were HIV-positive and receiving HAART (median duration of use = 31 months; IQR = 28, 33), 178 were HIV-positive and HAART-naive, and 214 were HIV-negative. Medical record review was conducted to confirm HIV status and clinical variables. Logistic regression models estimated adjusted associations between HIV status, receipt of HAART, and contraceptive use. Results: Overall, 78% of women reported using contraception, with significant variation by HIV status: 86% of HAART users, 82% of HAART-naive women, and 69% of HIV-negative women (p<0.0001). In adjusted models, compared with HIV-negative women, women receiving HAART were significantly more likely to use contraception while HAART-naive women were non-significantly more likely (AOR: 2.40; 95% CI: 1.25, 4.62 and AOR: 1.59; 95% CI: 0.88, 2.85; respectively). Among HIV-positive women, HAART users were non-significantly more likely to use contraception compared with HAART-naive women (AOR: 1.55; 95% CI: 0.84, 2.88). Similar patterns held for specific use of barrier (primarily male condoms), permanent, and dual protection contraceptive methods. Conclusion: Among HIV-positive women receiving HAART, the observed higher prevalence of contraceptive use overall and condoms in particular promises to yield fewer unintended pregnancies and reduced risks of vertical and sexual HIV transmission. These findings highlight the potential of integrated HIV and reproductive health services to positively impact maternal, partner, and child health.	[Kaida, Angela; Hogg, Robert S.] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada; [Laher, Fatima; Gray, Glenda] Univ Witwatersrand, Perinatal HIV Res Unit, Soweto, South Africa; [Strathdee, Steffanie A.] Univ Calif San Diego, Sch Med, Div Global Publ Hlth, San Diego, CA 92103 USA; [Money, Deborah] Womens Hlth Res Inst, Vancouver, BC, Canada; [Money, Deborah] Univ British Columbia, Dept Obstet & Gynaecol, Vancouver, BC V5Z 1M9, Canada; [Janssen, Patricia A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada; [Janssen, Patricia A.] Child & Family Res Inst, Vancouver, BC, Canada; [Hogg, Robert S.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada	Simon Fraser University; University of Witwatersrand; University of California System; University of California San Diego; University of British Columbia; University of British Columbia; Child & Family Research Institute; B.C. Centre for Excellence in HIV/AIDS	Kaida, A (corresponding author), Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada.	angela_kaida@sfu.ca	Janssen, Patricia/B-1036-2018; Hogg, Robert S/B-2783-2012; Strathdee, Steffanie A/B-9042-2009	Janssen, Patricia/0000-0002-4178-1195; Hogg, Robert S/0000-0003-3463-5488; Strathdee, Steffanie/0000-0002-7724-691X	Canadian Foundation for AIDS Research (CANFAR); University of California San Diego Center for AIDS Research (National Institute of Allergy and Infectious Diseases) [P30AI036214]; Social Sciences and Humanities Research Council (SSHRC) of Canada; Canadian Institutes of Health Research (CIHR); Michael Smith Foundation for Health Research (MSFHR); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036214] Funding Source: NIH RePORTER	Canadian Foundation for AIDS Research (CANFAR); University of California San Diego Center for AIDS Research (National Institute of Allergy and Infectious Diseases)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Social Sciences and Humanities Research Council (SSHRC) of Canada(Social Sciences and Humanities Research Council of Canada (SSHRC)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Funding: This research was supported by the Canadian Foundation for AIDS Research (CANFAR), the University of California San Diego Center for AIDS Research (grant P30AI036214 from the National Institute of Allergy and Infectious Diseases), and the Social Sciences and Humanities Research Council (SSHRC) of Canada. A. K. is supported by the Canadian Institutes of Health Research (CIHR) and the Michael Smith Foundation for Health Research (MSFHR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adair T, 2009, J BIOSOC SCI, V41, P269, DOI 10.1017/S0021932008003076; ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; Andia I, 2009, AM J PUBLIC HEALTH, V99, P340, DOI 10.2105/AJPH.2007.129528; Baeten JM, 2007, CLIN INFECT DIS, V45, P360, DOI 10.1086/519432; Balkus J, 2007, SEX TRANSM DIS, V34, P25, DOI 10.1097/01.olq.0000218880.88179.36; Barker PM, 2007, SAMJ S AFR MED J, V97, P916; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Coll O, 2008, CURR OPIN HIV AIDS, V3, P186, DOI 10.1097/COH.0b013e3282f51219; Cooper D, 2007, SOC SCI MED, V65, P274, DOI 10.1016/j.socscimed.2007.03.019; Cooper ER, 2002, J ACQ IMMUN DEF SYND, V29, P484, DOI 10.1097/00126334-200204150-00009; *DEP HLTH SA, 2007, NAT HIV SYPH PREV SU; Department of Health SA, 2004, NAT ANT TREATM GUID; Desgrees-du-Lou A, 2002, INT J STD AIDS, V13, P462, DOI 10.1258/09564620260079617; Gruskin S, 2007, REPROD HEALTH MATTER, V15, P4, DOI 10.1016/S0968-8080(07)29028-7; Hladik W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007691; Hoffman IF, 2008, JAIDS-J ACQ IMM DEF, V47, P477, DOI 10.1097/QAI.0b013e318165dc52; Hogan M., LANCET, V375, P1609; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; Homsy J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004149; HORTON R, LANCET, V375, P1941; Kaida A, 2008, AIDS CARE, V20, P21, DOI 10.1080/09540120701426540; Kaida Angela, 2006, Curr HIV/AIDS Rep, V3, P187, DOI 10.1007/s11904-006-0015-0; Kaida A, 2009, AIDS BEHAV, V13, pS72, DOI 10.1007/s10461-009-9553-y; Laher F, 2009, AIDS BEHAV, V13, pS47, DOI 10.1007/s10461-009-9544-z; Mitchell HS, 2004, SEX TRANSM INFECT, V80, P167, DOI 10.1136/sti.2003.008441; Myer L, 2006, AIDS CARE, V18, P772, DOI 10.1080/09540120500409283; *NAT COMM CONF ENQ, 2003, SAV MOTH 1999 2001; PAGANO M, 2000, PRINC BIOST; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; *PAN ANT GUID AD A, 2008, GUID US ANT AG HIV 1; Peltzer K, 2009, AIDS BEHAV, V13, P973, DOI 10.1007/s10461-008-9365-5; Petruney T, 2008, B WHO, V86, pB; Rehle T, 2007, SAMJ S AFR MED J, V97, P194; Reynolds HW, 2006, SEX TRANSM DIS, V33, P350, DOI 10.1097/01.olq.0000194602.01058.e1; Rochat TJ, 2006, JAMA-J AM MED ASSOC, V295, P1376, DOI 10.1001/jama.295.12.1376; *SADHS, 2004, S AFR DEM HLTH SURV; Seiber EE, 2007, INT FAM PLAN PERSPEC, V33, P117, DOI 10.1363/3311707; UN, 2007, WORLD CONTR US; *UNAIDS, 2008, REP GLOB HIV AIDS EP; UNAIDS UNICEF & USAID, 2004, CHILDR BRINK 2004 JO; Van Ness PH, 2007, USING SAS INVESTIGAT; Wallerstein N., 2006, WHAT IS EVIDENCE EFF; [WHO UNAIDS UNICEF], 2009, UN ACC SCAL PRIOR HI; WHO, 2006, ANT DRUGS TREAT PREG; WHO, 1995, HLTH BEN FAM PLANN; Wilcher R, 2009, AIDS, V23, pS1, DOI 10.1097/01.aids.0000363772.45635.35; Williams HA, 1996, CLIN OBSTET GYNECOL, V39, P333, DOI 10.1097/00003081-199606000-00008; World Health Organization, 2002, PREV HIV INF YOUNG C; World Health Organization, 2008, UN ACC SCAL PRIOR HI	51	57	57	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 5	2010	5	11							e13868	10.1371/journal.pone.0013868	http://dx.doi.org/10.1371/journal.pone.0013868			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	675OD	21079770	gold, Green Published, Green Submitted			2023-01-03	WOS:000283839100018
J	Scharf, C; Krasniqi, N; Hellermann, J; Rahn, M; Sutsch, G; Brunckhorst, C; Duru, F				Scharf, Christoph; Krasniqi, Nazmi; Hellermann, Jens; Rahn, Mariette; Suetsch, Gabor; Brunckhorst, Corinna; Duru, Firat			Electrical Activation in the Coronary Sinus Branches as a Guide to Cardiac Resynchronisation Therapy: Rationale for a Coordinate System	PLOS ONE			English	Article							RESYNCHRONIZATION THERAPY; HEART-FAILURE; VENTRICULAR ACTIVATION; BLOCK; CONDUCTION; DELAY; NOMENCLATURE; CARDIOLOGY; STATEMENT; ANATOMY	Background: For successful cardiac resynchronisation therapy (CRT) a spatial and electrical separation of right and left ventricular electrodes is essential. The spatial distribution of electrical delays within the coronary sinus (CS) tributaries has not yet been identified. Objective: Electrical delays within the CS are described during sinus rhythm (SR) and right ventricular pacing (RVP). A coordinate system grading the mitral ring from 0 degrees to 360 degrees and three vertical segments is proposed to define the lead positions irrespective of individual CS branch orientation. Methods: In 13 patients undergoing implantation of a CRT device 6 +/- 2.5, (median 5) lead positions within the CS were mapped during SR and RVP. The delay to the onset and the peak of the local signal was measured from the earliest QRS activation or the pacing spike. Fluoroscopic positions were compared to localizations on a nonfluoroscopic electrode imaging system. Results: During SR, electrical delays in the CS were inhomogenous in patients with or without left bundle branch block (LBBB). During RVP, the delays increased by 44 +/- 32 ms (signal onset from 36 +/- 33 ms to 95 +/- 30 ms; p<0.001, signal peak from 105 +/- 44 ms to 156 +/- 30 ms; p<0.001). The activation pattern during RVP was homogeneous and predictable by taking the grading on the CS ring into account: (% QRS) = 78-0.002 (grade-162)(2), p<0.0001. This indicates that 78% of the QRS duration can be expected as a maximum peak delay at 162 degrees on the CS ring. Conclusion: Electrical delays within the CS vary during SR, but prolong and become predictable during RVP. A coordinate system helps predicting the local delays and facilitates interindividual comparison of lead positions irrespective of CS branch anatomy.	[Scharf, Christoph; Krasniqi, Nazmi; Hellermann, Jens; Rahn, Mariette; Suetsch, Gabor; Brunckhorst, Corinna; Duru, Firat] Univ Zurich Hosp, Ctr Cardiovasc, Clin Cardiol, Div Pacing & Electrophysiol, CH-8091 Zurich, Switzerland; [Scharf, Christoph] Clin Pk, Zurich, Switzerland; [Duru, Firat] Univ Zurich, Ctr Integrat Human Physiol, Zurich, Switzerland	University of Zurich; University Zurich Hospital; University of Zurich; Zurich Center Integrative Human Physiology (ZIHP)	Scharf, C (corresponding author), Univ Zurich Hosp, Ctr Cardiovasc, Clin Cardiol, Div Pacing & Electrophysiol, CH-8091 Zurich, Switzerland.	christoph.scharf@gmail.com	Hellermann, Jens/ABB-2889-2020; Duru, Firat/F-7161-2011	Duru, Firat/0000-0002-4748-0158				Auricchio A, 2004, CIRCULATION, V109, P1133, DOI 10.1161/01.CIR.0000118502.91105.F6; CANNOM DS, 1980, CIRCULATION, V62, P621, DOI 10.1161/01.CIR.62.3.621; Cerqueira MD, 2002, CIRCULATION, V105, P539, DOI 10.1161/hc0402.102975; Cosio FG, 1999, CIRCULATION, V100, pE31, DOI 10.1161/01.CIR.100.5.e31; Lambiase PD, 2004, HEART, V90, P44, DOI 10.1136/heart.90.1.44; Merchant FM, 2010, PACE, V33, P575, DOI 10.1111/j.1540-8159.2009.02624.x; Peichl P, 2004, PACE, V27, P1105, DOI 10.1111/j.1540-8159.2004.00592.x; Rodriguez LM, 2003, J CARDIOVASC ELECTR, V14, P135, DOI 10.1046/j.1540-8167.2003.02421.x; Sassone B, 2010, EUROPACE, V12, P78, DOI 10.1093/europace/eup347; Singh JP, 2005, J AM COLL CARDIOL, V46, P68, DOI 10.1016/j.jacc.2005.04.017; Tse HF, 2005, J CARDIOVASC ELECTR, V16, P690, DOI 10.1046/j.1540-8167.2005.40568.x; Turner MS, 2004, CIRCULATION, V109, P2544, DOI 10.1161/01.CIR.0000131184.40893.40; VASSALLO JA, 1984, CIRCULATION, V69, P914, DOI 10.1161/01.CIR.69.5.914; Wittkampf FHM, 1999, CIRCULATION, V99, P1312, DOI 10.1161/01.CIR.99.10.1312	14	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	AUG 8	2011	6	8							e19914	10.1371/journal.pone.0019914	http://dx.doi.org/10.1371/journal.pone.0019914			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	806AM	21857896	gold, Green Submitted, Green Published, Green Accepted			2023-01-03	WOS:000293773300001
J	Mosqueda, L; Dong, XQ				Mosqueda, Laura; Dong, XinQi			Elder Abuse and Self-neglect "I Don't Care Anything About Going to the Doctor, to Be Honest ...."	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADULT PROTECTIVE SERVICES; OLDER-ADULTS; COGNITIVE FUNCTION; UNITED-STATES; RISK; MISTREATMENT; PREVALENCE; IMPAIRMENT; VALIDATION; DEPRESSION	Elder mistreatment encompasses a range of behaviors including emotional, financial, physical, and sexual abuse, neglect by other individuals, and self-neglect. This article discusses the range of elder mistreatment in community-living older adults, associated factors, and consequences. Although self-neglect is not considered a type of abuse in many research definitions, it is the most commonly reported form of elder mistreatment and is associated with increased morbidity and mortality. The case on which this article is based describes a 70-year-old woman who neglects herself and dies despite multiple contacts with the medical community. Despite significant gaps in research, enough is known to guide clinical practice. This article presents the practical approaches a health care professional can take when a reasonable suspicion of elder mistreatment arises. Public health and interdisciplinary team approaches are needed to manage what is becoming an increasing problem as the number of older adults around the world increases.	[Mosqueda, Laura] Univ Calif Irvine, Dept Family Med, Sch Med, Orange, CA 92868 USA; [Dong, XinQi] Rush Univ, Rush Inst Healthy Aging, Med Ctr, Chicago, IL 60612 USA	University of California System; University of California Irvine; Rush University	Mosqueda, L (corresponding author), Univ Calif Irvine, Dept Family Med, Sch Med, 101 City Dr S,Bldg 200,Ste 512,Rt 81, Orange, CA 92868 USA.	mosqueda@uci.edu			Archstone Foundation; National Institute on Aging [R21 AG028060, R01 AG11101]; American Recovery and Reinvestment Act [RC4 AG039085]; Paul B. Beeson Award in Aging [K23 AG030944]; Starr Foundation; John A. Hartford Foundation; Atlantic Philanthropies; SCAN Foundation; NATIONAL INSTITUTE ON AGING [R21AG028060, RC4AG039085, R01AG011101, K23AG030944] Funding Source: NIH RePORTER	Archstone Foundation; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Recovery and Reinvestment Act; Paul B. Beeson Award in Aging; Starr Foundation; John A. Hartford Foundation; Atlantic Philanthropies; SCAN Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Mosqueda reports receipt of support from the Archstone Foundation and National Institute on Aging grant R21 AG028060. Dr Dong reports receipt of support from National Institute on Aging grant R01 AG11101, American Recovery and Reinvestment Act (RC4 AG039085), Paul B. Beeson Award in Aging (K23 AG030944), The Starr Foundation, John A. Hartford Foundation, and The Atlantic Philanthropies. The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	Abrams RC, 2002, AM J PSYCHIAT, V159, P1724, DOI 10.1176/appi.ajp.159.10.1724; Acierno R, 2010, AM J PUBLIC HEALTH, V100, P292, DOI 10.2105/AJPH.2009.163089; American Bar Association Commission on Law and Aging, MAND REP COMP CHARTS; Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Begle AM, 2011, J INTERPERS VIOLENCE, V26, P2321, DOI 10.1177/0886260510383037; Bitondo C, 2007, AM J PUBLIC HEALTH, V97, P1671, DOI 10.2105/AJPH.2006.097113; Blakely BE, 2001, J ELDER ABUSE NEGL, V13, P1, DOI 10.1300/J084v13n03_01; Bonnie R. J., 2003, ELDER MISTREATMENT A; Burnett J, 2009, ARCH PHYS MED REHAB, V90, P1948, DOI 10.1016/j.apmr.2009.05.021; Choi NG, 2009, J GERONTOL SOC WORK, V52, P171, DOI 10.1080/01634370802609239; Comijs HC, 1999, J GERONTOL B-PSYCHOL, V54, pP240, DOI 10.1093/geronb/54B.4.P240; Cooper C, 2010, J AFFECT DISORDERS, V121, P136, DOI 10.1016/j.jad.2009.05.001; Cooper C, 2008, INT J GERIATR PSYCH, V23, P283, DOI 10.1002/gps.1875; Dong X, AM J EMERG MED; Dong XQ, 2010, GERONTOLOGY, V56, P325, DOI 10.1159/000243164; Dong XQ, 2007, J ELDER ABUSE NEGL, V19, P79, DOI 10.1300/J084v19n03_05; Dong XQ, 2005, J ELDER ABUSE NEGL, V17, P19, DOI 10.1300/J084v17n03_02; Dong X, 2007, J AM GERIATR SOC, V55, P1831, DOI 10.1111/j.1532-5415.2007.01429.x; Dong XQ, 2011, AM J GERIAT PSYCHIAT, V19, P743, DOI 10.1097/JGP.0b013e3182006a53; Dong XQ, 2011, J GERONTOL A-BIOL, V66, P695, DOI 10.1093/gerona/glr053; Dong XQ, 2010, J AM GERIATR SOC, V58, P2292, DOI 10.1111/j.1532-5415.2010.03156.x; Dong XQ, 2010, PUBLIC HEALTH REP, V125, P743; Dong XQ, 2010, INT J GERIATR PSYCH, V25, P798, DOI 10.1002/gps.2420; Dong XQ, 2010, GERONTOLOGIST, V50, P316, DOI 10.1093/geront/gnp164; Dong XQ, 2010, AGING MENT HEALTH, V14, P74, DOI 10.1080/13607860903421037; Dong XQ, 2010, ARCH GERONTOL GERIAT, V50, P202, DOI 10.1016/j.archger.2009.03.011; Dong XQ, 2008, J ELDER ABUSE NEGL, V20, P25, DOI 10.1300/J084v20n01_02; Dong XQ, 2009, J AGING HEALTH, V21, P596, DOI 10.1177/0898264309333323; Dong XQ, 2009, JAMA-J AM MED ASSOC, V302, P517, DOI 10.1001/jama.2009.1109; Dong XQ, GERONTOLOGY; Dyer C. B., 2003, ELDER MISTREATMENT A; Dyer CB, 2005, J GERONTOL A-BIOL, V60, P1000, DOI 10.1093/gerona/60.8.1000; Dyer CB, 2000, J AM GERIATR SOC, V48, P205, DOI 10.1111/j.1532-5415.2000.tb03913.x; Fisher JW, 2003, POSTGRAD MED, V113, P21, DOI 10.3810/pgm.2003.04.1403; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fulmer T, 2005, GERONTOLOGIST, V45, P525, DOI 10.1093/geront/45.4.525; Hildreth Carolyn J, 2011, JAMA, V306, P568, DOI 10.1001/jama.306.5.568; Kennedy RD, 2005, FAM MED, V37, P481; Lachs MS, 1998, JAMA-J AM MED ASSOC, V280, P428, DOI 10.1001/jama.280.5.428; Lachs MS, 2002, GERONTOLOGIST, V42, P734, DOI 10.1093/geront/42.6.734; LACHS MS, 1995, NEW ENGL J MED, V332, P437, DOI 10.1056/NEJM199502163320706; Lachs MS, 1996, ARCH INTERN MED, V156, P449, DOI 10.1001/archinte.156.4.449; Laumann EO, 2008, J GERONTOL B-PSYCHOL, V63, pS248, DOI 10.1093/geronb/63.4.S248; Mosqueda L, 2004, GERONTOLOGIST, V44, P703, DOI 10.1093/geront/44.5.703; Mosqueda L, 2010, J ELDER ABUSE NEGL, V22, P219, DOI 10.1080/08946566.2010.489884; Mouton CP, 2010, ANN FAM MED, V8, P206, DOI 10.1370/afm.1095; Naik AD, 2008, GERONTOLOGIST, V48, P388, DOI 10.1093/geront/48.3.388; National Center on Elder Abuse, MAJ TYP ELD AB; Navarro AE, 2010, GERONTOLOGIST, V50, P702, DOI 10.1093/geront/gnq018; Otto JM, 2000, GENERATIONS, V24, P33; Podnieks E, 2010, J ELDER ABUSE NEGL, V22, P131, DOI 10.1080/08946560903436403; Rinker AG, 2009, ARCH GERONTOL GERIAT, V48, P110, DOI 10.1016/j.archger.2007.11.002; Rodriguez MA, 2006, ANN FAM MED, V4, P403, DOI 10.1370/afm.575; Royall DR, 1998, J NEUROL NEUROSUR PS, V64, P588, DOI 10.1136/jnnp.64.5.588; Schillerstrom JE, 2009, AM J GERIAT PSYCHIAT, V17, P907, DOI 10.1097/JGP.0b013e3181b4bf64; Sessums LL, 2011, JAMA-J AM MED ASSOC, V306, P420, DOI 10.1001/jama.2011.1023; Smith SM, 2006, J NUTR, V136, P2534, DOI 10.1093/jn/136.10.2534; Spensley C, 2008, J ELDER ABUSE NEGL, V20, P43, DOI 10.1300/J084v20n01_03; Teaster PB, 2000, RESPONSE ABUSE VULNE; THOMSON LK, 1992, KOHLMAN EVALUATION L; Widera E, 2011, JAMA-J AM MED ASSOC, V305, P698, DOI 10.1001/jama.2011.164; Wiglesworth A, 2006, GERONTOLOGIST, V46, P277, DOI 10.1093/geront/46.2.277; Wiglesworth A, 2010, J AM GERIATR SOC, V58, P493, DOI 10.1111/j.1532-5415.2010.02737.x; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zou Y, 1998, Int Psychogeriatr, V10, P303, DOI 10.1017/S1041610298005390	65	58	59	0	25	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 3	2011	306	5					532	540		10.1001/jama.2011.1085	http://dx.doi.org/10.1001/jama.2011.1085			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	800SH	21813431				2023-01-03	WOS:000293386500020
J	Zanoni, BC; Phungula, T; Zanoni, HM; France, H; Feeney, ME				Zanoni, Brian C.; Phungula, Thuli; Zanoni, Holly M.; France, Holly; Feeney, Margaret E.			Risk Factors Associated with Increased Mortality among HIV Infected Children Initiating Antiretroviral Therapy (ART) in South Africa	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEX-DIFFERENCES; RNA LEVELS; GENDER-DIFFERENCES; CARE; PROGRESSION; OUTCOMES; WOMEN; COHORT; ADULTS	Objective: To identify demographic and clinical risk factors associated with mortality after initiation of antiretroviral therapy (ART) in a cohort of human immunodeficiency (HIV) infected children in KwaZulu-Natal, South Africa. Methods: We performed a retrospective cohort study of 537 children initiating antiretroviral therapy at McCord Hospital in KwaZulu-Natal, South Africa. Data were extracted from electronic medical records and risk factors associated with mortality were assessed using Cox regression analysis. Results: Overall there were 47 deaths from the cohort of 537 children initiating ART with over 991 child-years of follow-up (median 22 months on ART), yielding a mortality rate of 4.7 deaths per 100 child years on ART. Univariate analysis indicated that mortality was significantly associated with lower weight-for-age Z-score (p<0.0001), chronic diarrhea (p = 0.0002), lower hemoglobin (p = 0.002), age <3 years (p = 0.003), and CD4% <10% (p = 0.005). The final multivariable Cox proportional hazards mortality model found age less than 3 years (p = 0.004), CD4 <10% (p = 0.01), chronic diarrhea (p = 0.03), weight-for-age Z-score (<0.0001) and female gender as a covariate varying with time (p = 0.03) all significantly associated with mortality. Conclusion: In addition to recognized risk factors such as young age and advanced immunosuppression, we found female gender to be significantly associated with mortality in this pediatric ART cohort. Future studies are needed to determine whether intrinsic biologic differences or socio-cultural factors place female children with HIV at increased risk of death following initiation of ART.	[Zanoni, Brian C.; Feeney, Margaret E.] MIT, Ragon Inst Massachusetts Gen Hosp, Charlestown, MA USA; [Zanoni, Brian C.; Feeney, Margaret E.] Harvard Univ, Charlestown, MA USA; [Zanoni, Brian C.] Harvard Univ, Sch Med, Boston, MA USA; [Zanoni, Brian C.; Phungula, Thuli; Zanoni, Holly M.; France, Holly] McCord Hosp, Sinikithemba Clin & Philani Program, Durban, South Africa; [Feeney, Margaret E.] Univ Calif San Francisco, Div Expt Med, San Francisco, CA 94143 USA	Harvard University; Massachusetts Institute of Technology (MIT); Ragon Institute; Harvard University; Harvard University; Harvard Medical School; University of California System; University of California San Francisco	Zanoni, BC (corresponding author), MIT, Ragon Inst Massachusetts Gen Hosp, Charlestown, MA USA.	margaret.feeney@ucsf.edu	Zanoni, Brian/AAI-4916-2021		Sullivan Family Foundation; Elizabeth Glaser Pediatric AIDS Foundation; Jewelers for Children Elizabeth Glaser Scientist Award	Sullivan Family Foundation; Elizabeth Glaser Pediatric AIDS Foundation; Jewelers for Children Elizabeth Glaser Scientist Award	This work was generously supported by the Sullivan Family Foundation and the Elizabeth Glaser Pediatric AIDS Foundation (M. E. F.). M. E. F. is the recipient of the Jewelers for Children Elizabeth Glaser Scientist Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Bong CN, 2007, AIDS, V21, P1805, DOI 10.1097/QAD.0b013e3282c3a9e4; Box TL, 2003, J WOMEN HEALTH GEN-B, V12, P391, DOI 10.1089/154099903765448907; Braitstein P, 2008, J WOMENS HEALTH, V17, P47, DOI 10.1089/jwh.2007.0353; Callens SFJ, 2009, PEDIATR INFECT DIS J, V28, P35, DOI 10.1097/INF.0b013e318184eeb9; Chen SCC, 2008, TROP MED INT HEALTH, V13, P513, DOI 10.1111/j.1365-3156.2008.02029.x; Collazos J, 2007, AIDS, V21, P835, DOI 10.1097/QAD.0b013e3280b0774a; Farzadegan H, 1998, LANCET, V352, P1510, DOI 10.1016/S0140-6736(98)02372-1; Fenner L, 2010, JAIDS-J ACQ IMM DEF, V54, P524, DOI 10.1097/QAI.0b013e3181e0c4cf; Flynn P, 2007, PEDIATRICS, V119, P821, DOI 10.1542/peds.2006-3694; Foca M, 2006, PEDIATRICS, V118, P146, DOI 10.1542/peds.2005-0294; Gandhi M, 2002, CLIN INFECT DIS, V35, P313, DOI 10.1086/341249; Giaquinto C, 2002, AIDS, V16, P97, DOI 10.1097/00002030-200201040-00012; Kiboneka A, 2008, AIDS, V22, P2493, DOI 10.1097/QAD.0b013e328318f148; Kipp W, 2010, AIDS CARE, V22, P271, DOI 10.1080/09540120903193625; Leyenaar JK, 2010, PEDIATR INFECT DIS J, V29, P340, DOI 10.1097/INF.0b013e3181bf8ecb; Meier A, 2009, NAT MED, V15, P955, DOI 10.1038/nm.2004; Muula AS, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-63; Prendergast A, 2007, LANCET, V370, P68, DOI 10.1016/S0140-6736(07)61051-4; Reddi Anand, 2007, BMC Pediatr, V7, P13, DOI 10.1186/1471-2431-7-13; Richardson BA, 2003, J VIROL, V77, P7120, DOI 10.1128/JVI.77.12.7120-7123.2003; Shapiro MF, 1999, JAMA-J AM MED ASSOC, V281, P2305, DOI 10.1001/jama.281.24.2305; Sohler NL, 2009, AIDS PATIENT CARE ST, V23, P775, DOI 10.1089/apc.2009.0041; Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003; Sterling TR, 1999, J INFECT DIS, V180, P666, DOI 10.1086/314967; Taha T E, 2000, Pediatrics, V106, pE77, DOI 10.1542/peds.106.6.e77; *UNAIDS, 2009, AIDS EP UPD; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; Wamalwa DC, 2010, BMC PEDIATR, V10, DOI 10.1186/1471-2431-10-33; World Health Organization, 2010, ANT THER HIV INF INF; Yotebieng M, 2010, AIDS, V24, P1341, DOI 10.1097/QAD.0b013e328339e576; Zanoni BC, 2011, AIDS, V25, P49, DOI 10.1097/QAD.0b013e32833f9e04	32	43	43	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2011	6	7							e22706	10.1371/journal.pone.0022706	http://dx.doi.org/10.1371/journal.pone.0022706			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KV	21829487	Green Published, gold, Green Submitted			2023-01-03	WOS:000293286500020
J	Chen, ACH; Arany, PR; Huang, YY; Tomkinson, EM; Sharma, SK; Kharkwal, GB; Saleem, T; Mooney, D; Yull, FE; Blackwell, TS; Hamblin, MR				Chen, Aaron C-H; Arany, Praveen R.; Huang, Ying-Ying; Tomkinson, Elizabeth M.; Sharma, Sulbha K.; Kharkwal, Gitika B.; Saleem, Taimur; Mooney, David; Yull, Fiona E.; Blackwell, Timothy S.; Hamblin, Michael R.			Low-Level Laser Therapy Activates NF-kB via Generation of Reactive Oxygen Species in Mouse Embryonic Fibroblasts	PLOS ONE			English	Article							CYTOCHROME-C-OXIDASE; KAPPA-B ACTIVATION; PROTEIN-KINASE-D; SIGNALING PATHWAY; TRANSCRIPTION FACTOR; INFRARED RADIATION; GENE-EXPRESSION; IR RADIATION; RED-LIGHT; CELLS	Background: Despite over forty years of investigation on low-level light therapy (LLLT), the fundamental mechanisms underlying photobiomodulation at a cellular level remain unclear. Methodology/Principal Findings: In this study, we isolated murine embryonic fibroblasts (MEF) from transgenic NF-kB luciferase reporter mice and studied their response to 810 nm laser radiation. Significant activation of NF-kB was observed at fluences higher than 0.003 J/cm(2) and was confirmed by Western blot analysis. NF-kB was activated earlier (1 hour) by LLLT compared to conventional lipopolysaccharide treatment. We also observed that LLLT induced intracellular reactive oxygen species (ROS) production similar to mitochondrial inhibitors, such as antimycin A, rotenone and paraquat. Furthermore, we observed similar NF-kB activation with these mitochondrial inhibitors. These results, together with inhibition of laser induced NF-kB activation by antioxidants, suggests that ROS play an important role in the laser induced NF-kB signaling pathways. However, LLLT, unlike mitochondrial inhibitors, induced increased cellular ATP levels, which indicates that LLLT also upregulates mitochondrial respiration. Conclusion: We conclude that LLLT not only enhances mitochondrial respiration, but also activates the redox-sensitive NFkB signaling via generation of ROS. Expression of anti-apoptosis and pro-survival genes responsive to NFkB could explain many clinical effects of LLLT.	[Chen, Aaron C-H; Arany, Praveen R.; Huang, Ying-Ying; Tomkinson, Elizabeth M.; Sharma, Sulbha K.; Kharkwal, Gitika B.; Saleem, Taimur; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Arany, Praveen R.] Harvard Univ, Program Leder Human Biol & Translat Med, Cambridge, MA 02138 USA; [Arany, Praveen R.] Harvard Univ, Program Biol Sci Dent Med, Cambridge, MA 02138 USA; [Arany, Praveen R.] Harvard Univ, Sch Dent Med, Program Oral & Maxillofacial Pathol, Boston, MA 02115 USA; [Arany, Praveen R.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Arany, Praveen R.; Mooney, David; Hamblin, Michael R.] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA; [Huang, Ying-Ying; Kharkwal, Gitika B.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Huang, Ying-Ying] Guangxi Med Univ, Aesthet & Plast Ctr, Nanning, Peoples R China; [Tomkinson, Elizabeth M.] Smith Coll, Northampton, MA 01063 USA; [Saleem, Taimur] Aga Khan Med Coll, Karachi, Pakistan; [Yull, Fiona E.; Blackwell, Timothy S.] Vanderbilt Univ, Sch Med, Dept Med & Canc Biol, Nashville, TN 37212 USA; [Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard School of Dental Medicine; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard University; Harvard Medical School; Guangxi Medical University; Smith College; Vanderbilt University; Harvard University; Massachusetts Institute of Technology (MIT)	Chen, ACH (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Arany, Praveen/S-5329-2019; Hamblin, Mike/AAB-2511-2022; Huang, yingying/J-7329-2012; Huang, Ying-ying/G-3153-2011	Hamblin, Michael R/0000-0001-6431-4605; Arany, Praveen/0000-0002-6116-2340; Huang, yingying/0000-0002-4038-0277; Huang, Ying-ying/0000-0003-3066-6981; Mooney, David/0000-0001-6299-1194; Yull, Fiona/0000-0003-1636-7942; Chen, Aaron/0000-0002-8367-8399	National Institutes of Health (NIH) [R01AI050875]; Center for Integration of Medicine and Innovative Technology [DAMD17-02-2-0006]; CDMRP Program in TBI [W81XWH-09-1-0514]; Air Force Office of Scientific Research [FA9950-04-1-0079]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050875] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Integration of Medicine and Innovative Technology; CDMRP Program in TBI; Air Force Office of Scientific Research(United States Department of DefenseAir Force Office of Scientific Research (AFOSR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by National Institutes of Health (NIH) grant R01AI050875, Center for Integration of Medicine and Innovative Technology (DAMD17-02-2-0006), CDMRP Program in TBI (W81XWH-09-1-0514) and Air Force Office of Scientific Research (FA9950-04-1-0079). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexandratou E, 2002, PHOTOCH PHOTOBIO SCI, V1, P547, DOI 10.1039/b110213n; Ali S, 1996, BIOCHEM MOL BIOL INT, V39, P63; Arany PR, 2007, WOUND REPAIR REGEN, V15, P866, DOI 10.1111/j.1524-475X.2007.00306.x; Baichwal VR, 1997, CURR BIOL, V7, pR94, DOI 10.1016/S0960-9822(06)00046-7; Bilski P, 2002, FREE RADICAL BIO MED, V33, P938, DOI 10.1016/S0891-5849(02)00982-6; Blackwell TS, 2000, AM J RESP CRIT CARE, V162, P1095, DOI 10.1164/ajrccm.162.3.9906129; Callaghan GA, 1996, LASER SURG MED, V19, P201; Campbell KJ, 2006, BIOCHEM SOC SYMP, V73, P165, DOI 10.1042/bss0730165; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; D'Angio CT, 2000, MOL GENET METAB, V71, P371, DOI 10.1006/mgme.2000.3074; de Lima FM, 2009, CELL BIOL INT, V33, P1212, DOI 10.1016/j.cellbi.2009.04.025; DENG YT, 2009, MOL CARCINOG; Eichler M, 2007, PHOTOMED LASER SURG, V25, P170, DOI 10.1089/pho.2007.2046; GLASCOTT PA, 1987, CELL MOTIL CYTOSKEL, V8, P118, DOI 10.1002/cm.970080204; Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S; Hauer J, 2005, P NATL ACAD SCI USA, V102, P2874, DOI 10.1073/pnas.0500187102; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Hode L., 2002, LASER THERAPY CLIN P; Hoffmann A, 2002, SCIENCE, V298, P1241, DOI 10.1126/science.1071914; Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KARU T, 1989, HEALTH PHYS, V56, P691, DOI 10.1097/00004032-198905000-00015; Karu T., 1998, SCI LOW POWER LASER; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355; Karu TI, 2004, PHOTOCHEM PHOTOBIOL, V80, P366, DOI 10.1562/2004-03-25-RA-123.1; Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a; Lavi R, 2003, J BIOL CHEM, V278, P40917, DOI 10.1074/jbc.M303034200; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lubart R, 2005, PHOTOMED LASER SURG, V23, P3, DOI 10.1089/pho.2005.23.3; Moriyama Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P1351, DOI 10.1562/2005-02-28-RA-450; Pal G, 2007, J PHOTOCH PHOTOBIO B, V86, P252, DOI 10.1016/j.jphotobiol.2006.12.001; Park WH, 2007, J CELL BIOCHEM, V102, P98, DOI 10.1002/jcb.21280; Pastore D, 2000, INT J RADIAT BIOL, V76, P863, DOI 10.1080/09553000050029020; Sadikot RT, 2001, AM J RESP CRIT CARE, V164, P873, DOI 10.1164/ajrccm.164.5.2008059; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; Schroeder P, 2007, FREE RADICAL BIO MED, V43, P128, DOI 10.1016/j.freeradbiomed.2007.04.002; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Storz P, 2007, TRENDS CELL BIOL, V17, P13, DOI 10.1016/j.tcb.2006.11.003; Sun Hong, 2007, V383, P303, DOI 10.1007/978-1-59745-335-6_19; Szundi I, 2001, BIOCHEMISTRY-US, V40, P2332, DOI 10.1021/bi002220v; TAFUR J, 2008, PHOTOMED LASER SURG; Tergaonkar V, 2006, INT J BIOCHEM CELL B, V38, P1647, DOI 10.1016/j.biocel.2006.03.023; Wang TL, 2002, INT IMMUNOPHARMACOL, V2, P1509, DOI 10.1016/S1567-5769(02)00058-9; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200; Yu W, 1997, PHOTOCHEM PHOTOBIOL, V66, P866, DOI 10.1111/j.1751-1097.1997.tb03239.x; Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529; Zhang YO, 2003, J INVEST DERMATOL, V120, P849, DOI 10.1046/j.1523-1747.2003.12133.x	53	306	314	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2011	6	7							e22453	10.1371/journal.pone.0022453	http://dx.doi.org/10.1371/journal.pone.0022453			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	795FA	21814580	Green Published, gold			2023-01-03	WOS:000292956800058
J	Hirnschall, G; Schwartlander, B				Hirnschall, Gottfried; Schwartlaender, Bernhard			Treatment 2.0: catalysing the next phase of scale-up	LANCET			English	Editorial Material									[Schwartlaender, Bernhard] Joint United Nations Programme HIV AIDS, Evidence Strategy & Results Dept, CH-1211 Geneva, Switzerland; [Hirnschall, Gottfried] WHO, HIV Dept, CH-1211 Geneva, Switzerland	World Health Organization	Schwartlander, B (corresponding author), Joint United Nations Programme HIV AIDS, Evidence Strategy & Results Dept, CH-1211 Geneva, Switzerland.	schwartlanderb@unaids.org						GRUBB I, 2003, PUBLIC HLTH APPROACH; Kates J, 2010, FINANCING RESPONSE A; Lu CL, 2010, LANCET, V375, P1375, DOI 10.1016/S0140-6736(10)60233-4; MIDDELKOOP K, 2009, 5 IAS C HIV PATH TRE; Siegfried N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008272.pub2; *UN GEN ASS, 2006, 2006 HIGH LEV M AIDS; *UNAIDS, 2007, RES NEEDS AIDS LOW M; UNAIDS, 2010, TREATM 2 0 IS THIS F; UNAIDS, 2010, GLOB REP UNAIDS REP; Walensky RP, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000382; WHO, 2010, ANT THER HIV INF AD; World Health Organization, 2010, ANT THER HIV INF INF	12	34	34	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 16	2011	378	9787					209	211		10.1016/S0140-6736(11)60247-X	http://dx.doi.org/10.1016/S0140-6736(11)60247-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	798JD	21353697				2023-01-03	WOS:000293201100009
J	Thiele, P; Blair, S				Thiele, Pauline; Blair, Simon			A PATIENT'S JOURNEY Destined to die	BRITISH MEDICAL JOURNAL			English	Editorial Material												liam194@gmail.com							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 1	2011	343								d3625	10.1136/bmj.d3625	http://dx.doi.org/10.1136/bmj.d3625			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	788QD	21724563	Bronze			2023-01-03	WOS:000292458600001
J	Maitland, K; Kiguli, S; Opoka, RO; Engoru, C; Olupot-Olupot, P; Akech, SO; Nyeko, R; Mtove, G; Reyburn, H; Lang, T; Brent, B; Evans, JA; Tibenderana, JK; Crawley, J; Russell, EC; Levin, M; Babiker, AG; Gibb, DM				Maitland, Kathryn; Kiguli, Sarah; Opoka, Robert O.; Engoru, Charles; Olupot-Olupot, Peter; Akech, Samuel O.; Nyeko, Richard; Mtove, George; Reyburn, Hugh; Lang, Trudie; Brent, Bernadette; Evans, Jennifer A.; Tibenderana, James K.; Crawley, Jane; Russell, Elizabeth C.; Levin, Michael; Babiker, Abdel G.; Gibb, Diana M.		FEAST Trial Grp	Mortality after Fluid Bolus in African Children with Severe Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEONATAL SEPTIC SHOCK; VOLUME EXPANSION; CAPILLARY REFILL; SEVERE MALARIA; ALBUMIN; CARE; RESUSCITATION; SEPSIS; SALINE	BACKGROUND The role of fluid resuscitation in the treatment of children with shock and life-threatening infections who live in resource-limited settings is not established. METHODS We randomly assigned children with severe febrile illness and impaired perfusion to receive boluses of 20 to 40 ml of 5% albumin solution (albumin-bolus group) or 0.9% saline solution (saline-bolus group) per kilogram of body weight or no bolus (control group) at the time of admission to a hospital in Uganda, Kenya, or Tanzania (stratum A); children with severe hypotension were randomly assigned to one of the bolus groups only (stratum B). All children received appropriate antimicrobial treatment, intravenous maintenance fluids, and supportive care, according to guidelines. Children with malnutrition or gastroenteritis were excluded. The primary end point was 48-hour mortality; secondary end points included pulmonary edema, increased intracranial pressure, and mortality or neurologic sequelae at 4 weeks. RESULTS The data and safety monitoring committee recommended halting recruitment after 3141 of the projected 3600 children in stratum A were enrolled. Malaria status (57% overall) and clinical severity were similar across groups. The 48-hour mortality was 10.6% (111 of 1050 children), 10.5% (110 of 1047 children), and 7.3% (76 of 1044 children) in the albumin-bolus, saline-bolus, and control groups, respectively (relative risk for saline bolus vs. control, 1.44; 95% confidence interval [CI], 1.09 to 1.90; P = 0.01; relative risk for albumin bolus vs. saline bolus, 1.01; 95% CI, 0.78 to 1.29; P = 0.96; and relative risk for any bolus vs. control, 1.45; 95% CI, 1.13 to 1.86; P = 0.003). The 4-week mortality was 12.2%, 12.0%, and 8.7% in the three groups, respectively (P = 0.004 for the comparison of bolus with control). Neurologic sequelae occurred in 2.2%, 1.9%, and 2.0% of the children in the respective groups (P = 0.92), and pulmonary edema or increased intracranial pressure occurred in 2.6%, 2.2%, and 1.7% (P = 0.17), respectively. In stratum B, 69% of the children (9 of 13) in the albuminbolus group and 56% (9 of 16) in the saline-bolus group died (P = 0.45). The results were consistent across centers and across subgroups according to the severity of shock and status with respect to malaria, coma, sepsis, acidosis, and severe anemia. CONCLUSIONS Fluid boluses significantly increased 48-hour mortality in critically ill children with impaired perfusion in these resource-limited settings in Africa. (Funded by the Medical Research Council, United Kingdom; FEAST Current Controlled Trials number, ISRCTN69856593.)	[Maitland, Kathryn; Akech, Samuel O.; Lang, Trudie; Brent, Bernadette] KEMRI, Wellcome Trust Programme, Kilifi Clin Trials Facil, Kilifi, Kenya; [Maitland, Kathryn; Brent, Bernadette; Levin, Michael] Univ London Imperial Coll Sci Technol & Med, Wellcome Trust Ctr Clin Trop Med, Dept Paediat, Fac Med, London SW7 2AZ, England; [Crawley, Jane; Russell, Elizabeth C.; Babiker, Abdel G.; Gibb, Diana M.] MRC, Clin Trials Unit, London, England; [Kiguli, Sarah; Opoka, Robert O.] Makerere Univ, Dept Paediat, Mulago Hosp, Kampala, Uganda; [Engoru, Charles] Soroti Reg Referral Hosp, Soroti, Uganda; [Olupot-Olupot, Peter] Mbale Reg Referral Hosp, Mbale, Uganda; [Nyeko, Richard] St Marys Hosp, Lacor, Uganda; [Mtove, George; Reyburn, Hugh] Hosp Teule, Joint Malaria Programme, Muheza, Tanzania; [Evans, Jennifer A.] Univ Wales Hosp, Dept Paediat, Cardiff, Wales	Imperial College London; University of London; London School of Hygiene & Tropical Medicine; Medical Research Council Clinical Trials Unit; Makerere University; Mulago National Referral Hospital; Cardiff University	Maitland, K (corresponding author), KEMRI, Wellcome Trust Programme, Kilifi Clin Trials Facil, POB 230, Kilifi, Kenya.	kathryn.maitland@gmail.com	Tibenderana, James Kananura/M-2272-2018; George, Elizabeth/V-3381-2017; George, Elizabeth/C-7329-2013; Angus, Brian/L-9246-2019	Tibenderana, James Kananura/0000-0002-0755-4597; George, Elizabeth/0000-0002-2928-3580; Angus, Brian/0000-0003-3598-7784; Chebet, Martin/0000-0001-7013-7297; Thomason, Margaret/0000-0003-3590-0140; Ddungu, Ahmed/0000-0001-5653-0885; Gibb, Diana/0000-0002-9738-5490; Mtove, George/0000-0001-5173-0829; Kiprono, Julie/0000-0002-6396-2026; Levin, Michael/0000-0003-2767-6919; Maitland, Kathryn/0000-0002-0007-0645; Waithira, Naomi/0000-0002-2267-9347	Medical Research Council, United Kingdom [G0801439]; Medical Research Council [MC_U122886353, G0801439, G0601027] Funding Source: researchfish; MRC [G0801439, MC_U122886353, G0601027] Funding Source: UKRI	Medical Research Council, United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a grant (G0801439) from the Medical Research Council, United Kingdom; Baxter Healthcare donated the resuscitation fluids.	Akech S, 2006, PLOS CLIN TRIALS, V1, DOI 10.1371/journal.pctr.0010021; Akech S, 2010, BMJ-BRIT MED J, V341, DOI 10.1136/bmj.c4416; [Anonymous], 2005, HOSP CAR CHILDR GUID; Berkley JA, 2005, NEW ENGL J MED, V352, P39, DOI 10.1056/NEJMoa040275; Berkley JA, 2009, CLIN INFECT DIS, V49, P336, DOI 10.1086/600299; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Brierley J, 2009, CRIT CARE MED, V37, P666, DOI 10.1097/CCM.0b013e31819323c6; Crawley J, 2010, LANCET, V375, P1468, DOI 10.1016/S0140-6736(10)60447-3; Delaney AP, 2011, CRIT CARE MED, V39, P386, DOI 10.1097/CCM.0b013e3181ffe217; Dellinger RP, 2008, CRIT CARE MED, V36, P1394; English M, 2004, LANCET, V363, P1948, DOI 10.1016/S0140-6736(04)16408-8; English M, 2000, T ROY SOC TROP MED H, V94, P585, DOI 10.1016/S0035-9203(00)90197-4; Evans JA, 2004, QJM-INT J MED, V97, P591, DOI 10.1093/qjmed/hch093; Evans JA, 2006, J PEDIATR-US, V149, P676, DOI 10.1016/j.jpeds.2006.07.040; Finfer S, 2011, INTENS CARE MED, V37, P86, DOI 10.1007/s00134-010-2039-6; Goldstein Brahm, 2005, Pediatr Crit Care Med, V6, P2; Han YY, 2003, PEDIATRICS, V112, P793, DOI 10.1542/peds.112.4.793; Inwald DP, 2009, ARCH DIS CHILD, V94, P348, DOI 10.1136/adc.2008.153064; Maitland K, 2005, CLIN INFECT DIS, V40, P538, DOI 10.1086/427505; Maitland K, 2003, QJM-INT J MED, V96, P427, DOI 10.1093/qjmed/hcg077; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nadjm B, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1350; Nolan T, 2001, LANCET, V357, P106, DOI 10.1016/S0140-6736(00)03542-X; Otieno H, 2004, ARCH DIS CHILD, V89, P977, DOI 10.1136/adc.2003.043901; Pamba A, 2004, ARCH DIS CHILD, V89, P950, DOI 10.1136/adc.2003.032516; Parker Margaret M, 2004, Crit Care Med, V32, pS591, DOI 10.1097/01.CCM.0000145904.97821.0D; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Planche T, 2005, TRENDS PARASITOL, V21, P562, DOI 10.1016/j.pt.2005.09.010; Planche T, 2004, PLOS MED, V1, P56, DOI 10.1371/journal.pmed.0010018; Reddy EA, 2010, LANCET INFECT DIS, V10, P417, DOI 10.1016/S1473-3099(10)70072-4; Robertson MA, 2001, ARCH DIS CHILD, V85, P208, DOI 10.1136/adc.85.3.208; Rothman KJ., 1982, EPIDEMIOLOGIC ANAL P; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6	33	987	1021	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	2011	364	26					2483	2495		10.1056/NEJMoa1101549	http://dx.doi.org/10.1056/NEJMoa1101549			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	785AM	21615299	Green Submitted, Green Published			2023-01-03	WOS:000292199800004
J	Molinaro, S; Siciliano, V; Curzio, O; Denoth, F; Salvadori, S; Mariani, F				Molinaro, Sabrina; Siciliano, Valeria; Curzio, Olivia; Denoth, Francesca; Salvadori, Stefano; Mariani, Fabio			Illegal Substance Use among Italian High School Students: Trends over 11 Years (1999-2009)	PLOS ONE			English	Article							6 EUROPEAN COUNTRIES; DRUG-USE; COCAINE USE; ADOLESCENTS; SWITZERLAND; PREVALENCE; TRUANCY; HEALTH	Purpose: To monitor changes in habits in drug use among Italian high school students. Methods: Cross-sectional European School Survey Project on Alcohol and Other Drugs (ESPAD) carried out in Italy annually for 11 years (1999-2009) with representative samples of youth attending high school. The sample size considered ranges from 15,752 to 41,365 students and response rate ranged from 85.5% to 98.6%. Data were analyzed to obtain measures of life-time prevalence (LT), use in the last year (LY), use in the last 30 days (LM), frequent use. Comparisons utilized difference in proportion tests. Tests for linear trends in proportion were performed using the Royston p trend test. Results: When the time-averaged value was considered, cannabis (30% LT) was the most, and heroin the least (2%) frequently used, with cocaine (5%), hallucinogens (2%) and stimulants (2%) in between. A clear gender gap is evident for all drugs, more obvious for hallucinogens (average M/F LY prevalence ratio 2, range 1.7-2.4, p<0.05), less for cannabis (average M/F LY prevalence ratio 1.3, range 1.2-1.5, p<0.05). Data shows a change in trend between 2005 and 2008; in 2006 the trend for cannabis use and availability dropped and the price rose, while from 2005 cocaine and stimulant use prevalence showed a substantial increase and the price went down. After 2008 use of all substances seems to have decreased. Conclusions: Drug use is widespread among students in Italy, with cannabis being the most and heroin the least prevalent. Girls are less vulnerable than boys to illegal drug use. In recent years, a decrease in heroin use is overbalanced by a marked rise in hallucinogen and stimulant use.	[Molinaro, Sabrina; Siciliano, Valeria; Curzio, Olivia; Denoth, Francesca; Salvadori, Stefano; Mariani, Fabio] CNR, Inst Clin Physiol, Pisa, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica (IFC-CNR)	Molinaro, S (corresponding author), CNR, Inst Clin Physiol, Pisa, Italy.	molinaro@ifc.cnr.it	Molinaro, Sabrina/F-5828-2012; SALVADORI, STEFANO/AAL-3217-2021; Curzio, Olivia/T-2078-2019; Molinaro, Sabrina/B-3710-2013	Molinaro, Sabrina/0000-0001-7221-0873; SALVADORI, STEFANO/0000-0002-1266-3931; Curzio, Olivia/0000-0003-0784-302X; Molinaro, Sabrina/0000-0002-1140-0312	Italian Ministry of Welfare; Italian Ministry of Interior; Italian Ministry of Education and Research; Italian Presidenza del Consiglio dei Ministri	Italian Ministry of Welfare; Italian Ministry of Interior; Italian Ministry of Education and Research(Ministry of Education, Universities and Research (MIUR)); Italian Presidenza del Consiglio dei Ministri	Over the years 1999-2009, the study was supported by the Italian Ministry of Welfare (www.lavoro.gov.it/Lavoro), the Italian Ministry of Interior (www.interno.it/mininterno/export/sites/default/it/), the Italian Ministry of Education and Research (www.istruzione.it/web/hub) and the Italian Presidenza del Consiglio dei Ministri (www.governo.it/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assanangkornchai S, 2007, DRUG ALCOHOL DEPEN, V86, P167, DOI 10.1016/j.drugalcdep.2006.06.001; Bauman A, 1999, DRUG ALCOHOL DEPEN, V55, P187, DOI 10.1016/S0376-8716(99)00016-2; Beauvais F, 2004, J ADOLESCENT HEALTH, V34, P493, DOI 10.1016/S1054-139X(03)00340-9; Chen WJ, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-27; Chiou WB, 2007, CYBERPSYCHOL BEHAV, V10, P663, DOI 10.1089/cpb.2007.9972; Chou LC, 2006, ADDICT BEHAV, V31, P149, DOI 10.1016/j.addbeh.2005.04.011; Csemy L, 2002, EUR ADDICT RES, V8, P159, DOI 10.1159/000066134; De Preux E, 2004, SWISS MED WKLY, V134, P313; Doubeni CA, 2009, AM J PREV MED, V36, P239, DOI 10.1016/j.amepre.2008.11.006; *DPA, 2009, REL ANN PARL STAT TO; *EMCDDA, 2009, ANN REP STAT DRUGS P; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 2005, DIFF PATT DRUG US WO; Haasen C, 2004, EUR ADDICT RES, V10, P139, DOI 10.1159/000079834; Harrison L, 1997, NIDA Res Monogr, V167, P17; Hibell B, 2004, ESPAD REPORT 2003 AL; Hibell B., 2009, 2007 ESPAD REPORT SU, P1; JOHNSON CA, 1990, J CONSULT CLIN PSYCH, V58, P445; Johnston L., 2009, MONITORING FUTURE NA, VI; Kokkevi A, 2007, DRUG ALCOHOL DEPEN, V86, P67, DOI 10.1016/j.drugalcdep.2006.05.018; Kokkevi AE, 2007, DRUG ALCOHOL DEPEN, V88, P308, DOI 10.1016/j.drugalcdep.2006.10.004; Korf DJ, 2002, ADDICT BEHAV, V27, P851, DOI 10.1016/S0306-4603(02)00291-5; Michaud P, 2006, SWISS MED WKLY, V136, P318; Miller P, 1999, ALCOHOL ALCOHOLISM, V34, P886, DOI 10.1093/alcalc/34.6.886; NARRING F, 1995, SOZ PRAVENTIV MED, V40, P172, DOI 10.1007/BF01318638; Sells CW, 1996, AM J PUBLIC HEALTH, V86, P513, DOI 10.2105/AJPH.86.4.513; Tobler N.S., 2000, J PRIM PREV, V20, P275, DOI [DOI 10.1023/A:1021314704811, 10.1023/A:1021314704811]; Turnbull PJ, 2009, DRUG ALCOHOL REV, V28, P202, DOI 10.1111/j.1465-3362.2008.00045.x; van der Poel A, 2009, INT J DRUG POLICY, V20, P143, DOI 10.1016/j.drugpo.2008.02.005; Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539	29	19	19	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2011	6	6							e20482	10.1371/journal.pone.0020482	http://dx.doi.org/10.1371/journal.pone.0020482			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	777JU	21695199	Green Published, gold			2023-01-03	WOS:000291612600012
J	Wechsler, LR				Wechsler, Lawrence R.			Intravenous Thrombolytic Therapy for Acute Ischemic Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE-PLASMINOGEN-ACTIVATOR; ULTRASOUND-ENHANCED THROMBOLYSIS; COOPERATIVE ACUTE STROKE; QUALITY-OF-CARE; INTRACEREBRAL HEMORRHAGE; CEREBRAL-ISCHEMIA; OROLINGUAL ANGIOEDEMA; CLINICAL-PRACTICE; EARLY REPERFUSION; DOSE-ESCALATION		Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wechsler, LR (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 811 Lillian Kaufmann Bldg,3471 5th Ave, Pittsburgh, PA 15213 USA.	wechslerlr@upmc.edu	Wechsler, Lawrence/AAB-9176-2020		Abbott Vascular; Lundbeck; Ferrer; NMT Medical	Abbott Vascular(Abbott Laboratories); Lundbeck(Lundbeck Corporation); Ferrer; NMT Medical	Dr. Wechsler reports receiving consulting fees from Abbott Vascular, Lundbeck, and Ferrer and grant support from NMT Medical and holding stock in NeuroInterventions. No other potential conflict of interest relevant to this article was reported.	Adams, 2007, STROKE, V38, pE38, DOI 10.1161/STROKEAHA.106.110011; Adams, 2007, STROKE, V38, pE96; Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Adams Harold P Jr, 2009, Handb Clin Neurol, V94, P971, DOI 10.1016/S0072-9752(08)94048-3; Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; Albers GW, 2006, ANN NEUROL, V60, P508, DOI 10.1002/ana.20976; Albers GW, 2000, JAMA-J AM MED ASSOC, V283, P1145, DOI 10.1001/jama.283.9.1145; Alexandrov AV, 2000, STROKE, V31, P610, DOI 10.1161/01.STR.31.3.610; Alexandrov AV, 2004, NEW ENGL J MED, V351, P2170, DOI 10.1056/NEJMoa041175; Alexandrov AV, 2004, J NEUROIMAGING, V14, P113, DOI 10.1177/1051228403261462; *AM COLL EM PHYS, US INTR TPA MAN AC S; Asahi M, 2001, J NEUROSCI, V21, P7724, DOI 10.1523/JNEUROSCI.21-19-07724.2001; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Brott T, 2000, NEW ENGL J MED, V343, P710, DOI 10.1056/NEJM200009073431007; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brott T, 1997, STROKE, V28, P2119, DOI 10.1161/01.STR.28.11.2119; Chen CI, 2005, EUR NEUROL, V54, P140, DOI 10.1159/000089086; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Daffertshofer M, 2005, STROKE, V36, P1441, DOI 10.1161/01.STR.0000170707.86793.1a; Darby DG, 1999, STROKE, V30, P2043, DOI 10.1161/01.STR.30.10.2043; del Zoppo GJ, 2009, STROKE, V40, P2945, DOI 10.1161/STROKEAHA.109.192535; DELZOPPO GJ, 2010, STROKE, V4, pE562; Demchuk AM, 1999, STROKE, V30, P34, DOI 10.1161/01.STR.30.1.34; Eggers J, 2008, STROKE, V39, P1470, DOI 10.1161/STROKEAHA.107.503870; Engelter ST, 2005, J NEUROL, V252, P1167, DOI 10.1007/s00415-005-0789-9; European Stroke Organisation [ESO] Executive Committee and the ESO Writing Committee, GUID MAN ISCH STROK; Fisher M, 1997, STROKE, V28, P866, DOI 10.1161/01.STR.28.4.866; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Furlan AJ, 2006, STROKE, V37, P1227, DOI 10.1161/01.STR.0000217403.66996.6d; Goldstein JN, 2010, ARCH NEUROL-CHICAGO, V67, P965, DOI 10.1001/archneurol.2010.175; Hacke W, 2005, STROKE, V36, P66, DOI 10.1161/01.STR.0000149938.08731.2c; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hacke W, 2009, LANCET NEUROL, V8, P141, DOI 10.1016/S1474-4422(08)70267-9; Haley EC, 2010, STROKE, V41, P707, DOI 10.1161/STROKEAHA.109.572040; Haley EC, 2005, STROKE, V36, P607, DOI 10.1161/01.STR.0000154872.73240.e9; Hill MD, 2005, CAN MED ASSOC J, V172, P1307, DOI 10.1503/cmaj.1041561; Hill MD, 2003, NEUROLOGY, V60, P1525, DOI 10.1212/01.WNL.0000058840.66596.1A; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; Jauch EC, 2010, CIRCULATION, V122, pS818, DOI 10.1161/CIRCULATIONAHA.110.971044; Johnston SC, 2003, ANN NEUROL, V54, P439, DOI 10.1002/ana.10678; Johnston SC, 2003, STROKE, V34, P2446, DOI 10.1161/01.STR.0000090842.81076.68; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kelly-Hayes Margaret, 2003, J Stroke Cerebrovasc Dis, V12, P119, DOI 10.1016/S1052-3057(03)00042-9; Kidwell CS, 2010, CURR NEUROL NEUROSCI, V10, P21, DOI 10.1007/s11910-009-0075-9; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Larrue V, 1997, STROKE, V28, P957, DOI 10.1161/01.STR.28.5.957; Larrue V, 2001, STROKE, V32, P438, DOI 10.1161/01.STR.32.2.438; Lev MH, 2001, STROKE, V32, P2021, DOI 10.1161/hs0901.095680; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; Lo EH, 2003, NAT REV NEUROSCI, V4, P399, DOI 10.1038/nrn1106; Marder VJ, 2010, J THROMB HAEMOST, V8, P433, DOI 10.1111/j.1538-7836.2009.03701.x; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Mishra NK, 2010, STROKE, V41, pE25, DOI 10.1161/STROKEAHA.109.566869; Molina CA, 2002, STROKE, V33, P1551, DOI 10.1161/01.STR.0000016323.13456.E5; Moodie ML, 2004, STROKE, V35, P1041, DOI 10.1161/01.STR.0000125012.36134.89; Nakagawara J, 2010, STROKE, V41, P1984, DOI 10.1161/STROKEAHA.110.589606; Rasler F, 2007, ANN EMERG MED, V50, P485, DOI 10.1016/j.annemergmed.2007.04.030; Roger, 2011, CIRCULATION, V123, pE240, DOI 10.1161/CIR.0b013e3182117650; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Rosamond WD, 1999, STROKE, V30, P736, DOI 10.1161/01.STR.30.4.736; Sandercock P, 2004, STROKE, V35, P1490, DOI 10.1161/01.STR.0000126871.98801.6E; Saqqur M, 2008, NEUROLOGY, V71, P1304, DOI 10.1212/01.wnl.0000313936.15842.0d; Selim M, 2002, STROKE, V33, P2047, DOI 10.1161/01.STR.0000023577.65990.4E; Stahl JE, 2003, RADIOLOGY, V228, P659, DOI 10.1148/radiol.2283021557; Sylaja PN, 2006, J NEUROL NEUROSUR PS, V77, P826, DOI 10.1136/jnnp.2005.086595; Tanne D, 2002, CIRCULATION, V105, P1679, DOI 10.1161/01.CIR.0000012747.53592.6A; Tanswell P, 2002, CLIN PHARMACOKINET, V41, P1229, DOI 10.2165/00003088-200241150-00001; Tsivgoulis G, 2010, STROKE, V41, P280, DOI 10.1161/STROKEAHA.109.563304; von Kummer R, 2009, STROKE, V40, P2268, DOI 10.1161/STROKEAHA.108.539353; Wahlgren N, 2007, LANCET, V369, P275, DOI 10.1016/S0140-6736(07)60149-4; *WORK GROUP THROMB, POS STAT AM AC EM ME; Yamaguchi T, 2006, STROKE, V37, P1810, DOI 10.1161/01.STR.0000227191.01792.e3; CLIN PRACTICE STATEM	75	65	70	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 2	2011	364	22					2138	2146		10.1056/NEJMct1007370	http://dx.doi.org/10.1056/NEJMct1007370			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	772AB	21631326				2023-01-03	WOS:000291200700012
J	Aviello, G; Canadanovic-Brunet, JM; Milic, N; Capasso, R; Fattorusso, E; Taglialatela-Scafati, O; Fasolino, I; Izzo, AA; Borrelli, F				Aviello, Gabriella; Canadanovic-Brunet, Jasna M.; Milic, Natasa; Capasso, Raffaele; Fattorusso, Ernesto; Taglialatela-Scafati, Orazio; Fasolino, Ines; Izzo, Angelo A.; Borrelli, Francesca			Potent Antioxidant and Genoprotective Effects of Boeravinone G, a Rotenoid Isolated from Boerhaavia diffusa	PLOS ONE			English	Article							OXYGEN-FREE-RADICALS; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; GASTROINTESTINAL-TRACT; HYDROGEN-PEROXIDE; BOERHAVIA-DIFFUSA; GLUTATHIONE; ISCHEMIA; DAMAGE; ASSAY	Background and Aims: Free radicals are implicated in the aetiology of some gastrointestinal disorders such as gastric ulcer, colorectal cancer and inflammatory bowel disease. In the present study we investigated the antioxidant and genoprotective activity of some rotenoids (i.e. boeravinones) isolated from the roots of Boerhaavia diffusa, a plant used in the Ayurvedic medicine for the treatment of diseases affecting the gastrointestinal tract. Methods/Principal Findings: Antioxidant activity has been evaluated using both chemical (Electron Spin Resonance spectroscopy, ESR) and Caco-2 cells-based (TBARS and ROS) assays. DNA damage was evaluated by Comet assay, while pERK(1/2) and phospho-NF-kB p65 levels were estimated by western blot. Boeravinones G, D and H significantly reduced the signal intensity of ESR induced by hydroxyl radicals, suggesting a scavenging activity. Among rotenoids tested, boeravinone G exerted the most potent effect. Boeravinone G inhibited both TBARS and ROS formation induced by Fenton's reagent, increased SOD activity and reduced H2O2-induced DNA damage. Finally, boeravinone G reduced the levels of pERK(1) and phospho-NF-kB p65 (but not of pERK(2)) increased by Fenton's reagent. Conclusions: It is concluded that boeravinone G exhibits an extraordinary potent antioxidant activity (significant effect in the nanomolar range). The MAP kinase and NF-kB pathways seem to be involved in the antioxidant effect of boeravinone G. Boeravinone G might be considered as lead compound for the development of drugs potentially useful against those pathologies whose aetiology is related to ROS-mediated injuries.	[Aviello, Gabriella; Milic, Natasa; Capasso, Raffaele; Fasolino, Ines; Izzo, Angelo A.; Borrelli, Francesca] Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy; [Canadanovic-Brunet, Jasna M.] Univ Novi Sad, Fac Technol, Novi Sad 21000, Serbia; [Fattorusso, Ernesto; Taglialatela-Scafati, Orazio] Univ Naples Federico II, Dept Nat Prod Chem, Naples, Italy	University of Naples Federico II; University of Novi Sad; University of Naples Federico II	Aviello, G (corresponding author), Univ Naples Federico II, Dept Expt Pharmacol, Naples, Italy.	franborr@unina.it	Borrelli, Francesca/AAC-6715-2022	Izzo, Angelo/0000-0002-8557-2133; Borrelli, Francesca/0000-0002-2695-3294; Capasso, Raffaele/0000-0002-3335-1822	Enrico ed Enrica Sovena Foundation	Enrico ed Enrica Sovena Foundation	This work was supported by the Enrico ed Enrica Sovena Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agrawal A, 2004, J ENVIRON BIOL, V25, P307; Ahmed-Belkacem A, 2007, J MED CHEM, V50, P1933, DOI 10.1021/jm061450q; Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; Anderson D, 1999, FOOD CHEM TOXICOL, V37, P1015, DOI 10.1016/S0278-6915(99)00089-7; Aviello G, 2010, J CELL MOL MED, V14, P2006, DOI 10.1111/j.1582-4934.2009.00815.x; Bickers DR, 2006, J INVEST DERMATOL, V126, P2565, DOI 10.1038/sj.jid.5700340; Borrelli F, 2005, PLANTA MED, V71, P928, DOI 10.1055/s-2005-871282; Borrelli F, 2006, J NAT PROD, V69, P903, DOI 10.1021/np060073h; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Canadanovic-Brunet JM, 2005, J SCI FOOD AGR, V85, P265, DOI 10.1002/jsfa.1950; Collins AR, 2004, MOL BIOTECHNOL, V26, P249, DOI 10.1385/MB:26:3:249; Conde de la Rosa L, 2006, J HEPATOL, V44, P918, DOI 10.1016/j.jhep.2005.07.034; CROMBIE L, 1992, BIOORG MED CHEM LETT, V2, P13, DOI 10.1016/S0960-894X(00)80645-9; DHAR ML, 1968, INDIAN J EXP BIOL, V6, P232; Dryden Gerald W Jr, 2005, Curr Gastroenterol Rep, V7, P308, DOI 10.1007/s11894-005-0024-y; Dryden GW, 2006, CURR OPIN GASTROEN, V22, P165, DOI 10.1097/01.mog.0000208463.69266.8c; ESTERBAUER H, 1990, METHOD ENZYMOL, V186, P407; Gatof D, 2002, GASTROENTEROL CLIN N, V31, P587, DOI 10.1016/S0889-8553(02)00011-0; Goldstone AB, 2006, FREE RADICAL BIO MED, V41, P1860, DOI 10.1016/j.freeradbiomed.2006.09.015; GUTMAN M, 1970, J BIOL CHEM, V245, P1992; Halliwell B, 2000, FREE RADICAL RES, V33, P819, DOI 10.1080/10715760000301341; Hiruma-Lima CA, 2000, J ETHNOPHARMACOL, V71, P267, DOI 10.1016/S0378-8741(00)00178-1; Holmes EW, 1998, DIGEST DIS SCI, V43, P1088, DOI 10.1023/A:1018899222258; Ishihara T, 2009, J PHARMACOL EXP THER, V328, P152, DOI 10.1124/jpet.108.144451; Janne PA, 2000, NEW ENGL J MED, V342, P1960, DOI 10.1056/NEJM200006293422606; Ji LL, 2007, APPL PHYSIOL NUTR ME, V32, P930, DOI 10.1139/H07-098; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Kapoor LD., 1990, HDB AYURVEDIC MED PL; Karihtala P, 2007, APMIS, V115, P81, DOI 10.1111/j.1600-0463.2007.apm_514.x; Karp SM, 2006, DM-DIS MON, V52, P199, DOI 10.1016/j.disamonth.2006.05.005; Kefaloyianni E, 2006, CELL SIGNAL, V18, P2238, DOI 10.1016/j.cellsig.2006.05.004; Kim Hyeyoung, 2005, Inflammopharmacology, V13, P63, DOI 10.1163/156856005774423962; Kulich SM, 2003, J BIOSCIENCES, V28, P83, DOI 10.1007/BF02970136; KUPCHAN SM, 1973, J ORG CHEM, V38, P178, DOI 10.1021/jo00941a049; KUTHAN H, 1986, BIOCHEM J, V237, P175, DOI 10.1042/bj2370175; LAMI N, 1991, CHEM PHARM BULL, V39, P1863, DOI 10.1248/cpb.39.1863; Leyon PV, 2005, LIFE SCI, V76, P1339, DOI 10.1016/j.lfs.2004.06.031; Liu LN, 2005, WORLD J GASTROENTERO, V11, P1503, DOI 10.3748/wjg.v11.i10.1503; Mehrotra S, 2002, INT IMMUNOPHARMACOL, V2, P987, DOI 10.1016/S1567-5769(02)00031-0; Miralles-Barrachina O, 1999, CLIN NUTR, V18, P313, DOI 10.1016/S0261-5614(98)80030-7; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nakabeppu Y, 2006, BIOL CHEM, V387, P373, DOI 10.1515/BC.2006.050; Olaleye MT, 2010, FOOD CHEM TOXICOL, V48, P2200, DOI 10.1016/j.fct.2010.05.047; Opara EC, 2006, DM-DIS MON, V52, P183, DOI 10.1016/j.disamonth.2006.05.003; OTAMIRI T, 1991, DIGEST DIS, V9, P133, DOI 10.1159/000171299; Pari L, 2004, J MED FOOD, V7, P472, DOI 10.1089/jmf.2004.7.472; PARKS DA, 1983, SURGERY, V94, P428; Piquet MA, 2006, GASTROEN CLIN BIOL, V30, P262, DOI 10.1016/S0399-8320(06)73163-3; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Rego AC, 1999, FREE RADICAL BIO MED, V26, P1405, DOI 10.1016/S0891-5849(98)00337-2; Rezaie A, 2007, DIGEST DIS SCI, V52, P2015, DOI 10.1007/s10620-006-9622-2; Sachidanandam K, 2005, CARDIOVASC DRUG REV, V23, P115; Satheesh M. Amarnath, 2004, Indian Journal of Experimental Biology, V42, P989; Seril DN, 2003, CARCINOGENESIS, V24, P353, DOI 10.1093/carcin/24.3.353; Shi MJ, 2004, AM J HYPERTENS, V17, P450, DOI 10.1016/j.amjhyper.2003.12.019; Sido B, 1998, GUT, V42, P485, DOI 10.1136/gut.42.4.485; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Willcox JK, 2004, CRIT REV FOOD SCI, V44, P275, DOI 10.1080/10408690490468489; Yokomizo A, 2006, BIOSCI BIOTECH BIOCH, V70, P1317, DOI 10.1271/bbb.50604; ZIMMERMAN BJ, 1994, HEPATO-GASTROENTEROL, V41, P337	61	44	47	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2011	6	5							e19628	10.1371/journal.pone.0019628	http://dx.doi.org/10.1371/journal.pone.0019628			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766OI	21625488	Green Submitted, Green Published, gold			2023-01-03	WOS:000290793400006
J	Luk, SU; Lee, TKW; Liu, J; Lee, DTW; Chiu, YT; Ma, S; Ng, IOL; Wong, YC; Chan, FL; Ling, MT				Luk, Sze-Ue; Lee, Terence Kin-Wah; Liu, Ji; Lee, Davy Tak-Wing; Chiu, Yung-Tuen; Ma, Stephanie; Ng, Irene Oi-Lin; Wong, Yong-Chuan; Chan, Franky Leung; Ling, Ming-Tat			Chemopreventive Effect of PSP Through Targeting of Prostate Cancer Stem Cell-Like Population	PLOS ONE			English	Article							PROTEIN-BOUND POLYSACCHARIDE; TUMOR-INITIATING CELLS; IN-VITRO; VERSICOLOR; IDENTIFICATION; MODEL; TRIAL; GENE; EXPRESSION; INDUCTION	Recent evidence suggested that prostate cancer stem/progenitor cells (CSC) are responsible for cancer initiation as well as disease progression. Unfortunately, conventional therapies are only effective in targeting the more differentiated cancer cells and spare the CSCs. Here, we report that PSP, an active component extracted from the mushroom Turkey tail (also known as Coriolus versicolor), is effective in targeting prostate CSCs. We found that treatment of the prostate cancer cell line PC-3 with PSP led to the down-regulation of CSC markers (CD133 and CD44) in a time and dose-dependent manner. Meanwhile, PSP treatment not only suppressed the ability of PC-3 cells to form prostaspheres under non-adherent culture conditions, but also inhibited their tumorigenicity in vivo, further proving that PSP can suppress prostate CSC properties. To investigate if the anti-CSC effect of PSP may lead to prostate cancer chemoprevention, transgenic mice (TgMAP) that spontaneously develop prostate tumors were orally fed with PSP for 20 weeks. Whereas 100% of the mice that fed with water only developed prostate tumors at the end of experiment, no tumors could be found in any of the mice fed with PSP, suggesting that PSP treatment can completely inhibit prostate tumor formation. Our results not only demonstrated the intriguing anti-CSC effect of PSP, but also revealed, for the first time, the surprising chemopreventive property of oral PSP consumption against prostate cancer.	[Luk, Sze-Ue; Lee, Davy Tak-Wing; Chiu, Yung-Tuen; Wong, Yong-Chuan] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China; [Liu, Ji; Ling, Ming-Tat] Queensland Univ Technol, Australian Prostate Canc Res Ctr Queensland, Brisbane, Qld 4001, Australia; [Liu, Ji; Ling, Ming-Tat] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia; [Lee, Terence Kin-Wah; Ma, Stephanie; Ng, Irene Oi-Lin] Univ Hong Kong, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Chan, Franky Leung] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; Queensland University of Technology (QUT); Queensland University of Technology (QUT); University of Hong Kong; Chinese University of Hong Kong	Luk, SU (corresponding author), Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China.	mingtat.ling@qut.edu.au	Chan, Franky L./M-1043-2018; Ma, Stephanie Kwai Yee/C-4766-2009	Chan, Franky L./0000-0003-0567-2052; Ma, Stephanie Kwai Yee/0000-0002-2029-7943; Lee, Kin Wah/0000-0003-0682-322X; Ng, Irene Oi-lin/0000-0001-7532-2029	Vice Chancellor Research Fellowship	Vice Chancellor Research Fellowship	Vice Chancellor Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BISSON I, 2009, CELL RES; Chow LWC, 2003, AM J CHINESE MED, V31, P1, DOI 10.1142/S0192415X03000758; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Dong Y, 1996, RES COMMUN MOL PATH, V92, P140; Duan WM, 2005, ONCOGENE, V24, P1510, DOI 10.1038/sj.onc.1208229; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343; Folkins C, 2007, CANCER RES, V67, P3560, DOI 10.1158/0008-5472.CAN-06-4238; Gabril MY, 2002, GENE THER, V9, P1589, DOI 10.1038/sj.gt.3301895; Heinonen OP, 1998, J NATL CANCER I, V90, P440, DOI 10.1093/jnci/90.6.440; Ho CY, 2005, CANCER BIOL THER, V4, P638, DOI 10.4161/cbt.4.6.1721; Howard EW, 2007, CLIN CANCER RES, V13, P1847, DOI 10.1158/1078-0432.CCR-06-2074; Hsieh TC, 2001, INT J ONCOL, V18, P81; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Jimenez-Medina E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-78; Joniau S, 2005, EUR UROL, V48, P379, DOI 10.1016/j.eururo.2005.03.015; Khan N, 2008, ANTIOXID REDOX SIGN, V10, P475, DOI 10.1089/ars.2007.1740; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; LEE TK, 2011, HEPATOLOGY; Li H, 2008, CANCER RES, V68, P1820, DOI 10.1158/0008-5472.CAN-07-5878; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; LUK SU, 2011, INT J CANC; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Musquera M, 2008, EXPERT REV ANTICANC, V8, P1073, DOI 10.1586/14737140.8.7.1073; Ng TB, 1998, GEN PHARMACOL, V30, P1, DOI 10.1016/S0306-3623(97)00076-1; O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pomerantz M, 2007, ANNU REV MED, V58, P205, DOI 10.1146/annurev.med.58.101505.115650; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; SAKAGAMI H, 1991, ANTICANCER RES, V11, P993; Sarvis JA, 2008, CURR ONCOL REP, V10, P529, DOI 10.1007/s11912-008-0080-1; Scopelliti A, 2009, EXPERT OPIN BIOL TH, V9, P1005, DOI 10.1517/14712590903066687; Singh RP, 2006, ENDOCR-RELAT CANCER, V13, P751, DOI 10.1677/erc.1.01126; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wan JMF, 2008, INT J ONCOL, V32, P689; Wei C, 2007, CANCER BIOL THER, V6, P763, DOI 10.4161/cbt.6.5.3996; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855	38	37	38	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 16	2011	6	5							e19804	10.1371/journal.pone.0019804	http://dx.doi.org/10.1371/journal.pone.0019804			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	764TP	21603625	Green Published, gold			2023-01-03	WOS:000290656300028
J	Angus, DC				Angus, Derek C.			Management of Sepsis A 47-Year-Old Woman With an Indwelling Intravenous Catheter and Sepsis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; INTENSIVE INSULIN THERAPY; 2009 INFLUENZA A(H1N1); CRITICAL-CARE SERVICES; SEPTIC SHOCK; ANTIMICROBIAL THERAPY; INFLAMMATORY MARKERS; MORTALITY; EPIDEMIOLOGY; GUIDELINES	Severe sepsis is the term used to describe the host response to infection when complicated by acute organ dysfunction. Severe sepsis occurs in more than 750 000 individuals in the United States each year, with a hospital mortality of about 30%. Although the classic presentation is of florid shock with frank hypotension, fever, and elevated white blood cell count, many patients can present with cryptogenic shock (shock without hypotension) with more subtle signs of vital organ compromise. Using the case of Ms C, a 47-year-old woman with short gut syndrome and an indwelling intravenous catheter who developed an episode of severe sepsis secondary to a central line infection, treatment of sepsis is discussed. Management consists of prompt intervention with broad-spectrum antibiotics and fluid resuscitation, even in the absence of hypotension, and institution of a variety of strategies in the emergency setting to prevent development or worsening of vital organ dysfunction. Although advances in understanding the host immune response have fueled considerable interest in immunomodulatory therapy, the role of such agents in clinical practice remains limited and controversial. JAMA. 2011;305(14):1469-1477 www.jama.com	Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Ctr, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Angus, DC (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, CRISMA Ctr, 614 Scaife Hall,3550 Terrace St, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu	Angus, Derek C/E-9671-2012					Abraham E, 2003, JAMA-J AM MED ASSOC, V290, P238, DOI 10.1001/jama.290.2.238; Abraham E, 2005, NEW ENGL J MED, V353, P1332, DOI 10.1056/NEJMoa050935; *AC RESP DISTR SYN, 2000, NEW ENGL J MED, V342, P1301, DOI DOI 10.1056/NEJM200005043421801; Angus D C, 2001, Crit Care Med, V29, P1303, DOI 10.1097/00003246-200107000-00002; Angus DC, 2000, JAMA-J AM MED ASSOC, V283, P1723, DOI 10.1001/jama.283.13.1723; Angus DC, 2003, JAMA-J AM MED ASSOC, V290, P256, DOI 10.1001/jama.290.2.256; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Annane D, 2009, JAMA-J AM MED ASSOC, V301, P2362, DOI 10.1001/jama.2009.815; [Anonymous], 2009, CHEST; Australian New Zealand Clinical Trials Registry, AUSTR RES SEPS EV RA; Bellomo R, 2009, NEW ENGL J MED, V361, P1627, DOI 10.1056/NEJMoa0902413; Bernard GR, 2001, NEW ENGL J MED, V344, P699, DOI 10.1056/NEJM200103083441001; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Carlbom DJ, 2007, CRIT CARE MED, V35, P2525, DOI 10.1097/01.ccm.0000298122.49245.d7; ClinicalTrials.gov, PROT CAR EARL SEPT S; ClinicalTrials.gov, INV EFF SAF DROTR AL; Cook D, 2003, NEW ENGL J MED, V349, P1123, DOI 10.1056/NEJMoa030083; De Backer D, 2010, NEW ENGL J MED, V362, P779, DOI 10.1056/NEJMoa0907118; Deans KJ, 2005, J TRAUMA, V58, P867, DOI 10.1097/01.TA.0000158244.69179.94; Dellinger RP, 2008, CRIT CARE MED, V36, P296, DOI 10.1097/01.CCM.0000298158.12101.41; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Dominguez-Cherit G, 2009, JAMA-J AM MED ASSOC, V302, P1880, DOI 10.1001/jama.2009.1536; Ferrer R, 2008, JAMA-J AM MED ASSOC, V299, P2294, DOI 10.1001/jama.299.19.2294; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; ISRCTN, CLIN COST EFF EARL G; Jaeschke R, 2009, JAMA-J AM MED ASSOC, V301, P2388, DOI 10.1001/jama.2009.829; Jones AE, 2010, JAMA-J AM MED ASSOC, V303, P739, DOI 10.1001/jama.2010.158; Jones NE, 2008, JAMA-J AM MED ASSOC, V300, P2798, DOI 10.1001/jama.2008.814; Kaplan V, 2003, ARCH INTERN MED, V163, P317, DOI 10.1001/archinte.163.3.317; Kellum JA, 2007, ARCH INTERN MED, V167, P1655, DOI 10.1001/archinte.167.15.1655; Kress JP, 2000, NEW ENGL J MED, V342, P1471, DOI 10.1056/NEJM200005183422002; Kumar A, 2009, CHEST, V136, P1237, DOI 10.1378/chest.09-0087; Kumar A, 2009, JAMA-J AM MED ASSOC, V302, P1872, DOI 10.1001/jama.2009.1496; Kumar A, 2006, CRIT CARE MED, V34, P1589, DOI 10.1097/01.CCM.0000217961.75225.E9; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Lin MT, 2004, CRIT CARE MED, V32, P569, DOI 10.1097/01.CCM.0000110878.49476.42; Linde-Zwirble WT, 2004, CRIT CARE, V8, P222, DOI 10.1186/cc2917; Nadel S, 2007, LANCET, V369, P836, DOI 10.1016/S0140-6736(07)60411-5; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Quartin AA, 1997, JAMA-J AM MED ASSOC, V277, P1058, DOI 10.1001/jama.277.13.1058; Reade MC, 2010, EMERG MED J, V27, P110, DOI 10.1136/emj.2008.070912; Riedemann NC, 2003, NAT MED, V9, P517, DOI 10.1038/nm0503-517; Rivers E, 2001, NEW ENGL J MED, V345, P1368, DOI 10.1056/NEJMoa010307; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; Sprung CL, 2008, NEW ENGL J MED, V358, P111, DOI 10.1056/NEJMoa071366; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vincent JL, 2006, AM J RESP CRIT CARE, V173, P256, DOI 10.1164/rccm.200510-1604OE; Vinsonneau C, 2006, LANCET, V368, P379, DOI 10.1016/S0140-6736(06)69111-3; Webb SAR, 2009, NEW ENGL J MED, V361, P1925, DOI 10.1056/NEJMoa0908481; Weycker D, 2003, CRIT CARE MED, V31, P2316, DOI 10.1097/01.CCM.0000085178.80226.0B; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; Wunsch H, 2008, CRIT CARE MED, V36, P2787, DOI 10.1097/CCM.0b013e318186aec8; Yende S, 2008, AM J RESP CRIT CARE, V177, P1242, DOI 10.1164/rccm.200712-1777OC; Yende Sachin, 2007, Curr Infect Dis Rep, V9, P382, DOI 10.1007/s11908-007-0059-3	59	14	17	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 13	2011	305	14					1469	1477		10.1001/jama.2011.438	http://dx.doi.org/10.1001/jama.2011.438			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	748WQ	21467273				2023-01-03	WOS:000289424100024
J	Srinivasan, D; Muthukrishnan, N; Johnson, GA; Erazo-Oliveras, A; Lim, J; Simanek, EE; Pellois, JP				Srinivasan, Divyamani; Muthukrishnan, Nandhini; Johnson, Gregory A.; Erazo-Oliveras, Alfredo; Lim, Jongdoo; Simanek, Eric E.; Pellois, Jean-Philippe			Conjugation to the Cell-Penetrating Peptide TAT Potentiates the Photodynamic Effect of Carboxytetramethylrhodamine	PLOS ONE			English	Article							ARGININE-RICH PEPTIDES; BIOLOGICAL-MEMBRANES; INDUCED ENDOCYTOSIS; LIPID-PEROXIDATION; MECHANISM; THERAPY; PROTEOGLYCANS; TRANSLOCATION; EXPRESSION; LYSOSOMES	Background: Cell-penetrating peptides (CPPs) can transport macromolecular cargos into live cells. However, the cellular delivery efficiency of these reagents is often suboptimal because CPP-cargo conjugates typically remain trapped inside endosomes. Interestingly, irradiation of fluorescently labeled CPPs with light increases the release of the peptide and its cargos into the cytosol. However, the mechanism of this phenomenon is not clear. Here we investigate the molecular basis of the photo-induced endosomolytic activity of the prototypical CPPs TAT labeled to the fluorophore 5(6)carboxytetramethylrhodamine (TMR). Methodology/Principal Findings: We report that TMR-TAT acts as a photosensitizer that can destroy membranes. TMR-TAT escapes from endosomes after exposure to moderate light doses. However, this is also accompanied by loss of plasma membrane integrity, membrane blebbing, and cell-death. In addition, the peptide causes the destruction of cells when applied extracellularly and also triggers the photohemolysis of red blood cells. These photolytic and photocytotoxic effects were inhibited by hydrophobic singlet oxygen quenchers but not by hydrophilic quenchers. Conclusions/Significance: Together, these results suggest that TAT can convert an innocuous fluorophore such as TMR into a potent photolytic agent. This effect involves the targeting of the fluorophore to cellular membranes and the production of singlet oxygen within the hydrophobic environment of the membranes. Our findings may be relevant for the design of reagents with photo-induced endosomolytic activity. The photocytotoxicity exhibited by TMR-TAT also suggests that CPP-chromophore conjugates could aid the development of novel Photodynamic Therapy agents.	[Srinivasan, Divyamani; Muthukrishnan, Nandhini; Johnson, Gregory A.; Erazo-Oliveras, Alfredo; Pellois, Jean-Philippe] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Lim, Jongdoo; Simanek, Eric E.] Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Srinivasan, D (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	pellois@tamu.edu	Muthukrishnan, Nandhini/P-8906-2018; Johnson, Gregory/F-3793-2012	Pellois, Jean-Philippe/0000-0001-8528-4652; Johnson, Gregory/0000-0001-6917-4322	National Institute of General Medical Sciences [R01GM087227]; National Institutes of Health (NIH) [R01GM087227, T32GM065088, T32 GM008523]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008523, R01GM087227, T32GM065088] Funding Source: NIH RePORTER	National Institute of General Medical Sciences(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by Award Number R01GM087227 from the National Institute of General Medical Sciences. G.J. was supported by the National Institutes of Health (NIH) Molecular Biophysics training grant T32GM065088 and by grant R01GM087227. A.E.-O. was supported by the NIH Chemistry-Biology Interface training grant T32 GM008523. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLISON AC, 1966, NATURE, V209, P874, DOI 10.1038/209874a0; Bagdonas S, 2005, PHOTOCH PHOTOBIO SCI, V4, P497, DOI 10.1039/b503790e; BERG K, 1994, INT J CANCER, V59, P814, DOI 10.1002/ijc.2910590618; BIRCHMEIER W, 1979, J BIOL CHEM, V254, P9298; BLUM A, 1985, PHOTOCHEM PHOTOBIOL, V41, P27, DOI 10.1111/j.1751-1097.1985.tb03443.x; Bourre L, 2010, PHOTOCH PHOTOBIO SCI, V9, P1613, DOI 10.1039/c0pp00146e; Brown SB, 2004, LANCET ONCOL, V5, P497, DOI 10.1016/S1470-2045(04)01529-3; Choi Y, 2006, CHEMMEDCHEM, V1, P458, DOI 10.1002/cmdc.200500036; Ciobanasu C, 2009, BIOCHEMISTRY-US, V48, P4728, DOI 10.1021/bi900365s; COLIN FC, 1991, AM J HEMATOL, V37, P34, DOI 10.1002/ajh.2830370108; Console S, 2003, J BIOL CHEM, V278, P35109, DOI 10.1074/jbc.M301726200; Davies MJ, 2004, PHOTOCH PHOTOBIO SCI, V3, P17, DOI 10.1039/b307576c; DOLEIDEN FH, 1974, PHOTOCHEM PHOTOBIOL, V20, P519, DOI 10.1111/j.1751-1097.1974.tb06613.x; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Drzeniek Z, 1999, BLOOD, V93, P2884; Duchardt F, 2007, TRAFFIC, V8, P848, DOI 10.1111/j.1600-0854.2007.00572.x; Eggeling C, 1998, ANAL CHEM, V70, P2651, DOI 10.1021/ac980027p; EISENBERG WC, 1984, PHOTOCHEM PHOTOBIOL, V40, P55, DOI 10.1111/j.1751-1097.1984.tb04553.x; Endoh T, 2009, J CONTROL RELEASE, V137, P241, DOI 10.1016/j.jconrel.2009.04.015; EVANS EA, 1974, BIOPHYS J, V14, P923, DOI 10.1016/S0006-3495(74)85959-X; Geissbuehler M, 2010, BIOPHYS J, V98, P339, DOI 10.1016/j.bpj.2009.10.006; Grossweiner L I, 1984, Prog Clin Biol Res, V170, P391; Herce HD, 2009, BIOPHYS J, V97, P1917, DOI 10.1016/j.bpj.2009.05.066; Herce HD, 2007, P NATL ACAD SCI USA, V104, P20805, DOI 10.1073/pnas.0706574105; Hong SB, 2005, PHOTODERMATOL PHOTO, V21, P322, DOI 10.1111/j.1600-0781.2005.00181.x; JAY AWL, 1975, J PHYSIOL-LONDON, V252, P817, DOI 10.1113/jphysiol.1975.sp011172; Maiolo JR, 2004, J AM CHEM SOC, V126, P15376, DOI 10.1021/ja044867z; Matsushita M, 2004, FEBS LETT, V572, P221, DOI 10.1016/j.febslet.2004.07.033; MORLIERE P, 1991, BIOCHIM BIOPHYS ACTA, V1084, P261, DOI 10.1016/0005-2760(91)90068-S; Nakase I, 2007, BIOCHEMISTRY-US, V46, P492, DOI 10.1021/bi0612824; Ouedraogo GD, 2003, PHOTOCHEM PHOTOBIOL, V77, P192, DOI 10.1562/0031-8655(2003)077<0192:SROSET>2.0.CO;2; Poon GMK, 2007, BIOCHEM SOC T, V35, P788, DOI 10.1042/BST0350788; Redmond RW, 2006, PHOTOCHEM PHOTOBIOL, V82, P1178, DOI 10.1562/2006-04-14-IR-874; REYFTMANN JP, 1986, PHOTOCHEM PHOTOBIOL, V44, P461, DOI 10.1111/j.1751-1097.1986.tb04693.x; RUBEN S, 1989, J VIROL, V63, P1; Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177; Sehgal I, 2008, J MED CHEM, V51, P6014, DOI 10.1021/jm800444c; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; SHEETZ MP, 1974, P NATL ACAD SCI USA, V71, P4457, DOI 10.1073/pnas.71.11.4457; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; VALENZENO DP, 1987, PHOTOCHEM PHOTOBIOL, V46, P147, DOI 10.1111/j.1751-1097.1987.tb04749.x; Vogt AM, 2004, BIOCHEM J, V381, P593, DOI 10.1042/BJ20040762; WILSON PD, 1987, J CELL BIOL, V104, P1223, DOI 10.1083/jcb.104.5.1223; Zorko M, 2005, ADV DRUG DELIVER REV, V57, P529, DOI 10.1016/j.addr.2004.10.010	44	28	29	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 14	2011	6	3							e17732	10.1371/journal.pone.0017732	http://dx.doi.org/10.1371/journal.pone.0017732			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	736RS	21423812	Green Published, gold, Green Submitted			2023-01-03	WOS:000288512400023
J	Iglehart, JK				Iglehart, John K.			Bundled Payment for ESRD - Including ESAs in Medicare's Dialysis Package	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Besarab A, 1998, NEW ENGL J MED, V339, P584, DOI 10.1056/NEJM199808273390903; Centers for Medicare & Medicaid Services (CMS) HHS, 2010, Fed Regist, V75, P49029; FIELDS R, 2010, PROPUBLICA      1109; *MED PAYM ADV COMM, 2001, REP C MED PAYM POL; ZHANG Y, 2010, HLTH SERV RES   1209, DOI DOI 10.1111/J.1475-6773.2010.01219.X	5	24	25	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	2011	364	7					593	595		10.1056/NEJMp1014187	http://dx.doi.org/10.1056/NEJMp1014187			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722BW	21323538	Bronze			2023-01-03	WOS:000287406000001
J	Howell, P				Howell, Peter			Listen to the lessons of The King's Speech	NATURE			English	Editorial Material									UCL, London WC1E 6BT, England	University of London; University College London	Howell, P (corresponding author), UCL, London WC1E 6BT, England.	p.howell@ucl.ac.uk							0	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 3	2011	470	7332					7	7		10.1038/470007a	http://dx.doi.org/10.1038/470007a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	715LQ	21293331				2023-01-03	WOS:000286886400004
J	Crucitti, T; Jespers, V; Mulenga, C; Khondowe, S; Vandepitte, J; Buve, A				Crucitti, Tania; Jespers, Vicky; Mulenga, Chanda; Khondowe, Shepherd; Vandepitte, Judith; Buve, Anne			Non-Sexual Transmission of Trichomonas vaginalis in Adolescent Girls Attending School in Ndola, Zambia	PLOS ONE			English	Article							SEXUALLY-TRANSMITTED DISEASES; HIV-1; INFECTION; EPIDEMIOLOGY; ACQUISITION; PREVALENCE; WOMEN; RISK; PCR	Objectives: To identify risk factors for trichomoniasis among young women in Ndola, Zambia. Method: The study was a cross-sectional study among adolescent girls aged 13-16 years in Ndola, Zambia. Study participants were recruited from schools in selected administrative areas that represented the different socio-economic strata in town. Consenting participants were interviewed about their socio-demographic characteristics; sexual behaviour; and hygiene practices. Self-administered vaginal swabs were tested for Trichomonas vaginalis. HSV-2 antibodies were determined on serum to validate the self-reported sexual activity. Results: A total of 460 girls participated in the study. The overall prevalence of trichomoniasis was 27.1%, 33.9% among girls who reported that they had ever had sex and 24.7% among virgins. In multivariate analysis the only statistically significant risk factor for trichomoniasis was inconsistent use of soap. For the virgins, none of the risk factors was significantly associated with trichomoniasis, but the association with use of soap (not always versus always) and type of toilet used (pit latrine/bush versus flush toilet) was of borderline significance. Conclusion: We found a high prevalence of trichomoniasis in girls in Ndola who reported that they had never had sex. We postulate that the high prevalence of trichomoniasis in virgins in Ndola is due to non-sexual transmission of trichomoniasis via shared bathing water and inconsistent use of soap.	[Crucitti, Tania] Inst Trop Med, HIV STI Reference Lab, B-2000 Antwerp, Belgium; [Jespers, Vicky; Vandepitte, Judith; Buve, Anne] Inst Trop Med, HIV STI Epidemiol & Control Unit, B-2000 Antwerp, Belgium; [Mulenga, Chanda; Khondowe, Shepherd] Trop Dis Res Ctr, Ndola, Zambia	Institute of Tropical Medicine (ITM); Institute of Tropical Medicine (ITM)	Crucitti, T (corresponding author), Inst Trop Med, HIV STI Reference Lab, B-2000 Antwerp, Belgium.	tcrucitti@itg.be	Crucitti, Tania/AEQ-9792-2022; Crucitti, Tania/AAH-1902-2021; Crucitti, Tania/AAB-9967-2019	Crucitti, Tania/0000-0002-2235-6038; Crucitti, Tania/0000-0002-2235-6038	Directorate General for Development Cooperation of the Belgian Government [904100]	Directorate General for Development Cooperation of the Belgian Government	This study was made possible thanks to a grant from the Directorate General for Development Cooperation of the Belgian Government (AIDS Impuls Fonds no904100). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adu-Sarkodie Y, 2007, SEX TRANSM INFECT, V83, P130, DOI 10.1136/sti.2006.020941; ADUSARKODIE Y, 1995, GENITOURIN MED, V71, P199; BURCH TA, 1959, AM J TROP MED HYG, V8, P312, DOI 10.4269/ajtmh.1959.8.312; Buve A, 2001, AIDS, V15, pS5, DOI 10.1097/00002030-200108004-00002; Buve A, 2001, AIDS, V15, pS79, DOI 10.1097/00002030-200108004-00009; CATES W, 1993, AM J OBSTET GYNECOL, V169, P341, DOI 10.1016/0002-9378(93)90085-W; CHAPPAZ G, 1961, Rev Fr Gynecol Obstet, V56, P677; CHARLES SX, 1991, J TROP PEDIATRICS, V37, P90, DOI 10.1093/tropej/37.2.90; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Cotch MF, 1997, SEX TRANSM DIS, V24, P353, DOI 10.1097/00007435-199707000-00008; Crucitti T, 2003, SEX TRANSM INFECT, V79, P393, DOI 10.1136/sti.79.5.393; Crucitti T, 2010, SEX TRANSM DIS, V37, P223, DOI 10.1097/OLQ.0b013e3181c21f93; FOUTS A, 1980, J INFECT DIS, V41, P137; Gerbase AC, 1998, SEX TRANSM INFECT, V74, pS12; KENGNE P, 1994, CELL MOL BIOL, V40, P819; Kissinger P, 2009, SEX TRANSM DIS, V36, P11, DOI 10.1097/OLQ.0b013e318186decf; Krieger H, 1995, Gesundheitswesen, V57, P812; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; McClelland RS, 2007, J INFECT DIS, V195, P698, DOI 10.1086/511278; Peterson K, 2010, SEX TRANSM INFECT, V86, P353, DOI 10.1136/sti.2010.043125; Rottingen JA, 2001, SEX TRANSM DIS, V28, P579; Shaio MF, 1997, J CLIN MICROBIOL, V35, P132, DOI 10.1128/JCM.35.1.132-138.1997; UNAIDS/WHO, 2008, UNAIDS WHO EP FACT S; Van Der Pol B, 2008, J INFECT DIS, V197, P548, DOI 10.1086/526496; Wang CC, 2001, J INFECT DIS, V183, P1017, DOI 10.1086/319287; 1957, TRICHOMONAS INFECT, P1239	26	26	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16310	10.1371/journal.pone.0016310	http://dx.doi.org/10.1371/journal.pone.0016310			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	21305023	Green Published, gold			2023-01-03	WOS:000286834300049
J	Joynt, KE; Orav, EJ; Jha, AK				Joynt, Karen E.; Orav, E. John; Jha, Ashish K.			The Association Between Hospital Volume and Processes, Outcomes, and Costs of Care for Congestive Heart Failure	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; PERCUTANEOUS CORONARY INTERVENTIONS; REGIONAL-VARIATIONS; MORTALITY; EXPERIENCE	Background: Congestive heart failure (CHF) is common and costly, and outcomes remain suboptimal despite pharmacologic and technical advances. Objective: To examine whether hospitals with more experience in caring for patients with CHF provide better, more efficient care. Design: Retrospective cohort study. Setting: 4095 hospitals in the United States. Patients: Medicare fee-for-service patients with a primary discharge diagnosis of CHF. Measurements: Hospital Quality Alliance CHF process measures; 30-day, risk-adjusted mortality rates; 30-day, risk-adjusted readmission rates; and costs per discharge. National Medicare claims data from 2006 to 2007 were used to examine the relationship between hospital case volume and quality, outcomes, and costs for patients with CHF. Results: Hospitals in the low-volume group had lower performance on the process measures (80.2%) than did medium-volume (87.0%) or high-volume (89.1%) hospitals (P < 0.001). In the low-volume group, being admitted to a hospital with a higher case volume was associated with lower mortality, lower readmission, and higher costs. Similar, though smaller, relationships were found between case volume and both mortality and costs in the medium- and high-volume hospital groups. Limitations: Analysis was limited to Medicare patients 65 years or older. Risk adjustment was performed by using administrative data. Conclusion: Experience with managing CHF, as measured by an institution's volume, is associated with higher quality of care and better outcomes for patients but a higher cost. Understanding which practices employed by high-volume institutions account for these advantages can help improve quality of care and clinical outcomes for all patients with CHF. Primary Funding Source: American Heart Association. Ann Intern Med. 2011;154:94-102.	[Joynt, Karen E.] Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, Boston, MA 02115 USA; Vet Affairs Boston Hlth Care Syst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard T.H. Chan School of Public Health	Joynt, KE (corresponding author), Harvard Univ, Sch Publ Hlth, Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	kjoynt@partners.org			American Heart Association [10CRP3780037]; National Institutes of Health [T32HL007604-24]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007604] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	By an American Heart Association Clinical Research Program grant (10CRP3780037). Dr. Joynt was supported by a National Institutes of Health Training Grant (T32HL007604-24) held by Brigham and Women's Hospital Division of Cardiovascular Medicine.	Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; BENNETT CL, 1989, JAMA-J AM MED ASSOC, V261, P2975, DOI 10.1001/jama.261.20.2975; Birkmeyer JD, 2001, SURGERY, V130, P415, DOI 10.1067/msy.2001.117139; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Cunningham WE, 1999, AM J MED, V107, P137, DOI 10.1016/S0002-9343(99)00195-3; Desai MM, 2009, 2009 MEASURES MAINTE; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Fang J, 2008, J AM COLL CARDIOL, V52, P428, DOI 10.1016/j.jacc.2008.03.061; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fonarow GC, 2007, JAMA-J AM MED ASSOC, V297, P61, DOI 10.1001/jama.297.1.61; Hannan EL, 2005, CIRCULATION, V112, P1171, DOI 10.1161/CIRCULATIONAHA.104.528455; Hannan EL, 2003, CIRCULATION, V108, P795, DOI 10.1161/01.CIR.0000084551.52010.3B; Ho V, 2008, MED CARE, V46, P718, DOI 10.1097/MLR.0b013e3181653d6b; Jha AK, 2006, HEALTH AFFAIR, V25, P844, DOI 10.1377/hlthaff.25.3.844; Jha AK, 2009, HEALTH AFFAIR, V28, P897, DOI 10.1377/hlthaff.28.3.897; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Krumholz HM, 2009, CIRC-CARDIOVASC QUAL, V2, P407, DOI 10.1161/CIRCOUTCOMES.109.883256; Li B, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-12; Lindenauer PK, 2006, ANN INTERN MED, V144, P894, DOI 10.7326/0003-4819-144-12-200606200-00006; Lindenauer PK, 2006, ANN INTERN MED, V144, P262, DOI 10.7326/0003-4819-144-4-200602210-00008; LUFT HS, 1979, NEW ENGL J MED, V301, P1364, DOI 10.1056/NEJM197912203012503; LUFT HS, 1987, HEALTH SERV RES, V22, P157; McGrath PD, 2000, JAMA-J AM MED ASSOC, V284, P3139, DOI 10.1001/jama.284.24.3139; Mechanic R, 1998, JAMA-J AM MED ASSOC, V280, P1015, DOI 10.1001/jama.280.11.1015; Medicare Payment Advisory Commission, 2009, DAT BOOK HEALTHC SPE; Mukamel DB, 1998, MED CARE, V36, P945, DOI 10.1097/00005650-199807000-00002; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; Ross JS, 2008, ARCH INTERN MED, V168, P1371, DOI 10.1001/archinte.168.13.1371; Ross JS, 2010, NEW ENGL J MED, V362, P1110, DOI 10.1056/NEJMsa0907130; Schneider EC, 1998, JAMA-J AM MED ASSOC, V279, P1638, DOI 10.1001/jama.279.20.1638; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; Swisher SG, 2000, J THORAC CARDIOV SUR, V119, P1126, DOI 10.1067/mtc.2000.105644; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; US Department of Health and Human Services, 2010, HOSP COMP; Ward MM, 2002, J RHEUMATOL, V29, P1198; Wu CT, 2004, CIRCULATION, V110, P784, DOI 10.1161/01.CIR.0000138744.13516.B5; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566	39	124	125	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 18	2011	154	2					94	+		10.7326/0003-4819-154-2-201101180-00008	http://dx.doi.org/10.7326/0003-4819-154-2-201101180-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	706MW	21242366	Green Accepted			2023-01-03	WOS:000286223500003
J	Fang, KM; Chen, JK; Hung, SC; Chen, MC; Wu, YT; Wu, TJ; Lin, HI; Chen, CH; Cheng, H; Yang, CS; Tzeng, SF				Fang, Kuan-Min; Chen, Jen-Kun; Hung, Shih-Chieh; Chen, Mei-Chun; Wu, Yi-Ting; Wu, Tsung-Jung; Lin, Hsin-I; Chen, Chia-Hua; Cheng, Henrich; Yang, Chung-Shi; Tzeng, Shun-Fen			Effects of Combinatorial Treatment with Pituitary Adenylate Cyclase Activating Peptide and Human Mesenchymal Stem Cells on Spinal Cord Tissue Repair	PLOS ONE			English	Article							MARROW STROMAL CELLS; LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; FUNCTIONAL RECOVERY; NERVOUS-SYSTEM; GLUTAMATE UPTAKE; AXONAL REGENERATION; REACTIVE ASTROCYTES; NEUROTROPHIC FACTOR; MICROGLIAL CELLS; GROWTH-FACTOR	The aim of this study is to understand if human mesenchymal stem cells (hMSCs) and neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP) have synergistic protective effect that promotes functional recovery in rats with severe spinal cord injury (SCI). To evaluate the effect of delayed combinatorial therapy of PACAP and hMSCs on spinal cord tissue repair, we used the immortalized hMSCs that retain their potential of neuronal differentiation under the stimulation of neurogenic factors and possess the properties for the production of several growth factors beneficial for neural cell survival. The results indicated that delayed treatment with PACAP and hMSCs at day 7 post SCI increased the remaining neuronal fibers in the injured spinal cord, leading to better locomotor functional recovery in SCI rats when compared to treatment only with PACAP or hMSCs. Western blotting also showed that the levels of antioxidant enzymes, Mn-superoxide dismutase (MnSOD) and peroxiredoxin-1/6 (Prx-1 and Prx-6), were increased at the lesion center 1 week after the delayed treatment with the combinatorial therapy when compared to that observed in the vehicle-treated control. Furthermore, in vitro studies showed that co-culture with hMSCs in the presence of PACAP not only increased a subpopulation of microglia expressing galectin-3, but also enhanced the ability of astrocytes to uptake extracellular glutamate. In summary, our in vivo and in vitro studies reveal that delayed transplantation of hMSCs combined with PACAP provides trophic molecules to promote neuronal cell survival, which also foster beneficial microenvironment for endogenous glia to increase their neuroprotective effect on the repair of injured spinal cord tissue.	[Fang, Kuan-Min; Chen, Mei-Chun; Wu, Tsung-Jung; Lin, Hsin-I; Tzeng, Shun-Fen] Natl Cheng Kung Univ, Dept Life Sci, Tainan 70101, Taiwan; [Chen, Jen-Kun; Wu, Yi-Ting; Chen, Chia-Hua; Yang, Chung-Shi] Natl Hlth Res Inst, Ctr Nanomed Res, Zhunan, Taiwan; [Cheng, Henrich] Taipei Vet Gen Hosp, Neural Regenerat Ctr, Taipei, Taiwan; [Hung, Shih-Chieh] Natl Yang Ming Univ, Dept Surg, Sch Med, Taipei 112, Taiwan; [Cheng, Henrich] Natl Yang Ming Univ, Dept Pharmacol, Sch Med, Taipei 112, Taiwan; [Yang, Chung-Shi] Natl Chi Nan Univ, Grad Inst Biomed & Biomed Technol, Puli, Taiwan	National Cheng Kung University; National Health Research Institutes - Taiwan; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; National Chi Nan University	Fang, KM (corresponding author), Natl Cheng Kung Univ, Dept Life Sci, Tainan 70101, Taiwan.	cyang@nhri.org.tw; stzeng@mail.ncku.edu.tw	Chen, Jen-Kun/C-6225-2011; Yang, Chung-Shi/E-3999-2010		Volkswagen Foundation within its Evolutionary Biology initiative [I/84 196]	Volkswagen Foundation within its Evolutionary Biology initiative	NC was supported by the Volkswagen Foundation within its Evolutionary Biology initiative, grant I/84 196. OK holds a Heisenberg Professorship of the German Science Foundation (DFG) (KR 2089/2-1). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ankeny DP, 2004, EXP NEUROL, V190, P17, DOI 10.1016/J.expneurol.2004.05.045; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Barnabe-Heider F, 2008, CELL STEM CELL, V3, P16, DOI 10.1016/j.stem.2008.06.011; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bergles DE, 1998, J NEUROSCI, V18, P7709; Beschorner R, 2007, HISTOPATHOLOGY, V50, P897, DOI 10.1111/j.1365-2559.2007.02703.x; Bouhy D, 2006, FASEB J, V20, P1239, DOI 10.1096/fj.05-4382fje; Cafferty WBJ, 2004, J NEUROSCI, V24, P4432, DOI 10.1523/JNEUROSCI.2245-02.2004; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chen WH, 2005, NEUROSCI LETT, V384, P117, DOI 10.1016/j.neulet.2005.04.070; Cheng H, 2002, J NEUROSCI RES, V69, P397, DOI 10.1002/jnr.10303; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Deumens R, 2005, PROG NEUROBIOL, V77, P57, DOI 10.1016/j.pneurobio.2005.10.004; Dezawa M, 2005, CURR MOL MED, V5, P723, DOI 10.2174/156652405774641070; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Grill R, 1997, J NEUROSCI, V17, P5560; Ha Yoon, 2005, Clin Neurosurg, V52, P341; Hattori Fumiyuki, 2007, V44, P357; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Horner PJ, 2000, J NEUROSCI, V20, P2218; Hsiao HY, 2007, GLIA, V55, P214, DOI 10.1002/glia.20453; Huang X, 2009, J NEUROL SCI, V277, P87, DOI 10.1016/j.jns.2008.10.022; Hung SC, 2004, INT J CANCER, V110, P313, DOI 10.1002/ijc.20126; Kieran D, 2008, J NEUROSCI, V28, P14056, DOI 10.1523/JNEUROSCI.3399-08.2008; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kojima A, 2002, J NEUROTRAUM, V19, P223, DOI 10.1089/08977150252806974; Kong LY, 1999, NEUROSCIENCE, V91, P493, DOI 10.1016/S0306-4522(98)00606-X; Lindvall O, 2010, J CLIN INVEST, V120, P29, DOI 10.1172/JCI40543; Liu YP, 2008, J NEUROCHEM, V105, P137, DOI 10.1111/j.1471-4159.2007.05118.x; Lu P, 2005, EXP NEUROL, V191, P344, DOI 10.1016/j.expneurol.2004.09.018; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Mukaino M, 2010, EXP NEUROL, V224, P403, DOI 10.1016/j.expneurol.2010.04.020; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Ono K, 2003, J NEUROSCI RES, V72, P503, DOI 10.1002/jnr.10588; PARK DH, 2010, STEM CELL REV; Park HW, 2010, GLIA, V58, P1118, DOI 10.1002/glia.20992; Phinney DG, 2005, CURR PHARM DESIGN, V11, P1255, DOI 10.2174/1381612053507495; REICHERT F, 1994, J NEUROSCI, V14, P3231; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Reichert F, 1999, EXP NEUROL, V160, P508, DOI 10.1006/exnr.1999.7229; Ronaghi M, 2010, STEM CELLS, V28, P93, DOI 10.1002/stem.253; Rossi SL, 2009, CURR OPIN BIOTECH, V20, P552, DOI 10.1016/j.copbio.2009.09.008; Rotshenker S, 2008, GLIA, V56, P1607, DOI 10.1002/glia.20713; Rotshenker S, 2009, J MOL NEUROSCI, V39, P99, DOI 10.1007/s12031-009-9186-7; Schinkothe T, 2008, STEM CELLS DEV, V17, P199, DOI 10.1089/scd.2007.0175; Schultz SS, 2005, CURR DRUG TARGETS, V6, P63, DOI 10.2174/1389450053345046; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Tan YV, 2009, P NATL ACAD SCI USA, V106, P2012, DOI 10.1073/pnas.0812257106; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Tsai CC, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-64; Tzeng SF, 2004, NEUROSCI LETT, V367, P23, DOI 10.1016/j.neulet.2004.05.117; Vaudry D, 2000, PHARMACOL REV, V52, P269; Venkatesan C, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-32; Walther M, 2000, J NEUROSCI RES, V61, P430, DOI 10.1002/1097-4547(20000815)61:4<430::AID-JNR9>3.0.CO;2-3; Wang YC, 2008, BIOMATERIALS, V29, P4546, DOI 10.1016/j.biomaterials.2008.07.050; Waschek JA, 2002, DEV NEUROSCI-BASEL, V24, P14, DOI 10.1159/000064942; Waschek JA, 1998, P NATL ACAD SCI USA, V95, P9602, DOI 10.1073/pnas.95.16.9602; Watanabe J, 2007, PEPTIDES, V28, P1713, DOI 10.1016/j.peptides.2007.06.029; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yan YP, 2009, BRAIN RES, V1288, P116, DOI 10.1016/j.brainres.2009.06.073; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhou JZ, 2004, J NEUROSCI, V24, P6301, DOI 10.1523/JNEUROSCI.1404-04.2004	68	32	34	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 20	2010	5	12							e15299	10.1371/journal.pone.0015299	http://dx.doi.org/10.1371/journal.pone.0015299			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	698EM	21187959	Green Submitted, Green Published, gold			2023-01-03	WOS:000285575200034
J	Kuang, H; Lin, LN; Tsien, JZ				Kuang, Hui; Lin, Longnian; Tsien, Joe Z.			Temporal Dynamics of Distinct CA1 Cell Populations during Unconscious State Induced by Ketamine	PLOS ONE			English	Article							NMDA RECEPTOR-CHANNEL; OSCILLATIONS IN-VIVO; MEMORY CONSOLIDATION; HEALTHY-VOLUNTEERS; THETA RHYTHM; HIPPOCAMPUS; RAT; INTERNEURONS; PHENCYCLIDINE; CONSCIOUSNESS	Ketamine is a widely used dissociative anesthetic which can induce some psychotic-like symptoms and memory deficits in some patients during the post-operative period. To understand its effects on neural population dynamics in the brain, we employed large-scale in vivo ensemble recording techniques to monitor the activity patterns of simultaneously recorded hippocampal CA1 pyramidal cells and various interneurons during several conscious and unconscious states such as awake rest, running, slow wave sleep, and ketamine-induced anesthesia. Our analyses reveal that ketamine induces distinct oscillatory dynamics not only in pyramidal cells but also in at least seven different types of CA1 interneurons including putative basket cells, chandelier cells, bistratified cells, and O-LM cells. These emergent unique oscillatory dynamics may very well reflect the intrinsic temporal relationships within the CA1 circuit. It is conceivable that systematic characterization of network dynamics may eventually lead to better understanding of how ketamine induces unconsciousness and consequently alters the conscious mind.	[Kuang, Hui; Lin, Longnian] E China Normal Univ, Key Lab MOE, Shanghai Inst Brain Funct Genom, Shanghai 200062, Peoples R China; [Kuang, Hui; Lin, Longnian] E China Normal Univ, Key Lab STCSM, Shanghai Inst Brain Funct Genom, Shanghai 200062, Peoples R China; [Kuang, Hui; Tsien, Joe Z.] Med Coll Georgia, Sch Med, Brain & Behav Discovery Inst, Augusta, GA 30912 USA	East China Normal University; East China Normal University; University System of Georgia; Augusta University	Kuang, H (corresponding author), E China Normal Univ, Key Lab MOE, Shanghai Inst Brain Funct Genom, Shanghai 200062, Peoples R China.	jtsien@mcg.edu	Kuang, Hui/I-1006-2013	Kuang, Hui/0000-0002-7806-2864	National Institutes of Health: National Institute of Mental Health (NIMH) [MH060236]; National Institute on Aging (NIA) [AG024022, AG034663, AG025918]; Amry Research Laboratory [USAMRA00002]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH060236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG034663, R01AG025918, R01AG024022] Funding Source: NIH RePORTER	National Institutes of Health: National Institute of Mental Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Aging (NIA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Amry Research Laboratory; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by funds from National Institutes of Health: National Institute of Mental Health (NIMH) (MH060236), National Institute on Aging (NIA) (AG024022, AG034663 & AG025918), and from Amry Research Laboratory: USAMRA00002 (all to JZT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; ALONSO A, 1987, EXP BRAIN RES, V67, P493, DOI 10.1007/BF00247282; Buzsaki G, 2003, NEUROSCIENCE, V116, P201, DOI 10.1016/S0306-4522(02)00669-3; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; BUZSAKI G, 1985, ELECTROEN CLIN NEURO, V61, P77, DOI 10.1016/0013-4694(85)91075-2; BUZSAKI G, 1983, BRAIN RES, V266, P334, DOI 10.1016/0006-8993(83)90665-0; BUZSAKI G, 1992, SCIENCE, V256, P1025, DOI 10.1126/science.1589772; Chen GF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008256; CORSSEN G, 1966, ANESTH ANAL CURR RES, V45, P29; Craven R, 2007, ANAESTHESIA, V62, P48, DOI 10.1111/j.1365-2044.2007.05298.x; DOMINO EF, 1965, CLIN PHARMACOL THER, V6, P279; DURIEUX ME, 1995, ANESTH ANALG, V81, P57, DOI 10.1097/00000539-199507000-00012; ELLISON G, 1995, BRAIN RES REV, V20, P250, DOI 10.1016/0165-0173(94)00014-G; Fenton AA, 1998, P NATL ACAD SCI USA, V95, P3182, DOI 10.1073/pnas.95.6.3182; FOX SE, 1981, EXP BRAIN RES, V41, P399; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; Greene R, 2001, HIPPOCAMPUS, V11, P569, DOI 10.1002/hipo.1072.abs; Grunwald T, 1999, P NATL ACAD SCI USA, V96, P12085, DOI 10.1073/pnas.96.21.12085; Hakami T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006755; Harborne GC, 1996, J PSYCHOPHARMACOL, V10, P134, DOI 10.1177/026988119601000208; Honey GD, 2005, CEREB CORTEX, V15, P749, DOI 10.1093/cercor/bhh176; HUNT MJ, J PSYCHOPHARMACOL; Klausberger T, 2003, NATURE, V421, P844, DOI 10.1038/nature01374; Klausberger T, 2004, NAT NEUROSCI, V7, P41, DOI 10.1038/nn1159; Klausberger T, 2008, SCIENCE, V321, P53, DOI 10.1126/science.1149381; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; LAZAREWICZ MT, 2009, J COGN NEUROSCI; Lin LN, 2005, P NATL ACAD SCI USA, V102, P6125, DOI 10.1073/pnas.0408233102; Lin LN, 2006, J NEUROSCI METH, V155, P28, DOI 10.1016/j.jneumeth.2005.12.032; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; Morgan CJA, 2004, NEUROPSYCHOPHARMACOL, V29, P208, DOI 10.1038/sj.npp.1300342; Newcomer JW, 1999, NEUROPSYCHOPHARMACOL, V20, P106, DOI 10.1016/S0893-133X(98)00067-0; Newcomer JW, 2001, HIPPOCAMPUS, V11, P529, DOI 10.1002/hipo.1069; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; Perry E, 1999, TRENDS NEUROSCI, V22, P273, DOI 10.1016/S0166-2236(98)01361-7; RANCK JB, 1973, EXP NEUROL, V41, P462, DOI 10.1016/0014-4886(73)90290-2; Sara SJ, 2006, LEARN MEMORY, V13, P515, DOI 10.1101/lm.338406; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Shimizu E, 2000, SCIENCE, V290, P1170, DOI 10.1126/science.290.5494.1170; SIK A, 1995, J NEUROSCI, V15, P6651; Sinner B., 2008, V182, P313, DOI 10.1007/978-3-540-74806-9_15; Somogyi P, 2005, J PHYSIOL-LONDON, V562, P9, DOI 10.1113/jphysiol.2004.078915; Squire L. R., 1987, MEMORY BRAIN; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Tukker JJ, 2007, J NEUROSCI, V27, P8184, DOI 10.1523/JNEUROSCI.1685-07.2007; Tulving E, 2000, OXFORD HDB MEMORY; Wang HM, 2006, PROG NEUROBIOL, V79, P123, DOI 10.1016/j.pneurobio.2006.06.004; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	50	18	18	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2010	5	12							e15209	10.1371/journal.pone.0015209	http://dx.doi.org/10.1371/journal.pone.0015209			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691MJ	21165147	Green Published, gold, Green Submitted			2023-01-03	WOS:000285084100029
J	Burgess, P; Hutt, PB; Farokhzad, OC; Langer, R; Minick, S; Zale, S				Burgess, Paul; Hutt, Peter Barton; Farokhzad, Omid C.; Langer, Robert; Minick, Scott; Zale, Stephen			On firm ground: IP protection of therapeutic nanoparticles	NATURE BIOTECHNOLOGY			English	Editorial Material									[Burgess, Paul; Minick, Scott; Zale, Stephen] BIND Biosci, Cambridge, MA USA; [Hutt, Peter Barton] Covington & Burling Associates, Washington, DC USA; [Farokhzad, Omid C.] Brigham & Womens Hosp, Boston, MA 02115 USA; [Farokhzad, Omid C.] Harvard Univ, Sch Med, Boston, MA USA; [Langer, Robert] MIT, Cambridge, MA 02139 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Burgess, P (corresponding author), BIND Biosci, Cambridge, MA USA.	paulburgess@bindbio.com		Farokhzad, Omid/0000-0003-2009-270X				DAVIS M, 2006, NANOTECHNOL LAW  SEP, P255; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; *ORTH PROD LP, 2008, DOX PROD INF; U. S. Food and Drug Administration Department of Health and Human Services Office of Generic Drugs, 2010, DRAFT GUID DOX HYDR; U.S. Food & Drug Administration, 2003, GUID IND BIOAV BIOEQ; *US FDA, 2007, CRIT PATH OPP GEN DR; US Food & Drug Administration, OR BOOK APPR DRUG PR	7	63	66	0	32	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1087-0156			NAT BIOTECHNOL	Nat. Biotechnol.	DEC	2010	28	12					1267	1271		10.1038/nbt.1725	http://dx.doi.org/10.1038/nbt.1725			5	Biotechnology & Applied Microbiology	Science Citation Index Expanded (SCI-EXPANDED)	Biotechnology & Applied Microbiology	691NP	21139609				2023-01-03	WOS:000285088400017
J	Levi, M; Levy, JH; Andersen, HF; Truloff, D				Levi, Marcel; Levy, Jerrold H.; Andersen, Henning Friis; Truloff, David			Safety of Recombinant Activated Factor VII in Randomized Clinical Trials.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COAGULATION-FACTOR-VII; DOUBLE-BLIND; INTRACEREBRAL HEMORRHAGE; RISK-FACTORS; EFFICACY; CIRRHOSIS; THERAPY; SURGERY; PHARMACOKINETICS; TRANSFUSION	Background: The use of recombinant activated factor VII (rFVIIa) on an off-label basis to treat life-threatening bleeding has been associated with a perceived increased risk of thromboembolic complications. However, data from placebo-controlled trials are needed to properly assess the thromboembolic risk. To address this issue, we evaluated the rate of thromboembolic events in all published randomized, placebo-controlled trials of rFVIIa used on an off-label basis. Methods: We analyzed data from 35 randomized clinical trials (26 studies involving patients and 9 studies involving healthy volunteers) to determine the frequency of thromboembolic events. The data were pooled with the use of random-effects models to calculate the odds ratios and 95% confidence intervals. Results: Among 4468 subjects (4119 patients and 349 healthy volunteers), 498 had thromboembolic events (11.1%). Rates of arterial thromboembolic events among all 4468 subjects were higher among those who received rFVIIa than among those who received placebo (5.5% vs. 3.2%, P=0.003). Rates of venous thromboembolic events were similar among subjects who received rFVIIa and those who received placebo (5.3% vs. 5.7%). Among subjects who received rFVIIa, 2.9% had coronary arterial thromboembolic events, as compared with 1.1% of those who received placebo (P=0.002). Rates of arterial thromboembolic events were highest among subjects older than 65 years of age, as compared with those who were 65 years of age or younger (9.0% vs. 3.8%, P=0.003); the rates were especially high among subjects 75 years of age or older, as compared with those who were younger than 75 years of age (10.8% vs. 4.1%, P=0.02). Conclusions: In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.) N Engl J Med 2010;363:1791-800.	[Levi, Marcel] Univ Amsterdam, Acad Med Ctr, Dept Med F4, NL-1105 AZ Amsterdam, Netherlands; [Levy, Jerrold H.] Emory Univ, Sch Med, Atlanta, GA USA; [Andersen, Henning Friis; Truloff, David] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	University of Amsterdam; Academic Medical Center Amsterdam; Emory University; Novo Nordisk	Levi, M (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Med F4, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	m.m.levi@amc.uva.nl	Levi, Marcel/AAZ-8559-2020		Novo Nordisk	Novo Nordisk(Novo Nordisk)	Supported by Novo Nordisk.	Abbott RD, 2003, J CLIN EPIDEMIOL, V56, P479, DOI 10.1016/S0895-4356(02)00611-X; Abshire T, 2008, SEMIN HEMATOL, V45, pS3, DOI 10.1053/j.seminhematol.2008.03.006; Aledort LM, 2004, J THROMB HAEMOST, V2, P1700, DOI 10.1111/j.1538-7836.2004.00944.x; Bijsterveld NR, 2004, BRIT J HAEMATOL, V124, P653, DOI 10.1111/j.1365-2141.2003.04811.x; Bijsterveld NR, 2002, CIRCULATION, V106, P2550, DOI 10.1161/01.CIR.0000038501.87442.02; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bosch J, 2004, GASTROENTEROLOGY, V127, P1123, DOI 10.1053/j.gastro.2004.07.015; Bosch J, 2008, HEPATOLOGY, V47, P1604, DOI 10.1002/hep.22216; CARRENO V, 2001, 18 C INT SOC THROMB, pP2612; Chuansumrit A, 2005, BLOOD COAGUL FIBRIN, V16, P549, DOI 10.1097/01.mbc.0000186837.78432.2f; Diprose P, 2005, BRIT J ANAESTH, V95, P596, DOI 10.1093/bja/aei244; Ekert H, 2006, BLOOD COAGUL FIBRIN, V17, P389, DOI 10.1097/01.mbc.0000233369.03358.c1; Erhardtsen E, 1998, BLOOD COAGUL FIBRIN, V9, P741, DOI 10.1097/00001721-199811000-00003; Fridberg MJ, 2005, BLOOD COAGUL FIBRIN, V16, P259, DOI 10.1097/01.mbc.0000169218.15926.34; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Friederich PW, 2003, LANCET, V361, P1138; Friederich PW, 2001, CIRCULATION, V103, P2555; Gill R, 2009, CIRCULATION, V120, P21, DOI 10.1161/CIRCULATIONAHA.108.834275; Hedner U, 2008, THROMB HAEMOSTASIS, V100, P557, DOI 10.1160/TH08-07-0434; Hedner U, 2006, SEMIN THROMB HEMOST, V32, P77, DOI 10.1055/s-2006-939557; Heit JA, 2005, J THROMB HAEMOST, V3, P1611, DOI 10.1111/j.1538-7836.2005.01415.x; Levi M, 2005, CRIT CARE MED, V33, P883, DOI 10.1097/01.CCM.0000159087.85970.38; Levy JH, 2006, TRANSFUSION, V46, P919, DOI 10.1111/j.1537-2995.2006.00824.x; Lodge JPA, 2005, LIVER TRANSPLANT, V11, P973, DOI 10.1002/lt.20470; Lodge JPA, 2005, ANESTHESIOLOGY, V102, P269, DOI 10.1097/00000542-200502000-00006; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2005, STROKE, V36, P74, DOI 10.1161/01.STR.0000149628.80251.b8; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayer SA, 2006, NEUROCRIT CARE, V4, P206, DOI 10.1385/NCC:4:3:206; Murphy GJ, 2007, CIRCULATION, V116, P2544, DOI 10.1161/CIRCULATIONAHA.107.698977; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Pihusch M, 2005, J THROMB HAEMOST, V3, P1935, DOI 10.1111/j.1538-7836.2005.01523.x; Planinsic RM, 2005, LIVER TRANSPLANT, V11, P895, DOI 10.1002/lt.20458; Raobaikady R, 2005, BRIT J ANAESTH, V94, P586, DOI 10.1093/bja/aei102; Rosendaal FR, 1999, THROMB HAEMOSTASIS, V82, P610; Sachs B, 2007, SPINE, V32, P2285, DOI 10.1097/BRS.0b013e3181557d45; Samama MM, 2000, ARCH INTERN MED, V160, P3415, DOI 10.1001/archinte.160.22.3415; Shao YF, 2006, AM J SURG, V191, P245, DOI 10.1016/j.amjsurg.2005.10.019; Villar A, 2004, HAEMOPHILIA, V10, P352, DOI 10.1111/j.1365-2516.2004.00925.x; Wolzt M, 2004, THROMB HAEMOSTASIS, V91, P1090, DOI 10.1160/TH03-09-0605	41	445	466	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 4	2010	363	19					1791	1800		10.1056/NEJMoa1006221	http://dx.doi.org/10.1056/NEJMoa1006221			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YK	21047223				2023-01-03	WOS:000283787800004
J	Casaer, MP; Mesotten, D; Hermans, G; Wouters, PJ; Schetz, M; Meyfroidt, G; Van Cromphaut, S; Ingels, C; Meersseman, P; Muller, J; Vlasselaers, D; Debaveye, Y; Desmet, L; Dubois, J; Van Assche, A; Vanderheyden, S; Wilmer, A; Van den Berghe, G				Casaer, Michael P.; Mesotten, Dieter; Hermans, Greet; Wouters, Pieter J.; Schetz, Miet; Meyfroidt, Geert; Van Cromphaut, Sophie; Ingels, Catherine; Meersseman, Philippe; Muller, Jan; Vlasselaers, Dirk; Debaveye, Yves; Desmet, Lars; Dubois, Jasperina; Van Assche, Aime; Vanderheyden, Simon; Wilmer, Alexander; Van den Berghe, Greet			Early versus Late Parenteral Nutrition in Critically Ill Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE INSULIN THERAPY; ENTERAL NUTRITION; ENERGY-BALANCE; AUTOPHAGY; GUIDELINES; SUPPORT; METAANALYSIS; DEFINITIONS; MULTICENTER; INFECTIONS	Background Controversy exists about the timing of the initiation of parenteral nutrition in critically ill adults in whom caloric targets cannot be met by enteral nutrition alone. Methods In this randomized, multicenter trial, we compared early initiation of parenteral nutrition (European guidelines) with late initiation (American and Canadian guidelines) in adults in the intensive care unit (ICU) to supplement insufficient enteral nutrition. In 2312 patients, parenteral nutrition was initiated within 48 hours after ICU admission (early-initiation group), whereas in 2328 patients, parenteral nutrition was not initiated before day 8 (late-initiation group). A protocol for the early initiation of enteral nutrition was applied to both groups, and insulin was infused to achieve normoglycemia. Results Patients in the late-initiation group had a relative increase of 6.3% in the likelihood of being discharged alive earlier from the ICU (hazard ratio, 1.06; 95% confidence interval [CI], 1.00 to 1.13; P = 0.04) and from the hospital (hazard ratio, 1.06; 95% CI, 1.00 to 1.13; P = 0.04), without evidence of decreased functional status at hospital discharge. Rates of death in the ICU and in the hospital and rates of survival at 90 days were similar in the two groups. Patients in the late-initiation group, as compared with the early-initiation group, had fewer ICU infections (22.8% vs. 26.2%, P = 0.008) and a lower incidence of cholestasis (P<0.001). The late-initiation group had a relative reduction of 9.7% in the proportion of patients requiring more than 2 days of mechanical ventilation (P = 0.006), a median reduction of 3 days in the duration of renal-replacement therapy (P = 0.008), and a mean reduction in health care costs of ss1,110 (about $1,600) (P = 0.04). Conclusions Late initiation of parenteral nutrition was associated with faster recovery and fewer complications, as compared with early initiation.	[Casaer, Michael P.; Mesotten, Dieter; Wouters, Pieter J.; Schetz, Miet; Meyfroidt, Geert; Van Cromphaut, Sophie; Ingels, Catherine; Muller, Jan; Vlasselaers, Dirk; Debaveye, Yves; Desmet, Lars; Vanderheyden, Simon; Van den Berghe, Greet] Catholic Univ Louvain, Dept Intens Care Med, Univ Hosp Leuven, B-3000 Louvain, Belgium; [Hermans, Greet; Meersseman, Philippe; Wilmer, Alexander] Catholic Univ Louvain, Med Intens Care Unit, Dept Internal Med, Univ Hosp, B-3000 Louvain, Belgium; [Dubois, Jasperina; Van Assche, Aime] Jessa Hosp, Dept Anesthesia, Hasselt, Belgium; [Dubois, Jasperina; Van Assche, Aime] Jessa Hosp, Dept Intens Care, Hasselt, Belgium	KU Leuven; University Hospital Leuven; Universite Catholique Louvain; Universite Catholique Louvain	Van den Berghe, G (corresponding author), Catholic Univ Louvain, Dept Intens Care Med, Univ Hosp Leuven, B-3000 Louvain, Belgium.	greet.vandenberghe@med.kuleuven.be	Van den Berghe, Greet/J-6788-2018; Wilmer, Alexander/H-7784-2018; Casaer, Michael/Y-7131-2019; Hug, Balthasar L./G-1568-2010; Hermans, Greet M/E-6234-2018; Mesotten, Dieter/ABE-4176-2020	Van den Berghe, Greet/0000-0002-5320-1362; Wilmer, Alexander/0000-0002-4176-3608; Casaer, Michael/0000-0002-7087-0795; Hermans, Greet M/0000-0001-5340-1500; Mesotten, Dieter/0000-0002-3258-4720; Meyfroidt, Geert/0000-0003-4259-3935	Flemish government; Catholic University of Leuven [GOA-2007/14]; Research Foundation Flanders, Belgium; University Hospitals Leuven, Belgium; Baxter Healthcare	Flemish government(European Commission); Catholic University of Leuven(KU Leuven); Research Foundation Flanders, Belgium(FWO); University Hospitals Leuven, Belgium; Baxter Healthcare	Funded by the Methusalem program of the Flemish government and others; EPaNIC ClinicalTrials.gov number, NCT00512122.; Supported by the Methusalem program of the Flemish government (with a grant through the Catholic University of Leuven to Dr. Van den Berghe), the Research Fund of the Catholic University of Leuven (GOA-2007/14, to Dr. Van den Berghe), the Research Foundation Flanders, Belgium (doctoral fellowship to Dr. Casaer and postdoctoral fellowship to Dr. Van Cromphaut), and the Clinical Research Fund of the University Hospitals Leuven, Belgium (doctoral fellowship to Dr. Ingels and postdoctoral fellowships to Drs. Mesotten and Hermans). In addition, the Catholic University of Leuven received an unconditional and nonrestrictive research grant for this trial from Baxter Healthcare.	Alberda Cathy, 2009, Intensive Care Med, V35, P1728, DOI 10.1007/s00134-009-1567-4; Alberda C, 2009, INTENS CARE MED, V35, P1728, DOI 10.1007/s00134-009-1567-4; Andersen PK, 2002, STAT METHODS MED RES, V11, P91, DOI 10.1191/0962280202SM276ra; Andrews PJD, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d1542; Barber JA, 1998, BRIT MED J, V317, P1195, DOI 10.1136/bmj.317.7167.1195; Barr J, 2004, CHEST, V125, P1446, DOI 10.1378/chest.125.4.1446; Biolo G, 2008, CRIT CARE MED, V36, P1768, DOI 10.1097/CCM.0b013e318174de32; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Braunschweig CL, 2001, AM J CLIN NUTR, V74, P534; Cahill NE, 2010, CRIT CARE MED, V38, P395, DOI 10.1097/CCM.0b013e3181c0263d; Casaer MP, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-21; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Debaveye Y, 2006, ANNU REV NUTR, V26, P513, DOI 10.1146/annurev.nutr.26.061505.111307; Dhaliwal R, 2004, INTENS CARE MED, V30, P1666, DOI 10.1007/s00134-004-2345-y; Doig GS, 2008, JAMA-J AM MED ASSOC, V300, P2731, DOI 10.1001/jama.2008.826; Dvir D, 2006, CLIN NUTR, V25, P37, DOI 10.1016/j.clnu.2005.10.010; Grau T, 2007, CRIT CARE, V11, DOI 10.1186/cc5670; Grau T, 2011, CRIT CARE MED, V39, P1263, DOI 10.1097/CCM.0b013e31820eb774; Griffiths RD, 1997, NUTRITION, V13, P752, DOI 10.1016/S0899-9007(97)83039-0; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P74, DOI 10.1177/014860710302700174; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; HORAN TC, 1992, AM J INFECT CONTROL, V20, P271, DOI 10.1016/S0196-6553(05)80201-9; Ibrahim EH, 2002, JPEN-PARENTER ENTER, V26, P174, DOI 10.1177/0148607102026003174; Jolliet P, 1998, INTENS CARE MED, V24, P848, DOI 10.1007/s001340050677; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022; Kondrup J, 2003, CLIN NUTR, V22, P415, DOI 10.1016/S0261-5614(03)00098-0; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Langouche L, 2010, AM J RESP CRIT CARE, V182, P507, DOI 10.1164/rccm.200909-1395OC; Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782; Mangram AJ, 1999, INFECT CONT HOSP EP, V20, P250, DOI 10.1086/501620; Martin CM, 2004, CAN MED ASSOC J, V170, P197, DOI 10.1503/cmaj.1040621; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; Masiero E, 2009, CELL METAB, V10, P507, DOI 10.1016/j.cmet.2009.10.008; McClave SA, 1998, JPEN-PARENTER ENTER, V22, P375, DOI 10.1177/0148607198022006375; Nasraway SA, 2006, CRIT CARE MED, V34, P964, DOI 10.1097/01.CCM.0000205758.18891.70; O'Brien JM, 2006, CRIT CARE MED, V34, P738, DOI 10.1097/01.CCM.0000202207.87891.FC; Peter JV, 2005, CRIT CARE MED, V33, P213, DOI 10.1097/01.CCM.0000150960.36228.C0; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Reid C, 2006, J HUM NUTR DIET, V19, P13, DOI 10.1111/j.1365-277X.2006.00661.x; Rubinson L, 2004, CRIT CARE MED, V32, P350, DOI 10.1097/01.CCM.0000089641.06306.68; Saitoh T, 2010, J CELL BIOL, V189, P925, DOI 10.1083/jcb.201002021; Schetz M, 2008, J AM SOC NEPHROL, V19, P571, DOI 10.1681/ASN.2006101091; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; STREAT SJ, 1987, J TRAUMA, V27, P262, DOI 10.1097/00005373-198703000-00006; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vanhorebeek I, 2011, J CLIN ENDOCR METAB, V96, pE633, DOI 10.1210/jc.2010-2563; Villet S, 2005, CLIN NUTR, V24, P502, DOI 10.1016/j.clnu.2005.03.006; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1	52	960	1036	0	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 11	2011	365	6					506	517		10.1056/NEJMoa1102662	http://dx.doi.org/10.1056/NEJMoa1102662			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	805MW	21714640				2023-01-03	WOS:000293732100006
J	Lee, DM; Jackson, KW; Knowlton, N; Wages, J; Alaupovic, P; Samuelsson, O; Saeed, A; Centola, M; Attman, PO				Lee, Diana M.; Jackson, Kenneth W.; Knowlton, Nicholas; Wages, Joshua; Alaupovic, Petar; Samuelsson, Ola; Saeed, Aso; Centola, Michael; Attman, Per-Ola			Oxidative Stress and Inflammation in Renal Patients and Healthy Subjects	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; MASS-SPECTROMETRY; CARDIOVASCULAR-DISEASE; HEMODIALYSIS-PATIENTS; LIPID-PEROXIDATION; INSULIN-RESISTANCE; CHOLESTERYL ESTER; ENDOTHELIAL-CELLS; DIALYSIS PATIENTS; VITAMIN-E	The first goal of this study was to measure the oxidative stress (OS) and relate it to lipoprotein variables in 35 renal patients before dialysis (CKD), 37 on hemodialysis (HD) and 63 healthy subjects. The method for OS was based on the ratio of cholesteryl esters (CE) containing C18/C16 fatty acids (R2) measured by gas chromatography (GC) which is a simple, direct, rapid and reliable procedure. The second goal was to investigate and identify a triacylglycerol peak on GC, referred to as TG48 (48 represents the sum of the three fatty acids carbon chain lengths) which was markedly increased in renal patients compared to healthy controls. We measured TG48 in patients and controls. Mass spectrometry (MS) and MS twice in tandem were used to analyze the fatty acid composition of TG48. MS showed that TG48 was abundant in saturated fatty acids (SFAs) that were known for their pro-inflammatory property. TG48 was significantly and inversely correlated with OS. Renal patients were characterized by higher OS and inflammation than healthy subjects. Inflammation correlated strongly with TG, VLDL-cholesterol, apolipoprotein (apo) C-III and apoC-III bound to apoB-containing lipoproteins, but not with either total cholesterol or LDL-cholesterol. In conclusion, we have discovered a new inflammatory factor, TG48. It is characterized with TG rich in saturated fatty acids. Renal patients have increased TG48 than healthy controls.	[Lee, Diana M.; Knowlton, Nicholas; Wages, Joshua; Alaupovic, Petar; Centola, Michael] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; [Jackson, Kenneth W.] Univ Oklahoma, Hlth Sci Ctr, Mol Biol Protem Facil, Oklahoma City, OK USA; [Samuelsson, Ola; Saeed, Aso; Attman, Per-Ola] Univ Gothenburg, Dept Nephrol, Sahlgrenska Univ Hosp, Gothenburg, Sweden	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Sahlgrenska University Hospital; University of Gothenburg	Lee, DM (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.	alaupovicp@omrf.org		Knowlton, Nicholas/0000-0002-7022-3352	American Heart Association; Oklahoma Affiliate Inc.; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Swedish Medical Research Council; Sahlgrenska University Hospital; University of Goteborg; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR053483] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); Oklahoma Affiliate Inc.; Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Sahlgrenska University Hospital; University of Goteborg; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by the American Heart Association, Oklahoma Affiliate Inc.; the Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma; the Swedish Medical Research Council; Sahlgrenska University Hospital; and the University of Goteborg. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alaupovic P, 1997, ARTERIOSCL THROM VAS, V17, P715, DOI 10.1161/01.ATV.17.4.715; Alaupovic P, 2006, KIDNEY INT, V69, P1865, DOI 10.1038/sj.ki.5000327; Annuk M, 2005, J NEPHROL, V18, P721; ATTMAN PO, 1991, NEPHRON, V57, P401, DOI 10.1159/000186303; ATTMAN PO, 2011, NEPHROL DIAL TRANSPL, P1; Benjamini Y, 1995, J ROY STAT SOC, V57, P289; Boaz M, 1999, KIDNEY INT, V56, P1078, DOI 10.1046/j.1523-1755.1999.00613.x; Boulanger E, 2006, PERITON DIALYSIS INT, V26, P207; Bowden RG, 2010, POSTGRAD MED, V122, P196, DOI 10.3810/pgm.2010.05.2158; Byrdwell WC, 2005, LIPIDS, V40, P383, DOI 10.1007/s11745-006-1398-9; Diepeveen SHA, 2005, J INTERN MED, V257, P438, DOI 10.1111/j.1365-2796.2005.01484.x; Dogra G, 2006, AM J KIDNEY DIS, V48, P926, DOI 10.1053/j.ajkd.2006.08.008; Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470; Guilherme A, 2008, NAT REV MOL CELL BIO, V9, P367, DOI 10.1038/nrm2391; GUTTERIDGE JMC, 1990, TRENDS BIOCHEM SCI, V15, P129, DOI 10.1016/0968-0004(90)90206-Q; Handelman GJ, 2001, KIDNEY INT, V59, P1960, DOI 10.1046/j.1523-1755.2001.0590051960.x; Himmelfarb J, 2000, KIDNEY INT, V58, P2571, DOI 10.1046/j.1523-1755.2000.00443.x; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Kawakami A, 2006, CIRCULATION, V114, P681, DOI 10.1161/CIRCULATIONAHA.106.622514; Kennedy A, 2009, J NUTR, V139, P1, DOI 10.3945/jn.108.098269; KUKSIS A, 1975, J CHROMATOGR SCI, V13, P423, DOI 10.1093/chromsci/13.9.423; KUMANO K, 1992, ADV PERIT D, V8, P127; Lee DM, 1999, ATHEROSCLEROSIS, V146, P221, DOI 10.1016/S0021-9150(99)00136-7; Lee DM, 2002, J DIABETES COMPLICAT, V16, P294, DOI 10.1016/S1056-8727(01)00215-X; LEE DM, 2000, ATHEROSCLEROSIS, V151, P53; Liebisch G, 2006, BBA-MOL CELL BIOL L, V1761, P121, DOI 10.1016/j.bbalip.2005.12.007; McAnoy AM, 2005, J AM SOC MASS SPECTR, V16, P1498, DOI 10.1016/j.jasms.2005.04.017; Oberg BP, 2004, KIDNEY INT, V65, P1009, DOI 10.1111/j.1523-1755.2004.00465.x; Okada T, 2005, AM J CLIN NUTR, V82, P747, DOI 10.1093/ajcn/82.4.747; Ross R, 1999, AM HEART J, V138, pS419, DOI 10.1016/S0002-8703(99)70266-8; Siems W, 2002, CLIN NEPHROL, V58, pS12; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495, DOI 10.1080/07315724.2002.10719248; Singh U, 2005, ANNU REV NUTR, V25, P151, DOI 10.1146/annurev.nutr.24.012003.132446; Soejima A, 2002, AM J KIDNEY DIS, V39, P1040, DOI 10.1053/ajkd.2002.32787; SOGAMI M, 1985, J CHROMATOGR, V332, P19, DOI 10.1016/S0021-9673(01)83283-0; Staiger H, 2004, DIABETES, V53, P3209, DOI 10.2337/diabetes.53.12.3209; Suganami T, 2007, ARTERIOSCL THROM VAS, V27, P84, DOI 10.1161/01.ATV.0000251608.09329.9a; Takahashi K, 2008, AM J PHYSIOL-ENDOC M, V294, pE898, DOI 10.1152/ajpendo.00131.2007; Taki K, 2006, KIDNEY INT, V70, P218, DOI 10.1038/sj.ki.5000330; Terawaki H, 2004, KIDNEY INT, V66, P1988, DOI 10.1111/j.1523-1755.2004.00969.x; Winterbourn CC, 1999, METHOD ENZYMOL, V300, P106	41	54	58	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2011	6	7							e22360	10.1371/journal.pone.0022360	http://dx.doi.org/10.1371/journal.pone.0022360			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KC	21829457	Green Published, Green Submitted, gold			2023-01-03	WOS:000293284600010
J	Jones, DR; Salgo, P; Meltzer, J				Jones, Dean R.; Salgo, Peter; Meltzer, Joseph			Conscious Sedation for Minor Procedures in Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PRACTICE GUIDELINES; ANALGESIA; CARE		[Jones, Dean R.] Columbia Univ, Dept Anesthesiol, New York, NY 10032 USA; New York Presbyterian Hosp, New York, NY USA	Columbia University; NewYork-Presbyterian Hospital	Jones, DR (corresponding author), Columbia Univ, Dept Anesthesiol, 622 W 168th St PH5, New York, NY 10032 USA.	dean.jones@fraserhealth.ca						Bhananker SM, 2006, ANESTHESIOLOGY, V104, P228, DOI 10.1097/00000542-200602000-00005; Brown TB, 2005, AM FAM PHYSICIAN, V71, P85; Godwin SA, 2005, ANN EMERG MED, V45, P177, DOI 10.1016/j.annemergmed.2004.11.002; Gross JB, 2002, ANESTHESIOLOGY, V96, P1004; 1999, ANESTHESIOLOGY, V90, P896	5	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 23	2011	364	25					E54	U113		10.1056/NEJMvcm0800732	http://dx.doi.org/10.1056/NEJMvcm0800732			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	781MG	21696303				2023-01-03	WOS:000291936100010
J	Hamai, A; Duperrier-Amouriaux, K; Pignon, P; Raimbaud, I; Memeo, L; Colarossi, C; Canzonieri, V; Perin, T; Classe, JM; Campone, M; Jezequel, P; Campion, L; Ayyoub, M; Valmori, D				Hamai, Ahmed; Duperrier-Amouriaux, Karine; Pignon, Pascale; Raimbaud, Isabelle; Memeo, Lorenzo; Colarossi, Cristina; Canzonieri, Vincenzo; Perin, Tiziana; Classe, Jean-Marc; Campone, Mario; Jezequel, Pascal; Campion, Loic; Ayyoub, Maha; Valmori, Danila			Antibody Responses to NY-ESO-1 in Primary Breast Cancer Identify a Subtype Target for Immunotherapy	PLOS ONE			English	Article							TESTIS ANTIGEN NY-ESO-1; IMMUNE-RESPONSES; EXPRESSION; MELANOMA; EPITOPES; CELLS	The highly immunogenic human tumor antigen NY-ESO-1 (ESO) is a target of choice for anti-cancer immune therapy. In this study, we assessed spontaneous antibody (Ab) responses to ESO in a large cohort of patients with primary breast cancer (BC) and addressed the correlation between the presence of anti-ESO Ab, the expression of ESO in the tumors and their characteristics. We found detectable Ab responses to ESO in 1% of the patients. Tumors from patients with circulating Ab to ESO exhibited common characteristics, being mainly hormone receptor (HR)(-) invasive ductal carcinomas of high grade, including both HER2(-) and HER2(+) tumors. In line with these results, we detected ESO expression in 20% of primary HR(-) BC, including both ESO Ab(+) and Ab(-) patients, but not in HR(+) BC. Interestingly, whereas expression levels in ESO(+) BC were not significantly different between ESO Ab(+) and Ab(-) patients, the former had, in average, significantly higher numbers of tumor-infiltrated lymph nodes, indicating that lymph node invasion may be required for the development of spontaneous anti-tumor immune responses. Thus, the presence of ESO Ab identifies a tumor subtype of HR(-) (HER2(-) or HER2(+)) primary BC with frequent ESO expression and, together with the assessment of antigen expression in the tumor, may be instrumental for the selection of patients for whom ESO-based immunotherapy may complement standard therapy.	[Hamai, Ahmed; Duperrier-Amouriaux, Karine; Pignon, Pascale; Raimbaud, Isabelle; Ayyoub, Maha; Valmori, Danila] CLCC Rene Gauducheau, INSERM, U892, St Herblain, France; [Memeo, Lorenzo; Colarossi, Cristina] Mediterranean Inst Oncol, Pathol Unit, Catania, Italy; [Canzonieri, Vincenzo; Perin, Tiziana] IRCCS, Ctr Riferimento Oncol, Aviano, Pordenone, Italy; [Classe, Jean-Marc] CLCC Rene Gauducheau, Dept Surg, St Herblain, France; [Campone, Mario] CLCC Rene Gauducheau, Dept Med Oncol, St Herblain, France; [Jezequel, Pascal] CLCC Rene Gauducheau, Dept Oncobiol, St Herblain, France; [Campion, Loic] CLCC Rene Gauducheau, Dept Biostat, St Herblain, France; [Campone, Mario] IRT UN, INSERM, U892, Nantes, France; [Valmori, Danila] Univ Nantes, Fac Med, Nantes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Mediterranean Institute of Oncology; IRCCS Aviano (CRO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite	Hamai, A (corresponding author), CLCC Rene Gauducheau, INSERM, U892, St Herblain, France.	Maha.Ayyoub@univ-nantes.fr; Danila.Valmori@univ-nantes.fr	Ayyoub, Maha/A-2074-2017; Valmori, Danila/AAL-9766-2021; Canzonieri, Vincenzo/Z-5933-2019; Ayyoub, Maha/G-2778-2013; Canzonieri, Vincenzo/AAA-7951-2019; Perin, Tiziana/AAC-2403-2020; Campion, Loic/K-4726-2015; Jézéquel, Pascal/K-8206-2015; Ansquer, Catherine/M-1519-2015; Valmori, Danila/K-2439-2015	Ayyoub, Maha/0000-0003-2022-0898; Canzonieri, Vincenzo/0000-0001-6010-0976; Perin, Tiziana/0000-0002-9823-0167; Campion, Loic/0000-0003-4903-0908; Colarossi, Cristina/0000-0001-5395-8608; Memeo, Lorenzo/0000-0003-4251-7203	Cancer Research Institute; Ludwig Institute for Cancer Research; Institut National du Cancer; Canceropole Grand Ouest	Cancer Research Institute; Ludwig Institute for Cancer Research; Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Grand Ouest	This study was supported by the Cancer Research Institute (http://www.cancerresearch.org) and the Ludwig Institute for Cancer Research (http://www.licr.org). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; Sera and surgical tumor specimens from breast cancer patients were obtained from the tumor bank of the Institut Regional du Cancer Nantes-Atlantique, supported by the Institut National du Cancer and the Canceropole Grand Ouest. We are grateful to Drs. G. Ritter and L.J. Old for providing the recombinant proteins and for helpful advice, and to Dr. Maryam Mehrpour for providing the BC lines. We would like to thank Mrs. Nicole Andrieux for assistance with clinical data analysis, and Mr. Sandro Barbuscia for IHC staining.	Ayyoub M, 2009, P NATL ACAD SCI USA, V106, P8635, DOI 10.1073/pnas.0900621106; Burstein HJ, 2005, NEW ENGL J MED, V353, P1652, DOI 10.1056/NEJMp058197; Cheever MA, 2009, CLIN CANCER RES, V15, P5323, DOI 10.1158/1078-0432.CCR-09-0737; Hortobagyi GN, 2005, NEW ENGL J MED, V353, P1734, DOI 10.1056/NEJMe058196; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Jager E, 1998, J EXP MED, V187, P265, DOI 10.1084/jem.187.2.265; Jager E, 1999, INT J CANCER, V84, P506, DOI 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6; Jungbluth AA, 2001, INT J CANCER, V92, P856, DOI 10.1002/ijc.1282; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Odunsi K, 2003, CANCER RES, V63, P6076; Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669; Smith IE, 2003, NEW ENGL J MED, V348, P2431, DOI 10.1056/NEJMra023246; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Valmori D, 2005, CLIN IMMUNOL, V117, P24, DOI 10.1016/j.clim.2005.05.003; Valmori D, 2000, CANCER RES, V60, P4499; Valmori D, 2007, P NATL ACAD SCI USA, V104, P8947, DOI 10.1073/pnas.0703395104	21	19	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2011	6	6							e21129	10.1371/journal.pone.0021129	http://dx.doi.org/10.1371/journal.pone.0021129			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778VR	21747904	Green Published, gold, Green Submitted			2023-01-03	WOS:000291737600045
J	Wijndaele, K; Brage, S; Besson, H; Khaw, KT; Sharp, SJ; Luben, R; Bhaniani, A; Wareham, NJ; Ekelund, U				Wijndaele, Katrien; Brage, Soren; Besson, Herve; Khaw, Kay-Tee; Sharp, Stephen J.; Luben, Robert; Bhaniani, Amit; Wareham, Nicholas J.; Ekelund, Ulf			Television Viewing and Incident Cardiovascular Disease: Prospective Associations and Mediation Analysis in the EPIC Norfolk Study	PLOS ONE			English	Article							TYPE-2 DIABETES-MELLITUS; PHYSICAL-ACTIVITY; SEDENTARY BEHAVIORS; TIME SPENT; MORTALITY; RISK; OBESITY; EXERCISE; WEIGHT; GAIN	Background: Although television viewing time is detrimentally associated with intermediate cardiovascular risk factors, the relationship with incident total (i.e. combined fatal and non-fatal) cardiovascular disease (CVD), non-fatal CVD and coronary heart disease is largely unknown. This study examined whether television viewing time is associated with these three outcomes, independently of physical activity energy expenditure and other confounding variables. Methodology/Principal Findings: A population-based cohort of 12,608 men and women (aged 61.4 +/- 9.0), free from stroke, myocardial infarction and cancer at baseline in 1998-2000 were followed up until 2007 (6.9 +/- 1.9 years). Participants self-reported education, smoking, alcohol use, antihypertensive, lipid lowering and antidepressant medication, disease history, total energy intake, sleep duration, physical activity and television viewing. BMI, waist circumference, blood pressure, triglycerides, HDL cholesterol and glycated haemoglobin (HbA(1c)) were measured by standardized procedures; a clustered metabolic risk score was constructed. Every one hour/day increase in television viewing was associated with an increased hazard for total (HR = 1.06, 95% CI = 1.03-1.08; 2,620 cases), non-fatal CVD (HR = 1.06, 95% CI = 1.03-1.09; 2,134 cases), and coronary heart disease (HR = 1.08, 95% CI = 1.03-1.13; 940 cases), independent of gender, age, education, smoking, alcohol, medication, diabetes status, CVD family history, sleep duration and physical activity energy expenditure. Energy intake, BMI, waist circumference, blood pressure, triglycerides, HDL cholesterol, HbA(1c) and the clustered metabolic risk score only partially mediated these associations. Conclusions: These results indicate that the most prevalent leisure time (sedentary) behaviour, television viewing, independently contributes to increased CVD risk. Recommendations on reducing television viewing time should be considered.	[Wijndaele, Katrien; Brage, Soren; Besson, Herve; Sharp, Stephen J.; Wareham, Nicholas J.; Ekelund, Ulf] Med Res Council Epidemiol Unit, Cambridge, England; [Wijndaele, Katrien] Res Fdn Flanders, Brussels, Belgium; [Wijndaele, Katrien] Univ Ghent, Dept Movement & Sports Sci, B-9000 Ghent, Belgium; [Khaw, Kay-Tee; Luben, Robert; Bhaniani, Amit] Univ Cambridge, Inst Publ Hlth, Dept Publ Hlth & Primary Care, Cambridge, England	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Ghent University; University of Cambridge	Wijndaele, K (corresponding author), Med Res Council Epidemiol Unit, Cambridge, England.	ulf.ekelund@mrc-epid.cam.ac.uk	Ekelund, Ulf/AAE-8471-2019; Khaw, Kay-Tee/AAZ-3209-2021; Luben, Robert N/H-5519-2015; Brage, Soren/C-6415-2013; Wijndaele, Katrien/H-5465-2013	Ekelund, Ulf/0000-0003-2115-9267; Luben, Robert N/0000-0002-5088-6343; Brage, Soren/0000-0002-1265-7355; Wijndaele, Katrien/0000-0003-2199-7981	Cancer Research Campaign; Medical Research Council; Stroke Association; British Heart Foundation; Department of Health; Europe Against Cancer Programme Commission of the European Union; Ministry of Agriculture, Fisheries and Food; MRC [MC_U106179473] Funding Source: UKRI; Medical Research Council [G1000143, MC_U106179473, MC_U106179471, G0401527] Funding Source: researchfish	Cancer Research Campaign(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Stroke Association; British Heart Foundation(British Heart Foundation); Department of Health; Europe Against Cancer Programme Commission of the European Union; Ministry of Agriculture, Fisheries and Food; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	EPIC-Norfolk is funded by Cancer Research Campaign; Medical Research Council; Stroke Association; British Heart Foundation; Department of Health; Europe Against Cancer Programme Commission of the European Union and the Ministry of Agriculture, Fisheries and Food. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ainsworth BE, 2000, MED SCI SPORT EXER, V32, pS498, DOI 10.1097/00005768-200009001-00009; [Anonymous], 2010, INT J EPIDEMIOL, V26, P670, DOI [DOI 10.1093/IJE/DYQ105, 10.1093/ije/26.3.670]; *AUST BUR STAT, 2008, AUST US THEIR TIM 20; Ball K, 2002, INT J OBESITY, V26, P1570, DOI 10.1038/sj.ijo.0802150; Besson H, 2008, MED SCI SPORT EXER, V40, P1909, DOI 10.1249/MSS.0b013e318180bcad; Beunza JJ, 2007, AM J HYPERTENS, V20, P1156, DOI 10.1016/j.amjhyper.2007.06.007; Bingham SA, 1997, INT J EPIDEMIOL, V26, pS137, DOI 10.1093/ije/26.suppl_1.S137; Blanck HM, 2007, OBESITY, V15, P1578, DOI 10.1038/oby.2007.187; Brage S, 2004, DIABETES CARE, V27, P2141, DOI 10.2337/diacare.27.9.2141; CLARK BK, 2010, RELATIONSHIP TELEVIS, DOI DOI 10.1249/MSS.0B013E3182019510; Day N, 1999, BRIT J CANCER, V80, P95; Dunstan DW, 2010, CIRCULATION, V121, P384, DOI 10.1161/CIRCULATIONAHA.109.894824; Fung TT, 2000, AM J EPIDEMIOL, V152, P1171, DOI 10.1093/aje/152.12.1171; Hamilton MT, 2008, CURR CARDIOVASC RISK, V2, P292, DOI 10.1007/s12170-008-0054-8; Harris JL, 2009, HEALTH PSYCHOL, V28, P404, DOI 10.1037/a0014399; Helmerhorst HJF, 2009, DIABETES, V58, P1776, DOI 10.2337/db08-1773; Hu FB, 2003, JAMA-J AM MED ASSOC, V289, P1785, DOI 10.1001/jama.289.14.1785; Hu FB, 2001, ARCH INTERN MED, V161, P1542, DOI 10.1001/archinte.161.12.1542; Katzmarzyk PT, 2009, MED SCI SPORT EXER, V41, P998, DOI 10.1249/MSS.0b013e3181930355; Manson JE, 2002, NEW ENGL J MED, V347, P716, DOI 10.1056/NEJMoa021067; Matthews CE, 2008, AM J EPIDEMIOL, V167, P875, DOI 10.1093/aje/kwm390; Office for National Statistics, 2006, TIM US SURV 2005 WE; Patel AV, 2010, AM J EPIDEMIOL, V172, P419, DOI 10.1093/aje/kwq155; Research NM, 2000, NIELS REP TEL; Sinha S, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-74; STAMATAKIS E, 2011, EUR HEART J, V27, P1610; Sugiyama T, 2008, ANN BEHAV MED, V35, P245, DOI 10.1007/s12160-008-9017-z; Tendera M, 2006, EUR HEART J, V27, P1521, DOI 10.1093/eurheartj/ehl075; Wareham NJ, 2002, INT J EPIDEMIOL, V31, P168, DOI 10.1093/ije/31.1.168; Warren TY, 2010, MED SCI SPORT EXER, V42, P879, DOI 10.1249/MSS.0b013e3181c3aa7e	30	82	82	0	21	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2011	6	5							e20058	10.1371/journal.pone.0020058	http://dx.doi.org/10.1371/journal.pone.0020058			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	769IQ	21647437	Green Submitted, Green Published, gold			2023-01-03	WOS:000291006500022
J	Glick, S				Glick, Shimon			Personal View Withholding versus withdrawal of life support: is there an ethical difference?	BRITISH MEDICAL JOURNAL			English	Editorial Material							ASSISTED SUICIDE; EUTHANASIA; END; ATTITUDES		Ben Gurion Univ Negev, Joyce & Irving Goldman Sch Med, Lord Rabbi Immanuel Jakobovits Ctr Jewish Med Eth, IL-84105 Beer Sheva, Israel	Ben Gurion University	Glick, S (corresponding author), Ben Gurion Univ Negev, Joyce & Irving Goldman Sch Med, Lord Rabbi Immanuel Jakobovits Ctr Jewish Med Eth, IL-84105 Beer Sheva, Israel.	gshimon@bgu.ac.il						Abramson N, 1998, SOUTHERN MED J, V91, P637, DOI 10.1097/00007611-199807000-00006; Dickenson DL, 2000, J MED ETHICS, V26, P254, DOI 10.1136/jme.26.4.254; Elliott C, 1996, BRIT MED J, V313, P1088; Grossman D., 2000, PSYCHOL EFFECTS COMB; Hopkins PD, 1997, HASTINGS CENT REP, V27, P29, DOI 10.2307/3528666; Meisel A, 2000, JAMA-J AM MED ASSOC, V284, P2495, DOI 10.1001/jama.284.19.2495; Ravitsky V, 2005, BRIT MED J, V330, P415, DOI 10.1136/bmj.330.7488.415; RAVITSKY V, 2008, J JEWISH MED ETHICS, V6, P13; Rebagliato M, 2000, JAMA-J AM MED ASSOC, V284, P2451, DOI 10.1001/jama.284.19.2451	9	1	1	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 9	2011	342								d728	10.1136/bmj.d728	http://dx.doi.org/10.1136/bmj.d728			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	722AZ	21307111				2023-01-03	WOS:000287402900017
J	Dong, LF; Jameson, VJA; Tilly, D; Cerny, J; Mahdavian, E; Marin-Hernandez, A; Hernandez-Esquivel, L; Rodriguez-Enriquez, S; Stursa, J; Witting, PK; Stantic, B; Rohlena, J; Truksa, J; Kluckova, K; Dyason, JC; Ledvina, M; Salvatore, BA; Moreno-Sanchez, R; Coster, MJ; Ralph, SJ; Smith, RAJ; Neuzil, J				Dong, Lan-Feng; Jameson, Victoria J. A.; Tilly, David; Cerny, Jiri; Mahdavian, Elahe; Marin-Hernandez, Alvaro; Hernandez-Esquivel, Luz; Rodriguez-Enriquez, Sara; Stursa, Jan; Witting, Paul K.; Stantic, Bela; Rohlena, Jakub; Truksa, Jaroslav; Kluckova, Katarina; Dyason, Jeffrey C.; Ledvina, Miroslav; Salvatore, Brian A.; Moreno-Sanchez, Rafael; Coster, Mark J.; Ralph, Stephen J.; Smith, Robin A. J.; Neuzil, Jiri			Mitochondrial Targeting of Vitamin E Succinate Enhances Its Pro-apoptotic and Anti-cancer Activity via Mitochondrial Complex II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TOCOPHERYL SUCCINATE; BREAST-CANCER CELLS; E ANALOGS; RESPIRATORY-CHAIN; OXIDATIVE STRESS; BINDING SITE; DEHYDROGENASE; UBIQUINONE; ANTIOXIDANT; GROWTH	Mitochondrial complex II (CII) has been recently identified as a novel target for anti-cancer drugs. Mitochondrially targeted vitamin E succinate (MitoVES) is modified so that it is preferentially localized to mitochondria, greatly enhancing its pro-apoptotic and anti-cancer activity. Using genetically manipulated cells, MitoVES caused apoptosis and generation of reactive oxygen species (ROS) in CII-proficient malignant cells but not their CII-dysfunctional counterparts. MitoVES inhibited the succinate dehydrogenase (SDH) activity of CII with IC50 of 80 mu M, whereas the electron transfer from CII to CIII was inhibited with IC50 of 1.5 mu M. The agent had no effect either on the enzymatic activity of CI or on electron transfer from CI to CIII. Over 24 h, MitoVES caused stabilization of the oxygen-dependent destruction domain of HIF1 alpha fused to GFP, indicating promotion of the state of pseudohypoxia. Molecular modeling predicted the succinyl group anchored into the proximal CII ubiquinone (UbQ)-binding site and successively reduced interaction energies for serially shorter phytyl chain homologs of MitoVES correlated with their lower effects on apoptosis induction, ROS generation, and SDH activity. Mutation of the UbQ-binding Ser(68) within the proximal site of the CII SDHC subunit (S68A or S68L) suppressed both ROS generation and apoptosis induction by MitoVES. In vivo studies indicated that MitoVES also acts by causing pseudohypoxia in the context of tumor suppression. We propose that mitochondrial targeting of VES with an 11-carbon chain localizes the agent into an ideal position across the interface of the mitochondrial inner membrane and matrix, optimizing its biological effects as an anti-cancer drug.	[Neuzil, Jiri] Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Griffith Hlth Inst, Southport, Qld 4222, Australia; [Stantic, Bela] Griffith Univ, Inst Integrated & Intelligent Syst, Southport, Qld 4222, Australia; [Dyason, Jeffrey C.; Neuzil, Jiri] Griffith Univ, Inst Glyc, Southport, Qld 4222, Australia; [Jameson, Victoria J. A.; Smith, Robin A. J.] Univ Otago, Dept Chem, Dunedin 9016, New Zealand; [Tilly, David; Coster, Mark J.] Griffith Univ, Eskitis Inst Cell & Mol Therapies, Nathan, Qld 4111, Australia; [Cerny, Jiri; Rohlena, Jakub; Truksa, Jaroslav; Kluckova, Katarina] Acad Sci Czech Republ, Inst Biotechnol, Prague 14220, Czech Republic; [Stursa, Jan; Ledvina, Miroslav] Acad Sci Czech Republ, Inst Organ Chem & Biochem, Prague 14220, Czech Republic; [Mahdavian, Elahe; Salvatore, Brian A.] Louisiana State Univ, Dept Chem & Phys, Shreveport, LA 71115 USA; [Marin-Hernandez, Alvaro; Hernandez-Esquivel, Luz; Rodriguez-Enriquez, Sara; Moreno-Sanchez, Rafael] Natl Inst Cardiol, Dept Biochem, Mexico City 14080, DF, Mexico; [Witting, Paul K.] Univ Sydney, Sydney Med Sch, Bosch Res Inst, Discipline Pathol, Sydney, NSW 2006, Australia	Griffith University; Menzies Health Institute Queensland; Griffith University; Griffith University; University of Otago; Griffith University; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; National Institute of Cardiology - Mexico; Bosch; University of Sydney	Neuzil, J (corresponding author), Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Griffith Hlth Inst, Griffith Univ Gold Coast Campus,Parklands Av, Southport, Qld 4222, Australia.	j.neuzil@griffith.edu.au	Truksa, Jaroslav/G-9454-2014; Coster, Mark/C-4621-2008; Witting, Paul/ABD-2053-2020; DONG, LANFENG/S-8805-2019; Kluckova, Katarina/H-4802-2014; Rohlena, Jakub/H-6699-2014; Ralph, Stephen J./AAE-4888-2019; Dyason, Jeffrey C/L-5534-2014; Witting, Paul/L-9786-2019; Kluckova, Katarina/ABF-2155-2020; Truksa, Jaroslav/AAB-5089-2020; Černý, Jiří/I-4733-2012; Neuzil, Jiri/H-7204-2014; Moreno-Sanchez, Rafael/A-3158-2011; Stursa, Jan/J-4255-2014; RODRIGUEZ-ENRIQUEZ, SARA/I-8376-2017	Truksa, Jaroslav/0000-0002-8967-7354; Coster, Mark/0000-0002-0910-6819; Witting, Paul/0000-0003-2237-7004; Kluckova, Katarina/0000-0002-9693-7708; Rohlena, Jakub/0000-0001-5427-6502; Ralph, Stephen J./0000-0002-4335-092X; Truksa, Jaroslav/0000-0002-8967-7354; Černý, Jiří/0000-0002-1969-9304; Neuzil, Jiri/0000-0002-2478-2460; Moreno-Sanchez, Rafael/0000-0002-9587-7184; Dong, Lanfeng/0000-0002-9857-6352; RODRIGUEZ-ENRIQUEZ, SARA/0000-0002-0822-1233; Tilly, David/0000-0002-4859-961X; Marin-Hernandez, Alvaro/0000-0002-7968-7225	Australian Research Council; Cancer Council Queensland; National Breast Cancer Foundation; Grant Agency of the Czech Republic [204/08/0811, P301/10/1937]; Grant Agency of the Academy of Sciences of the Czech Republic [IAA500520702, KJB500970904, KAN200520703]; Griffith Health Institute; Otago University Research Grants Committee; Consejo Nacional de Ciencia y Tecnologia-Mexico [80534, 20675]; National Institutes of Health, NCRR [P20RR016456]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016456] Funding Source: NIH RePORTER	Australian Research Council(Australian Research Council); Cancer Council Queensland(Cancer Council Queensland); National Breast Cancer Foundation; Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Grant Agency of the Academy of Sciences of the Czech Republic(Czech Academy of SciencesGrant Agency of the Czech Republic); Griffith Health Institute; Otago University Research Grants Committee; Consejo Nacional de Ciencia y Tecnologia-Mexico(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); National Institutes of Health, NCRR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by grants from the Australian Research Council, the Cancer Council Queensland, the National Breast Cancer Foundation, Grant Agency of the Czech Republic Grants 204/08/0811 and P301/10/1937, Grant Agency of the Academy of Sciences of the Czech Republic Grants IAA500520702, KJB500970904, and KAN200520703) (to J. N.), the Griffith Health Institute (to L.-F.D.), the Otago University Research Grants Committee (to R. A. J. S.), Consejo Nacional de Ciencia y Tecnologia-Mexico Grants 80534 and 20675 (to R.M.-S. and S. R.-E.), and National Institutes of Health, NCRR, Grant P20RR016456 (to E. M. and B. A. S.).	Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; BAYLY CI, 1993, J PHYS CHEM-US, V97, P10269, DOI 10.1021/j100142a004; Belousov VV, 2006, NAT METHODS, V3, P281, DOI 10.1038/NMETH866; BIASSUTTO L, 2010, MITOCHONDRI IN PRESS; Biasutto L, 2010, BBA-BIOENERGETICS, V1797, P189, DOI 10.1016/j.bbabio.2009.10.001; Cervera AM, 2008, CANCER RES, V68, P4058, DOI 10.1158/0008-5472.CAN-07-5580; Covian R, 2001, EUR J BIOCHEM, V268, P5783, DOI 10.1046/j.0014-2956.2001.02521.x; DAVIS S, 1985, J BIOL CHEM, V260, P3844; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038/onc.2008.69; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Dong LF, 2009, CLIN CANCER RES, V15, P1593, DOI 10.1158/1078-0432.CCR-08-2439; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Fantin VR, 2006, ONCOGENE, V25, P4787, DOI 10.1038/sj.onc.1209599; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137; Galluzzi L, 2010, MOL ASPECTS MED, V31, P1, DOI 10.1016/j.mam.2009.08.002; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Hahn T, 2006, CANCER RES, V66, P9374, DOI 10.1158/0008-5472.CAN-06-2403; Hawkins BJ, 2010, J BIOL CHEM, V285, P26494, DOI 10.1074/jbc.M110.143164; Hayden EC, 2008, NATURE, V455, P158; Ishii T, 2005, CANCER RES, V65, P203; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Jasso-Chavez R, 2001, ARCH BIOCHEM BIOPHYS, V390, P295, DOI 10.1006/abbi.2001.2353; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; King A, 2006, ONCOGENE, V25, P4675, DOI 10.1038/sj.onc.1209594; Krieger E, 2002, PROTEINS, V47, P393, DOI 10.1002/prot.10104; Lawson KA, 2003, MOL CANCER THER, V2, P437; Lemarie A, 2009, MITOCHONDRION, V9, P254, DOI 10.1016/j.mito.2009.03.004; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; MAIOROV VN, 1994, J MOL BIOL, V235, P625, DOI 10.1006/jmbi.1994.1017; Malafa MP, 2002, SURGERY, V131, P85, DOI 10.1067/msy.2002.119191; Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Murphy MP, 2007, ANNU REV PHARMACOL, V47, P629, DOI 10.1146/annurev.pharmtox.47.120505.105110; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Neuzil J, 2007, MOL ASPECTS MED, V28, P607, DOI 10.1016/j.mam.2007.02.003; Neuzil J, 2007, REDOX REP, V12, P148, DOI 10.1179/135100007X200227; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124/mol.106.030122; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Peczkowska M, 2008, NAT CLIN PRACT ENDOC, V4, P111, DOI 10.1038/ncpendmet0726; Piantadosi CA, 2008, J BIOL CHEM, V283, P10967, DOI 10.1074/jbc.M709741200; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Prochazka L, 2010, APOPTOSIS, V15, P782, DOI 10.1007/s10495-010-0482-z; Rodriguez-Cuenca S, 2010, FREE RADICAL BIO MED, V48, P161, DOI 10.1016/j.freeradbiomed.2009.10.039; Rodriguez-Enriquez S, 2009, MOL NUTR FOOD RES, V53, P29, DOI 10.1002/mnfr.200700470; Schiavi F, 2005, JAMA-J AM MED ASSOC, V294, P2057, DOI 10.1001/jama.294.16.2057; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Shiau CW, 2006, J BIOL CHEM, V281, P11819, DOI 10.1074/jbc.M511015200; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Stapelberg M, 2005, J BIOL CHEM, V280, P25369, DOI 10.1074/jbc.M414498200; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Szeto SSW, 2007, J BIOL CHEM, V282, P27518, DOI 10.1074/jbc.M700601200; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Twombly R, 2005, J NATL CANCER I, V97, P330, DOI 10.1093/jnci/97.5.330; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; Wang JM, 2000, J COMPUT CHEM, V21, P1049, DOI 10.1002/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Yang XD, 1998, J BIOL CHEM, V273, P31916, DOI 10.1074/jbc.273.48.31916; Yu WP, 2003, CANCER RES, V63, P2483	71	149	156	1	47	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 4	2011	286	5					3717	3728		10.1074/jbc.M110.186643	http://dx.doi.org/10.1074/jbc.M110.186643			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	712GE	21059645	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000286653200054
J	Hudson, T				Hudson, Tom			Genomics and Clinical Relevance	SCIENCE			English	Editorial Material									Ontario Inst Canc Res, Toronto, ON, Canada	Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates	Hudson, T (corresponding author), Ontario Inst Canc Res, Toronto, ON, Canada.								0	2	5	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	2011	331	6017					547	547		10.1126/science.1202572	http://dx.doi.org/10.1126/science.1202572			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	715ZE	21292965				2023-01-03	WOS:000286933600040
J	Lee, CH; Wang, JD; Chen, PC				Lee, Chang-Hsing; Wang, Jung-Der; Chen, Pau-Chung			Risk of Liver Injury Associated with Chinese Herbal Products Containing Radix bupleuri in 639,779 Patients with Hepatitis B Virus Infection	PLOS ONE			English	Article							AUTOIMMUNE HEPATITIS; MEDICINE; TAIWAN	Background: Chinese herbal products (CHPs) containing Radix bupleuri are often prescribed for chronic hepatitis. There have been no epidemiological studies in populations with hepatitis B virus (HBV) infection. Our study was conducted to determine the association between the use of CHPs containing Radix bupleuri and the risk of hospitalisation related to liver injury among HBV-infected patients in Taiwan. Methods: From a total of 639,779 patients with diagnoses related to HBV infection, we included hospitalised adult cases with a primary diagnosis of liver injury in the database of Taiwan's national health insurance during the period 1997-2004. Case-control and case-crossover designs were used to assess the risk of hospitalisation with conditional logistic regression models constructed and adjusted for 270 conventionally hepatotoxic drugs. Cumulative doses of these CHPs and Radix bupleuri were assessed for any dose-response relationship. Findings: In total, we collected 1,080 cases fulfilled the inclusion criteria. In the case-control design, the adjusted odds ratio was 1.90 (95% confidence interval [CI]: 1.30 to 2.77). The risks from prescribing the CHPs Xiao-Chai-Hu-Tang and Long-Dan-Xie-Gan-Tang were significantly high, and dose-response relationships were found. The risk of adding each 19 gm dose of Radix bupleuri was 2.19 (95% CI: 1.66 to 2.89). The results using the case-crossover design remained similar. Conclusions: Prescribing Xiao-Chai-Hu-Tang, Long-Dan-Xie-Gan-Tang, or CHPs containing more than 19 gram of Radix bupleuri in HBV-infected patients might increase their risks of liver injury. Further studies are indicated to corroborate the above findings.	[Lee, Chang-Hsing; Wang, Jung-Der; Chen, Pau-Chung] Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei 10764, Taiwan; [Lee, Chang-Hsing] Ton Yen Gen Hosp, Dept Occupat Med, Hsinchu, Taiwan; [Wang, Jung-Der] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan; [Wang, Jung-Der] Natl Taiwan Univ Hosp, Dept Environm & Occupat Med, Taipei, Taiwan	National Taiwan University; National Cheng Kung University; National Taiwan University; National Taiwan University Hospital	Lee, CH (corresponding author), Natl Taiwan Univ, Coll Publ Hlth, Inst Occupat Med & Ind Hyg, Taipei 10764, Taiwan.	pchen@ntu.edu.tw	Chen, Pau-Chung/H-5686-2011	Chen, Pau-Chung/0000-0002-6242-5974	National Science Council, Taiwan [NSC98-2314-B-002-129]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan)	Funding was provided by the National Science Council (NSC98-2314-B-002-129), Taiwan (http://web1.nsc.gov.tw/mp.aspx?mp=7). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALLEN BR, 1990, LANCET, V336, P177, DOI 10.1016/0140-6736(90)91696-8; Borum ML, 2001, AM J GASTROENTEROL, V96, P1654, DOI 10.1111/j.1572-0241.2001.03827.x; *CDCP, 2008, GUID COMM DIS SURV; Centers for Disease Control and Prevention, 1979, INT CLASS DIS 9 REV; Chen CJ, 2004, HEPATOLOGY, V39, P1196, DOI 10.1002/hep.20222; Chen FP, 2008, J ETHNOPHARMACOL, V117, P84, DOI 10.1016/j.jep.2008.01.018; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Haller CA, 2002, WESTERN J MED, V176, P39, DOI 10.1136/ewjm.176.1.39; Hsu Li-Ming, 2006, J Chin Med Assoc, V69, P86, DOI 10.1016/S1726-4901(09)70119-4; Ikegami F, 2006, HUM EXP TOXICOL, V25, P481, DOI 10.1191/0960327106het654oa; ITOH S, 1995, DIGEST DIS SCI, V40, P1845, DOI 10.1007/BF02212712; Kamiyama T, 1997, AM J GASTROENTEROL, V92, P703; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Larrey D, 2002, SEMIN LIVER DIS, V22, P145, DOI 10.1055/s-2002-30101; Lee CH, 2006, J ALTERN COMPLEM MED, V12, P233, DOI 10.1089/acm.2006.12.233; Mantani N, 2002, PHYTOMEDICINE, V9, P280, DOI 10.1078/0944-7113-00141; Melchart D, 1999, JAMA-J AM MED ASSOC, V282, P28, DOI 10.1001/jama.282.1.28; Modi AA, 2007, ANTIVIR THER, V12, P285; National Health Research Institutes, 2003, NAT HLTH INS RES DAT; OKA H, 1995, CANCER-AM CANCER SOC, V76, P743, DOI 10.1002/1097-0142(19950901)76:5<743::AID-CNCR2820760506>3.0.CO;2-V; Park GJH, 2001, J GASTROEN HEPATOL, V16, P115, DOI 10.1046/j.1440-1746.2001.02309.x; *THOMS HEALTHC, 2006, MICROMEDEX HEALTHC S, V127; *WHO, 1999, WHO MON MED PLANTS R; Wong VWS, 2005, COMPLEMENT THER MED, V13, P175, DOI 10.1016/j.ctim.2005.04.006; Yuen MF, 2006, ALIMENT PHARM THER, V24, P1179, DOI 10.1111/j.1365-2036.2006.03111.x; 2000, J FOOD DRUG ANAL, V8, P270	26	36	38	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 12	2011	6	1							e16064	10.1371/journal.pone.0016064	http://dx.doi.org/10.1371/journal.pone.0016064			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710LX	21264326	Green Submitted, Green Published, gold			2023-01-03	WOS:000286514300005
J	Richardson, PG				Richardson, Paul G.			A new standard of care in newly diagnosed multiple myeloma	LANCET			English	Editorial Material							STEM-CELL TRANSPLANTATION; PLUS DEXAMETHASONE; ELDERLY-PATIENTS; CLINICAL-TRIAL; THALIDOMIDE; BORTEZOMIB; PREDNISONE; MELPHALAN; INDUCTION; THERAPY		[Richardson, Paul G.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Richardson, Paul G.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute	Richardson, PG (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.	paul_richardson@dfci.harvard.edu						[Anonymous], ASH ANN M; ATTAL M, 2010, P SOC AM CLIN ONCO S, V28, P8018; Cavo M, 2005, BLOOD, V106, P35, DOI 10.1182/blood-2005-02-0522; CAVO M, 2010, LANCET          1210, DOI DOI 10.1016/S0140-6736(10)61424-9; Facon T, 2007, LANCET, V370, P1209, DOI 10.1016/S0140-6736(07)61537-2; Harousseau JL, 2010, J CLIN ONCOL, V28, P4621, DOI 10.1200/JCO.2009.27.9158; HAROUSSEAU JL, 2009, 51 AM SOC HEM ANN M, P354; JAKUBOWIAK AJ, 2009, 51 AM SOC HEM ANN M, P132; KUMAR S, 2009, 51 AM SOC HEM ANN M, P127; MCCARTHY PL, 2010, P SOC AM CLIN ONCO S, V28, P8017; Palumbo A, 2008, BLOOD, V112, P3107, DOI 10.1182/blood-2008-04-149427; Rajkumar SV, 2010, LANCET ONCOL, V11, P29, DOI 10.1016/S1470-2045(09)70284-0; Rajkumar SV, 2006, J CLIN ONCOL, V24, P431, DOI 10.1200/JCO.2005.03.0221; Reeder CB, 2009, LEUKEMIA, V23, P1337, DOI 10.1038/leu.2009.26; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479	16	0	0	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 18	2010	376	9758					2043	2044		10.1016/S0140-6736(10)62177-0	http://dx.doi.org/10.1016/S0140-6736(10)62177-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	702LA	21146204				2023-01-03	WOS:000285895000004
J	Moon, JC; Flett, AS; Godman, BB; Grosso, AM; Wierzbicki, AS				Moon, James C.; Flett, Andrew S.; Godman, Brian B.; Grosso, Anthony M.; Wierzbicki, Anthony S.			Getting better value from the NHS drug budget	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SWITCHING STATINS; INITIATIVES; SIMVASTATIN; EFFICIENCY; REFORMS; ENHANCE; IMPACT; COST		[Moon, James C.; Flett, Andrew S.] Univ Coll London Hosp, Heart Hosp, London W1M 8PH, England; [Godman, Brian B.] Mario Negri Inst Pharmacol Res, Milan, Italy; [Godman, Brian B.] Karolinska Inst, Dept Lab Med, Div Clin Pharmacol, Stockholm, Sweden; [Grosso, Anthony M.] Univ Coll London Hosp, Dept Pharm, London NW1 2PG, England; [Wierzbicki, Anthony S.] Guys & St Thomas NHS Trust, St Thomas Hosp, London SE1 7EH, England	University College London Hospitals NHS Foundation Trust; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Karolinska Institutet; University College London Hospitals NHS Foundation Trust; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust	Moon, JC (corresponding author), Univ Coll London Hosp, Heart Hosp, London W1M 8PH, England.	james.moon@uclh.nhs.uk	Wierzbicki, Anthony/AAP-1735-2020; Godman, Brian/R-8897-2019; Moon, James/AAA-9905-2020; Moon, James C/F-1031-2014	Wierzbicki, Anthony/0000-0003-2756-372X; Moon, James/0000-0001-8071-1491; Moon, James C/0000-0001-8071-1491				British Hypertension Society, 2010, GUID MAN HYP; Erhardt LR, 2005, INT J CLIN PRACT, V59, P571, DOI 10.1111/j.1368-5031.2005.00513.x; Godman B, 2008, PHARMACOECONOMICS, V26, P91, DOI 10.2165/00019053-200826020-00001; Godman B, 2010, PHARMACEUTICALS, V3, P2470, DOI 10.3390/ph3082470; Godman B, 2010, EXPERT REV PHARM OUT, V10, P199, DOI [10.1586/erp.10.6, 10.1586/ERP.10.6]; Godman Brian, 2009, Expert Rev Pharmacoecon Outcomes Res, V9, P475, DOI 10.1586/erp.09.43; Gumbs PD, 2007, BRIT J CLIN PHARMACO, V64, P680, DOI 10.1111/j.1365-2125.2007.02958.x; Kjeldsen SE, 2010, J HUM HYPERTENS, V24, P263, DOI 10.1038/jhh.2009.77; Konstam MA, 2009, LANCET, V374, P1840, DOI 10.1016/S0140-6736(09)61913-9; Light D., 2010, RISKS PRESCRIPTION D; McGinn D, 2010, EXPERT REV PHARM OUT, V10, P73, DOI [10.1586/erp.09.73, 10.1586/ERP.09.73]; Meredith PA, 2010, J HUM HYPERTENS, V24, P525, DOI 10.1038/jhh.2009.99; Moon JC, 2006, BMJ-BRIT MED J, V332, P1344, DOI 10.1136/bmj.332.7554.1344; NHS Information Centre, 2010, PRESCR COST AN 2009; Prosser H, 2005, SOC SCI MED, V60, P1335, DOI 10.1016/j.socscimed.2004.07.013; Sakshaug S, 2007, BRIT J CLIN PHARMACO, V64, P476, DOI 10.1111/j.1365-2125.2007.02907.x; Sermet C, 2010, APPL HEALTH ECON HEA, V8, P7, DOI 10.2165/11313900-000000000-00000; Universtiy College London Hospital NHS Trust, 2010, UCLH GUID ANG 2 REC; Usher-Smith J, 2008, INT J CLIN PRACT, V62, P480, DOI 10.1111/j.1742-1241.2007.01690.x; Wettermark B, 2008, PHARMACOECONOMICS, V26, P537, DOI 10.2165/00019053-200826070-00001; Wright J.M, 2008, COCHRANE DB SYST REV, V2008, DOI [10.1002/14651858.CD003822.pub2., DOI 10.1002/14651858.CD003822.PUB2]	21	14	15	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2010	341								c6449	10.1136/bmj.c6449	http://dx.doi.org/10.1136/bmj.c6449			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	697XO	21169320				2023-01-03	WOS:000285553300006
J	Shrank, WH; Choudhry, NK; Fischer, MA; Avorn, J; Powell, M; Schneeweiss, S; Liberman, JN; Dollear, T; Brennan, TA; Brookhart, MA				Shrank, William H.; Choudhry, Niteesh K.; Fischer, Michael A.; Avorn, Jerry; Powell, Mark; Schneeweiss, Sebastian; Liberman, Joshua N.; Dollear, Timothy; Brennan, Troyen A.; Brookhart, M. Alan			The Epidemiology of Prescriptions Abandoned at the Pharmacy	ANNALS OF INTERNAL MEDICINE			English	Article							MEDICATION ADHERENCE; NONADHERENCE; PERSISTENCE; MORTALITY; VALIDITY; DRUGS; PROXY	Background: Picking up prescriptions is an essential but previously unstudied component of adherence for patients who use retail pharmacies. Understanding the epidemiology and correlates of prescription abandonment may have an important effect on health care quality. Objective: To evaluate the rates and correlates of prescription abandonment. Design: Cross-sectional cohort study. Setting: One large retail pharmacy chain and one large pharmacy benefits manager (PBM) in the United States. Measurements: Prescriptions bottled at the retail pharmacy chain between 1 July 2008 and 30 September 2008 by patients insured by the PBM were identified. Pharmacy data were used to identify medications that were bottled and either dispensed or returned to stock (RTS) or abandoned. Data from the PBM were used to identify previous or subsequent dispensing at any pharmacy. The first (index) prescription in a class for each patient was assigned to 1 of 3 mutually exclusive outcomes: filled, RTS, or RTS with fill (in the 30 days after abandonment, the patient purchased a prescription for a medication in the same medication class at any pharmacy). Outcome rates were assessed by drug class, and generalized estimating equations were used to assess patient, neighborhood, insurance, and prescription characteristics associated with abandonment. Results: 10 349 139 index prescriptions were filled by 5 249 380 patients. Overall, 3.27% of index prescriptions were abandoned; 1.77% were RTS and 1.50% were RTS with fill. Patients were least likely to abandon opiate prescriptions. Prescriptions with copayments of $40 to $50 and prescriptions costing more than $50 were 3.40 times and 4.68 times more likely, respectively, to be abandoned than prescriptions with no copayment (P < 0.001 for both comparisons). New users of medications had a 2.74 times greater probability of abandonment than prevalent users (P < 0.001), and prescriptions delivered electronically were 1.64 times more likely to be abandoned than those that were not electronic (P < 0.001). Limitation: The study included mainly insured patients and analyzed data collected during the summer months only. Conclusion: Although prescription abandonment represents a small component of medication nonadherence, the correlates to abandonment highlight important opportunities to intervene and thereby improve medication taking.	[Shrank, William H.] Brigham & Womens Hosp, Boston, MA 02120 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Ctr Amer Polit Studies, Cambridge, MA 02138 USA; CVS Caremark, Woonsocket, RI USA; CVS Caremark, Hunt Valley, MD USA; Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; University of North Carolina; University of North Carolina Chapel Hill	Shrank, WH (corresponding author), Brigham & Womens Hosp, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	wshrank@partners.org			CVS Caremark; National Heart, Lung, and Blood Institute [HL-090505]; National Institutes of Health [AG-027400]; Pfizer; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL090505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K25AG027400] Funding Source: NIH RePORTER	CVS Caremark; National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By a research grant from CVS Caremark. Dr. Shrank is supported by a career development award from the National Heart, Lung, and Blood Institute (HL-090505), and Dr. Brookhart is supported by a career development grant from the National Institutes of Health (AG-027400).; Dr. Shrank: Grants (money to institution): National Institutes of Health (National Heart, Lung, and Blood career development award), CVS Caremark. Drs. Choudhry, Fischer, Avorn, and Brookhart: Grants (money to institution): CVS Caremark. Dr. Schneeweiss: Grants (money to institution): CVS Caremark. Board membership: HealthCore. Consultancy: WHISCON, RTI Health Solutions, The Lewin Group. Grants/grants pending: Pfizer. Drs. Liberman, Dollear, and Brennan: Employment: CVS Caremark. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOf InterestForms.do?msNum = M10-1125.	Avorn J, 1998, JAMA-J AM MED ASSOC, V279, P1458, DOI 10.1001/jama.279.18.1458; Benner JS, 2002, JAMA-J AM MED ASSOC, V288, P455, DOI 10.1001/jama.288.4.455; Chernew ME, 2007, HEALTH AFFAIR, V26, pW195, DOI 10.1377/hlthaff.26.2.w195; Choudhry NK, 2007, HEALTH AFFAIR, V26, P186, DOI 10.1377/hlthaff.26.1.186; CHOUDHRY NK, 2010, ARCH INTERN IN PRESS, P27953; Fischer MA, 2010, J GEN INTERN MED, V25, P284, DOI 10.1007/s11606-010-1253-9; Gellad WF, 2009, HEALTH SERV RES, V44, P606, DOI 10.1111/j.1475-6773.2008.00917.x; Geronimus AT, 1998, AM J EPIDEMIOL, V148, P475; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; *GRANT THORNT, 2007, COST DISP STUD IND C, P27953; Ho PM, 2006, ARCH INTERN MED, V166, P1836, DOI 10.1001/archinte.166.17.1836; Institute of Medicine, 2009, IN NAT PRIOR COMP EF; *KAIS FAM FDN, US PRESCR DRUGS, P27953; Kripalani S, 2007, ARCH INTERN MED, V167, P540, DOI 10.1001/archinte.167.6.540; Lee JY, 1996, AM J HYPERTENS, V9, P719, DOI 10.1016/0895-7061(96)00056-8; Lee TJ, 2004, ALIMENT PHARM THER, V20, P1241, DOI 10.1111/j.1365-2036.2004.02289.x; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Organization WH, 2003, ADHERENCE LONG TERM; Rasmussen JN, 2007, JAMA-J AM MED ASSOC, V297, P177, DOI 10.1001/jama.297.2.177; Schneeweiss S, 2001, AM J EPIDEMIOL, V154, P854, DOI 10.1093/aje/154.9.854; Shah NR, 2009, J GEN INTERN MED, V24, P233, DOI 10.1007/s11606-008-0870-z; Shrank WH, 2006, ARCH INTERN MED, V166, P332, DOI 10.1001/archinte.166.3.332; Shrank WH, 2005, AM J MANAG CARE, V11, P16; Shrank WH, 2006, ANN PHARMACOTHER, V40, P1534, DOI 10.1345/aph.1H158; Shrank WH, 2009, MED CARE, V47, P319, DOI 10.1097/MLR.0b013e31818af850; Soobader MJ, 2001, AM J PUBLIC HEALTH, V91, P632, DOI 10.2105/AJPH.91.4.632; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; U. S. Bureau of the Census, 2002, CENS 2000 URB RUR CL	28	79	79	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	2010	153	10					633	640		10.7326/0003-4819-153-10-201011160-00005	http://dx.doi.org/10.7326/0003-4819-153-10-201011160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680ES	21079218				2023-01-03	WOS:000284215800015
J	Hingorani, AD; Shah, T; Kumari, M; Sofat, R; Smeeth, L				Hingorani, Aroon D.; Shah, Tina; Kumari, Meena; Sofat, Reecha; Smeeth, Liam			Science, medicine, and the future Translating genomics into improved healthcare	BMJ-BRITISH MEDICAL JOURNAL			English	Review							C-REACTIVE PROTEIN; FAMILIAL HYPERCHOLESTEROLEMIA; WIDE ASSOCIATION; LINKAGE; METAANALYSIS; SEQUENCE; DISEASE; LOCI		[Smeeth, Liam] Univ London London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, London WC1E 7HT, England; [Hingorani, Aroon D.; Kumari, Meena] UCL, Dept Epidemiol & Publ Hlth, Genet Epidemiol Grp, London WC1E 6BT, England; [Hingorani, Aroon D.; Shah, Tina; Sofat, Reecha] UCL, Div Med, Ctr Clin Pharmacol, London WC1E 6BT, England	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; University of London; University College London	Smeeth, L (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Noncommunicable Dis Epidemiol, Keppel St, London WC1E 7HT, England.	liam.smeeth@lshtm.ac.uk	; Smeeth, Liam/X-5862-2018	Sofat, Reecha/0000-0002-0242-6115; Shah, Tina/0000-0001-7724-7210; Hingorani, Aroon/0000-0001-8365-0081; Smeeth, Liam/0000-0002-9168-6022; Kumari, Meena/0000-0001-9716-1035	Wellcome Trust [082178]; British Heart Foundation [FS05/125]; MRC; Pfizer; MRC [G0902037] Funding Source: UKRI; British Heart Foundation [RG/07/008/23674] Funding Source: researchfish; Medical Research Council [G8802774, G0100222, G19/35, G0902037] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); British Heart Foundation(British Heart Foundation); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Pfizer(Pfizer); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	LS is supported by a Wellcome Trust Senior Clinical Fellowship (082178). AH is supported by a senior fellowship from the British Heart Foundation (FS05/125) and is the principal investigator on a MRC Biomarker Award with funding from Pfizer. The funders had no role in the manuscript.	Annes JP, 2010, NEW ENGL J MED, V363, P1100, DOI 10.1056/NEJMp1006029; BENLIAN P, 1990, ANN GENET-PARIS, V33, P65; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Casas JP, 2008, J INTERN MED, V264, P295, DOI 10.1111/j.1365-2796.2008.02015.x; Casas JP, 2006, INT J EPIDEMIOL, V35, P922, DOI 10.1093/ije/dyl041; De La Vega FM, 2002, BIOTECHNIQUES, P48; Duggal P, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-516; Edelman E, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4253; Elliott P, 2009, JAMA-J AM MED ASSOC, V302, P37, DOI 10.1001/jama.2009.954; Freeman BD, 2000, SURGERY, V128, P281, DOI 10.1067/msy.2000.107283; Haddad L, 1999, J LIPID RES, V40, P1113; Heath KE, 2001, EUR J HUM GENET, V9, P244, DOI 10.1038/sj.ejhg.5200633; Hingorani A, 2005, LANCET, V366, P1906, DOI 10.1016/S0140-6736(05)67767-7; Holmes MV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007960; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kong A, 2009, NATURE, V462, P868, DOI 10.1038/nature08625; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; McPherson JD, 2001, NATURE, V409, P934, DOI 10.1038/35057157; Mendel G, 1865, EXPT PLANT HYBRIDIZA; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Sofat R, 2010, CIRCULATION, V121, P52, DOI 10.1161/CIRCULATIONAHA.109.865444; Talmud PJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b4838; Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; WHITE R, 1989, GENOME, V31, P1066, DOI 10.1139/g89-183; Zeggini E, 2008, NAT GENET, V40, P638, DOI 10.1038/ng.120	35	13	13	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2010	341								c5945	10.1136/bmj.c5945	http://dx.doi.org/10.1136/bmj.c5945			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	678DN	21056961	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000284052400007
J	Jones, CU; Hunt, D; McGowan, DG; Amin, MB; Chetner, MP; Bruner, DW; Leibenhaut, MH; Husain, SM; Rotman, M; Souhami, L; Sandler, HM; Shipley, WU				Jones, Christopher U.; Hunt, Daniel; McGowan, David G.; Amin, Mahul B.; Chetner, Michael P.; Bruner, Deborah W.; Leibenhaut, Mark H.; Husain, Siraj M.; Rotman, Marvin; Souhami, Luis; Sandler, Howard M.; Shipley, William U.			Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOSE-ESCALATION TRIAL; ONCOLOGY GROUP RTOG; RADIATION-THERAPY; RADICAL PROSTATECTOMY; HORMONAL-THERAPY; FOLLOW-UP; SUPPRESSION; CARCINOMA; SURVIVAL; DISEASE	BACKGROUND It is not known whether short-term androgen-deprivation therapy (ADT) before and during radiotherapy improves cancer control and overall survival among patients with early, localized prostate adenocarcinoma. METHODS From 1994 through 2001, we randomly assigned 1979 eligible patients with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a prostate-specific antigen (PSA) level of 20 ng per milliliter or less to radiotherapy alone (992 patients) or radiotherapy with 4 months of total androgen suppression starting 2 months before radiotherapy (radiotherapy plus short-term ADT, 987 patients). The primary end point was overall survival. Secondary end points included disease-specific mortality, distant metastases, biochemical failure (an increasing level of PSA), and the rate of positive findings on repeat prostate biopsy at 2 years. RESULTS The median follow-up period was 9.1 years. The 10-year rate of overall survival was 62% among patients receiving radiotherapy plus short-term ADT (the combined-therapy group), as compared with 57% among patients receiving radiotherapy alone (hazard ratio for death with radiotherapy alone, 1.17; P = 0.03). The addition of short-term ADT was associated with a decrease in the 10-year disease-specific mortality from 8% to 4% (hazard ratio for radiotherapy alone, 1.87; P = 0.001). Biochemical failure, distant metastases, and the rate of positive findings on repeat prostate biopsy at 2 years were significantly improved with radiotherapy plus short-term ADT. Acute and late radiation-induced toxic effects were similar in the two groups. The incidence of grade 3 or higher hormone-related toxic effects was less than 5%. Reanalysis according to risk showed reductions in overall and disease-specific mortality primarily among intermediate-risk patients, with no significant reductions among low-risk patients. CONCLUSIONS Among patients with stage T1b, T1c, T2a, or T2b prostate adenocarcinoma and a PSA level of 20 ng per milliliter or less, the use of short-term ADT for 4 months before and during radiotherapy was associated with significantly decreased disease-specific mortality and increased overall survival. According to post hoc risk analysis, the benefit was mainly seen in intermediate-risk, but not low-risk, men. (Funded by the National Cancer Institute; RTOG 94-08 ClinicalTrials.gov number, NCT00002597.)	[Jones, Christopher U.; Leibenhaut, Mark H.] Radiol Associates Sacramento, Sacramento, CA 95816 USA; [Hunt, Daniel] Univ Penn, Radiat Therapy Oncol Grp, Ctr Stat, Philadelphia, PA 19104 USA; [Bruner, Deborah W.] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; [McGowan, David G.] Cross Canc Inst, Dept Radiat Oncol, Edmonton, AB T6G 1Z2, Canada; [Chetner, Michael P.] Univ Alberta, Dept Surg, Div Urol, Edmonton, AB, Canada; [Husain, Siraj M.] Tom Baker Canc Clin, Dept Radiat Oncol, Calgary, AB, Canada; [Amin, Mahul B.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Sandler, Howard M.] Cedars Sinai Med Ctr, Dept Radiat Oncol, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA 90048 USA; [Rotman, Marvin] SUNY Hlth Sci Ctr, Dept Radiat Oncol, Brooklyn, NY 11203 USA; [Souhami, Luis] McGill Univ, Dept Radiat Oncol, Montreal, PQ H3A 2T5, Canada; [Shipley, William U.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA	Radiological Associates of Sacramento; Radiation Therapy Oncology Group (RTOG); University of Pennsylvania; University of Pennsylvania; University of Alberta; University of Alberta; Tom Baker Cancer Clinic; University of Calgary; Cedars Sinai Medical Center; Cedars Sinai Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; McGill University; Harvard University; Massachusetts General Hospital	Jones, CU (corresponding author), Radiol Associates Sacramento, 1500 Expo Pkwy, Sacramento, CA 95816 USA.	jonesc@radiological.com		Bruner, Deborah/0000-0002-5770-9948	National Cancer Institute [U10 CA21661, U10 CA37422, U10 CA32115]; Amgen; Ferring; GlaxoSmithKline; Eli Lilly; Calypso Medical; Varian; NATIONAL CANCER INSTITUTE [U10CA037422, U10CA032115, U10CA021661] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Amgen(Amgen); Ferring(Ferring Pharmaceuticals); GlaxoSmithKline(GlaxoSmithKline); Eli Lilly(Eli Lilly); Calypso Medical; Varian; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by grants (U10 CA21661, to the Radiation Therapy Oncology Group [RTOG]; U10 CA37422, to the Community Clinical Oncology Program; and U10 CA32115, to the RTOG Statistical Center) from the National Cancer Institute.; Dr. Chetner reports receiving lecture fees from and serving on the advisory boards of Amgen, Ferring, GlaxoSmithKline, and Eli Lilly and receiving fees for the development of educational presentations from Amgen and GlaxoSmithKline; and Dr. Sandler, consulting fees from Calypso Medical and Varian. No other potential conflict of interest relevant to this article was reported.	Al-Mamgani A, 2008, INT J RADIAT ONCOL, V72, P980, DOI 10.1016/j.ijrobp.2008.02.073; Beahrs O, 1992, AJCC CANC STAGING MA, V4th; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; Bolla M, 2009, NEW ENGL J MED, V360, P2516, DOI 10.1056/NEJMoa0810095; Bruner DW, 2011, J SEX MED, V8, P1228, DOI 10.1111/j.1743-6109.2010.02164.x; Bruner DW, 1997, ONCOL NEWS INT S3, V6, P22; Cooperberg MR, 2004, J UROLOGY, V171, P1393, DOI 10.1097/01.ju.0000107247.81471.06; COX DR, 1972, J R STAT SOC B, V34, P187; COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C; D'Amico AV, 2008, JAMA-J AM MED ASSOC, V299, P289, DOI 10.1001/jama.299.3.289; Dearnaley DP, 2007, LANCET ONCOL, V8, P475, DOI 10.1016/S1470-2045(07)70143-2; Debruyne FMJ, 2000, MOL UROL, V4, P251; Denham JW, 2005, LANCET ONCOL, V6, P841, DOI 10.1016/S1470-2045(05)70348-X; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; GRIFFITHS K, 1994, SEMIN ONCOL, V21, P672; Horwitz EM, 2008, J CLIN ONCOL, V26, P2497, DOI 10.1200/JCO.2007.14.9021; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Keating NL, 2006, J CLIN ONCOL, V24, P4448, DOI 10.1200/JCO.2006.06.2497; KORN EL, 1992, STAT MED, V11, P813, DOI 10.1002/sim.4780110611; Kuban DA, 2008, INT J RADIAT ONCOL, V70, P67, DOI 10.1016/j.ijrobp.2007.06.054; Kupelian PA, 2004, INT J RADIAT ONCOL, V58, P25, DOI 10.1016/S0360-3016(03)00784-3; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Lawton CA, 2001, INT J RADIAT ONCOL, V49, P937, DOI 10.1016/S0360-3016(00)01516-9; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Mohler JL, 2010, J NATL COMPR CANC NE, V8, P145, DOI 10.6004/jnccn.2010.0010; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; Pilepich MV, 2005, INT J RADIAT ONCOL, V61, P1285, DOI 10.1016/j.ijrobp.2004.08.047; Potosky AL, 2000, JNCI-J NATL CANCER I, V92, P1582, DOI 10.1093/jnci/92.19.1582; Roach M, 2000, INT J RADIAT ONCOL, V47, P617, DOI 10.1016/S0360-3016(00)00577-0; Roach M, 1999, J UROLOGY, V161, P864, DOI 10.1016/S0022-5347(01)61793-2; Roach M, 2008, J CLIN ONCOL, V26, P585, DOI 10.1200/JCO.2007.13.9881; Roach M, 2006, INT J RADIAT ONCOL, V65, P965, DOI 10.1016/j.ijrobp.2006.04.029; Saylor PJ, 2009, J UROLOGY, V181, P1998, DOI 10.1016/j.juro.2009.01.047; Soloway MS, 2002, J UROLOGY, V167, P112, DOI 10.1016/S0022-5347(05)65393-1; Waterhouse J, 1986, Oncol Nurs Forum, V13, P53; Yee DS, 2010, BJU INT, V105, P185, DOI 10.1111/j.1464-410X.2009.08698.x; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0; Zietman AL, 2004, J UROLOGY, V171, P210, DOI 10.1097/01.ju.0000100980.13364.a6; Zietman AL, 2010, J CLIN ONCOL, V28, P1106, DOI 10.1200/JCO.2009.25.8475	39	505	512	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	2011	365	2					107	118		10.1056/NEJMoa1012348	http://dx.doi.org/10.1056/NEJMoa1012348			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	791SP	21751904				2023-01-03	WOS:000292685500007
J	Wechsler, ME; Kelley, JM; Boyd, IOE; Dutile, S; Marigowda, G; Kirsch, I; Israel, E; Kaptchuk, TJ				Wechsler, Michael E.; Kelley, John M.; Boyd, Ingrid O. E.; Dutile, Stefanie; Marigowda, Gautham; Kirsch, Irving; Israel, Elliot; Kaptchuk, Ted J.			Active Albuterol or Placebo, Sham Acupuncture, or No Intervention in Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERCEPTION; SUGGESTION; TRIALS; AIR	BACKGROUND In prospective experimental studies in patients with asthma, it is difficult to determine whether responses to placebo differ from the natural course of physiological changes that occur without any intervention. We compared the effects of a bronchodilator, two placebo interventions, and no intervention on outcomes in patients with asthma. METHODS In a double-blind, crossover pilot study, we randomly assigned 46 patients with asthma to active treatment with an albuterol inhaler, a placebo inhaler, sham acupuncture, or no intervention. Using a block design, we administered one each of these four interventions in random order during four sequential visits (3 to 7 days apart); this procedure was repeated in two more blocks of visits (for a total of 12 visits by each patient). At each visit, spirometry was performed repeatedly over a period of 2 hours. Maximum forced expiratory volume in 1 second (FEV1) was measured, and patients' self-reported improvement ratings were recorded. RESULTS Among the 39 patients who completed the study, albuterol resulted in a 20% increase in FEV1, as compared with approximately 7% with each of the other three interventions (P<0.001). However, patients' reports of improvement after the intervention did not differ significantly for the albuterol inhaler (50% improvement), placebo inhaler (45%), or sham acupuncture (46%), but the subjective improvement with all three of these interventions was significantly greater than that with the no-intervention control (21%) (P<0.001). CONCLUSIONS Although albuterol, but not the two placebo interventions, improved FEV1 in these patients with asthma, albuterol provided no incremental benefit with respect to the self-reported outcomes. Placebo effects can be clinically meaningful and can rival the effects of active medication in patients with asthma. However, from a clinical-management and research-design perspective, patient self-reports can be unreliable. An assessment of untreated responses in asthma may be essential in evaluating patient-reported outcomes. (Funded by the National Center for Complementary and Alternative Medicine.)	[Wechsler, Michael E.; Boyd, Ingrid O. E.; Dutile, Stefanie; Marigowda, Gautham; Israel, Elliot] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Wechsler, Michael E.; Kelley, John M.; Boyd, Ingrid O. E.; Dutile, Stefanie; Marigowda, Gautham; Kirsch, Irving; Israel, Elliot; Kaptchuk, Ted J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Kelley, John M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA; [Kirsch, Irving; Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA; [Kelley, John M.] Endicott Coll, Dept Psychol, Beverly, MA USA; [Kirsch, Irving] Univ Hull, Dept Psychol, Kingston Upon Hull HU6 7RX, N Humberside, England	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center; University of Hull	Wechsler, ME (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.	mwechsler@partners.org	Kirsch, Irving/P-9316-2019; Wechsler, Michael/AAC-5506-2019; Wechsler, Michael/B-3979-2013	Wechsler, Michael/0000-0003-3505-2946	National Center for Complementary and Alternative Medicine; National Center for Complementary and Alternative Medicine, National Institutes of Health [R21-AT002793-01, K24-AT004095]; GlaxoSmithKline; Merck; Schering-Plough; Asthmatx; Genentech; Sunovion; Cephalon; MedImmune; NKT Therapeutics; Boehringer Ingelheim; Novartis; AstraZeneca; Abbott; Amgen; Astellas Pharma US; BI Worldwide; Cowen; Gilead Sciences; Icagen; Johnson Johnson; newMentor; Ono Pharmaceutical; PDL BioPharma; Pulmatrix; Teva Pharmaceuticals; Ficksman and Conley; Prince, Lobel, Glovsky, and Tye; Campbell, Campbell, Edwards, and Conroy; Diedrich and Donohue; Sulloway and Hollis; Ryan Ryan Deluca; Aerovance; Biota; Ception; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [R21AT002793] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [K24AT004095] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary and Alternative Medicine, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); GlaxoSmithKline(GlaxoSmithKline); Merck(Merck & Company); Schering-Plough(Merck & CompanySchering Plough Corporation); Asthmatx; Genentech(Roche HoldingGenentech); Sunovion; Cephalon; MedImmune(AstraZenecaMedimmune); NKT Therapeutics; Boehringer Ingelheim(Boehringer Ingelheim); Novartis(Novartis); AstraZeneca(AstraZeneca); Abbott(Abbott Laboratories); Amgen(Amgen); Astellas Pharma US(Astellas Pharmaceuticals); BI Worldwide; Cowen; Gilead Sciences(Gilead Sciences); Icagen; Johnson Johnson(Johnson & JohnsonJohnson & Johnson USA); newMentor; Ono Pharmaceutical; PDL BioPharma; Pulmatrix; Teva Pharmaceuticals(Teva Pharmaceutical Industries); Ficksman and Conley; Prince, Lobel, Glovsky, and Tye; Campbell, Campbell, Edwards, and Conroy; Diedrich and Donohue; Sulloway and Hollis; Ryan Ryan Deluca; Aerovance; Biota; Ception; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Funded by the National Center for Complementary and Alternative Medicine.; Supported by grants (R21-AT002793-01 and K24-AT004095) from the National Center for Complementary and Alternative Medicine, National Institutes of Health.; Dr. Wechsler reports receiving fees for consulting and advisory-board membership from GlaxoSmithKline, Merck, Schering-Plough, Asthmatx, Genentech, Sunovion (formerly Sepracor), Cephalon, MedImmune, NKT Therapeutics, and Boehringer Ingelheim; lecture fees from Merck, Novartis, AstraZeneca, and GlaxoSmithKline; and grant support from GlaxoSmithKline and Asthmatx. Dr. Israel reports receiving fees for consulting and advisory-board membership from Abbott, Amgen, Astellas Pharma US, BI Worldwide, Cowen, Gilead Sciences, GlaxoSmithKline, Icagen, Johnson & Johnson, MedImmune, Merck, newMentor, NKT Therapeutics, Novartis, Ono Pharmaceutical, PDL BioPharma, Pulmatrix, Schering-Plough, Sunovion (formerly Sepracor), and Teva Pharmaceuticals; lecture fees from Merck; fees for expert testimony from Ficksman and Conley; Prince, Lobel, Glovsky, and Tye; Campbell, Campbell, Edwards, and Conroy; Diedrich and Donohue; Sulloway and Hollis; and Ryan Ryan Deluca; and grant support from Aerovance, Amgen, Biota, Ception, Genentech, Icagen, Johnson & Johnson, MedImmune, and Novartis. No other potential conflict of interest relevant to this article was reported.	Apter AJ, 1997, J ALLERGY CLIN IMMUN, V99, P605, DOI 10.1016/S0091-6749(97)70020-4; Beecher H. K., 1959, MEASUREMENT SUBJECTI; Benedetti F., 2020, PLACEBO EFFECTS, DOI [10.1093/oso/9780198843177.001.0001, DOI 10.1093/OSO/9780198843177.001.0001]; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BUTLER C, 1986, BRIT J CLIN PSYCHOL, V25, P173, DOI 10.1111/j.2044-8260.1986.tb00693.x; Cohen J., 2013, STAT POWER ANAL BEHA; Eisenberg L, 1977, Cult Med Psychiatry, V1, P9, DOI 10.1007/BF00114808; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; GODFREY S, 1973, J PSYCHOSOM RES, V17, P293, DOI 10.1016/0022-3999(73)90106-2; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; ISENBERG SA, 1992, J PSYCHOSOM RES, V36, P769, DOI 10.1016/0022-3999(92)90135-O; Jenkinson C, 1994, MEASURING HLTH MED O; Kaptchuk Ted, 2008, Nat Rev Drug Discov, V7, P554, DOI 10.1038/nrd2629; Kaptchuk TJ, 2008, CONTEMP CLIN TRIALS, V29, P587, DOI 10.1016/j.cct.2008.02.002; Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kemeny ME, 2007, J ALLERGY CLIN IMMUN, V119, P1375, DOI 10.1016/j.jaci.2007.03.016; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KLEINMAN A, 1978, ANN INTERN MED, V88, P251, DOI 10.7326/0003-4819-88-2-251; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819, DOI 10.1097/00006842-196811000-00002; Magadle R, 2002, CHEST, V121, P329, DOI 10.1378/chest.121.2.329; MAY O, 1988, EUR RESPIR J, V1, P527; MCCORMACK HM, 1988, PSYCHOL MED, V18, P1007, DOI 10.1017/S0033291700009934; National Asthma Education and Prevention Program, 2007, J Allergy Clin Immunol, V120, pS94; Sodergren SC, 1999, EXPECTANCIES SHAPE E, P333; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015	28	224	229	0	67	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 14	2011	365	2					119	126		10.1056/NEJMoa1103319	http://dx.doi.org/10.1056/NEJMoa1103319			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	791SP	21751905	Bronze, Green Accepted			2023-01-03	WOS:000292685500008
J	Kowey, PR				Kowey, Peter R.			The Silent Majority	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIABILITY; REFORM		[Kowey, Peter R.] Main Line Hlth Syst, Lankenau Med Ctr, Wynnewood, PA USA; [Kowey, Peter R.] Main Line Hlth Syst, Inst Med Res, Wynnewood, PA USA; [Kowey, Peter R.] Thomas Jefferson Univ, Jefferson Med Coll, Philadelphia, PA 19107 USA	Lankenau Medical Center; Jefferson University	Kowey, PR (corresponding author), Main Line Hlth Syst, Lankenau Med Ctr, Wynnewood, PA USA.	koweyp@mlhs.org						Alpert JS, 2011, AM J MED, V124, P187, DOI 10.1016/j.amjmed.2010.10.010; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Dove JT, 2010, J AM COLL CARDIOL, V55, P2801, DOI 10.1016/j.jacc.2010.03.028; *GOV ACC OFF, 2003, MED MALPR IMPL RIS P; Mello MM, 2009, NEW ENGL J MED, V361, P1, DOI 10.1056/NEJMp0903765; Shanafelt TD, 2011, ARCH SURG-CHICAGO, V146, P54, DOI 10.1001/archsurg.2010.292; Tu JV, 1997, NEW ENGL J MED, V336, P1500, DOI 10.1056/NEJM199705223362106	7	2	3	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 6	2011	306	1					18	19		10.1001/jama.2011.904	http://dx.doi.org/10.1001/jama.2011.904			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	787LV	21730231				2023-01-03	WOS:000292378700001
J	Aujesky, D; Roy, PM; Verschuren, F; Righini, M; Osterwalder, J; Egloff, M; Renaud, B; Verhamme, P; Stone, RA; Legal, C; Sanchez, O; Pugh, NA; N'gako, A; Cornuz, J; Hugii, O; Beer, HJ; Perrier, A; Fine, MJ; Yealy, DM				Aujesky, Drahomir; Roy, Pierre-Marie; Verschuren, Franck; Righini, Marc; Osterwalder, Joseph; Egloff, Michael; Renaud, Bertrand; Verhamme, Peter; Stone, Roslyn A.; Legal, Catherine; Sanchez, Olivier; Pugh, Nathan A.; N'gako, Alfred; Cornuz, Jacques; Hugii, Olivier; Beer, Hans-Juerg; Perrier, Arnaud; Fine, Michael J.; Yealy, Donald M.			Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial	LANCET			English	Article							MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; INTRAVENOUS UNFRACTIONATED HEPARIN; VENOUS THROMBOEMBOLIC DISEASE; CLINICAL PROGNOSTIC MODEL; LOW-RISK PATIENTS; EARLY DISCHARGE; ANTICOAGULANT-THERAPY; INITIAL TREATMENT; SEVERITY INDEX	Background Although practice guidelines recommend outpatient care for selected, haemodynamically stable patients with pulmonary embolism, most treatment is presently inpatient based. We aimed to assess non-inferiority of outpatient care compared with inpatient care. Methods We undertook an open-label, randomised non-inferiority trial at 19 emergency departments in Switzerland, France, Belgium, and the USA. We randomly assigned patients with acute, symptomatic pulmonary embolism and a low risk of death (pulmonary embolism severity index risk classes I or II) with a computer-generated randomisation sequence (blocks of 2-4) in a 1:1 ratio to initial outpatient (ie, discharged from hospital <= 24 h after randomisation) or inpatient treatment with subcutaneous enoxaparin (>= 5 days) followed by oral anticoagulation (>= 90 days). The primary outcome was symptomatic, recurrent venous thromboembolism within 90 days; safety outcomes included major bleeding within 14 or 90 days and mortality within 90 days. We used a non-inferiority margin of 4% for a difference between inpatient and outpatient groups. We included all enrolled patients in the primary analysis, excluding those lost to follow-up. This trial is registered with ClinicalTrials.gov, number NCT00425542. Findings Between February, 2007, and June, 2010, we enrolled 344 eligible patients. In the primary analysis, one (0.6%) of 171 outpatients developed recurrent venous thromboembolism within 90 days compared with none of 168 inpatients (95% upper confidence limit [UCL] 2-7%; p=0.011). Only one (0.6%) patient in each treatment group died within 90 days (95% UCL 2.1%; p=0.005), and two (1.2%) of 171 outpatients and no inpatients had major bleeding within 14 days (95% UCL 3.6%; p=0.031). By 90 days, three (1.8%) outpatients but no inpatients had developed major bleeding (95% UCL 4.5%; p=0.086). Mean length of stay was 0.5 days (SD 1.0) for outpatients and 3.9 days (SD 3.1) for inpatients. Interpretation In selected low-risk patients with pulmonary embolism, outpatient care can safely and effectively be used in place of inpatient care.	[Aujesky, Drahomir] Univ Hosp Bern, Univ Klin Allgemeine Innere Med, Inselspital, CH-3010 Bern, Switzerland; [Roy, Pierre-Marie] LUNAM Univ, Angers, France; [Roy, Pierre-Marie] Univ Angers, Angers, France; [Verschuren, Franck] Univ Louvain, Brussels, Belgium; [Righini, Marc; Perrier, Arnaud] Univ Geneva, Geneva, Switzerland; [Osterwalder, Joseph] Cantonal Hosp St Gallen, St Gallen, Switzerland; [Egloff, Michael; Beer, Hans-Juerg] Cantonal Hosp Baden, Baden, Switzerland; [Renaud, Bertrand; N'gako, Alfred] Univ Hosp Henri Mondor, Creteil, France; [Verhamme, Peter] Univ Louvain, Louvain, Belgium; [Fine, Michael J.] Univ Pittsburgh, VA Ctr Hlth Equity Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA; [Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Sch Med, Pittsburgh, PA 15260 USA; [Stone, Roslyn A.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15260 USA; [Yealy, Donald M.] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15260 USA; [Legal, Catherine] Univ Argenteuil, Argenteuil, France; [Sanchez, Olivier] Hop Europeen Georges Pompidou, Paris, France; [Cornuz, Jacques; Hugii, Olivier] Univ Lausanne, Lausanne, Switzerland	University of Bern; University Hospital of Bern; Universite d'Angers; Universite Catholique Louvain; University of Geneva; Kantonsspital St. Gallen; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Lausanne	Aujesky, D (corresponding author), Univ Hosp Bern, Univ Klin Allgemeine Innere Med, Inselspital, CH-3010 Bern, Switzerland.	drahomir.aujesky@insel.ch	Righini, Marc/AAX-8731-2020; Perrier, Arnaud/M-2263-2014; Hug, Balthasar L./G-1568-2010; Roy, Pierre-Marie/AAA-7737-2022	Aujesky, Drahomir/0000-0002-3970-2670; Beer, Jurg Hans/0000-0002-7199-0406; Hugli, Olivier/0000-0003-2312-1625	Swiss National Science Foundation [3200B0-1121]; Programme Hospitalier de Recherche Clinique [21-03]; US National Heart, Lung, and Blood Institute [1R01HL085565-01A2]; GlaxoSmithKline; Sanofi-Aventis; Bayer; Biomerieux; Boehringer Ingelheim; Eli Lilly; LFB Biomedicaments; Daiichi-Sankyo; ThromboGenics; Leo; Pfizer; MSD; Menarini; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL085565] Funding Source: NIH RePORTER	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Programme Hospitalier de Recherche Clinique; US National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); GlaxoSmithKline(GlaxoSmithKline); Sanofi-Aventis(Sanofi-Aventis); Bayer(Bayer AG); Biomerieux; Boehringer Ingelheim(Boehringer Ingelheim); Eli Lilly(Eli Lilly); LFB Biomedicaments; Daiichi-Sankyo(Daiichi Sankyo Company Limited); ThromboGenics; Leo(LEO Pharma); Pfizer(Pfizer); MSD; Menarini(Menarini Group); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Swiss National Science Foundation, Programme Hospitalier de Recherche Clinique, and the US National Heart, Lung, and Blood Institute. Sanofi-Aventis provided free drug supply in the participating European centres.; DA has received honoraria from Sanofi-Aventis and Bayer. PM R has received grants, honoraria, consultancy fees, and payments from GlaxoSmithKline, Sanofi-Aventis, Bayer, Biomerieux, Boehringer Ingelheim, Eli Lilly, and LFB Biomedicaments. PV has received grants, consultancy fees, and payments from Sanofi-Aventis, Bayer, Boehringer Ingelheim, Daiichi-Sankyo, ThromboGenics, Leo, and Pfizer. OH has received grants from Pfizer and MSD. HJB has received honoraria from Sariofi-Aventis, Bayer, Boehringer Ingelheim, Menarini, and GlaxoSmithKline.; This study was supported by grants from the Swiss National Science Foundation (3200B0-1121), the Programme Hospitalier de Recherche Clinique 2007 (21-03), and the US National Heart, Lung, and Blood Institute (1R01HL085565-01A2). Sanofi-Aventis provided free drug supply in the participating European centres. We thank Emmanuelle Le Moigne (Brest, France), David Elkharrat (Boulogne, France), Dominique Elkouri (Nantes, France), Mark Courtney (Chicago, IL, USA), Didier Honnart (Dijon, France), Jeannot Schmidt (Clermont-Ferrand, France), Jeffrey Kline (Charlotte, NC, USA), Yves Poitrineau (Thiers, France), and Bertrand Yersin (Lausanne, Switzerland).	Agterof MJ, 2010, J THROMB HAEMOST, V8, P1235, DOI 10.1111/j.1538-7836.2010.03831.x; Aujesky D, 2007, J INTERN MED, V261, P597, DOI 10.1111/j.1365-2796.2007.01785.x; Aujesky D, 2006, EUR HEART J, V27, P476, DOI 10.1093/eurheartj/ehi588; Aujesky D, 2006, ARCH INTERN MED, V166, P169, DOI 10.1001/archinte.166.2.169; Aujesky D, 2005, AM J RESP CRIT CARE, V172, P1041, DOI 10.1164/rccm.200506-862OC; Bauersachs R, 2010, NEW ENGL J MED, V363, P2499, DOI 10.1056/NEJMoa1007903; Beer JH, 2003, J THROMB HAEMOST, V1, P186, DOI 10.1046/j.1538-7836.2003.00005.x; Buller HR, 2007, NEW ENGL J MED, V357, P1094; Buller HR, 2004, ANN INTERN MED, V140, P867, DOI 10.7326/0003-4819-140-11-200406010-00007; Buller HR, 2003, NEW ENGL J MED, V349, P1695; Campbell IA, 2003, THORAX, V58, P470; Chan ISF, 2003, STAT METHODS MED RES, V12, P37, DOI 10.1191/0962280203sm314ra; Davies CWH, 2007, EUR RESPIR J, V30, P708, DOI 10.1183/09031936.00140506; Donze J, 2008, THROMB HAEMOSTASIS, V100, P943, DOI 10.1160/TH08-05-0285; Erkens PMG, 2010, J THROMB HAEMOST, V8, P2412, DOI 10.1111/j.1538-7836.2010.04041.x; Fiessinger JN, 2005, JAMA-J AM MED ASSOC, V293, P681, DOI 10.1001/jama.293.6.681; Fraga M, 2010, THROMB HAEMOSTASIS, V104, P1258, DOI 10.1160/TH10-07-0426; Heit JA, 1999, ARCH INTERN MED, V159, P445, DOI 10.1001/archinte.159.5.445; Janjua M, 2008, THROMB HAEMOSTASIS, V100, P756, DOI 10.1160/TH08-05-0319; Kaul S, 2006, ANN INTERN MED, V145, P62, DOI 10.7326/0003-4819-145-1-200607040-00011; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Kovacs MJ, 2010, J THROMB HAEMOST, V8, P2406, DOI 10.1111/j.1538-7836.2010.03981.x; Kovacs MJ, 2000, THROMB HAEMOSTASIS, V83, P209; Le Gal G, 2006, THROMB HAEMOSTASIS, V95, P963, DOI 10.1160/TH06-03-0158; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; Merli G, 2001, ANN INTERN MED, V134, P191, DOI 10.7326/0003-4819-134-3-200102060-00009; OLSSON CG, 2006, MED SCI MONITOR, V12, pP19; Ong BS, 2005, MED J AUSTRALIA, V183, P239, DOI 10.5694/j.1326-5377.2005.tb07027.x; Otero R, 2010, THROMB RES, V126, pE1, DOI 10.1016/j.thromres.2009.09.026; Piaggio G, 2006, JAMA-J AM MED ASSOC, V295, P1152, DOI 10.1001/jama.295.10.1152; ROSENDAAL FR, 1993, THROMB HAEMOSTASIS, V69, P236; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schulman S, 2009, NEW ENGL J MED, V361, P2342, DOI 10.1056/NEJMoa0906598; Siragusa S, 2005, ANN ONCOL, V16, P136, DOI 10.1093/annonc/mdi923; Snow V, 2007, ANN INTERN MED, V146, P204, DOI 10.7326/0003-4819-146-3-200702060-00149; Squizzato A, 2009, EUR RESPIR J, V33, P1148, DOI 10.1183/09031936.00133608; tenCate JW, 1997, NEW ENGL J MED, V337, P657; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310; van Bladel ER, 2010, THROMB RES, V126, P481, DOI 10.1016/j.thromres.2010.08.019; Wells PS, 2005, ARCH INTERN MED, V165, P733, DOI 10.1001/archinte.165.7.733; Wells PS, 1998, ARCH INTERN MED, V158, P1809, DOI 10.1001/archinte.158.16.1809; ZONDAG W, 2010, BLOOD, V116, pLBA1	43	411	418	0	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 2	2011	378	9785					41	48		10.1016/S0140-6736(11)60824-6	http://dx.doi.org/10.1016/S0140-6736(11)60824-6			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	791IU	21703676				2023-01-03	WOS:000292659700032
J	Crabtree-Ramirez, B; Caro-Vega, Y; Shepherd, BE; Wehbe, F; Cesar, C; Cortes, C; Padgett, D; Koenig, S; Gotuzzo, E; Cahn, P; McGowan, C; Masys, D; Sierra-Madero, J				Crabtree-Ramirez, Brenda; Caro-Vega, Yanink; Shepherd, Bryan E.; Wehbe, Firas; Cesar, Carina; Cortes, Claudia; Padgett, Denis; Koenig, Serena; Gotuzzo, Eduardo; Cahn, Pedro; McGowan, Catherine; Masys, Daniel; Sierra-Madero, Juan		CCASAnet Team	Cross-Sectional Analysis of Late HAART Initiation in Latin America and the Caribbean: Late Testers and Late Presenters	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; LATE DIAGNOSIS; HIV-INFECTION; HIV-1-INFECTED PATIENTS; COLLABORATIVE ANALYSIS; AIDS; CONSEQUENCES; MORTALITY; ENGLAND; ACCESS	Background: Starting HAART in a very advanced stage of disease is assumed to be the most prevalent form of initiation in HIV-infected subjects in developing countries. Data from Latin America and the Caribbean is still lacking. Our main objective was to determine the frequency, risk factors and trends in time for being late HAART initiator (LHI) in this region. Methodology: Cross-sectional analysis from 9817 HIV-infected treatment-naive patients initiating HAART at 6 sites (Argentina, Chile, Haiti, Honduras, Peru and Mexico) from October 1999 to July 2010. LHI had CD4(+) count <= 200cells/mm(3) prior to HAART. Late testers (LT) were those LHI who initiated HAART within 6 months of HIV diagnosis. Late presenters (LP) initiated after 6 months of diagnosis. Prevalence, risk factors and trends over time were analyzed. Principal Findings: Among subjects starting HAART (n = 9817) who had baseline CD4+ available (n = 8515), 76% were LHI: Argentina (56%[95% CI: 52-59]), Chile (80%[95% CI: 77-82]), Haiti (76%[95% CI: 74-77]), Honduras (91%[95% CI: 87-94]), Mexico (79%[95% CI: 75-83]), Peru (86%[95% CI: 84-88]). The proportion of LHI statistically changed over time (except in Honduras) (p <= 0.02; Honduras p=0.7), with a tendency towards lower rates in recent years. Males had increased risk of LHI in Chile, Haiti, Peru, and in the combined site analyses (CSA). Older patients were more likely LHI in Argentina and Peru (OR 1.21 per +10-year of age, 95% CI: 1.02-1.45; OR 1.20, 95% CI: 1.02-1.43; respectively), but not in CSA (OR 1.07, 95% CI: 0.94-1.21). Higher education was associated with decreased risk for LHI in Chile (OR 0.92 per +1-year of education, 95% CI: 0.87-0.98) (similar trends in Mexico, Peru, and CSA). LHI with date of HIV-diagnosis available, 55% were LT and 45% LP. Conclusion: LHI was highly prevalent in CCASAnet sites, mostly due to LT; the main risk factors associated were being male and older age. Earlier HIV-diagnosis and earlier treatment initiation are needed to maximize benefits from HAART in the region.	[Crabtree-Ramirez, Brenda; Caro-Vega, Yanink; Sierra-Madero, Juan] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico; [Shepherd, Bryan E.; Wehbe, Firas; McGowan, Catherine; Masys, Daniel] Vanderbilt Univ, Nashville, TN USA; [Cortes, Claudia] Univ Chile, Fdn Arriaran, Santiago, Chile; [Padgett, Denis] Inst Honduren Seguro Social & Hosp Escuela, Tegucigalpa, Honduras; [Koenig, Serena] Cornell Univ, GHESKIO Weill Med Coll, Port Au Prince, Haiti; [Koenig, Serena] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Gotuzzo, Eduardo] Inst Med Trop Alexander von Humboldt, Lima, Peru	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran - Mexico; Vanderbilt University; Universidad de Chile; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Universidad Peruana Cayetano Heredia	Crabtree-Ramirez, B (corresponding author), Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Mexico City, DF, Mexico.	jsmadero@yahoo.com	Wehbe, Firas/Q-6176-2019; Cesar, Carina/H-2831-2019; Cortes, Claudia P/AAF-7326-2020; Sierra Madero, Juan/AAW-8825-2021	Wehbe, Firas/0000-0002-3984-9584; Cortes, Claudia P/0000-0001-9101-9783; Caro-Vega, Yanink/0000-0003-3806-5806; Crabtree-Ramirez, Brenda/0000-0002-2587-1123	National Institutes of Health [1-U01-AI069923]; Pfizer; MSD; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI069923] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer(Pfizer); MSD; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the National Institutes of Health Cooperative Agreement (1-U01-AI069923). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; BCR: speaker for BMS and MSD and grant for clinical trial of MSD; C. Cortes: speaker for MSD and GSK; EG: received grants from Pfizer and MSD; PC: board membership of MSD, GSK, Pfizer, Tibotec, Shering Plough, and speaker for Abbot, Tibotec, BMS, GSK, MSD, Pfizer and Boeringer Ingelheim; JSM: speaker for ViiV and Stendahl and has received grant for research from Pfizer. Authors YCV, BES, FW, C. Cesar, DP, SK, CM, and DM have no conflict of interest.	Althoff KN, 2010, CLIN INFECT DIS, V50, P1512, DOI 10.1086/652650; Assefa Y, 2010, AIDS PATIENT CARE ST, V24, P521, DOI 10.1089/apc.2009.0286; Bonjour Maeva A, 2008, AIDS Res Ther, V5, P6, DOI 10.1186/1742-6405-5-6; Castilla J, 2005, JAIDS-J ACQ IMM DEF, V40, P96, DOI 10.1097/01.qai.0000157389.78374.45; Castilla J, 2002, AIDS, V16, P1945, DOI 10.1097/00002030-200209270-00012; *CENSIDA, 2008, GUIA MAN ANT PERS CO; Cesar C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010490; Chadborn TR, 2006, AIDS, V20, P2371, DOI 10.1097/QAD.0b013e32801138f7; Chadborn TR, 2005, AIDS, V19, P513, DOI 10.1097/01.aids.0000162340.43310.08; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Duffus W., 2006, Morbidity and Mortality Weekly Report, V55, P1269; *EACS, 2009, CLIN MAN TREATM HIV; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Fisher M, 2008, CURR OPIN INFECT DIS, V21, P1, DOI 10.1097/QCO.0b013e3282f2d8fb; Friedman J H, 1984, 1 STANF U LAB COMP S; Gilks CF, 2006, LANCET, V368, P505, DOI 10.1016/S0140-6736(06)69158-7; Girardi E, 2004, JAIDS-J ACQ IMM DEF, V36, P951, DOI 10.1097/00126334-200408010-00009; Harrell Frank E., 2001, REGRESSION MODELING; Hocking JS, 2000, INT J STD AIDS, V11, P503, DOI 10.1258/0956462001916407; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Krentz HB, 2004, HIV MED, V5, P93, DOI 10.1111/j.1468-1293.2004.00193.x; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Losina E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009538; McGowan CC, 2007, INT J EPIDEMIOL, V36, P969, DOI 10.1093/ije/dym073; Mills EJ, 2011, AIDS, V25, P851, DOI 10.1097/QAD.0b013e32834564e9; *MIN SAL, 2005, GUI CLIN SINDR INM A; *MIN SAL, 2007, REC TRAT ANT 2007; Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0; Nash D, 2008, AIDS, V22, P2291, DOI 10.1097/QAD.0b013e3283121ca9; *OARAC, 2009, GUID US ANT AG HIV 1; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Sabin CA, 2004, AIDS, V18, P2145, DOI 10.1097/00002030-200411050-00006; Sabin CA, 2010, AIDS, V24, P723, DOI 10.1097/QAD.0b013e328333fa0f; *SADI, 2007, REC SEG TRAT INF HIV; Schwarcz S, 2006, JAIDS-J ACQ IMM DEF, V43, P491, DOI 10.1097/01.qai.0000243114.37035.de; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; SHAFER JL, 1997, ANAL INCOMPLETE MULT; Smith-Warner SA, 2006, AM J EPIDEMIOL, V163, P1053, DOI 10.1093/aje/kwj127; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; Tuboi SH, 2009, JAIDS-J ACQ IMM DEF, V51, P615, DOI 10.1097/QAI.0b013e3181a44f0a; Walensky RP, 2009, ANN INTERN MED, V151, P157, DOI 10.7326/0003-4819-151-3-200908040-00138; WHO, 2010, ANT THER HIV INF AD; WHO, 2004, SCAL ANT THER RES LI; World Health Organization, 2006, ANT THER HIV INF AD; Zala Carlos, 2008, Medscape J Med, V10, P78, DOI 10.1186/1758-2652-10-4-78	45	57	57	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2011	6	5							e20272	10.1371/journal.pone.0020272	http://dx.doi.org/10.1371/journal.pone.0020272			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769XS	21637802	Green Published, Green Submitted, gold			2023-01-03	WOS:000291052200046
J	Conroy, T; Desseigne, F; Ychou, M; Bouche, O; Guimbaud, R; Becouarn, Y; Adenis, A; Raoul, JL; Gourgou-Bourgade, S; de la Fouchardiere, C; Bennouna, J; Bachet, JB; Khemissa-Akouz, F; Pere-Verge, D; Delbaldo, C; Assenat, E; Chauffert, B; Michel, P; Montoto-Grillot, C; Ducreux, M				Conroy, Thierry; Desseigne, Francoise; Ychou, Marc; Bouche, Olivier; Guimbaud, Rosine; Becouarn, Yves; Adenis, Antoine; Raoul, Jean-Luc; Gourgou-Bourgade, Sophie; de la Fouchardiere, Christelle; Bennouna, Jaafar; Bachet, Jean-Baptiste; Khemissa-Akouz, Faiza; Pere-Verge, Denis; Delbaldo, Catherine; Assenat, Eric; Chauffert, Bruno; Michel, Pierre; Montoto-Grillot, Christine; Ducreux, Michel		Grp Tumeurs Digestives Unicanc; PRODIGE Intergrp	FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-III TRIAL; CLINICAL-TRIALS; 1ST-LINE THERAPY; COMBINATION; IRINOTECAN; OXALIPLATIN; 5-FLUOROURACIL; CARCINOMA; CISPLATIN; SURVIVAL	BACKGROUND Data are lacking on the efficacy and safety of a combination chemotherapy regimen consisting of oxaliplatin, irinotecan, fluorouracil, and leucovorin (FOLFIRINOX) as compared with gemcitabine as first-line therapy in patients with metastatic pancreatic cancer. METHODS We randomly assigned 342 patients with an Eastern Cooperative Oncology Group performance status score of 0 or 1 (on a scale of 0 to 5, with higher scores indicating a greater severity of illness) to receive FOLFIRINOX (oxaliplatin, 85 mg per square meter of body-surface area; irinotecan, 180 mg per square meter; leucovorin, 400 mg per square meter; and fluorouracil, 400 mg per square meter given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks) or gemcitabine at a dose of 1000 mg per square meter weekly for 7 of 8 weeks and then weekly for 3 of 4 weeks. Six months of chemotherapy were recommended in both groups in patients who had a response. The primary end point was overall survival. RESULTS The median overall survival was 11.1 months in the FOLFIRINOX group as compared with 6.8 months in the gemcitabine group (hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). Median progression-free survival was 6.4 months in the FOLFIRINOX group and 3.3 months in the gemcitabine group (hazard ratio for disease progression, 0.47; 95% CI, 0.37 to 0.59; P<0.001). The objective response rate was 31.6% in the FOLFIRINOX group versus 9.4% in the gemcitabine group (P<0.001). More adverse events were noted in the FOLFIRINOX group; 5.4% of patients in this group had febrile neutropenia. At 6 months, 31% of the patients in the FOLFIRINOX group had a definitive degradation of the quality of life versus 66% in the gemcitabine group (hazard ratio, 0.47; 95% CI, 0.30 to 0.70; P<0.001). CONCLUSIONS As compared with gemcitabine, FOLFIRINOX was associated with a survival advantage and had increased toxicity. FOLFIRINOX is an option for the treatment of patients with metastatic pancreatic cancer and good performance status. (Funded by the French government and others; ClinicalTrials. gov number, NCT00112658.)	[Conroy, Thierry] Ctr Alexis Vautrin, Nancy, France; [Conroy, Thierry] Nancy Univ, Nancy, France; [Desseigne, Francoise; de la Fouchardiere, Christelle] Ctr Leon Berard, F-69373 Lyon, France; [Ychou, Marc; Gourgou-Bourgade, Sophie] Ctr Val Aurelle, Montpellier, France; [Assenat, Eric] Ctr Hosp Univ St Eloi, Montpellier, France; [Bouche, Olivier] Ctr Hosp Univ Robert Debre, Reims, France; [Guimbaud, Rosine] Inst Claudius Regaud, Toulouse, France; [Becouarn, Yves] Inst Bergonie, Bordeaux, France; [Adenis, Antoine] Ctr Oscar Lambret, F-59020 Lille, France; [Raoul, Jean-Luc] Ctr Eugene Marquis, Rennes, France; [Bennouna, Jaafar] Ctr Rene Gauducheau, F-44035 Nantes, France; [Bachet, Jean-Baptiste] Hop Ambroise Pare, Boulogne, France; [Khemissa-Akouz, Faiza] Ctr Hosp, Perpignan, France; [Pere-Verge, Denis] Hop Croix Rousse, F-69317 Lyon, France; [Delbaldo, Catherine] Ctr Hosp Henri Mondor, Creteil, France; [Chauffert, Bruno] Ctr Georges Francois Leclerc, Dijon, France; [Michel, Pierre] Rouen Univ Hosp, Rouen, France; [Michel, Pierre] Univ Rouen, Rouen, France; [Montoto-Grillot, Christine] Uni Canc Bur Etud Clin & Therapeut, Paris, France; [Ducreux, Michel] Inst Gustave Roussy, Villejuif, France; [Ducreux, Michel] Univ Paris 11, Le Kremlin Bicetre, France	UNICANCER; Institut de cancerologie de Lorraine (ICL); Universite de Lorraine; UNICANCER; Centre Leon Berard; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier; CHU de Reims; UNICANCER; Institut Claudius Regaud; UNICANCER; Institut Bergonie; UNICANCER; Centre Oscar Lambret; UNICANCER; Centre Eugene Marquis; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; CHU Lyon; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; UNICANCER; Centre Georges-Francois Leclerc; CHU de Rouen; Universite de Rouen Normandie; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Conroy, T (corresponding author), Ctr Alexis Vautrin, Dept Med Oncol, F-54511 Vandoeuvre Les Nancy, France.	t.conroy@nancy.fnclcc.fr	ADENIS, ANTOINE/AAH-2034-2022; ADENIS, ANTOINE/AFL-9835-2022; Conroy, Thierry/X-8127-2019; de la Fouchardiere, Christelle/AAW-7887-2021; Ducreux, Michel/AAG-9415-2019; BACHET, Jean-Baptiste/N-6943-2017; Sperduti, Isabella/K-8902-2016	Ducreux, Michel/0000-0001-8649-7449; Raoul, Jean-Luc/0000-0001-6305-8953; ghiringhelli, francois/0000-0002-5465-8305; LECOMTE, Thierry/0000-0001-5093-0212; Ychou, Marc/0000-0001-7378-9469; Bennouna, Jaafar/0000-0002-5034-1108; BACHET, Jean-Baptiste/0000-0003-4337-286X; Sperduti, Isabella/0000-0001-5115-3099; DE LA FOUCHARDIERE, CHRISTELLE/0000-0003-2291-5693	French government; French Ministry of Health; Amgen; French National League against Cancer; Pfizer; Roche; AstraZeneca; Boehringer	French government; French Ministry of Health; Amgen(Amgen); French National League against Cancer; Pfizer(Pfizer); Roche(Roche Holding); AstraZeneca(AstraZeneca); Boehringer(Boehringer Ingelheim)	Funded by the French government and others; ClinicalTrials. gov number, NCT00112658.); Supported by Clinical Research Hospital Program grants (PHRC 2004 and 2007) from the French Ministry of Health, and grants from Amgen and the French National League against Cancer.; Dr. Ducreux reports receiving consulting fees from Pfizer, serving on an advisory board for Sanofi-Aventis, receiving payment for the development of educational presentations from Pfizer and Sanofi-Aventis, and receiving grant support to his institution from Pfizer; Dr. Bennouna, serving on advisory boards for Roche, Boehringer, and Bayer, receiving lecture fees from Roche, AstraZeneca, and Amgen, and receiving travel fees from Boehringer and Roche; Dr. Bouche, serving on advisory boards for Roche and Pfizer; Dr. Ychou, serving on advisory boards for Amgen, Bayer, Merck, Novartis, and Roche; and Dr. Bachet, receiving payment for the development of an educational presentation from Janssen-Cilag. No other potential conflict of interest relevant to this article was reported.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Azrak RG, 2004, CLIN CANCER RES, V10, P1121, DOI 10.1158/1078-0432.CCR-0913-3; Bonnetain F, 2010, EUR J CANCER, V46, P2753, DOI 10.1016/j.ejca.2010.07.023; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Colucci G, 2002, CANCER, V94, P902, DOI 10.1002/cncr.10323.abs; Common Terminology Criteria for Adverse Events v3.0 (CTCAE), 2006, COMMON TERMINOLOGY C; Conroy T, 2005, J CLIN ONCOL, V23, P1228, DOI 10.1200/JCO.2005.06.050; Cunningham D, 2009, J CLIN ONCOL, V27, P5513, DOI 10.1200/JCO.2009.24.2446; Di Marco M, 2010, ONCOL REP, V23, P1183, DOI 10.3892/or_00000749; Ducreux M, 2004, ANN ONCOL, V15, P467, DOI 10.1093/annonc/mdh098; *EARL BREAST CANC, 1990, TREATM EARL BREAST C, V1; Fayers P, 2001, QLQC30 EORTC; Fayers P, 1998, QLQC30 EORTC; GAIL M, 1985, BIOMETRICS, V41, P361, DOI 10.2307/2530862; Heinemann V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-82; Heinemann V, 2006, J CLIN ONCOL, V24, P3946, DOI 10.1200/JCO.2005.05.1490; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Hidalgo M, 2010, NEW ENGL J MED, V363, P298; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lima CMR, 2004, J CLIN ONCOL, V22, P3776, DOI 10.1200/JCO.2004.12.082; Louvet C, 2005, J CLIN ONCOL, V23, P3509, DOI 10.1200/JCO.2005.06.023; Mans DRA, 1999, EUR J CANCER, V35, P1851, DOI 10.1016/S0959-8049(99)00222-1; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Mullany S, 1998, CANCER CHEMOTH PHARM, V42, P391, DOI 10.1007/s002800050835; Oettle H, 2006, ANN ONCOL, V17, P535, DOI 10.1093/annonc/mdl032; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Osoba D, 1998, J CLIN ONCOL, V16, P139, DOI 10.1200/JCO.1998.16.1.139; Pavillard V, 1998, BIOCHEM PHARMACOL, V56, P1315, DOI 10.1016/S0006-2952(98)00205-6; Sant M, 2009, EUR J CANCER, V45, P931, DOI 10.1016/j.ejca.2008.11.018; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Ueno H, 2007, CANCER CHEMOTH PHARM, V59, P447, DOI 10.1007/s00280-006-0283-9; WAGENER DJT, 1995, ANN ONCOL, V6, P129, DOI 10.1093/oxfordjournals.annonc.a059107; Ychou M, 2003, ANN ONCOL, V14, P481, DOI 10.1093/annonc/mdg119; Zeghari-Squalli N, 1999, CLIN CANCER RES, V5, P1189	36	4796	4924	8	267	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 12	2011	364	19					1817	1825		10.1056/NEJMoa1011923	http://dx.doi.org/10.1056/NEJMoa1011923			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	762MM	21561347	Bronze			2023-01-03	WOS:000290483000009
J	Iheanacho, I				Iheanacho, Ike			Drug Tales and Other Stories Prescription charges: a tax on the English	BRITISH MEDICAL JOURNAL			English	Editorial Material												iiheanacho@bmjgroup.com							0	0	0	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 23	2011	342								d1790	10.1136/bmj.d1790	http://dx.doi.org/10.1136/bmj.d1790			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742MJ	21429994				2023-01-03	WOS:000288948000020
J	Biadgilign, S; Deribew, A; Amberbir, A; Escudero, HR; Deribe, K				Biadgilign, Sibhatu; Deribew, Amare; Amberbir, Alemayehu; Escudero, Horacio Ruisenor; Deribe, Kebede			Factors Associated with HIV/AIDS Diagnostic Disclosure to HIV Infected Children Receiving HAART: A Multi-Center Study in Addis Ababa, Ethiopia	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MATERNAL DISCLOSURE; OLDER CHILDREN; DISCUSSING HIV; ADOLESCENTS; MOTHERS; AIDS; PERSPECTIVES; CAREGIVERS; ADHERENCE	Background: Diagnostic disclosure of HIV/AIDS to a child is becoming an increasingly common issue in clinical practice. Nevertheless, some parents and health care professionals are reluctant to inform children about their HIV infection status. The objective of this study was to identify the proportion of children who have knowledge of their serostatus and factors associated with disclosure in HIV-infected children receiving HAART in Addis Ababa, Ethiopia. Methods: A cross-sectional study was conducted in five hospitals in Addis Ababa from February 18, 2008-April 28, 2008. The study populations were parents/caretakers and children living with HIV/AIDS who were receiving Highly Active Antiretroviral Therapy (HAART) in selected hospitals in Addis Ababa. Univariate and multivariate logistic regression analysis were carried out using SPSS 12.0.1 statistical software. Results: A total of 390 children/caretaker pairs were included in the study. Two hundred forty three children (62.3%) were between 6-9 years of age. HIV/AIDS status was known by 68 (17.4%) children, 93 (29%) caretakers reported knowing the child's serostatus two years prior to our survey, 180 (46.2%) respondents said that the child should be told about his/her HIV/AIDS status when he/she is older than 14 years of age. Children less than 9 years of age and those living with educated caregivers are less likely to know their results than their counterparts. Children referred from hospital's in-patient ward before attending the HIV clinic and private clinic were more likely to know their results than those from community clinic. Conclusion: The proportion of disclosure of HIV/AIDS diagnosis to HIV-infected children is low. Strengthening referral linkage and health education tailored to educated caregivers are recommended to increase the rate of disclosure.	[Biadgilign, Sibhatu; Deribew, Amare] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Epidemiol & Biostat, Jimma, Ethiopia; [Escudero, Horacio Ruisenor] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Amberbir, Alemayehu] Univ Addis Ababa, Addis Ababa, Ethiopia; [Deribe, Kebede] Jimma Univ, Coll Publ Hlth & Med Sci, Dept Gen Publ Hlth, Jimma, Ethiopia	Jimma University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Addis Ababa University; Jimma University	Biadgilign, S (corresponding author), Jimma Univ, Coll Publ Hlth & Med Sci, Dept Epidemiol & Biostat, Jimma, Ethiopia.	sibhatu2005@yahoo.com	Amberbir, Alemayehu/HGC-2647-2022; Deribe, Kebede/K-7055-2019; Deribe, Kebede/I-5422-2019	Deribe, Kebede/0000-0002-8526-6996; Biadgilign, Sibhatu/0000-0002-7582-5977; Deribew, Amare/0000-0003-2031-6080	Jimma University	Jimma University	This study was funded by Jimma University. The university had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armistead L, 2001, J PEDIATR PSYCHOL, V26, P11, DOI 10.1093/jpepsy/26.1.11; Biadgilign S, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-53; Bikaako-Kajura W, 2006, AIDS BEHAV, V10, pS85, DOI 10.1007/s10461-006-9141-3; Blasini I, 2004, J DEV BEHAV PEDIATR, V25, P181, DOI 10.1097/00004703-200406000-00007; BOR R, 1996, AIDS CARE, V9, P49; Brown LK, 2000, J CHILD PSYCHOL PSYC, V41, P81, DOI 10.1111/1469-7610.00550; Butler AM, 2009, PEDIATRICS, V123, P935, DOI 10.1542/peds.2008-1290; Cohen J, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.1.e8; Ferris M, 2007, AIDS CARE, V19, P1088, DOI 10.1080/09540120701367124; Flanagan-Klygis E, 2002, AIDS PUBLIC POLICY J, V17, P3; FunckBrentano I, 1997, ARCH PEDIAT ADOL MED, V151, P978, DOI 10.1001/archpedi.1997.02170470012002; GRUBMAN S, 1995, PEDIATRICS, V95, P657; Herek GM, 1999, AM BEHAV SCI, V42, P1106, DOI 10.1177/00027649921954787; Kirshenbaum SB, 2002, AIDS EDUC PREV, V14, P1, DOI 10.1521/aeap.14.1.1.24331; Landau G, 2004, HEALTH SOC WORK, V29, P116, DOI 10.1093/hsw/29.2.116; Ledlie SW, 1999, NURS RES, V48, P141, DOI 10.1097/00006199-199905000-00004; Lee CL, 1999, AIDS PATIENT CARE ST, V13, P41, DOI 10.1089/apc.1999.13.41; Lesch A, 2007, AIDS CARE, V19, P811, DOI 10.1080/09540120601129301; LESTER P, 2002, CLIN CHILD PSYCHOL P, V7, P85, DOI DOI 10.1177/1359104502007001007; LIPSON M, 1994, J DEV BEHAV PEDIATR, V15, pS61; Lipson M., 1993, AIDS Clinical Care, V5, P43; Mellins C.A., 2002, CLIN CHILD PSYCHOL P, V7, P101, DOI [https://doi.org/10.1177/1359104502007001008, DOI 10.1177/1359104502007001008, 10.1177/1359104502007001008]; *MIN HLTH ETH FED, 2008, GUID PAED HIV AI JUL; Moodley K, 2006, SAMJ S AFR MED J, V96, pA201; Murphy DA, 2001, J FAM PSYCHOL, V15, P441, DOI 10.1037/0893-3200.15.3.441; Myer L, 2006, J TROP PEDIATRICS, V52, P293, DOI 10.1093/tropej/fml004; NAEEMSHEIK A, 2005, S AFR J HIV MED, V21, P46; NISHI EA, 2004, INT C AIDS JUL 11 16, V15; Oberdorfer P, 2006, J PAEDIATR CHILD H, V42, P283, DOI 10.1111/j.1440-1754.2006.00855.x; Peretti-Watel P, 2006, AIDS CARE, V18, P254, DOI 10.1080/09540120500456193; SEMPLE SJ, 1993, WOMEN HEALTH, V20, P15, DOI 10.1300/J013v20n04_02; Thorne C, 2002, J ACQ IMMUN DEF SYND, V29, P396, DOI 10.1097/00126334-200204010-00011; Thorne C, 2000, CHILD CARE HLTH DEV, V26, P29, DOI 10.1046/j.1365-2214.2000.00128.x; TOMPKINS TL, 1999, CULTURAL DIVERSITY E, V5, P197, DOI DOI 10.1037/1099-9809.5.3.197; UNAIDS, 2010, GLOB AIDS EP UPD REP; WALSH ME, 1991, J PEDIATR PSYCHOL, V16, P273, DOI 10.1093/jpepsy/16.3.273; Weiner L., 1996, PEDIATR AIDS HIV INF, V7, P310; WHO UNICEF, 2008, SCAL HIV REL PREV DI; Wilfert C, 1999, PEDIATRICS, V103, P164	39	69	69	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2011	6	3							e17572	10.1371/journal.pone.0017572	http://dx.doi.org/10.1371/journal.pone.0017572			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	738BC	21445289	gold, Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000288613300009
J	Wanten, G; Calder, PC; Forbes, A				Wanten, Geert; Calder, Philip C.; Forbes, Alastair			Managing adult patients who need home parenteral nutrition	BRITISH MEDICAL JOURNAL			English	Review							SHORT-BOWEL SYNDROME; INTESTINAL FAILURE; MULTICENTER SURVEY; LIVER-DISEASE; TRANSPLANTATION; EUROPE; HYPERMANGANESEMIA; INFECTIONS; PREVALENCE; SEPSIS		[Wanten, Geert] Nutr Support Team, Osaka, Japan		Wanten, G (corresponding author), Nutr Support Team, Osaka, Japan.	g.wanten@mdl.umcn.nl	Calder, Philip C/E-9739-2013; Wanten, G.J.A./L-4742-2015	Calder, Philip C/0000-0002-6038-710X; 	Baxter Healthcare; Geistlich Pharma	Baxter Healthcare; Geistlich Pharma	All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; GW has received speaking fees from Fresenius Kabi, B Braun, Baxter Healthcare, and Geistlich Pharma and is a consultant to Nycomed and Baxter Healthcare; PCC has received speaking honorariums from Fresenius Kabi, B Braun, Baxter Healthcare, Abbott Nutrition, and Nestle and is a consultant to Danone; AF has received speaking honorariums from all these nutrition companies, performed consultative work for Baxter Healthcare and B Braun, and received support from the UK NIHR through its support of the Comprehensive Biomedical Research Centre at University College London; no other relationships or activities that could appear to have influenced the submitted work.	Acca M, 2007, J Endocrinol Invest, V30, P54; Bisseling TM, 2010, CLIN NUTR, V29, P464, DOI 10.1016/j.clnu.2009.12.005; Bozzetti F, 2002, CLIN NUTR, V21, P475, DOI 10.1054/clnu.2002.0578; Bozzetti F, 2009, CLIN NUTR, V28, P359, DOI 10.1016/j.clnu.2009.05.010; Buchman AL, 2003, GASTROENTEROLOGY, V124, P1111, DOI 10.1053/gast.2003.50139; Calder PC, 2010, P NUTR SOC, V69, P565, DOI 10.1017/S0029665110000157; Cauley JA, 2010, J BONE MINER RES; Cavicchi M, 2000, ANN INTERN MED, V132, P525, DOI 10.7326/0003-4819-132-7-200004040-00003; Clare A, 2008, CLIN NUTR, V27, P552, DOI 10.1016/j.clnu.2008.04.013; Crenn P, 2008, CLIN NUTR, V27, P328, DOI 10.1016/j.clnu.2008.02.005; Fishbein TM, 2009, NEW ENGL J MED, V361, P998, DOI 10.1056/NEJMra0804605; Huisman-de Waal G, 2007, CLIN NUTR, V26, P275, DOI 10.1016/j.clnu.2006.10.002; Jeppesen PB, 1999, GUT, V44, P844, DOI 10.1136/gut.44.6.844; Lal S, 2006, ALIMENT PHARM THER, V24, P19, DOI 10.1111/j.1365-2036.2006.02941.x; Messing B, 1999, GASTROENTEROLOGY, V117, P1043, DOI 10.1016/S0016-5085(99)70388-4; O'Keefe SJD, 2006, CLIN GASTROENTEROL H, V4, P6, DOI 10.1016/j.cgh.2005.10.002; OKEEFE SJD, 1994, JPEN-PARENTER ENTER, V18, P256, DOI 10.1177/0148607194018003256; Pironi L, 2002, CLIN NUTR, V21, P289, DOI 10.1054/clnu.2002.0548; Pironi L, 2006, AM J GASTROENTEROL, V101, P1633, DOI 10.1111/j.1572-0241.2006.00710.x; Pittiruti M, 2009, CLIN NUTR, V28, P365, DOI 10.1016/j.clnu.2009.03.015; Reimund JM, 2000, CLIN NUTR, V19, P343, DOI 10.1054/clnu.2000.0120; Santarpia L, 2010, JPEN-PARENTER ENTER, V34, P254, DOI 10.1177/0148607110362900; Staun M, 2009, CLIN NUTR, V28, P467, DOI 10.1016/j.clnu.2009.04.001; Thomas-Gibson S, 2004, CLIN NUTR, V23, P697, DOI 10.1016/j.clnu.2003.11.007; Ugur A, 2006, SCAND J GASTROENTERO, V41, P401, DOI 10.1080/00365520500441247; Van Gossum A, 1999, CLIN NUTR, V18, P135, DOI 10.1016/S0261-5614(99)80002-8; VanGossum A, 1996, CLIN NUTR, V15, P53, DOI 10.1016/S0261-5614(96)80019-7; Versleijen MWJ, 2009, GASTROENTEROLOGY, V136, P1577, DOI 10.1053/j.gastro.2009.02.005; Hernandez MV, 2010, AM J MED SCI, V339, P225, DOI 10.1097/MAJ.0b013e3181c7c89c; Wallis K, 2009, CURR OPIN CLIN NUTR, V12, P526, DOI 10.1097/MCO.0b013e32832d23cd; Wardle CA, 1999, JPEN-PARENTER ENTER, V23, P350, DOI 10.1177/0148607199023006350; Wengler A, 2006, CLIN NUTR, V25, P693, DOI 10.1016/j.clnu.2006.01.026	32	38	38	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 18	2011	342								d1447	10.1136/bmj.d1447	http://dx.doi.org/10.1136/bmj.d1447			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739FR	21421667				2023-01-03	WOS:000288700400003
J	Bleijenberg, G; Knoop, H				Bleijenberg, Gijs; Knoop, Hans			Chronic fatigue syndrome: where to PACE from here?	LANCET			English	Editorial Material							COGNITIVE-BEHAVIOR THERAPY		[Bleijenberg, Gijs; Knoop, Hans] Radboud Univ Nijmegen, Expert Ctr Chron Fatigue, Med Ctr, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Bleijenberg, G (corresponding author), Radboud Univ Nijmegen, Expert Ctr Chron Fatigue, Med Ctr, NL-6500 HB Nijmegen, Netherlands.	G.Bleijenberg@nkcv.umcn.nl	Knoop, Hans/D-3264-2009; Bleijenberg, Gijs/E-6984-2010	Knoop, Hans/0000-0001-7763-3517; 	Medical Research Council [G0200434] Funding Source: Medline; MRC [G0200434] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Heins MJ, 2010, PSYCHOTHER PSYCHOSOM, V79, P249, DOI 10.1159/000315130; Knoop H, 2007, PSYCHOTHER PSYCHOSOM, V76, P171, DOI 10.1159/000099844; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; White PD, 2011, LANCET, V377, P823, DOI 10.1016/S0140-6736(11)60096-2; Wiborg JF, 2010, PSYCHOL MED, V40, P1281, DOI 10.1017/S0033291709992212; WIBORG JF, 2011, J PSYCHOSOM RES	6	7	7	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 5	2011	377	9768					786	788		10.1016/S0140-6736(11)60172-4	http://dx.doi.org/10.1016/S0140-6736(11)60172-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	738GO	21334060				2023-01-03	WOS:000288628500005
J	Martiniova, L; Lu, J; Chiang, J; Bernardo, M; Lonser, R; Zhuang, ZP; Pacak, K				Martiniova, Lucia; Lu, Jie; Chiang, Jeffrey; Bernardo, Marcelino; Lonser, Russell; Zhuang, Zhengping; Pacak, Karel			Pharmacologic Modulation of Serine/Threonine Phosphorylation Highly Sensitizes PHEO in a MPC Cell and Mouse Model to Conventional Chemotherapy	PLOS ONE			English	Article							POLO-LIKE KINASE-1; DNA-DAMAGE; CANCER-CHEMOTHERAPY; PHEOCHROMOCYTOMA; INHIBITION; CYCLE; PARAGANGLIOMA; TEMOZOLOMIDE; DACARBAZINE; CYCLOPHOSPHAMIDE	Background: The failure of cytotoxic cancer regimens to cure the most drug-resistant, well-differentiated solid tumors has attributed to the heterogeneity of cell types that differ in their capacities for growth, differentiation, and metastases. We investigated the effect of LB1, a small molecule inhibitor of serine/threonine protein phosphatase 2A (PP2A), on its ability to inhibit a low growth fraction and highly drug-resistant solid neuroendocrine tumor, such as metastatic pheochromocytoma (PHEO). Subsequently, we evaluated the increased efficacy of chemotherapy combined with LB1. Methodology/Principal Findings: The effect of LB1 and temozolomide (TMZ), a standard chemotherapeutic agent that alone only transiently suppressed the growth and regression of metastatic PHEO, was evaluated in vitro on a single PHEO cell line and in vivo on mouse model of metastatic PHEO. In the present study, we show that metastatic PHEO, for which there is currently no cure, can be eliminated by combining LB1, thereby inhibiting PP2A, with TMZ. This new treatment approach resulted in long term, disease-free survival of up to 40% of animals bearing multiple intrahepatic metastases, a disease state that the majority of patients die from. Inhibition of PP2A was associated with prevention of G1/S phase arrest by p53 and of mitotic arrest mediated by polo-like kinase 1 (Plk-1). Conclusions/Significance: The elimination of DNA damage-induced defense mechanisms, through transient pharmacologic inhibition of PP2A, is proposed as a new approach for enhancing the efficacy of non-specific cancer chemotherapy regimens against a broad spectrum of low growth fraction tumors very commonly resistant to cytotoxic drugs.	[Martiniova, Lucia; Pacak, Karel] NICHHD, Reprod & Adult Endocrinol Program, NIH, Bethesda, MD 20892 USA; [Lu, Jie; Lonser, Russell; Zhuang, Zhengping] Natl Inst Neurol Disorders & Stroke, Surg Neurol Branch, NIH, Bethesda, MD USA; [Chiang, Jeffrey] NCI, Expt Immunol Branch, NIH, Bethesda, MD 20892 USA; [Bernardo, Marcelino] NCI, Mol Imaging Program, NIH, Bethesda, MD 20892 USA; [Bernardo, Marcelino] NCI, Lab Anim Sci Program, SAIC Frederick, Frederick, MD 21701 USA; [Martiniova, Lucia] Slovak Acad Sci, Inst Expt Endocrinol, Bratislava, Slovakia	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Slovak Academy of Sciences	Martiniova, L (corresponding author), NICHHD, Reprod & Adult Endocrinol Program, NIH, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov; karel@mail.nih.gov			National Institutes of Health; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Cancer Institute; National Institute of Neurological Disorders and Stroke (NINDS); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD008735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [ZIANS003052] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute of Neurological Disorders and Stroke (NINDS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This research was supported by the Intramural Research Programs of the National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Cancer Institute, and the National Institute of Neurological Disorders and Stroke (NINDS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amar L, 2005, J CLIN ONCOL, V23, P8812, DOI 10.1200/JCO.2005.03.1484; Baysal BE, 2008, J MED GENET, V45, P689, DOI 10.1136/jmg.2008.058560; Bazin PL, 2007, J NEUROSCI METH, V165, P111, DOI 10.1016/j.jneumeth.2007.05.024; Blagosklonny MV, 2007, CELL CYCLE, V6, P70, DOI 10.4161/cc.6.1.3682; Bravo EL, 2009, HORM METAB RES, V41, P703, DOI 10.1055/s-0029-1224135; Brouwers FM, 2006, J CLIN ENDOCR METAB, V91, P4505, DOI 10.1210/jc.2006-0423; Burnichon N, 2009, J CLIN ENDOCR METAB, V94, P2817, DOI 10.1210/jc.2008-2504; Chiang YJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002639; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Darzynkiewicz Z, 2009, EUR J PHARMACOL, V625, P143, DOI 10.1016/j.ejphar.2009.05.032; Goodarzi H, 2009, MOL CELL, V36, P900, DOI 10.1016/j.molcel.2009.11.016; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj/onc/1205181; Huang H, 2008, CANCER-AM CANCER SOC, V113, P2020, DOI 10.1002/cncr.23812; Jang YJ, 2007, J BIOL CHEM, V282, P2473, DOI 10.1074/jbc.M605480200; KOVACH JS, 2008, Patent No. 2008097561; Kulke MH, 2006, J CLIN ONCOL, V24, P401, DOI 10.1200/JCO.2005.03.6046; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Lu J, 2009, P NATL ACAD SCI USA, V106, P11697, DOI 10.1073/pnas.0905930106; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; MARTINIOVA L, 2010, ENDOCR RELAT CA 1122; Martiniova L, 2009, J MAGN RESON IMAGING, V29, P685, DOI 10.1002/jmri.21654; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Middleton MR, 2000, J CLIN ONCOL, V18, P158, DOI 10.1200/JCO.2000.18.1.158; Mougey AM, 2007, HOSP PHYS, V43, P12; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Nomura K, 2009, J CLIN ENDOCR METAB, V94, P2850, DOI 10.1210/jc.2008-2697; PACAK K, 1995, ENDOCRINOLOGY, V136, P4814, DOI 10.1210/en.136.11.4814; PARDEE AB, 1975, P NATL ACAD SCI USA, V72, P4994, DOI 10.1073/pnas.72.12.4994; Powers JF, 2000, CELL TISSUE RES, V302, P309, DOI 10.1007/s004410000290; Shah MA, 2001, CLIN CANCER RES, V7, P2168; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Tischler AS, 2008, ENDOCR PATHOL, V19, P207, DOI 10.1007/s12022-008-9047-x; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Zhuang ZP, 2009, CELL CYCLE, V8, P3303, DOI 10.4161/cc.8.20.9689	36	34	39	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 14	2011	6	2							e14678	10.1371/journal.pone.0014678	http://dx.doi.org/10.1371/journal.pone.0014678			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721PR	21339823	Green Published, Green Submitted, gold			2023-01-03	WOS:000287367600007
J	Spencer, B; Marr, RA; Gindi, R; Potkar, R; Michael, S; Adame, A; Rockenstein, E; Verma, IM; Masliah, E				Spencer, Brian; Marr, Robert A.; Gindi, Ryan; Potkar, Rewati; Michael, Sarah; Adame, Anthony; Rockenstein, Edward; Verma, Inder M.; Masliah, Eliezer			Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces A beta Toxicity in a Mouse Model of Alzheimer's Disease	PLOS ONE			English	Article							AMYLOID-BETA; TRANSGENIC MICE; PLAQUE-FORMATION; IN-VIVO; NEUTRAL ENDOPEPTIDASE; TAU PHOSPHORYLATION; PEPTIDE DEGRADATION; LENTIVIRAL VECTORS; NEPRILYSIN; OLIGOMERS	Alzheimer's disease (AD), an incurable, progressive neurodegenerative disorder, is the most common form of dementia. Therapeutic options have been elusive due to the inability to deliver proteins across the blood-brain barrier (BBB). In order to improve the therapeutic potential for AD, we utilized a promising new approach for delivery of proteins across the BBB. We generated a lentivirus vector expressing the amyloid beta-degrading enzyme, neprilysin, fused to the ApoB transport domain and delivered this by intra-peritoneal injection to amyloid protein precursor (APP) transgenic model of AD. Treated mice had reduced levels of A beta, reduced plaques and increased synaptic density in the CNS. Furthermore, mice treated with the neprilysin targeting the CNS had a reversal of memory deficits. Thus, the addition of the ApoB transport domain to the secreted neprilysin generated a non-invasive therapeutic approach that may be a potential treatment in patients with AD.	[Spencer, Brian; Gindi, Ryan; Potkar, Rewati; Michael, Sarah; Adame, Anthony; Rockenstein, Edward; Masliah, Eliezer] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Marr, Robert A.] Rosalind Franklin Univ Med & Sci, Ctr Stem Cell & Regenerat Med, Dept Neurosci, N Chicago, IL USA; [Verma, Inder M.] Salk Inst Biol Studies, Genet Lab, San Diego, CA USA; [Masliah, Eliezer] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Rosalind Franklin University Medical & Science; Salk Institute; University of California System; University of California San Diego	Spencer, B (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	emasliah@ucsd.edu			National Institutes of Health [AG022074, AG18440, AG010435]; NATIONAL INSTITUTE ON AGING [P01AG010435, R37AG018440, P01AG022074, R01AG018440] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institutes of Health AG022074, AG18440, AG010435. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arvanitis DN, 2007, J NEUROCHEM, V103, P216, DOI 10.1111/j.1471-4159.2007.04704.x; Ashford JW, 2004, J MOL NEUROSCI, V23, P157, DOI 10.1385/JMN:23:3:157; Betts V, 2008, NEUROBIOL DIS, V31, P442, DOI 10.1016/j.nbd.2008.06.001; CONNELLY JC, 1993, J LEUKOCYTE BIOL, V53, P685, DOI 10.1002/jlb.53.6.685; Crouch PJ, 2009, P NATL ACAD SCI USA, V106, P381, DOI 10.1073/pnas.0809057106; Cuello AC, 2008, NEURODEGENER DIS, V5, P146, DOI 10.1159/000113686; Cuello AC, 2005, BRAIN PATHOL, V15, P66; Eisele YS, 2007, MOL BIOL CELL, V18, P3591, DOI 10.1091/mbc.E07-01-0035; Gouras GK, 2010, ACTA NEUROPATHOL, V119, P523, DOI 10.1007/s00401-010-0679-9; Hemming ML, 2007, PLOS MED, V4, P1405, DOI 10.1371/journal.pmed.0040262; Hof PR, 1996, J AM GERIATR SOC, V44, P857, DOI 10.1111/j.1532-5415.1996.tb03748.x; Hong CS, 2006, GENE THER, V13, P1068, DOI 10.1038/sj.gt.3302719; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Huang F, 1999, AM J PATHOL, V155, P1741, DOI 10.1016/S0002-9440(10)65489-2; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; IIJIMAANDO K, 2008, J BIOL CHEM; Iwata N, 2004, J NEUROSCI, V24, P991, DOI 10.1523/JNEUROSCI.4792-03.2004; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; LaFerla FM, 2007, NAT REV NEUROSCI, V8, P499, DOI 10.1038/nrn2168; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Li SM, 2009, NEURON, V62, P788, DOI 10.1016/j.neuron.2009.05.012; Liu YX, 2009, MOL THER, V17, P1381, DOI 10.1038/mt.2009.115; Marr RA, 2010, CURR ALZHEIMER RES, V7, P223, DOI 10.2174/156720510791050849; Marr RA, 2003, J NEUROSCI, V23, P1992; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Meilandt WJ, 2009, J NEUROSCI, V29, P1977, DOI 10.1523/JNEUROSCI.2984-08.2009; Mohajeri MH, 2004, FEBS LETT, V562, P16, DOI 10.1016/S0014-5793(04)00169-3; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Pardridge WM, 2002, NEURON, V36, P555, DOI 10.1016/S0896-6273(02)01054-1; Pfeifer A, 2001, MOL THER, V3, P319, DOI 10.1006/mthe.2001.0276; Pham E, 2010, FEBS J, V277, P3051, DOI 10.1111/j.1742-4658.2010.07719.x; Poon HF, 2004, BRAIN RES, V1018, P86, DOI 10.1016/j.brainres.2004.05.048; Ray J, 1997, P NATL ACAD SCI USA, V94, P7047, DOI 10.1073/pnas.94.13.7047; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; Rockenstein E, 2005, J NEUROSCI RES, V80, P247, DOI 10.1002/jnr.20446; Rockenstein E, 2001, J NEUROSCI RES, V66, P573, DOI 10.1002/jnr.1247; Rose JB, 2009, J NEUROSCI, V29, P1115, DOI 10.1523/JNEUROSCI.4220-08.2009; Saito T, 2005, NAT MED, V11, P434, DOI 10.1038/nm1206; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; SHIPP MA, 1991, BLOOD, V78, P1834; Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531; Spencer B. J., 2007, P NATL ACAD SCI US; Spencer B, 2009, J NEUROSCI, V29, P13578, DOI 10.1523/JNEUROSCI.4390-09.2009; Spencer B, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-109; Terry Robert D., 1994, P179; Tian JZ, 2009, CURR ALZHEIMER RES, V6, P118, DOI 10.2174/156720509787602942; Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37; Tomiyama T, 2010, J NEUROSCI, V30, P4845, DOI 10.1523/JNEUROSCI.5825-09.2010; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wirths O, 2010, J NEURAL TRANSM, V117, P85, DOI 10.1007/s00702-009-0314-x; Yamamoto M, 2008, J IMMUNOL, V181, P3877, DOI 10.4049/jimmunol.181.6.3877; Yang LL, 2009, J PHARM PHARMACOL, V61, P375, DOI [10.1211/jpp/61.03.0013, 10.1211/jpp.61.03.0013]	55	56	59	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16575	10.1371/journal.pone.0016575	http://dx.doi.org/10.1371/journal.pone.0016575			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	21304989	Green Published, gold, Green Submitted			2023-01-03	WOS:000286834300089
J	Stepney, R				Stepney, Rob			Christmas 2010: Reading Between the Lines A dose by any other name would not sell as sweet	BRITISH MEDICAL JOURNAL			English	Editorial Material												walcot2@freenetname.co.uk						*GLAXOSMITHKLINE, 2010, OUR HIST; HERPER M, 2004, FORBES          0316; Mills JG, 1997, ALIMENT PHARM THER, V11, P129, DOI 10.1046/j.1365-2036.1997.136312000.x; *WELLC TRUST, INV HIST; 2010, FASTEST CARS WORLD T	5	6	6	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	DEC 15	2010	341								c6895	10.1136/bmj.c6895	http://dx.doi.org/10.1136/bmj.c6895			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	697XJ	21159760				2023-01-03	WOS:000285552800001
J	McLachlan, JC				McLachlan, John C.			Christmas 2010: Reading between the Lines Integrative medicine and the point of credulity	BRITISH MEDICAL JOURNAL			English	Editorial Material									[McLachlan, John C.] Univ Durham, Sch Med & Hlth, Stockton On Tees TS17 6BH, England	Durham University	McLachlan, JC (corresponding author), Univ Durham, Sch Med & Hlth, Stockton On Tees TS17 6BH, England.	j.c.mclachlan@durham.ac.uk	McLachlan, John/AAF-4203-2021	McLachlan, John/0000-0001-5493-2645				DIXON M, 2009, SCI BASED MED; *HOUS COMM SCI TEC, 4 HOUS COMM SCI TECH; Sokal A., 1998, INTELLECTUAL IMPOSTU; Sokal A., 1996, SOCIAL TEXT, V46/47, P217, DOI [10.2307/466856, DOI 10.2307/466856]; Strauss S, 2005, EVIDENCE BASED MED P, V3rd; 2009, DCS IMPROBABLE SCI	6	7	7	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 8	2010	341								c6979	10.1136/bmj.c6979	http://dx.doi.org/10.1136/bmj.c6979			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	694ZL	21147748				2023-01-03	WOS:000285340300006
J	Zhang, YT; Baicker, K; Newhouse, JP				Zhang, Yuting; Baicker, Katherine; Newhouse, Joseph P.			Geographic Variation in the Quality of Prescribing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Zhang, Yuting] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA; [Baicker, Katherine; Newhouse, Joseph P.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Newhouse, Joseph P.] Harvard Univ, Kennedy Sch Govt, Cambridge, MA 02138 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University	Zhang, YT (corresponding author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA.		Newhouse, Joseph/AGJ-5632-2022; Newhouse, Joseph/AAD-9763-2019	Zhang, Yuting/0000-0002-6460-6779	NATIONAL INSTITUTE OF MENTAL HEALTH [RC1MH088510] Funding Source: NIH RePORTER; NIMH NIH HHS [RC1 MH088510-01, RC1 MH088510] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		*NAT COMM QUAL ASS, 2009, STAT HLTH CAR QUAL; National Committee for Quality Assurance, 2010, HEALTHC EFF DAT INF; Song YJ, 2010, NEW ENGL J MED, V363, P198; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Zhang YT, 2010, NEW ENGL J MED, V363, P405, DOI 10.1056/NEJMp1004872	5	93	93	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1985	1988		10.1056/NEJMp1010220	http://dx.doi.org/10.1056/NEJMp1010220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21047217	Green Accepted			2023-01-03	WOS:000284310000002
J	van Rijn, RM; van Ochten, J; Luijsterburg, PAJ; van Middelkoop, M; Koes, BW; Bierma-Zeinstra, SMA				van Rijn, Rogier M.; van Ochten, John; Luijsterburg, Pim A. J.; van Middelkoop, Marienke; Koes, Bart W.; Bierma-Zeinstra, Sita M. A.			Effectiveness of additional supervised exercises compared with conventional treatment alone in patients with acute lateral ankle sprains: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							REHABILITATION; LIGAMENTS; INTERVENTION; INJURY; TEARS	Objective To summarise the effectiveness of adding supervised exercises to conventional treatment compared with conventional treatment alone in patients with acute lateral ankle sprains. Design Systematic review. Datasources Medline, Embase, Cochrane Central Register of Controlled Trials, Cinahl, and reference screening. Study selection Included studies were randomised controlled trials, quasi-randomised controlled trials, or clinical trials. Patients were adolescents or adults with an acute lateral ankle sprain. The treatment options were conventional treatment alone or conventional treatment combined with supervised exercises. Two reviewers independently assessed the risk of bias, and one reviewer extracted data. Because of clinical heterogeneity we analysed the data using a best evidence synthesis. Follow-up was classified as short term (up to two weeks), intermediate (two weeks to three months), and long term (more than three months). Results 11 studies were included. There was limited to moderate evidence to suggest that the addition of supervised exercises to conventional treatment leads to faster and better recovery and a faster return to sport at short term follow-up than conventional treatment alone. In specific populations (athletes, soldiers, and patients with severe injuries) this evidence was restricted to a faster return to work and sport only. There was no strong evidence of effectiveness for any of the outcome measures. Most of the included studies had a high risk of bias, with few having adequate statistical power to detect clinically relevant differences. Conclusion Additional supervised exercises compared with conventional treatment alone have some benefit for recovery and return to sport in patients with ankle sprain, though the evidence is limited or moderate and many studies are subject to bias.	[van Rijn, Rogier M.; van Ochten, John; Luijsterburg, Pim A. J.; van Middelkoop, Marienke; Koes, Bart W.; Bierma-Zeinstra, Sita M. A.] Erasmus MC, Univ Med Ctr, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	van Rijn, RM (corresponding author), Erasmus MC, Univ Med Ctr, Dept Gen Practice, POB 2040, NL-3000 CA Rotterdam, Netherlands.	r.vanrijn@erasmusmc.nl	Bierma-Zeinstra, Sita/AAF-2122-2019; Koes, Bart w/K-4614-2016	Koes, Bart w/0000-0002-0450-9969; van Middelkoop, Marienke/0000-0001-6926-0618	Department of General Practice, Erasmus MC University Medical Center	Department of General Practice, Erasmus MC University Medical Center	This study was funded by the Department of General Practice, Erasmus MC University Medical Center.	Bassett SF, 2007, PHYS THER, V87, P1132, DOI 10.2522/ptj.20060260; Bleakley CM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1964; BROOKS SC, 1981, BMJ-BRIT MED J, V282, P606, DOI 10.1136/bmj.282.6264.606; Fong DTP, 2007, SPORTS MED, V37, P73, DOI 10.2165/00007256-200737010-00006; Freeman M A, 1965, J Bone Joint Surg Br, V47, P661; Freeman M A, 1965, J Bone Joint Surg Br, V47, P678; GOUDSWAARD AN, 2000, DUTCH COLL GEN PRACT; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Holme E, 1999, SCAND J MED SCI SPOR, V9, P104; Hultman K, 2010, EUR J PHYSIOTHER, V12, P65, DOI 10.3109/14038190903174262; KANNUS P, 1991, J BONE JOINT SURG AM, V73A, P305, DOI 10.2106/00004623-199173020-00021; Karlsson J, 1996, SCAND J MED SCI SPOR, V6, P341; Kerkhoffs GM, 2002, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003762; Kerkhoffs GMMJ, 2002, COCHRANE DB SYST REV, V3; KERKHOFFSGM, 2002, COCHRANE DB SYST REV, V3; Mattacola CG, 2002, J ATHL TRAINING, V37, P413; McKeon PO, 2008, J ATHL TRAINING, V43, P305, DOI 10.4085/1062-6050-43.3.305; Nilsson S, 1983, J Oslo City Hosp, V33, P13; Oostendorp RAB, 1987, GENEESKD SPORT, V20, P45; Pijnenburg ACM, 2000, J BONE JOINT SURG AM, V82A, P761, DOI 10.2106/00004623-200006000-00002; Reinhardt C, 1999, DTSCH Z SPORTMED, V50, P89; Roycroft S, 1983, Physiotherapy, V69, P355; Rozzi SL, 1999, J ORTHOP SPORT PHYS, V29, P478, DOI 10.2519/jospt.1999.29.8.478; SCHMIKLI SL, 2004, NOC NSF ARNHEM; van der Linden M.W., 2004, 2 NATL STUDIE NAAR Z; van Os AG, 2005, J ORTHOP SPORT PHYS, V35, P95, DOI 10.2519/jospt.2005.35.2.95; van Rijn RM, 2008, AM J MED, V121, P324, DOI 10.1016/j.amjmed.2007.11.018; van Rijn RM, 2007, BRIT J GEN PRACT, V57, P793; van Rijn RM, 2009, AUST J PHYSIOTHER, V55, P107, DOI 10.1016/S0004-9514(09)70040-6; van Tulder MW, 2009, SPINE, V34, P1685, DOI 10.1097/BRS.0b013e3181ab6a78; Van Tulder MW, 2000, COCHRANE DB SYST REV, V2; VANDERWEES PJ, 2006, ROYAL DUTCH SOC PHYS; Wester JU, 1996, J ORTHOP SPORT PHYS, V23, P332, DOI 10.2519/jospt.1996.23.5.332	33	34	36	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 26	2010	341								c5688	10.1136/bmj.c5688	http://dx.doi.org/10.1136/bmj.c5688			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	674YE	20978065	Green Published, Green Submitted, hybrid			2023-01-03	WOS:000283786800006
J	Dutton, AJ; Hepburn, C; Macdonald, DW				Dutton, Adam J.; Hepburn, Cameron; Macdonald, David W.			A Stated Preference Investigation into the Chinese Demand for Farmed vs. Wild Bear Bile	PLOS ONE			English	Article							URSODEOXYCHOLIC ACID; HEALTH	Farming of animals and plants has recently been considered not merely as a more efficient and plentiful supply of their products but also as a means of protecting wild populations from that trade. Amongst these nascent farming products might be listed bear bile. Bear bile has been exploited by traditional Chinese medicinalists for millennia. Since the 1980s consumers have had the options of: illegal wild gall bladders, bile extracted from caged live bears or the acid synthesised chemically. Despite these alternatives bears continue to be harvested from the wild. In this paper we use stated preference techniques using a random sample of the Chinese population to estimate demand functions for wild bear bile with and without competition from farmed bear bile. We find a willingness to pay considerably more for wild bear bile than farmed. Wild bear bile has low own price elasticity and cross price elasticity with farmed bear bile. The ability of farmed bear bile to reduce demand for wild bear bile is at best limited and, at prevailing prices, may be close to zero or have the opposite effect. The demand functions estimated suggest that the own price elasticity of wild bear bile is lower when competing with farmed bear bile than when it is the only option available. This means that the incumbent product may actually sell more items at a higher price when competing than when alone in the market. This finding may be of broader interest to behavioural economists as we argue that one explanation may be that as product choice increases price has less impact on decision making. For the wildlife farming debate this indicates that at some prices the introduction of farmed competition might increase the demand for the wild product.	[Dutton, Adam J.; Macdonald, David W.] Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Recanati Kaplan Ctr, Oxford OX1 3PS, England; [Hepburn, Cameron] Univ Oxford, Smith Sch Enterprise & Environm, Said Business Sch, Oxford, England; [Hepburn, Cameron] Univ Oxford, James Martin Inst, Said Business Sch, Oxford, England	University of Oxford; University of Oxford; University of Oxford	Dutton, AJ (corresponding author), Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Recanati Kaplan Ctr, S Parks Rd, Oxford OX1 3PS, England.	adam.dutton@zoo.ox.ac.uk		Hepburn, Cameron/0000-0003-0467-7441	World Society for the Protection of Animals (WSPA)	World Society for the Protection of Animals (WSPA)	The funding for this work came from the World Society for the Protection of Animals (WSPA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], PRESS CS CHIN STAT Y; [Anonymous], AHAN BEAR BIL FARM V; [Anonymous], 2005, FINDING HERBAL ALTER; Barclay L, 2003, ANN SURG, V238, P697; Bateman I.J., 2002, EC VALUATION STATED, DOI DOI 10.4337/9781781009727; Bekoff M, 2009, BEAR TAPPING BILE BU; Bensky D., 2004, MAT MED CHINESE HERB, Vthird; Blamey RK, 2000, ECOL ECON, V32, P269, DOI 10.1016/S0921-8009(99)00101-9; de Bekker-Grob EW, 2010, VALUE HEALTH, V13, P315, DOI 10.1111/j.1524-4733.2009.00670.x; Dutton A, KEY TOPICS IN PRESS; eTranslate, 2006, SHOP SURV CHIN; GARSHELIS DL, 2007, URSUS THIBETANUS ASI; Gratwicke B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002544; Group ICS, 2006, CSG STEER COMM M MON; HAGEY LR, 1993, J LIPID RES, V34, P1911; Howitt P., 1987, MONEY ILLUSION NEW P, VIII, P518; Huang J, 1994, ASIAN PERSPECTIVES T; Hutchings JA, 2000, NATURE, V406, P882, DOI 10.1038/35022565; Hutton J, 2003, TRADE IN WILDLIFE: REGULATION FOR CONSERVATION, P108; Ikegami T, 1998, CANCER LETT, V134, P129, DOI 10.1016/S0304-3835(98)00248-1; IUCN, IUCN RED LIST THREAT; Kanazawa T, 1954, P JPN ACAD, V30, P391, DOI 10.2183/pjab1945.30.391; KISH L, 1949, J AM STAT ASSOC, V44, P380, DOI 10.2307/2280236; Loeffler IK, 2009, ANIM WELFARE, V18, P225; Mainka SA, 1995, J ZOO WILDLIFE MED, V26, P193; Mills J, 1994, ASIAN TRADE BEARS BE, P161; MISHAN EJ, 1971, J POLIT ECON, V79, P687, DOI 10.1086/259784; Nowell K., 2000, FAR CURE TIGER TRADE; Peppin L, 2008, J FORENSIC SCI, V53, P1358, DOI 10.1111/j.1556-4029.2008.00857.x; Peyton B., 1999, BEARS STATUS SURVEY; Phillips T, 2002, BEAR BILE BUSINESS; Raloff J, 2005, SCI NEWS, V168, P250; Roda E, 2002, DIGEST LIVER DIS, V34, P523, DOI 10.1016/S1590-8658(02)80112-8; Servheen C., 1994, P INT S TRAD BEAR PA; Shoda M, 1927, J BIOCH, V7, P505; Tanaka MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005192; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WSPA, 2010, INS BEAR FARMS; Wyler LS, 2009, INT ILLEGAL WILDLIFE	39	65	67	3	47	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2011	6	7							e21243	10.1371/journal.pone.0021243	http://dx.doi.org/10.1371/journal.pone.0021243			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	794WE	21799733	Green Published, gold, Green Submitted			2023-01-03	WOS:000292931200006
J	Deweerdt, S				DeWeerdt, Sarah			PREVENTION Activity is the best medicine	NATURE			English	Editorial Material							COGNITIVE DECLINE; ALZHEIMER-DISEASE; PHYSICAL-ACTIVITY; OLDER-ADULTS; RISK; DEMENTIA; DIET											Barnes LL, 2004, NEUROLOGY, V63, P2322, DOI 10.1212/01.WNL.0000147473.04043.B3; Belleville S, 2011, BRAIN, V134, P1623, DOI 10.1093/brain/awr037; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Feart C, 2009, JAMA-J AM MED ASSOC, V302, P638, DOI 10.1001/jama.2009.1146; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Savica R, 2011, PSYCHIAT CLIN N AM, V34, P127, DOI 10.1016/j.psc.2010.11.006; Scarmeas N, 2009, JAMA-J AM MED ASSOC, V302, P627, DOI 10.1001/jama.2009.1144; Tangney CC, 2011, AM J CLIN NUTR, V93, P601, DOI 10.3945/ajcn.110.007369; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805	9	32	33	3	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2011	475	7355					S16	S17		10.1038/475S16a	http://dx.doi.org/10.1038/475S16a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	791UA	21760577	Bronze			2023-01-03	WOS:000292690500008
J	Gray, RA; Wikswo, JP				Gray, Richard A.; Wikswo, John P.			CARDIOVASCULAR DISEASE Several small shocks beat one big one	NATURE			English	Editorial Material							ATRIAL-FIBRILLATION; FIELD STIMULATION; VIRTUAL ELECTRODES; CARDIAC TISSUE; DEFIBRILLATION; MECHANISM; FEEDBACK; HEART; TIME		[Gray, Richard A.] US FDA, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA; [Wikswo, John P.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA; [Wikswo, John P.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37235 USA; [Wikswo, John P.] Vanderbilt Univ, Dept Phys & Astron, Nashville, TN 37235 USA	US Food & Drug Administration (FDA); Vanderbilt University; Vanderbilt University; Vanderbilt University	Gray, RA (corresponding author), US FDA, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.	richard.gray@fda.hhs.gov; john.wikswo@vanderbilt.edu	Gray, Richard/F-3916-2015	Gray, Richard/0000-0003-2798-6378				ALLESSIE M, 1991, CIRCULATION, V84, P1689, DOI 10.1161/01.CIR.84.4.1689; Bishop MJ, 2010, IEEE T BIO-MED ENG, V57, P2335, DOI 10.1109/TBME.2010.2051227; CARTEE LA, 1992, IEEE T BIO-MED ENG, V39, P76, DOI 10.1109/10.108130; DAVIDENKO JM, 1995, CIRC RES, V77, P1166, DOI 10.1161/01.RES.77.6.1166; Ditto WL, 2000, INT J BIFURCAT CHAOS, V10, P593, DOI 10.1142/S0218127400000402; Dosdall DJ, 2007, HEART RHYTHM, V4, pS51, DOI 10.1016/j.hrthm.2006.12.030; Fishler MG, 1998, J CARDIOVASC ELECTR, V9, P384, DOI 10.1111/j.1540-8167.1998.tb00926.x; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; Hosfeld VD, 2007, J BIOL PHYS, V33, P145, DOI 10.1007/s10867-007-9049-9; IDEKER RE, 1995, PACE, V18, P512, DOI 10.1111/j.1540-8159.1995.tb02562.x; Kok LC, 2004, CARDIOL CLIN, V22, P71, DOI 10.1016/S0733-8651(03)00113-9; Luther S, 2011, NATURE, V475, P235, DOI 10.1038/nature10216; Maleckar MM, 2008, AM J PHYSIOL-HEART C, V295, pH1626, DOI 10.1152/ajpheart.00706.2008; Pak HN, 2003, AM J PHYSIOL-HEART C, V285, pH2704, DOI 10.1152/ajpheart.00366.2003; Pumir A, 2007, PHYS REV LETT, V99, DOI 10.1103/PhysRevLett.99.208101; Sobie EA, 1997, BIOPHYS J, V73, P1410, DOI 10.1016/S0006-3495(97)78173-6; TRAYANOVA NA, 1993, IEEE T BIO-MED ENG, V40, P899, DOI 10.1109/10.245611; Wikswo JP, 1995, BIOPHYS J, V69, P2195, DOI 10.1016/S0006-3495(95)80115-3	18	13	14	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 14	2011	475	7355					181	182		10.1038/475181a	http://dx.doi.org/10.1038/475181a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	791UA	21753846				2023-01-03	WOS:000292690500039
J	Chen, K; Xu, XM; Kobayashi, S; Timm, D; Jepperson, T; Liang, QR				Chen, Kai; Xu, Xianmin; Kobayashi, Satoru; Timm, Derek; Jepperson, Tyler; Liang, Qiangrong			Caloric Restriction Mimetic 2-Deoxyglucose Antagonizes Doxorubicin-induced Cardiomyocyte Death by Multiple Mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; HEART-FAILURE; SIGNALING PATHWAY; OXIDATIVE STRESS; IN-VITRO; DIETARY SUPPLEMENTATION; REGULATES AUTOPHAGY; ENERGY RESTRICTION; TRANSGENIC MICE; CANCER-THERAPY	Caloric restriction (CR) is a dietary intervention known to enhance cardiovascular health. The glucose analog 2-deoxy-D-glucose (2-DG) mimics CR effects in several animal models. However, whether 2-DG is beneficial to the heart remains obscure. Here, we tested the ability of 2-DG to reduce cardiomyocyte death triggered by doxorubicin (DOX, 1 mu M), an antitumor drug that can cause heart failure. Treatment of neonatal rat cardiomyocytes with 0.5 mM 2-DG dramatically suppressed DOX cytotoxicity as indicated by a decreased number of cells that stained positive for propidium iodide and reduced apoptotic markers. 2-DG decreased intracellular ATP levels by 17.9%, but it prevented DOX-induced severe depletion of ATP, which may contribute to 2-DG-mediated cytoprotection. Also, 2-DG increased the activity of AMP-activated protein kinase (AMPK). Blocking AMPK signaling with compound C or small interfering RNA-mediated knockdown of the catalytic subunit markedly attenuated the protective effects of 2-DG. Conversely, AMPK activation by pharmacological or genetic approach reduced DOX cardiotoxicity but did not produce additive effects when used together with 2-DG. In addition, 2-DG induced autophagy, a cellular degradation pathway whose activation could be either protective or detrimental depending on the context. Paradoxically, despite its ability to activate autophagy, 2-DG prevented DOX-induced detrimental autophagy. Together, these results suggest that the CR mimetic 2-DG can antagonize DOX-induced cardiomyocyte death, which is mediated through multiple mechanisms, including the preservation of ATP content, the activation of AMPK, and the inhibition of autophagy.	[Chen, Kai; Xu, Xianmin; Kobayashi, Satoru; Timm, Derek; Jepperson, Tyler; Liang, Qiangrong] Univ S Dakota, Sanford Res, Cardiovasc Hlth Res Ctr, Sioux Falls, SD 57104 USA	Sanford Health; University of South Dakota	Liang, QR (corresponding author), Univ S Dakota, Sanford Res, Cardiovasc Hlth Res Ctr, Sioux Falls, SD 57104 USA.	Qiangrong.Liang@sanfordhealth.org			National Institutes of Health [2P20RR017662-06A1]; American Diabetes Association [1-09-CD-09, 1-2007-741]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR017662] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported, in whole or in part, by National Institutes of Health Grant 2P20RR017662-06A1 (Project 3) from the NCRR (to Q. L.).; Supported by Juvenile Diabetes Research Foundation Research Grant 1-2007-741 and Career Development Grant 1-09-CD-09 from the American Diabetes Association.	Aft RL, 2002, BRIT J CANCER, V87, P805, DOI 10.1038/sj.bjc.6600547; Bampton ETW, 2005, AUTOPHAGY, V1, P23, DOI 10.4161/auto.1.1.1495; Bergamini E, 2007, ANN NY ACAD SCI, V1114, P69, DOI 10.1196/annals.1396.020; Bhamra GS, 2008, BASIC RES CARDIOL, V103, P274, DOI [10.1007/s00395-007-0691-y, 10.1007/s00395-008-0736-x]; Calvert JW, 2008, DIABETES, V57, P696, DOI 10.2337/db07-1098; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dwarakanath BS, 2009, FUTURE ONCOL, V5, P581, DOI [10.2217/fon.09.44, 10.2217/FON.09.44]; Dwarakanath BS, 2009, J CANCER RES THER, V5, P21, DOI 10.4103/0973-1482.55136; Dwarukanath BS, 2004, CANCER BIOL THER, V3, P864, DOI 10.4161/cbt.3.9.1040; Dwivedi M, 2009, BMB REP, V42, P65, DOI 10.5483/BMBRep.2009.42.2.065; Eisenberg-Lerner A, 2009, CELL DEATH DIFFER, V16, P966, DOI 10.1038/cdd.2009.33; Farooque A, 2009, J CANCER RES THER, V5, P32, DOI 10.4103/0973-1482.55138; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Gundewar S, 2009, CIRC RES, V104, P403, DOI 10.1161/CIRCRESAHA.108.190918; Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994; Hoyer-Hansen M, 2007, AUTOPHAGY, V3, P381, DOI 10.4161/auto.4240; Ingram DK, 2006, AGING CELL, V5, P97, DOI 10.1111/j.1474-9726.2006.00202.x; Ingram DK, 2004, ANN NY ACAD SCI, V1019, P412, DOI 10.1196/annals.1297.074; Ingram DK, 2011, EXP GERONTOL, V46, P148, DOI 10.1016/j.exger.2010.12.001; Jia KL, 2007, AUTOPHAGY, V3, P597, DOI 10.4161/auto.4989; Jiang WQ, 2008, CANCER RES, V68, P5492, DOI 10.1158/0008-5472.CAN-07-6721; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kang CH, 2008, AUTOPHAGY, V4, P82, DOI 10.4161/auto.5154; Kang YJ, 1996, J BIOL CHEM, V271, P12610, DOI 10.1074/jbc.271.21.12610; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Kobayashi S, 2007, J BIOL CHEM, V282, P21945, DOI 10.1074/jbc.M703048200; Kobayashi S, 2006, FASEB J, V20, P800, DOI 10.1096/fj.05-5426fje; Kobayashi S, 2010, J BIOL CHEM, V285, P793, DOI 10.1074/jbc.M109.070037; Kritchevsky D, 2003, J NUTR, V133, p3827S, DOI 10.1093/jn/133.11.3827S; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Ladas EJ, 2004, J CLIN ONCOL, V22, P517, DOI 10.1200/JCO.2004.03.086; Lane Mark A, 2007, Methods Mol Biol, V371, P143; Lee HT, 2002, J AM SOC NEPHROL, V13, P2753, DOI 10.1097/01.ASN.0000032421.79225.6E; Levine B, 2008, AUTOPHAGY, V4, P600, DOI 10.4161/auto.6260; Lipshultz SE, 2010, LANCET ONCOL, V11, P950, DOI 10.1016/S1470-2045(10)70204-7; Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004; Lu LH, 2009, INT J CARDIOL, V134, P82, DOI 10.1016/j.ijcard.2008.01.043; Maher JC, 2004, CANCER CHEMOTH PHARM, V53, P116, DOI 10.1007/s00280-003-0724-7; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Martin Bronwen, 2007, IBS J Sci, V2, P35; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; Masoro EJ, 2009, BBA-GEN SUBJECTS, V1790, P1040, DOI 10.1016/j.bbagen.2009.02.011; Matsuda F, 2009, AUTOPHAGY, V5, P484, DOI 10.4161/auto.5.4.7760; Matsui Y, 2007, CIRC RES, V100, P914, DOI 10.1161/01.RES.0000261924.76669.36; Mattson MP, 2005, J NUTR BIOCHEM, V16, P129, DOI 10.1016/j.jnutbio.2004.12.007; McCarty MF, 2004, MED HYPOTHESES, V63, P334, DOI 10.1016/j.mehy.2004.01.043; Minor RK, 2010, TOXICOL APPL PHARM, V243, P332, DOI 10.1016/j.taap.2009.11.025; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Mitra MS, 2007, TOXICOL APPL PHARM, V225, P90, DOI 10.1016/j.taap.2007.07.018; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; Muthukumar A, 2003, J CLIN IMMUNOL, V23, P23, DOI 10.1023/A:1021996130672; Nagata D, 2010, HYPERTENS RES, V33, P22, DOI 10.1038/hr.2009.187; Osborne TB, 1917, SCIENCE, V45, P294, DOI 10.1126/science.45.1160.294; Paiva M, 2009, J CARDIOVASC PHARM, V53, P373, DOI 10.1097/FJC.0b013e31819fd4e7; Perumal V, 2009, J CANCER RES THER, V5, P48, DOI 10.4103/0973-1482.55142; Pointon AV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012733; Raeini-Sarjaz M, 2001, AM J CLIN NUTR, V73, P262; Rattan SIS, 2004, MECH AGEING DEV, V125, P285, DOI 10.1016/j.mad.2004.01.006; Sasaki H, 2009, CIRCULATION, V119, P2568, DOI 10.1161/CIRCULATIONAHA.108.798561; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Simons AL, 2007, CANCER RES, V67, P3364, DOI 10.1158/0008-5472.CAN-06-3717; Singal PK, 1998, NEW ENGL J MED, V339, P900, DOI 10.1056/NEJM199809243391307; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Spindler SR, 2010, AGEING RES REV, V9, P324, DOI 10.1016/j.arr.2009.10.003; Sun XH, 2001, CANCER RES, V61, P3382; Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Tebbi CK, 2007, J CLIN ONCOL, V25, P493, DOI 10.1200/JCO.2005.02.3879; THAKKAR NS, 1993, CANCER RES, V53, P2057; Vijg J, 2008, NATURE, V454, P1065, DOI 10.1038/nature07216; Viollet B, 2009, FRONT BIOSCI-LANDMRK, V14, P19, DOI 10.2741/3229; Wan RQ, 2004, AM J PHYSIOL-HEART C, V287, pH1186, DOI 10.1152/ajpheart.00932.2003; Wan RQ, 2003, FASEB J, V17, P1133, DOI 10.1096/fj.02-0996fje; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Wu H, 2006, CANCER RES, V66, P3015, DOI 10.1158/0008-5472.CAN-05-1554; Wu H, 2009, CANCER RES, V69, P2453, DOI 10.1158/0008-5472.CAN-08-2872; Xiao H, 2010, CARDIOVASC RES, V87, P504, DOI 10.1093/cvr/cvq066; Young LH, 2005, TRENDS CARDIOVAS MED, V15, P110, DOI 10.1016/j.tcm.2005.04.005; Yu ZF, 1999, J NEUROSCI RES, V57, P830, DOI 10.1002/(SICI)1097-4547(19990915)57:6&lt;830::AID-JNR8&gt;3.0.CO;2-2; Zhang FJ, 2009, J CANCER RES THER, V5, P41, DOI 10.4103/0973-1482.55140; Zhang XD, 2006, ANTICANCER RES, V26, P3561; Zhang YW, 2009, ARCH IMMUNOL THER EX, V57, P435, DOI 10.1007/s00005-009-0051-8	88	50	54	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 24	2011	286	25					21993	22006		10.1074/jbc.M111.225805	http://dx.doi.org/10.1074/jbc.M111.225805			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	778QP	21521688	Green Published, hybrid			2023-01-03	WOS:000291719900006
J	Spence, D				Spence, Des			FROM THE FRONTLINE The importance of mistrust: drugs of diversion	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	2011	342								d2465	10.1136/bmj.d2465	http://dx.doi.org/10.1136/bmj.d2465			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755ON	21508049				2023-01-03	WOS:000289942900011
J	Guo, L; Mishra, G; Taylor, K; Wang, XM				Guo, Liang; Mishra, Girish; Taylor, Kyle; Wang, Xuemin			Phosphatidic Acid Binds and Stimulates Arabidopsis Sphingosine Kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE DILUTION KINETICS; PLANT STRESS RESPONSES; PHOSPHOLIPASE D-ALPHA; PLASMA-MEMBRANE; PROTEIN; SPHINGOSINE-1-PHOSPHATE; EXPRESSION; THALIANA; LOCALIZATION; ACTIVATION	Phosphatidic acid (PA) and phytosphingosine-1-phosphate (phyto-S1P) have both been identified as lipid messengers mediating plant response to abscisic acid (ABA). To determine the relationship of these messengers, we investigated the direct interaction of PA with Arabidopsis sphingosine kinases (SPHKs) that phosphorylate phytosphingosine to generate phyto-S1P. Two unique SPHK cDNAs were cloned from the annotated At4g21540 locus of Arabidopsis, and the two transcripts are differentially expressed in Arabidopsis tissues. Both SPHKs are catalytically active, phosphorylating various long-chain sphingoid bases (LCBs) and are associated with the tonoplast. They both interact with PA as demonstrated by lipid-filter binding, liposome binding, and surface plasmon resonance (SPR). SPHK1 and SPHK2 exhibited strong binding to 18:1/18:1, 16:0/18:1, and 16:0/18:2 PA, but poor binding to 16:0/16:0, 8:0/8:0, 18:0/18:0, and 18:2/18:2 PA. Surface dilution kinetics analysis indicates that PA stimulates SPHK activity by increasing the specificity constant through decreasing K-m(B). The results show that the annotated At4g21540 locus is actually comprised of two separate SPHK genes. PA binds to both SPHKs, and the interaction promotes lipid substrate binding to the catalytic site of the enzyme. The PA-SPHK interaction depends on the PA molecular species. The data suggest that these two Arabidopsis SPHKs are molecular targets of PA, and the PA stimulation of SPHK is part of the signaling networks in Arabidopsis.	[Wang, Xuemin] Univ Missouri, Dept Biol, St Louis, MO 63121 USA; Univ Missouri, Donald Danforth Plant Sci Ctr, St Louis, MO 63121 USA	University of Missouri System; University of Missouri Saint Louis; Donald Danforth Plant Science Center; University of Missouri System; University of Missouri Saint Louis	Wang, XM (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	wangxue@umsl.edu	Guo, Liang/AAW-4739-2021; Wang, Xuemin/M-2853-2013	Guo, Liang/0000-0001-7191-5062; wang, xuemin/0000-0002-6251-6745	National Science Foundation [IOS-0818740]; United States Department of Agriculture [2007-35318-18393]	National Science Foundation(National Science Foundation (NSF)); United States Department of Agriculture(United States Department of Agriculture (USDA))	This work was supported by National Science Foundation Grant IOS-0818740 and United States Department of Agriculture Grant 2007-35318-18393.	Anthony RG, 2004, EMBO J, V23, P572, DOI 10.1038/sj.emboj.7600068; Bargmann BO, 2006, CURR OPIN PLANT BIOL, V9, P515, DOI 10.1016/j.pbi.2006.07.011; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; Coursol S, 2005, PLANT PHYSIOL, V137, P724, DOI 10.1104/pp.104.055806; Coursol S, 2003, NATURE, V423, P651, DOI 10.1038/nature01643; Delon C, 2004, J BIOL CHEM, V279, P44763, DOI 10.1074/jbc.M405771200; DENNIS EA, 1973, ARCH BIOCHEM BIOPHYS, V158, P485, DOI 10.1016/0003-9861(73)90540-7; Fan L, 1999, PLANT PHYSIOL, V119, P1371, DOI 10.1104/pp.119.4.1371; Foster DA, 2009, BBA-MOL CELL BIOL L, V1791, P949, DOI 10.1016/j.bbalip.2009.02.009; Hong YY, 2008, PLANT CELL, V20, P803, DOI 10.1105/tpc.107.056390; Jaquinod M, 2007, MOL CELL PROTEOMICS, V6, P394, DOI 10.1074/mcp.M600250-MCP200; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Kooijman EE, 2007, J BIOL CHEM, V282, P11356, DOI 10.1074/jbc.M609737200; Kooijman EE, 2009, BBA-MOL CELL BIOL L, V1791, P881, DOI 10.1016/j.bbalip.2009.04.001; Li MY, 2009, BBA-MOL CELL BIOL L, V1791, P927, DOI 10.1016/j.bbalip.2009.02.017; Liang H, 2003, GENE DEV, V17, P2636, DOI 10.1101/gad.1140503; Lu BB, 2009, J BIOL CHEM, V284, P17420, DOI 10.1074/jbc.M109.016014; Lynch DV, 2009, TRENDS PLANT SCI, V14, P463, DOI 10.1016/j.tplants.2009.06.008; Marion J, 2008, PLANT J, V56, P169, DOI 10.1111/j.1365-313X.2008.03596.x; Markham JE, 2007, RAPID COMMUN MASS SP, V21, P1304, DOI 10.1002/rcm.2962; Melendez AJ, 2002, SEMIN IMMUNOL, V14, P49, DOI 10.1006/smim.2001.0341; Michaelson LV, 2009, PLANT PHYSIOL, V149, P487, DOI 10.1104/pp.108.129411; Mishra G, 2006, SCIENCE, V312, P264, DOI 10.1126/science.1123769; Ng CKY, 2001, NATURE, V410, P596, DOI 10.1038/35069092; Nishiura H, 2000, BIOCHEM SOC T, V28, P747, DOI 10.1042/BST0280747; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; Qin CB, 2002, J BIOL CHEM, V277, P49685, DOI 10.1074/jbc.M209598200; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Testerink C, 2004, PLANT J, V39, P527, DOI 10.1111/j.1365-313X.2004.02152.x; Testerink C, 2005, TRENDS PLANT SCI, V10, P368, DOI 10.1016/j.tplants.2005.06.002; Testerink C, 2007, J EXP BOT, V58, P3905, DOI 10.1093/jxb/erm243; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Wang CX, 2001, PLANT PHYSIOL, V127, P1102, DOI 10.1104/pp.010444; Wang XM, 2006, PROG LIPID RES, V45, P250, DOI 10.1016/j.plipres.2006.01.005; Wattenberg BW, 2006, J LIPID RES, V47, P1128, DOI 10.1194/jlr.R600003-JLR200; Welti R, 2002, J BIOL CHEM, V277, P31994, DOI 10.1074/jbc.M205375200; Worrall D, 2008, PLANT J, V56, P64, DOI 10.1111/j.1365-313X.2008.03579.x; Yoo SD, 2007, NAT PROTOC, V2, P1565, DOI 10.1038/nprot.2007.199; YOSHIDA S, 1986, PLANT PHYSIOL, V82, P807, DOI 10.1104/pp.82.3.807; Zhang WH, 2004, P NATL ACAD SCI USA, V101, P9508, DOI 10.1073/pnas.0402112101; Zhang YB, 2009, J PHYS-CONDENS MAT, V21, DOI 10.1088/0953-8984/21/17/175802	42	84	90	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	2011	286	15					13336	13345		10.1074/jbc.M110.190892	http://dx.doi.org/10.1074/jbc.M110.190892			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746XH	21330371	Green Published, hybrid			2023-01-03	WOS:000289282200054
J	Jeong, HJ; Choi, Y; Kim, MH; Kang, IC; Lee, JH; Park, C; Park, R; Kim, HM				Jeong, Hyun-Ja; Choi, Youngjin; Kim, Min-Ho; Kang, In-Cheol; Lee, Jeong-Han; Park, Channy; Park, Raekil; Kim, Hyung-Min			Rosmarinic Acid, Active Component of Dansam-Eum Attenuates Ototoxicity of Cochlear Hair Cells through Blockage of Caspase-1 Activity	PLOS ONE			English	Article							CISPLATIN-INDUCED APOPTOSIS; DEATH; HYPOXIA; LINE; SAGE	Cisplatin causes auditory impairment due to the apoptosis of auditory hair cells. There is no strategy to regulate ototoxicity by cisplatin thus far. Dansam-Eum (DSE) has been used for treating the central nerve system injury including hearing loss in Korea. However, disease-related scientific investigation by DSE has not been elucidated. Here, we demonstrated that DSE and its component rosmarinic acid (RA) were shown to inhibit apoptosis of the primary organ of Corti explants as well as the auditory cells. Administration of DSE and RA reduced the thresholds of the auditory brainstem response in cisplatin-injected mice. A molecular docking simulation and a kinetic assay show that RA controls the activity of caspase-1 by interaction with the active site of caspase-1. Pretreatment of RA inhibited caspase-1 downstream signal pathway, such as the activation of caspase-3 and 9, release of cytochrome c, translocation of apoptosis-inducing factor, up-regulation of Bax, down-regulation of Bcl-2, generation of reactive oxygen species, and activation of nuclear factor-kappa B. Anticancer activity by cisplatin was not affected by treatment with RA in SNU668, A549, HCT116, and HeLa cells but not B16F10 cells. These findings show that blocking a critical step by RA in apoptosis may be useful strategy to prevent harmful side effects of ototoxicity in patients with having to undergo chemotherapy.	[Jeong, Hyun-Ja; Choi, Youngjin; Kang, In-Cheol] Hoseo Univ, Biochip Res Ctr, Asan, Chungnam, South Korea; [Kim, Min-Ho] Chonbuk Natl Univ, High Enthalpy Plasma Res Ctr, Jeonju, South Korea; [Lee, Jeong-Han; Park, Raekil] Wonkwang Univ, Sch Med, Vestibulocochlear Res Ctr, Jeonbuk, South Korea; [Lee, Jeong-Han; Park, Raekil] Wonkwang Univ, Sch Med, Dept Microbiol, Jeonbuk, South Korea; [Park, Channy] Nambu Univ, Dept Audiol, Kwangju, Jeonnam, South Korea; [Kim, Hyung-Min] Kyung Hee Univ, Coll Oriental Med, Dept Pharmacol, Seoul, South Korea	Hoseo University; Jeonbuk National University; Wonkwang University; Wonkwang University; Nambu University; Kyung Hee University	Jeong, HJ (corresponding author), Hoseo Univ, Biochip Res Ctr, Asan, Chungnam, South Korea.	hmkim@khu.ac.kr			Ministry of Education, Science and Technology [2009-0067477]; Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Vestibulocochlear Research Center (VCRC) at Wonkwang University [R13-2002-055-00000-0]	Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Vestibulocochlear Research Center (VCRC) at Wonkwang University(Korea Science and Engineering Foundation)	This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2009-0067477) and the Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Vestibulocochlear Research Center (VCRC) at Wonkwang University (R13-2002-055-00000-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alam SA, 2000, HEARING RES, V141, P28, DOI 10.1016/S0378-5955(99)00211-7; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Cao H, 2005, J MOL STRUC-THEOCHEM, V719, P177, DOI 10.1016/j.theochem.2005.01.029; Cardinaal RM, 2000, HEARING RES, V144, P147, DOI 10.1016/S0378-5955(00)00060-5; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Devarajan P, 2002, HEARING RES, V174, P45, DOI 10.1016/S0378-5955(02)00634-2; Exarchou V, 2002, J AGR FOOD CHEM, V50, P5294, DOI 10.1021/jf020408a; Feng Q, 2005, CANCER RES, V65, P8591, DOI 10.1158/0008-5472.CAN-05-0239; Fernandez-Luna JL, 2007, CLIN TRANSL ONCOL, V9, P555, DOI 10.1007/s12094-007-0103-7; Gao LP, 2005, PHARMAZIE, V60, P62; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; HUANG Y S, 1992, Yaoxue Xuebao, V27, P96; Humes HD, 1999, ANN NY ACAD SCI, V884, P15, DOI 10.1111/j.1749-6632.1999.tb00278.x; Iuvone T, 2006, J PHARMACOL EXP THER, V317, P1143, DOI 10.1124/jpet.105.099317; Jeong HJ, 2007, J NEUROSCI RES, V85, P896, DOI 10.1002/jnr.21168; Kalinec GM, 2003, AUDIOL NEURO-OTOL, V8, P177, DOI 10.1159/000071059; KIM BC, 2000, J KOREAN ORIENTAL ME, V21, P126; KONDO S, 1995, CANCER RES, V55, P6166; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Lamkanfi M, 2004, J BIOL CHEM, V279, P24785, DOI 10.1074/jbc.M400985200; Lee HJ, 2008, TOXICOLOGY, V250, P109, DOI 10.1016/j.tox.2008.06.010; Lee S, 2006, NEPHROL DIAL TRANSPL, V21, P2085, DOI 10.1093/ndt/gfl209; Li XC, 2007, DRUG METAB DISPOS, V35, P234, DOI 10.1124/dmd.106.013045; Liu W, 1998, NEUROREPORT, V9, P2609, DOI 10.1097/00001756-199808030-00034; Osakabe N, 2004, CARCINOGENESIS, V25, P549, DOI 10.1093/carcin/bgh034; Pirvola U, 2000, J NEUROSCI, V20, P43, DOI 10.1523/JNEUROSCI.20-01-00043.2000; Renzulli C, 2004, J APPL TOXICOL, V24, P289, DOI 10.1002/jat.982; So HS, 2005, HEARING RES, V204, P127, DOI 10.1016/j.heares.2005.01.011; Takeda H, 2002, EUR J PHARMACOL, V449, P261, DOI 10.1016/S0014-2999(02)02037-X; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Trimmer EE, 1999, ESSAYS BIOCHEM, V34, P191, DOI 10.1042/bse0340191; Tschopp J, 2003, NAT REV MOL CELL BIO, V4, P95, DOI 10.1038/nrm1019; Youn J, 2003, J RHEUMATOL, V30, P1203; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100	34	20	21	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 15	2011	6	4							e18815	10.1371/journal.pone.0018815	http://dx.doi.org/10.1371/journal.pone.0018815			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	750WK	21526214	Green Submitted, Green Published, gold			2023-01-03	WOS:000289578600035
J	Avorn, J				Avorn, Jerry			Teaching Clinicians about Drugs - 50 Years Later, Whose Job Is It?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Avorn, Jerry] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Avorn, Jerry] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Avorn, J (corresponding author), Harvard Univ, Sch Med, Boston, MA 02115 USA.							[Anonymous], 1961, NEW ENGL J MED, V265, P910; Avorn J, 2005, POWERFUL MED BENEFIT, P313; Carpenter D, 2010, PRINC STUD AM POLIT, P1; Gray BH, 2003, HLTH AFF MILLWOOD S, pW3; Greene JA, 2009, B HIST MED, V83, P331, DOI 10.1353/bhm.0.0218	5	24	24	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2011	364	13					1185	1187		10.1056/NEJMp1011713	http://dx.doi.org/10.1056/NEJMp1011713			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	742NO	21449781				2023-01-03	WOS:000288951300001
J	Sinnott, M; Shaban, RZ				Sinnott, Michael; Shaban, Ramon Z.			Personal View Can we have a culture of patient safety without one of staff safety?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Sinnott, Michael; Shaban, Ramon Z.] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Sinnott, Michael] Univ Queensland, Brisbane, Qld, Australia; [Shaban, Ramon Z.] Griffith Univ, Griffith Hlth Inst, Brisbane, Qld 4111, Australia	University of Queensland; Griffith University; Menzies Health Institute Queensland	Sinnott, M (corresponding author), Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.	michael_sinnott@health.qld.gov.au	Sinnott, Michael/D-1155-2012	Sinnott, Michael/0000-0002-2338-3126; Shaban, Ramon/0000-0002-5203-0557				Occupational Safety and Health Administration, 2008, OCC SAF HLTH STAND; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; SINNOTT M, 2010, PERIOPERAT NURS CLIN, V5, P59; *SOC THOR SURG, 2009, HIST PAT SAF PAT SAF; Tseng D, 2005, INFECT DIS HEALTH, V10, P89, DOI 10.1071/HI05089	5	7	7	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	2011	342								c6171	10.1136/bmj.c6171	http://dx.doi.org/10.1136/bmj.c6171			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	732EU	21378073	Green Published			2023-01-03	WOS:000288168600001
J	Pflugfelder, A; Eigentler, TK; Keim, U; Weide, B; Leiter, U; Ikenberg, K; Berneburg, M; Garbe, C				Pflugfelder, Annette; Eigentler, Thomas K.; Keim, Ulrike; Weide, Benjamin; Leiter, Ulrike; Ikenberg, Kristian; Berneburg, Mark; Garbe, Claus			Effectiveness of Carboplatin and Paclitaxel as First- and Second-Line Treatment in 61 Patients with Metastatic Melanoma	PLOS ONE			English	Article							PHASE-II; ADVANCED-CARCINOMA; PLUS CARBOPLATIN; OVARIAN-CANCER; TRIAL; COMBINATION; CHEMOTHERAPY; THERAPY	Background: Patients with metastatic melanoma have a very unfavorable prognosis with few therapeutic options. Based on previous promising experiences within a clinical trial involving carboplatin and paclitaxel a series of advanced metastatic melanoma patients were treated with this combination. Methods: Data of all patients with cutaneous metastatic melanoma treated with carboplatin and paclitaxel (CP) at our institution between October 2005 and December 2007 were retrospectively evaluated. For all patients a once-every-3-weeks dose-intensified regimen was used. Overall and progression free survival were calculated using the method of Kaplan and Meier. Tumour response was evaluated according to RECIST criteria. Results: 61 patients with cutaneous metastatic melanoma were treated with CP. 20 patients (85% M1c) received CP as first-line treatment, 41 patients (90.2% M1c) had received at least one prior systemic therapy for metastatic disease. Main toxicities were myelosuppression, fatigue and peripheral neuropathy. Partial responses were noted in 4.9% of patients, stable disease in 23% of patients. No complete response was observed. Median progression free survival was 10 weeks. Median overall survival was 31 weeks. Response, progression-free and overall survival were equivalent in first-and second-line patients. 60 patients of 61 died after a median follow up of 7 months. Median overall survival differed for patients with controlled disease (PR+SD) (49 weeks) compared to patients with progressive disease (18 weeks). Conclusions: Among patients with metastatic melanoma a subgroup achieved disease control under CP therapy which may be associated with a survival benefit. This potential advantage has to be weighed against considerable toxicity. Since response rates and survival were not improved in previously untreated patients compared to pretreated patients, CP should thus not be applied as first-line treatment.	[Pflugfelder, Annette; Eigentler, Thomas K.; Keim, Ulrike; Weide, Benjamin; Leiter, Ulrike; Ikenberg, Kristian; Berneburg, Mark; Garbe, Claus] Univ Tubingen Hosp, Dept Dermatol, Ctr Dermatooncol, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Pflugfelder, A (corresponding author), Univ Tubingen Hosp, Dept Dermatol, Ctr Dermatooncol, Tubingen, Germany.	annette.pflugfelder@med.uni-tuebingen.de	Eigentler, Thomas/K-8570-2015; Pflugfelder, Annette/Q-2659-2016; Garbe, Claus/ABH-2128-2021; Keim, Ulrike/C-4938-2017; Weide, Benjamin/N-3698-2013	Eigentler, Thomas/0000-0003-0019-2770; Garbe, Claus/0000-0001-8530-780X; Keim, Ulrike/0000-0001-7236-0548; Leiter, Ulrike/0000-0002-8019-1577	University Hospital Tuebingen	University Hospital Tuebingen	The work was funded by the University Hospital Tuebingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bamias A, 2004, J CLIN ONCOL, V22, P2150, DOI 10.1200/JCO.2004.09.043; Belani CP, 2008, J CLIN ONCOL, V26, P468, DOI 10.1200/JCO.2007.13.1912; Bookman MA, 2009, J CLIN ONCOL, V27, P1419, DOI 10.1200/JCO.2008.19.1684; du Bois A, 1999, ANN ONCOL, V10, P35, DOI 10.1023/A:1008355317514; Eggermont AMM, 2004, EUR J CANCER, V40, P1825, DOI 10.1016/j.ejca.2004.04.030; Eigentler TK, 2003, LANCET ONCOL, V4, P748, DOI 10.1016/S1470-2045(03)01280-4; Einzig A I, 1991, Cancer Treat Res, V58, P89; Flaherty KT, 2008, CLIN CANCER RES, V14, P4836, DOI 10.1158/1078-0432.CCR-07-4123; Hauschild A, 2009, J CLIN ONCOL, V27, P2823, DOI 10.1200/JCO.2007.15.7636; Hodi FS, 2002, AM J CLIN ONCOL-CANC, V25, P283, DOI 10.1097/00000421-200206000-00016; Johnson DH, 1996, J CLIN ONCOL, V14, P2054, DOI 10.1200/JCO.1996.14.7.2054; Kaplan EL, 2009, J AM STAT ASSOC, V53, P457; Lee CW, 2005, GYNECOL ONCOL, V99, P393, DOI 10.1016/j.ygyno.2005.06.028; Parmar MKB, 2002, LANCET, V360, P505; Perez DG, 2009, CANCER-AM CANCER SOC, V115, P119, DOI 10.1002/cncr.23987; Rao RD, 2006, CANCER, V106, P375, DOI 10.1002/cncr.21611; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Vaughn DJ, 2002, CANCER-AM CANCER SOC, V95, P1022, DOI 10.1002/cncr.10782; Zamagni C, 1998, AM J CLIN ONCOL-CANC, V21, P491, DOI 10.1097/00000421-199810000-00015; Zimpfer-Rechner C, 2003, MELANOMA RES, V13, P531, DOI 10.1097/00008390-200310000-00012	20	20	22	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2011	6	2							e16882	10.1371/journal.pone.0016882	http://dx.doi.org/10.1371/journal.pone.0016882			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721YC	21359173	gold, Green Submitted, Green Published			2023-01-03	WOS:000287392700027
J	Kansagara, D; Fu, RW; Freeman, M; Wolf, F; Helfand, M				Kansagara, Devan; Fu, Rongwei; Freeman, Michele; Wolf, Fawn; Helfand, Mark			Intensive Insulin Therapy in Hospitalized Patients: A Systematic Review	ANNALS OF INTERNAL MEDICINE			English	Review							CRITICALLY-ILL PATIENTS; BLOOD-GLUCOSE CONTROL; TIGHT GLYCEMIC CONTROL; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; PREDICTIVE CONTROL ALGORITHM; CLINICAL-PRACTICE GUIDELINES; DEPENDENT DIABETES-MELLITUS; CARDIAC SURGICAL-PROCEDURES; STERNAL WOUND-INFECTION	Background: The benefits and harms of intensive insulin therapy (IIT) titrated to strict glycemic targets in hospitalized patients remain uncertain. Purpose: To evaluate the benefits and harms of IIT in hospitalized patients. Data Sources: MEDLINE and Cochrane Database of Systematic Reviews from 1950 to January 2010, reference lists, experts, and unpublished sources. Study Selection: English-language randomized, controlled trials comparing protocols titrated to strict or less strict glycemic targets. Data Extraction: Two reviewers independently abstracted data from each study on sample, setting, glycemic control interventions, glycemic targets, mean glucose levels achieved, and outcomes. Results were grouped by patient population or setting. A random-effects model was used to combine trial data on short-term mortality (<= 28 days), long-term mortality (90 or 180 days), infection, length of stay, and hypoglycemia. The Grading of Recommendations Assessment, Development, and Evaluation system was used to rate the overall body of evidence for each outcome. Data Synthesis: In a meta-analysis of 21 trials in intensive care unit, perioperative care, myocardial infarction, and stroke or brain injury settings, IIT did not affect short-term mortality (relative risk, 1.00 [95% CI, 0.94 to 1.07]). No consistent evidence showed that IIT reduced long-term mortality, infection rates, length of stay, or the need for renal replacement therapy. No evidence of benefit from IIT was reported in any hospital setting, although the best evidence for lack of benefit was in intensive care unit settings. Data combined from 10 trials showed that IIT was associated with a high risk for severe hypoglycemia (relative risk, 6.00 [CI, 4.06 to 8.87]; P < 0.001). Risk for IIT-associated hypoglycemia was increased in all hospital settings. Limitations: Methodological shortcomings and inconsistencies limit the data in perioperative care, myocardial infarction, and stroke or brain injury settings. Differences in insulin protocols and patient and hospital characteristics may affect generalizability across treatment settings. Conclusion: No consistent evidence demonstrates that IIT targeted to strict glycemic control compared with less strict glycemic control improves health outcomes in hospitalized patients. Furthermore, IIT is associated with an increased risk for severe hypoglycemia.	[Kansagara, Devan] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Portland Diabet & Endocrinol Ctr, Portland, OR 97239 USA	Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Portland VA Medical Center; VA Portland Health Care System; Oregon Health & Science University	Kansagara, D (corresponding author), Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, 3710 SW US Vet Hosp Rd,Mailcode R&D 71, Portland, OR 97239 USA.	kansagar@ohsu.edu			Department of Veterans Affairs, Veterans Health Administration [ESP 05-225, 01-0206]; American College of Physicians	Department of Veterans Affairs, Veterans Health Administration(US Department of Veterans Affairs); American College of Physicians	Financial Support: By the Department of Veterans Affairs, Veterans Health Administration (VHA Project ESP 05-225, VA #01-0206). The American College of Physicians provided funding for the preparation of this manuscript.	Ahmann AJ, 2008, J HOSP MED, V3, pS42, DOI 10.1002/jhm.366; Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Aragon D, 2006, AM J CRIT CARE, V15, P370, DOI 10.4037/ajcc2006.15.4.370; Balkin M, 2007, DIABETES-METAB RES, V23, P49, DOI 10.1002/dmrr.673; BARCELLOS DS, 2007, REV BRAS CIR CARDIOV, V22, P275; Beilman Greg J, 2005, Diabetes Technol Ther, V7, P823, DOI 10.1089/dia.2005.7.823; Bell DA, 2005, BRIT J NEUROSURG, V19, P21, DOI 10.1080/02688690500089423; Biffl W, 2007, J TRAUMA, V62, P1375; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bistrian BR, 2006, CRIT CARE MED, V34, P1525, DOI 10.1097/01.CCM.0000216704.54446.FD; Bland DK, 2005, AM J CRIT CARE, V14, P370; Blunt M, 2008, BR J INTENSIVE CARE, V18, P121; Bochicchio GV, 2005, AM SURGEON, V71, P171; Braithwaite SS, 2006, DIABETES TECHNOL THE, V8, P476, DOI 10.1089/dia.2006.8.476; Brozek JL, 2009, ALLERGY, V64, P669, DOI 10.1111/j.1398-9995.2009.01973.x; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Bruno A, 2008, STROKE, V39, P384, DOI 10.1161/STROKEAHA.107.493544; Butterworth J, 2005, J THORAC CARDIOV SUR, V130, P1319, DOI 10.1016/j.jtcvs.2005.02.049; Button E, 2006, CRIT CARE NURS CLIN, V18, P257; Button Elaine, 2006, Crit Care Nurs Clin North Am, V18, P257, DOI 10.1016/j.ccell.2006.01.001; Capes SE, 2000, LANCET, V355, P773, DOI 10.1016/S0140-6736(99)08415-9; Capes SE, 2001, STROKE, V32, P2426, DOI 10.1161/hs1001.096194; Carvalho G, 2004, ANESTH ANALG, V99, P319, DOI 10.1213/01.ANE.0000121769.62638.EB; Chaney MA, 1999, ANESTH ANALG, V89, P1091, DOI 10.1213/00000539-199911000-00004; Chant C, 2005, PHARMACOTHERAPY, V25, P352, DOI 10.1592/phco.25.3.352.61594; Chee F, 2003, IEEE T INF TECHNOL B, V7, P419, DOI 10.1109/TITB.2003.821326; Cheung NW, 2006, DIABETES CARE, V29, P765, DOI 10.2337/diacare.29.04.06.dc05-1894; Clayton SB, 2006, CRIT CARE MED, V34, P2974, DOI 10.1097/01.CCM.0000248906.10399.CF; Clement S, 2004, DIABETES CARE, V27, P553, DOI 10.2337/diacare.27.2.553; Cochran A, 2008, J BURN CARE RES, V29, P187, DOI 10.1097/BCR.0b013e318160d066; Datta Swati, 2007, Endocr Pract, V13, P225; Davis ED, 2005, DIABETES EDUCATOR, V31, P818, DOI 10.1177/0145721705283077; de Azevedo JRA, 2007, ARQ NEURO-PSIQUIAT, V65, P733, DOI 10.1590/S0004-282X2007000500001; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DeSantis Anthony J, 2006, Endocr Pract, V12, P491; Dickerson Lori M, 2003, Ann Fam Med, V1, P29, DOI 10.1370/afm.2; Dilkhush D, 2005, AM J HEALTH-SYST PH, V62, P2260, DOI 10.2146/ajhp040590; Dortch MJ, 2008, JPEN-PARENTER ENTER, V32, P18, DOI 10.1177/014860710803200118; Eigsti J, 2006, DIMENS CRIT CARE NUR, V25, P62, DOI 10.1097/00003465-200603000-00004; Elinav H, 2007, CURR MED RES OPIN, V23, P757, DOI 10.1185/030079907X178748; Farah R, 2007, ISRAEL MED ASSOC J, V9, P140; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finney SJ, 2003, JAMA-J AM MED ASSOC, V290, P2041, DOI 10.1001/jama.290.15.2041; FISCHER KF, 1986, NEW ENGL J MED, V315, P1245, DOI 10.1056/NEJM198611133152002; Furnary AP, 2006, SEMIN THORAC CARDIOV, V18, P339, DOI 10.1053/j.semtcvs.2007.01.004; Furnary AP, 1999, ANN THORAC SURG, V67, P352, DOI 10.1016/S0003-4975(99)00014-4; Furnary AP, 2003, J THORAC CARDIOV SUR, V125, P1007, DOI 10.1067/mtc.2003.181; Gandhi GY, 2007, ANN INTERN MED, V146, P233, DOI 10.7326/0003-4819-146-4-200702200-00002; Goldberg PA, 2004, J CARDIOTHOR VASC AN, V18, P690, DOI 10.1053/j.jvca.2004.08.003; GOLDBERG PA, 2005, DIABETES SPECTRUM, V18, P28; Gonzalez-Michaca L, 2002, ARCH MED RES, V33, P48, DOI 10.1016/S0188-4409(01)00354-X; Gray CS, 2007, LANCET NEUROL, V6, P397, DOI 10.1016/S1474-4422(07)70080-7; Grey Neil J, 2004, Endocr Pract, V10 Suppl 2, P46; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; Hemmerling TM, 2001, J CLIN ANESTH, V13, P293, DOI 10.1016/S0952-8180(01)00276-8; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirshberg E, 2008, CHEST, V133, P1328, DOI 10.1378/chest.07-2702; Hovorka R, 2007, J CLIN ENDOCR METAB, V92, P2960, DOI 10.1210/jc.2007-0434; *I HLTH CAR IMPR, 2008, IMPL EFF GLUC CONTR; Iapichino G, 2008, INTENS CARE MED, V34, P1843, DOI 10.1007/s00134-008-1158-9; Ingels C, 2006, EUR HEART J, V27, P2716, DOI 10.1093/eurheartj/ehi855; Inzucchi SE, 2009, NEW ENGL J MED, V360, P1346, DOI 10.1056/NEJMe0901507; IWAMOTO G, COMP TRIAL COMPUTER; Juneja R, 2007, DIABETES TECHNOL THE, V9, P232, DOI 10.1089/dia.2006.0015; Kanji S, 2005, CRIT CARE MED, V33, P2778, DOI 10.1097/01.CCM.0000189939.10881.60; Kanji S, 2004, INTENS CARE MED, V30, P804, DOI 10.1007/s00134-004-2252-2; Kansagara D, 2008, MANAGEMENT INPATIENT; Kirdemir P, 2008, J CARDIOTHOR VASC AN, V22, P383, DOI 10.1053/j.jvca.2007.09.015; Korytkowski MT, 2009, DIABETES CARE, V32, P594, DOI 10.2337/dc08-1436; Kosiborod M, 2009, JAMA-J AM MED ASSOC, V301, P1556, DOI 10.1001/jama.2009.496; Kreisel SH, 2009, CEREBROVASC DIS, V27, P167, DOI 10.1159/000185608; Krinsley J, 2007, CHEST, V132, P1, DOI 10.1378/chest.07-0834; Krinsley JS, 2006, SEMIN THORAC CARDIOV, V18, P317, DOI 10.1053/j.semtcvs.2006.12.003; Ku SY, 2005, JT COMM J QUAL PATIE, V31, P141, DOI 10.1016/S1553-7250(05)31019-1; LACHERADE JC, MULTICENTRE RANDOMIZ; Lazar HL, 2004, CIRCULATION, V109, P1497, DOI 10.1161/01.CIR.0000121747.71054.79; Levetan CS, 1998, DIABETES CARE, V21, P246, DOI 10.2337/diacare.21.2.246; Li JY, 2006, TEX HEART I J, V33, P445; Lien Lillian F, 2005, Endocr Pract, V11, P240; Malmberg K, 2005, EUR HEART J, V26, P650, DOI 10.1093/eurheartj/ehi199; MALMBERG K, 1995, J AM COLL CARDIOL, V26, P57, DOI 10.1016/0735-1097(95)00126-K; Markovitz Lawrence J, 2002, Endocr Pract, V8, P10; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; McMullin J, 2007, J CRIT CARE, V22, P112, DOI 10.1016/j.jcrc.2006.08.002; Meijering S, 2006, CRIT CARE, V10, DOI 10.1186/cc3981; Metchick LN, 2002, AM J MED, V113, P317, DOI 10.1016/S0002-9343(02)01213-5; Miriam A, 2004, ANESTH ANALG, V99, P598, DOI 10.1213/01.ANE.0000122824.21065.CA; Mitchell Imogen, 2006, Crit Care Resusc, V8, P289; Nazer Lama H, 2007, Endocr Pract, V13, P137; Oksanen T, 2007, INTENS CARE MED, V33, P2093, DOI 10.1007/s00134-007-0876-8; Osburne RC, 2006, DIABETES EDUCATOR, V32, P394, DOI 10.1177/0145721706288072; Pachler C, 2008, INTENS CARE MED, V34, P1224, DOI 10.1007/s00134-008-1033-8; Plank J, 2006, DIABETES CARE, V29, P271, DOI 10.2337/diacare.29.02.06.dc05-1689; Pomposelli JJ, 1998, JPEN-PARENTER ENTER, V22, P77, DOI 10.1177/014860719802200277; Preiser JC, 2007, INTENS CARE MED, V33, P570, DOI 10.1007/s00134-006-0485-y; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Quinn JA, 2006, PHARMACOTHERAPY, V26, P1410, DOI 10.1592/phco.26.10.1410; Rasoul S, 2007, INT J CARDIOL, V122, P52, DOI 10.1016/j.ijcard.2006.11.037; RaucoulesAime M, 1996, BRIT J ANAESTH, V76, P198, DOI 10.1093/bja/76.2.198; Rea RS, 2007, AM J HEALTH-SYST PH, V64, P385, DOI 10.2146/ajhp060014; Reed CC, 2007, J AM COLL SURGEONS, V204, P1048, DOI 10.1016/j.jamcollsurg.2006.12.047; Rood E, 2005, J AM MED INFORM ASSN, V12, P172, DOI 10.1197/jamia.M1598; Rowen M, 2007, CORONARY ARTERY DIS, V18, P405, DOI 10.1097/MCA.0b013e328224bb02; Saager L, 2008, J CARDIOTHOR VASC AN, V22, P377, DOI 10.1053/j.jvca.2007.09.013; Savioli M, 2009, CRIT CARE MED, V37, P424, DOI 10.1097/CCM.0b013e31819542da; Scalea TM, 2007, ANN SURG, V246, P605, DOI 10.1097/SLA.0b013e318155a789; Shaw Geoffrey M, 2006, Crit Care Resusc, V8, P90; Shilo S, 1998, J AM GERIATR SOC, V46, P978, DOI 10.1111/j.1532-5415.1998.tb02752.x; SIMMONS D, 1994, DIABETES EDUCATOR, V20, P422, DOI 10.1177/014572179402000510; Smith A, 2002, J CARDIOTHOR VASC AN, V16, P413, DOI 10.1053/jcan.2002.125151; Smith SM, 2007, DIABETES CARE, V30, P2503, DOI 10.2337/dc07-0865; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Subramaniam B, 2009, ANESTHESIOLOGY, V110, P970, DOI 10.1097/ALN.0b013e3181a1005b; Svensson AM, 2005, EUR HEART J, V26, P1255, DOI 10.1093/eurheartj/ehi230; Tamaki M, 2008, DIABETES RES CLIN PR, V81, P296, DOI 10.1016/j.diabres.2008.03.021; Taylor BE, 2006, J AM COLL SURGEONS, V202, P1, DOI 10.1016/j.jamcollsurg.2005.09.015; Theilen Brenda M, 2008, Endocr Pract, V14, P185; Toschlog EA, 2007, J TRAUMA, V62, P1370, DOI 10.1097/TA.0b013e318047b7dc; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Turchin A, 2009, DIABETES CARE, V32, P1153, DOI 10.2337/dc08-2127; Umpierrez GE, 2002, J CLIN ENDOCR METAB, V87, P978, DOI 10.1210/jc.87.3.978; UMPIERREZ GE, COMP TRIAL COMPUTER; Umpierrez GE, 2007, DIABETES CARE, V30, P2181, DOI 10.2337/dc07-0295; Van den Berghe G, 2006, CRIT CARE MED, V34, P612, DOI 10.1097/01.CCM.0000201408.15502.24; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; van der Horst ICC, 2003, J AM COLL CARDIOL, V42, P784, DOI 10.1016/S0735-1097(03)00830-1; van Wezel HB, 2006, J CLIN ENDOCR METAB, V91, P4144, DOI 10.1210/jc.2006-1199; Vogelzang M, 2008, INTENS CARE MED, V34, P1421, DOI 10.1007/s00134-008-1091-y; Vogelzang Mathijs, 2005, BMC Med Inform Decis Mak, V5, P38, DOI 10.1186/1472-6947-5-38; Vriesendorp TM, 2006, CRIT CARE MED, V34, P96, DOI 10.1097/01.CCM.0000194536.89694.06; Walters MR, 2006, CEREBROVASC DIS, V22, P116, DOI 10.1159/000093239; Whitmer RA, 2009, JAMA-J AM MED ASSOC, V301, P1565, DOI 10.1001/jama.2009.460; Wilson M, 2007, DIABETES CARE, V30, P1005, DOI 10.2337/dc06-1964; Wong XW, 2006, MED ENG PHYS, V28, P665, DOI 10.1016/j.medengphy.2005.10.015; Yang M, 2009, INT J NURS STUD, V46, P753, DOI 10.1016/j.ijnurstu.2009.01.004; Zerr KJ, 1997, ANN THORAC SURG, V63, P356; Zimmerman CR, 2004, ANN PHARMACOTHER, V38, P1123, DOI 10.1345/aph.1E018	141	136	145	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2011	154	4					268	W89		10.7326/0003-4819-154-4-201102150-00008	http://dx.doi.org/10.7326/0003-4819-154-4-201102150-00008			23	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	720VF	21320942				2023-01-03	WOS:000287310000019
J	Tanaka, H; Kono, E; Tran, CP; Miyazaki, H; Yamashiro, J; Shimomura, T; Fazli, L; Wada, R; Huang, JT; Vessella, RL; An, JB; Horvath, S; Gleave, M; Rettig, MB; Wainberg, ZA; Reiter, RE				Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Miyazaki, Hideyo; Yamashiro, Joyce; Shimomura, Tatsuya; Fazli, Ladan; Wada, Robert; Huang, Jiaoti; Vessella, Robert L.; An, Jaibin; Horvath, Steven; Gleave, Martin; Rettig, Matthew B.; Wainberg, Zev A.; Reiter, Robert E.			Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance	NATURE MEDICINE			English	Article							MESENCHYMAL TRANSITION; ANDROGEN RECEPTOR; ANTITUMOR-ACTIVITY; STEM-CELLS; PROGRESSION; THERAPY; INDEPENDENCE; INCREASES; PATHWAY; BIOLOGY	The transition from androgen-dependent to castration-resistant prostate cancer (CRPC) is a lethal event of uncertain molecular etiology. Comparing gene expression in isogenic androgen-dependent and CRPC xenografts, we found a reproducible increase in N-cadherin expression, which was also elevated in primary and metastatic tumors of individuals with CRPC. Ectopic expression of N-cadherin in nonmetastatic, androgen-dependent prostate cancer models caused castration resistance, invasion and metastasis. Monoclonal antibodies against the ectodomain of N-cadherin reduced proliferation, adhesion and invasion of prostate cancer cells in vitro. In vivo, these antibodies slowed the growth of multiple established CRPC xenografts, blocked local invasion and metastasis and, at higher doses, led to complete regression. N-cadherin-specific antibodies markedly delayed the time to emergence of castration resistance, markedly affected tumor histology and angiogenesis, and reduced both AKT serine-threonine kinase activity and serum interleukin-8 (IL-8) secretion. These data indicate that N-cadherin is a major cause of both prostate cancer metastasis and castration resistance. Therapeutic targeting of this factor with monoclonal antibodies may have considerable clinical benefit. (C) 2010 Nature America, Inc. All rights reserved.	[Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Wada, Robert; An, Jaibin; Rettig, Matthew B.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA; [Tanaka, Hiroshi; Kono, Evelyn; Tran, Chau P.; Yamashiro, Joyce; Shimomura, Tatsuya; Huang, Jiaoti; Rettig, Matthew B.; Wainberg, Zev A.; Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Miyazaki, Hideyo] Univ Tokyo, Dept Urol, Tokyo, Japan; [Fazli, Ladan; Gleave, Martin] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC V5Z 1M9, Canada; [Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA; [Vessella, Robert L.] Univ Washington, Med Ctr, Dept Urol, Puget Sound Vet Hlth Care Adm, Seattle, WA 98195 USA; [An, Jaibin; Rettig, Matthew B.] Vet Affairs Greater Los Angeles Healthcare Syst W, Dept Med, Los Angeles, CA USA; [Horvath, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA; [Horvath, Steven] Univ Calif Los Angeles, Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90095 USA; [Wainberg, Zev A.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA; [Reiter, Robert E.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Tokyo; University of British Columbia; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Reiter, RE (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Urol, Los Angeles, CA 90095 USA.	rreiter@mednet.ucla.edu	Tran, Chau/GRX-4633-2022	Huang, Jiaoti/0000-0003-1195-1998	US National Cancer Institute Prostate Cancer SPORE at the University of California-Los Angeles [P50CA092131-09]; US Department of Defense [W81XWH-06-1-0324, W81XWH-09-1-0630, PC061456]; Takeda Pharmaceuticals; Jean Perkins Foundation; American Cancer Society [RSG-07-092-01-TBE]; NATIONAL CANCER INSTITUTE [P50CA092131] Funding Source: NIH RePORTER	US National Cancer Institute Prostate Cancer SPORE at the University of California-Los Angeles(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); US Department of Defense(United States Department of Defense); Takeda Pharmaceuticals(Takeda Pharmaceutical Company Ltd); Jean Perkins Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in parts by the US National Cancer Institute Prostate Cancer SPORE at the University of California-Los Angeles (P50CA092131-09 to R. E. R.), US Department of Defense Prostate Cancer Research grants (W81XWH-06-1-0324 to Z.A.W., W81XWH-09-1-0630 to R. E. R. and M. B. R., PC061456 to J.H.), Takeda Pharmaceuticals, the Jean Perkins Foundation and the American Cancer Society (RSG-07-092-01-TBE to J.H.). We also thank S. and L. Resnick, the Prostate Cancer Foundation and the Luskin Foundation for generous support and J. Said and N. Doan for immunohistochemical assessments. LNCaP-CL1 cells were provided by C. L. Tso (University of California-Los Angeles). Plasmid p Delta VPR was provided by I. Chen (University of California-Los Angeles).	Araki S, 2007, CANCER RES, V67, P6854, DOI 10.1158/0008-5472.CAN-07-1162; Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008-5472.CAN-08-4531; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767; Gleave M, 2005, CANCER CHEMOTH PHARM, V56, pS47, DOI 10.1007/s00280-005-0098-0; Gravdal K, 2007, CLIN CANCER RES, V13, P7003, DOI 10.1158/1078-0432.CCR-07-1263; Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426; Gu ZN, 2005, CLIN CANCER RES, V11, P2237, DOI 10.1158/1078-0432.CCR-04-0356; Hara T, 2008, CANCER RES, V68, P1128, DOI 10.1158/0008-5472.CAN-07-1929; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Isaacs JT, 1999, UROL CLIN N AM, V26, P263, DOI 10.1016/S0094-0143(05)70066-5; Jaggi M, 2006, PROSTATE, V66, P193, DOI 10.1002/pros.20334; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Lassi K, 2009, CURR OPIN ONCOL, V21, P260, DOI 10.1097/CCO.0b013e32832a1868; Li JF, 2005, CIRC RES, V97, P474, DOI 10.1161/01.RES.0000181132.11393.18; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mason MJ, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-327; Mellado B, 2009, CLIN TRANSL ONCOL, V11, P5, DOI 10.1007/s12094-009-0304-3; Rizzi F, 2008, J PHYSIOL PHARMACOL, V59, P265; Roudier MP, 2003, HUM PATHOL, V34, P646, DOI 10.1016/S0046-8177(03)00190-4; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sharifi N, 2006, CANCER BIOL THER, V5, P901, DOI 10.4161/cbt.5.8.2949; Suzuki H, 2003, ENDOCR-RELAT CANCER, V10, P209, DOI 10.1677/erc.0.0100209; Tomita K, 2000, CANCER RES, V60, P3650; Tran NL, 2002, J BIOL CHEM, V277, P32905, DOI 10.1074/jbc.M200300200; Tso CL, 2000, CANCER J, V6, P220	28	240	259	0	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	DEC	2010	16	12					1414	U96		10.1038/nm.2236	http://dx.doi.org/10.1038/nm.2236			8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	690ZH	21057494	Green Accepted			2023-01-03	WOS:000285048900035
J	Gagnadoux, F; Le Vaillant, M; Goupil, F; Pigeanne, T; Chollet, S; Masson, P; Humeau, MP; Bizieux-Thaminy, A; Meslier, N				Gagnadoux, Frederic; Le Vaillant, Marc; Goupil, Francois; Pigeanne, Thierry; Chollet, Sylvaine; Masson, Philippe; Humeau, Marie-Pierre; Bizieux-Thaminy, Acya; Meslier, Nicole		IRSR Sleep Cohort Grp	Influence of Marital Status and Employment Status on Long-Term Adherence with Continuous Positive Airway Pressure in Sleep Apnea Patients	PLOS ONE			English	Article							CPAP USE; DAYTIME SLEEPINESS; APNOEA/HYPOPNOEA SYNDROME; THERAPY; PREDICTORS; MODERATE; REDUCTION; DIAGNOSIS; HYPOPNEA; QUALITY	Background: Long-term adherence is a major issue in patients receiving home continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea-hypopnea syndrome (OSAHS). In a multicenter prospective cohort (the Institut de Recherche en Sante Respiratoire des Pays de la Loire [IRSR] sleep cohort) of consecutive OSAHS patients in whom CPAP had been prescribed for at least 90 days, we studied the impact on long-term treatment adherence of socioeconomic factors, patients and disease characteristics prior to CPAP initiation. Methods and Principal Findings: Among 1,141 patients in whom CPAP had been prescribed for an average of 5046251 days (range: 91 to 1035), 674 (59%) were adherent with a mean daily use of CPAP >= 4 h (mean: 6.42 +/- 61.35 h). Stepwise regression analysis identified 4 independent factors of CPAP adherence including apnea-hypopnea index (AHI) (OR: 1.549, 95% CI 1.163 to 2.062 for AHI >= 30 vs. AHI < 30; p = 0.003), body mass index (BMI) (OR: 1.786, 95% CI 1.131 to 2.822 for BMI >= 25 and <30 kg/m(2), p = 0.01; OR: 1.768, 95% CI 1.145-2.731 for BMI >= 30 kg/m(2), p = 0.01 vs. BMI < 25 kg/m(2)), employment status (OR: 1.414, 95% CI 1.097-1.821 for retired vs. employed; p = 0.007) and marital status (OR: 1.482, 95% CI 1.088-2.019 for married or living as a couple vs. living alone; p = 0.01). Age, gender, Epworth sleepiness scale, depressive syndrome, associated cardiovascular morbidities, educational attainment and occupation category did not influence CPAP adherence. Conclusions: Marital status and employment status are independent factors of CPAP adherence in addition to BMI and disease severity. Patients living alone and/or working patients are at greater risk of non-adherence, whereas adherence is higher in married and retired patients. These findings suggest that the social context of daily life should be taken into account in risk screening for CPAP non-adherence. Future interventional studies targeting at-risk patients should be designed to address social motivating factors and work-related barriers to CPAP adherence.	[Gagnadoux, Frederic; Meslier, Nicole] LUNAM Univ, Angers, France; [Gagnadoux, Frederic; Meslier, Nicole] Univ Angers, CHU Angers, Dept Pneumol, Angers, France; [Le Vaillant, Marc] EHESS, INSERM, U988, CNRS,UMR8211,CERMES, Villejuif, France; [Goupil, Francois] Ctr Hosp, Serv Pneumol, Le Mans, France; [Pigeanne, Thierry] Unite Pneumol, Olonne Sur Mer, France; [Chollet, Sylvaine] Hop Laennec, Inst Thorax, Nantes, France; [Masson, Philippe] Ctr Hosp, Serv Pneumol, Cholet, France; [Humeau, Marie-Pierre] Nouvelles Clin Nantaises, Pneumol, Nantes, France; [Bizieux-Thaminy, Acya] Ctr Hosp, Serv Pneumol, La Roche Sur Yon, France	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Humanities & Social Sciences (INSHS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre Hospitalier Le Mans; Nantes Universite; CHU de Nantes; CHD Vendee	Gagnadoux, F (corresponding author), LUNAM Univ, Angers, France.	frgagnadoux@chu-angers.fr	Pelletier-Fleury, Nathalie/R-4220-2018	Pelletier-Fleury, Nathalie/0000-0002-4821-4863	Institut de Recherche en Sante Respiratoire des Pays de la Loire	Institut de Recherche en Sante Respiratoire des Pays de la Loire	The study was funded by the Institut de Recherche en Sante Respiratoire des Pays de la Loire. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Antic NA, 2011, SLEEP, V34, P111, DOI 10.1093/sleep/34.1.111; Antic NA, 2009, AM J RESP CRIT CARE, V179, P501, DOI 10.1164/rccm.200810-1558OC; Ayas NT, 2004, SLEEP, V27, P249, DOI 10.1093/sleep/27.2.249; BARON KG, 2010, SLEEP BREATH; Bazzano LA, 2007, HYPERTENSION, V50, P417, DOI 10.1161/HYPERTENSIONAHA.106.085175; Buchner NJ, 2007, AM J RESP CRIT CARE, V176, P1274, DOI 10.1164/rccm.200611-1588OC; Cartwright R, 2008, J CLIN SLEEP MED, V4, P123; Chai CL, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005308.pub2; DEBONIS M, 1991, J AFFECT DISORDERS, V22, P55, DOI 10.1016/0165-0327(91)90084-6; Ediger JP, 2007, AM J GASTROENTEROL, V102, P1417, DOI 10.1111/j.1572-0241.2007.01212.x; Engleman HM, 2003, SLEEP MED REV, V7, P81, DOI 10.1053/smrv.2001.0197; George CFP, 2001, THORAX, V56, P508, DOI 10.1136/thorax.56.7.508; Giles T. L., 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001103.PUB3; Greenberg Harly, 2004, Sleep Breath, V8, P185, DOI 10.1055/s-2004-860895; Haniffa M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003531.PUB2; *INSEE, 2003, PCS 2003; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kohler M, 2010, THORAX, V65, P829, DOI 10.1136/thx.2010.135848; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P887, DOI 10.1164/ajrccm/147.4.887; Lewis KE, 2004, SLEEP, V27, P134, DOI 10.1093/sleep/27.1.134; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; McArdle N, 1999, AM J RESP CRIT CARE, V159, P1108, DOI 10.1164/ajrccm.159.4.9807111; McArdle N, 2001, THORAX, V56, P513, DOI 10.1136/thorax.56.7.513; McDaid C, 2009, HEALTH TECHNOL ASSES, V13, P1; Mills EJ, 2006, PLOS MED, V3, P2039, DOI 10.1371/journal.pmed.0030438; Mulgrew AT, 2007, SLEEP MED, V9, P42, DOI 10.1016/j.sleep.2007.01.009; Mulgrew AT, 2007, ANN INTERN MED, V146, P157, DOI 10.7326/0003-4819-146-3-200702060-00004; Nguyen XL, 2010, SLEEP MED, V11, P777, DOI 10.1016/j.sleep.2010.04.008; Olsen S, 2008, EUR RESPIR J, V32, P710, DOI 10.1183/09031936.00127507; Pelletier-Fleury N, 2001, SLEEP MED, V2, P225, DOI 10.1016/S1389-9457(00)00063-0; Pepin JL, 2009, CHEST, V136, P490, DOI 10.1378/chest.08-2646; Pepin JL, 1999, AM J RESP CRIT CARE, V160, P1124, DOI 10.1164/ajrccm.160.4.9802027; Platt AB, 2008, PHARMACOEPIDEM DR S, V17, P853, DOI 10.1002/pds.1556; Platt AB, 2009, SLEEP, V32, P799, DOI 10.1093/sleep/32.6.799; Rakotonanahary D, 2001, CHEST, V119, P460, DOI 10.1378/chest.119.2.460; Richards D, 2007, SLEEP, V30, P635, DOI 10.1093/sleep/30.5.635; Ryan S, 2011, J SLEEP RES, V20, P367, DOI 10.1111/j.1365-2869.2010.00873.x; SANDERS MH, 1994, CHEST, V106, P774, DOI 10.1378/chest.106.3.774; Sawyer AM, 2010, QUAL HEALTH RES, V20, P873, DOI 10.1177/1049732310365502; Simon-Tuval T, 2009, SLEEP, V32, P545, DOI 10.1093/sleep/32.4.545; Societe de Pneumologie de Langue Francaise, 2010, Rev Mal Respir, V27, P806, DOI 10.1016/j.rmr.2010.05.011; Stradling JR, 2000, SLEEP, V23, pS150; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Weaver TE, 2007, SLEEP, V30, P711, DOI 10.1093/sleep/30.6.711; Weaver TE, 2010, INDIAN J MED RES, V131, P245; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zonato AI, 2004, BRAZ J MED BIOL RES, V37, P69, DOI 10.1590/S0100-879X2004000100010	47	80	80	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2011	6	8							e22503	10.1371/journal.pone.0022503	http://dx.doi.org/10.1371/journal.pone.0022503			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810JJ	21857929	Green Published, gold, Green Submitted			2023-01-03	WOS:000294121300004
J	Cappuccio, FP; Capewell, S; Lincoln, P; McPherson, K				Cappuccio, Francesco P.; Capewell, Simon; Lincoln, Paul; McPherson, Klim			Policy options to reduce population salt intake	BRITISH MEDICAL JOURNAL			English	Editorial Material							BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; RANDOMIZED-TRIALS; SODIUM-CHLORIDE; PUBLIC-HEALTH; METAANALYSIS; FOOD		[Cappuccio, Francesco P.] Univ Warwick, Warwick Med Sch, WHO Collaborating Ctr Nutr, WHO Collaborating Ctr, Coventry CV2 2DX, W Midlands, England; [Capewell, Simon] Univ Liverpool, Liverpool L69 3BX, Merseyside, England; [Lincoln, Paul] Natl Heart Forum, London, England; [McPherson, Klim] Univ Oxford, Oxford, England	University of Warwick; World Health Organization; University of Liverpool; University of Oxford	Cappuccio, FP (corresponding author), Univ Warwick, Warwick Med Sch, WHO Collaborating Ctr Nutr, WHO Collaborating Ctr, Coventry CV2 2DX, W Midlands, England.	f.p.cappuccio@warwick.ac.uk	Cappuccio, Francesco Paolo/ABF-1094-2020	Cappuccio, Francesco Paolo/0000-0002-7842-5493				Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0; BLAIS CA, 1986, AM J CLIN NUTR, V44, P232, DOI 10.1093/ajcn/44.2.232; Cappuccio FP, 2007, BMJ-BRIT MED J, V334, P859, DOI 10.1136/bmj.39175.364954.BE; FORTE JG, 1989, J HUM HYPERTENS, V3, P179; He F, 2002, J HUM HYPERTENS, V16, P761, DOI 10.1038/sj.jhh.1001459; He FJ, 2003, HYPERTENSION, V42, P1093, DOI 10.1161/01.HYP.0000102864.05174.E8; Karppanen H, 2006, PROG CARDIOVASC DIS, V49, P59, DOI 10.1016/j.pcad.2006.07.001; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Malik VS, 2006, AM J CLIN NUTR, V84, P274; National Institute for Health and Clinical Excellence, 2010, PREV CARD DIS POP LE; Sasaki N., 1979, PROPHYLACTIC APPROAC, P467; Sharma LL, 2010, AM J PUBLIC HEALTH, V100, P240, DOI 10.2105/AJPH.2009.160960; Strazzullo P, 2011, J HYPERTENS, V29, P829, DOI 10.1097/HJH.0b013e3283459568; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; Takahashi Y, 2006, J HYPERTENS, V24, P451, DOI 10.1097/01.hjh.0000209980.36359.16; TEOW BH, 1985, CLIN EXP HYPERTENS A, V7, P1681, DOI 10.3109/10641968509073618; Turnbull F, 2003, LANCET, V362, P1527; Webster JL, 2011, J HYPERTENS, V29, P1043, DOI 10.1097/HJH.0b013e328345ed83	19	86	90	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 11	2011	343								d4995	10.1136/bmj.d4995	http://dx.doi.org/10.1136/bmj.d4995			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	808DP	21835876	Green Submitted			2023-01-03	WOS:000293956900003
J	Lu, RZ; Niesen, MJM; Hu, WD; Vaidehi, N; Shively, JE				Lu, Rongze; Niesen, Michiel J. M.; Hu, Weidong; Vaidehi, Nagarajan; Shively, John E.			Interaction of Actin with Carcinoembryonic Antigen-related Cell Adhesion Molecule 1 (CEACAM1) Receptor in Liposomes Is Ca2+- and Phospholipid-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATION-PI INTERACTIONS; DYNAMICS SIMULATIONS; CYTOPLASMIC DOMAIN; CONSTANT-PRESSURE; MEMBRANE; DIMERIZATION; HYDRATION; RESIDUES; SYSTEMS; VIEW	The regulation of binding of G-actin to cytoplasmic domains of cell surface receptors is a common mechanism to control diverse biological processes. To model the regulation of G-actin binding to a cell surface receptor we used the cell-cell adhesion molecule carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1-S) in which G-actin binds to its short cytoplasmic domain (12 amino acids; Chen, C. J., Kirshner, J., Sherman, M. A., Hu, W., Nguyen, T., and Shively, J. E. (2007) J. Biol. Chem. 282, 5749-5760). A liposome model system demonstrates that G-actin binds to the cytosolic domain peptide of CEACAM1-S in the presence of negatively charged palmitoyloleoyl phosphatidylserine (POPS) liposomes and Ca2+. In contrast, no binding of G-actin was observed in palmitoyl-oleoyl phosphatidylcholine (POPC) liposomes or when a key residue in the peptide, Phe-454, is replaced with Ala. Molecular Dynamics simulations on CEACAM1-S in an asymmetric phospholipid bilayer show migration of Ca2+ ions to the lipid leaflet containing POPS and reveal two conformations for Phe-454 explaining the reversible availability of this residue for G-actin binding. NMR transverse relaxation optimized spectroscopic analysis of C-13-labeled Phe-454 CEACAM1-S peptide in liposomes plus actin further confirmed the existence of two peptide conformers and the Ca2+ dependence of actin binding. These findings explain how a receptor with a short cytoplasmic domain can recruit a cytosolic protein in a phospholipid and Ca2+-specific manner. In addition, this model system provides a powerful approach that can be applied to study other membrane protein interactions with their cytosolic targets.	[Niesen, Michiel J. M.; Hu, Weidong; Vaidehi, Nagarajan; Shively, John E.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunol, Duarte, CA 91010 USA; [Lu, Rongze] City Hope Natl Med Ctr, Irell & Manella Grad Sch Biol Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org	Niesen, Michiel/AAF-6824-2020; Niesen, Michiel JM/L-8985-2013; Lu, Rongze/R-2149-2016		National Institutes of Health [CA 84202]; NATIONAL CANCER INSTITUTE [R01CA084202] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by National Institutes of Health Grant CA 84202.	Berendsen HJC, 1981, INTERMOLECULAR FORCE, P331, DOI 10.1007/978-94-015-7658-1_21; Berger O, 1997, BIOPHYS J, V72, P2002, DOI 10.1016/S0006-3495(97)78845-3; Bouchard M, 1998, BIOCHEMISTRY-US, V37, P3149, DOI 10.1021/bi971892r; Bouschet T, 2008, TRENDS PHARMACOL SCI, V29, P633, DOI 10.1016/j.tips.2008.09.002; Brozinick JT, 2007, CURR DIABETES REV, V3, P111, DOI 10.2174/157339907780598199; Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Chen CJ, 2004, J IMMUNOL, V172, P3544, DOI 10.4049/jimmunol.172.6.3544; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Dougherty DA, 2007, J NUTR, V137, p1504S, DOI 10.1093/jn/137.6.1504S; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fallahi-Sichani M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006604; Fawzi NL, 2010, J AM CHEM SOC, V132, P9948, DOI 10.1021/ja1048253; Gray-Owen SD, 2006, NAT REV IMMUNOL, V6, P433, DOI 10.1038/nri1864; Hess B, 1997, J COMPUT CHEM, V18, P1463, DOI 10.1002/(SICI)1096-987X(199709)18:12<1463::AID-JCC4>3.0.CO;2-H; Huang YP, 2007, J CELL SCI, V120, P723, DOI 10.1242/jcs.000786; Ida M, 2004, J BIOCHEM, V135, P583, DOI 10.1093/jb/mvh071; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kandt C, 2007, METHODS, V41, P475, DOI 10.1016/j.ymeth.2006.08.006; Ko KS, 2001, J CELL SCI, V114, P1155; KUMPF RA, 1993, SCIENCE, V261, P1708, DOI 10.1126/science.8378771; Muenzner P, 2008, CELL MICROBIOL, V10, P1074, DOI 10.1111/j.1462-5822.2007.01106.x; Muller MM, 2009, J CELL BIOL, V187, P569, DOI 10.1083/jcb.200904150; NOSE S, 1984, J CHEM PHYS, V81, P511, DOI 10.1063/1.447334; NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851; Oostenbrink C, 2004, J COMPUT CHEM, V25, P1656, DOI 10.1002/jcc.20090; PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693; Pervushin K, 1998, J AM CHEM SOC, V120, P6394, DOI 10.1021/ja980742g; Scita G, 2008, TRENDS CELL BIOL, V18, P52, DOI 10.1016/j.tcb.2007.12.002; Thorp EB, 2004, J VIROL, V78, P2682, DOI 10.1128/JVI.78.6.2682-2692.2004; Tieleman DP, 1998, BIOCHEMISTRY-US, V37, P17554, DOI 10.1021/bi981802y; Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; Wider G, 2006, J AM CHEM SOC, V128, P2571, DOI 10.1021/ja055336t	38	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	2011	286	31					27528	27536		10.1074/jbc.M111.235762	http://dx.doi.org/10.1074/jbc.M111.235762			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	799EZ	21669871	Green Published, hybrid			2023-01-03	WOS:000293268700047
J	Savino, M; Annibali, D; Carucci, N; Favuzzi, E; Cole, MD; Evan, GI; Soucek, L; Nasi, S				Savino, Mauro; Annibali, Daniela; Carucci, Nicoletta; Favuzzi, Emilia; Cole, Michael D.; Evan, Gerard I.; Soucek, Laura; Nasi, Sergio			The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy	PLOS ONE			English	Article							EMBRYONIC STEM-CELLS; LOOP-HELIX PROTEINS; C-MYC; TRANSCRIPTION FACTOR; GENE-REGULATION; LEUCINE ZIPPER; DNA-BINDING; IN-VIVO; N-MYC; EXPRESSION	Recent evidence points to Myc - a multifaceted bHLHZip transcription factor deregulated in the majority of human cancers - as a priority target for therapy. How to target Myc is less clear, given its involvement in a variety of key functions in healthy cells. Here we report on the action mechanism of the Myc interfering molecule termed Omomyc, which demonstrated astounding therapeutic efficacy in transgenic mouse cancer models in vivo. Omomyc action is different from the one that can be obtained by gene knockout or RNA interference, approaches designed to block all functions of a gene product. This molecule - instead - appears to cause an edge-specific perturbation that destroys some protein interactions of the Myc node and keeps others intact, with the result of reshaping the Myc transcriptome. Omomyc selectively targets Myc protein interactions: it binds c-and N-Myc, Max and Miz-1, but does not bind Mad or select HLH proteins. Specifically, it prevents Myc binding to promoter E-boxes and transactivation of target genes while retaining Miz-1 dependent binding to promoters and transrepression. This is accompanied by broad epigenetic changes such as decreased acetylation and increased methylation at H3 lysine 9. In the presence of Omomyc, the Myc interactome is channeled to repression and its activity appears to switch from a pro-oncogenic to a tumor suppressive one. Given the extraordinary therapeutic impact of Omomyc in animal models, these data suggest that successfully targeting Myc for cancer therapy might require a similar twofold action, in order to prevent Myc/Max binding to E-boxes and, at the same time, keep repressing genes that would be repressed by Myc.	[Savino, Mauro; Annibali, Daniela; Carucci, Nicoletta; Favuzzi, Emilia; Nasi, Sergio] Univ Roma La Sapienza, Dipartimento Biol & Biotecnol, CNR, IBPM, Rome, Italy; [Cole, Michael D.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Evan, Gerard I.; Soucek, Laura] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Soucek, Laura] VHIO, Barcelona, Spain	Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome; Princeton University; University of California System; University of California San Francisco; Vall d'Hebron Institut d'Oncologia (VHIO)	Savino, M (corresponding author), Univ Roma La Sapienza, Dipartimento Biol & Biotecnol, CNR, IBPM, Rome, Italy.	sergio.nasi@uniroma1.it	Soucek, Laura/AAG-7393-2019; Soucek, Laura/AAG-8377-2019; Annibali, Daniela/AAE-3004-2019; Annibali, Daniela/AAC-5270-2019	Soucek, Laura/0000-0002-4750-7971; Annibali, Daniela/0000-0001-8413-7669; Favuzzi, Emilia/0000-0003-4256-1490	AIRC; ASI; MIUR; Fondazione Guido Berlucchi; Bear Necessities Pediatric Cancer Foundation; CNR; CNR - Sapienza University; NATIONAL CANCER INSTITUTE [R01CA055248] Funding Source: NIH RePORTER; Cancer Research UK [12077] Funding Source: researchfish	AIRC(Fondazione AIRC per la ricerca sul cancro); ASI(Agenzia Spaziale Italiana (ASI)); MIUR(Ministry of Education, Universities and Research (MIUR)); Fondazione Guido Berlucchi; Bear Necessities Pediatric Cancer Foundation; CNR(Consiglio Nazionale delle Ricerche (CNR)); CNR - Sapienza University; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	This work was supported by research grants from AIRC, ASI, MIUR and Fondazione Guido Berlucchi (SN), a Bear Necessities Pediatric Cancer Foundation grant (LS), a CNR short term mobility fellowship (SN) and by CNR - Sapienza University PhD fellowships (MS, DA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chandriani S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006693; Chang HY, 2004, PLOS BIOL, V2, P206, DOI 10.1371/journal.pbio.0020007; Chen YL, 2007, PLOS COMPUT BIOL, V3, P602, DOI 10.1371/journal.pcbi.0030063; Ciarapica R, 2009, ONCOGENE, V28, P1881, DOI 10.1038/onc.2009.56; Clausen DM, 2010, J PHARMACOL EXP THER, V335, P715, DOI 10.1124/jpet.110.170555; Cole MD, 2006, CURR TOP MICROBIOL, V302, P33; Cotterman R, 2008, CANCER RES, V68, P9654, DOI 10.1158/0008-5472.CAN-08-1961; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; Dang CV, 1999, MOL CELL BIOL, V19, P1; Dugan KA, 2002, ONCOGENE, V21, P5835, DOI 10.1038/sj.onc.1205763; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gordan JD, 2007, CANCER CELL, V12, P108, DOI 10.1016/j.ccr.2007.07.006; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Knoepfler PS, 2007, CANCER RES, V67, P5061, DOI 10.1158/0008-5472.CAN-07-0426; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lin CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007839; Lofstedt T, 2009, EXP CELL RES, V315, P1924, DOI 10.1016/j.yexcr.2009.02.015; Martinato F, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003650; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; O'Connell BC, 2003, J BIOL CHEM, V278, P12563, DOI 10.1074/jbc.M210462200; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Patel JH, 2006, J BIOL CHEM, V281, P3283, DOI 10.1074/jbc.M513038200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Ponzielli R, 2005, EUR J CANCER, V41, P2485, DOI 10.1016/j.ejca.2005.08.017; Prochownik EV, 1998, GENE CHROMOSOME CANC, V22, P295, DOI 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q; Qing GL, 2010, CANCER RES, V70, P10351, DOI 10.1158/0008-5472.CAN-10-0740; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 1998, ONCOGENE, V17, P2463, DOI 10.1038/sj.onc.1202199; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; von Eyss B, 2011, GENE DEV, V25, P895, DOI 10.1101/gad.2053311; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wechsler DS, 1997, CANCER RES, V57, P4905; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yin XY, 2003, ONCOGENE, V22, P6151, DOI 10.1038/sj.onc.1206641; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhong Q, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.80	66	73	79	0	20	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2011	6	7							e22284	10.1371/journal.pone.0022284	http://dx.doi.org/10.1371/journal.pone.0022284			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	795FA	21811581	Green Submitted, gold, Green Published			2023-01-03	WOS:000292956800038
J	Lim, S; Yoon, JW; Kang, SM; Choi, SH; Cho, BJ; Kim, M; Park, HS; Cho, HJ; Shin, H; Kim, YB; Kim, HS; Jang, HC; Park, KS				Lim, Soo; Yoon, Ji Won; Kang, Seon Mee; Choi, Sung Hee; Cho, Bong Jun; Kim, Min; Park, Ho Seon; Cho, Hyun Ju; Shin, Hayley; Kim, Young-Bum; Kim, Hyo Soo; Jang, Hak Chul; Park, Kyong Soo			EGb761, a Ginkgo Biloba Extract, Is Effective Against Atherosclerosis In Vitro, and in a Rat Model of Type 2 Diabetes	PLOS ONE			English	Article							C-REACTIVE PROTEIN; CARDIOVASCULAR RISK-FACTOR; NEOINTIMAL HYPERPLASIA; MOLECULAR-MECHANISMS; BALLOON ANGIOPLASTY; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; ADIPONECTIN; RESTENOSIS; DISEASE	Background: EGb761, a standardized Ginkgo biloba extract, has antioxidant and antiplatelet aggregation and thus might protect against atherosclerosis. However, molecular and functional properties of EGb761 and its major subcomponents have not been well characterized. We investigated the effect of EGb761 and its major subcomponents (bilobalide, kaemferol, and quercetin) on preventing atherosclerosis in vitro, and in a rat model of type 2 diabetes. Methods and Results: EGb761 (100 and 200 mg/kg) or normal saline (control) were administered to Otsuka Long-Evans Tokushima Fatty rats, an obese insulin-resistant rat model, for 6 weeks (from 3 weeks before to 3 weeks after carotid artery injury). Immunohistochemical staining was performed to investigate cell proliferation and apoptosis in the injured arteries. Cell migration, caspase-3 activity and DNA fragmentation, monocyte adhesion, and ICAM-1/VCAM-1 levels were explored in vitro. Treatment with EGb761 dose-dependently reduced intima-media ratio, proliferation of vascular smooth muscle cells (VSMCs) and induced greater apoptosis than the controls. Proliferation and migration of VSMCs in vitro were also decreased by the treatment of EGb761. Glucose homeostasis and circulating adiponectin levels were improved, and plasma hsCRP concentrations were decreased in the treatment groups. Caspase-3 activity and DNA fragmentation increased while monocyte adhesion and ICAM-1/VCAM-1 levels decreased significantly. Among subcomponents of EGb761, kaemferol and quercetin reduced VSMC migration and increased caspase activity. Conclusions: EGb761 has a protective role in the development of atherosclerosis and is a potential therapeutic agent for preventing atherosclerosis.	[Lim, Soo; Yoon, Ji Won; Kang, Seon Mee; Choi, Sung Hee; Cho, Bong Jun; Jang, Hak Chul] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea; [Lim, Soo; Yoon, Ji Won; Kang, Seon Mee; Choi, Sung Hee; Kim, Min; Park, Ho Seon; Cho, Hyun Ju; Kim, Hyo Soo; Jang, Hak Chul; Park, Kyong Soo] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul Natl Univ Hosp, Seoul 151, South Korea; [Shin, Hayley] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Kim, Young-Bum] Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol Diabet & Metab, Boston, MA 02215 USA; [Kim, Young-Bum] Harvard Univ, Sch Med, Boston, MA USA	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Lim, S (corresponding author), Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea.	kspark@snu.ac.kr	Choi, Sung-hee/J-5689-2012; Jang, Hak Chul/D-9637-2012; Lim, Soo/AAU-8107-2020; Park, Kyong Soo/C-2265-2008	Jang, Hak Chul/0000-0002-4188-6536; Lim, Soo/0000-0002-4137-1671; Park, Kyong Soo/0000-0003-3597-342X; Park, Ho Seon/0000-0003-1200-4626; CHOI, SUNG HEE/0000-0003-0740-8116	Korean Society of Lipidology and Atherosclerosis; Korea Science and Engineering Foundation [M10642140004-06N4214-00410]; Ministry of Information and Communication/Institute for Information Technology Advancement [2006-S075-01]	Korean Society of Lipidology and Atherosclerosis; Korea Science and Engineering Foundation(Korea Science and Engineering Foundation); Ministry of Information and Communication/Institute for Information Technology Advancement	This work was supported by the Korean Society of Lipidology and Atherosclerosis (2008), the Korea Science and Engineering Foundation grants (M10642140004-06N4214-00410) and the Information Technology R&D program of Ministry of Information and Communication/Institute for Information Technology Advancement (2006-S075-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ANSARI B, 1993, J PATHOL, V170, P1, DOI 10.1002/path.1711700102; Bhagat K, 1997, CIRCULATION, V96, P3042, DOI 10.1161/01.CIR.96.9.3042; Boveris AD, 2007, PHYTOTHER RES, V21, P735, DOI 10.1002/ptr.2153; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Chao JCJ, 2004, WORLD J GASTROENTERO, V10, P37; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Choi SE, 2007, J ETHNOPHARMACOL, V110, P49, DOI 10.1016/j.jep.2006.09.001; CLOWES AW, 1983, LAB INVEST, V49, P327; Defeudis FV, 2002, PHARMACOL RES, V46, P565, DOI 10.1016/S1043-6618(02)00233-5; Ferns GAA, 2000, INT J EXP PATHOL, V81, P63, DOI 10.1046/j.1365-2613.2000.00143.x; Gohil K, 2002, CELL MOL BIOL, V48, P625; Han SH, 2007, J AM COLL CARDIOL, V49, P531, DOI 10.1016/j.jacc.2006.08.061; Henke N, 2007, CIRC RES, V101, P268, DOI 10.1161/CIRCRESAHA.107.150474; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; Kim KS, 2005, ORAL ONCOL, V41, P383, DOI 10.1016/j.oraloncology.2004.09.013; Kudolo GB, 2005, DIABETES RES CLIN PR, V68, P29, DOI 10.1016/j.diabres.2004.08.007; Kudolo GB, 2001, J CLIN PHARMACOL, V41, P600, DOI 10.1177/00912700122010483; Kumada M, 2003, ARTERIOSCL THROM VAS, V23, P85, DOI 10.1161/01.ATV.0000048856.22331.50; Lagrand WK, 1999, CIRCULATION, V100, P96, DOI 10.1161/01.CIR.100.1.96; Lim S, 2006, ARTERIOSCL THROM VAS, V26, P808, DOI 10.1161/01.ATV.0000204634.26163.a7; Lim S, 2008, ATHEROSCLEROSIS, V196, P398, DOI 10.1016/j.atherosclerosis.2006.11.017; Lim S, 2009, ATHEROSCLEROSIS, V206, P411, DOI 10.1016/j.atherosclerosis.2009.02.031; Liu FY, 2008, PHYTOTHER RES, V22, P506, DOI 10.1002/ptr.2353; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Mahadevan S, 2008, J FOOD SCI, V73, pR14, DOI 10.1111/j.1750-3841.2007.00597.x; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; Moreno PR, 1996, CIRCULATION, V94, P3098, DOI 10.1161/01.CIR.94.12.3098; Moreno PR, 1999, J AM COLL CARDIOL, V34, P1045, DOI 10.1016/S0735-1097(99)00338-1; Mori E, 2002, CIRCULATION, V105, P2905, DOI 10.1161/01.CIR.0000018603.67989.71; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Orban Z, 1999, J CLIN ENDOCR METAB, V84, P2126, DOI 10.1210/jc.84.6.2126; Oyama Y, 1996, BRAIN RES, V712, P349, DOI 10.1016/0006-8993(95)01440-3; Pasceri V, 2000, CIRCULATION, V102, P2165; PEPYS MB, 1985, INT REV EXP PATHOL, V27, P83; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Rapin JR, 1997, DRUG DEVELOP RES, V40, P68; Rodriguez M, 2007, ATHEROSCLEROSIS, V192, P438, DOI 10.1016/j.atherosclerosis.2007.02.021; Rogers C, 1996, ARTERIOSCL THROM VAS, V16, P1312, DOI 10.1161/01.ATV.16.10.1312; Schulze MB, 2005, DIABETES, V54, P534, DOI 10.2337/diabetes.54.2.534; SCHWARTZ RS, 1990, CIRCULATION, V82, P2190, DOI 10.1161/01.CIR.82.6.2190; Smith JV, 2003, J ALZHEIMERS DIS, V5, P287, DOI 10.3233/JAD-2003-5404; Smith JV, 2004, APPL MICROBIOL BIOT, V64, P465, DOI 10.1007/s00253-003-1527-9; Smith PF, 1996, J ETHNOPHARMACOL, V50, P131, DOI 10.1016/0378-8741(96)01379-7; Tanaka S, 2004, YAKUGAKU ZASSHI, V124, P605, DOI 10.1248/yakushi.124.605; Valli G, 2002, J AM COLL CARDIOL, V39, P1083, DOI 10.1016/S0735-1097(02)01749-7; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Welt FGP, 2000, ARTERIOSCL THROM VAS, V20, P2553, DOI 10.1161/01.ATV.20.12.2553; Wolbink GJ, 1996, J IMMUNOL, V157, P473; Zhang Q, 2009, ACTA PHARMACOL SIN, V30, P1674, DOI 10.1038/aps.2009.173; Zietz B, 2003, FEBS LETT, V545, P103, DOI 10.1016/S0014-5793(03)00568-4; Zimmermann M, 2002, CELL MOL BIOL, V48, P613	51	33	43	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2011	6	6							e20301	10.1371/journal.pone.0020301	http://dx.doi.org/10.1371/journal.pone.0020301			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773ME	21655098	gold, Green Submitted, Green Published			2023-01-03	WOS:000291310600008
J	[Anonymous]				[Anonymous]			Stroke care-a work in progress	LANCET			English	Editorial Material																			0	0	0	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1625	1625						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571128				2023-01-03	WOS:000290777700001
J	Hickman, DT; Lopez-Deber, MP; Ndao, DM; Silva, AB; Nand, D; Pihlgren, M; Giriens, V; Madani, R; St-Pierre, A; Karastaneva, H; Nagel-Steger, L; Willbold, D; Riesner, D; Nicolau, C; Baldus, M; Pfeifer, A; Muhs, A				Hickman, David T.; Lopez-Deber, Maria Pilar; Ndao, Dorin Mlaki; Silva, Alberto B.; Nand, Deepak; Pihlgren, Maria; Giriens, Valerie; Madani, Rime; St-Pierre, Annie; Karastaneva, Hristina; Nagel-Steger, Luitgard; Willbold, Dieter; Riesner, Detlev; Nicolau, Claude; Baldus, Marc; Pfeifer, Andrea; Muhs, Andreas			Sequence-independent Control of Peptide Conformation in Liposomal Vaccines for Targeting Protein Misfolding Diseases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOFLAVINE-T INTERACTION; BETA-SHEET STRUCTURES; ALZHEIMERS-DISEASE; COMMON MECHANISM; IMMUNE-RESPONSE; AMYLOID FIBRILS; PRION PROTEIN; ANTIBODIES; OLIGOMERS; VACCINATION	Synthetic peptide immunogens that mimic the conformation of a target epitope of pathological relevance offer the possibility to precisely control the immune response specificity. Here, we performed conformational analyses using a panel of peptides in order to investigate the key parameters controlling their conformation upon integration into liposomal bilayers. These revealed that the peptide lipidation pattern, the lipid anchor chain length, and the liposome surface charge all significantly alter peptide conformation. Peptide aggregation could also be modulated post-liposome assembly by the addition of distinct small molecule beta-sheet breakers. Immunization of both mice and monkeys with a model liposomal vaccine containing beta-sheet aggregated lipopeptide (Palm1-15) induced polyclonal IgG antibodies that specifically recognized beta-sheet multimers over monomer or non-pathological native protein. The rational design of liposome-bound peptide immunogens with defined conformation opens up the possibility to generate vaccines against a range of protein misfolding diseases, such as Alzheimer disease.	[Hickman, David T.; Lopez-Deber, Maria Pilar; Ndao, Dorin Mlaki; Silva, Alberto B.; Pihlgren, Maria; Giriens, Valerie; Madani, Rime; St-Pierre, Annie; Pfeifer, Andrea; Muhs, Andreas] AC Immune SA, PSE B, EPFL, CH-1015 Lausanne, Switzerland; [Nand, Deepak; Baldus, Marc] Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; [Karastaneva, Hristina; Nagel-Steger, Luitgard; Willbold, Dieter; Riesner, Detlev] Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany; [Willbold, Dieter] Forschungszentrum Julich, Inst Strukturbiol & Biophys ISB 3, D-52425 Julich, Germany; [Nicolau, Claude] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02115 USA	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Utrecht University; Heinrich Heine University Dusseldorf; Helmholtz Association; Research Center Julich; Tufts University	Muhs, A (corresponding author), AC Immune SA, PSE B, EPFL, CH-1015 Lausanne, Switzerland.	andreas.muhs@acimmune.com	Silva, Alberto B/H-3630-2011; Baldus, Marc/C-2737-2009; Willbold, Dieter/A-6280-2013; Nagel-Steger, Luitgard/H-6415-2013	Baldus, Marc/0000-0001-7068-5613; Willbold, Dieter/0000-0002-0065-7366; Nagel-Steger, Luitgard/0000-0001-5232-2149	Netherlands Organization for Scientific Research [700.26.121]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	Solid-state NMR studies were supported by Netherlands Organization for Scientific Research Grant 700.26.121. D.R. is a member of the Board of Directors and Scientific Advisory Board of AC Immune SA.	Bokvist M, 2004, J MOL BIOL, V335, P1039, DOI 10.1016/j.jmb.2003.11.046; Bosco DA, 2006, NAT CHEM BIOL, V2, P249, DOI 10.1038/nchembio782; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; BURDICK D, 1992, J BIOL CHEM, V267, P546; Chimon S, 2007, NAT STRUCT MOL BIOL, V14, P1157, DOI 10.1038/nsmb1345; Chiti F, 2009, NAT CHEM BIOL, V5, P15, DOI 10.1038/nchembio.131; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; FIESER TM, 1987, P NATL ACAD SCI USA, V84, P8568, DOI 10.1073/pnas.84.23.8568; Gao JJ, 2009, P NATL ACAD SCI USA, V106, P3071, DOI 10.1073/pnas.0812952106; Groenning Minna, 2010, J Chem Biol, V3, P1, DOI 10.1007/s12154-009-0027-5; Hock C, 2002, NAT MED, V8, P1270, DOI 10.1038/nm783; House E, 2009, J ALZHEIMERS DIS, V18, P811, DOI 10.3233/JAD-2009-1235; Janus C, 2000, NATURE, V408, P979, DOI 10.1038/35050110; Jha S, 2009, J MOL BIOL, V389, P907, DOI 10.1016/j.jmb.2009.04.077; Kawarabayashi T, 2004, J NEUROSCI, V24, P3801, DOI 10.1523/JNEUROSCI.5543-03.2004; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Khurana R, 2005, J STRUCT BIOL, V151, P229, DOI 10.1016/j.jsb.2005.06.006; Laczko I, 1998, BIOCHEM BIOPH RES CO, V249, P213, DOI 10.1006/bbrc.1998.9109; Lambert MP, 2001, J NEUROCHEM, V79, P595, DOI 10.1046/j.1471-4159.2001.00592.x; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LEVINE H, 1995, AMYLOID, V2, P1, DOI 10.3109/13506129509031881; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; Lowik DWPM, 2003, ORG BIOMOL CHEM, V1, P1827, DOI 10.1039/b303749e; Lu SM, 2002, J BIOL CHEM, V277, P23515, DOI 10.1074/jbc.M201981200; Maezawa I, 2008, J NEUROCHEM, V104, P457, DOI 10.1111/j.1471-4159.2007.04972.x; Maji SK, 2009, J BIOL CHEM, V284, P23580, DOI 10.1074/jbc.M109.038133; Meier M, 2008, J AM CHEM SOC, V130, P1017, DOI 10.1021/ja077231r; Misumi S, 2006, J IMMUNOL, V176, P463, DOI 10.4049/jimmunol.176.1.463; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Muhs A, 2007, P NATL ACAD SCI USA, V104, P9810, DOI 10.1073/pnas.0703137104; Nicolau C, 2002, P NATL ACAD SCI USA, V99, P2332, DOI 10.1073/pnas.022627199; Noguchi A, 2009, J BIOL CHEM, V284, P32895, DOI 10.1074/jbc.M109.000208; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; Ono K, 2009, P NATL ACAD SCI USA, V106, P14745, DOI 10.1073/pnas.0905127106; Orgogozo JM, 2003, NEUROLOGY, V61, P46, DOI 10.1212/01.WNL.0000073623.84147.A8; Paramithiotis E, 2003, NAT MED, V9, P893, DOI 10.1038/nm883; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; Pimentel TAPF, 2009, CHEM BIOL DRUG DES, V73, P53, DOI 10.1111/j.1747-0285.2008.00746.x; Roychaudhuri R, 2009, J BIOL CHEM, V284, P4749, DOI 10.1074/jbc.R800036200; Sarell CJ, 2009, BIOCHEMISTRY-US, V48, P4388, DOI 10.1021/bi900254n; Schmechel A, 2003, J BIOL CHEM, V278, P35317, DOI 10.1074/jbc.M303547200; Shankar GM, 2008, NAT MED, V14, P837, DOI 10.1038/nm1782; Su HP, 2007, VIROLOGY, V368, P331, DOI 10.1016/j.virol.2007.06.042; TOSI PF, 1995, BIOCHEM BIOPH RES CO, V212, P494, DOI 10.1006/bbrc.1995.1997; Villard V, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000645; Wang YJ, 2002, PROTEIN SCI, V11, P852, DOI 10.1110/ps.3180102; Weaver-Feldhaus JM, 2005, PROTEIN ENG DES SEL, V18, P527, DOI 10.1093/protein/gzi060; Yokoyama T, 2001, J BIOL CHEM, V276, P11265, DOI 10.1074/jbc.M008734200; Zhang QH, 2004, P NATL ACAD SCI USA, V101, P4752, DOI 10.1073/pnas.0400924101	49	59	64	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 22	2011	286	16					13966	13976		10.1074/jbc.M110.186338	http://dx.doi.org/10.1074/jbc.M110.186338			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	750NW	21343310	Green Published, hybrid			2023-01-03	WOS:000289556200019
J	Sack, DA				Sack, David A.			How many cholera deaths can be averted in Haiti?	LANCET			English	Editorial Material									Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sack, DA (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD 21205 USA.	dsack@jhsph.edu						Andrews JR, 2011, LANCET, V377, P1248, DOI 10.1016/S0140-6736(11)60273-0; Bompangue D, 2009, PLOS NEGLECT TROP D, V3, DOI 10.1371/journal.pntd.0000436; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; *COTS PROGR, CHOL OUTBR TRAIN SHI; LINDENBA.J, 1967, B WORLD HEALTH ORGAN, V36, P871; Luby SP, 2008, AM J TROP MED HYG, V78, P382, DOI 10.4269/ajtmh.2008.78.382; Nelson EJ, 2011, NEW ENGL J MED, V364, P5, DOI 10.1056/NEJMp1013771; QUICK RE, 1993, AM J TROP MED HYG, V48, P597, DOI 10.4269/ajtmh.1993.48.597; Sack DA, 2004, LANCET, V363, P223, DOI 10.1016/S0140-6736(03)15328-7; Sur D, 2009, LANCET, V374, P1694, DOI 10.1016/S0140-6736(09)61297-6; Waldor MK, 2010, NEW ENGL J MED, V363, P2279, DOI 10.1056/NEJMp1012300; World Health Organization, 2010, WKLY EPIDEMIOL REC, V85, P117	13	9	9	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 9	2011	377	9773					1214	1216		10.1016/S0140-6736(11)60356-5	http://dx.doi.org/10.1016/S0140-6736(11)60356-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	751DI	21414660				2023-01-03	WOS:000289597300005
J	Koole, O; Thai, S; Khun, KE; Pe, R; van Griensven, J; Apers, L; Van den Ende, J; Mao, TE; Lynen, L				Koole, Olivier; Thai, Sopheak; Khun, Kim Eam; Pe, Reaksmey; van Griensven, Johan; Apers, Ludwig; Van den Ende, Jef; Mao, Tan Eang; Lynen, Lutgarde			Evaluation of the 2007 WHO Guideline to Improve the Diagnosis of Tuberculosis in Ambulatory HIV-Positive Adults	PLOS ONE			English	Article							NEGATIVE PULMONARY TUBERCULOSIS; RESOURCE-LIMITED SETTINGS; INFECTED PERSONS; AFRICA; PEOPLE; DEATH; CAMBODIA; RATES	Background: In 2007 WHO issued a guideline to improve the diagnosis of smear-negative and extrapulmonary tuberculosis (EPTB) in HIV-positive patients. This guideline relies heavily on the acceptance of HIV-testing and availability of chest X-rays. Methods and Findings: Cohort study of TB suspects in four tuberculosis (TB) clinics in Phnom Penh, Cambodia. We assessed the operational performance of the guideline, the incremental yield of investigations, and the diagnostic accuracy for smear-negative tuberculosis in HIV-positive patients using culture positivity as reference standard. 1,147 (68.9%) of 1,665 TB suspects presented with unknown HIV status, 1,124 (98.0%) agreed to be tested, 79 (7.0%) were HIV-positive. Compliance with the guideline for chest X-rays and sputum culture requests was 97.1% and 98.3% respectively. Only 35 of 79 HIV-positive patients (44.3%) with a chest X-ray suggestive of TB started TB treatment within 10 days. 105 of 442 HIV-positive TB suspects started TB treatment (56.2% smear-negative pulmonary TB (PTB), 28.6% smear-positive PTB, 15.2% EPTB). The median time to TB treatment initiation was 5 days (IQR: 2-13 days), ranging from 2 days (IQR: 1-11.5 days) for EPTB, over 2.5 days (IQR: 1-4 days) for smear-positive PTB to 9 days (IQR: 3-17 days) for smear-negative PTB. Among the 34 smear-negative TB patients with a confirmed diagnosis, the incremental yield of chest X-ray, clinical suspicion or abdominal ultrasound, and culture was 41.2%, 17.6% and 41.2% respectively. The sensitivity and specificity of the algorithm to diagnose smear-negative TB in HIV-positive TB suspects was 58.8% (95% CI: 42.2%-73.6%) and 79.4% (95% CI: 74.8%-82.4%) respectively. Conclusions: Pending point-of-care rapid diagnostic tests for TB disease, diagnostic algorithms are needed. The diagnostic accuracy of the 2007 WHO guideline to diagnose smear-negative TB is acceptable. There is, however, reluctance to comply with the guideline in terms of immediate treatment initiation.	[Koole, Olivier; van Griensven, Johan; Apers, Ludwig; Van den Ende, Jef; Lynen, Lutgarde] Inst Trop Med, B-2000 Antwerp, Belgium; [Thai, Sopheak; Pe, Reaksmey] Sihanouk Hosp Ctr HOPE SHCH, Phnom Penh, Cambodia; [Khun, Kim Eam; Mao, Tan Eang] Natl Ctr TB & Leprosy Control CENAT, Phnom Penh, Cambodia	Institute of Tropical Medicine (ITM)	Koole, O (corresponding author), Inst Trop Med, B-2000 Antwerp, Belgium.	okoole@itg.be	Lynen, Lutgarde/AAT-9180-2020; Lynen, Lutgarde/A-1212-2014	Lynen, Lutgarde/0000-0001-7183-4895; Lynen, Lutgarde/0000-0001-7183-4895; Koole, Olivier/0000-0002-1122-5382	WHO [T9-181-298]; Belgian Development cooperation (DGDC); Institute of Tropical Medicine in Antwerp [920800]; Belgian National Association against Tuberculosis (BNBTTB)	WHO(World Health Organization); Belgian Development cooperation (DGDC); Institute of Tropical Medicine in Antwerp; Belgian National Association against Tuberculosis (BNBTTB)	The study was funded by WHO (WHO registry file number T9-181-298), with additional funding from the Belgian Development cooperation (DGDC) through a framework agreement with the Institute of Tropical Medicine in Antwerp (institutional strengthening project 920800) and the Belgian National Association against Tuberculosis (BNBTTB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansari NA, 2002, INT J TUBERC LUNG D, V6, P55; Banda H, 2000, INT J TUBERC LUNG D, V4, P968; Bassett IV, 2010, CLIN INFECT DIS, V51, P823, DOI 10.1086/656282; Boehme CC, 2010, NEW ENGL J MED, V363, P1005, DOI 10.1056/NEJMoa0907847; Cain KR, 2007, INT J TUBERC LUNG D, V11, P1008; Cain KP, 2010, NEW ENGL J MED, V362, P707, DOI 10.1056/NEJMoa0907488; Cain KP, 2009, EMERG INFECT DIS, V15, P258, DOI 10.3201/eid1502.080942; Cohen T, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000296; Colebunders R, 2000, INT J TUBERC LUNG D, V4, P97; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; Deribew A, 2010, INT J TUBERC LUNG D, V14, P1442; Getahun H, 2007, LANCET, V369, P2042, DOI 10.1016/S0140-6736(07)60284-0; Getahun H, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000391; GREENBERG AE, 1995, AIDS, V9, P1251, DOI 10.1097/00002030-199511000-00006; Hargreaves NJ, 2001, INT J TUBERC LUNG D, V5, P847; Harries AD, 1998, T ROY SOC TROP MED H, V92, P343, DOI 10.1016/S0035-9203(98)91036-7; Johnson JL, 1998, INT J TUBERC LUNG D, V2, P397; Kranzer K, 2010, LANCET INFECT DIS, V10, P93, DOI 10.1016/S1473-3099(09)70326-3; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; *MIN HLTH CAMB, 2008, TUB REP; MONKONGDEE P, 2009, AM J RESP CRIT CARE; Mukadi YD, 2001, AIDS, V15, P143, DOI 10.1097/00002030-200101260-00002; National AIDS Authority, 2008, UNGASS COUNTR PROGR; Perkins MD, 2007, J INFECT DIS, V196, pS15, DOI 10.1086/518656; Post FA, 1995, TUBERCLE LUNG DIS, V76, P518, DOI 10.1016/0962-8479(95)90527-8; Ralph AP, 2009, CLIN INFECT DIS, V49, P574, DOI 10.1086/600889; Reid MJA, 2009, LANCET INFECT DIS, V9, P173, DOI 10.1016/S1473-3099(09)70043-X; Sculier D, 2010, JAIDS-J ACQ IMM DEF, V55, P500, DOI 10.1097/QAI.0b013e3181e6a703; Siddiqi K, 2003, LANCET INFECT DIS, V3, P288, DOI 10.1016/S1473-3099(03)00609-1; Sreeramareddy CT, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-91; TRINH TT, 2007, PLOS ONE, V2, pE507; WHO, 2010, TREATMENT OF TUBERCULOSIS: GUIDELINES, FOURTH EDITION, P1; *WHO, 2009, GLOB TUB CONTR SHORT; WHO, 2009, STRAT TECHN ADV GROU; WHO, 2007, IMPR DIAGN TREATM SM; WHO, 2009, GLOB TUB CONTR 2009; Wilson D, 2006, INT J TUBERC LUNG D, V10, P31; World Health Organization, 2003, TREATM TUB GUID NAT, DOI DOI 10.1016/S0035-9203(99)90185-2	39	28	28	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 6	2011	6	4							e18502	10.1371/journal.pone.0018502	http://dx.doi.org/10.1371/journal.pone.0018502			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745UM	21494694	gold, Green Published, Green Submitted, Green Accepted			2023-01-03	WOS:000289192400032
J	Myles, PS; Peyton, P; Silbert, B; Hunt, J; Rigg, JRA; Sessler, DI				Myles, Paul S.; Peyton, Philip; Silbert, Brendan; Hunt, Jennifer; Rigg, John R. A.; Sessler, Daniel I.		ANZCA Trials Grp Investigators	Perioperative epidural analgesia for major abdominal surgery for cancer and recurrence-free survival: randomised trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RADICAL PROSTATECTOMY; ANESTHETIC TECHNIQUE; STRESS; IMMUNOSUPPRESSION; ANGIOGENESIS; METASTASIS; MORPHINE; GROWTH; RATES; PAIN	Objective To compare long term recurrence of cancer and survival of patients having major abdominal surgery for cancer. Design Long term follow-up of prospective randomised controlled clinical trial in which patients were randomly assigned to receive general anaesthesia with or without epidural block for at least three postoperative days. Setting 23 hospitals in Australia, New Zealand, and Asia. Participants 503 adult patients who had potentially curative surgery for cancer. Main outcome measure Cancer-free survival (analysis was by intention to treat). Results Long term follow-up data were available for 94% (n=446) of eligible participants. The median time to recurrence of cancer or death was 2.8 (95% confidence interval 0.7 to 8.7) years in the control group and 2.6 (0.7 to 8.7) years in the epidural group (P=0.61). Recurrence-free survival was similar in both epidural and control groups (hazard ratio 0.95, 95% confidence interval 0.76 to 1.17; P=0.61). Conclusion Use of epidural block in abdominal surgery for cancer is not associated with improved cancer-free survival.	[Myles, Paul S.; Hunt, Jennifer] Alfred Hosp, Dept Anaesthesia & Perioperat Med, Melbourne, Vic, Australia; [Myles, Paul S.] Monash Univ, Acad Board Anaesthesia & Perioperat Med, Melbourne, Vic, Australia; [Peyton, Philip] Austin Hosp, Dept Anaesthesia, Heidelberg, Vic 3084, Australia; [Hunt, Jennifer] St Vincents Hosp, Dept Anaesthesia, Fitzroy, Vic 3065, Australia; [Rigg, John R. A.] Australian & New Zealand Coll Anaesthetists Trial, Melbourne, Vic, Australia; [Sessler, Daniel I.] Cleveland Clin, Dept Outcomes Res, Cleveland, OH 44106 USA	Florey Institute of Neuroscience & Mental Health; Monash University; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; St Vincent's Hospital Melbourne; Cleveland Clinic Foundation	Myles, PS (corresponding author), Alfred Hosp, Dept Anaesthesia & Perioperat Med, Melbourne, Vic, Australia.	p.myles@alfred.org.au	Myles, Paul/AAU-9524-2020; van Os, Jim/C-2113-2014; Sessler, Daniel/D-3504-2011	Myles, Paul/0000-0002-3324-5456; Sessler, Daniel/0000-0001-9932-3077; Hunt, Jennifer/0000-0002-3740-6851	The Australian National Health and Medical Research Council; Australian and New Zealand College of Anaesthetists; Alfred Hospital Research Trust (Melbourne, Australia); Department of Outcomes Research at the Cleveland Clinic (OH, USA); Australian National Health; Medical Research Council	The Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian and New Zealand College of Anaesthetists; Alfred Hospital Research Trust (Melbourne, Australia); Department of Outcomes Research at the Cleveland Clinic (OH, USA); Australian National Health(National Health and Medical Research Council (NHMRC) of Australia); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The Australian National Health and Medical Research Council funded the MASTER trial. The cancer follow-up study was funded by the Australian and New Zealand College of Anaesthetists, the Alfred Hospital Research Trust (Melbourne, Australia), and the Department of Outcomes Research at the Cleveland Clinic (OH, USA). PSM is funded by an Australian National Health and Medical Research Council practitioner fellowship. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.	Ahlers O, 2008, BRIT J ANAESTH, V101, P781, DOI 10.1093/bja/aen287; *AM JOINT COMM CAN, 2002, AJCC CANC STAG MAN; Antoni MH, 2006, NAT REV CANCER, V6, P240, DOI 10.1038/nrc1820; Australian Institute of Health and Welfare Australasian Association of Cancer Registries, 2010, CANC SER AIHW, V60; Bar-Yosef S, 2001, ANESTHESIOLOGY, V94, P1066, DOI 10.1097/00000542-200106000-00022; Ben-Eliyahu S, 1999, INT J CANCER, V80, P880; Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73; Breslow NE, 1980, IARC SCI PUBL, P5; Chae BK, 1998, SURG TODAY, V28, P727, DOI 10.1007/BF02484619; Christopherson R, 2008, ANESTH ANALG, V107, P325, DOI 10.1213/ane.0b013e3181770f55; de Leon-Casasola OA, 2003, ANESTH ANALG, V96, P315, DOI 10.1097/00000539-200302000-00002; Denis MG, 1997, INT J CANCER, V74, P540, DOI 10.1002/(SICI)1097-0215(19971021)74:5<540::AID-IJC11>3.0.CO;2-A; Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008; Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d; Gupta K, 2002, CANCER RES, V62, P4491; Hodgson PS, 2001, ANESTHESIOLOGY, V94, P799, DOI 10.1097/00000542-200105000-00018; Ismail H, 2010, BRIT J ANAESTH, V105, P145, DOI 10.1093/bja/aeq156; MacMahon S, 2001, LANCET, V357, P455, DOI 10.1016/S0140-6736(00)04017-4; O'Riain SC, 2005, ANESTH ANALG, V100, P244, DOI 10.1213/01.ANE.0000143336.37946.7D; Page GG, 2001, PAIN, V90, P191, DOI 10.1016/S0304-3959(00)00403-6; Peyton PJ, 2003, ANESTH ANALG, V96, P548, DOI 10.1097/00000539-200302000-00046; Rigg JRA, 2000, CONTROL CLIN TRIALS, V21, P244, DOI 10.1016/S0197-2456(00)00045-3; Rigg JRA, 2002, LANCET, V359, P1276, DOI 10.1016/S0140-6736(02)08266-1; Sacerdote P, 2000, ANESTH ANALG, V90, P1411, DOI 10.1097/00000539-200006000-00028; Shakhar G, 2003, ANN SURG ONCOL, V10, P972, DOI 10.1245/ASO.2003.02.007; Tsui BCH, 2010, CAN J ANAESTH, V57, P107, DOI 10.1007/s12630-009-9214-7; Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec; Zetter BR, 1998, ANNU REV MED, V49, P407, DOI 10.1146/annurev.med.49.1.407	28	189	195	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 29	2011	342								d1491	10.1136/bmj.d1491	http://dx.doi.org/10.1136/bmj.d1491			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	745WE	21447587	hybrid, Green Published			2023-01-03	WOS:000289200800001
J	Deshpande, CN; Harrop, SJ; Boucher, Y; Hassan, KA; Di Leo, R; Xu, XH; Cui, H; Savchenko, A; Chang, CS; Labbate, M; Paulsen, IT; Stokes, HW; Curmi, PMG; Mabbutt, BC				Deshpande, Chandrika N.; Harrop, Stephen J.; Boucher, Yan; Hassan, Karl A.; Di Leo, Rosa; Xu, Xiaohui; Cui, Hong; Savchenko, Alexei; Chang, Changsoo; Labbate, Maurizio; Paulsen, Ian T.; Stokes, H. W.; Curmi, Paul M. G.; Mabbutt, Bridget C.			Crystal Structure of an Integron Gene Cassette-Associated Protein from Vibrio cholerae Identifies a Cationic Drug-Binding Module	PLOS ONE			English	Article							RESPONDING TRANSCRIPTIONAL REGULATOR; LIVIDANS TIPAL PROTEIN; MULTIDRUG RECOGNITION; MERR FAMILY; BMRR; MECHANISM; ACTIVATION; DATABASE; PHENIX; TOXIN	Background: The direct isolation of integron gene cassettes from cultivated and environmental microbial sources allows an assessment of the impact of the integron/gene cassette system on the emergence of new phenotypes, such as drug resistance or virulence. A structural approach is being exploited to investigate the modularity and function of novel integron gene cassettes. Methodology/Principal Findings: We report the 1.8 A crystal structure of Cass2, an integron-associated protein derived from an environmental V. cholerae. The structure defines a monomeric beta-barrel protein with a fold related to the effector-binding portion of AraC/XylS transcription activators. The closest homologs of Cass2 are multi-drug binding proteins, such as BmrR. Consistent with this, a binding pocket made up of hydrophobic residues and a single glutamate side chain is evident in Cass2, occupied in the crystal form by polyethylene glycol. Fluorescence assays demonstrate that Cass2 is capable of binding cationic drug compounds with submicromolar affinity. The Cass2 module possesses a protein interaction surface proximal to its drug-binding cavity with features homologous to those seen in multi-domain transcriptional regulators. Conclusions/Significance: Genetic analysis identifies Cass2 to be representative of a larger family of independent effector-binding proteins associated with lateral gene transfer within Vibrio and closely-related species. We propose that the Cass2 family not only has capacity to form functional transcription regulator complexes, but represents possible evolutionary precursors to multi-domain regulators associated with cationic drug compounds.	[Deshpande, Chandrika N.; Hassan, Karl A.; Paulsen, Ian T.; Mabbutt, Bridget C.] Macquarie Univ, Dept Chem & Biomol Sci, Sydney, NSW 2109, Australia; [Harrop, Stephen J.; Curmi, Paul M. G.] Univ New S Wales, Sch Phys, Sydney, NSW, Australia; [Harrop, Stephen J.; Curmi, Paul M. G.] St Vincents Ctr Appl Med Res, Sydney, NSW, Australia; [Boucher, Yan] MIT, Dept Civil & Environm Engn, Cambridge, MA 02139 USA; [Di Leo, Rosa; Xu, Xiaohui; Cui, Hong; Savchenko, Alexei; Chang, Changsoo] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON, Canada; [Labbate, Maurizio; Stokes, H. W.] Univ Technol Sydney, Inst Biotechnol Infect Dis, Sydney, NSW 2007, Australia	Macquarie University; University of New South Wales Sydney; Massachusetts Institute of Technology (MIT); University of Toronto; University of Technology Sydney	Deshpande, CN (corresponding author), Macquarie Univ, Dept Chem & Biomol Sci, Sydney, NSW 2109, Australia.	bridget.mabbutt@mq.edu.au	Boucher, Yan/A-2618-2014; Curmi, Paul/G-7185-2011; Boucher, Yann Felix/H-4576-2019; Paulsen, Ian T/K-3832-2012; Chang, Changsoo/X-3271-2018; Hassan, Karl/B-2802-2013	Curmi, Paul/0000-0001-5762-7638; Boucher, Yann Felix/0000-0002-0036-6083; Paulsen, Ian T/0000-0001-9015-9418; Chang, Changsoo/0000-0003-1860-2969; Labbate, Maurizio/0000-0003-1428-3382; Deshpande, Chandrika/0000-0002-5557-519X; Hassan, Karl/0000-0003-2031-9679	NHMRC [488502]; National Institutes of Health [GM62414-0]; Ontario Research and Development Challenge Fund; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM094585, P50GM062414] Funding Source: NIH RePORTER	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ontario Research and Development Challenge Fund(General Electric); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work is funded by Australian NHMRC grant 488502 (http://www.nhmrc.gov.au/) and supported by National Institutes of Health Grant GM62414-0 and the Ontario Research and Development Challenge Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; Afonine PV, 2005, CCP4 NEWSL, V42; AHMED M, 1994, J BIOL CHEM, V269, P28506; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boucher Y, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-3; Boucher Y, 2007, TRENDS MICROBIOL, V15, P301, DOI 10.1016/j.tim.2007.05.004; Boucher Y, 2006, BIOLOGY OF VIBRIOS, P84; Brown NL, 2003, FEMS MICROBIOL REV, V27, P145, DOI 10.1016/S0168-6445(03)00051-2; Chakraborty S, 2000, APPL ENVIRON MICROB, V66, P4022, DOI 10.1128/AEM.66.9.4022-4028.2000; Chiu ML, 2001, BIOCHEMISTRY-US, V40, P12950, DOI 10.1021/bi010328k; Chiu ML, 1999, J BIOL CHEM, V274, P20578, DOI 10.1074/jbc.274.29.20578; Chun J, 2009, P NATL ACAD SCI USA, V106, P15442, DOI 10.1073/pnas.0907787106; COLLIS CM, 1993, MOL MICROBIOL, V9, P41, DOI 10.1111/j.1365-2958.1993.tb01667.x; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DUTTA NK, 1972, BRIT J PHARMACOL, V44, P153, DOI 10.1111/j.1476-5381.1972.tb07247.x; Egan SM, 2002, J BACTERIOL, V184, P5529, DOI 10.1128/JB.184.20.5529-5532.2002; Elsaied H, 2007, ENVIRON MICROBIOL, V9, P2298, DOI 10.1111/j.1462-2920.2007.01344.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; Faruque SM, 2003, TRENDS MICROBIOL, V11, P505, DOI 10.1016/j.tim.2003.09.003; Faruque SM, 2003, INFECT IMMUN, V71, P1020, DOI 10.1128/IAI.71.2.1020-1025.2003; Felsenstein J., 1989, CLADISTICS, V5, P164; Gallegos MT, 1997, MICROBIOL MOL BIOL R, V61, P393, DOI 10.1128/.61.4.393-410.1997; Grkovic S, 2002, MICROBIOL MOL BIOL R, V66, P671, DOI 10.1128/MMBR.66.4.671-701.2002; Hall RM, 1998, DRUG RESIST UPDATE, V1, P109, DOI 10.1016/S1368-7646(98)80026-5; Hall T.A., 1999, NUCL ACIDS S SER, V41, P95; Heldwein EEZ, 2001, NATURE, V409, P378, DOI 10.1038/35053138; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; ISLAM MR, 1982, GASTROENTEROLOGY, V82, P1335; Kahmann JD, 2003, EMBO J, V22, P1824, DOI 10.1093/emboj/cdg181; Kleywegt GJ, 2007, ACTA CRYSTALLOGR D, V63, P94, DOI [10.1107/S0907444906022657, 10.1107/S907444906022657]; KOBAYASHI TOSHIKAZU, 1963, JAPAN JOUR BACTERIOL, V18, P387; Koenig JE, 2008, ENVIRON MICROBIOL, V10, P1024, DOI 10.1111/j.1462-2920.2007.01524.x; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kwon HJ, 2000, NAT STRUCT BIOL, V7, P424; Labbate M, 2007, MICROBIOL-SGM, V153, P1488, DOI 10.1099/mic.0.2006/001065-0; Labbate Maurizio, 2009, V532, P103, DOI 10.1007/978-1-60327-853-9_6; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Letunic I, 2009, NUCLEIC ACIDS RES, V37, pD229, DOI 10.1093/nar/gkn808; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Markham PN, 1996, J BACTERIOL, V178, P1473, DOI 10.1128/jb.178.5.1473-1475.1996; Martin RG, 2001, CURR OPIN MICROBIOL, V4, P132, DOI 10.1016/S1369-5274(00)00178-8; Mazel D, 2006, NAT REV MICROBIOL, V4, P608, DOI 10.1038/nrmicro1462; McCoy AJ, 2004, ACTA CRYSTALLOGR D, V60, P1220, DOI 10.1107/S0907444904009990; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Neron B, 2009, BIOINFORMATICS, V25, P3005, DOI 10.1093/bioinformatics/btp493; Newberry KJ, 2008, J BIOL CHEM, V283, P26795, DOI 10.1074/jbc.M804191200; Newberry KJ, 2004, J BIOL CHEM, V279, P20356, DOI 10.1074/jbc.M400960200; Ramamurthy T, 2003, MICROBES INFECT, V5, P329, DOI 10.1016/S1286-4579(03)00035-2; Rhee S, 1998, P NATL ACAD SCI USA, V95, P10413, DOI 10.1073/pnas.95.18.10413; Romanowski MJ, 2002, PROTEINS, V47, P403, DOI 10.1002/prot.10102; Rowe-Magnus DA, 2003, GENOME RES, V13, P428, DOI 10.1101/gr.617103; Sayers EW, 2009, NUCLEIC ACIDS RES, V37, pD5, DOI [10.1093/nar/gkn741, 10.1093/nar/gkp967]; Schumacher MA, 2002, MOL MICROBIOL, V45, P885, DOI 10.1046/j.1365-2958.2002.03039.x; SOFER A, 1995, J BIOL CHEM, V270, P12117, DOI 10.1074/jbc.270.20.12117; Stokes HW, 1997, MOL MICROBIOL, V26, P731, DOI 10.1046/j.1365-2958.1997.6091980.x; Stokes HW, 2001, APPL ENVIRON MICROB, V67, P5240, DOI 10.1128/AEM.67.11.5240-5246.2001; Terwilliger TC, 2008, ACTA CRYSTALLOGR D, V64, P61, DOI 10.1107/S090744490705024X; Terwilliger TC, 2009, ACTA CRYSTALLOGR D, V65, P582, DOI 10.1107/S0907444909012098; Thompson FL, 2004, MICROBIOL MOL BIOL R, V68, P403, DOI 10.1128/MMBR.68.3.403-431.2004; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; WEST PA, 1982, J CLIN MICROBIOL, V16, P1110, DOI 10.1128/JCM.16.6.1110-1116.1982; Westbrook J, 2003, METHOD ENZYMOL, V374, P370, DOI 10.1016/S0076-6879(03)74017-8; Wiegand I, 2008, NAT PROTOC, V3, P163, DOI 10.1038/nprot.2007.521; Yanai I, 2001, P NATL ACAD SCI USA, V98, P7940, DOI 10.1073/pnas.141236298; Zheleznova EE, 1999, CELL, V96, P353, DOI 10.1016/S0092-8674(00)80548-6	68	12	12	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 3	2011	6	3							e16934	10.1371/journal.pone.0016934	http://dx.doi.org/10.1371/journal.pone.0016934			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	729QI	21390267	Green Published, gold, Green Submitted			2023-01-03	WOS:000287965200008
J	Jaiswal, AS; Banerjee, S; Aneja, R; Sarkar, FH; Ostrov, DA; Narayan, S				Jaiswal, Aruna S.; Banerjee, Sanjeev; Aneja, Ritu; Sarkar, Fazlul H.; Ostrov, David A.; Narayan, Satya			DNA Polymerase beta as a Novel Target for Chemotherapeutic Intervention of Colorectal Cancer	PLOS ONE			English	Article							ADENOMATOUS POLYPOSIS-COLI; BASE EXCISION-REPAIR; MISMATCH REPAIR; LONG-PATCH; CELL-LINES; PHASE-I; TEMOZOLOMIDE; APC; MUTATIONS; PROTEIN	Chemoprevention presents a major strategy for the medical management of colorectal cancer. Most drugs used for colorectal cancer therapy induce DNA-alkylation damage, which is primarily repaired by the base excision repair (BER) pathway. Thus, blockade of BER pathway is an attractive option to inhibit the spread of colorectal cancer. Using an in silico approach, we performed a structure-based screen by docking small-molecules onto DNA polymerase beta (Pol-beta) and identified a potent anti-Pol-beta compound, NSC-124854. Our goal was to examine whether NSC-124854 could enhance the therapeutic efficacy of DNA-alkylating agent, Temozolomide (TMZ), by blocking BER. First, we determined the specificity of NSC-124854 for Pol-beta by examining in vitro activities of APE1, Fen1, DNA ligase I, and Pol-beta-directed single nucleotide (SN)and long-patch (LP)-BER. Second, we investigated the effect of NSC-124854 on the efficacy of TMZ to inhibit the growth of mismatch repair (MMR)-deficient and MMR-proficient colon cancer cell lines using in vitro clonogenic assays. Third, we explored the effect of NSC-124854 on TMZ-induced in vivo tumor growth inhibition of MMR-deficient and MMR-proficient colonic xenografts implanted in female homozygous SCID mice. Our data showed that NSC-124854 has high specificity to Pol-beta and blocked Pol-beta-directed SN- and LP-BER activities in in vitro reconstituted system. Furthermore, NSC-124854 effectively induced the sensitivity of TMZ to MMR-deficient and MMR-proficient colon cancer cells both in vitro cell culture and in vivo xenograft models. Our findings suggest a potential novel strategy for the development of highly specific structure-based inhibitor for the prevention of colonic tumor progression.	[Jaiswal, Aruna S.; Narayan, Satya] Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; [Banerjee, Sanjeev; Sarkar, Fazlul H.] Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; [Aneja, Ritu] Georgia State Univ, Dept Biol, Atlanta, GA USA; [Ostrov, David A.] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA	State University System of Florida; University of Florida; Barbara Ann Karmanos Cancer Institute; Wayne State University; University System of Georgia; Georgia State University; State University System of Florida; University of Florida	Jaiswal, AS (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA.	snarayan@ufl.edu			National Cancer Institute, National Institutes of Health, Bethesda, MD, USA [R01 CA-097031, CA-100247]; NATIONAL CANCER INSTITUTE [R01CA097031, R01CA100247] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health, Bethesda, MD, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	National Cancer Institute, National Institutes of Health, Bethesda, MD, USA (R01 CA-097031 and CA-100247). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas A, 2010, ONCOLOGY-NY, V24, P417; Adhikari S, 2008, ANTI-CANCER AGENT ME, V8, P351, DOI 10.2174/187152008784220366; Balusu R, 2007, BIOCHEMISTRY-US, V46, P13961, DOI 10.1021/bi701632e; Barcellos GB, 2008, CURR DRUG TARGETS, V9, P1084, DOI 10.2174/138945008786949388; Barth AIM, 1997, J CELL BIOL, V136, P693, DOI 10.1083/jcb.136.3.693; Bei R, 2010, RECENT PAT ANTI-CANC, V5, P172, DOI 10.2174/157489210791760526; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Brandes AA, 2002, ONCOLOGY-BASEL, V63, P38, DOI 10.1159/000065718; Cai W, 2010, BRIT J CANCER, V103, P1369, DOI 10.1038/sj.bjc.6605927; De Azevedo WF, 2010, CURR DRUG TARGETS, V11, P327, DOI 10.2174/138945010790711941; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Dhaliwal B., 2009, Infectious Disorders - Drug Targets, V9, P557; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fishel ML, 2007, CLIN CANCER RES, V13, P260, DOI 10.1158/1078-0432.CCR-06-1920; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Green RA, 2005, MOL BIOL CELL, V16, P4609, DOI 10.1091/mbc.E05-03-0259; Hainsworth JD, 2010, CANCER-AM CANCER SOC, V116, P3663, DOI 10.1002/cncr.25275; Horton JK, 2007, DNA REPAIR, V6, P530, DOI 10.1016/j.dnarep.2006.10.016; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jacob S, 2001, CANCER RES, V61, P6555; Jaiswal AS, 2008, CANCER LETT, V271, P272, DOI 10.1016/j.canlet.2008.06.024; Jaiswal AS, 2006, BIOCHEMISTRY-US, V45, P15903, DOI 10.1021/bi0607958; Jaiswal AS, 2009, MOL CANCER RES, V7, P1973, DOI 10.1158/1541-7786.MCR-09-0309; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; KARRAN P, 1994, BIOESSAYS, V16, P833, DOI 10.1002/bies.950161110; Kawate H, 1998, P NATL ACAD SCI USA, V95, P5116, DOI 10.1073/pnas.95.9.5116; Khan OA, 2008, BRIT J CANCER, V98, P1614, DOI 10.1038/sj.bjc.6604366; KOI M, 1994, CANCER RES, V54, P4308; Kouzmenko AP, 2008, ONCOGENE, V27, P4888, DOI 10.1038/onc.2008.127; Kroemer RT, 2007, CURR PROTEIN PEPT SC, V8, P312; Kundu CN, 2007, ONCOGENE, V26, P1428, DOI 10.1038/sj.onc.1209925; Kundu CN, 2007, CARCINOGENESIS, V28, P2089, DOI 10.1093/carcin/bgm125; Liu L, 1999, CLIN CANCER RES, V5, P2908; Liu Lili, 2004, Curr Opin Investig Drugs, V5, P623; Liu LL, 2002, CLIN CANCER RES, V8, P2985; Liu LL, 1996, CANCER RES, V56, P5375; Liu LL, 2006, CLIN CANCER RES, V12, P328, DOI 10.1158/1078-0432.CCR-05-2543; Liu Y, 2005, J BIOL CHEM, V280, P3665, DOI 10.1074/jbc.M412922200; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Narayan S, 2005, J BIOL CHEM, V280, P6942, DOI 10.1074/jbc.M409200200; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; NEWLANDS ES, 1992, BRIT J CANCER, V65, P287, DOI 10.1038/bjc.1992.57; Panda H, 2009, BIOCHEMISTRY-US, V48, P9952, DOI 10.1021/bi9010754; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Prasad R, 2000, J BIOL CHEM, V275, P4460, DOI 10.1074/jbc.275.6.4460; Qian J, 2008, GASTROENTEROLOGY, V135, P152, DOI 10.1053/j.gastro.2008.03.074; Sarkaria JN, 2008, CLIN CANCER RES, V14, P2900, DOI 10.1158/1078-0432.CCR-07-1719; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095; Seiter K, 2002, J CLIN ONCOL, V20, P3249, DOI 10.1200/JCO.2002.01.030; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Spiro TP, 2001, CLIN CANCER RES, V7, P2309; Taverna P, 2000, CANCER CHEMOTH PHARM, V46, P507, DOI 10.1007/s002800000186; Taverna P, 2001, MUTAT RES-DNA REPAIR, V485, P269, DOI 10.1016/S0921-8777(01)00076-3; Tentori L, 1998, J PHARMACOL EXP THER, V285, P884; Thompson Patricia A, 2009, Expert Rev Gastroenterol Hepatol, V3, P369, DOI 10.1586/egh.09.28; Trivedi RN, 2008, MOL PHARMACOL, V74, P505, DOI 10.1124/mol.108.045112; Trivedi RN, 2005, CANCER RES, V65, P6394, DOI 10.1158/0008-5472.CAN-05-0715; Trudeau ME, 2006, ANN ONCOL, V17, P952, DOI 10.1093/annonc/mdl056; Veselovsky A. V., 2003, Current Drug Targets - Infectious Disorders, V3, P33, DOI 10.2174/1568005033342145; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127	67	38	39	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 2	2011	6	2							e16691	10.1371/journal.pone.0016691	http://dx.doi.org/10.1371/journal.pone.0016691			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717IF	21311763	Green Published, gold			2023-01-03	WOS:000287036200032
J	Dal-Pan, A; Pifferi, F; Marchal, J; Picq, JL; Aujard, F				Dal-Pan, Alexandre; Pifferi, Fabien; Marchal, Julia; Picq, Jean-Luc; Aujard, Fabienne		RESTRIKAL Consortium	Cognitive Performances Are Selectively Enhanced during Chronic Caloric Restriction or Resveratrol Supplementation in a Primate	PLOS ONE			English	Article							MOUSE LEMUR PRIMATES; DIETARY RESTRICTION; OXIDATIVE STRESS; RHESUS-MONKEYS; LIFE-SPAN; MEMORY; RATS; DISEASE; BEHAVIOR; SYSTEM	Effects of an 18-month treatment with a moderate, chronic caloric restriction (CR) or an oral supplementation with resveratrol (RSV), a potential CR mimetic, on cognitive and motor performances were studied in non-human primates, grey mouse lemurs (Microcebus murinus). Thirty-three adult male mouse lemurs were assigned to three different groups: a control (CTL) group fed ad libitum, a CR group fed 70% of the CTL caloric intake, and an RSV group (RSV supplementation of 200 mg.kg(-1).day(-1)) fed ad libitum. Three different cognitive tests, two motor tests, one emotional test and an analysis of cortisol level were performed in each group. Compared to CTL animals, CR or RSV animals did not show any change in motor performances evaluated by rotarod and jump tests, but an increase in spontaneous locomotor activity was observed in both groups. Working memory was improved by both treatments in the spontaneous alternation task. Despite a trend for CR group, only RSV supplementation increased spatial memory performances in the circular platform task. Finally, none of these treatments induced additional stress to the animals as reflected by similar results in the open field test and cortisol analyses compared to CTL animals. The present data provided the earliest evidence for a beneficial effect of CR or RSV supplementation on specific cognitive functions in a primate. Taken together, these results suggest that RSV could be a good candidate to mimic long-term CR effects and support the growing evidences that nutritional interventions can have beneficial effects on brain functions even in adults.	[Dal-Pan, Alexandre; Pifferi, Fabien; Marchal, Julia; Aujard, Fabienne] Museum Natl Hist Nat, CNRS, UMR 7179, Brunoy, France; [Picq, Jean-Luc] Univ Paris 08, Lab Psychopathol & Neuropsychol, UFR Psychol, St Denis, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); Museum National d'Histoire Naturelle (MNHN); Universite Paris-VIII	Dal-Pan, A (corresponding author), Museum Natl Hist Nat, CNRS, UMR 7179, Brunoy, France.	aujard@mnhn.fr		Pifferi, Fabien/0000-0001-9316-1935	French National Research Agency [ANR-06-PNRA-010-01]; Foundation for French Medical Research	French National Research Agency(French National Research Agency (ANR)); Foundation for French Medical Research	This work was carried out with the financial support of The French National Research Agency (project ANR-06-PNRA-010-01) and the Foundation for French Medical Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAHAM J, 2009, REJUVENATION RES, V12; Allard JS, 2009, MOL CELL ENDOCRINOL, V299, P58, DOI 10.1016/j.mce.2008.10.018; Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005; Antoniadis EA, 2000, BEHAV BRAIN RES, V111, P25, DOI 10.1016/S0166-4328(00)00145-5; Babovic D, 2008, NEUROSCIENCE, V155, P1021, DOI 10.1016/j.neuroscience.2008.07.006; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BATTIG K, 1960, J COMP PHYSIOL PSYCH, V53, P400, DOI 10.1037/h0047392; Borra MT, 2005, J BIOL CHEM, V280, P17187, DOI 10.1074/jbc.M501250200; Challet E, 2010, J COMP PHYSIOL B, V180, P631, DOI 10.1007/s00360-010-0451-4; Chen D, 2007, TRENDS MOL MED, V13, P64, DOI 10.1016/j.molmed.2006.12.004; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; DALPAN A, 2010, AGE DORDR; DAS D, 2010, HEART FAILURE REV; Denburg NL, 2003, EMOTION, V3, P239, DOI 10.1037/1528-3542.3.3.239; Dhenain M, 2003, MAGNET RESON MED, V50, P984, DOI 10.1002/mrm.10612; EVERITT BJ, 1991, NEUROSCIENCE, V42, P1, DOI 10.1016/0306-4522(91)90145-E; Filali M, 2009, BRAIN RES, V1292, P93, DOI 10.1016/j.brainres.2009.07.066; Fontan-Lozano A, 2007, J NEUROSCI, V27, P10185, DOI 10.1523/JNEUROSCI.2757-07.2007; Genin F, 2000, PHYSIOL BEHAV, V71, P315, DOI 10.1016/S0031-9384(00)00335-8; Genin F, 2003, COMP BIOCHEM PHYS B, V136, P71, DOI 10.1016/S1096-4959(03)00172-6; GIROUD S, 2008, AM J PHYSIOL-REG I, pR1958; Giroud S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008823; Gold PE, 2005, NEUROBIOL AGING, V26, pS60, DOI 10.1016/j.neurobiolaging.2005.09.002; Grieve SM, 2005, HUM BRAIN MAPP, V25, P391, DOI 10.1002/hbm.20115; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Ingram DK, 2007, NEUROSCIENCE, V145, P1359, DOI 10.1016/j.neuroscience.2006.10.031; INGRAM DK, 1987, J GERONTOL, V42, P78, DOI 10.1093/geronj/42.1.78; Jin F, 2008, EUR J PHARMACOL, V600, P78, DOI 10.1016/j.ejphar.2008.10.005; JONES DNC, 1995, J NEUROSCI, V15, P7282; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; KRASKA A, 2010, NEUROBIOLOGY AGING; Kumar A, 2007, PHARMACOLOGY, V79, P17, DOI 10.1159/000097511; Lagouge M, 2006, CELL, V127, P1109, DOI 10.1016/j.cell.2006.11.013; Markowska AL, 1999, NEUROBIOL AGING, V20, P177, DOI 10.1016/S0197-4580(99)00031-7; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MEANS LW, 1993, PHYSIOL BEHAV, V54, P503, DOI 10.1016/0031-9384(93)90243-9; Picq JL, 2007, EXP GERONTOL, V42, P223, DOI 10.1016/j.exger.2006.09.013; ROSSI L, 2008, NEUROCHEMICAL RES; SCHMATZ R, 2009, EUROPEAN J IN PRESS; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; SPINDLER SR, 2009, AGEING RES REV UNPUB; Valenzano DR, 2006, CURR BIOL, V16, P296, DOI 10.1016/j.cub.2005.12.038; Wakeling LA, 2009, AGE, V31, P327, DOI 10.1007/s11357-009-9104-5; Weatherall D., 2006, USE NONHUMAN PRIMATE; Weed JL, 1997, PHYSIOL BEHAV, V62, P97, DOI 10.1016/S0031-9384(97)00147-9; Weindruch R, 2001, J GERONTOL A-BIOL, V56, P20, DOI 10.1093/gerona/56.suppl_1.20; Wenk GL, 1997, NEUROBIOL LEARN MEM, V67, P85, DOI 10.1006/nlme.1996.3757; Wise SP, 1996, CRIT REV NEUROBIOL, V10, P317, DOI 10.1615/CritRevNeurobiol.v10.i3-4.30; Witte AV, 2009, P NATL ACAD SCI USA, V106, P1255, DOI 10.1073/pnas.0808587106; Wu AG, 2003, NEUROSCI LETT, V339, P166, DOI 10.1016/S0304-3940(03)00008-9; Yanai S, 2004, NEUROBIOL AGING, V25, P325, DOI 10.1016/S0197-4580(03)00115-5	52	93	95	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16581	10.1371/journal.pone.0016581	http://dx.doi.org/10.1371/journal.pone.0016581			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	21304942	Green Published, Green Submitted, gold			2023-01-03	WOS:000286834300091
J	Banjo, OC; Nadler, R; Reiner, PB				Banjo, Opeyemi C.; Nadler, Roland; Reiner, Peter B.			Physician Attitudes towards Pharmacological Cognitive Enhancement: Safety Concerns Are Paramount	PLOS ONE			English	Article								The ethical dimensions of pharmacological cognitive enhancement have been widely discussed in academic circles and the popular media, but missing from the conversation have been the perspectives of physicians - key decision makers in the adoption of new technologies into medical practice. We queried primary care physicians in major urban centers in Canada and the United States with the aim of understanding their attitudes towards cognitive enhancement. Our primary hypothesis was that physicians would be more comfortable prescribing cognitive enhancers to older patients than to young adults. Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant adverse side effects. Respondents overwhelmingly reported increasing comfort with prescribing cognitive enhancers as the patient age increased from 25 to 65. When asked about their comfort with prescribing extant drugs that might be considered enhancements (sildenafil, modafinil, and methylphenidate) or our hypothetical cognitive enhancer to a normal, healthy 40 year old, physicians were more comfortable prescribing sildenafil than any of the other three agents. When queried as to the reasons they answered as they did, the most prominent concerns physicians expressed were issues of safety that were not offset by the benefit afforded the individual, even in the face of explicit safety claims. Moreover, many physicians indicated that they viewed safety claims with considerable skepticism. It has become routine for safety to be raised and summarily dismissed as an issue in the debate over pharmacological cognitive enhancement; the observation that physicians were so skeptical in the face of explicit safety claims suggests that such a conclusion may be premature. Thus, physician attitudes suggest that greater weight be placed upon the balance between safety and benefit in consideration of pharmacological cognitive enhancement.	[Banjo, Opeyemi C.; Nadler, Roland; Reiner, Peter B.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Banjo, OC (corresponding author), Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.	peter.reiner@ubc.ca		Nadler, Roland/0000-0002-9504-7527	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) (http://www.cihr.ca/e/193.html). (F08-04061: Normality, normalization and enhancement in the neurosciences: ethical, sociocultural and neuropsychiatric aspects of cognitive enhancement). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bergstrom LS, 2008, SCAND J PUBLIC HEALT, V36, P532, DOI 10.1177/1403494807087558; Bostrom N, 2005, BIOETHICS, V19, P202, DOI 10.1111/j.1467-8519.2005.00437.x; BOSTROM N, ENHANCING H IN PRESS; *BRIT MED ASS, 2007, BOOST YOUR BRAINP ET; BROOKS D, 2008, NY TIMES        0502; BUSCH C, 2010, CONTENT ANAL; Bush SS, 2006, APPL NEUROPSYCHOL, V13, P125, DOI 10.1207/s15324826an1302_7; Cakic V, 2009, J MED ETHICS, V35, P611, DOI 10.1136/jme.2009.030882; Caplan A, 2004, PLOS MED, V1, P172, DOI 10.1371/journal.pmed.0010052; CASCIO J, 2009, ATLANTIC, V304, P94; Chatterjee A, 2004, NEUROLOGY, V63, P968, DOI 10.1212/01.WNL.0000138438.88589.7C; CHATTERJEE A, 2007, CAMB Q HEALTHC ETHIC, V2, P129; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; Daniels N, 2000, CAMB Q HEALTHC ETHIC, V9, P309, DOI 10.1017/S0963180100903037; Farah MJ, 2004, NAT REV NEUROSCI, V5, P421, DOI 10.1038/nrn1390; Flower R, 2004, TRENDS PHARMACOL SCI, V25, P182, DOI 10.1016/j.tips.2004.02.006; FREELON D, 2010, RECAL SOFTWARE; Fukuyama F., 2002, OUR POSTHUMAN FUTURE; GARREAU J, 2006, WASHINGTON POST 0611; Gauthier S, 2006, LANCET, V367, P1262, DOI 10.1016/S0140-6736(06)68542-5; Greely H, 2008, NATURE, V456, P702, DOI 10.1038/456702a; Hughes JJ, 2007, FUTURES, V39, P942, DOI 10.1016/j.futures.2007.03.002; HUNT E, 1995, AM SCI, V83, P356; HYMAN SE, 2006, BIOSOCIETIES, V1, P103; KOIVISTO K, 1995, NEUROLOGY, V45, P741, DOI 10.1212/WNL.45.4.741; Larrabee G J, 1994, Int Psychogeriatr, V6, P95, DOI 10.1017/S1041610294001663; Larriviere D, 2009, NEUROLOGY, V73, P1406, DOI 10.1212/WNL.0b013e3181beecfe; Metzl JM, 2007, LANCET, V369, P697, DOI 10.1016/S0140-6736(07)60317-1; PERSSON I, 2008, J APPL PHILOS, V3, P162; Pieters T, 2009, NEUROETHICS-NETH, V2, P63, DOI 10.1007/s12152-009-9033-0; POITRAS G, 2008, J BUS ETHICS, V3, P313; President's Council on Bioethics, 2003, THER BIOT PURS HAPP; Racine E, 2009, J MED ETHICS, V35, P469, DOI 10.1136/jme.2009.030460; Ravelingien A, 2009, NEUROETHICS-NETH, V2, P151, DOI 10.1007/s12152-009-9042-z; Reiner Peter B, 2010, Virtual Mentor, V12, P885, DOI 10.1001/virtualmentor.2010.12.11.msoc1-1011; Rose SPR, 2002, NAT REV NEUROSCI, V3, P975, DOI 10.1038/nrn984; Sarewitz D., 2006, POLICY IMPLICATIONS; Savulescu J, 2006, ANN NY ACAD SCI, V1093, P321, DOI 10.1196/annals.1382.021; SCHNEIDER S, 2008, PENN CTR GUIDE BIOET, P95; Schulz K, 2006, NATION, V282, P11; Scripko PD, 2010, J MED ETHICS, V36, P293, DOI 10.1136/jme.2009.032383; Synofzik M, 2009, NEUROETHICS-NETH, V2, P89, DOI 10.1007/s12152-008-9029-1; Turner D.C., 2006, BIOSOCIETIES, V1, P113, DOI DOI 10.1017/S1745855205040044; Whitehouse PJ, 1997, HASTINGS CENT REP, V27, P14, DOI 10.2307/3528662; Wiesing U, 2008, INT LIBR ETH LAW TEC, V2, P9; YOUNG M, 2008, N 1, V7, P209	46	49	49	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2010	5	12							e14322	10.1371/journal.pone.0014322	http://dx.doi.org/10.1371/journal.pone.0014322			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	694JH	21179461	Green Submitted, Green Published, gold			2023-01-03	WOS:000285292500006
J	Mroz, P; Szokalska, A; Wu, MX; Hamblin, MR				Mroz, Pawel; Szokalska, Angelika; Wu, Mei X.; Hamblin, Michael R.			Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune Response	PLOS ONE			English	Article							CYTOLYTIC T-LYMPHOCYTES; COMPLEMENT ACTIVATION; ANTITUMOR IMMUNITY; COLON-TUMOR; IFN-GAMMA; GENE; RECOMBINANT; CELLS; INDUCTION; MICE	Background: The mechanism by which the immune system can effectively recognize and destroy tumors is dependent on recognition of tumor antigens. The molecular identity of a number of these antigens has recently been identified and several immunotherapies have explored them as targets. Photodynamic therapy (PDT) is an anti-cancer modality that uses a non-toxic photosensitizer and visible light to produce cytotoxic reactive oxygen species that destroy tumors. PDT has been shown to lead to local destruction of tumors as well as to induction of anti-tumor immune response. Methodology/Principal Findings: We used a pair of equally lethal BALB/c colon adenocarcinomas, CT26 wild-type (CT26WT) and CT26.CL25 that expressed a tumor antigen, beta-galactosidase (beta-gal), and we treated them with vascular PDT. All mice bearing antigen-positive, but not antigen-negative tumors were cured and resistant to rechallenge. T lymphocytes isolated from cured mice were able to specifically lyse antigen positive cells and recognize the epitope derived from beta-galactosidase antigen. PDT was capable of destroying distant, untreated, established, antigen-expressing tumors in 70% of the mice. The remaining 30% escaped destruction due to loss of expression of tumor antigen. The PDT anti-tumor effects were completely abrogated in the absence of the adaptive immune response. Conclusion: Understanding the role of antigen-expression in PDT immune response may allow application of PDT in metastatic as well as localized disease. To the best of our knowledge, this is the first time that PDT has been shown to lead to systemic, antigen-specific anti-tumor immunity.	[Mroz, Pawel; Szokalska, Angelika; Wu, Mei X.; Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA; [Mroz, Pawel; Wu, Mei X.; Hamblin, Michael R.] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Szokalska, Angelika] Med Univ Warsaw, Dept Immunol, Warsaw, Poland; [Wu, Mei X.; Hamblin, Michael R.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Medical University of Warsaw; Harvard University; Massachusetts Institute of Technology (MIT)	Mroz, P (corresponding author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.	hamblin@helix.mgh.harvard.edu	Hamblin, Michael R/H-2758-2019; Muchowicz, Angelika/J-7494-2012; Mroz, Pawel/P-1258-2019; Hamblin, Mike/AAB-2511-2022	Hamblin, Michael R/0000-0001-6431-4605; Muchowicz, Angelika/0000-0003-4707-1722; Mroz, Pawel/0000-0003-3838-4743	US NIH National Cancer Institute [RO1CA/AI838801, R01AI050875]; Genzyme-Partners Translational Research Grant; Foundation for Polish Science, International Union Against Cancer and European Structural Fund; NATIONAL CANCER INSTITUTE [R01CA083882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050875] Funding Source: NIH RePORTER	US NIH National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Genzyme-Partners Translational Research Grant; Foundation for Polish Science, International Union Against Cancer and European Structural Fund(Foundation for Polish Science); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Supported by US NIH National Cancer Institute (grants RO1CA/AI838801 and R01AI050875 to MRH). P.M. was partly supported by Genzyme-Partners Translational Research Grant. A.S. was supported by the Foundation for Polish Science, International Union Against Cancer and European Structural Fund: "Mazowieckie Stypendium Doktoranckie." The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Beatty GL, 2000, J IMMUNOL, V165, P5502, DOI 10.4049/jimmunol.165.10.5502; Betts MR, 2003, J IMMUNOL METHODS, V281, P65, DOI 10.1016/S0022-1759(03)00265-5; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Carroll MW, 1997, VACCINE, V15, P387, DOI 10.1016/S0264-410X(96)00195-8; Castano AP, 2008, P NATL ACAD SCI USA, V105, P5495, DOI 10.1073/pnas.0709256105; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Cecic I, 2006, PHOTOCHEM PHOTOBIOL, V82, P558, DOI 10.1562/2005-09-09-RA-681; Cecic I, 2006, J ENVIRON PATHOL TOX, V25, P189; Cecic I, 2005, CANCER LETT, V225, P215, DOI 10.1016/j.canlet.2004.11.059; Cecic I, 2002, CANCER LETT, V183, P43, DOI 10.1016/S0304-3835(02)00092-7; Cecic I, 2001, PHOTOCHEM PHOTOBIOL, V74, P712, DOI 10.1562/0031-8655(2001)074<0712:IOSNRI>2.0.CO;2; Cecic I, 2006, INT IMMUNOPHARMACOL, V6, P1259, DOI 10.1016/j.intimp.2006.03.008; Chen PW, 1996, J IMMUNOL, V156, P224; COULIE PG, 1994, J EXP MED, V180, P35, DOI 10.1084/jem.180.1.35; COULIE PG, 1995, P NATL ACAD SCI USA, V92, P7976, DOI 10.1073/pnas.92.17.7976; DALPORTO J, 1993, P NATL ACAD SCI USA, V90, P6671, DOI 10.1073/pnas.90.14.6671; Disis ML, 2002, J CLIN ONCOL, V20, P2624, DOI 10.1200/JCO.2002.06.171; Donohue KB, 2006, IMMUNOLOGY, V119, P63, DOI 10.1111/j.1365-2567.2006.02406.x; Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889; Dougherty TJ, 2002, J CLIN LASER MED SUR, V20, P3, DOI 10.1089/104454702753474931; Dubey P, 1997, J EXP MED, V185, P695, DOI 10.1084/jem.185.4.695; GARRIDO F, CANC IMMUNOL IMMUNOT, V59, P1601; GAUGLER B, 1994, J EXP MED, V179, P921, DOI 10.1084/jem.179.3.921; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Gollnick SO, 2006, LASER SURG MED, V38, P509, DOI 10.1002/lsm.20362; Gollnick SO, 2003, BRIT J CANCER, V88, P1772, DOI 10.1038/sj.bjc.6600864; Hance KW, 2009, CLIN CANCER RES, V15, P2387, DOI 10.1158/1078-0432.CCR-08-1752; Hirohashi Y, 2009, CANCER SCI, V100, P798, DOI 10.1111/j.1349-7006.2009.01137.x; Huang AYC, 1996, P NATL ACAD SCI USA, V93, P9730, DOI 10.1073/pnas.93.18.9730; Huang Z, 2005, TECHNOL CANCER RES T, V4, P283, DOI 10.1177/153303460500400308; Irvine KR, 1996, J IMMUNOL, V156, P238; Jalili A, 2004, CLIN CANCER RES, V10, P4498, DOI 10.1158/1078-0432.CCR-04-0367; Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400; Korbelik M, 2005, CANCER RES, V65, P1018; Korbelik M, 2007, BRIT J CANCER, V96, P67, DOI 10.1038/sj.bjc.6603508; Korbelik M, 1996, J Clin Laser Med Surg, V14, P329; Korbelik M, 2008, J PHOTOCH PHOTOBIO B, V93, P53, DOI 10.1016/j.jphotobiol.2008.04.005; Korbelik M, 2008, INT J CANCER, V122, P1411, DOI 10.1002/ijc.23248; Korbelik M, 2006, LASER SURG MED, V38, P500, DOI 10.1002/lsm.20337; KROSL G, 1995, BRIT J CANCER, V71, P549, DOI 10.1038/bjc.1995.108; Laheru D, 2005, NAT REV CANCER, V5, P459, DOI 10.1038/nrc1630; LETHE B, 1992, EUR J IMMUNOL, V22, P2283, DOI 10.1002/eji.1830220916; MANDELBOIM O, 1994, NATURE, V369, P67, DOI 10.1038/369067a0; Marshall JL, 2005, J CLIN ONCOL, V23, P720, DOI 10.1200/JCO.2005.10.206; McWilliams JA, 2008, VACCINE, V26, P1863, DOI 10.1016/j.vaccine.2008.01.052; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; Mroz P, 2007, PHOTOCH PHOTOBIO SCI, V6, P1139, DOI 10.1039/b711141j; MULE JJ, 1992, J IMMUNOL, V148, P2622; NASTALA CL, 1994, J IMMUNOL, V153, P1697; Paglia P, 1996, J EXP MED, V183, P317, DOI 10.1084/jem.183.1.317; Parkinson-Lawrence EJ, 2005, CELL IMMUNOL, V236, P161, DOI 10.1016/j.cellimm.2005.08.024; Quesnel B, 2008, APMIS, V116, P685, DOI 10.1111/j.1600-0463.2008.01163.x; Restifo NP, 2002, SEMIN CANCER BIOL, V12, P81, DOI 10.1006/scbi.2001.0399; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; Stewart TJ, 2008, ONCOGENE, V27, P5894, DOI 10.1038/onc.2008.268; Stott B, 2007, CANCER IMMUNOL IMMUN, V56, P649, DOI 10.1007/s00262-006-0221-z; Takeda J, 2000, CELL IMMUNOL, V204, P11, DOI 10.1006/cimm.2000.1691; TRAVERSARI C, 1992, J EXP MED, V176, P1453, DOI 10.1084/jem.176.5.1453; van der Bruggen P, 2006, CURR OPIN IMMUNOL, V18, P98, DOI 10.1016/j.coi.2005.11.013; VANDENEYNDE B, 1991, J EXP MED, V173, P1373, DOI 10.1084/jem.173.6.1373; VANDENEYNDE B, 1995, J EXP MED, V182, P689, DOI 10.1084/jem.182.3.689; VandenEynde BJ, 1997, CURR OPIN IMMUNOL, V9, P684, DOI 10.1016/S0952-7915(97)80050-7; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; Wang M, 1995, J IMMUNOTHER, V18, P139, DOI 10.1097/00002371-199510000-00001	65	98	103	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 14	2010	5	12							e15194	10.1371/journal.pone.0015194	http://dx.doi.org/10.1371/journal.pone.0015194			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	694JH	21179470	gold, Green Published, Green Submitted			2023-01-03	WOS:000285292500016
J	Morgan, DJ; Day, HR; Harris, AD; Furuno, JP; Perencevich, EN				Morgan, Daniel J.; Day, Hannah R.; Harris, Anthony D.; Furuno, Jon P.; Perencevich, Eli N.			The Impact of Contact Isolation on the Quality of Inpatient Hospital Care	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; ACTIVE SURVEILLANCE CULTURES; OF-CARE; MORTALITY-RATES; PERFORMANCE; INFECTIONS; ASSOCIATION; PRECAUTIONS; IMPROVEMENT; PREVENTION	Background: Contact Isolation is a common hospital infection prevention method that may improve infectious outcomes but may also hinder healthcare delivery. Methods: To evaluate the impact of Contact Isolation on compliance with individual and composite process of care quality measures, we formed four retrospective diagnosis-based cohorts from a 662-bed tertiary-care medical center. Each cohort contained patients evaluated for one of four Centers for Medicare and Medicaid Services (CMS) Hospital Compare process measures including Acute Myocardial Infarction (AMI), Congestive Heart Failure (CHF), Pneumonia (PNA) and Surgical Care Improvement Project (SCIP) from January 1, 2007 through May 30, 2009. Results: The 6716-admission cohort included 1259 with AMI, 834 with CHF, 1377 with PNA and 3246 in SCIP. Contact Isolation was associated with not meeting 4 of 23 individual hospital measures (4 of 10 measures were not met for care provided while patients are typically isolated). Contact Isolation was independently associated with lower compliance with the composite pneumonia process-of-care measure (OR 0.3, 95% CI 0.1-0.7). AMI, CHF and SCIP composite measures were not impacted by Contact Isolation. Conclusions: Contact Isolation was associated with lower adherence to some pneumonia quality of care process measures of care on inpatient wards but did not impact CHF, AMI or SCIP measures.	[Morgan, Daniel J.; Day, Hannah R.; Harris, Anthony D.; Furuno, Jon P.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA; [Morgan, Daniel J.; Harris, Anthony D.] VA Maryland Hlth Care Syst, Baltimore, MD USA; [Perencevich, Eli N.] Univ Iowa, Carver Coll Med & Iowa City VA, Iowa City, IA USA	University System of Maryland; University of Maryland Baltimore; University of Iowa	Morgan, DJ (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA.	dmorgan@epi.umaryland.edu		Perencevich, Eli/0000-0002-3721-3355	AHRQ [K08 HS18111-01]; NIH [5K24AI079040-02]; VA HSRD Merit IIR [05-123]; AHRQ [5K08HS018111-03] Funding Source: Federal RePORTER; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K24AI079040] Funding Source: NIH RePORTER	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA HSRD Merit IIR; AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was funded by K08 HS18111-01 AHRQ to DJM, 5K24AI079040-02 NIH to ADH and a VA HSR&D Merit IIR, 05-123 to ENP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Braun BI, 1999, EVAL HEALTH PROF, V22, P283, DOI 10.1177/016327879902200301; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; *CTR MED MED SERV, MED MOD UPD; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Edmond MB, 2008, AM J INFECT CONTROL, V36, P461, DOI 10.1016/j.ajic.2007.09.011; Evans HL, 2003, SURGERY, V134, P180, DOI 10.1067/msy.2003.222; Fetter RB, 1980, MED CARE S, V18, P1; Fiore Anthony E., 2009, Morbidity and Mortality Weekly Report, V58, P1; Haley CC, 2007, J CLIN MICROBIOL, V45, P3031, DOI 10.1128/JCM.00315-07; Harris AD, 2002, ANTIMICROB AGENTS CH, V46, P854, DOI 10.1128/AAC.46.3.854-858.2002; Harris AD, 2010, ANTIMICROB AGENTS CH, V54, P3143, DOI 10.1128/AAC.01590-09; Higashi T, 2007, NEW ENGL J MED, V356, P2496, DOI 10.1056/NEJMsa066253; Jha AK, 2007, HEALTH AFFAIR, V26, P1104, DOI 10.1377/hlthaff.26.4.1104; KIRKLAND K, 2008, ISOLATION PRECAUTION; Kirkland KB, 1999, LANCET, V354, P1177, DOI 10.1016/S0140-6736(99)04196-3; Min LC, 2007, MED CARE, V45, P480, DOI 10.1097/MLR.0b013e318030fff9; Morgan DJ, 2009, AM J INFECT CONTROL, V37, P85, DOI 10.1016/j.ajic.2008.04.257; National Quality Forum, NQF END STAND; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Saint S, 2003, AM J INFECT CONTROL, V31, P354, DOI 10.1016/S0196-6553(02)48250-8; SALEMI C, 1995, AM J INFECT CONTROL, V23, P188, DOI 10.1016/0196-6553(95)90040-3; Siegel JD, 2007, AM J INFECT CONTROL, V35, pS65, DOI 10.1016/j.ajic.2007.10.007; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Stulberg JJ, 2010, JAMA-J AM MED ASSOC, V303, P2479, DOI 10.1001/jama.2010.841; Weber SG, 2007, INFECT CONT HOSP EP, V28, P249, DOI 10.1086/512261; Werner RM, 2006, JAMA-J AM MED ASSOC, V296, P2694, DOI 10.1001/jama.296.22.2694; Williams SC, 2005, NEW ENGL J MED, V353, P255, DOI 10.1056/NEJMsa043778	29	28	29	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2011	6	7							e22190	10.1371/journal.pone.0022190	http://dx.doi.org/10.1371/journal.pone.0022190			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	795FA	21811572	Green Published, gold, Green Submitted			2023-01-03	WOS:000292956800028
J	Kammerer, R; Buchner, A; Palluch, P; Pongratz, T; Oboukhovskij, K; Beyer, W; Johansson, A; Stepp, H; Baumgartner, R; Zimmermann, W				Kammerer, Robert; Buchner, Alexander; Palluch, Patrick; Pongratz, Thomas; Oboukhovskij, Konstantin; Beyer, Wolfgang; Johansson, Ann; Stepp, Herbert; Baumgartner, Reinhold; Zimmermann, Wolfgang			Induction of Immune Mediators in Glioma and Prostate Cancer Cells by Non-Lethal Photodynamic Therapy	PLOS ONE			English	Article							INDUCED PROTOPORPHYRIN-IX; NF-KAPPA-B; ANTITUMOR IMMUNITY; GLIOBLASTOMA-MULTIFORME; MALIGNANT GLIOMA; CARCINOMA-CELLS; STRESS-RESPONSE; EXPRESSION; ACTIVATION; DEATH	Background: Photodynamic therapy (PDT) uses the combination of photosensitizing drugs and harmless light to cause selective damage to tumor cells. PDT is therefore an option for focal therapy of localized disease or for otherwise unresectable tumors. In addition, there is increasing evidence that PDT can induce systemic anti-tumor immunity, supporting control of tumor cells, which were not eliminated by the primary treatment. However, the effect of non-lethal PDT on the behavior and malignant potential of tumor cells surviving PDT is molecularly not well defined. Methodology/Principal Findings: Here we have evaluated changes in the transcriptome of human glioblastoma (U87, U373) and human (PC-3, DU145) and murine prostate cancer cells (TRAMP-C1, TRAMP-C2) after non-lethal PDT in vitro and in vivo using oligonucleotide microarray analyses. We found that the overall response was similar between the different cell lines and photosensitizers both in vitro and in vivo. The most prominently upregulated genes encoded proteins that belong to pathways activated by cellular stress or are involved in cell cycle arrest. This response was similar to the rescue response of tumor cells following high-dose PDT. In contrast, tumor cells dealing with non-lethal PDT were found to significantly upregulate a number of immune genes, which included the chemokine genes CXCL2, CXCL3 and IL8/CXCL8 as well as the genes for IL6 and its receptor IL6R, which can stimulate proinflammatory reactions, while IL6 and IL6R can also enhance tumor growth. Conclusions: Our results indicate that PDT can support anti-tumor immune responses and is, therefore, a rational therapy even if tumor cells cannot be completely eliminated by primary phototoxic mechanisms alone. However, non-lethal PDT can also stimulate tumor growth-promoting autocrine loops, as seen by the upregulation of IL6 and its receptor. Thus the efficacy of PDT to treat tumors may be improved by controlling unwanted and potentially deleterious growth-stimulatory pathways.	[Kammerer, Robert] Friedrich Loeffler Inst, Inst Immunol, Tubingen, Germany; [Buchner, Alexander] Univ Hosp Munich, Dept Urol, Munich, Germany; [Buchner, Alexander; Palluch, Patrick; Oboukhovskij, Konstantin; Zimmermann, Wolfgang] Univ Hosp Munich, Tumor Immunol Lab, LIFE Ctr, Munich, Germany; [Pongratz, Thomas; Beyer, Wolfgang; Johansson, Ann; Stepp, Herbert; Baumgartner, Reinhold] Univ Hosp Munich, Laser Res Lab, LIFE Ctr, Munich, Germany	Friedrich Loeffler Institute; University of Munich; University of Munich; University of Munich	Kammerer, R (corresponding author), Friedrich Loeffler Inst, Inst Immunol, Tubingen, Germany.	wolfgang.zimmermann@med.uni-muenchen.de	Stepp, Herbert/E-1990-2013; Zimmermann, Wolfgang/L-9277-2013; Kammerer, Robert/AAQ-1338-2021	Kammerer, Robert/0000-0003-3038-8205; Buchner, Alexander/0000-0001-7895-7070	Deutsche Krebshilfe [107320]	Deutsche Krebshilfe(Deutsche Krebshilfe)	This work was supported by a grant from the Deutsche Krebshilfe (107320; http://www.krebshilfe.de/deutsche-krebshilfe.html). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmed HU, 2009, SURG ONCOL, V18, P219, DOI 10.1016/j.suronc.2009.02.002; Beck TJ, 2007, LASER SURG MED, V39, P386, DOI 10.1002/lsm.20507; Bento C, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-89; Buytaert E, 2008, ONCOGENE, V27, P1916, DOI 10.1038/sj.onc.1210825; Castano AP, 2006, NAT REV CANCER, V6, P535, DOI 10.1038/nrc1894; Cecic I, 2006, INT IMMUNOPHARMACOL, V6, P1259, DOI 10.1016/j.intimp.2006.03.008; Cekaite L, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-273; Chun JY, 2009, CLIN CANCER RES, V15, P4815, DOI 10.1158/1078-0432.CCR-09-0640; COHEN S, 1990, BIOCHEM J, V270, P325, DOI 10.1042/bj2700325; Decarvalho AC, 2007, GLIA, V55, P1053, DOI 10.1002/glia.20525; DESUZINGESMANDO.E, 2010, J BIOL CHEM; Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071; Duan ZF, 2009, CANCER CHEMOTH PHARM, V63, P681, DOI 10.1007/s00280-008-0785-8; Eleouet S, 2000, NEUROL RES, V22, P361, DOI 10.1080/01616412.2000.11740685; Eljamel MS, 2008, LASER MED SCI, V23, P361, DOI 10.1007/s10103-007-0494-2; Eljamel S, 2010, PHOTODIAGN PHOTODYN, V7, P76, DOI 10.1016/j.pdpdt.2010.02.002; Foster BA, 1997, CANCER RES, V57, P3325; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Garg AD, 2010, APOPTOSIS, V15, P1050, DOI 10.1007/s10495-010-0479-7; Gingrich JR, 1996, CANCER RES, V56, P4096; Gollnick SO, 2010, IMMUNOL RES, V46, P216, DOI 10.1007/s12026-009-8119-4; Hsieh YJ, 2003, J CELL PHYSIOL, V194, P363, DOI 10.1002/jcp.10273; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Johansson A, 2010, PHOTOCHEM PHOTOBIOL, V86, P1373, DOI 10.1111/j.1751-1097.2010.00799.x; Joo JH, 2007, CANCER RES, V67, P7929, DOI 10.1158/0008-5472.CAN-07-0931; Kabingu E, 2009, CLIN CANCER RES, V15, P4460, DOI 10.1158/1078-0432.CCR-09-0400; KAMMERER R, 2009, MED LASER APPL, V24, P237; KICK G, 1995, CANCER RES, V55, P2373; Kousis PC, 2007, CANCER RES, V67, P10501, DOI 10.1158/0008-5472.CAN-07-1778; Lee SY, 2010, BRIT J CANCER, V103, P362, DOI 10.1038/sj.bjc.6605797; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Lindner U, 2010, NAT REV UROL, V7, P562, DOI 10.1038/nrurol.2010.142; Liu B, 2009, CANCER SCI, V100, P2126, DOI 10.1111/j.1349-7006.2009.01290.x; Matroule JY, 2006, PHOTOCHEM PHOTOBIOL, V82, P1241, DOI 10.1562/2006-03-30-IR-862; Moore CM, 2009, NAT CLIN PRACT UROL, V6, P18, DOI 10.1038/ncpuro1274; Naderi A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-111; Nilsson CL, 2010, J PROTEOME RES, V9, P430, DOI 10.1021/pr9007927; Nowis D, 2005, ACTA BIOCHIM POL, V52, P339; Nozaki I, 2005, LAB INVEST, V85, P109, DOI 10.1038/labinvest.3700213; Prasmickaite L, 2006, FEBS LETT, V580, P5739, DOI 10.1016/j.febslet.2006.09.028; Sanovic R, 2009, INT J ONCOL, V35, P921, DOI 10.3892/ijo_00000407; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shedden K, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-26; Stummer W, 2008, J NEURO-ONCOL, V87, P103, DOI 10.1007/s11060-007-9497-x; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stylli SS, 2005, J CLIN NEUROSCI, V12, P389, DOI 10.1016/j.jocn.2005.01.006; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Susanto J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004023; Theilgaard-Monch K, 2004, J IMMUNOL, V172, P7684, DOI 10.4049/jimmunol.172.12.7684; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Verwanger T, 2002, INT J ONCOL, V21, P1353; Wild PJ, 2005, MOL CANCER THER, V4, P516, DOI 10.1158/1535-7163.MCT-04-0141; Yang H, 2010, CARCINOGENESIS, V31, P703, DOI 10.1093/carcin/bgq008; Zheng XG, 2008, CANCER LETT, V265, P177, DOI 10.1016/j.canlet.2008.02.023	55	39	39	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2011	6	6							e21834	10.1371/journal.pone.0021834	http://dx.doi.org/10.1371/journal.pone.0021834			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	786GP	21738796	Green Published, gold			2023-01-03	WOS:000292291800047
J	Stover, J; Korenromp, EL; Blakley, M; Komatsu, R; Viisainen, K; Bollinger, L; Atun, R				Stover, John; Korenromp, Eline L.; Blakley, Matthew; Komatsu, Ryuichi; Viisainen, Kirsi; Bollinger, Lori; Atun, Rifat			Long-Term Costs and Health Impact of Continued Global Fund Support for Antiretroviral Therapy	PLOS ONE			English	Article							PATIENT RETENTION; LOW-INCOME; FOLLOW-UP; HIV; MORTALITY; PROGRAMS; HIV/AIDS; ART; SERVICES; AFRICA	Background: By the end of 2011 Global Fund investments will be supporting 3.5 million people on antiretroviral therapy (ART) in 104 low-and middle-income countries. We estimated the cost and health impact of continuing treatment for these patients through 2020. Methods and Findings: Survival on first-line and second-line ART regimens is estimated based on annual retention rates reported by national AIDS programs. Costs per patient-year were calculated from country-reported ARV procurement prices, and expenditures on laboratory tests, health care utilization and end-of-life care from in-depth costing studies. Of the 3.5 million ART patients in 2011, 2.3 million will still need treatment in 2020. The annual cost of maintaining ART falls from $1.9 billion in 2011 to $1.7 billion in 2020, as a result of a declining number of surviving patients partially offset by increasing costs as more patients migrate to second-line therapy. The Global Fund is expected to continue being a major contributor to meeting this financial need, alongside other international funders and domestic resources. Costs would be $150 million less in 2020 with an annual 5% decline in first-line ARV prices and $150-370 million less with a 5%-12% annual decline in second-line prices, but $200 million higher in 2020 with phase out of stavudine (d4T), or $200 million higher with increased migration to second-line regimens expected if all countries routinely adopted viral load monitoring. Deaths postponed by ART correspond to 830,000 life-years saved in 2011, increasing to around 2.3 million life-years every year between 2015 and 2020. Conclusions: Annual patient-level direct costs of supporting a patient cohort remain fairly stable over 2011-2020, if current antiretroviral prices and delivery costs are maintained. Second-line antiretroviral prices are a major cost driver, underscoring the importance of investing in treatment quality to improve retention on first-line regimens.	[Stover, John; Bollinger, Lori] Futures Inst, Glastonbury, CT USA; [Korenromp, Eline L.; Blakley, Matthew; Komatsu, Ryuichi; Viisainen, Kirsi; Atun, Rifat] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland; [Korenromp, Eline L.; Atun, Rifat] Univ Med Ctr Rotterdam, Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Atun, Rifat] Univ London Imperial Coll Sci Technol & Med, London, England	Erasmus University Rotterdam; Erasmus MC; Imperial College London	Stover, J (corresponding author), Futures Inst, Glastonbury, CT USA.	jstover@futuresinstitute.org	Atun, Rifat/AAH-5537-2021	Atun, Rifat/0000-0002-1531-5983	The Global Fund	The Global Fund	The Global Fund commissioned this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; *AIDS 2031 COSTS F, 2010, COSTS CHOIC FIN LONG; [Anonymous], ANT MED LOW MIDDL IN; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; BAUTISTA SA, 2003, COSTING HIV AIDS TRE; CHANDLER R, 2005, ESTIMATING RESOURCE; CHANG LW, 2010, COCHRANE DB SYST REV, V14; Cleary Susan M, 2006, Cost Eff Resour Alloc, V4, P20, DOI 10.1186/1478-7547-4-20; *EART LINC COLL, 2008, SEX TRANSM INFECT, V84, pI31; Fox MP, 2010, TROP MED INT HEALTH, V15, P1, DOI 10.1111/j.1365-3156.2010.02508.x; Fox MP, 2010, TROP MED INT HEALTH, V15, P405, DOI 10.1111/j.1365-3156.2010.02473.x; GALARRAGA O, 2010, PHARMAC IN PRESS SEP; Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2; *GLOB FUND FIGHT A, 2009, IMPR VAL MON GLOB FU; *GLOB FUND FIGHT A, 2010, KEY PERF IND 2010; *GLOB FUND FIGHT A, 2011, GLOB FUND RES REP 20; Goldie SJ, 2006, NEW ENGL J MED, V355, P1141, DOI 10.1056/NEJMsa060247; HARLING G, 2007, J ACQ IMMUN DEF SYND, V45, P3; Harries AD, 2010, TROP MED INT HEALTH, V15, P70, DOI 10.1111/j.1365-3156.2010.02506.x; Izazola-Licea JA, 2009, JAIDS-J ACQ IMM DEF, V52, pS119, DOI 10.1097/QAI.0b013e3181baeeda; Jack C, 2004, JAIDS-J ACQ IMM DEF, V36, P929, DOI 10.1097/00126334-200408010-00006; Jahn A, 2008, LANCET, V371, P1603, DOI 10.1016/S0140-6736(08)60693-5; *KAIS FAM FDN, 2009, FIN RESP AIDS LOW MI; Kitajima T, 2003, AIDS, V17, P2375, DOI 10.1097/00002030-200311070-00013; KOENIG S, 2006, AIDS 2006 16 INT AID; KOENIG S, 2006, AIDS 16 INT AIDS C 2; Komatsu R, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-109; KOMBE G, 2004, COSTS ANTIRETROVIRAL; Kombe G., 2005, HUMAN FINANCIAL RESO; Korenromp EL, 2005, EMERG INFECT DIS, V11, P1410, DOI 10.3201/eid1109.050337; Korenromp EL, 2011, AIDS, V25, P857, DOI 10.1097/QAD.0b013e3283454401; LABASTIDE W, 2002, INT C AIDS JUL 7 12, P14; LONG L, 2009, COSTING TREATMENT GU; Loubiere S, 2010, CURR OPIN HIV AIDS, V5, P225, DOI 10.1097/COH.0b013e3283384a9d; Marston M, 2007, AIDS, V21, pS65, DOI 10.1097/01.aids.0000299412.82893.62; Medecins Sans Frontieres, 2008, UNT WEB ANT PRIC RED; MEDINALARA A, 2009, 5 IAS C HIV PATH TRE; Mugyenyi P, 2010, LANCET, V375, P123, DOI 10.1016/S0140-6736(09)62067-5; Phillips AN, 2011, AIDS, V25, P843, DOI 10.1097/QAD.0b013e328344037a; *PHRPLUS, 2004, NIG RAP ASS HIV AIDS; Quentin W, 2008, TROP MED INT HEALTH, V13, P1245, DOI 10.1111/j.1365-3156.2008.02142.x; SILVESTRI A, 2009, EVALUATION ANTIRETRO; Stover J, 2008, SEX TRANSM INFECT, V84, pI24, DOI 10.1136/sti.2008.029868; Stover J, 2006, SCIENCE, V311, P1474, DOI 10.1126/science.1121176; Stover J, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/738271; The Global Fund to Fight AIDS Tuberculosis and Malaria, 2010, GLOB FUND RES REP 20; TODD K, 2007, AIDS S, V6, pS55; Tweya H, 2010, TROP MED INT HEALTH, V15, P82, DOI 10.1111/j.1365-3156.2010.02509.x; *UK DEP INT DEV, 2008, ACH UN ACC UK STRAT; *UNAIDS, GLOB EC CRIS HIV PRE; UNAIDS, 2009, WHAT COUNTR NEED INV; WHO, 2010, ANT THER HIV INF AD; WHO, 2004, MAL HIV AIDS INT IMP; *WHO, 2009, U ACC SCAL PRIOR HIV; World Health Organization, 2006, ANT THER HIV INF AD; World Health Organization UNAIDS and UNICEF, 2010, U ACC SCAL PRIOR HIV; 2010, REPORT C COSTS TREAT	57	27	27	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2011	6	6							e21048	10.1371/journal.pone.0021048	http://dx.doi.org/10.1371/journal.pone.0021048			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	782TT	21731646	Green Published, gold, Green Submitted			2023-01-03	WOS:000292035400007
J	Courtine, G; van den Brand, R; Musienko, P				Courtine, Gregoire; van den Brand, Rubio; Musienko, Pavel			Spinal cord injury: time to move	LANCET			English	Editorial Material									[Courtine, Gregoire; van den Brand, Rubio; Musienko, Pavel] Univ Zurich, Dept Neurol, Expt Neurorehabil Lab, CH-8008 Zurich, Switzerland; [Musienko, Pavel] Pavlov Inst Physiol, Motor Physiol Lab, St Petersburg, Russia	University of Zurich; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Pavlov Institute of Physiology Russian Academy of Sciences	Courtine, G (corresponding author), Univ Zurich, Dept Neurol, Expt Neurorehabil Lab, CH-8008 Zurich, Switzerland.	gregoire.courtine@uzh.ch	Musienko, Pavel/L-6677-2015	Musienko, Pavel/0000-0002-7324-9021; courtine, gregoire/0000-0002-5744-4142				Behmran AL, 2000, PHYS THER, V80, P688, DOI 10.1093/ptj/80.7.688; Capaday C, 2002, TRENDS NEUROSCI, V25, P370, DOI 10.1016/S0166-2236(02)02173-2; Courtine G, 2009, NAT NEUROSCI, V12, P1333, DOI 10.1038/nn.2401; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; Dietz V, 2008, BRAIN, V131, P2240, DOI 10.1093/brain/awn185; Harkema S, 2011, LANCET, V377, P1938, DOI 10.1016/S0140-6736(11)60547-3; Harkema SJ, 2008, BRAIN RES REV, V57, P255, DOI 10.1016/j.brainresrev.2007.07.012; Musienko P E, 2007, Neurosci Behav Physiol, V37, P181, DOI 10.1007/s11055-007-0166-5; Musienko PE, 2010, J NEUROPHYSIOL, V103, P1080, DOI 10.1152/jn.00575.2009; Musienko P, 2009, IEEE T BIO-MED ENG, V56, P2707, DOI 10.1109/TBME.2009.2027226; MUSIENKO PE, J NEUROSCI IN PRESS; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; VANDENBRAND R, 2010, NEUR M PLANN SAN DIE	13	31	31	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 4	2011	377	9781					1896	1898		10.1016/S0140-6736(11)60711-3	http://dx.doi.org/10.1016/S0140-6736(11)60711-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777LW	21601272				2023-01-03	WOS:000291623200006
J	Peterson, PN; Shetterly, SM; Clarke, CL; Bekelman, DB; Chan, PS; Allen, LA; Matlock, DD; Magid, DJ; Masoudi, FA				Peterson, Pamela N.; Shetterly, Susan M.; Clarke, Christina L.; Bekelman, David B.; Chan, Paul S.; Allen, Larry A.; Matlock, Daniel D.; Magid, David J.; Masoudi, Frederick A.			Health Literacy and Outcomes Among Patients With Heart Failure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIMITED LITERACY; CONTROLLED-TRIAL; HOSPITAL ADMISSION; IDENTIFY PATIENTS; SKILLS; RISK; POPULATION; QUESTIONS; ENROLLEES; MORTALITY	Context Little is known about the effects of low health literacy among patients with heart failure, a condition that requires self-management and frequent interactions with the health care system. Objective To evaluate the association between low health literacy and all-cause mortality and hospitalization among outpatients with heart failure. Design, Setting, and Patients Retrospective cohort study conducted at Kaiser Permanente Colorado, an integrated managed care organization. Outpatients with heart failure were identified between January 2001 and May 2008, were surveyed by mail, and underwent follow-up for a median of 1.2 years. Health literacy was assessed using 3 established screening questions and categorized as adequate or low. Responders were excluded if they did not complete at least 1 health literacy question or if they did not have at least 1 year of enrollment prior to the survey date. Main Outcome Measures All-cause mortality and all-cause hospitalization. Results Of the 2156 patients surveyed, 1547 responded (72% response rate). Of 1494 included responders, 262 (17.5%) had low health literacy. Patients with low health literacy were older, of lower socioeconomic status, less likely to have at least a high school education, and had higher rates of coexisting illnesses. In multivariable Cox regression, low health literacy was independently associated with higher mortality (unadjusted rate, 17.6% vs 6.3%; adjusted hazard ratio, 1.97 [95% confidence interval, 1.3-2.97]; P=.001) but not hospitalization (unadjusted rate, 30.5% vs 23.2%; adjusted hazard ratio, 1.05 [95% confidence interval, 0.8-1.37]; P=.73). Conclusion Among patients with heart failure in an integrated managed care organization, low health literacy was significantly associated with higher all-cause mortality. JAMA. 2011;305(16):1695-1701 www.jama.com	[Peterson, Pamela N.] Denver Hlth Med Ctr, Div Cardiol, Denver, CO 80204 USA; [Peterson, Pamela N.; Shetterly, Susan M.; Clarke, Christina L.; Magid, David J.; Masoudi, Frederick A.] Kaiser Permanente Colorado Inst Hlth Res, Denver, CO USA; [Peterson, Pamela N.; Bekelman, David B.; Allen, Larry A.; Matlock, Daniel D.; Magid, David J.; Masoudi, Frederick A.] Univ Colorado Denver, Aurora, CO USA; [Bekelman, David B.] Denver VA Med Ctr, Denver, CO USA; [Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA; [Chan, Paul S.] Univ Missouri, Kansas City, MO 64110 USA	Denver Health Medical Center; Kaiser Permanente; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; Saint Luke's Mid America Heart Institute; University of Missouri System; University of Missouri Kansas City	Peterson, PN (corresponding author), Denver Hlth Med Ctr, Div Cardiol, Mail Code 0960,777 Bannock St, Denver, CO 80204 USA.	pamela.peterson@ucdenver.edu	Allen, Larry/AAI-1323-2020; Masoudi, Frederick/Q-7467-2019	Matlock, Dan/0000-0001-9597-9642	American Heart Association [067001N]; National Heart, Lung, and Blood Institute [K23HL102224]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224] Funding Source: NIH RePORTER	American Heart Association(American Heart Association); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Peterson is supported by American Heart Association Pharmaceutical Roundtable grant 067001N. Dr Chan is supported by a Career Development Grant Award (K23HL102224) from the National Heart, Lung, and Blood Institute. Dr Allen is supported by an American Heart Association Scientist Development Award.	Baker DW, 2007, ARCH INTERN MED, V167, P1503, DOI 10.1001/archinte.167.14.1503; Baker DW, 2006, J GEN INTERN MED, V21, P878, DOI 10.1111/j.1525-1497.2006.00540.x; Baker DW, 1998, J GEN INTERN MED, V13, P791, DOI 10.1046/j.1525-1497.1998.00242.x; Baker DW, 2002, AM J PUBLIC HEALTH, V92, P1278, DOI 10.2105/AJPH.92.8.1278; Cavanaugh K, 2009, DIABETES CARE, V32, P2149, DOI 10.2337/dc09-0563; Chew LD, 2004, FAM MED, V36, P588; Chew LD, 2008, J GEN INTERN MED, V23, P561, DOI 10.1007/s11606-008-0520-5; COX DR, 1972, J R STAT SOC B, V34, P187; Davis T C, 1993, Fam Med, V25, P391; Davis TC, 2006, ANN INTERN MED, V145, P887, DOI 10.7326/0003-4819-145-12-200612190-00144; DeWalt DA, 2004, J GEN INTERN MED, V19, P1228, DOI 10.1111/j.1525-1497.2004.40153.x; DeWalt DA, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-30; Eichler K, 2009, INT J PUBLIC HEALTH, V54, P313, DOI 10.1007/s00038-009-0058-2; Evangelista LS, 2010, J CARD FAIL, V16, P9, DOI 10.1016/j.cardfail.2009.10.026; Gazmararian JA, 1999, JAMA-J AM MED ASSOC, V281, P545, DOI 10.1001/jama.281.6.545; Go AS, 2006, CIRCULATION, V113, P2713, DOI 10.1161/CIRCULATIONAHA.105.577577; Institute of Medicine, 2004, PRESCR END CONF; Kripalani S, 2006, J GEN INTERN MED, V21, P852, DOI 10.1111/j.1525-1497.2006.00536.x; Kumler T, 2008, EUR J HEART FAIL, V10, P658, DOI 10.1016/j.ejheart.2008.05.006; Lee DS, 2005, MED CARE, V43, P182, DOI 10.1097/00005650-200502000-00012; Murray MD, 2009, CLIN PHARMACOL THER, V85, P651, DOI 10.1038/clpt.2009.7; Paasche-Orlow MK, 2006, J GEN INTERN MED, V21, P884, DOI 10.1111/j.1525-1497.2006.00544.x; PARKER RM, 1995, J GEN INTERN MED, V10, P537, DOI 10.1007/BF02640361; Powers BJ, 2010, JAMA-J AM MED ASSOC, V304, P76, DOI 10.1001/jama.2010.896; Riegel B, 2009, CIRCULATION, V120, P1141, DOI 10.1161/CIRCULATIONAHA.109.192628; Seligman HK, 2005, J GEN INTERN MED, V20, P1001, DOI 10.1111/j.1525-1497.2005.00189.x; Sudore RL, 2006, J GEN INTERN MED, V21, P806, DOI 10.1111/j.1525-1497.2006.00539.x; von Wagner C, 2009, HEALTH EDUC BEHAV, V36, P860, DOI 10.1177/1090198108322819; Wallace LS, 2007, J SURG RES, V140, P208, DOI 10.1016/j.jss.2007.01.029; Wallace LS, 2006, J GEN INTERN MED, V21, P874, DOI 10.1111/j.1525-1497.2006.00532.x; Weiss BD, 2006, J GEN INTERN MED, V21, P823, DOI 10.1111/j.1525-1497.2006.00531.x; Williams MV, 1998, ARCH INTERN MED, V158, P166, DOI 10.1001/archinte.158.2.166	32	269	276	0	30	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	2011	305	16					1695	1701		10.1001/jama.2011.512	http://dx.doi.org/10.1001/jama.2011.512			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	754XG	21521851	Green Accepted, Bronze			2023-01-03	WOS:000289890500023
J	Parkin, L; Sharples, K; Hernandez, RK; Jick, SS				Parkin, Lianne; Sharples, Katrina; Hernandez, Rohini K.; Jick, Susan S.			Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE IMPUTATION; WOMEN; CYPROTERONE; THROMBOSIS	Objective To examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oral contraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel. Design Nested case-control study. Setting UK General Practice Research Database. Participants Women aged 15-44 years without major risk factors for venous thromboembolism who started a new episode of use of an oral contraceptive containing 30 mu g oestrogen in combination with either drospirenone or levonorgestrel between May 2002 and September 2009. Cases were women with a first diagnosis of venous thromboembolism; up to four controls, matched by age, duration of recorded information, and general practice, were randomly selected for each case. Main outcome measures Odds ratios and 95% confidence intervals estimated with conditional logistic regression; age adjusted incidence rate ratio estimated with Poisson regression. Results 61 cases of idiopathic venous thromboembolism and 215 matched controls were identified. In the case-control analysis, current use of the drospirenone contraceptive was associated with a threefold higher risk of non-fatal idiopathic venous thromboembolism compared with levonorgestrel use; the odds ratio adjusted for body mass index was 3.3 (95% confidence interval 1.4 to 7.6). Subanalyses suggested that referral, diagnostic, first time user, duration of use, and switching biases were unlikely explanations for this finding. The crude incidence rate was 23.0 (95% confidence interval 13.4 to 36.9) per 100 000 woman years in current users of drospirenone and 9.1 (6.6 to 12.2) per 100 000 woman years in current users of levonorgestrel oral contraceptives. The age adjusted incidence rate ratio was 2.7 (1.5 to 4.7). Conclusions These findings contribute to emerging evidence that the combined oral contraceptive containing drospirenone carries a higher risk of venous thromboembolism than do formulations containing levonorgestrel.	[Hernandez, Rohini K.; Jick, Susan S.] Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA; [Parkin, Lianne; Sharples, Katrina] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin 9054, New Zealand	Boston University; University of Otago	Jick, SS (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.	sjick@bu.edu		Parkin, Lianne/0000-0002-6824-6176; Jick, Susan/0000-0002-2215-1067				AROWOJOLU AO, 2009, COCHRANE DB SYST REV, V1; BLOEMENKAMP KWM, 1995, LANCET, V346, P1593, DOI 10.1016/S0140-6736(95)91929-5; Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; FARLEY TMM, 1995, LANCET, V346, P1582; GALLO MF, 2009, COCHRANE DB SYST REV, V1; Jick H, 2000, BMJ-BRIT MED J, V321, P1190, DOI 10.1136/bmj.321.7270.1190; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick H, 1998, LANCET, V352, P1767, DOI 10.1016/S0140-6736(98)04350-5; Jick SS, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2151; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890; LOPEZ LM, 2009, COCHRANE DB SYST REV, V1; MAITRA NN, 2009, COCHRANE DB SYST REV, V1; Parkin L, 2000, LANCET, V355, P2133, DOI 10.1016/S0140-6736(00)02382-5; POULTER NR, 1995, LANCET, V346, P1575; Raghunathan T.E., 2001, SURV METHODOL, V27, P85; ROTHMAN KJ, 1988, INT J EPIDEMIOL, V17, P955, DOI 10.1093/ije/17.4.955; Royston P, 2005, STATA J, V5, P279, DOI 10.1177/1536867X0500500212; Seeger JD, 2007, OBSTET GYNECOL, V110, P587, DOI 10.1097/01.AOG.0000279448.62221.a8; Sheldon T, 2002, BRIT MED J, V324, P869, DOI 10.1136/bmj.324.7342.869; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Tchaikovski SN, 2007, THROMB HAEMOSTASIS, V98, P1350, DOI 10.1160/TH07-07-0439; van Buuren S, 2007, STAT METHODS MED RES, V16, P219, DOI 10.1177/0962280206074463; Van Vliet HAAM, 2004, J THROMB HAEMOST, V2, P2060, DOI 10.1111/j.1538-7836.2004.00983.x; Vasilakis-Scaramozza C, 2001, LANCET, V358, P1427, DOI 10.1016/S0140-6736(01)06522-9; Vlieg AV, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2921; Winter M, 2005, CLIN LAB HAEMATOL, V27, P61, DOI 10.1111/j.1365-2257.2004.00660.x; 2005, EPISHEET SPREADSHEET	28	129	131	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2011	342								d2139	10.1136/bmj.d2139	http://dx.doi.org/10.1136/bmj.d2139			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755OR	21511804	Green Published, hybrid			2023-01-03	WOS:000289943400005
J	Heijink, DM; Fehrmann, RSN; de Vries, EGE; Koornstra, JJ; Oosterhuis, D; van der Zee, AGJ; Kleibeuker, JH; de Jong, S				Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Koornstra, J. J.; Oosterhuis, D.; van der Zee, A. G. J.; Kleibeuker, J. H.; de Jong, S.			A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer	ONCOGENE			English	Article						pathways; microarray; gene set enrichment; adenoma; chemoprevention	DEPENDENT KINASE INHIBITOR; GENE-EXPRESSION; PROTEIN-KINASE; EARLY EVENT; DNA-DAMAGE; RB-PATHWAY; CYCLIN D1; COLON; ADENOMAS; DASATINIB	Comparing normal colorectal mucosa and adenomas focusing on deregulated pathways obtains insight into the biological processes of early colorectal carcinogenesis. Publicly available microarray expression data from 26 normal mucosa and 47 adenoma samples were analyzed. Biological pathways enriched in adenomas were identified with Gene Set Enrichment Analysis (GSEA). The analysis revealed 10, 11 and 16 gene sets distinguishing adenomas from normal mucosa according to Kyoto Encyclopedia of Genes and Genomes (KEGG), Gene Map Annotator and Pathway Profiler (GenMAPP) and Biocarta databases, respectively. Biological pathways known to be involved in colon carcinogenesis such as cell cycle (P = 0.002) and Wnt signaling (P = 0.007) were enriched in adenomas. In addition, we found enrichment of novel pathways such as retinoblastoma (Rb) pathway (P = 0.002), Src pathway (P = 0.004), folate biosynthesis (P = 0.019) and Hedgehog signaling (P = 0.037) in adenomas. Microarray results for Rb and Src pathway genes were validated by quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) on mRNA isolated from an independent set of adenoma and normal colon samples. A high correlation between microarray data and qRT-PCR expression data was found. The relevance of targeting of identified pathways was shown using the Rb pathway inhibitors roscovitine and PD-0332991 and the Src pathway inhibitor dasatinib. All inhibitors used induced cell growth reduction in adenoma cells. This study shows a bioinformatical and functional approach leading to potentially new options for chemoprevention of colorectal cancer. Oncogene (2011) 30, 2026-2036; doi:10.1038/onc.2010.578; published online 10 January 2011	[Heijink, D. M.; Fehrmann, R. S. N.; de Vries, E. G. E.; Oosterhuis, D.; de Jong, S.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; [Heijink, D. M.; Koornstra, J. J.; Kleibeuker, J. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.; van der Zee, A. G. J.] Univ Groningen, Univ Med Ctr Groningen, Dept Gynecol Oncol, NL-9713 GZ Groningen, Netherlands; [Fehrmann, R. S. N.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen; University of Groningen	de Vries, EGE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	e.g.e.de.vries@int.umcg.nl	Pillay, Nischalan/F-9536-2012; Fehrmann, Rudolf/E-2551-2011	Fehrmann, Rudolf/0000-0002-7516-315X; de Vries, Elisabeth/0000-0002-8949-7425	Dutch Cancer Society [RUG 2005-3361]	Dutch Cancer Society(KWF Kankerbestrijding)	This study was supported by Grant RUG 2005-3361 from the Dutch Cancer Society.	Aldoss IT, 2009, EXPERT OPIN INV DRUG, V18, P1957, DOI 10.1517/13543780903418445; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Arber N, 1996, GASTROENTEROLOGY, V110, P669, DOI 10.1053/gast.1996.v110.pm8608874; Arber N, 2008, GASTROENTEROLOGY, V134, P1224, DOI 10.1053/j.gastro.2008.02.012; Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; Arima Y, 2008, CANCER RES, V68, P5104, DOI 10.1158/0008-5472.CAN-07-5680; Bartkova J, 2001, GASTROENTEROLOGY, V120, P1680, DOI 10.1053/gast.2001.24880; Bild AH, 2006, NAT REV CANCER, V6, P735, DOI 10.1038/nrc1976; Boquoi A, 2009, CANCER PREV RES, V2, P800, DOI 10.1158/1940-6207.CAPR-09-0053; Carey R, 2008, INFLAMM BOWEL DIS, V14, P446, DOI 10.1002/ibd.20342; CARTWRIGHT CA, 1990, P NATL ACAD SCI USA, V87, P558, DOI 10.1073/pnas.87.2.558; Chen R, 2009, BLOOD, V113, P4637, DOI 10.1182/blood-2008-12-190256; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Crijns APG, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-232; Crijns APG, 2009, PLOS MED, V6, P181, DOI 10.1371/journal.pmed.1000024; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; de Hoon MJL, 2004, BIOINFORMATICS, V20, P1453, DOI 10.1093/bioinformatics/bth078; Du W, 2009, CURR DRUG TARGETS, V10, P581, DOI 10.2174/138945009788680392; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Einspahr JG, 2006, CANCER EPIDEM BIOMAR, V15, P1443, DOI 10.1158/1055-9965.EPI-06-0144; Fry DW, 2004, MOL CANCER THER, V3, P1427; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Galamb O, 2008, DIS MARKERS, V25, P1, DOI 10.1155/2008/586721; Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615; Guillen-Ahlers H, 2008, CARCINOGENESIS, V29, P1421, DOI 10.1093/carcin/bgn123; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Hong Y, 2007, CLIN CANCER RES, V13, P1107, DOI 10.1158/1078-0432.CCR-06-1633; Imazeki F, 1996, GASTROENTEROLOGY, V110, P362, DOI 10.1053/gast.1996.v110.pm8566581; Jalving M, 2006, CLIN CANCER RES, V12, P4350, DOI 10.1158/1078-0432.CCR-05-2487; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kantarjian H, 2007, BLOOD, V109, P5143, DOI 10.1182/blood-2006-11-056028; Kita H, 2006, J GASTROENTEROL, V41, P1053, DOI 10.1007/s00535-006-1894-y; Knudsen ES, 2010, CLIN CANCER RES, V16, P1094, DOI 10.1158/1078-0432.CCR-09-0787; Koornstra JJ, 2004, HISTOPATHOLOGY, V44, P9, DOI 10.1111/j.1365-2559.2004.01739.x; Kopetz S, 2009, CANCER RES, V69, P3842, DOI 10.1158/0008-5472.CAN-08-2246; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; LaPointe LC, 2008, PHYSIOL GENOMICS, V33, P50, DOI 10.1152/physiolgenomics.00185.2006; Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]; Lin YM, 2002, ONCOGENE, V21, P4120, DOI 10.1038/sj.onc.1205518; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Paulson QX, 2008, ONCOGENE, V27, P4954, DOI 10.1038/onc.2008.138; Payne SR, 2008, MOL CELL BIOL, V28, P258, DOI 10.1128/MCB.01536-07; RENCHER A, 1998, MUTIVARIATE STAT INT; Sabates-Beliver J, 2007, MOL CANCER RES, V5, P1263, DOI 10.1158/1541-7786.MCR-07-0267; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Serrels A, 2006, MOL CANCER THER, V5, P3014, DOI 10.1158/1535-7163.MCT-06-0382; Sherlock G, 2001, Brief Bioinform, V2, P350, DOI 10.1093/bib/2.4.350; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; van Geelen CMM, 2003, BRIT J CANCER, V89, P363, DOI 10.1038/sj.bjc.6601065; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wai PY, 2006, J BIOL CHEM, V281, P18973, DOI 10.1074/jbc.M511962200; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhao P, 2006, WORLD J GASTROENTERO, V12, P6391, DOI 10.3748/wjg.v12.i39.6391	62	18	19	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2011	30	17					2026	2036		10.1038/onc.2010.578	http://dx.doi.org/10.1038/onc.2010.578			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755YL	21217777				2023-01-03	WOS:000289977400006
J	Al-Majed, NS; McAlister, FA; Bakal, JA; Ezekowitz, JA				Al-Majed, Nawaf S.; McAlister, Finlay A.; Bakal, Jeffrey A.; Ezekowitz, Justin A.			Meta-analysis: Cardiac Resynchronization Therapy for Patients With Less Symptomatic Heart Failure	ANNALS OF INTERNAL MEDICINE			English	Review							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; VENTRICULAR SYSTOLIC DYSFUNCTION; DEVICE THERAPY; ATRIAL-FIBRILLATION; RANDOMIZED-TRIAL; FOCUSED UPDATE; ESC GUIDELINES; PACED PATIENTS; TASK-FORCE; ASSOCIATION	Background: Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in patients with advanced symptoms of heart failure. Purpose: To assess the benefits and harms of CRT in patients with advanced heart failure and those with less symptomatic disease. Data Sources: A search of electronic databases (1950 to December 2010), hand-searching of reference lists, and unpublished data from principal investigators. Searches were not limited to the English language. Study Selection: Randomized, controlled trials of CRT compared with usual care and right or left ventricular pacing in adults with heart failure and a left ventricular ejection fraction of 0.40 or less. Data Extraction: Two reviewers performed independent study selection, data abstraction, and quality assessment by using the Cochrane tool for assessing risk for bias. Data Synthesis: There were 9082 patients in 25 trials. In patients with New York Heart Association (NYHA) class I and II symptoms, CRT reduced all-cause mortality (6 trials, 4572 participants; risk ratio [RR], 0.83 [95% CI, 0.72 to 0.96]) and heart failure hospitalizations (4 trials, 4349 participants; RR, 0.71 [CI, 0.57 to 0.87]) without improving functional outcomes or quality of life. In patients with NYHA class III or IV symptoms, CRT improved functional outcomes and reduced both all-cause mortality (19 trials, 4510 participants; RR, 0.78 [CI, 0.67 to 0.91]) and heart failure hospitalizations (11 trials, 2663 participants; RR, 0.65 [CI, 0.50 to 0.86]). The implant success rate was 94.4%; peri-implantation deaths occurred in 0.3% of trial participants, mechanical complications in 3.2%, lead problems in 6.2%, and infections in 1.4%. Limitation: Subgroup analyses were underpowered and lack data for persons with NYHA class I symptoms, atrial fibrillation, chronic kidney disease, or right bundle branch block. Conclusion: Cardiac resynchronization therapy is beneficial for patients with reduced left ventricular ejection fraction, symptoms of heart failure, and prolonged QRS, regardless of NYHA class.	[McAlister, Finlay A.; Ezekowitz, Justin A.] Walter Mackenzie Ctr, Edmonton, AB T6G 2B7, Canada; [Al-Majed, Nawaf S.] Univ Alberta, Dept Med, Edmonton, AB T6G 2B7, Canada; [Bakal, Jeffrey A.] Univ Alberta, Edmonton, AB T6G 2M8, Canada	University of Alberta; University of Alberta; University of Alberta	Ezekowitz, JA (corresponding author), Walter Mackenzie Ctr, 8440 112 St, Edmonton, AB T6G 2B7, Canada.	justin.ezekowitz@ualberta.ca	Bakal, Jeff/ABE-4051-2021; McAlister, Finlay/C-4151-2013; Ezekowitz, Justin A/C-4579-2013	McAlister, Finlay/0000-0001-7435-3341; Ezekowitz, Justin A/0000-0002-2724-4086; Bakal, Jeffrey/0000-0002-3658-2554	New Investigator program of the Canadian Institutes of Health Research; Alberta Heritage Foundation for Medical Research (AHFMR)	New Investigator program of the Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research)	Dr. Ezekowitz is supported by the New Investigator program of the Canadian Institutes of Health Research and by the Alberta Heritage Foundation for Medical Research (AHFMR). Dr. McAlister holds a Senior Health Scholar Award from AHFMR.	Abraham WT, 2004, CIRCULATION, V110, P2864, DOI 10.1161/01.CIR.0000146336.92331.D1; Abraham WT, 2002, NEW ENGL J MED, V346, P1845, DOI 10.1056/NEJMoa013168; Auricchio A, 2002, J AM COLL CARDIOL, V39, P2026, DOI 10.1016/S0735-1097(02)01895-8; Auricchio A, 2003, J AM COLL CARDIOL, V42, P2109, DOI 10.1016/j.jacc.2003.04.003; Beshai JF, 2007, NEW ENGL J MED, V357, P2461, DOI 10.1056/NEJMoa0706695; Bleeker GB, 2006, J AM COLL CARDIOL, V48, P2243, DOI 10.1016/j.jacc.2006.07.067; Boriani G, 2010, AM HEART J, V159, P1052, DOI 10.1016/j.ahj.2010.03.008; Bristow MR, 2004, NEW ENGL J MED, V350, P2140, DOI 10.1056/NEJMoa032423; Bueno H, 2010, JAMA-J AM MED ASSOC, V303, P2141, DOI 10.1001/jama.2010.748; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; Chakeabarti S, 2010, J CARD FAIL, V16, pS53, DOI 10.1016/j.cardfail.2010.04.004; Chung ES, 2010, EUR J HEART FAIL, V12, P581, DOI 10.1093/eurjhf/hfq009; Cleland JGF, 2005, NEW ENGL J MED, V352, P1539, DOI 10.1056/NEJMoa050496; Curtis AB, 2009, AM HEART J, V158, P956, DOI 10.1016/j.ahj.2009.10.011; Curtis JP, 2009, JAMA-J AM MED ASSOC, V301, P1661, DOI 10.1001/jama.2009.547; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dickstein K, 2008, EUR HEART J, V29, P2388, DOI 10.1093/eurheartj/ehn309; Dickstein K, 2010, EUR J HEART FAIL, V12, P1143, DOI [10.1093/eurjhf/hfq192, 10.1093/europace/euq392]; Dickstein K, 2009, EUR HEART J, V30, P2450, DOI 10.1093/eurheartj/ehp359; EZEKOWITZ JA, 2010, EUR J HEART FAIL; Ezekowitz JA, 2007, ANN INTERN MED, V147, P251, DOI 10.7326/0003-4819-147-4-200708210-00007; Fein AS, 2010, J AM COLL CARDIOL, V56, P766, DOI 10.1016/j.jacc.2010.05.025; FILHO MM, 2010, J CARD FAIL, V16, P293; Fornwalt BK, 2010, CIRCULATION, V121, P1985, DOI 10.1161/CIRCULATIONAHA.109.910778; Fox M, 2007, Health Technol Assess, V11, piii; Fox M, 2007, HLTH TECHNOL ASSESS, V11; Freeman JV, 2010, J AM COLL CARDIOL, V56, P1133, DOI 10.1016/j.jacc.2010.07.007; Gasparini M, 2006, AM HEART J, V152, DOI 10.1016/j.ahj.2006.08.018; Higgins J., 2009, COCHRANE HDB SYSTEMA; Higgins SL, 2003, J AM COLL CARDIOL, V42, P1454, DOI 10.1016/S0735-1097(03)01042-8; Hoppe UC, 2006, CIRCULATION, V114, P18, DOI 10.1161/CIRCULATIONAHA.106.614560; Howlett JG, 2009, CAN J CARDIOL, V25, P85, DOI 10.1016/S0828-282X(09)70477-5; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Kindermann M, 2006, J AM COLL CARDIOL, V47, P1927, DOI 10.1016/j.jacc.2005.12.056; Landolina M, 2007, AM J CARDIOL, V100, P1007, DOI 10.1016/j.amjcard.2007.04.043; Leclercq C, 2002, EUR HEART J, V23, P1780, DOI 10.1053/euhj.2002.3232; Leclercq C, 2007, PACE, V30, pS23; Linde C, 2008, J AM COLL CARDIOL, V52, P1834, DOI 10.1016/j.jacc.2008.08.027; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; Lloyd-Jones D, 2009, CIRCULATION, V119, pE21, DOI 10.1161/CIRCULATIONAHA.108.191261; Lubitz SA, 2010, EUR J HEART FAIL, V12, P360, DOI 10.1093/eurjhf/hfq029; Maass AH, 2010, EUR J HEART FAIL, V12, P527, DOI 10.1093/eurjhf/hfq084; McAlister FA, 2006, EUR HEART J, V27, P323, DOI 10.1093/eurheartj/ehi446; McAlister FA, 2008, CIRCULATION, V118, P901, DOI 10.1161/CIRCULATIONAHA.108.800722; McAlister FA, 2007, JAMA-J AM MED ASSOC, V297, P2502, DOI 10.1001/jama.297.22.2502; Moss AJ, 2009, NEW ENGL J MED, V361, P1329, DOI 10.1056/NEJMoa0906431; Piccini JP, 2008, CIRCULATION, V118, P926, DOI 10.1161/CIRCULATIONAHA.108.773838; Piepoli MF, 2008, PACE, V31, P701, DOI 10.1111/j.1540-8159.2008.01073.x; Rao RK, 2007, CIRCULATION, V115, P2136, DOI 10.1161/CIRCULATIONAHA.106.634444; RECTOR TS, 1993, CIRCULATION, V87, P71; Shenkman HJ, 2002, CHEST, V122, P528, DOI 10.1378/chest.122.2.528; Solomon SD, 2010, CIRCULATION, V122, P985, DOI 10.1161/CIRCULATIONAHA.110.955039; Sutton MSJ, 2009, CIRCULATION, V120, P1858, DOI 10.1161/CIRCULATIONAHA.108.818724; Sutton MGS, 2006, CIRCULATION, V113, P266, DOI 10.1161/CIRCULATIONAHA.104.520817; Tang ASL, 2010, NEW ENGL J MED, V363, P2385, DOI 10.1056/NEJMoa1009540; THIBAULT B, 2010, HEART RHYTHM SOC 31A; U.S. Food and Drug Administration, 2005, ST JUD FRONT CARD RE; U.S. Food and Drug Administration, 2005, SUMM SAF EFF DAT; Upadhyay GA, 2008, J AM COLL CARDIOL, V52, P1239, DOI 10.1016/j.jacc.2008.06.043; *USFDA, 2009, MULT AUT DEF IMPL TR; van Geldorp IE, 2010, EUROPACE, V12, P223, DOI 10.1093/europace/eup378; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Yao GQ, 2007, EUR HEART J, V28, P42, DOI 10.1093/eurheartj/ehl382; Young JB, 2003, JAMA-J AM MED ASSOC, V289, P2685, DOI 10.1001/jama.289.20.2685; Yu CM, 2006, J AM COLL CARDIOL, V48, P2251, DOI 10.1016/j.jacc.2006.07.054	65	92	98	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	2011	154	6					401	+		10.7326/0003-4819-154-6-201103150-00313	http://dx.doi.org/10.7326/0003-4819-154-6-201103150-00313			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	734WA	21320922				2023-01-03	WOS:000288370000004
J	Gouya, G; Sturm, G; Lamina, C; Zitt, E; Freistatter, O; Struck, J; Wolzt, M; Knoll, F; Lins, F; Lhotta, K; Neyer, U; Kronenberg, F				Gouya, Ghazaleh; Sturm, Gisela; Lamina, Claudia; Zitt, Emanuel; Freistaetter, Otto; Struck, Joachim; Wolzt, Michael; Knoll, Florian; Lins, Friederike; Lhotta, Karl; Neyer, Ulrich; Kronenberg, Florian			The Association of Mid-Regional Pro-Adrenomedullin and Mid-Regional Pro-Atrial Natriuretic Peptide with Mortality in an Incident Dialysis Cohort	PLOS ONE			English	Article							CHRONIC KIDNEY-DISEASE; REFLECTS CARDIAC DYSFUNCTION; HEMODIALYSIS-PATIENTS; MIDREGIONAL PROADRENOMEDULLIN; IMMUNOLUMINOMETRIC ASSAY; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATION; FOLLOW-UP; A-TYPE; MARKERS	High levels of the plasma peptides mid-regional pro-adrenomedullin (MR-proADM) and mid-regional pro-atrial natriuretic peptide (MR-proANP) are associated with clinical outcomes in the general population. Data in patients with chronic kidney disease are sparse. We therefore investigated the association of MR-proANP and MR-proADM levels with all-cause and cardiovascular (CV) mortality, CV events and peripheral arterial disease in 201 incident dialysis patients of the INVOR-Study prospectively followed for a period of up to more than 7 years. The overall mortality rate was 43%, thereof 43% due to CV events. Both baseline MR-proANP and MR-proADM were associated with higher risk of all-cause (HR = 1.44, p = 0.001 and HR = 1.32, p = 0.002, respectively) and CV mortality (HR = 1.75, p < 0.001 and HR = 1.41, p = 0.007, respectively) after adjustment for age, sex, previous CV events, diabetes mellitus and time-dependent type of renal replacement therapy. We then stratified patients in high risk (both peptides in the upper tertile), intermediate risk (only one of the two peptides in the upper tertile) and low risk (none in the upper tertile). Although demographic, clinical and laboratory variables were similar among the intermediate and high risk group, to be with both parameters in the upper tertile was associated with a 3-fold higher risk for all-cause (HR = 2.87, p < 0.001) and CV mortality (HR = 3.58, p = 0.001). In summary, among incident dialysis patients MR-proANP and MR-proADM were shown to be associated with all-cause and CV mortality, with the highest risk when both parameters were in the upper tertiles.	[Gouya, Ghazaleh; Wolzt, Michael] Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria; [Sturm, Gisela; Lamina, Claudia; Kronenberg, Florian] Innsbruck Med Univ, Dept Med Genet Mol & Clin Pharmacol, Div Genet Epidemiol, Innsbruck, Austria; [Zitt, Emanuel; Knoll, Florian; Lhotta, Karl; Neyer, Ulrich] Acad Teaching Hosp Feldkirch, Dept Nephrol & Dialysis, Feldkirch, Austria; [Freistaetter, Otto; Lins, Friederike; Lhotta, Karl; Neyer, Ulrich] VIVIT, Feldkirch, Austria; [Struck, Joachim] BRAHMS GmbH, Res Dept, Hennigsdorf, Germany	Medical University of Vienna; Medical University of Innsbruck; Thermo Fisher Scientific; Brahms AG	Gouya, G (corresponding author), Med Univ Vienna, Dept Clin Pharmacol, Vienna, Austria.	Florian.Kronenberg@i-med.ac.at	Kronenberg, Florian/B-1736-2008; Lamina, Claudia/F-7608-2010; Zitt, Emanuel/ABE-1926-2020	Kronenberg, Florian/0000-0003-2229-1120; Lamina, Claudia/0000-0002-5398-5806; Zitt, Emanuel/0000-0001-6944-6041; Wolzt, Michael/0000-0001-6049-1890; Knoll, Florian/0000-0001-5357-8656				Ala-Kopsala M, 2004, CLIN CHEM, V50, P1576, DOI 10.1373/clinchem.2004.032490; de Jager DJ, 2009, JAMA-J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488; Dieplinger B, 2009, KIDNEY INT, V75, P408, DOI 10.1038/ki.2008.560; Franz M, 2001, KIDNEY INT, V59, P1928, DOI 10.1046/j.1523-1755.2001.0590051928.x; Goto T, 2002, NEPHRON, V92, P610, DOI 10.1159/000064100; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Khan SQ, 2007, J AM COLL CARDIOL, V49, P1525, DOI 10.1016/j.jacc.2006.12.038; Kronenberg F, 1999, J AM SOC NEPHROL, V10, P1027; Kronenberg F, 2009, NAT REV NEPHROL, V5, P677, DOI 10.1038/nrneph.2009.173; Kwan BCH, 2007, J AM SOC NEPHROL, V18, P1246, DOI 10.1681/ASN.2006091006; Lewis LK, 1998, CLIN CHEM, V44, P571; Lo CS, 2009, J CELL PHYSIOL, V219, P776, DOI 10.1002/jcp.21728; Maier C, 2009, DIABETES CARE, V32, P1890, DOI 10.2337/dc08-2168; Maisel A, 2010, J AM COLL CARDIOL, V55, P2062, DOI 10.1016/j.jacc.2010.02.025; Meeran K, 1997, J CLIN ENDOCR METAB, V82, P95, DOI 10.1210/jc.82.1.95; Melander O, 2009, JAMA-J AM MED ASSOC, V302, P49, DOI 10.1001/jama.2009.943; Moertl D, 2009, J AM COLL CARDIOL, V53, P1783, DOI 10.1016/j.jacc.2009.01.057; Morgenthaler NG, 2004, CLIN CHEM, V50, P234, DOI 10.1373/clinchem.2003.021204; Morgenthaler NG, 2005, CLIN CHEM, V51, P1823, DOI 10.1373/clinchem.2005.051110; Nakatani T, 2003, BLOOD PURIFICAT, V21, P395, DOI 10.1159/000073442; Nishikimi T, 2007, CURR MED CHEM, V14, P1689, DOI 10.2174/092986707780830943; Odar-Cederlof I, 2003, ASAIO J, V49, P74, DOI 10.1097/01.MAT.0000044738.93079.F0; Pio R, 2001, J BIOL CHEM, V276, P12292, DOI 10.1074/jbc.M007822200; Rutten JHW, 2006, PERITON DIALYSIS INT, V26, P598; Schwaiger JP, 2006, KIDNEY INT, V70, P543, DOI 10.1038/sj.ki.5001589; Schwaiger JP, 2006, AM J KIDNEY DIS, V47, P888, DOI 10.1053/j.ajkd.2006.01.011; Sturm G, 2010, NEPHROL DIAL TRANSPL, V25, P2715, DOI 10.1093/ndt/gfq101; Yoshihara F, 2005, KIDNEY INT, V68, P1355, DOI 10.1111/j.1523-1755.2005.00534.x; Yoshihara F, 2007, NEPHROL DIAL TRANSPL, V22, P2263, DOI 10.1093/ndt/gfm029; Zoccali C, 2001, J AM SOC NEPHROL, V12, P1508, DOI 10.1681/ASN.V1271508	30	20	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2011	6	3							e17803	10.1371/journal.pone.0017803	http://dx.doi.org/10.1371/journal.pone.0017803			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	731IP	21408188	Green Published, Green Submitted, gold			2023-01-03	WOS:000288099800041
J	White, PD; Goldsmith, KA; Johnson, AL; Potts, L; Walwyn, R; DeCesare, JC; Baber, HL; Burgess, M; Clark, LV; Cox, DL; Bavinton, J; Angus, BJ; Murphy, G; Murphy, M; O'Dowd, H; Wilks, D; McCrone, P; Chalder, T; Sharpe, M				White, P. D.; Goldsmith, K. A.; Johnson, A. L.; Potts, L.; Walwyn, R.; DeCesare, J. C.; Baber, H. L.; Burgess, M.; Clark, L. V.; Cox, D. L.; Bavinton, J.; Angus, B. J.; Murphy, G.; Murphy, M.; O'Dowd, H.; Wilks, D.; McCrone, P.; Chalder, T.; Sharpe, M.		PACE Trial Management Grp	Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial	LANCET			English	Article							HEALTH SURVEY; SCALE; SF-36; TESTS	Background Trial findings show cognitive behaviour therapy (CBT) and graded exercise therapy (GET) can be effective treatments for chronic fatigue syndrome, but patients' organisations have reported that these treatments can be harmful and favour pacing and specialist health care. We aimed to assess effectiveness and safety of all four treatments. Methods In our parallel-group randomised trial, patients meeting Oxford criteria for chronic fatigue syndrome were recruited from six secondary-care clinics in the UK and randomly allocated by computer-generated sequence to receive specialist medical care (SMC) alone or with adaptive pacing therapy (APT), CBT, or GET Primary outcomes were fatigue (measured by Chalder fatigue questionnaire score) and physical function (measured by short form-36 subscale score) up to 52 weeks after randomisation, and safety was assessed primarily by recording all serious adverse events, including serious adverse reactions to trial treatments. Primary outcomes were rated by participants, who were necessarily unmasked to treatment assignment; the statistician was masked to treatment assignment for the analysis of primary outcomes. We used longitudinal regression models to compare SMC alone with other treatments, APT with CBT, and APT with GET The final analysis included all participants for whom we had data for primary outcomes. This trial is registered at http://isrctn.org, number ISRCTN54285094. Findings We recruited 641 eligible patients, of whom 160 were assigned to the APT group, 161 to the CBT group, 160 to the GET group, and 160 to the SMC-alone group. Compared with SMC alone, mean fatigue scores at 52 weeks were 3-4 (95% CI 1.8 to 5.0) points lower for CBT (p=0.0001) and 3.2 (1.7 to 4.8) points lower for GET (p=0.0003), but did not differ for APT (0.7 [-0.9 to 2-3] points lower; p=0.38). Compared with SMC alone, mean physical function scores were 7.1 (2.0 to 12.1) points higher for CBT (p=0.0068) and 9.4 (4.4 to 14.4) points higher for GET (p=0.0005), but did not differ for APT (3.4 [-1.6 to 8.4] points lower; p=0.18). Compared with APT, CBT and GET were associated with less fatigue (CBT p=0.0027; GET p=0.0059) and better physical function (CBT p=0.0002; GET p<0.0001). Subgroup analysis of 427 participants meeting international criteria for chronic fatigue syndrome and 329 participants meeting London criteria for myalgic encephalomyelitis yielded equivalent results. Serious adverse reactions were recorded in two (1%) of 159 participants in the APT group, three (2%) of 161 in the CBT group, two (1%) of 160 in the GET group, and two (1%) of 160 in the SMC-alone group. Interpretation CBT and GET can safely be added to SMC to moderately improve outcomes for chronic fatigue syndrome, but APT is not an effective addition.	[White, P. D.; DeCesare, J. C.; Baber, H. L.; Clark, L. V.] Queen Mary Univ London, Barts & London Sch Med, Wolfson Inst Prevent Med, London, England; [Goldsmith, K. A.; Potts, L.; Walwyn, R.] Kings Coll London, Inst Psychiat, Mental Hlth & Neurosci Clin Trials Unit, London WC2R 2LS, England; [Johnson, A. L.] Univ Cambridge, Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 1TN, England; [Johnson, A. L.] MRC, Clin Trials Unit, London, England; [Burgess, M.] S London & Maudsley NHS Fdn Trust, London, England; [Cox, D. L.] Univ Cumbria, Fac Hlth & Well Being, Lancaster, England; [Angus, B. J.] Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; [Murphy, G.] Royal Free Hosp NHS Trust, London, England; [Bavinton, J.; Murphy, M.] Baits & London NHS Trust, London, England; [O'Dowd, H.] Frenchay Hosp NHS Trust, Bristol, Avon, England; [Wilks, D.] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland; [McCrone, P.] Kings Coll London, Ctr Econ Mental Hlth Serv & Populat, London WC2R 2LS, England; [Chalder, T.] Kings Coll London, Acad Dept Psychol Med, London WC2R 2LS, England; [Sharpe, M.] Univ Edinburgh, Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland	University of London; Queen Mary University London; University of London; King's College London; MRC Biostatistics Unit; University of Cambridge; Medical Research Council Clinical Trials Unit; South London & Maudsley NHS Trust; University of Cumbria; University of Oxford; University of London; University College London; University of Edinburgh; University of London; King's College London; University of London; King's College London; University of Edinburgh	White, PD (corresponding author), St Bartholomews Hosp, London EC1A 7BE, England.	p.d.white@qmul.ac.uk	Cox, Diane/O-7326-2014; Angus, Brian/L-9246-2019; Goldsmith, Kimberley/B-9107-2011; Chalder, Trudie/A-5717-2011	Cox, Diane/0000-0003-2691-6423; Angus, Brian/0000-0003-3598-7784; Goldsmith, Kimberley/0000-0002-0620-7868; Wilks, David/0000-0001-8284-5610; Clark, Lucy/0000-0001-7162-0512; sharpe, michael/0000-0002-6474-9980; White, Peter/0000-0002-8193-5355	UK Medical Research Council [MRC G0200434]; Department of Health for England; UK Department for Work and Pensions; Chief Scientist Office of the Scottish Government Health Directorates; Department of Health; MRC [G0200434] Funding Source: UKRI; Medical Research Council [G0200434] Funding Source: researchfish	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Department of Health for England; UK Department for Work and Pensions; Chief Scientist Office of the Scottish Government Health Directorates; Department of Health; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	The PACE trial was funded by the UK Medical Research Council (MRC G0200434), the Department of Health for England, the UK Department for Work and Pensions, and the Chief Scientist Office of the Scottish Government Health Directorates, The Department of Health and the Chief Scientist Office provided excess treatment and service support costs for the trial therapists and doctors. We thank the participants who took part in the PACE trial, staff from all the centres (including all PACE research nurses or assistants: Susan Begg, Matteo Cella, Sally Cregeen, Sarah Home, Chris James, Julie Richards, Joanna Smee, and Vicky Toghill; data managers: Victoria Bates, Ann M Doust, Emma Hartley, Kate Lievesley, Sandy Smith, and Olga Zielona; therapists: Mary Barker, Jen Bobrow, Laura Butler, Nathan Butler, Richard-John Chippindall, Ruth Cowlishaw, Vincent Deary, Caroline J Heading, Lindsey Hume, Vicky Johnson, Sally Ludlam, Lorraine Maher-Edwards, Louise Mason, Christina Michailidou, Stacey Millet-Clay, Karen Shute, CM Simpson, Sheena E Spence, Valerie Suarez, Brendan Thomas, Tracey Turner, Rebecca Van Klinken, S M Wagner, Sue Wilkins, Giselle Withers, Fiona Wright, and Daniel Zahl; and specialist medical care doctors: Janet Andrews, Michael Broughton, Frauke Fehse, Eleanor Feldman, Janet Gray, Michael E. Jones, Tara Lawn, Brian Marien, Tim Peto, Angharad Ruttley, Alastair Santhouse, Adrian Vos, and Simon Wessely. Kathy Fulcher, Tom Meade, C L Murphy, Anthony J Pinching, and Rajesh Shah contributed and provided advice about the study, and Kurt Kroenke, Jan Scott, Peter Tyrer, and Simon Wessely commented on an early draft of the report.	Action for ME, PAC PEOPL ME; Action for ME, 2008, ME 2008 WHAT PROGR A; [Anonymous], 1994, REP CHRON FAT SYNDR; Bagnall A-M, 22 CRD; Bowling A, 1999, J PUBLIC HEALTH MED, V21, P255, DOI 10.1093/pubmed/21.3.255; BUTLAND RJA, 1982, BRIT MED J, V284, P1607, DOI 10.1136/bmj.284.6329.1607; Cairns R, 2005, OCCUP MED-OXFORD, V55, P20, DOI 10.1093/occmed/kqi013; Cella M, 2010, J PSYCHOSOM RES, V69, P17, DOI 10.1016/j.jpsychores.2009.10.007; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Cox DL, 2009, LEARN HLTH SOC CARE, V8, P301; Deale A, 1997, AM J PSYCHIAT, V154, P408; Edmonds M, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD003200.PUB2; Fulcher KY, 1997, BRIT MED J, V314, P1647, DOI 10.1136/bmj.314.7095.1647; Guy W., 1976, ASSESSMENT MANUAL PS, P217; Guyatt GH, 2002, MAYO CLIN PROC, V77, P371, DOI 10.4065/77.4.371; Heins MJ, 2010, PSYCHOTHER PSYCHOSOM, V79, P249, DOI 10.1159/000315130; Jason LA, 2000, J HUMAN BEHAV SOCIAL, V3, P59; Jason LA, 2007, J CLIN PSYCHOL MED S, V14, P275, DOI 10.1007/s10880-007-9090-7; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Malouff JA, 2008, CLIN PSYCHOL REV, V28, P736, DOI 10.1016/j.cpr.2007.10.004; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; ME Association, MAN MY ME WHAT PEOPL; Mitchell E, 2008, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858; Moss-Morris R, 2005, J HEALTH PSYCHOL, V10, P245, DOI 10.1177/1359105305049774; Mundt JC, 2002, BRIT J PSYCHIAT, V180, P461, DOI 10.1192/bjp.180.5.461; National Institute for Health and Clinical Excellence, CG53 NIH CLIN EXC; Prins JB, 2006, LANCET, V367, P346, DOI 10.1016/S0140-6736(06)68073-2; Prins JB, 2001, LANCET, V357, P841, DOI 10.1016/S0140-6736(00)04198-2; Reeves WC, 2003, BMC HEALTH SERV RES, V3, DOI 10.1186/1472-6963-3-25; Senn S, 2009, STAT MED, V28, P3189, DOI 10.1002/sim.3603; Sharpe M, 1996, BRIT MED J, V312, P22, DOI 10.1136/bmj.312.7022.22; SHARPE MC, 1991, J ROY SOC MED, V84, P118, DOI 10.1177/014107689108400224; Wearden AJ, 1998, BRIT J PSYCHIAT, V172, P485, DOI 10.1192/bjp.172.6.485; Wearden AJ, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1777; White PD, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-6; Williams J.B.W., 2002, STRUCTURED CLIN INTE; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	37	555	561	2	162	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 5	2011	377	9768					823	836		10.1016/S0140-6736(11)60096-2	http://dx.doi.org/10.1016/S0140-6736(11)60096-2			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	738GO	21334061	Green Accepted, Green Published			2023-01-03	WOS:000288628500030
J	Castillo-Trivino, T; Mowry, EM; Gajofatto, A; Chabas, D; Crabtree-Hartman, E; Cree, BA; Goodin, DS; Green, AJ; Okuda, DT; Pelletier, D; Zamvil, SS; Vittinghoff, E; Waubant, E				Castillo-Trivino, Tamara; Mowry, Ellen M.; Gajofatto, Alberto; Chabas, Dorothee; Crabtree-Hartman, Elizabeth; Cree, Bruce A.; Goodin, Douglas S.; Green, Ari J.; Okuda, Darin T.; Pelletier, Daniel; Zamvil, Scott S.; Vittinghoff, Eric; Waubant, Emmanuelle			Switching Multiple Sclerosis Patients with Breakthrough Disease to Second-Line Therapy	PLOS ONE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLUS INTERFERON BETA-1A; COMBINATION THERAPY; NATALIZUMAB; MITOXANTRONE; TRIAL; CYCLOPHOSPHAMIDE; MULTICENTER; MS	Background: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with breakthrough disease is unknown. Methods: This is an open-label retrospective cohort study of 993 patients seen at least four times at the University of California San Francisco MS Center, 95 had breakthrough disease on first-line therapy (60 patients switched to natalizumab, 22 to immunosuppressants and 13 declined the switch [non-switchers]). We used Poisson regression adjusted for potential confounders to compare the relapse rate within and across groups before and after the switch. Results: In the within-group analyses, the relapse rate decreased by 70% (95% CI 50,82%; p < 0.001) in switchers to natalizumab and by 77% (95% CI 59,87%; p < 0.001) in switchers to immunosuppressants; relapse rate in non-switchers did not decrease (6%, p = 0.87). Relative to the reduction among non-switchers, the relapse rate was reduced by 68% among natalizumab switchers (95% CI 19,87%; p = 0.017) and by 76% among the immunosuppressant switchers (95% CI 36,91%; p = 0.004). Conclusions: Switching to natalizumab or immunosuppressants in patients with breakthrough disease is effective in reducing clinical activity of relapsing MS. The magnitude of the effect and the risk-benefit ratio should be evaluated in randomized clinical trials and prospective cohort studies.	[Castillo-Trivino, Tamara; Mowry, Ellen M.; Chabas, Dorothee; Crabtree-Hartman, Elizabeth; Cree, Bruce A.; Goodin, Douglas S.; Green, Ari J.; Okuda, Darin T.; Pelletier, Daniel; Zamvil, Scott S.; Waubant, Emmanuelle] Univ Calif San Francisco, Multiple Sclerosis Ctr, Dept Neurol, San Francisco, CA 94143 USA; [Castillo-Trivino, Tamara] Hosp Donostia, Dept Neurol, Multiple Sclerosis Unit, San Sebastian, Spain; [Gajofatto, Alberto] Univ Verona, Dept Neurol & Vision Sci, I-37100 Verona, Italy; [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University Hospital Donostia; University of Verona; University of California System; University of California San Francisco	Castillo-Trivino, T (corresponding author), Univ Calif San Francisco, Multiple Sclerosis Ctr, Dept Neurol, San Francisco, CA 94143 USA.	emmanuelle.waubant@ucsf.edu	Castillo, Tamara/ABH-4121-2020; Castillo, Tamara/GYQ-5428-2022; Cree, Bruce C/AAV-6109-2020	Cree, Bruce C/0000-0001-7689-2533; Gajofatto, Alberto/0000-0001-6539-0458; Mowry, Ellen/0000-0003-0623-5188; Castillo-Trivino, Tamara/0000-0002-9249-3185; Okuda, Darin/0000-0002-6499-1523	Partners MS Center; Foundation ILUNDAIN Fundazioa	Partners MS Center; Foundation ILUNDAIN Fundazioa	This study was supported by a Clinical Research Fellowship Award from the Partners MS Center and by the Foundation ILUNDAIN Fundazioa. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Caon C, 2006, EUR J NEUROL, V13, P471, DOI 10.1111/j.1468-1331.2006.01273.x; Carra A, 2008, EUR J NEUROL, V15, P386, DOI 10.1111/j.1468-1331.2008.02071.x; Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4; Conway D, 2010, LANCET NEUROL, V9, P299, DOI 10.1016/S1474-4422(10)70007-7; Ellis R, 2009, MULT SCLER J, V15, P505, DOI 10.1177/1352458508100967; *FOOD DRUG ADM, NAT INF MARK TYS; Gajofatto A, 2009, MULT SCLER J, V15, P50, DOI 10.1177/1352458508096687; Ghalie RG, 2002, NEUROLOGY, V59, P909, DOI 10.1212/WNL.59.6.909; Hartung HP, 2002, LANCET, V360, P2018, DOI 10.1016/S0140-6736(02)12023-X; KAUFMAN MD, 2010, MULT SCLER      1206; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Polman CH, 2006, NEW ENGL J MED, V354, P899, DOI 10.1056/NEJMoa044397; Putzki N, 2010, EUR J NEUROL, V17, P31, DOI 10.1111/j.1468-1331.2009.02728.x; RADIS CD, 1995, ARTHRITIS RHEUM, V38, P1120, DOI 10.1002/art.1780380815; Radue EW, 2010, J NEUROL SCI, V292, P28, DOI 10.1016/j.jns.2010.02.012; Rudick RA, 2006, NEW ENGL J MED, V354, P911, DOI 10.1056/NEJMoa044396; Rudick RA, 2009, LANCET NEUROL, V8, P545, DOI 10.1016/S1474-4422(09)70082-1; Smith DR, 2005, MULT SCLER J, V11, P573, DOI 10.1191/1352458505ms1210oa; Waubant E, 2003, NEUROLOGY, V61, P184, DOI 10.1212/01.WNL.0000078888.07196.0B; West TW, 2010, ANN NEUROL, V68, P395, DOI 10.1002/ana.22163	21	41	41	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 3	2011	6	2							e16664	10.1371/journal.pone.0016664	http://dx.doi.org/10.1371/journal.pone.0016664			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	717IJ	21304907	Green Submitted, Green Published, gold			2023-01-03	WOS:000287036600013
J	Hibbert, B; Ma, XL; Pourdjabbar, A; Simard, T; Rayner, K; Sun, JF; Chen, YX; Filion, L; O'Brien, ER				Hibbert, Benjamin; Ma, Xiaoli; Pourdjabbar, Ali; Simard, Trevor; Rayner, Katey; Sun, Jiangfeng; Chen, Yong-Xiang; Filion, Lionel; O'Brien, Edward R.			Pre-Procedural Atorvastatin Mobilizes Endothelial Progenitor Cells: Clues to the Salutary Effects of Statins on Healing of Stented Human Arteries	PLOS ONE			English	Article							PERCUTANEOUS CORONARY INTERVENTION; RE-ENDOTHELIALIZATION; INCREASE; THERAPY; DISEASE; NUMBER; NEOVASCULARIZATION; OUTCOMES; REPAIR	Objectives: Recent clinical trials suggest an LDL-independent superiority of intensive statin therapy in reducing target vessel revascularization and peri-procedural myocardial infarctions in patients who undergo percutaneous coronary interventions (PCI). While animal studies demonstrate that statins mobilize endothelial progenitor cells (EPCs) which can enhance arterial repair and attenuate neointimal formation, the precise explanation for the clinical PCI benefits of high dose statin therapy remain elusive. Thus we serially assessed patients undergoing PCI to test the hypothesis that high dose Atorvastatin therapy initiated prior to PCI mobilizes EPCs that may be capable of enhancing arterial repair. Methods and Results: Statin naive male patients undergoing angiography for stent placement were randomized to standard therapy without Atorvastatin (n = 10) or treatment with Atorvastatin 80 mg (n = 10) beginning three days prior to stent implantation. EPCs were defined by flow cytometry (e.g., surface marker profile of CD45dim/34+/133+/117+). As well, we also enumerated cultured angiogenic cells (CACs) by standard in vitro culture assay. While EPC levels did not fluctuate over time for the patients free of Atorvastatin, there was a 3.5-fold increase in EPC levels with high dose Atorvastatin beginning within 3 days of the first dose (and immediately pre-PCI) which persisted at 4 and 24 hours post-PCI (p < 0.05). There was a similar rise in CAC levels as assessed by in vitro culture. CACs cultured in the presence of Atorvastatin failed to show augmented survival or VEGF secretion but displayed a 2-fold increase in adhesion to stent struts (p < 0.05). Conclusions: High dose Atorvastatin therapy pre-PCI improves EPC number and CAC number and function in humans which may in part explain the benefit in clinical outcomes seen in patients undergoing coronary interventions.	[Hibbert, Benjamin; Ma, Xiaoli; Pourdjabbar, Ali; Simard, Trevor; Rayner, Katey; Sun, Jiangfeng; Chen, Yong-Xiang; O'Brien, Edward R.] Univ Ottawa, Inst Heart, Ottawa, ON, Canada; [Filion, Lionel] Univ Ottawa, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON, Canada	University of Ottawa; University of Ottawa Heart Institute; University of Ottawa	Hibbert, B (corresponding author), Univ Ottawa, Inst Heart, Ottawa, ON, Canada.	eobrien@ottawaheart.ca	O'Brien, Edward R/J-6621-2013; Rayner, Katey/K-8914-2012	O'Brien, Edward R/0000-0003-1039-9425; Rayner, Katey/0000-0001-6230-426X	Pfizer Canada; University of Ottawa Heart Institute Interventional Cardiology Group	Pfizer Canada(Pfizer); University of Ottawa Heart Institute Interventional Cardiology Group	This work was supported by grants from Pfizer Canada and The University of Ottawa Heart Institute Interventional Cardiology Group. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; Banerjee S, 2006, ATHEROSCLEROSIS, V189, P70, DOI 10.1016/j.atherosclerosis.2006.04.026; Bearzi C, 2009, P NATL ACAD SCI USA, V106, P15885, DOI 10.1073/pnas.0907622106; Di Sciascio G, 2009, J AM COLL CARDIOL, V54, P558, DOI 10.1016/j.jacc.2009.05.028; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Egan CG, 2009, THROMB HAEMOSTASIS, V101, P1138, DOI 10.1160/TH08-11-0723; Fadini GP, 2008, ATHEROSCLEROSIS, V197, P496, DOI 10.1016/j.atherosclerosis.2007.12.039; Fellstrom BC, 2009, NEW ENGL J MED, V360, P1395, DOI 10.1056/NEJMoa0810177; George J, 2003, ARTERIOSCL THROM VAS, V23, pE57, DOI 10.1161/01.ATV.0000107029.65274.db; Gibson CM, 2009, J AM COLL CARDIOL, V54, P2290, DOI 10.1016/j.jacc.2009.09.010; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hibbert B, 2004, AM J PHYSIOL-HEART C, V287, pH518, DOI 10.1152/ajpheart.00002.2004; Hibbert B, 2003, TRENDS CARDIOVAS MED, V13, P322, DOI 10.1016/j.tcm.2003.09.002; Hibbert B, 2009, CARDIOVASC RES, V83, P16, DOI 10.1093/cvr/cvp156; Hill JM, 2003, NEW ENGL J MED, V348, P593, DOI 10.1056/NEJMoa022287; Hirschi KK, 2008, ARTERIOSCL THROM VAS, V28, P1584, DOI 10.1161/ATVBAHA.107.155960; Hristov M, 2007, ATHEROSCLEROSIS, V192, P413, DOI 10.1016/j.atherosclerosis.2006.05.031; Inoue T, 2007, CIRCULATION, V115, P553, DOI 10.1161/CIRCULATIONAHA.106.621714; Kong DL, 2004, CIRCULATION, V110, P2039, DOI 10.1161/01.CIR.0000143161.01901.BD; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; Ma XL, 2010, CARDIOVASC RES, V86, P338, DOI 10.1093/cvr/cvq047; Ma XL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001894; Mauri L, 2007, NEW ENGL J MED, V356, P1020, DOI 10.1056/NEJMoa067731; Mills NL, 2009, HEART, V95, P2003, DOI 10.1136/hrt.2008.163162; Padfield GJ, 2010, J AM COLL CARDIOL, V55, P1553, DOI 10.1016/j.jacc.2009.10.070; Pasceri V, 2004, CIRCULATION, V110, P674, DOI 10.1161/01.CIR.0000137828.06205.87; Patti G, 2007, J AM COLL CARDIOL, V49, P1272, DOI 10.1016/j.jacc.2007.02.025; Schmidt-Lucke C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013790; Schroeter MR, 2009, ATHEROSCLEROSIS, V205, P63, DOI 10.1016/j.atherosclerosis.2008.11.013; Strehlow K, 2003, CIRCULATION, V107, P3059, DOI 10.1161/01.CIR.0000077911.81151.30; Sutherland D R, 1996, J Hematother, V5, P213, DOI 10.1089/scd.1.1996.5.213; Timmermans F, 2007, ARTERIOSCL THROM VAS, V27, P1572, DOI 10.1161/ATVBAHA.107.144972; Vasa M, 2001, CIRC RES, V89, pE1, DOI 10.1161/hh1301.093953; Vasa M, 2001, CIRCULATION, V103, P2885, DOI 10.1161/hc2401.092816; Walter DH, 2002, CIRCULATION, V105, P3017, DOI 10.1161/01.CIR.0000018166.84319.55; Wang CH, 2006, J MOL CELL CARDIOL, V41, P34, DOI 10.1016/j.yjmcc.2006.03.006; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Werner C, 2007, DIABETES, V56, P2609, DOI 10.2337/db07-0069; Zampetaki A, 2008, CARDIOVASC RES, V78, P413, DOI 10.1093/cvr/cvn081; Zentilin L, 2006, BLOOD, V107, P3546, DOI 10.1182/blood-2005-08-3215	40	38	40	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 25	2011	6	1							e16413	10.1371/journal.pone.0016413	http://dx.doi.org/10.1371/journal.pone.0016413			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	712IZ	21283543	Green Published, Green Submitted, gold			2023-01-03	WOS:000286661400048
J	Brittenham, GM				Brittenham, Gary M.			Iron-Chelating Therapy for Transfusional Iron Overload	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THALASSEMIA MAJOR; MYELODYSPLASTIC SYNDROMES; DEPENDENT THALASSEMIA; DEFERASIROX ICL670; DEFEROXAMINE; SICKLE; DESFERRIOXAMINE; GUIDELINES; HEMOCHROMATOSIS; METABOLISM	A 16-year-old boy with sickle cell anemia undergoes routine screening with transcranial Doppler ultrasonography to assess the risk of stroke. This examination shows an abnormally elevated blood-flow velocity in the middle cerebral artery. The hemoglobin level is 7.2 g per deciliter, the reticulocyte count is 12.5%, and the fetal hemoglobin level is 8.0%. Long-term treatment with red-cell transfusion is initiated to prevent stroke. A hematologist recommends prophylactic iron-chelating therapy.	[Brittenham, Gary M.] Columbia Univ Coll Phys & Surg, Dept Pediat, Div Pediat Hematol, New York, NY 10032 USA	Columbia University	Brittenham, GM (corresponding author), Columbia Univ, Med Ctr, Dept Pediat, Div Pediat Hematol, Rm CHN 10-08,3959 Broadway, New York, NY 10032 USA.	gmb31@columbia.edu	Noce, Annalisa/B-5558-2019		St. Giles Foundation; Food and Drug Administration [R01 FD003702]; National Institutes of Health [R37 DK049108, R01 DK066251]; FOOD AND DRUG ADMINISTRATION [R01FD003702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK049108, R01DK066251] Funding Source: NIH RePORTER	St. Giles Foundation; Food and Drug Administration(United States Department of Health & Human Services); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOOD AND DRUG ADMINISTRATION(United States Department of Health & Human Services); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by grants from the St. Giles Foundation, the Food and Drug Administration (R01 FD003702), and the National Institutes of Health (R37 DK049108; R01 DK066251).	Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Aessopos A., 2008, GUIDELINES CLIN MANA, P33; Anderson LJ, 2004, BRIT J HAEMATOL, V127, P348, DOI 10.1111/j.1365-2141.2004.05202.x; Angelucci E, 2008, HAEMATOLOGICA, V93, P741, DOI 10.3324/haematol.12413; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; Beau-Salinas F, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a2319; Bennett JM, 2008, AM J HEMATOL, V83, P858, DOI 10.1002/ajh.21269; Borgna-Pignatti C, 2006, BLOOD, V107, P3733, DOI 10.1182/blood-2005-07-2933; Borgna-Pignatti C, 2004, HAEMATOLOGICA, V89, P1187; Borgna-Pignatti C, 2004, BRIT J HAEMATOL, V124, P114, DOI 10.1046/j.1365-2141.2003.04732.x; Breuer W, 2000, TRANSFUS SCI, V23, P185, DOI 10.1016/S0955-3886(00)00087-4; Cappellini MD, 2010, HAEMATOL-HEMATOL J, V95, P557, DOI 10.3324/haematol.2009.014696; Cappellini MD, 2006, BLOOD, V107, P3455, DOI 10.1182/blood-2005-08-3430; Chan YL, 2002, PEDIATR RADIOL, V32, P492, DOI 10.1007/s00247-002-0664-0; Claster S, 2009, AM J HEMATOL, V84, P344, DOI 10.1002/ajh.21416; COHEN A, 1990, J PEDIATR-US, V117, P326, DOI 10.1016/S0022-3476(05)80556-6; Cohen AR, COMPASSIONATE USE DE; Darbari DS, 2006, AM J HEMATOL, V81, P858, DOI 10.1002/ajh.20685; Davis BA, 2000, BLOOD, V95, P1229, DOI 10.1182/blood.V95.4.1229.004k32_1229_1236; De Domenico I, 2009, BLOOD, V114, P4546, DOI 10.1182/blood-2009-05-224188; De Sanctis V, 2006, J PEDIATR ENDOCR MET, V19, P471; Delea TE, 2007, TRANSFUSION, V47, P1919, DOI 10.1111/j.1537-2995.2007.01416.x; Delea TE, 2007, PHARMACOECONOMICS, V25, P329, DOI 10.2165/00019053-200725040-00005; Division of Blood Diseases and Resources NHLBI, 2002, MAN SICKL CELL DIS; European Medicines Agency, 2009, FERR DEF SUMM PROD C, P14; FILLET G, 1989, BLOOD, V74, P844; FINCH CA, 1982, ARCH INTERN MED, V142, P279, DOI 10.1001/archinte.142.2.279; Gattermann N, 2008, INT J HEMATOL, V88, P24, DOI 10.1007/s12185-008-0118-z; Jensen PD, 1996, BRIT J HAEMATOL, V94, P288, DOI 10.1046/j.1365-2141.1996.d01-1795.x; Ko C, 2007, LIVER INT, V27, P1394, DOI 10.1111/j.1478-3231.2007.01596.x; Leitch HA, 2010, BLOOD REV       1026; Marsh JCW, 2009, BRIT J HAEMATOL, V147, P43, DOI 10.1111/j.1365-2141.2009.07842.x; MODELL B, 1982, BRIT MED J, V284, P1081, DOI 10.1136/bmj.284.6322.1081; Novartis Pharmaceuticals, 2010, DESF DEF MES PRESCR; Novartis Pharmaceuticals, MYEL PLAST SYNDR MDS; Novartis Pharmaceuticals, 2010, EXJ DEF PRESCR INF; Olivieri, 1997, BLOOD, V89, P2621; Olivieri NF, 1997, BLOOD, V89, P739, DOI 10.1182/blood.V89.3.739; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; Piga A, 2006, HAEMATOL-HEMATOL J, V91, P873; Porter J, 2008, EUR J HAEMATOL, V80, P168, DOI 10.1111/j.1600-0609.2007.00985.x; Roberts D., 2007, COCHRANE DB SYST REV, V3; Sickle Cell Society, 2008, STANDARDS CLIN CARE; Vichinsky E, 2005, AM J HEMATOL, V80, P70, DOI 10.1002/ajh.20402; Vichinsky E, 2007, BRIT J HAEMATOL, V136, P501, DOI 10.1111/j.1365-2141.2006.06455.x; Vichinsky EP, 2005, PEDIATRICS, V116, pE818, DOI 10.1542/peds.2005-0843; Vlachos A, 2008, BRIT J HAEMATOL, V142, P859, DOI 10.1111/j.1365-2141.2008.07269.x; Waldmeier F, 2010, DRUG METAB DISPOS, V38, P808, DOI 10.1124/dmd.109.030833; Walter PB, 2006, BRIT J HAEMATOL, V135, P254, DOI 10.1111/j.1365-2141.2006.06277.x; Weatherall DJ, 2010, BLOOD, V115, P4331, DOI 10.1182/blood-2010-01-251348; Weatherall DJ., 2001, THALASSAEMIA SYNDROM, V4th ed	51	228	236	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	2011	364	2					146	156		10.1056/NEJMct1004810	http://dx.doi.org/10.1056/NEJMct1004810			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	705NJ	21226580	Green Accepted			2023-01-03	WOS:000286142900008
J	Penfold, S; Hill, Z; Mrisho, M; Manzi, F; Tanner, M; Mshinda, H; Schellenberg, D; Schellenberg, JRMA				Penfold, Suzanne; Hill, Zelee; Mrisho, Mwifadhi; Manzi, Fatuma; Tanner, Marcel; Mshinda, Hassan; Schellenberg, David; Schellenberg, Joanna R. M. Armstrong			A Large Cross-Sectional Community-Based Study of Newborn Care Practices in Southern Tanzania	PLOS ONE			English	Article							NEONATAL-MORTALITY; RURAL GHANA; SURVIVAL; TRANSMISSION; INITIATION; INFECTION; PROGRAM; NEPAL; RISK	Despite recent improvements in child survival in sub-Saharan Africa, neonatal mortality rates remain largely unchanged. This study aimed to determine the frequency of delivery and newborn-care practices in southern Tanzania, where neonatal mortality is higher than the national average. All households in five districts of Southern Tanzania were approached to participate. Of 213,220 female residents aged 13-49 years, 92% participated. Cross-sectional, retrospective data on childbirth and newborn care practices were collected from 22,243 female respondents who had delivered a live baby in the preceding year. Health facility deliveries accounted for 41% of births, with nearly all non-facility deliveries occurring at home (57% of deliveries). Skilled attendants assisted 40% of births. Over half of women reported drying the baby and over a third reported wrapping the baby within 5 minutes of delivery. The majority of mothers delivering at home reported that they had made preparations for delivery, including buying soap (84%) and preparing a cloth for drying the child (85%). Although 95% of these women reported that the cord was cut with a clean razor blade, only half reported that it was tied with a clean thread. Furthermore, out of all respondents 10% reported that their baby was dipped in cold water immediately after delivery, around two-thirds reported bathing their babies within 6 hours of delivery, and 28% reported putting something on the cord to help it dry. Skin-to-skin contact between mother and baby after delivery was rarely practiced. Although 83% of women breastfed within 24 hours of delivery, only 18% did so within an hour. Fewer than half of women exclusively breastfed in the three days after delivery. The findings suggest a need to promote and facilitate health facility deliveries, hygienic delivery practices for home births, delayed bathing and immediate and exclusive breastfeeding in Southern Tanzania to improve newborn health.	[Penfold, Suzanne; Schellenberg, David; Schellenberg, Joanna R. M. Armstrong] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England; [Hill, Zelee] UCL, Inst Child Hlth, London, England; [Mrisho, Mwifadhi; Manzi, Fatuma] Ifakara Hlth Inst, Dar Es Salaam, Tanzania; [Tanner, Marcel] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Tanner, Marcel] Univ Basel, Basel, Switzerland; [Mshinda, Hassan] COSTECH, Dar Es Salaam, Tanzania	University of London; London School of Hygiene & Tropical Medicine; University of London; University College London; Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Penfold, S (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1, England.	Suzanne.penfold@lshtm.ac.uk		Schellenberg, Joanna/0000-0002-0708-3676; Schellenberg, David/0000-0001-8222-0186	Bill and Melinda Gates Foundation through the Intermittent Preventative Treatment in Infants (IPTi) consortium; Saving Newborn Lives program of Save the Children [NCT00152204]	Bill and Melinda Gates Foundation through the Intermittent Preventative Treatment in Infants (IPTi) consortium; Saving Newborn Lives program of Save the Children	The study was funded by the Bill and Melinda Gates Foundation through the Intermittent Preventative Treatment in Infants (IPTi) consortium (www.ipti-malaria.org) and the Saving Newborn Lives program of Save the Children (www.savethechildren.org/programs/health/saving-newborn-lives/), clinical trial number NCT00152204. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], TECHN WORK GROUP M N; [Anonymous], 2005, POVERTY HUMAN DEV RE; Baqui AH, 2008, B WORLD HEALTH ORGAN, V86, P796, DOI 10.2471/BLT.07.042226; Black RE, 2010, LANCET, V375, P1969, DOI 10.1016/S0140-6736(10)60549-1; Coovadia HM, 2007, LANCET, V369, P1107, DOI 10.1016/S0140-6736(07)60283-9; Darmstadt GL, 2006, J HEALTH POPUL NUTR, V24, P380; Edmond KM, 2007, AM J CLIN NUTR, V86, P1126, DOI 10.1093/ajcn/86.4.1126; Edmond KM, 2006, PEDIATRICS, V117, pE380, DOI 10.1542/peds.2005-1496; Hill Z., 2009, REPORT FORMATIVE RES; Hill Z, 2010, PEDIATR INFECT DIS J, V29, P1004, DOI 10.1097/INF.0b013e3181f5ddb1; Hill Z, 2010, TROP MED INT HEALTH, V15, P1118, DOI 10.1111/j.1365-3156.2010.02593.x; Iliff PJ, 2005, AIDS, V19, P699, DOI 10.1097/01.aids.0000166093.16446.c9; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE, INT J EPIDEMIOL S1, V39, pi144; Manji K., 2009, SITUATION ANAL NEWBO; Masanja H, 2008, LANCET, V371, P1276, DOI 10.1016/S0140-6736(08)60562-0; Mbuyita S, 2008, NEONATAL CARE PRACTI; Mrisho M, 2008, T ROY SOC TROP MED H, V102, P669, DOI 10.1016/j.trstmh.2008.04.029; NBS, TANZ DEM HLTH SURV 2; Osrin D, 2002, BMJ-BRIT MED J, V325, P1063, DOI 10.1136/bmj.325.7372.1063; Rhee V, 2008, ARCH PEDIAT ADOL MED, V162, P603, DOI 10.1001/archpedi.162.7.603; Schellenberg JRA, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-194; Shirima K, 2007, EMERG THEMES EPIDEMI, V4, DOI 10.1186/1742-7622-4-5; *STAT CORP LP, 2007, STAT STAT SOFTW REL; Syed U, 2008, J PERINATOL, V28, pS9, DOI 10.1038/jp.2008.165; Tawiah-Agyemang C, 2008, J PERINATOL, V28, pS46, DOI 10.1038/jp.2008.173; Waiswa P, BMC PREGNANCY CHILDB, V10, P9; White E, 2008, PRINCIPLES EXPOSURE; World Health Organization, 1994, ESS NEWB CAR REP TEC	29	43	43	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 21	2010	5	12							e15593	10.1371/journal.pone.0015593	http://dx.doi.org/10.1371/journal.pone.0015593			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	698EY	21203574	Green Published, Green Accepted, Green Submitted, gold			2023-01-03	WOS:000285576900033
J	Sury, M; Bullock, I; Rabar, S; DeMott, K				Sury, Mike; Bullock, Ian; Rabar, Silvia; DeMott, Kathleen			Guidelines Sedation for diagnostic and therapeutic procedures in children and young people: summary of NICE guidance	BRITISH MEDICAL JOURNAL			English	Editorial Material									[Sury, Mike] Great Ormond St Hosp Childrens NHS Trust, London WC1N 3JH, England; [Sury, Mike] UCL, Inst Child Hlth, PORTEX Unit Paediat Anaesthesia, London WC1N 1EH, England; [Bullock, Ian; Rabar, Silvia; DeMott, Kathleen] Royal Coll Physicians, Natl Clin Guideline Ctr, London NW1 4LE, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Royal College of Physicians	Sury, M (corresponding author), Great Ormond St Hosp Childrens NHS Trust, London WC1N 3JH, England.	surym@gosh.nhs.uk						British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2011, BRIT NAT FORM CHILDR; National Institute for Health and Clinical Excellence, 2010, CLIN GUID, V112; Saklad M., 1941, ANESTHESIOLOGY, V2, P281, DOI [10.1097/00000542-194105000-00004, DOI 10.1097/00000542-194105000-00004]	3	35	38	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BRIT MED J	Br. Med. J.	DEC 16	2010	341								c6819	10.1136/bmj.c6819	http://dx.doi.org/10.1136/bmj.c6819			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	697XM	21163835				2023-01-03	WOS:000285553100008
J	Craig, M; Pennacchia, A; Wright, NR; Chase, HW; Hogarth, L				Craig, Martin; Pennacchia, Antonio; Wright, Neil R.; Chase, Henry W.; Hogarth, Lee			Evaluation of Un-Medicated, Self-Paced Alcohol Withdrawal	PLOS ONE			English	Article							ETHANOL	It is currently unclear how effective un-medicated, self-paced alcohol withdrawal is in reducing alcohol consumption in alcohol dependent clients. To address this question, the current study examined the reduction in alcohol consumption, assessed by breath alcohol and drink diary self-report, of 405 alcohol-dependent clients over a 10-day, un-medicated, self-paced alcohol reduction program that included group discussion of strategies for titrating between withdrawal and intoxication. It was found that attendance at treatment sessions was associated with a reduction in alcohol consumption, reflected in both breath alcohol and diary measures, and these two measures were significantly correlated. Overall, 35% of clients achieved a zero breath alcohol reading by their final session, although this percentage increased to 56% of clients who attended all 10 sessions. Withdrawal seizures occurred in only 0.5% of clients despite 17.2% having a history of seizures in other settings. It is concluded that the alcohol reduction protocol outlined here provides an effective and safe method for reducing alcohol consumption in severely alcohol dependent clients, and that methods for augmenting attendance, such as contingency management, should enhance the effectiveness of this treatment.	[Craig, Martin; Wright, Neil R.] Nottingham Substance Misuse Serv, Nottingham, England; [Pennacchia, Antonio] NHS, Mental Hlth Grp, Nottingham, England; [Pennacchia, Antonio] NHS, Learning Disabil Grp, Nottingham, England; [Pennacchia, Antonio] NHS, Marginalised Grp, Nottingham, England; [Chase, Henry W.] Univ Pittsburgh, Western Psychiat Inst & Clin, Dept Psychiat, Sch Med, Pittsburgh, PA 15213 USA; [Hogarth, Lee] Univ Nottingham, Sch Psychol, Nottingham NG7 2RD, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; University of Nottingham	Craig, M (corresponding author), Nottingham Substance Misuse Serv, Nottingham, England.	Lee.Hogarth@nottingham.ac.uk	Hogarth, Lee/J-7823-2019	Hogarth, Lee/0000-0002-0299-5748	MRC at the University of Nottingham [G0701456]; Nottinghamshire Healthcare NHS Trust; Medical Research Council [G0701456] Funding Source: researchfish; MRC [G0701456] Funding Source: UKRI	MRC at the University of Nottingham(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Nottinghamshire Healthcare NHS Trust; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The academic contribution of LH and HWC was supported by an MRC (http://www.mrc.ac.uk/Fundingopportunities/Grants/index.htm) grant (# G0701456) held by LH at the University of Nottingham. The treatment protocols run by MC and AP were funded by the Nottinghamshire Healthcare NHS Trust (http://www.nottinghamshirehealthcare.nhs.uk/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamson SJ, 2009, J SUBST ABUSE TREAT, V36, P75, DOI 10.1016/j.jsat.2008.05.007; Campbell JM, 2010, ADDICT BEHAV, V35, P73, DOI 10.1016/j.addbeh.2009.09.013; CANTER FM, 1968, PSYCHIAT QUART, V42, P217, DOI 10.1007/BF01563474; COOPER A, 2003, DRUG ALCOHOL PROFESS, V3; FAILLACE LA, 1972, Q J STUD ALCOHOL, V33, P85; FUNDERBURK FR, 1978, J NERV MENT DIS, V166, P195, DOI 10.1097/00005053-197803000-00005; Garner BR, 2009, J SUBST ABUSE TREAT, V36, P376, DOI 10.1016/j.jsat.2008.08.004; Heather N., 1997, PROBLEM DRINKING; Prendergast M, 2006, ADDICTION, V101, P1546, DOI 10.1111/j.1360-0443.2006.01581.x; Stephens DN, 2005, BIOL PSYCHIAT, V58, P392, DOI 10.1016/j.biopsych.2005.04.025; STOCKWELL T, 1979, BRIT J ADDICT, V74, P79; Wright NR, 2002, ALCOHOL ALCOHOLISM, V37, P344, DOI 10.1093/alcalc/37.4.344	12	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2011	6	7							e22994	10.1371/journal.pone.0022994	http://dx.doi.org/10.1371/journal.pone.0022994			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	799KC	21829573	Green Published, Green Accepted, gold			2023-01-03	WOS:000293284600069
J	Chiu, SS; Chan, KH; Wong, WHS; Chan, ELY; Peiris, JSM				Chiu, Susan S.; Chan, Kwok-Hung; Wong, Wilfred H. S.; Chan, Eunice L. Y.; Peiris, J. S. M.			Age- Matched Comparison of Children Hospitalized for 2009 Pandemic H1N1 Influenza with Those Hospitalized for Seasonal H1N1 and H3N2	PLOS ONE			English	Article							A H1N1; CLINICAL CHARACTERISTICS; RELATIVE LYMPHOPENIA; RESPIRATORY VIRUSES; RAPID DIAGNOSIS; OUTCOMES; MARKER	Background: A wide spectrum of clinical manifestation ranging from deaths to a mild course of disease has been reported in children infected with the 2009 pandemic H1N1 (pH1N1) influenza. Methodology/Major Findings: We conducted an age-matched control study comparing children hospitalized for pH1N1 with historic controls infected with seasonal H1N1 and H3N2 influenza to correct for the effect of age on disease susceptibility and clinical manifestations. We also compared children with pH1N1 to children concurrently admitted for seasonal influenza during the pandemic period to adjust for differences in health-seeking behavior during the pandemic or other potential bias associated with historic controls. There was no death or intensive care admission. Children with pH1N1 were more likely to have at least one risk condition for influenza, an underlying chronic pulmonary condition, more likely to have asthma exacerbation and to be treated with oseltamivir. There was no difference in other aspects of the clinical course or outcome. Conclusion: Disease manifestation of children hospitalized for pH1N1 infection was mild in our patient population.	[Chiu, Susan S.; Wong, Wilfred H. S.; Chan, Eunice L. Y.] Univ Hong Kong, Dept Paediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China; [Chan, Kwok-Hung; Peiris, J. S. M.] Univ Hong Kong, Dept Microbiol, Pokfulam, Hong Kong, Peoples R China; [Peiris, J. S. M.] Univ Hong Kong, Pasteur Res Ctr, Pokfulam, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; University of Hong Kong	Chiu, SS (corresponding author), Univ Hong Kong, Dept Paediat & Adolescent Med, Pokfulam, Hong Kong, Peoples R China.	ssschiu@hkucc.hku.hk	Wong, Wilfred/Q-8751-2019; Chan, Kwok Hung/ABD-5399-2021; Peiris, Joseph Sriyal Malik/C-4380-2009; Chiu, Susan Shui Seng/C-4247-2009	Peiris, Joseph Sriyal Malik/0000-0001-8217-5995; Chiu, Susan Shui Seng/0000-0002-3908-1974; Wong, Hing Sang Wilfred/0000-0001-8396-2368	Area of Excellence of University Grants Committee [AoE/M-12/06]	Area of Excellence of University Grants Committee	This work was supported by the Area of Excellence Scheme of the University Grants Committee (grant AoE/M-12/06). The funders had no role in study design, data collection and analaysis, decision to publish, or preparation of the manuscript.	Belongia EA, 2010, JAMA-J AM MED ASSOC, V304, P1091, DOI 10.1001/jama.2010.1277; Bettinger JA, 2010, VACCINE, V28, P3180, DOI 10.1016/j.vaccine.2010.02.044; Brady MT, 2010, PEDIATRICS, V126, P816, DOI 10.1542/peds.2010-2216; Calitri C, 2010, EUR J PEDIATR, V169, P1511, DOI 10.1007/s00431-010-1255-y; Centers for Disease Control and Prevention (CDC), 2009, MMWR Morb Mortal Wkly Rep, V58, P941; Chan KH, 2008, J CLIN VIROL, V42, P65, DOI 10.1016/j.jcv.2007.12.003; Chan KH, 2008, J CLIN MICROBIOL, V46, P2195, DOI 10.1128/JCM.00315-08; Chien YS, 2010, J INFECTION, V60, P168, DOI 10.1016/j.jinf.2009.12.012; Chowell G, 2009, NEW ENGL J MED, V361, P674, DOI 10.1056/NEJMoa0904023; Coskun O, 2010, J CLIN VIROL, V47, P388, DOI 10.1016/j.jcv.2010.01.007; Cunha BA, 2009, CLIN INFECT DIS, V49, P1454, DOI 10.1086/644496; Farias JA, 2010, INTENS CARE MED, V36, P1015, DOI 10.1007/s00134-010-1853-1; Gordon A, 2010, CLIN INFECT DIS, V50, P1462, DOI 10.1086/652647; *GOV HONG KONG SPE, 2010, COMMUNICABLE DIS WAT, V7; *GOV HONG KONG SPE, OP PLAN EFL; Hackett S, 2009, LANCET, V374, P605, DOI 10.1016/S0140-6736(09)61511-7; Halasa NB, 2010, CURR OPIN PEDIATR, V22, P83, DOI 10.1097/MOP.0b013e3283350317; Kumar S, 2010, PEDIATR INFECT DIS J, V29, P591, DOI 10.1097/INF.0b013e3181d73e32; Larcombe PJ, 2011, ARCH DIS CHILD, V96, P96, DOI 10.1136/adc.2009.176859; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lister P, 2009, LANCET, V374, P605, DOI [10.1016/S0140-6736(09)61512-9, 10.1016/S0140-6736(09)61513-0]; Miroballi Y, 2010, ARCH PEDIAT ADOL MED, V164, P24, DOI 10.1001/archpediatrics.2009.259; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Perez-Padilla R, 2009, NEW ENGL J MED, V361, P680, DOI 10.1056/NEJMoa0904252; Shin SY, 2010, PEDIATR PULM, V45, P1014, DOI 10.1002/ppul.21288; To KKW, 2010, J MED VIROL, V82, P1, DOI 10.1002/jmv.21664; van Zwol A, 2011, CLIN PEDIATR, V50, P69, DOI 10.1177/0009922810381426; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997	28	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2011	6	7							e21837	10.1371/journal.pone.0021837	http://dx.doi.org/10.1371/journal.pone.0021837			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	794WE	21799750	Green Published, Green Submitted, gold			2023-01-03	WOS:000292931200014
J	Keown, P; Weich, S; Bhui, KS; Scott, J				Keown, Patrick; Weich, Scott; Bhui, Kamaldeep S.; Scott, Jan			Association between provision of mental illness beds and rate of involuntary admissions in the NHS in England 1988-2008: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED-TRIAL; PSYCHIATRIC ADMISSION; HEALTH-CARE; SERVICES; TEAM	Objective To examine the rise in the rate of involuntary admissions for mental illness in England that has occurred as community alternatives to hospital admission have been introduced. Design Ecological analysis. Setting England, 1988-2008. Data source Publicly available data on provision of beds for people with mental illness in the National Health Service from Hospital Activity Statistics and involuntary admission rates from the NHS Information Centre. Main outcome measures Association between annual changes in provision of mental illness beds in the NHS and involuntary admission rates, using cross correlation. Partial correlation coefficients were calculated and regression analysis carried out for the time lag (interval) over which the largest association between these variables was identified. Results The rate of involuntary admissions per annum in the NHS increased by more than 60%, whereas the provision of mental illness beds decreased by more than 60% over the same period; these changes seemed to be synchronous. The strongest association between these variables was observed when a time lag of one year was introduced, with bed reductions preceding increases in involuntary admissions (cross correlation -0.60, 95% confidence interval -1.06 to -0.15). This association increased in magnitude when analyses were restricted to civil (non-forensic) involuntary admissions and non-secure mental illness beds. Conclusion The annual reduction in provision of mental illness beds was associated with the rate of involuntary admissions over the short to medium term, with the closure of two mental illness beds leading to one additional involuntary admission in the subsequent year. This study provides a method for predicting rates of involuntary admissions and what may happen in the future if bed closures continue.	[Keown, Patrick] Queen Elizabeth Hosp, Tranwell Unit, Gateshead NE10 9R, Tyne & Wear, England; [Keown, Patrick; Scott, Jan] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Weich, Scott] Warwick Med Sch, Hlth Sci Res Inst, Coventry, W Midlands, England; [Bhui, Kamaldeep S.] Queen Mary Univ London, Barts & London Sch Med & Dent, Wolfson Inst Prevent Med, London, England	Newcastle University - UK; University of Warwick; University of London; Queen Mary University London	Keown, P (corresponding author), Queen Elizabeth Hosp, Tranwell Unit, Gateshead NE10 9R, Tyne & Wear, England.	patrick.keown@ncl.ac.uk	Scott, Jan/F-2966-2010; Bhui, Kamaldeep/AAX-2576-2020	Scott, Jan/0000-0002-7203-8601; Bhui, Kamaldeep/0000-0002-9205-2144; Weich, Scott/0000-0002-7552-7697	SDO grant	SDO grant	All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare: no support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years. All authors are applicants for an SDO grant pending review to build on these analyses.	Bennewith O, 2010, BRIT J PSYCHIAT, V196, P75, DOI 10.1192/bjp.bp.109.068890; Bhui K, 2003, BRIT J PSYCHIAT, V182, P105, DOI 10.1192/bjp.182.2.105; Bindman J, 2002, SOC PSYCH PSYCH EPID, V37, P341, DOI 10.1007/s00127-002-0558-3; Craig TK, 2004, BMJ-BRIT MED J, V329, P1067, DOI 10.1136/bmj.38246.594873.7C; Davidge M., 1993, SURVEY ENGLISH MENTA; Dean C, 1993, BRIT MED J, V307, P642; Department of Health, 1988, IN PAT FORM DET HOSP; Department of Health, 2009, BED AV OCC; Glover G, 2006, BRIT J PSYCHIAT, V189, P441, DOI 10.1192/bjp.bp.105.020362; Information Centre (2009m), 2009, INP FORM DET HOSP ME; Johnson S, 2005, BRIT MED J, V331, P599, DOI 10.1136/bmj.38519.678148.8F; Keown P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1837; NHSX, 2022, EL PRESCR MED ADM ME; Priebe S, 2005, BMJ-BRIT MED J, V330, P123, DOI 10.1136/bmj.38296.611215.AE; Rethink, 2005, FUT PERF OUTL ALT PA; Saxena S, 2007, LANCET, V370, P878, DOI 10.1016/S0140-6736(07)61239-2; VELLEMAN PF, 1980, J AM STAT ASSOC, V75, P609, DOI 10.2307/2287657; Wall S, 1999, BRIT MED J, V318, P1520, DOI 10.1136/bmj.318.7197.1520; Weich S, 2008, BRIT MED J, V337, P970; Weich S, 2010, SOC PSYCHIAT PSYCHIA	20	80	81	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 5	2011	343								d3736	10.1136/bmj.d3736	http://dx.doi.org/10.1136/bmj.d3736			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	791RV	21729994	Green Submitted, Green Published, hybrid			2023-01-03	WOS:000292683200001
J	Luo, HM; Yang, J; Jin, HL; Huang, C; Fu, JW; Yang, F; Gong, H; Zeng, SQ; Luo, QM; Zhang, ZH				Luo, Haiming; Yang, Jie; Jin, Honglin; Huang, Chuan; Fu, Jianwei; Yang, Fei; Gong, Hui; Zeng, Shaoqun; Luo, Qingming; Zhang, Zhihong			Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo	FASEB JOURNAL			English	Article						optical imaging; multivalent probe; genetic engineering	CANCER; VISUALIZATION; SYSTEM; ORANGE; DRUGS	Relatively weak tumor affinities and short retention time in vivo hinder the application of targeting peptides in tumor molecular imaging. Multivalent strategies based on various scaffolds have been utilized to improve the ability of peptide-receptor binding or extend the clearance time of peptide-based probes. Here, we use a tetrameric far-red fluorescent protein (tfRFP) as a scaffold to create a self-assembled octavalent peptide fluorescent nanoprobe (Octa-FNP) using a genetic engineering approach. The multiligand connecting, fluorophore labeling and nanostructure formation of Octa-FNP were performed in one step. In vitro studies showed Octa-FNP is a 10-nm fluorescent probe with excellent serum stability. Cellular uptake of Octa-FNP by human nasopharyngeal cancer 5-8F cells is 15-fold of tetravalent probe, similar to 80-fold of monovalent probe and similar to 600-fold of nulvalent tfRFP. In vivo enhanced tumor targeting and intracellular uptake of Octa-FNP were confirmed using optical imaging and Western blot analysis. It achieved extremely high contrast of Octa-FNP signal between tumor tissue and normal organs, especially seldom Octa-FNP detected in liver and spleen. Owing to easy preparation, precise structural and functional control, and multivalent effect, Octa-FNP provides a powerful tool for tumor optical molecular imaging and evaluating the targeting ability of numerous peptides in vivo.-Luo, H., Yang, J., Jin, H., Huang, C., Fu, J., Yang, F., Gong, H., Zeng, S., Luo, Q., Zhang, Z. Tetrameric far-red fluorescent protein as a scaffold to assemble an octavalent peptide nanoprobe for enhanced tumor targeting and intracellular uptake in vivo. FASEB J. 25, 1865-1873 (2011). www.fasebj.org	[Luo, Haiming; Yang, Jie; Jin, Honglin; Huang, Chuan; Fu, Jianwei; Yang, Fei; Gong, Hui; Zeng, Shaoqun; Luo, Qingming; Zhang, Zhihong] Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Hubei, Peoples R China	Huazhong University of Science & Technology	Zhang, ZH (corresponding author), Huazhong Univ Sci & Technol, Britton Chance Ctr Biomed Photon, Wuhan Natl Lab Optoelect, Wuhan 430074, Hubei, Peoples R China.	czyzzh@mail.hust.edu.cn		Luo, Qingming/0000-0002-6725-9311; Jin, Honglin/0000-0002-4398-9539; Luo, Haiming/0000-0002-6226-5800	National Natural Science Foundation of China [30770525]; Program for New Century Excellent Talents in University of China [NCET-08-0220]; China-Canada Joint Health Research Initiative [NSFC30911120489]; CIHR [CCI-102936]; National High-Tech Research and Development Program of China [2006AA020801]; 111 Project of China [B07038]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); China-Canada Joint Health Research Initiative; CIHR(Canadian Institutes of Health Research (CIHR)); National High-Tech Research and Development Program of China(National High Technology Research and Development Program of China); 111 Project of China(Ministry of Education, China - 111 Project)	The authors thank Dr. Gang Zheng (University of Toronto, Toronto, ON, Canada) for discussion. The authors thank Prof. Yi-Xin Zeng and Prof. Mu-Sheng Zeng (Sun Yat-sen University Cancer Center, Guangzhou, China) for providing the 5-8F cell line, and Jiabin Huang for the schematic diagram of Octa-FNP. The authors also thank the Analytical and Testing Center (Huazhong University of Science and Technology) for spectral measurements. This work was supported by the National Natural Science Foundation of China (grant 30770525), the Program for New Century Excellent Talents in University of China (NCET-08-0220 to Z.H.Z.), the China-Canada Joint Health Research Initiative (NSFC30911120489; CIHR CCI-102936), the National High-Tech Research and Development Program of China (2006AA020801), and the 111 Project of China (B07038).	Chu J, 2009, BIOSENS BIOELECTRON, V25, P234, DOI 10.1016/j.bios.2009.06.008; Chudakov DM, 2004, NAT BIOTECHNOL, V22, P1435, DOI 10.1038/nbt1025; Cuesta AM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005381; Dacosta RS, 2009, J INNOV OPT HEAL SCI, V2, P407, DOI 10.1142/S1793545809000759; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Douglas T, 2006, SCIENCE, V312, P873, DOI 10.1126/science.1123223; Fan CY, 2008, FASEB J, V22, P3795, DOI 10.1096/fj.08-111484; Gao JH, 2010, BIOCONJUGATE CHEM, V21, P604, DOI 10.1021/bc900323v; Gross LA, 2000, P NATL ACAD SCI USA, V97, P11990, DOI 10.1073/pnas.97.22.11990; Huang YF, 2009, J AM CHEM SOC, V131, P17328, DOI 10.1021/ja907125t; Kredel S, 2008, CHEM BIOL, V15, P224, DOI 10.1016/j.chembiol.2008.02.008; Lee S, 2010, CHEM REV, V110, P3087, DOI 10.1021/cr900361p; Liu W, 2009, ANGEW CHEM INT EDIT, V48, P7346, DOI 10.1002/anie.200903556; Montet X, 2006, J MED CHEM, V49, P6087, DOI 10.1021/jm060515m; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Reubi JC, 2003, ENDOCR REV, V24, P389, DOI 10.1210/er.2002-0007; Ruoslahti E, 2010, J CELL BIOL, V188, P759, DOI 10.1083/jcb.200910104; Shadidi M, 2002, FASEB J, V16, P256, DOI 10.1096/fj.02-0280fje; Shaner NC, 2008, NAT METHODS, V5, P545, DOI 10.1038/nmeth.1209; Shaner NC, 2004, NAT BIOTECHNOL, V22, P1567, DOI 10.1038/nbt1037; Shcherbo D, 2007, NAT METHODS, V4, P741, DOI 10.1038/NMETH1083; Shcherbo D, 2009, BIOCHEM J, V418, P567, DOI 10.1042/BJ20081949; Strack RL, 2009, BIOCHEMISTRY-US, V48, P8279, DOI 10.1021/bi900870u; Ueno Y, 2007, J ELECTRON MICROSC, V56, P103, DOI 10.1093/jmicro/dfm011; Voskuhl J, 2009, CHEM SOC REV, V38, P495, DOI 10.1039/b803782p; Wang LJ, 2009, MOL PHARMACEUT, V6, P231, DOI 10.1021/mp800150r; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Werle M, 2006, AMINO ACIDS, V30, P351, DOI 10.1007/s00726-005-0289-3; Xiong T, 2005, ORAL ONCOL, V41, P709, DOI 10.1016/j.oraloncology.2005.03.012; Yan YJ, 2011, AMINO ACIDS, V41, P1081, DOI 10.1007/s00726-010-0546-y	30	26	28	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2011	25	6					1865	1873		10.1096/fj.10-174318	http://dx.doi.org/10.1096/fj.10-174318			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	769NT	21350116				2023-01-03	WOS:000291023800010
J	Astrow, AB; Popp, B				Astrow, Alan B.; Popp, Beth			The Palliative Care Information Act in Real Life	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Astrow, Alan B.; Popp, Beth] Maimonides Hosp, Brooklyn, NY 11219 USA	Maimonides Medical Center	Astrow, AB (corresponding author), Maimonides Hosp, Brooklyn, NY 11219 USA.								0	28	28	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 19	2011	364	20					1885	1887		10.1056/NEJMp1102392	http://dx.doi.org/10.1056/NEJMp1102392			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	765PJ	21591941				2023-01-03	WOS:000290720700001
J	Miggins, M; Hasan, A; Hohmann, S; Southwick, F; Casella, G; Schain, D; Liu, HZ; Bihorac, A; Moldawer, L; Efron, P; Ang, D				Miggins, Makesha; Hasan, Anjum; Hohmann, Samuel; Southwick, Frederick; Casella, George; Schain, Denise; Liu, Huazhi; Bihorac, Azra; Moldawer, Lyle; Efron, Philip; Ang, Darwin			The Potential Influence of Common Viral Infections Diagnosed during Hospitalization among Critically Ill Patients in the United States	PLOS ONE			English	Article							HERPES-SIMPLEX-VIRUS; INTENSIVE-CARE-UNIT; ACTIVE CYTOMEGALOVIRUS-INFECTION; SURGICAL-PATIENTS; VENTILATION; MORTALITY; TYPE-1; REACTIVATION; DISEASE	Viruses are the most common source of infection among immunocompetent individuals, yet they are not considered a clinically meaningful risk factor among the critically ill. This work examines the association of viral infections diagnosed during the hospital stay or not documented as present on admission to the outcomes of ICU patients with no evidence of immunosuppression on admission. This is a population-based retrospective cohort study of University HealthSystem Consortium (UHC) academic centers in the U. S. from the years 2006 to 2009. The UHC is an alliance of over 90% of the non-profit academic medical centers in the U. S. A total of 209,695 critically ill patients were used in this analysis. Eight hospital complications were examined. Patients were grouped into four cohorts: absence of infection, bacterial infection only, viral infection only, and bacterial and viral infection during same hospital admission. Viral infections diagnosed during hospitalization significantly increased the risk of all complications. There was also a seasonal pattern for viral infections. Specific viruses associated with poor outcomes included influenza, RSV, CMV, and HSV. Patients who had both viral and bacterial infections during the same hospitalization had the greatest risk of mortality RR 6.58, 95% CI (5.47, 7.91); multi-organ failure RR 8.25, 95% CI (7.50, 9.07); and septic shock RR 271.2, 95% CI (188.0, 391.3). Viral infections may play a significant yet unrecognized role in the outcomes of ICU patients. They may serve as biological markers or play an active role in the development of certain adverse complications by interacting with coincident bacterial infection.	[Miggins, Makesha; Liu, Huazhi; Moldawer, Lyle; Efron, Philip; Ang, Darwin] Univ Florida, Dept Surg, Gainesville, FL 32611 USA; [Hasan, Anjum; Southwick, Frederick; Schain, Denise] Univ Florida, Dept Infect Dis, Gainesville, FL USA; [Hohmann, Samuel] Univ HealthSyst Consortium, Gainesville, FL USA; [Casella, George] Univ Florida, Dept Stat, Gainesville, FL 32611 USA; [Bihorac, Azra] Univ Florida, Dept Anesthesiol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Miggins, M (corresponding author), Univ Florida, Dept Surg, Gainesville, FL 32611 USA.	darwin.ang@surgery.ufl.edu	Ang, Darwin/AIA-3852-2022; Bihorac, Azra/Q-6500-2016	Bihorac, Azra/0000-0002-5745-2863; Moldawer, Lyle/0000-0002-9041-9838	NCI NIH HHS [T32 CA106493] Funding Source: Medline; NIGMS NIH HHS [K23 GM087709] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA106493] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K23GM087709] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahlbom A, 2005, EUR J EPIDEMIOL, V20, P563, DOI 10.1007/s10654-005-4410-4; Andersson T, 2005, EUR J EPIDEMIOL, V20, P575, DOI 10.1007/s10654-005-7835-x; Beadling C, 2004, CURR OPIN INFECT DIS, V17, P185, DOI 10.1097/00001432-200406000-00003; Bruynseels P, 2003, LANCET, V362, P1536, DOI 10.1016/S0140-6736(03)14740-X; Cameron RJ, 2006, INTENS CARE MED, V32, P1022, DOI 10.1007/s00134-006-0202-x; Centers for Disease Control and Prevention, 2010, OV BRFSS 2010; Chiche L, 2009, CRIT CARE MED, V37, P1850, DOI 10.1097/CCM.0b013e31819ffea6; Cook CH, 1998, AM J SURG, V176, P357, DOI 10.1016/S0002-9610(98)00205-0; Cook CH, 2003, CRIT CARE MED, V31, P1923, DOI 10.1097/01.CCM.0000070222.11325.C4; Couch Robert B., 1997, American Journal of Medicine, V102, P2, DOI 10.1016/S0002-9343(97)00003-X; da Silva AR, 2007, BRAZ J INFECT DIS, V11, P163, DOI 10.1590/S1413-86702007000100034; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1111/j.1574-695X.1999.tb01389.x; Heininger A, 2001, CRIT CARE MED, V29, P541, DOI 10.1097/00003246-200103000-00012; Jaber S, 2005, CHEST, V127, P233, DOI 10.1378/chest.127.1.233; Kalil AC, 2009, CRIT CARE MED, V37, P2350, DOI 10.1097/CCM.0b013e3181a3aa43; Limaye AP, 2008, JAMA-J AM MED ASSOC, V300, P413, DOI 10.1001/jama.300.4.413; Luyt CE, 2008, CURR OPIN CRIT CARE, V14, P605, DOI 10.1097/MCC.0b013e32830f1e12; Luyt CE, 2007, AM J RESP CRIT CARE, V175, P935, DOI 10.1164/rccm.200609-1322OC; Ong GM, 2004, J MED VIROL, V72, P121, DOI 10.1002/jmv.10524; Papazian L, 1996, ANESTHESIOLOGY, V84, P280, DOI 10.1097/00000542-199602000-00005; PORTEOUS C, 1984, CRIT CARE MED, V12, P626, DOI 10.1097/00003246-198408000-00003; ROTHMAN KJ, 1976, AM J EPIDEMIOL, V104, P587, DOI 10.1093/oxfordjournals.aje.a112335; Stollenwerk N, 2008, CRIT CARE, V12, DOI 10.1186/cc6917; van den Brink JW, 2004, J CLIN VIROL, V30, P68, DOI 10.1016/j.jcv.2003.09.003; Xu FJ, 2006, JAMA-J AM MED ASSOC, V296, P964, DOI 10.1001/jama.296.8.964; Ziemann M, 2008, CRIT CARE MED, V36, P3145, DOI 10.1097/CCM.0b013e31818f3fc4	26	21	22	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 29	2011	6	4							e18890	10.1371/journal.pone.0018890	http://dx.doi.org/10.1371/journal.pone.0018890			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	756OZ	21573031	Green Published, gold, Green Submitted			2023-01-03	WOS:000290024700034
J	Belloni, B; Andres, C				Belloni, Benedetta; Andres, Christian			Extravasation of Peripherally Administered Parenteral Nutrition	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Belloni, Benedetta; Andres, Christian] Tech Univ Munich, Munich, Germany	Technical University of Munich	Belloni, B (corresponding author), Tech Univ Munich, Munich, Germany.	benedetta.belloni@lrz.tum.de							0	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2011	364	10					E20	E20		10.1056/NEJMicm1006399	http://dx.doi.org/10.1056/NEJMicm1006399			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732FL	21388305				2023-01-03	WOS:000288170300013
J	Clarke, JG; Adashi, EY				Clarke, Jennifer G.; Adashi, Eli Y.			Perinatal Care for Incarcerated Patients A 25-Year-Old Woman Pregnant in Jail	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								More than 6 million men and 1 million women are under US correctional control, be it jail, prison, probation, or parole. On any given day, about 250 000 women and adolescent girls are behind bars, a number well in excess of those documented for all other sovereign nations. Moreover, women and girls represent the fastest-growing segment of the prison and jail populations. Approximately 75% of these women are mothers of minor children (leaving 200 000 children "motherless") and as many as 10 000 may be pregnant. Primarily designed for male offenders, the US correctional system is struggling to meet the specialized needs of its female inmates. Although incarceration during pregnancy is both stressful and dehumanizing, most studies paradoxically document better outcomes for pregnancies managed behind bars than for women of similar socioeconomic status whose pregnancies are managed in the community. Using the case of Ms A as a springboard for discussion, the issues, benefits, and challenges of caring for an incarcerated pregnant woman are addressed, as is the importance of family planning services to those about to be released. JAMA. 2011;305(9):923-929 www.jama.com	[Clarke, Jennifer G.; Adashi, Eli Y.] Brown Univ, Providence, RI 02906 USA	Brown University	Adashi, EY (corresponding author), Brown Univ, 272 George St, Providence, RI 02906 USA.	eli_adashi@brown.edu						American Bar Association, 2369 ABA; American Civil Liberties Union, STAT STAND PREGN REL; American Congress of Obstetricians and Gynecologists, 2005, OB GYNS ADDR HLTH NE; American Public Health Association, 2003, NEW MAN PROV GUID PR; Amnesty International, 1999, NOT PART MY SENT VIO; [Anonymous], 2009, PRISONERS 2008; BONCZAR T, PREVALENCE IMPRISONM; BREUNER CC, 1995, WESTERN J MED, V162, P328; Buergenthal Thomas, 1971, BUFFALO LAW REV, V21, P121; Centers for Disease Control and Prevention, 2001, WOM INJ DRUG US CRIM; Clarke JG, 2006, WOMEN HEALTH, V43, P111, DOI 10.1300/J013v43n02_07; Clarke Jennifer G, 2010, J Correct Health Care, V16, P133, DOI 10.1177/1078345809356533; Clarke JG, 2006, AM J PUBLIC HEALTH, V96, P840, DOI 10.2105/AJPH.2005.062869; Clarke JG, 2006, AM J PUBLIC HEALTH, V96, P834, DOI 10.2105/AJPH.2004.060236; DeVille KA, 1998, OBSTET GYN CLIN N AM, V25, P237, DOI 10.1016/S0889-8545(05)70367-3; Durrah TL, 2005, AM J PUBLIC HEALTH, V95, P1788, DOI 10.2105/AJPH.2004.056457; ELTON PJ, 1988, BRIT J HOSP MED, V39, P9; Fogel C I, 1992, West J Nurs Res, V14, P30, DOI 10.1177/019394599201400103; Fogel C I, 1993, J Obstet Gynecol Neonatal Nurs, V22, P33, DOI 10.1111/j.1552-6909.1993.tb01780.x; General Accounting Office, 1999, WOM PRIS ISS CHALL C; Glaze L.E., 2008, PARENTS PRISON THEIR; Harrison P., 2005, PRISONERS 2004; Hartney C., 2006, US RATES INCARCERATI; Howard DL, 2009, MATERN CHILD HLTH J, V13, P457, DOI 10.1007/s10995-008-0376-7; Institute on Women and Criminal Justice, 2009, MOTH INF IMPR; Jordan BK, 1996, ARCH GEN PSYCHIAT, V53, P513; Kline W, 2001, INBUILDING BETTER RA, P32; Knight M, 2005, BJOG-INT J OBSTET GY, V112, P1467, DOI 10.1111/j.1471-0528.2005.00749.x; Kyei-Aboagye K, 2000, J REPROD MED, V45, P190; Laughlin Harry H, 1922, EUGENICAL STERILIZAT; Macalino GE, 2004, AM J PUBLIC HEALTH, V94, P1218, DOI 10.2105/AJPH.94.7.1218; Martin SL, 1997, AM J PUBLIC HEALTH, V87, P1526, DOI 10.2105/AJPH.87.9.1526; Martin SL, 1997, PUBLIC HEALTH REP, V112, P340; Maruschak Laura M., 2006, MED PROBLEMS JAIL IN; Maruschak LM, 2006, MEDICAL PROBLEMS PRI; Maruschak LM, 2004, MED PROBLEMS PRISONE; Mauer M., 2003, COMP INT RATES INCAR; MILLER JM, 1995, AM J OBSTET GYNECOL, V172, P180, DOI 10.1016/0002-9378(95)90110-8; National Commission on Correctional Health Care, 2005, WOM HLTH CAR CORR SE; NCCD Center for Girls and Young Women, 2010, SHACKL PREGN WOM GIR; [Office of Civil Rights Department of Health and Human Services], 2002, STAND PRIV IND ID HL; Okie S, 2007, NEW ENGL J MED, V356, P105, DOI 10.1056/NEJMp068277; Pew Center on the States, 2009, ON 31 LONG REACH AM; Ramsay M, 2003, PRISONERS DRUG USE T; Sabol W. J., 2007, PRISON JAIL INMATES; Schirmer S., 2009, INCARCERATED PARENTS; Simpler AH, 2005, ADDICT RES THEORY, V13, P503, DOI 10.1080/16066350500151739; United Nations Department of Economic and Social Affairs, 2010, CONV EL ALL FORMS DI; US Department of Justice, 1996, PROGR STAT 6070 05 B; Willers DM, 2008, SEX TRANSM DIS, V35, P68, DOI 10.1097/OLQ.0b013e318154bdb2; William J, 2008, J CORRECT HLTH CARE, V14, P11	51	33	33	1	42	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	2011	305	9					923	929		10.1001/jama.2011.125	http://dx.doi.org/10.1001/jama.2011.125			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	728DP	21304069				2023-01-03	WOS:000287854700025
J	Pinnock, H; Kendall, M; Murray, SA; Worth, A; Levack, P; Porter, M; MacNee, W; Sheikh, A				Pinnock, Hilary; Kendall, Marilyn; Murray, Scott A.; Worth, Allison; Levack, Pamela; Porter, Mike; MacNee, William; Sheikh, Aziz			Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							END-STAGE COPD; PALLIATIVE CARE; CHRONIC ILLNESS; BIOGRAPHICAL DISRUPTION; LUNG-CANCER; OLDER AGE; OF-LIFE; COMMUNITY	Objectives To understand the perspectives of people with severe chronic obstructive pulmonary disease (COPD) as their illness progresses, and of their informal and professional carers, to inform provision of care for people living and dying with COPD. Design Up to four serial qualitative interviews were conducted with each patient and nominated carer over 18 months. Interviews were transcribed and analysed both thematically and as narratives. Participants 21 patients, and 13 informal carers (a family member, friend, or neighbour) and 18 professional carers (a key health or social care professional) nominated by the patients. Setting Primary and secondary care in Lothian, Tayside, and Forth Valley, Scotland, during 2007-9. Results Eleven patients died during the study period. Our final dataset comprised 92 interviews (23 conducted with patient and informal carer together). Severe symptoms that caused major disruption to normal life were described, often in terms implying acceptance of the situation as a "way of life" rather than an "illness." Patients and their informal carers adapted to and accepted the debilitating symptoms of a lifelong condition. Professional carers' familiarity with the patients' condition, typically over many years, and prognostic uncertainty contributed to the difficulty of recognising and actively managing end stage disease. Overall, patients told a "chaos narrative" of their illness that was indistinguishable from their life story, with no clear beginning and an unanticipated end described in terms comparable with attitudes to death in a normal elderly population. Conclusions Our findings challenge current assumptions underpinning provision of end of life care for people with COPD. The policy focus on identifying a time point for transition to palliative care has little resonance for people with COPD or their clinicians and is counter productive if it distracts from early phased introduction of supportive care. Careful assessment of possible supportive and palliative care needs should be triggered at key disease milestones along a lifetime journey with COPD, in particular after hospital admission for an exacerbation.	[Pinnock, Hilary] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, GP Sect,Med Sch, Edinburgh EH8 9AG, Midlothian, Scotland; [Kendall, Marilyn; Murray, Scott A.] Univ Edinburgh, Ctr Populat Hlth Sci, Primary Palliat Care Res Grp, GP Sect, Edinburgh EH8 9AG, Midlothian, Scotland; [Levack, Pamela] Ninewells Hosp, NHS Tayside, Dundee DD1 9SY, Scotland; [MacNee, William] Univ Edinburgh, Queens Med Res Inst, MRC Ctr Inflammat Res, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh; University of Edinburgh; University of Edinburgh	Pinnock, H (corresponding author), Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, GP Sect,Med Sch, Doorway 3,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	hilary.pinnock@ed.ac.uk	Sheikh, Aziz/D-2818-2009	Sheikh, Aziz/0000-0001-7022-3056; MacNee, William/0000-0002-3692-1448	Chief Scientist's Office of the Scottish Government	Chief Scientist's Office of the Scottish Government	This study was supported by the Chief Scientist's Office of the Scottish Government. HP is supported by a primary care research career award from the Chief Scientist's Office of the Scottish Government.	Almagro P, 2002, CHEST, V121, P1441, DOI 10.1378/chest.121.5.1441; [Anonymous], 2004, SOL FACTS PALL CAR; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Centers for Medicare & Medicaid Services, 2008, PUBL US DEP HLTH HUM; Charmaz K, 1983, Sociol Health Illn, V5, P168, DOI 10.1111/1467-9566.ep10491512; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959, DOI 10.1164/ajrccm.154.4.8887592; Cornwell Jocelyn, 1984, HARD EARNED LIVES AC; Coventry PA, 2005, AGE AGEING, V34, P218, DOI 10.1093/ageing/afi054; Department of Health, 2008, NHS END LIF CAR STRA; Department of Health, 2010, CONS STRAT SERV CHRO; Diffen E, 2010, BBC NEWS        0322; Elofsson LC, 2004, PALLIATIVE MED, V18, P611, DOI 10.1191/0269216304pm922oa; Exley C, 2005, PALLIATIVE MED, V19, P76, DOI 10.1191/0269216305pm973oa; FLETCHER C, 1977, BMJ-BRIT MED J, V1, P1645, DOI 10.1136/bmj.1.6077.1645; Frank A. W., 2013, WOUNDED STORYTELLER; Gore JM, 2000, THORAX, V55, P1000, DOI 10.1136/thorax.55.12.1000; Habraken JM, 2007, PATIENT EDUC COUNS, V68, P121, DOI 10.1016/j.pec.2007.05.011; Habraken JM, 2008, BRIT J GEN PRACT, V58, P844, DOI 10.3399/bjgp08X376186; Ito K, 2009, CHEST, V135, P173, DOI 10.1378/chest.08-1419; Kendall M, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4122; Lynn J, 2000, J AM GERIATR SOC, V48, pS91, DOI 10.1111/j.1532-5415.2000.tb03147.x; Malterud K, 2001, LANCET, V358, P483, DOI 10.1016/S0140-6736(01)05627-6; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Murray SA, 2005, BRIT MED J, V330, P611, DOI 10.1136/bmj.330.7492.611; Murray SA, 2002, BRIT MED J, V325, P929, DOI 10.1136/bmj.325.7370.929; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Murray SA, 2006, LANCET, V368, P901, DOI 10.1016/S0140-6736(06)69350-1; NHS End of Life Care Program, 2010, GOLD STAND FRAM; NHS Quality Improvement Scotland, 2010, CLIN STAND CHRON OBS; Pound P, 1998, SOCIOL HEALTH ILL, V20, P489, DOI 10.1111/1467-9566.00112; Reissman CatherineKohler., 1993, NARRATIVE ANAL; Rocker GM, 2007, J PALLIAT MED, V10, P783, DOI 10.1089/jpm.2007.9951; Sanders C, 2002, SOCIOL HEALTH ILL, V24, P227, DOI 10.1111/1467-9566.00292; Seamark DA, 2007, J ROY SOC MED, V100, P225, DOI 10.1258/jrsm.100.5.225; Seymour JE, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4860; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Williams B, 2009, QUAL HEALTH RES, V19, P1443, DOI 10.1177/1049732309348363; WILLIAMS G, 1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250; Williams SJ, 2000, SOCIOL HEALTH ILL, V22, P40, DOI 10.1111/1467-9566.00191	41	203	205	0	49	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 24	2011	342								d142	10.1136/bmj.d142	http://dx.doi.org/10.1136/bmj.d142			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	715LP	21262897	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000286886300001
J	Abou-Alfa, GK; Johnson, P; Knox, JJ; Capanu, M; Davidenko, I; Lacava, J; Leung, T; Gansukh, B; Saltz, LB				Abou-Alfa, Ghassan K.; Johnson, Philip; Knox, Jennifer J.; Capanu, Marinela; Davidenko, Irina; Lacava, Juan; Leung, Thomas; Gansukh, Bolorsukh; Saltz, Leonard B.			Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma A Randomized Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SOLID TUMORS; PHASE-III; RAF/MEK/ERK; BAY-43-9006; COMBINATION; RESISTANCE; SURVIVAL; THERAPY; KINASE	Context In a randomized phase 3 trial, 400 mg of sorafenib twice daily prolonged overall survival of patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh A disease. In a phase 1 study, sorafenib combined with doxorubicin, 60 mg/m(2), was well tolerated by patients with refractory solid tumors. The combination of sorafenib and doxorubicin in patients with advanced HCC has not been evaluated in a phase 2 or 3 trial. Objective To evaluate the efficacy and safety of doxorubicin plus sorafenib compared with doxorubicin alone in patients with advanced HCC and Child-Pugh A disease. Design, Setting, and Patients In a double-blind phase 2 multinational study, conducted from April 2005 to October 2006, 96 patients (76% male; median age, 65 years [range, 38-82 years]) with advanced HCC, Eastern Cooperative Oncology Group performance status 0 to 2, Child-Pugh A status, and no prior systemic therapy were randomly assigned to receive 60 mg/m2 of doxorubicin intravenously every 21 days plus either 400 mg of sorafenib or placebo orally twice a day. The date of the last patient's follow-up was April 2008. Main Outcome Measure Time to progression as determined by independent review. Results Following complete accrual, an unplanned early analysis for efficacy was performed by the independent data monitoring committee, so the trial was halted. The 2 patients remaining in the placebo group at that time were offered sorafenib. Based on 51 progressions, 63 deaths, and 70 events for progression-free survival, median time to progression was 6.4 months in the sorafenib-doxorubicin group (95% confidence interval [CI], 4.8-9.2), and 2.8 months (95% CI, 1.6-5) in the doxorubicin-placebo monotherapy group (P=.02). Median overall survival was 13.7 months (95% CI, 8.9-not reached) and 6.5 months (95% CI, 4.5-9.9; P=.006), and progression-free survival was 6.0 months (95% CI, 4.6-8.6) and 2.7 months (95% CI, 1.4-2.8) in these groups, respectively (P=.006). Toxicity profiles were similar to those for the single agents. Conclusions Among patients with advanced HCC, treatment with sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in greater median time to progression, overall survival, and progression-free survival. The degree to which this improvement may represent synergism between sorafenib and doxorubicin remains to be defined. The combination of sorafenib and doxorubicin is not yet indicated for routine clinical use.	[Abou-Alfa, Ghassan K.; Gansukh, Bolorsukh; Saltz, Leonard B.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA; [Capanu, Marinela] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA; [Johnson, Philip] Univ Birmingham, Sch Canc Sci, Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England; [Knox, Jennifer J.] Princess Margaret Hosp, Dept Med Oncol, Toronto, ON M4X 1K9, Canada; [Davidenko, Irina] Krasnodar City Oncol Ctr, Krasnodar, Russia; [Lacava, Juan] Oncol Serv, Unidad Oncol Neuquen, Neuquen, Argentina; [Leung, Thomas] Hong Kong Sanat & Hosp, Comprehens Oncol Ctr, Hong Kong, Hong Kong, Peoples R China	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cancer Research UK; University of Birmingham; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Abou-Alfa, GK (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10065 USA.	abou-alg@mskcc.org		Saltz, Leonard/0000-0001-8353-4670	Bayer	Bayer(Bayer AG)	This work was supported by a research grant from Bayer.	Abou-Alfa GK, 2006, SEMIN ONCOL, V33, pS79, DOI 10.1053/j.seminoncol.2006.10.015; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Alavi AS, 2007, CANCER RES, V67, P2766, DOI 10.1158/0008-5472.CAN-06-3648; Gish RG, 2007, J CLIN ONCOL, V25, P3069, DOI 10.1200/JCO.2006.08.4046; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; IHDE DC, 1977, CANCER TREAT REP, V61, P1385; JOHNSON PJ, 1978, LANCET, V1, P1006; Lacouture ME, 2008, ONCOLOGIST, V13, P1001, DOI 10.1634/theoncologist.2008-0131; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; *NAT CAN I CLIN TR, PHAS 3 RAND STUD SOR; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Richly H, 2006, ANN ONCOL, V17, P866, DOI 10.1093/annonc/mdl017; Satagopan JM, 2004, BRIT J CANCER, V91, P1229, DOI 10.1038/sj.bjc.6602102; SCIARRINO E, 1985, CANCER, V56, P2751, DOI 10.1002/1097-0142(19851215)56:12<2751::AID-CNCR2820561205>3.0.CO;2-O; Song SH, 2000, P NATL ACAD SCI USA, V97, P8658, DOI 10.1073/pnas.140210697; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Wakabayashi I, 2003, CURR MED CHEM, V10, P427, DOI 10.2174/0929867033368259; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yeo W, 2005, JNCI-J NATL CANCER I, V97, P1532, DOI 10.1093/jnci/dji315; Zhang YL, 2001, J PHARMACOL EXP THER, V299, P426	21	341	353	0	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	2010	304	19					2154	2160		10.1001/jama.2010.1672	http://dx.doi.org/10.1001/jama.2010.1672			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680XC	21081728	Bronze			2023-01-03	WOS:000284269800026
J	Ensoli, B; Bellino, S; Tripiciano, A; Longo, O; Francavilla, V; Marcotullio, S; Cafaro, A; Picconi, O; Paniccia, G; Scoglio, A; Arancio, A; Ariola, C; Alvarez, MJR; Campagna, M; Scaramuzzi, D; Iori, C; Esposito, R; Mussini, C; Ghinelli, F; Sighinolfi, L; Palamara, G; Latini, A; Angarano, G; Ladisa, N; Soscia, F; Mercurio, VS; Lazzarin, A; Tambussi, G; Visintini, R; Mazzotta, F; Di Pietro, M; Galli, M; Rusconi, S; Carosi, G; Torti, C; Di Perri, G; Bonora, S; Ensoli, F; Garaci, E				Ensoli, Barbara; Bellino, Stefania; Tripiciano, Antonella; Longo, Olimpia; Francavilla, Vittorio; Marcotullio, Simone; Cafaro, Aurelio; Picconi, Orietta; Paniccia, Giovanni; Scoglio, Arianna; Arancio, Angela; Ariola, Cristina; Alvarez, Maria J. Ruiz; Campagna, Massimo; Scaramuzzi, Donato; Iori, Cristina; Esposito, Roberto; Mussini, Cristina; Ghinelli, Florio; Sighinolfi, Laura; Palamara, Guido; Latini, Alessandra; Angarano, Gioacchino; Ladisa, Nicoletta; Soscia, Fabrizio; Mercurio, Vito S.; Lazzarin, Adriano; Tambussi, Giuseppe; Visintini, Raffaele; Mazzotta, Francesco; Di Pietro, Massimo; Galli, Massimo; Rusconi, Stefano; Carosi, Giampiero; Torti, Carlo; Di Perri, Giovanni; Bonora, Stefano; Ensoli, Fabrizio; Garaci, Enrico			Therapeutic Immunization with HIV-1 Tat Reduces Immune Activation and Loss of Regulatory T-Cells and Improves Immune Function in Subjects on HAART	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; GENE-EXPRESSION; HLA-DR; ANTIRETROVIRAL THERAPY; CYNOMOLGUS MONKEYS; PERIPHERAL-BLOOD; DENDRITIC CELLS; PROTEIN; INFECTION; AIDS	Although HAART suppresses HIV replication, it is often unable to restore immune homeostasis. Consequently, non-AIDS-defining diseases are increasingly seen in treated individuals. This is attributed to persistent virus expression in reservoirs and to cell activation. Of note, in CD4(+) T cells and monocyte-macrophages of virologically-suppressed individuals, there is continued expression of multi-spliced transcripts encoding HIV regulatory proteins. Among them, Tat is essential for virus gene expression and replication, either in primary infection or for virus reactivation during HAART, when Tat is expressed, released extracellularly and exerts, on both the virus and the immune system, effects that contribute to disease maintenance. Here we report results of an ad hoc exploratory interim analysis (up to 48 weeks) on 87 virologically-suppressed HAART-treated individuals enrolled in a phase II randomized open-label multicentric clinical trial of therapeutic immunization with Tat (ISS T-002). Eighty-eight virologically-suppressed HAART-treated individuals, enrolled in a parallel prospective observational study at the same sites (ISS OBS T-002), served for intergroup comparison. Immunization with Tat was safe, induced durable immune responses, and modified the pattern of CD4(+) and CD8(+) cellular activation (CD38 and HLA-DR) together with reduction of biochemical activation markers and persistent increases of regulatory T cells. This was accompanied by a progressive increment of CD4(+) T cells and B cells with reduction of CD8(+) T cells and NK cells, which were independent from the type of antiretroviral regimen. Increase in central and effector memory and reduction in terminally-differentiated effector memory CD4(+) and CD8(+) T cells were accompanied by increases of CD4(+) and CD8(+) T cell responses against Env and recall antigens. Of note, more immune-compromised individuals experienced greater therapeutic effects. In contrast, these changes were opposite, absent or partial in the OBS population. These findings support the use of Tat immunization to intensify HAART efficacy and to restore immune homeostasis.	[Ensoli, Barbara; Bellino, Stefania; Tripiciano, Antonella; Longo, Olimpia; Francavilla, Vittorio; Marcotullio, Simone; Cafaro, Aurelio; Picconi, Orietta; Paniccia, Giovanni; Scoglio, Arianna; Alvarez, Maria J. Ruiz] Ist Super Sanita, Natl AIDS Ctr, I-00161 Rome, Italy; [Tripiciano, Antonella; Francavilla, Vittorio; Paniccia, Giovanni; Scoglio, Arianna; Arancio, Angela; Ariola, Cristina; Alvarez, Maria J. Ruiz; Campagna, Massimo; Scaramuzzi, Donato; Iori, Cristina; Ensoli, Fabrizio] San Gallicano Hosp, Ist Fisioterapici Ospetalieri, Core Lab Virol & Immunol, Rome, Italy; [Esposito, Roberto; Mussini, Cristina] Univ Policlin Modena, Div Infect Dis, Modena, Italy; [Ghinelli, Florio; Sighinolfi, Laura] Univ Hosp Ferrara, Infect Dis Unit, Ferrara, Italy; [Palamara, Guido; Latini, Alessandra] San Gallicano Hosp, Dept Infect Dermatol, Rome, Italy; [Angarano, Gioacchino; Ladisa, Nicoletta] Univ Bari, Policlin Hosp, Div Infect Dis, Bari, Italy; [Soscia, Fabrizio; Mercurio, Vito S.] S Maria Goretti Hosp, Dept Infect Dis, Latina, Italy; [Lazzarin, Adriano; Tambussi, Giuseppe; Visintini, Raffaele] Hosp San Raffaele, Div Infect Dis, I-20132 Milan, Italy; [Mazzotta, Francesco; Di Pietro, Massimo] SM Annunziata Hosp, Infect Dis Unit, Florence, Italy; [Galli, Massimo; Rusconi, Stefano] Univ Milan, L Sacco Hosp Vialba, Inst Trop & Infect Dis, Milan, Italy; [Carosi, Giampiero; Torti, Carlo] Spedali Civil Brescia, Div Trop & Infect Dis, I-25125 Brescia, Italy; [Di Perri, Giovanni; Bonora, Stefano] Amedeo di Savoia Hosp, Clin Infect Dis, Turin, Italy	Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital; University of Ferrara; Arcispedale Sant'Anna; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Universita degli Studi di Bari Aldo Moro; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Milan; Luigi Sacco Hospital; Hospital Spedali Civili Brescia	Ensoli, B (corresponding author), Ist Super Sanita, Natl AIDS Ctr, Viale Regina Elena 299, I-00161 Rome, Italy.	barbara.ensoli@iss.it	Sighinolfi, Laura/AAH-1426-2020; Ensoli, Fabrizio/J-6540-2018; latini, alessandra/J-8186-2018; Mussini, Cristina/K-8672-2016; Rusconi, Stefano/H-9263-2012; RUIZ ALVAREZ, MARIA JOSEFINA/D-7968-2016; Paniccia, Giovanni/M-7440-2017; bonora, stefano/AAC-2993-2019; Di Perri, Giovanni/AAC-1882-2019; Tripiciano, Antonella/K-4635-2016; Ensoli, Barbara/J-9169-2016; Cafaro, Aurelio/K-5314-2016; GARACI, ENRICO/AAB-3349-2021; Picconi, Orietta/L-4613-2016; LAZZARIN, Adriano/K-3607-2018; GALLI, MASSIMO/L-7282-2017	Ensoli, Fabrizio/0000-0003-4995-3067; Mussini, Cristina/0000-0002-6615-4198; Rusconi, Stefano/0000-0002-0375-9990; RUIZ ALVAREZ, MARIA JOSEFINA/0000-0003-1751-780X; Paniccia, Giovanni/0000-0002-9850-5802; bonora, stefano/0000-0002-7537-3341; Tripiciano, Antonella/0000-0001-7814-984X; Ensoli, Barbara/0000-0002-0545-8737; Picconi, Orietta/0000-0003-3626-9952; LAZZARIN, Adriano/0000-0003-2551-7754; Cafaro, Aurelio/0000-0001-9675-6344; Arancio, Angela/0000-0002-6747-0475; ANGARANO, Gioacchino/0000-0003-3207-7523; Latini, Alessandra/0000-0002-9421-6560; Segala, Daniela/0000-0001-6133-0386; GALLI, MASSIMO/0000-0001-8887-6215; Tambussi, Giuseppe/0000-0002-0604-2960; Bellino, Stefania/0000-0003-1149-3835	Italian Ministry of Health	Italian Ministry of Health(Ministry of Health, Italy)	This work was funded by the special project for 'The development of clinical trials of vaccines against HIV/AIDS' funded by the Italian Ministry of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alexaki A, 2008, CURR HIV RES, V6, P388, DOI 10.2174/157016208785861195; Allen TM, 2000, NATURE, V407, P386, DOI 10.1038/35030124; Almeida JR, 2007, J EXP MED, V204, P2473, DOI 10.1084/jem.20070784; Alves NL, 2007, J IMMUNOL, V179, P221, DOI 10.4049/jimmunol.179.1.221; Appay V, 2008, J PATHOL, V214, P231, DOI 10.1002/path.2276; BARILLARI G, 1992, J IMMUNOL, V149, P3727; Bellino S, 2009, REV RECENT CLIN TRIA, V4, P195, DOI 10.2174/157488709789957529; Betts MR, 2006, BLOOD, V107, P4781, DOI 10.1182/blood-2005-12-4818; Biancotto A, 2008, BLOOD, V111, P699, DOI 10.1182/blood-2007-05-088435; Borsetti A, 2009, VIRAL IMMUNOL, V22, P117, DOI 10.1089/vim.2008.0082; BUONAGURO L, 1994, J VIROL, V68, P2677, DOI 10.1128/JVI.68.4.2677-2682.1994; BUONAGURO L, 1992, J VIROL, V66, P7159, DOI 10.1128/JVI.66.12.7159-7167.1992; Burtis C.A., 1994, TIETZ TXB CLIN CHEM, V2th; Butto S, 2003, J INFECT DIS, V188, P1171, DOI 10.1086/378412; Cafaro A, 1999, NAT MED, V5, P643, DOI 10.1038/9488; Cafaro A, 2010, J VIROL, V84, P8953, DOI 10.1128/JVI.00377-10; CAGIGI A, 2010, AIDS; Cagigi A, 2010, LANCET INFECT DIS, V10, P499, DOI 10.1016/S1473-3099(10)70117-1; Campbell GR, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-50; Cao JH, 2003, J IMMUNOL, V171, P3837, DOI 10.4049/jimmunol.171.7.3837; Carter CC, 2010, NAT MED, V16, P446, DOI 10.1038/nm.2109; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; Chase AJ, 2008, J VIROL, V82, P8307, DOI 10.1128/JVI.00520-08; Chertova E, 2006, J VIROL, V80, P9039, DOI 10.1128/JVI.01013-06; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Cullen B R, 1995, AIDS, V9 Suppl A, pS19; DAYTON AI, 1986, CELL, V44, P941, DOI 10.1016/0092-8674(86)90017-6; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Deeks Steven G, 2009, Top HIV Med, V17, P118; Deeks SG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.a3172; Dinoso JB, 2009, P NATL ACAD SCI USA, V106, P9403, DOI 10.1073/pnas.0903107106; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1990, NATURE, V345, P84, DOI 10.1038/345084a0; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; ENSOLI B, 2005, AIDS VACCINE INTEGRA, V9, P38; Ensoli B, 2008, AIDS, V22, P2207, DOI 10.1097/QAD.0b013e32831392d4; Ensoli B, 2006, AIDS, V20, P2245, DOI 10.1097/QAD.0b013e3280112cd1; Ensoli B, 2009, VACCINE, V28, P371, DOI 10.1016/j.vaccine.2009.10.038; Fanales-Belasio E, 2002, J IMMUNOL, V168, P197, DOI 10.4049/jimmunol.168.1.197; Fanales-Belasio E, 2009, J IMMUNOL, V182, P2888, DOI 10.4049/jimmunol.0711406; FINKEL TH, 1995, NAT MED, V1, P129, DOI 10.1038/nm0295-129; Fischer M, 2004, J INFECT DIS, V189, P273, DOI 10.1086/380797; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GATHE J, 2010, 17 C RETR OPP INF; Gavioli R, 2004, J IMMUNOL, V173, P3838, DOI 10.4049/jimmunol.173.6.3838; Gavioli R, 2008, VACCINE, V26, P727, DOI 10.1016/j.vaccine.2007.11.040; HAUBER J, 1987, P NATL ACAD SCI USA, V84, P6364, DOI 10.1073/pnas.84.18.6364; HO HN, 1993, J IMMUNOL, V150, P3070; Huang L, 1998, J VIROL, V72, P8952, DOI 10.1128/JVI.72.11.8952-8960.1998; Hunt PW, 2006, AIDS, V20, P691, DOI 10.1097/01.aids.0000216369.30948.18; JACKSON DG, 1990, J IMMUNOL, V144, P2811; Jiao YM, 2009, IMMUNOLOGY, V128, pe366, DOI 10.1111/j.1365-2567.2008.02978.x; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Jordan A, 2001, EMBO J, V20, P1726, DOI 10.1093/emboj/20.7.1726; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kelly J, 2008, VIROLOGY, V372, P300, DOI 10.1016/j.virol.2007.11.007; Lafrenie RM, 1997, J IMMUNOL, V159, P4077; Lambotte O, 2000, J ACQ IMMUN DEF SYND, V23, P114; Lassen Kara G., 2006, PLoS Pathogens, V2, DOI 10.1371/journal.ppat.0020068; Lassen KG, 2004, J VIROL, V78, P9105, DOI 10.1128/JVI.78.17.9105-9114.2004; Li CJ, 1997, P NATL ACAD SCI USA, V94, P8116, DOI 10.1073/pnas.94.15.8116; Li JCB, 2010, AIDS, V24, P1609, DOI 10.1097/QAD.0b013e32833ac6a0; Lin X, 2003, J VIROL, V77, P8227, DOI 10.1128/JVI.77.15.8227-8236.2003; Liu ZY, 1997, J ACQ IMMUN DEF SYND, V16, P83, DOI 10.1097/00042560-199710010-00003; Longo O, 2009, VACCINE, V27, P3306, DOI 10.1016/j.vaccine.2009.01.090; Maggiorella MT, 2004, VACCINE, V22, P3258, DOI 10.1016/j.vaccine.2004.03.009; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Miller JD, 2008, IMMUNITY, V28, P710, DOI 10.1016/j.immuni.2008.02.020; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; Nappi F, 2009, J GENE MED, V11, P955, DOI 10.1002/jgm.1381; Natarajan V, 1999, LANCET, V353, P119, DOI 10.1016/S0140-6736(05)76156-0; O'Connor DH, 2002, NAT MED, V8, P493, DOI 10.1038/nm0502-493; Ott M, 1997, SCIENCE, V275, P1481, DOI 10.1126/science.275.5305.1481; Pasternak AO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008490; Pensierosoa S, 2009, P NATL ACAD SCI USA, V106, P7939, DOI 10.1073/pnas.0901702106; PURI RK, 1992, CANCER RES, V52, P3787; RAYNE F, 2010, EMBO J; REISS P, 1991, J ACQ IMMUN DEF SYND, V4, P165; Remoli AL, 2006, BIOCHEM J, V396, P371, DOI 10.1042/BJ20051570; Rezza G, 2005, J INFECT DIS, V191, P1321, DOI 10.1086/428909; Richman DD, 2009, SCIENCE, V323, P1304, DOI 10.1126/science.1165706; Robbins GK, 2009, CLIN INFECT DIS, V48, P350, DOI 10.1086/595888; Saez-Cirion A, 2007, P NATL ACAD SCI USA, V104, P6776, DOI 10.1073/pnas.0611244104; SASTRY KJ, 1990, J BIOL CHEM, V265, P20091; Savarino A, 1999, FASEB J, V13, P2265, DOI 10.1096/fasebj.13.15.2265; SCALA G, 1994, J EXP MED, V179, P961, DOI 10.1084/jem.179.3.961; Secchiero P, 1999, J IMMUNOL, V162, P2427; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Speiser DE, 2001, EUR J IMMUNOL, V31, P459, DOI 10.1002/1521-4141(200102)31:2<459::AID-IMMU459>3.0.CO;2-Y; Szabo S E, 2004, Lab Hematol, V10, P109, DOI 10.1532/LH96.04020; TIMOTHY W, 2010, 17 C RETR OPP INF; Trono D, 2010, SCIENCE, V329, P174, DOI 10.1126/science.1191047; Valentin A, 2002, P NATL ACAD SCI USA, V99, P7015, DOI 10.1073/pnas.102672999; vanBaalen CA, 1997, J GEN VIROL, V78, P1913, DOI 10.1099/0022-1317-78-8-1913; Volberding PA, 2010, LANCET, V376, P49, DOI 10.1016/S0140-6736(10)60676-9; Walensky RP, 2006, J INFECT DIS, V194, P11, DOI 10.1086/505147; Weinberger LS, 2005, CELL, V122, P169, DOI 10.1016/j.cell.2005.06.006; Welles SL, 1996, J INFECT DIS, V174, P696, DOI 10.1093/infdis/174.4.696; Wu YT, 2001, SCIENCE, V293, P1503, DOI 10.1126/science.1061548; Wu YT, 2003, J VIROL, V77, P10376, DOI 10.1128/JVI.77.19.10376-10382.2003; Zauli G, 1996, J IMMUNOL, V157, P2216; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101; Zhu TF, 2002, J VIROL, V76, P707, DOI 10.1128/JVI.76.2.707-716.2002	103	75	78	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 11	2010	5	11							e13540	10.1371/journal.pone.0013540	http://dx.doi.org/10.1371/journal.pone.0013540			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	678OA	21085635	Green Published, gold			2023-01-03	WOS:000284087800001
J	Nunez, CMV; Adelman, JS; Rubenstein, DI				Nunez, Cassandra M. V.; Adelman, James S.; Rubenstein, Daniel I.			Immunocontraception in Wild Horses (Equus caballus) Extends Reproductive Cycling Beyond the Normal Breeding Season	PLOS ONE			English	Article							FERAL HORSES; SEXUAL-BEHAVIOR; TIME-BUDGETS; POPULATION; EXPOSURE; SUCCESS; LENGTH; ESTRUS; MICE	Background: Although the physiological effects of immunocontraceptive treatment with porcine zona pellucida (PZP) have been well studied, little is known about PZP's effects on the scheduling of reproductive cycling. Recent behavioral research has suggested that recipients of PZP extend the receptive breeding period into what is normally the non-breeding season. Methodology/Principal Findings: To determine if this is the case, we compiled foaling data from wild horses (Equus caballus) living on Shackleford Banks, North Carolina for 4 years pre- and 8 years post-contraception management with PZP (pre-contraception, n = 65 births from 45 mares; post-contraception, n = 97 births from 46 mares). Gestation lasts approximately 11-12 months in wild horses, placing conception at approximately 11.5 months prior to birth. Since the contraception program began in January 2000, foaling has occurred over a significantly broader range than it had before the contraception program. Foaling in PZP recipients (n = 45 births from 27 mares) has consistently occurred over a broader range than has foaling in non-recipients (n = 52 births from 19 mares). In addition, current recipients of PZP foaled later in the year than did prior recipient and non-recipient mares. Females receiving more consecutive PZP applications gave birth later in the season than did females receiving fewer applications. Finally, the efficacy of PZP declined with increasing consecutive applications before reaching 100% after five consecutive applications. Conclusions/Significance: For a gregarious species such as the horse, the extension of reproductive cycling into the fall months has important social consequences, including decreased group stability and the extension of male reproductive behavior. In addition, reproductive cycling into the fall months could have long-term effects on foal survivorship. Managers should consider these factors before enacting immunocontraceptive programs in new populations. We suggest minor alterations to management strategies to help alleviate such unintended effects in new populations.	[Nunez, Cassandra M. V.; Adelman, James S.; Rubenstein, Daniel I.] Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Nunez, CMV (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	cmvnunez@princeton.edu		Adelman, James/0000-0002-5577-8798; Nunez, Cassandra/0000-0002-6702-0730	National Science Foundation [IIS-0705311]	National Science Foundation(National Science Foundation (NSF))	This research was funded by the National Science Foundation, IIS-0705311 to D.I. Rubenstein, http://www.nsf.gov/ and a National Science Foundation Graduate Research Fellowship to J.S. Adelman. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, R BOOK; Asa Cheryl S., 2002, P113; ASA CS, 1980, HORM BEHAV, V14, P46, DOI 10.1016/0018-506X(80)90014-8; ASA CS, 1979, HORM BEHAV, V13, P49, DOI 10.1016/0018-506X(79)90034-5; Ball Gregory F., 2002, P649; BOS H, 1980, LIVEST PROD SCI, V7, P181, DOI 10.1016/0301-6226(80)90105-0; Cameron EZ, 2003, BEHAV ECOL SOCIOBIOL, V53, P92, DOI 10.1007/s00265-002-0556-1; Churcher C.S., 1993, Mammalian Species, V453, P1; Crowell-Davis SL, 2007, HORM BEHAV, V52, P12, DOI 10.1016/j.yhbeh.2007.03.020; Davies Morel M C G, 2003, EQUINE REPROD PHYSL, V2nd; Delsink AK, 2006, S AFR J SCI, V102, P403; DUNCAN P, 1985, BEHAVIOUR, V92, P188, DOI 10.1163/156853985X00442; EBERHARDT LL, 1982, J WILDLIFE MANAGE, V46, P367, DOI 10.2307/3808648; Feh C, 1999, ANIM BEHAV, V57, P705, DOI 10.1006/anbe.1998.1009; FEIST JD, 1976, Z TIERPSYCHOL, V41, P337; Goldsby RA, 2000, KUBY IMMUNOLOGY; Groux H, 1997, NATURE, V389, P737, DOI 10.1038/39614; GRUBB P, 1981, MAMMALIAN SPECIES, V157, P1; Heilmann TJ, 1998, J WILDLIFE MANAGE, V62, P243, DOI 10.2307/3802284; HORNBUCKLE T, 1995, THERIOGENOLOGY, V43, P411, DOI 10.1016/0093-691X(94)00034-R; KASEDA Y, 1995, EQUINE VET J, V27, P368, DOI 10.1111/j.2042-3306.1995.tb04072.x; KEARNS M, 2009, MALE HARASSMENT INFL; KEIPER R, 1984, AM J VET RES, V45, P991; Kirkpatrick J. F., 1995, NATL PARK SERVICE MO; Kirkpatrick Jay F., 2003, Journal of Applied Animal Welfare Science, V6, P301, DOI 10.1207/s15327604jaws0604_4; Kirkpatrick JF, 1996, J REPROD FERTIL, P183; Kirkpatrick JF, 1997, REPROD FERT DEVELOP, V9, P105, DOI 10.1071/R96052; Kirkpatrick JF, 2002, REPRODUCTION, P197; KIRKPATRICK JF, 1991, J WILDLIFE MANAGE, V55, P649, DOI 10.2307/3809514; KIRKPATRICK JF, 1992, J REPROD FERTIL, V94, P437, DOI 10.1530/jrf.0.0940437; Lane VM, 2007, REPROD FERT DEVELOP, V19, P617, DOI 10.1071/RD06154; Lea J, 2001, ANIM BEHAV, V61, P373, DOI 10.1006/anbe.2000.1604; LINDZEY J, 1988, HORM BEHAV, V22, P279, DOI 10.1016/0018-506X(88)90001-3; LIU IKM, 1989, J REPROD FERTIL, V85, P19, DOI 10.1530/jrf.0.0850019; Lyda RO, 2005, J ZOO WILDLIFE MED, V36, P610, DOI 10.1638/04104.1; MARSDEN HM, 1964, SCIENCE, V144, P1469, DOI 10.1126/science.144.3625.1469; MCCOMB K, 1987, NATURE, V330, P648, DOI 10.1038/330648a0; McShea WJ, 1997, J WILDLIFE MANAGE, V61, P560, DOI 10.2307/3802615; Morel MCGD, 2006, ANIM SCI, V82, P581, DOI 10.1079/ASC200669; Morris J, 2001, IN PRACTICE, V23, P606, DOI 10.1136/inpract.23.10.606; Nunez CMV, 2009, APPL ANIM BEHAV SCI, V117, P74, DOI 10.1016/j.applanim.2008.12.001; NUNEZ CMV, 2000, THESIS PRINCETON U P; NUNEZ CMV, 2009, EQUINC REPROD; Pacheco MA, 1997, J MAMMAL, V78, P15, DOI 10.2307/1382634; Pinheiro J. C., 2000, MIXED EFFECTS MODELS, pXVI; POLLOCK J, 1980, BEHAV ECOLOGY BODY C, P63; Powell D. M., 2001, Journal of Applied Animal Welfare Science, V4, P271, DOI 10.1207/S15327604JAWS0404_04; Powell D M, 1999, J Appl Anim Welf Sci, V2, P321, DOI 10.1207/s15327604jaws0204_6; Ransom JI, 2010, APPL ANIM BEHAV SCI, V124, P51, DOI 10.1016/j.applanim.2010.01.015; Rubenstein D.I., 1986, P282; Rubenstein DI, 2009, REPRODUCTIVE SKEW IN VERTEBRATES: PROXIMATE AND ULTIMATE CAUSES, P196, DOI 10.1017/CBO9780511641954.010; RUBENSTEIN DI, 1981, EQUINE VET J, V13, P27, DOI 10.1111/j.2042-3306.1981.tb03443.x; SACCO AG, 1977, BIOL REPROD, V16, P164, DOI 10.1095/biolreprod16.2.164; Sadleir R.M.F.S., 1969, ECOLOGY REPROD WILD; STEVENS EF, 1990, BEHAVIOUR, V112, P149, DOI 10.1163/156853990X00167; Sundaresan SR, 2007, BEHAV ECOL, V18, P860, DOI 10.1093/beheco/arm055; TORIBIO RE, 1995, ACTA VET SCAND, V36, P343; TURNER A, 2002, EFFECTS IMMUNOCONTRA, P187; TURNER JW, 2005, J WILDLIFE MANAGE, V71, P662; Valera M, 2006, ANIM REPROD SCI, V95, P75, DOI 10.1016/j.anireprosci.2005.09.008; Venables WN, 2002, MODERN APPL STAT S, pxi; WHITTEN WK, 1968, SCIENCE, V161, P584, DOI 10.1126/science.161.3841.584	62	30	31	1	35	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 26	2010	5	10							e13635	10.1371/journal.pone.0013635	http://dx.doi.org/10.1371/journal.pone.0013635			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	671GB	21049017	gold, Green Published			2023-01-03	WOS:000283487400025
J	Mellor, D; Prieto, E; Mathieson, L; Moscato, P				Mellor, Drew; Prieto, Elena; Mathieson, Luke; Moscato, Pablo			A Kernelisation Approach for Multiple d-Hitting Set and Its Application in Optimal Multi-Drug Therapeutic Combinations	PLOS ONE			English	Article							CANCER; DOCETAXEL; PROTEIN; CHEMOTHERAPY; ARRY-142886; AZD6244; POTENT; TIME	Therapies consisting of a combination of agents are an attractive proposition, especially in the context of diseases such as cancer, which can manifest with a variety of tumor types in a single case. However uncovering usable drug combinations is expensive both financially and temporally. By employing computational methods to identify candidate combinations with a greater likelihood of success we can avoid these problems, even when the amount of data is prohibitively large. HITTING SET is a combinatorial problem that has useful application across many fields, however as it is NP-complete it is traditionally considered hard to solve exactly. We introduce a more general version of the problem (alpha,beta,d)-HITTING SET, which allows more precise control over how and what the hitting set targets. Employing the framework of Parameterized Complexity we show that despite being NP-complete, the (alpha,beta,d) HITTING SET problem is fixed-parameter tractable with a kernel of size O(alpha dk(d)) when we parameterize by the size k of the hitting set and the maximum number alpha of the minimum number of hits, and taking the maximum degree d of the target sets as a constant. We demonstrate the application of this problem to multiple drug selection for cancer therapy, showing the flexibility of the problem in tailoring such drug sets. The fixed-parameter tractability result indicates that for low values of the parameters the problem can be solved quickly using exact methods. We also demonstrate that the problem is indeed practical, with computation times on the order of 5 seconds, as compared to previous Hitting Set applications using the same dataset which exhibited times on the order of 1 day, even with relatively relaxed notions for what constitutes a low value for the parameters. Furthermore the existence of a kernelization for (alpha,beta,d)-HITTING SET indicates that the problem is readily scalable to large datasets.	[Mellor, Drew; Prieto, Elena; Mathieson, Luke; Moscato, Pablo] Univ Newcastle, Ctr Bioinformat Biomarker Discovery & Informat Ba, Newcastle, NSW 2308, Australia; [Mellor, Drew; Prieto, Elena; Mathieson, Luke; Moscato, Pablo] Hunter Med Res Inst, Informat Based Med Program, Newcastle, NSW, Australia	University of Newcastle; Hunter Medical Research Institute; University of Newcastle	Mellor, D (corresponding author), Univ Newcastle, Ctr Bioinformat Biomarker Discovery & Informat Ba, Newcastle, NSW 2308, Australia.	pablo.moscato@newcastle.edu.au	MOSCATO, PABLO ALBERTO/G-7668-2013; Prieto, Elena/G-7614-2013	Prieto, Elena/0000-0002-3814-6692; Moscato, Pablo/0000-0003-2570-5966; Mathieson, Luke/0000-0001-6470-2296	Hunter Medical Research Institute; University of Newcastle; ARC [DP0773279]	Hunter Medical Research Institute; University of Newcastle; ARC(Australian Research Council)	The authors acknowledge the support of the Hunter Medical Research Institute, The University of Newcastle, and ARC Discovery Project DP0773279 (Application of novel exact combinatorial optimisation techniques and metaheuristic methods for problems in cancer research). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abu-Khzam FN, 2010, J COMPUT SYST SCI, V76, P524, DOI 10.1016/j.jcss.2009.09.002; ALBAIN KS, 1990, J CLIN ONCOL, V8, P1563, DOI 10.1200/JCO.1990.8.9.1563; Berman P, 2007, DISCRETE APPL MATH, V155, P733, DOI 10.1016/j.dam.2004.11.009; Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528; Cotta C, 2003, J COMPUT SYST SCI, V67, P686, DOI 10.1016/S0022-0000(03)00081-3; Davies BR, 2007, MOL CANCER THER, V6, P2209, DOI 10.1158/1535-7163.MCT-07-0231; Davies S., 1994, P AAAI S RELEVANCE, P41; DEKLEER J, 1992, ARTIF INTELL, V56, P197, DOI 10.1016/0004-3702(92)90027-U; Downey R.G., 1999, MG COMP SCI; Feige U, 1998, J ACM, V45, P634, DOI 10.1145/285055.285059; Fernau H., 2005, PARAMETERIZED ALGORI; FLAMANT F, 1984, CANCER, V54, P1687, DOI 10.1002/1097-0142(19841015)54:8<1687::AID-CNCR2820540833>3.0.CO;2-U; Flum J., 2006, TEXT THEORET COMP S; FU KK, 1979, CANCER TREAT REP, V63, P351; Garey M. R., 1979, COMPUTERS INTRACTABI, V174; Haus UU, 2008, J COMPUT BIOL, V15, P259, DOI 10.1089/cmb.2007.0229; Hvidsten TR, 2003, BIOINFORMATICS, V19, P1116, DOI 10.1093/bioinformatics/btg047; IBM, ILOG CPLEX; Joensuu H, 2009, J CLIN ONCOL, V27, P5685, DOI 10.1200/JCO.2008.21.4577; LEIPINS GE, 1991, HDB GENETIC ALGORITH, P237; Lorenzi PL, 2009, MOL CANCER THER, V8, P713, DOI 10.1158/1535-7163.MCT-08-0921; Lyseng-Williamson KA, 2005, DRUGS, V65, P2513, DOI 10.2165/00003495-200565170-00007; Niedermeier Rolf, 2006, OXFORD LECT SERIES M; PAZ A, 1981, THEOR COMPUT SCI, V15, P251, DOI 10.1016/0304-3975(81)90081-5; Perez EA, 2010, ANN ONCOL, V21, P269, DOI 10.1093/annonc/mdp512; PEYTON JD, 2009, J CLIN ONCOL, V27, P9027; Polyzos A, 2010, BREAST CANCER RES TR, V119, P95, DOI 10.1007/s10549-009-0468-0; Rao RD, 2006, J CLIN ONCOL, V24, p463S; REITER R, 1987, ARTIF INTELL, V32, P57, DOI 10.1016/0004-3702(87)90062-2; Ruchkys DP, 2002, 14TH SYMPOSIUM ON COMPUTER ARCHITECTURE AND HIGH PERFORMANCE COMPUTING, PROCEEDINGS, P75, DOI 10.1109/CAHPC.2002.1180762; Shin SY, 2010, CANCER LETT, V287, P231, DOI 10.1016/j.canlet.2009.06.019; Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951; Slamon D, 2009, CANCER RES, V69, P62; Sparano JA, 2009, J CLIN ONCOL, V27, P4522, DOI 10.1200/JCO.2008.20.5013; Vazquez A, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-81; Vinterbo SA, 2005, BIOINFORMATICS, V21, P1964, DOI 10.1093/bioinformatics/bti287; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150	38	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 18	2010	5	10							e13055	10.1371/journal.pone.0013055	http://dx.doi.org/10.1371/journal.pone.0013055			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	665ON	20976188	Green Published, gold, Green Submitted			2023-01-03	WOS:000283045300001
J	Dou, ZH; Xu, JH; Jiao, JH; Ma, Y; Durako, S; Yu, L; Zhao, Y; Zhang, FJ				Dou, Zhihui; Xu, Jiahong; Jiao, Jin Hua; Ma, Ye; Durako, Stephen; Yu, Lan; Zhao, Yan; Zhang, Fujie			Gender Difference in 2-Year Mortality and Immunological Response to ART in an HIV-Infected Chinese Population, 2006-2008	PLOS ONE			English	Article							UNITED-STATES; RNA LEVELS; PROGRESSION; WOMEN; AIDS	Background: Since it was initiated in 2002, the China Free Antiretroviral Treatment (ART) Program has been progressing from an emergency response to a standardized treatment and care system. As of December 31, 2009, a total of 81,880 patients in 31 provinces, autonomous regions, and special municipalities received free ART. Gender differences, however, in mortality and immunological response to ART in this cohort have never been described. Objective: To understand whether women and men who enrolled in the China National Free ART Program responded equally well to the treatment. Methods: A retrospective analysis of the national free ART databases from June 2006-December 2008 was performed. HIV-infected subjects who were 18 years or older, ART naive at baseline, and on a 3TC regimen enrolled in the program from June 1 to December 31, 2006, were included in this study, then followed up to 2 years. Results: Among 3457 enrolled subjects who met the inclusion criteria, 59.2% were male and 40.8% female. The majority of the subjects were 19-44 years old (77%) and married (72%). Over the full 24 months of follow-up, the mortality rate was 19.0% in males and 11.4% in females (p = 0.0014). Males on therapy for 3-24 months were more likely to die than females (HR = 1.46, 95% CI: 1.04-2.06, p = 0.0307) after adjusting for baseline characteristics. Compared to men, women had higher CD4+ counts over time after initiating ART (p < 0.0001). Conclusions: Our study showed that women had an overall lower mortality and higher CD4+ counts than men in response to ART treatment, which may be attributed to adherence, biological factors, social, cultural and economic reasons. Further study is needed to explore these factors that might contribute to the gender differences in mortality and immunological response to ART.	[Dou, Zhihui; Ma, Ye; Yu, Lan; Zhao, Yan; Zhang, Fujie] Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China; [Xu, Jiahong; Jiao, Jin Hua; Durako, Stephen] Westat Corp, Rockville, MD USA	Chinese Center for Disease Control & Prevention; National Center for AIDS/STD Control & Prevention, Chinese Center for Disease Control & Prevention; Westat	Dou, ZH (corresponding author), Chinese Ctr Dis Control & Prevent, Natl Ctr AIDS STD Control & Prevent, Beijing, Peoples R China.	treatment@chinaaids.cn			Chinese National Antiretroviral Treatment Program; U.S. National Institutes of Health [1R03TW008203-01]; FOGARTY INTERNATIONAL CENTER [R03TW008203] Funding Source: NIH RePORTER	Chinese National Antiretroviral Treatment Program; U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This work was supported by the Chinese National Antiretroviral Treatment Program, and by U.S. National Institutes of Health Research Grants (1R03TW008203-01). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alibhail A, 2010, UGANDA INT J WOMENS, V2, P45; Anastos K, 2000, J ACQ IMMUN DEF SYND, V24, P218; Collazos J, 2007, AIDS, V21, P835, DOI 10.1097/QAD.0b013e3280b0774a; Cornell M, 2009, TROP MED INT HEALTH, V14, P722, DOI 10.1111/j.1365-3156.2009.02290.x; Hall HI, 2006, ANN EPIDEMIOL, V16, P824, DOI 10.1016/j.annepidem.2006.01.009; Heath KV, 2002, INT J EPIDEMIOL, V31, P1016, DOI 10.1093/ije/31.5.1016; Jain MK, 2003, CLIN INFECT DIS, V36, P1030, DOI 10.1086/368186; Joint United Nations Program on HIV/AIDS (UNAIDS), 2007, UNAIDS0727EJC1322E W; Kaleebu P, 2006, AIDS, V20, P1391, DOI 10.1097/01.aids.0000233572.59522.45; Ma Y., 2009, P IEEE WORLD NONGR C, P1, DOI DOI 10.1109/NAPS.2009.5484048; Moore J, 1999, AIDS, V13, P2459, DOI 10.1097/00002030-199912030-00018; Nicastri E, 2005, AIDS, V19, P577, DOI 10.1097/01.aids.0000163934.22273.06; Quinn TC, 2005, SCIENCE, V308, P1582, DOI 10.1126/science.1112489; Rotger Margalida, 2006, Curr HIV/AIDS Rep, V3, P118, DOI 10.1007/BF02696655; Sterling TR, 2001, NEW ENGL J MED, V344, P720, DOI 10.1056/NEJM200103083441003; van Leth F, 2005, AIDS, V19, P463, DOI 10.1097/01.aids.0000162334.12815.5b; van Sighem AI, 2003, AIDS, V17, P2227, DOI 10.1097/00002030-200310170-00011; Wu ZY, 2007, LANCET, V369, P679, DOI 10.1016/S0140-6736(07)60315-8; Zhang FJ, 2005, CELL RES, V15, P877, DOI 10.1038/sj.cr.7290362; Zhang FJ, 2009, ANN INTERN MED, V151, P241, DOI 10.7326/0003-4819-151-4-200908180-00006	20	21	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 16	2011	6	8							e22707	10.1371/journal.pone.0022707	http://dx.doi.org/10.1371/journal.pone.0022707			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	810KZ	21857947	Green Published, gold, Green Submitted			2023-01-03	WOS:000294125500011
J	Liang, QL; Wu, QA; Jiang, JH; Duan, JA; Wang, C; Smith, MD; Lu, H; Wang, Q; Nagarkatti, P; Fan, DP				Liang, Qiaoli; Wu, Qinan; Jiang, Jihong; Duan, Jin'ao; Wang, Chao; Smith, Mark D.; Lu, Hong; Wang, Qian; Nagarkatti, Prakash; Fan, Daping			Characterization of Sparstolonin B, a Chinese Herb-derived Compound, as a Selective Toll-like Receptor Antagonist with Potent Anti-inflammatory Properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNE CELLS; DOUBLE-BLIND; INNATE; ACTIVATION; EXPRESSION; TOLL-LIKE-RECEPTOR-4; INFLAMMATION; TAK-242; MICE; TLR	BlockadeofexcessiveToll-likereceptor(TLR) signalingisatherapeutic approach being actively pursued for many inflammatory diseases. Here we report a Chinese herb-derived compound, sparstoloninB(SsnB), which selectively blocks TLR2-and TLR4-mediated inflammatory signaling. SsnB was isolated from a Chinese herb, Spaganium stoloniferum; its structure was determined by NMR spectroscopy and x-ray crystallography. SsnB effectively inhibited inflammatory cytokine expression in mouse macrophages induced by lipopolysaccharide (LPS, a TLR4 ligand), Pam3CSK4 (a TLR1/TLR2 ligand), and Fsl-1 (a TLR2/TLR6 ligand) but not that by poly(I: C) (a TLR3 ligand) or ODN1668 (a TLR9 ligand). It suppressed LPS-induced cytokine secretion from macrophages and diminished phosphorylation of Erk1/2, p38a, I kappa B alpha, and JNK in these cells. In THP-1 cells expressing a chimeric receptor CD4-TLR4, which triggers constitutive NF-kappa Bactivation, SsnB effectively blunted the NF-kappa B activity. Co-immunoprecipitation showed that SsnB reduced the association of MyD88 with TLR4 and TLR2, but not that with TLR9, in HEK293T cells and THP-1 cells overexpressing MyD88 and TLRs. Furthermore, administration of SsnB suppressed splenocyte inflammatory cytokine expression in mice challenged with LPS. These results demonstrate that SsnB acts as a selective TLR2 and TLR4 antagonist by blocking the early intracellular events in the TLR2 and TLR4 signaling. Thus, SssB may serve as a promising lead for the development of selective TLR antagonistic agents for inflammatory diseases.	[Liang, Qiaoli; Lu, Hong; Fan, Daping] Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29209 USA; [Nagarkatti, Prakash] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC 29209 USA; [Liang, Qiaoli; Wu, Qinan; Duan, Jin'ao] Nanjing Univ Chinese Med, Sch Pharm, Nanjing 210046, Peoples R China; [Jiang, Jihong] Xuzhou Normal Univ, Key Lab Biotechnol Med Plant Jiangsu Prov, Xuzhou 221116, Peoples R China; [Wang, Chao; Smith, Mark D.; Wang, Qian] Univ S Carolina, Dept Chem & Biochem, Coll Arts & Sci, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia; Nanjing University of Chinese Medicine; Jiangsu Normal University; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Fan, DP (corresponding author), Univ S Carolina, Sch Med, Dept Cell Biol & Anat, Columbia, SC 29209 USA.	daping.fan@uscmed.sc.edu	Lu, Hong S./ABH-3929-2020	Lu, Hong/0000-0002-0577-2558; Smith, Mark/0000-0001-6977-7131; Wu, Qinan/0000-0002-7836-0941; Nagarkatti, Prakash/0000-0003-2663-0759; Wang, Qian/0000-0002-2149-384X	National Institutes of Health [P01AT003961, P20 RR-016434, P20 RR-016461]; National Science Foundation/EPSCoR under Cooperative Agreement [EPS-0903795]; National Natural Science Foundation of China [81073002]; Innovation Grant of Production, Study, and Research (Jiangsu, China) [BY2009116]; National Center for Complementary & Integrative Health [P01AT003961] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR029882, P20RR016434, P20RR016461] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Science Foundation/EPSCoR under Cooperative Agreement(National Science Foundation (NSF)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Grant of Production, Study, and Research (Jiangsu, China); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported, in whole or in part, by National Institutes of Health Grants P01AT003961, P20 RR-016434, and P20 RR-016461. This work was also supported by the National Science Foundation/EPSCoR under Cooperative Agreement EPS-0903795, the National Natural Science Foundation of China (81073002), and by an Innovation Grant of Production, Study, and Research (Jiangsu, China, BY2009116).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; [Anonymous], 2000, PHARMACOPOEIA COMM 1, P11; Barochia AV, 2010, CRIT CARE MED, V38, P306, DOI 10.1097/CCM.0b013e3181b77fe3; Bennett-Guerrero E, 2007, ANESTH ANALG, V104, P378, DOI 10.1213/01.ane.0000253501.07183.2a; Beutler BA, 2009, BLOOD, V113, P1399, DOI 10.1182/blood-2008-07-019307; Cao CX, 2007, BIOCHEM BIOPH RES CO, V353, P509, DOI 10.1016/j.bbrc.2006.12.057; Carpenter S, 2009, BIOCHEM J, V422, P1, DOI 10.1042/BJ20090616; Caso JR, 2008, STROKE, V39, P1314, DOI 10.1161/STROKEAHA.107.498212; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Curtiss LK, 2009, J LIPID RES, V50, pS340, DOI 10.1194/jlr.R800056-JLR200; de Oliveira FJ, 2010, REV BRAS CIR CARDIOV, V25, P51, DOI 10.1590/S0102-76382010000100013; Gomariz RP, 2005, J LEUKOCYTE BIOL, V78, P491, DOI 10.1189/jlb.1004564; Han JH, 2005, NAT IMMUNOL, V6, P1198, DOI 10.1038/ni1274; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hennessy EJ, 2010, NAT REV DRUG DISCOV, V9, P293, DOI 10.1038/nrd3203; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Hua HM, 2007, FITOTERAPIA, V78, P274, DOI 10.1016/j.fitote.2006.11.014; Ii M, 2006, MOL PHARMACOL, V69, P1288, DOI 10.1124/mol.105.019695; Inaba H, 2010, J PHARMACOL SCI, V113, P103, DOI 10.1254/jphs.09R23FM; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kawai T, 2001, J IMMUNOL, V167, P5887, DOI 10.4049/jimmunol.167.10.5887; Kolek MJ, 2004, AM HEART J, V148, P1034, DOI 10.1016/j.ahj.2004.05.049; Kuno M, 2009, CLIN EXP PHARMACOL P, V36, P589, DOI 10.1111/j.1440-1681.2008.05121.x; Lakhani SA, 2003, CURR OPIN PEDIATR, V15, P278, DOI 10.1097/00008480-200306000-00009; Landreth GE, 2009, CURR TOP MICROBIOL, V336, P137, DOI 10.1007/978-3-642-00549-7_8; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Ledeboer A, 2006, NEURON GLIA BIOL, V2, P279, DOI 10.1017/S1740925X0700035X; Lee J, 2006, NAT CELL BIOL, V8, P1327, DOI 10.1038/ncb1500; Lee SY, 2010, ARCH PHARM RES, V33, P515, DOI 10.1007/s12272-010-0404-1; Li SX, 2010, J ASIAN NAT PROD RES, V12, P331, DOI 10.1080/10286021003730330; Lin FY, 2006, ARTERIOSCL THROM VAS, V26, P2630, DOI 10.1161/01.ATV.0000247259.01257.b3; Loke WM, 2010, ARTERIOSCL THROM VAS, V30, P749, DOI 10.1161/ATVBAHA.109.199687; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michelsen KS, 2004, P NATL ACAD SCI USA, V101, P10679, DOI 10.1073/pnas.0403249101; Muzio M, 2000, J IMMUNOL, V164, P5998, DOI 10.4049/jimmunol.164.11.5998; Opal SM, 2002, J ENDOTOXIN RES, V8, P473, DOI 10.1179/096805102125001109; Park BS, 2009, NATURE, V458, P1191, DOI 10.1038/nature07830; Pinto MMM, 2005, CURR MED CHEM, V12, P2517, DOI 10.2174/092986705774370691; Pochet L, 2004, CURR PHARM DESIGN, V10, P3781, DOI 10.2174/1381612043382684; Qiu C., 2008, PHARM CLIN CHINESE M, V14, P7; Reed-Geaghan EG, 2009, J NEUROSCI, V29, P11982, DOI 10.1523/JNEUROSCI.3158-09.2009; Rice TW, 2010, CRIT CARE MED, V38, P1685, DOI 10.1097/CCM.0b013e3181e7c5c9; Roger T, 2009, P NATL ACAD SCI USA, V106, P2348, DOI 10.1073/pnas.0808146106; Salomao R, 2008, SHOCK, V30, P73, DOI 10.1097/SHK.0b013e318181af2a; Sansonetti PJ, 2006, NAT IMMUNOL, V7, P1237, DOI 10.1038/ni1420; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Toshchakov V, 2002, NAT IMMUNOL, V3, P392, DOI 10.1038/ni774; Urbonaviciute V, 2008, J EXP MED, V205, P3007, DOI 10.1084/jem.20081165; Xiong Y, 2009, ARCH PHARM RES, V32, P717, DOI 10.1007/s12272-009-1510-9; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yethon J. A., 2001, Current Drug Targets - Infectious Disorders, V1, P91, DOI 10.2174/1568005014606143; Zipris D, 2005, J IMMUNOL, V174, P131, DOI 10.4049/jimmunol.174.1.131	58	92	101	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 29	2011	286	30					26470	26479		10.1074/jbc.M111.227934	http://dx.doi.org/10.1074/jbc.M111.227934			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	796UK	21665946	Green Published, hybrid			2023-01-03	WOS:000293078200025
J	Wilke, RA; Dolan, ME				Wilke, Russell A.; Dolan, M. Eileen			Genetics and Variable Drug Response	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GENOTYPE		[Wilke, Russell A.] Vanderbilt Univ, Med Ctr, Oates Inst Expt Therapeut, Div Clin Pharmacol, Nashville, TN 37232 USA; [Wilke, Russell A.] Vanderbilt Univ, Dept Med, Div Gen Internal Med, Nashville, TN 37232 USA; [Dolan, M. Eileen] Univ Chicago, Dept Med, Comprehens Canc Res Ctr, Comm Clin Pharmacol & Pharmacogen, Chicago, IL 60637 USA	Vanderbilt University; Vanderbilt University; University of Chicago	Wilke, RA (corresponding author), Vanderbilt Univ, Med Ctr, Oates Inst Expt Therapeut, Div Clin Pharmacol, 23rd Ave S & Pierce Ave,550 RRB, Nashville, TN 37232 USA.	russell.a.wilke@vanderbilt.edu			NCI NIH HHS [CA136765, R01 CA136765, P50 CA125183] Funding Source: Medline; NHLBI NIH HHS [U01HL069757, U01 HL069757, U19 HL069757, U19HL065962, U19 HL065962] Funding Source: Medline; NIDDK NIH HHS [R01DK080007, R01 DK080007] Funding Source: Medline; NIGMS NIH HHS [U01GM61393, U01 GM061393] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA136765, P50CA125183] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL069757, U19HL065962, U19HL069757] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK080007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Epstein RS, 2010, J AM COLL CARDIOL, V55, P2804, DOI 10.1016/j.jacc.2010.03.009; Ge DL, 2009, NATURE, V461, P399, DOI 10.1038/nature08309; Klein TE, 2009, NEW ENGL J MED, V360, P753, DOI 10.1056/NEJMoa0809329; Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936; McCormack M, 2011, NEW ENGL J MED, V364, P1134, DOI 10.1056/NEJMoa1013297; Relling MV, 2011, CLIN PHARMACOL THER, V89, P387, DOI 10.1038/clpt.2010.320; Shuldiner AR, 2009, JAMA-J AM MED ASSOC, V302, P849, DOI 10.1001/jama.2009.1232; US Food and Drug Administration, TABL PHARM BIOM DRUG	10	41	41	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	2011	306	3					306	307		10.1001/jama.2011.998	http://dx.doi.org/10.1001/jama.2011.998			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	794BS	21771992	Green Accepted			2023-01-03	WOS:000292870500025
J	Xiong, J; Wang, H; Guo, GM; Wang, SZ; He, LQ; Chen, HF; Wu, J				Xiong, Ji; Wang, Hu; Guo, Guangming; Wang, Shuzeng; He, Liqun; Chen, Haifeng; Wu, Ji			Male Germ Cell Apoptosis and Epigenetic Histone Modification Induced by Tripterygium wilfordii Hook F	PLOS ONE			English	Article							SEX-CHROMOSOME INACTIVATION; SPERMATOGONIAL STEM-CELLS; REPRESSIVE COMPLEX 2; PB-CADHERIN; FORCE-FIELD; AUTOMATED DOCKING; SELF-RENEWAL; SPERMATOGENESIS; METHYLATION; EXPRESSION	Multiglycosides of Tripterygium wilfordii Hook f (GTW), a Chinese herb-derived medicine used as a remedy for rheumatoid arthritis, are considered to be a reversible anti-fertility drug affecting the mammalian spermatids. However, the mechanism behind this effect is still unknown. To study the possible mechanism behind the impact of GTW on spermatogenesis, we administered 4 groups of 4-week-old male mice with different doses of GTW. We found a dose-dependent decrease in the number of germ cells after 40 days of GTW treatment, and an increase in apoptotic cells from the low-dose to the high-dose group. During this same period the dimethylated level of histone H3 lysine 9 (H3K9me2) in GTW-treated testes germ cells declined. Additionally, spermatogonial stem cells (SSCs) from 6-day-old mice were isolated to evaluate the possible effect of GTW or triptolide on development of SSCs. We found a significantly higher incidence of apoptosis and lower dimethylation level of H3K9me2 in the SSCs of GTW or triptolide treatment than in controls. Thus, these data suggest that the GTW-induced apoptosis might be responsible for the fertility impairment in mice. This damage could be traced back to the early stages of spermatogenesis. GTW also affected the epigenetic modification of H3K9 in spermatogenesis. Molecular dynamics simulation suggested that triptolide and dimethylated or trimethylated H3K9 might have similar interaction mechanisms with EED (embryonic ectoderm development). These candidate activation mechanisms provide the first glimpse into the pathway of GTW-induced gonad toxicity, which is crucial for further research and clinical application.	[Xiong, Ji; Wang, Hu; Guo, Guangming; Wang, Shuzeng; Wu, Ji] Shanghai Jiao Tong Univ, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, BioX Res Inst, Shanghai 200030, Peoples R China; [Xiong, Ji; Wang, Hu; Guo, Guangming; Wang, Shuzeng; Wu, Ji] Shanghai Jiao Tong Univ, Dept Biol Sci & Biotechnol, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China; [Chen, Haifeng] Shanghai Jiao Tong Univ, Dept Bioinformat & Biostat, Sch Life Sci & Biotechnol, Shanghai 200030, Peoples R China; [He, Liqun] Shanghai Univ Tradit Chinese Med, Dept Nephrol, Key Lab Liver & Kidney Dis, Shanghai Shuguang Hosp,Minist Educ, Shanghai, Peoples R China; [He, Liqun] Shanghai Tradit Chinese Med Univ, E Inst Tradit Chinese Internal Med, Shanghai Municipal Educ Commiss, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai University of Traditional Chinese Medicine; Shanghai Municipal Education Commission (SHMEC)	Xiong, J (corresponding author), Shanghai Jiao Tong Univ, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, BioX Res Inst, Shanghai 200030, Peoples R China.	Heliqun59@yahoo.com.cn; haifengchen@sjtu.edu.cn; jiwu@sjtu.edu.cn	Chen, Haifeng/AAT-7444-2020	Wang, Hu/0000-0001-6132-8788	National Natural Science Foundation of China [30630012, 90919020]; National Basic Research Program of China [2010CB945001, 2011CB965104]; Ministry of Agriculture of the People's Republic of China [2009ZX08006-010B]; Program of Shanghai Subject Chief Scientist [10XD1402200]; Specialized Research Fund for the Doctoral Program of Higher Education in China [20090073110032]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Ministry of Agriculture of the People's Republic of China(Ministry of Agriculture & Rural Affairs); Program of Shanghai Subject Chief Scientist; Specialized Research Fund for the Doctoral Program of Higher Education in China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP))	Funding is from the Key Program and the Major Research Plan of the National Natural Science Foundation of China [no. 30630012 and 90919020], http://www.nsfc.gov.cn; the National Basic Research Program of China [no. 2010CB945001 and 2011CB965104], http://www.most.gov.cn; the Ministry of Agriculture of the People's Republic of China [no. 2009ZX08006-010B], http://www.moa.gov.cn/sjzz/jiaoyusi; the Program of Shanghai Subject Chief Scientist [no. 10XD1402200], http://www.stcsm.gov.cn/; and the Specialized Research Fund for the Doctoral Program of Higher Education in China [no. 20090073110032], http://www.moe.edu.cn. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bai JP, 2002, CONTRACEPTION, V65, P441, DOI 10.1016/S0010-7824(02)00312-8; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bettegowda A, 2010, PHILOS T R SOC B, V365, P1637, DOI 10.1098/rstb.2009.0196; CASE DA, 2004, AMBER8; Chen HF, 2007, J AM CHEM SOC, V129, P2930, DOI 10.1021/ja0678774; CLERMONT Y, 1962, AM J ANAT, V111, P111, DOI 10.1002/aja.1001110202; Clermont Y., 1993, FRONT ENDOCRINOL, P332; DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397; Davis TL, 1999, GENOMICS, V58, P18, DOI 10.1006/geno.1999.5813; De Rooij DG, 2000, J ANDROL, V21, P776; HUCKINS C, 1978, ANAT REC, V190, P905, DOI 10.1002/ar.1091900410; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Khalil AM, 2004, P NATL ACAD SCI USA, V101, P16583, DOI 10.1073/pnas.0406325101; Kollman PA, 1997, COMPUTER SIMULATION, P83; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Li Jie, 2009, Zhonghua Nan Ke Xue, V15, P569; Li JY, 2004, GENOMICS, V84, P952, DOI 10.1016/j.ygeno.2004.08.012; Liu ZL, 2010, J BIOL CHEM, V285, P2758, DOI 10.1074/jbc.M109.066845; LU QX, 1990, ACTA ACADEMIAE MED S, V12, P203; Morris GM, 1996, J COMPUT AID MOL DES, V10, P293, DOI 10.1007/BF00124499; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Nagano M, 1998, TISSUE CELL, V30, P389, DOI 10.1016/S0040-8166(98)80053-0; Oatley JA, 2008, ANNU REV CELL DEV BI, V24, P263, DOI 10.1146/annurev.cellbio.24.110707.175355; Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236; Pasini D, 2008, COLD SH Q B, V73, P253, DOI 10.1101/sqb.2008.73.009; Payne C, 2006, DEV BIOL, V293, P461, DOI 10.1016/j.ydbio.2006.02.013; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Phillips BT, 2010, PHILOS T R SOC B, V365, P1663, DOI 10.1098/rstb.2010.0026; Qian S., 1989, CHIN J ANDROL, V3, P129; Qin F, 2010, RNA, V16, P1053, DOI 10.1261/rna.2008110; Riising EM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002704; RUSSELL LD, 1990, AM J ANAT, V188, P21, DOI 10.1002/aja.1001880104; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; Sharpe Richard M., 1994, P1363; STERN H, 1993, CELL MOL BIOL TESTIS, P296; Tachibana M, 2007, EMBO J, V26, P3346, DOI 10.1038/sj.emboj.7601767; TONG JS, 1988, STUD TRAD CHINESE ME, V1, P25; Turner JMA, 2007, DEVELOPMENT, V134, P1823, DOI 10.1242/dev.000018; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; Wu J, 2005, DEV BIOL, V284, P437, DOI 10.1016/j.ydbio.2005.05.042; Wu J, 2003, J ENDOCRINOL, V176, P381, DOI 10.1677/joe.0.1760381; Wu J, 2008, CELL SIGNAL, V20, P1052, DOI 10.1016/j.cellsig.2008.01.011; Wu R, 2005, MOL BIOL CELL, V16, P2872, DOI 10.1091/mbc.e04-11-0997; Xu C, 2010, P NATL ACAD SCI USA, V107, P19266, DOI 10.1073/pnas.1008937107; YANG JY, 2008, CARCINOGENESIS TERAT, V5, P393; Yang Zhi-xia, 2008, Zhongguo Yaolixue Tongbao, V24, P838; Ye W, 1991, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V13, P235; Yuan Z, 2009, CELL PROLIFERAT, V42, P123, DOI 10.1111/j.1365-2184.2009.00589.x; Zhang CT, 2008, J REPROD MED, V17, P118; ZHANG YH, 2007, CHINESE J DERMATOVEN, V6, P138; Zhang Y, 2011, J MOL CELL BIOL, V3, P132, DOI 10.1093/jmcb/mjq043; ZHEN QS, 1995, CONTRACEPTION, V51, P121, DOI 10.1016/0010-7824(94)00018-R; Zou K, 2009, NAT CELL BIOL, V11, P631, DOI 10.1038/ncb1869; 李凡, 2008, [生殖与避孕, Reproduction and Contraception], V28, P571	56	24	31	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2011	6	6							e20751	10.1371/journal.pone.0020751	http://dx.doi.org/10.1371/journal.pone.0020751			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	778TS	21698297	Green Submitted, gold, Green Published			2023-01-03	WOS:000291730000023
J	Biagi, JJ; Raphael, MJ; Mackillop, WJ; Kong, WD; King, WD; Booth, CM				Biagi, James J.; Raphael, Michael J.; Mackillop, William J.; Kong, Weidong; King, Will D.; Booth, Christopher M.			Association Between Time to Initiation of Adjuvant Chemotherapy and Survival in Colorectal Cancer A Systematic Review and Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							III COLON-CANCER; STAGE-II; PUBLICATION BIAS; RECTAL-CANCER; FLUOROURACIL; LEUCOVORIN; THERAPY; ANGIOGENESIS; RADIOTHERAPY; OXALIPLATIN	Context Adjuvant chemotherapy (AC) improves survival among patients with resected colorectal cancer. However, the optimal timing from surgery to initiation of AC is unknown. Objective To determine the relationship between time to AC and survival outcomes via a systematic review and meta-analysis. Data Sources MEDLINE (1975 through January 2011), EMBASE, the Cochrane Database of Systematic Reviews, and the Cochrane Central Register of Controlled Trials were searched to identify studies that described the relationship between time to AC and survival. Study Selection Studies were only included if the relevant prognostic factors were adequately described and either comparative groups were balanced or results adjusted for these prognostic factors. Data Extraction Hazard ratios (HRs) for overall survival and disease-free survival from each study were converted to a regression coefficient (beta) and standard error corresponding to a continuous representation per 4 weeks of time to AC. The adjusted beta from individual studies were combined using a fixed-effects model. Inverse variance (1/SE2) was used to weight individual studies. Publication bias was investigated using the trim and fill approach. Results We identified 10 eligible studies involving 15 410 patients (7 published articles, 3 abstracts). Nine of the studies were cohort or population based and 1 was a secondary analysis from a randomized trial of chemotherapy. Six studies reported time to AC as a binary variable and 4 as 3 or more categories. Meta-analysis demonstrated that a 4-week increase in time to AC was associated with a significant decrease in both overall survival (HR, 1.14; 95% confidence interval [CI], 1.10-1.17) and disease-free survival (HR, 1.14; 95% CI, 1.10-1.18). There was no significant heterogeneity among included studies. Results remained significant after adjustment for potential publication bias and when the analysis was repeated to exclude studies of largest weight. Conclusion In a meta-analysis of the available literature on time to AC, longer time to AC was associated with worse survival among patients with resected colorectal cancer.	[Biagi, James J.; Mackillop, William J.; Booth, Christopher M.] Queens Univ, Dept Oncol, Kingston, ON K7L 5P9, Canada; [Raphael, Michael J.; Mackillop, William J.; Kong, Weidong; Booth, Christopher M.] Queens Univ, Div Canc Care & Epidemiol, Canc Res Inst, Kingston, ON K7L 5P9, Canada; [Mackillop, William J.; King, Will D.] Queens Univ, Dept Community Hlth & Epidemiol, Kingston, ON K7L 5P9, Canada	Queens University - Canada; Queens University - Canada; Queens University - Canada	Biagi, JJ (corresponding author), Queens Univ, Dept Oncol, 25 King St W, Kingston, ON K7L 5P9, Canada.	jim.biagi@krcc.on.ca			Canadian Institutes of Health Research; Cancer Care Ontario Chair in Health Services Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Care Ontario Chair in Health Services Research	This work was supported in part by a grant from the Canadian Institutes of Health Research (W.J.M.). Dr Booth is supported as a Cancer Care Ontario Chair in Health Services Research.	Ahmed S, 2010, DIS COLON RECTUM, V53, P1432, DOI 10.1007/DCR.0b013e3181e78815; Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709; Andre T, 2007, J CLIN ONCOL, V25, P3732, DOI 10.1200/JCO.2007.12.2234; [Anonymous], DEC MAK TOOLS HLTH C; [Anonymous], SYST TREATM WAIT TIM; Bayraktar UD, CANCER, DOI [10.1002/cncr.25720, DOI 10.1002/CNCR.25720]; Benson AB, 2004, J CLIN ONCOL, V22, P3408, DOI 10.1200/JCO.2004.05.063; Berglund A, 2008, ANN ONCOL, V19, P400, DOI 10.1093/annonc/mdm582; Biagi JJ, 2007, 2007 AM SOC CLIN ONC; Chau I, 2005, ANN ONCOL, V16, P549, DOI 10.1093/annonc/mdi116; Chen Z, 2008, RADIOTHER ONCOL, V87, P3, DOI 10.1016/j.radonc.2007.11.016; Cheung WY, 2009, DIS COLON RECTUM, V52, P1054, DOI 10.1007/DCR.0b013e3181a51173; Czaykowski P, 2007, 2007 AM SOC CLIN ONC; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Des Guetz G, 2010, EUR J CANCER, V46, P1049, DOI 10.1016/j.ejca.2010.01.020; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; EGGERMONT AMM, 1987, SURGERY, V102, P71; FIDLER IJ, 1994, CELL, V79, P185, DOI 10.1016/0092-8674(94)90187-2; Figueredo A, 2004, J CLIN ONCOL, V22, P3395, DOI 10.1200/JCO.2004.03.087; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301, DOI 10.1093/oxfordjournals.aje.a116237; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P643; GUNDUZ N, 1979, CANCER RES, V39, P3861; Hershman D, 2006, CANCER-AM CANCER SOC, V107, P2581, DOI 10.1002/cncr.22316; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974; Lacy AM, 2002, LANCET, V359, P2224, DOI 10.1016/S0140-6736(02)09290-5; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; Lima ISF, 2011, CANCER-AM CANCER SOC, V117, P3833, DOI 10.1002/cncr.25954; Mackillop WJ, 2007, RADIOTHER ONCOL, V84, P1, DOI 10.1016/j.radonc.2007.05.006; MCCULLOCH P, 1994, LANCET, V344, P402; National Institutes of Health, 1990, ADJ THER PAT COL REC, V8, P1; Ng CSH, 2005, WORLD J SURG, V29, P975, DOI 10.1007/s00268-005-0029-6; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; ONO I, 1994, SCAND J PLAST RECONS, V28, P269, DOI 10.3109/02844319409022010; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Taal BG, 2001, BRIT J CANCER, V85, P1437, DOI 10.1054/bjoc.2001.2117; Wadd N, 2008, ANN ONCOL, V19, P24; Zeig-Owens Rachel, 2009, J Registry Manag, V36, P30	45	435	455	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	2011	305	22					2335	2342		10.1001/jama.2011.749	http://dx.doi.org/10.1001/jama.2011.749			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	773YV	21642686				2023-01-03	WOS:000291349100027
J	Cockayne, S; Hewitt, C; Hicks, K; Jayakody, S; Kang'ombe, AR; Stamuli, E; Turner, G; Thomas, K; Curran, M; Denby, G; Hashmi, F; McIntosh, C; McLarnon, N; Torgerson, D; Watt, I				Cockayne, Sarah; Hewitt, Catherine; Hicks, Kate; Jayakody, Shalmini; Kang'ombe, Arthur Ricky; Stamuli, Eugena; Turner, Gwen; Thomas, Kim; Curran, Mike; Denby, Gary; Hashmi, Farina; McIntosh, Caroline; McLarnon, Nichola; Torgerson, David; Watt, Ian		EVerT Team	Cryotherapy versus salicylic acid for the treatment of plantar warts (verrucae): a randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective To compare the clinical effectiveness of cryotherapy versus salicylic acid for the treatment of plantar warts. Design A multicentre, open, two arm randomised controlled trial. Setting University podiatry school clinics, NHS podiatry clinics, and primary care in England, Scotland, and Ireland. Participants 240 patients aged 12 years and over, with a plantar wart that in the opinion of the healthcare professional was suitable for treatment with both cryotherapy and salicylic acid. Interventions Cryotherapy with liquid nitrogen delivered by a healthcare professional, up to four treatments two to three weeks apart. Patient self treatment with 50% salicylic acid (Verrugon) daily up to a maximum of eight weeks. Main outcome measures Complete clearance of all plantar warts at 12 weeks. Secondary outcomes were (a) complete clearance of all plantar warts at 12 weeks controlling for age, whether the wart had been treated previously, and type of wart, (b) patient self reported clearance of plantar warts at six months, (c) time to clearance of plantar wart, (d) number of plantar warts at 12 weeks, and (e) patient satisfaction with the treatment. Results There was no evidence of a difference between the salicylic acid and cryotherapy groups in the proportions of participants with complete clearance of all plantar warts at 12 weeks (17/119 (14%) v 15/110 (14%), difference 0.65% (95% CI -8.33 to 9.63), P=0.89). The results did not change when the analysis was repeated but with adjustment for age, whether the wart had been treated previously, and type of plantar wart or for patients' preferences at baseline. There was no evidence of a difference between the salicylic acid and cryotherapy groups in self reported clearance of plantar warts at six months (29/95 (31%) v 33/98 (34%), difference -3.15% (-16.31 to 10.02), P=0.64) or in time to clearance (hazard ratio 0.80 (95% CI 0.51 to 1.25), P=0.33). There was also no evidence of a difference in the number of plantar warts at 12 weeks (incident rate ratio 1.08 (0.81 to 1.43), P=0.62). Conclusions Salicylic acid and the cryotherapy were equally effective for clearance of plantar warts.	[Cockayne, Sarah; Hewitt, Catherine; Hicks, Kate; Jayakody, Shalmini; Kang'ombe, Arthur Ricky; Stamuli, Eugena; Turner, Gwen; Torgerson, David; Watt, Ian] Univ York, York Trials Unit, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Thomas, Kim] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2RD, England; [Curran, Mike; Denby, Gary] Univ Northampton, Sch Hlth, Northampton, England; [Hashmi, Farina] Univ Brighton, Sch Hlth Profess, Brighton BN2 4AT, E Sussex, England; [McIntosh, Caroline] Natl Univ Ireland, Discipline Podiatry, Galway, Ireland; [McLarnon, Nichola] Glasgow Caledonian Univ, Sch Hlth & Social Care, Glasgow G4 0BA, Lanark, Scotland; [Watt, Ian] Hull York Med Sch, York, N Yorkshire, England	University of York - UK; University of Nottingham; University of Northampton; University of Brighton; Ollscoil na Gaillimhe-University of Galway; Glasgow Caledonian University; University of Hull; University of York - UK	Cockayne, S (corresponding author), Univ York, York Trials Unit, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.	sarah.cockayne@york.ac.uk	Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Cockayne, Sarah/0000-0002-1288-5497; Hashmi, Farina/0000-0002-6257-2165; Hewitt, Catherine Elizabeth/0000-0002-0415-3536; Thomas, Kim/0000-0001-7785-7465	UK National Institute for Health Research [05/513/02]	UK National Institute for Health Research(National Institute for Health Research (NIHR))	This project was funded by the UK National Institute for Health Research, Health Technology Assessment Programme (project No 05/513/02) and will be published in full in the journal Health Technology Assessment. The views and opinions expressed are those of the authors and do not necessarily reflect those of the Department of Health. William Ransom and Son supplied the 50% salicylic acid (Verrugon) at no cost, and BOC provided one site with liquid nitrogen storage equipment at reduced cost. These manufacturers had no role in the design of the trial or in the collection, analysis, and interpretation of data.	Bruggink SC, 2008, J INVEST DERMATOL, V128, P2549; BUNNEY MH, 1976, BRIT J DERMATOL, V94, P667, DOI 10.1111/j.1365-2133.1976.tb05167.x; Gibbs S, 2006, COCHRANE DB SYST REV, V3; Johnston M. R., 1978, Special Report, New York State Agricultural Experiment Station, P1; Keogh-Brown MR., 2006, HEALTH TECHNOL ASSES, V10, piii, ix; Kilkenny M, 1998, BRIT J DERMATOL, V138, P840; MASSING AM, 1963, ARCH DERMATOL, V87, P306, DOI 10.1001/archderm.1963.01590150022004; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; Schofield J., 2009, SKIN CONDITIONS UK H; STEELE K, 1988, J ROY COLL GEN PRACT, V38, P256; Thomas KS, 2006, HEALTH TECHNOL ASSES, V10, P1; WILLIAMS HC, 1993, BRIT J DERMATOL, V128, P504, DOI 10.1111/j.1365-2133.1993.tb00226.x	12	43	46	1	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 7	2011	342								d3271	10.1136/bmj.d3271	http://dx.doi.org/10.1136/bmj.d3271			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	777SL	21652750	Green Published, Green Submitted, hybrid, Green Accepted			2023-01-03	WOS:000291645200003
J	Granot, T; Venticinque, L; Tseng, JC; Meruelo, D				Granot, Tomer; Venticinque, Lisa; Tseng, Jen-Chieh; Meruelo, Daniel			Activation of Cytotoxic and Regulatory Functions of NK Cells by Sindbis Viral Vectors	PLOS ONE			English	Article							NATURAL-KILLER-CELLS; IN-VIVO; STIMULATORY FACTOR; OVARIAN-CANCER; TUMOR-CELLS; IFN-GAMMA; VIRUS; EXPRESSION; INTERLEUKIN-12; XENOGRAFTS	Oncolytic viruses (OVs) represent a relatively novel anti-cancer modality. Like other new cancer treatments, effective OV therapy will likely require combination with conventional treatments. In order to design combinatorial treatments that work well together, a greater scrutiny of the mechanisms behind the individual treatments is needed. Sindbis virus (SV) based vectors have previously been shown to target and kill tumors in xenograft, syngeneic, and spontaneous mouse models. However, the effect of SV treatment on the immune system has not yet been studied. Here we used a variety of methods, including FACS analysis, cytotoxicity assays, cell depletion, imaging of tumor growth, cytokine blockade, and survival experiments, to study how SV therapy affects Natural Killer (NK) cell function in SCID mice bearing human ovarian carcinoma tumors. Surprisingly, we found that SV anti-cancer efficacy is largely NK cell-dependent. Furthermore, the enhanced therapeutic effect previously observed from Sin/IL12 vectors, which carry the gene for interleukin 12, is also NK cell dependent, but works through a separate IFN gamma-dependent mechanism, which also induces the activation of peritoneal macrophages. These results demonstrate the multimodular nature of SV therapy, and open up new possibilities for potential synergistic or additive combinatorial therapies with other treatments.	[Granot, Tomer; Venticinque, Lisa; Meruelo, Daniel] NYU, Sch Med, Inst Canc, Gene Therapy Ctr, New York, NY 10016 USA; [Granot, Tomer; Venticinque, Lisa; Meruelo, Daniel] NYU, Sch Med, Dept Pathol, New York, NY USA; [Tseng, Jen-Chieh] Dana Farber Canc Inst, Boston, MA 02115 USA	New York University; New York University; Harvard University; Dana-Farber Cancer Institute	Granot, T (corresponding author), NYU, Sch Med, Inst Canc, Gene Therapy Ctr, New York, NY 10016 USA.	DM01@mac.com			U. S. Public Health [CA100687]; National Cancer Institute; National Institutes of Health; Department of Health and Human Services; Litwin Foundation; NATIONAL CANCER INSTITUTE [R01CA100687] Funding Source: NIH RePORTER	U. S. Public Health(United States Department of Health & Human ServicesUnited States Public Health Service); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Health and Human Services; Litwin Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by U. S. Public Health grants CA100687 from the National Cancer Institute, National Institutes of Health, and Department of Health and Human Services. Funding was also provided by a gift from the Litwin Foundation and a Research and License agreement between NYU and CynVec. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altomonte J, 2009, CANCER GENE THER, V16, P266, DOI 10.1038/cgt.2008.74; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bramson JL, 1996, HUM GENE THER, V7, P1995, DOI 10.1089/hum.1996.7.16-1995; BREDENBEEK PJ, 1993, J VIROL, V67, P6439, DOI 10.1128/JVI.67.11.6439-6446.1993; Cerwenka A, 2001, P NATL ACAD SCI USA, V98, P11521, DOI 10.1073/pnas.201238598; CHAN SH, 1991, J EXP MED, V173, P869, DOI 10.1084/jem.173.4.869; Colombo MP, 2002, CYTOKINE GROWTH F R, V13, P155, DOI 10.1016/S1359-6101(01)00032-6; Diaz RM, 2007, CANCER RES, V67, P2840, DOI 10.1158/0008-5472.CAN-06-3974; Elgert KD, 1998, J LEUKOCYTE BIOL, V64, P275, DOI 10.1002/jlb.64.3.275; Galivo F, 2010, GENE THER, V17, P158, DOI 10.1038/gt.2009.161; Grote D, 2001, BLOOD, V97, P3746, DOI 10.1182/blood.V97.12.3746; HABU S, 1981, J IMMUNOL, V127, P34; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Hicks AM, 2006, P NATL ACAD SCI USA, V103, P7753, DOI 10.1073/pnas.0602382103; Hirasawa K, 2003, CANCER RES, V63, P348; Ikeda H, 2002, CYTOKINE GROWTH F R, V13, P95, DOI 10.1016/S1359-6101(01)00038-7; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KARRE K, 1986, NATURE, V319, P675, DOI 10.1038/319675a0; Kayagaki N, 1999, J IMMUNOL, V163, P1906; KING DP, 1983, J IMMUNOL, V131, P315; Leonard JP, 1997, BLOOD, V90, P2541; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Ogbomo H, 2010, MED MICROBIOL IMMUN, V199, P93, DOI 10.1007/s00430-009-0139-0; Prestwich RJ, 2009, HUM GENE THER, V20, P1119, DOI 10.1089/hum.2009.135; Routes JM, 2005, J EXP MED, V202, P1477, DOI 10.1084/jem.20050240; Shafren DR, 2004, CLIN CANCER RES, V10, P53, DOI 10.1158/1078-0432.CCR-0690-3; Smyth MJ, 2006, J IMMUNOL, V176, P1582, DOI 10.4049/jimmunol.176.3.1582; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Toda M, 1999, HUM GENE THER, V10, P385, DOI 10.1089/10430349950018832; Tseng JC, 2007, GENE THER, V14, P1166, DOI 10.1038/sj.gt.3302973; Tseng JC, 2002, JNCI-J NATL CANCER I, V94, P1790; Tseng JC, 2004, NAT BIOTECHNOL, V22, P70, DOI 10.1038/nbt917; Tseng JC, 2004, CANCER RES, V64, P6684, DOI 10.1158/0008-5472.CAN-04-1924; Tseng JC, 2006, J NUCL MED, V47, P1136; Unno Y, 2005, CLIN CANCER RES, V11, P4553, DOI 10.1158/1078-0432.CCR-04-2610; Vaha-Koskela MJV, 2007, CANCER LETT, V254, P178, DOI 10.1016/j.canlet.2007.02.002; Vaha-Koskela MJV, 2006, CANCER RES, V66, P7185, DOI 10.1158/0008-5472.CAN-05-2214; Venticinque L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-37; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; WANG KS, 1992, J VIROL, V66, P4992, DOI 10.1128/JVI.66.8.4992-5001.1992; Worschech A, 2009, CANCER IMMUNOL IMMUN, V58, P1355, DOI 10.1007/s00262-009-0686-7; Worschech A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-301; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Zamai L, 1998, J EXP MED, V188, P2375, DOI 10.1084/jem.188.12.2375	50	16	17	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2011	6	6							e20598	10.1371/journal.pone.0020598	http://dx.doi.org/10.1371/journal.pone.0020598			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	773ME	21674047	Green Published, gold, Green Submitted			2023-01-03	WOS:000291310600018
J	Cleland, K; Peipert, JF; Westhoff, C; Spear, S; Trussell, J				Cleland, Kelly; Peipert, Jeffrey F.; Westhoff, Carolyn; Spear, Scott; Trussell, James			Family Planning as a Cost-Saving Preventive Health Service	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Cleland, Kelly; Trussell, James] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA; [Peipert, Jeffrey F.] Washington Univ, Sch Med, Dept Obstet & Gynecol, St Louis, MO 63110 USA; [Westhoff, Carolyn] Columbia Univ, Dept Obstet & Gynecol, New York, NY USA; [Westhoff, Carolyn] Columbia Univ, Dept Epidemiol, New York, NY USA; [Westhoff, Carolyn] Columbia Univ, Dept Populat & Family Hlth, New York, NY USA; [Spear, Scott] Planned Parenthood Texas Capital Reg, Austin, TX USA; [Spear, Scott] Planned Parenthood Cent Texas, Austin, TX USA; [Trussell, James] Univ Hull, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England	Princeton University; Washington University (WUSTL); Columbia University; Columbia University; Columbia University; University of Hull; University of York - UK	Cleland, K (corresponding author), Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA.		Potter, Joseph E/A-3122-2008	Cleland, Kelly/0000-0001-9966-1260	NICHD NIH HHS [R24 HD047879] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R24HD047879] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Brown S.S., 1995, BEST INTENTIONS UNIN; Frost JJ, 2008, PERSPECT SEX REPRO H, V40, P94, DOI 10.1363/4009408; Postlethwaite D, 2007, CONTRACEPTION, V76, P360, DOI 10.1016/j.contraception.2007.07.006; Secura GM, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.04.017; Trussell J, 2010, CONTRACEPTION, V82, P391, DOI 10.1016/j.contraception.2010.04.008	5	66	69	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 5	2011	364	18								10.1056/NEJMp1104373	http://dx.doi.org/10.1056/NEJMp1104373			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	759DC	21506736				2023-01-03	WOS:000290219800005
J	Colquhoun, D				Colquhoun, David			WELLBEING The A to Z of the wellbeing industry: from angelic reiki to patient centred care	BRITISH MEDICAL JOURNAL			English	Editorial Material							SURVIVAL		UCL, London WC1E 6BT, England	University of London; University College London	Colquhoun, D (corresponding author), UCL, London WC1E 6BT, England.	d.colquhoun@ucl.ac.uk	Colquhoun, David/C-1664-2008	Colquhoun, David/0000-0002-4263-017X				Coyne JC, 2007, PSYCHOL BULL, V133, P367, DOI 10.1037/0033-2909.133.3.367; *DEP BUS INN SKILL, MENT CAP WELLB PROJ; Epstein RM, 2011, ANN FAM MED, V9, P100, DOI 10.1370/afm.1239; Lynch J, 2004, MILBANK Q, V82, P5, DOI 10.1111/j.0887-378X.2004.00302.x; Marmot, 2010, FAIR SOC HLTH LIVES; MARMOT M, WORK STRESS HLTH WHI; Schofield P, 2004, CANCER-AM CANCER SOC, V100, P1276, DOI 10.1002/cncr.20076; Wilkinson R., 2009, SPIRIT LEVEL WHY MOR	8	1	1	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 4	2011	342								d2711	10.1136/bmj.d2711	http://dx.doi.org/10.1136/bmj.d2711			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	762MB	21543407				2023-01-03	WOS:000290481700007
J	Kang, JS; Lee, DW; Koh, YH; Lee, SH				Kang, Jae Soon; Lee, Dae-Weon; Koh, Young Ho; Lee, Si Hyeock			A Soluble Acetylcholinesterase Provides Chemical Defense against Xenobiotics in the Pinewood Nematode	PLOS ONE			English	Article							BUTYRYLCHOLINESTERASE GENETIC-VARIANTS; CAENORHABDITIS-ELEGANS; MOLECULAR-FORMS; BURSAPHELENCHUS-XYLOPHILUS; DEFICIENT MUTANTS; EXPRESSION; INHIBITION; PROTECTION; CHOLINESTERASES; TISSUE	The pinewood nematode genome encodes at least three distinct acetylcholinesterases (AChEs). To understand physiological roles of the three pinewood nematode AChEs (BxACE-1, BxACE-2, and BxACE-3), BxACE-3 in particular, their tissue distribution and inhibition profiles were investigated. Immunohistochemistry revealed that BxACE-1 and BxACE-2 were distributed in neuronal tissues. In contrast, BxACE-3 was detected from some specific tissues and extracted without the aid of detergent, suggesting its soluble nature unlike BxACE-1 and BxACE-2. When present together, BxAChE3 significantly reduced the inhibition of BxACE-1 and BxACE-2 by cholinesterase inhibitors. Knockdown of BxACE-3 by RNA interference significantly increased the toxicity of three nematicidal compounds, supporting the protective role of BxACE-3 against chemicals. In summary, BxACE-3 appears to have a non-neuronal function of chemical defense whereas both BxACE-1 and BxACE-2 have classical neuronal function of synaptic transmission.	[Kang, Jae Soon; Lee, Si Hyeock] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea; [Lee, Dae-Weon; Koh, Young Ho] Hallym Univ, Ilsong Inst Life Sci, Anyang, South Korea; [Lee, Si Hyeock] Seoul Natl Univ, Dept Agr Biotechnol, Seoul, South Korea	Seoul National University (SNU); Hallym University; Seoul National University (SNU)	Kang, JS (corresponding author), Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul, South Korea.	shlee22@snu.ac.kr			Korea Forest Service [500-20060168]; Brain Korea 21 program	Korea Forest Service(Korea Forest Service); Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea)	This work was supported by Grant No. 500-20060168 from the Korea Forest Service (http://english.forest.go.kr). Jae Soon Kang was supported in part by the Brain Korea 21 program (http://bk.snu.ac.kr/_eng/engmain.asp). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alles GA, 1940, J BIOL CHEM, V133, P375; ANGSTADT JD, 1989, J COMP NEUROL, V284, P374, DOI 10.1002/cne.902840305; AUGUSTINSSON KB, 1948, BIOL BULL, V95, P241; BALASUBRAMANIAN AS, 1993, FASEB J, V7, P1354, DOI 10.1096/fasebj.7.14.8224608; Bentley GN, 2005, MOL BIOCHEM PARASIT, V141, P119, DOI 10.1016/j.molbiopara.2005.01.019; Bery A, 2010, DEV GENES EVOL, V220, P61, DOI 10.1007/s00427-010-0328-2; Casida JE, 2004, CHEM RES TOXICOL, V17, P983, DOI 10.1021/tx0499259; CHANG S, 1991, MOL BIOCHEM PARASIT, V49, P205, DOI 10.1016/0166-6851(91)90064-D; CHANG S, 1992, J NEMATOL, V24, P148; Combes D, 2003, EUR J NEUROSCI, V18, P497, DOI 10.1046/j.1460-9568.2003.02749.x; Combes D, 2001, INT REV CYTOL, V209, P207; Combes D, 2000, J MOL BIOL, V300, P727, DOI 10.1006/jmbi.2000.3917; Culetto E, 1999, J MOL BIOL, V290, P951, DOI 10.1006/jmbi.1999.2937; CULOTTI JG, 1981, GENETICS, V97, P281; Denker E, 2008, CHEM-BIOL INTERACT, V175, P125, DOI 10.1016/j.cbi.2008.03.004; DUERR JS, 2006, COMMUNITY; Duysen EG, 2007, TOXICOLOGY, V233, P60, DOI 10.1016/j.tox.2006.11.069; JOHNSON CD, 1981, GENETICS, V97, P261; Kang JS, 2011, MOL BIOCHEM PARASIT, V175, P154, DOI 10.1016/j.molbiopara.2010.11.005; Kang JS, 2009, NEMATOLOGY, V11, P289, DOI 10.1163/156854109X429619; KOLSON DL, 1985, J NEUROGENET, V2, P93, DOI 10.3109/01677068509100145; KOLSON DL, 1985, J NEUROGENET, V2, P69, DOI 10.3109/01677068509100144; Kumar P, 2009, PHYTOTHER RES, V23, P172, DOI 10.1002/ptr.2578; LADU BN, 1991, CELL MOL NEUROBIOL, V11, P79, DOI 10.1007/BF00712801; LAYER PG, 1991, CELL MOL NEUROBIOL, V11, P7, DOI 10.1007/BF00712798; Lazari O, 2003, MOL BIOCHEM PARASIT, V132, P83, DOI 10.1016/j.molbiopara.2003.09.001; Lenz DE, 2005, CHEM-BIOL INTERACT, V157, P205, DOI 10.1016/j.cbi.2005.10.025; Lockridge O, 2000, NEUROTOXICOLOGY, V21, P113; Manoharan I, 2007, CLIN CHIM ACTA, V378, P128, DOI 10.1016/j.cca.2006.11.005; MARTELLY I, 1988, BRAIN RES, V460, P205, DOI 10.1016/0006-8993(88)90365-4; Masson P, 2010, ARCH BIOCHEM BIOPHYS, V494, P107, DOI 10.1016/j.abb.2009.12.005; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; Miyazawa M, 1997, J AGR FOOD CHEM, V45, P677, DOI 10.1021/jf960398b; Miyazawa M, 2005, J AGR FOOD CHEM, V53, P1765, DOI 10.1021/jf040019b; Nickel M, 2010, INVERTEBR BIOL, V129, P1, DOI 10.1111/j.1744-7410.2010.00193.x; Perry NSL, 2000, J PHARM PHARMACOL, V52, P895, DOI 10.1211/0022357001774598; PEZZEMENTI L, 2010, CHEMICOBIOL IN PRESS; Phillips MA, 1999, TRENDS PLANT SCI, V4, P184, DOI 10.1016/S1360-1385(99)01401-6; Raveh L, 1997, TOXICOL APPL PHARM, V145, P43, DOI 10.1006/taap.1997.8160; Ryan TJ, 2009, NAT REV NEUROSCI, V10, P701, DOI 10.1038/nrn2717; Saxena A, 2006, J MOL NEUROSCI, V30, P145, DOI 10.1385/JMN:30:1:145; Takahashi T, 2010, FEBS LETT, V584, P511, DOI 10.1016/j.febslet.2009.11.081; Thullbery MD, 2005, J CELL BIOCHEM, V96, P599, DOI 10.1002/jcb.20530; TOUTANT JP, 1989, PROG NEUROBIOL, V32, P423, DOI 10.1016/0301-0082(89)90031-2; Trapp S, 2001, ANNU REV PLANT PHYS, V52, P689, DOI 10.1146/annurev.arplant.52.1.689; Wood WB, 1988, NEMATODE CAENORHABDI	46	46	50	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 27	2011	6	4							e19063	10.1371/journal.pone.0019063	http://dx.doi.org/10.1371/journal.pone.0019063			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	756NO	21556353	Green Published, gold, Green Submitted			2023-01-03	WOS:000290019400025
J	Kovochich, M; Marsden, MD; Zack, JA				Kovochich, Michael; Marsden, Matthew D.; Zack, Jerome A.			Activation of Latent HIV Using Drug-Loaded Nanoparticles	PLOS ONE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; IMMUNODEFICIENCY-VIRUS TYPE-1; NON-HODGKINS-LYMPHOMA; CELLS-IN-VITRO; BRYOSTATIN 1; PHASE-II; T-CELLS; HIV-1-INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; LIPOSOMES	Antiretroviral therapy is currently only capable of controlling HIV replication rather than completely eradicating virus from patients. This is due in part to the establishment of a latent virus reservoir in resting CD4(+) T cells, which persists even in the presence of HAART. It is thought that forced activation of latently infected cells could induce virus production, allowing targeting of the cell by the immune response. A variety of molecules are able to stimulate HIV from latency. However no tested purging strategy has proven capable of eliminating the infection completely or preventing viral rebound if therapy is stopped. Hence novel latency activation approaches are required. Nanoparticles can offer several advantages over more traditional drug delivery methods, including improved drug solubility, stability, and the ability to simultaneously target multiple different molecules to particular cell or tissue types. Here we describe the development of a novel lipid nanoparticle with the protein kinase C activator bryostatin-2 incorporated (LNP-Bry). These particles can target and activate primary human CD4(+) T-cells and stimulate latent virus production from human T-cell lines in vitro and from latently infected cells in a humanized mouse model ex vivo. This activation was synergistically enhanced by the HDAC inhibitor sodium butyrate. Furthermore, LNP-Bry can also be loaded with the protease inhibitor nelfinavir (LNP-Bry-Nel), producing a particle capable of both activating latent virus and inhibiting viral spread. Taken together these data demonstrate the ability of nanotechnological approaches to provide improved methods for activating latent HIV and provide key proof-of-principle experiments showing how novel delivery systems may enhance future HIV therapy.	[Kovochich, Michael; Zack, Jerome A.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA; [Marsden, Matthew D.; Zack, Jerome A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol & Oncol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kovochich, M (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA.	jzack@ucla.edu			NIH [AI070010]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI070010] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by NIH grant AI070010 and by the UCLA CFAR. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arlen PA, 2006, J VIROL, V80, P1599, DOI 10.1128/JVI.80.3.1599-1603.2006; Baert L, 2009, EUR J PHARM BIOPHARM, V72, P502, DOI 10.1016/j.ejpb.2009.03.006; Brooks DG, 2002, J VIROL, V76, P1673, DOI 10.1128/JVI.76.4.1673-1681.2002; Brooks DG, 2001, NAT MED, V7, P459, DOI 10.1038/86531; Brooks DG, 2003, P NATL ACAD SCI USA, V100, P12955, DOI 10.1073/pnas.2233345100; Brooks DG, 2003, IMMUNITY, V19, P413, DOI 10.1016/S1074-7613(03)00236-X; CAGDAS FM, PHARM DEV TECHNOL; Chun TW, 1999, NAT MED, V5, P651, DOI 10.1038/9498; Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614; Desormeaux A, 2005, METHOD ENZYMOL, V391, P330, DOI 10.1016/S0076-6879(05)91019-7; Dou HY, 2009, J IMMUNOL, V183, P661, DOI 10.4049/jimmunol.0900274; Dutta T, 2008, EUR J PHARM SCI, V34, P181, DOI 10.1016/j.ejps.2008.04.002; Dutta T, 2007, J DRUG TARGET, V15, P89, DOI 10.1080/10611860600965914; Farokhzad OC, 2009, ACS NANO, V3, P16, DOI 10.1021/nn900002m; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; GABIZON A, 1994, CANCER RES, V54, P987; GABIZON A, 1994, ACTA ONCOL, V33, P779, DOI 10.3109/02841869409083948; Gagne JF, 2002, BBA-BIOMEMBRANES, V1558, P198, DOI 10.1016/S0005-2736(01)00432-1; Garg M, 2006, J PHARM PHARMACOL, V58, P605, DOI 10.1211/jpp.58.5.0005; HANSEN CB, 1995, BBA-BIOMEMBRANES, V1239, P133, DOI 10.1016/0005-2736(95)00138-S; JONES HW, 1971, OBSTET GYNECOL, V38, P945; Jordan A, 2003, EMBO J, V22, P1868, DOI 10.1093/emboj/cdg188; Kaur CD, 2008, J DRUG TARGET, V16, P798, DOI 10.1080/10611860802475688 ; Korin YD, 2002, J VIROL, V76, P8118, DOI 10.1128/JVI.76.16.8118-8123.2002; LAUGHLIN MA, 1993, VIROLOGY, V196, P496, DOI 10.1006/viro.1993.1505; Lehrman G, 2005, LANCET, V366, P549, DOI 10.1016/S0140-6736(05)67098-5; Levchenko TS, 2002, INT J PHARMACEUT, V240, P95, DOI 10.1016/S0378-5173(02)00129-1; Lindkvist Annica, 2009, AIDS Res Ther, V6, P15, DOI 10.1186/1742-6405-6-15; MEHLA R, PLOS ONE, V5; Mohammad RM, 1998, CLIN CANCER RES, V4, P445; Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4; Oussoren C, 2001, ADV DRUG DELIVER REV, V50, P143, DOI 10.1016/S0169-409X(01)00154-5; PEREZ M, CURR HIV RES; PETROS RA, NAT REV DRUG DISCOV, V9, P615; Pollock S, 2008, AIDS, V22, P1961, DOI 10.1097/QAD.0b013e32830efd96; Prins JM, 1999, AIDS, V13, P2405, DOI 10.1097/00002030-199912030-00012; Propper DJ, 1998, BRIT J CANCER, V78, P1337, DOI 10.1038/bjc.1998.680; QATSHA KA, 1993, P NATL ACAD SCI USA, V90, P4674, DOI 10.1073/pnas.90.10.4674; Reuse S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006093; Scripture-Adams DD, 2002, J VIROL, V76, P13077, DOI 10.1128/JVI.76.24.13077-13082.2002; Torchilin VP, 2005, NAT REV DRUG DISCOV, V4, P145, DOI 10.1038/nrd1632; Van Praag RME, 2001, J CLIN IMMUNOL, V21, P218, DOI 10.1023/A:1011091300321; Varterasian ML, 2000, CLIN CANCER RES, V6, P825; Varterasian ML, 2001, INVEST NEW DRUG, V19, P245, DOI 10.1023/A:1010676719178; Varterasian ML, 1998, J CLIN ONCOL, V16, P56, DOI 10.1200/JCO.1998.16.1.56; VLACH J, 1992, VIROLOGY, V187, P63, DOI 10.1016/0042-6822(92)90295-Z; Wagner V, 2006, NAT BIOTECHNOL, V24, P1211, DOI 10.1038/nbt1006-1211; Zhang L, 2008, CLIN PHARMACOL THER, V83, P761, DOI 10.1038/sj.clpt.6100400	49	69	74	1	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 5	2011	6	4							e18270	10.1371/journal.pone.0018270	http://dx.doi.org/10.1371/journal.pone.0018270			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	745UD	21483687	Green Submitted, gold, Green Published			2023-01-03	WOS:000289191300015
J	Panouilleres, M; Urquizar, C; Salemme, R; Pelisson, D				Panouilleres, Muriel; Urquizar, Christian; Salemme, Romeo; Pelisson, Denis			Sensory Processing of Motor Inaccuracy Depends on Previously Performed Movement and on Subsequent Motor Corrections: A Study of the Saccadic System	PLOS ONE			English	Article							SHORT-TERM ADAPTATION; EYE-MOVEMENTS; VOLUNTARY SACCADES; GAIN ADAPTATION; VOLITIONAL SACCADES; ANTISACCADE TASK; CORTICAL CONTROL; VISUAL ERROR; REFLEXIVE; SEPARATE	When goal-directed movements are inaccurate, two responses are generated by the brain: a fast motor correction toward the target and an adaptive motor recalibration developing progressively across subsequent trials. For the saccadic system, there is a clear dissociation between the fast motor correction (corrective saccade production) and the adaptive motor recalibration (primary saccade modification). Error signals used to trigger corrective saccades and to induce adaptation are based on post-saccadic visual feedback. The goal of this study was to determine if similar or different error signals are involved in saccadic adaptation and in corrective saccade generation. Saccadic accuracy was experimentally altered by systematically displacing the visual target during motor execution. Post-saccadic error signals were studied by manipulating visual information in two ways. First, the duration of the displaced target after primary saccade termination was set at 15, 50, 100 or 800 ms in different adaptation sessions. Second, in some sessions, the displaced target was followed by a visual mask that interfered with visual processing. Because they rely on different mechanisms, the adaptation of reactive saccades and the adaptation of voluntary saccades were both evaluated. We found that saccadic adaptation and corrective saccade production were both affected by the manipulations of post-saccadic visual information, but in different ways. This first finding suggests that different types of error signal processing are involved in the induction of these two motor corrections. Interestingly, voluntary saccades required a longer duration of post-saccadic target presentation to reach the same amount of adaptation as reactive saccades. Finally, the visual mask interfered with the production of corrective saccades only during the voluntary saccades adaptation task. These last observations suggest that post-saccadic perception depends on the previously performed action and that the differences between saccade categories of motor correction and adaptation occur at an early level of visual processing.	[Panouilleres, Muriel] Lyon Neurosci Res Ctr, CNRS UMR5292, INSERM U1028, IMPACT Integrat Multisensory Percept Act & Cognit, Lyon, France; Univ Lyon 1, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Panouilleres, M (corresponding author), Lyon Neurosci Res Ctr, CNRS UMR5292, INSERM U1028, IMPACT Integrat Multisensory Percept Act & Cognit, Lyon, France.	muriel.panouilleres@inserm.fr	Pelisson, Denis/H-2916-2017	Pelisson, Denis/0000-0002-9114-7758; Panouilleres, Muriel/0000-0003-0264-2093	Agence Nationale pour la Recherche; Institut National de la Sante et de la Recherche Medicale [U864]; Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite Claude Bernard Lyon 1; Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS))	This work was supported by an Agence Nationale pour la Recherche grant (ANR Adapt-Eye) and Institut National de la Sante et de la Recherche Medicale U864. MP was supported by Universite Claude Bernard Lyon 1, and DP was supported by Centre National de la Recherche Scientifique. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aitsebaomo AP, 2000, OPTOMETRY VISION SCI, V77, P321, DOI 10.1097/00006324-200006000-00012; Alahyane N, 2008, CEREBELLUM, V7, P595, DOI 10.1007/s12311-008-0065-5; Alahyane N, 2007, BRAIN RES, V1135, P107, DOI 10.1016/j.brainres.2006.11.077; Albano JE, 1996, VISION RES, V36, P2087, DOI 10.1016/0042-6989(96)89627-1; Bahcall DO, 2000, VISION RES, V40, P2779, DOI 10.1016/S0042-6989(00)00117-6; Cameron BD, 2009, EXP BRAIN RES, V195, P445, DOI 10.1007/s00221-009-1812-7; Collins T, 2008, J NEUROPHYSIOL, V99, P2708, DOI 10.1152/jn.01082.2007; Collins T, 2006, VISION RES, V46, P3659, DOI 10.1016/j.visres.2006.04.004; Cotti J, 2007, J NEUROPHYSIOL, V98, P602, DOI 10.1152/jn.00293.2007; Cotti J, 2009, J PHYSIOL-LONDON, V587, P127, DOI 10.1113/jphysiol.2008.159459; DEGRAAF JB, 1995, NEUROREPORT, V6, P1733, DOI 10.1097/00001756-199509000-00007; DEUBEL H, 1995, VISION RES, V35, P3529, DOI 10.1016/0042-6989(95)00058-M; DEUBEL H, 1986, HUM NEUROBIOL, V5, P245; DEUBEL H, 1987, BIOL CYBERN, V57, P37, DOI 10.1007/BF00318714; ERKELENS CJ, 1993, EXP BRAIN RES, V93, P157; FRENS MA, 1994, EXP BRAIN RES, V100, P293, DOI 10.1007/BF00227199; Fuchs AF, 1996, J NEUROPHYSIOL, V76, P2522, DOI 10.1152/jn.1996.76.4.2522; Fujita M, 2002, COGNITIVE BRAIN RES, V13, P41, DOI 10.1016/S0926-6410(01)00088-X; Gaveau V, 2003, NEUROREPORT, V14, P875, DOI 10.1097/00001756-200305060-00020; Hernandez TD, 2008, J VISION, V8, DOI 10.1167/8.8.3; Hopp J, 2004, PROG NEUROBIOL, V72, P27, DOI 10.1016/j.pneurobio.2003.12.002; Iwamoto Y, 2010, EXP BRAIN RES, V204, P145, DOI 10.1007/s00221-010-2314-3; Kroller J, 1996, EXP BRAIN RES, V111, P477; Mazzoni P, 2006, J NEUROSCI, V26, P3642, DOI 10.1523/JNEUROSCI.5317-05.2006; McDowell JE, 2008, BRAIN COGNITION, V68, P255, DOI 10.1016/j.bandc.2008.08.016; MCLAUGHLIN SC, 1967, PERCEPT PSYCHOPHYS, V2, P359, DOI 10.3758/BF03210071; Montagnini A, 2005, VISION RES, V45, P3391, DOI 10.1016/j.visres.2005.07.013; Muri RM, 2008, BRAIN COGNITION, V68, P284, DOI 10.1016/j.bandc.2008.08.018; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Noto CT, 2001, COGNITIVE BRAIN RES, V12, P301, DOI 10.1016/S0926-6410(01)00062-3; Panouilleres M, 2009, J NEUROPHYSIOL, V101, P1550, DOI 10.1152/jn.90988.2008; Pelisson D, 2010, NEUROSCI BIOBEHAV R, V34, P1103, DOI 10.1016/j.neubiorev.2009.12.010; Pierrot-Deseilligny C, 2003, PROG BRAIN RES, V142, P3; PIERROTDESEILLIGNY C, 1995, ANN NEUROL, V37, P557, DOI 10.1002/ana.410370504; Reingold EM, 2004, J EXP PSYCHOL HUMAN, V30, P194, DOI 10.1037/0096-1523.30.1.194; Reingold EM, 2002, J COGNITIVE NEUROSCI, V14, P371, DOI 10.1162/089892902317361903; Shadmehr R, 2010, ANNU REV NEUROSCI, V33, P89, DOI 10.1146/annurev-neuro-060909-153135; Shafer JL, 2000, J NEUROPHYSIOL, V84, P88, DOI 10.1152/jn.2000.84.1.88; Straube A, 1997, J NEUROPHYSIOL, V77, P874, DOI 10.1152/jn.1997.77.2.874; Wallman J, 1998, J NEUROPHYSIOL, V80, P2405, DOI 10.1152/jn.1998.80.5.2405; Watanabe S, 2003, AURIS NASUS LARYNX, V30, pS41; Zimmermann E, 2009, J NEUROSCI, V29, P11055, DOI 10.1523/JNEUROSCI.1604-09.2009	43	20	20	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2011	6	2							e17329	10.1371/journal.pone.0017329	http://dx.doi.org/10.1371/journal.pone.0017329			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725PJ	21383849	Green Published, Green Submitted, gold			2023-01-03	WOS:000287657500051
J	Martin-Montalvo, A; Villalba, JM; Navas, P; de Cabo, R				Martin-Montalvo, A.; Villalba, J. M.; Navas, P.; de Cabo, R.			NRF2, cancer and calorie restriction	ONCOGENE			English	Review						calorie restriction; carcinogenesis; NRF2; phytochemicals	ANTIOXIDANT-RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; GLUTATHIONE-S-TRANSFERASE; DIETARY ENERGY RESTRICTION; SKIN TUMOR PROMOTION; SMALL MAF PROTEINS; CHEMICALLY-INDUCED MAMMARY; TRANSGENIC MOUSE MODEL; CENTRAL-NERVOUS-SYSTEM; CUL3-BASED E3 LIGASE	The transcription factor NF-E2-related factor (NRF2) is a key regulator of several enzymatic pathways, including cytoprotective enzymes in highly metabolic organs. In this review, we summarize the ongoing research related to NRF2 activity in cancer development, focusing on in vivo studies using NRF2 knockout (KO) mice, which have helped in defining the crucial role of NRF2 in chemoprevention. The lower cancer protection observed in NRF2 KO mice under calorie restriction (CR) suggests that most of the beneficial effects of CR on the carcinogenesis process are likely mediated by NRF2. We propose that future interventions in cancer treatment would be carried out through the activation of NRF2 in somatic cells, which will lead to a delay or prevention of the onset of some forms of human cancers, and subsequently an extension of health-and lifespan. Oncogene (2011) 30, 505-520; doi: 10.1038/onc.2010.492; published online 8 November 2010	[Martin-Montalvo, A.; de Cabo, R.] NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA; [Villalba, J. M.] Univ Cordoba, Dept Biol Celular Fisiol & Inmunol, Cordoba, Spain; [Navas, P.] Univ Pablo Olavide, CSIC, Ctr Andaluz Biol Desarrollo, Seville, Spain; [Navas, P.] ISCIII, Ctr Biomed Res Rare Dis CIBERER, Seville, Spain	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Universidad de Cordoba; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for Developmental Biology (CABD); CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III	de Cabo, R (corresponding author), NIA, Aging Metab & Nutr Unit, Lab Expt Gerontol, NIH, Baltimore, MD 21224 USA.	decabora@mail.nih.gov	NAVAS, PLACIDO/R-5943-2019; Martin-Montalvo, Alejandro/C-2031-2017; de Cabo, Rafael/E-7996-2010; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	NAVAS, PLACIDO/0000-0002-4115-7966; Martin-Montalvo, Alejandro/0000-0002-3886-5355; de Cabo, Rafael/0000-0003-2830-5693; de Cabo, Rafael Carlos/0000-0003-2830-5693; Villalba Montoro, Jose Manuel/0000-0001-8554-3802; de Cabo, Rafael/0000-0002-3354-2442	National Institute on Aging, National Institutes of Health; Junta de Andalucia [CVI 4887, CVI-276]; NIH [1R01AG028125-01A1]; Ministry of Health, Spain [PI080500]; NATIONAL INSTITUTE ON AGING [R01AG028125, ZIAAG000361, ZIAAG000368] Funding Source: NIH RePORTER	National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Junta de Andalucia(Junta de Andalucia); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ministry of Health, Spain(Spanish Government); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	AM-M and RdC are supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. The work was partially supported by Junta de Andalucia International Projects, CVI 4887 and CVI-276, NIH Grant 1R01AG028125-01A1 and FIS Grant PI080500 of the Ministry of Health, Spain. We thank Alex Sossong and Andrew Levette for critiquing the manuscript.	Alam ZI, 1997, J NEUROCHEM, V69, P1326; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Aleksunes LM, 2010, J PHARMACOL EXP THER, V333, P140, DOI 10.1124/jpet.109.162271; ANDREOU KK, 1981, ARCH ORAL BIOL, V26, P525, DOI 10.1016/0003-9969(81)90011-X; ANSHER SS, 1986, FOOD CHEM TOXICOL, V24, P405, DOI 10.1016/0278-6915(86)90205-X; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Bae SY, 2006, CANCER SCI, V97, P774, DOI 10.1111/j.1349-7006.2006.00241.x; Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2; Banning A, 2008, CANCER RES, V68, P9746, DOI 10.1158/0008-5472.CAN-08-1321; Bartke Andrzej, 2007, V35, P69; Birt DF, 1999, J NUTR, V129, p571S, DOI 10.1093/jn/129.2.571S; Birt DF, 2004, J CELL BIOCHEM, V91, P258, DOI 10.1002/jcb.10741; BIRT DF, 1993, CANCER RES, V53, P27; Birt DF, 1998, NUTR CANCER, V31, P119, DOI 10.1080/01635589809514690; BIRT DF, 1991, CANCER RES, V51, P1851; Bishop NA, 2007, NATURE, V447, P545, DOI 10.1038/nature05904; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; BOISSONNEAULT GA, 1986, J NATL CANCER I, V76, P335; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; BREESE CR, 1991, J GERONTOL, V46, pB180, DOI 10.1093/geronj/46.5.B180; Brigelius-Flohe R, 2006, FREE RADICAL RES, V40, P775, DOI 10.1080/10715760600722643; BrownBorg HM, 1996, NATURE, V384, P33, DOI 10.1038/384033a0; Burton NC, 2006, NEUROTOXICOLOGY, V27, P1094, DOI 10.1016/j.neuro.2006.07.019; Butt AJ, 2002, ENDOCRINOLOGY, V143, P2693, DOI 10.1210/en.143.7.2693; CABRAL JRP, 1983, CANCER LETT, V19, P125, DOI 10.1016/0304-3835(83)90146-5; Cakatay U, 2001, EXP GERONTOL, V36, P221, DOI 10.1016/S0531-5565(00)00197-2; Calkins MJ, 2005, P NATL ACAD SCI USA, V102, P244, DOI 10.1073/pnas.0408487101; Campbell JK, 2004, J NUTR, V134, p3486S, DOI 10.1093/jn/134.12.3486S; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Castello L, 2010, FREE RADICAL BIO MED, V48, P47, DOI 10.1016/j.freeradbiomed.2009.10.003; Chan JM, 2001, EPIDEMIOL REV, V23, P82, DOI 10.1093/oxfordjournals.epirev.a000799; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; CHANDRASEKAR B, 1995, CLIN IMMUNOL IMMUNOP, V76, P291, DOI 10.1006/clin.1995.1128; Chang XZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1789; Chartoumpekis D, 2010, BIOCHEM BIOPH RES CO, V396, P463, DOI 10.1016/j.bbrc.2010.04.117; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Chen XL, 2003, J BIOL CHEM, V278, P703, DOI 10.1074/jbc.M203161200; CHENEY KE, 1983, J GERONTOL, V38, P420, DOI 10.1093/geronj/38.4.420; Chiao JW, 2004, CARCINOGENESIS, V25, P1403, DOI 10.1093/carcin/bgh136; Clinton SK, 1996, CANCER EPIDEM BIOMAR, V5, P823; COHEN ND, 1974, CANCER RES, V34, P3245; Collins AR, 2009, CIRC RES, V104, pe42, DOI 10.1161/CIRCRESAHA.108.188771; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cullinan SB, 2004, MOL CELL BIOL, V24, P8477, DOI 10.1128/MCB.24.19.8477-8486.2004; Dai G, 2007, CIRC RES, V101, P723, DOI 10.1161/CIRCRESAHA.107.152942; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; De Cabo R, 2004, EXP GERONTOL, V39, P297, DOI 10.1016/j.exger.2003.12.003; Derjuga A, 2004, MOL CELL BIOL, V24, P3286, DOI 10.1128/MCB.24.8.3286-3294.2004; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; Ding Y, 2008, AM J PATHOL, V172, P1529, DOI 10.2353/ajpath.2008.070429; Dinikova-Kostova AT, 2004, METHOD ENZYMOL, V382, P423; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Dinkova-Kostova AT, 2001, P NATL ACAD SCI USA, V98, P3404, DOI 10.1073/pnas.051632198; DJURIC Z, 1993, MUTAT RES, V295, P181, DOI 10.1016/0921-8734(93)90019-Y; Duan WS, 2009, IN VITRO CELL DEV-AN, V45, P388, DOI 10.1007/s11626-009-9194-5; Efferth T, 2005, IN VIVO, V19, P225; Eggler AL, 2005, P NATL ACAD SCI USA, V102, P10070, DOI 10.1073/pnas.0502402102; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Fialka F, 2008, ORAL ONCOL, V44, P941, DOI 10.1016/j.oraloncology.2007.10.011; Fields WR, 1999, CARCINOGENESIS, V20, P1121, DOI 10.1093/carcin/20.6.1121; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; Franke TF, 2008, ONCOGENE, V27, P6473, DOI 10.1038/onc.2008.313; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; GARCEA R, 1988, CARCINOGENESIS, V9, P931, DOI 10.1093/carcin/9.6.931; Gerhauser C, 1997, CANCER RES, V57, P272; GIOVANNUCCI E, 1995, J NATL CANCER I, V87, P1767, DOI 10.1093/jnci/87.23.1767; GORDON GB, 1987, ADV ENZYME REGUL, V26, P355, DOI 10.1016/0065-2571(87)90023-9; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; GROSS L, 1986, P NATL ACAD SCI USA, V83, P7928, DOI 10.1073/pnas.83.20.7928; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; Halagappa VKM, 2007, NEUROBIOL DIS, V26, P212, DOI 10.1016/j.nbd.2006.12.019; Halliwell B, 1996, FREE RADICAL RES, V25, P57, DOI 10.3109/10715769609145656; Halliwell B, 1996, BIOCHEM SOC T, V24, P1023, DOI 10.1042/bst0241023; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; HANSEN BC, 1995, OBES RES, V3, pS199, DOI 10.1002/j.1550-8528.1995.tb00464.x; Hayes JD, 2000, BIOCHEM SOC T, V28, P33, DOI 10.1042/bst0280033; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; HECHT SS, 1995, CANCER EPIDEM BIOMAR, V4, P877; Heiss E, 2001, J BIOL CHEM, V276, P32008, DOI 10.1074/jbc.M104794200; Henderson CJ, 1998, P NATL ACAD SCI USA, V95, P5275, DOI 10.1073/pnas.95.9.5275; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; HOWELL TH, 1987, AGE AGEING, V16, P194; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; HURSTING SD, 1994, P NATL ACAD SCI USA, V91, P7036, DOI 10.1073/pnas.91.15.7036; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Hyer ML, 2005, CANCER RES, V65, P4799, DOI 10.1158/0008-5472.CAN-04-3319; Hyun DH, 2007, J NEUROCHEM, V100, P1364, DOI 10.1111/j.1471-4159.2006.04411.x; Hyun DH, 2006, P NATL ACAD SCI USA, V103, P19908, DOI 10.1073/pnas.0608008103; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; INGRAM DK, 1990, J GERONTOL, V45, pB148, DOI 10.1093/geronj/45.5.B148; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jiang T, 2010, DIABETES, V59, P850, DOI 10.2337/db09-1342; Jimenez-Hidalgo M, 2009, AGING CELL, V8, P140, DOI 10.1111/j.1474-9726.2009.00461.x; Johnson JB, 2007, FREE RADICAL BIO MED, V42, P665, DOI 10.1016/j.freeradbiomed.2006.12.005; Juge N, 2007, CELL MOL LIFE SCI, V64, P1105, DOI 10.1007/s00018-007-6484-5; Jung KJ, 2009, INFLAMM RES, V58, P143, DOI 10.1007/s00011-008-7227-2; Kalaany NY, 2009, NATURE, V458, P725, DOI 10.1038/nature07782; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kanninen K, 2009, P NATL ACAD SCI USA, V106, P16505, DOI 10.1073/pnas.0908397106; Keller UAD, 2006, MOL CELL BIOL, V26, P3773, DOI 10.1128/MCB.26.10.3773-3784.2006; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; KENSLER TW, 1995, J CELL BIOCHEM, P101; KENSLER TW, 1987, CANCER RES, V47, P4271; Khor TO, 2008, PLANTA MED, V74, P1540, DOI 10.1055/s-0028-1088303; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kiritoshi S, 2003, DIABETES, V52, P2570, DOI 10.2337/diabetes.52.10.2570; Kitamura Y, 2007, CANCER SCI, V98, P19, DOI 10.1111/j.1349-7006.2006.00352.x; Klaassen CD, 2005, CURR DRUG METAB, V6, P309, DOI 10.2174/1389200054633826; KLURFELD DM, 1987, CANCER RES, V47, P2759; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2004, METHOD ENZYMOL, V378, P273; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kraft AD, 2004, J NEUROSCI, V24, P1101, DOI 10.1523/JNEUROSCI.3817-03.2004; KRITCHEVSKY D, 1984, CANCER RES, V44, P3174; Kritchevsky D, 2001, J NUTR SCI VITAMINOL, V47, P13, DOI 10.3177/jnsv.47.13; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; LAGOPOULOS L, 1987, CARCINOGENESIS, V8, P33, DOI 10.1093/carcin/8.1.33; Lal S, 2008, CANCER SCI, V99, P2045, DOI 10.1111/j.1349-7006.2008.00903.x; Lapillonne H, 2003, CANCER RES, V63, P5926; Lee HH, 2010, ARCH BIOCHEM BIOPHYS, V501, P142, DOI 10.1016/j.abb.2010.06.011; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, J BIOL CHEM, V278, P37948, DOI 10.1074/jbc.M305204200; Lee KW, 2005, J BIOL CHEM, V280, P16942, DOI 10.1074/jbc.M412757200; Lee SK, 2010, LIFE SCI, V86, P107, DOI 10.1016/j.lfs.2009.11.013; Leifert WR, 2008, NUTR RES, V28, P729, DOI [10.1016/j.nutres.2008.08.007, 10.1016/j.nutres.2008.09.001]; Leonard MO, 2006, FASEB J, V20, P2624, DOI 10.1096/fj.06-5097fje; LI Y, 1992, J BIOL CHEM, V267, P15097; Lii CK, 2010, J NUTR, V140, P885, DOI 10.3945/jn.110.121418; Liu XM, 2007, CARDIOVASC RES, V75, P381, DOI 10.1016/j.cardiores.2007.03.004; LOK E, 1988, CANCER LETT, V38, P249, DOI 10.1016/0304-3835(88)90016-X; Love R, 2005, LANCET NEUROL, V4, P84, DOI 10.1016/S1474-4422(05)00985-3; Maher J, 2010, TOXICOL APPL PHARM, V244, P4, DOI 10.1016/j.taap.2010.01.011; Mandlekar S, 2006, CURR DRUG METAB, V7, P661, DOI 10.2174/138920006778017795; MANJGALADZE M, 1993, MUTAT RES, V295, P201, DOI 10.1016/0921-8734(93)90021-T; Marzetti E, 2009, BIOFACTORS, V35, P28, DOI 10.1002/biof.5; MASORO EJ, 1995, OBES RES, V3, pS241, DOI 10.1002/j.1550-8528.1995.tb00470.x; Mattison Julie A., 2007, V35, P137; Mattson MP, 2003, NEUROLOGY, V60, P690, DOI 10.1212/01.WNL.0000042785.02850.11; Mattson MP, 2001, MECH AGEING DEV, V122, pIII; McKiernan S, 2004, FASEB J, V18, P580, DOI 10.1096/fj.03-0667fje; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2004, J BIOL CHEM, V279, P31556, DOI 10.1074/jbc.M403061200; Miller EC, 2002, UROL CLIN N AM, V29, P83, DOI 10.1016/S0094-0143(02)00020-4; Mitra A, 2009, CLIN EXP METASTAS, V26, P559, DOI 10.1007/s10585-009-9255-x; Miyagi S, 2003, Asia Pac J Public Health, V15 Suppl, pS3, DOI 10.1177/101053950301500S03; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Moreschi C., 1909, Z IMMUNITATSFORSCH, V2, P661; Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]; Motohashi H, 2004, P NATL ACAD SCI USA, V101, P6379, DOI 10.1073/pnas.0305902101; Motohashi H, 2004, TRENDS MOL MED, V10, P549, DOI 10.1016/j.molmed.2004.09.003; Muguruma M, 2006, TOXICOLOGY, V228, P178, DOI 10.1016/j.tox.2006.08.029; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Murakami S, 1996, GENETICS, V143, P1207; Muto A, 1998, EMBO J, V17, P5734, DOI 10.1093/emboj/17.19.5734; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nair S, 2006, PHARM RES-DORDR, V23, P2621, DOI 10.1007/s11095-006-9099-x; Nguyen T, 2004, FREE RADICAL BIO MED, V37, P433, DOI 10.1016/j.freeradbiomed.2004.04.033; Nguyen T, 2003, J BIOL CHEM, V278, P4536, DOI 10.1074/jbc.M207293200; Nguyen TV, 2009, ONCOL RES, V18, P349, DOI 10.3727/096504010X12626118080064; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Nolan KA, 2010, BIOCHEM PHARMACOL, V80, P977, DOI 10.1016/j.bcp.2010.06.024; Numazawa S, 2003, AM J PHYSIOL-CELL PH, V285, pC334, DOI 10.1152/ajpcell.00043.2003; Okawa H, 2006, BIOCHEM BIOPH RES CO, V339, P79, DOI 10.1016/j.bbrc.2005.10.185; Onken B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008758; Osburn WO, 2008, TOXICOL SCI, V104, P218, DOI 10.1093/toxsci/kfn079; Oyake T, 1996, MOL CELL BIOL, V16, P6083; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Palli D, 2000, INT J CANCER, V87, P444, DOI 10.1002/1097-0215(20000801)87:3&lt;444::AID-IJC21&gt;3.0.CO;2-#; PASHKO LL, 1991, CARCINOGENESIS, V12, P2189, DOI 10.1093/carcin/12.11.2189; PASHKO LL, 1992, CARCINOGENESIS, V13, P1925, DOI 10.1093/carcin/13.10.1925; Patel M, 2008, LUNG CANCER, V59, P340, DOI 10.1016/j.lungcan.2007.08.033; Pearson KJ, 2008, P NATL ACAD SCI USA, V105, P2325, DOI 10.1073/pnas.0712162105; Philip M, 2004, SEMIN CANCER BIOL, V14, P433, DOI 10.1016/j.semcancer.2004.06.006; Pietsch EC, 2003, J BIOL CHEM, V278, P2361, DOI 10.1074/jbc.M210664200; Pollak M, 2009, CANCER PREV RES, V2, P698, DOI 10.1158/1940-6207.CAPR-09-0134; POLLARD M, 1984, CANCER TREAT REP, V68, P405; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; PRESTERA T, 1995, MOL MED, V1, P827, DOI 10.1007/BF03401897; Pugh TD, 1999, CANCER RES, V59, P1642; Qin WP, 2008, ANN NY ACAD SCI, V1147, P335, DOI 10.1196/annals.1427.024; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Ramsey JJ, 2000, EXP GERONTOL, V35, P1131, DOI 10.1016/S0531-5565(00)00166-2; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; REINHART J, 1993, ARCH BIOCHEM BIOPHYS, V303, P383, DOI 10.1006/abbi.1993.1299; Rous P, 1914, J EXP MED, V20, P433, DOI 10.1084/jem.20.5.433; RUGGERI BA, 1989, CANCER RES, V49, P4130; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; Sell C, 2003, HORM METAB RES, V35, P705, DOI 10.1055/s-2004-814156; SHANTZ LM, 1989, P NATL ACAD SCI USA, V86, P3852, DOI 10.1073/pnas.86.10.3852; SHAW PJ, 1995, ANN NEUROL, V38, P691, DOI 10.1002/ana.410380424; Shen GX, 2006, MOL CANCER THER, V5, P39, DOI 10.1158/1535-7163.MCT-05-0293; Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082; Shih AY, 2005, J BIOL CHEM, V280, P22925, DOI 10.1074/jbc.M414635200; Shih AY, 2003, J NEUROSCI, V23, P3394, DOI 10.1523/jneurosci.23-08-03394.2003; Shih PH, 2007, BIOGERONTOLOGY, V8, P71, DOI 10.1007/s10522-006-9033-y; SHIMOKAWA I, 1991, J GERONTOL, V46, pB228, DOI 10.1093/geronj/46.6.B228; Shou M, 2001, J BIOL CHEM, V276, P2256, DOI 10.1074/jbc.M008799200; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Stack C, 2010, FREE RADICAL BIO MED, V49, P147, DOI 10.1016/j.freeradbiomed.2010.03.017; Stadtman ER, 1998, DRUG METAB REV, V30, P225, DOI 10.3109/03602539808996310; Stewart JW, 2005, CARCINOGENESIS, V26, P1077, DOI 10.1093/carcin/bgi051; Suh JH, 2004, P NATL ACAD SCI USA, V101, P3381, DOI 10.1073/pnas.0400282101; Suzuki M, 2001, Nihon Ronen Igakkai Zasshi, V38, P163; Suzuki T, 2005, BIOCHEM J, V388, P65, DOI 10.1042/BJ20041860; Sykiotis GP, 2008, DEV CELL, V14, P76, DOI 10.1016/j.devcel.2007.12.002; TANNENBAUM A, 1949, CANCER RES, V9, P162; TANNENBAUM A, 1953, ADV CANCER RES, V1, P451, DOI 10.1016/S0065-230X(08)60009-3; TAUB R, 1987, J BIOL CHEM, V262, P10893; Thatcher Gregory R. J., 2005, Current Alzheimer Research, V2, P171, DOI 10.2174/1567205053585945; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Thompson HJ, 2003, J MAMMARY GLAND BIOL, V8, P133, DOI 10.1023/A:1025743607445; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; Tong KI, 2006, MOL CELL BIOL, V26, P2887, DOI 10.1128/MCB.26.8.2887-2900.2006; Tong KI, 2006, BIOL CHEM, V387, P1311, DOI 10.1515/BC.2006.164; Tullet JMA, 2008, CELL, V132, P1025, DOI 10.1016/j.cell.2008.01.030; Udenigwe CC, 2008, NUTR REV, V66, P445, DOI 10.1111/j.1753-4887.2008.00076.x; Ungvari Z, 2008, CIRC RES, V102, P519, DOI 10.1161/CIRCRESAHA.107.168369; Volchegorskii I A, 2004, Neurosci Behav Physiol, V34, P303, DOI 10.1023/B:NEAB.0000018736.84877.4f; Wakabayashi N, 2004, P NATL ACAD SCI USA, V101, P2040, DOI 10.1073/pnas.0307301101; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Wang HJ, 2010, J HUAZHONG U SCI-MED, V30, P415, DOI 10.1007/s11596-010-0441-5; Warabi E, 2007, FREE RADICAL BIO MED, V42, P260, DOI 10.1016/j.freeradbiomed.2006.10.043; Warita H, 2001, MOL BRAIN RES, V89, P147, DOI 10.1016/S0169-328X(01)00029-8; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WATTENBERG LW, 1972, JNCI-J NATL CANCER I, V48, P1425; Weed JL, 1997, PHYSIOL BEHAV, V62, P97, DOI 10.1016/S0031-9384(97)00147-9; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Westerbeek ZW, 2008, J GERONTOL A-BIOL, V63, P1131, DOI 10.1093/gerona/63.11.1131; Willcox BJ, 2007, ANN NY ACAD SCI, V1114, P434, DOI 10.1196/annals.1396.037; Williams KV, 1998, DIABETES CARE, V21, P2, DOI 10.2337/diacare.21.1.2; Wilson LA, 2005, FASEB J, V19, P2085, DOI 10.1096/fj.05-4401fje; Xu CJ, 2006, CANCER RES, V66, P8293, DOI 10.1158/0008-5472.CAN-06-0300; Xue MZ, 2008, DIABETES, V57, P2809, DOI 10.2337/db06-1003; Yamamoto T, 2006, GENES CELLS, V11, P575, DOI 10.1111/j.1365-2443.2006.00965.x; Yang H, 2004, J GERONTOL A-BIOL, V59, P316; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Ye G, 2004, DIABETES, V53, P1336, DOI 10.2337/diabetes.53.5.1336; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Zakkar M, 2009, ARTERIOSCL THROM VAS, V29, P1851, DOI 10.1161/ATVBAHA.109.193375; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147	263	95	98	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2011	30	5					505	520		10.1038/onc.2010.492	http://dx.doi.org/10.1038/onc.2010.492			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	715WG	21057541	Green Accepted, Green Submitted			2023-01-03	WOS:000286922300001
J	Poste, G				Poste, George			Bring on the biomarkers	NATURE			English	Editorial Material							MEDICINE		[Poste, George] Complex Adapt Syst Initiat, Scottsdale, AZ 85257 USA; [Poste, George] Arizona State Univ, Scottsdale, AZ 85257 USA	Arizona State University	Poste, G (corresponding author), Complex Adapt Syst Initiat, Scottsdale, AZ 85257 USA.	george.poste@asu.edu						Auffray C, 2009, GENOME MED, V1, DOI 10.1186/gm2; Biesecker LG, 2009, GENOME RES, V19, P1665, DOI 10.1101/gr.092841.109; Davis JC, 2009, NAT REV DRUG DISCOV, V8, P279, DOI 10.1038/nrd2825; Javitt G, 2010, NATURE, V466, P817, DOI 10.1038/466817a; Meckley LM, 2010, HEALTH POLICY, V94, P91, DOI 10.1016/j.healthpol.2009.09.006; Moore Helen M, 2009, Cancer Res, V69, P6770, DOI 10.1158/0008-5472.CAN-09-1795; Ransohoff DF, 2010, J CLIN ONCOL, V28, P698, DOI 10.1200/JCO.2009.25.6065; Schadt EE, 2009, NATURE, V461, P218, DOI 10.1038/nature08454; Vaught J., 2009, RES POLICY INITIATIV	9	386	393	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 13	2011	469	7329					156	157		10.1038/469156a	http://dx.doi.org/10.1038/469156a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	705NO	21228852				2023-01-03	WOS:000286143400015
J	Parker, C; Waters, R; Leighton, C; Hancock, J; Sutton, R; Moorman, AV; Ancliff, P; Morgan, M; Masurekar, A; Goulden, N; Green, N; Revesz, T; Darbyshire, P; Love, S; Saha, V				Parker, Catriona; Waters, Rachel; Leighton, Carly; Hancock, Jeremy; Sutton, Rosemary; Moorman, Anthony V.; Ancliff, Philip; Morgan, Mary; Masurekar, Ashish; Goulden, Nicholas; Green, Nina; Revesz, Tamas; Darbyshire, Philip; Love, Sharon; Saha, Vaskar			Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial	LANCET			English	Article							DOSE ARA-C; CHILDHOOD LEUKEMIA; ACCELERATED APPROVAL; PEDIATRIC-PATIENTS; ONCOLOGY GROUP; RISK; IDARUBICIN; EXPERIENCE; THERAPY; SENSITIVITY	Background Although survival of children with acute lymphoblastic leukaemia has improved greatly in the past two decades, the outcome of those who relapse has remained static. We investigated the outcome of children with acute lymphoblastic leukaemia who relapsed on present therapeutic regimens. Methods This open-label randomised trial was undertaken in 22 centres in the UK and Ireland and nine in Australia and New Zealand. Patients aged 1-18 years with first relapse of acute lymphoblastic leukaemia were stratified into high-risk, intermediate-risk, and standard-risk groups on the basis of duration of first complete remission, site of relapse, and immunophenotype. All patients were allocated to receive either idarubicin or mitoxantrone in induction by stratified concealed randomisation. Neither patients nor those giving interventions were masked. After three blocks of therapy, all high-risk group patients and those from the intermediate group with postinduction high minimal residual disease (>= 10(-4) cells) received an allogenic stem-cell transplant. Standard-risk and intermediate-risk patients with postinduction low minimal residual disease (<10(-4) cells) continued chemotherapy. The primary outcome was progression-free survival and the method of analysis was intention-to-treat. Randomisation was stopped in December, 2007 because of differences in progression-free and overall survival between the two groups. This trial is registered, reference number ISCRTN45724312. Findings Of 239 registered patients, 216 were randomly assigned to either idarubicin (109 analysed) or mitoxantrone (103 analysed). Estimated 3-year progression-free survival was 35.9% (95% CI 25.9-45.9) in the idarubicin group versus 64.6% (54.2-73.2) in the mitoxantrone group (p=0.0004), and 3-year overall survival was 45.2% (34.5-55.3) versus 69.0% (58.5-77.3; p=0.004). Differences in progression-free survival between groups were mainly related to a decrease in disease events (progression, second relapse, disease-related deaths; HR 0.56, 0.34-0.92, p=0.007) rather than an increase in adverse treatment effects (treatment death, second malignancy; HR 0.52, 0.24-1.11). Interpretation As compared with idarubicin, mitoxantrone conferred a significant benefit in progression-free and overall survival in children with relapsed acute lymphobastic leukaemia, a potentially useful clinical finding that warrants further investigation.	[Saha, Vaskar] Christie NHS Fdn Trust, Paediat & Adolescent Oncol Unit, Manchester M20 4BX, Lancs, England; [Parker, Catriona; Leighton, Carly; Masurekar, Ashish; Saha, Vaskar] Univ Manchester, Manchester Acad Hlth Sci Ctr, Cent Manchester Univ Hosp Fdn Trust, Sch Canc & Enabling Sci,Canc Res UK Childrens Can, Manchester, Lancs, England; [Leighton, Carly] Royal Childrens Hosp, Haematol Oncol Dept, Herston, Qld, Australia; [Waters, Rachel; Love, Sharon] Univ Oxford, Ctr Stat Med, Oxford, England; [Hancock, Jeremy] Southmead Hosp, Bristol Genet Lab, Bristol, Avon, England; [Sutton, Rosemary] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia; [Moorman, Anthony V.] Newcastle Univ, No Inst Canc Res, Leukaemia Res Cytogenet Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; [Ancliff, Philip; Goulden, Nicholas] Great Ormond St Hosp Sick Children, London, England; [Morgan, Mary] Southampton Gen Hosp, Child Oncol & Haematol Ctr, Southampton SO9 4XY, Hants, England; [Green, Nina; Revesz, Tamas] Children Youth & Womens Hlth Serv, Dept Clin Haematol Oncol, Adelaide, SA, Australia; [Darbyshire, Philip] Birmingham Childrens Hosp, Dept Haematol, Birmingham, W Midlands, England	Christie NHS Foundation Trust; University of Manchester; Royal Children's Hospital Brisbane; University of Oxford; Southmead Hospital; Children's Cancer Institute; Children's Medical Research Institute - Australia; University of New South Wales Sydney; Newcastle University - UK; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Southampton; University of Birmingham	Saha, V (corresponding author), Christie NHS Fdn Trust, Paediat & Adolescent Oncol Unit, Manchester M20 4BX, Lancs, England.	vaskar.saha@manchester.ac.uk	Love, Seth/E-6545-2012; Moorman, Anthony/G-1468-2014; Sutton, Rosemary/J-3784-2014; Moorman, Anthony/F-5518-2010	Moorman, Anthony/0000-0002-9781-6107; Sutton, Rosemary/0000-0002-0188-6005; Parker, Catriona/0000-0002-3826-2554; Love, Sharon/0000-0002-6695-5390; Saha, Vaskar/0000-0002-2916-9649	Cancer Research UK; Leukaemia and Lymphoma Research; Cancer Council NSW; Sporting Chance Cancer Foundation; Barts; London NHS Trust; University of Leicester NHS Trust; Great Ormond Street Hospital Childrens Charity [V0903] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Leukaemia and Lymphoma Research; Cancer Council NSW(Cancer Council New South Wales); Sporting Chance Cancer Foundation; Barts; London NHS Trust; University of Leicester NHS Trust; Great Ormond Street Hospital Childrens Charity	This study was funded in part by a programme grant from Cancer Research UK (VS); grants from the Leukaemia and Lymphoma Research funded in part the analysis of minimal residual disease (NGo) and the Leukaemia Research Cytogenetics Group (AVM). The Cancer Council NSW and Sporting Chance Cancer Foundation funded analysis of minimal residual disease at CCIA (RS). MRD standardisation and quality control were supported by EuroMRD. The trial was initially sponsored by the Barts and the London NHS Trust (2003-6) and then by the University of Leicester NHS Trust (2006-09). In the UK, assessments of minimal residual disease were done at the UK MRD Network Laboratories (Barts, Bristol, Glasgow, Sheffield). We thank the participating children and their families and the physicians who enrolled their patients into the study. Marita Marshall, Helen Crowne, John Fox, and members of the Cancer Research UK IS team helped to design and run the database. We thank the members of the Data Monitoring Committee-namely, Mike Stevens, Moira Stewart, and Rob Edwards, as well as Tim Eden, Shelchar Krishnan, Louise Chessman, and Anita Lim for their contributions. This paper is dedicated to the memory of Tony Oakhill, who pioneered the management of relapsed acute lymphoblastic leukaemia in the UK.	Cao CY, 2009, CELL MOL IMMUNOL, V6, P469, DOI 10.1038/cmi.2009.59; Chan A, 2005, CLIN EXP IMMUNOL, V139, P152, DOI 10.1111/j.1365-2249.2005.02653.x; Einsiedel HG, 2005, J CLIN ONCOL, V23, P7942, DOI 10.1200/JCO.2005.01.1031; Errington F, 2004, CANCER CHEMOTH PHARM, V53, P155, DOI 10.1007/s00280-003-0701-1; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fleming TR, 2005, HEALTH AFFAIR, V24, P67, DOI 10.1377/hlthaff.24.1.67; Gibson BES, 2005, LEUKEMIA, V19, P2130, DOI 10.1038/sj.leu.2403924; Gray R, 1988, ANN STAT, V16, P1140; Harned TM, 2008, CURR ONCOL REP, V10, P453, DOI 10.1007/s11912-008-0070-3; HENZE G, 1991, BLOOD, V78, P1166; HONGO T, 1991, INT J HEMATOL, V54, P219; Karl S, 2009, J CELL MOL MED, V13, P4239, DOI 10.1111/j.1582-4934.2009.00888.x; Ko RH, 2010, J CLIN ONCOL, V28, P648, DOI 10.1200/JCO.2009.22.2950; Krishnan S, 2010, LEUKEMIA, V24, P450, DOI 10.1038/leu.2009.264; Lawson SE, 2000, BRIT J HAEMATOL, V108, P531; Malempati S, 2007, J CLIN ONCOL, V25, P5800, DOI 10.1200/JCO.2007.10.7508; McCullagh P., 2019, GEN LINEAR MODELS, DOI DOI 10.1007/978-1-4899-3242-6; Nachman JB, 1998, NEW ENGL J MED, V338, P1663, DOI 10.1056/NEJM199806043382304; Parker BS, 2004, J BIOL CHEM, V279, P18814, DOI 10.1074/jbc.M400931200; Raetz EA, 2008, J CLIN ONCOL, V26, P3971, DOI 10.1200/JCO.2008.16.1414; REID JM, 1990, CANCER RES, V50, P6525; Roy A, 2005, BRIT J HAEMATOL, V130, P67, DOI 10.1111/j.1365-2141.2005.05572.x; Schrappe M, 2010, LEUKEMIA, V24, P253, DOI 10.1038/leu.2009.276; Seibel NL, 2008, BLOOD, V111, P2548, DOI 10.1182/blood-2007-02-070342; Stam RW, 2003, BLOOD, V101, P1270, DOI 10.1182/blood-2002-05-1600; Susman E, 2004, J NATL CANCER I, V96, P1495, DOI 10.1093/jnci/96.20.1495; Tallen G, 2010, J CLIN ONCOL, V28, P2339, DOI 10.1200/JCO.2009.25.1983; Testi AM, 2002, BRIT J HAEMATOL, V118, P741, DOI 10.1046/j.1365-2141.2002.03706.x; Testi AM, 1997, HAEMATOLOGICA, V82, P664; Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6; van der Velden VHJ, 2003, LEUKEMIA, V17, P1013, DOI 10.1038/sj.leu.2402922; von Stackelberg A, 2008, BLOOD, V111, P2573, DOI 10.1182/blood-2007-07-102525; WELLS RJ, 1985, J CLIN ONCOL, V3, P998, DOI 10.1200/JCO.1985.3.7.998; 2010, CLIN TRIAL AUTHORISA	34	228	250	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	2010	376	9757					2009	2017		10.1016/S0140-6736(10)62002-8	http://dx.doi.org/10.1016/S0140-6736(10)62002-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701GZ	21131038	Green Published			2023-01-03	WOS:000285807700030
J	van Herpen, TWJM; Cankar, K; Nogueira, M; Bosch, D; Bouwmeester, HJ; Beekwilder, J				van Herpen, Teun W. J. M.; Cankar, Katarina; Nogueira, Marilise; Bosch, Dirk; Bouwmeester, Harro J.; Beekwilder, Jules			Nicotiana benthamiana as a Production Platform for Artemisinin Precursors	PLOS ONE			English	Article							ANTIMALARIAL-DRUG ARTEMISININ; EXPRESSION SYSTEM; MOLECULAR-CLONING; PLANTS; BIOSYNTHESIS; ANNUA; REDUCTASE; TOBACCO; YIELD; ACID	Background: Production of pharmaceuticals in plants provides an alternative for chemical synthesis, fermentation or natural sources. Nicotiana benthamiana is deployed at commercial scale for production of therapeutic proteins. Here the potential of this plant is explored for rapid production of precursors of artemisinin, a sesquiterpenoid compound that is used for malaria treatment. Methodology/Principal Findings: Biosynthetic genes leading to artemisinic acid, a precursor of artemisinin, were combined and expressed in N. benthamiana by agro-infiltration. The first committed precursor of artemisinin, amorpha-4,11-diene, was produced upon infiltration of a construct containing amorpha-4,11-diene synthase, accompanied by 3-hydroxy-3-methylglutaryl-CoA reductase and farnesyl diphosphate synthase. Amorpha-4,11-diene was detected both in extracts and in the headspace of the N. benthamiana leaves. When the amorphadiene oxidase CYP71AV1 was co-infiltrated with the amorphadiene-synthesizing construct, the amorpha-4,11-diene levels strongly decreased, suggesting it was oxidized. Surprisingly, no anticipated oxidation products, such as artemisinic acid, were detected upon GC-MS analysis. However, analysis of leaf extracts with a non-targeted metabolomics approach, using LC-QTOF-MS, revealed the presence of another compound, which was identified as artemisinic acid-12-beta-diglucoside. This compound accumulated to 39.5 mg.kg(-1) fwt. Apparently the product of the heterologous pathway that was introduced, artemisinic acid, is further metabolized efficiently by glycosyl transferases that are endogenous to N. benthamiana. Conclusion/Significance: This work shows that agroinfiltration of N. bentamiana can be used as a model to study the production of sesquiterpenoid pharmaceutical compounds. The interaction between the ectopically introduced pathway and the endogenous metabolism of the plant is discussed.	[van Herpen, Teun W. J. M.; Cankar, Katarina; Nogueira, Marilise; Bouwmeester, Harro J.; Beekwilder, Jules] Wageningen Univ, Lab Plant Physiol, Wageningen, Netherlands; [Bosch, Dirk; Beekwilder, Jules] Plant Res Int, Wageningen, Netherlands; [Bosch, Dirk] Univ Utrecht, Dept Chem, NL-3584 CH Utrecht, Netherlands	Wageningen University & Research; Utrecht University	van Herpen, TWJM (corresponding author), Wageningen Univ, Lab Plant Physiol, Wageningen, Netherlands.	jules.beekwilder@wur.nl	Beekwilder, Jules/A-6802-2011; Bouwmeester, Harro J/C-1414-2008	Beekwilder, Jules/0000-0003-3238-4427; Bouwmeester, Harro/0000-0003-0907-2732; Cankar, Katarina/0000-0001-5149-4192	Dutch science foundation NWO [053.63.305]; Dafra Pharma RD	Dutch science foundation NWO(Netherlands Organization for Scientific Research (NWO)); Dafra Pharma RD	This work has been supported by grant 053.63.305 of the IBOS (Integration of Biosynthesis and Organic Synthesis) program of the ACTS (Advanced Chemical Technologies for Sustainability) platform, funded by the Dutch science foundation NWO. Additional support was supplied by Dafra Pharma R&D. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aharoni A, 2005, TRENDS PLANT SCI, V10, P594, DOI 10.1016/j.tplants.2005.10.005; [Anonymous], 2008, WORLD MAL REP 2008; Bartholomew DM, 2002, PLANT PHYSIOL, V130, P1562, DOI 10.1104/pp.008334; Beale MH, 2006, P NATL ACAD SCI USA, V103, P10509, DOI 10.1073/pnas.0603998103; Bender J, 2004, CURR OPIN PLANT BIOL, V7, P521, DOI 10.1016/j.pbi.2004.07.003; Bertea CM, 2005, PLANTA MED, V71, P40, DOI 10.1055/s-2005-837749; CHAPPELL J, 1995, PLANT PHYSIOL, V109, P1337, DOI 10.1104/pp.109.4.1337; Cui LW, 2009, EXPERT REV ANTI-INFE, V7, P999, DOI [10.1586/eri.09.68, 10.1586/ERI.09.68]; Cunillera N, 1997, J BIOL CHEM, V272, P15381, DOI 10.1074/jbc.272.24.15381; De Vos RCH, 2007, NAT PROTOC, V2, P778, DOI 10.1038/nprot.2007.95; Fraissinet-Tachet L, 1998, FEBS LETT, V437, P319, DOI 10.1016/S0014-5793(98)01257-5; Geu-Flores F, 2009, PLANTA, V229, P261, DOI 10.1007/s00425-008-0825-y; Geu-Flores F, 2009, NAT CHEM BIOL, V5, P575, DOI 10.1038/nchembio.185; Gils M, 2005, PLANT BIOTECHNOL J, V3, P613, DOI 10.1111/j.1467-7652.2005.00154.x; Giritch A, 2006, P NATL ACAD SCI USA, V103, P14701, DOI 10.1073/pnas.0606631103; Graham IA, 2010, SCIENCE, V327, P328, DOI 10.1126/science.1182612; Harker M, 2003, PLANT BIOTECHNOL J, V1, P113, DOI 10.1046/j.1467-7652.2003.00011.x; Hellens R, 2000, TRENDS PLANT SCI, V5, P446, DOI 10.1016/S1360-1385(00)01740-4; Kappers IF, 2005, SCIENCE, V309, P2070, DOI 10.1126/science.1116232; Loreto F, 2010, TRENDS PLANT SCI, V15, P154, DOI 10.1016/j.tplants.2009.12.006; Lucker J, 2004, PLANT J, V39, P135, DOI 10.1111/j.1365-313X.2004.02113.x; Moglia A, 2010, METAB ENG, V12, P223, DOI 10.1016/j.ymben.2009.11.003; Ralley L, 2004, PLANT J, V39, P477, DOI 10.1111/j.1365-313X.2004.02151.x; Ro DK, 2006, NATURE, V440, P940, DOI 10.1038/nature04640; Teoh KH, 2009, BOTANY, V87, P635, DOI 10.1139/B09-032; Teoh KH, 2006, FEBS LETT, V580, P1411, DOI 10.1016/j.febslet.2006.01.065; Tremblay R, 2010, BIOTECHNOL ADV, V28, P214, DOI 10.1016/j.biotechadv.2009.11.008; Twyman RM, 2003, TRENDS BIOTECHNOL, V21, P570, DOI 10.1016/j.tibtech.2003.10.002; van Leeuwen W, 2001, J EXP BOT, V52, P949, DOI 10.1093/jexbot/52.358.949; VANENGELEN FA, 1995, TRANSGENIC RES, V4, P288, DOI 10.1007/BF01969123; Voinnet O, 2003, PLANT J, V33, P949, DOI 10.1046/j.1365-313X.2003.01676.x; Wallaart TE, 2001, PLANTA, V212, P460, DOI 10.1007/s004250000428; Whitty C, 2008, TROP DOCT, V38, P1, DOI 10.1258/td.2008.080013; Wu SQ, 2006, NAT BIOTECHNOL, V24, P1441, DOI 10.1038/nbt1251; Zhang Y, 2008, J BIOL CHEM, V283, P21501, DOI 10.1074/jbc.M803090200	35	116	121	2	50	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 3	2010	5	12							e14222	10.1371/journal.pone.0014222	http://dx.doi.org/10.1371/journal.pone.0014222			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	689PF	21151979	Green Published, gold			2023-01-03	WOS:000284939600015
J	Mudur, G				Mudur, Ganapati			Save the Children BMJ Christmas Appeal Mobile clinics in Delhi	BRITISH MEDICAL JOURNAL			English	Editorial Material												gsmudur@hotmail.com						Agarwal S, 2005, Indian J Public Health, V49, P141	1	0	0	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 30	2010	341								c6800	10.1136/bmj.c6800	http://dx.doi.org/10.1136/bmj.c6800			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	691OG	21118876				2023-01-03	WOS:000285090100015
J	Law, MR; Ystma, A; Morgan, SG				Law, Michael R.; Ystma, Alison; Morgan, Steven G.			The Short-Term Impact of Ontario's Generic Pricing Reforms	PLOS ONE			English	Article								Background: Canadians pay amongst the highest generic drug prices in the world. In July 2010, the province of Ontario enacted a policy that halved reimbursement for generic drugs from the public drug plan, and substantially lowered prices for private purchases. We quantified the impact of this policy on overall generic drug expenditures in the province, and projected the impact in other provinces had they mimicked this pricing change. Methods: We used quarterly prescription generic drug dispensing data from the IMS-Brogan CompuScript Audit. We used the price per unit in both the pre- and post-policy period and two economics price indexes to estimate the expenditure reduction in Ontario. Further, we used the post-policy Ontario prices to estimate the potential reduction in other provinces. Results: We estimate that total expenditure on generic drugs in Ontario during the second half of 2010 was between $ 181 and $ 194 million below what would be expected if prices had remained at pre-policy level. Over half of the reduction in spending was due to savings on just 10 generic ingredients. If other provinces had matched Ontario's prices, their expenditures over during the latter half of 2010 would have been $ 445 million lower. Discussion: We found that if Ontario's pricing scheme were adopted nationally, overall spending on generic drugs in Canada would drop at least $ 1.28 billion annually-a 5% decrease in total prescription drug expenditure. Other provinces should seriously consider both changes to their generic drug prices and the use of more competitive bulk purchasing policies.	[Law, Michael R.; Ystma, Alison; Morgan, Steven G.] Univ British Columbia, Ctr Hlth Serv & Policy Res, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada	University of British Columbia	Law, MR (corresponding author), Univ British Columbia, Ctr Hlth Serv & Policy Res, Sch Populat & Publ Hlth, Vancouver, BC V5Z 1M9, Canada.	mlaw@chspr.ubc.ca	Morgan, Steven/J-8814-2015	Morgan, Steven/0000-0002-7529-0028	Canadian Institutes of Health Researc; Peter Wall Institute	Canadian Institutes of Health Researc(Canadian Institutes of Health Research (CIHR)); Peter Wall Institute	Data access for this work was supported by an operating grant from the Canadian Institutes of Health Research ("For Whom the Bill Tolls: Private Drug Insurance in Canada", P. I.: Michael R. Law). Dr. Law receives salary support through a New Investigator Award from the Canadian Institutes of Health Research and an Early Career Scholar Award from the Peter Wall Institute for Advanced Studies. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Canadian Cancer Society, 2009, CANC DRUG ACC CAN; Canadian Institute for Health Information, 2010, NAT HLTH EXP TRENDS; Competition Bureau Canada, 2007, GEN DRUG SECT STUD; Competition Bureau Canada, 2008, BEN GEN DRUG COMP CA; Diewert W., 1993, ESSAYS INDEX NUMBER; *GOV ONT, 2010, REF ONT DRUG SYST; Grootendorst P, 2011, MANAGING PHARM EXPEN; *HLTH CAN, 2006, NAT PHARM STRAT; Howlett K., 2010, GLOBE MAIL; *IMS BROG, 2009, RET PHARM PROV TERR; Law Michael R, 2011, Healthc Policy, V6, P36; MCCOMB G, 2010, PUBLIC DRUG PLAN PRO; Morgan Steve, 2007, Healthc Policy, V3, pe121; *PMPRB, 2010, GEN DRUGS CAN PRIC T; Statistics Canada, 2010, ANN DEM EST CAN PROV	15	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2011	6	7							e23030	10.1371/journal.pone.0023030	http://dx.doi.org/10.1371/journal.pone.0023030			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KC	21829581	Green Published, Green Submitted, gold			2023-01-03	WOS:000293284600073
J	Vaid, M; Singh, T; Katiyar, SK				Vaid, Mudit; Singh, Tripti; Katiyar, Santosh K.			Grape Seed Proanthocyanidins Inhibit Melanoma Cell Invasiveness by Reduction of PGE(2) Synthesis and Reversal of Epithelial-to-Mesenchymal Transition	PLOS ONE			English	Article							NF-KAPPA-B; LUNG-CANCER; MOUSE SKIN; INFLAMMATORY RESPONSES; GUANYLATE-CYCLASE; PROSTAGLANDIN E-2; CARCINOMA-CELLS; NITRIC-OXIDE; CYCLOOXYGENASE-2; MIGRATION	Melanoma is the leading cause of death from skin disease due, in large part, to its propensity to metastasize. We have examined the effect of grape seed proanthocyanidins (GSPs) on melanoma cancer cell migration and the molecular mechanisms underlying these effects using highly metastasis-specific human melanoma cell lines, A375 and Hs294t. Using in vitro cell invasion assays, we observed that treatment of A375 and Hs294t cells with GSPs resulted in a concentration-dependent inhibition of invasion or cell migration of these cells, which was associated with a reduction in the levels of cyclooxygenase (COX)-2 expression and prostaglandin (PG) E-2 production. Treatment of cells with celecoxib, a COX-2 inhibitor, or transient transfection of melanoma cells with COX-2 small interfering RNA, also inhibited melanoma cell migration. Treatment of cells with 12-O-tetradecanoylphorbol-13-acetate, an inducer of COX-2, enhanced the phosphorylation of ERK1/2, a protein of mitogen-activated protein kinase family, and subsequently cell migration whereas both GSPs and celecoxib significantly inhibited 12-O-tetradecanoylphorbol-13-acetate - promoted cell migration as well as phosphorylation of ERK1/2. Treatment of cells with UO126, an inhibitor of MEK, also inhibited the migration of melanoma cells. Further, GSPs inhibited the activation of NF-kappa B/p65, an upstream regulator of COX-2, in melanoma cells, and treatment of cells with caffeic acid phenethyl ester, an inhibitor of NF-kappa B, also inhibited cell migration. Additionally, inhibition of melanoma cell migration by GSPs was associated with reversal of epithelial-mesenchymal transition process, which resulted in an increase in the levels of epithelial biomarkers (E-cadherin and cytokeratins) while loss of mesenchymal biomarkers (vimentin, fibronectin and N-cadherin) in melanoma cells. Together, these results indicate that GSPs have the ability to inhibit melanoma cell invasion/migration by targeting the endogenous expression of COX-2 and reversing the process of epithelial-to-mesenchymal transition.	[Vaid, Mudit; Singh, Tripti; Katiyar, Santosh K.] Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA; [Katiyar, Santosh K.] Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Katiyar, Santosh K.] Birmingham VA Med Ctr, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Birmingham	Vaid, M (corresponding author), Univ Alabama, Dept Dermatol, Birmingham, AL 35294 USA.	skatiyar@uab.edu			Veterans Administration	Veterans Administration(US Department of Veterans Affairs)	This work was supported by funds from the Veterans Administration Merit Review Award (SKK). There is no grant number. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AM FAM PHYS, 2010, EARL DET TREATM SKIN; America Cancer Society, 2011, CANC FACTS FIG; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Dannenberg AJ, 2003, CANCER CELL, V4, P431, DOI 10.1016/S1535-6108(03)00310-6; Dohadwala M, 2002, J BIOL CHEM, V277, P50828, DOI 10.1074/jbc.M210707200; Hall HI, 1999, J AM ACAD DERMATOL, V40, P35, DOI 10.1016/S0190-9622(99)70562-1; Huber MA, 2004, CELL CYCLE, V3, P1477, DOI 10.4161/cc.3.12.1280; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Maddodi N, 2008, PHOTOCHEM PHOTOBIOL, V84, P528, DOI 10.1111/j.1751-1097.2007.00283.x; Maier Harald J, 2010, Cancers (Basel), V2, P2058, DOI 10.3390/cancers2042058; Mantena SK, 2006, MOL CANCER THER, V5, P296, DOI 10.1158/1535-7163.MCT-05-0448; Meeran SM, 2008, J INVEST DERMATOL, V128, P2716, DOI 10.1038/jid.2008.140; Meeran SM, 2009, NEOPLASIA, V11, P846, DOI 10.1593/neo.09528; Meeran SM, 2009, CARCINOGENESIS, V30, P520, DOI 10.1093/carcin/bgp019; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Mittal A, 2003, CARCINOGENESIS, V24, P1379, DOI 10.1093/carcin/bgg095; Mukhtar H, 1996, PHOTOCHEM PHOTOBIOL, V63, P355, DOI 10.1111/j.1751-1097.1996.tb03040.x; Nandakumar V, 2008, CANCER LETT, V269, P378, DOI 10.1016/j.canlet.2008.03.049; Punathil T, 2008, BIOCHEM BIOPH RES CO, V375, P162, DOI 10.1016/j.bbrc.2008.07.157; Punathil T, 2009, MOL CARCINOGEN, V48, P232, DOI 10.1002/mc.20473; Riedl K, 2004, DRUG RESIST UPDATE, V7, P169, DOI 10.1016/j.drup.2004.04.003; Sharma SD, 2010, PHARM RES-DORDR, V27, P1092, DOI 10.1007/s11095-010-0050-9; Sharma SD, 2009, CARCINOGENESIS, V30, P1970, DOI 10.1093/carcin/bgp228; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Singh T, 2011, CARCINOGENESIS, V32, P86, DOI 10.1093/carcin/bgq215; Strouse JJ, 2005, J CLIN ONCOL, V23, P4735, DOI 10.1200/JCO.2005.02.899; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2	27	39	40	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 27	2011	6	6							e21539	10.1371/journal.pone.0021539	http://dx.doi.org/10.1371/journal.pone.0021539			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	783OD	21738696	gold, Green Published, Green Submitted			2023-01-03	WOS:000292092600051
J	Raghavan, R; Nuila, R				Raghavan, Rajeev; Nuila, Ricardo			Survivors - Dialysis, Immigration, and U.S. Law	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Raghavan, Rajeev; Nuila, Ricardo] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Raghavan, Rajeev] Baylor Coll Med, Div Nephrol, Houston, TX 77030 USA; [Nuila, Ricardo] Baylor Coll Med, Dept Family & Community Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Raghavan, R (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.							Campbell GA, 2010, AM J KIDNEY DIS, V55, P181, DOI 10.1053/j.ajkd.2009.06.039; Goldberg AM, 2007, TRANSPLANTATION, V83, P17, DOI 10.1097/01.tp.0000247795.41898.55; Raghavan R, 2011, DIALYSIS TRANSPLANT, V40, P78, DOI 10.1002/dat.20535; Sheikh-Hamad David, 2007, Tex Med, V103, P54; USRDS, 2008, ANN DAT REP ATL CHRO	5	23	23	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 9	2011	364	23					2183	2185		10.1056/NEJMp1101195	http://dx.doi.org/10.1056/NEJMp1101195			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	774NA	21651391				2023-01-03	WOS:000291392100004
J	Duncan, PW; Sullivan, KJ; Behrman, AL; Azen, SP; Wu, SS; Nadeau, SE; Dobkin, BH; Rose, DK; Tilson, JK; Cen, S; Hayden, SK				Duncan, Pamela W.; Sullivan, Katherine J.; Behrman, Andrea L.; Azen, Stanley P.; Wu, Samuel S.; Nadeau, Stephen E.; Dobkin, Bruce H.; Rose, Dorian K.; Tilson, Julie K.; Cen, Steven; Hayden, Sarah K.		LEAPS Investigative Team	Body-Weight-Supported Treadmill Rehabilitation after Stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SUBACUTE-STROKE; MOTOR RECOVERY; 6-MINUTE WALK; EXERCISE; INDIVIDUALS; LOCOMOTOR; BALANCE; FALLS; SPEED; GAIT	BACKGROUND Locomotor training, including the use of body-weight support in treadmill stepping, is a physical therapy intervention used to improve recovery of the ability to walk after stroke. The effectiveness and appropriate timing of this intervention have not been established. METHODS We stratified 408 participants who had had a stroke 2 months earlier according to the extent of walking impairment - moderate (able to walk 0.4 to <0.8 m per second) or severe (able to walk <0.4 m per second) - and randomly assigned them to one of three training groups. One group received training on a treadmill with the use of body-weight support 2 months after the stroke had occurred (early locomotor training), the second group received this training 6 months after the stroke had occurred (late locomotor training), and the third group participated in an exercise program at home managed by a physical therapist 2 months after the stroke (home-exercise program). Each intervention included 36 sessions of 90 minutes each for 12 to 16 weeks. The primary outcome was the proportion of participants in each group who had an improvement in functional walking ability 1 year after the stroke. RESULTS At 1 year, 52.0% of all participants had increased functional walking ability. No significant differences in improvement were found between early locomotor training and home exercise (adjusted odds ratio for the primary outcome, 0.83; 95% confidence interval [CI], 0.50 to 1.39) or between late locomotor training and home exercise (adjusted odds ratio, 1.19; 95% CI, 0.72 to 1.99). All groups had similar improvements in walking speed, motor recovery, balance, functional status, and quality of life. Neither the delay in initiating the late locomotor training nor the severity of the initial impairment affected the outcome at 1 year. Ten related serious adverse events were reported (occurring in 2.2% of participants undergoing early locomotor training, 3.5% of those undergoing late locomotor training, and 1.6% of those engaging in home exercise). As compared with the home-exercise group, each of the groups receiving locomotor training had a higher frequency of dizziness or faintness during treatment (P=0.008). Among patients with severe walking impairment, multiple falls were more common in the group receiving early locomotor training than in the other two groups (P=0.02). CONCLUSIONS Locomotor training, including the use of body-weight support in stepping on a treadmill, was not shown to be superior to progressive exercise at home managed by a physical therapist. (Funded by the National Institute of Neurological Disorders and Stroke and the National Center for Medical Rehabilitation Research; LEAPS ClinicalTrials.gov number, NCT00243919.)	[Duncan, Pamela W.; Hayden, Sarah K.] Duke Univ, Div Phys Therapy, Dept Community & Family Med, Durham, NC 27705 USA; [Sullivan, Katherine J.; Tilson, Julie K.; Cen, Steven] Univ So Calif, Div Biokinesiol & Phys Therapy, Los Angeles, CA 90089 USA; [Azen, Stanley P.] Univ So Calif, Dept Prevent Med, Div Biostat, Los Angeles, CA 90089 USA; [Dobkin, Bruce H.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Behrman, Andrea L.; Rose, Dorian K.] Univ Florida, Dept Phys Therapy, Gainesville, FL 32611 USA; [Wu, Samuel S.] Univ Florida, Dept Biostat, Gainesville, FL 32611 USA; [Nadeau, Stephen E.] Univ Florida, Dept Neurol, Gainesville, FL 32611 USA; [Nadeau, Stephen E.] Dept Vet Affairs, Gainesville, FL USA	Duke University; University of Southern California; University of Southern California; University of California System; University of California Los Angeles; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Duncan, PW (corresponding author), Duke Univ, Div Phys Therapy, Dept Community & Family Med, 2200 W Main St,Suite B-230, Durham, NC 27705 USA.	pamela.duke@duke.edu		Duncan, Pamela/0000-0002-4838-3253	National Institute of Neurological Disorders and Stroke [RO1 NS050506]; National Center for Medical Rehabilitation Research; National Institutes of Health; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG028740] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Center for Medical Rehabilitation Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by the National Institute of Neurological Disorders and Stroke (RO1 NS050506) and the National Center for Medical Rehabilitation Research. The body-weight support treadmill systems and the cost of all study screenings and interventions were supported by funding from the National Institutes of Health.	American Heart Association, 2010, HEART DIS STROK STAT; Barbeau H, 2003, ARCH PHYS MED REHAB, V84, P1458, DOI 10.1016/S0003-9993(03)00361-7; Batchelor F, 2010, STROKE, V41, P1715, DOI 10.1161/STROKEAHA.109.570390; BERG K, 1995, SCAND J REHABIL MED, V27, P27; Duncan P, 2003, STROKE, V34, P2173, DOI 10.1161/01.STR.0000083699.95351.F2; Duncan PW, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-39; DUNCAN PW, 1994, STROKE, V25, P1181, DOI 10.1161/01.STR.25.6.1181; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Eich HJ, 2004, CLIN REHABIL, V18, P640, DOI 10.1191/0269215504cr779oa; Eng JJ, 2002, STROKE, V33, P756, DOI 10.1161/hs0302.104195; FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812; Fulk George D., 2008, Physiotherapy Theory and Practice, V24, P195, DOI 10.1080/09593980701588284; Gladstone DJ, 2002, NEUROREHAB NEURAL RE, V16, P232, DOI 10.1177/154596802401105171; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Hesse S, 2008, NEUROREHABILITATION, V23, P55; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Lin KC, 2010, NEUROREHAB NEURAL RE, V24, P486, DOI 10.1177/1545968309356295; Lundebjerg N, 2001, J AM GERIATR SOC, V49, P664, DOI 10.1046/j.1532-5415.2001.49115.x; Macko RF, 2005, STROKE, V36, P2206, DOI 10.1161/01.STR.0000181076.91805.89; Michael KM, 2005, ARCH PHYS MED REHAB, V86, P1552, DOI 10.1016/j.apmr.2004.12.026; MOSELEY AM, 2005, COCHRANE DB SYST REV, V4; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; Pouwels S, 2009, STROKE, V40, P3281, DOI 10.1161/STROKEAHA.109.554055; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Resnick B, 2001, J Nurs Meas, V9, P275; Rigler SK, 2002, CLIN REHABIL, V16, P420, DOI 10.1191/0269215502cr515oa; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Sherrington C, 2008, J AM GERIATR SOC, V56, P2234, DOI 10.1111/j.1532-5415.2008.02014.x; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Sullivan KJ, 2002, ARCH PHYS MED REHAB, V83, P683, DOI 10.1053/apmr.2002.32488; Tilson JK, 2010, PHYS THER, V90, P196, DOI 10.2522/ptj.20090079; Visintin M, 1998, STROKE, V29, P1122, DOI 10.1161/01.STR.29.6.1122; Weerdesteyn V, 2008, J REHABIL RES DEV, V45, P1195, DOI 10.1682/JRRD.2007.09.0145; Weinrich M, 2004, NEUROREHAB NEURAL RE, V18, P12, DOI 10.1177/0888439003262041; Williams LS, 2005, STROKE, V36, P635, DOI 10.1161/01.STR.0000155688.18207.33; Yates JS, 2004, J AGING PHYS ACTIV, V12, P64, DOI 10.1123/japa.12.1.64	40	392	400	0	93	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2026	2036		10.1056/NEJMoa1010790	http://dx.doi.org/10.1056/NEJMoa1010790			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QR	21612471	Bronze, Green Accepted			2023-01-03	WOS:000290952000007
J	Langhorne, P; Bernhardt, J; Kwakkel, G				Langhorne, Peter; Bernhardt, Julie; Kwakkel, Gert			Stroke Care 2 Stroke rehabilitation	LANCET			English	Article							WALKING COMPETENCE; RECOVERY; THERAPY; INTERVENTIONS; METAANALYSIS; IMPROVEMENT; INTENSITY; STRENGTH; PROGRAMS; TIME	Stroke is a common, serious, and disabling global health-care problem, and rehabilitation is a major part of patient care. There is evidence to support rehabilitation in well coordinated multidisciplinary stroke units or through provision of early supported provision of discharge teams. Potentially beneficial treatment options for motor recovery of the arm include constraint-induced movement therapy and robotics. Promising interventions that could be beneficial to improve aspects of gait include fitness training, high-intensity therapy, and repetitive-task training. Repetitive-task training might also improve transfer functions. Occupational therapy can improve activities of daily living; however, information about the clinical effect of various strategies of cognitive rehabilitation and strategies for aphasia and dysarthria is scarce. Several large trials of rehabilitation practice and of novel therapies (eg, stem-cell therapy, repetitive transcranial magnetic stimulation, virtual reality, robotic therapies, and drug augmentation) are underway to inform future practice.	[Langhorne, Peter] Univ Glasgow, Royal Infirm, Acad Sect Geriatr Med, Inst Cardiovasc & Med Sci, Glasgow G4 0SF, Lanark, Scotland; [Bernhardt, Julie] Florey Neurosci Inst, Stroke Div, Melbourne, Vic, Australia; [Bernhardt, Julie] La Trobe Univ, Bundoora, Vic, Australia; [Kwakkel, Gert] Vrije Univ Amsterdam Med Ctr, Res Inst MOVE, Dept Rehabil Med, Amsterdam, Netherlands; [Kwakkel, Gert] Univ Med Ctr Utrecht, Rudolf Magnus Inst, Utrecht, Netherlands	Royal Infirmary of Edinburgh; University of Glasgow; Florey Institute of Neuroscience & Mental Health; La Trobe University; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center	Langhorne, P (corresponding author), Univ Glasgow, Royal Infirm, Acad Sect Geriatr Med, Inst Cardiovasc & Med Sci, Level 4,Walton Bldg, Glasgow G4 0SF, Lanark, Scotland.	peter.langhorne@glasgow.ac.uk	; Bernhardt, Julie/F-9538-2015	Kwakkel, Gert/0000-0002-4041-4043; Bernhardt, Julie/0000-0002-2787-8484	Stroke Association; Chest, Heart and Stroke, Scotland; Wiley	Stroke Association; Chest, Heart and Stroke, Scotland; Wiley	PL has received honoraria and travel expenses for educational conference sessions run by Sanofi-Aventis and Boehringer Ingelheim, grant support from The Stroke Association and Chest, Heart and Stroke, Scotland, and royalties from Wiley. JB and GK declare that they have no conflicts of interest.	Ada L, 2006, AUST J PHYSIOTHER, V52, P241, DOI 10.1016/S0004-9514(06)70003-4; Anderson C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub2; [Anonymous], [No title captured], DOI DOI 10.1002/14651858.CD004129.PUB2; [Anonymous], 2008, NAT CLIN GUID STROK; Aziz NA, 2008, COCHRANE DB SYST REV, V2; BARCLAYGODDARD RE, 2010, COCHRANE DB SYST REV, V1; BATH PM, 1999, COCHRANE DB SYST REV, V2; Bernhardt J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006187.pub2; Boncoraglio GB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007231.pub2; Bonita R, 2004, LANCET NEUROL, V3, P391, DOI 10.1016/S1474-4422(04)00800-2; Borisova Y, 2009, CLIN REHABIL, V23, P681, DOI 10.1177/0269215509334841; BOWEN A, 2008, COCHRANE DB SYST REV, V2; Bowen A, 2007, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003586.PUB2; BRADT J, 2010, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD006787.PUB2; Brady M., 2006, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003864.PUB2; Cherney LR, 2008, J SPEECH LANG HEAR R, V51, P1282, DOI 10.1044/1092-4388(2008/07-0206); COUPAR F, 2007, COCHRANE DB SYST REV, V4; Coupar F., 2010, COCHRANE DB SYST REV, V4; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Doyle S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006331.pub2; Ellis G, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005066.pub2; English C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub2; Foley N, 2008, AGE AGEING, V37, P258, DOI 10.1093/ageing/afn064; Forster A., 2009, COCHRANE DB SYST REV, V1; Forster A, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001730.PUB2; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Govender Paran, 2007, Expert Rev Neurother, V7, P1013, DOI 10.1586/14737175.7.8.1013; Hacke W, 2008, CEREBROVASC DIS, V25, P457, DOI 10.1159/000131083; Henderson A, 2007, TOP STROKE REHABIL, V14, P52, DOI 10.1310/tsr1402-52; Hoffmann T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006430.pub2; Hurn J, 2006, CLIN REHABIL, V20, P756, DOI 10.1177/0269215506070793; Kelly H, 2010, COCHRANE DB SYST REV, V5; Kottink AIR, 2004, ARTIF ORGANS, V28, P577, DOI 10.1111/j.1525-1594.2004.07310.x; Kwakkel G, 2004, RESTOR NEUROL NEUROS, V22, P281; Kwakkel G, 2004, STROKE, V35, P2529, DOI 10.1161/01.STR.0000143153.76460.7d; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Kwakkel G, 2006, STROKE, V37, P2348, DOI 10.1161/01.STR.0000238594.91938.1e; KWAN J, 2004, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD002924.PUB2; Langhorne P, 2007, J REHABIL MED, V39, P103, DOI 10.2340/16501977-0042; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Langhorne P, 2009, LANCET NEUROL, V8, P741, DOI 10.1016/S1474-4422(09)70150-4; Langhorne P, 2009, LANCET NEUROL, V8, P308, DOI 10.1016/S1474-4422(09)70060-2; Legg L, 2000, BRIT J THERAPY REHAB, V7, P319; Legg LA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003585.pub2; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Lincoln NB, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002842, DOI 10.1002/14651858.CD002842]; MARTINSSON L, 2007, COCHRANE DB SYST REV, V1; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2008, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD006876.PUB2; Morris SL, 2004, CLIN REHABIL, V18, P27, DOI 10.1191/0269215504cr699oa; MOSELEY AM, 2005, COCHRANE DB SYST REV, V4; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Nair RD, 2007, COCHRANE DB SYST REV, V3; National Stroke Foundation, 2010, CLIN GUID STROK MAN; Nijland R, 2010, J REHABIL MED, V42, P694, DOI 10.2340/16501977-0560; Outpatient Service Trialists, 2003, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD002925; Patterson CJ, 1999, CLIN REHABIL, V13, P101, DOI 10.1191/026921599677096598; Pohl M, 2002, STROKE, V33, P553, DOI 10.1161/hs0202.102365; POLLOCK A, 2007, COCHRANE DB SYST REV, V1; POLLOCK A, 2010, COCHRANE DB SYST REV, V3; Pomeroy V, 2006, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD003241.PUB2; Richards LG, 2008, NEUROPSYCHOLOGIA, V46, P3, DOI 10.1016/j.neuropsychologia.2007.08.013; Sackley C, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003908.pub3; Saposnik G, 2009, STROKE, V40, P3321, DOI 10.1161/STROKEAHA.109.554907; Saunders DH, 2009, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003316.PUB2; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; SELLARS C, 2005, COCHRANE DB SYST REV, V3; Sirtori V, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004433.pub2; Smith J, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001919.pub2; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; THIEME H, 2010, COCHRANE DB SYST REV, V4; Thomas LH, 2008, COCHRANE DB SYST REV, V1; TYSON SF, 2009, COCHRANE DB SYST REV, V3; van de Port IGL, 2007, AM J PHYS MED REHAB, V86, P935, DOI 10.1097/PHM.0b013e31802ee464; Van Peppen RPS, 2006, J REHABIL MED, V38, P3, DOI 10.1080/16501970500344902; Wade DT., 1992, MEASUREMENT NEUROLOG; Walker MF, 2004, STROKE, V35, P2226, DOI 10.1161/01.STR.0000137766.17092.fb; Warlow C, 2008, STROKE PRACTICAL MAN; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; WEST C, 2008, COCHRANE DB SYST REV, V1; West C, 2005, COCHRANE DB SYST REV, V4; Wevers L, 2009, STROKE, V40, P2450, DOI 10.1161/STROKEAHA.108.541946; Woodford H, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004585.pub2; World Health Organisation, 2001, ICF INT CLASFUNCT; World Health Organization, 2003, WORLD HLTH REP 2003; WU HM, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004131.PUB2; Zimmermann-Schlatter A, 2008, J NEUROENG REHABIL, V5, DOI 10.1186/1743-0003-5-8	87	1353	1405	36	1095	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1693	1702		10.1016/S0140-6736(11)60325-5	http://dx.doi.org/10.1016/S0140-6736(11)60325-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	766JF	21571152				2023-01-03	WOS:000290777700034
J	Herbst, RS; Ansari, R; Bustin, F; Flynn, P; Hart, L; Otterson, GA; Vlahovic, G; Soh, CH; O'Connor, P; Hainsworth, J				Herbst, Roy S.; Ansari, Rafat; Bustin, Frederique; Flynn, Patrick; Hart, Lowell; Otterson, Gregory A.; Vlahovic, Gordana; Soh, Chang-Heok; O'Connor, Paula; Hainsworth, John			Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial	LANCET			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITOR; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; COMBINATION; MUTATIONS; CARBOPLATIN; PACLITAXEL; GEFITINIB; VANDETANIB	Background Bevacizumab and erlotinib target different tumour growth pathways with little overlap in their toxic-effect profiles. On the basis of promising results from a phase 1/2 trial assessing safety and activity of erlotinib plus bevacizumab for recurrent or refractory non-small-cell lung cancer (NSCLC), we aimed to assess efficacy and safety of this combination in a phase 3 trial. Methods In our double-blind, placebo-controlled, randomised phase 3 trial (BeTa), we enrolled patients with recurrent or refractory NSCLC who presented to 177 study sites in 12 countries after failure of first-line treatment. Patients were randomly allocated in a one-to-one ratio to receive erlotinib plus bevacizumab (bevacizumab group) or erlotinib plus placebo (control group) according to a computer-generated randomisation sequence by use of an interactive voice response system. The primary endpoint was overall survival in all enrolled patients. Patients, study staff, and investigators were masked to treatment assignment. We assessed safety by calculation of incidence of adverse events and tissue was collected for biomarker analyses. This trial is registered with ClinicalTrials.gov, number NCT00130728. Findings Overall survival did not differ between 317 controls and 319 patients in the bevacizumab group (hazard ratio [HR] 0.97, 95% CI 0.80-1.18, p=0.7583). Median overall survival was 9.3 months (IQR 4.1-21.6) for patients in the bevacizumab group compared with 9.2 months (3.8-20.2) for controls. Progression-free survival seemed to be longer in the bevacizumab group (3.4 months [1.4-8.4]) than in the control group (1.7 months [1.3-4-1]; HR 0.62, 95% CI 0.52-0.75) and objective response rate suggested some clinical activity of bevacizumab and erlotinib. However, these secondary endpoint differences could not be defined as significant because the study prespecified that the primary endpoint had to be significant before testing of secondary endpoints could be done, to control type I error rate. In the bevacizumab group, 130 (42%) of 313 patients with safety data had a serious adverse event, compared with 114 (36%) controls. There were 20 (6%) grade 5 adverse events, including two arterial thromboembolic events, in the bevacizumab group, and 14 (4%) in the control group. Interpretation Addition of bevacizumab to erlotinib does not improve survival in patients with recurrent or refractory NSCLC.	[Herbst, Roy S.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Ansari, Rafat] Michiana Hematol Oncol, South Bend, IN USA; [Bustin, Frederique] Ctr Hosp Reg Citadelle, Liege, Belgium; [Flynn, Patrick] Minnesota Oncol Hematol PA, Maplewood, MN USA; [Hart, Lowell] Florida Canc Specialists, Ft Myers, FL USA; [Otterson, Gregory A.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA; [Vlahovic, Gordana] Duke Univ, Med Ctr, Durham, NC USA; [Soh, Chang-Heok; O'Connor, Paula] Genentech Inc, San Francisco, CA 94080 USA; [Hainsworth, John] Sarah Cannon Res Inst, Nashville, TN USA	University of Texas System; UTMD Anderson Cancer Center; Florida Cancer Specialists; University System of Ohio; Ohio State University; Duke University; Roche Holding; Genentech; Sarah Cannon Research Institute	Herbst, RS (corresponding author), Yale Canc Ctr, 333 Cedar St,POB 208028, New Haven, CT 06520 USA.	roy.herbst@yale.edu			Genentech; Metro Minnesota Community; NCI; NATIONAL CANCER INSTITUTE [P30CA016672, P30CA016058] Funding Source: NIH RePORTER	Genentech(Roche HoldingGenentech); Metro Minnesota Community; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Genentech funded this clinical trial. RSH, LH, PF, and GAO have received funding from Genentech. RSH has consulted for Genentech, OSI, and Roche. GAO has consulted for Genentech and Abraxis. PP has consulted for Genentech, participated in speakers' bureaux for Genentech and 051 Pharmaceuticals, and grant funding from the Metro Minnesota Community Clinical Oncology Program, a non-profit research program sponsored by NCI. CV has consulted for Genentech and participated in speakers' bureaux for Genentech and Sanofi-Aventis. C-HS and PO'C have been employed by Genentech and were stockholders with Roche.	Andratschke Nicolaus H, 2004, Clin Lung Cancer, V5, P340, DOI 10.3816/CLC.2004.n.012; [Anonymous], 2007, BEV AV PACK INS; [Anonymous], 2017, ANAL CLIN TRIALS USI; [Anonymous], 2007, ERL TARC PACK INS; Bozec A, 2008, BRIT J CANCER, V99, P93, DOI 10.1038/sj.bjc.6604429; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Ciardiello F, 2000, CLIN CANCER RES, V6, P3739; Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Herbst RS, 2010, LANCET ONCOL, V11, P619, DOI 10.1016/S1470-2045(10)70132-7; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Hirsch FR, 2008, CLIN CANCER RES, V14, P6317, DOI 10.1158/1078-0432.CCR-08-0539; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Miller VA, 2009, P AN M AM SOC CLIN, V27; Miller VA, 2008, J CLIN ONCOL, V26, P1472, DOI 10.1200/JCO.2007.13.0062; Natale RB, 2009, J CLIN ONCOL, V27, P2523, DOI 10.1200/JCO.2008.18.6015; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pazdur R, 2004, CANC MANAGEMENT MULT; Reck, 2009, J CLIN ONCOL, V27, P2415, DOI 10.1200/JCO.2009.23.1373; Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schicher N, 2009, CLIN CANCER RES, V15, P3495, DOI 10.1158/1078-0432.CCR-08-2407; Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Westfall PH, 2001, J STAT PLAN INFER, V99, P25, DOI 10.1016/S0378-3758(01)00077-5; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416	33	317	322	0	30	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY-JUN	2011	377	9780					1846	1854		10.1016/S0140-6736(11)60545-X	http://dx.doi.org/10.1016/S0140-6736(11)60545-X			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621716	Green Accepted			2023-01-03	WOS:000291411700030
J	Fitzpatrick, K				Fitzpatrick, Kevin			Should the law on assisted dying be changed? No	BRITISH MEDICAL JOURNAL			English	Editorial Material									Not Dead Yet UK, Reynoldston, Wales		Fitzpatrick, K (corresponding author), Not Dead Yet UK, Reynoldston, Wales.	kevin@inclusion21.org						CAMPBELL J, 2006, HMV UK M ST THOM HOS; O'Neill O, 2010, AUTONOMY ASSISTED SU; Tiernan E, 2002, J ROY SOC MED, V95, P386, DOI 10.1258/jrsm.95.8.386; Wittgenstein L., 1974, TRACTATUS LOGICO PHI	4	3	3	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 21	2011	342								d1883	10.1136/bmj.d1883	http://dx.doi.org/10.1136/bmj.d1883			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755OR	21511803				2023-01-03	WOS:000289943400001
J	Kirby, T				Kirby, Tony			Profile Colin Sullivan: inventive pioneer of sleep medicine	LANCET			English	Biographical-Item												tony.kirby@lancet.com							0	3	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR-MAY	2011	377	9776					1485	1485		10.1016/S0140-6736(11)60589-8	http://dx.doi.org/10.1016/S0140-6736(11)60589-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	761RX	21531260	Bronze			2023-01-03	WOS:000290419400014
J	Grabrucker, AM; Garner, CC; Boeckers, TM; Bondioli, L; Ruozi, B; Forni, F; Vandelli, MA; Tosi, G				Grabrucker, Andreas M.; Garner, Craig C.; Boeckers, Tobias M.; Bondioli, Lucia; Ruozi, Barbara; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni			Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; FORCED SWIMMING TEST; BLOOD-BRAIN-BARRIER; POSTSYNAPTIC DENSITY; ZINC; ANTIDEPRESSANT; DEPRESSION; MICE; ACTIVATION; VIVO	Intact synaptic function and plasticity are fundamental prerequisites to a healthy brain. Therefore, synaptic proteins are one of the major targets for drugs used as neuro-chemical therapeutics. Unfortunately, the majority of drugs is not able to cross the blood-brain barrier (BBB) and is therefore distributed within the CNS parenchyma. Here, we report the development of novel biodegradable Nanoparticles (NPs), made of poly-lactide-co-glycolide (PLGA) conjugated with glycopeptides that are able to cross the BBB and deliver for example Zn2+ ions. We also provide a thorough characterization of loaded and unloaded NPs for their stability, cellular uptake, release properties, toxicity, and impact on cell trafficking. Our data reveal that these NPs are biocompatible, and can be used to elevate intracellular levels of Zn2+. Importantly, by engineering the surface of NPs with antibodies against NCAM1 and CD44, we were able to selectively target neurons or glial cells, respectively. Our results indicate that these biodegradable NPs provide a potential new venue for the delivery Zn2+ to the CNS and thus a means to explore the influence of altered zinc levels linked to neuropsychological disorders such as depression.	[Grabrucker, Andreas M.; Garner, Craig C.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford Sch Med, Stanford, CA 94305 USA; [Grabrucker, Andreas M.; Boeckers, Tobias M.] Univ Ulm, Inst Anat & Cell Biol, Ulm, Germany; [Bondioli, Lucia; Ruozi, Barbara; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, TeFarTI Grp, Modena, Italy; [Bondioli, Lucia; Ruozi, Barbara; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Pharmaceut Sci, TeFarTI Grp, Reggio Emilia, Italy	Stanford University; Ulm University; Universita di Modena e Reggio Emilia; Universita di Modena e Reggio Emilia	Grabrucker, AM (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, Stanford Sch Med, Stanford, CA 94305 USA.	andreas.grabrucker@stanford.edu; giovanni.tosi@unimore.it	Forni, Flavio/D-5492-2015; Ruozi, Barbara/D-5500-2015; Vandelli, Maria Angela/D-5497-2015; Tosi, Giovanni/D-4547-2011	Forni, Flavio/0000-0001-5974-6286; Ruozi, Barbara/0000-0002-2400-9910; Vandelli, Maria Angela/0000-0003-1462-8133; Tosi, Giovanni/0000-0001-8318-667X; Garner, Craig/0000-0003-1970-5417; Grabrucker, Andreas/0000-0003-0005-4810	Deutsche Forschungsgemeinschaft (DFG); National Institutes of Health [PO1 NS053862, R21MH091471]; NATIONAL INSTITUTE OF MENTAL HEALTH [R21MH091471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS053862] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	AMG has been supported by a fellowship from the Deutsche Forschungsgemeinschaft (DFG) and the National Institutes of Health (PO1 NS053862; R21MH091471) to CCG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amani R, 2010, BIOL TRACE ELEM RES, V137, P150, DOI 10.1007/s12011-009-8572-x; Baron MK, 2006, SCIENCE, V311, P531, DOI 10.1126/science.1118995; Blanco MD, 1997, EUR J PHARM BIOPHARM, V43, P287, DOI 10.1016/S0939-6411(97)00056-8; BURKE M, 1999, CENTRAL NERVOUS SYST, P184; Canzoniero LMT, 1999, J NEUROSCI, V19; Cope EC, 2010, CURR OPIN CLIN NUTR, V13, P685, DOI 10.1097/MCO.0b013e32833df61a; Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013; Cunha MP, 2008, PROG NEURO-PSYCHOPH, V32, P1913, DOI 10.1016/j.pnpbp.2008.09.006; Depino AM, 2003, EUR J NEUROSCI, V18, P2731, DOI 10.1111/j.1460-9568.2003.03014.x; Dresbach T, 2003, MOL CELL NEUROSCI, V23, P279, DOI 10.1016/S1044-7431(03)00015-0; Garcia-Garcia E, 2005, INT J PHARMACEUT, V298, P274, DOI 10.1016/j.ijpharm.2005.03.031; Goslin K., 1991, CULTURING NERVE CELL, P251; GRABRUCKER AM, 2011, EMBO J; Gundelfinger ED, 2006, TRENDS BIOCHEM SCI, V31, P366, DOI 10.1016/j.tibs.2006.05.007; Hansen GH, 2009, AM J PHYSIOL-GASTR L, V297, pG708, DOI 10.1152/ajpgi.00192.2009; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; Kreuter J, 2007, INT J PHARMACEUT, V331, P1, DOI 10.1016/j.ijpharm.2006.10.021; Kroczka B, 2001, BRAIN RES BULL, V55, P297, DOI 10.1016/S0361-9230(01)00473-7; Kroczka B, 2000, POL J PHARMACOL, V52, P403; Levenson CW, 2006, NUTR REV, V64, P39, DOI 10.1301/nr.2006.jan.39-42; Liu YT, 2010, BIOMATERIALS, V31, P9145, DOI 10.1016/j.biomaterials.2010.08.053; Lom B, 1999, J NEUROSCI, V19, P9928; MAES M, 1994, J AFFECT DISORDERS, V31, P135, DOI 10.1016/0165-0327(94)90117-1; Manser W W, 1989, J Pak Med Assoc, V39, P269; Marchetti B, 2005, ANN NY ACAD SCI, V1057, P296, DOI 10.1196/annals.1356.023; Mattson MP, 2003, CELL CALCIUM, V34, P385, DOI 10.1016/S0143-4160(03)00128-3; MCLOUGHLIN IJ, 1990, ACTA PSYCHIAT SCAND, V82, P451, DOI 10.1111/j.1600-0447.1990.tb03077.x; Nowak G, 2005, PHARMACOL REP, V57, P713; Nowak G, 2003, BRAIN RES BULL, V61, P159, DOI 10.1016/S0361-9230(03)00104-7; Nowak G, 2002, POL J PHARMACOL, V54, P587; Pardridge William M, 2003, Mol Interv, V3, P90, DOI 10.1124/mi.3.2.90; Qiao Feng, 2005, Sci STKE, V2005, pre7, DOI 10.1126/stke.2862005re7; Rosa AO, 2003, BEHAV BRAIN RES, V144, P87, DOI 10.1016/S0166-4328(03)00069-X; Sawada T, 2010, EUR J CLIN NUTR, V64, P331, DOI 10.1038/ejcn.2009.158; SCHUBERT P, 2005, ALZHEIMERS DIS, P209; Seidenbecher CI, 1998, J BIOL CHEM, V273, P21324, DOI 10.1074/jbc.273.33.21324; Shi NY, 2000, P NATL ACAD SCI USA, V97, P7567, DOI 10.1073/pnas.130187497; Szewczyk B, 2002, POL J PHARMACOL, V54, P681; Tassabehji NM, 2008, PHYSIOL BEHAV, V95, P365, DOI 10.1016/j.physbeh.2008.06.017; Tosi G, 2007, J CONTROL RELEASE, V122, P1, DOI 10.1016/j.jconrel.2007.05.022; Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008; TOSI G, 2010, INVESTIGATI IN PRESS; Tosi G, 2008, EXPERT OPIN DRUG DEL, V5, P155, DOI 10.1517/17425247.5.2.155; Vergoni AV, 2009, NANOMED-NANOTECHNOL, V5, P369, DOI 10.1016/j.nano.2009.02.005; WEISS JH, 1993, NEURON, V10, P43, DOI 10.1016/0896-6273(93)90240-R; Whittle N, 2009, AMINO ACIDS, V36, P147, DOI 10.1007/s00726-008-0195-6; Wojcik J, 2006, PHARMACOL REP, V58, P571; YOKOYAMA M, 1986, NEUROSCI LETT, V71, P351, DOI 10.1016/0304-3940(86)90646-4	48	38	40	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 23	2011	6	3							e17851	10.1371/journal.pone.0017851	http://dx.doi.org/10.1371/journal.pone.0017851			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740QW	21448455	gold, Green Submitted, Green Published			2023-01-03	WOS:000288810500017
J	Vanpouille-Box, C; Lacoeuille, F; Roux, J; Aube, C; Garcion, E; Lepareur, N; Oberti, F; Bouchet, F; Noiret, N; Garin, E; Benoit, JP; Couturier, O; Hindre, F				Vanpouille-Box, Claire; Lacoeuille, Franck; Roux, Jerome; Aube, Christophe; Garcion, Emmanuel; Lepareur, Nicolas; Oberti, Frederic; Bouchet, Francis; Noiret, Nicolas; Garin, Etienne; Benoit, Jean-Pierre; Couturier, Olivier; Hindre, Francois			Lipid Nanocapsules Loaded with Rhenium-188 Reduce Tumor Progression in a Rat Hepatocellular Carcinoma Model	PLOS ONE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DRUG ELUTING BEADS; RADIATION-THERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; CHITOSAN NANOPARTICLES; MICROSPHERES; RADIOEMBOLIZATION; BIODISTRIBUTION; FORMULATION; LIPIODOL	Background: Due to their nanometric scale (50 nm) along with their biomimetic properties, lipid nanocapsules loaded with Rhenium-188 (LNC(188)Re-SSS) constitute a promising radiopharmaceutical carrier for hepatocellular carcinoma treatment as its size may improve tumor penetration in comparison with microspheres devices. This study was conducted to confirm the feasibility and to assess the efficacy of internal radiation with LNC(188)Re-SSS in a chemically induced hepatocellular carcinoma rat model. Methodology/Principal Findings: Animals were treated with an injection of LNC(188)Re-SSS (80 MBq or 120 MBq). The treated animals (80 MBq, n = 12; 120 MBq, n = 11) were compared with sham (n = 12), blank LNC (n = 7) and (188)Re-perrhenate (n = 4) animals. The evaluation criteria included rat survival, tumor volume assessment, and vascular endothelial growth factor quantification. Following treatment with LNC(188)Re-SSS (80 MBq) therapeutic efficiency was demonstrated by an increase in the median survival from 54 to 107% compared with control groups with up to 7 long-term survivors in the LNC(188)Re-SSS group. Decreased vascular endothelial growth factor expression in the treated rats could indicate alterations in the angiogenesis process. Conclusions/Significance: Overall, these results demonstrate that internal radiation with LNC(188)Re-SSS is a promising new strategy for hepatocellular carcinoma treatment.	[Vanpouille-Box, Claire; Lacoeuille, Franck; Garcion, Emmanuel; Benoit, Jean-Pierre; Couturier, Olivier; Hindre, Francois] Univ Angers, LUNAM Univ, INSERM U646, Angers, France; [Lacoeuille, Franck; Bouchet, Francis; Couturier, Olivier] CHU Angers, Dept Nucl Med, Angers, France; [Roux, Jerome] Univ Angers, LUNAM Univ, SCAHU, UFR Med, Angers, France; [Lepareur, Nicolas; Garin, Etienne] CRLCC Eugene Marquis, Dept Med Imaging, Rennes, France; [Noiret, Nicolas] European Univ Brittany, Rennes, France; [Aube, Christophe] CHU Angers, Dept Radiol, Angers, France; [Aube, Christophe; Oberti, Frederic] Univ Angers, LUNAM Univ, Lab HIFI, UPRES EA3589, Angers, France; [Lepareur, Nicolas] ENSCR, UMR CNRS 6226, Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; UNICANCER; Centre Eugene Marquis; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Ecole Nationale Superieure de Chimie de Rennes (ENSCR)	Vanpouille-Box, C (corresponding author), Univ Angers, LUNAM Univ, INSERM U646, Angers, France.	francois.hindre@univ-angers.fr	Lepareur, Nicolas/N-8914-2019; Vanpouille-Box, Claire/F-7137-2011; Lepareur, Nicolas/K-7174-2018; Vanpouille-Box, Claire/AAO-5355-2021; hindré, françois/K-5613-2015; Benoit, Jean-Pierre/K-4387-2015; Couturier, Olivier F/L-6635-2015; GARCION, Emmanuel/K-5417-2015; LACOEUILLE, Franck/K-4430-2015	Lepareur, Nicolas/0000-0001-9860-5451; Lepareur, Nicolas/0000-0001-9860-5451; GARCION, Emmanuel/0000-0003-0887-272X; LACOEUILLE, Franck/0000-0002-7070-7664; couturier, olivier-francois/0000-0002-4900-7807; Garin, Etienne/0000-0003-1416-2863; Hindre, Francois/0000-0002-2727-7996; BENOIT, Jean-Pierre/0000-0002-6178-7199; Vanpouille-Box, Claire/0000-0001-7213-0670	Maine et Loire	Maine et Loire	This work was funded by "the Canceropole Grand Ouest" and "La Ligue Contre le Cancer" of "Maine et Loire." Claire Vanpouille-Box was a fellow from Angers Loire Metropole. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ballot S, 2006, EUR J NUCL MED MOL I, V33, P602, DOI 10.1007/s00259-005-0007-0; Brown DB, 2009, J VASC INTERV RADIOL, V20, pS425, DOI 10.1016/j.jvir.2009.04.021; Cha CH, 2010, CURR PROB SURG, V47, P10, DOI 10.1067/j.cpsurg.2009.09.003; Cheng JCH, 2002, RADIOTHER ONCOL, V63, P41, DOI 10.1016/S0167-8140(02)00061-0; Dai LC, 2009, WORLD J GASTROENTERO, V15, P1966, DOI 10.3748/wjg.15.1966; Dancey JE, 2000, J NUCL MED, V41, P1673; Decuzzi P, 2009, PHARM RES-DORD, V26, P235, DOI 10.1007/s11095-008-9697-x; DEUTSCH E, 1986, NUCL MED BIOL, V13, P465, DOI 10.1016/0883-2897(86)90027-9; Dhanasekaran R, 2010, J SURG ONCOL, V101, P476, DOI 10.1002/jso.21522; Folkman J, 2003, CURR MOL MED, V3, P643, DOI 10.2174/1566524033479465; Garin E, 2005, LAB ANIM-UK, V39, P314, DOI 10.1258/0023677054307051; Gibaud S, 1996, J PHARM SCI, V85, P944, DOI 10.1021/js960032d; Hafeli UO, 1999, INT J RADIAT ONCOL, V44, P189, DOI 10.1016/S0360-3016(98)00554-9; Heurtault B, 2002, PHARMACEUT RES, V19, P875, DOI 10.1023/A:1016121319668; Hsieh BT, 1999, NUCL MED BIOL, V26, P967, DOI 10.1016/S0969-8051(99)00074-8; Jin-no K, 1998, J GASTROENTEROL, V33, P376, DOI 10.1007/s005350050099; Kulik LM, 2006, J SURG ONCOL, V94, P572, DOI 10.1002/jso.20609; Kumar A, 2007, RADIOLOGY, V243, P509, DOI 10.1148/radiol.2432051246; Lacoeuille F, 2007, INT J PHARM, V344, P143, DOI 10.1016/j.ijpharm.2007.06.014; Lau WY, 1998, INT J RADIAT ONCOL, V40, P583, DOI 10.1016/S0360-3016(97)00818-3; Lepareur N, 2004, J LABELLED COMPD RAD, V47, P857, DOI 10.1002/jlcr.863; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5; Malagari K, 2008, ABDOM IMAGING, V33, P512, DOI 10.1007/s00261-007-9334-x; Malagari K, 2008, CARDIOVASC INTER RAD, V31, P269, DOI 10.1007/s00270-007-9226-z; Salem R, 2005, J VASC INTERV RADIOL, V16, P1627; Semela D, 2004, J HEPATOL, V41, P864, DOI 10.1016/j.jhep.2004.09.006; Wang Q, 2010, NANOMED-NANOTECHNOL, V6, P371, DOI 10.1016/j.nano.2009.07.006; Wunderlich G, 2005, APPL RADIAT ISOTOPES, V62, P745, DOI 10.1016/j.apradiso.2004.11.003; Xu YL, 2009, ANTICANCER RES, V29, P5103; Xu ZH, 2009, BIOMATERIALS, V30, P226, DOI 10.1016/j.biomaterials.2008.09.014; Yamaguchi R, 1998, HEPATOLOGY, V28, P68, DOI 10.1002/hep.510280111; Zeng ZC, 2002, EUR J NUCL MED MOL I, V29, P1657, DOI 10.1007/s00259-002-0996-x	33	32	34	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 7	2011	6	3							e16926	10.1371/journal.pone.0016926	http://dx.doi.org/10.1371/journal.pone.0016926			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	731IP	21408224	Green Published, gold			2023-01-03	WOS:000288099800008
J	Barone-Adesi, F; Gasparrini, A; Vizzini, L; Merletti, F; Richiardi, L				Barone-Adesi, Francesco; Gasparrini, Antonio; Vizzini, Loredana; Merletti, Franco; Richiardi, Lorenzo			Effects of Italian Smoking Regulation on Rates of Hospital Admission for Acute Coronary Events: A Country-Wide Study	PLOS ONE			English	Article							ACUTE MYOCARDIAL-INFARCTION; FREE LEGISLATION; HEART-DISEASE; BAN; TIME; ACT	Background: Several studies have reported a reduction in acute coronary events (ACEs) in the general population after the enforcement of smoking regulations, although there is uncertainty concerning the magnitude of the effect of such interventions. We conducted a country-wide evaluation of the health effects of the introduction of a smoking ban in public places, using data on hospital admissions for ACEs from the Italian population after the implementation of a national smoking regulation in January 2005. Methods and Findings: Rates of admission for ACEs in the 20 Italian regions from January 2002 to November 2006 were analysed using mixed-effect regression models that allowed for long-term trends and seasonality. Standard methods for interrupted time-series were adopted to assess the immediate and gradual effects of the smoking ban. Effect modification by age was investigated, with the assumption that exposure to passive smoking in public places would be greater among young people. In total, 936,519 hospital admissions for ACEs occurred in the Italian population during the study period. A 4% reduction in hospital admissions for ACEs among persons aged less than 70 years was evident after the introduction of the ban (Rate Ratio [RR], 0.96; 95% Confidence Interval [CI], 0.95-0.98). No effect was found among persons aged at least 70 years (RR 1.00; 95% CI 0.99-1.02). Effect modification by age was further suggested by analyses using narrower age categories. Conclusions: Smoke-free policies can constitute a simple and inexpensive intervention for the prevention of cardiovascular diseases and thus should be included in prevention programmes.	[Barone-Adesi, Francesco; Vizzini, Loredana; Merletti, Franco; Richiardi, Lorenzo] Univ Turin, Canc Epidemiol Unit, CeRMS, Turin, Italy; [Barone-Adesi, Francesco; Vizzini, Loredana; Merletti, Franco; Richiardi, Lorenzo] Univ Turin, CPO Piemonte, Turin, Italy; [Gasparrini, Antonio] London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1, England	University of Turin; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte; University of Turin; University of London; London School of Hygiene & Tropical Medicine	Barone-Adesi, F (corresponding author), Univ Turin, Canc Epidemiol Unit, CeRMS, Turin, Italy.	fbaroneadesi@yahoo.it	Gasparrini, Antonio/F-7627-2012; Barone-Adesi, Francesco/ABG-1580-2020; richiardi, lorenzo/J-3480-2018	Gasparrini, Antonio/0000-0002-2271-3568; Barone-Adesi, Francesco/0000-0003-1550-436X; richiardi, lorenzo/0000-0003-0316-9402	Compagnia San Paolo/Fondazione Internazionale in Medicina Sperimentale (FIRMS); Regione Piemonte	Compagnia San Paolo/Fondazione Internazionale in Medicina Sperimentale (FIRMS)(Compagnia di San Paolo); Regione Piemonte(Regione Piemonte)	This work was partially supported by the Compagnia San Paolo/Fondazione Internazionale in Medicina Sperimentale (FIRMS) and the Regione Piemonte. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barnett R, 2009, AUST NZ J PUBL HEAL, V33, P515, DOI 10.1111/j.1753-6405.2009.00446.x; Barnoya J, 2005, CIRCULATION, V112, P456, DOI 10.1161/CIRCULATIONAHA.105.554741; Barone-Adesi F, 2006, EUR HEART J, V27, P2468, DOI 10.1093/eurheartj/ehl201; Brocco S, 2006, J CARDIOVASC MED, V7, P45, DOI 10.2459/01.JCM.0000199787.45940.68; Cesaroni G, 2008, CIRCULATION, V117, P1183, DOI 10.1161/CIRCULATIONAHA.107.729889; CHENG TO, 2010, INT J CARDI IN PRESS; DOLL R, 1967, INT J CANCER, V2, P269, DOI 10.1002/ijc.2910020310; *EPA CAL OFF ENV H, HLTH EFF ASS ENV TOB; Gallus S, 2006, ANN ONCOL, V17, P346, DOI 10.1093/annonc/mdj070; Gasparrini A, 2009, EUR J EPIDEMIOL, V24, P597, DOI 10.1007/s10654-009-9377-0; Gorini G, 2007, ANN ONCOL, V18, P1620, DOI 10.1093/annonc/mdm279; Gorini G, 2007, PREV MED, V45, P123, DOI 10.1016/j.ypmed.2007.06.019; Hunsberger S, 2002, BIOSTATISTICS, V3, P289, DOI 10.1093/biostatistics/3.2.289; Institute of Medicine, 2009, SEC SMOK EXP CARD EF; Juster HR, 2007, AM J PUBLIC HEALTH, V97, P2035, DOI 10.2105/AJPH.2006.099994; Lightwood JM, 2009, CIRCULATION, V120, P1373, DOI 10.1161/CIRCULATIONAHA.109.870691; Lightwood JM, 1997, CIRCULATION, V96, P1089, DOI 10.1161/01.CIR.96.4.1089; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Palmieri L, 2010, AM J PUBLIC HEALTH, V100, P684, DOI 10.2105/AJPH.2008.147173; Panagiotakos DB, 2004, INT J CARDIOL, V94, P229, DOI 10.1016/j.ijcard.2003.04.050; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; *PRACT MAN INF COR, 1993, INT CLASS DIS CLIN M; Richiardi L, 2009, PREV MED, V48, P167, DOI 10.1016/j.ypmed.2008.11.013; Salomaa V, 2005, EUR HEART J, V26, P1719, DOI 10.1093/eurheartj/ehi185; SCHULZE A, 2006, SOZIALE UNTERSCHIEDE; Seo DC, 2007, J DRUG EDUC, V37, P217, DOI 10.2190/DE.37.3.a; Sims M, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2161; Twose J, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-194; Vasselli S, 2008, Minerva Cardioangiol, V56, P197; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x	31	50	53	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 2	2011	6	3							e17419	10.1371/journal.pone.0017419	http://dx.doi.org/10.1371/journal.pone.0017419			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	729FF	21399685	Green Submitted, Green Published, Green Accepted, gold			2023-01-03	WOS:000287933300022
J	Staats, HF; Fielhauer, JR; Thompson, AL; Tripp, AA; Sobel, AE; Maddaloni, M; Abraham, SN; Pascual, DW				Staats, Herman F.; Fielhauer, Jeffrey R.; Thompson, Afton L.; Tripp, Alice A.; Sobel, Ashley E.; Maddaloni, Massimo; Abraham, Soman N.; Pascual, David W.			Mucosal Targeting of a BoNT/A Subunit Vaccine Adjuvanted with a Mast Cell Activator Enhances Induction of BoNT/A Neutralizing Antibodies in Rabbits	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; NASAL LYMPHOID-TISSUE; BOTULINUM NEUROTOXIN; PROTECTIVE ANTIGEN; INFLUENZA VACCINE; CHOLERA-TOXIN; INTRANASAL IMMUNIZATION; MONOCLONAL-ANTIBODIES; SYSTEMIC IMMUNITY; BELLS-PALSY	Background: We previously reported that the immunogenicity of Hc beta tre, a botulinum neurotoxin A (BoNT/A) immunogen, was enhanced by fusion to an epithelial cell binding domain, Ad2F, when nasally delivered to mice with cholera toxin (CT). This study was performed to determine if Ad2F would enhance the nasal immunogenicity of Hc beta tre in rabbits, an animal model with a nasal cavity anatomy similar to humans. Since CT is not safe for human use, we also tested the adjuvant activity of compound 48/80 (C48/80), a mast cell activating compound previously determined to safely exhibit nasal adjuvant activity in mice. Methods: New Zealand White or Dutch Belted rabbits were nasally immunized with Hc beta tre or Hc beta tre-Ad2F alone or combined with CT or C48/80, and serum samples were tested for the presence of Hc beta tre-specific binding (ELISA) or BoNT/A neutralizing antibodies. Results: Hc beta tre-Ad2F nasally administered with CT induced serum anti-Hc beta tre IgG ELISA and BoNT/A neutralizing antibody titers greater than those induced by Hc beta tre + CT. C48/80 provided significant nasal adjuvant activity and induced BoNT/A-neutralizing antibodies similar to those induced by CT. Conclusions: Ad2F enhanced the nasal immunogenicity of Hc beta tre, and the mast cell activator C48/80 was an effective adjuvant for nasal immunization in rabbits, an animal model with a nasal cavity anatomy similar to that in humans.	[Staats, Herman F.; Fielhauer, Jeffrey R.; Thompson, Afton L.; Tripp, Alice A.; Sobel, Ashley E.; Abraham, Soman N.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; [Staats, Herman F.; Abraham, Soman N.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA; [Abraham, Soman N.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; [Staats, Herman F.] Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27710 USA; [Maddaloni, Massimo; Pascual, David W.] Montana State Univ, Dept Immunol & Infect Dis, Bozeman, MT 59717 USA	Duke University; Duke University; Duke University; Duke University; Montana State University System; Montana State University Bozeman	Staats, HF (corresponding author), Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.	herman.staats@duke.edu	Pascual, David/AAC-2248-2022	Staats, Herman/0000-0003-1039-1087	NIH [R01 AI064879, R21 AI059591, R01 AI078938]; Rocky Mountain Research Center of Excellence, NIH [U54 AI06537]; Montana Agricultural Station; U.S. Department of Agriculture; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078938, R01AI064879, R21AI059591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK077159] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Rocky Mountain Research Center of Excellence, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Montana Agricultural Station; U.S. Department of Agriculture(United States Department of Agriculture (USDA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grants R01 AI064879, R21 AI059591, R01 AI078938, and Rocky Mountain Research Center of Excellence, NIH U54 AI06537, and in part by Montana Agricultural Station and U.S. Department of Agriculture Formula Funds. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggerbeck H, 1997, VACCINE, V15, P307, DOI 10.1016/S0264-410X(96)00175-2; Allegranzi B, 2007, J HOSP INFECT, V65, P115, DOI 10.1016/S0195-6701(07)60027-9; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; Baldwin MR, 2005, INFECT IMMUN, V73, P6998, DOI 10.1128/IAI.73.10.6998-7005.2005; Beyer WEP, 2002, VACCINE, V20, P1340, DOI 10.1016/S0264-410X(01)00471-6; Bienenstock J, 2005, IMMUNOL REV, V206, P22, DOI 10.1111/j.0105-2896.2005.00299.x; Boyaka PN, 2000, AM J PATHOL, V157, P2023, DOI 10.1016/S0002-9440(10)64841-9; Boyaka PN, 2003, J IMMUNOL, V170, P5636, DOI 10.4049/jimmunol.170.11.5636; Bradney CP, 2002, J VIROL, V76, P517, DOI 10.1128/JVI.76.2.517-524.2002; Brandtzaeg P, 2003, INT J PEDIATR OTORHI, V67, pS69, DOI 10.1016/j.ijporl.2003.08.018; Brandtzaeg P, 2007, VACCINE, V25, P5467, DOI 10.1016/j.vaccine.2006.12.001; Casteleyn C, 2010, VET IMMUNOL IMMUNOP, V133, P212, DOI 10.1016/j.vetimm.2009.08.011; Chen D, 2002, AIDS RES HUM RETROV, V18, P715, DOI 10.1089/088922202760072348; Couch RB, 2004, NEW ENGL J MED, V350, P860, DOI 10.1056/NEJMp048006; Coucke D, 2009, VACCINE, V27, P1279, DOI 10.1016/j.vaccine.2008.12.013; Cox RJ, 2004, SCAND J IMMUNOL, V59, P1, DOI 10.1111/j.0300-9475.2004.01382.x; De Villiers PJT, 2009, VACCINE, V28, P228, DOI 10.1016/j.vaccine.2009.09.092; Debertin AS, 2003, CLIN EXP IMMUNOL, V134, P503, DOI 10.1111/j.1365-2249.2003.02311.x; Egan MA, 2004, VACCINE, V22, P3774, DOI 10.1016/j.vaccine.2004.03.011; Ginalski K, 2000, FEBS LETT, V482, P119, DOI 10.1016/S0014-5793(00)01954-2; Gwinn WM, 2010, VACCINE, V28, P6901, DOI 10.1016/j.vaccine.2010.08.006; GWINN WM, 2010, VACCINE; Harris SL, 2003, INFECT IMMUN, V71, P275, DOI 10.1128/IAI.71.1.275-286.2003; HEIMSCH RC, 1970, P SOC EXP BIOL MED, V135, P151; Huang J, 2007, HUM VACCINES, V3, P90, DOI 10.4161/hv.3.3.4011; Jodar L, 2001, VACCINE, V19, P1594, DOI 10.1016/S0264-410X(00)00358-3; Kermode M, 2004, HEALTH PROMOT INT, V19, P95, DOI 10.1093/heapro/dah110; Kiyono H, 2004, NAT REV IMMUNOL, V4, P699, DOI 10.1038/nri1439; Kleinstreuer C, 2008, ANNU REV BIOMED ENG, V10, P195, DOI 10.1146/annurev.bioeng.10.061807.160544; Kobayashi R, 2005, J IMMUNOL, V174, P2190, DOI 10.4049/jimmunol.174.4.2190; KRIEGLSTEIN KG, 1994, J PROTEIN CHEM, V13, P49, DOI 10.1007/BF01891992; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lewis DJM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006999; Maddaloni M, 2006, J IMMUNOL, V177, P5524, DOI 10.4049/jimmunol.177.8.5524; Mallory RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013755; MARINARO M, 1995, J IMMUNOL, V155, P4621; Marks JD, 2004, MOVEMENT DISORD, V19, pS101, DOI 10.1002/mds.20023; Maynard JA, 2002, NAT BIOTECHNOL, V20, P597, DOI 10.1038/nbt0602-597; McCloskey N, 1997, J IMMUNOL METHODS, V205, P67, DOI 10.1016/S0022-1759(97)00059-8; McGowen AL, 2009, VACCINE, V27, P3544, DOI 10.1016/j.vaccine.2009.03.069; McLachlan JB, 2008, NAT MED, V14, P536, DOI 10.1038/nm1757; Millner VS, 2010, SOUTH MED J, V103, P993, DOI 10.1097/SMJ.0b013e3181eda3d5; MORO PL, 2010, AM J OBSTET GYNECOLO; Mutsch M, 2004, NEW ENGL J MED, V350, P896, DOI 10.1056/NEJMoa030595; Newman SP, 2004, CRIT REV THER DRUG, V21, P21, DOI 10.1615/CritRevTherDrugCarrierSyst.v21.20; Nir Y, 2003, AM J TROP MED HYG, V68, P341, DOI 10.4269/ajtmh.2003.68.341; Nochi T, 2010, NAT MATER, V9, P572, DOI [10.1038/NMAT2784, 10.1038/nmat2784]; Nordone SK, 2006, AIDS RES HUM RETROV, V22, P558, DOI 10.1089/aid.2006.22.558; Olszewska W, 2000, VIROLOGY, V272, P98, DOI 10.1006/viro.2000.0285; Reid S, 2009, INT J STD AIDS, V20, P295, DOI 10.1258/ijsa.2008.008441; RUSNAK JM, 2009, HUM VACCIN, V5; SCHLESINGER Y, 1992, JAMA-J AM MED ASSOC, V267, P1489, DOI 10.1001/jama.267.11.1489; Schoggins JW, 2005, J VIROL, V79, P11627, DOI 10.1128/JVI.79.18.11627-11637.2005; Simecka JW, 2000, INFECT IMMUN, V68, P672, DOI 10.1128/IAI.68.2.672-679.2000; SINGH BR, 1989, TOXICON, V27, P403, DOI 10.1016/0041-0101(89)90202-X; Smith LA, 2007, CRIT REV IMMUNOL, V27, P303, DOI 10.1615/CritRevImmunol.v27.i4.20; Smith LA, 2009, VACCINE, V27, pD33, DOI 10.1016/j.vaccine.2009.08.059; SNIDER DP, 1994, J IMMUNOL, V153, P647; Srivastava IK, 2002, J VIROL, V76, P2835, DOI 10.1128/JVI.76.6.2835-2847.2002; Staats HF, 2007, INFECT IMMUN, V75, P5443, DOI 10.1128/IAI.00529-07; Staats HF, 1996, J IMMUNOL, V157, P462; van Ginkel FW, 2000, J IMMUNOL, V165, P4778, DOI 10.4049/jimmunol.165.9.4778; Vermont CL, 2002, INFECT IMMUN, V70, P584, DOI 10.1128/IAI.70.2.584-590.2002; *WHO, 2002, 231 WHO; Wu HY, 1997, SCAND J IMMUNOL, V46, P506, DOI 10.1046/j.1365-3083.1997.d01-159.x; Wu HY, 1997, IMMUNOL RES, V16, P187, DOI 10.1007/BF02786362; Zuercher AW, 2002, EUR J IMMUNOL, V32, P3191, DOI 10.1002/1521-4141(200211)32:11<3191::AID-IMMU3191>3.0.CO;2-0	67	31	31	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 27	2011	6	1							e16532	10.1371/journal.pone.0016532	http://dx.doi.org/10.1371/journal.pone.0016532			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	712JV	21304600	gold, Green Published, Green Submitted			2023-01-03	WOS:000286663900064
J	Ferreira, KS; Maranhao, AQ; Garcia, MCC; Brigido, MM; Santos, SS; Lopes, JD; Almeida, SR				Ferreira, Karen S.; Maranhao, Andrea Q.; Garcia, Maria C. C.; Brigido, Marcelo M.; Santos, Suelen S.; Lopes, Jose D.; Almeida, Sandro R.			Dendritic Cells Transfected with scFv from Mab 7.B12 Mimicking Original Antigen gp43 Induces Protection against Experimental Paracoccidioidomycosis	PLOS ONE			English	Article							SINGLE-CHAIN FV; CYTOTOXIC T-LYMPHOCYTES; PLASMID DNA; ANTIIDIOTYPIC ANTIBODIES; IDIOTYPIC ANTIBODIES; DISPLAY LIBRARY; INTERNAL IMAGE; GENE GUN; CLASS-I; PROTEIN	Paracoccidioidomycosis (PCM), endemic in Latin America, is a progressive systemic mycosis caused by Paracoccidioides brasiliensis (P. brasiliensis), which primarily attacks lung tissue. Dendritic cells (DCs) are able to initiate a response in naive T cells, and they also participate in Th-cell education. Furthermore, these cells have been used for therapy in several disease models. Here we transfected DCs with a plasmid (pMAC/PS-scFv) encoding a single chain variable fragment (scFv) of an anti-Id antibody that is capable of mimicking gp43, the main antigenic component of P. brasiliensis. First, Balb/c mice were immunized subcutaneously with pMAC/PS-scFv and, after seven days, scFv protein was presented to the regional lymph nodes cells. Moreover, we showed that the DCs transfected with scFv were capable of efficiently activating proliferation of total lymph node cells and inducing a decrease in lung infection. Therefore, our results suggested that the use of scFv-transfected DCs may be a promising therapy in the paracoccidioidomycosis (PCM) model.	[Ferreira, Karen S.] Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Dept Ciencias Biol, Sao Paulo, Brazil; [Maranhao, Andrea Q.; Brigido, Marcelo M.] Univ Brasilia, Dept Biol Celular, Brasilia, DF, Brazil; [Garcia, Maria C. C.; Santos, Suelen S.; Almeida, Sandro R.] Univ Sao Paulo, Dept Anal Clin & Toxicol, Sao Paulo, Brazil; [Lopes, Jose D.] Univ Fed Sao Paulo, Dept Microbiol Imunol & Parasitol, Sao Paulo, Brazil	Universidade Federal de Sao Paulo (UNIFESP); Universidade de Brasilia; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP)	Ferreira, KS (corresponding author), Univ Fed Sao Paulo, Inst Ciencias Ambientais Quim & Farmaceut, Dept Ciencias Biol, Sao Paulo, Brazil.	karenspadari@gmail.com	Brigido, Marcelo Macedo/A-1972-2015; Maranhão, Andrea Q/L-4474-2013; Ferreira, Karen/AAA-4363-2022; Maranhão, Andrea Queiroz/S-8696-2019; Brigido, Marcelo/H-2718-2019; almeida, sandro r/F-5816-2012; Santos, Suelen/F-3048-2014; Ferreira/Spadari, Karen SF/D-4437-2013; Maranhão, Andrea/AAC-3560-2019	Brigido, Marcelo Macedo/0000-0002-7136-7059; Maranhão, Andrea Q/0000-0002-1946-7191; Brigido, Marcelo/0000-0002-7136-7059; almeida, sandro r/0000-0002-0562-1610; Maranhão, Andrea/0000-0002-1946-7191; Spadari, Karen/0000-0003-2832-5942	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [07/57594-9, 07/50568-2]; CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP Process: 07/57594-9)(scholarship to K.S.F. process: 07/50568-2) and CNPq (Conselho Nacional de Desenvolvimento Cientifico e Tecnologico, research fellowships to S.R.A. and J.D.L.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe H, 2002, ANTICANCER RES, V22, P1575; Beninati C, 2006, J EXP MED, V203, P111, DOI 10.1084/jem.20051540; Beninati C, 2000, NAT BIOTECHNOL, V18, P1060, DOI 10.1038/80250; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; Bona CA, 1996, P SOC EXP BIOL MED, V213, P32; Boyle JS, 1998, NATURE, V392, P408, DOI 10.1038/32932; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIGIDO MM, 1993, J IMMUNOL, V150, P469; Caldas C, 2000, PROTEIN ENG, V13, P353, DOI 10.1093/protein/13.5.353; Campos-Da-Paz M, 2008, MOL BIOTECHNOL, V39, P155, DOI 10.1007/s12033-008-9055-6; Chang JT, 2000, J IMMUNOL, V164, P100, DOI 10.4049/jimmunol.164.1.100; COLOMA MJ, 1991, BIOTECHNIQUES, V11, P152; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Corr M, 1996, J EXP MED, V184, P1555, DOI 10.1084/jem.184.4.1555; DECAMARGO ZP, 1988, J CLIN MICROBIOL, V26, P2147, DOI 10.1128/JCM.26.10.2147-2151.1988; Depetris M, 2008, J IMMUNOL METHODS, V334, P104, DOI 10.1016/j.jim.2008.02.003; Doe B, 1996, P NATL ACAD SCI USA, V93, P8578, DOI 10.1073/pnas.93.16.8578; Erlandsson A, 2006, MOL IMMUNOL, V43, P599, DOI 10.1016/j.molimm.2005.04.019; Feltquate DM, 1997, J IMMUNOL, V158, P2278; Franco MF., 1989, BAILLIERE CLIN TROP, V4, P185, DOI DOI 10.1590/S0036-46651994000100017; Gesztesi JL, 1996, HYBRIDOMA, V15, P415, DOI 10.1089/hyb.1996.15.415; He FT, 2002, WORLD J GASTROENTERO, V8, P258; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 1997, J IMMUNOL, V159, P11; JERNE NK, 1982, EMBO J, V1, P243, DOI 10.1002/j.1460-2075.1982.tb01154.x; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Juvenale M, 2001, J MED MICROBIOL, V50, P127, DOI 10.1099/0022-1317-50-2-127; Kawano Y, 1996, IMMUNOLOGY, V88, P40, DOI 10.1046/j.1365-2567.1996.d01-634.x; KITANI A, 1993, J IMMUNOL, V151, P3478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Magliani W, 1997, NAT BIOTECHNOL, V15, P155, DOI 10.1038/nbt0297-155; MENEZES VM, 2006, COCHRANE DB SYST REV, V2; Moll H, 2001, IMMUNOBIOLOGY, V204, P659, DOI 10.1078/0171-2985-00105; NISONOFF A, 1981, CLIN IMMUNOL IMMUNOP, V21, P397, DOI 10.1016/0090-1229(81)90228-2; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Palucka K, 2002, CURR OPIN IMMUNOL, V14, P420, DOI 10.1016/S0952-7915(02)00365-5; PAN Y, 1995, FASEB J, V9, P43, DOI 10.1096/fasebj.9.1.7821758; Pignatari GC, 2007, J BIOTECHNOL, V127, P615, DOI 10.1016/j.jbiotec.2006.08.007; Pokorna Dana, 2008, Genet Vaccines Ther, V6, P4, DOI 10.1186/1479-0556-6-4; RESTREPO A, 2005, PRINCIPLES PRACTICE, P3062; Schwegler C, 2005, CANCER RES, V65, P1925, DOI 10.1158/0008-5472.CAN-04-3591; Shibagaki N, 2003, EUR J IMMUNOL, V33, P850, DOI 10.1002/eji.200323709; Shibagaki N, 2002, J IMMUNOL, V168, P2393, DOI 10.4049/jimmunol.168.5.2393; Souza AR, 1998, CLIN EXP IMMUNOL, V114, P40; Souza EB, 2004, CLIN EXP IMMUNOL, V137, P123, DOI 10.1111/j.1365-2249.2004.02507.x; Torres CAT, 1997, J IMMUNOL, V158, P4529; Ulmer JB, 1996, IMMUNOLOGY, V89, P59, DOI 10.1046/j.1365-2567.1996.d01-718.x; WARRENS AN, 1994, INT IMMUNOL, V6, P847, DOI 10.1093/intimm/6.6.847; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; ZAGHOUANI H, 1993, EUR J IMMUNOL, V23, P2746, DOI 10.1002/eji.1830231104; ZHOU H, 1994, NUCLEIC ACIDS RES, V22, P888, DOI 10.1093/nar/22.5.888	52	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2011	6	1							e15935	10.1371/journal.pone.0015935	http://dx.doi.org/10.1371/journal.pone.0015935			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710LJ	21249212	Green Submitted, Green Published, gold			2023-01-03	WOS:000286512900013
J	Christian, P; Murray-Kolb, LE; Khatry, SK; Katz, J; Schaefer, BA; Cole, PM; LeClerq, SC; Tielsch, JM				Christian, Parul; Murray-Kolb, Laura E.; Khatry, Subarna K.; Katz, Joanne; Schaefer, Barbara A.; Cole, Pamela M.; LeClerq, Steven C.; Tielsch, James M.			Prenatal Micronutrient Supplementation and Intellectual and Motor Function in Early School-aged Children in Nepal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IRON-DEFICIENCY ALTERS; PLACEBO-CONTROLLED TRIAL; ZINC SUPPLEMENTATION; FOLIC-ACID; FOLLOW-UP; PSYCHOMOTOR DEVELOPMENT; MENTAL-DEVELOPMENT; INFANT DEVELOPMENT; RANDOMIZED-TRIAL; PREGNANT-WOMEN	Context Iron and zinc are important for the development of both intellectual and motor skills. Few studies have examined whether iron and zinc supplementation during gestation, a critical period of central nervous system development, affects children's later functioning. Objective To examine intellectual and motor functioning of children whose mothers received micronutrient supplementation during pregnancy. Design, Setting, and Participants Cohort follow-up of 676 children aged 7 to 9 years in June 2007-April 2009 who had been born to women in 4 of 5 groups of a community-based, double-blind, randomized controlled trial of prenatal micronutrient supplementation between 1999 and 2001 in rural Nepal. Study children were also in the placebo group of a subsequent preschool iron and zinc supplementation trial. Interventions Women whose children were followed up had been randomly assigned to receive daily iron/folic acid, iron/folic acid/zinc, or multiple micronutrients containing these plus 11 other micronutrients, all with vitamin A, vs a control group of vitamin A alone from early pregnancy through 3 months postpartum. These children did not receive additional micronutrient supplementation other than biannual vitamin A supplementation. Main Outcome Measures Children's intellectual functioning, assessed using the Universal Nonverbal Intelligence Test (UNIT); tests of executive function, including go/no-go, the Stroop test, and backward digit span; and motor function, assessed using the Movement Assessment Battery for Children (MABC) and finger-tapping test. Results The difference across outcomes was significant (Bonferroni-adjusted P<.001) for iron/folic acid vs control but not for other supplement groups. The mean UNIT T score in the iron/folic acid group was 51.7 (SD, 8.5) and in the control group was 48.2 (SD, 10.2), withanadjustedmeandifference of 2.38 (95% confidence interval [CI], 0.06-4.70; P=.04). Differences were not significant between the control group and either the iron/folic acid/zinc (0.73; 95% CI, -0.95 to 2.42) or multiple micronutrient (1.00; 95% CI, -0.55 to 2.56) groups. In tests of executive function, scores were better in the iron/folic acid group relative to the control group for the Stroop test (adjusted mean difference in proportion who failed, -0.14; 95% CI, -0.23 to -0.04) and backward digit span (adjusted mean difference, 0.36; 95% CI, 0.01-0.71) but not for the go/no-go test. The MABC score was lower (better) in the iron/folic acid group compared with the control group but not after adjustment for confounders (mean difference, -1.47; 95% CI, -3.06 to 0.12; P=.07). Finger-tapping test scores were higher (mean difference, 2.05; 95% CI, 0.87-3.24; P=.001) in the iron/folic acid group. Conclusion Aspects of intellectual functioning including working memory, inhibitory control, and fine motor functioning among offspring were positively associated with prenatal iron/folic acid supplementation in an area where iron deficiency is prevalent.	[Christian, Parul; Murray-Kolb, Laura E.; Katz, Joanne; LeClerq, Steven C.; Tielsch, James M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Ctr Human Nutr, Baltimore, MD USA; [Murray-Kolb, Laura E.] Penn State Univ, Dept Nutr Sci, University Pk, PA 16802 USA; [Schaefer, Barbara A.] Penn State Univ, Dept Educ, University Pk, PA 16802 USA; [Schaefer, Barbara A.] Penn State Univ, Sch Psychol & Special Educ, University Pk, PA 16802 USA; [Khatry, Subarna K.; LeClerq, Steven C.] Nepal Eye Hosp Complex, Nepal Nutr Intervent Project Sarlahi, Kathmandu, Nepal	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Christian, P (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Human Nutr, 615 N Wolfe St,Room W2041, Baltimore, MD 21205 USA.	pchristi@jhsph.edu	Mireku, Michael/D-5262-2016	Tielsch, James/0000-0002-1151-060X; Katz, Joanne/0000-0002-5997-7823	National Institutes of Health [R01 HD050254-01, HD 38753]; Bill and Melinda Gates Foundation, Seattle, Washington; Johns Hopkins University [HRN-A-00-97-00015-00, GHS-A-00-03-00019-00]; Office of Health, Infectious Diseases, and Nutrition, US Agency for International Development, Washington, DC [HRN-A-00-97-00015-00, GHS-A-00-03-00019-00]; Bill and Melinda Gates Foundation; US Agency for International Development [HRN-A-00-97-00015-00]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD050254, R01HD038753] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bill and Melinda Gates Foundation, Seattle, Washington(Bill & Melinda Gates Foundation); Johns Hopkins University(Johns Hopkins University); Office of Health, Infectious Diseases, and Nutrition, US Agency for International Development, Washington, DC(United States Agency for International Development (USAID)); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); US Agency for International Development(United States Agency for International Development (USAID)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	This work was carried out by the Center for Human Nutrition, Department of International Health of the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, in collaboration with the National Society for the Prevention of Blindness, Kathmandu, Nepal, with funding from National Institutes of Health grant R01 HD050254-01 and the Bill and Melinda Gates Foundation, Seattle, Washington. The antenatal micronutrient supplementation study was conducted under Micronutrients for Health Cooperative Agreement HRN-A-00-97-00015-00 and Global Research Activity Cooperative Agreement GHS-A-00-03-00019-00 between Johns Hopkins University and the Office of Health, Infectious Diseases, and Nutrition, US Agency for International Development, Washington, DC. Bill and Melinda Gates Foundation and Sight and Life Research Institute, Baltimore, Maryland, provided additional support for the study. The preschool child iron and zinc supplementation study was funded by the National Institutes of Health (HD 38753), the Bill and Melinda Gates Foundation, and a cooperative agreement between Johns Hopkins University and the Office of Health, Infectious Diseases, and Nutrition, US Agency for International Development (HRN-A-00-97-00015-00).	Beard JL, 2008, J NUTR, V138, P2534, DOI 10.1093/jn/138.12.2534; Bracken B.A., 1998, UNIVERSAL NONVERBAL; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Caldwell B., 1984, HOME OBSERVATION MEA; Carlson ES, 2007, HIPPOCAMPUS, V17, P679, DOI 10.1002/hipo.20307; Christian P, 2003, AM J CLIN NUTR, V78, P1194, DOI 10.1093/ajcn/78.6.1194; Christian P, 2003, J NUTR, V133, p1969S, DOI 10.1093/jn/133.6.1969S; Christian P, 2003, BMJ-BRIT MED J, V326, P571, DOI 10.1136/bmj.326.7389.571; Clardy SL, 2006, J NEURAL TRANSM-SUPP, P173; Connor J., 1997, METALS OXIDATIVE DAM, P23; de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; deUngria M, 2000, PEDIATR RES, V48, P169, DOI 10.1203/00006450-200008000-00009; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Dreyfuss ML, 2000, J NUTR, V130, P2527, DOI 10.1093/jn/130.10.2527; Georgieff MK, 2008, BIOCHEM SOC T, V36, P1267, DOI 10.1042/BST0361267; Gillian BJ, 2009, THESIS J HOPKINS U B; Golub MS, 2006, NEUROTOXICOL TERATOL, V28, P3, DOI 10.1016/j.ntt.2005.10.005; Hamadani JD, 2002, LANCET, V360, P290, DOI 10.1016/S0140-6736(02)09551-X; Henderson S, 1992, MOVEMENT ASSESSMENT; Konishi S, 1998, EUR J NEUROSCI, V10, P1209, DOI 10.1046/j.1460-9568.1998.00167.x; Li Q, 2009, PEDIATRICS, V123, pE685, DOI 10.1542/peds.2008-3007; Lozoff B, 2007, FOOD NUTR BULL, V28, pS560, DOI 10.1177/15648265070284S409; Lozoff B, 2006, NUTR REV, V64, pS34, DOI 10.1301/nr.2006.may.S34-S43; Malouf M, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD004514; McCallum S, 2001, ESSENTIALS NONVERBAL; McGrath N, 2006, PEDIATRICS, V117, pE216, DOI 10.1542/peds.2004-1668; Merialdi M, 1999, AM J OBSTET GYNECOL, V180, P483, DOI 10.1016/S0002-9378(99)70236-X; Olivares M, 2007, NUTRITION, V23, P292, DOI 10.1016/j.nut.2007.01.006; Ortiz E, 2004, J NEUROSCI RES, V77, P681, DOI 10.1002/jnr.20207; Rao R, 2003, J NUTR, V133, P3215, DOI 10.1093/jn/133.10.3215; Raven JC., 1992, MANUAL RAVENS PROGR; Roza SJ, 2010, BRIT J NUTR, V103, P445, DOI 10.1017/S0007114509991954; Siddappa AM, 2004, PEDIATR RES, V55, P1034, DOI 10.1203/01.pdr.0000127021.38207.62; Snedecor GW, 1980, STAT METHODS; Tamura T, 2003, AM J CLIN NUTR, V77, P1512, DOI 10.1093/ajcn/77.6.1512; Tielsch JM, 2007, LANCET, V370, P1230, DOI 10.1016/S0140-6736(07)61539-6; Tielsch JM, 2006, LANCET, V367, P144, DOI 10.1016/S0140-6736(06)67963-4; Todorich B, 2009, GLIA, V57, P467, DOI 10.1002/glia.20784; Tofail F, 2008, AM J CLIN NUTR, V87, P704, DOI 10.1093/ajcn/87.3.704; Ward KL, 2007, J NUTR, V137, P1043, DOI 10.1093/jn/137.4.1043; Wechsler D, 2009, WISC 3 WECHSLER INTE, V4th; Wehby GL, 2008, MATERN CHILD HLTH J, V12, P180, DOI 10.1007/s10995-007-0230-3; Whittaker P, 1998, AM J CLIN NUTR, V68, p442S, DOI 10.1093/ajcn/68.2.442S; Zhou SJ, 2006, AM J CLIN NUTR, V83, P1112, DOI 10.1093/ajcn/83.5.1112	44	169	174	0	55	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 22	2010	304	24					2716	2723		10.1001/jama.2010.1861	http://dx.doi.org/10.1001/jama.2010.1861			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697MP	21177506				2023-01-03	WOS:000285518000016
J	van Amsterdam, J; van den Brink, W				van Amsterdam, Jan; van den Brink, Wim			Ranking of drugs: a more balanced risk-assessment	LANCET			English	Editorial Material							ALCOHOL; HARM		[van Amsterdam, Jan] Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Bilthoven, Netherlands; [van den Brink, Wim] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1105 AZ Amsterdam, Netherlands; [van den Brink, Wim] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Addict Res, NL-1105 AZ Amsterdam, Netherlands	Netherlands National Institute for Public Health & the Environment; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	van Amsterdam, J (corresponding author), Natl Inst Publ Hlth & Environm, Lab Hlth Protect Res, NL-3720 BA Bilthoven, Netherlands.	Jan.van.Amsterdam@rivm.nl						HEARN WL, 1991, PHARMACOL BIOCHEM BE, V39, P531, DOI 10.1016/0091-3057(91)90222-N; Nutt D, 2007, LANCET, V369, P1047, DOI 10.1016/S0140-6736(07)60464-4; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; Ramaekers JG, 2000, HUM PSYCHOPHARM CLIN, V15, P551, DOI 10.1002/1099-1077(200010)15:7<551::AID-HUP236>3.0.CO;2-P; van Amsterdam J, 2010, EUR ADDICT RES, V16, P202, DOI 10.1159/000317249; van den Brink W, 2008, CURR OPIN PSYCHIATR, V21, P122, DOI 10.1097/YCO.0b013e3282f57e04	6	10	11	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	2010	376	9752					1524	1525		10.1016/S0140-6736(10)62000-4	http://dx.doi.org/10.1016/S0140-6736(10)62000-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	680QE	21036391				2023-01-03	WOS:000284248700008
J	Pfeffer, MA; Bowler, MB				Pfeffer, Marc A.; Bowler, Marianne B.			Access to Safety Data - Stockholders versus Prescribers	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Pfeffer, Marc A.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA; [Pfeffer, Marc A.] Harvard Univ, Sch Med, Boston, MA USA; [Bowler, Marianne B.] US Dist Court, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Pfeffer, MA (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.							BREYER STEPHEN, 2010, MAKING OUR DEMOCRACY; Curfman GD, 2006, NEW ENGL J MED, V354, P1193, DOI 10.1056/NEJMe068054; *FOOD DRUG ADM, SENT IN NAT STRAT MO	3	2	2	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2011	365	1					1	3		10.1056/NEJMp1104699	http://dx.doi.org/10.1056/NEJMp1104699			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	788QL	21714642				2023-01-03	WOS:000292459400001
J	Flenady, V; Middleton, P; Smith, GC; Duke, W; Erwich, JJ; Khong, TY; Neilson, J; Ezzati, M; Koopmans, L; Ellwood, D; Fretts, R; Froen, JF				Flenady, Vicki; Middleton, Philippa; Smith, Gordon C.; Duke, Wes; Erwich, Jan Jaap; Khong, T. Yee; Neilson, Jim; Ezzati, Majid; Koopmans, Laura; Ellwood, David; Fretts, Ruth; Froen, J. Frederik		Lancet's Stillbirths Series Steeri	Stillbirths 5 Stillbirths: the way forward in high-income countries	LANCET			English	Article							PERINATAL-MORTALITY; GESTATIONAL-AGE; FETAL-DEATH; PERIODONTAL-DISEASE; AVOIDABLE MORTALITY; ALCOHOL-CONSUMPTION; NEONATAL DEATHS; AUTOPSY RATES; PRENATAL-CARE; BIRTH-WEIGHT	Stillbirth rates in high-income countries declined dramatically from about 1940, but this decline has slowed or stalled over recent times. The present variation in stillbirth rates across and within high-income countries indicates that further reduction in stillbirth is possible. Large disparities (linked to disadvantage such as poverty) in stillbirth rates need to be addressed by providing more educational opportunities and improving living conditions for women. Placental pathologies and infection associated with preterm birth are linked to a substantial proportion of stillbirths. The proportion of unexplained stillbirths associated with under investigation continues to impede efforts in stillbirth prevention. Overweight, obesity, and smoking are important modifiable risk factors for stillbirth, and advanced maternal age is also an increasingly prevalent risk factor. Intensified efforts are needed to ameliorate the effects of these factors on stillbirth rates. Culturally appropriate preconception care and quality antenatal care that is accessible to all women has the potential to reduce stillbirth rates in high-income countries. Implementation of national perinatal mortality audit programmes aimed at improving the quality of care could substantially reduce stillbirths. Better data on numbers and causes of stillbirth are needed, and international consensus on definition and classification related to stillbirth is a priority. All parents should be offered a thorough investigation including a high-quality autopsy and placental histopathology. Parent organisations are powerful change agents and could have an important role in raising awareness to prevent stillbirth. Future research must focus on screening and interventions to reduce antepartum stillbirth as a result of placental dysfunction. Identification of ways to reduce maternal overweight and obesity is a high priority for high-income countries.	[Flenady, Vicki] Mater Med Res Inst, Mater Hlth Serv, Brisbane, Qld 4101, Australia; [Flenady, Vicki] Univ Queensland, Brisbane, Qld, Australia; [Flenady, Vicki] Int Stillbirth Alliance, Baltimore, MD USA; [Middleton, Philippa] Univ Adelaide, Adelaide, SA, Australia; [Smith, Gordon C.] Univ Cambridge, Dept Obstet & Gynaecol, Cambridge, England; [Duke, Wes] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA; [Erwich, Jan Jaap] Univ Groningen, Dept Obstet, Utrecht, Netherlands; [Erwich, Jan Jaap] Fdn Perinatal Audit Netherlands, Utrecht, Netherlands; [Khong, T. Yee] Womens & Childrens Hosp, SA Pathol, Adelaide, SA, Australia; [Neilson, Jim] Univ Liverpool, Cochrane Pregnancy & Childbirth Grp, Liverpool L69 3BX, Merseyside, England; [Ezzati, Majid] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England; [Ellwood, David] Canberra Hosp, Canberra, ACT, Australia; [Ellwood, David] Australian Natl Univ, Sch Med, Canberra, ACT, Australia; [Fretts, Ruth] Harvard Vanguard Med Associates, Wellesley, MA USA; [Froen, J. Frederik] Norwegian Inst Publ Hlth, Div Epidemiol, Oslo, Norway	Mater Health Services; Mater Research; University of Queensland; University of Adelaide; University of Cambridge; Centers for Disease Control & Prevention - USA; University of Groningen; SA Pathology; Womens & Childrens Hospital Australia; University of Liverpool; Imperial College London; Australian National University; Canberra Hospital; Australian National University; Harvard Vanguard Medical Associates; Norwegian Institute of Public Health (NIPH)	Flenady, V (corresponding author), Mater Med Res Inst, Mater Hlth Serv, Brisbane, Qld 4101, Australia.	Vicki.Flenady@mmri.mater.org.au	Flenady, Vicki Jane/O-9609-2014; Lawn, Joy/ABE-6382-2020; Smith, Gordon/A-8070-2008; Frøen, J. Frederik/C-3271-2009; Ellwood, David Alan/GNW-4485-2022	Flenady, Vicki Jane/0000-0001-8114-7677; Lawn, Joy/0000-0002-4573-1443; Smith, Gordon/0000-0003-2124-0997; Ellwood, David Alan/0000-0003-4512-6443; Froen Froen, Jahn Frederik/0000-0001-9390-8509	Bill & Melinda Gates Foundation; International Stillbirth Alliance; Norwegian Institute of Public Health; Medical Research Council [G0801056B] Funding Source: researchfish	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); International Stillbirth Alliance; Norwegian Institute of Public Health; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank the Bill & Melinda Gates Foundation for a grant to support this work to the International Stillbirth Alliance administered by the Mater Medical Research Institute, Brisbane, QLD, Australia. Additionally, we thank the International Stillbirth Alliance and the Norwegian Institute of Public Health for seed funding to support meetings of the steering committee. We thank the following for technical support: Dominique Rossouw, Madeleine Elder, and, Elizabeth Flenady for literature searching and reference management, Kristen Gibbons for statistical advice, and Glenda Hawley, Teresa Walsh, Shelley Wilkinson, and Ann Kingsbury for providing feedback on the report. We thank Janet Scott of Sands UK, Sue Hale of Sands UK and ISA Parent Advisory Committee, and Liz Conway Sands Australia and the ISA Parent Advisory Committee for their comments and contributions to the report. We thank the following for their contributions to the research priority component: Justus Hofmeyr for his assistance with the development of the research priority questions, review of interventions, and comment of drafts of the report; Eckhart Buchmann for development of the initial drafts of all the research questions; Igor Rudan for guidance and support; and Ibinabo Ibiebele for data analysis. We thank all those who scored the stillbirth research priorities: Adrian Charles, Paul Colditz, Linda Dodds, Lelia Duley, Jason Gardosi, Sanne Gordijn, Grace Guyon, Justus Hofmeyr, Alex Heazell, Robyn Kennare, Russell Kirby, Wolfgang Kuenzel, Kassam Mahomed, Luigi Matturri, Elizabeth M McClure, Lesley McCowan, Giorgio Mello, Ayman el Mohandes, Halit Pinar, Ingela Radestad, Uma M Reddy, Birgit Reime, Bob Silver, and Bert Timmer, and members of the GAPPS Basic Biology Working Group: Craig Rubens, Michael Gravett, Gordon Smith, Leslie Myatt, Oslem Equils, Roger Smith, and Sarah England.	Acolet D, 2005, PEDIATRICS, V116, P1457, DOI 10.1542/peds.2004-2691; Alderliesten ME, 2008, EUR J OBSTET GYN R B, V137, P141, DOI 10.1016/j.ejogrb.2007.06.002; Alfirevic Z, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007529.pub2; Aliyu MH, 2008, ALCOHOL, V42, P369, DOI 10.1016/j.alcohol.2008.04.003; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; [Anonymous], 2007, DIAB PREGN AR WE PRO; Askie LM, 2007, LANCET, V369, P1791, DOI 10.1016/S0140-6736(07)60712-0; Bateman BT, 2006, AM J OBSTET GYNECOL, V194, P840, DOI 10.1016/j.ajog.2005.08.038; Bergsjo P, 2003, ACTA OBSTET GYN SCAN, V82, P780, DOI 10.1034/j.1600-0412.2003.00224.x; BHUTTA ZA, 2011, LANCET, DOI DOI 10.1016/S0140-6736(10)62050-8; Bolling K, 2007, INFANT FEEDING SURVE; Breeze ACG, 2008, ULTRASOUND OBST GYN, V31, P187, DOI 10.1002/uog.5199; Brookes JS, 2006, J MAGN RESON IMAGING, V24, P1221, DOI 10.1002/jmri.20770; Bryant AS, 2010, AM J OBSTET GYNECOL, V202, P335, DOI 10.1016/j.ajog.2009.10.864; Burnley H, 2005, J CLIN PATHOL, V58, P93, DOI 10.1136/jcp.2004.020636; *CCOPMM, 2007, ANN REP YEAR 2007 IN; *CESDI, 2001, 8 CESDI; Chan A, 2004, J PAEDIATR CHILD H, V40, P340, DOI 10.1111/j.1440-1754.2004.00398.x; *CMACE, 2010, CTR MAT CHILD ENQ PE; Cnattingius S, 1998, BRIT MED J, V316, P1483, DOI 10.1136/bmj.316.7143.1483; Cogswell ME, 1999, OBSTET GYNECOL, V94, P616, DOI 10.1016/S0029-7844(99)00375-0; Cohen MC, 2008, PEDIATR DEVEL PATHOL, V11, P1, DOI 10.2350/07-01-0213.1; Corabian P, 2007, J OBSTET GYNAECOL CA, V29, P560, DOI 10.1016/S1701-2163(16)32500-2; Crowther CA, 1999, AUST NZ J OBSTET GYN, V39, P12, DOI 10.1111/j.1479-828X.1999.tb03434.x; d'Espaignet ET, 2008, FORENSIC SCI MED PAT, V4, P83, DOI 10.1007/s12024-007-9011-y; Darmstadt GL, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S6; De Lange TE, 2008, AUST NZ J OBSTET GYN, V48, P50, DOI 10.1111/j.1479-828X.2007.00801.x; De Reu PAOM, 2000, EUR J OBSTET GYN R B, V88, P65, DOI 10.1016/S0301-2115(99)00135-9; De Reu P, 2009, ACTA OBSTET GYN SCAN, V88, P1201, DOI 10.3109/00016340903280990; De Reu PAOM, 2010, J PERINAT MED, V38, P311, DOI [10.1515/JPM.2010.027, 10.1515/jpm.2010.027]; Dodd JM, 2010, BJOG-INT J OBSTET GY, V117, P1316, DOI 10.1111/j.1471-0528.2010.02540.x; Doumit G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000125.pub3; Doyle LW, 2000, LANCET, V355, P2093, DOI 10.1016/S0140-6736(00)02373-4; Dudley DJ, 2010, OBSTET GYNECOL, V116, P254, DOI 10.1097/AOG.0b013e3181e7d975; Duke W, 2010, WOMEN HEALTH ISS, V20, P366, DOI 10.1016/j.whi.2010.06.004; Duley L, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004659.pub2; Essen B, 2002, BJOG-INT J OBSTET GY, V109, P677, DOI 10.1016/S1470-0328(02)01077-7; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Finucane MM, 2011, LANCET, V377, P557, DOI 10.1016/S0140-6736(10)62037-5; Flenady V, 2010, AUST NZ J OBSTET GYN, V50, P138, DOI 10.1111/j.1479-828X.2009.01125.x; Flenady V, 2010, STILLBIRTH UNDERSTAN; FLENADY V, 2010, J PAEDIATR CHILD H, V46, P46; Flenady V., 2009, CLIN PRACTICE GUIDEL; Flenady V, 2011, LANCET, V377, P1331, DOI 10.1016/S0140-6736(10)62233-7; Flenady V, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-24; Floyd RL, 2007, AM J PREV MED, V32, P1, DOI 10.1016/j.amepre.2006.08.028; Floyd RL, 1999, AM J PREV MED, V17, P101, DOI 10.1016/S0749-3797(99)00059-8; Froen JF, 2011, LANCET, V377, P1353, DOI 10.1016/S0140-6736(10)62232-5; Froen JF, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-58; Froen JF, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-22; Froen JF, 2004, ACTA OBSTET GYN SCAN, V83, P801, DOI 10.1111/j.0001-6349.2004.00602.x; Froen JF, 2004, J PERINAT MED, V32, P13, DOI 10.1515/JPM.2004.003; Gardosi J, 2005, BMJ-BRIT MED J, V331, P1113, DOI 10.1136/bmj.38629.587639.7C; Getahun D, 2005, OBSTET GYNECOL, V106, P81, DOI 10.1097/01.AOG.0000165274.06811.86; Gissler M, 2010, INFORM HEALTH SOC CA, V35, P64, DOI 10.3109/17538157.2010.492923; Goldenberg R L, 2004, J Matern Fetal Neonatal Med, V16, P79; Goldenberg RL, 2010, LANCET, V375, P1482, DOI 10.1016/S0140-6736(09)61712-8; Gordijn SJ, 2007, EUR J OBSTET GYN R B, V132, P3, DOI 10.1016/j.ejogrb.2006.10.031; Gordijn SJ, 2002, PEDIATR DEVEL PATHOL, V5, P480, DOI 10.1007/s10024-002-0008-y; Gulmezoglu AM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004945; Haavaldsen C, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.014; Hagmann CF, 2007, ARCH DIS CHILD-FETAL, V92, pF215, DOI 10.1136/fnn.2005.092387; HALL MH, 1980, LANCET, V2, P78; HARVEY SM, 1993, FAM PLANN PERSPECT, V25, P32, DOI 10.2307/2135990; Haws RA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S5; Hawthorne G, 1997, BRIT MED J, V315, P279, DOI 10.1136/bmj.315.7103.279; Henderson-Smart DJ, 2003, CLIN PERINATOL, V30, P333, DOI 10.1016/S0095-5108(03)00026-5; Herring Sharon J, 2008, BMC Pregnancy Childbirth, V8, P54, DOI 10.1186/1471-2393-8-54; Hofmeyr GJ, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001059.pub2, 10.1002/14651858.CD001059.pub4, 10.1002/14651858.CD001059.pub5]; Holt J, 2002, ACTA OBSTET GYN SCAN, V81, P899, DOI 10.1034/j.1600-0412.2002.811001.x; Huisman Thierry A G M, 2004, Semin Neonatol, V9, P347, DOI 10.1016/j.siny.2003.09.004; Hutcheon JA, 2011, PAEDIATR PERINAT EP, V25, P11, DOI 10.1111/j.1365-3016.2010.01155.x; *I MED NAT RES COU, 2009, WEIGHT GAIN PREGN RE; *INT STILLB ALL, 2009, ISA POS STAT FET MOV; Jack BW, 2008, AM J OBSTET GYNECOL, V199, pS266, DOI 10.1016/j.ajog.2008.07.067; Jorgensen T, 2008, SCAND J PUBLIC HEALT, V36, P635, DOI 10.1177/1403494808089653; Kenyon S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001058.pub2; Khong TY, 2006, J PAEDIATR CHILD H, V42, P366, DOI 10.1111/j.1440-1754.2006.00874.x; KHONG TY, 1986, BRIT J OBSTET GYNAEC, V93, P1049, DOI 10.1111/j.1471-0528.1986.tb07830.x; Khong TY, 2003, PEDIATR DEVEL PATHOL, V6, P54, DOI 10.1007/s10024-001-0263-3; Khong TY, 1996, PAEDIATR PERINAT EP, V10, P97, DOI 10.1111/j.1365-3016.1996.tb00030.x; Khong TY., 2006, CURR DIAG PATHOL, V12, P61, DOI 10.1016/j.cdip.2006.03.001; KHONG TY, 2009, STILLBIRTH UNDERSTAN, P91; Korteweg FJ, 2008, PLACENTA, V29, P71, DOI 10.1016/j.placenta.2007.07.003; Korteweg FJ, 2006, BJOG-INT J OBSTET GY, V113, P393, DOI 10.1111/j.1471-0528.2006.00881.x; Korteweg FJ, 2010, OBSTET GYNECOL, V116, P355, DOI 10.1097/AOG.0b013e3181e66d58; Krebs L, 2002, J PERINAT MED, V30, P220, DOI 10.1515/JPM.2002.030; Laing Ian A, 2004, Semin Neonatol, V9, P247, DOI 10.1016/j.siny.2003.11.004; Lauenborg J, 2003, DIABETES CARE, V26, P1385, DOI 10.2337/diacare.26.5.1385; Lawn JE, 2011, LANCET, V377, P1448, DOI 10.1016/S0140-6736(10)62187-3; Laws P, 2009, PERINATAL STAT SERIE; Loftin Ryan W, 2010, Rev Obstet Gynecol, V3, P10; Lumley J, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001055.pub3; Luo ZC, 2010, CAN MED ASSOC J, V182, P235, DOI 10.1503/cmaj.082042; Macdorman Marian F, 2009, NCHS Data Brief, P1; Macones GA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.10.892; MANGESI L, 2007, COCHRANE DB SYST REV, V1; McDonnell KA, 2004, MATERN CHILD HLTH J, V8, P231, DOI 10.1023/B:MACI.0000047421.93207.51; McIntire DD, 1999, NEW ENGL J MED, V340, P1234, DOI 10.1056/NEJM199904223401603; Menezes EV, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S4; Michalowicz BS, 2006, NEW ENGL J MED, V355, P1885, DOI 10.1056/NEJMoa062249; *NAT I HLTH CLIN E, 2010, NICE CLIN GUID, V107; *NAT I HLTH CLIN E, 2010, QUITT SMOK PREGN FOL, V26; National Collaborating Centre for Women's and Children's Health (UK), 2008, DIAB PREGN MAN DIAB; National Institute for Health and Clinical Excellence, 2010, WEIGHT MAN PREGN, V27; NEILSON JP, 2000, COCHRANE DB SYST REV, V2; Newnham JP, 2009, OBSTET GYNECOL, V114, P1239, DOI 10.1097/AOG.0b013e3181c15b40; Orentlicher D, 2010, HASTINGS CENT REP, V40, P12; Pattinson RC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002961.pub2; Pattinson R, 2011, LANCET, V377, P1610, DOI 10.1016/S0140-6736(10)62306-9; Pattinson R, 2009, INT J GYNECOL OBSTET, V107, pS113, DOI 10.1016/j.ijgo.2009.07.011; Pinar H, 2010, CLIN OBSTET GYNECOL, V53, P656, DOI 10.1097/GRF.0b013e3181eb68fe; *PMMRC, 2010, 4 PMMRC MIN HLTH; PRESTON P, 2010, J PAEDIAT CHILD H S3, V46, P45; Ravelli ACJ, 2011, J EPIDEMIOL COMMUN H, V65, P696, DOI 10.1136/jech.2009.095406; Richardus J H, 2003, J Matern Fetal Neonatal Med, V14, P267, DOI 10.1080/713606659; Roberts CL, 2000, AUST NZ J PUBL HEAL, V24, P291, DOI 10.1111/j.1467-842X.2000.tb01571.x; Robson S, 2006, AUST NZ J OBSTET GYN, V46, P305, DOI 10.1111/j.1479-828X.2006.00597.x; Rotter T, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006632.pub2; *ROYAL COLL PAED C, 2002, FUT PAED PATH SERV F; Saastad E, 2007, ACTA OBSTET GYN SCAN, V86, P444, DOI 10.1080/00016340701207724; Salihu H, 2004, OBSTET GYNECOL, V104, P734, DOI 10.1097/01.AOG.0000139944.15133.e3; Salihu HM, 2003, OBSTET GYNECOL, V102, P1006, DOI 10.1016/S0029-7844(03)00739-7; Silver RM, 2007, OBSTET GYNECOL, V109, P153, DOI 10.1097/01.AOG.0000248537.89739.96; Silver RM, 2007, AM J OBSTET GYNECOL, V196, P433, DOI 10.1016/j.ajog.2006.11.041; Smith GCS, 2001, AM J OBSTET GYNECOL, V184, P489, DOI 10.1067/mob.2001.109735; Smith GCS, 2007, LANCET, V370, P1715, DOI 10.1016/S0140-6736(07)61723-1; Smith GCS, 2010, JAMA-J AM MED ASSOC, V303, P561, DOI 10.1001/jama.2010.102; Stade BC, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004228.pub2; Stock SJ, 2010, EUR J OBSTET GYN R B, V153, P148, DOI 10.1016/j.ejogrb.2010.07.022; Streuling I, 2010, AM J CLIN NUTR, V92, P678, DOI 10.3945/ajcn.2010.29363; Sun CCJ, 2002, ARCH PATHOL LAB MED, V126, P706; Tan K. H., 1999, SMJ, V40, P251; Thomas LH, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000349, DOI 10.1002/14651858.CD000349]; Thornton CM, 1998, BRIT J OBSTET GYNAEC, V105, P18, DOI 10.1111/j.1471-0528.1998.tb09344.x; Tieu J, 2010, COCHRANE DB SYST REV, V12; TUGWELL P, 1985, J CHRON DIS, V38, P339, DOI 10.1016/0021-9681(85)90080-3; Tveit JVH, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-32; Van Diem M, 2010, ACTA OBSTET GYN SCAN, V89, P1168, DOI 10.3109/00016349.2010.500468; VERKERK PH, 1993, EARLY HUM DEV, V32, P121, DOI 10.1016/0378-3782(93)90006-G; Vintzileos AM, 2002, OBSTET GYNECOL, V99, P483, DOI 10.1016/S0029-7844(01)01758-6; Vredevoogd C B, 2001, Ned Tijdschr Geneeskd, V145, P482; VUJANIC GM, 1995, J CLIN PATHOL, V48, P998, DOI 10.1136/jcp.48.11.998; *W MIDL PER I, 2009, W MIDL KEY HLTH DAT, pCH13; Whitworth M, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007058.pub2; Whitworth M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007536.pub2; WIGGLESWORTH JS, 1987, ARCH DIS CHILD, V62, P1207, DOI 10.1136/adc.62.12.1207; Willinger M, 2009, AM J OBSTET GYNECOL, V201, DOI 10.1016/j.ajog.2009.06.057; Wolleswinkel-van den Bosch JH, 2002, ACTA OBSTET GYN SCAN, V81, P17, DOI 10.1034/j.1600-0412.2002.810104.x; Woods R, 2008, B WORLD HEALTH ORGAN, V86, P460, DOI 10.2471/BLT.07.043471; Wright C, 1998, BRIT J OBSTET GYNAEC, V105, P24, DOI 10.1111/j.1471-0528.1998.tb09345.x; Wylie BJ, 2010, OBSTET GYNECOL, V115, P1039, DOI 10.1097/AOG.0b013e3181da7929; Yakoob MY, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S3; YUDKIN PL, 1987, LANCET, V1, P1192; [No title captured]	155	301	309	3	49	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 14	2011	377	9778					1703	1717		10.1016/S0140-6736(11)60064-0	http://dx.doi.org/10.1016/S0140-6736(11)60064-0			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21496907				2023-01-03	WOS:000290777700035
J	Stolarz-Skrzypek, K; Kuznetsova, T; Thijs, L; Tikhonoff, V; Seidlerova, J; Richart, T; Jin, Y; Olszanecka, A; Malyutina, S; Casiglia, E; Filipovsky, J; Kawecka-Jaszcz, K; Nikitin, Y; Staessen, JA				Stolarz-Skrzypek, Katarzyna; Kuznetsova, Tatiana; Thijs, Lutgarde; Tikhonoff, Valerie; Seidlerova, Jitka; Richart, Tom; Jin, Yu; Olszanecka, Agnieszka; Malyutina, Sofia; Casiglia, Edoardo; Filipovsky, Jan; Kawecka-Jaszcz, Kalina; Nikitin, Yuri; Staessen, Jan A.		European Project Genes Hypertensio	Fatal and Nonfatal Outcomes, Incidence of Hypertension, and Blood Pressure Changes in Relation to Urinary Sodium Excretion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REDUCED DIETARY-SODIUM; CARDIOVASCULAR-DISEASE; SALT INTAKE; NATIONAL-HEALTH; POTASSIUM; MORTALITY; RISK; POPULATION; METAANALYSIS; CONSUMPTION	Context Extrapolations from observational studies and short-term intervention trials suggest that population-wide moderation of salt intake might reduce cardiovascular events. Objective To assess whether 24-hour urinary sodium excretion predicts blood pressure (BP) and health outcomes. Design, Setting, and Participants Prospective population study, involving 3681 participants without cardiovascular disease (CVD) who are members of families that were randomly enrolled in the Flemish Study on Genes, Environment, and Health Outcomes (1985-2004) or in the European Project on Genes in Hypertension (1999-2001). Of 3681 participants without CVD, 2096 were normotensive at baseline and 1499 had BP and sodium excretion measured at baseline and last follow-up (2005-2008). Main Outcome Measures Incidence of mortality and morbidity and association between changes in BP and sodium excretion. Multivariable-adjusted hazard ratios (HRs) express the risk in tertiles of sodium excretion relative to average risk in the whole study population. Results Among 3681 participants followed up for a median 7.9 years, CVD deaths decreased across increasing tertiles of 24-hour sodium excretion, from 50 deaths in the low (mean, 107 mmol), 24 in the medium (mean, 168 mmol), and 10 in the high excretion group (mean, 260 mmol; P<.001), resulting in respective death rates of 4.1% (95% confidence interval [CI], 3.5%-4.7%), 1.9% (95% CI, 1.5%-2.3%), and 0.8% (95% CI, 0.5%-1.1%). In multivariable-adjusted analyses, this inverse association retained significance (P=.02): the HR in the low tertile was 1.56 (95% CI, 1.02-2.36; P=.04). Baseline sodium excretion predicted neither total mortality (P=.10) nor fatal combined with nonfatal CVD events (P=.55). Among 2096 participants followed up for 6.5 years, the risk of hypertension did not increase across increasing tertiles (P=.93). Incident hypertension was 187 (27.0%; HR, 1.00; 95% CI, 0.87-1.16) in the low, 190 (26.6%; HR, 1.02; 95% CI, 0.89-1.16) in the medium, and 175 (25.4%; HR, 0.98; 95% CI, 0.86-1.12) in the high sodium excretion group. In 1499 participants followed up for 6.1 years, systolic blood pressure increased by 0.37 mm Hg per year (P<.001), whereas sodium excretion did not change (-0.45 mmol per year, P=.15). However, in multivariable-adjusted analyses, a 100-mmol increase in sodium excretion was associated with 1.71 mm Hg increase in systolic blood pressure (P.<001) but no change in diastolic BP. Conclusions In this population-based cohort, systolic blood pressure, but not diastolic pressure, changes over time aligned with change in sodium excretion, but this association did not translate into a higher risk of hypertension or CVD complications. Lower sodium excretion was associated with higher CVD mortality. JAMA. 2011;305(17):1777-1785 www.jama.com	[Staessen, Jan A.] Katholieke Univ Leuven, Studies Coordinating Ctr, Div Hypertens & Cardiovasc Rehabil, Dept Cardiovasc Dis,Lab Hypertens, BE-3000 Louvain, Belgium; [Stolarz-Skrzypek, Katarzyna; Olszanecka, Agnieszka; Kawecka-Jaszcz, Kalina] Jagiellonian Univ, Coll Med, Dept Cardiol & Hypertens 1, Krakow, Poland; [Tikhonoff, Valerie; Casiglia, Edoardo] Univ Padua, Dept Clin & Expt Med, Padua, Italy; [Seidlerova, Jitka; Filipovsky, Jan] Charles Univ Prague, Fac Med Pilsen, Plzen, Czech Republic; [Malyutina, Sofia; Nikitin, Yuri] Inst Internal Med, Novosibirsk, Russia; [Richart, Tom; Staessen, Jan A.] Maastricht Univ, Dept Epidemiol, Maastricht, Netherlands	KU Leuven; Jagiellonian University; Collegium Medicum Jagiellonian University; University of Padua; Charles University Prague; Maastricht University	Staessen, JA (corresponding author), Katholieke Univ Leuven, Studies Coordinating Ctr, Div Hypertens & Cardiovasc Rehabil, Dept Cardiovasc Dis,Lab Hypertens, Campus Sint Rafael,Kapucijnenvoer 35,Block D,POB, BE-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.be	Tikhonoff, Valerie/AAC-3728-2019; Seidlerova, Jitka/P-1188-2017; Stolarz-Skrzypek, Katarzyna/E-1589-2011; Malyutina, Sofia/J-1651-2018; Nikitin, Yuri/D-2774-2018; Staessen, Jan A/A-1065-2011; Kuznetsova, Tatiana/ABI-5662-2020	Tikhonoff, Valerie/0000-0001-7846-0101; Seidlerova, Jitka/0000-0002-2731-4961; Malyutina, Sofia/0000-0001-6539-0466; Nikitin, Yuri/0000-0002-3932-2299; Staessen, Jan A/0000-0002-3026-1637; Kuznetsova, Tatiana/0000-0003-4293-4576; Casiglia, Edoardo/0000-0002-0003-3289; Thijs, Lutgarde/0000-0002-8108-2356; Olszanecka, Agnieszka/0000-0001-7020-9641	European Union [IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093]; Studies Coordinating Centre (Leuven, Belgium) [HEALTH-F4-2007-201550]; studies in Pilsen (Czech Republic); studies in Pilsen, Padova (Italy); studies in Pilsen, Krakow (Poland); Novosibirsk (Russian Federation); Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium [G.0575.06, G.0734.09]; Katholieke Universiteit Leuven, Belgium [OT/00/25, OT/05/49]; Polish Ministry for Science and Higher Education; Czech Society of Hypertension	European Union(European Commission); Studies Coordinating Centre (Leuven, Belgium); studies in Pilsen (Czech Republic)(Czech Republic Government); studies in Pilsen, Padova (Italy); studies in Pilsen, Krakow (Poland); Novosibirsk (Russian Federation)(Russian Federation); Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium(FWO); Katholieke Universiteit Leuven, Belgium(KU Leuven); Polish Ministry for Science and Higher Education(Ministry of Science and Higher Education, Poland); Czech Society of Hypertension	The European Union grants IC15-CT98-0329-EPOGH, LSHM-CT-2006-037093. InGenious HyperCare, and HEALTH-F4-2007-201550 HyperGenes supported the Studies Coordinating Centre (Leuven, Belgium) and the studies in Pilsen (Czech Republic), Padova (Italy), Krakow (Poland), and Novosibirsk (Russian Federation). The Studies Coordinating Centre also received grants G.0575.06 and G.0734.09 from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen, Ministry of the Flemish Community, Brussels, Belgium, and the grants OT/00/25 and OT/05/49 from the Katholieke Universiteit Leuven, Belgium. The Polish Ministry for Science and Higher Education supported the fellowship of Dr Stolarz-Skrzypek in Leuven. The Czech Society of Hypertension provided additional funding to Dr Seidlerova.	ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; Alderman MH, 2010, JAMA-J AM MED ASSOC, V303, P448, DOI 10.1001/jama.2010.69; Bernstein AM, 2010, AM J CLIN NUTR, V92, P1172, DOI 10.3945/ajcn.2010.29367; Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Campese VM, 1999, NUTR METAB CARDIOVAS, V9, P143; Chien KL, 2008, J HYPERTENS, V26, P1750, DOI 10.1097/HJH.0b013e328306a0a7; CLELAND JGF, 1987, BRIT HEART J, V58, P230; Cohen HW, 2008, J GEN INTERN MED, V23, P1297, DOI 10.1007/s11606-008-0645-6; Cohen HW, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.042; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; ELLIOTT P, 1988, BRIT MED J, V297, P319; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Franklin SS, 1997, CIRCULATION, V96, P308; Gavin JR, 1999, DIABETES CARE, V22, pS5; GELEIJNSE JM, 1990, BMJ-BRIT MED J, V300, P899, DOI 10.1136/bmj.300.6729.899; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; Hansen TW, 2010, HYPERTENSION, V55, P1049, DOI [10.1161/HYPERTENSIONAHA.109.140798, 10.1161/HYP.0b013e3181dfc0ad]; He FJ, 2003, HYPERTENSION, V42, P1093, DOI 10.1161/01.HYP.0000102864.05174.E8; He FJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004937; He JA, 2000, HYPERTENSION, V35, P544, DOI 10.1161/01.HYP.35.2.544; He JA, 1999, JAMA-J AM MED ASSOC, V282, P2027, DOI 10.1001/jama.282.21.2027; Hosmer Jr D. W, 2004, APPL LOGISTIC REGRES; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; Kuznetsova T, 2002, BLOOD PRESS MONIT, V7, P215, DOI 10.1097/00126097-200208000-00003; LEVER AF, 1981, BRIT MED J, V283, P463, DOI 10.1136/bmj.283.6289.463; Li Y, 2007, HYPERTENSION, V49, P1291, DOI 10.1161/HYPERTENSIONAHA.106.085498; LUFT FC, 1982, HYPERTENSION, V4, P805, DOI 10.1161/01.HYP.4.6.805; McCarron DA, 2009, CLIN J AM SOC NEPHRO, V4, P1878, DOI 10.2215/CJN.04660709; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; Morris RC, 1999, HYPERTENSION, V33, P18, DOI 10.1161/01.HYP.33.1.18; Palar K, 2009, AM J HEALTH PROMOT, V24, P49, DOI 10.4278/ajhp.080826-QUAN-164; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; Schmidlin O, 1999, HYPERTENSION, V33, P633, DOI 10.1161/01.HYP.33.2.633; SMITH WCS, 1988, BRIT MED J, V297, P329, DOI 10.1136/bmj.297.6644.329; Smith-Spangler CM, 2010, ANN INTERN MED, V152, P481, DOI 10.7326/0003-4819-152-8-201004200-00212; STAESSEN J, 1983, AM J EPIDEMIOL, V117, P676, DOI 10.1093/oxfordjournals.aje.a113601; STAESSEN J, 1988, J HYPERTENS, V6, P965, DOI 10.1097/00004872-198812000-00003; Staessen JA, 2001, J HYPERTENS, V19, P1349, DOI 10.1097/00004872-200108000-00002; Staessen JA, 1997, AM J CLIN NUTR, V65, P661; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; TunstallPedoe H, 1997, BRIT MED J, V315, P722, DOI 10.1136/bmj.315.7110.722; Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4; Umesawa M, 2008, AM J CLIN NUTR, V88, P195, DOI 10.1093/ajcn/88.1.195; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	45	419	431	0	53	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 4	2011	305	17					1777	1785		10.1001/jama.2011.574	http://dx.doi.org/10.1001/jama.2011.574			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	758HZ	21540421	Green Published, Bronze			2023-01-03	WOS:000290156200018
J	Merlini, E; Bai, F; Bellistri, GM; Tincati, C; Monforte, AD; Marchetti, G				Merlini, Esther; Bai, Francesca; Bellistri, Giusi Maria; Tincati, Camilla; Monforte, Antonella d'Arminio; Marchetti, Giulia			Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy	PLOS ONE			English	Article							MICROBIAL TRANSLOCATION; ACTIVATION; RECONSTITUTION	In advanced HIV infection, the homeostatic balance between gastrointestinal indigenous bacteria and gut immunity fails and microbes are able to overcome the intestinal barrier and gain the systemic circulation. Because microbial translocation is not fully controlled by antiviral therapy and is associated with inefficient CD4+ reconstitution, we investigated the profile of translocating bacteria in peripheral blood of 44 HIV-infected patients starting therapy with advanced CD4+ T-lymphopenia and displaying poor CD4+ recovery on virologically suppressive HAART. According to CD4+ reconstitution at 12-months HAART, patients were considered Partial Immunological Responders, PIRs (CD4+>= 250/mu l, n = 29) and Immunological non Responders, INRs (CD4+< 200/mu l, n = 15)). We show that PIRs and INRs present similarly elevated plasma levels of lipopolysaccharide (LPS) and its ligand sCD14 that were not lowered by virologically suppressive therapy. Bacterial 16S rRNA gene amplification and sequencing resulted in a highly polymicrobic peripheral blood microbiota both prior and after 12-month HAART. Several differences in bacterial composition were shown between patients' groups, mainly the lack of probiotic Lactobacillaceae both prior and after therapy in INRs. Failure to control microbial translocation on HAART is associated with a polymicrobic flora circulating in peripheral blood that is not substantially modified by therapy.	[Merlini, Esther; Bai, Francesca; Bellistri, Giusi Maria; Tincati, Camilla; Monforte, Antonella d'Arminio; Marchetti, Giulia] Univ Milan, Dept Med Surg & Dent, Clin Infect Dis, San Paolo Hosp, Milan, Italy	San Paolo-Polo Universitaria Hospital; University of Milan	Merlini, E (corresponding author), Univ Milan, Dept Med Surg & Dent, Clin Infect Dis, San Paolo Hosp, Milan, Italy.	giulia.marchetti@unimi.it	Marchetti, Giulia/GPX-7655-2022; Bai, Francesca/K-4823-2018; Gori, Andrea/AAC-6078-2022; TINCATI, CAMILLA/K-4501-2018; MARCHETTI, GIULIA CARLA/K-4384-2018	TINCATI, CAMILLA/0000-0002-3083-2962; MARCHETTI, GIULIA CARLA/0000-0002-4498-4828	Fondo Interno Ricerca Scientifica e Tecnologica (FIRST); Universita degli Studi di Milano; Istituto Superiore di Sanita, Italy [30G.50, 30G.63, 50G]	Fondo Interno Ricerca Scientifica e Tecnologica (FIRST); Universita degli Studi di Milano; Istituto Superiore di Sanita, Italy	The work was supported by grants from Fondo Interno Ricerca Scientifica e Tecnologica (FIRST) 2009 Universita degli Studi di Milano, and from Istituto Superiore di Sanita, National research program on AIDS, grants #30G.50; 30G.63, 50G; 2006, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Brenchley JM, 2008, BLOOD, V112, P2826, DOI 10.1182/blood-2008-05-159301; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2006, NAT IMMUNOL, V7, P235, DOI 10.1038/ni1316; Cassol E, 2010, J INFECT DIS, V202, P723, DOI 10.1086/655229; Cecchinato V, 2008, MUCOSAL IMMUNOL, V1, P279, DOI 10.1038/mi.2008.14; Diggle MA, 2004, MOL BIOTECHNOL, V28, P129, DOI 10.1385/MB:28:2:129; Douek DC, 2009, ANNU REV MED, V60, P471, DOI 10.1146/annurev.med.60.041807.123549; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; Estes J, 2008, J INFECT DIS, V198, P456, DOI 10.1086/590112; Estes JD, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001052; FERRI E, J INFECT DIS, V202, P178; Ferri E, 2010, J INFECT DIS, V202, P176, DOI 10.1086/653215; GORI A, 2007, J CLIN MICROBIOL; GREISEN K, 1994, J CLIN MICROBIOL, V32, P335, DOI 10.1128/JCM.32.2.335-351.1994; Hooper LV, 2010, NAT REV IMMUNOL, V10, P159, DOI 10.1038/nri2710; Jiang W, 2009, J INFECT DIS, V199, P1177, DOI 10.1086/597476; Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484; Lin YP, 2008, INFLAMM BOWEL DIS, V14, P1068, DOI 10.1002/ibd.20448; Liu ZZ, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm541; MARCHETTI G, 2010, ROLE MICROBIAL TRANS; Marchetti G, 2008, AIDS, V22, P2035, DOI 10.1097/QAD.0b013e3283112d29; Moore RD, 2007, CLIN INFECT DIS, V44, P441, DOI 10.1086/510746; Paiardini M, 2008, AIDS REV, V10, P36; Perdigon G, 1999, J DAIRY SCI, V82, P1108, DOI 10.3168/jds.S0022-0302(99)75333-6; SANDLER NG, J INFECT DIS; VANTLAND B, 2008, SPECIFIC MIXTURE PRE	26	92	95	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 11	2011	6	4							e18580	10.1371/journal.pone.0018580	http://dx.doi.org/10.1371/journal.pone.0018580			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	747XH	21494598	Green Published, Green Submitted, gold			2023-01-03	WOS:000289354100023
J	Choi, SS; Chivers, PT; Berg, DE				Choi, Sung Sook; Chivers, Peter T.; Berg, Douglas E.			Point Mutations in Helicobacter pylori's fur Regulatory Gene that Alter Resistance to Metronidazole, a Prodrug Activated by Chemical Reduction	PLOS ONE			English	Article							FERRIC UPTAKE REGULATOR; DNA-BINDING; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DOMAIN INTERACTIONS; AMINO-ACIDS; REPRESSOR; PROTEIN; RDXA; PERR	Background: Helicobacter pylori's Fur regulatory protein controls transcription of dozens of genes in response to iron availability, acidity and oxidative stress, and affects the vigor of infection and severity of disease. It is unusual among Fur family proteins in being active both when iron-loaded and iron-free. Metholodolgy/Principal Findings: We tested if H. pylori fur mutations could affect resistance to metronidazole (Mtz), an anti-H. pylori prodrug rendered bactericidal by chemical reduction. Point mutations were made by PCR in DNA containing fur and a downstream chloramphenicol resistance gene, and were placed in the H. pylori chromosome by transformation of a fur-deletion (Dfur) strain. Several substitutions affecting H. pylori Fur's,10 residue N terminal arm, which has no counterpart in prototype (E. coli-type) Fur proteins, increased Mtz resistance, as did mutations affecting the region between DNA binding and dimerization domains. Three types of mutations decreased resistance more than did Dfur: substitutions affecting the N-terminal arm; substitutions affecting the metal binding pocket; and nonsense mutations that resulted in a truncated Fur protein with no C-terminal dimerization domain. Most metal binding pocket mutations were obtained only in fur genes with additional inactivating mutations, and thus seemed deleterious or lethal because they. Conclusions/Significance: These results establish that H. pylori Fur's distinctive N terminal arm is functional, and more generally illustrate that point mutations can confer informative phenotypes, distinct from those conferred by null mutations. We propose that fur mutations can affect Mtz susceptibility by altering the balance among Fur's several competing activities, and thereby the expression of genes that control cellular redox potential or elimination of bactericidal Mtz activation products. Further analyses of selected mutants should provide insights into Fur interactions with other cellular components, metabolic circuitry, and how H. pylori thrives in its special gastric niche.	[Choi, Sung Sook; Berg, Douglas E.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; [Chivers, Peter T.] Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Choi, SS (corresponding author), Sahmyook Univ, Coll Pharm, Seoul, South Korea.	berg@borcim.wustl.edu		Chivers, Peter/0000-0002-8779-1452	U.S. National Institutes of Health (NIH) [RO1 DK63041, R21 AI078237, R21 AI088337]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI088337, R21AI078237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063041] Funding Source: NIH RePORTER	U.S. National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was supported by grants from the U.S. National Institutes of Health (NIH) RO1 DK63041, R21 AI078237 and R21 AI088337. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akada JK, 2003, MICROBIOL-SGM, V149, P1901, DOI 10.1099/mic.0.26129-0; Albert TJ, 2005, NAT METHODS, V2, P951, DOI 10.1038/NMETH805; Benanti EL, 2007, J BIOL CHEM, V282, P20365, DOI 10.1074/jbc.M702982200; Benanti EL, 2010, J BACTERIOL, V192, P4327, DOI 10.1128/JB.00152-10; Boneca IG, 2008, APPL ENVIRON MICROB, V74, P2095, DOI 10.1128/AEM.01348-07; Carpenter BM, 2010, J BACTERIOL, V192, P5037, DOI 10.1128/JB.00198-10; Carpenter BM, 2009, INFECT IMMUN, V77, P2590, DOI 10.1128/IAI.00116-09; Chalker AF, 2001, J BACTERIOL, V183, P1259, DOI 10.1128/JB.183.4.1259-1268.2001; Cover TL, 2009, GASTROENTEROLOGY, V136, P1863, DOI 10.1053/j.gastro.2009.01.073; Croxen MA, 2006, J BACTERIOL, V188, P2656, DOI 10.1128/JB.188.7.2656-2665.2006; Danielli A, 2010, FEMS MICROBIOL REV, V34, P738, DOI 10.1111/j.1574-6976.2010.00233.x; Dian C, 2011, MOL MICROBIOL, V79, P1260, DOI 10.1111/j.1365-2958.2010.07517.x; Ernst FD, 2005, MICROBIOL-SGM, V151, P533, DOI 10.1099/mic.0.27404-0; Goodwin A, 1998, MOL MICROBIOL, V28, P383, DOI 10.1046/j.1365-2958.1998.00806.x; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; Jacquamet L, 2009, MOL MICROBIOL, V73, P20, DOI 10.1111/j.1365-2958.2009.06753.x; Jeong JY, 2000, ANTIMICROB AGENTS CH, V44, P3127, DOI 10.1128/AAC.44.11.3127-3132.2000; Jeong JY, 2001, J BACTERIOL, V183, P5155, DOI 10.1128/JB.183.17.5155-5162.2001; Kumar A, 2007, P NATL ACAD SCI USA, V104, P11568, DOI 10.1073/pnas.0705054104; Lee JW, 2007, BIOMETALS, V20, P485, DOI 10.1007/s10534-006-9070-7; Lee JW, 2006, NATURE, V440, P363, DOI 10.1038/nature04537; PABO CO, 1982, NATURE, V298, P441, DOI 10.1038/298441a0; Pecqueur L, 2006, J BIOL CHEM, V281, P21286, DOI 10.1074/jbc.M601278200; Peek RM, 2010, PHYSIOL REV, V90, P831, DOI 10.1152/physrev.00039.2009; Pennella MA, 2006, J MOL BIOL, V356, P1124, DOI 10.1016/j.jmb.2005.12.019; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; Saviola B, 1998, J MOL BIOL, V278, P539, DOI 10.1006/jmbi.1998.1712; Schreiber S, 2004, P NATL ACAD SCI USA, V101, P5024, DOI 10.1073/pnas.0308386101; Sharma CM, 2010, NATURE, V464, P250, DOI 10.1038/nature08756; Sheikh MA, 2009, MOL MICROBIOL, V72, P1208, DOI 10.1111/j.1365-2958.2009.06718.x; Sisson G, 2000, J BACTERIOL, V182, P5091, DOI 10.1128/JB.182.18.5091-5096.2000; Tan SM, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000407; Tan SM, 2004, J BACTERIOL, V186, P885, DOI 10.1128/JB.186.3.885-888.2004; Tiss A, 2005, FEBS LETT, V579, P5454, DOI 10.1016/j.febslet.2005.08.067; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Traore DAK, 2006, MOL MICROBIOL, V61, P1211, DOI 10.1111/j.1365-2958.2006.05313.x; Tsugawa H, 2011, ANTIOXID REDOX SIGN, V14, P15, DOI 10.1089/ars.2010.3146; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; Whitmire JM, 2007, CURR MED CHEM, V14, P469, DOI 10.2174/092986707779941069; Wu M, 2001, J MOL BIOL, V307, P1001, DOI 10.1006/jmbi.2001.4531	43	27	27	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 25	2011	6	3							e18236	10.1371/journal.pone.0018236	http://dx.doi.org/10.1371/journal.pone.0018236			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	740SE	21464913	Green Published, gold			2023-01-03	WOS:000288813900055
J	Cataldo, VD; Gibbons, DL; Perez-Soler, R; Quintas-Cardama, A				Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso			Treatment of Non-Small-Cell Lung Cancer with Erlotinib or Gefitinib	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDERMAL-GROWTH-FACTOR; PHASE-III TRIAL; PREVIOUSLY TREATED PATIENTS; FACTOR-RECEPTOR; ACQUIRED-RESISTANCE; T790M MUTATIONS; SUPPORTIVE CARE; EGFR MUTATIONS; CARBOPLATIN; PACLITAXEL		[Cataldo, Vince D.] Louisiana State Univ, Dept Hematol & Oncol, Hlth Sci Ctr, Baton Rouge, LA 70805 USA; [Cataldo, Vince D.] Hematol Oncol Clin, Baton Rouge, LA USA; [Gibbons, Don L.; Quintas-Cardama, Alfonso] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Perez-Soler, Roman] Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA	Louisiana State University System; Louisiana State University; Louisiana State University Health Sciences Center at Shreveport; University of Texas System; UTMD Anderson Cancer Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Cataldo, VD (corresponding author), Louisiana State Univ, Dept Hematol & Oncol, Hlth Sci Ctr, 5825 Airline Hwy, Baton Rouge, LA 70805 USA.	vincelsu@aol.com			NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Boone SL, 2007, ONCOLOGY-BASEL, V72, P152, DOI 10.1159/000112795; Choong NW, 2008, J THORAC ONCOL, V3, P1003, DOI 10.1097/JTO.0b013e31818396a4; CLARK GM, 2003, P AN M AM SOC CLIN, V22, P196; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Giaccone G, 2004, J CLIN ONCOL, V22, P777, DOI 10.1200/JCO.2004.08.001; Gridelli C, 2008, CRIT REV ONCOL HEMAT, V66, P155, DOI 10.1016/j.critrevonc.2007.10.004; HAINSWORTH J, 2008, MULT S THOR ONC CHIC; Hamilton M, 2006, CLIN CANCER RES, V12, P2166, DOI 10.1158/1078-0432.CCR-05-2235; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Herbst RS, 2004, J CLIN ONCOL, V22, P785, DOI 10.1200/JCO.2004.07.215; Herbst RS, 2005, J CLIN ONCOL, V23, P5892, DOI 10.1200/JCO.2005.02.840; Jackman DM, 2006, CLIN CANCER RES, V12, P3908, DOI 10.1158/1078-0432.CCR-06-0462; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Kim ES, 2008, LANCET, V372, P1809, DOI 10.1016/S0140-6736(08)61758-4; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Li J, 2007, CLIN CANCER RES, V13, P3731, DOI 10.1158/1078-0432.CCR-07-0088; Liu WT, 2007, CLIN GASTROENTEROL H, V5, P917, DOI 10.1016/j.cgh.2007.04.014; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Miller AA, 2007, J CLIN ONCOL, V25, P3055, DOI 10.1200/JCO.2007.11.6210; Miller VA, 2009, J CLIN ONCOL, V27; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Ready N, 2010, J THORAC ONCOL, V5, P1382, DOI 10.1097/JTO.0b013e3181eba657; Riely GJ, 2008, J THORAC ONCOL, V3, pS146, DOI 10.1097/JTO.0b013e318174e96e; Riely GJ, 2007, CLIN CANCER RES, V13, P5150, DOI 10.1158/1078-0432.CCR-07-0560; Riely GJ, 2006, CLIN CANCER RES, V12, P7232, DOI 10.1158/1078-0432.CCR-06-0658; Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554; Rudin CM, 2008, J CLIN ONCOL, V26, P1119, DOI 10.1200/JCO.2007.13.1128; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sandler A, 2006, NEW ENGL J MED, V355, P2542, DOI 10.1056/NEJMoa061884; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Shah NT, 2005, J CLIN ONCOL, V23, P165, DOI 10.1200/JCO.2005.04.057; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8; TODARO GJ, 1976, NATURE, V264, P26, DOI 10.1038/264026a0; Wacker B, 2007, CLIN CANCER RES, V13, P3913, DOI 10.1158/1078-0432.CCR-06-2610; Wheatley-Price P, 2008, J CLIN ONCOL, V26, P2350, DOI 10.1200/JCO.2007.15.2280; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013; IRESSA GEFITINIB PAC; TARCEVA ERLOTINIB PA	53	315	341	3	77	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 10	2011	364	10					947	955		10.1056/NEJMct0807960	http://dx.doi.org/10.1056/NEJMct0807960			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	732FL	21388312				2023-01-03	WOS:000288170300011
J	Potenza, MN; Sofuoglu, M; Carroll, KM; Rounsaville, BJ				Potenza, Marc N.; Sofuoglu, Mehmet; Carroll, Kathleen M.; Rounsaville, Bruce J.			Neuroscience of Behavioral and Pharmacological Treatments for Addictions	NEURON			English	Review							SUBSTANCE-USE DISORDERS; PLACEBO-CONTROLLED TRIAL; IMPULSE CONTROL DISORDERS; WHITE-MATTER INTEGRITY; OPIOID RECEPTOR GENE; DOUBLE-BLIND; COCAINE DEPENDENCE; DRUG-USE; SMOKING-CESSATION; PREFRONTAL CORTEX	Although substantial advances have been made in behavioral and pharmacological treatments for addictions, moving treatment development to the next stage may require novel ways of approaching addictions, particularly ways based on new findings regarding the neurobiological underpinnings of addictions that also assimilate and incorporate relevant information from earlier approaches. In this review, we first briefly review theoretical and biological models of addiction and then describe existing behavioral and pharmacologic therapies for the addictions within this framework. We then propose new directions for treatment development and targets that are informed by recent evidence regarding the heterogeneity of addictions and the neurobiological contributions to these disorders.	[Potenza, Marc N.; Sofuoglu, Mehmet; Carroll, Kathleen M.; Rounsaville, Bruce J.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06519 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06519 USA; [Potenza, Marc N.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06519 USA	Yale University; Yale University; Yale University	Potenza, MN (corresponding author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06519 USA.	marc.potenza@yale.edu	Carroll, Kathleen/A-7526-2009	Carroll, Kathleen/0000-0003-3263-3374	Somaxon; National Institutes of Health; Veteran's Administration; Mohegan Sun Casino; National Center for Responsible Gaming; National Institute on Drug Abuse [P50-DA09241, P50-DA016556, P20-DA027844, R37-DA015969, K02-DA021304, R01-DA020908, RC1-DA028279, R01-DA018647, R21 DA029445, R01-DA019039]; National Institute on Alcoholism and Alcohol Abuse [RL1-AA017539]; VISN 1 Mental Illness Educational, Research, and Clinical Center (MIRECC); Center of Excellence in Gambling Research from the National Center for Responsible Gaming; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [RL1AA017539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA020752, R01DA019885, P50DA009241, R21DA029445, U10DA013038, R01DA029577, R01DA014537, R01DA019039, RC1DA028279, K02DA021304, P20DA027844, K05DA000457, P50DA016556, R37DA015969, R01DA015969, K05DA000089, K12DA000167, R01DA018647, R01DA020908] Funding Source: NIH RePORTER	Somaxon; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veteran's Administration(US Department of Veterans Affairs); Mohegan Sun Casino; National Center for Responsible Gaming; National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); National Institute on Alcoholism and Alcohol Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); VISN 1 Mental Illness Educational, Research, and Clinical Center (MIRECC); Center of Excellence in Gambling Research from the National Center for Responsible Gaming; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	The authors report that they have no financial conflicts of interest with respect to the content of this manuscript. Dr. Potenza has received financial support or compensation for the following: Dr. Potenza has consulted for and advised Boehringer Ingelheim; has consulted for and has financial interests in Somaxon; has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, the National Center for Responsible Gaming and its affiliated Institute for Research on Gambling Disorders, and Forest Laboratories, Ortho-McNeil, Oy-Control/Biotie and Glaxo-SmithKline pharmaceuticals; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; has consulted for law offices and the federal public defender's office in issues related to impulse control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies. Support was provided by National Institute on Drug Abuse grants P50-DA09241, P50-DA016556, P20-DA027844, R37-DA015969, K02-DA021304, R01-DA020908, RC1-DA028279, R01-DA018647, R21 DA029445, and R01-DA019039, the National Institute on Alcoholism and Alcohol Abuse grant RL1-AA017539, the VISN 1 Mental Illness Educational, Research, and Clinical Center (MIRECC), and a Center of Excellence in Gambling Research from the National Center for Responsible Gaming.	Achat-Mendes C, 2010, J PHARMACOL EXP THER, V334, P556, DOI 10.1124/jpet.110.167619; Adewale AS, 2006, J PHARMACOL EXP THER, V318, P922, DOI 10.1124/jpet.106.105387; Aharonovich E, 2006, DRUG ALCOHOL DEPEN, V81, P313, DOI 10.1016/j.drugalcdep.2005.08.003; *ALC AN, 1986, 12 STEPS 12 TRAD; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Anderson AL, 2009, DRUG ALCOHOL DEPEN, V104, P133, DOI 10.1016/j.drugalcdep.2009.04.015; Andrews MM, 2011, BIOL PSYCHIAT, V69, P675, DOI 10.1016/j.biopsych.2010.09.049; Arias AJ, 2008, ALCOHOL CLIN EXP RES, V32, P1159, DOI 10.1111/j.1530-0277.2008.00735.x; Baker DA, 2003, ANN NY ACAD SCI, V1003, P349, DOI 10.1196/annals.1300.023; Ball J.C., 2012, EFFECTIVENESS METHAD; Balleine BW, 2007, ANN NY ACAD SCI, V1104, pXI, DOI 10.1196/annals.1390.2226; Baptista MAS, 2004, J NEUROSCI, V24, P4723, DOI 10.1523/JNEUROSCI.0176-04.2004; Bates ME, 2006, PSYCHOL ADDICT BEHAV, V20, P241, DOI 10.1037/0893-164X.20.3.241; Bechara Antoine, 2003, J Gambl Stud, V19, P23, DOI 10.1023/A:1021223113233; Belin D, 2008, SCIENCE, V320, P1352, DOI 10.1126/science.1158136; Bell M, 2001, ARCH GEN PSYCHIAT, V58, P763, DOI 10.1001/archpsyc.58.8.763; Berridge KC, 2009, CURR OPIN PHARMACOL, V9, P65, DOI 10.1016/j.coph.2008.12.014; Beveridge TJR, 2008, PHILOS T R SOC B, V363, P3257, DOI 10.1098/rstb.2008.0102; Bickel WK, 2011, BIOL PSYCHIAT, V69, P260, DOI 10.1016/j.biopsych.2010.08.017; Bickel WK, 2008, ADV HEALTH ECON HEAL, V20, P289, DOI 10.1016/S0731-2199(08)20012-9; Bisaga A, 2010, DRUG ALCOHOL DEPEN, V111, P97, DOI 10.1016/j.drugalcdep.2010.04.006; Blanco C, 2009, PSYCHIAT RES, V167, P161, DOI 10.1016/j.psychres.2008.04.023; Blum K, 1996, AM SCI, V84, P132; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brauer LH, 1997, PHARMACOL BIOCHEM BE, V56, P265, DOI 10.1016/S0091-3057(96)00240-7; Brewer JA, 2008, BIOCHEM PHARMACOL, V75, P63, DOI 10.1016/j.bcp.2007.06.043; Brewer JA, 2010, ADDICTION, V105, P1698, DOI 10.1111/j.1360-0443.2009.02890.x; Brewer JA, 2009, SUBST ABUS, V30, P306, DOI 10.1080/08897070903250241; Brewer JA, 2008, BIOL PSYCHIAT, V64, P998, DOI 10.1016/j.biopsych.2008.05.024; Buckholtz JW, 2010, SCIENCE, V329, P532, DOI 10.1126/science.1185778; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Bush G, 2002, P NATL ACAD SCI USA, V99, P523, DOI 10.1073/pnas.012470999; Bymaster FP, 2002, NEUROPSYCHOPHARMACOL, V27, P699, DOI 10.1016/S0893-133X(02)00346-9; Cahill K, 2010, COCHRANE DB SYST REV, V12; Carroll K, 1998, COGNITIVE BEHAV APPR; Carroll KM, 2008, AM J PSYCHIAT, V165, P881, DOI 10.1176/appi.ajp.2008.07111835; Carroll KM, 2009, DRUG ALCOHOL DEPEN, V100, P178, DOI 10.1016/j.drugalcdep.2008.09.015; CARROLL KM, 1994, ARCH GEN PSYCHIAT, V51, P989; Carroll KM, 2005, AM J PSYCHIAT, V162, P1452, DOI 10.1176/appi.ajp.162.8.1452; Carroll KM, 2004, DRUG ALCOHOL DEPEN, V75, P123, DOI 10.1016/j.drugalcdep.2004.02.007; Casey BJ, 2010, NEURON, V67, P749, DOI 10.1016/j.neuron.2010.08.033; Chamberlain SR, 2007, BIOL PSYCHIAT, V62, P977, DOI 10.1016/j.biopsych.2007.03.003; Chamberlain SR, 2009, BIOL PSYCHIAT, V65, P550, DOI 10.1016/j.biopsych.2008.10.014; Chambers RA, 2001, BIOL PSYCHIAT, V50, P71, DOI 10.1016/S0006-3223(01)01134-9; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; Chen BT, 2010, ANN NY ACAD SCI, V1187, P129, DOI 10.1111/j.1749-6632.2009.05154.x; Cheon Y, 2008, INT J NEUROPSYCHOPH, V11, P971, DOI 10.1017/S1461145708008663; Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; Costello MR, 2010, NEUROPSYCHOPHARMACOL, V35, P605, DOI 10.1038/npp.2009.165; Culbertson CS, 2011, ARCH GEN PSYCHIAT, V68, P505, DOI 10.1001/archgenpsychiatry.2010.193; Cutler RB, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-75; Dackis CA, 2005, NEUROPSYCHOPHARMACOL, V30, P205, DOI 10.1038/sj.npp.1300600; Dalley JW, 2007, SCIENCE, V315, P1267, DOI 10.1126/science.1137073; Dalley JW, 2011, NEURON, V69, P680, DOI 10.1016/j.neuron.2011.01.020; Dalley JW, 2009, SEMIN CELL DEV BIOL, V20, P403, DOI 10.1016/j.semcdb.2009.01.002; Danaei G, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000058; de Wit H, 2009, ADDICT BIOL, V14, P22, DOI 10.1111/j.1369-1600.2008.00129.x; Decharms RC, 2008, NAT REV NEUROSCI, V9, P720, DOI 10.1038/nrn2414; DeRubeis RJ, 1999, AM J PSYCHIAT, V156, P1007; DeRubeis RJ, 2008, NAT REV NEUROSCI, V9, P788, DOI 10.1038/nrn2345; Dutra L, 2008, AM J PSYCHIAT, V165, P179, DOI 10.1176/appi.ajp.2007.06111851; Economidou D, 2011, BIOL PSYCHIAT, V69, P266, DOI 10.1016/j.biopsych.2010.09.040; Edwards S, 2010, FUTUR NEUROL, V5, P393, DOI 10.2217/FNL.10.14; Eisenberg MJ, 2008, CAN MED ASSOC J, V179, P135, DOI 10.1503/cmaj.070256; Ersche KD, 2007, NEUROPSYCHOL REV, V17, P317, DOI 10.1007/s11065-007-9033-y; Ersche KD, 2006, PSYCHOPHARMACOLOGY, V188, P364, DOI 10.1007/s00213-006-0515-z; Evans SM, 2007, ALCOHOL CLIN EXP RES, V31, P775, DOI 10.1111/j.1530-0277.2007.00360.x; Everitt BJ, 2005, NAT NEUROSCI, V8, P1481, DOI 10.1038/nn1579; Faraone SV, 2005, J CHILD ADOL PSYCHOP, V15, P664, DOI 10.1089/cap.2005.15.664; Fineberg NA, 2010, NEUROPSYCHOPHARMACOL, V35, P591, DOI 10.1038/npp.2009.185; Fiore M. C., 2008, TREATING TOBACCO USE; Fong T, 2008, PHARMACOL BIOCHEM BE, V89, P298, DOI 10.1016/j.pbb.2007.12.025; Frascella J, 2010, ANN NY ACAD SCI, V1187, P294, DOI 10.1111/j.1749-6632.2009.05420.x; Frewen PA, 2008, CLIN PSYCHOL REV, V28, P228, DOI 10.1016/j.cpr.2007.05.002; George O, 2010, NEUROSCI BIOBEHAV R, V35, P232, DOI 10.1016/j.neubiorev.2010.05.002; George TP, 2002, BIOL PSYCHIAT, V52, P53, DOI 10.1016/S0006-3223(02)01339-2; GHAHREMANI DG, 2011, NEUROPSYCHO IN PRESS, DOI DOI 10.1038/NPP.2010.233; Giacobini E, 2004, PHARMACOL RES, V50, P433, DOI 10.1016/j.phrs.2003.11.017; Glimcher PW, 2004, SCIENCE, V306, P447, DOI 10.1126/science.1102566; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635; Goldstein RZ, 2002, AM J PSYCHIAT, V159, P1642, DOI 10.1176/appi.ajp.159.10.1642; Gottesman II, 2003, AM J PSYCHIAT, V160, P636, DOI 10.1176/appi.ajp.160.4.636; Grabowski J, 2004, NEUROPSYCHOPHARMACOL, V29, P969, DOI 10.1038/sj.npp.1300392; Grant JE, 2008, PSYCHOPHARMACOLOGY, V200, P521, DOI 10.1007/s00213-008-1235-3; Grant JE, 2010, PSYCHOPHARMACOLOGY, V212, P603, DOI 10.1007/s00213-010-1994-5; Grant JE, 2010, AM J DRUG ALCOHOL AB, V36, P233, DOI 10.3109/00952990.2010.491884; Grant JE, 2009, BRIT J PSYCHIAT, V195, P266, DOI 10.1192/bjp.bp.108.062414; Grohman K, 2006, BRAIN COGNITION, V60, P203; Gual A, 2001, ALCOHOL ALCOHOLISM, V36, P413, DOI 10.1093/alcalc/36.5.413; Haber SN, 2010, NEUROPSYCHOPHARMACOL, V35, P4, DOI 10.1038/npp.2009.129; Hall SM, 2002, ARCH GEN PSYCHIAT, V59, P930, DOI 10.1001/archpsyc.59.10.930; Haney M, 2001, PSYCHOPHARMACOLOGY, V155, P330, DOI 10.1007/s002130100725; Haney M, 2010, BIOL PSYCHIAT, V67, P59, DOI 10.1016/j.biopsych.2009.08.031; Harsan LA, 2008, J NEUROSCI, V28, P14189, DOI 10.1523/JNEUROSCI.4453-08.2008; Hasin DS, 2007, ARCH GEN PSYCHIAT, V64, P830, DOI 10.1001/archpsyc.64.7.830; Havassy BE, 2004, AM J PSYCHIAT, V161, P139, DOI 10.1176/appi.ajp.161.1.139; Heidbreder CA, 2010, ANN NY ACAD SCI, V1187, P4, DOI 10.1111/j.1749-6632.2009.05149.x; Herin DV, 2010, ANN NY ACAD SCI, V1187, P76, DOI 10.1111/j.1749-6632.2009.05145.x; HIGGINS ST, 1991, AM J PSYCHIAT, V148, P1218; Highfield D, 2001, NEUROPSYCHOPHARMACOL, V25, P320, DOI 10.1016/S0893-133X(01)00227-5; Hogarty GE, 2004, ARCH GEN PSYCHIAT, V61, P866, DOI 10.1001/archpsyc.61.9.866; Holden C, 2001, SCIENCE, V294, P980, DOI 10.1126/science.294.5544.980; Holden C, 2010, SCIENCE, V327, P935, DOI 10.1126/science.327.5968.935; Horder J, 2010, INT J NEUROPSYCHOPH, V13, P1103, DOI 10.1017/S1461145710000453; Hu J, 2010, BIOL PSYCHIAT, V67, P800, DOI 10.1016/j.biopsych.2009.12.028; Irvin JE, 1999, J CONSULT CLIN PSYCH, V67, P563, DOI 10.1037/0022-006X.67.4.563; Janes AC, 2010, BIOL PSYCHIAT, V67, P722, DOI 10.1016/j.biopsych.2009.12.034; Jentsch JD, 2009, PSYCHOPHARMACOLOGY, V202, P497, DOI 10.1007/s00213-008-1181-0; Johansson BA, 2006, ADDICTION, V101, P491, DOI 10.1111/j.1360-0443.2006.01369.x; Johnson BA, 2008, PROG NEURO-PSYCHOPH, V32, P209, DOI 10.1016/j.pnpbp.2007.07.030; Johnson MW, 2007, EXP CLIN PSYCHOPHARM, V15, P187, DOI 10.1037/1064-1297.15.2.187; Johnson MW, 2010, EXP CLIN PSYCHOPHARM, V18, P99, DOI 10.1037/a0018333; Kable JW, 2007, NAT NEUROSCI, V10, P1625, DOI 10.1038/nn2007; Kampman KM, 2006, DRUG ALCOHOL DEPEN, V85, P129, DOI 10.1016/j.drugalcdep.2006.04.002; Kenny PJ, 2011, NEURON, V69, P664, DOI 10.1016/j.neuron.2011.02.016; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kim CH, 2006, P NATL ACAD SCI USA, V103, P19164, DOI 10.1073/pnas.0510836103; Knackstedt LA, 2009, BIOL PSYCHIAT, V65, P841, DOI 10.1016/j.biopsych.2008.10.040; Knutson B, 2008, PHILOS T R SOC B, V363, P3771, DOI 10.1098/rstb.2008.0155; Kober H, 2010, P NATL ACAD SCI USA, V107, P14811, DOI 10.1073/pnas.1007779107; Koob GF, 2010, CURR OPIN INVEST DR, V11, P63; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Koob GF, 2001, NEUROPSYCHOPHARMACOL, V24, P97, DOI 10.1016/S0893-133X(00)00195-0; Kosten T, 2003, DRUG ALCOHOL DEPEN, V70, P315, DOI 10.1016/S0376-8716(03)00032-2; Kosten TR, 2006, NEUROPSYCHOPHARMACOL, V31, P644, DOI 10.1038/sj.npp.1300851; Kreek MJ, 2005, NAT NEUROSCI, V8, P1450, DOI 10.1038/nn1583; Krishnan-Sarin S, 2007, DRUG ALCOHOL DEPEN, V88, P79, DOI 10.1016/j.drugalcdep.2006.09.006; Krupitsky EM, 2007, AM J PSYCHIAT, V164, P519, DOI 10.1176/appi.ajp.164.3.519; Lajtha A, 2010, NEUROCHEM RES, V35, P851, DOI 10.1007/s11064-009-0096-4; Lane SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011591; Laucht M, 2009, BIOL PSYCHIAT, V66, P102, DOI 10.1016/j.biopsych.2009.02.010; Lawrence AJ, 2009, ADDICTION, V104, P1006, DOI 10.1111/j.1360-0443.2009.02533.x; Le Moal M, 2009, PHARMACOPSYCHIATRY, V42, pS42, DOI 10.1055/s-0029-1216355; Lehrer Jonah, 2009, New Yorker, P26; LeSage MG, 2006, AAPS J, V8, pE65, DOI 10.1208/aapsj080108; Lewisa CM, 2009, P NATL ACAD SCI USA, V106, P17558, DOI 10.1073/pnas.0902455106; Leyton M, 2002, NEUROPSYCHOPHARMACOL, V27, P1027, DOI 10.1016/S0893-133X(02)00366-4; Leyton M, 2005, BEHAV NEUROSCI, V119, P1619, DOI 10.1037/0735-7044.119.6.1619; Li CSR, 2006, DRUG ALCOHOL DEPEN, V85, P205, DOI 10.1016/j.drugalcdep.2006.04.008; Li NX, 2010, SCIENCE, V329, P959, DOI 10.1126/science.1190287; Liechti ME, 2007, J NEUROSCI, V27, P9077, DOI 10.1523/JNEUROSCI.1766-07.2007; Lim KO, 2008, DRUG ALCOHOL DEPEN, V92, P164, DOI 10.1016/j.drugalcdep.2007.07.019; Lim KO, 2002, BIOL PSYCHIAT, V51, P890, DOI 10.1016/S0006-3223(01)01355-5; Longo M, 2010, ADDICTION, V105, P146, DOI 10.1111/j.1360-0443.2009.02717.x; Lussier JP, 2006, ADDICTION, V101, P192, DOI 10.1111/j.1360-0443.2006.01311.x; Maddux JF, 2000, ADDICTION, V95, P661, DOI 10.1046/j.1360-0443.2000.9556611.x; Magill M, 2009, J STUD ALCOHOL DRUGS, V70, P516, DOI 10.15288/jsad.2009.70.516; Mann K, 2004, CNS DRUGS, V18, P485, DOI 10.2165/00023210-200418080-00002; Mardikian PN, 2007, PROG NEURO-PSYCHOPH, V31, P389, DOI 10.1016/j.pnpbp.2006.10.001; Martell BA, 2005, BIOL PSYCHIAT, V58, P158, DOI 10.1016/j.biopsych.2005.04.032; Martell BA, 2009, ARCH GEN PSYCHIAT, V66, P1116, DOI 10.1001/archgenpsychiatry.2009.128; Martelle JL, 2007, J PHARMACOL EXP THER, V321, P573, DOI 10.1124/jpet.106.113571; Martinez-Raga Jose, 2008, Curr Drug Abuse Rev, V1, P213; Mason BJ, 2010, EXPERT OPIN DRUG SAF, V9, P177, DOI 10.1517/14740330903512943; Mattick RP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002207.pub3; Mattick RP, 2009, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD002209; McClure SM, 2004, SCIENCE, V306, P503, DOI 10.1126/science.1100907; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; Meda SA, 2009, BEHAV PHARMACOL, V20, P390, DOI 10.1097/FBP.0b013e32833113a3; MISCHEL W, 1989, SCIENCE, V244, P933, DOI 10.1126/science.2658056; Moeller FG, 2001, AM J PSYCHIAT, V158, P1783, DOI 10.1176/appi.ajp.158.11.1783; Moll J, 2005, NAT REV NEUROSCI, V6, P799, DOI 10.1038/nrn1768; Monterosso JR, 2005, DRUG ALCOHOL DEPEN, V79, P273, DOI 10.1016/j.drugalcdep.2005.02.002; Naqvi NH, 2009, TRENDS NEUROSCI, V32, P56, DOI 10.1016/j.tins.2008.09.009; Nasrallah NA, 2009, P NATL ACAD SCI USA, V106, P17600, DOI 10.1073/pnas.0906629106; National Institute on Drug Abuse, 2007, PRINC DRUG ADD TREAT; Nunes EV, 2004, JAMA-J AM MED ASSOC, V291, P1887, DOI 10.1001/jama.291.15.1887; O'Brien CP, 2006, AM J PSYCHIAT, V163, P764, DOI 10.1176/appi.ajp.163.5.764; Olive MF, 2010, EUR J PHARMACOL, V639, P47, DOI 10.1016/j.ejphar.2010.01.029; Orson FM, 2008, ANN NY ACAD SCI, V1141, P257, DOI 10.1196/annals.1441.027; Oslin DW, 2003, NEUROPSYCHOPHARMACOL, V28, P1546, DOI 10.1038/sj.npp.1300219; Partilla JS, 2006, J PHARMACOL EXP THER, V319, P237, DOI 10.1124/jpet.106.103622; Perry JL, 2008, PSYCHOPHARMACOLOGY, V200, P1, DOI 10.1007/s00213-008-1173-0; Peterson BS, 2009, AM J PSYCHIAT, V166, P1286, DOI 10.1176/appi.ajp.2009.08050724; Petry N., 2005, PATHOLOGICAL GAMBLIN; Petry NM, 2001, J ABNORM PSYCHOL, V110, P482, DOI 10.1037/0021-843X.110.3.482; Petry NM, 2001, PSYCHOPHARMACOLOGY, V154, P243, DOI 10.1007/s002130000638; Poling J, 2006, ARCH GEN PSYCHIAT, V63, P219, DOI 10.1001/archpsyc.63.2.219; Potenza MN, 2007, J WOMENS HEALTH, V16, P1108; Potenza MN, 2006, ADDICTION, V101, P142, DOI 10.1111/j.1360-0443.2006.01591.x; Potenza MN, 2008, PHILOS T R SOC B, V363, P3181, DOI 10.1098/rstb.2008.0100; Potenza MN, 2010, ALCOHOL CLIN EXP RES, V34, P1303, DOI 10.1111/j.1530-0277.2010.01214.x; Potenza MN, 2009, ADDICTION, V104, P1016, DOI 10.1111/j.1360-0443.2009.02619.x; Potenza MN, 2005, ARCH GEN PSYCHIAT, V62, P1015, DOI 10.1001/archpsyc.62.9.1015; Potenza MN, 2007, J DUAL DIAGN, V3, P47, DOI DOI 10.1300/J374v03n02_06; POTENZA MN, 2009, GAMBLING MAPPING AM, P175; Ray LA, 2008, AM J ADDICTION, V17, P257, DOI 10.1080/10550490802138400; Reissner KJ, 2010, BEHAV PHARMACOL, V21, P514, DOI 10.1097/FBP.0b013e32833d41b2; Renthal W, 2008, TRENDS MOL MED, V14, P341, DOI 10.1016/j.molmed.2008.06.004; Reynolds B, 2006, PERS INDIV DIFFER, V40, P305, DOI 10.1016/j.paid.2005.03.024; RITCHEY M, 2010, J PSYCHIAT RES; Robbins TW, 2009, ANNU REV NEUROSCI, V32, P267, DOI 10.1146/annurev.neuro.051508.135535; Robinson TE, 2001, ADDICTION, V96, P103, DOI 10.1046/j.1360-0443.2001.9611038.x; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; ROSS D, 2009, WHAT IS ADDICTION; Rutherford HJV, 2010, CHILD ADOL PSYCH CL, V19, P479, DOI 10.1016/j.chc.2010.03.003; Saxena S, 2009, MOL PSYCHIATR, V14, P197, DOI 10.1038/sj.mp.4002134; Schilstrom B, 2007, NEUROPSYCHOPHARMACOL, V32, P43, DOI 10.1038/sj.npp.1301087; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Schultz W, 2011, NEURON, V69, P603, DOI 10.1016/j.neuron.2011.02.014; Schultz W, 2010, BEHAV BRAIN FUNCT, V6, DOI 10.1186/1744-9081-6-24; Seu E, 2009, PSYCHOPHARMACOLOGY, V202, P505, DOI 10.1007/s00213-008-1250-4; Shaffer HJ, 1999, ADDICTION, V94, P1445, DOI 10.1046/j.1360-0443.1999.941014451.x; Shearer J, 2003, ADDICTION, V98, P1137, DOI 10.1046/j.1360-0443.2003.00447.x; Shearer J, 2001, ADDICTION, V96, P1289, DOI 10.1046/j.1360-0443.2001.96912898.x; Sidhpura N, 2010, BIOL PSYCHIAT, V67, P804, DOI 10.1016/j.biopsych.2010.01.005; Siegle GJ, 2006, AM J PSYCHIAT, V163, P735, DOI 10.1176/appi.ajp.163.4.735; Sinha R, 2006, ARCH GEN PSYCHIAT, V63, P324, DOI 10.1001/archpsyc.63.3.324; Sinha R, 2008, ANN NY ACAD SCI, V1141, P105, DOI 10.1196/annals.1441.030; Sinha R, 2007, PSYCHOPHARMACOLOGY, V190, P569, DOI 10.1007/s00213-006-0640-8; Sinha R, 2009, BIOL PSYCHIAT, V66, P100, DOI 10.1016/j.biopsych.2009.05.003; Sofuoglu M, 2009, PSYCHOPHARMACOLOGY, V207, P153, DOI 10.1007/s00213-009-1643-z; Somerville LH, 2010, BRAIN COGNITION, V72, P124, DOI 10.1016/j.bandc.2009.07.003; Srisurapanont M, 2005, INT J NEUROPSYCHOPH, V8, P267, DOI 10.1017/S1461145704004997; Steeves TDL, 2009, BRAIN, V132, P1376, DOI 10.1093/brain/awp054; Streeter CC, 2008, NEUROPSYCHOPHARMACOL, V33, P827, DOI 10.1038/sj.npp.1301465; Sulzer D, 2011, NEURON, V69, P628, DOI 10.1016/j.neuron.2011.02.010; Tanabe J, 2007, HUM BRAIN MAPP, V28, P1276, DOI 10.1002/hbm.20344; Tolin DF, 2010, CLIN PSYCHOL REV, V30, P710, DOI 10.1016/j.cpr.2010.05.003; Treadway MT, 2011, NEUROSCI BIOBEHAV R, V35, P537, DOI 10.1016/j.neubiorev.2010.06.006; Uhl GR, 2009, J NEUROGENET, V23, P272, DOI 10.1080/01677060802572929; Uhl GR, 2004, ARCH GEN PSYCHIAT, V61, P223, DOI 10.1001/archpsyc.61.3.223; VanBuskirk KA, 2010, J ADDICT MED, V4, P1, DOI 10.1097/ADM.0b013e3181ce38e7; Verdejo-Garcia A, 2008, NEUROSCI BIOBEHAV R, V32, P777, DOI 10.1016/j.neubiorev.2007.11.003; Vocci FJ, 2005, AM J PSYCHIAT, V162, P1432, DOI 10.1176/appi.ajp.162.8.1432; Volkow ND, 2004, NAT REV NEUROSCI, V5, P963, DOI 10.1038/nrn1539; Volkow ND, 2011, NEURON, V69, P599, DOI 10.1016/j.neuron.2011.01.027; Volkow ND, 2009, JAMA-J AM MED ASSOC, V301, P1148, DOI 10.1001/jama.2009.351; Wagner FA, 2002, NEUROPSYCHOPHARMACOL, V26, P479, DOI 10.1016/S0893-133X(01)00367-0; Walker M, 2006, ADDICTION, V101, P504, DOI 10.1111/j.1360-0443.2005.01341.x; Wang GJ, 2009, J ADDICT MED, V3, P8, DOI 10.1097/ADM.0b013e31819a86f7; Weintraub D, 2010, ARCH NEUROL-CHICAGO, V67, P589, DOI 10.1001/archneurol.2010.65; West R, 2008, PSYCHOPHARMACOLOGY, V197, P371, DOI 10.1007/s00213-007-1041-3; Wexler BE, 2001, AM J PSYCHIAT, V158, P86, DOI 10.1176/appi.ajp.158.1.86; Wexler BE, 2011, BIOL PSYCHIAT, V69, P197, DOI 10.1016/j.biopsych.2010.11.016; Wrase J, 2007, NEUROIMAGE, V35, P787, DOI 10.1016/j.neuroimage.2006.11.043; Xu JS, 2010, NEUROPSYCHOPHARMACOL, V35, P1541, DOI 10.1038/npp.2010.25; Zack M, 2007, NEUROPSYCHOPHARMACOL, V32, P1678, DOI 10.1038/sj.npp.1301295; Zhao Y, 2006, J NEUROSCI, V26, P9967, DOI 10.1523/JNEUROSCI.2384-06.2006	243	148	150	3	65	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	FEB 24	2011	69	4					695	712		10.1016/j.neuron.2011.02.009	http://dx.doi.org/10.1016/j.neuron.2011.02.009			18	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	735KO	21338880	Green Accepted, Bronze			2023-01-03	WOS:000288413200012
J	Berry, JG; Hall, DE; Kuo, DZ; Cohen, E; Agrawal, R; Feudtner, C; Hall, M; Kueser, J; Kaplan, W; Neff, J				Berry, Jay G.; Hall, David E.; Kuo, Dennis Z.; Cohen, Eyal; Agrawal, Rishi; Feudtner, Chris; Hall, Matt; Kueser, Jacqueline; Kaplan, William; Neff, John			Hospital Utilization and Characteristics of Patients Experiencing Recurrent Readmissions Within Children's Hospitals	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEX CHRONIC CONDITIONS; DURABLE MEDICAL EQUIPMENT; WASHINGTON-STATE; CARE; PREVALENCE; EMERGENCY; PATTERNS	Context Early hospital readmission is emerging as an indicator of care quality. Some children with chronic illnesses may be readmitted on a recurrent basis, but there are limited data describing their rehospitalization patterns and impact. Objectives To describe the inpatient resource utilization, clinical characteristics, and admission reasons of patients recurrently readmitted to children's hospitals. Design, Setting, and Patients Retrospective cohort analysis of 317 643 patients (n=579 504 admissions) admitted to 37 US children's hospitals in 2003 with follow-up through 2008. Main Outcome Measure Maximum number of readmissions experienced by each child within any 365-day interval during the 5-year follow-up period. Results In the sample, 69 294 patients (21.8%) experienced at least 1 readmission within 365 days of a prior admission. Within a 365-day interval, 9237 patients (2.9%) experienced 4 or more readmissions; time between admissions was a median 37 days (interquartile range [IQR], 21-63). These patients accounted for 18.8% (109 155 admissions) of all admissions and 23.2% ($3.4 billion) of total inpatient charges for the study cohort during the entire follow-up period. Tests for trend indicated that as the number of readmissions increased from 0 to 4 or more, the prevalences increased for a complex chronic condition (from 22.3% [n=55 382/248 349] to 89.0% [n=8225/9237]; P<.001), technology assistance (from 5.3% [n=13 163] to 52.6% [n=4859]; P<.001), public insurance use (from 40.9% [n=101 575] to 56.3% [n=5202]; P<.001), and non-Hispanic black race (from 21.8% [n=54 140] to 34.4% [n=3181]; P<.001); and the prevalence decreased for readmissions associated with an ambulatory care-sensitive condition (from 23.1% [62 847/272 065] to 14.0% [15 282/109 155], P<.001). Of patients readmitted 4 or more times in a 365-day interval, 2633 (28.5%) were rehospitalized for a problem in the same organ system across all admissions during the interval. Conclusions Among a group of pediatric hospitals, 18.8% of admissions and 23.2% of inpatient charges were accounted for by the 2.9% of patients with frequent recurrent admissions. Many of these patients were rehospitalized recurrently for a problem in the same organ system. JAMA. 2011;305(7):682-690 www.jama.com	[Berry, Jay G.; Kaplan, William] Harvard Univ, Sch Med, Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA; [Hall, David E.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Kuo, Dennis Z.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72205 USA; [Cohen, Eyal] Univ Toronto, Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Agrawal, Rishi] Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Chicago, IL 60611 USA; [Feudtner, Chris] Childrens Hosp Philadelphia, Div Gen Pediat, PolicyLab, Philadelphia, PA 19104 USA; [Feudtner, Chris] Childrens Hosp Philadelphia, Dept Med Eth, Philadelphia, PA 19104 USA; [Hall, David E.; Kueser, Jacqueline] Child Hlth Corp Amer, Shawnee Mission, KS USA; [Neff, John] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Cincinnati Children's Hospital Medical Center; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Seattle Children's Hospital; University of Washington; University of Washington Seattle	Berry, JG (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, Div Gen Pediat, 300 Longwood Ave, Boston, MA 02115 USA.	jay.berry@childrens.harvard.edu	Feudtner, Chris/AAI-1126-2019; Hall, Matt/AAT-1349-2021; Cohen, Eyal/K-2575-2014; Dalla Zuanna, Teresa/G-3133-2015	Feudtner, Chris/0000-0002-5879-0434; Hall, Matt/0000-0001-7778-5887; Cohen, Eyal/0000-0003-0112-7188; 	Eunice Kennedy Shriver National Institute of Child Health and Human Development [K23 HD058092]; Arkansas Biosciences Institute National Health Center for Research Resources [KL2RR029883]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K23HD058092] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR029883] Funding Source: NIH RePORTER	Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Arkansas Biosciences Institute National Health Center for Research Resources; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Dr Berry was supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development career development award (K23 HD058092). Dr Kuo was supported by grant KL2RR029883 from the Arkansas Biosciences Institute National Health Center for Research Resources.	[Anonymous], CHILD HLTH CORPORATI; [Anonymous], PREV HOSP WIND PRIM; Beck Carolyn E, 2006, Paediatr Child Health, V11, P409; Berry JG, 2007, ARCH PEDIAT ADOL MED, V161, P38, DOI 10.1001/archpedi.161.1.38; Berry JG, 2009, PEDIATRICS, V124, P563, DOI 10.1542/peds.2008-3491; Berry SA, 2009, QUAL SAF HEALTH CARE, V18, P360, DOI 10.1136/qshc.2007.025056; Bhogal S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005306.pub2; Bowles EJA, 2009, MED CARE, V47, P1091, DOI 10.1097/MLR.0b013e3181a7e569; Buescher PA, 2006, MATERN CHILD HLTH J, V10, P461, DOI 10.1007/s10995-006-0081-3; Carrns Ann, 2010, US News World Rep, V147, P22; Consumer Price Index, CONS PRIC IND; COYE MJ, 2008, HOSP HEALTH NETWORK, V82, pA10; Curtis P, GUARDIAN; Czaja AS, 2009, PEDIATRICS, V123, P849, DOI 10.1542/peds.2008-0856; Feudtner C, 2000, PEDIATRICS, V106, P205; Feudtner C, 2002, PEDIATRICS, V109, P656, DOI 10.1542/peds.109.4.656; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Feudtner C, 2009, PEDIATRICS, V123, P286, DOI 10.1542/peds.2007-3395; Frei-Jones MJ, 2009, PEDIATR BLOOD CANCER, V53, P401, DOI 10.1002/pbc.22048; Frei-Jones MJ, 2009, PEDIATR BLOOD CANCER, V52, P481, DOI 10.1002/pbc.21854; Goodman DM, 2002, PEDIATRICS, V110, P583, DOI 10.1542/peds.110.3.583; Guterman S, 2010, HEALTH AFFAIR, V29, P1188, DOI 10.1377/hlthaff.2010.0442; Hansagi H, 2001, ANN EMERG MED, V37, P561, DOI 10.1067/mem.2001.111762; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kne T, 1998, AM J EMERG MED, V16, P648, DOI 10.1016/S0735-6757(98)90166-8; Kripalani S, 2007, J HOSP MED, V2, P314, DOI 10.1002/jhm.228; Lubell Jennifer, 2007, Mod Healthc, V37, P37; Lye PS, 2010, PEDIATRICS, V126, P829, DOI 10.1542/peds.2010-1535; Mackie AS, 2008, AM HEART J, V155, P577, DOI 10.1016/j.ahj.2007.11.003; Massin MM, 2006, ACTA PAEDIATR, V95, P208, DOI 10.1080/08035250500346443; Medicare Payment Advisory Commission (U.S.), REP C PROM GREAT EFF; Millman M, 1993, ACCESS HLTH CARE AM; Moore Keith D, 2010, Healthc Financ Manage, V64, P57; Palfrey JS, 2004, PEDIATRICS, V113, P1507; PALFREY JS, 1994, PUBLIC HEALTH REP, V109, P226; Reynolds S, 1996, PEDIATR EMERG CARE, V12, P166, DOI 10.1097/00006565-199606000-00005; Rice KL, 2010, AM J RESP CRIT CARE, V182, P890, DOI 10.1164/rccm.200910-1579OC; Shah SS, 2008, NEUROSURGERY, V62, P1095, DOI 10.1227/01.neu.0000325871.60129.23; Simon TD, 2010, PEDIATRICS, V126, P647, DOI 10.1542/peds.2009-3266; Sneed RC, 2004, PEDIATRICS, V114, pE612, DOI 10.1542/peds.2004-1063; Sneed RC, 2001, PEDIATRICS, V107, P1283, DOI 10.1542/peds.107.6.1283; Srivastava R, 2005, PEDIATR CLIN N AM, V52, P1165, DOI 10.1016/j.pcl.2005.03.007; Srivastava R, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b4411; Stone BL, 2008, J PEDIATR REHAB MED, V1, P237; Turnock AC, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005074.pub2; Young NL, 2009, PHYS OCCUP THER PEDI, V29, P345, DOI 10.3109/01942630903245994	46	351	353	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	2011	305	7					682	690		10.1001/jama.2011.122	http://dx.doi.org/10.1001/jama.2011.122			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	721NH	21325184	Green Accepted, Bronze			2023-01-03	WOS:000287361100019
J	Cox, H; van Cutsem, G				Cox, Helen; van Cutsem, Gilles			Household screening and multidrug-resistant tuberculosis	LANCET			English	Editorial Material									[Cox, Helen] Ctr Populat Hlth, Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3000, Australia; [Cox, Helen; van Cutsem, Gilles] Med San Frontieres, Cape Town, South Africa	Burnet Institute	Cox, H (corresponding author), Ctr Populat Hlth, Burnet Inst Med Res & Publ Hlth, Melbourne, Vic 3000, Australia.	hcox@burnet.edu.au	Van Cutsem, Gilles/ABB-1171-2021	Van Cutsem, Gilles/0000-0002-8972-4480; Cox, Helen/0000-0002-6538-7192				[Anonymous], 1999, EPIDEMIOLOGIC BASIS; [Anonymous], 2010, MULTIDRUG EXTENSIVEL; Becerra MC, 2011, LANCET, V377, P147, DOI 10.1016/S0140-6736(10)61972-1; Cox H, 2010, S AFR NAT TB C DURB; Keshavjee S, 2008, LANCET, V372, P1403, DOI 10.1016/S0140-6736(08)61204-0; London L, 2009, INT J TUBERC LUNG D, V13, P1200; Mitnick C, 2003, NEW ENGL J MED, V348, P119, DOI 10.1056/NEJMoa022928; Mitnick CD, 2008, NEW ENGL J MED, V359, P563, DOI 10.1056/NEJMoa0800106; Moran-Mendoza O, 2010, INT J TUBERC LUNG D, V14, P1112; World Health Organization (WHO), GUID PROGR MAN DRUG; Xu L, 2008, T ROY SOC TROP MED H, V102, P797, DOI 10.1016/j.trstmh.2008.04.027	11	3	4	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 8	2011	377	9760					103	104		10.1016/S0140-6736(10)61390-6	http://dx.doi.org/10.1016/S0140-6736(10)61390-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	707NH	21145582				2023-01-03	WOS:000286292800006
J	Trivedi, NS; Delbanco, T				Trivedi, Neha S.; Delbanco, Tom			Update: An 86-Year-Old Woman With Cardiac Cachexia Contemplating the End of Her Life Review of Hospice Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material														Trivedi, Neha/0000-0003-1006-1408				Kutner JS, 2010, JAMA-J AM MED ASSOC, V303, P349, DOI 10.1001/jama.2009.2015	1	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2011	306	6					645	645		10.1001/jama.2011.1134	http://dx.doi.org/10.1001/jama.2011.1134			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804XD	21828327				2023-01-03	WOS:000293687300026
J	Slagman, MCJ; Waanders, F; Hemmelder, MH; Woittiez, AJ; Janssen, WMT; Lambers Heerspink, HJ; Navis, G; Laverman, GD				Slagman, Maartje C. J.; Waanders, Femke; Hemmelder, Marc H.; Woittiez, Arend-Jan; Janssen, Wilbert M. T.; Lambers Heerspink, Hiddo J.; Navis, Gerjan; Laverman, Gozewijn D.		HONEST Grp	Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CHRONIC KIDNEY-DISEASE; TERM ANTIHYPERTENSIVE TREATMENT; GLOMERULAR-FILTRATION-RATE; ANTIPROTEINURIC EFFICACY; ACE-INHIBITION; CARDIOVASCULAR RISK; ALDOSTERONE SYSTEM; RENAL HEMODYNAMICS; PROGRESSION; METAANALYSIS	Objective To compare the effects on proteinuria and blood pressure of addition of dietary sodium restriction or angiotensin receptor blockade at maximum dose, or their combination, in patients with non-diabetic nephropathy receiving background treatment with angiotensin converting enzyme (ACE) inhibition at maximum dose. Design Multicentre crossover randomised controlled trial. Setting Outpatient clinics in the Netherlands. Participants 52 patients with non-diabetic nephropathy. Interventions All patients were treated during four 6 week periods, in random order, with angiotensin receptor blockade (valsartan 320 mg/day) or placebo, each combined with, consecutively, a low sodium diet (target 50 mmol Na+/day) and a regular sodium diet (target 200 mmol Na+/day), with a background of ACE inhibition (lisinopril 40 mg/day) during the entire study. The drug interventions were double blind; the dietary interventions were open label. Main outcome measures The primary outcome measure was proteinuria; the secondary outcome measure was blood pressure. Results Mean urinary sodium excretion, a measure of dietary sodium intake, was 106 (SE 5) mmol Na+/day during a low sodium diet and 184 (6) mmol Na+/day during a regular sodium diet (P<0.001). Geometric mean residual proteinuria was 1.68 (95% confidence interval 1.31 to 2.14) g/day during ACE inhibition plus a regular sodium diet. Addition of angiotensin receptor blockade to ACE inhibition reduced proteinuria to 1.44 (1.07 to 1.93) g/day (P=0.003), addition of a low sodium diet reduced it to 0.85 (0.66 to 1.10) g/day (P<0.001), and addition of angiotensin receptor blockade plus a low sodium diet reduced it to 0.67 0.50 to 0.91) g/day (P<0.001). The reduction of proteinuria by the addition of a low sodium diet to ACE inhibition (51%, 95% confidence interval 43% to 58%) was significantly larger (P<0.001) than the reduction of proteinuria by the addition of angiotensin receptor blockade to ACE inhibition (21%, (8% to 32%) and was comparable (P=0.009, not significant after Bonferroni correction) to the reduction of proteinuria by the addition of both angiotensin receptor blockade and a low sodium diet to ACE inhibition (62%, 53% to 70%). Mean systolic blood pressure was 134 (3) mm Hg during ACE inhibition plus a regular sodium diet. Mean systolic blood pressure was not significantly altered by the addition of angiotensin receptor blockade (131 (3) mm Hg; P=0.12) but was reduced by the addition of a low sodium diet (123 (2) mm Hg; P<0.001) and angiotensin receptor blockade plus a low sodium diet (121 (3) mm Hg; P<0.001) to ACE inhibition. The reduction of systolic blood pressure by the addition of a low sodium diet (7% (SE 1%)) was significantly larger (P=0.003) than the reduction of systolic blood pressure by the addition of angiotensin receptor blockade (2% (1)) and was similar (P=0.14) to the reduction of systolic blood pressure by the addition of both angiotensin receptor blockade and low sodium diet (9% (1)), to ACE inhibition. Conclusions Dietary sodium restriction to a level recommended in guidelines was more effective than dual blockade for reduction of proteinuria and blood pressure in non-diabetic nephropathy. The findings support the combined endeavours of patients and health professionals to reduce sodium intake.	[Slagman, Maartje C. J.; Waanders, Femke; Navis, Gerjan; Laverman, Gozewijn D.] Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands; [Hemmelder, Marc H.] Med Ctr Leeuwarden, Div Nephrol, Dept Internal Med, Leeuwarden, Netherlands; [Woittiez, Arend-Jan; Laverman, Gozewijn D.] ZGT Hosp Almelo, Div Nephrol, Dept Internal Med, Almelo, Netherlands; [Janssen, Wilbert M. T.] Martini Hosp Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands; [Lambers Heerspink, Hiddo J.] Univ Groningen, Univ Med Ctr Groningen, Dept Pharmacol, Groningen, Netherlands	University of Groningen; Medical Center Leeuwarden; Martini Hospital; University of Groningen; University of Groningen	Laverman, GD (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands.	g.d.laverman@umcg.nl	Hemmelder, Marc/AFQ-0383-2022; Heerspink, Hiddo J Lambers/K-3358-2014	Heerspink, Hiddo J Lambers/0000-0002-3126-3730	Novartis [CVAL489ANL08]	Novartis(Novartis)	The study was supported by an unrestricted grant from Novartis (CVAL489ANL08). The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.	[Anonymous], 2009, Lancet, V374, P1226, DOI 10.1016/S0140-6736(09)61768-2; Apperloo AJ, 1997, KIDNEY INT, V51, P793, DOI 10.1038/ki.1997.111; Bakris GL, 2000, ARCH INTERN MED, V160, P685, DOI 10.1001/archinte.160.5.685; Basi S, 2006, AM J KIDNEY DIS, V47, P927, DOI 10.1053/j.ajkd.2006.02.182; Bibbins-Domingo K, 2010, NEW ENGL J MED, V362, P590, DOI 10.1056/NEJMoa0907355; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brown IJ, 2009, INT J EPIDEMIOL, V38, P791, DOI 10.1093/ije/dyp139; Buter H, 1998, NEPHROL DIAL TRANSPL, V13, P1682, DOI 10.1093/ndt/13.7.1682; Catapano F, 2008, AM J KIDNEY DIS, V52, P475, DOI 10.1053/j.ajkd.2008.03.008; Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55; Correa JA, 2001, STAT MED, V20, P1185, DOI 10.1002/sim.776; De Nicola L, 2006, KIDNEY INT, V69, P538, DOI 10.1038/sj.ki.5000085; Einhorn LM, 2009, ARCH INTERN MED, V169, P1156, DOI 10.1001/archinternmed.2009.132; Ekinci EI, 2009, DIABETES CARE, V32, P1398, DOI 10.2337/dc08-2297; Esnault VLM, 2010, NEPHROL DIAL TRANSPL, V25, P2218, DOI 10.1093/ndt/gfp776; Esnault VLM, 2005, J AM SOC NEPHROL, V16, P474, DOI 10.1681/ASN.2004060505; HANSEN HP, 1995, KIDNEY INT, V47, P1726, DOI 10.1038/ki.1995.238; He FJ, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004937; Heaney RP, 2006, J AM COLL NUTR, V25, p271S, DOI 10.1080/07315724.2006.10719577; HEEG JE, 1989, KIDNEY INT, V36, P272, DOI 10.1038/ki.1989.190; Houlihan CA, 2002, DIABETES CARE, V25, P663, DOI 10.2337/diacare.25.4.663; Jafar TH, 2003, ANN INTERN MED, V139, P244, DOI 10.7326/0003-4819-139-4-200308190-00006; Korgaonkar S, 2010, CLIN J AM SOC NEPHRO, V5, P762, DOI 10.2215/CJN.05850809; Krikken JA, 2007, KIDNEY INT, V71, P260, DOI 10.1038/sj.ki.5002011; Kunz R, 2008, ANN INTERN MED, V148, P30, DOI 10.7326/0003-4819-148-1-200801010-00190; Laverman GD, 2004, J AM SOC NEPHROL, V15, pS64, DOI 10.1097/01.ASN.0000093368.27046.3C; Laverman GD, 2002, KIDNEY INT, V62, P1020, DOI 10.1046/j.1523-1755.2002.00536.x; Laverman GD, 2001, AM J KIDNEY DIS, V38, P1381, DOI 10.1053/ajkd.2001.29262; Levey AS, 1999, J AM SOC NEPHROL, V10, P2426; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MARONI BJ, 1985, KIDNEY INT, V27, P58, DOI 10.1038/ki.1985.10; Masud T, 2002, KIDNEY INT, V62, P1750, DOI 10.1046/j.1523-1755.2002.00606.x; NAVIS G, 1987, J CARDIOVASC PHARM, V9, P743, DOI 10.1097/00005344-198706000-00016; PETERSON JC, 1995, ANN INTERN MED, V123, P754, DOI 10.7326/0003-4819-123-10-199511150-00003; Pfeffer MA, 2003, NEW ENGL J MED, V349, P1893, DOI 10.1056/NEJMoa032292; Pijls LTJ, 1999, NEPHROL DIAL TRANSPL, V14, P1445, DOI 10.1093/ndt/14.6.1445; Rossing K, 2005, KIDNEY INT, V68, P1190, DOI 10.1111/j.1523-1755.2005.00511.x; Ruggenenti P, 1997, LANCET, V349, P1857; Ruggenenti P, 2001, LANCET, V357, P1601, DOI 10.1016/S0140-6736(00)04728-0; Ruggenenti P, 2008, J AM SOC NEPHROL, V19, P1213, DOI 10.1681/ASN.2007090970; Slagman MCJ, 2010, AM J KIDNEY DIS, V56, P601, DOI 10.1053/j.ajkd.2010.06.008; Slagman MCJ, 2010, CURR OPIN NEPHROL HY, V19, P140, DOI 10.1097/MNH.0b013e3283361887; Strazzullo P, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4567; Suzuki T, 2009, CLIN NEPHROL, V72, P274; The National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) Workgroup, 2004, AM J KIDNEY DIS, V43, P11, DOI [10.1053/j.ajkd.2004.03.003, DOI 10.1053/J.AJKD.2004.03.003]; Thomas MC, 2008, DIABETES RES CLIN PR, V80, P83, DOI 10.1016/j.diabres.2007.10.024; Vallon V, 2005, CURR HYPERTENS REP, V7, P141, DOI 10.1007/s11906-005-0089-x; van Zuilen AD, 2008, J NEPHROL, V21, P261; Vogt L, 2008, J AM SOC NEPHROL, V19, P999, DOI 10.1681/ASN.2007060693; WEIR MR, 1995, HYPERTENSION, V25, P1339, DOI 10.1161/01.HYP.25.6.1339; Yusuf S, 2008, NEW ENGL J MED, V358, P1547, DOI 10.1056/NEJMoa0801317; Zhou JH, 2006, CLIN PHARMACOKINET, V45, P623, DOI 10.2165/00003088-200645060-00005	52	166	170	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 26	2011	343								d4366	10.1136/bmj.d4366	http://dx.doi.org/10.1136/bmj.d4366			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	801LP	21791491	Green Submitted, hybrid, Green Published			2023-01-03	WOS:000293440700004
J	Montini, G; Tullus, K; Hewitt, I				Montini, Giovanni; Tullus, Kjell; Hewitt, Ian			MEDICAL PROGRESS Febrile Urinary Tract Infections in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CHRONIC-RENAL-FAILURE; SWEDISH REFLUX TRIAL; SEVERE VESICOURETERAL REFLUX; ACUTE PYELONEPHRITIS; ANTIBIOTIC-PROPHYLAXIS; VOIDING CYSTOURETHROGRAPHY; ANTENATAL DIAGNOSIS; ACID SCINTIGRAPHY; YOUNG-CHILDREN; CHILDHOOD		[Montini, Giovanni] Azienda Osped Univ StOrsola Malpighi, Dept Pediat, I-40138 Bologna, Italy; [Tullus, Kjell] Great Ormond St Hosp Sick Children, Dept Pediat Nephrol, London, England; [Hewitt, Ian] Princess Margaret Hosp Children, Perth, WA, Australia	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of Western Australia	Montini, G (corresponding author), Azienda Osped Univ StOrsola Malpighi, Dept Pediat, Via Massarenti 11,Padigl 13, I-40138 Bologna, Italy.	giovanni.montini@aosp.bo.it	Tullus, Kjell/C-6589-2008; Montini, Giovanni/AAC-6612-2022	Montini, Giovanni/0000-0002-7350-4475	AstraZeneca	AstraZeneca(AstraZeneca)	Dr. Montini reports that his prior institution, Azienda Ospedaliera di Padova, has received grant support from AstraZeneca. No other potential conflict of interest relevant to this article was reported.	*AM AC PED COMM QU, 2000, PEDIATRICS, V105, P141; *AM UR ASS, CLIN GUID; American Academy of Pediatrics, 1999, PEDIATRICS, V103, P1052; [Anonymous], 1991, J R Coll Physicians Lond, V25, P36; Ardissino G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e382; Bailey R R, 1973, Clin Nephrol, V1, P132; Benador D, 1997, LANCET, V349, P17, DOI 10.1016/S0140-6736(96)06126-0; Benador D, 2001, ARCH DIS CHILD, V84, P241, DOI 10.1136/adc.84.3.241; Bergman DA, 1999, PEDIATRICS, V103, P843; Bergman DA, 1999, PEDIATRICS, V104, P118; Bhide A, 2005, ULTRASOUND OBST GYN, V25, P489, DOI 10.1002/uog.1875; Bloomfield P, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003772.pub2; Bosio M, 1998, PEDIATR RADIOL, V28, P250, DOI 10.1007/s002470050343; Brandstrom P, 2010, J UROLOGY, V184, P274, DOI 10.1016/j.juro.2010.01.055; Brandstrom P, 2010, J UROLOGY, V184, P286, DOI 10.1016/j.juro.2010.01.061; Brandstrom P, 2010, J UROLOGY, V184, P292, DOI 10.1016/j.juro.2010.01.060; Bricker L, 2000, HEALTH TECHNOL ASSES, V4, P1; BROYER M, 1993, PEDIATR NEPHROL, V7, P758, DOI 10.1007/BF01213347; Contopoulos-Ioannidis DG, 2004, PEDIATRICS, V114, pE111, DOI 10.1542/peds.114.1.e111; Coulthard MG, 2009, PEDIATR NEPHROL, V24, P227, DOI 10.1007/s00467-008-0911-1; Craig JC, 2010, NEW ENGL J MED, V362, P1250; Dai B, 2010, ARCH DIS CHILD, V95, P499, DOI 10.1136/adc.2009.173112; DELUCA FG, 1963, NEW ENGL J MED, V268, P75, DOI 10.1056/NEJM196301102680204; Doganis D, 2007, PEDIATRICS, V120, pE922, DOI 10.1542/peds.2006-2417; ELKHATIB M, 1994, CLIN NEPHROL, V41, P50; Esbjorner E, 1997, PEDIATR NEPHROL, V11, P438, DOI 10.1007/s004670050312; Faust WC, 2009, J UROLOGY, V181, P290, DOI 10.1016/j.juro.2008.09.039; Ferrara P, 2009, SCAND J UROL NEPHROL, V43, P47, DOI 10.1080/00365590802442086; FORBES GS, 1976, AM J ROENTGENOL, V127, P683, DOI 10.2214/ajr.127.4.683; Fouzas S, 2010, PEDIATRICS, V126, pE513, DOI 10.1542/peds.2009-3635; FRANCOIS P, 1995, ARCH PEDIATRIE, V2, P136, DOI 10.1016/0929-693X(96)89873-3; Garin EH, 2006, PEDIATRICS, V117, P626, DOI 10.1542/peds.2005-1362; Grattan-Smith JD, 2008, PEDIATR RADIOL, V38, pS83, DOI 10.1007/s00247-007-0668-x; Guay DRP, 2009, DRUGS, V69, P775, DOI 10.2165/00003495-200969070-00002; Hannson S, 2004, PEDIAT NEPHROLOGY, P1007; Hansson S, 2004, J UROLOGY, V172, P1071, DOI 10.1097/01.ju.0000135337.71154.60; HELLSTROM A, 1991, ARCH DIS CHILD, V66, P232, DOI 10.1136/adc.66.2.232; Hewitt IK, 2008, PEDIATRICS, V122, P486, DOI 10.1542/peds.2007-2894; Hiel JA, 2000, ARCH DIS CHILD, V82, P400; Hoberman A, 2003, NEW ENGL J MED, V348, P195, DOI 10.1056/NEJMoa021698; Hoberman A, 1999, PEDIATRICS, V104, P79, DOI 10.1542/peds.104.1.79; Hussein A, 2010, NEPHROL DIAL TRANSPL, V25, P779, DOI 10.1093/ndt/gfp532; JACOBSON SH, 1989, BMJ-BRIT MED J, V299, P703, DOI 10.1136/bmj.299.6701.703; Jakobsson B, 1997, ACTA PAEDIATR, V86, P803; Jantunen ME, 2001, PEDIATR INFECT DIS J, V20, P597, DOI 10.1097/00006454-200106000-00010; Jepson R. G., 2008, COCHRANE DB SYST REV, V2008, DOI DOI 10.1002/14651858.CD001321.PUB4; Jodal U, 2006, PEDIATR NEPHROL, V21, P785, DOI 10.1007/s00467-006-0063-0; Keren R, 2007, CURR OPIN PEDIATR, V19, P705, DOI 10.1097/MOP.0b013e3282f1dcd7; Keren R, 2008, PEDIATRICS, V122, P1409, DOI 10.1542/peds.2008-1285d; Koyle MA, 2010, J UROLOGY, V184, P285, DOI 10.1016/j.juro.2010.01.109; Lee HY, 2009, PEDIATR NEPHROL, V24, P2009, DOI 10.1007/s00467-009-1232-8; Lee MD, 2009, J PEDIATR-US, V154, P797, DOI 10.1016/j.jpeds.2008.12.045; LEVITT SB, 1981, PEDIATRICS, V67, P392; Levtchenko E, 2001, PEDIATR NEPHROL, V16, P878, DOI 10.1007/s004670100690; Li YH, 2002, RESP RES, V3, DOI 10.1186/rr173; Lim R, 2009, AM J ROENTGENOL, V192, P1197, DOI 10.2214/AJR.08.2187; Marild S, 1998, ACTA PAEDIATR, V87, P549, DOI 10.1080/08035259850158272; Marks SD, 2008, PEDIATR NEPHROL, V23, P9, DOI 10.1007/s00467-007-0552-9; Marra G, 2004, J PEDIATR-US, V144, P677, DOI 10.1016/j.jpeds.2004.01.043; Montini G, 2008, PEDIATRICS, V122, P1064, DOI 10.1542/peds.2007-3770; Montini G, 2007, BMJ-BRIT MED J, V335, P386, DOI 10.1136/bmj.39244.692442.55; Montini G, 2009, PEDIATRICS, V123, pE239, DOI 10.1542/peds.2008-1003; Montini G, 2009, PEDIATR NEPHROL, V24, P1605, DOI 10.1007/s00467-009-1213-y; *N AM PED REN TRIA, 2008, ANN REP N AM PED REN; NORMAND ICS, 1965, BMJ-BRIT MED J, V1, P1023, DOI 10.1136/bmj.1.5441.1023; Pennesi M, 2008, PEDIATRICS, V121, pE1489, DOI 10.1542/peds.2007-2652; PISTOR K, 1985, CLIN NEPHROL, V23, P278; Pohl HG, 1999, J UROLOGY, V162, P815, DOI 10.1097/00005392-199909010-00067; POLITANO VA, 1958, J UROLOGY, V79, P932, DOI 10.1016/S0022-5347(17)66369-9; Preda I, 2007, J PEDIATR-US, V151, P581, DOI 10.1016/j.jpeds.2007.05.008; Ragnarsdottir B, 2008, EUR J CLIN INVEST, V38, P12, DOI 10.1111/j.1365-2362.2008.02004.x; REUSS A, 1987, PEDIATR NEPHROL, V1, P546, DOI 10.1007/BF00849268; ROMERO R, 1985, AM J OBSTET GYNECOL, V151, P38, DOI 10.1016/0002-9378(85)90420-X; Roussey-Kesler G, 2008, J UROLOGY, V179, P674, DOI 10.1016/j.juro.2007.09.090; Royal Children's Hospital Melbourne, CLIN PRACT GUID; SAVAGE DCL, 1969, BRIT MED J, V3, P75, DOI 10.1136/bmj.3.5662.75; Sharifian M, 2008, PEDIATR NEPHROL, V23, P1511, DOI 10.1007/s00467-008-0864-4; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; Singh-Grewal D, 2005, ARCH DIS CHILD, V90, P853, DOI 10.1136/adc.2004.049353; SMELLIE JM, 1978, LANCET, V2, P175; Smellie JM, 2001, LANCET, V357, P1329, DOI 10.1016/S0140-6736(00)04520-7; Smith T, 1996, J NUCL MED, V37, P1336; STANSFELD JM, 1975, BRIT MED J, V3, P65, DOI 10.1136/bmj.3.5975.65; STEELE RE, 1963, NEW ENGL J MED, V269, P883, DOI 10.1056/NEJM196310242691702; Stefanidis CJ, 2007, PEDIATR NEPHROL, V22, P937, DOI 10.1007/s00467-006-0396-8; Tullus K, 1997, ACTA PAEDIATR, V86, P1198, DOI 10.1111/j.1651-2227.1997.tb14845.x; TULLUS K, 1991, J UROLOGY, V146, P1153, DOI 10.1016/S0022-5347(17)38029-1; Urinary tract infection in children, 2007, UR TRACT INF CHILDR; Vilaichone Aimon, 2001, Journal of the Medical Association of Thailand, V84, pS61; Wennerstrom M, 2000, ARCH PEDIAT ADOL MED, V154, P339, DOI 10.1001/archpedi.154.4.339; Wennerstrom M, 2000, J HYPERTENS, V18, P485, DOI 10.1097/00004872-200018040-00019; Wennerstrom M, 2000, J PEDIATR-US, V136, P30, DOI 10.1016/S0022-3476(00)90045-3; WHITE RHR, 1983, BRIT MED J, V287, P171; WILLIAMS GJ, 2001, COCHRANE DB SYST REV, V4; WISWELL TE, 1985, PEDIATRICS, V75, P901; Zamir G, 2004, ARCH DIS CHILD, V89, P466, DOI 10.1136/adc.2002.019182; ZHANG YY, 1995, NEW ZEAL MED J, V108, P142	97	176	198	1	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	2011	365	3					239	250		10.1056/NEJMra1007755	http://dx.doi.org/10.1056/NEJMra1007755			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	794QI	21774712				2023-01-03	WOS:000292915500008
J	Greene, JA; Kesselheim, AS				Greene, Jeremy A.; Kesselheim, Aaron S.			Why Do the Same Drugs Look Different? Pills, Trade Dress, and Public Health	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							COLOR; PLACEBO; LITERACY		[Greene, Jeremy A.; Kesselheim, Aaron S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02120 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Greene, JA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	greene@fas.harvard.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS018465] Funding Source: NIH RePORTER	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		[Anonymous], 2010, CBS 60 MINUTES  1229; Berman Adrienne, 2004, J Med Syst, V28, P9, DOI 10.1023/B:JOMS.0000021518.60670.10; Cardenas-Valladolid J, 2010, DRUG AGING, V27, P641, DOI 10.2165/11537320-000000000-00000; CARPENTER D, B HIST MED IN PRESS; Cutler C, 2011, BIOL BLOOD MARROW TR, V17, P285, DOI 10.1016/j.bbmt.2010.11.006; Davit BM, 2009, ANN PHARMACOTHER, V43, P1583, DOI 10.1345/aph.1M141; deCraen AJM, 1996, BRIT MED J, V313, P1624, DOI 10.1136/bmj.313.7072.1624; Donohue JM, 2007, NEW ENGL J MED, V357, P673, DOI 10.1056/NEJMsa070502; FACCHINETTI NJ, 1982, AM J PUBLIC HEALTH, V72, P468, DOI 10.2105/AJPH.72.5.468; Frank RG, 2007, NEW ENGL J MED, V357, P1993, DOI 10.1056/NEJMp078193; Fritsch David, 2006, INTELLECTUAL PROPERT, V47, P171; Generic Pharmaceutical Association, FACTS GLANC; Gray S, NHS EVIDENCE RESP; Greene Jeremy A., 2007, PRESCRIBING NUMBERS; Greenslit Nathan, 2002, Mol Interv, V2, P342, DOI 10.1124/mi.2.6.342; HARRINGTON A, 1997, PLACEBO EFFECT; Hellier Elizabeth, 2010, J Patient Saf, V6, P158; HORN CR, 1986, LANCET, V1, P165; HUSKISSON EC, 1974, BMJ-BRIT MED J, V4, P196, DOI 10.1136/bmj.4.5938.196; JACOBS KW, 1979, PERCEPT MOTOR SKILL, V49, P367, DOI 10.2466/pms.1979.49.2.367; Kenagy JW, 2001, AM J HEALTH-SYST PH, V58, P2033, DOI 10.1093/ajhp/58.21.2033; Kesselheim AS, 2008, JAMA-J AM MED ASSOC, V300, P2514, DOI 10.1001/jama.2008.758; Khan A, 2010, PSYCHOPHARMACOLOGY, V211, P113, DOI 10.1007/s00213-010-1874-z; Kirsche ML, 2005, DRUG STORE NEWS 0822; Kohn LT, 2000, ERR IS HUMAN BUILDIN; Krieg M, 1967, BLACK MARKET MED; Lambert BL, 2005, DRUG SAFETY, V28, P495, DOI 10.2165/00002018-200528060-00003; Levinthal BR, 2008, J GEN INTERN MED, V23, P1172, DOI 10.1007/s11606-008-0612-2; LUCCHELLI PE, 1978, EUR J CLIN PHARMACOL, V13, P153, DOI 10.1007/BF00609760; Matheson Julia Anne, 2009, MED MARKET MEDIA, V44, P55; NEWMAN SJ, 1994, U CHICAGO LAW REV, V61, P1595, DOI 10.2307/1600127; Ngoh LN, 2009, J AM PHARM ASSOC, V49, pE132, DOI 10.1331/JAPhA.2009.07075; Sabat E, 2003, ADHERENCE LONG TERM; Schiff Gordon, 2004, J Med Syst, V28, P1, DOI 10.1023/B:JOMS.0000021517.51673.f3; Shrank WH, 2010, HEALTH AFFAIR, V29, P1383, DOI 10.1377/hlthaff.2009.0424; Stinson Nina, 1982, INDIANA LAW REV, V15, P733; Waber RL, 2008, JAMA-J AM MED ASSOC, V299, P1016, DOI 10.1001/jama.299.9.1016; Wolf MS, 2011, ARCH INTERN MED, V171, P300, DOI 10.1001/archinternmed.2011.39	38	55	55	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 7	2011	365	1					83	89		10.1056/NEJMhle1101722	http://dx.doi.org/10.1056/NEJMhle1101722			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	788QL	21732842				2023-01-03	WOS:000292459400016
J	De Bono, JS; Logothetis, CJ; Molina, A; Fizazi, K; North, S; Chu, L; Chi, KN; Jones, RJ; Goodman, OB; Saad, F; Staffurth, JN; Mainwaring, P; Harland, S; Flaig, TW; Hutson, TE; Cheng, T; Patterson, H; Hainsworth, JD; Ryan, CJ; Sternberg, CN; Ellard, SL; Flechon, A; Saleh, M; Scholz, M; Efstathiou, E; Zivi, A; Bianchini, D; Loriot, Y; Chieffo, N; Kheoh, T; Haqq, CM; Scher, HI				De Bono, Johann S.; Logothetis, Christopher J.; Molina, Arturo; Fizazi, Karim; North, Scott; Chu, Luis; Chi, Kim N.; Jones, Robert J.; Goodman, Oscar B., Jr.; Saad, Fred; Staffurth, John N.; Mainwaring, Paul; Harland, Stephen; Flaig, Thomas W.; Hutson, Thomas E.; Cheng, Tina; Patterson, Helen; Hainsworth, John D.; Ryan, Charles J.; Sternberg, Cora N.; Ellard, Susan L.; Flechon, Aude; Saleh, Mansoor; Scholz, Mark; Efstathiou, Eleni; Zivi, Andrea; Bianchini, Diletta; Loriot, Yohann; Chieffo, Nicole; Thian Kheoh; Haqq, Christopher M.; Scher, Howard I.		COU-AA-301 Investigators	Abiraterone and Increased Survival in Metastatic Prostate Cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANDROGEN-DEPRIVATION THERAPY; HUMAN CYTOCHROME P450(17-ALPHA); I CLINICAL-TRIAL; HORMONAL-THERAPY; PLUS PREDNISONE; CASTRATION; ACETATE; CYP17; TESTOSTERONE; DOCETAXEL	BACKGROUND Biosynthesis of extragonadal androgen may contribute to the progression of castration-resistant prostate cancer. We evaluated whether abiraterone acetate, an inhibitor of androgen biosynthesis, prolongs overall survival among patients with metastatic castration-resistant prostate cancer who have received chemotherapy. METHODS We randomly assigned, in a 2: 1 ratio, 1195 patients who had previously received docetaxel to receive 5 mg of prednisone twice daily with either 1000 mg of abiraterone acetate (797 patients) or placebo (398 patients). The primary end point was overall survival. The secondary end points included time to prostate-specific antigen (PSA) progression (elevation in the PSA level according to prespecified criteria), progression-free survival according to radiologic findings based on prespecified criteria, and the PSA response rate. RESULTS After a median follow-up of 12.8 months, overall survival was longer in the abiraterone acetate-prednisone group than in the placebo-prednisone group (14.8 months vs. 10.9 months; hazard ratio, 0.65; 95% confidence interval, 0.54 to 0.77; P<0.001). Data were unblinded at the interim analysis, since these results exceeded the pre-planned criteria for study termination. All secondary end points, including time to PSA progression (10.2 vs. 6.6 months; P<0.001), progression-free survival (5.6 months vs. 3.6 months; P<0.001), and PSA response rate (29% vs. 6%, P<0.001), favored the treatment group. Mineralocorticoid-related adverse events, including fluid retention, hypertension, and hypokalemia, were more frequently reported in the abiraterone acetate-prednisone group than in the placebo-prednisone group. CONCLUSIONS The inhibition of androgen biosynthesis by abiraterone acetate prolonged overall survival among patients with metastatic castration-resistant prostate cancer who previously received chemotherapy. (Funded by Cougar Biotechnology; COU-AA-301 ClinicalTrials.gov number, NCT00638690.)	[De Bono, Johann S.; Zivi, Andrea; Bianchini, Diletta] Inst Canc Res, Sutton SM2 5PT, Surrey, England; [De Bono, Johann S.; Zivi, Andrea; Bianchini, Diletta] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England; [Jones, Robert J.] Inst Canc Sci, Glasgow, Lanark, Scotland; [Staffurth, John N.] Cardiff Univ, Velindre Hosp, Cardiff, S Glam, Wales; [Patterson, Helen] Univ Cardiff, Velindre Hosp, Cambridge, England; [Logothetis, Christopher J.; Efstathiou, Eleni] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Molina, Arturo; Chieffo, Nicole; Thian Kheoh; Haqq, Christopher M.] Ortho Biotech Oncol Res & Dev Unit Cougar Biotech, Los Angeles, CA USA; [Fizazi, Karim; Loriot, Yohann] Inst Gustave Roussy, Villejuif, France; [Flechon, Aude] Ctr Leon Berard, F-69373 Lyon, France; [North, Scott] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada; [Chi, Kim N.] Vancouver Canc Ctr, BC Canc Agcy, Vancouver, BC, Canada; [Cheng, Tina] Univ Calgary, Calgary, AB, Canada; [Ellard, Susan L.] Ctr So Interior, BC Canc Agcy, Kelowna, BC, Canada; [Goodman, Oscar B., Jr.] Nevada Canc Inst, Las Vegas, NV USA; [Saad, Fred] Univ Montreal, Montreal, PQ, Canada; [Mainwaring, Paul] Haematol & Oncol Clin Australasia, Milton, Australia; [Harland, Stephen] UCL Canc Inst, London, England; [Flaig, Thomas W.] Univ Colorado, Ctr Canc, Aurora, CO USA; [Hutson, Thomas E.] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [Hainsworth, John D.] Sarah Cannon Res Inst, Nashville, TN USA; [Ryan, Charles J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Sternberg, Cora N.] San Camillo Hosp, Rome, Italy; [Scher, Howard I.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; [Scher, Howard I.] Weill Cornell Med Coll, New York, NY USA; [Sternberg, Cora N.] Forlanini Hosp, Rome, Italy	University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of Glasgow; Cardiff University; Velindre Hospital; Cardiff University; Velindre Hospital; University of Texas System; UTMD Anderson Cancer Center; UNICANCER; Gustave Roussy; UNICANCER; Centre Leon Berard; University of Alberta; British Columbia Cancer Agency; University of Calgary; British Columbia Cancer Agency; University of California System; University of California San Diego; Universite de Montreal; University of London; University College London; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor University Medical Center; Sarah Cannon Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Azienda Ospedaliera San Camillo-Forlanini	De Bono, JS (corresponding author), Inst Canc Res, Downs Rd, Sutton SM2 5PT, Surrey, England.	johann.de-bono@icr.ac.uk	Hutson, Thomas/AAS-9639-2020; Loriot, Yohann/W-5572-2019; Mulders, Peter F.A./H-8076-2014; Sonpavde/L-7107-2019	Hutson, Thomas/0000-0002-4529-4212; Sonpavde/0000-0002-1010-9611; North, scott/0000-0003-4427-5439; Horvath, Lisa/0000-0001-6842-9223; Goodman, Oscar/0000-0002-0882-3621; de Bono, Johann S/0000-0002-2034-595X; joly, florence/0000-0001-6168-4942; Jones, Robert/0000-0002-2904-6980; DURAN, IGNACIO/0000-0001-8571-7163; OUDARD, Stephane/0000-0003-0893-285X; Ellard, Susan/0000-0001-5757-9787; McDermott, Ray/0000-0002-8952-4315	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Medical Research Council of the United Kingdom; Experimental Cancer Medical Centre; National Institute for Health Research Biomedical Research Centre; Prostate Cancer Foundation; Amgen; Astellas; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Enzon; Exelixis; Genentech; GlaxoSmithKline; Medivation; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Supergen; Takeda; Janssen-Cilag; Abraxis; Ortho Biotech; Veridex (a division of Johnson Johnson); Pierre Fabre Laboratories; Bayer; Aragon; Foundation Medicine; Millenium; Veridex; NATIONAL CANCER INSTITUTE [P50CA092629] Funding Source: NIH RePORTER	Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology); Medical Research Council of the United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Experimental Cancer Medical Centre; National Institute for Health Research Biomedical Research Centre(National Institute for Health Research (NIHR)); Prostate Cancer Foundation; Amgen(Amgen); Astellas(Astellas Pharmaceuticals); AstraZeneca(AstraZeneca); Boehringer Ingelheim(Boehringer Ingelheim); Bristol-Myers Squibb(Bristol-Myers Squibb); Dendreon; Enzon; Exelixis; Genentech(Roche HoldingGenentech); GlaxoSmithKline(GlaxoSmithKline); Medivation; Merck(Merck & Company); Novartis(Novartis); Pfizer(Pfizer); Roche(Roche Holding); Sanofi-Aventis(Sanofi-Aventis); Supergen; Takeda(Takeda Pharmaceutical Company Ltd); Janssen-Cilag(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Abraxis; Ortho Biotech; Veridex (a division of Johnson Johnson); Pierre Fabre Laboratories; Bayer(Bayer AG); Aragon; Foundation Medicine; Millenium; Veridex; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Supported by Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology) and grants from the Medical Research Council of the United Kingdom, Experimental Cancer Medical Centre, National Institute for Health Research Biomedical Research Centre, and Prostate Cancer Foundation (to Dr. Scher).; Dr. de Bono reports being an employee of the Institute of Cancer Research, where abiraterone was first designed and synthesized and which has a commercial interest in abiraterone, and receiving consulting fees from Ortho Biotech Oncology Research and Development (a unit of Cougar Biotechnology), consulting fees and travel support from Amgen, Astellas, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Dendreon, Enzon, Exelixis, Genentech, GlaxoSmithKline, Medivation, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Supergen, and Takeda, and grant support from AstraZeneca; Dr. Logothetis, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Drs. Molina, Haqq, and Kheoh and Ms. Chieffo, being employees of and holding stock options in Johnson & Johnson; Dr. Fizazi, receiving lecture fees from Janssen-Cilag and consulting fees from Ortho Biotech Oncology Research and Development; Dr. North, receiving consulting fees from AstraZeneca, Pfizer, Sanofi-Aventis, Novartis, Abraxis, Ortho Biotech, Amgen, and GlaxoSmithKline and lecture fees from Novartis and Ortho Biotech; Dr. Chu, holding stock in Johnson & Johnson, GlaxoSmithKline, Eli Lilly, Novartis, Rigel Pharmaceuticals, and Sanofi-Aventis; Dr. Jones, receiving grant and travel support from Ortho Biotech Oncology Research and Development; Dr. Goodman, receiving consulting and lecture fees from Veridex (a division of Johnson & Johnson); Dr. Saad, receiving consulting fees from Amgen, Novartis, Sanofi-Aventis, and AstraZeneca and receiving payment for the development of educational presentations from Amgen and Novartis; Dr. Staffurth, receiving consulting fees from Pierre Fabre Laboratories and Ortho Biotech Oncology Research and Development, receiving travel support from Sanofi-Aventis, and holding stock in Johnson & Johnson; Dr. Harland, receiving consulting fees from Sanofi-Aventis and travel support from Ortho Biotech Oncology Research and Development; Dr. Flaig, receiving consulting fees from Sanofi-Aventis and lecture fees from Amgen; Dr. Sternberg, receiving consulting fees and travel support from Ortho Biotech Oncology Research and Development; Dr. Flechon, receiving travel support from Novartis, Bayer, Pfizer, and Ortho Biotech Oncology Research and Development, serving as a board member for Novartis, Sanofi-Aventis, and Ferring, and receiving payment for the development of educational presentations from Novartis, AstraZeneca, Bayer, and Pfizer; Dr. Efstathiou, receiving consulting fees and travel support from Janssen-Cilag; and Dr. Scher, receiving consulting fees from Aragon, Bristol-Myers Squibb, Exelixis, Foundation Medicine, Genentech, and Medivation, consulting fees and travel support from Amgen, Ortho Biotech Oncology Research and Development, Dendreon, Enzon, Millenium, Novartis, Roche, and Sanofi-Aventis, travel support from AstraZeneca, Bristol-Myers Squibb, Exelixis, Genentech, Medivation, and Veridex, and grant support from Bristol-Myers Squibb, Ortho Biotech Services, Medivation, and Veridex, and holding stock in Eli Lilly, Genta, and Johnson & Johnson. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM. org.	Attard G, 2005, BJU INT, V96, P1241, DOI 10.1111/j.1464-410X.2005.05821.x; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200/JCO.2007.15.9749; Attard G, 2010, J CLIN ONCOL, V28, pE560, DOI 10.1200/JCO.2010.29.5170; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642; Barrie SE, 1997, J STEROID BIOCHEM, V60, P347, DOI 10.1016/S0960-0760(96)00225-7; BENNETT CL, 1994, CANCER INVEST, V12, P336, DOI 10.3109/07357909409023033; Bubley, 2007, J CLIN ONCOL, V25, P1154, DOI 10.1200/JCO.2007.11.1963; Bubley, 2000, J CLIN ONCOL, V18, P2644; Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Costa-Santos M, 2004, J CLIN ENDOCR METAB, V89, P49, DOI 10.1210/jc.2003-031021; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; Danila DC, 2010, J CLIN ONCOL, V28, P1496, DOI 10.1200/JCO.2009.25.9259; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; de Bono JS, 2009, CLIN CANCER RES, V15, P1506; de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078-0432.CCR-08-0872; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; de Bono JS, 2010, ANN ONCOL S8, V21, pLBA5; Esper P, 1997, UROLOGY, V50, P920, DOI 10.1016/S0090-4295(97)00459-7; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Harris K, 2007, CLIN ONCOL-UK, V19, P523, DOI 10.1016/j.clon.2007.04.007; Hellerstedt BA, 2002, CA-CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jarman M, 1998, J MED CHEM, V41, P5375, DOI 10.1021/jm981017j; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Keating NL, 2010, J NATL CANCER I, V102, P39, DOI 10.1093/jnci/djp404; Lam JS, 2006, J UROLOGY, V175, P27, DOI 10.1016/S0022-5347(05)00034-0; Levine GN, 2010, CA-CANCER J CLIN, V60, P194, DOI 10.3322/caac.20061; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Mendoza TR, 1999, CANCER-AM CANCER SOC, V85, P1186, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N; Michaelson MD, 2008, CA-CANCER J CLIN, V58, P196, DOI 10.3322/CA.2008.0002; Michaelson MD, 2004, CLIN CANCER RES, V10, P2705, DOI 10.1158/1078-0432.CCR-03-0735; Miller WL, 2011, ENDOCR REV, V32, P81, DOI 10.1210/er.2010-0013; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Molina A, 2011, J UROLOGY, V185, P787, DOI 10.1016/j.juro.2010.10.042; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Page ST, 2006, J CLIN ENDOCR METAB, V91, P3850, DOI 10.1210/jc.2006-0968; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021/jm00013a022; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200/JCO.2009.24.6819; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525	50	3104	3163	6	229	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					1995	2005		10.1056/NEJMoa1014618	http://dx.doi.org/10.1056/NEJMoa1014618			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	768QR	21612468	Green Accepted, Green Published			2023-01-03	WOS:000290952000004
J	Ferrari, R; Rapezzi, C				Ferrari, Roberto; Rapezzi, Claudio			The Mediterranean diet: a cultural journey	LANCET			English	Editorial Material							ADHERENCE		[Ferrari, Roberto] Univ Ferrara, Dept Cardiol, I-44121 Ferrara, Italy; [Ferrari, Roberto] IRCCS, Salvatore Maugeri Fdn, Lumezzane, Italy; [Rapezzi, Claudio] Univ Bologna, Policlin S Orsola Malpighi, Inst Cardiol, Bologna, Italy	University of Ferrara; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Ferrari, R (corresponding author), Univ Ferrara, Dept Cardiol, I-44121 Ferrara, Italy.	fri@unife.it	FERRARI, ROBERTO/ABD-5169-2020	Ferrari, Roberto/0000-0003-2046-9175; Rapezzi, Claudio/0000-0002-9198-2657				KEYS A, 1970, CIRCULATION, V41, pI1; Sofi F, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1344; Trichopoulou A, 2003, NEW ENGL J MED, V348, P2599, DOI 10.1056/NEJMoa025039; Vernaglione L, 2009, J NEPHROL, V22, pS149	4	13	14	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 21	2011	377	9779					1730	1731		10.1016/S0140-6736(11)60316-4	http://dx.doi.org/10.1016/S0140-6736(11)60316-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	771AS	21397318				2023-01-03	WOS:000291130200010
J	Marconi, VC; Grandits, G; Okulicz, JF; Wortmann, G; Ganesan, A; Crum-Cianflone, N; Polis, M; Landrum, M; Dolan, MJ; Ahuja, SK; Agan, B; Kulkarni, H				Marconi, Vincent C.; Grandits, Greg; Okulicz, Jason F.; Wortmann, Glenn; Ganesan, Anuradha; Crum-Cianflone, Nancy; Polis, Michael; Landrum, Michael; Dolan, Matthew J.; Ahuja, Sunil K.; Agan, Brian; Kulkarni, Hemant		Infect Dis Clinical Res Program	Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS	PLOS ONE			English	Article							PROTEASE INHIBITOR THERAPY; TERM-FOLLOW-UP; HIV-1-INFECTED PATIENTS; CELL COUNT; RNA LEVEL; INTERMITTENT VIREMIA; DISEASE PROGRESSION; CLINICAL-OUTCOMES; LYMPHOCYTE COUNTS; PREDICTIVE VALUE	Background: The impact of viral load (VL) decay and cumulative VL on CD4 recovery and AIDS after highly-active antiretroviral therapy (HAART) is unknown. Methods and Findings: Three virologic kinetic parameters (first year and overall exponential VL decay constants, and first year VL slope) and cumulative VL during HAART were estimated for 2,278 patients who initiated HAART in the U. S. Military HIV Natural History Study. CD4 and VL trajectories were computed using linear and nonlinear Generalized Estimating Equations models. Multivariate Poisson and linear regression models were used to determine associations of VL parameters with CD4 recovery, adjusted for factors known to correlate with immune recovery. Cumulative VL higher than the sample median was independently associated with an increased risk of AIDS (relative risk 2.38, 95% confidence interval 1.56-3.62, p < 0.001). Among patients with VL suppression, first year VL decay and slope were independent predictors of early CD4 recovery (p = 0.001) and overall gain (p < 0.05). Despite VL suppression, those with slow decay during the first year of HAART as well as during the entire therapy period (overall), in general, gained less CD4 cells compared to the other subjects (133 vs. 195.4 cells/mu L; p = 0.001) even after adjusting for potential confounders. Conclusions: In a cohort with free access to healthcare, independent of established predictors of AIDS and CD4 recovery during HAART, cumulative VL and virologic decay patterns were associated with AIDS and distinct aspects of CD4 reconstitution.	[Marconi, Vincent C.] Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA; [Marconi, Vincent C.; Grandits, Greg; Okulicz, Jason F.; Wortmann, Glenn; Ganesan, Anuradha; Crum-Cianflone, Nancy; Polis, Michael; Landrum, Michael; Agan, Brian] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA; [Grandits, Greg] Univ Minnesota, Div Biostat, Minneapolis, MN USA; [Okulicz, Jason F.; Landrum, Michael] Brooke Army Med Ctr, San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA; [Wortmann, Glenn] Walter Reed Army Med Ctr, Infect Dis Serv, Washington, DC 20307 USA; [Ganesan, Anuradha] Natl Naval Med Ctr, Infect Dis Clin, Bethesda, MD USA; [Crum-Cianflone, Nancy] USN, Infect Dis Clin, San Diego Med Ctr, San Diego, CA 92152 USA; [Polis, Michael] NIAID, NIH, Bethesda, MD 20892 USA; [Dolan, Matthew J.] Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Lackland AFB, TX 78236 USA; [Ahuja, Sunil K.; Kulkarni, Hemant] S Texas Vet Hlth Care Syst, Vet Adm Res Ctr AIDS & HIV 1 Infect, San Antonio, TX USA; [Ahuja, Sunil K.; Kulkarni, Hemant] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA; [Ahuja, Sunil K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Microbiol & Immunol, San Antonio, TX 78229 USA	Emory University; Uniformed Services University of the Health Sciences - USA; University of Minnesota System; University of Minnesota Twin Cities; San Antonio Military Medical Center; United States Department of Defense; United States Army; United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Walter Reed National Military Medical Center; United States Department of Defense; United States Navy; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); United States Department of Defense; United States Air Force; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Marconi, VC (corresponding author), Emory Univ, Sch Med, Div Infect Dis, Atlanta, GA 30322 USA.	vcmarco@emory.edu; kulkarnih@uthscsa.edu	Marconi, Vincent/GRJ-4553-2022; Marconi, Vincent/N-3210-2014; Marconi, Vincent/AFK-5812-2022; Kulkarni, Hemant/AEM-5750-2022	Marconi, Vincent/0000-0001-8409-4689; Marconi, Vincent/0000-0001-8409-4689; Agan, Brian/0000-0002-5114-1669; Polis, Michael/0000-0002-9151-2268	Infectious Disease Clinical Research Program [IDCRP-000-03]; Department of Defense through the Uniformed Services University of the Health Sciences; National Institute of Allergy and Infectious Diseases, National Institutes of Health [Y1-AI-5072]; Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System; NIH [R37046326]; VA; Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award; Doris Duke Distinguished Clinical Scientist Award; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI046326, N01AI005072] Funding Source: NIH RePORTER	Infectious Disease Clinical Research Program; Department of Defense through the Uniformed Services University of the Health Sciences; National Institute of Allergy and Infectious Diseases, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA(US Department of Veterans Affairs); Elizabeth Glaser Scientist Award; Burroughs Wellcome Clinical Scientist Award(Burroughs Wellcome Fund); Doris Duke Distinguished Clinical Scientist Award(Doris Duke Charitable Foundation (DDCF)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support for this work (IDCRP-000-03) was provided by the Infectious Disease Clinical Research Program, a Department of Defense program executed through the Uniformed Services University of the Health Sciences. This project has been funded in whole, or in part, with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under Inter-Agency Agreement Y1-AI-5072. This work was also supported by the Veterans Administration Center on AIDS and HIV infection of the South Texas Veterans Health Care System, and a MERIT (R37046326) award from the NIH to SKA. SKA is also supported by a VA MERIT award and is a recipient of the Elizabeth Glaser Scientist Award, the Burroughs Wellcome Clinical Scientist Award in Translational Research, and the Doris Duke Distinguished Clinical Scientist Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahuja SK, 2008, NAT MED, V14, P413, DOI 10.1038/nm1741; Anastos K, 2004, ANN INTERN MED, V140, P256, DOI 10.7326/0003-4819-140-4-200402170-00007; Anastos K, 2002, ARCH INTERN MED, V162, P1973, DOI 10.1001/archinte.162.17.1973; [Anonymous], 1993, JAMA, V269, P729; [Anonymous], [No title captured]; Babiker A, 2000, AIDS RES HUM RETROV, V16, P1123; Barbour JD, 2002, J VIROL, V76, P11104, DOI 10.1128/JVI.76.21.11104-11112.2002; Breban R, 2006, LANCET, V367, P1285, DOI 10.1016/S0140-6736(06)68543-7; Bruyand M, 2009, CLIN INFECT DIS, V49, P1109, DOI 10.1086/605594; Casado JL, 1998, AIDS, V12, pF131, DOI 10.1097/00002030-199811000-00005; Choi AI, 2009, AIDS, V23, P2143, DOI 10.1097/QAD.0b013e3283313c91; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Cole SR, 2010, AM J EPIDEMIOL, V171, P198, DOI 10.1093/aje/kwp347; Demeter LM, 2001, ANN INTERN MED, V135, P954, DOI 10.7326/0003-4819-135-11-200112040-00007; Easterbrook PJ, 2002, AIDS, V16, P1521, DOI 10.1097/00002030-200207260-00009; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283, DOI 10.1056/NEJMoa062360; Gazzola L, 2009, CLIN INFECT DIS, V48, P328, DOI 10.1086/595851; Ghani AC, 2002, J ACQ IMMUN DEF SYND, V30, P167, DOI 10.1097/00042560-200206010-00005; Ghani AC, 2001, J ACQ IMMUN DEF SYND, V28, P226, DOI 10.1097/00042560-200111010-00004; Gilson R, 2010, HIV MED, V11, P152, DOI 10.1111/j.1468-1293.2009.00755.x; Giorgi JV, 2002, J ACQ IMMUN DEF SYND, V29, P346, DOI 10.1097/00126334-200204010-00004; Guiguet M, 2009, LANCET ONCOL, V10, P1152, DOI 10.1016/S1470-2045(09)70282-7; Gutierrez F, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000089; Havlir DV, 2001, JAMA-J AM MED ASSOC, V286, P171, DOI 10.1001/jama.286.2.171; Hermankova M, 2001, JAMA-J AM MED ASSOC, V286, P196, DOI 10.1001/jama.286.2.196; Hulgan T, 2007, J INFECT DIS, V195, P425, DOI 10.1086/510536; Jacobson LP, 2002, AM J EPIDEMIOL, V155, P760, DOI 10.1093/aje/155.8.760; Journot V, 2001, CONTROL CLIN TRIALS, V22, P639, DOI 10.1016/S0197-2456(01)00158-1; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Kim S, 2000, AIDS RES HUM RETROV, V16, P645, DOI 10.1089/088922200308873; Kitchen CM, 2001, CLIN INFECT DIS, V33, P466, DOI 10.1086/321900; Kousignian I, 2003, JAIDS-J ACQ IMM DEF, V34, P50, DOI 10.1097/00126334-200309010-00007; Kravcik S, 2001, HIV Clin Trials, V2, P160, DOI 10.1310/F45L-FDKK-Y48N-N2BT; Kuritzkes DR, 2007, J INFECT DIS, V195, P1169, DOI 10.1086/512619; Kuritzkes DR, 2000, J INFECT DIS, V181, P491, DOI 10.1086/315244; Le Moing V, 2002, J INFECT DIS, V185, P471, DOI 10.1086/338929; Lewden C, 2002, J INFECT DIS, V186, P710, DOI 10.1086/342047; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; Lundgren JD, 2002, J INFECT DIS, V185, P178, DOI 10.1086/338267; Maggiolo F, 2000, J ACQ IMMUN DEF SYND, V25, P36, DOI 10.1097/00126334-200009010-00005; Marconi VC, 2010, AIDS RES THER, V7, DOI 10.1186/1742-6405-7-14; Marschner IC, 1998, J INFECT DIS, V177, P40, DOI 10.1086/513823; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; Nettles RE, 2005, JAMA-J AM MED ASSOC, V293, P817, DOI 10.1001/jama.293.7.817; Notermans DW, 1998, AIDS, V12, P1483, DOI 10.1097/00002030-199812000-00010; PHILLIPS AN, 1994, BRIT MED J, V309, P309, DOI 10.1136/bmj.309.6950.309; Polis MA, 2001, LANCET, V358, P1760, DOI 10.1016/S0140-6736(01)06802-7; Rong LB, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000533; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Sprout M, 2005, ANTIVIR THER, V10, P357; Tan RM, 2008, JAIDS-J ACQ IMM DEF, V47, P553, DOI 10.1097/QAI.0b013e31816856c5; Tomasoni LR, 2003, HIV CLIN TRIALS, V4, P311, DOI 10.1310/FGMF-Y0LY-DMX8-371V; Torti C, 2004, VIRAL IMMUNOL, V17, P279, DOI 10.1089/0882824041310630; Vlahov D, 1998, JAMA-J AM MED ASSOC, V279, P35, DOI 10.1001/jama.279.1.35; Vo TTN, 2008, J INFECT DIS, V197, P1685, DOI 10.1086/588141; Weintrob AC, 2008, JAIDS-J ACQ IMM DEF, V49, P40, DOI 10.1097/QAI.0b013e31817bec05; Weintrob AC, 2009, JAIDS-J ACQ IMM DEF, V52, P574, DOI 10.1097/QAI.0b013e3181b98537; Weverling GJ, 1998, AIDS, V12, pF117, DOI 10.1097/00002030-199811000-00003; Wu HL, 2005, JAIDS-J ACQ IMM DEF, V39, P272, DOI 10.1097/01.qai.0000165907.04710.da; Wu HL, 1999, J INFECT DIS, V179, P799, DOI 10.1086/314670; Zoufaly A, 2009, J INFECT DIS, V200, P79, DOI 10.1086/599313	63	36	36	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 20	2011	6	5							e17956	10.1371/journal.pone.0017956	http://dx.doi.org/10.1371/journal.pone.0017956			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766OI	21625477	Green Published, Green Submitted, gold			2023-01-03	WOS:000290793400001
J	Beatty, GL; Chiorean, EG; Fishman, MP; Saboury, B; Teitelbaum, UR; Sun, WJ; Huhn, RD; Song, WR; Li, DG; Sharp, LL; Torigian, DA; O'Dwyer, PJ; Vonderheide, RH				Beatty, Gregory L.; Chiorean, Elena G.; Fishman, Matthew P.; Saboury, Babak; Teitelbaum, Ursina R.; Sun, Weijing; Huhn, Richard D.; Song, Wenru; Li, Dongguang; Sharp, Leslie L.; Torigian, Drew A.; O'Dwyer, Peter J.; Vonderheide, Robert H.			CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans	SCIENCE			English	Article							T-CELL HELP; CANCER; CHEMOTHERAPY; IMMUNOTHERAPY; ACTIVATION; TOLERANCE; ANTIBODY; THERAPY; VACCINE; TRIAL	Immunosuppressive tumor microenvironments can restrain antitumor immunity, particularly in pancreatic ductal adenocarcinoma (PDA). Because CD40 activation can reverse immune suppression and drive antitumor T cell responses, we tested the combination of an agonist CD40 antibody with gemcitabine chemotherapy in a small cohort of patients with surgically incurable PDA and observed tumor regressions in some patients. We reproduced this treatment effect in a genetically engineered mouse model of PDA and found unexpectedly that tumor regression required macrophages but not T cells or gemcitabine. CD40-activated macrophages rapidly infiltrated tumors, became tumoricidal, and facilitated the depletion of tumor stroma. Thus, cancer immune surveillance does not necessarily depend on therapy-induced T cells; rather, our findings demonstrate a CD40-dependent mechanism for targeting tumor stroma in the treatment of cancer.	[Beatty, Gregory L.; Fishman, Matthew P.; Vonderheide, Robert H.] Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Beatty, Gregory L.; Teitelbaum, Ursina R.; Sun, Weijing; Torigian, Drew A.; O'Dwyer, Peter J.; Vonderheide, Robert H.] Univ Penn, Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Chiorean, Elena G.] Indiana Univ Sch Med, Dept Med, Div Hematol Oncol, Indianapolis, IN 46202 USA; [Huhn, Richard D.; Song, Wenru; Li, Dongguang; Sharp, Leslie L.] Pfizer Corp, New London, CT 06320 USA; [Saboury, Babak; Torigian, Drew A.] Univ Penn, Dept Med, Dept Radiol, Sch Med, Philadelphia, PA 19104 USA; [Beatty, Gregory L.; Teitelbaum, Ursina R.; Sun, Weijing; O'Dwyer, Peter J.; Vonderheide, Robert H.] Univ Penn, Dept Med, Div Hematol Oncol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Indiana University System; Indiana University Bloomington; Pfizer; University of Pennsylvania; University of Pennsylvania	Vonderheide, RH (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 421 Curie Blvd, Philadelphia, PA 19104 USA.	rhv@exchange.upenn.edu	Saboury, Babak/F-7453-2011; Saboury, Babak/F-1769-2018	Saboury, Babak/0000-0002-8632-6292; Beatty, Gregory/0000-0001-7165-5993	Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; NIH [P30 CA016520, K12 CA076931]; Pfizer Corp; NATIONAL CANCER INSTITUTE [K12CA076931, P30CA016520, K08CA138907] Funding Source: NIH RePORTER	Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pfizer Corp; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C. Abrams, E. Furth, C. June, B. Keith, G. Koretzky, C. Simon, and B. Stanger for helpful discussions. This research was supported by the Abramson Family Cancer Research Institute of the University of Pennsylvania School of Medicine (R. H. V.) and by NIH grants P30 CA016520 (P.J.O. and R. H. V.) and K12 CA076931 (G. L. B.). The clinical study and part of the preclinical studies were supported by funding from Pfizer Corp (to R. H. V. and P.J.D). W. Song, D. Li, and L. L. Sharp are employees of Pfizer Corp. P. J. O'Dwyer discloses receiving honoraria from Pfizer; D. A. Torigian owns stock in Pfizer. CP-870,893 is owned and patented by Pfizer Corp., which manages its distribution. Although now at a new address, R. D. Huhn was affiliated with Pfizer Corp. during the conduct and analysis of this study. Some of the clinical data were presented at the 2010 American Society of Clinical Oncology Annual Meeting.	Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Diehl L, 1999, NAT MED, V5, P774, DOI 10.1038/10495; French RR, 1999, NAT MED, V5, P548, DOI 10.1038/8426; Gabrilovich DI, 2007, LANCET ONCOL, V8, P2, DOI 10.1016/S1470-2045(06)70985-8; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Jaffee EM, 2001, J CLIN ONCOL, V19, P145, DOI 10.1200/JCO.2001.19.1.145; Lake RA, 2005, NAT REV CANCER, V5, P397, DOI 10.1038/nrc1613; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Nowak AK, 2003, CANCER RES, V63, P4490; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Sotomayor EM, 1999, NAT MED, V5, P780, DOI 10.1038/10503; Van Dyke T, 2010, NAT MED, V16, P976, DOI 10.1038/nm0910-976; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Vonderheide RH, 2007, J CLIN ONCOL, V25, P876, DOI 10.1200/JCO.2006.08.3311; Vonderheide RH, 2007, CLIN CANCER RES, V13, P1083, DOI 10.1158/1078-0432.CCR-06-1893; Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180	22	1119	1164	9	199	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 25	2011	331	6024					1612	1616		10.1126/science.1198443	http://dx.doi.org/10.1126/science.1198443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	739XH	21436454	Green Accepted			2023-01-03	WOS:000288754500058
J	Andrews, PJD; Avenell, A; Noble, DW; Campbell, MK; Croal, BL; Simpson, WG; Vale, LD; Battison, CG; Jenkinson, DJ; Cook, JA				Andrews, Peter J. D.; Avenell, Alison; Noble, David W.; Campbell, Marion K.; Croal, Bernard L.; Simpson, William G.; Vale, Luke D.; Battison, Claire G.; Jenkinson, David J.; Cook, Jonathan A.		SIGNET Scottish Intensive Care	Randomised trial of glutamine, selenium, or both, to supplement parenteral nutrition for critically ill patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ENTERAL NUTRITION; FACTORIAL TRIALS; QUALITY	Objective To determine whether inclusion of glutamine, selenium, or both in a standard isonitrogenous, isocaloric preparation of parenteral nutrition influenced new infections and mortality among critically ill patients. Design Randomised, double blinded, factorial, controlled trial. Setting Level 2 and 3 (or combined) critical care units in Scotland. All 22 units were invited, and 10 participated. Participants 502 adults in intensive care units and high dependency units for >= 48 hours, with gastrointestinal failure and requiring parenteral nutrition. Interventions Parenteral glutamine (20.2 g/day) or selenium (500 mu g/day), or both, for up to seven days. Main outcome measures Primary outcomes were participants with new infections in the first 14 days and mortality. An intention to treat analysis and a prespecified analysis of patients who received >= 5 days of the trial intervention are presented. Secondary outcomes included critical care unit and acute hospital lengths of stay, days of antibiotic use, and modified SOFA (Sepsis-related Organ Failure Assessment) score. Results Selenium supplementation did not significantly affect patients developing a new infection (126/251 v 139/251, odds ratio 0.81 (95% CI 0.57 to 1.15)), except for those who had received >= 5 days of supplementation (odds ratio 0.53 (0.30 to 0.93)). There was no overall effect of glutamine on new infections (134/250 v 131/252, odds ratio 1.07 (0.75 to 1.53)), even if patients received >= 5 days of supplementation (odds ratio 0.99 (0.56 to 1.75)). Six month mortality was not significantly different for selenium (107/251 v 114/251, odds ratio 0.89 (0.62 to 1.29)) or glutamine (115/250 v 106/252, 1.18 (0.82 to 1.70)). Length of stay, days of antibiotic use, and modified SOFA score were not significantly affected by selenium or glutamine supplementation. Conclusions The primary (intention to treat) analysis showed no effect on new infections or on mortality when parenteral nutrition was supplemented with glutamine or selenium. Patients who received parenteral nutrition supplemented with selenium for >= 5 days did show a reduction in new infections. This finding requires confirmation.	[Andrews, Peter J. D.; Battison, Claire G.] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH4 2XU, Midlothian, Scotland; [Andrews, Peter J. D.] Lothian Univ, Western Gen Hosp, Hosp Div, Edinburgh EH4 2XU3, Midlothian, Scotland; [Avenell, Alison; Campbell, Marion K.; Vale, Luke D.; Jenkinson, David J.; Cook, Jonathan A.] Univ Aberdeen, Hlth Serv Res Unit, Aberdeen AB25 2ZD, Scotland; [Noble, David W.] Aberdeen Royal Infirm, Dept Anaesthet & Intens Care, Aberdeen AB25 2ZN, Scotland; [Croal, Bernard L.; Simpson, William G.] Aberdeen Royal Infirm, Dept Clin Biochem, Aberdeen AB25 2ZN, Scotland; [Vale, Luke D.] Univ Aberdeen, Hlth Econ Res Unit, Aberdeen AB25 2ZD, Scotland	University of Edinburgh; University of Edinburgh; University of Aberdeen; University of Aberdeen; University of Aberdeen; University of Aberdeen	Andrews, PJD (corresponding author), Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh EH4 2XU, Midlothian, Scotland.	p.andrews@ed.ac.uk	Cook, Jonathan/A-3474-2012; Cook, Jonathan/D-3648-2015; Campbell, Marion/ABB-7063-2020	Cook, Jonathan/0000-0002-4156-6989; Battison, Claire/0000-0001-9549-4522; Murray, Gordon/0000-0001-9866-4734; Campbell, Marion/0000-0001-5386-4097; Vale, Luke/0000-0001-8574-8429	Chief Scientist Office of the Scottish Government Health Directorates; Medical Research Council; Fresenius-Kabi and Oxford Nutrition; Medical Research Council [G0601938, G0401633] Funding Source: researchfish; Chief Scientist Office [HSRU1] Funding Source: researchfish; MRC [G0601938, G0401633] Funding Source: UKRI	Chief Scientist Office of the Scottish Government Health Directorates; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Fresenius-Kabi and Oxford Nutrition; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); Chief Scientist Office; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	A pilot trial was funded by the Chief Scientist Office of the Scottish Government Health Directorates, followed by funding from the Medical Research Council for the full trial. Funding was also provided by Fresenius-Kabi and Oxford Nutrition as unrestricted grants for the trial nutrition components. Health Services Research Unit is funded by the Chief Scientist Office of the Scottish Government Health Directorates. JC holds a MRC fellowship. AA was funded by a career scientist award of the Chief Scientist Office of the Scottish Government Health Directorates. The trial was managed in accordance with MRC guidelines and independent of industry. The trial was conducted under the auspices of independent trial steering and data monitoring committees. The views expressed are those of the authors alone.	Allan R, 2007, CLIN MED, V7, P429, DOI 10.7861/clinmedicine.7-5-429; Altman DG, 2000, STAT MED, V19, P3275, DOI 10.1002/1097-0258(20001215)19:23<3275::AID-SIM626>3.3.CO;2-D; Andrews PJD, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-25; ASPEN Board of Directors and the Clinical Guidelines Task Force, 2002, JPEN S1, V26, P1; Avenell A, 2004, COCHRANE DB SYST REV, V4; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Doig GS, 2005, ANESTH ANALG, V100, P527, DOI 10.1213/01.ANE.0000141676.12552.D0; Doig GS, 2010, INTENS CARE MED, V36, P1087; Forceville X, 1998, CRIT CARE MED, V26, P1536, DOI 10.1097/00003246-199809000-00021; Hennekens CH, 2009, JAMA-J AM MED ASSOC, V302, P2361, DOI 10.1001/jama.2009.1756; Heyland DK, 2007, CRIT CARE, V11, DOI 10.1186/cc5975; Heyland DK, 2007, JPEN-PARENTER ENTER, V31, P109, DOI 10.1177/0148607107031002109; Heyland DK, 2005, INTENS CARE MED, V31, P327, DOI 10.1007/s00134-004-2522-z; Kochevar M, 2007, JPEN-PARENTER ENTER, V31, P441, DOI 10.1177/0148607107031005441; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; LUBSEN J, 1994, EUR HEART J, V15, P585, DOI 10.1093/oxfordjournals.eurheartj.a060552; McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545; Mead GE, 1998, INT J CLIN PRACT, V52, P316; Sheiner LB, 2002, BRIT J CLIN PHARMACO, V54, P203, DOI 10.1046/j.1365-2125.2002.01628.x; Simpson F, 2005, INTENS CARE MED, V31, P12, DOI 10.1007/s00134-004-2511-2; Singer P, 2009, CLIN NUTR, V28, P387, DOI 10.1016/j.clnu.2009.04.024; Treasure T, 1998, BRIT MED J, V317, P362; Ziegler TR, 2009, NEW ENGL J MED, V361, P1088, DOI 10.1056/NEJMct0806956	23	213	225	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 17	2011	342								d1542	10.1136/bmj.d1542	http://dx.doi.org/10.1136/bmj.d1542			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	739FQ	21415104	Green Submitted, hybrid			2023-01-03	WOS:000288700200002
J	Casarett, DJ				Casarett, David J.			Rethinking Hospice Eligibility Criteria	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PALLIATIVE CARE; CANCER		[Casarett, David J.] Univ Penn, Sch Med, Ctr Bioeth, Philadelphia, PA 19104 USA; [Casarett, David J.] Univ Penn, Sch Med, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Casarett, DJ (corresponding author), Univ Penn, Sch Med, Ctr Bioeth, 3615 Chestnut St, Philadelphia, PA 19104 USA.	casarett@mail.med.upenn.edu						Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Casarett DJ, 2009, J CLIN ONCOL, V27, P953, DOI 10.1200/JCO.2008.17.8079; Fishman J, 2009, CANCER-AM CANCER SOC, V115, P689, DOI 10.1002/cncr.24046; Johnson KS, 2008, ARCH INTERN MED, V168, P218, DOI 10.1001/archinternmed.2007.36; National Hospice and Palliative Care Organization Facts and Figures, 2010, HOSP CAR AM; Rickerson E, 2005, J AM GERIATR SOC, V53, P819, DOI 10.1111/j.1532-5415.2005.53259.x; Schockett ER, 2005, J PAIN SYMPTOM MANAG, V30, P400, DOI 10.1016/j.jpainsymman.2005.04.013; Taylor DH, 2007, SOC SCI MED, V65, P1466, DOI 10.1016/j.socscimed.2007.05.028; Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678	9	28	28	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	2011	305	10					1031	1032		10.1001/jama.2011.271	http://dx.doi.org/10.1001/jama.2011.271			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	731SM	21386081				2023-01-03	WOS:000288129600024
J	Evans-Brown, M; Bellis, MA; McVeigh, J				Evans-Brown, Michael; Bellis, Mark A.; McVeigh, Jim			Should "legal highs" be regulated as medicinal products?	BRITISH MEDICAL JOURNAL			English	Editorial Material							UK					m.j.evans-brown@ljmu.ac.uk	Bellis, Mark A./HGA-2019-2022; McVeigh, Jim/O-7851-2019	Evans-Brown, Michael/0000-0002-2695-5740; McVeigh, Jim/0000-0001-5319-6885				Ben-Yehudah Nahman., 2009, SOCIAL CONSTRUCTION; BIRCH R, 2010, NEW LAW J, V160; BIRCH R, 2009, NEW LAW J, V159; Brandt SD, 2010, DRUG TEST ANAL, V2, P377, DOI 10.1002/dta.155; Csizmadi I, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P791; *EUR UN, 2004, OFFICIAL J EUROPEAN, V47, P34; European Monitoring Centre for Drugs and Drug Addiction, 2009, UND SPIC PHEN, DOI [10.2810/27063, DOI 10.2810/27063]; European Monitoring Centre for Drugs and Drug Addiction, 2010, RISK ASS REP NEW PSY; European Parliament, 2001, OFF J EUR COMMUNITIE, V311, P67; Gunningham N., 2010, OXFORD HDB REGULATIO, P120; *HOUS COMM, 2010, HOUS COMM OFF REP HA, pC149; *HOUS LORD, 1984, HOUS LORDS OFF REP H; House of Commons Science and Technology Committee, 2006, DRUG CLASS MAK HASH; *MED HEALTHC PROD, 2007, 8 MHRA; MONAGHAN M, 2010, EVIDENCE VERSUS POLI; Nutt DJ, 2010, LANCET, V376, P1558, DOI 10.1016/S0140-6736(10)61462-6; STEPHENS M, 2004, STEPHENS DETECTION N, P63; Tyler T. R., 2006, CONTEMP SOCIOL, DOI [10.1515/9781400828609, DOI 10.2307/2076193]	18	5	5	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 23	2011	342								d1101	10.1136/bmj.d1101	http://dx.doi.org/10.1136/bmj.d1101			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	729AZ	21345907				2023-01-03	WOS:000287920100020
J	Kelley, AS; Ettner, SL; Morrison, RS; Du, QL; Wenger, NS; Sarkisian, CA				Kelley, Amy S.; Ettner, Susan L.; Morrison, R. Sean; Du, Qingling; Wenger, Neil S.; Sarkisian, Catherine A.			Determinants of Medical Expenditures in the Last 6 Months of Life	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-CARE; REGIONAL-VARIATIONS; PATIENT PREFERENCES; TREATMENT INTENSITY; END; DISABILITY; CANCER; DEATH; AGE; HOSPITALIZATION	Background: End-of-life medical expenditures exceed costs of care during other years, vary across regions, and are likely to be unsustainable. Identifying determinants of expenditure variation may reveal opportunities for reducing costs. Objective: To identify patient-level determinants of Medicare expenditures at the end of life and to determine the contributions of these factors to expenditure variation while accounting for regional characteristics. It was hypothesized that race or ethnicity, social support, and functional status are independently associated with treatment intensity and controlling for regional characteristics, and that individual characteristics account for a substantial proportion of expenditure variation. Design: Using data from the Health and Retirement Study, Medicare claims, and The Dartmouth Atlas of Health Care, relationships were modeled between expenditures and patient and regional characteristics. Setting: United States, 2000 to 2006. Participants: 2394 Health and Retirement Study decedents aged 65.5 years or older. Measurements: Medicare expenditures in the last 6 months of life were estimated in a series of 2-level multivariable regression models that included patient, regional, and patient and regional characteristics. Results: Decline in function (rate ratio [RR], 1.64 [95% CI, 1.46 to 1.83]); Hispanic ethnicity (RR, 1.50 [CI, 1.22 to 1.85]); black race (RR, 1.43 [CI, 1.25 to 1.64]); and certain chronic diseases, including diabetes (RR, 1.16 [CI, 1.06 to 1.27]), were associated with higher expenditures. Nearby family (RR, 0.90 [CI, 0.82 to 0.98]) and dementia (RR, 0.78 CI, 0.71 to 0.87]) were associated with lower expenditures, and advance care planning had no association. Regional characteristics, including end-of-life practice patterns (RR, 1.09 [CI, 1.06 to 1.14]) and hospital beds per capita (RR, 1.01 [CI, 1.00 to 1.02]), were associated with higher expenditures. Patient characteristics explained 10% of overall variance and retained statistically significant relationships with expenditures after regional characteristics were controlled for. Limitation: The study limitations include the decedent sample, proxy informants, and a large proportion of unexplained variation. Conclusion: Patient characteristics, such as functional decline, race or ethnicity, chronic disease, and nearby family, are important determinants of expenditures at the end of life, independent of regional characteristics.	[Kelley, Amy S.] Mt Sinai Sch Med, Dept Geriatr & Palliat Med, New York, NY 10029 USA; Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; James J Peters Vet Affairs Med Ctr, Bronx, NY USA; Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ Clin Ctr, Los Angeles, CA USA	Icahn School of Medicine at Mount Sinai; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); James J. Peters VA Medical Center; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Kelley, AS (corresponding author), Mt Sinai Sch Med, Dept Geriatr & Palliat Med, 1 Gustave L Levy Pl,Box 1070, New York, NY 10029 USA.	amy.kelley@mssm.edu			Brookdale Foundation; National Institute on Aging [K24 AG022345]; National Palliative Care Research Center; Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research Education Clinical Center; NATIONAL INSTITUTE ON AGING [K24AG022345] Funding Source: NIH RePORTER	Brookdale Foundation; National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Palliative Care Research Center; Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research Education Clinical Center; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Grant Support: By the Brookdale Foundation. Dr. Kelley is a Brookdale Leadership in Aging Fellow. Dr. Morrison is the recipient of a MidCareer Investigator Award in Patient-Oriented Research (K24 AG022345) from the National Institute on Aging and is supported by the National Palliative Care Research Center. Dr. Sarkisian is supported by the Veterans Affairs Greater Los Angeles Healthcare System Geriatric Research Education Clinical Center.	[Anonymous], HLTH RETIREMENT STUD; Baicker K, 2004, HEALTH AFFAIR, V23, pW4184, DOI 10.1377/hlthaff.W4.184; Barnato AE, 2007, MED CARE, V45, P386, DOI 10.1097/01.mlr.0000255248.79308.41; Barnato AE, 2007, J GEN INTERN MED, V22, P338, DOI 10.1007/s11606-006-0088-x; Bhandari A, 2006, MED CARE RES REV, V63, P217, DOI 10.1177/1077558705285298; Bird Chloe E, 2002, J Palliat Med, V5, P705, DOI 10.1089/109662102320880525; Boyd CM, 2005, AM J MED, V118, P1225, DOI 10.1016/j.amjmed.2005.01.062; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Buccaneer Computer Systems and Services, 2009, CHRON COND DAT WAR U; Cortese D, 2007, HEALTH AFFAIR, V26, pW68, DOI 10.1377/hlthaff.26.1.w68; Covinsky KE, 2003, J AM GERIATR SOC, V51, P451, DOI 10.1046/j.1532-5415.2003.51152.x; Earle CC, 2004, J CLIN ONCOL, V22, P315, DOI 10.1200/JCO.2004.08.136; Emanuel EJ, 2003, ANN INTERN MED, V138, P639, DOI 10.7326/0003-4819-138-8-200304150-00011; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; Fisher LS, 2000, HEALTH SERV RES, V34, P1351; Fried LP, 2004, J GERONTOL A-BIOL, V59, P255; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Gill TM, 2004, JAMA-J AM MED ASSOC, V292, P2115, DOI 10.1001/jama.292.17.2115; Hanchate A, 2009, ARCH INTERN MED, V169, P493, DOI 10.1001/archinternmed.2008.616; Hogan C, 2001, HEALTH AFFAIR, V20, P188, DOI 10.1377/hlthaff.20.4.188; Hoover DR, 2002, HEALTH SERV RES, V37, P1625, DOI 10.1111/1475-6773.01113; Kelley AS, 2010, J PALLIAT MED, V13, P807, DOI 10.1089/jpm.2010.0007; Kelley AS, 2010, J AM GERIATR SOC, V58, P1109, DOI 10.1111/j.1532-5415.2010.02853.x; Levinsky NG, 2001, JAMA-J AM MED ASSOC, V286, P1349, DOI 10.1001/jama.286.11.1349; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Phelps AC, 2009, JAMA-J AM MED ASSOC, V301, P1140, DOI 10.1001/jama.2009.341; Pritchard RS, 1998, J AM GERIATR SOC, V46, P1242, DOI 10.1111/j.1532-5415.1998.tb04540.x; Raudenbush S. W., 2002, HIERARCHICAL LINEAR; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; Schafer JL, 1999, STAT METHODS MED RES, V8, P3, DOI 10.1191/096228099671525676; Shortell SM, 2008, JAMA-J AM MED ASSOC, V300, P95, DOI 10.1001/jama.300.1.95; Shugarman LR, 2007, J WOMENS HEALTH, V16, P214, DOI 10.1089/jwh.2006.0012; Shugarman LR, 2004, J GEN INTERN MED, V19, P127, DOI 10.1111/j.1525-1497.2004.30223.x; Skinner J, 2010, NEW ENGL J MED, V362, P569, DOI 10.1056/NEJMp1000448; Skinner J, 2009, HEALTH AFFAIR, V28, pW119, DOI 10.1377/hlthaff.28.1.w119; Song YJ, 2010, NEW ENGL J MED, V363, P45, DOI 10.1056/NEJMsa0910881; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Virnig B A, 1999, J Palliat Med, V2, P23, DOI 10.1089/jpm.1999.2.23; Virnig BA, 2000, J AM GERIATR SOC, V48, P1117, DOI 10.1111/j.1532-5415.2000.tb04789.x; Welch LC, 2005, J AM GERIATR SOC, V53, P1145, DOI 10.1111/j.1532-5415.2005.53357.x; Wenger NS, 2000, J AM GERIATR SOC, V48, pS44, DOI 10.1111/j.1532-5415.2000.tb03140.x; Wennberg JE., DARTMOUTH ATLAS HLTH; Wennberg JE, 2009, HEALTH AFFAIR, V28, P103, DOI 10.1377/hlthaff.28.1.103; Werner RM, 2007, J GEN INTERN MED, V22, P1206, DOI 10.1007/s11606-007-0230-4; Wolff JL, 2002, ARCH INTERN MED, V162, P2269, DOI 10.1001/archinte.162.20.2269; Yasaitis L, 2009, HEALTH AFFAIR, V28, pW566, DOI 10.1377/hlthaff.28.4.w566; Zuckerman S, 2010, NEW ENGL J MED, V363, P54, DOI 10.1056/NEJMsa0909253	49	124	124	1	38	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	2011	154	4					235	W78		10.7326/0003-4819-154-4-201102150-00004	http://dx.doi.org/10.7326/0003-4819-154-4-201102150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	720VF	21320939	Green Accepted			2023-01-03	WOS:000287310000015
J	Lipitz-Snyderman, A; Steinwachs, D; Needham, D; Colantuoni, E; Morlock, LL; Pronovos, PJ				Lipitz-Snyderman, Allison; Steinwachs, Donald; Needham, Dale M.; Colantuoni, Elizabeth; Morlock, Laura L; Pronovos, Peter J			Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis	BRITISH MEDICAL JOURNAL			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; BLOOD-STREAM INFECTIONS; CRITICALLY-ILL PATIENTS; ADVERSE EVENTS; PREVENTION; INTERVENTION; COST	Objective To evaluate whether implementation of the Michigan Keystone ICU project, a comprehensive statewide quality improvement initiative focused on reduction of infections, was associated with reductions in hospital mortality and length of stay for adults aged 65 or more admitted to intensive care units. Design Retrospective comparative study, using data from Medicare claims. Setting Michigan and Midwest region, United States. Population The study period (October 2001 to December 2006) spanned two years before the project was initiated to 22 months after its implementation. The study sample included hospital admissions for patients treated in 95 study hospitals in Michigan (238 937 total admissions)compared with 364 hospitals in the surrounding Midwest region (1 091 547 total admissions). Main outcome measures Hospital mortality and length of hospital stay. Results The overall trajectory of mortality outcomes differed significantly between the two groups upon implementation of the project (Wald test chi(2)=8.73,P=0.033). Reductions in mortality were significantly greater for the study group than for the comparison group 1-12 months (odds ratio 0.83, 95% confidence interval 0.79 to 0.87 v 0.88, 0.85 to 0.90, P=0.041) and 13-22 months (0.76, 0.72 to 0.81 v 0.84, 0.81 to 0.86, P=0.007) after implementation of the project. The overall trajectory of length of stay did not differ significantly between the groups upon implementation of the project (Wald test chi 2=2.05, P=0.560). Group differences in adjusted length of stay compared with baseline did not reach significance during implementation of the project(.0.45 days, 95% confidence interval -0.62 to -0.28 v -0.35, -0.52 to -0.19) or during post-implementation months 1-12 (-0.59, -0.80 to -0.37 v -0.42, -0.59 to -0.25) and 13-22 (-0.67, -0.91 to -0.43 v -0.54, -0.72 to -0.37). Conclusions Implementation of the Keystone ICU project was associated with a significant decrease in hospital mortality in Michigan compared with the surroundingarea. The project was not, however, sufficiently powered to show a significant difference in length of stay.	[Lipitz-Snyderman, Allison; Steinwachs, Donald; Morlock, Laura L] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; [Needham, Dale M.] Johns Hopkins Sch Med, Div Pulm & Crit Care Med, Outcomes After Crit Illness & Surg Grp, Baltimore, MD USA; [Colantuoni, Elizabeth] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; [Pronovos, Peter J] Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med, Qual & Safety Res Grp, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University	Lipitz-Snyderman, A (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA.	alipitz@jhsph.edu						Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; BERENHOLTZ S, 2010, INFECT CONTROL HOSP; Bosk CL, 2009, LANCET, V374, P444, DOI 10.1016/S0140-6736(09)61440-9; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Elixhauser A., 1996, CLIN CLASSIFICATIONS; KHAUS WA, 1993, ANN INTERN MED, V118, P753; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KOHN LT, 1999, ERR HUMAN BUILDING S; Melsen WG, 2009, CRIT CARE MED, V37, P2709, DOI 10.1097/CCM.0b013e3181ab8655; Mermel LA, 2000, ANN INTERN MED, V132, P391, DOI 10.7326/0003-4819-132-5-200003070-00009; PITTET D, 1994, JAMA-J AM MED ASSOC, V271, P1598, DOI 10.1001/jama.271.20.1598; POTTER L, 1997, P 5 ANN WESTERN USER; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2008, J CRIT CARE, V23, P207, DOI 10.1016/j.jcrc.2007.09.002; Pronovost PJ, 2006, HEALTH SERV RES, V41, P1599, DOI 10.1111/j.1475-6773.2006.00567.x; PRONOVOST PJ, 2010, BRIT MED J, P340; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Shorr AF, 2001, CHEST, V119, P228, DOI 10.1378/chest.119.1.228; Soufir L, 1999, INFECT CONT HOSP EP, V20, P396, DOI 10.1086/501639; Thomas EJ, 2000, BRIT MED J, V320, P741, DOI 10.1136/bmj.320.7237.741; Veenstra DL, 1999, JAMA-J AM MED ASSOC, V282, P554, DOI 10.1001/jama.282.6.554; Warren DK, 2006, INFECT CONT HOSP EP, V27, P662, DOI 10.1086/506184; Warren DK, 2006, CRIT CARE MED, V34, P2084, DOI 10.1097/01.CCM.0000227648.15804.2D	24	83	83	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 31	2011	342								d219	10.1136/bmj.d219	http://dx.doi.org/10.1136/bmj.d219			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	718PN	21282262	Green Published, hybrid			2023-01-03	WOS:000287137500014
J	Martin, M; Segui, MA; Anton, A; Ruiz, A; Ramos, M; Adrover, E; Aranda, I; Rodriguez-Lescure, A; Grosse, R; Calvo, L; Barnadas, A; Isla, D; del Prado, PM; Borrego, M; Zaluski, J; Arcusa, A; Munoz, M; Vega, JM; Mel, JR; Munarriz, B; Llorca, C; Jara, C; Alba, E; Florian, J; Li, JF; Garcia-Asenjo, JA; Saez, A; Rios, M; Almenar, S; Peiro, G; Lluch, A				Martin, Miguel; Segui, Miguel A.; Anton, Antonio; Ruiz, Amparo; Ramos, Manuel; Adrover, Encarna; Aranda, Ignacio; Rodriguez-Lescure, Alvaro; Grosse, Regina; Calvo, Lourdes; Barnadas, Agusti; Isla, Dolores; Martinez del Prado, Purificacion; Ruiz Borrego, Manuel; Zaluski, Jerzy; Arcusa, Angels; Munoz, Montserrat; Lopez Vega, Jose M.; Mel, Jose R.; Munarriz, Blanca; Llorca, Cristina; Jara, Carlos; Alba, Emilio; Florian, Jesus; Li, Junfang; Lopez Garcia-Asenjo, Jose A.; Saez, Amparo; Jose Rios, Maria; Almenar, Sergio; Peiro, Gloria; Lluch, Ana		GEICAM 9805 Investigators	Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOXORUBICIN PLUS CYCLOPHOSPHAMIDE; CHEMOTHERAPY; PACLITAXEL; THERAPY; TRIAL; FLUOROURACIL; EPIRUBICIN; HIGHLIGHTS; CONSENSUS; REGIMEN	Background: A regimen of docetaxel, doxorubicin, and cyclophosphamide (TAC) is superior to a regimen of fluorouracil, doxorubicin, and cyclophosphamide (FAC) when used as adjuvant therapy in women with node-positive breast cancer. The value of taxanes in the treatment of node-negative disease has not been determined. Methods: We randomly assigned 1060 women with axillary-node-negative breast cancer and at least one high-risk factor for recurrence (according to the 1998 St. Gallen criteria) to treatment with TAC or FAC every 3 weeks for six cycles after surgery. The primary end point was disease-free survival after at least 5 years of follow-up. Secondary end points included overall survival and toxicity. Results: At a median follow-up of 77 months, the proportion of patients alive and disease-free was higher among the 539 women in the TAC group (87.8%) than among the 521 women in the FAC group (81.8%), representing a 32% reduction in the risk of recurrence with TAC (hazard ratio, 0.68; 95% confidence interval [CI], 0.49 to 0.93; P=0.01 by the log-rank test). This benefit was consistent, regardless of hormone-receptor status, menopausal status, or number of high-risk factors. The difference in survival rates (TAC, 95.2%; FAC, 93.5%) was not significant (hazard ratio, 0.76; 95% CI, 0.45 to 1.26); however, the number of events was small (TAC, 26; FAC, 34). Rates of grade 3 or 4 adverse events were 28.2% with TAC and 17.0% with FAC (P<0.001). Toxicity associated with TAC was diminished when primary prophylaxis with granulocyte colony-stimulating factor was provided. Conclusions: As compared with adjuvant FAC, adjuvant TAC improved the rate of disease-free survival among women with high-risk, node-negative breast cancer. (Funded by GEICAM and Sanofi-Aventis; ClinicalTrials.gov number, NCT00121992.) N Engl J Med 2010;363:2200-10.	[Martin, Miguel] Univ Complutense, Hosp Gen Univ Gregorio Maranon, Med Oncol Serv, Madrid 28007, Spain; [Segui, Miguel A.; Saez, Amparo] Corp Sanitaria Parc Tauli, Sabadell, Spain; [Anton, Antonio; Jose Rios, Maria] Hosp Univ Miguel Servet, Zaragoza, Spain; [Isla, Dolores] Hosp Clin Univ Lozano Blesa, Zaragoza, Spain; [Ruiz, Amparo; Almenar, Sergio] Inst Valenciano Oncol, Valencia, Spain; [Munarriz, Blanca] Hosp La Fe, E-46009 Valencia, Spain; [Lluch, Ana] Hosp Clin Valencia, Valencia, Spain; [Ramos, Manuel] Ctr Oncol Galicia, Corunna, Spain; [Calvo, Lourdes] Complejo Hosp Coruna, Corunna, Spain; [Adrover, Encarna; Aranda, Ignacio; Peiro, Gloria] Hosp Gen Univ Alicante, Alicante, Spain; [Rodriguez-Lescure, Alvaro] Hosp Univ Elche, Elche, Spain; [Barnadas, Agusti] Hosp Badalona Germans Trias & Pujol, Badalona, Spain; [Martinez del Prado, Purificacion] Hosp Basurto, Bilbao, Spain; [Ruiz Borrego, Manuel] Hosp Virgen del Rocio, Seville, Spain; [Arcusa, Angels] Consorci Sanit Terrassa, Terrassa, Spain; [Martin, Miguel] Hosp Clin Barcelona, Barcelona, Spain; [Lopez Vega, Jose M.] Hosp Marques de Valdecilla, Santander, Spain; [Mel, Jose R.] Complejo Hosp Xeral Calde, Lugo, Spain; [Llorca, Cristina] Hosp Gen Elda, Elda, Spain; [Jara, Carlos] Fdn Hosp Alcorcon, Alcorcon, Spain; [Alba, Emilio] Hosp Clin Virgen de la Victoria, Malaga, Spain; [Florian, Jesus] Hosp Comarcal de Barbastro, Huesca, Spain; [Lopez Garcia-Asenjo, Jose A.] Hosp Univ Principe de Asturias, Alcala De Henares, Spain; [Grosse, Regina] Martin Luther Univ Klin, Klin & Poliklin Gynakol, Halle, Germany; [Zaluski, Jerzy] Wielkopolskie Ctr Onkol, Poznan, Poland; [Li, Junfang] Sanofi Aventis, Bridgewater, NJ USA	Complutense University of Madrid; General University Gregorio Maranon Hospital; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Miguel Servet University Hospital; Lozano Blesa University Clinical Hospital; Instituto Valenciano De Oncologia; Hospital Universitari i Politecnic La Fe; Complejo Hospitalario Universitario A Coruna; General University Hospital of Alicante; Hospital Germans Trias i Pujol; Basurto Hospital; Virgen del Rocio University Hospital; University of Barcelona; Hospital Clinic de Barcelona; Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Lucus Augusti-Lugo; Alcorcon Foundation University Hospital; Hospital Virgen de la Victoria; Prince of Asturias University Hospital; Martin Luther University Halle Wittenberg; Wielkopolskie Centrum Onkologii; Sanofi-Aventis	Martin, M (corresponding author), Univ Complutense, Hosp Gen Univ Gregorio Maranon, Med Oncol Serv, Dr Esquerdo 46, Madrid 28007, Spain.	mmartin@geicam.org	Lluch, Ana/R-5493-2019; Alba, Emilio/S-1435-2019; Martin, Miguel/V-6589-2019; Muñoz, Montserrat/AAO-9617-2020; Rodríguez-Lescure, Álvaro/AAB-7039-2019; Calvo, Lourdes/M-2352-2014; Adrover, Encarna/AAC-8454-2020; ARANDA, FRANCISCO I/L-5525-2015; MORALES, SERAFIN/L-7216-2019; Martin, Miguel/AAJ-9242-2020; CALVO, LOURDES/F-2329-2015; Anton, Antonio/AAP-6563-2020; Aranda, F. Ignacio/H-5029-2011; Castellà, Eva/K-4140-2017	Lluch, Ana/0000-0003-2766-407X; Alba, Emilio/0000-0002-3364-2603; Muñoz, Montserrat/0000-0001-7772-1437; Rodríguez-Lescure, Álvaro/0000-0002-6823-5290; ARANDA, FRANCISCO I/0000-0003-2338-2286; MORALES, SERAFIN/0000-0001-7445-4193; Martin, Miguel/0000-0001-9237-3231; CALVO, LOURDES/0000-0001-8314-0241; Aranda, F. Ignacio/0000-0003-2338-2286; Adrover, Encarna/0000-0001-8676-8560; Isla, Dolores/0000-0002-2483-198X; SEGUI PALMER, MIQUEL ANGEL/0000-0002-5103-6746	GEICAM; Sanofi-Aventis; Adelphi Communications	GEICAM; Sanofi-Aventis(Sanofi-Aventis); Adelphi Communications	Supported by GEICAM and Sanofi-Aventis; the latter provided funding for molecular studies and for writing support from Helen Jones, Ph.D., of Adelphi Communications.	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Allred DC, 1998, MODERN PATHOL, V11, P155; Bria E, 2006, CANCER-AM CANCER SOC, V106, P2337, DOI 10.1002/cncr.21886; De Laurentiis M, 2008, J CLIN ONCOL, V26, P44, DOI 10.1200/JCO.2007.11.3787; Ferguson T, 2007, COCHRANE DB SYST REV, V4; Fisher B, 1997, JNCI-J NATL CANCER I, V89, P1673, DOI 10.1093/jnci/89.22.1673; Fisher B, 2004, JNCI-J NATL CANCER I, V96, P1823, DOI 10.1093/jnci/djh338; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Harlan LC, 2006, J CLIN ONCOL, V24, P872, DOI 10.1200/JCO.2005.03.5840; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hugh J, 2009, J CLIN ONCOL, V27, P1168, DOI 10.1200/JCO.2008.18.1024; Jones, 2007, J CLIN ONCOL, V25, P1819, DOI 10.1200/JCO.2007.11.9602; Jones S, 2009, J CLIN ONCOL, V27, P1177, DOI 10.1200/JCO.2008.18.4028; Jones SE, 2006, J CLIN ONCOL, V24, P5381, DOI 10.1200/JCO.2006.06.5391; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; Martin M, 2006, ANN ONCOL, V17, P1205, DOI 10.1093/annonc/mdl135; Martin M, 2003, ANN ONCOL, V14, P833, DOI 10.1093/annonc/mdg260; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Martin M, 2008, JNCI-J NATL CANCER I, V100, P805, DOI 10.1093/jnci/djn151; *NAT COMPR CANC NE, 2010, BREAST CANC, V2; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; *SEER CANC STAT, 2000, FAST STATS CANC SIT; Sparano JA, 2008, NEW ENGL J MED, V359, P106; Sparano JA, 2009, NEW ENGL J MED, V360, P1685; Sparano JA, 2008, NEW ENGL J MED, V358, P1663, DOI 10.1056/NEJMoa0707056; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775	27	135	139	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	2010	363	23					2200	2210		10.1056/NEJMoa0910320	http://dx.doi.org/10.1056/NEJMoa0910320			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	688EP	21121833	Bronze			2023-01-03	WOS:000284832900007
J	Blanco, G; Lemus, JA				Blanco, Guillermo; Lemus, Jesus A.			Livestock Drugs and Disease: The Fatal Combination behind Breeding Failure in Endangered Bearded Vultures	PLOS ONE			English	Article							POLYMERASE-CHAIN-REACTION; INFECTIOUS BURSAL DISEASE; WEST-NILE-VIRUS; AVIAN INFLUENZA; GYPAETUS-BARBATUS; WILD BIRDS; RT-PCR; REAL; CONSERVATION; DIVERSITY	There is increasing concern about the impact of veterinary drugs and livestock pathogens as factors damaging wildlife health, especially of threatened avian scavengers feeding upon medicated livestock carcasses. We conducted a comprehensive study of failed eggs and dead nestlings in bearded vultures (Gypaetus barbatus) to attempt to elucidate the proximate causes of breeding failure behind the recent decline in productivity in the Spanish Pyrenees. We found high concentrations of multiple veterinary drugs, primarily fluoroquinolones, in most failed eggs and nestlings, associated with multiple internal organ damage and livestock pathogens causing disease, especially septicaemia by swine pathogens and infectious bursal disease. The combined impact of drugs and disease as stochastic factors may result in potentially devastating effects exacerbating an already high risk of extinction and should be considered in current conservation programs for bearded vultures and other scavenger species, especially in regards to dangerous veterinary drugs and highly pathogenic poultry viruses.	[Blanco, Guillermo; Lemus, Jesus A.] CSIC, Dept Ecol Evolut, Museo Ciencias Nat, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Museu de Ciencies Naturals de Barcelona	Blanco, G (corresponding author), CSIC, Dept Ecol Evolut, Museo Ciencias Nat, Madrid, Spain.	gblanco@mncn.csic.es	Blanco, Guillermo/L-3170-2014	Blanco, Guillermo/0000-0001-5742-4929	Spanish Ministerio de Educacion y Ciencia [CGL2007-61395/BOS]	Spanish Ministerio de Educacion y Ciencia(Spanish Government)	The study was funded by the project CGL2007-61395/BOS of Spanish Ministerio de Educacion y Ciencia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernanke J, 2009, REV ENVIRON CONTAM T, V198, P1, DOI 10.1007/978-0-387-09647-6_1; Blanco G, 2003, ENVIRON TOXICOL CHEM, V22, P2711, DOI 10.1897/02-519; Blanco G, 2009, ANIM CONSERV, V12, P571, DOI 10.1111/j.1469-1795.2009.00283.x; Blanco G., 2007, ENV RES TRENDS, P153; BLANCO G, 2009, VULTURES FEEDING S S, P402; Blanco G, 2007, ENVIRON MICROBIOL, V9, P1738, DOI 10.1111/j.1462-2920.2007.01291.x; Blanco G, 2006, J APPL ECOL, V43, P990, DOI 10.1111/j.1365-2664.2006.01200.x; Cardoso M, 2005, VIRUS GENES, V30, P371, DOI 10.1007/s11262-005-6781-8; Carrete M, 2006, ECOL APPL, V16, P1674, DOI 10.1890/1051-0761(2006)016[1674:DPDIPB]2.0.CO;2; Carrete M, 2009, ECOL APPL, V19, P840, DOI 10.1890/07-2134.1; Carrete M, 2006, BIOL LETTERS, V2, P624, DOI 10.1098/rsbl.2006.0498; Chen BY, 1996, AVIAN PATHOL, V25, P269, DOI 10.1080/03079459608419141; Childs J.E., 2007, WILDLIFE EMERGING ZO; Cho KO, 1999, VET PATHOL, V36, P314, DOI 10.1354/vp.36-4-314; Davidson I, 2008, VIRUS GENES, V36, P1, DOI 10.1007/s11262-007-0165-1; Elliott JE, 1996, J WILDLIFE DIS, V32, P486, DOI 10.7589/0090-3558-32.3.486; Farkas T, 2007, ZOONOSES PUBLIC HLTH, V54, P38, DOI 10.1111/j.1863-2378.2007.01005.x; Gangoso L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006333; Gauthier-Clerc M, 2007, IBIS, V149, P202, DOI 10.1111/j.1474-919X.2007.00699.x; Gibbs E. P. J., 2002, DOMESTIC ANIMAL WILD; Godoy JA, 2004, MOL ECOL, V13, P371, DOI 10.1046/j.1365-294X.2003.02075.x; Gottdenker NL, 2005, BIOL CONSERV, V126, P429, DOI 10.1016/j.biocon.2005.06.025; Greiner Ellis C., 1994, P1007; Hamoud MM, 2007, J VET DIAGN INVEST, V19, P35, DOI 10.1177/104063870701900106; Hernandez-Divers SM, 2008, AVIAN DIS, V52, P558, DOI 10.1637/8298-032808-Reg.1; HILL E F, 1982, Environmental Toxicology and Chemistry, V1, P27, DOI 10.1897/1552-8618(1982)1[27:APOBFM]2.0.CO;2; HILL EF, 1988, J WILDLIFE DIS, V24, P51, DOI 10.7589/0090-3558-24.1.51; Himsworth CG, 2009, AVIAN DIS, V53, P129, DOI 10.1637/8387-063008-Case.1; HIRALDO F, 1979, MONOGRAFIAS ICONA, V22; Hsu CM, 2006, AVIAN DIS, V50, P348, DOI 10.1637/7485-121105R.1; Islam A, 2006, J VIROL METHODS, V132, P127, DOI 10.1016/j.jviromet.2005.10.009; Jeon WJ, 2008, VIRUS RES, V137, P153, DOI 10.1016/j.virusres.2008.06.013; Kiss I, 2006, ACTA VET HUNG, V54, P525, DOI 10.1556/AVet.54.2006.4.10; Kuscu B, 2008, J VET SCI, V9, P15, DOI 10.4142/jvs.2008.9.1.15; Lemus JA, 2009, ENVIRON POLLUT, V157, P2421, DOI 10.1016/j.envpol.2009.03.013; Lemus J. A., 2009, VULTURES SUPPLEMENTA, P374; Lemus JA, 2009, P ROY SOC B-BIOL SCI, V276, P2307, DOI 10.1098/rspb.2009.0071; Lemus JA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001444; Lun ZR, 2007, LANCET INFECT DIS, V7, P201, DOI 10.1016/S1473-3099(07)70001-4; Malkinson M, 2002, EMERG INFECT DIS, V8, P392, DOI 10.3201/eid0804.010217; Margalida A, 2003, IBIS, V145, P244, DOI 10.1046/j.1474-919X.2003.00148.x; Margalida A, 2010, J APPL ECOL, V47, P931, DOI 10.1111/j.1365-2664.2010.01835.x; Mekkes DR, 2005, AVIAN PATHOL, V34, P348, DOI 10.1080/03079450500179954; Muller H, 2003, VET MICROBIOL, V97, P153, DOI 10.1016/j.vetmic.2003.08.005; Newell DG, 2010, INT J FOOD MICROBIOL, V139, pS3, DOI 10.1016/j.ijfoodmicro.2010.01.021; Oaks JL, 2004, NATURE, V427, P630, DOI 10.1038/nature02317; Oro D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004084; Parrish CR, 2008, MICROBIOL MOL BIOL R, V72, P457, DOI 10.1128/MMBR.00004-08; Potti J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001276; Prescott J. F., 2000, ANTIMICROBIAL THERAP; Sarmah AK, 2006, CHEMOSPHERE, V65, P725, DOI 10.1016/j.chemosphere.2006.03.026; Schettler E, 2003, J WILDLIFE DIS, V39, P57, DOI 10.7589/0090-3558-39.1.57; Schrenzel M, 2007, J VET DIAGN INVEST, V19, P479, DOI 10.1177/104063870701900504; Selgrade MK, 2007, TOXICOL SCI, V100, P328, DOI 10.1093/toxsci/kfm244; Smith KF, 2009, ANIM CONSERV, V12, P1, DOI 10.1111/j.1469-1795.2008.00228.x; SOINE C, 1993, AVIAN DIS, V37, P467, DOI 10.2307/1591674; SYLVESTER SA, 2006, INDIAN J POULTRY SCI, V3, P283; Tadese T, 2003, J VET DIAGN INVEST, V15, P141, DOI 10.1177/104063870301500208; Whiteman NK, 2006, P ROY SOC B-BIOL SCI, V273, P797, DOI 10.1098/rspb.2005.3396; Wray C., 2000, SALMONELLA DOMESTIC; Zhang Y, 2006, ARCH VIROL, V151, P1525, DOI 10.1007/s00705-006-0731-1	61	5	5	2	29	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 30	2010	5	11							e14163	10.1371/journal.pone.0014163	http://dx.doi.org/10.1371/journal.pone.0014163			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	687DK	21152405	Green Published, gold, Green Submitted			2023-01-03	WOS:000284755100040
J	Sabbatini, F; Bandera, A; Ferrario, G; Trabattoni, D; Marchetti, G; Franzetti, F; Clerici, M; Gori, A				Sabbatini, Francesca; Bandera, Alessandra; Ferrario, Giulio; Trabattoni, Daria; Marchetti, Giulia; Franzetti, Fabio; Clerici, Mario; Gori, Andrea			Qualitative Immune Modulation by Interleukin-2 (IL-2) Adjuvant Therapy in Immunological Non Responder HIV-Infected Patients	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; MYCOBACTERIUM-AVIUM; HUMAN MACROPHAGES; CELL COUNT; IN-VITRO; CD4; RESTORATION; TRIAL; IMMUNOTHERAPY	Background: Treatment of HIV-infected patients with interleukin-2 (IL-2) produces significant increases in CD4 T cell counts; however an associated qualitative improvement in cells function has yet to be conclusively demonstrated. By measuring mycobacterial killing activity, we evaluated IL-2-mediated functional immune enhancement ex vivo in immunological non-responders (INRs). Methods and Findings: PBMC from 12 immunological non-responders (INRs) (CD4+<200/mu l, HIV-RNA<50 cp/ml) on combination antiretroviral treatment (cART) were collected at baseline, and after 3 IL-2 cycles. Eight INRs receiving only cART were studied as controls. After 21 days of PBMC incubation with a virulent M. avium suspension, counts of residual colony forming units (CFUs) and concentrations of TNF-alpha, IL-10 and IFN-gamma were determined. In IL-2 treated patients, a significant reduction in mean residual CFUs of PBMC cultures was observed (p<0.01). Moreover, following IL-2 treatment, significant increases in PBMC's IFN gamma production (p = 0.02) and substantial reductions in IL-10 levels were observed. Conclusions: IL-2 therapy restores the ability of the lympho-monocyte system in eliciting an effective response against mycobacterial infections. Our data indicate the possibility of a clinical role held by IL-2 in enhancing the immune function of subjects unable to achieve immune competence through cART alone.	[Sabbatini, Francesca; Bandera, Alessandra; Gori, Andrea] Univ Milano Bicocca, San Gerardo Hosp, Dept Internal Med, Div Infect Dis, Monza, Italy; [Ferrario, Giulio; Franzetti, Fabio] Univ Milan, Luigi Sacco Hosp, Infect Dis Sect, Dept Clin Sci, Milan, Italy; [Trabattoni, Daria] Univ Milan, Dept Preclin Sci, Chair Immunol, LITA VIALBA, Milan, Italy; [Marchetti, Giulia] Univ Milan, San Paolo Hosp, Clin Infect Dis, Dept Med Surg & Dent, Milan, Italy; [Clerici, Mario] Univ Milan, Sch Med, Chair Immunol, Milan, Italy; [Clerici, Mario] Don C Gnocchi Fdn IRCCS, Milan, Italy	San Gerardo Hospital; University of Milano-Bicocca; University of Milan; Luigi Sacco Hospital; University of Milan; San Paolo-Polo Universitaria Hospital; University of Milan; University of Milan; IRCCS Fondazione Don Carlo Gnocchi Onlus	Sabbatini, F (corresponding author), Univ Milano Bicocca, San Gerardo Hosp, Dept Internal Med, Div Infect Dis, Monza, Italy.	f.sabbatini@hsgerardo.org	Trabattoni, Daria/G-7424-2012; franzetti, fabio/AAK-9158-2020; Marchetti, Giulia/GPX-7655-2022; Bandera, Alessandra/AAC-6081-2022; Gori, Andrea/AAC-6078-2022; Bandera, Alessandra/D-6255-2015; MARCHETTI, GIULIA CARLA/K-4384-2018	Trabattoni, Daria/0000-0001-9535-3359; franzetti, fabio/0000-0001-9253-4453; MARCHETTI, GIULIA CARLA/0000-0002-4498-4828; Clerici, Mario/0000-0001-5920-6191; BANDERA, ALESSANDRA/0000-0001-9440-4601; Bandera, Alessandra/0000-0003-1626-0328	Ermenegildo Zegna Foundation, Italy; Angelantoni Heraeus Scientific Instruments (A.H.S.I.) S.p.A., Milan, Italy	Ermenegildo Zegna Foundation, Italy; Angelantoni Heraeus Scientific Instruments (A.H.S.I.) S.p.A., Milan, Italy	The present study was funded by a grant from the Ermenegildo Zegna Foundation, Italy, and Angelantoni Heraeus Scientific Instruments (A.H.S.I.) S.p.A., Milan, Italy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrams D, 2009, NEW ENGL J MED, V361, P1548, DOI 10.1056/NEJMoa0903175; Autran B, 1999, IMMUNOL LETT, V66, P207, DOI 10.1016/S0165-2478(98)00159-X; BAGBY GC, 2000, HEMATOLOGY BASIC PRI, P154; Bahr GM, 2003, J ANTIMICROB CHEMOTH, V51, P5, DOI 10.1093/jac/dkg063; BERMUDEZ LEM, 1990, J LEUKOCYTE BIOL, V48, P67, DOI 10.1002/jlb.48.1.67; Blattman JN, 2003, NAT MED, V9, P540, DOI 10.1038/nm866; CROWLE AJ, 1992, INFECT IMMUN, V60, P3697, DOI 10.1128/IAI.60.9.3697-3703.1992; Gazzola L, 2009, CLIN INFECT DIS, V48, P328, DOI 10.1086/595851; Gori A, 2004, ANTIVIR THER, V9, P603; Gutierrez F, 2008, CURR HIV RES, V6, P100, DOI 10.2174/157016208783885038; JENKINS PA, 1982, BIOL MYCOBACTERIA; Kaufmann GR, 2005, CLIN INFECT DIS, V41, P361, DOI 10.1086/431484; Kelley CF, 2009, CLIN INFECT DIS, V48, P787, DOI 10.1086/597093; Levy Y, 2003, AIDS, V17, P343, DOI 10.1097/00002030-200302140-00008; Luo Y, 2010, CLIN EXP IMMUNOL, V160, P359, DOI 10.1111/j.1365-2249.2010.04105.x; Marchetti G, 2004, AIDS, V18, P211, DOI 10.1097/00002030-200401230-00010; Marchetti G, 2002, J INFECT DIS, V186, P606, DOI 10.1086/342479; Marchetti G, 2005, J ANTIMICROB CHEMOTH, V55, P401, DOI 10.1093/jac/dkh557; MEYLAN PRA, 1992, J INFECT DIS, V165, P80, DOI 10.1093/infdis/165.1.80; Miller V, 2002, J INFECT DIS, V186, P189, DOI 10.1086/341466; Newman GW, 1997, J INFECT DIS, V175, P891, DOI 10.1086/513987; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Piketty C, 1998, AIDS, V12, P745, DOI 10.1097/00002030-199807000-00011; RELJIC R, 2010, CYTOKINE        0428; Vazquez N, 2006, J LEUKOCYTE BIOL, V80, P1136, DOI 10.1189/jlb.0306206	25	11	14	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	NOV 29	2010	5	11							e14119	10.1371/journal.pone.0014119	http://dx.doi.org/10.1371/journal.pone.0014119			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	686HD	21124762	Green Published, gold, Green Submitted			2023-01-03	WOS:000284686500009
J	Fyfe, I; Schuh, AL; Edwardson, JM; Audhya, A				Fyfe, Ian; Schuh, Amber L.; Edwardson, J. Michael; Audhya, Anjon			Association of the Endosomal Sorting Complex ESCRT-II with the Vps20 Subunit of ESCRT-III Generates a Curvature-sensitive Complex Capable of Nucleating ESCRT-III Filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; MECHANISM; TSG101; MODEL; RECONSTITUTION; SIMULATIONS; MACHINERY; SCISSION	The scission of membranes necessary for vesicle biogenesis and cytokinesis is mediated by cytoplasmic proteins, which include members of the ESCRT (endosomal sorting complex required for transport) machinery. During the formation of intralumenal vesicles that bud into multivesicular endosomes, the ESCRT-II complex initiates polymerization of ESCRT-III subunits essential for membrane fission. However, mechanisms underlying the spatial and temporal regulation of this process remain unclear. Here, we show that purified ESCRT-II binds to the ESCRT-III subunit Vps20 on chemically defined membranes in a curvature-dependent manner. Using a combination of liposome co-flotation assays, fluorescence-based liposome interaction studies, and high-resolution atomic force microscopy, we found that the interaction between ESCRT-II and Vps20 decreases the affinity of ESCRT-II for flat lipid bilayers. We additionally demonstrate that ESCRT-II and Vps20 nucleate flexible filaments of Vps32 that polymerize specifically along highly curved membranes as a single string of monomers. Strikingly, Vps32 filaments are shown to modulate membrane dynamics in vitro, a prerequisite for membrane scission events in cells. We propose that a curvature-dependent assembly pathway provides the spatial regulation of ESCRT-III to fuse juxtaposed bilayers of elevated curvature.	[Schuh, Amber L.; Audhya, Anjon] Univ Wisconsin, Madison Med Sch, Dept Biomol Chem, Madison, WI 53706 USA; [Fyfe, Ian; Edwardson, J. Michael] Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Wisconsin System; University of Wisconsin Madison; University of Cambridge	Audhya, A (corresponding author), Univ Wisconsin, Madison Med Sch, Dept Biomol Chem, Madison, WI 53706 USA.	audhya@wisc.edu		Fyfe, Ian/0000-0002-9362-0254	National Institutes of Health [1R01GM088151-01A1]; Greater Milwaukee Foundation; Biotechnology and Biological Sciences Research Council; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM088151] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Greater Milwaukee Foundation; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grant 1R01GM088151-01A1 (to A. A.). This work was also supported by a Shaw Scientist award (Greater Milwaukee Foundation; to A. A.) and a Biotechnology and Biological Sciences Research Council doctoral training award (to I. F.).	Audhya A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000956; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Barrera NP, 2005, J BIOL CHEM, V280, P10759, DOI 10.1074/jbc.M412265200; Carlton JG, 2007, SCIENCE, V316, P1908, DOI 10.1126/science.1143422; de Joannis J, 2006, LANGMUIR, V22, P998, DOI 10.1021/la051278d; Fabrikant G, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000575; Fujii K, 2007, NAT REV MICROBIOL, V5, P912, DOI 10.1038/nrmicro1790; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Guizetti J, 2011, SCIENCE, V331, P1616, DOI 10.1126/science.1201847; Hanson PI, 2008, J CELL BIOL, V180, P389, DOI 10.1083/jcb.200707031; Henne WM, 2007, STRUCTURE, V15, P839, DOI 10.1016/j.str.2007.05.002; Hurley JH, 2006, ANNU REV BIOPH BIOM, V35, P277, DOI 10.1146/annurev.biophys.35.040405.102126; Im YJ, 2008, DEV CELL, V14, P902, DOI 10.1016/j.devcel.2008.04.004; Im YJ, 2009, DEV CELL, V17, P234, DOI 10.1016/j.devcel.2009.07.008; Jackson MB, 2009, J MEMBRANE BIOL, V231, P101, DOI 10.1007/s00232-009-9209-x; Jiang FY, 2004, BIOPHYS J, V87, P182, DOI 10.1529/biophysj.103.031054; Jiang Y, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2430714; Kasson PM, 2004, BIOPHYS J, V86, P3744, DOI 10.1529/biophysj.103.029652; Kozlovsky Y, 2003, BIOPHYS J, V85, P85, DOI 10.1016/S0006-3495(03)74457-9; Langelier C, 2006, J VIROL, V80, P9465, DOI 10.1128/JVI.01049-06; Lata S, 2008, SCIENCE, V321, P1354, DOI 10.1126/science.1161070; Lee HH, 2008, SCIENCE, V322, P576, DOI 10.1126/science.1162042; Lee MCS, 2004, SCIENCE, V303, P479, DOI 10.1126/science.1094231; LITSTER JD, 1975, PHYS LETT A, VA 53, P193, DOI 10.1016/0375-9601(75)90402-8; Liu J, 2006, P NATL ACAD SCI USA, V103, P10277, DOI 10.1073/pnas.0601045103; Liu J, 2010, CURR OPIN CELL BIOL, V22, P36, DOI 10.1016/j.ceb.2009.11.009; Mayers JR, 2011, J BIOL CHEM, V286, P9636, DOI 10.1074/jbc.M110.185363; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Saksena S, 2009, BIOCHEM SOC T, V37, P167, DOI 10.1042/BST0370167; Saksena S, 2009, CELL, V136, P97, DOI 10.1016/j.cell.2008.11.013; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Tan S, 2001, PROTEIN EXPRES PURIF, V21, P224, DOI 10.1006/prep.2000.1363; Teis D, 2010, EMBO J, V29, P871, DOI 10.1038/emboj.2009.408; Teo H, 2004, DEV CELL, V7, P559, DOI 10.1016/j.devcel.2004.09.003; Tucker WC, 2004, SCIENCE, V304, P435, DOI 10.1126/science.1097196; Wang H, 2008, BIOPHYS J, V95, P2647, DOI 10.1529/biophysj.108.131409; Wollert T, 2010, NATURE, V464, P864, DOI 10.1038/nature08849; Wollert T, 2009, NATURE, V458, P172, DOI 10.1038/nature07836; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zamborlini A, 2006, P NATL ACAD SCI USA, V103, P19140, DOI 10.1073/pnas.0603788103	41	65	67	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 30	2011	286	39					34262	34270		10.1074/jbc.M111.266411	http://dx.doi.org/10.1074/jbc.M111.266411			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	823WW	21835927	hybrid, Green Published			2023-01-03	WOS:000295159200056
J	Barr, MS; Farzan, F; Arenovich, T; Chen, R; Fitzgerald, PB; Daskalakis, ZJ				Barr, Mera S.; Farzan, Faranak; Arenovich, Tamara; Chen, Robert; Fitzgerald, Paul B.; Daskalakis, Zafiris J.			The Effect of Repetitive Transcranial Magnetic Stimulation on Gamma Oscillatory Activity in Schizophrenia	PLOS ONE			English	Article							DORSOLATERAL PREFRONTAL CORTEX; INTERVAL CORTICAL INHIBITION; POTENTIALLY DELETERIOUS IMPACT; HEALTHY-HUMAN SUBJECTS; WORKING-MEMORY; HOMEOSTATIC PLASTICITY; TMS-EEG; NETWORK OSCILLATIONS; INTERNEURON NETWORKS; PARKINSONS-DISEASE	Background: Gamma (c) oscillations (30-50 Hz) have been shown to be excessive in patients with schizophrenia (SCZ) during working memory (WM). WM is a cognitive process that involves the online maintenance and manipulation of information that is mediated largely by the dorsolateral prefrontal cortex (DLPFC). Repetitive transcranial magnetic stimulation (rTMS) represents a non-invasive method to stimulate the cortex that has been shown to enhance cognition and c oscillatory activity during WM. Methodology and Principal Findings: We examined the effect of 20 Hz rTMS over the DLPFC on gamma oscillatory activity elicited during the N-back task in 24 patients with SCZ compared to 22 healthy subjects. Prior to rTMS, patients with SCZ elicited excessive gamma oscillatory activity compared to healthy subjects across WM load. Active rTMS resulted in the reduction of frontal gamma oscillatory activity in patients with SCZ, while potentiating activity in healthy subjects in the 3-back, the most difficult condition. Further, these effects on gamma oscillatory activity were found to be specific to the frontal brain region and were absent in the parieto-occipital brain region. Conclusions and Significance: We suggest that this opposing effect of rTMS on gamma oscillatory activity in patients with SCZ versus healthy subjects may be related to homeostatic plasticity leading to differential effects of rTMS on gamma oscillatory activity depending on baseline differences. These findings provide important insights into the neurophysiological mechanisms underlying WM deficits in SCZ and demonstrated that rTMS can modulate gamma oscillatory activity that may be a possible avenue for cognitive potentiation in this disorder.	[Barr, Mera S.; Farzan, Faranak; Daskalakis, Zafiris J.] Univ Toronto, Dept Psychiat, Schizophrenia Program, Ctr Addict & Mental Hlth, Toronto, ON, Canada; [Chen, Robert] Univ Toronto, Div Neurol, Toronto Res Inst, Toronto, ON, Canada; [Fitzgerald, Paul B.] Alfred & Monash Univ, Monash Alfred Psychiat Res Ctr, Sch Psychol & Psychiat, Melbourne, Vic, Australia	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; Monash University	Barr, MS (corresponding author), Univ Toronto, Dept Psychiat, Schizophrenia Program, Ctr Addict & Mental Hlth, Toronto, ON, Canada.	Jeff_Daskalakis@camh.net	Fitzgerald, Paul B/A-1225-2008; Chen, Robert/B-3899-2009; Daskalakis, Zafiris J/J-5503-2013	Fitzgerald, Paul B/0000-0003-4217-8096; Chen, Robert/0000-0002-8371-8629; Daskalakis, Zafiris J/0000-0001-9502-0538; Barr, Mera/0000-0002-1103-1887; Farzan, Faranak/0000-0001-9249-2994	Canadian Institutes of Health Research (CIHR) [MOP 62917]; Ontario Mental Health Foundation; National Health and Medical Research Council (NHMRC); Constance and Stephen Lieber through a National Alliance for Research on Schizophrenia and Depression (NARSAD); Neuronetics Inc; Medical Inc	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Ontario Mental Health Foundation; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Constance and Stephen Lieber through a National Alliance for Research on Schizophrenia and Depression (NARSAD)(NARSAD); Neuronetics Inc; Medical Inc	This work was funded, in part, by the Canadian Institutes of Health Research (CIHR) (grant no. MOP 62917 to RC), CIHR Industry Partnered (Medtronic Inc) Investigator Award (RC), CIHR Clinician Scientist Award (ZJD), CIHR doctoral award (FF), by an operating and studentship award from the Ontario Mental Health Foundation (ZJD and MB, respectively), by a National Health and Medical Research Council (NHMRC) Practitioner Fellowship (PBF), and by Constance and Stephen Lieber through a National Alliance for Research on Schizophrenia and Depression (NARSAD) Lieber Young Investigator award (ZJD, PBF). ZJD and PBF have both received external funding through Neuronetics Inc and ZJD has also received external funding through Aspect Medical Inc and travel support through Pfizer Inc. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADDINGTON D, 1993, BRIT J PSYCHIAT, V163, P39, DOI 10.1192/S0007125000292581; AKBARIAN S, 1995, ARCH GEN PSYCHIAT, V52, P258, DOI 10.1001/archpsyc.1995.03950160008002; ANDREASEN NC, 1989, BRITISH JOURNAL OF PSYCHIATRY, VOL 155, SUPP NO. 7, P49; Baddeley A., 1986, WORKING MEMORY; Barr MS, 2010, SCHIZOPHR RES, V121, P146, DOI 10.1016/j.schres.2010.05.023; Barr MS, 2010, NEUROPSYCHOPHARMACOL, V35, P848, DOI 10.1038/npp.2009.174; Barr MS, 2009, NEUROPSYCHOPHARMACOL, V34, P2359, DOI 10.1038/npp.2009.79; Bartos M, 2007, NAT REV NEUROSCI, V8, P45, DOI 10.1038/nrn2044; Basar-Eroglu C, 2007, INT J PSYCHOPHYSIOL, V64, P39, DOI 10.1016/j.ijpsycho.2006.07.007; BENDER R, 1992, METHOD INFORM MED, V31, P56; BENES FM, 1991, ARCH GEN PSYCHIAT, V48, P996; Bilder RM, 2002, AM J PSYCHIAT, V159, P1018, DOI 10.1176/appi.ajp.159.6.1018; Boggio PS, 2005, MOVEMENT DISORD, V20, P1178, DOI 10.1002/mds.20508; Brahmbhatt SB, 2006, SCHIZOPHR RES, V87, P191, DOI 10.1016/j.schres.2006.05.019; Brown JT, 2007, EUR J NEUROSCI, V25, P2982, DOI 10.1111/j.1460-9568.2007.05544.x; Callicott JH, 2003, AM J PSYCHIAT, V160, P2209, DOI 10.1176/appi.ajp.160.12.2209; Cannon TD, 2005, ARCH GEN PSYCHIAT, V62, P1071, DOI 10.1001/archpsyc.62.10.1071; Chen R, 1997, ELECTROMYOGR MOTOR C, V105, P415, DOI 10.1016/S0924-980X(97)00036-2; Chen XD, 2010, J NEUROSCI, V30, P2611, DOI 10.1523/JNEUROSCI.3771-09.2010; Cho RY, 2006, P NATL ACAD SCI USA, V103, P19878, DOI 10.1073/pnas.0609440103; Daskalakis ZJ, 2008, NEUROPSYCHOPHARMACOL, V33, P2860, DOI 10.1038/npp.2008.22; Daskalakis ZJ, 2006, EXP BRAIN RES, V174, P403, DOI 10.1007/s00221-006-0472-0; Deiber MP, 2007, J COGNITIVE NEUROSCI, V19, P158, DOI 10.1162/jocn.2007.19.1.158; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Farzan F, 2010, J NEUROPHYSIOL, V104, P1339, DOI 10.1152/jn.00279.2010; Farzan F, 2010, BRAIN, V133, P1505, DOI 10.1093/brain/awq046; Farzan F, 2009, NEUROPSYCHOPHARMACOL, V34, P1543, DOI 10.1038/npp.2008.211; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; Goncharova II, 2003, CLIN NEUROPHYSIOL, V114, P1580, DOI 10.1016/S1388-2457(03)00093-2; Gonzalez-Burgos G, 2008, SCHIZOPHRENIA BULL, V34, P944, DOI 10.1093/schbul/sbn070; Haenschel C, 2009, J NEUROSCI, V29, P9481, DOI 10.1523/JNEUROSCI.1428-09.2009; Hartmann K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002979; Hashimoto T, 2003, J NEUROSCI, V23, P6315; Hong LE, 2004, SCHIZOPHR RES, V70, P293, DOI 10.1016/j.schres.2003.12.011; Howard MW, 2003, CEREB CORTEX, V13, P1369, DOI 10.1093/cercor/bhg084; Jandl M, 2005, J NEURAL TRANSM, V112, P955, DOI 10.1007/s00702-004-0229-5; Jung SH, 2008, CLIN NEUROPHYSIOL, V119, P71, DOI 10.1016/j.clinph.2007.09.124; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Khedr EM, 2006, MOVEMENT DISORD, V21, P2201, DOI 10.1002/mds.21089; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Koos T, 1999, NAT NEUROSCI, V2, P467, DOI 10.1038/8138; Le Roux N, 2008, EUR J NEUROSCI, V27, P3244, DOI 10.1111/j.1460-9568.2008.06288.x; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Lewis DA, 2008, AM J PSYCHIAT, V165, P1585, DOI 10.1176/appi.ajp.2008.08030395; Mann EO, 2007, TRENDS NEUROSCI, V30, P343, DOI 10.1016/j.tins.2007.05.003; Meltzer HY, 1999, SCHIZOPHRENIA BULL, V25, P233, DOI 10.1093/oxfordjournals.schbul.a033376; Mendrek A, 2005, PSYCHOL MED, V35, P187, DOI 10.1017/S0033291704003228; Norman GR., 2000, BIOSTATISTICS BARE E, V2nd; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Penttonen Markku, 2003, Thalamus & Related Systems, V2, P145, DOI 10.1016/S1472-9288(03)00007-4; Rao SG, 2000, J NEUROSCI, V20, P485, DOI 10.1523/JNEUROSCI.20-01-00485.2000; RIECANSKY I, 2010, SCHIZOPHR RES; Roopun AK, 2008, FRONT NEUROSCI-SWITZ, V2, P145, DOI 10.3389/neuro.01.034.2008; Saliba RS, 2007, J NEUROSCI, V27, P13341, DOI 10.1523/JNEUROSCI.3277-07.2007; Saliba RS, 2009, J BIOL CHEM, V284, P32544, DOI 10.1074/jbc.M109.040071; SAWAGUCHI T, 1989, EXP BRAIN RES, V75, P457; Schulze-Rauschenbach SC, 2005, BRIT J PSYCHIAT, V186, P410, DOI 10.1192/bjp.186.5.410; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; Shackman AJ, 2010, NEUROPSYCHOPHARMACOL, V35, P847, DOI 10.1038/npp.2009.173; Sharma T, 2003, PSYCHOPHARMACOLOGY, V169, P398, DOI 10.1007/s00213-003-1506-y; Siebner HR, 2004, J NEUROSCI, V24, P3379, DOI 10.1523/JNEUROSCI.5316-03.2004; Spencer KM, 2008, BIOL PSYCHIAT, V63, P744, DOI 10.1016/j.biopsych.2007.10.017; Spitzer RL, 1994, DIAGNOSTIC STAT MANU; Strafella AP, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-15-j0003.2001; Swanwick CC, 2006, MOL CELL NEUROSCI, V31, P481, DOI 10.1016/j.mcn.2005.11.002; Tallon-Baudry C, 1999, VISUAL NEUROSCI, V16, P449, DOI 10.1017/S0952523899163065; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; Tan HY, 2005, AM J PSYCHIAT, V162, P1849, DOI 10.1176/appi.ajp.162.10.1849; Traub RD, 2004, ADV EXP MED BIOL, V548, P110; Traub RD, 1996, J PHYSIOL-LONDON, V493, P471, DOI 10.1113/jphysiol.1996.sp021397; Wang XJ, 1996, J NEUROSCI, V16, P6402; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Wilhelm JC, 2008, P NATL ACAD SCI USA, V105, P11412, DOI 10.1073/pnas.0806037105; WILSON FAW, 1994, P NATL ACAD SCI USA, V91, P4009, DOI 10.1073/pnas.91.9.4009; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607; Yuval-Greenberg S, 2008, NEURON, V58, P429, DOI 10.1016/j.neuron.2008.03.027; Ziemann U, 1996, EXP BRAIN RES, V109, P127	79	56	56	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2011	6	7							e22627	10.1371/journal.pone.0022627	http://dx.doi.org/10.1371/journal.pone.0022627			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799JJ	21818354	gold, Green Published, Green Submitted			2023-01-03	WOS:000293282700052
J	Kamerow, D				Kamerow, Douglas			YANKEE DOODLING The pros and cons of generic drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												dkamerow@rti.org	Mendoza, Elvia/A-9361-2012	Kamerow, Douglas/0000-0001-7000-9957				Briesacher BA, 2009, AM J MANAG CARE, V15, P450; Emery J, 2010, BMJ; Ferner RE, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c2548; Greene JA, 2011, NEW ENGL J MED, V365, P83, DOI 10.1056/NEJMhle1101722; Hellier Elizabeth, 2010, J Patient Saf, V6, P158; Kaiser Family Foundation, 2010, US HLTH CAR COSTS; Mishori R, 2011, WASHINGTON POST 0712, pE1; Shrank WH, 2011, AM J MED, V124, P309, DOI 10.1016/j.amjmed.2010.11.020; Tanne JH, 2003, BRIT MED J, V327, P565, DOI 10.1136/bmj.327.7414.565	9	5	5	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2011	343								d4584	10.1136/bmj.d4584	http://dx.doi.org/10.1136/bmj.d4584			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	797ZH	21775394				2023-01-03	WOS:000293168700009
J	Lee, M; Ovbiagele, B				Lee, Meng; Ovbiagele, Bruce			Vascular events after stroke: terutroban fails to PERFORM	LANCET			English	Editorial Material							ACETYLSALICYLIC-ACID; ISCHEMIC-STROKE; ASPIRIN; PREVENTION; RISK; TRIAL; TICLOPIDINE		[Ovbiagele, Bruce] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; [Lee, Meng] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Chiayi, Dept Neurol, Tao Yuan, Taiwan	University of California System; University of California San Diego; Chang Gung Memorial Hospital; Chang Gung University	Ovbiagele, B (corresponding author), Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA.	ovibes@ucsd.edu		Lee, Meng/0000-0002-7491-0571				Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Bousser MG, 2011, LANCET, V377, P2013, DOI 10.1016/S0140-6736(11)60600-4; Chen ZM, 2000, STROKE, V31, P1240, DOI 10.1161/01.STR.31.6.1240; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Rodriguez LAG, 2011, NEUROLOGY, V76, P740, DOI 10.1212/WNL.0b013e31820d62b5; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gorelick PB, 2003, JAMA-J AM MED ASSOC, V289, P2947, DOI 10.1001/jama.289.22.2947; Halkes PHA, 2006, LANCET, V367, P1665; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; Lovett JK, 2004, NEUROLOGY, V62, P569, DOI 10.1212/01.WNL.0000110311.09970.83; Matias-Guiu J, 2003, STROKE, V34, P840, DOI 10.1161/01.STR.0000063141.24491.50; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8	12	8	8	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					1980	1982		10.1016/S0140-6736(11)60708-3	http://dx.doi.org/10.1016/S0140-6736(11)60708-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21616526				2023-01-03	WOS:000292011700005
J	Beck, EJ; Mandalia, S; Lo, G; Sharott, P; Youle, M; Anderson, J; Baily, G; Brettle, R; Fisher, M; Gompels, M; Kinghorn, G; Johnson, M; McCarron, B; Pozniak, A; Tang, A; Walsh, J; White, D; Williams, I; Gazzard, B				Beck, Eduard J.; Mandalia, Sundhiya; Lo, Gary; Sharott, Peter; Youle, Mike; Anderson, Jane; Baily, Guy; Brettle, Ray; Fisher, Martin; Gompels, Mark; Kinghorn, George; Johnson, Margaret; McCarron, Brendan; Pozniak, Anton; Tang, Alan; Walsh, John; White, David; Williams, Ian; Gazzard, Brian		NPMS-HHC Steering Grp	Cost-Effectiveness of Early Treatment with First-Line NNRTI-Based HAART Regimens in the UK, 1996-2006	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; CD4 CELL COUNT; HIV-INFECTION; SOUTH-AFRICA; POPULATION	Aim: Calculate time to first-line treatment failure, annual cost and cost-effectiveness of NNRTI versus PIboosted first-line HAART regimens in the UK, 1996-2006. Background: Population costs for HIV services are increasing in the UK and interventions need to be effective and efficient to reduce or stabilize costs. 2NRTIs + NNRTI regimens are cost-effective regimens for first-line HAART, but these regimens have not been compared with first-line PI(boosted) regimens. Methods: Times to first-line treatment failure and annual costs were calculated for first-line HAART regimens by CD4 count when starting HAART (2006 UK prices). Cost-effectiveness of 2NRTIs+NNRTI versus 2NRTIs+PI(boosted) regimens was calculated for four CD4 strata. Results: 55% of 5,541 people living with HIV (PLHIV) started HAART with CD4 count <= 200 cells/mm(3), many of whom were Black Africans. Annual treatment cost decreased as CD4 count increased; most marked differences were observed between starting HAART with CD4 <= 200 cells/mm3 compared with CD4 count >200 cells/mm3. 2NRTI+PI(boosted) and 2NRTI+NNRTI regimens were the most effective regimens across the four CD4 strata; 2NRTI+NNRTI was cost-saving or cost-effective compared with 2NRTI + PI(boosted) regimens. Conclusion: To ensure more effective and efficient provision of HIV services, 2NRTI+NNRTI should be started as first-line HAART regimen at CD4 counts <= 350 cell/mm3, unless specific contra-indications exist. This will increase the number of PLHIV receiving HAART and will initially increase population costs of providing HIV services. However, starting PLHIV earlier on cost-effective regimens will maintain them in better health and use fewer health or social services, thereby generating fewer treatment and care costs, enabling them to remain socially and economically active members of society. This does raise a number of ethical issues, which will have to be acknowledged and addressed, especially in countries with limited resources.	[Beck, Eduard J.; Mandalia, Sundhiya; Lo, Gary; Youle, Mike; Gazzard, Brian] NPMS HHC Coordinating & Analyt Ctr, London, England; [Beck, Eduard J.] London Sch Hyg & Trop Med, London WC1, England; [Mandalia, Sundhiya; Gazzard, Brian] Univ London Imperial Coll Sci Technol & Med, London, England; [Sharott, Peter] London Procurement Programme, London Specialised Commissioning Grp, London, England; [Youle, Mike; Johnson, Margaret] Royal Free Hosp, London NW3 2QG, England; [Anderson, Jane] Homerton Univ Hosp NHS Fdn Trust, London, England; [Baily, Guy] London Hosp, London E1 1BB, England; [Baily, Guy] Barts Hosp, London, England; [Brettle, Ray] Edinburgh Gen Hosp, Edinburgh, Midlothian, Scotland; [Fisher, Martin] Royal Sussex Cty Hosp, Brighton BN2 5BE, E Sussex, England; [Gompels, Mark] Southmead Hosp, Bristol, Avon, England; [Kinghorn, George] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England; [McCarron, Brendan] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Beck, Eduard J.; Mandalia, Sundhiya; Lo, Gary; Pozniak, Anton; Gazzard, Brian] Chelsea & Westminster Hosp, London, England; [Tang, Alan] Royal Berkshire Hosp, Reading, Berks, England; [Walsh, John] St Marys Hosp, London, England; [White, David] Birmingham Heartsland Hosp, Birmingham, W Midlands, England; [Williams, Ian] Mortimer Market Ctr, London, England	University of London; London School of Hygiene & Tropical Medicine; Imperial College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; Queen Mary University London; University of Brighton; Southmead Hospital; University of Sheffield; James Cook University Hospital; Imperial College London; Royal Berkshire Hospital; Imperial College London	Beck, EJ (corresponding author), NPMS HHC Coordinating & Analyt Ctr, London, England.	becke@unaids.org	Anderson, Jane/A-1632-2012; Kinghorn, George/AAO-1425-2021	Anderson, Jane/0000-0001-5294-8707; Kinghorn, George/0000-0001-6608-5076	Tibotec	Tibotec	During 2008/2009, the NPMS-HHC was financially supported through a non-restrictive grant from Tibotec, with no influence on the independence of the Steering Group and its editorial policy. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Beck EJ, 2008, INT J STD AIDS, V19, P297, DOI 10.1258/ijsa.2007.007236; Beck E.J., 2001, EFFECTIVE MANAGEMENT, P113; Beck EJ, 1999, AIDS, V13, P2157, DOI 10.1097/00002030-199910220-00020; Beck EJ, 1998, PHARMACOECONOMICS, V14, P639, DOI 10.2165/00019053-199814060-00005; Beck EJ, 2004, AIDS, V18, P2411; Beck EJ, 2003, BRIT J SEX MED, V27, P21; BECK EJ, 2010, 18 INT AIDS C VIENN; BECK EJ, 2003, BRIT J SEX MED, V27, P19; BECK EJ, 2008, USE COST HIV SERVICE; BECK EJ, 2006, HIV PANDEMIC LOCAL G, P769; BECK EJ, 2008, DECADE HAART, P45; Brouwer WBF, 2005, BRIT MED J, V331, P446, DOI 10.1136/bmj.331.7514.446; Crum-Cianflone NF, 2010, JAIDS-J ACQ IMM DEF, V54, P248, DOI 10.1097/QAI.0b013e3181c8ef22; Ford N, 2009, NEW ENGL J MED, V360, P1808, DOI 10.1056/NEJMp0902820; Gazzard BG, 2008, HIV MED, V9, P563, DOI 10.1111/j.1468-1293.2008.00636.x; Geng EH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014098; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Hammer SM, 2008, JAMA-J AM MED ASSOC, V300, P555, DOI 10.1001/jama.300.5.555; Hogg RS, 2001, JAMA-J AM MED ASSOC, V286, P2568, DOI 10.1001/jama.286.20.2568; *INSIGHT COMM AD B, 2010, COMM STAT START TRIA; John A, 2010, MED CARE, V48, P1071; Josefsson L, 2010, CURR OPIN INFECT DIS, V23, P628, DOI 10.1097/QCO.0b013e32833ff1d0; Krentz HB, 2008, HIV MED, V9, P721, DOI 10.1111/j.1468-1293.2008.00613.x; Long EF, 2010, ANN INTERN MED, V153, P778, DOI 10.7326/0003-4819-153-12-201012210-00004; Mandalia S, 2002, HIV Med, V3, P254, DOI 10.1046/j.1468-1293.2002.00110.x; Mandalia S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015677; NEATON JD, 2009, STRATEGIC TIMING ANT; Panel on antiretroviral guidelines for adults and adolescents, 2009, GUID US ANT AG HIV 1, P1, DOI DOI 10.1111/J.1468-1293.2008.00636.X; Rawlins MD, 2004, BRIT MED J, V329, P224, DOI 10.1136/bmj.329.7459.224; Sterne JAC, 2009, LANCET, V373, P1352, DOI 10.1016/S0140-6736(09)60612-7; THAKKAR B, 1998, SUGI 23 MARCH 22 25; *UNAIDS PEPFAR, 2007, P WORKSH 15 17 MAY 2; Wagner B, 2010, LANCET, V376, P953, DOI 10.1016/S0140-6736(10)61442-0; WHO, 2010, ANT THER HIV INF AD; Wood E, 2003, AIDS, V17, P711, DOI 10.1097/00002030-200303280-00009	36	10	10	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 25	2011	6	5							e20200	10.1371/journal.pone.0020200	http://dx.doi.org/10.1371/journal.pone.0020200			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769IQ	21633514	Green Published, gold, Green Accepted			2023-01-03	WOS:000291006500041
J	Kashyap, MP; Singh, AK; Kumar, V; Tripathi, VK; Srivastava, RK; Agrawal, M; Khanna, VK; Yadav, S; Jain, SK; Pant, AB				Kashyap, Mahendra Pratap; Singh, Abhishek Kumar; Kumar, Vivek; Tripathi, Vinay Kumar; Srivastava, Ritesh Kumar; Agrawal, Megha; Khanna, Vinay Kumar; Yadav, Sanjay; Jain, Swatantra Kumar; Pant, Aditya Bhushan			Monocrotophos Induced Apoptosis in PC12 Cells: Role of Xenobiotic Metabolizing Cytochrome P450s	PLOS ONE			English	Article							OXIDATIVE DNA-DAMAGE; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; GLUTATHIONE-S-TRANSFERASE; IN-VITRO; RODENT LIVER; HEPG2 CELLS; RAT-BRAIN; GST P1-1; STRESS; ACTIVATION	Monocrotophos (MCP) is a widely used organophosphate (OP) pesticide. We studied apoptotic changes and their correlation with expression of selected cytochrome P450s (CYPs) in PC12 cells exposed to MCP. A significant induction in reactive oxygen species (ROS) and decrease in glutathione (GSH) levels were observed in cells exposed to MCP. Following the exposure of PC12 cells to MCP (10(-5) M), the levels of protein and mRNA expressions of caspase-3/9, Bax, Bcl(2), P-53, P-21, GSTP1-1 were significantly upregulated, whereas the levels of Bclw, Mcl1 were downregulated. A significant induction in the expression of CYP1A1/1A2, 2B1/2B2, 2E1 was also observed in PC12 cells exposed to MCP (10(-5) M), whereas induction of CYPs was insignificant in cells exposed to 10(-6) M concentration of MCP. We believe that this is the first report showing altered expressions of selected CYPs in MCP-induced apoptosis in PC12 cells. These apoptotic changes were mitochondria mediated and regulated by caspase cascade. Our data confirm the involvement of specific CYPs in MCP-induced apoptosis in PC12 cells and also identifies possible cellular and molecular mechanisms of organophosphate pesticide-induced apoptosis in neuronal cells.	[Kashyap, Mahendra Pratap; Singh, Abhishek Kumar; Kumar, Vivek; Tripathi, Vinay Kumar; Srivastava, Ritesh Kumar; Agrawal, Megha; Khanna, Vinay Kumar; Yadav, Sanjay; Pant, Aditya Bhushan] Indian Inst Toxicol Res, Lucknow, Uttar Pradesh, India; [Kashyap, Mahendra Pratap; Singh, Abhishek Kumar; Kumar, Vivek; Tripathi, Vinay Kumar; Srivastava, Ritesh Kumar; Agrawal, Megha; Khanna, Vinay Kumar; Yadav, Sanjay; Pant, Aditya Bhushan] CSIR, New Delhi, India; [Jain, Swatantra Kumar] Jamia Hamdard, Dept Biotechnol, New Delhi, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Toxicology Research (IITR); Council of Scientific & Industrial Research (CSIR) - India; Jamia Hamdard University	Kashyap, MP (corresponding author), Indian Inst Toxicol Res, Lucknow, Uttar Pradesh, India.	abpant@rediffmail.com	Srivastava, Ritesh/V-6029-2019; Yadav, Sanjay/E-2902-2010; Singh, Abhishek K/G-4032-2011; Kashyap, Mahendra/G-4305-2011	Kashyap, Mahendra/0000-0001-7924-4793; Agrawal, Megha/0000-0001-5280-7699; Singh, Abhishek Kumar/0000-0002-3186-9898	Council of Scientific and Industrial Research, New Delhi [SIP-08]; University Grant Commission, New Delhi [GAP-155]	Council of Scientific and Industrial Research, New Delhi(Council of Scientific & Industrial Research (CSIR) - India); University Grant Commission, New Delhi(University Grants Commission, India)	Financial support by Council of Scientific and Industrial Research, New Delhi, (SIP-08) is acknowledged. University Grant Commission, New Delhi is acknowledged for providing the fellowship to Mr. M.P. Kashyap (GAP-155). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bernardini S, 2002, J CELL BIOCHEM, V86, P340, DOI 10.1002/jcb.10219; Bernardini S, 2000, J CELL BIOCHEM, V77, P645, DOI 10.1002/(SICI)1097-4644(20000615)77:4<645::AID-JCB12>3.3.CO;2-0; Bernardini S, 2006, ANN HEMATOL, V85, P681, DOI 10.1007/s00277-006-0139-8; Bradford BU, 2005, HEPATOLOGY, V41, P336, DOI 10.1002/hep.20532; Cederbaum AI, 2006, MT SINAI J MED, V73, P657; Chan JYH, 2006, NEUROPHARMACOLOGY, V51, P1109, DOI 10.1016/j.neuropharm.2006.06.024; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Chen ZH, 2004, CARCINOGENESIS, V25, P2005, DOI 10.1093/carcin/bgh183; Costa LG, 2006, CLIN CHIM ACTA, V366, P1, DOI 10.1016/j.cca.2005.10.008; Dostalek M, 2008, J BIOL CHEM, V283, P17147, DOI 10.1074/jbc.M802447200; Fujita K, 2001, MUTAT RES-FUND MOL M, V483, P35, DOI 10.1016/S0027-5107(01)00223-8; Galluzzi L, 2008, CELL CYCLE, V7, P1949, DOI 10.4161/cc.7.13.6222; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Gong PF, 2006, HEPATOLOGY, V43, P144, DOI 10.1002/hep.21004; Hashizume T, 2009, MUTAT RES-GEN TOX EN, V677, P1, DOI 10.1016/j.mrgentox.2009.03.009; Hewitt R, 2007, ENVIRON HEALTH PERSP, V115, P129, DOI 10.1289/ehp.9361; Huk OL, 2004, J ARTHROPLASTY, V19, P84, DOI 10.1016/j.arth.2004.09.011; Johri A, 2008, TOXICOL APPL PHARM, V231, P10, DOI 10.1016/j.taap.2008.03.019; Kapoor N, 2006, LIFE SCI, V79, P1514, DOI 10.1016/j.lfs.2006.04.023; Kashyap MP, 2010, CHEM RES TOXICOL, V23, P1663, DOI 10.1021/tx100234m; Kaur P, 2007, NEUROTOXICOLOGY, V28, P1208, DOI 10.1016/j.neuro.2007.08.001; Kim JY, 2007, ENDOCRINOLOGY, V148, P5112, DOI 10.1210/en.2007-0096; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; KUMAR S, 2009, BIOCHEM PHARMACOL, V79, P1182; Li Q, 2009, TOXICOLOGY, V255, P53, DOI 10.1016/j.tox.2008.10.003; Li Y, 2009, EXP CELL RES, V315, P2463, DOI 10.1016/j.yexcr.2009.05.016; Loft S, 1998, FREE RADICAL RES, V29, P525, DOI 10.1080/10715769800300571; Lupp A, 2006, INT J CLIN PHARM TH, V44, P225; Mari M, 2001, HEPATOLOGY, V33, P652, DOI 10.1053/jhep.2001.22521; Masoud A, 2009, CELL MOL NEUROBIOL, V29, P1245, DOI 10.1007/s10571-009-9420-4; McConnachie LA, 2007, TOXICOL SCI, V99, P628, DOI 10.1093/toxsci/kfm165; Moore PD, 2010, ENVIRON TOXICOL, V25, P221, DOI 10.1002/tox.20492; Namazi M R, 2009, J Autoimmune Dis, V6, P4, DOI 10.1186/1740-2557-6-4; Naraharisetti SB, 2009, ENVIRON TOXICOL PHAR, V28, P213, DOI 10.1016/j.etap.2009.04.006; Nebert DW, 2006, NAT REV CANCER, V6, P947, DOI 10.1038/nrc2015; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; NORDMANN R, 1992, FREE RADICAL BIO MED, V12, P219, DOI 10.1016/0891-5849(92)90030-K; Perera PMS, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-73; Perez-Maldonado IN, 2005, ENVIRON RES, V98, P177, DOI 10.1016/j.envres.2004.11.001; Ramakrishna V, 2008, ACTA DIABETOL, V45, P41, DOI 10.1007/s00592-007-0018-3; Raza H, 2006, TOXICOL APPL PHARM, V216, P309, DOI 10.1016/j.taap.2006.06.001; Sarabia L, 2009, ECOTOX ENVIRON SAFE, V72, P938, DOI 10.1016/j.ecoenv.2008.04.022; Saulsbury MD, 2008, TOXICOLOGY, V244, P98, DOI 10.1016/j.tox.2007.10.020; Shenouda J, 2009, TOXICOL APPL PHARM, V241, P135, DOI 10.1016/j.taap.2009.08.014; Siddiqui MA, 2010, TOXICOL IN VITRO, V24, P1681, DOI 10.1016/j.tiv.2010.05.019; Singh Mohan, 2004, Indian Journal of Experimental Biology, V42, P292; Slotkin TA, 2007, BRAIN RES BULL, V72, P232, DOI 10.1016/j.brainresbull.2007.01.005; Slotkin TA, 2009, ENVIRON HEALTH PERSP, V117, P587, DOI 10.1289/ehp.0800251; Srivastava RK, 2011, NANOTOXICOLOGY, V5, P195, DOI 10.3109/17435390.2010.503944; Wang XY, 2004, NEUROBIOL DIS, V16, P179, DOI 10.1016/j.nbd.2004.01.014; Zhao MR, 2009, CHEM RES TOXICOL, V22, P504, DOI 10.1021/tx800358b	51	41	45	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 21	2011	6	3							e17757	10.1371/journal.pone.0017757	http://dx.doi.org/10.1371/journal.pone.0017757			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	738BC	21445290	gold, Green Published, Green Submitted			2023-01-03	WOS:000288613300012
J	Thompson, AM; Hu, TA; Eshelbrenner, CL; Reynolds, K; He, JA; Bazzano, LA				Thompson, Angela M.; Hu, Tian; Eshelbrenner, Carrie L.; Reynolds, Kristi; He, Jiang; Bazzano, Lydia A.			Antihypertensive Treatment and Secondary Prevention of Cardiovascular Disease Events Among Persons Without Hypertension A Meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CONVERTING-ENZYME-INHIBITOR; ACUTE MYOCARDIAL-INFARCTION; BLOOD-PRESSURE REDUCTION; LEFT-VENTRICULAR DYSFUNCTION; HEART-FAILURE; DOUBLE-BLIND; CORONARY-DISEASE; RECURRENT STROKE; CONTROLLED-TRIAL; GLOBAL BURDEN	Context Cardiovascular disease (CVD) risk increases beginning at systolic blood pressure levels of 115 mm Hg. Use of antihypertensive medications among patients with a history of CVD or diabetes and without hypertension has been debated. Objective To evaluate the effect of antihypertensive treatment on secondary prevention of CVD events and all-cause mortality among persons without clinically defined hypertension. Data Sources Meta-analysis with systematic search of MEDLINE (1950 to week 3 of January 2011), EMBASE, and the Cochrane Collaboration Central Register of Controlled Clinical Trials and manual examination of references in selected articles and studies. Study Selection From 874 potentially relevant publications, 25 trials that fulfilled the predetermined inclusion and exclusion criteria were included in the meta-analysis. Data Extraction Information on participant characteristics, trial design and duration, treatment drug, dose, control, and clinical events were extracted using a standardized protocol. Outcomes included stroke, myocardial infarction (MI), congestive heart failure (CHF), composite CVD outcomes, CVD mortality, and all-cause mortality. Results Compared with controls, participants receiving antihypertensive medications had a pooled relative risk of 0.77 (95% confidence interval [CI], 0.61 to 0.98) for stroke, 0.80 (95% CI, 0.69 to 0.93) for MI, 0.71 (95% CI, 0.65 to 0.77) for CHF, 0.85 (95% CI, 0.80 to 0.90) for composite CVD events, 0.83 (95% CI, 0.69 to 0.99) for CVD mortality, and 0.87 (95% CI, 0.80 to 0.95) for all-cause mortality from random-effects models. The corresponding absolute risk reductions per 1000 persons were -7.7 (95% CI, -15.2 to -0.3) for stroke, -13.3 (95% CI, -28.4 to 1.7) for MI, -43.6 (95% CI, -65.2 to -22.0) for CHF events, -27.1(95% CI, -40.3 to -13.9) for composite CVD events, -15.4 (95% CI, -32.5 to 1.7) for CVD mortality, and -13.7 (95% CI, -24.6 to -2.8) for all-cause mortality. Results did not differ according to trial characteristics or subgroups defined by clinical history. Conclusions Among patients with clinical history of CVD but without hypertension, antihypertensive treatment was associated with decreased risk of stroke, CHF, composite CVD events, and all-cause mortality. Additional randomized trial data are necessary to assess these outcomes in patients without CVD clinical recommendations. JAMA. 2011;305(9):913-922 www.jama.com	[Thompson, Angela M.; Hu, Tian; He, Jiang; Bazzano, Lydia A.] Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, New Orleans, LA 70112 USA; [Eshelbrenner, Carrie L.; He, Jiang; Bazzano, Lydia A.] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA; [Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA USA	Tulane University; Tulane University; Kaiser Permanente	Bazzano, LA (corresponding author), Tulane Univ, Dept Epidemiol, Sch Publ Hlth & Trop Med, 1440 Canal St,SL 18, New Orleans, LA 70112 USA.	lbazzano@tulane.edu	Reynolds, Kristi/AAN-1434-2021; He, Jiang/AAF-5303-2020; Thompson-Paul, Angela/N-7067-2016	Reynolds, Kristi/0000-0001-7619-1649; He, Jiang/0000-0002-8286-9652; Thompson-Paul, Angela/0000-0003-1186-9150	Tulane University; National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health [R01 HL087263, R01 HL090682]; NHLBI [K08 HL091108]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL087263, K08HL091108, R01HL090682] Funding Source: NIH RePORTER	Tulane University; National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Ms Thompson is supported by a grant from the Research Enhancement Fund of Tulane University. Dr He is supported by research grants R01 HL087263 and R01 HL090682 from the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health. Dr Bazzano is supported by grant K08 HL091108 from the NHLBI.	AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; Ambrosioni Ettore, 1994, Controlled Clinical Trials, V15, P201, DOI 10.1016/0197-2456(94)90057-4; [Anonymous], 2001, J Hypertens Suppl, V19, pS21; [Anonymous], 1990, Am J Cardiol, V66, P315; [Anonymous], 1975, Br Med J, V3, P735; Arima H, 2006, J HYPERTENS, V24, P1201, DOI 10.1097/01.hjh.0000226212.34055.86; BABER NS, 1980, BRIT HEART J, V44, P96; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Borghi C, 1999, AM J HYPERTENS, V12, P665, DOI 10.1016/S0895-7061(99)00042-4; Braunwald E, 2004, NEW ENGL J MED, V351, P2058; Chalmers J, 1996, J HYPERTENS, V14, pS41; Chobanian AV, 2003, HYPERTENSION, V42, P1206, DOI 10.1161/01.HYP.0000107251.49515.c2; Choi KM, 2006, J HYPERTENS, V24, P1515, DOI 10.1097/01.hjh.0000239286.02389.0f; CLELAND JGF, 1993, J CARDIOVASC PHARM, V22, pS22, DOI 10.1097/00005344-199306229-00006; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diener HC, 2007, CEREBROVASC DIS, V23, P368, DOI 10.1159/000100105; Egan BM, 2008, CURR HYPERTENS REP, V10, P359, DOI 10.1007/s11906-008-0068-0; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Estacio RO, 1996, CONTROL CLIN TRIALS, V17, P242, DOI 10.1016/0197-2456(95)00154-9; Fox KM, 2003, LANCET, V362, P782; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; Gerstein HC, 2000, LANCET, V355, P253; Gomma AH, 2001, CARDIOVASC DRUG THER, V15, P169, DOI 10.1023/A:1011131130922; Greenlund KJ, 2004, ARCH INTERN MED, V164, P2113, DOI 10.1001/archinte.164.19.2113; Gu DF, 2002, HYPERTENSION, V40, P920, DOI 10.1161/01.HYP.0000040263.94619.D5; Gustafsson F, 1997, J HYPERTENS, V15, P793, DOI 10.1097/00004872-199715070-00012; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Hjalmarson A, 2000, JAMA-J AM MED ASSOC, V283, P1295, DOI 10.1001/jama.283.10.1295; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Investigators TS., 1992, NEW ENGL J MED, V327, P685, DOI 10.1056/NEJM199209033271003.Erratumin; Julius S, 2006, NEW ENGL J MED, V354, P1685, DOI 10.1056/NEJMoa060838; Kenchaiah S, 2004, AM HEART J, V148, P356, DOI 10.1016/j.ahj.2004.02.011; Kiely AE, 2009, BLOOD PRESSURE, V18, P300, DOI 10.3109/08037050903444024; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; KOSTIS JB, 1995, AM J HYPERTENS, V8, P909, DOI 10.1016/0895-7061(95)00156-J; Lawes CMM, 2008, LANCET, V371, P1513, DOI 10.1016/S0140-6736(08)60655-8; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Liu LS, 2009, HYPERTENS RES, V32, P1032, DOI 10.1038/hr.2009.139; Liu LS, 2001, CHINESE MED J-PEKING, V114, P115; Liu LS, 1997, CHINESE MED J-PEKING, V110, P834; Luders S, 2008, J HYPERTENS, V26, P1487, DOI 10.1097/HJH.0b013e3282ff8864; Marre M, 2004, BRIT MED J, V328, P495, DOI 10.1136/bmj.37970.629537.0D; Mcinnes GT, 2009, BLOOD PRESSURE, V18, P304, DOI 10.3109/08037050903416436; Mindlen F, 1996, CAN J CARDIOL, V12, P127; Mitka M, 2006, JAMA-J AM MED ASSOC, V295, P2125, DOI 10.1001/jama.295.18.2125; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; [National Heart Lung and Blood Institute Biologic Specimen and Data Repository Information Coordinating Center], PEACE STUD FORM DAT; Nissen SE, 2004, JAMA-J AM MED ASSOC, V292, P2217, DOI 10.1001/jama.292.18.2217; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Papadopoulos DP, 2008, HYPERTENS RES, V31, P1681, DOI 10.1291/hypres.31.1681; Patel A, 2007, LANCET, V370, P829, DOI 10.1016/S0140-6736(07)61303-8; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; Pfeffer MA, 1998, AM J CARDIOL, V82, p25H; Pimenta E, 2010, NAT REV NEPHROL, V6, P21, DOI 10.1038/nrneph.2009.191; PROGRESS Collaborat Grp, 2001, LANCET, V358, P1556; Remme WJ, 2009, CARDIOVASC DRUG THER, V23, P161, DOI 10.1007/s10557-008-6143-6; Rouleau JL, 2004, J AM COLL CARDIOL, V43, P1423, DOI 10.1016/j.jacc.2003.11.037; Schrier RW, 2002, KIDNEY INT, V61, P1086, DOI 10.1046/j.1523-1755.2002.00213.x; SCHUTZ W, 1983, EUR HEART J, V4, P367; Sleight P, 2001, LANCET, V358, P2130, DOI 10.1016/S0140-6736(01)07186-0; Spargias KS, 1999, J HUM HYPERTENS, V13, P511, DOI 10.1038/sj.jhh.1000883; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; Vasan RS, 2002, JAMA-J AM MED ASSOC, V287, P1003, DOI 10.1001/jama.287.8.1003; Vasan RS, 2001, LANCET, V358, P1682, DOI 10.1016/S0140-6736(01)06710-1; Verhagen AP, 1998, J CLIN EPIDEMIOL, V51, P1235, DOI 10.1016/S0895-4356(98)00131-0; Wang YF, 2004, ARCH INTERN MED, V164, P2126, DOI 10.1001/archinte.164.19.2126; WHELTON PK, 2004, CLIN TRIALS CARDIOVA, P282; Yusuf S, 2008, LANCET, V372, P1174, DOI 10.1016/S0140-6736(08)61242-8; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Yusuf S, 2008, NEW ENGL J MED, V359, P1225, DOI 10.1056/NEJMoa0804593; Yusuf S, 2010, HYPERTENSION, V55, P832, DOI 10.1161/HYPERTENSIONAHA.109.142349	75	156	164	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	2011	305	9					913	922		10.1001/jama.2011.250	http://dx.doi.org/10.1001/jama.2011.250			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	728DP	21364140	Green Accepted			2023-01-03	WOS:000287854700024
J	Chin, L; Andersen, JN; Futreal, PA				Chin, Lynda; Andersen, Jannik N.; Futreal, P. Andrew			Cancer genomics: from discovery science to personalized medicine	NATURE MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; ANAPLASTIC LYMPHOMA KINASE; EML4-ALK FUSION GENE; SOMATIC MUTATIONS; ALK KINASE; ACTIVATING MUTATIONS; MONOCLONAL-ANTIBODY; FGFR2 MUTATIONS; PIK3CA GENE	Recent advances in genome technologies and the ensuing outpouring of genomic information related to cancer have accelerated the convergence of discovery science and clinical medicine. Successful examples of translating cancer genomics into therapeutics and diagnostics reinforce its potential to make possible personalized cancer medicine. However, the bottlenecks along the path of converting a genome discovery into a tangible clinical endpoint are numerous and formidable. In this Perspective, we emphasize the importance of establishing the biological relevance of a cancer genomic discovery in realizing its clinical potential and discuss some of the major obstacles to moving from the bench to the bedside.	[Chin, Lynda; Andersen, Jannik N.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA; [Chin, Lynda] Harvard Univ, Sch Med, Dept Dermatol, Boston, MA 02115 USA; [Chin, Lynda] Broad Inst MIT & Harvard, Cambridge, MA USA; [Futreal, P. Andrew] Wellcome Trust Sanger Inst, Canc Genome Project, Hinxton, England	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Wellcome Trust Sanger Institute	Chin, L (corresponding author), Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.	lynda_chin@dfci.harvard.edu		Andersen, Jannik/0000-0003-4528-2120				Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170; Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116; Bachman KE, 2004, CANCER BIOL THER, V3, P772, DOI 10.4161/cbt.3.8.994; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; Brachmann S, 2009, CURR OPIN CELL BIOL, V21, P194, DOI 10.1016/j.ceb.2008.12.011; Campbell IG, 2004, CANCER RES, V64, P7678, DOI 10.1158/0008-5472.CAN-04-2933; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Chin L, 2008, NATURE, V452, P553, DOI 10.1038/nature06914; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dierks C, 2010, CANCER RES, V70, P6193, DOI 10.1158/0008-5472.CAN-08-3719; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dutt A, 2008, P NATL ACAD SCI USA, V105, P8713, DOI 10.1073/pnas.0803379105; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Handolias D, 2010, BRIT J CANCER, V102, P1219, DOI 10.1038/sj.bjc.6605635; Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Koivunen JP, 2008, CLIN CANCER RES, V14, P4275, DOI 10.1158/1078-0432.CCR-08-0168; Kralovics R, 2005, NEW ENGL J MED, V352, P1779, DOI 10.1056/NEJMoa051113; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Kwitkowski VE, 2010, ONCOLOGIST, V15, P428, DOI 10.1634/theoncologist.2009-0178; Kwong LN, 2010, CELL, V140, P180, DOI 10.1016/j.cell.2010.01.013; Levine RL, 2005, CANCER CELL, V7, P387, DOI 10.1016/j.ccr.2005.03.023; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pechloff K, 2010, J EXP MED, V207, P1031, DOI 10.1084/jem.20092042; Pollock PM, 2007, ONCOGENE, V26, P7158, DOI 10.1038/sj.onc.1210529; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Reitman ZJ, 2010, JNCI-J NATL CANCER I, V102, P932, DOI 10.1093/jnci/djq187; Riccaboni M, 2010, DRUG DISCOV TODAY, V15, P517, DOI 10.1016/j.drudis.2010.05.001; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105; Sousa SF, 2008, CURR MED CHEM, V15, P1478, DOI 10.2174/092986708784638825; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Turke AB, 2010, CLIN CANCER RES, V16, P3523, DOI 10.1158/1078-0432.CCR-10-1201; Uckun FM, 2010, BRIT J HAEMATOL, V149, P508, DOI 10.1111/j.1365-2141.2010.08106.x; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105	67	410	421	1	109	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	MAR	2011	17	3					297	303		10.1038/nm.2323	http://dx.doi.org/10.1038/nm.2323			7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	730XF	21383744				2023-01-03	WOS:000288070000040
J	Benning, A; Dixon-Woods, M; Nwulu, U; Ghaleb, M; Dawson, J; Barber, N; Franklin, BD; Girling, A; Hemming, K; Carmalt, M; Rudge, G; Naicker, T; Kotecha, A; Derrington, MC; Lilford, R				Benning, Amirta; Dixon-Woods, Mary; Nwulu, Ugochi; Ghaleb, Maisoon; Dawson, Jeremy; Barber, Nick; Franklin, Bryony Dean; Girling, Alan; Hemming, Karla; Carmalt, Martin; Rudge, Gavin; Naicker, Thirumalai; Kotecha, Amit; Derrington, M. Clare; Lilford, Richard			Multiple component patient safety intervention in English hospitals: controlled evaluation of second phase	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE-NATIONAL-AUDIT; FRAMEWORK; ADMISSIONS; MORTALITY; ADULT; UNITS; WORK	Objective To independently evaluate the impact of the second phase of the Health Foundation's Safer Patients Initiative (SPI2) on a range of patient safety measures. Design A controlled before and after design. Five substudies: survey of staff attitudes; review of case notes from high risk (respiratory) patients in medical wards; review of case notes from surgical patients; indirect evaluation of hand hygiene by measuring hospital use of handwashing materials; measurement of outcomes (adverse events, mortality among high risk patients admitted to medical wards, patients' satisfaction, mortality in intensive care, rates of hospital acquired infection). Setting NHS hospitals in England. Participants Nine hospitals participating in SPI2 and nine matched control hospitals. Intervention The SPI2 intervention was similar to the SPI1, with somewhat modified goals, a slightly longer intervention period, and a smaller budget per hospital. Results One of the scores (organisational climate) showed a significant (P=0.009) difference in rate of change over time, which favoured the control hospitals, though the difference was only 0.07 points on a five point scale. Results of the explicit case note reviews of high risk medical patients showed that certain practices improved over time in both control and SPI2 hospitals (and none deteriorated), but there were no significant differences between control and SPI2 hospitals. Monitoring of vital signs improved across control and SPI2 sites. This temporal effect was significant for monitoring the respiratory rate at both the six hour (adjusted odds ratio 2.1, 99% confidence interval 1.0 to 4.3; P=0.010) and 12 hour (2.4, 1.1 to 5.0; P=0.002) periods after admission. There was no significant effect of SPI for any of the measures of vital signs. Use of a recommended system for scoring the severity of pneumonia improved from 1.9% (1/52) to 21.4% (12/56) of control and from 2.0% (1/50) to 41.7% (25/60) of SPI2 patients. This temporal change was significant (7.3, 1.4 to 37.7; P=0.002), but the difference in difference was not significant (2.1, 0.4 to 11.1; P=0.236). There were no notable or significant changes in the pattern of prescribing errors, either over time or between control and SPI2 hospitals. Two items of medical history taking (exercise tolerance and occupation) showed significant improvement over time, across both control and SPI2 hospitals, but no additional SPI2 effect. The holistic review showed no significant changes in error rates either over time or between control and SPI2 hospitals. The explicit case note review of perioperative care showed that adherence rates for two of the four perioperative standards targeted by SPI2 were already good at baseline, exceeding 94% for antibiotic prophylaxis and 98% for deep vein thrombosis prophylaxis. Intraoperative monitoring of temperature improved over time in both groups, but this was not significant (1.8, 0.4 to 7.6; P=0.279), and there were no additional effects of SPI2. A dramatic rise in consumption of soap and alcohol hand rub was similar in control and SPI2 hospitals (P=0.760 and P=0.889, respectively), as was the corresponding decrease in rates of Clostridium difficile and meticillin resistant Staphylococcus aureus infection (P=0.652 and P=0.693, respectively). Mortality rates of medical patients included in the case note reviews in control hospitals increased from 17.3% (42/ 243) to 21.4% (24/112), while in SPI2 hospitals they fell from 10.3% (24/233) to 6.1% (7/114) (P=0.043). Fewer than 8% of deaths were classed as avoidable; changes in proportions could not explain the divergence of overall death rates between control and SPI2 hospitals. There was no significant difference in the rate of change in mortality in intensive care. Patients' satisfaction improved in both control and SPI2 hospitals on all dimensions, but again there were no significant changes between the two groups of hospitals. Conclusions Many aspects of care are already good or improving across the NHS in England, suggesting considerable improvements in quality across the board. These improvements are probably due to contemporaneous policy activities relating to patient safety, including those with features similar to the SPI, and the emergence of professional consensus on some clinical processes. This phenomenon might have attenuated the incremental effect of the SPI, making it difficult to detect. Alternatively, the full impact of the SPI might be observable only in the longer term. The conclusion of this study could have been different if concurrent controls had not been used.	[Benning, Amirta; Girling, Alan; Hemming, Karla; Rudge, Gavin; Naicker, Thirumalai; Lilford, Richard] Univ Birmingham, Sch Hlth & Populat Sci, Edgbaston B15 2TT, W Midlands, England; [Dixon-Woods, Mary] Univ Leicester, Dept Hlth Sci, Leicester LE1 7RH, Leics, England; [Nwulu, Ugochi] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp, Clin Invest Unit, Birmingham B15 2TH, W Midlands, England; [Franklin, Bryony Dean] Univ London, Sch Pharm, Dept Practice & Policy, Ctr Medicat Safety & Serv Qual, London WC1N 1AX, England; [Ghaleb, Maisoon] Univ Hertfordshire, Sch Pharm, Hatfield AL10 9AB, Herts, England; [Dawson, Jeremy] Aston Univ, Aston Business Sch, Work & Org Psychol Grp, Birmingham B4 7ET, W Midlands, England; [Franklin, Bryony Dean] Imperial Coll Healthcare NHS Trust, St Marys Hosp, Ctr Medicat Safety & Serv Qual, London W2 1NY, England; [Carmalt, Martin; Kotecha, Amit] Royal Orthopaed Hosp, Birmingham B31 2AP, W Midlands, England	University of Birmingham; University of Leicester; University of Birmingham; University of London; University College London; University of London School of Pharmacy; University of Hertfordshire; Aston University; Imperial College London; Royal Orthopaedic Hospital	Lilford, R (corresponding author), Univ Birmingham, Sch Hlth & Populat Sci, Edgbaston B15 2TT, W Midlands, England.	r.j.lilford@bham.ac.uk	Girling, Alan J/A-7843-2012; Hemming, karla/AAB-3391-2021; Nwulu, Ugochi/G-9245-2011	Hemming, karla/0000-0002-2226-6550; Nwulu, Ugochi/0000-0002-4720-4751; Dixon-Woods, Mary/0000-0002-5915-0041; Girling, Alan/0000-0003-2022-045X; Franklin, Bryony/0000-0002-2892-1245; Nwulu, Ugochi/0000-0001-6372-176X	Health Foundation; National Patient Safety Agency; National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country; Engineering and Physical Sciences Research Council, Multidisciplinary Assessment of Technology Centre for Healthcare; National Institute of Health Research; EPSRC [EP/F063822/1] Funding Source: UKRI; MRC [G0800808] Funding Source: UKRI; Engineering and Physical Sciences Research Council [EP/F063822/1] Funding Source: researchfish; Medical Research Council [G0800808] Funding Source: researchfish	Health Foundation; National Patient Safety Agency; National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country; Engineering and Physical Sciences Research Council, Multidisciplinary Assessment of Technology Centre for Healthcare(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); National Institute of Health Research(National Institute for Health Research (NIHR)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This study was funded by the Health Foundation and the National Patient Safety Agency. KH was funded by the National Institute for Health Research Collaborations for Leadership in Applied Health Research and Care for Birmingham and Black Country, and AG by the Engineering and Physical Sciences Research Council, Multidisciplinary Assessment of Technology Centre for Healthcare programme. The Centre for Medication Safety and Service Quality is affiliated with the Centre for Patient Safety and Service Quality at Imperial College Healthcare NHS Trust, which is funded by the National Institute of Health Research. The evaluation was sponsored for research governance purposes by the University of Birmingham. The study was designed independently by the researchers. The researchers acted independently but worked collaboratively with the funder. The researchers independently collected, analysed and interpreted the data. The researchers wrote this article independently. The funders were given the opportunity to provide comments before submission. All researchers (apart from CD) had the opportunity to access participant anonymised data.	Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Bate P., 2008, ORG QUALITY IMPROVEM; Benning A, 2010, CONTROLLED EVALUATIO; Benning A, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d195; Borrill C, 2000, BRIT J HLTH CARE, V6, P364, DOI DOI 10.12968/BJHC.2000.6.8.19300; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; British Orthopaedic Association, 2006, PRIM TOT HIP REPL GU; Brown C, 2008, QUAL SAF HEALTH CARE, V17, P163, DOI 10.1136/qshc.2007.023648; Campbell SE, 2001, INT J QUAL HEALTH C, V13, P309, DOI 10.1093/intqhc/13.4.309; Davidoff F, 2009, JAMA-J AM MED ASSOC, V302, P2580, DOI 10.1001/jama.2009.1845; Department of Health, 2010, BEDS OP OV ENGL; Department of Health, 2007, SAV LIV RED INF DEL; Dixon-Woods M, 2010, QUAL SAF HEALTH CARE, V19, P74, DOI 10.1136/qshc.2008.029504; EPSTEIN S, 1995, SCI TECHNOL HUM VAL, V20, P408, DOI 10.1177/016224399502000402; Gallivan S, 2008, DRUG SAFETY, V31, P637, DOI 10.2165/00002018-200831080-00001; GUZZO RA, 1985, PERS PSYCHOL, V38, P275, DOI 10.1111/j.1744-6570.1985.tb00547.x; Harrison DA, 2006, CRIT CARE MED, V34, P1378, DOI 10.1097/01.CCM.0000216702.94014.75; Harrison DA, 2004, CRIT CARE, V8, pR99, DOI 10.1186/cc2834; Harrison DA, 2007, CRIT CARE MED, V35, P1091, DOI 10.1097/01.CCM.0000259468.24532.44; Healthcare Commission, 2006, MAK SENS YOUR STAFF; Hillman K, 2005, LANCET, V365, P2091; House of Commons Health Committee, 2009, 6 HOUS COMM HLTH COM; Institute for Healthcare Improvement, 2007, GUID PREV SURG SIT I; Keogh-Brown M, 2007, HEALTH TECHNOL ASSES, V11, P1; Leape LL, 2005, JAMA-J AM MED ASSOC, V293, P2384, DOI 10.1001/jama.293.19.2384; Lilford Richard, 2007, J Health Serv Res Policy, V12, P173, DOI 10.1258/135581907781543012; LILFORD RJ, 2010, BMJ-BRIT MED J, V341, pC4413, DOI DOI 10.1136/BMJ.C4413; Michie S, 2004, INT J MANAG REV, V5-6, P91, DOI 10.1111/j.1460-8545.2004.00098.x; National Institute for Health and Clinical Excellence, 2008, 65 NAT I HLTH CLIN E; National Institute for Health and Clinical Excellence, 2010, 74 NAT I HLTH CLIN E; National Institute for Health and Clinical Excellence, 2007, CG50  NAT I HLTH CLI; National Patient Safety Agency, 2010, CLEAN CAMP; SACKS H, 1982, AM J MED, V72, P233, DOI 10.1016/0002-9343(82)90815-4; Slaughter MJ, 2001, J INT ECON, V55, P203, DOI 10.1016/S0022-1996(00)00087-8; Stone S, 2007, J HOSP INFECT, V66, P293, DOI 10.1016/j.jhin.2007.04.011; West MA, 2006, J ORGAN BEHAV, V27, P983, DOI 10.1002/job.396	36	75	78	0	26	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	2011	342								d199	10.1136/bmj.d199	http://dx.doi.org/10.1136/bmj.d199			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	718PW	21292720	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000287138500003
J	Xian, Y; Holloway, RG; Chan, PS; Noyes, K; Shah, MN; Ting, HH; Chappel, AR; Peterson, ED; Friedman, B				Xian, Ying; Holloway, Robert G.; Chan, Paul S.; Noyes, Katia; Shah, Manish N.; Ting, Henry H.; Chappel, Andre R.; Peterson, Eric D.; Friedman, Bruce			Association Between Stroke Center Hospitalization for Acute Ischemic Stroke and Mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; REDUCE MORTALITY; TRAUMA CENTERS; CARE; OUTCOMES; QUALITY; COMPARE; DISEASE; BIAS	Context Although stroke centers are widely accepted and supported, little is known about their effect on patient outcomes. Objective To examine the association between admission to stroke centers for acute ischemic stroke and mortality. Design, Setting, and Participants Observational study using data from the New York Statewide Planning and Research Cooperative System. We compared mortality for patients admitted with acute ischemic stroke (n = 30 947) between 2005 and 2006 at designated stroke centers and nondesignated hospitals using differential distance to hospitals as an instrumental variable to adjust for potential prehospital selection bias. Patients were followed up for mortality for 1 year after the index hospitalization through 2007. To assess whether our findings were specific to stroke, we also compared mortality for patients admitted with gastrointestinal hemorrhage (n = 39 409) or acute myocardial infarction (n = 40 024) at designated stroke centers and nondesignated hospitals. Main Outcome Measure Thirty-day all-cause mortality. Results Among 30 947 patients with acute ischemic stroke, 15 297 (49.4%) were admitted to designated stroke centers. Using the instrumental variable analysis, admission to designated stroke centers was associated with lower 30-day all-cause mortality (10.1% vs 12.5%; adjusted mortality difference, -2.5%; 95% confidence interval [CI], -3.6% to -1.4%; P<.001) and greater use of thrombolytic therapy (4.8% vs 1.7%; adjusted difference, 2.2%; 95% CI, 1.6% to 2.8%; P<.001). Differences in mortality also were observed at 1-day, 7-day, and 1-year follow-up. The outcome differences were specific for stroke, as stroke centers and nondesignated hospitals had similar 30-day all-cause mortality rates among those with gastrointestinal hemorrhage (5.0% vs 5.8%; adjusted mortality difference, +0.3%; 95% CI, -0.5% to 1.0%; P=.50) or acute myocardial infarction (10.5% vs 12.7%; adjusted mortality difference, +0.1%; 95% CI, -0.9% to 1.1%; P=.83). Conclusion Among patients with acute ischemic stroke, admission to a designated stroke center was associated with modestly lower mortality and more frequent use of thrombolytic therapy. JAMA. 2011;305(4):373-380 www.jama.com	[Xian, Ying; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC 27705 USA; [Holloway, Robert G.; Noyes, Katia; Shah, Manish N.; Chappel, Andre R.; Friedman, Bruce] Univ Rochester, Rochester, NY USA; [Chan, Paul S.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA; [Ting, Henry H.] Mayo Clin, Rochester, MN USA	Duke University; University of Rochester; Saint Luke's Mid America Heart Institute; Mayo Clinic	Xian, Y (corresponding author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA.	ying.xian@duke.edu	Peterson, Eric David/ABF-5033-2021; Xian, Ying/O-1956-2019	Xian, Ying/0000-0002-1237-1162; Shah, Manish/0000-0001-6331-1074	Schering Plough; Bristol-Myers Squibb; Merck/Schering Plough; Sanofi Aventis; Saint Judes; American Heart Association (AHA) [0815772D]; Agency for Healthcare Research and Quality (AHRQ) [U18HS016964]; National Heart, Lung, and Blood Institute [K23HL102224]; National Institute on Aging [1K23AG028942]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [U18HS016964] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL102224] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG028942] Funding Source: NIH RePORTER	Schering Plough(Merck & CompanySchering Plough Corporation); Bristol-Myers Squibb(Bristol-Myers Squibb); Merck/Schering Plough(Merck & CompanySchering Plough Corporation); Sanofi Aventis(Sanofi-Aventis); Saint Judes; American Heart Association (AHA)(American Heart Association); Agency for Healthcare Research and Quality (AHRQ)(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Holloway reported being a consultant for Milliman Guidelines, reviewing neurology guidelines. Dr Peterson reported receiving research grants from Schering Plough, Bristol-Myers Squibb, Merck/Schering Plough, Sanofi Aventis, and Saint Judes and being a consultant/advisory board member to Pfizer and Bayer Corp. No other disclosures were reported.; This study was funded in part by a predoctoral fellowship 0815772D from the American Heart Association (AHA) Founders Affiliate (Dr Xian). This study received infrastructure support from the Agency for Healthcare Research and Quality (AHRQ) (U18HS016964). Dr Chan is supported by a Career Development Grant Award (K23HL102224) from the National Heart, Lung, and Blood Institute. Dr Shah is supported by the Paul B. Beeson Career Development Award (National Institute on Aging 1K23AG028942).	Agency for Healthcare Research and Quality, 2006, INP QUAL IND OV; Alberts MJ, 2010, STROKE, V41, P1100, DOI 10.1161/STROKEAHA.110.582148; Alberts MJ, 2000, JAMA-J AM MED ASSOC, V283, P3102, DOI 10.1001/jama.283.23.3102; [Anonymous], NEW YORK STATE EMT A; Austin PC, 2009, COMMUN STAT-SIMUL C, V38, P1228, DOI 10.1080/03610910902859574; Beck CA, 2003, HEALTH SERV RES, V38, P1423, DOI 10.1111/j.1475-6773.2003.00186.x; Bhattacharya J, 2006, STAT MED, V25, P389, DOI 10.1002/sim.2226; Bravata DM, 2010, ARCH INTERN MED, V170, P804, DOI 10.1001/archinternmed.2010.92; Douglas VC, 2005, NEUROLOGY, V64, P422, DOI 10.1212/01.WNL.0000150903.38639.E1; Fonarow GC, 2010, CIRCULATION, V122, P2459, DOI 10.1161/CIR.0b013e3182011a81; Goldstein LB, 2004, STROKE, V35, P1941, DOI 10.1161/01.STR.0000135225.80898.1c; Goldstein LB, 2003, NEUROLOGY, V61, P792, DOI 10.1212/01.WNL.0000082724.77447.3A; Greene W. H., 2003, ECONOMETRIC ANAL; Gropen TI, 2006, NEUROLOGY, V67, P88, DOI 10.1212/01.wnl.0000223622.13641.6d; Holloway RG, 2007, JAMA-J AM MED ASSOC, V298, P802, DOI 10.1001/jama.298.7.802; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; Lattimore SU, 2003, STROKE, V34, pE55, DOI 10.1161/01.STR.0000073789.12120.F3; Lichtman JH, 2009, STROKE, V40, pE127; Lloyd-Jones D, 2010, CIRCULATION, V121, pE46, DOI 10.1161/CIRCULATIONAHA.109.192667; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McConnell KJ, 2005, HEALTH SERV RES, V40, P435, DOI 10.1111/j.1475-6773.2005.0u367.x; Meretoja A, 2010, STROKE, V41, pE361; Mitchell JB, 1996, STROKE, V27, P1937, DOI 10.1161/01.STR.27.11.1937; Newhouse JP, 1998, ANNU REV PUBL HEALTH, V19, P17, DOI 10.1146/annurev.publhealth.19.1.17; Peterson ED, 2006, JAMA-J AM MED ASSOC, V295, P1912, DOI 10.1001/jama.295.16.1912; Pracht EE, 2007, MED CARE RES REV, V64, P83, DOI 10.1177/1077558706296241; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Stradling D, 2007, NEUROLOGY, V68, P469, DOI 10.1212/01.wnl.0000252930.82140.65; Stukel TA, 2007, JAMA-J AM MED ASSOC, V297, P278, DOI 10.1001/jama.297.3.278; U.S. Department of Agriculture, MEAS RUR RUR URB COM; *US DEP HHS, HOSP COMP	31	234	235	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2011	305	4					373	380		10.1001/jama.2011.22	http://dx.doi.org/10.1001/jama.2011.22			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	711MH	21266684	Green Accepted, Bronze			2023-01-03	WOS:000286595200022
J	Kane, RL				Kane, Robert L.			Finding the Right Level of Posthospital Care "We Didn't Realize There Was Any Other Option for Him"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM-CARE; INPATIENT REHABILITATION FACILITIES; NURSING-HOME RESIDENTS; OUTCOMES; QUALITY; TRANSITIONS; FRACTURE; STROKE; REIMBURSEMENT; REPLACEMENT	Many families considering posthospital care options are ill-prepared and in need of guidance. They may not know the range of available options, the relative benefits of each, or have considered their therapeutic goals. Physicians should be informants, advocates, and facilitators of this big leap for their patients. Making a good long-term care decision requires information and structure, but such decisions are often made under great time pressure as part of a hospital discharge. Professional intervention and guidance by an informed but disinterested facilitator may be needed, but hospital discharge planners may not be well suited for this role because their mandate is a rapid discharge. Physicians have 2 crucial roles in these transitions: to ensure the seamless delivery of primary care and to advocate for and facilitate, however possible, better decision making. Physicians need at least a rudimentary knowledge of the array of options and the implications of each. Even if the physician cannot serve as the planning facilitator, the physician should ensure that this task is done well. This review describes the range of options and the implications of each option for long-term care in the United States. It suggests the need for evaluating each patient's care goals, family circumstances and resources, and clinical status to determine if more aggressive medical care might improve an individual's clinical trajectory. JAMA. 2011; 305(3): 284-293	Univ Minnesota, Sch Publ Hlth, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kane, RL (corresponding author), Univ Minnesota, Sch Publ Hlth, D351 Mayo MMC 197,420 Delaware St SE, Minneapolis, MN 55455 USA.	kanex001@umn.edu			SCAN Foundation	SCAN Foundation	The Care of the Aging Patient series is made possible by funding from The SCAN Foundation.	[Anonymous], DOES MED COV HOM CAR; [Anonymous], NURS HOM REP CARD; [Anonymous], AD FOST CAR OV; [Anonymous], MED STAT WALV PROGR; Borson S, 2000, INT J GERIATR PSYCH, V15, P1021, DOI 10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6; Bostick JE, 2006, J AM MED DIR ASSOC, V7, P366, DOI 10.1016/j.jamda.2006.01.024; Buntin MB, 2010, MED CARE, V48, P776, DOI 10.1097/MLR.0b013e3181e359df; Chudyk AM, 2009, ARCH PHYS MED REHAB, V90, P246, DOI 10.1016/j.apmr.2008.06.036; Coleman E. A., 2003, ANN LONG TERM CARE, V11, P33; Coleman EA, 2005, ARCH INTERN MED, V165, P1842, DOI 10.1001/archinte.165.16.1842; Coleman EA, 2004, HEALTH SERV RES, V39, P1449, DOI 10.1111/j.1475-6773.2004.00298.x; Coleman EA, 2004, J AM GERIATR SOC, V52, pS1; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Collier E, 2008, RES GERONTOL NURS, V1, P157, DOI 10.3928/00220124-20091301-03; Comondore VR, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2732; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1269, DOI 10.1016/j.apmr.2008.11.021; DeJong G, 2009, ARCH PHYS MED REHAB, V90, P1306, DOI 10.1016/j.apmr.2009.04.003; Deutsch A, 2005, MED CARE, V43, P892, DOI 10.1097/01.mlr.0000173591.23310.d5; Deutsch A, 2006, STROKE, V37, P1477, DOI 10.1161/01.STR.0000221172.99375.5a; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fukuda Y, 2008, GERIATR GERONTOL INT, V8, P166, DOI 10.1111/j.1447-0594.2008.00466.x; Golant S, 2008, ASSISTED LIVING RESI; Hilliard JL, 2005, J LEGAL MED, V26, P41, DOI 10.1080/01947640590917945; Hillmer MP, 2005, MED CARE RES REV, V62, P139, DOI 10.1177/1077558704273769; Hunt R, 2004, CASE MANAGING LONG T; Jarman Brian, 2004, BMJ, V328, P605, DOI 10.1136/bmj.328.7440.605; Kane RL, 2003, J AM GERIATR SOC, V51, P1427, DOI 10.1046/j.1532-5415.2003.51461.x; Kane RL, 1998, J AM GERIATR SOC, V46, P1525, DOI 10.1111/j.1532-5415.1998.tb01537.x; Kane RL, 2011, GOOD CAREGIVER; Kane RL, 2009, ESSENTIALS CLIN GERI; Kane RL, 2007, MED CARE, V45, P1195, DOI 10.1097/MLR.0b013e3181468ca3; Kane RL, 2006, GERONTOLOGIST, V46, P474, DOI 10.1093/geront/46.4.474; Kane RA, 2007, GERONTOLOGIST, V47, P125, DOI 10.1093/geront/47.Supplement_1.125; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LAWTON MP, 1969, GERONTOLOGIST, V9, P9, DOI 10.1093/geront/9.1.9; Lynn J, 2001, JAMA-J AM MED ASSOC, V285, P925, DOI 10.1001/jama.285.7.925; MAHONEY F I, 1965, Md State Med J, V14, P61; *MED, NURS HOM COMP; Mor V, 2007, HEALTH AFFAIR, V26, P1762, DOI 10.1377/hlthaff.26.6.1762; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor M, 2008, AM J NURS, V108, P58, DOI 10.1097/01.NAJ.0000336420.34946.3a; Naylor MD, 2004, J AM GERIATR SOC, V52, P675, DOI 10.1111/j.1532-5415.2004.52202.x; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Ouslander JG, 2010, J AM GERIATR SOC, V58, P760; Ouslander JG, 2010, J AM GERIATR SOC, V58, P627, DOI 10.1111/j.1532-5415.2010.02768.x; Spillman BC, 2002, MED CARE, V40, P965, DOI 10.1097/00005650-200210000-00013; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stevenson DG, 2010, HEALTH AFFAIR, V29, P35, DOI 10.1377/hlthaff.2009.0527; Stone RI, 2007, GERONTOLOGIST, V47, P23, DOI 10.1093/geront/47.Supplement_1.23; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; Tsutsui T, 2007, J AM GERIATR SOC, V55, P1458, DOI 10.1111/j.1532-5415.2007.01281.x; Wiener JM, 1999, J AGING HEALTH, V11, P417, DOI 10.1177/089826439901100308; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4; Zimmerman S, 2007, GERONTOLOGIST, V47, P33, DOI 10.1093/geront/47.Supplement_1.33	57	71	71	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2011	305	3					284	293		10.1001/jama.2010.2015	http://dx.doi.org/10.1001/jama.2010.2015			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	707YY	21245184				2023-01-03	WOS:000286328700024
J	Chertow, GM; Levin, NW; Beck, GJ; Depner, TA; Eggers, PW; Gassman, JJ; Gorodetskaya, I; Greene, T; James, S; Larive, B; Lindsay, RM; Mehta, RL; Miller, B; Ornt, DB; Rajagopalan, S; Rastogi, A; Rocco, MV; Schiller, B; Sergeyeva, O; Schulman, G; Ting, GO; Unruh, ML; Star, RA; Kliger, AS				Chertow, Glenn M.; Levin, Nathan W.; Beck, Gerald J.; Depner, Thomas A.; Eggers, Paul W.; Gassman, Jennifer J.; Gorodetskaya, Irina; Greene, Tom; James, Sam; Larive, Brett; Lindsay, Robert M.; Mehta, Ravindra L.; Miller, Brent; Ornt, Daniel B.; Rajagopalan, Sanjay; Rastogi, Anjay; Rocco, Michael V.; Schiller, Brigitte; Sergeyeva, Olga; Schulman, Gerald; Ting, George O.; Unruh, Mark L.; Star, Robert A.; Kliger, Alan S.		FHN Trial Grp	In-Center Hemodialysis Six Times per Week versus Three Times per Week	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LEFT-VENTRICULAR HYPERTROPHY; QUALITY-OF-LIFE; STAGE RENAL-DISEASE; CONVENTIONAL HEMODIALYSIS; NOCTURNAL HEMODIALYSIS; BLOOD-PRESSURE; LONG-TERM; FOLLOW-UP; MORTALITY; UREA	BACKGROUND In this randomized clinical trial, we aimed to determine whether increasing the frequency of in-center hemodialysis would result in beneficial changes in left ventricular mass, self-reported physical health, and other intermediate outcomes among patients undergoing maintenance hemodialysis. METHODS Patients were randomly assigned to undergo hemodialysis six times per week (frequent hemodialysis, 125 patients) or three times per week (conventional hemodialysis, 120 patients) for 12 months. The two coprimary composite outcomes were death or change (from baseline to 12 months) in left ventricular mass, as assessed by cardiac magnetic resonance imaging, and death or change in the physical-health composite score of the RAND 36-item health survey. Secondary outcomes included cognitive performance; self-reported depression; laboratory markers of nutrition, mineral metabolism, and anemia; blood pressure; and rates of hospitalization and of interventions related to vascular access. RESULTS Patients in the frequent-hemodialysis group averaged 5.2 sessions per week; the weekly standard Kt/V-urea (the product of the urea clearance and the duration of the dialysis session normalized to the volume of distribution of urea) was significantly higher in the frequent-hemodialysis group than in the conventional-hemodialysis group (3.54 +/- 0.56 vs. 2.49 +/- 0.27). Frequent hemodialysis was associated with significant benefits with respect to both coprimary composite outcomes (hazard ratio for death or increase in left ventricular mass, 0.61; 95% confidence interval [CI], 0.46 to 0.82; hazard ratio for death or a decrease in the physical-health composite score, 0.70; 95% CI, 0.53 to 0.92). Patients randomly assigned to frequent hemodialysis were more likely to undergo interventions related to vascular access than were patients assigned to conventional hemodialysis (hazard ratio, 1.71; 95% CI, 1.08 to 2.73). Frequent hemodialysis was associated with improved control of hypertension and hyperphosphatemia. There were no significant effects of frequent hemodialysis on cognitive performance, self-reported depression, serum albumin concentration, or use of erythropoiesis-stimulating agents. CONCLUSIONS Frequent hemodialysis, as compared with conventional hemodialysis, was associated with favorable results with respect to the composite outcomes of death or change in left ventricular mass and death or change in a physical-health composite score but prompted more frequent interventions related to vascular access.	[Chertow, Glenn M.; Gorodetskaya, Irina; Schiller, Brigitte; Ting, George O.] Stanford Univ, Palo Alto, CA 94304 USA; [Chertow, Glenn M.; Gorodetskaya, Irina; James, Sam] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Levin, Nathan W.; Sergeyeva, Olga] Renal Res Inst, New York, NY USA; [Beck, Gerald J.; Gassman, Jennifer J.; Greene, Tom; Larive, Brett] Cleveland Clin Fdn, Cleveland, OH USA; [Depner, Thomas A.] Univ Calif Davis, Davis, CA 95616 USA; [Eggers, Paul W.; Star, Robert A.] NIDDK, Bethesda, MD USA; [Greene, Tom] Univ Utah, Salt Lake City, UT USA; [Lindsay, Robert M.] Univ Western Ontario, London, ON, Canada; [Mehta, Ravindra L.] Univ Calif San Diego, La Jolla, CA 92093 USA; [Miller, Brent] Washington Univ, St Louis, MO 63130 USA; [Ornt, Daniel B.] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Rajagopalan, Sanjay] Ohio State Univ, Columbus, OH 43210 USA; [Rastogi, Anjay] Univ Calif Los Angeles, Los Angeles, CA USA; [Rocco, Michael V.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Schiller, Brigitte] Satellite Healthcare, San Jose, CA USA; [Schulman, Gerald] Vanderbilt Univ, Nashville, TN USA; [Ting, George O.] El Camino Hosp, Mountain View, CA USA; [Unruh, Mark L.] Univ Pittsburgh, Pittsburgh, PA USA; [Kliger, Alan S.] Hosp St Raphael, New Haven, CT 06511 USA; [Kliger, Alan S.] Yale Univ, New Haven, CT USA	Stanford University; University of California System; University of California San Francisco; Renal Research Institute; Cleveland Clinic Foundation; University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Utah System of Higher Education; University of Utah; Western University (University of Western Ontario); University of California System; University of California San Diego; Washington University (WUSTL); Case Western Reserve University; University System of Ohio; Ohio State University; University of California System; University of California Los Angeles; Wake Forest University; Vanderbilt University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Hospital Saint Raphael; Yale University	Chertow, GM (corresponding author), Stanford Univ, Palo Alto, CA 94304 USA.		Schiller, Brigitte/AAW-3230-2021; Kliger, Alan/AAN-6653-2021; Mehta, Ravindra/ACD-4769-2022; Lindsay, Bob/G-3321-2011	Mehta, Ravindra/0000-0002-0908-2968; Chertow, Glenn/0000-0002-7599-0534	National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases; Center for Medicare and Medical Services; NIH Research Foundation; Amgen; Baxter; Dialysis Clinics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK085446, U01DK066481] Funding Source: NIH RePORTER	National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Center for Medicare and Medical Services; NIH Research Foundation(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Amgen(Amgen); Baxter; Dialysis Clinics; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Supported by the National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases, the Center for Medicare and Medical Services, and the NIH Research Foundation. Contributors to the NIH Foundation in support of the FHN trials included Amgen, Baxter, and Dialysis Clinics. Additional support was provided by DaVita, Dialysis Clinics, Fresenius Medical Care, Renal Advantage, Renal Research Institute, and Satellite Healthcare.	Ayus JC, 2005, J AM SOC NEPHROL, V16, P2778, DOI 10.1681/ASN.2005040392; Bock HA, 2008, NEPHROL DIAL TRANSPL, V23, P301, DOI 10.1093/ndt/gfm579; Buoncristiani U, 1988, Kidney Int Suppl, V24, pS137; Culleton BF, 2007, JAMA-J AM MED ASSOC, V298, P1291, DOI 10.1001/jama.298.11.1291; Daugirdas JT, 2010, KIDNEY INT, V77, P637, DOI 10.1038/ki.2009.525; DAUGIRDAS SURI, 2004, HEMO STUDY J AM SOC, V15, P194; DePalma John R, 2004, Hemodial Int, V8, P19, DOI 10.1111/j.1492-7535.2004.00082.x; Depner T, 2004, KIDNEY INT, V65, P1386, DOI 10.1111/j.1523-1755.2004.00519.x; Depner TA, 2001, ADV RENAL REPLACE TH, V8, P227, DOI 10.1053/jarr.2001.27594; Eknoyan G, 2002, NEW ENGL J MED, V347, P2010, DOI 10.1056/NEJMoa021583; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Foley RN, 2002, KIDNEY INT, V62, P1784, DOI 10.1046/j.1523-1755.2002.00636.x; Gorodetskaya I, 2005, KIDNEY INT, V68, P2801, DOI 10.1111/j.1523-1755.2005.00752.x; Gotch FA, 1998, NEPHROL DIAL TRANSPL, V13, P10, DOI 10.1093/ndt/13.suppl_6.10; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; HELD PJ, 1983, J HEALTH ECON, V2, P95, DOI 10.1016/0167-6296(83)90001-2; Held PJ, 1996, KIDNEY INT, V50, P550, DOI 10.1038/ki.1996.348; Hemmelgarn BR, 2003, AM J KIDNEY DIS, V42, P125, DOI 10.1016/S0272-6386(03)00415-3; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.2307/2336325; Lacson E, 2010, CLIN J AM SOC NEPHRO, V5, P252, DOI 10.2215/CJN.07231009; Lockridge Robert S Jr, 2004, Hemodial Int, V8, P61, DOI 10.1111/j.1492-7535.2004.00076.x; London GM, 2001, J AM SOC NEPHROL, V12, P2759, DOI 10.1681/ASN.V12122759; LOWRIE EG, 1981, NEW ENGL J MED, V305, P1176, DOI 10.1056/NEJM198111123052003; Mapes DL, 2003, KIDNEY INT, V64, P339, DOI 10.1046/j.1523-1755.2003.00072.x; McClellan WM, 1998, J AM SOC NEPHROL, V9, P1940; Miskulin DC, 2001, KIDNEY INT, V60, P1498, DOI 10.1046/j.1523-1755.2001.00954.x; Neves PL, 1997, AM J KIDNEY DIS, V30, P224, DOI 10.1016/S0272-6386(97)90056-1; Okin PM, 2004, JAMA-J AM MED ASSOC, V292, P2343, DOI 10.1001/jama.292.19.2343; OWEN WF, 1993, NEW ENGL J MED, V329, P1001, DOI 10.1056/NEJM199309303291404; *REN DAT SYST, 2009, USRDS 2009 ANN DAT R; SCRIBNER BH, 1960, T AM SOC ART INT ORG, V6, P114; Suri RS, 2007, KIDNEY INT, V71, P349, DOI 10.1038/sj.ki.5002032; Suri RS, 2006, CLIN J AM SOC NEPHRO, V1, P33, DOI 10.2215/CJN.00340705; Szczech LA, 2003, NEPHROL DIAL TRANSPL, V18, P1585, DOI 10.1093/ndt/gfg225; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; TESCHAN PE, 1975, T AM SOC ART INT ORG, V21, P488; Ting GO, 2003, AM J KIDNEY DIS, V42, P1020, DOI 10.1016/j.ajkd.2003.07.020; Walsh M, 2005, KIDNEY INT, V67, P1500, DOI 10.1111/j.1523-1755.2005.00228.x; Zoccali C, 2004, KIDNEY INT, V65, P1492, DOI 10.1111/j.1523-1755.2004.00530.x	39	725	765	1	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	2010	363	24					2287	2300		10.1056/NEJMoa1001593	http://dx.doi.org/10.1056/NEJMoa1001593			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	691PA	21091062	Green Accepted, Green Published			2023-01-03	WOS:000285092100004
J	Allen, KD; Oddone, EZ; Coffman, CJ; Datta, SK; Juntilla, KA; Lindquist, JH; Walker, TA; Weinberger, M; Bosworth, HB				Allen, Kelli D.; Oddone, Eugene Z.; Coffman, Cynthia J.; Datta, Santanu K.; Juntilla, Karen A.; Lindquist, Jennifer H.; Walker, Tessa A.; Weinberger, Morris; Bosworth, Hayden B.			Telephone-Based Self-management of Osteoarthritis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							HEALTH-STATUS; EDUCATION-PROGRAMS; CLINICAL-TRIALS; CHRONIC DISEASE; ARTHRITIS; VETERANS; OUTCOMES; KNEE; INTERVENTIONS; METAANALYSIS	Background: Osteoarthritis is a leading cause of pain and disability, and self-management behaviors for osteoarthritis are underutilized. Objective: To examine the effectiveness of a telephone-based self-management intervention for hip or knee osteoarthritis in a primary care setting. Design: Randomized clinical trial with equal assignment to osteoarthritis self-management, health education (attention control), and usual care control groups. (ClinicalTrials.gov registration number: NCT00288912) Setting: Primary care clinics in a Veterans Affairs Medical Center. Patients: 515 patients with symptomatic hip or knee osteoarthritis. Intervention: The osteoarthritis self-management intervention involved educational materials and 12 monthly telephone calls to support individualized goals and action plans. The health education intervention involved nonosteoarthritis educational materials and 12 monthly telephone calls related to general health screening topics. Measurements: The primary outcome was score on the Arthritis Impact Measurement Scales-2 pain subscale (range, 0 to 10). Pain was also assessed with a 10-cm visual analog scale. Measurements were collected at baseline and 12 months. Results: 461 participants (90%) completed the 12-month assessment. The mean Arthritis Impact Measurement Scales-2 pain score in the osteoarthritis self-management group was 0.4 point lower (95% CI, -0.8 to 0.1 point; P = 0.105) than in the usual care group and 0.6 point lower (CI, -1.0 to -0.2 point; P = 0.007) than in the health education group at 12 months. The mean visual analog scale pain score in the osteoarthritis self-management group was 1.1 points lower (CI, -1.6 to -0.6 point; P < 0.001) than in the usual care group and 1.0 point lower (CI, -1.5 to -0.5 point; P < 0.001) than in the health education group. Health care use did not differ across the groups. Limitation: The study was conducted at 1 Veterans Affairs Medical Center, and the sample consisted primarily of men. Conclusion: A telephone-based osteoarthritis self-management program produced moderate improvements in pain, particularly compared with a health education control group.	Duke Univ, Med Ctr, Durham Vet Affairs Med Ctr, Durham, NC 27706 USA; Univ N Carolina, Chapel Hill, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Durham VA Medical Center; University of North Carolina; University of North Carolina Chapel Hill	Allen, KD (corresponding author), US Dept Vet Affairs, Hlth Serv Res & Dev Serv 152, Durham Vet Affairs Med Ctr, 508 Fulton St, Durham, NC 27705 USA.	kelli.allen@duke.edu			U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service [IIR 04-016, 08-027, 91-408]	U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service(US Department of Veterans Affairs)	By the U.S. Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service (IIR 04-016 and Career Scientist Awards 08-027 [Dr. Bosworth] and 91-408 [Dr. Weinberger]).	Agha Z, 2000, ARCH INTERN MED, V160, P3252, DOI 10.1001/archinte.160.21.3252; Allen KD, 2010, OSTEOARTHR CARTILAGE, V18, P160, DOI 10.1016/j.joca.2009.09.010; Allen KD, 2009, OSTEOARTHR CARTILAGE, V17, P1132, DOI 10.1016/j.joca.2009.03.003; Allen KD, 2008, CONTEMP CLIN TRIALS, V29, P596, DOI 10.1016/j.cct.2007.11.004; [Anonymous], 1999, STAT MED, V18, P1905; Bandura A, 2004, HEALTH EDUC BEHAV, V31, P143, DOI 10.1177/1090198104263660; BELLAMY N, 1992, J RHEUMATOL, V19, P451; Brady TJ, 2003, HEALTH EDUC BEHAV, V30, P44, DOI 10.1177/1090198102239258; Centers for Disease Control and Prevention (CDC), 2005, MMWR Morb Mortal Wkly Rep, V54, P484; Centers for Disease Control and Prevention (CDC), 2002, MMWR MORB MORTAL WKL, V51, P948; Cherry Donald K, 2007, Adv Data, P1; Chodosh J, 2005, ANN INTERN MED, V143, P427, DOI 10.7326/0003-4819-143-6-200509200-00007; Devos-Comby L, 2006, J RHEUMATOL, V33, P744; Dominick Kelli L, 2005, Ethn Dis, V15, P116; Dominick KL, 2006, J RHEUMATOL, V33, P348; Eberle E, 1999, OSTEOARTHR CARTILAGE, V7, P502, DOI 10.1053/joca.1999.0246; Fitzmaurice GM, 2004, APPL LONGITUDINAL AN; Fontaine KR, 2004, ARTHRITIS RHEUM-US, V50, P624, DOI 10.1002/art.20057; Hootman JM, 2003, ARTHRIT RHEUM-ARTHR, V49, P129, DOI 10.1002/art.10911; Johnson SS, 2008, PREV MED, V46, P238, DOI 10.1016/j.ypmed.2007.09.010; Lawrence RC, 2008, ARTHRITIS RHEUM, V58, P26, DOI 10.1002/art.23176; Little R. J., 2019, STAT ANAL MISSING DA, V793; LORIG K, 1989, ARTHRITIS RHEUM, V32, P37, DOI 10.1002/anr.1780320107; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; Lorig KR, 2004, MED CARE, V42, P346, DOI 10.1097/01.mlr.0000118709.74348.65; Lorig KR, 2003, ANN BEHAV MED, V26, P1, DOI 10.1207/S15324796ABM2601_01; Maisiak R, 1996, ARTHRITIS RHEUM-US, V39, P1391, DOI 10.1002/art.1780390818; Marcus BH, 1998, ANN BEHAV MED, V20, P174, DOI 10.1007/BF02884958; Mazzuca SA, 1997, ARTHRIT CARE RES, V10, P289, DOI 10.1002/art.1790100503; Mcdowell I., 2006, MEASURING HLTH GUIDE, V3, P37, DOI [DOI 10.1093/ACPROF:OSO/9780195165678.001.0001, 10.1093/acprof:oso/9780195165678.001.0001]; MEENAN RF, 1984, ARTHRITIS RHEUM, V27, P1344, DOI 10.1002/art.1780271204; MEENAN RF, 1992, ARTHRITIS RHEUM, V35, P1, DOI 10.1002/art.1780350102; Phibbs CS, 2003, MED CARE RES REV, V60, p54S, DOI 10.1177/1077558703256725; ROGERS WH, 2004, PMID, V27, P249; STASON WB, 1994, MED CARE, V32, P1197, DOI 10.1097/00005650-199412000-00004; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Verbeke G, 2000, LINEAR MIXED MODELS, P55; Warsi A, 2004, ARCH INTERN MED, V164, P1641, DOI 10.1001/archinte.164.15.1641; Warsi A, 2003, ARTHRITIS RHEUM-US, V48, P2207, DOI 10.1002/art.11210; WEINBERGER M, 1989, ARTHRITIS RHEUM, V32, P1577, DOI 10.1002/anr.1780321212; Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013; Zhao GX, 2009, PREV MED, V48, P117, DOI 10.1016/j.ypmed.2008.11.002	42	76	80	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	2010	153	9					570	579		10.7326/0003-4819-153-9-201011020-00006	http://dx.doi.org/10.7326/0003-4819-153-9-201011020-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	673MH	21041576				2023-01-03	WOS:000283667000003
J	Heath, I				Heath, Iona			LIFE AND DEATH Opt in not out	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CARDIOPULMONARY-RESUSCITATION		Royal Coll Gen Practitioners, London, England		Heath, I (corresponding author), Royal Coll Gen Practitioners, London, England.	iona.heath22@yahoo.co.uk						Conroy SP, 2006, BRIT MED J, V332, P479, DOI 10.1136/bmj.332.7539.479; Guru V, 1999, CAN MED ASSOC J, V161, P1251; Mallery L, 2011, J PALLIAT CARE, V27, P12, DOI 10.1177/082585971102700104; Ramenofsky DH, FAST FACTS CONCEPTS, V179; Schaper J, 2005, CIRCULATION, V112, P6, DOI 10.1161/CIRCULATIONAHA.105.551846	5	4	4	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 17	2011	343								d5251	10.1136/bmj.d5251	http://dx.doi.org/10.1136/bmj.d5251			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811LB	21849380				2023-01-03	WOS:000294210500008
J	Alvergne, A; Gibson, MA; Gurmu, E; Mace, R				Alvergne, Alexandra; Gibson, Mhairi A.; Gurmu, Eshetu; Mace, Ruth			Social Transmission and the Spread of Modern Contraception in Rural Ethiopia	PLOS ONE			English	Article							PARENTAL INVESTMENT; FERTILITY; NETWORKS; EVOLUTIONARY; WOMEN; TIME	Socio-economic development has proven to be insufficient to explain the time and pace of the human demographic transition. Shifts to low fertility norms have thus been thought to result from social diffusion, yet to date, micro-level studies are limited and are often unable to disentangle the effect of social transmission from that of extrinsic factors. We used data which included the first ever use of modern contraception among a population of over 900 women in four villages in rural Ethiopia, where contraceptive prevalence is still low (<20%). We investigated whether the time of adoption of modern contraception is predicted by (i) the proportion of ever-users/non ever-users within both women and their husbands' friendships networks and (ii) the geographic distance to contraceptive ever-users. Using a model comparison approach, we found that individual socio-demographic characteristics (e.g. parity, education) and a religious norm are the most likely explanatory factors of temporal and spatial patterns of contraceptive uptake, while the role of person-to-person contact through either friendship or spatial networks remains marginal. Our study has broad implications for understanding the processes that initiate transitions to low fertility and the uptake of birth control technologies in the developing world.	[Alvergne, Alexandra; Mace, Ruth] UCL, Dept Anthropol, London, England; [Gibson, Mhairi A.] Univ Bristol, Dept Archaeol & Anthropol, Bristol, Avon, England; [Gurmu, Eshetu] Univ Addis Ababa, Inst Populat Studies, Coll Dev Studies, Addis Ababa, Ethiopia	University of London; University College London; University of Bristol; Addis Ababa University	Alvergne, A (corresponding author), UCL, Dept Anthropol, London, England.	a.alvergne@ucl.ac.uk	Gibson, Mhairi A/D-4726-2009	Gibson, Mhairi A/0000-0001-7963-4759; Alvergne, Alexandra/0000-0002-3151-9919; Mace, Ruth/0000-0002-6137-7739; Gurmu, Eshetu/0000-0001-7487-0058	Royal Society; British Academy; European Research Council	Royal Society(Royal Society of London); British Academy; European Research Council(European Research Council (ERC)European Commission)	AA is a Newton fellow funded by the Royal Society and the British Academy. RM is funded by the European Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Addai I, 1999, REV RELIG RES, V40, P259, DOI 10.2307/3512371; AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson DR, 2000, J WILDLIFE MANAGE, V64, P912, DOI 10.2307/3803199; Anderson DR, 2001, J WILDLIFE MANAGE, V65, P373, DOI 10.2307/3803088; Bathia S, 1982, STUD FAMILY PLANN, V13, P4; Behrman JR, 2002, DEMOGRAPHY, V39, P713, DOI 10.2307/3180828; Bongaarts J, 1996, POPUL DEV REV, V22, P639, DOI 10.2307/2137804; Casterline JB, 2001, DIFFUSION PROCESSES AND FERTILITY TRANSITION: SELECTED PERSPECTIVES, P1; Christakis NA, 2008, NEW ENGL J MED, V358, P2249, DOI 10.1056/NEJMsa0706154; Christakis NA, 2007, NEW ENGL J MED, V357, P370, DOI 10.1056/NEJMsa066082; Coale Ansley J., 1986, DECLINE FERTILITY EU; Cohen-Cole E, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a2533; Gayen K, 2010, SOC SCI MED, V71, P1584, DOI 10.1016/j.socscimed.2010.08.002; Gibson MA, 2011, P NAT AC SC IN PRESS; Gibson MA, 2002, THESIS U COLL LONDON; Gibson MA, 2006, PLOS MED, V3, P476, DOI 10.1371/journal.pmed.0030087; Godley J, 2001, INT FAMILY PLANNING, V27, P4; GRANOVETTER MS, 1973, AM J SOCIOL, V78, P1360, DOI 10.1086/225469; Henrich J, 2001, EVOL HUM BEHAV, V22, P165, DOI 10.1016/S1090-5138(00)00071-4; Hill SE, 2005, BEHAV ECOL, V16, P398, DOI 10.1093/beheco/ari001; Jejeebhoy S., 1995, WOMENS ED AUTONOMY R; Kaplan H, 2002, AM J HUM BIOL, V14, P233, DOI 10.1002/ajhb.10041; Kaplan H, 1996, YEARB PHYS ANTHROPOL, V39, P91; KAPLAN HS, 1995, HUM NATURE-INT BIOS, V6, P325, DOI 10.1007/BF02734205; Kendal JR, 2005, MORRISON I WORKING P; Kincaid DL, 2000, SOC SCI MED, V50, P215, DOI 10.1016/S0277-9536(99)00276-2; Kohler HP, 2001, DEMOGRAPHY, V38, P43, DOI 10.1353/dem.2001.0005; Kohler HP, 1997, DEMOGRAPHY, V34, P369, DOI 10.2307/3038290; Lawson DW, 2011, PHILOS T R SOC B, V366, P333, DOI 10.1098/rstb.2010.0297; Lee R, 2003, J ECON PERSPECT, V17, P167, DOI 10.1257/089533003772034943; Lummaa V, 2002, TRENDS ECOL EVOL, V17, P141, DOI 10.1016/S0169-5347(01)02414-4; Mace R, 2006, SOCIAL INFORM TRANSM, P191; Mace R, 2009, AM J HUM BIOL, V21, P472, DOI 10.1002/ajhb.20940; Macro CSAEaO, 2006, ETH DEM HLTH SURV 20; Madhavan S, 2003, INT FAM PLAN PERSPEC, V29, P58, DOI 10.2307/3181059; MANSKI CF, 1993, REV ECON STUD, V60, P531, DOI 10.2307/2298123; Mason KO, 1997, DEMOGRAPHY, V34, P443, DOI 10.2307/3038299; Montgomery MR, 1996, POPUL DEV REV, V22, P151, DOI 10.2307/2808010; MONTGOMERY MR, 1993, POP STUD-J DEMOG, V47, P457, DOI 10.1080/0032472031000147246; Mulder MB, 1998, TRENDS ECOL EVOL, V13, P266, DOI 10.1016/S0169-5347(98)01357-3; Mulder MB, 2009, AM J HUM BIOL, V21, P478, DOI 10.1002/ajhb.20885; Newson L, 2005, PERS SOC PSYCHOL REV, V9, P360, DOI 10.1207/s15327957pspr0904_5; Panchanathan K, 2004, NATURE, V432, P499, DOI 10.1038/nature02978; POLLAK RA, 1993, POPUL DEV REV, V19, P467, DOI 10.2307/2938463; Potter JE, 2004, POPUL DEV REV, V25, P703; Richerson PJ, 2005, NOT GENES ALONE CULT; Rob A K, 1988, Asia Pac Popul J, V3, P55; Rogers EM, 2010, DIFFUSION INNOVATION; Samandari G, 2010, INT PERSPECT SEX R H, V36, P122, DOI 10.1363/ipsrh.36.122.10; Shalizi CR, 2011, SOCIOL METHOD RES, V40, P211, DOI 10.1177/0049124111404820; Singer JD, 2003, APPL LONGITUDINAL AN; Stephenson R, 2007, AM J PUBLIC HEALTH, V97, P1; Valente TW, 1997, SOC SCI MED, V45, P677, DOI 10.1016/S0277-9536(96)00385-1; Valente TW, 1994, NETWORK MODELS DIFFU	54	41	41	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2011	6	7							e22515	10.1371/journal.pone.0022515	http://dx.doi.org/10.1371/journal.pone.0022515			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	797BJ	21799882	Green Published, Green Submitted, gold			2023-01-03	WOS:000293097300059
J	Shen, YC; Hsia, RY				Shen, Yu-Chu; Hsia, Renee Y.			Association Between Ambulance Diversion and Survival Among Patients With Acute Myocardial Infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITAL CARDIAC-ARREST; LENGTH-OF-STAY; EMERGENCY-DEPARTMENTS; MORTALITY; IMPACT; DELAYS; TIMES; CARE	Context Ambulance diversion, a practice in which emergency departments (EDs) are temporarily closed to ambulance traffic, might be problematic for patients experiencing time-sensitive conditions, such as acute myocardial infarction (AMI). However, there is little empirical evidence to show whether diversion is associated with worse patient outcomes. Objective To analyze whether temporary ED closure on the day a patient experiences AMI, as measured by ambulance diversion hours of the nearest ED, is associated with increased mortality rates among patients with AMI. Design, Study, and Participants A case-crossover design of 13 860 Medicare patients with AMI from 508 zip codes within 4 California counties (Los Angeles, San Francisco, San Mateo, and Santa Clara) whose admission date was between 2000 and 2005. Data included 100% Medicare claims data that covered admissions between 2000 and 2005, linked with date of death until 2006, and daily ambulance diversion logs from the same 4 counties. Among the hospital universe, 149 EDs were identified as the nearest ED to these patients. Main Outcome Measures The percentage of patients with AMI who died within 7 days, 30 days, 90 days, 9 months, and 1 year from admission (when their nearest ED was not on diversion and when that same ED was exposed to <6, 6 to <12, and >= 12 hours of diversion out of 24 hours on the day of admission). Results Between 2000 and 2006, the mean (SD) daily diversion duration was 7.9 (6.1) hours. Based on analysis of 11 625 patients admitted to the ED between 2000 and 2005, and whose nearest ED had at least 3 diversion exposure levels (3541, 3357, 2667, and 2060 patients for no exposure, exposure to <6, 6 to <12, and >= 12 hours of diversion, respectively), there were no statistically significant differences in mortality rates between no diversion and exposure to less than 12 hours of diversion. Exposure to 12 or more hours of diversion was associated with higher 30-day mortality vs no diversion status (unadjusted mortality rate, 392 patients [19%] vs 545 patients [15%]; regression adjusted difference, 3.24 percentage points; 95% confidence interval [CI], 0.60-5.88); higher 90-day mortality (537 patients [26%] vs 762 patients [22%]; 2.89 percentage points; 95% CI, 0.13-5.64); higher 9-month mortality (680 patients [33%] vs 980 patients [28%]; 2.93 percentage points; 95% CI, 0.15-5.71); and higher 1-year mortality (731 patients [35%] vs 1034 patients [29%]; 3.04 percentage points; 95% CI, 0.33-5.75). Conclusion Among Medicare patients with AMI in 4 populous California counties, exposure to at least 12 hours of diversion by the nearest ED was associated with increased 30-day, 90-day, 9-month, and 1-year mortality. JAMA. 2011;305(23):2440-2447 www.jama.com	[Shen, Yu-Chu] USN, Postgrad Sch, Grad Sch Business & Publ Policy, Monterey, CA 93943 USA; [Shen, Yu-Chu] Natl Bur Econ Res, Cambridge, MA 02138 USA; [Hsia, Renee Y.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Emergency Med, San Francisco, CA USA	United States Department of Defense; United States Navy; Naval Postgraduate School; National Bureau of Economic Research; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Shen, YC (corresponding author), USN, Postgrad Sch, Grad Sch Business & Publ Policy, 555 Dyer Rd,Code GB, Monterey, CA 93943 USA.	yshen@nps.edu			Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization initiative [63974]; National Institutes of Health/National Center for Research Resources, University of California, San Francisco Clinical and Translational Science [KL2 RR024130]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000143] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR024130] Funding Source: NIH RePORTER	Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization initiative(Robert Wood Johnson Foundation (RWJF)); National Institutes of Health/National Center for Research Resources, University of California, San Francisco Clinical and Translational Science(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)University of California System); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by grant 63974 from the Robert Wood Johnson Foundation's Changes in Health Care Financing and Organization initiative (Dr Shen), grant KL2 RR024130 from the National Institutes of Health/National Center for Research Resources, University of California, San Francisco Clinical and Translational Science (Dr Hsia), and the Robert Wood Johnson Foundation Physician Faculty Scholars (Dr Hsia).	ANDRULIS DP, 1991, ANN EMERG MED, V20, P980, DOI 10.1016/S0196-0644(05)82976-2; Auerbach J, 0807494 DHCQ; Bernstein SL, 2009, ACAD EMERG MED, V16, P1, DOI 10.1111/j.1553-2712.2008.00295.x; Buchmueller TC, 2006, J HEALTH ECON, V25, P740, DOI 10.1016/j.jhealeco.2005.10.006; Burke Laura, 2010, Virtual Mentor, V12, P483, DOI 10.1001/virtualmentor.2010.12.6.pfor2-1006; Burt Catharine W, 2006, Adv Data, P1; Burt Catharine W, 2004, Vital Health Stat 13, P1; Burt CW, 2006, ANN EMERG MED, V47, P317, DOI 10.1016/j.annemergmed.2005.12.001; Cameron Peter, 2002, Aust Health Rev, V25, P59; Castillo EM, 2011, J EMERG MED, V40, P300, DOI 10.1016/j.jemermed.2010.02.023; Cuong J, 2006, ACAD EMERG MED, V13, P1220, DOI 10.1197/j.aem.2006.05.024; Derlet RW, 2000, ANN EMERG MED, V35, P63, DOI 10.1016/S0196-0644(00)70105-3; Greene W., 2018, ECONOMETRIC ANAL; Health Economics Research Center, I EST TRAV COSTS; Horwitz JR, 2009, J HEALTH ECON, V28, P924, DOI 10.1016/j.jhealeco.2009.06.008; Institute of Medicine, 2007, HOSP BAS EM CAR BREA; Lambe S, 2003, ANN EMERG MED, V41, P35, DOI 10.1067/mem.2003.2; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; Magid DJ, 2004, ANN EMERG MED, V44, P586, DOI 10.1016/j.annemergmed.2004.07.449; Mailer's Software, 2006, MAIL SOFTW ZIP DAT; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; McConnell KJ, 2005, ANN EMERG MED, V45, P471, DOI 10.1016/j.annemergmed.2004.10.032; Millard WB, 2011, ANN EMERG MED, V57, p15A, DOI 10.1016/j.annemergmed.2011.03.015; National Association of State EMS Officials, IMPL STAT AMB NO DIV; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Norris RM, 2005, HEART, V91, P1537, DOI 10.1136/hrt.2004.057018; Phibbs CS, 1995, MED CARE RES REV, V52, P532, DOI 10.1177/107755879505200406; Pines JM, 2008, ANN EMERG MED, V51, P1, DOI 10.1016/j.annemergmed.2007.07.008; Pines JM, 2007, ANN EMERG MED, V50, P510, DOI 10.1016/j.annemergmed.2007.07.021; Pines JM, 2010, ACAD EMERG MED, V17, P834, DOI 10.1111/j.1553-2712.2010.00780.x; Robert Wood Johnson Foundation, EM DEP UT CAP; Schafermeyer Robert W, 2003, Emerg Med (Fremantle), V15, P22, DOI 10.1046/j.1442-2026.2003.00403.x; Schneider S, 2001, ACAD EMERG MED, V8, P1044, DOI 10.1111/j.1553-2712.2001.tb01113.x; Schull MJ, 2004, ANN EMERG MED, V44, P577, DOI 10.1016/j.annemergmed.2004.05.004; Schull MJ, 2003, ACAD EMERG MED, V10, P709, DOI 10.1111/j.1553-2712.2003.tb00064.x; Shenoi RP, 2009, ACAD EMERG MED, V16, P116, DOI 10.1111/j.1553-2712.2008.00317.x; Skinner J, 2009, NBER TECHNICAL WORKI; Stock JH, 2006, NBER TECHNICAL WOR T; Tang N, 2010, JAMA-J AM MED ASSOC, V304, P664, DOI 10.1001/jama.2010.1112; WILSON M, 2004, BURSTING SEAMS IMPRO; Yankovic N, 2010, INQUIRY-J HEALTH CAR, V47, P81, DOI 10.5034/inquiryjrnl_47.01.81	41	63	63	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 15	2011	305	23					2440	2447		10.1001/jama.2011.811	http://dx.doi.org/10.1001/jama.2011.811			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	777EB	21666277	Green Accepted			2023-01-03	WOS:000291597300024
J	Bousser, MG; Amarenco, P; Chamorro, A; Fisher, M; Ford, I; Fox, KM; Hennerici, MG; Mattle, HP; Rothwell, PM; de Cordoue, A; Fratacci, MD				Bousser, Marie-Germaine; Amarenco, Pierre; Chamorro, Angel; Fisher, Marc; Ford, Ian; Fox, Kim M.; Hennerici, Michael G.; Mattle, Heinrich P.; Rothwell, Peter M.; de Cordouee, Agnes; Fratacci, Marie-Dominique		PERFORM Study Investigators	Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial	LANCET			English	Article							CARDIOVASCULAR EVENTS; CORONARY ANGIOPLASTY; THROMBOXANE; PREVENTION; STROKE; ATTACK; CLOPIDOGREL; DIPYRIDAMOLE; INHIBITION; RESTENOSIS	Background Patients with ischaemic stroke or transient ischaemic attack (TIA) are at high risk of recurrent stroke or other cardiovascular events. We compared the selective thromboxane-prostaglandin receptor antagonist terutroban with aspirin in the prevention of cerebral and cardiovascular ischaemic events in patients with a recent non-cardioembolic cerebral ischaemic event. Methods This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 countries. Patients who had an ischaemic stroke in the previous 3 months or a TIA in the previous 8 days were randomly allocated with a central interactive response system to 30 mg per day terutroban or 100 mg per day aspirin. Patients and investigators were masked to treatment allocation. The primary efficacy endpoint was a composite of fatal or non-fatal ischaemic stroke, fatal or non-fatal myocardial infarction, or other vascular death (excluding haemorrhagic death). We planned a sequential statistical analysis of non-inferiority (margin 1.05) followed by analysis of superiority. Analysis was by intention to treat. The study was stopped prematurely for futility on the basis of the recommendation of the Data Monitoring Committee. This study is registered, number ISRCTN66157730. Findings 9562 patients were assigned to terutroban (9556 analysed) and 9558 to aspirin (9544 analysed); mean follow-up was 28-3 months (SD 7.7). The primary endpoint occurred in 1091 (11%) patients receiving terutroban and 1062 (11%) receiving aspirin (hazard ratio [HR.] 1.02, 95% CI 0.94-1.12). There was no evidence of a difference between terutroban and aspirin for the secondary or tertiary endpoints. We recorded some increase in minor bleedings with terutroban compared with aspirin (1147 [12%] vs 1045 [11%]; HR 1.11, 95% CI 1.02-1.21), but no significant differences in other safety endpoints. Interpretation The trial did not meet the predefined criteria for non-inferiority, but showed similar rates of the primary endpoint with terutroban and aspirin, without safety advantages for terutroban. In a worldwide perspective, aspirin remains the gold standard antiplatelet drug for secondary stroke prevention in view of its efficacy, tolerance, and cost.	[Bousser, Marie-Germaine] Paris Diderot Univ, Hop Lariboisiere, AP HP, Dept Neurol,INSERM,U740, F-75010 Paris, France; [Amarenco, Pierre] Paris Diderot Univ, Hop Bichat, INSERM, U698, F-75010 Paris, France; [Chamorro, Angel] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain; [Fisher, Marc] Univ Massachusetts, Sch Med, Worcester, MA USA; [Ford, Ian] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland; [Fox, Kim M.] Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Inst Cardiovasc Med & Sci, London, England; [Hennerici, Michael G.] Heidelberg Univ, Univ Med Mannheim, D-6800 Mannheim, Germany; [Mattle, Heinrich P.] Univ Bern, Inselspital, CH-3010 Bern, Switzerland; [Rothwell, Peter M.] Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; [de Cordouee, Agnes; Fratacci, Marie-Dominique] Inst Rech Int Servier, F-92415 Courbevoie, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Barcelona; Hospital Clinic de Barcelona; University of Massachusetts System; University of Massachusetts Worcester; University of Glasgow; Imperial College London; Royal Brompton Hospital; Ruprecht Karls University Heidelberg; University of Bern; University of Oxford; Servier; Institut de Recherches Internationales Servier	Bousser, MG (corresponding author), Paris Diderot Univ, Hop Lariboisiere, AP HP, Dept Neurol,INSERM,U740, F-75010 Paris, France.	mg.bousser@lrb.aphp.fr	Хабиров, Фарит/AAU-6652-2020; Ford, Ian/ABE-6145-2020; DIOMEDI, MARINA/AAF-7211-2021; Lueck, Christian Joseph/O-4031-2016; Egido, Jose A/E-3837-2015; Pavel, Kamchatnov/P-6116-2016; Hankey, Graeme J/H-4968-2014; Rothwell, Peter/ABE-5913-2020; Hirt, Lorenz/G-3553-2010; Chen, Christopher/E-7023-2013; Vanhooren, Geert/H-4433-2011; Hamann, Gerhard F./J-6300-2014; Di Lazzaro, Vincenzo/L-3731-2018; Ford, Gary A/A-6353-2012; Vécsei, László/B-2066-2010; Parati, Eugenio A/G-8765-2011; Bar, Michal/I-4516-2017; de Leeuw, Frank-Erik/E-4795-2012; Sanahuja, Jordi/B-6299-2009; DIOMEDI, MARINA/K-9047-2016; Parati, Eugenio Agostino/AAN-5893-2021; Laskov, Vitalii B/H-8548-2013; bladin, chris/B-9136-2013; Witte, Otto/P-4127-2018; Gómez-Escalonilla, Carlos/AAU-1050-2021; Macleod, Malcolm Robert/B-2052-2010; Di Piero, Vittorio/F-6335-2010; Milanov, Ivan/D-4318-2015	Хабиров, Фарит/0000-0002-2572-6970; DIOMEDI, MARINA/0000-0001-7569-1414; Lueck, Christian Joseph/0000-0003-1537-7612; Egido, Jose A/0000-0003-1698-9127; Pavel, Kamchatnov/0000-0001-6747-3476; Hankey, Graeme J/0000-0002-6044-7328; Rothwell, Peter/0000-0001-9739-9211; Hirt, Lorenz/0000-0002-2921-5000; Chen, Christopher/0000-0002-1047-9225; Vanhooren, Geert/0000-0001-6818-9346; Di Lazzaro, Vincenzo/0000-0002-9113-5925; Vécsei, László/0000-0001-8037-3672; Bar, Michal/0000-0002-5049-5844; DIOMEDI, MARINA/0000-0001-7569-1414; Parati, Eugenio Agostino/0000-0001-5020-6523; Laskov, Vitalii B/0000-0002-2391-5823; Witte, Otto/0000-0003-2101-4105; Macleod, Malcolm Robert/0000-0001-9187-9839; Cunha, Luis/0000-0002-0828-3485; Roine, Risto/0000-0002-3824-3003; Boon, Paul/0000-0002-4180-8896; Laskov, Vitalii/0000-0003-2870-4547; Smolanka, Volodymyr/0000-0001-7296-8297; Di Piero, Vittorio/0000-0002-2631-7562; Minea, Dan Ioan/0000-0001-6661-2219; Bogdanov, E.I./0000-0001-9332-8053; Moulin, thierry/0000-0002-6639-8117; Poppert, Holger/0000-0003-2189-7681; Gomez-Sanchez, Jose Carlos/0000-0001-6096-7051; Dalkara, Turgay/0000-0003-3943-7819; Tyrrell, Pippa/0000-0001-9609-1231; iudice, alfonso/0000-0003-4661-641X; corsi, fabio massimo/0000-0002-4219-4283; Gommans, John/0000-0003-3750-765X; Milanov, Ivan/0000-0002-4522-4070; Consoli, Domenico/0000-0002-2050-5538; De Falco, Fabrizio/0000-0001-5065-1678; Kaste, Markku/0000-0001-6557-6412; Reyes-Gutierrez, Gerardo-Ali/0000-0002-4667-1446; Teitelbaum, Jeanne/0000-0002-9834-3882; Dichgans, Martin/0000-0002-0654-387X; Turcani, Peter/0000-0002-4868-6836; Laska, Ann Charlotte/0000-0002-7330-940X	Servier, France; Servier; Sanofi-Aventis; Fondation Bouygues; INSERM; Ministere du travail, de l'emploi et de la sante; Pfizer; Boehringer Ingelheim; Bayer; Biogen	Servier, France(Servier); Servier(Servier); Sanofi-Aventis(Sanofi-Aventis); Fondation Bouygues; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ministere du travail, de l'emploi et de la sante; Pfizer(Pfizer); Boehringer Ingelheim(Boehringer Ingelheim); Bayer(Bayer AG); Biogen(Biogen)	Servier, France.; MGB has received travel and accommodation support for meetings from Servier and Sanofi-Aventis, and research funding and grants from Servier, Sanofi-Aventis, Fondation Bouygues, INSERM, and Ministere du travail, de l'emploi et de la sante. PA has received honoraria for talks, advisory boards, or clinical trial committees from Pfizer, Astra-Zeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, Lundbeck, PAION, Novartis, Merck, EV3, and Servier; and has received research funding from Pfizer, Sanofi-Aventis, Servier and Boehringer Ingelheim. AC has received honoraria for talks, advisory boards, and clinical trial committees from Boehringer Ingelheim, Grupo Ferrer, Sanofi-Aventis, Bristol-Myers Squibb, Pfizer, Service, and Sygnis Bioscience; and has received research funding from Boehringer Ingelheim. MF has received consulting fees, travel fees, and research grants from Servier IF has received research grants, support for attending conferences, and study Executive Committee honoraria from Servier. KMF has received fees, honoraria, and research grants from Servier. MGH has received honoraria for talks, travel support, and advisory board membership from Servier; additionally, he also received similar support from Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, Bayer, Novartis, and Pfizer. HPM has received honoraria for lectures, advisory boards, and clinical trial committees from Bayer, Biogen, Boehringer Ingelheim, Merck, Novartis, Pfizer, Servier, and Teva; and research support from Bayer, Biogen, and Pfizer. PM R has received honoraria for talks, advisory boards, and clinical trial committees from Astra-Zeneca, Bayer, Boehringer Ingelheim, Sanofi-Aventis, Bristol-Myers Squibb, and Servier; and has received research funding from Boehringer Ingelheim. AdC and MDF are employed by Servier.	Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Belhassen L, 2003, J AM COLL CARDIOL, V41, P1198, DOI 10.1016/S0735-1097(03)00048-2; Bousser MG, 2009, CEREBROVASC DIS, V27, P608, DOI 10.1159/000216835; Bousser MG, 2009, CEREBROVASC DIS, V27, P509, DOI 10.1159/000212671; Bousser Marie-Germaine, 2009, Cerebrovasc Dis, V27 Suppl 3, P12, DOI 10.1159/000209261; Cattaneo M, 2010, CIRCULATION, V121, P171, DOI 10.1161/CIRCULATIONAHA.109.853069; Cayatte AJ, 2000, ARTERIOSCL THROM VAS, V20, P1724, DOI 10.1161/01.ATV.20.7.1724; Chamorro Angel, 2009, Cerebrovasc Dis, V27 Suppl 3, P20, DOI 10.1159/000209262; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Diener HC, 2004, LANCET, V364, P331, DOI 10.1016/S0140-6736(04)16721-4; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Egan KM, 2005, CIRCULATION, V111, P334, DOI 10.1161/01.CIR.0000153386.95356.78; Fiessinger JN, 2010, J THROMB HAEMOST, V8, P2369, DOI 10.1111/j.1538-7836.2010.04020.x; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; GONZALEZ JFV, 2005, EUR HEART J, V26, P1557; Hankey GJ, 2010, LANCET NEUROL, V9, P273, DOI 10.1016/S1474-4422(10)70038-7; Sacco RL, 2008, NEW ENGL J MED, V359, P1238, DOI 10.1056/NEJMoa0805002; Sacco RL, 2006, STROKE, V37, P577, DOI 10.1161/01.STR.0000199147.30016.74; Santilli F, 2009, J AM COLL CARDIOL, V53, P667, DOI 10.1016/j.jacc.2008.10.047; SAVAGE MP, 1995, CIRCULATION, V92, P3194, DOI 10.1161/01.CIR.92.11.3194; SERRUYS PW, 1991, CIRCULATION, V84, P1568, DOI 10.1161/01.CIR.84.4.1568; Shi Y, 2008, ACTA PHARMACOL SIN, V29, P185, DOI 10.1111/j.1745-7254.2008.00749.x; Shinohara Y, 2010, LANCET NEUROL, V9, P959, DOI 10.1016/S1474-4422(10)70198-8; Sollier CBD, 2009, CEREBROVASC DIS, V28, P505, DOI 10.1159/000236915; VANDEWERF F, 1994, CIRCULATION, V89, P588	25	149	165	0	57	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					2013	2022		10.1016/S0140-6736(11)60600-4	http://dx.doi.org/10.1016/S0140-6736(11)60600-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21616527				2023-01-03	WOS:000292011700036
J	Roffe, C; Ali, K; Warusevitane, A; Sills, S; Pountain, S; Allen, M; Hodsoll, J; Lally, F; Jones, P; Crome, P				Roffe, Christine; Ali, Khalid; Warusevitane, Anushka; Sills, Sheila; Pountain, Sarah; Allen, Martin; Hodsoll, John; Lally, Frank; Jones, Peter; Crome, Peter			The SOS Pilot Study: A RCT of Routine Oxygen Supplementation Early after Acute Stroke-Effect on Recovery of Neurological Function at One Week	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; ACUTE ISCHEMIC-STROKE; CONSUMER INVOLVEMENT; NORMOBARIC HYPEROXIA; CEREBRAL-ISCHEMIA; PULSE OXIMETRY; RAT MODEL; BRAIN; SCALE; SATURATION	Mild hypoxia is common after stroke and associated with poor long-term outcome. Oxygen supplementation could prevent hypoxia and improve recovery. A previous study of routine oxygen supplementation showed no significant benefit at 7 and 12 months. This pilot study reports the effects of routine oxygen supplementation for 72 hours on oxygen saturation and neurological outcomes at 1 week after a stroke. Methods: Patients with a clinical diagnosis of acute stroke were recruited within 24 h of hospital admission between October 2004 and April 2008. Participants were randomized to oxygen via nasal cannulae (72 h) or control (room air, oxygen given only if clinically indicated). Clinical outcomes were assessed by research team members at 1 week. Baseline data for oxygen (n = 148) and control (n = 141) did not differ between groups. Results: The median (interquartile range) National Institutes of Health Stroke Scale (NIHSS) score for the groups at baseline was 6 (7) and 5 (7) respectively. The median Nocturnal Oxygen Saturation during treatment was 1.4% (0.3) higher in the oxygen than in the control group (p < 0.001) during the intervention. At 1 week, the median NIHSS score had reduced by 2 (3) in the oxygen and by 1 (2) in the control group. 31% of participants in the oxygen group and 14% in the control group had an improvement of >= 4 NIHSS points at 1 week doubling the odds of improvement in the oxygen group (OR: 2.9). Conclusion: Our data show that routine oxygen supplementation started within 24 hours of hospital admission with acute stroke led to a small, but statistically significant, improvement in neurological recovery at 1 week. However, the difference in NIHSS improvement may be due to baseline imbalance in stroke severity between the two groups and needs to be confirmed in a larger study and linked to longer-term clinical outcome.	[Roffe, Christine; Warusevitane, Anushka; Sills, Sheila; Pountain, Sarah; Hodsoll, John] N Staffordshire Combined Healthcare Trust, Stoke Stroke Res Grp, Stoke On Trent, Staffs, England; [Roffe, Christine; Lally, Frank] Keele Univ, Inst Sci & Technol Med, Keele, Staffs, England; [Ali, Khalid] Brighton & Sussex Med Sch, Acad Dept Geriatr, Brighton, E Sussex, England; [Allen, Martin] Univ Hosp N Staffordshire, Dept Resp Med, Stoke On Trent, Staffs, England; [Jones, Peter] Keele Univ, Sch Comp & Math, Keele, Staffs, England; [Crome, Peter] Keele Univ, Inst Life Course Studies, Keele, Staffs, England	Keele University; University of Brighton; University of Sussex; Keele University; Keele University; Keele University	Roffe, C (corresponding author), N Staffordshire Combined Healthcare Trust, Stoke Stroke Res Grp, Stoke On Trent, Staffs, England.	christine.roffe@northstaffs.nhs.uk	Roffe, Christine/AAT-5611-2020; Hodsoll, John/I-3928-2012	Roffe, Christine/0000-0002-5259-6649; Hodsoll, John/0000-0001-7546-9901	British Geriatrics Society; North Staffordshire Medical Institute	British Geriatrics Society; North Staffordshire Medical Institute	We would like to thank the North Staffordshire Medical Institute for funding the purchase of the pulse oximeters, Professor R. Gray and his staff at the Birmingham Clinical Trials Unit (University of Birmingham) for supporting the trial with expert advice and for developing and running the web-based randomization, the British Geriatrics Society for supporting Dr KM Ali with an Specialist Registrar Research Start Up Grant, and staff at the University Hospital of North Staffordshire for ensuring that participants kept the oxygen and pulse oximeters in place. Finally, we would like to thank all of the patients and their families who very kindly consented to take part in this study.	Adams HP, 2007, STROKE, V38, P1655, DOI 10.1161/STROKEAHA.107.181486; Ali K, 2006, STROKE, V37, P865, DOI 10.1161/01.STR.0000204053.36966.80; Ali K, 2005, NEUROCRIT CARE, V3, P24, DOI 10.1385/NCC:3:1:024; Appelros P, 2004, CEREBROVASC DIS, V17, P21, DOI 10.1159/000073894; ASPLUND K, 1985, STROKE, V16, P885; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Bateman NT, 1998, BRIT MED J, V317, P798, DOI 10.1136/bmj.317.7161.798; Bennett MH, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD004954.PUB2; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Bruno A, 2006, STROKE, V37, P920, DOI 10.1161/01.STR.0000202679.88377.e4; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; *EUR STROK ORG, EUR STROK ORG GUID M; Flynn EP, 2002, ANN NEUROL, V52, P566, DOI 10.1002/ana.10322; Indredavik B, 1999, STROKE, V30, P917, DOI 10.1161/01.STR.30.5.917; Kontos HA, 2001, STROKE, V32, P2712, DOI 10.1161/hs1101.098653; Koops L, 2002, BRIT MED J, V325, P415, DOI 10.1136/bmj.325.7361.415; Langhorne P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000197.pub3; LEWIS LD, 1973, ACTA PHYSIOL SCAND, V88, P284, DOI 10.1111/j.1748-1716.1973.tb05455.x; Liu SM, 2006, J CEREBR BLOOD F MET, V26, P1274, DOI 10.1038/sj.jcbfm.9600277; Mattson MP, 2000, CELL TISSUE RES, V301, P173, DOI 10.1007/s004419900154; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; NAKAJIMA S, 1983, ARCH NEUROL-CHICAGO, V40, P271, DOI 10.1001/archneur.1983.04050050039004; Nuutinen J, 2006, ACTA NEUROL SCAND, V113, P100, DOI 10.1111/j.1600-0404.2005.00550.x; Rocco A, 2007, STROKE, V38, P1225, DOI 10.1161/01.STR.0000259659.91505.40; Roffe C, 2003, STROKE, V34, P2641, DOI 10.1161/01.STR.0000095188.65567.4F; Roffe C, 2001, STROKE, V32, P1808, DOI 10.1161/01.STR.32.8.1808; ROFFE C, 2009, CME J GERIATRIC MED, V11, P3; ROFFE C, STROKE OXYGEN STUDY; Roffe C, 2010, J STROKE CEREBROVASC, V19, P29, DOI 10.1016/j.jstrokecerebrovasdis.2009.02.008; Ronning OM, 1999, STROKE, V30, P2033, DOI 10.1161/01.STR.30.10.2033; Rowat AM, 2006, CEREBROVASC DIS, V21, P166, DOI 10.1159/000090528; *ROY COLL PHYS, INT STROK WORK PART; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Silva Y, 2005, CEREBROVASC DIS, V19, P23, DOI 10.1159/000081908; SILVA Y, 2001, CEREBROVASC DIS, V11, P70; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; Singhal AB, 2005, STROKE, V36, P797, DOI 10.1161/01.STR.0000158914.66827.2e; Singhal AB, 2002, J CEREBR BLOOD F MET, V22, P861, DOI 10.1097/00004647-200207000-00011; Sugawara Taku, 2004, NeuroRx, V1, P17, DOI 10.1602/neurorx.1.1.17; Sulter G, 2000, J NEUROL SCI, V179, P65, DOI 10.1016/S0022-510X(00)00378-6; Sulter G, 2003, STROKE, V34, P101, DOI 10.1161/01.STR.0000048148.09143.6C; *THOR, BTS GUID EM OX US AD; THORVALDSEN P, 1995, STROKE, V26, P361, DOI 10.1161/01.STR.26.3.361; Wijesinghe M, 2009, HEART, V95, P198, DOI 10.1136/hrt.2008.148742; WITYK RJ, 1994, STROKE, V25, P362, DOI 10.1161/01.STR.25.2.362; Yager JY, 1997, NEUROSCI BIOBEHAV R, V21, P167, DOI 10.1016/S0149-7634(96)00006-1; YAMAMOTO M, 1980, ARCH NEUROL-CHICAGO, V37, P489, DOI 10.1001/archneur.1980.00500570037005; Young FB, 2005, STROKE, V36, P2187, DOI 10.1161/01.STR.0000181089.41324.70	49	42	43	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 19	2011	6	5							e19113	10.1371/journal.pone.0019113	http://dx.doi.org/10.1371/journal.pone.0019113			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	766HI	21625533	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000290771200004
J	Fu, SF; Zhang, JH; Menniti-Ippolito, F; Gao, XM; Galeotti, F; Massari, M; Hu, LM; Zhang, BL; Ferrelli, R; Fauci, A; Firenzuoli, F; Shang, HC; Guerra, R; Raschetti, R				Fu, Shufei; Zhang, Junhua; Menniti-Ippolito, Francesca; Gao, Xiumei; Galeotti, Francesca; Massari, Marco; Hu, Limin; Zhang, Boli; Ferrelli, Rita; Fauci, Alice; Firenzuoli, Fabio; Shang, Hongcai; Guerra, Ranieri; Raschetti, Roberto			Huangqi Injection (a Traditional Chinese Patent Medicine) for Chronic Heart Failure: A Systematic Review	PLOS ONE			English	Article							DIAGNOSIS; UPDATE	Background: Chronic heart failure (CHF) is a global public health problem. Therefore, novel and effective drugs that show few side-effects are needed. Early literature studies indicated that Huangqi injection is one of the most commonly used traditional Chinese patent medicines for CHF in China. As a large number of clinical studies has been carried out and published, it is essential to evaluate the effectiveness and safety of Huangqi injection. Therefore, we carried out this systematic review under the support of the framework of the Joint Sino-Italian Laboratory (JoSIL). Objectives: To evaluate the efficacy and safety of Huangqi injection for CHF according to the available scientific knowledge. Methods: An extensive search including PubMed, EMBASE, CBM, the Cochrane Library and Chinese literature databases was performed up to July 2008. Clinical trials regarding Huangqi injection for the treatment of CHF were searched for, irrespective of languages. The quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5.0, and RevMan 5.0 provided by the Cochrane Collaboration and STATA 9.2 were used for data analysis. Results: After selection of 1,205 articles, 62 RCTs and quasi-RCTs conducted in China and published in Chinese journals were included in the review. The methodological quality of the trials was low. In most trials inclusion and exclusion criteria were not specified. Furthermore, only one study evaluated the outcomes for drug efficacy after an adequate period of time. For these reasons and because of the different baseline characteristics we did not conduct a meta-analysis. Conclusions: Although available studies are not adequate to draw a conclusion on the efficacy and safety of Huangqi injection (a traditional Chinese patent medicine), we hope that our work could provide useful experience on further studies on Huangqi injections. The overall level of TCM clinical research needs to be improved so that the efficacy of TCM can be evaluated by the international community and possibly some TCM can enter into the international market.	[Fu, Shufei; Zhang, Junhua; Gao, Xiumei; Hu, Limin; Shang, Hongcai] Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China; [Fu, Shufei; Zhang, Junhua; Gao, Xiumei; Hu, Limin; Shang, Hongcai] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China; [Menniti-Ippolito, Francesca; Galeotti, Francesca; Massari, Marco; Raschetti, Roberto] Natl Inst Hlth, Natl Ctr Epidemiol Surveillance & Hlth Promot, Rome, Italy; [Zhang, Boli; Ferrelli, Rita; Fauci, Alice; Guerra, Ranieri] Natl Inst Hlth, External Relat Off, Rome, Italy; [Firenzuoli, Fabio] San Giuseppe Hosp, Ctr Nat Med, Empoli, Italy	Tianjin University of Traditional Chinese Medicine; Tianjin University of Traditional Chinese Medicine; Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Fu, SF (corresponding author), Tianjin Univ Tradit Chinese Med, Inst Tradit Chinese Med, Evidence Based Med Ctr, Tianjin, Peoples R China.	francesca.menniti@iss.it; gaoxiumei@tjutcm.edu.cn	Firenzuoli, Fabio/ABG-9563-2021; Ferrelli, Rita Maria/A-7072-2015; shang, hongcai/H-1257-2014; Fauci, Alice Josephine/F-4394-2015	zhang, Junhua/0000-0003-4043-1967; Ferrelli, Rita Maria/0000-0002-6665-5697; Fauci, Alice Josephine/0000-0002-7699-4633	Science and Technology Ministry [2008DFB30070]; International Science and Technology Supportive Project of China [2009ZX09311-002]; Italian Ministry of Health [6 C I 2]	Science and Technology Ministry; International Science and Technology Supportive Project of China; Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by the International Cooperative Project of Science and Technology Ministry (2008DFB30070); International Science and Technology Supportive Project of China (2009ZX09311-002); Italian Ministry of Health, finalized research ex art. 12 d.lgs 229/99 (6 C I 2). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2007, LANCET, V369, P880; [Anonymous], HEART ASIA, V2, P24; Bai R, 1999, J SHANXI MED COLL CO, V9, P39; Bao X, 1999, PHARM CLIN CHINESE M, V15, P39; Bu Q, 2005, CHINESE J INTEGRATIV, V3, P1006; Cai Q, 2005, SHANXI MED J, V34, P860; Cho WCS, 2007, CANCER LETT, V252, P43, DOI 10.1016/j.canlet.2006.12.001; Chu G, 2000, HUBEI J TRADITIONAL, V22, P29; Denzler KL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012561; Durst R, 2011, CARDIOVASC THER, V29, P17, DOI 10.1111/j.1755-5922.2010.00233.x; Ernst E, 2008, J POSTGRAD MED, V54, P214, DOI 10.4103/0022-3859.41806; Fan L, 2004, J PRACTICAL TRADITIO, V20, P501; Fang Z, 2003, CENTRAL PLAINS MED J, V30, P6; Fu SF, 2010, HEART ASIA, V2, P24, DOI 10.1136/ha.2009.001123; Fu T, 2006, CHIN SCI TECHN ACH D; Fu X, 2000, J CHINESE PRACTICAL, V2, P72; Gao J, 2005, ACAD J GUANGDONG COL, V21, P610; Gao Z, 1999, HEBEI MED, V5, P7; Gu D. F., 2003, CHIN J CARDIO, V31, P3, DOI DOI 10.3760/J:ISSN:0253-3758.2003.01.002; Gu X, 2003, HER MED, V22, P556; Guo H., 2006, CENT PLAINS MED J, V33, P85, DOI [10.3760/cma.j.issn.1674-4756.2006.02.070, DOI 10.3760/CMA.J.ISSN.1674-4756.2006.02.070]; Guo H, 2005, PRACTICAL CLIN J INT, V5, P22; Higgins J., 2009, COCHRANE HDB SYSTEMA; Hu J, 2001, CHIN J CLIN PHARM TH, V6, P78; Hu S., 2008, MED INNOVATION RES, V5, P102; Hunt SA, 2005, CIRCULATION, V112, pE154, DOI 10.1161/CIRCULATIONAHA.105.167586; Jiao X, 2006, J SHANXI COLL TRADIT, V29, P19; Jin ZC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010822; Jining Medical College Hospital, 2007, CHIN SCI TECHN ACH D; Kroon PA, 2010, CURR MED CHEM, V17, P2442; Li C, 2002, J MED THEOR PRAC, V15, P1277; Li H, 2006, SICHUAN J PHYSL SCI, V28, P81; Li JianHui, 2007, China Tropical Medicine, V7, P1343; Li MX, 2011, J ETHNOPHARMACOL, V133, P412, DOI 10.1016/j.jep.2010.10.012; Li S, 1997, J ANHUI TCM COLL, V16, P19; Li S, 2003, CHINESE J PRACTICAL, V3, P1665; Li W, 2002, 7 NAT CHIN W MED AC, P35; Liu A, 2005, ZHEJIANG JLTCWM, V15, P32; Liu C, 2004, J LIAONING COLL TCM, V6, P390; Liu Y, 2005, J PRACTICAL TRADITIO, V21, P198; Liu Y, 2005, J XINXIANG MED COLL, V22, P244; Liu Y, 2001, TIANJIN J TRADITIONA, V18, P8; Liu Z, 2006, J CHINESE MODERN MED, V3, P5; Lu Q, 2000, MODERN J INTEGRATED, V9, P61; Lu Z, 2006, PUBLIC MED FORUM MAG, V10, P1; Luo Q, 2004, HEILONGJIANG J TRADI, V3, P8; Luo X, 2003, J EMERG SYNDROMES TR, V12, P35; Lv J, 2008, J PRACTICAL TRADITIO, V24, P164; Ma A, 2007, CHIN J CARDIOL, V35, P1076; Ma L, 2005, HENAN TRADITIONAL CH, V25, P78; Ma Z, 2001, SHANXI J TRADITIONAL, V22, P579; Pang M, 2000, CHINA PHARM, V9, P44; Pittler MH, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005312.pub2; Qin L, 2000, J SHAANXI COLL TRADI, V23, P46; Ramani GV, 2010, MAYO CLIN PROC, V85, P180, DOI 10.4065/mcp.2009.0494; Rosamond W, 2008, CIRCULATION, V117, pE25, DOI 10.1161/CIRCULATIONAHA.107.187998; *STATACORP, 2003, STAT STAT SOFTW REL; Su X, 2002, J HEZE MED COLL, V14, P21; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; Tang JL, 2008, LANCET, V372, P1938, DOI 10.1016/S0140-6736(08)61354-9; The Cochrane Collaboration, 2008, REV MAN REVMAN COMP; The European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit, 1999, NOTE GUIDANCE CLIN I; Tian L, 1997, SHANGHAI MED PHARM J, V11, P16; Tian L, 2005, MODERN J INTEGRATED, V14, P610; Wang H, 2005, J EMERGENCY TRADITIO, V14, P1070; Wang L, 2000, CHONGQING MED J, V29, P71; Wang S, 2002, CHINESE J INTEGRATED, V9, P230; Wang X. N., 2003, HUNAN GUIDING J TCM, V9, P15, DOI [10.3969/j.issn.1672-951X.2003.05.011, DOI 10.3969/J.ISSN.1672-951X.2003.05.011]; Wei Y, 2006, CHINESE J CLIN REHAB, V10, P54; Wongcharoen W, 2009, INT J CARDIOL, V133, P145, DOI 10.1016/j.ijcard.2009.01.073; Wu C, 2001, GUILIN MED, V3, P19; Wu L, 2004, XINJIANG MED J, V34, P107; Wu TX, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-46; Xi Z, 2005, MODERN MED HLTH, V21, P2337; Xu L, 2008, CONTEMP CLIN TRIALS, V29, P727, DOI 10.1016/j.cct.2008.05.003; Yang H, 2005, CHINESE HLTH CARE, V13, P9; Yang J, 2000, MODERN J INTEGRATED, V9, P1131; Yang L, 1996, SHANGHAI MED PHARM J, V2, P17; Yang Y, 2007, WORLD HLTH DIGEST, V4, P31; Yang Z, 1998, TRADITIONAL CHINESE, V9, P80; Yin J, 2002, HEBEI J TCM, V24, P308; Zeng J, 2005, ACADEMIC P NATL EMER, P156; Zhai L, 1995, SHANGHAI MED PHARM J, V11, P11; Zhang D, 2002, MODERN J INTEGRATED, V11, P408; Zhang J, 2005, CHINESE ARCH TRADITI, V23, P2096; Zhang J, 2003, PRACTICAL GERIATRICS, V17, P192; Zhang L, 2000, TIBETAN MED J, V21, P14; Zhao Z, 1998, PRACTICAL J INTEGRAT, V11, P26; Zhenbao Island Pharmaceutical Co. Ltd. in Heilongjiang Province, 2007, CHIN SCI TECHN ACH D; Zhou Z, 2002, HUBEI J TRADITIONAL, V24, P11	90	51	59	2	49	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 6	2011	6	5							e19604	10.1371/journal.pone.0019604	http://dx.doi.org/10.1371/journal.pone.0019604			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	760DZ	21573109	gold, Green Published, Green Submitted			2023-01-03	WOS:000290305600034
J	Jick, SS; Hernandez, RK				Jick, Susan S.; Hernandez, Rohini K.			Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HORMONAL CONTRACEPTIVES; TRANSDERMAL PATCH; ETHINYL ESTRADIOL; NORGESTIMATE; DISEASE; USERS; THROMBOSIS	Objective To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel. Design Nested case-control and cohort study. Setting The study was based on information from PharMetrics, a United States based company that collects information on claims paid by managed care plans. Participants The study encompassed all women aged 15 to 44 years who received an oral contraceptive containing either drospirenone or levonorgestrel after 1 January 2002. Cases were women with current use of a study oral contraceptive and a diagnosis of venous thromboembolism in the absence of identifiable clinical risk factors (idiopathic venous thromboembolism). Up to four controls were matched to each case by age and calendar time. Main outcome measures Odds ratios comparing the risk of non-fatal venous thromboembolism in users of the two contraceptives; incidence rates and rate ratios of non-fatal venous thromboembolism for users of each of the study contraceptives. Results 186 newly diagnosed, idiopathic cases of venous thromboembolism were identified in the study population and matched with 681 controls. In the case-control analysis, the conditional odds ratio for venous thromboembolism comparing use of oral contraceptives containing drospirenone with use of those containing levonorgestrel was 2.3 (95% confidence interval 1.6 to 3.2). The incidence rates for venous thromboembolism in the study population were 30.8 (95% confidence interval 25.6 to 36.8) per 100 000 woman years among users of oral contraceptives containing drospirenone and 12.5 (9.61 to 15.9) per 100 000 woman years among users of oral contraceptives containing levonorgestrel. The age adjusted incidence rate ratio for venous thromboembolism for current use of oral contraceptives containing drospirenone compared with those containing levonorgestrel was 2.8 (2.1 to 3.8). Conclusions The risk of non-fatal venous thromboembolism among users of oral contraceptives containing drospirenone seems to be around twice that of users of oral contraceptives containing levonorgestrel, after the effects of potential confounders and prescribing biases have been taken into account.	[Jick, Susan S.; Hernandez, Rohini K.] Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA	Boston University	Jick, SS (corresponding author), Boston Univ, Sch Med, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.	sjick@bu.edu		Jick, Susan/0000-0002-2215-1067				Dinger JC, 2007, CONTRACEPTION, V75, P344, DOI 10.1016/j.contraception.2006.12.019; Farmer RDT, 2000, BRIT J CLIN PHARMACO, V49, P580, DOI 10.1046/j.1365-2125.2000.00198.x; Gomes MPV, 2004, ARCH INTERN MED, V164, P1965, DOI 10.1001/archinte.164.18.1965; Jick H, 2000, BMJ-BRIT MED J, V321, P1190, DOI 10.1136/bmj.321.7270.1190; JICK H, 1995, LANCET, V346, P1589, DOI 10.1016/S0140-6736(95)91928-7; Jick SS, 2006, CONTRACEPTION, V73, P223, DOI 10.1016/j.contraception.2006.01.001; Jick S, 2007, CONTRACEPTION, V76, P4, DOI 10.1016/j.contraception.2007.03.003; Jick SS, 2007, PHARMACOTHERAPY, V27, P218, DOI 10.1592/phco.27.2.218; Jick SS, 2006, CONTRACEPTION, V74, P290, DOI 10.1016/j.contraception.2006.05.071; Jick SS, 2006, CONTRACEPTION, V73, P566, DOI 10.1016/j.contraception.2006.02.002; Kemmeren JM, 2001, BRIT MED J, V323, P131, DOI 10.1136/bmj.323.7305.131; Lidegaard O, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b2890; Parkin L, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d2139; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; POULTER NR, 1995, LANCET, V346, P1575; Rothman JK, 2008, MODERN EPIDEMIOLOGY, V3rd; ROTHMAN KJ, 1988, INT J EPIDEMIOL, V17, P955, DOI 10.1093/ije/17.4.955; Seeger JD, 2007, OBSTET GYNECOL, V110, P587, DOI 10.1097/01.AOG.0000279448.62221.a8; Spitzer WO, 1996, BRIT MED J, V312, P83; Vasilakis-Scaramozza C, 2001, LANCET, V358, P1427, DOI 10.1016/S0140-6736(01)06522-9; Vlieg AV, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2921; 2005, EPISHEET SPREADSHEET	22	152	155	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 21	2011	342								d2151	10.1136/bmj.d2151	http://dx.doi.org/10.1136/bmj.d2151			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	755OR	21511805	hybrid, Green Published			2023-01-03	WOS:000289943400006
J	Giugliano, D; Esposito, K				Giugliano, Dario; Esposito, Katherine			Clinical Inertia as a Clinical Safeguard	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BLOOD-PRESSURE CONTROL; PREVENTION		[Giugliano, Dario; Esposito, Katherine] Univ Naples 2, Dept Geriatr & Metab Dis, I-80138 Naples, Italy	Universita della Campania Vanvitelli	Giugliano, D (corresponding author), Univ Naples 2, Dept Geriatr & Metab Dis, Piazza L Miraglia 2, I-80138 Naples, Italy.	dario.giugliano@unina2.it	Esposito, Katherine/AHE-2564-2022; Maiorino, Maria Ida/AHE-9986-2022	Esposito, Katherine/0000-0002-3652-5154; Maiorino, Maria Ida/0000-0003-4659-7546; Giugliano, Dario/0000-0002-9377-873X				Cooper-DeHoff RM, 2010, JAMA-J AM MED ASSOC, V304, P61, DOI 10.1001/jama.2010.884; Cushman WC, 2010, NEW ENGL J MED, V362, P1575, DOI 10.1056/NEJMoa1001286; Egan BM, 2010, JAMA-J AM MED ASSOC, V303, P2043, DOI 10.1001/jama.2010.650; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Gerstein HC, 2008, NEW ENGL J MED, V358, P2545, DOI 10.1056/NEJMoa0802743; National Center for Health Statistics, 2010, HLTH US 2009 SPEC FE; Phillips LS, 2001, ANN INTERN MED, V135, P825, DOI 10.7326/0003-4819-135-9-200111060-00012; Ray KK, 2010, ARCH INTERN MED, V170, P1024, DOI 10.1001/archinternmed.2010.182; Skyler JS, 2009, DIABETES CARE, V32, P187, DOI 10.2337/dc08-9026; Yudkin JS, 2010, DIABETOLOGIA, V53, P2079, DOI 10.1007/s00125-010-1864-z	10	61	63	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	2011	305	15					1591	1592		10.1001/jama.2011.490	http://dx.doi.org/10.1001/jama.2011.490			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	752HU	21505139				2023-01-03	WOS:000289683000031
J	Lawler, K; Jeremiah, K; Mosepele, M; Ratcliffe, SJ; Cherry, C; Seloilwe, E; Steenhoff, AP				Lawler, Kathy; Jeremiah, Kealeboga; Mosepele, Mosepele; Ratcliffe, Sarah J.; Cherry, Catherine; Seloilwe, Esther; Steenhoff, Andrew P.			Neurobehavioral Effects in HIV-Positive Individuals Receiving Highly Active Antiretroviral Therapy (HAART) in Gaborone, Botswana	PLOS ONE			English	Article							SUB-SAHARAN AFRICA; FORMER PLASMA DONORS; COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL IMPAIRMENT; NEUROCOGNITIVE DISORDERS; PRIMARY-CARE; DEMENTIA; INFECTION; VALIDITY; IMPACT	Objective: To explore the prevalence and features of HIV-associated neurocognitive disorders (HANDS) in Botswana, a sub-Saharan country at the center of the HIV epidemic. Design and Methods: A cross sectional study of 60 HIV-positive individuals, all receiving highly active antiretroviral therapy (HAART), and 80 demographically matched HIV-seronegative control subjects. We administered a comprehensive neuropsychological test battery and structured psychiatric interview. The lowest 10(th) percentile of results achieved by control subjects was used to define the lower limit of normal performance on cognitive measures. Subjects who scored abnormal on three or more measures were classified as cognitively impaired. To determine the clinical significance of any cognitive impairment, we assessed medication adherence, employment, and independence in activities of daily living (ADL). Results: HIV+ subjects were impaired for all cognitive-motor ability areas compared with matched, uninfected control subjects. Thirty seven percent of HIV+ patients met criteria for cognitive impairment. Conclusion: These findings indicate that neurocognitive impairment is likely to be an important feature of HIV infection in resource-limited countries; underscoring the need to develop effective treatments for subjects with, or at risk of developing, cognitive impairment.	[Lawler, Kathy; Ratcliffe, Sarah J.; Steenhoff, Andrew P.] Univ Penn, Ctr AIDS Res & Botswana UPenn Partnership, Philadelphia, PA 19104 USA; [Seloilwe, Esther] Univ Botswana, Ctr Study HIV & AIDS, Gaborone, Botswana; [Mosepele, Mosepele] Princess Marina Hosp, Infect Dis Care Ctr, Gaborone, Botswana; [Lawler, Kathy] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Ratcliffe, Sarah J.; Steenhoff, Andrew P.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Mosepele, Mosepele] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Steenhoff, Andrew P.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Jeremiah, Kealeboga; Cherry, Catherine] Monash Univ, Melbourne, Vic 3004, Australia; [Cherry, Catherine] Burnet Inst, Ctr Virol, Melbourne, Vic, Australia; [Cherry, Catherine] Alfred Hosp, Dept Infect Dis, Melbourne, Vic, Australia	University of Pennsylvania; University of Botswana; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Monash University; Burnet Institute; Florey Institute of Neuroscience & Mental Health	Lawler, K (corresponding author), Univ Penn, Ctr AIDS Res & Botswana UPenn Partnership, Philadelphia, PA 19104 USA.	kathy.lawler@uphs.upenn.edu	Ratcliffe, Sarah J/GYR-1110-2022	Ratcliffe, Sarah J/0000-0002-6644-8284; Cherry, Catherine Louise/0000-0001-9816-5193				*AIDSTAR ON, 2008, BOTSW NAT HIV AIDS T; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; An SF, 1999, J NEUROPATH EXP NEUR, V58, P1156, DOI 10.1097/00005072-199911000-00005; Antinori A, 2007, NEUROLOGY, V69, P1789, DOI 10.1212/01.WNL.0000287431.88658.8b; Bhaskaran K, 2008, ANN NEUROL, V63, P213, DOI 10.1002/ana.21225; Carey CL, 2004, J CLIN EXP NEUROPSYC, V26, P307, DOI 10.1080/13803390490510031; Clifford DB, 2007, J NEUROVIROL, V13, P67, DOI 10.1080/13550280601169837; Cysique LAJ, 2006, NEUROLOGY, V66, P1447, DOI 10.1212/01.wnl.0000210477.63851.d3; Cysique LA, 2007, J INT NEUROPSYCH SOC, V13, P1, DOI 10.1017/S1355617707070026; Cysique LA, 2010, AIDS, V24, P983, DOI 10.1097/QAD.0b013e32833336c8; Cysique LA, 2009, NEUROPSYCHOL REV, V19, P169, DOI 10.1007/s11065-009-9092-3; Das Gupta J, 2007, J NEUROVIROL, V13, P195, DOI 10.1080/13550280701258407; Dawes S, 2008, J CLIN EXP NEUROPSYC, V30, P613, DOI 10.1080/13803390701565225; Heaton RK, 2004, J INT NEUROPSYCH SOC, V10, P317, DOI 10.1017/S1355617704102130; HEATON RK, 2009, 16 C RETR OPP INF MO, P396; Heaton RK, 2008, J NEUROVIROL, V14, P536, DOI 10.1080/13550280802378880; Jin H, 2006, J AFFECT DISORDERS, V94, P269, DOI 10.1016/j.jad.2006.04.013; JOSKA JA, 2010, AIDS BEHAV       JUL; Kanmogne GD, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-60; *LAF INSTR, LAF INSTR GROOV PEG; Lawler K, 2010, J INT AIDS SOC, V13, DOI 10.1186/1758-2652-13-15; Lawler K, 2011, AIDS BEHAV, V15, P204, DOI 10.1007/s10461-009-9622-2; Letendre S, 2008, ARCH NEUROL-CHICAGO, V65, P65, DOI 10.1001/archneurol.2007.31; Liner KJ, 2007, J NEUROVIROL, V13, P291, DOI 10.1080/13550280701422383; Livingston J, 2009, CULT ANTHROPOL, V24, P652, DOI 10.1111/j.1548-1360.2009.01043.x; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; MAJ M, 1994, ARCH GEN PSYCHIAT, V51, P51; Osowiecki DM, 2000, AIDS, V14, P1327, DOI 10.1097/00002030-200007070-00004; Reitan R. M., 1985, HALSTEAD REITAN NEUR, V4; Robertson K, 2009, NEUROPSYCHOL REV, V19, P232, DOI 10.1007/s11065-009-9096-z; Robertson KR, 2007, BMC NEUROL, V7, DOI 10.1186/1471-2377-7-8; Sacktor N, 2006, NEUROLOGY, V67, P311, DOI 10.1212/01.wnl.0000225183.74521.72; Sacktor NC, 2005, AIDS, V19, P1367; Sacktor N, 2007, NAT CLIN PRACT NEURO, V3, P436, DOI 10.1038/ncpneuro0559; SCARAVILLI F, 1993, NEUROPATHOLOGY HIV I; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; Suarez SV, 2000, EUR J NEUROL, V7, P151, DOI 10.1046/j.1468-1331.2000.00050.x; Tommasello AC, 2006, AIDS CARE, V18, P911, DOI 10.1080/09540120500331297; Tozzi V, 2009, JAIDS-J ACQ IMM DEF, V52, P56, DOI 10.1097/QAI.0b013e3181af83d6; *UNAIDS, NACA BOTSW 2010 COUN; Wechsler D, WECHSLER ADULT INTEL; Wong M, 2004, NEUROLOGY, V62, pA444; Wong MH, 2007, NEUROLOGY, V68, P350, DOI 10.1212/01.wnl.0000252811.48891.6d; Woods SP, 2005, J INT NEUROPSYCH SOC, V11, P408, DOI 10.1017/S1355617705050460; Wright E, 2008, NEUROLOGY, V71, P50, DOI 10.1212/01.wnl.0000316390.17248.65	45	36	36	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 18	2011	6	2							e17233	10.1371/journal.pone.0017233	http://dx.doi.org/10.1371/journal.pone.0017233			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	723CC	21365002	gold, Green Submitted, Green Published			2023-01-03	WOS:000287482800037
J	Bernini, F; Ebranati, E; De Maddalena, C; Shkjezi, R; Milazzo, L; Lo Presti, A; Ciccozzi, M; Galli, M; Zehender, G				Bernini, Flavia; Ebranati, Erika; De Maddalena, Chiara; Shkjezi, Renata; Milazzo, Laura; Lo Presti, Alessandra; Ciccozzi, Massimo; Galli, Massimo; Zehender, Gianguglielmo			Within-Host Dynamics of the Hepatitis C Virus Quasispecies Population in HIV-1/HCV Coinfected Patients	PLOS ONE			English	Article							ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; AMINO-ACID SITES; HYPERVARIABLE REGION; NEUTRALIZING ANTIBODIES; SCAVENGER RECEPTOR; SEQUENCE VARIATION; EVOLUTIONARY DYNAMICS; POSITIVE SELECTION	HIV/HCV coinfected individuals under highly active antiretroviral therapy (HAART) represent an interesting model for the investigation of the role played by the immune system in driving the evolution of the HCV quasispecies. We prospectively studied the intra-host evolution of the HCV heterogeneity in 8 coinfected subjects, selected from a cohort of 32 patients initiating HAART: 5 immunological responders (group A) and 3 immunological non-responders (group B), and in two HCV singly infected controls not assuming drugs (group C). For all these subjects at least two serial samples obtained at the first observation (before HAART) and more than 1 year later, underwent clonal sequence analysis of partial E1/E2 sequences, encompassing the whole HVR1. Evolutionary rates, dated phylogenies and population dynamics were co-estimated by using a Bayesian Markov Chain Monte Carlo approach, and site specific selection pressures were estimated by maximum likelihood-based methods. The intra-host evolutionary rates of HCV quasispecies was 10 times higher in subjects treated with HAART than in controls without immunodeficiency (1.9 and 2.3x10(-3) sub/site/month in group A and B and 0.29x10(-3) sub/site/month in group C individuals). The within-host Bayesian Skyline plot analysis showed an exponential growth of the quasispecies populations in immunological responders, coinciding with a peak in CD4 cell counts. On the contrary, quasispecies population remained constant in group B and in group C controls. A significant positive selection pressure was detected in a half of the patients under HAART and in none of the group C controls. Several sites under significant positive selection were described, mainly included in the HVR1. Our data indicate that different forces, in addition to the selection pressure, drive an exceptionally fast evolution of HCV during HAART immune restoration. We hypothesize that an important role is played by the enlargement of the viral replicative space.	[Bernini, Flavia; Ebranati, Erika; De Maddalena, Chiara; Shkjezi, Renata; Milazzo, Laura; Galli, Massimo; Zehender, Gianguglielmo] Univ Milan, Dept Clin Sci L Sacco, Milan, Italy; [Lo Presti, Alessandra; Ciccozzi, Massimo] Inst Super Sanita, Dept Infect Parasit & Immune Mediated Dis, Rome, Italy	University of Milan; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); Istituto Superiore di Sanita (ISS)	Bernini, F (corresponding author), Univ Milan, Dept Clin Sci L Sacco, Milan, Italy.	gianguglielmo.zehender@unimi.it	Ciccozzi, Massimo/AAC-3271-2022; Lo Presti, Alessandra/K-1451-2016; CICCOZZI, MASSIMO/C-6484-2016; GALLI, MASSIMO/L-7282-2017	Ciccozzi, Massimo/0000-0003-3866-9239; Lo Presti, Alessandra/0000-0001-7611-5021; CICCOZZI, MASSIMO/0000-0003-3866-9239; GALLI, MASSIMO/0000-0001-8887-6215				ABE K, 1992, J GEN VIROL, V73, P2725, DOI 10.1099/0022-1317-73-10-2725; Allain JP, 2000, J VIROL, V74, P2541, DOI 10.1128/JVI.74.6.2541-2549.2000; Babik JM, 2003, J VIROL, V77, P1940, DOI 10.1128/JVI.77.3.1940-1950.2003; Bartosch B, 2005, J VIROL, V79, P8217, DOI 10.1128/JVI.79.13.8217-8229.2005; Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Blackard JT, 2004, J INFECT DIS, V189, P1472, DOI 10.1086/382959; Booth JCL, 1998, HEPATOLOGY, V27, P223, DOI 10.1002/hep.510270134; Brown RJP, 2005, J GEN VIROL, V86, P1931, DOI 10.1099/vir.0.80957-0; Callens N, 2005, J VIROL, V79, P15331, DOI 10.1128/JVI.79.24.15331-15341.2005; Christie JML, 1999, HEPATOLOGY, V30, P1037, DOI 10.1002/hep.510300403; Chung RT, 2002, AIDS, V16, P1915, DOI 10.1097/00002030-200209270-00008; Cuevas JM, 2009, INFECT GENET EVOL, V9, P860, DOI 10.1016/j.meegid.2009.05.007; Curran R, 2002, J GEN VIROL, V83, P11, DOI 10.1099/0022-1317-83-1-11; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; Dubuisson J, 2007, WORLD J GASTROENTERO, V13, P2406, DOI 10.3748/wjg.v13.i17.2406; Duffy M, 2002, VIROLOGY, V301, P354, DOI 10.1006/viro.2002.1597; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; Farci P, 2000, SEMIN LIVER DIS, V20, P103; Felsenstein J, 2006, MOL BIOL EVOL, V23, P691, DOI 10.1093/molbev/msj079; Grenfell BT, 2004, SCIENCE, V303, P327, DOI 10.1126/science.1090727; HASEGAWA M, 1985, J MOL EVOL, V22, P160, DOI 10.1007/BF02101694; Holmes EC, 2008, ANNU REV MICROBIOL, V62, P307, DOI 10.1146/annurev.micro.62.081307.162912; Huelsenbeck JP, 2001, SCIENCE, V294, P2310, DOI 10.1126/science.1065889; KATO N, 1992, BIOCHEM BIOPH RES CO, V189, P119, DOI 10.1016/0006-291X(92)91533-V; Kingman JFC, 2000, GENETICS, V156, P1461; Krey T, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000762; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Laskus T, 1998, J INFECT DIS, V178, P1189, DOI 10.1086/515682; Laskus T, 2007, HEPATOLOGY, V46, P359, DOI 10.1002/hep.21715; Marine-Barjoan E, 2004, AIDS, V18, P2163, DOI 10.1097/00002030-200411050-00008; McAllister J, 1998, J VIROL, V72, P4893, DOI 10.1128/JVI.72.6.4893-4905.1998; PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607; Pond SLK, 2006, BIOINFORMATICS, V22, P3096, DOI 10.1093/bioinformatics/btl474; Pond SLK, 2005, MOL BIOL EVOL, V22, P1208, DOI 10.1093/molbev/msi105; Pond SLK, 2005, BIOINFORMATICS, V21, P676, DOI 10.1093/bioinformatics/bti079; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Pybus OG, 2000, GENETICS, V155, P1429; Qurishi N, 2003, LANCET, V362, P1708, DOI 10.1016/S0140-6736(03)14844-1; Ray SC, 1999, J VIROL, V73, P2938, DOI 10.1128/JVI.73.4.2938-2946.1999; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Salemi M, 2005, J VIROL, V79, P11343, DOI 10.1128/JVI.79.17.11343-11352.2005; Salemi M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008153; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Sheridan I, 2004, J VIROL, V78, P3447, DOI 10.1128/JVI.78.7.3447-3454.2004; Shuhart MC, 2006, J INFECT DIS, V193, P1211, DOI 10.1086/502974; Smith DB, 1999, J VIRAL HEPATITIS, V6, P41, DOI 10.1046/j.1365-2893.1999.00010.x; Solmone M, 2006, ANTIVIR THER, V11, P87; Suchard MA, 2001, MOL BIOL EVOL, V18, P1001, DOI 10.1093/oxfordjournals.molbev.a003872; Suzuki Y, 1999, MOL BIOL EVOL, V16, P1315, DOI 10.1093/oxfordjournals.molbev.a026042; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoda H, 1997, J HEPATOL, V26, P975, DOI 10.1016/S0168-8278(97)80105-5; Valdez H, 2001, CLIN INFECT DIS, V32, P1487, DOI 10.1086/320164; Vento S, 1998, AIDS, V12, P116; Yang ZH, 2000, MOL BIOL EVOL, V17, P32, DOI 10.1093/oxfordjournals.molbev.a026236; Zehender G, 2005, J VIROL, V79, P9145, DOI 10.1128/JVI.79.14.9145-9156.2005; Zehender G, 1997, J INFECT DIS, V176, P1209, DOI 10.1086/514114; Zeisel MB, 2007, WORLD J GASTROENTERO, V13, P4824, DOI 10.3748/wjg.v13.i36.4824	57	17	17	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JAN 31	2011	6	1							e16551	10.1371/journal.pone.0016551	http://dx.doi.org/10.1371/journal.pone.0016551			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	714UK	21304985	Green Published, gold			2023-01-03	WOS:000286834300084
J	Kind, AJH; Bartels, C; Mell, MW; Mullahy, J; Smith, M				Kind, Amy J. H.; Bartels, Christie; Mell, Matthew W.; Mullahy, John; Smith, Maureen			For-Profit Hospital Status and Rehospitalizations at Different Hospitals: An Analysis of Medicare Data	ANNALS OF INTERNAL MEDICINE			English	Article							PRIMARY-CARE PHYSICIANS; CONFIDENCE-INTERVALS; INSURANCE STATUS; PATIENT SAFETY; VOLUME; MORTALITY; QUALITY; MARKET; RISK; OPPORTUNITIES	Background: About one quarter of rehospitalized Medicare patients are admitted to hospitals different from their original hospital. The extent to which this practice is related to for-profit hospital status and affects payments and mortality is unknown. Objective: To describe and examine predictors of and payments for rehospitalization at a different hospital among Medicare patients rehospitalized within 30 days at for-profit and nonprofit or public hospitals. Design: Cohort study of patients discharged and rehospitalized from January 2005 to November 2006. Setting: Medicare fee-for-service hospitals throughout the United States. Participants: A 5% random national sample of Medicare patients with acute care rehospitalizations within 30 days of discharge (n = 74 564). Measurements: 30-day rehospitalizations at different hospitals and total payments or mortality over the subsequent 30 days. Multivariate logistic and quantile regression models included index hospital for-profit status, discharge counts, geographic region, rural-urban commuting area, and teaching status; patient socio-demographic characteristics, disability status, and comorbid conditions; and a measure of risk adjustment. Results: 16 622 patients (22%) in the sample were rehospitalized at a different hospital. Factors associated with increased risk for rehospitalization at a different hospital included index hospitalization at a for-profit, major medical school-affiliated, or low-volume hospital and having a Medicare-defined disability. Compared with patients rehospitalized at the same hospital, patients rehospitalized at different hospitals had higher adjusted 30-day total payments (median additional cost, $1308 per patient; P < 0.001) but no statistically significant differences in 30-day mortality, regardless of index hospital for-profit status. Limitation: The database lacked detailed clinical information about patients and did not include information about specific provider practice motivations or the role of patient choice in hospitalization venues. Conclusion: Rehospitalizations at different hospitals are common among Medicare patients, are more likely among those initially hospitalized at a for-profit hospital, and are related to increased overall payments without improved mortality.	[Kind, Amy J. H.] William S Middleton Vet Affairs Hosp, Geriatr Res Educ & Clin Ctr, Madison, WI 53705 USA; [Bartels, Christie; Smith, Maureen] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53705 USA; [Mell, Matthew W.] Stanford Univ, Stanford, CA 94305 USA; [Mullahy, John] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53726 USA	Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Kind, AJH (corresponding author), William S Middleton Vet Affairs Hosp, Geriatr Res Educ & Clin Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA.	ajk@medicine.wisc.edu	Bartels, Christie Michels/ABG-4072-2020	Bartels, Christie Michels/0000-0001-6523-0374; Kind, Amy/0000-0002-7183-610X	University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics; UW Health Innovation Program; National Center for Research Resources, National Institutes of Health through UW-Madison [1KL2RR025012-01, 1UL1RR025011]; UW Institute for Clinical and Translational Research; National Institutes of Health; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR025012, UL1RR025011] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG034551] Funding Source: NIH RePORTER	University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics; UW Health Innovation Program; National Center for Research Resources, National Institutes of Health through UW-Madison(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); UW Institute for Clinical and Translational Research; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	By the University of Wisconsin (UW) Hartford Center of Excellence in Geriatrics; the UW Health Innovation Program; a KL-2 grant from the National Center for Research Resources, National Institutes of Health (1KL2RR025012-01) through the Institutional Clinical and Translational Science Award (UW-Madison) program (1UL1RR025011 to Dr. Kind); and the Community-Academic Partnerships core of the UW Institute for Clinical and Translational Research.; University of Wisconsin Hartford Center of Excellence in Geriatrics, National Institutes of Health.	[Anonymous], 2009, CLIN CLASS SOFTW CCS; Archdeacon MT, 2007, J BONE JOINT SURG AM, V89A, P2625, DOI 10.2106/JBJS.F.01499; Berman L, 2010, J PEDIATR SURG, V45, P38, DOI 10.1016/j.jpedsurg.2009.10.006; Bhalla R, 2010, ANN INTERN MED, V152, P114, DOI 10.7326/0003-4819-152-2-201001190-00185; Billingsley KG, 2007, ARCH SURG-CHICAGO, V142, P23, DOI 10.1001/archsurg.142.1.23; Birkmeyer JD, 2003, NEW ENGL J MED, V349, P2117, DOI 10.1056/NEJMsa035205; Birkmeyer JD, 2002, NEW ENGL J MED, V346, P1128, DOI 10.1056/NEJMsa012337; Carpenter J, 2000, STAT MED, V19, P1141, DOI 10.1002/(SICI)1097-0258(20000515)19:9<1141::AID-SIM479>3.0.CO;2-F; Casalino LP, 2003, HEALTH AFFAIR, V22, P56, DOI 10.1377/hlthaff.22.6.56; Coleman EA, 2003, J AM GERIATR SOC, V51, P549, DOI 10.1046/j.1532-5415.2003.51185.x; Coleman EA, 2004, ANN INTERN MED, V141, P533, DOI 10.7326/0003-4819-141-7-200410050-00009; Cram P, 2008, MED CARE, V46, P467, DOI 10.1097/MLR.0b013e31816c43d9; Duggan M, 2002, RAND J ECON, V33, P433, DOI 10.2307/3087466; EFRON B, 1979, ANN STAT, V7, P1, DOI 10.1214/aos/1176344552; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Elixhauser A, 2003, HEALTH AFFAIR, V22, P167, DOI 10.1377/hlthaff.22.2.167; Fisher ES, 2009, HEALTH AFFAIR, V28, pW219, DOI 10.1377/hlthaff.28.2.w219; Goldsmith J, 2003, HEALTH AFFAIR, V22, P44, DOI 10.1377/hlthaff.22.4.44; Greene W.H., 2017, ECONOMETRIC ANAL, Veighth; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kessler DP, 2002, RAND J ECON, V33, P488, DOI 10.2307/3087469; Kind AJH, 2007, J AM GERIATR SOC, V55, P365, DOI 10.1111/j.1532-5415.2007.01091.x; Kind AJH, 2010, ARCH PHYS MED REHAB, V91, P189, DOI 10.1016/j.apmr.2009.10.015; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Kolstad JT, 2009, MED CARE RES REV, V66, p28S, DOI 10.1177/1077558708325887; Koval KJ, 2006, J BONE JOINT SURG AM, V88A, P2124, DOI 10.2106/JBJS.F.00245; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Localio AR, 2007, J CLIN EPIDEMIOL, V60, P874, DOI 10.1016/j.jclinepi.2006.12.001; LUFT HS, 1990, JAMA-J AM MED ASSOC, V263, P2899, DOI 10.1001/jama.263.21.2899; *MED PAYM ADV COMM, 2009, C IMPR  INC MED PROG; Medicare Payment Advisory Commission, 2008, C REF DEL SYST WASH; Medicare Payment Advisory Commission, 2007, C PROM GREAT EFF MED; Mukamel DB, 2007, MED CARE, V45, P1227, DOI 10.1097/MLR.0b013e31812f56bb; Nathens AB, 2001, J TRAUMA, V50, P776, DOI 10.1097/00005373-200105000-00002; PETERSON ED, 1994, ANN INTERN MED, V121, P919, DOI 10.7326/0003-4819-121-12-199412150-00003; Pope GC, 2004, HEALTH CARE FINANC R, V25, P119; Sharma G, 2009, JAMA-J AM MED ASSOC, V301, P1671, DOI 10.1001/jama.2009.517; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Trzeciak S, 2003, EMERG MED J, V20, P402, DOI 10.1136/emj.20.5.402; Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care (full printed version), 2003, UN TREATM CONFR RAC; United States Department of Agriculture (USDA) Economic Research Service, 2005, MEAS RUR RUR URB COM; *WA STAT DEP HLTH, 2010, 4 TIER CONS RUCA SYS; Weiss SJ, 2004, ACAD EMERG MED, V11, P38, DOI 10.1197/S1069-6563(03)00583-9; Yuan Z, 2000, MED CARE, V38, P231, DOI 10.1097/00005650-200002000-00012	44	55	55	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 7	2010	153	11					718	727		10.7326/0003-4819-153-11-201012070-00005	http://dx.doi.org/10.7326/0003-4819-153-11-201012070-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	690KN	21135295	Green Accepted			2023-01-03	WOS:000285003800004
J	Hiratsuka, T; Matsuzaki, S; Miyata, S; Kinoshita, M; Kakehi, K; Nishida, S; Katayama, T; Tohyama, M				Hiratsuka, Toru; Matsuzaki, Shinsuke; Miyata, Shingo; Kinoshita, Mitsuhiro; Kakehi, Kazuaki; Nishida, Shinji; Katayama, Taiichi; Tohyama, Masaya			Yokukansan Inhibits Neuronal Death during ER Stress by Regulating the Unfolded Protein Response	PLOS ONE			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRADITIONAL JAPANESE MEDICINE; ALZHEIMERS-DISEASE; FERULIC ACID; PSYCHOLOGICAL SYMPTOMS; SIGNALING PATHWAY; CHOLINESTERASE-INHIBITORS; OXIDATIVE STRESS; MESSENGER-RNA; IMMUNOTHERAPY	Background: Recently, several studies have reported Yokukansan (Tsumura TJ-54), a traditional Japanese medicine, as a potential new drug for the treatment of Alzheimer's disease (AD). Endoplasmic reticulum (ER) stress is known to play an important role in the pathogenesis of AD, particularly in neuronal death. Therefore, we examined the effect of Yokukansan on ER stress-induced neurotoxicity and on familial AD-linked presenilin-1 mutation-associated cell death. Methods: We employed the WST-1 assay and monitored morphological changes to evaluate cell viability following Yokukansan treatment or treatment with its components. Western blotting and PCR were used to observe the expression levels of GRP78/BiP, caspase-4 and C/EBP homologous protein. Results: Yokukansan inhibited neuronal death during ER stress, with Cnidii Rhizoma (Senkyu), a component of Yokukansan, being particularly effective. We also showed that Yokukansan and Senkyu affect the unfolded protein response following ER stress and that these drugs inhibit the activation of caspase-4, resulting in the inhibition of ER stress-induced neuronal death. Furthermore, we found that the protective effect of Yokukansan and Senkyu against ER stress could be attributed to the ferulic acid content of these two drugs. Conclusions: Our results indicate that Yokukansan, Senkyu and ferulic acid are protective against ER stress-induced neuronal cell death and may provide a possible new treatment for AD.	[Hiratsuka, Toru; Matsuzaki, Shinsuke; Miyata, Shingo; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka, Japan; [Matsuzaki, Shinsuke; Katayama, Taiichi; Tohyama, Masaya] Hamamatsu Univ Sch Med, Suita, Osaka, Japan; [Matsuzaki, Shinsuke; Katayama, Taiichi; Tohyama, Masaya] Kanazawa Univ, Osaka Univ, United Grad Sch Child Dev, Dept Child Dev & Mol Brain Sci, Suita, Osaka, Japan; [Matsuzaki, Shinsuke; Miyata, Shingo; Tohyama, Masaya] Osaka Univ, Grad Sch Med, Osaka Hamamatsu Joint Res Ctr Child Mental Dev, Suita, Osaka, Japan; [Kinoshita, Mitsuhiro; Kakehi, Kazuaki] Kinki Univ, Sch Pharmaceut Sci, Lab Biopharmaco Informat, Higashiosaka, Osaka 577, Japan; [Nishida, Shinji] Osaka Univ, Grad Sch Med, Dept Kampo Med, Suita, Osaka, Japan	Osaka University; Kanazawa University; Osaka University; Osaka University; Kindai University (Kinki University); Osaka University	Hiratsuka, T (corresponding author), Osaka Univ, Grad Sch Med, Dept Anat & Neurosci, Suita, Osaka, Japan.	s-matsuzaki@anat2.med.osaka-u.ac.jp		Hiratsuka, Toru/0000-0002-5359-2690	Health Labour Sciences Research Grant; Ministry of Education, Science, Sports and Culture; Global COE project	Health Labour Sciences Research Grant(Ministry of Health, Labour and Welfare, Japan); Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE project(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was partially supported by the Global COE project, by Health Labour Sciences Research Grant, by Grant-in-Aid for Young Scientists(B) and by the Ministry of Education, Science, Sports and Culture, Grant-in-Aid KAKENHI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arbel M, 2007, CURR ALZHEIMER RES, V4, P437, DOI 10.2174/156720507781788792; Balasubashini MS, 2004, PHYTOTHER RES, V18, P310, DOI 10.1002/ptr.1440; Brody DL, 2008, ANNU REV NEUROSCI, V31, P175, DOI 10.1146/annurev.neuro.31.060407.125529; Chafekar SM, 2007, ANTIOXID REDOX SIGN, V9, P2245, DOI 10.1089/ars.2007.1797; Getsios D, 2007, PHARMACOECONOMICS, V25, P997, DOI 10.2165/00019053-200725120-00003; Giacobini E, 2007, J ALZHEIMERS DIS, V12, P37; Hayashi H, 2005, BIOL PHARM BULL, V28, P744, DOI 10.1248/bpb.28.744; He LM, 2002, BRAIN RES, V939, P65, DOI 10.1016/S0006-8993(02)02549-0; Hitomi J, 2004, J CELL BIOL, V165, P347, DOI 10.1083/jcb.200310015; Hutton M, 2004, NEURON, V43, P293, DOI 10.1016/j.neuron.2004.07.023; IIZUKA S, 2010, NEUROPATHOL IN PRESS; Ikarashi Y, 2009, BIOL PHARM BULL, V32, P1701, DOI 10.1248/bpb.32.1701; JACKSON TR, 1988, BIOCHEM J, V253, P81, DOI 10.1042/bj2530081; Katayama T, 2001, J BIOL CHEM, V276, P43446, DOI 10.1074/jbc.M104096200; Katayama T, 1999, NAT CELL BIOL, V1, P479, DOI 10.1038/70265; Kawabata K, 2000, CANCER LETT, V157, P15, DOI 10.1016/S0304-3835(00)00461-4; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Manabe T, 2003, CELL DEATH DIFFER, V10, P698, DOI 10.1038/sj.cdd.4401221; Matsuzaki S, 2004, J NEUROCHEM, V88, P1345, DOI 10.1111/j.1471-4159.2004.02290.x; McShane R, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003154.pub5; Mizukami K, 2009, INT J NEUROPSYCHOPH, V12, P191, DOI 10.1017/S146114570800970X; Monji A, 2009, PROG NEURO-PSYCHOPH, V33, P308, DOI 10.1016/j.pnpbp.2008.12.008; MUKHOPADHYAY A, 1982, AGENTS ACTIONS, V12, P508, DOI 10.1007/BF01965935; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Pereira C, 2004, J MOL NEUROSCI, V23, P97, DOI 10.1385/JMN:23:1-2:097; Picone P, 2009, FREE RADICAL RES, V43, P1133, DOI 10.1080/10715760903214454; Pierrot N, 2004, J NEUROCHEM, V88, P1140, DOI 10.1046/j.1471-4159.2003.02227.x; Raina P, 2008, ANN INTERN MED, V148, P379, DOI 10.7326/0003-4819-148-5-200803040-00009; Sato N, 1999, J NEUROCHEM, V72, P2498, DOI 10.1046/j.1471-4159.1999.0722498.x; Sato N, 2001, J BIOL CHEM, V276, P2108, DOI 10.1074/jbc.M006886200; Sekiguchi K, 2009, PHYTOTHER RES, V23, P1175, DOI 10.1002/ptr.2777; Seltzer B, 2007, DRUG AGING, V24, P881, DOI 10.2165/00002512-200724110-00001; Shinno H, 2008, PROG NEURO-PSYCHOPH, V32, P1749, DOI 10.1016/j.pnpbp.2008.06.015; Sidrauski C, 1998, TRENDS CELL BIOL, V8, P245, DOI 10.1016/S0962-8924(98)01267-7; Sigurdsson EM, 2008, J ALZHEIMERS DIS, V15, P157; Solomon B, 2007, CURR OPIN MOL THER, V9, P79; Srinivasan M, 2007, J CLIN BIOCHEM NUTR, V40, P92, DOI 10.3164/jcbn.40.92; Sultana R, 2005, J NEUROCHEM, V92, P749, DOI 10.1111/j.1471-4159.2004.02899.x; Sun XD, 2003, NEUROBIOL DIS, V14, P567, DOI 10.1016/j.nbd.2003.08.007; Tateno M, 2008, PROG NEURO-PSYCHOPH, V32, P1704, DOI 10.1016/j.pnpbp.2008.07.006; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Wang X, 2007, NEUROSCIENCE, V144, P1045, DOI 10.1016/j.neuroscience.2006.10.008; Yan JJ, 2001, BRIT J PHARMACOL, V133, P89, DOI 10.1038/sj.bjp.0704047; Yogeeta SK, 2006, BASIC CLIN PHARMACOL, V98, P467, DOI 10.1111/j.1742-7843.2006.pto_335.x; Yu MS, 2006, APOPTOSIS, V11, P687, DOI 10.1007/s10495-006-5540-1; Yukioka F, 2008, NEUROCHEM INT, V52, P683, DOI 10.1016/j.neuint.2007.08.017	49	27	28	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 12	2010	5	10							e13280	10.1371/journal.pone.0013280	http://dx.doi.org/10.1371/journal.pone.0013280			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	662KX	20967273	Green Submitted, Green Published, gold			2023-01-03	WOS:000282807300015
J	Keller, G; Cour, M; Hernu, R; Illinger, J; Robert, D; Argaud, L				Keller, Geoffray; Cour, Martin; Hernu, Romain; Illinger, Julien; Robert, Dominique; Argaud, Laurent			Management of Metformin-Associated Lactic Acidosis by Continuous Renal Replacement Therapy	PLOS ONE			English	Article							ACUTE PHYSIOLOGY; HEMODIALYSIS; HEMOFILTRATION; ABSENCE; SCORE	Background: Metformin-associated lactic acidosis (MALA) is a severe metabolic failure with high related mortality. Although its use is controversial, intermittent hemodialysis is reported to be the most frequently used treatment in conjunction with nonspecific supportive measures. Our aim was to report the evolution and outcome of cases managed by continuous renal replacement therapy (CRRT). Methodology and Principal Findings: Over a 3-year period, we retrospectively identified patients admitted to the intensive care unit for severe lactic acidosis caused by metformin. We included patients in our study who were treated with CRRT because of shock. We describe their clinical and biological features at admission and during renal support, as well as their evolution. We enrolled six patients with severe lactic acidosis; the mean pH and mean lactate was 6.92 +/- 0.20 and 14.4 +/- 5.1 mmol/l, respectively. Patients had high illness severity scores, including the Simplified Acute Physiology Score II (SAPS II) (average score 63 +/- 12 points). Early CRRT comprised either venovenous hemofiltration (n = 3) or hemodiafiltration (n = 3) with a mean effluent flow rate of 34 +/- 6 ml/kg/h. Metabolic acidosis control and metformin elimination was rapid and there was no rebound. Outcome was favorable in all cases. Conclusions and Significance: Standard use of CRRT efficiently treated MALA in association with symptomatic organ supportive therapies.	[Keller, Geoffray; Cour, Martin; Hernu, Romain; Illinger, Julien; Robert, Dominique; Argaud, Laurent] Groupement Hosp Edouard Herriot, Hosp Civils Lyon, Serv Reanimat Med, Lyon, France; [Keller, Geoffray; Cour, Martin; Robert, Dominique; Argaud, Laurent] Univ Lyon 1, Fac Med Lyon Est, F-69365 Lyon, France	CHU Lyon; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Keller, G (corresponding author), Groupement Hosp Edouard Herriot, Hosp Civils Lyon, Serv Reanimat Med, Lyon, France.	laurent.argaud@chu-lyon.fr	Cour, M/T-2525-2019	cour, martin/0000-0003-4909-9761				Arroyo AM, 2010, AM J THER, V17, P96, DOI 10.1097/MJT.0b013e318197eab6; Bruijstens LA, 2008, NETH J MED, V66, P185; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; FAGON JY, 1993, INTENS CARE MED, V19, P137, DOI 10.1007/BF01720528; Finkel KW, 2009, SEMIN DIALYSIS, V22, P155, DOI 10.1111/j.1525-139X.2008.00550.x; Galea M, 2007, BRIT J ANAESTH, V98, P213, DOI 10.1093/bja/ael347; Guo PYF, 2006, SEMIN DIALYSIS, V19, P80, DOI 10.1111/j.1525-139X.2006.00123.x; JACKSON GG, 1962, ARCH INTERN MED, V110, P663, DOI 10.1001/archinte.1962.03620230109016; Kirpichnikov D, 2002, ANN INTERN MED, V137, P25, DOI 10.7326/0003-4819-137-1-200207020-00009; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Kruse JA, 2001, J EMERG MED, V20, P267, DOI 10.1016/S0736-4679(00)00320-6; Lalau JD, 1999, DRUG SAFETY, V20, P377, DOI 10.2165/00002018-199920040-00006; Lalau JD, 2003, DIABETES OBES METAB, V5, P93, DOI 10.1046/j.1463-1326.2003.00241.x; LALAU JD, 1987, INTENS CARE MED, V13, P383; Lalau JD, 2000, DIABETES OBES METAB, V2, P131, DOI 10.1046/j.1463-1326.2000.00053.x; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Leverve XM, 2005, CRIT CARE, V9, P622, DOI 10.1186/cc3935; Levraut J, 1997, CRIT CARE MED, V25, P58, DOI 10.1097/00003246-199701000-00013; Misbin RI, 1998, NEW ENGL J MED, V338, P265, DOI 10.1056/NEJM199801223380415; Pan LTT, 2009, ANAESTH INTENS CARE, V37, P830, DOI 10.1177/0310057X0903700520; Panzer U, 2004, NEPHROL DIAL TRANSPL, V19, P2157, DOI 10.1093/ndt/gfh337; Peters N, 2008, CRIT CARE, V12, DOI 10.1186/cc7137; Ronco C, 2008, INTENS CARE MED, V34, P2139, DOI 10.1007/s00134-008-1258-6; Sambol NC, 1996, J CLIN PHARMACOL, V36, P1012, DOI 10.1177/009127009603601105; Seidowsky A, 2009, CRIT CARE MED, V37, P2191, DOI 10.1097/CCM.0b013e3181a02490; Stades AME, 2004, J INTERN MED, V255, P179, DOI 10.1046/j.1365-2796.2003.01271.x; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Uchino S, 2009, CRIT CARE MED, V37, P2576, DOI 10.1097/CCM.0b013e3181a38241; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	30	39	39	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2011	6	8							e23200	10.1371/journal.pone.0023200	http://dx.doi.org/10.1371/journal.pone.0023200			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	808CS	21853087	Green Published, Green Submitted, gold			2023-01-03	WOS:000293953400031
J	Viviani, S; Zinzani, PL; Rambaldi, A; Brusamolino, E; Levis, A; Bonfante, V; Vitolo, U; Pulsoni, A; Liberati, AM; Specchia, G; Valagussa, P; Rossi, A; Zaja, F; Pogliani, EM; Pregno, P; Gotti, M; Gallamini, A; Scalabrini, DR; Bonadonna, G; Gianni, AM				Viviani, Simonetta; Zinzani, Pier Luigi; Rambaldi, Alessandro; Brusamolino, Ercole; Levis, Alessandro; Bonfante, Valeria; Vitolo, Umberto; Pulsoni, Alessandro; Liberati, Anna Marina; Specchia, Giorgina; Valagussa, Pinuccia; Rossi, Andrea; Zaja, Francesco; Pogliani, Enrico M.; Pregno, Patrizia; Gotti, Manuel; Gallamini, Andrea; Scalabrini, Delia Rota; Bonadonna, Gianni; Gianni, Alessandro M.		Michelangelo Fdn; Grp Italiano Terapie Innovative Ne; Intergrp Italiano Linfomi	ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CELL TRANSPLANT; CHEMOTHERAPY; DISEASE; IFOSFAMIDE; VINORELBINE; FERTILITY; STANDARD; REGIMEN; HYBRID; MOPP	Background BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). Methods We randomly assigned 331 patients with previously untreated and unfavorable Hodgkin's lymphoma (stage IIB, III, or IV, or an international prognostic score of >= 3 on a scale of 0 to 7, with higher scores indicating increased risk), to receive either BEACOPP or ABVD, each followed by local radiotherapy when indicated. Patients with residual or progressive disease after the initial therapy were to be treated according to a state-of-the-art high-dose salvage program. The median follow-up period was 61 months. Results The 7-year rate of freedom from first progression was 85% among patients who had received initial treatment with BEACOPP and 73% among those who had received initial treatment with ABVD (P = 0.004), and the 7-year rate of event-free survival was 78% and 71%, respectively (P = 0.15). A total of 65 patients (20 in the BEACOPP group, and 45 in the ABVD group) went on to receive the intended high-dose salvage regimen. As of the cutoff date, 3 of the 20 patients in the BEACOPP group and 15 of the 45 in the ABVD group who had had progressive disease or relapse after the initial therapy were alive and free of disease. After completion of the overall planned treatment, including salvage therapy, the 7-year rate of freedom from a second progression was 88% in the BEACOPP group and 82% in the ABVD group (P = 0.12), and the 7-year rate of overall survival was 89% and 84%, respectively (P = 0.39). Severe adverse events occurred more frequently in the BEACOPP group than in the ABVD group. Conclusions Treatment with BEACOPP, as compared with ABVD, resulted in better initial tumor control, but the long-term clinical outcome did not differ significantly between the two regimens.	[Gianni, Alessandro M.] Univ Milan, Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy; [Viviani, Simonetta; Valagussa, Pinuccia; Bonadonna, Gianni; Gianni, Alessandro M.] Milan Canc Inst, Milan, Italy; [Pogliani, Enrico M.] Univ Milano Bicocca, Milan, Italy; [Pulsoni, Alessandro] Univ Roma La Sapienza, Rome, Italy; [Zinzani, Pier Luigi] Univ Bologna, Bologna, Italy; [Rambaldi, Alessandro; Rossi, Andrea] Osped Riuniti Bergamo, I-24100 Bergamo, Italy; [Brusamolino, Ercole; Gotti, Manuel] Policlin San Matteo, I-27100 Pavia, Italy; [Levis, Alessandro] Azienda Osped SS Antonio & Biagio & Cesare Arrigo, Alessandria, Italy; [Vitolo, Umberto; Pregno, Patrizia] Azienda Osped Univ San Giovanni Battista, Turin, Italy; [Liberati, Anna Marina] Azienda Osped Santa Maria Terni, Terni, Italy; [Specchia, Giorgina] Azienda Osped Policlin Consorziale, Bari, Italy; [Zaja, Francesco] Policlin Univ, Udine, Italy; [Gallamini, Andrea] Osped Santa Croce & Carle, Cuneo, Italy; [Scalabrini, Delia Rota] Ist Ric & Cura Cancro, Candiolo, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan; University of Milano-Bicocca; Sapienza University Rome; University of Bologna; Ospedali Riuniti di Bergamo; IRCCS Fondazione San Matteo; Azienda Ospedaliera SS Antonio Biagio Cesare Arrigo; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette; University of Turin; Hospital Santa Maria della Misericordia; IRCCS Fondazione del Piemonte per l'Oncologia	Gianni, AM (corresponding author), Univ Milan, Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy.	alessandro.gianni@unimi.it	Italiana Linfomi, Fondazione/AAW-6910-2021; Gotti, Manuel/K-9120-2016; Rambaldi, Alessandro/M-6172-2019; Zinzani, Pier Luigi/J-9182-2016; Liberati, Anna Marina/I-8834-2012; Rambaldi, Alessandro/P-2603-2018; Viviani, Simonetta/F-6919-2017; Viviani, Siimonetta/AAA-5685-2021; Liberati, Anna Marina/C-1925-2017; Specchia, Giorgina/K-3084-2016	Italiana Linfomi, Fondazione/0000-0002-5918-8824; Rambaldi, Alessandro/0000-0002-3739-7502; Zinzani, Pier Luigi/0000-0002-2112-2651; Rambaldi, Alessandro/0000-0002-3739-7502; Viviani, Simonetta/0000-0002-5014-9546; Valagussa, Pinuccia/0000-0003-3590-7916; vitolo, umberto/0000-0001-7772-2747; Specchia, Giorgina/0000-0002-2479-9529; Zaja, Francesco/0000-0003-3995-8817	Fondazione Michelangelo	Fondazione Michelangelo	Funded by Fondazione Michelangelo	Bartlett Nancy L, 2005, Hematology Am Soc Hematol Educ Program, P245; BONADONNA G, 1975, CANCER, V36, P252, DOI 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7; Bonfante V, 1998, BRIT J HAEMATOL, V103, P533; CANELLOS GP, 1992, NEW ENGL J MED, V327, P1478, DOI 10.1056/NEJM199211193272102; Cheson, 2000, J CLIN ONCOL, V18, P2351; Cheson BD, 1999, J CLIN ONCOL, V17, P1244, DOI 10.1200/JCO.1999.17.4.1244; Cheson Bruce D, 2007, Curr Hematol Malig Rep, V2, P161, DOI 10.1007/s11899-007-0022-2; Clavio M, 2005, ONCOL REP, V14, P933; Diehl V, 2003, NEW ENGL J MED, V348, P2386, DOI 10.1056/NEJMoa022473; Diehl V, 2009, J CLIN ONCOL, V27; DIEHL V, 2005, NEW ENGL J MED, V353, P744; Diehl V, 2007, TRANSFUS APHER SCI, V37, P37, DOI 10.1016/j.transci.2007.04.004; Duggan DB, 2003, J CLIN ONCOL, V21, P607, DOI 10.1200/JCO.2003.12.086; Engert A, 2009, J CLIN ONCOL, V27, P4548, DOI 10.1200/JCO.2008.19.8820; Federico M, 2009, J CLIN ONCOL, V27, P805, DOI 10.1200/JCO.2008.17.0910; Forrest DL, 2005, J CLIN ONCOL, V23, P7994, DOI 10.1200/JCO.2005.01.9083; Hasenclever D, 1998, NEW ENGL J MED, V339, P1506, DOI 10.1056/NEJM199811193392104; Horning Sandra J, 2007, Hematology Am Soc Hematol Educ Program, P197; Hoskin PJ, 2009, J CLIN ONCOL, V27, P5390, DOI 10.1200/JCO.2009.23.3239; Jantunen E, 2006, EUR J HAEMATOL, V76, P245, DOI 10.1111/j.1600-0609.2005.00605.x; Johnson PWM, 2005, J CLIN ONCOL, V23, P9208, DOI 10.1200/JCO.2005.03.2151; Jurczak W, 2009, HAEMATOL-HEMATOL J, V94, P35; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MILLS W, 1995, J CLIN ONCOL, V13, P588, DOI 10.1200/JCO.1995.13.3.588; SANTORO A, 1987, J CLIN ONCOL, V5, P27, DOI 10.1200/JCO.1987.5.1.27; Santoro A, 2007, HAEMATOL-HEMATOL J, V92, P35, DOI 10.3324/haematol.10661; Sieniawski M, 2008, BLOOD, V111, P71, DOI 10.1182/blood-2007-02-073544	27	287	301	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 21	2011	365	3					203	212		10.1056/NEJMoa1100340	http://dx.doi.org/10.1056/NEJMoa1100340			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	794QI	21774708	Bronze			2023-01-03	WOS:000292915500004
J	Bhunia, A; Saravanan, R; Mohanram, H; Mangoni, ML; Bhattacharjya, S				Bhunia, Anirban; Saravanan, Rathi; Mohanram, Harini; Mangoni, Maria L.; Bhattacharjya, Surajit			NMR Structures and Interactions of Temporin-1Tl and Temporin-1Tb with Lipopolysaccharide Micelles MECHANISTIC INSIGHTS INTO OUTER MEMBRANE PERMEABILIZATION AND SYNERGISTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER DIFFERENCE NMR; HOST-DEFENSE PEPTIDES; HELICAL ANTIMICROBIAL PEPTIDES; GRAM-NEGATIVE BACTERIA; ENDOTOXIN NEUTRALIZATION; INNATE IMMUNITY; MOLECULAR-BASIS; LIGAND-BINDING; SPECTROSCOPY; RESISTANCE	Temporins are a group of closely related short antimicrobial peptides from frog skin. Lipopolysaccharide (LPS), the major constituent of the outer membrane of Gram-negative bacteria, plays important roles in the activity of temporins. Earlier studies have found that LPS induces oligomerization of temporin-1Tb (TB) thus preventing its translocation across the outer membrane and, as a result, reduces its activity on Gram-negative bacteria. On the other hand, temporin-1Tl (TL) exhibits higher activity, presumably because of lack of such oligomerization. A synergistic mechanism was proposed, involving TL and TB in overcoming the LPS-mediated barrier. Here, to gain insights into interactions of TL and TB within LPS, we investigated the structures and interactions of TL, TB, and TL+TB in LPS micelles, using NMR and fluorescence spectroscopy. In the context of LPS, TL assumes a novel antiparallel dimeric helical structure sustained by intimate packing between aromatic-aromatic and aromatic-aliphatic residues. By contrast, independent TB has populations of helical and aggregated conformations in LPS. The LPS-induced aggregated states of TB are largely destabilized in the presence of TL. Saturation transfer difference NMR studies have delineated residues of TL and TB in close contact with LPS and enhanced interactions of these two peptides with LPS, when combined together. Fluorescence resonance energy transfer and P-31 NMR have pointed out the proximity of TL and TB in LPS and conformational changes of LPS, respectively. Importantly, these results provide the first structural insights into the mode of action and synergism of antimicrobial peptides at the level of the LPS-outer membrane.	[Bhunia, Anirban; Saravanan, Rathi; Mohanram, Harini; Bhattacharjya, Surajit] Nanyang Technol Univ, Div Struct & Computat Biol, Sch Biol Sci, Singapore 637551, Singapore; [Mangoni, Maria L.] Univ Roma La Sapienza, Dipartimento Sci Biochim, Ist Pasteur, Fdn Cenci Bolognetti, I-00185 Rome, Italy	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Fondazione Cenci Bolognetti; Sapienza University Rome	Bhattacharjya, S (corresponding author), 60 Nanyang Dr, Singapore 637551, Singapore.	surajit@ntu.edu.sg	Bhattacharjya, SURAJIT/A-2183-2011; Mohanram, Harini/L-9207-2019	Mohanram, Harini/0000-0002-8179-2665; Bhunia, Anirban/0000-0002-8752-2842; Saravanan, Rathi/0000-0002-3884-6023; Mangoni, Maria Luisa/0000-0002-5991-5868	A*Star Biomedical Research Council, Singapore [06/1/22/19/446, 08/1/22/19/556]	A*Star Biomedical Research Council, Singapore(Agency for Science Technology & Research (A*STAR))	This work was supported by Grants 06/1/22/19/446 and 08/1/22/19/556 from A*Star Biomedical Research Council, Singapore.	ADAIR BD, 1994, BIOCHEMISTRY-US, V33, P5539, DOI 10.1021/bi00184a024; Angus DC, 2001, CRIT CARE MED, V29, pS109, DOI 10.1097/00003246-200107001-00035; Bechinger B, 1999, BBA-BIOMEMBRANES, V1462, P157, DOI 10.1016/S0005-2736(99)00205-9; Bhattacharjya S, 2010, CURR MED CHEM, V17, P3080, DOI 10.2174/092986710791959756; Bhattacharjya S, 2007, BIOCHEMISTRY-US, V46, P5864, DOI 10.1021/bi6025159; Bhattacharjya S, 2009, FEBS J, V276, P6465, DOI 10.1111/j.1742-4658.2009.07357.x; Bhunia A, 2007, BBA-BIOMEMBRANES, V1768, P3282, DOI 10.1016/j.bbamem.2007.07.017; Bhunia A, 2011, BIOPOLYMERS, V96, P273, DOI 10.1002/bip.21530; Bhunia A, 2010, J BIOL CHEM, V285, P3883, DOI 10.1074/jbc.M109.065672; Bhunia A, 2009, CHEM-EUR J, V15, P2036, DOI 10.1002/chem.200802635; Bhunia A, 2009, J BIOL CHEM, V284, P21991, DOI 10.1074/jbc.M109.013573; Bhunia A, 2009, BIOPOLYMERS, V92, P9, DOI 10.1002/bip.21104; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; Brogden KA, 2005, NAT REV MICROBIOL, V3, P238, DOI 10.1038/nrmicro1098; Brown KL, 2006, CURR OPIN IMMUNOL, V18, P24, DOI 10.1016/j.coi.2005.11.004; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bulet P, 2004, IMMUNOL REV, V198, P169, DOI 10.1111/j.0105-2896.2004.0124.x; Carotenuto A, 2008, J MED CHEM, V51, P2354, DOI 10.1021/jm701604t; CHATTOPADHYAY A, 1984, ANAL BIOCHEM, V139, P408, DOI 10.1016/0003-2697(84)90026-5; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Delcour AH, 2009, BBA-PROTEINS PROTEOM, V1794, P808, DOI 10.1016/j.bbapap.2008.11.005; Egal M, 1999, INT J ANTIMICROB AG, V13, P57, DOI 10.1016/S0924-8579(99)00094-1; Epand RM, 1999, BBA-BIOMEMBRANES, V1462, P11, DOI 10.1016/S0005-2736(99)00198-4; FINK PF, 1990, HDB CRITICAL CARE, P619; Ganz T, 2003, NAT REV IMMUNOL, V3, P710, DOI 10.1038/nri1180; Giacometti A, 2006, ANTIMICROB AGENTS CH, V50, P2478, DOI 10.1128/AAC.01553-05; Gottler LM, 2009, BBA-BIOMEMBRANES, V1788, P1680, DOI 10.1016/j.bbamem.2008.10.009; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Hancock REW, 2000, P NATL ACAD SCI USA, V97, P8856, DOI 10.1073/pnas.97.16.8856; HANCOCK REW, 1984, ANNU REV MICROBIOL, V38, P237, DOI 10.1146/annurev.mi.38.100184.001321; Hancock REW, 2006, IMMUNOBIOLOGY, V211, P315, DOI 10.1016/j.imbio.2005.10.017; Haney EF, 2009, BBA-BIOMEMBRANES, V1788, P1639, DOI 10.1016/j.bbamem.2009.01.002; Haselhorst T, 2001, J AM CHEM SOC, V123, P10705, DOI 10.1021/ja011156h; Huang YJ, 2005, J AM CHEM SOC, V127, P1665, DOI 10.1021/ja047109h; Japelj B, 2005, J BIOL CHEM, V280, P16955, DOI 10.1074/jbc.M500266200; Jerala R, 2004, CURR TOP MED CHEM, V4, P1173, DOI 10.2174/1568026043388079; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, V3rd, DOI [10.1007/978-0-387-46312-4, DOI 10.1007/978-0-387-46312-4]; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Mangoni ML, 2006, CELL MOL LIFE SCI, V63, P1060, DOI 10.1007/s00018-005-5536-y; Mangoni ML, 2008, J BIOL CHEM, V283, P22907, DOI 10.1074/jbc.M800495200; Mangoni ML, 2007, J PEPT SCI, V13, P603, DOI 10.1002/psc.853; Mangoni ML, 2009, BBA-BIOMEMBRANES, V1788, P1610, DOI 10.1016/j.bbamem.2009.04.021; Martin GS, 2003, NEW ENGL J MED, V348, P1546, DOI 10.1056/NEJMoa022139; Mayer M, 1999, ANGEW CHEM INT EDIT, V38, P1784, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q; Mayer M, 2001, J AM CHEM SOC, V123, P6108, DOI 10.1021/ja0100120; Meyer B, 2003, ANGEW CHEM INT EDIT, V42, P864, DOI 10.1002/anie.200390233; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Mor A, 2009, FEBS J, V276, P6474, DOI 10.1111/j.1742-4658.2009.07358.x; Nikaido H, 2003, MICROBIOL MOL BIOL R, V67, P593, DOI 10.1128/MMBR.67.4.593-656.2003; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Post CB, 2003, CURR OPIN STRUC BIOL, V13, P581, DOI 10.1016/j.sbi.2003.09.012; Pristovsek P, 2004, CURR TOP MED CHEM, V4, P1185, DOI 10.2174/1568026043388105; Rademacher C, 2008, J AM CHEM SOC, V130, P3669, DOI 10.1021/ja710854r; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Rath A, 2006, J BIOL CHEM, V281, P15546, DOI 10.1074/jbc.M600434200; Rosenfeld Y, 2006, BBA-BIOMEMBRANES, V1758, P1513, DOI 10.1016/j.bbamem.2006.05.017; Rosenfeld Y, 2006, J BIOL CHEM, V281, P28565, DOI 10.1074/jbc.M606031200; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Simmaco M, 1996, EUR J BIOCHEM, V242, P788, DOI 10.1111/j.1432-1033.1996.0788r.x; STEINER H, 1981, NATURE, V292, P246, DOI 10.1038/292246a0; STRAIN SM, 1983, J BIOL CHEM, V258, P3466; Taubes G, 2008, SCIENCE, V321, P356, DOI 10.1126/science.321.5887.356; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tossi A, 2000, BIOPOLYMERS, V55, P4; Weinstein RA, 2001, EMERG INFECT DIS, V7, P188, DOI 10.3201/eid0702.010206; WILKINSON SG, 1981, BIOCHEM J, V199, P833, DOI 10.1042/bj1990833; Wuthrich K, 1986, NMR PROTEIN NUCL ACI; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2; Yu LL, 2006, ANAL CHIM ACTA, V556, P216, DOI 10.1016/j.aca.2005.09.008; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhao HX, 2002, J BIOL CHEM, V277, P25170, DOI 10.1074/jbc.M203186200; Zhao HX, 2002, BIOCHEMISTRY-US, V41, P4425, DOI 10.1021/bi011929e	78	80	81	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 8	2011	286	27					24394	24406		10.1074/jbc.M110.189662	http://dx.doi.org/10.1074/jbc.M110.189662			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	786HO	21586570	Green Published, hybrid			2023-01-03	WOS:000292294900079
J	Zhu, WJ; Jiao, YM; Lei, RY; Hua, W; Wang, R; Ji, YX; Liu, ZY; Wei, FL; Zhang, T; Shi, XL; Wu, H; Zhang, LQ				Zhu, Weijun; Jiao, Yanmei; Lei, Rongyue; Hua, Wei; Wang, Rui; Ji, Yunxia; Liu, Zhiying; Wei, Feili; Zhang, Tong; Shi, Xuanlin; Wu, Hao; Zhang, Linqi			Rapid Turnover of 2-LTR HIV-1 DNA during Early Stage of Highly Active Antiretroviral Therapy	PLOS ONE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TERMINAL REPEAT CIRCLES; BLOOD MONONUCLEAR-CELLS; CD4(+) T-CELLS; TIME PCR ASSAY; IN-VIVO; COMBINATION THERAPY; PLASMA VIREMIA; MICROBIAL TRANSLOCATION; LIFELONG PERSISTENCE	Background: Despite prolonged treatment with highly active antiretroviral therapy (HAART), the infectious HIV-1 continues to replicate and resides latently in the resting memory CD4+ T lymphocytes, which blocks the eradication of HIV-1. The viral persistence of HIV-1 is mainly caused by its proviral DNA being either linear nonintegrated, circular nonintegrated, or integrated. Previous reports have largely focused on the dynamics of HIV-1 DNA from the samples collected with relatively long time intervals during the process of disease and HAART treatment, which may have missed the intricate changes during the intervals in early treatment. Methodology/Principal Findings: In this study, we investigated the dynamics of HIV-1 DNA in patients during the early phase of HARRT treatment. Using optimized real time PCR, we observed significant changes in 2-LTR during the first 12-week of treatment, while total and integrated HIV-1 DNA remained stable. The doubling time and half-life of 2-LTR were not correlated with the baseline and the rate of changes in plasma viral load and various CD4+ T-cell populations. Longitudinal analyses on 2-LTR sequences and plasma lipopolysaccharide (LPS) levels did not reveal any significant changes in the same treatment period. Conclusions/Significance: Our study revealed the rapid changes in 2-LTR concentration in a relatively large number of patients during the early HAART treatment. The rapid changes indicate the rapid infusion and clearance of cells bearing 2-LTR in the peripheral blood. Those changes are not expected to be caused by the blocking of viral integration, as our study did not include the integrase inhibitor raltegravir. Our study helps better understand the dynamics of HIV-DNA and its potential role as a biomarker for the diseases and for the treatment efficacy of HAART.	[Zhu, Weijun; Lei, Rongyue; Zhang, Linqi] Chinese Acad Med Sci, AIDS Res Ctr, Inst Pathogen Biol, Beijing 100730, Peoples R China; [Zhu, Weijun; Lei, Rongyue; Zhang, Linqi] Peking Union Med Coll, Beijing 100021, Peoples R China; [Jiao, Yanmei; Hua, Wei; Wang, Rui; Ji, Yunxia; Liu, Zhiying; Wei, Feili; Zhang, Tong; Wu, Hao] Capital Med Univ, Ctr Infect Dis, Beijing You An Hosp, Beijing, Peoples R China; [Shi, Xuanlin; Zhang, Linqi] Tsinghua Univ, Comprehens AIDS Res Ctr, Beijing 100084, Peoples R China; [Shi, Xuanlin; Zhang, Linqi] Tsinghua Univ, Res Ctr Publ Hlth, Sch Med, Beijing 100084, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Pathogen Biology - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Tsinghua University; Tsinghua University	Zhu, WJ (corresponding author), Chinese Acad Med Sci, AIDS Res Ctr, Inst Pathogen Biol, Beijing 100730, Peoples R China.	wuhd@public.bta.net.cn; zhanglinqi@tsinghua.edu.cn	Zhang, Tong/HGC-1090-2022; ZHANG, LIN/GYD-9123-2022	Zhu, Weijun/0000-0002-6060-133X	Natural Science Foundation of China [30800980, 30825035]; Chinese 973 program [2006CB504202]; National 11th 5-year project [2008ZX10001-006, 2008ZX10001-011]; IPB, CAMS [2007IPB009, 2007IPB12]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese 973 program(National Basic Research Program of China); National 11th 5-year project; IPB, CAMS	This study was supported by the Natural Science Foundation of China (grant 30800980 to W.Z and grant 30825035 to L.Z), the Chinese 973 program (grant 2006CB504202 to L.Z.), the National 11th 5-year project 2008ZX10001-006 and 2008ZX10001-011 and grants from IPB, CAMS (2007IPB009 to W.Z and 2007IPB12 to L.Z.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ancuta P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002516; Andreoni A, 2000, AIDS, V14, P23, DOI 10.1097/00002030-200001070-00003; Bart PA, 2000, AIDS, V14, P1887, DOI 10.1097/00002030-200009080-00002; Beloukas A, 2009, J CLIN MICROBIOL, V47, P2194, DOI 10.1128/JCM.01264-08; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brussel A, 2003, J VIROL, V77, P10119, DOI 10.1128/JVI.77.18.10119-10124.2003; Brussel A, 2003, AIDS, V17, P645, DOI 10.1097/00002030-200303280-00001; Butler SL, 2002, J VIROL, V76, P3739, DOI 10.1128/JVI.76.8.3739-3747.2002; Butler SL, 2001, NAT MED, V7, P631, DOI 10.1038/87979; Buzon MJ, 2010, NAT MED, V16, P460, DOI 10.1038/nm.2111; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Chomont N, 2009, NAT MED, V15, P893, DOI 10.1038/nm.1972; Chun TW, 2010, AIDS, V24, P2803, DOI 10.1097/QAD.0b013e328340a239; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1999, NATURE, V401, P874, DOI 10.1038/44755; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; Delaugerre C, 2010, AIDS, V24, P2391, DOI 10.1097/QAD.0b013e32833d214c; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Fischer M, 2003, ANTIVIR THER, V8, P97; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Gillim-Ross L, 2005, VIRAL IMMUNOL, V18, P190, DOI 10.1089/vim.2005.18.190; Gunthard HF, 1999, J VIROL, V73, P9404; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; Ibanez A, 1999, AIDS, V13, P1045, DOI 10.1097/00002030-199906180-00007; Koelsch KK, 2008, J INFECT DIS, V197, P411, DOI 10.1086/525283; Lai JP, 2003, CLIN DIAGN LAB IMMUN, V10, P1123, DOI 10.1128/CDLI.10.6.1123-1128.2003; Martinez-Picado J, 2002, J VIROL, V76, P12344, DOI 10.1128/JVI.76.23.12344-12348.2002; Ngo-Giang-Huong N, 2001, AIDS, V15, P665, DOI 10.1097/00002030-200104130-00001; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Pierson TC, 2002, J VIROL, V76, P4138, DOI 10.1128/JVI.76.8.4138-4144.2002; Reigadas S, 2010, J ANTIMICROB CHEMOTH, V65, P434, DOI 10.1093/jac/dkp473; Sachsenberg N, 1998, J EXP MED, V187, P1295, DOI 10.1084/jem.187.8.1295; Sharkey M, 2005, J VIROL, V79, P5203, DOI 10.1128/JVI.79.8.5203-5210.2005; Sharkey M, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001303; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Siliciano JD, 2003, NAT MED, V9, P727, DOI 10.1038/nm880; Strain MC, 2003, P NATL ACAD SCI USA, V100, P4819, DOI 10.1073/pnas.0736332100; Sum SSM, 2004, J CLIN MICROBIOL, V42, P3438, DOI 10.1128/JCM.42.8.3438-3440.2004; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Viard JP, 2004, AIDS, V18, P45, DOI 10.1097/00002030-200401020-00005; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Wong JK, 1997, P NATL ACAD SCI USA, V94, P12574, DOI 10.1073/pnas.94.23.12574; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 2000, AIDS, V14, P2805, DOI 10.1097/00002030-200012220-00001; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; Zanchetta M, 2006, J INFECT DIS, V193, P1718, DOI 10.1086/504264; Zhang LQ, 2000, J CLIN INVEST, V106, P839, DOI 10.1172/JCI10565; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	54	24	27	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2011	6	6							e21081	10.1371/journal.pone.0021081	http://dx.doi.org/10.1371/journal.pone.0021081			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	777JJ	21687638	Green Submitted, Green Published, gold			2023-01-03	WOS:000291611500059
J	Chang, CH; Stukel, TA; Flood, AB; Goodman, DC				Chang, Chiang-Hua; Stukel, Therese A.; Flood, Ann Barry; Goodman, David C.			Primary Care Physician Workforce and Medicare Beneficiaries' Health Outcomes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							US PRIMARY-CARE; REGIONAL-VARIATIONS; MORTALITY; STATES; CHALLENGE; QUALITY; REFORM; RATES; LIFE	Context Despite a widespread interest in increasing the numbers of primary care physicians to improve care and to moderate costs, the relationship of the primary care physician workforce to patient-level outcomes remains poorly understood. Objective To measure the association between the adult primary care physician workforce and individual patient outcomes. Design, Setting, and Participants A cross-sectional analysis of the outcomes of a 2007 20% sample of fee-for-service Medicare beneficiaries aged 65 years or older (N=5 132 936), which used 2 measures of adult primary care physicians (general internists and family physicians) across Primary Care Service Areas (N=6542): (1) American Medical Association (AMA) Masterfile nonfederal, office-based physicians per total population and (2) office-based primary care clinical full-time equivalents (FTEs) per Medicare beneficiary derived from Medicare claims. Main Outcome Measures Annual individual-level outcomes (mortality, ambulatory care sensitive condition [ACSC] hospitalizations, and Medicare program spending), adjusted for individual patient characteristics and geographic area variables. Results Marked variation was observed in the primary care physician workforce across areas, but low correlation was observed between the 2 primary care workforce measures (Spearman r=0.056; P<.001). Compared with areas with the lowest quintile of primary care physician measure using AMA Masterfile counts, beneficiaries in the highest quintile had fewer ACSC hospitalizations (74.90 vs 79.61 per 1000 beneficiaries; relative rate [RR], 0.94; 95% confidence interval [CI], 0.93-0.95), lower mortality (5.38 vs 5.47 per 100 beneficiaries; RR, 0.98; 95% CI, 0.97-0.997), and no significant difference in total Medicare spending ($8722 vs $8765 per beneficiary; RR, 1.00; 95% CI, 0.99-1.00). Beneficiaries residing in areas with the highest quintile of primary care clinician FTEs compared with those in the lowest quintile had lower mortality (5.19 vs 5.49 per 100 beneficiaries; RR, 0.95; 95% CI, 0.93-0.96), fewer ACSC hospitalizations (72.53 vs 79.48 per 1000 beneficiaries; RR, 0.91; 95% CI, 0.90-0.92), and higher overall Medicare spending ($8857 vs $8769 per beneficiary; RR, 1.01; 95% CI, 1.004-1.02). Conclusion A higher level of primary care physician workforce, particularly with an FTE measure that may more accurately reflect ambulatory primary care, was generally associated with favorable patient outcomes. JAMA. 2011; 305(20): 2096-2105	[Chang, Chiang-Hua] Ctr Hlth Policy Res, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH 03766 USA; [Goodman, David C.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Pediat, Hanover, NH 03756 USA; [Flood, Ann Barry] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA; [Stukel, Therese A.] Univ Toronto, Inst Clin Evaluat Sci, Toronto, ON, Canada; [Stukel, Therese A.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada	Dartmouth College; Dartmouth College; Dartmouth College; University of Toronto; University of Toronto	Chang, CH (corresponding author), Ctr Hlth Policy Res, Dartmouth Med Sch, Dartmouth Inst Hlth Policy & Clin Practice, 35 Centerra Pkwy, Lebanon, NH 03766 USA.	chiang-hua.chang@dartmouth.edu	Goodman, David/AAG-7497-2020	Stukel, Therese/0000-0002-2951-1360	Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; American Medical Forensic Specialists; Robert Wood Johnson Foundation; National Institute on Aging [P01 AG19783]; NATIONAL INSTITUTE ON AGING [P01AG019783] Funding Source: NIH RePORTER	Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; Intermountain Healthcare; Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; American Medical Forensic Specialists; Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Goodman reported speaking fees from Texas Medical Association; Health Action Council, Cincinnati; Richard Stockton College of New Jersey; Iowa Health Business Alliance; Alliance for Academic Internal Medicine; American Medical Association; Connecticut Children's Hospital; Mt Sinai Hospital, New York; World Congress; Rutgers University; Baystate Medical Center; Brigham and Women's Hospital; ESRI Inc; Illinois Hospital Association; National Hospice Workgroup; National Association of Health Data Organizations; St. Peters University Hospital, New Brunswick, New Jersey; Massachusetts Hospital Association; Cooper Health System, Camden, New Jersey; Organizzato dal Laboratorio Management e Sanita Scuola Superiore Sant'Anna di Pisa; Kentucky Academy of Family Physicians; Southern Illinois University Health Policy Institute; Ohio University College of Osteopathic Medicine; Institute for Clinical Quality and Value; The Marwood Group; American Society of Clinical Oncologists; OR Manager; Delta Health Alliance; SUNY Upstate University; and Intermountain Healthcare; and consulting fees from Vermont Department of Banking, Insurance, Securities and Health Care Administration; HealthDialog; Colorado Foundation for Medical Care; Seyferth Blumenthal and Harris; and American Medical Forensic Specialists. Drs Chang, Stukel, and Flood reported no disclosures.; This research was supported in part by the Robert Wood Johnson Foundation and grant P01 AG19783 from the National Institute on Aging.	Billings J, 2003, USING ADM DATA MONIT; Bodenheimer T, 2010, HEALTH AFFAIR, V29, P799, DOI 10.1377/hlthaff.2010.0026; Center for the Evaluative Clinical Sciences at Dartmouth, 1996, QUAL MED CAR US REP; Chernew ME, 2009, HEALTH AFFAIR, V28, P1327, DOI 10.1377/hlthaff.28.5.1327; Collwill JM, 2008, HEALTH AFFAIR, V27, pW232, DOI 10.1377/hlthaff.27.3.w232; Council on Graduate Medical Education, 2010, 20 REP ADV PRIM CAR; Fisher ES, 2003, ANN INTERN MED, V138, P288, DOI 10.7326/0003-4819-138-4-200302180-00007; Fisher ES, 2003, ANN INTERN MED, V138, P273, DOI 10.7326/0003-4819-138-4-200302180-00006; Fisher ES, 2003, PERSPECT BIOL MED, V46, P69, DOI 10.1353/pbm.2003.0004; Franks P, 1999, HEALTH SERV RES, V34, P323; Goodman DC, 2006, HEALTH AFFAIR, V25, P521, DOI 10.1377/hlthaff.25.2.521; Goodman DC, 1996, JAMA-J AM MED ASSOC, V276, P1811, DOI 10.1001/jama.276.22.1811; Goodman DC, 2003, HEALTH SERV RES, V38, P287, DOI 10.1111/1475-6773.00116; Goodman DC., 2010, REGIONAL RACIAL VARI; Gottlieb DJ, 2010, HEALTH AFFAIR, V29, P537, DOI 10.1377/hlthaff.2009.0609; GRUMBACH K, 1995, AM J PUBLIC HEALTH, V85, P1402, DOI 10.2105/AJPH.85.10.1402; Guttmann A, 2010, PEDIATRICS, V125, P1119, DOI 10.1542/peds.2009-2821; Krakauer H, 1996, HEALTH SERV RES, V31, P191; Laditka JN, 2005, HEALTH SERV RES, V40, P1148, DOI 10.1111/j.1475-6773.2005.00403.x; Phillips RL, 2004, AM FAM PHYSICIAN, V70, P440; Ricketts TC, 2007, HEALTH SERV RES, V42, P2233, DOI 10.1111/j.1475-6773.2007.00728.x; Rittenhouse DR, 2009, NEW ENGL J MED, V361, P2301, DOI 10.1056/NEJMp0909327; Rittenhouse DR, 2009, JAMA-J AM MED ASSOC, V301, P2038, DOI 10.1001/jama.2009.691; Rosser WW, 2010, NEW ENGL J MED, V362, DOI 10.1056/NEJMp0911519; Salsberg E, 2008, JAMA-J AM MED ASSOC, V300, P1174, DOI 10.1001/jama.300.10.1174; Sandy LG, 2009, HEALTH AFFAIR, V28, P1136, DOI 10.1377/hlthaff.28.4.1136; Shi LY, 2005, SOC SCI MED, V61, P65, DOI 10.1016/j.socscimed.2004.11.056; Shi LY, 2003, J AM BOARD FAM PRACT, V16, P412, DOI 10.3122/jabfm.16.5.412; Starfield B, 2005, MILBANK Q, V83, P457, DOI 10.1111/j.1468-0009.2005.00409.x; Starfield B, 2005, HLTH AFF MILLWOOD S; Steinbrook R, 2009, NEW ENGL J MED, V360, P2696, DOI 10.1056/NEJMp0903460; Wennberg JE, 2004, BMJ-BRIT MED J, V328, P607, DOI 10.1136/bmj.328.7440.607; Wennberg JE, 2008, TRACKING CARE PATIEN	33	120	121	1	18	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	2011	305	20					2096	2105		10.1001/jama.2011.665	http://dx.doi.org/10.1001/jama.2011.665			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768AC	21610242	Bronze, Green Accepted			2023-01-03	WOS:000290901700023
J	Lakhani, M				Lakhani, Mayur			PERSONAL VIEW Let's talk about dying	BRITISH MEDICAL JOURNAL			English	Editorial Material												MK.Lakhani@GP-C82644.nhs.uk							0	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 17	2011	342								d3018	10.1136/bmj.d3018	http://dx.doi.org/10.1136/bmj.d3018			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	768QO	21586451				2023-01-03	WOS:000290951700007
J	Bohnert, ASB; Valenstein, M; Bair, MJ; Ganoczy, D; McCarthy, JF; Ilgen, MA; Blow, FC				Bohnert, Amy S. B.; Valenstein, Marcia; Bair, Matthew J.; Ganoczy, Dara; McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.			Association Between Opioid Prescribing Patterns and Opioid Overdose-Related Deaths	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAKTHROUGH PAIN; CANCER PAIN; CASE-COHORT; MORTALITY; TIME	Context The rate of prescription opioid-related overdose death increased substantially in the United States over the past decade. Patterns of opioid prescribing may be related to risk of overdose mortality. Objective To examine the association of maximum prescribed daily opioid dose and dosing schedule ("as needed," regularly scheduled, or both) with risk of opioid overdose death among patients with cancer, chronic pain, acute pain, and substance use disorders. Design Case-cohort study. Setting Veterans Health Administration (VHA), 2004 through 2008. Participants All unintentional prescription opioid overdose decedents (n=750) and a random sample of patients (n=154 684) among those individuals who used medical services in 2004 or 2005 and received opioid therapy for pain. Main Outcome Measure Associations of opioid regimens (dose and schedule) with death by unintentional prescription opioid overdose in subgroups defined by clinical diagnoses, adjusting for age group, sex, race, ethnicity, and comorbid conditions. Results The frequency of fatal overdose over the study period among individuals treated with opioids was estimated to be 0.04%. The risk of overdose death was directly related to the maximum prescribed daily dose of opioid medication. The adjusted hazard ratios (HRs) associated with a maximum prescribed dose of 100 mg/d or more, compared with the dose category 1 mg/d to less than 20 mg/d, were as follows: among those with substance use disorders, adjusted HR=4.54 (95% confidence interval [CI], 2.46-8.37; absolute risk difference approximation [ARDA]=0.14%); among those with chronic pain, adjusted HR=7.18 (95% CI, 4.85-10.65; ARDA=0.25%); among those with acute pain, adjusted HR=6.64 (95% CI, 3.31-13.31; ARDA=0.23%); and among those with cancer, adjusted HR=11.99 (95% CI, 4.42-32.56; ARDA=0.45%). Receiving both as-needed and regularly scheduled doses was not associated with overdose risk after adjustment. Conclusion Among patients receiving opioid prescriptions for pain, higher opioid doses were associated with increased risk of opioid overdose death. JAMA. 2011;305(13):1315-1321 www.jama.com	[Bohnert, Amy S. B.; Valenstein, Marcia; Ganoczy, Dara; McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA; [Bohnert, Amy S. B.; Valenstein, Marcia; Ganoczy, Dara; McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.] Ctr Excellence, Dept Vet Affairs Hlth Serv Res & Dev HSR&D, Ann Arbor, MI USA; [Bohnert, Amy S. B.; Valenstein, Marcia; Ganoczy, Dara; McCarthy, John F.; Ilgen, Mark A.; Blow, Frederic C.] Serious Mental Illness Treatment Resource & Evalu, Ann Arbor, MI USA; [Bair, Matthew J.] Ctr Excellence, Dept Vet Affairs HSR&D, Indianapolis, IN USA; [Bair, Matthew J.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN USA	University of Michigan System; University of Michigan; Indiana University System; Indiana University Bloomington	Bohnert, ASB (corresponding author), Univ Michigan, Sch Med, Dept Psychiat, 4250 Plymouth Rd,Box 5765, Ann Arbor, MI 48109 USA.	amybohne@med.umich.edu	Bohnert, Amy SB/C-7313-2015		Health Services Research and Development Service (HSRD) [CDA-09-204]; Department of Veterans Affairs Office of Mental Health Services, Patient Care Services	Health Services Research and Development Service (HSRD)(US Department of Veterans Affairs); Department of Veterans Affairs Office of Mental Health Services, Patient Care Services(US Department of Veterans Affairs)	This work was financially supported by the Department of Veterans Affairs Office of Mental Health Services, Patient Care Services, and a Health Services Research and Development Service (HSR&D) Career Development Award (CDA-09-204; A.S.B.B.).	[Anonymous], NAT DEATH IND; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chou R, 2009, J PAIN, V10, P113, DOI 10.1016/j.jpain.2008.10.008; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; Donaldson AE, 2006, INJURY PREV, V12, P338, DOI 10.1136/ip.2005.011171; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Gammaitoni AR, 2003, CLIN J PAIN, V19, P286, DOI 10.1097/00002508-200309000-00002; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Langholz B, 2007, COMPUT STAT DATA AN, V51, P3737, DOI 10.1016/j.csda.2006.12.028; Lash TL, 2009, J CLIN ONCOL, V27, pE55, DOI 10.1200/JCO.2009.24.1877; Lawlor PG, 1998, CANCER, V82, P1167, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3; Lo B, 2005, JAMA-J AM MED ASSOC, V294, P1810, DOI 10.1001/jama.294.14.1810; McCarthy JF, 2009, AM J EPIDEMIOL, V169, P1033, DOI 10.1093/aje/kwp010; McLellan AT, 2008, JAMA-J AM MED ASSOC, V300, P2672, DOI 10.1001/jama.2008.793; Okie S, 2010, NEW ENGL J MED, V363, P1981, DOI 10.1056/NEJMp1011512; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Portenoy RK, 1999, PAIN, V81, P129, DOI 10.1016/S0304-3959(99)00006-8; Portenoy RK, 2007, CURR MED RES OPIN, V23, P222, DOI 10.1185/030079906X162818; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Prommer E, 2006, SUPPORT CARE CANCER, V14, P109, DOI 10.1007/s00520-005-0917-1; Schumann H, 2008, CLIN TOXICOL, V46, P501, DOI 10.1080/15563650701877374; Simpson DM, 2007, CLIN THER, V29, P588, DOI 10.1016/j.clinthera.2007.04.007; Sohn Min-Woong, 2006, Popul Health Metr, V4, P2, DOI 10.1186/1478-7954-4-2; Suissa S, 2008, AM J EPIDEMIOL, V167, P492, DOI 10.1093/aje/kwm324; The Management of Posttraumatic Stress Disorder Work Group, 2017, VA DOD CLIN PRACT GU; Valenstein M, 2004, AM J PSYCHIAT, V161, P654, DOI 10.1176/appi.ajp.161.4.654; Wysowski DK, 2007, DRUG SAFETY, V30, P533, DOI 10.2165/00002018-200730060-00007	27	1046	1055	2	73	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 6	2011	305	13					1315	1321		10.1001/jama.2011.370	http://dx.doi.org/10.1001/jama.2011.370			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	745JT	21467284				2023-01-03	WOS:000289162400020
J	Kavanagh, BP; McCowen, KC				Kavanagh, Brian P.; McCowen, Karen C.			Glycemic Control in the ICU.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTENSIVE INSULIN THERAPY; BLOOD-GLUCOSE; NUTRITION SUPPORT; CRITICAL ILLNESS; GUIDELINES; MORTALITY; STRESS; CARE; HYPERGLYCEMIA; HYPOGLYCEMIA		[Kavanagh, Brian P.] Univ Toronto, Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Kavanagh, Brian P.] Univ Toronto, Hosp Sick Children, Dept Anesthesia, Toronto, ON M5G 1X8, Canada; [McCowen, Karen C.] Harvard Univ, Sch Med, Harvard Vanguard Med Associates, Boston, MA USA; [McCowen, Karen C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Harvard University; Harvard Medical School; Harvard Vanguard Medical Associates; Harvard University; Beth Israel Deaconess Medical Center	Kavanagh, BP (corresponding author), Univ Toronto, Hosp Sick Children, Dept Crit Care Med, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	brian.kavanagh@sickkids.ca						American Diabetes Association, 2010, Diabetes Care, V33 Suppl 1, pS11, DOI 10.2337/dc10-S011; Annane D, 2010, JAMA-J AM MED ASSOC, V303, P1698; Annane D, 2010, JAMA-J AM MED ASSOC, V303, P341, DOI 10.1001/jama.2010.2; Arabi YM, 2008, CRIT CARE MED, V36, P3190, DOI 10.1097/CCM.0b013e31818f21aa; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Corstjens AM, 2006, CRIT CARE, V10, DOI 10.1186/cc5048; Davidson PC, 2005, DIABETES CARE, V28, P2418, DOI 10.2337/diacare.28.10.2418; De la Rosa GD, 2008, CRIT CARE, V12, DOI 10.1186/cc7017; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Dellinger RP, 2004, CRIT CARE MED, V32, P1448; Dungan KM, 2009, LANCET, V373, P1798, DOI 10.1016/S0140-6736(09)60553-5; Egi M, 2008, CRIT CARE MED, V36, P2249, DOI 10.1097/CCM.0b013e318181039a; Egi M, 2010, MAYO CLIN PROC, V85, P217, DOI 10.4065/mcp.2009.0394; Erickson SE, 2009, CRIT CARE MED, V37, P1, DOI 10.1097/CCM.0b013e31819292ea; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Fogelholm R, 2005, J NEUROL NEUROSUR PS, V76, P349, DOI 10.1136/jnnp.2003.034819; Garber Alan J, 2004, Endocr Pract, V10, P77; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Heyland DK, 2003, JPEN-PARENTER ENTER, V27, P355, DOI 10.1177/0148607103027005355; Ingels C, 2006, EUR HEART J, V27, P2716, DOI 10.1093/eurheartj/ehi855; Juhl CB, 2010, DIABETES RES CLIN PR, V88, P22, DOI 10.1016/j.diabres.2010.01.007; Kosiborod M, 2009, JAMA-J AM MED ASSOC, V301, P1556, DOI 10.1001/jama.2009.496; Krinsley JS, 2008, CRIT CARE MED, V36, P3008, DOI 10.1097/CCM.0b013e31818b38d2; Louie K, 2010, QUAL SAF HLTH C 0804; Malhotra A, 2006, NEW ENGL J MED, V354, P516, DOI 10.1056/NEJMe058304; Marik PE, 2010, CHEST, V137, P544, DOI 10.1378/chest.09-1737; McCowen KC, 2001, CRIT CARE CLIN, V17, P107, DOI 10.1016/S0749-0704(05)70154-8; Meyfroidt G, 2010, CRIT CARE MED, V38, P1021, DOI 10.1097/CCM.0b013e3181cf710e; Moghissi ES, 2010, CURR MED RES OPIN, V26, P589, DOI 10.1185/03007990903566822; Monnier L, 2006, JAMA-J AM MED ASSOC, V295, P1681, DOI 10.1001/jama.295.14.1681; Preiser JC, 2009, INTENS CARE MED, V35, P1738, DOI 10.1007/s00134-009-1585-2; Rabiee Atoosa, 2009, J Diabetes Sci Technol, V3, P951; Rood E, 2005, J AM MED INFORM ASSN, V12, P172, DOI 10.1197/jamia.M1598; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Treggiari MM, 2008, CRIT CARE, V12, DOI 10.1186/cc6807; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wiener RS, 2009, JAMA-J AM MED ASSOC, V301, P936; Worthley MI, 2007, AM J MED, V120, p643e1	39	118	136	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 23	2010	363	26					2540	2546		10.1056/NEJMcp1001115	http://dx.doi.org/10.1056/NEJMcp1001115			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	697YL	21175316				2023-01-03	WOS:000285555600009
J	Mello, MM; Messing, NA				Mello, Michelle M.; Messing, Noah A.			Restrictions on the Use of Prescribing Data for Drug Promotion	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PHYSICIANS; 1ST-AMENDMENT		[Mello, Michelle M.] Harvard Univ, Sch Med, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Messing, Noah A.] Yale Univ, Sch Law, New Haven, CT 06520 USA	Harvard University; Harvard Medical School; Yale University	Mello, MM (corresponding author), Harvard Univ, Sch Med, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	mmello@hsph.harvard.edu		Mello, Michelle/0000-0003-2877-4270				*AM MED ASS, AMA PROGR HELPS PROT; Campo Katia, 2005, Health Mark Q, V22, P73; Caudill TS, 1996, ARCH FAM MED, V5, P201, DOI 10.1001/archfami.5.4.201; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Curfman GD, 2011, NEW ENGL J MED, V364, P2053, DOI 10.1056/NEJMe1104460; Grande D, 2007, ANN INTERN MED, V146, P751, DOI 10.7326/0003-4819-146-10-200705150-00010; Grande D, 2009, NEW ENGL J MED, V360, P747, DOI 10.1056/NEJMp0810410; Greene JA, 2007, ANN INTERN MED, V146, P742, DOI 10.7326/0003-4819-146-10-200705150-00008; Kesselheim AS, 2008, NEW ENGL J MED, V358, P1727, DOI 10.1056/NEJMsb0708920; Orentlicher D, 2010, J LAW MED ETHICS, V38, P74, DOI 10.1111/j.1748-720X.2010.00468.x; PEAY MY, 1988, SOC SCI MED, V26, P1183, DOI 10.1016/0277-9536(88)90149-9; Post R, 2009, NEW ENGL J MED, V360, P745, DOI 10.1056/NEJMp0810339; Steinbrook R, 2006, NEW ENGL J MED, V354, P2745, DOI 10.1056/NEJMp068125; Wazana A, 2000, JAMA-J AM MED ASSOC, V283, P373, DOI 10.1001/jama.283.3.373; 2004, INT M AMA HOUS DEL D, P140	15	16	17	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 29	2011	365	13					1248	1254		10.1056/NEJMhle1107678	http://dx.doi.org/10.1056/NEJMhle1107678			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	825YO	21812664				2023-01-03	WOS:000295318400016
J	Porter, DL; Levine, BL; Kalos, M; Bagg, A; June, CH				Porter, David L.; Levine, Bruce L.; Kalos, Michael; Bagg, Adam; June, Carl H.			Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADVERSE EVENT; PHASE-I; SURVIVAL; CANCER; TRANSPLANTATION; SPECIFICITY; EXPRESSION; RITUXIMAB	We designed a lentiviral vector expressing a chimeric antigen receptor with specificity for the B-cell antigen CD19, coupled with CD137 (a costimulatory receptor in T cells [4-1BB]) and CD3-zeta (a signal-transduction component of the T-cell antigen receptor) signaling domains. A low dose (approximately 1.5x10(5) cells per kilogram of body weight) of autologous chimeric antigen receptor-modified T cells reinfused into a patient with refractory chronic lymphocytic leukemia (CLL) expanded to a level that was more than 1000 times as high as the initial engraftment level in vivo, with delayed development of the tumor lysis syndrome and with complete remission. Apart from the tumor lysis syndrome, the only other grade 3/4 toxic effect related to chimeric antigen receptor T cells was lymphopenia. Engineered cells persisted at high levels for 6 months in the blood and bone marrow and continued to express the chimeric antigen receptor. A specific immune response was detected in the bone marrow, accompanied by loss of normal B cells and leukemia cells that express CD19. Remission was ongoing 10 months after treatment. Hypogammaglobulinemia was an expected chronic toxic effect.	[Porter, David L.; Levine, Bruce L.; Kalos, Michael; Bagg, Adam; June, Carl H.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Porter, David L.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Levine, Bruce L.; Kalos, Michael; Bagg, Adam; June, Carl H.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; [Levine, Bruce L.; Kalos, Michael; June, Carl H.] Univ Penn, Abramson Family Canc Res Inst, Perelman Sch Med, Philadelphia, PA 19104 USA; [Porter, David L.] Univ Penn, Med Ctr, Div Hematol & Oncol, Dept Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Porter, DL (corresponding author), Univ Penn, Med Ctr, Div Hematol & Oncol, Dept Med, 3400 Civ Ctr Blvd,PCAM 2 W Pavil, Philadelphia, PA 19104 USA.	david.porter@uphs.upenn.edu	Levine, Bruce L/D-1688-2009; Bagg, Adam/R-8450-2019	June, Carl/0000-0003-0241-3557	National Institutes of Health [K24 CA11787901, 1PN2-EY016586, R01CA120409]; Alliance for Cancer Gene Therapy; Leukemia and Lymphoma Society [7000-02]; NATIONAL CANCER INSTITUTE [K24CA117879, R01CA120409] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [PN2EY016586] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Cancer Gene Therapy; Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	Supported in part by grants from the National Institutes of Health (K24 CA11787901, 1PN2-EY016586, and R01CA120409), the Alliance for Cancer Gene Therapy, and the Leukemia and Lymphoma Society (7000-02).	Baeksgaard L, 2003, CANCER CHEMOTH PHARM, V51, P187, DOI 10.1007/s00280-002-0556-x; Brentjens R, 2010, MOL THER, V18, P666, DOI 10.1038/mt.2010.31; Carpenito C, 2009, P NATL ACAD SCI USA, V106, P3360, DOI 10.1073/pnas.0813101106; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Gribben JG, 2011, BIOL BLOOD MARROW TR, V17, pS63, DOI 10.1016/j.bbmt.2010.10.011; GROSS G, 1989, P NATL ACAD SCI USA, V86, P10024, DOI 10.1073/pnas.86.24.10024; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; Jena B, 2010, BLOOD, V116, P1035, DOI 10.1182/blood-2010-01-043737; Johnson LA, 2009, BLOOD, V114, P535, DOI 10.1182/blood-2009-03-211714; June CH, 2009, NAT REV IMMUNOL, V9, P704, DOI 10.1038/nri2635; Kalos M, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002842; Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183; Klebanoff CA, 2005, TRENDS IMMUNOL, V26, P298, DOI 10.1016/j.it.2004.04.006; Klebanoff CA, 2005, TRENDS IMMUNOL, V26, P111, DOI 10.1016/j.it.2004.12.003; Kohn DB, 2011, MOL THER, V19, P432, DOI 10.1038/mt.2011.1; Lamanna N, 2006, J CLIN ONCOL, V24, P1575, DOI 10.1200/JCO.2005.04.3836; Milone MC, 2009, MOL THER, V17, P1453, DOI 10.1038/mt.2009.83; Molina A, 2008, ANNU REV MED, V59, P237, DOI 10.1146/annurev.med.59.060906.220345; Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24; Porter DL, 2006, BLOOD, V107, P1325, DOI 10.1182/blood-2005-08-3373; Pule MA, 2008, NAT MED, V14, P1264, DOI 10.1038/nm.1882; Ramakrishnan R, 2010, J CLIN INVEST, V120, P1111, DOI 10.1172/JCI40269; Sadelain M, 2009, CURR OPIN IMMUNOL, V21, P215, DOI 10.1016/j.coi.2009.02.009; Sorror ML, 2008, BLOOD, V111, P446, DOI 10.1182/blood-2007-07-098483; Till BG, 2008, BLOOD, V112, P2261, DOI 10.1182/blood-2007-12-128843; UCKUN FM, 1988, BLOOD, V71, P13; Zitvogel L, 2008, NAT REV IMMUNOL, V8, P59, DOI 10.1038/nri2216	27	2455	2834	92	818	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 25	2011	365	8					725	733		10.1056/NEJMoa1103849	http://dx.doi.org/10.1056/NEJMoa1103849			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	811JM	21830940	Green Accepted			2023-01-03	WOS:000294205300008
J	Pena-Gomez, C; Vidal-Pineiro, D; Clemente, IC; Pascual-Leone, A; Bartres-Faz, D				Pena-Gomez, Cleofe; Vidal-Pineiro, Didac; Clemente, Immaculada C.; Pascual-Leone, Alvaro; Bartres-Faz, David			Down-Regulation of Negative Emotional Processing by Transcranial Direct Current Stimulation: Effects of Personality Characteristics	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; HUMAN MOTOR CORTEX; PREFRONTAL CORTEX; INDIVIDUAL-DIFFERENCES; DC-STIMULATION; MAGNETIC STIMULATION; STOCHASTIC RESONANCE; FMRI; EXCITABILITY; MECHANISMS	Evidence from neuroimaging and electrophysiological studies indicates that the left dorsolateral prefrontal cortex (DLPFC) is a core region in emotional processing, particularly during down-regulation of negative emotional conditions. However, emotional regulation is a process subject to major inter-individual differences, some of which may be explained by personality traits. In the present study we used transcranial direct current stimulation (tDCS) over the left DLPFC to investigate whether transiently increasing the activity of this region resulted in changes in the ratings of positive, neutral and negative emotional pictures. Results revealed that anodal, but not cathodal, tDCS reduced the perceived degree of emotional valence for negative stimuli, possibly due to an enhancement of cognitive control of emotional expression. We also aimed to determine whether personality traits (extraversion and neuroticism) might condition the impact of tDCS. We found that individuals with higher scores on the introversion personality dimension were more permeable than extraverts to the modulatory effects of the stimulation. The present study underlines the role of the left DLPFC in emotional regulation, and stresses the importance of considering individual personality characteristics as a relevant variable, although replication is needed given the limited sample size of our study.	[Pena-Gomez, Cleofe; Vidal-Pineiro, Didac; Bartres-Faz, David] Univ Barcelona, Fac Med, Dept Psiquiatria & Psicobiol Clin, Barcelona 7, Spain; [Clemente, Immaculada C.] Univ Barcelona, Fac Psicol, Dept Psiquiatria & Psicobiol Clin, Barcelona 7, Spain; [Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA; [Pascual-Leone, Alvaro] Inst Univ Neurorehabil Guttmann UAB, Badalona, Spain; [Bartres-Faz, David] Inst Nvestigac Biomed August Pi & Sunyer, Barcelona, Spain	University of Barcelona; University of Barcelona; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Pena-Gomez, C (corresponding author), Univ Barcelona, Fac Med, Dept Psiquiatria & Psicobiol Clin, Barcelona 7, Spain.	dbartres@ub.edu	Clemente, I Concepcion/H-5399-2013; Pascual-Leone, Alvaro/G-6566-2011; Pascual-Leone, Alvaro/AAC-5101-2019; Vidal-Piñeiro, Didac/O-5012-2016; Bartres-Faz, David/C-8997-2011	Clemente, I Concepcion/0000-0003-0728-0925; Pascual-Leone, Alvaro/0000-0001-8975-0382; Vidal-Piñeiro, Didac/0000-0001-9997-9156; Bartres-Faz, David/0000-0001-6020-4118	Spanish Ministerio de Educacion y Ciencia [SAF2007-66270]; Spanish Ministerio de Ciencia e Innovacion [SAF2009-07489]; National Institutes of Health [K24 RR018875, RO1-NS 20068, R01-EB 005047]; Harvard Clinical and Translational Science Center, from the National Center for Research Resources [UL1 RR025758]; NATIONAL CENTER FOR RESEARCH RESOURCES [K24RR018875, UL1RR025758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB005047] Funding Source: NIH RePORTER	Spanish Ministerio de Educacion y Ciencia(Spanish Government); Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard Clinical and Translational Science Center, from the National Center for Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	Partially funded by a Spanish Ministerio de Educacion y Ciencia research grant (SAF2007-66270) and the Spanish Ministerio de Ciencia e Innovacion (SAF2009-07489). AP-L was supported in part by grants from the National Institutes of Health (K24 RR018875, RO1-NS 20068, R01-EB 005047), and Grant Number UL1 RR025758 - Harvard Clinical and Translational Science Center, from the National Center for Research Resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amstadter A, 2008, J ANXIETY DISORD, V22, P211, DOI 10.1016/j.janxdis.2007.02.004; Amting JM, 2010, J NEUROSCI, V30, P10039, DOI 10.1523/JNEUROSCI.6434-09.2010; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECK AT, 1996, ANUAL BECK DEPRESSIO; Bestmann S, 2008, CEREB CORTEX, V18, P1281, DOI 10.1093/cercor/bhm159; Blair KS, 2007, NEUROIMAGE, V35, P430, DOI 10.1016/j.neuroimage.2006.11.048; Boggio PS, 2009, J NEUROL NEUROSUR PS, V80, P444, DOI 10.1136/jnnp.2007.141853; Boggio PS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004959; Boggio PS, 2009, NEUROPSYCHOLOGIA, V47, P212, DOI 10.1016/j.neuropsychologia.2008.07.022; Canli T, 2001, BEHAV NEUROSCI, V115, P33, DOI 10.1037//0735-7044.115.1.33; Canli T, 2002, SCIENCE, V296, P2191, DOI 10.1126/science.1068749; Canli T, 1998, NEUROREPORT, V9, P3233, DOI 10.1097/00001756-199810050-00019; Caspi A, 2005, ANNU REV PSYCHOL, V56, P453, DOI 10.1146/annurev.psych.55.090902.141913; COSTA PT, 1980, J PERS SOC PSYCHOL, V38, P668, DOI 10.1037/0022-3514.38.4.668; Costa PT, 1992, SAGE HDB PERSONALITY; COSTA PT, 1991, NEO 5 FACTOR INVENTO; Cremers HR, 2010, NEUROIMAGE, V49, P963, DOI 10.1016/j.neuroimage.2009.08.023; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; DAVIDSON RJ, 2007, HDB EMOTION REGULATI, P47; Dolcos F, 2004, NEUROIMAGE, V23, P64, DOI 10.1016/j.neuroimage.2004.05.015; DRABANT EM, 2010, NEUROIMAGE; Eisenberger NI, 2005, COGN AFFECT BEHAV NE, V5, P169, DOI 10.3758/CABN.5.2.169; Eysenck H. J., 1967, BIOL BASIS PERSONALI; Eysenck HJ., 1993, MANUAL EYSENCK PERSO, DOI 10.1037/t05461-000; Eysenck HJ, 1981, MODEL PERSONALITY, p1~37, DOI DOI 10.1007/978-3-642-67783-0_1; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; Gandiga PC, 2006, CLIN NEUROPHYSIOL, V117, P845, DOI 10.1016/j.clinph.2005.12.003; George MS, 2010, EXPERT REV NEUROTHER, V10, P1761, DOI [10.1586/ern.10.95, 10.1586/ERN.10.95]; Gross J.J., 1998, REV GEN PSYCHOL, V2, P271, DOI 10.1037/1089-2680.2.3.271; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Gross JJ, 2002, PSYCHOPHYSIOLOGY, V39, P281, DOI 10.1017/S0048577201393198; Hofman D, 2009, PSYCHOPHYSIOLOGY, V46, P1054, DOI 10.1111/j.1469-8986.2009.00849.x; Jackson DC, 2000, PSYCHOPHYSIOLOGY, V37, pS50; Jackson DC, 2003, PSYCHOL SCI, V14, P612, DOI 10.1046/j.0956-7976.2003.psci_1473.x; John OP, 2004, J PERS, V72, P1301, DOI 10.1111/j.1467-6494.2004.00298.x; Kim SH, 2007, J COGNITIVE NEUROSCI, V19, P776, DOI 10.1162/jocn.2007.19.5.776; Kincses TZ, 2004, NEUROPSYCHOLOGIA, V42, P113, DOI 10.1016/S0028-3932(03)00124-6; Koenigsberg HW, 2009, BIOL PSYCHIAT, V66, P854, DOI 10.1016/j.biopsych.2009.06.010; Kumari V, 2004, J NEUROSCI, V24, P10636, DOI 10.1523/JNEUROSCI.3206-04.2004; Kwon YH, 2008, NEUROSCI LETT, V435, P56, DOI 10.1016/j.neulet.2008.02.012; Lang N, 2005, EUR J NEUROSCI, V22, P495, DOI 10.1111/j.1460-9568.2005.04233.x; LANG PJ, 1993, PSYCHOPHYSIOLOGY, V30, P261, DOI 10.1111/j.1469-8986.1993.tb03352.x; LANG PJ, 2001, A5 U FLOR; LARBAR KS, 2006, NAT REV NEUROSCI, V7, P54; Liebetanz D, 2002, BRAIN, V125, P2238, DOI 10.1093/brain/awf238; McCrae RR, 2004, PERS INDIV DIFFER, V36, P587, DOI 10.1016/S0191-8869(03)00118-1; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mogg K, 2007, BIOL PSYCHOL, V76, P163, DOI 10.1016/j.biopsycho.2007.07.005; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; NOLENHOEKSEMA S, 1994, J PERS SOC PSYCHOL, V67, P92, DOI 10.1037/0022-3514.67.1.92; Ochsner KN, 2009, J COGNITIVE NEUROSCI, V21, P1841, DOI 10.1162/jocn.2009.21129; Ochsner KN, 2002, J COGNITIVE NEUROSCI, V14, P1215, DOI 10.1162/089892902760807212; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Ochsner KN, 2004, NEUROIMAGE, V23, P483, DOI 10.1016/j.neuroimage.2004.06.030; PENAGOMEZ C, 2010, HUM BRAIN MAPP C; POLANIA R, 2010, HUM BRAIN MAPP  0606; Ray RD, 2005, COGN AFFECT BEHAV NE, V5, P156, DOI 10.3758/CABN.5.2.156; Sabatinelli D, 2005, NEUROIMAGE, V24, P1265, DOI 10.1016/j.neuroimage.2004.12.015; Schwarzkopf DS, 2011, J NEUROSCI, V31, P3143, DOI 10.1523/JNEUROSCI.4863-10.2011; Silvanto J, 2008, J NEUROPHYSIOL, V99, P2725, DOI 10.1152/jn.01392.2007; Silvanto J, 2008, TRENDS COGN SCI, V12, P447, DOI 10.1016/j.tics.2008.09.004; Sotres-Bayon F, 2010, CURR OPIN NEUROBIOL, V20, P231, DOI 10.1016/j.conb.2010.02.005; Spielberger C.D., 1989, REDW CITY MIND GARD, Vsecond; Stahl J, 2004, BRAIN COGNITION, V56, P293, DOI 10.1016/j.bandc.2004.07.004; Stocks NG, 2000, PHYS REV LETT, V84, P2310, DOI 10.1103/PhysRevLett.84.2310; Suslow T, 2010, NEUROSCIENCE, V167, P111, DOI 10.1016/j.neuroscience.2010.01.038; Urry HL, 2006, J NEUROSCI, V26, P4415, DOI 10.1523/JNEUROSCI.3215-05.2006; Wager TD, 2008, NEURON, V59, P1037, DOI 10.1016/j.neuron.2008.09.006; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063; Zaghi S, 2010, NEUROSCIENTIST, V16, P285, DOI 10.1177/1073858409336227	73	102	107	2	38	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2011	6	7							e22812	10.1371/journal.pone.0022812	http://dx.doi.org/10.1371/journal.pone.0022812			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KV	21829522	gold, Green Published, Green Submitted			2023-01-03	WOS:000293286500033
J	Guhr, T; Bloem, J; Derksen, NIL; Wuhrer, M; Koenderman, AHL; Aalberse, RC; Rispens, T				Guhr, Theresa; Bloem, Judith; Derksen, Ninotska I. L.; Wuhrer, Manfred; Koenderman, Anky H. L.; Aalberse, Rob C.; Rispens, Theo			Enrichment of Sialylated IgG by Lectin Fractionation Does Not Enhance the Efficacy of Immunoglobulin G in a Murine Model of Immune Thrombocytopenia	PLOS ONE			English	Article							INTRAVENOUS GAMMA-GLOBULIN; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE-DISEASES; IVIG; MECHANISMS; PURPURA; FC; GLYCOSYLATION; SUBCLASSES; RECEPTOR	Intravenous immunoglobulin G (IVIg) is widely used against a range of clinical symptoms. For its use in immune modulating therapies such as treatment of immune thrombocytopenic purpura high doses of IVIg are required. It has been suggested that only a fraction of IVIg causes this anti immune modulating effect. Recent studies indicated that this fraction is the Fc-sialylated IgG fraction. The aim of our study was to determine the efficacy of IVIg enriched for sialylated IgG (IVIg-SA (+)) in a murine model of passive immune thrombocytopenia (PIT). We enriched IVIg for sialylated IgG by Sambucus nigra agglutinin (SNA) lectin fractionation and determined the degree of sialylation. Analysis of IVIg-SA (+) using a lectin-based ELISA revealed that we enriched predominantly for Fab-sialylated IgG, whereas we did not find an increase in Fc-sialylated IgG. Mass spectrometric analysis confirmed that Fc sialylation did not change after SNA lectin fractionation. The efficacy of sialylated IgG was measured by administering IVIg or IVIg-SA (+) 24 hours prior to an injection of a rat anti-mouse platelet mAb. We found an 85% decrease in platelet count after injection of an anti-platelet mAb, which was reduced to a 70% decrease by injecting IVIg (p<0.01). In contrast, IVIg-SA (+) had no effect on the platelet count. Serum levels of IVIg and IVIg-SA (+) were similar, ruling out enhanced IgG clearance as a possible explanation. Our results indicate that SNA lectin fractionation is not a suitable method to enrich IVIg for Fc-sialylated IgG. The use of IVIg enriched for Fab-sialylated IgG abolishes the efficacy of IVIg in the murine PIT model.	[Guhr, Theresa; Derksen, Ninotska I. L.; Aalberse, Rob C.; Rispens, Theo] Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, NL-1105 AZ Amsterdam, Netherlands; [Bloem, Judith; Koenderman, Anky H. L.] Sanquin, Prod Dev Dept, Amsterdam, Netherlands; [Wuhrer, Manfred] Leiden Univ, Med Ctr, Dept Parasitol, Biomol Mass Spectrometry Unit, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Guhr, T (corresponding author), Univ Amsterdam, Acad Med Ctr, Sanquin Res & Landsteiner Lab, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	T.Rispens@sanquin.nl	Wuhrer, Manfred/ABE-9168-2020	Wuhrer, Manfred/0000-0002-0814-4995				Anthony RM, 2008, SCIENCE, V320, P373, DOI 10.1126/science.1154315; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Baerenwaldt A, 2010, EXPERT REV CLIN IMMU, V6, P425, DOI [10.1586/eci.10.9, 10.1586/ECI.10.9]; Ballow M, 2011, J ALLERGY CLIN IMMUN, V127, P315, DOI 10.1016/j.jaci.2010.10.030; BERCHTOLD P, 1989, BLOOD, V73, P662; Crow AR, 2001, BRIT J HAEMATOL, V115, P679, DOI 10.1046/j.1365-2141.2001.03136.x; Dalziel M, 1999, GLYCOCONJUGATE J, V16, P801, DOI 10.1023/A:1007183915921; Fernandez-Cruz E, 2009, CLIN EXP IMMUNOL, V158, P60, DOI 10.1111/j.1365-2249.2009.04028.x; FINNEY JD, 1979, STAT METHOD BIOL ASS; Flynn GC, 2010, MOL IMMUNOL, V47, P2074, DOI 10.1016/j.molimm.2010.04.006; GELFAND EW, 1992, SEMIN HEMATOL, V29, P127; Huang HS, 2010, BLOOD, V116, P5002, DOI 10.1182/blood-2010-03-275123; IMBACH P, 1981, LANCET, V1, P1228; Imbach P, 2010, VOX SANG, V98, P385, DOI 10.1111/j.1423-0410.2009.01264.x; IMBACH P, 1991, CANCER-AM CANCER SOC, V68, P1422, DOI 10.1002/1097-0142(19910915)68:6+<1422::AID-CNCR2820681403>3.0.CO;2-5; Jin F, 2005, HUM IMMUNOL, V66, P403, DOI 10.1016/j.humimm.2005.01.029; Kaneko Y, 2006, SCIENCE, V313, P670, DOI 10.1126/science.1129594; KAVERI SV, 1991, CLIN EXP IMMUNOL, V86, P192; Kazatchkine MD, 2001, NEW ENGL J MED, V345, P747, DOI 10.1056/NEJMra993360; Kumar A, 2006, INT ARCH ALLERGY IMM, V140, P185, DOI 10.1159/000093204; Lazarus AH, 2002, VOX SANG, V83, P53, DOI 10.1111/j.1423-0410.2002.tb05268.x; Looney RJ, 2006, BEST PRACT RES CL HA, V19, P3, DOI 10.1016/j.beha.2005.01.032; Negi VS, 2007, J CLIN IMMUNOL, V27, P233, DOI 10.1007/s10875-007-9088-9; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Seite JF, 2010, BLOOD, V116, P1698, DOI 10.1182/blood-2009-12-261461; Stadlmann J, 2008, PROTEOMICS, V8, P2858, DOI 10.1002/pmic.200700968; Stadlmann J, 2010, J CLIN IMMUNOL, V30, pS15, DOI 10.1007/s10875-010-9409-2; Stadlmann J, 2009, PROTEOMICS, V9, P4143, DOI 10.1002/pmic.200800931; Teeling JL, 2001, BLOOD, V98, P1095, DOI 10.1182/blood.V98.4.1095; Tha-In T, 2008, TRENDS IMMUNOL, V29, P608, DOI 10.1016/j.it.2008.08.004; VLUG A, 1994, ANN BIOL CLIN-PARIS, V52, P561; Wuhrer M, 2007, PROTEOMICS, V7, P4070, DOI 10.1002/pmic.200700289	32	88	96	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2011	6	6							e21246	10.1371/journal.pone.0021246	http://dx.doi.org/10.1371/journal.pone.0021246			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	782TT	21731683	Green Published, Green Submitted, gold			2023-01-03	WOS:000292035400016
J	Kusters, I; Mukherjee, N; de Jong, MR; Tans, S; Kocer, A; Driessen, AJM				Kusters, Ilja; Mukherjee, Nobina; de Jong, Menno R.; Tans, Sander; Kocer, Armagan; Driessen, Arnold J. M.			Taming Membranes: Functional Immobilization of Biological Membranes in Hydrogels	PLOS ONE			English	Article							FLUORESCENCE-BURST ANALYSIS; MECHANOSENSITIVE CHANNEL MSCL; PREPROTEIN TRANSLOCATION; PROTEIN TRANSLOCATION; SUPPORTED MEMBRANES; CATALYTIC CYCLE; LIPID-BILAYERS; RECONSTITUTION; PORE; EVENTS	Single molecule studies on membrane proteins embedded in their native environment are hampered by the intrinsic difficulty of immobilizing elastic and sensitive biological membranes without interfering with protein activity. Here, we present hydrogels composed of nano-scaled fibers as a generally applicable tool to immobilize biological membrane vesicles of various size and lipid composition. Importantly, membrane proteins immobilized in the hydrogel as well as soluble proteins are fully active. The triggered opening of the mechanosensitive channel of large conductance (MscL) reconstituted in giant unilamellar vesicles (GUVs) was followed in time on single GUVs. Thus, kinetic studies of vectorial transport processes across biological membranes can be assessed on single, hydrogel immobilized, GUVs. Furthermore, protein translocation activity by the membrane embedded protein conducting channel of bacteria, SecYEG, in association with the soluble motor protein SecA was quantitatively assessed in bulk and at the single vesicle level in the hydrogel. This technique provides a new way to investigate membrane proteins in their native environment at the single molecule level by means of fluorescence microscopy.	[Kusters, Ilja; Driessen, Arnold J. M.] Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, Ag Groningen, Netherlands; [Kusters, Ilja; Driessen, Arnold J. M.] Univ Groningen, Zernike Inst Adv Mat, Ag Groningen, Netherlands; [Mukherjee, Nobina; Kocer, Armagan] Univ Groningen, Dept Membrane Enzymol, Groningen Biomol Sci & Biotechnol Inst, Groningen, Netherlands; [de Jong, Menno R.] BiOMaDe Technol Fdn, Groningen, Netherlands; [Tans, Sander] AMOLF Inst, Amsterdam, Netherlands	University of Groningen; University of Groningen; University of Groningen; AMOLF	Driessen, AJM (corresponding author), Univ Groningen, Dept Mol Microbiol, Groningen Biomol Sci & Biotechnol Inst, Ag Groningen, Netherlands.	a.j.m.driessen@rug.nl	Tans, Sander/AAS-2901-2020; Kocer, A/M-6371-2013; Driessen, Arnold J.M./D-1876-2012; Kusters, Ilja/J-3492-2019; Institute, Zernike/W-7033-2019; Kusters, Ilja/A-3256-2012	Kusters, Ilja/0000-0003-3739-8764; Driessen, Arnold J.M./0000-0001-9258-9104; Mukherjee, Nobina/0000-0003-4655-2188; kocer, Armagan/0000-0001-7343-3139	NanoNed; MEDITRANS; NWO VIDI; ERC	NanoNed; MEDITRANS; NWO VIDI(Netherlands Organization for Scientific Research (NWO)); ERC(European Research Council (ERC)European Commission)	This work was funded by NanoNed (IK, MDJ, AJMD), a national nanotechnology program coordinated by the Dutch Ministry of Economical Affairs and the Zernike Institute for Advanced Materials (IK, AJMD), and by the Chemical Sciences division of The Netherlands Organization for Scientific Research (NWO-CW; IK, AJMD). Further, this project was supported by MEDITRANS Sixth Framework Programme (AK,NM), NWO VIDI (AK), ERC-Starting grant (AK). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARKOWITZ RA, 1993, EMBO J, V12, P243, DOI 10.1002/j.1460-2075.1993.tb05650.x; Bagatolli LA, 2006, BBA-BIOMEMBRANES, V1758, P1541, DOI 10.1016/j.bbamem.2006.05.019; Bakheet TM, 2009, BIOINFORMATICS, V25, P451, DOI 10.1093/bioinformatics/btp002; Bol R, 2007, J BIOL CHEM, V282, P29785, DOI 10.1074/jbc.M702140200; Brizard A, 2008, ANGEW CHEM INT EDIT, V47, P2063, DOI 10.1002/anie.200704609; DEVILLE K, 2010, J BIOL CHEM; Driessen AJM, 2008, ANNU REV BIOCHEM, V77, P643, DOI 10.1146/annurev.biochem.77.061606.160747; Dudia A, 2008, NANO LETT, V8, P1105, DOI 10.1021/nl073211b; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Girard P, 2004, BIOPHYS J, V87, P419, DOI 10.1529/biophysj.104.040360; Hamai C, 2007, BIOPHYS J, V92, P1988, DOI 10.1529/biophysj.106.093831; Joo C, 2008, ANNU REV BIOCHEM, V77, P51, DOI 10.1146/annurev.biochem.77.070606.101543; Kocer A, 2007, NAT PROTOC, V2, P1426, DOI 10.1038/nprot.2007.196; Kusters I, 2010, METHODS MOL BIOL, V619, P131, DOI 10.1007/978-1-60327-412-8_8; Lin CW, 2005, DIABETES, V54, P2852, DOI 10.2337/diabetes.54.10.2852; Meleard P, 2009, METHOD ENZYMOL, V465, P161, DOI 10.1016/S0076-6879(09)65009-6; Richter RP, 2006, LANGMUIR, V22, P3497, DOI 10.1021/la052687c; Sackmann E, 1996, SCIENCE, V271, P43, DOI 10.1126/science.271.5245.43; Sackmann E, 2000, TRENDS BIOTECHNOL, V18, P58, DOI 10.1016/S0167-7799(99)01412-2; SCHIEBEL E, 1991, CELL, V64, P927, DOI 10.1016/0092-8674(91)90317-R; SUKHAREV SI, 1994, NATURE, V368, P265, DOI 10.1038/368265a0; TAMM LK, 1985, BIOPHYS J, V47, P105, DOI 10.1016/S0006-3495(85)83882-0; Toprak E, 2007, ANNU REV BIOPH BIOM, V36, P349, DOI 10.1146/annurev.biophys.36.040306.132700; van den Bogaart G, 2007, BIOPHYS J, V93, P154, DOI 10.1529/biophysj.107.106005; van den Bogaart G, 2007, BIOPHYS J, V92, P1233, DOI 10.1529/biophysj.106.088708; van den Bogaart G, 2008, METHODS, V46, P123, DOI 10.1016/j.ymeth.2008.06.016; van der Wolk JPW, 1997, EMBO J, V16, P7297, DOI 10.1093/emboj/16.24.7297; Wagner ML, 2000, BIOPHYS J, V79, P1400, DOI 10.1016/S0006-3495(00)76392-2; Yoshimura K, 2001, BIOPHYS J, V80, P2198, DOI 10.1016/S0006-3495(01)76192-9	29	16	16	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2011	6	5							e20435	10.1371/journal.pone.0020435	http://dx.doi.org/10.1371/journal.pone.0020435			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770OP	21655266	Green Published, gold			2023-01-03	WOS:000291097600068
J	Shekelle, PG; Pronovost, PJ; Wachter, RM; Taylor, SL; Dy, SM; Foy, R; Hempel, S; McDonald, KM; Ovretveit, J; Rubenstein, LV; Adams, AS; Angood, PB; Bates, DW; Bickman, L; Carayon, P; Donaldson, L; Duan, N; Farley, DO; Greenhalgh, T; Haughom, J; Lake, ET; Lilford, R; Lohr, KN; Meyer, GS; Miller, MR; Neuhauser, DV; Ryan, G; Saint, S; Shojania, KG; Shortell, SM; Stevens, DP; Walshe, K				Shekelle, Paul G.; Pronovost, Peter J.; Wachter, Robert M.; Taylor, Stephanie L.; Dy, Sydney M.; Foy, Robbie; Hempel, Susanne; McDonald, Kathryn M.; Ovretveit, John; Rubenstein, Lisa V.; Adams, Alyce S.; Angood, Peter B.; Bates, David W.; Bickman, Leonard; Carayon, Pascale; Donaldson, Liam; Duan, Naihua; Farley, Donna O.; Greenhalgh, Trisha; Haughom, John; Lake, Eileen T.; Lilford, Richard; Lohr, Kathleen N.; Meyer, Gregg S.; Miller, Marlene R.; Neuhauser, Duncan V.; Ryan, Gery; Saint, Sanjay; Shojania, Kaveh G.; Shortell, Stephen M.; Stevens, David P.; Walshe, Kieran			Advancing the Science of Patient Safety	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							EVIDENCE-BASED MEDICINE; PHYSICIAN ORDER ENTRY; QUALITY IMPROVEMENT; MEDICATION ERRORS; CARE; ACCOUNTABILITY; INTERVENTION; PUBLICATION	Despite a decade's worth of effort, patient safety has improved slowly, in part because of the limited evidence base for the development and widespread dissemination of successful patient safety practices. The Agency for Healthcare Research and Quality sponsored an international group of experts in patient safety and evaluation methods to develop criteria to improve the design, evaluation, and reporting of practice research in patient safety. This article reports the findings and recommendations of this group, which include greater use of theory and logic models, more detailed descriptions of interventions and their implementation, enhanced explanation of desired and unintended outcomes, and better description and measurement of context and of how context influences interventions. Using these criteria and measuring and reporting contexts will improve the science of patient safety.	RAND Hlth, Santa Monica, CA USA; RAND Hlth, Pittsburgh, PA USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Johns Hopkins Univ, Baltimore, MD USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Univ Leeds, Leeds, W Yorkshire, England; Stanford Univ, Stanford, CA 94305 USA; Karolinska Inst, Stockholm, Sweden; Kaiser Permanente, Oakland, CA USA; Natl Qual Forum, Washington, DC USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Phys Org, Boston, MA USA; Vanderbilt Univ, Nashville, TN USA; Univ Wisconsin, Madison, WI USA; Dept Hlth, London SE1 6TE, England; UCL, London, England; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; PeaceHealth, Bellevue, WA USA; Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA; Univ Birmingham, Birmingham, W Midlands, England; RTI Int, Res Triangle Pk, NC USA; Case Western Reserve Univ, Cleveland, OH 44106 USA; Univ Michigan, Ann Arbor, MI 48109 USA; [Shojania, Kaveh G.] Univ Toronto, Toronto, ON, Canada; Univ Calif Berkeley, Berkeley, CA 94720 USA; Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA; Univ Manchester, Manchester, Lancs, England	RAND Corporation; RAND Corporation; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; Johns Hopkins University; University of California System; University of California San Francisco; University of Leeds; Stanford University; Karolinska Institutet; Kaiser Permanente; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison; University of London; University College London; New York State Psychiatry Institute; University of Pennsylvania; University of Birmingham; Research Triangle Institute; Case Western Reserve University; University of Michigan System; University of Michigan; University of Toronto; University of California System; University of California Berkeley; Dartmouth College; University of Manchester	Shekelle, PG (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.	shekelle@rand.org	Saint, Sanjay/AAF-5126-2019; Bates, David/AAE-7283-2019; Chang, Shulan/H-2270-2011; TAYLOR, STEPHANIE/GYV-4768-2022; Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088; Foy, Robbie/0000-0003-0605-7713; Walshe, Kieran/0000-0002-0696-480X; ovretveit, john/0000-0002-5177-6613; Duan, Naihua/0000-0001-9411-2924; Lilford, Richard/0000-0002-0634-984X; Hempel, Susanne/0000-0003-1597-5110; Taylor, Stephanie/0000-0002-3266-1132; Bickman, Leonard/0000-0002-0746-3791; Lohr, Kathleen/0000-0002-3825-0713	AHRQ [HHSA-290-2009-10001C]	AHRQ(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Grant Support: By the AHRQ (contract HHSA-290-2009-10001C).	Auerbach AD, 2007, NEW ENGL J MED, V357, P608, DOI 10.1056/NEJMsb070738; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bosk CL, 2009, LANCET, V374, P444, DOI 10.1016/S0140-6736(09)61440-9; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Davidoff F, 2008, ANN INTERN MED, V149, P670, DOI 10.7326/0003-4819-149-9-200811040-00009; Glasziou P, 2010, BMJ-BRIT MED J, V341, pc3852; Haynes AB, 2009, NEW ENGL J MED, V360, P491, DOI 10.1056/NEJMsa0810119; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Landrigan CP, 2010, NEW ENGL J MED, V363, P2124, DOI 10.1056/NEJMsa1004404; Leape LL, 2002, JAMA-J AM MED ASSOC, V288, P501, DOI 10.1001/jama.288.4.501; Office of the Inspector General, 2010, ADVERSE EVENTS HOSP; Pronovost P, 2006, QUAL SAF HEALTH CARE, V15, P152, DOI 10.1136/qshc.2006.018432; Pronovost P, 2006, NEW ENGL J MED, V355, P2725, DOI 10.1056/NEJMoa061115; Pronovost PJ, 2008, J CRIT CARE, V23, P207, DOI 10.1016/j.jcrc.2007.09.002; Pronovost PJ, 2009, JAMA-J AM MED ASSOC, V302, P890, DOI 10.1001/jama.2009.1177; Pronovost PJ, 2010, BMJ-BRIT MED J, V340, pc309; Shekelle PG, 2010, AHRQ PUBLICATION; Shojania KG, 2010, CAN MED ASSOC J, V182, pE216, DOI 10.1503/cmaj.090578; Shojania KG, 2002, JAMA-J AM MED ASSOC, V288, P508, DOI 10.1001/jama.288.4.508; Smith GCS, 2003, BRIT MED J, V327, P1459, DOI 10.1136/bmj.327.7429.1459; Stelfox HT, 2003, JAMA-J AM MED ASSOC, V290, P1899, DOI 10.1001/jama.290.14.1899; Wachter RM, 2010, HEALTH AFFAIR, V29, P165, DOI 10.1377/hlthaff.2009.0785	23	134	134	2	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 17	2011	154	10					693	696		10.7326/0003-4819-154-10-201105170-00011	http://dx.doi.org/10.7326/0003-4819-154-10-201105170-00011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	764HK	21576538				2023-01-03	WOS:000290620300019
J	Kallmes, DF; Molyneux, AJ				Kallmes, David F.; Molyneux, Andrew J.			Endovascular coils for cerebral aneurysm: HELPS has arrived	LANCET			English	Editorial Material									[Kallmes, David F.] Mayo Clin, Rochester, MN 55905 USA; [Molyneux, Andrew J.] Oxford Radcliffe Hosp, Nuffield Dept Surg Sci, Oxford Neurovasc & Neuroradiol Res Unit, Oxford, England	Mayo Clinic; University of Oxford	Kallmes, DF (corresponding author), Mayo Clin, Rochester, MN 55905 USA.	kallmes.david@mayo.edu						Im SH, 2007, AM J NEURORADIOL, V28, P511; Molyneux AJ, 2005, LANCET, V366, P809, DOI 10.1016/S0140-6736(05)67214-5; Molyneux AJ, 2009, LANCET NEUROL, V8, P427, DOI 10.1016/S1474-4422(09)70080-8; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; White PM, 2011, LANCET, V377, P1655, DOI 10.1016/S0140-6736(11)60408-X	5	0	0	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY 14	2011	377	9778					1627	1628		10.1016/S0140-6736(11)60601-6	http://dx.doi.org/10.1016/S0140-6736(11)60601-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	766JF	21571131				2023-01-03	WOS:000290777700004
J	Yank, V; Tuohy, CV; Logan, AC; Bravata, DM; Staudenmayer, K; Eisenhut, R; Sundaram, V; McMahon, D; Olkin, I; McDonald, KM; Owens, DK; Stafford, RS				Yank, Veronica; Tuohy, C. Vaughan; Logan, Aaron C.; Bravata, Dena M.; Staudenmayer, Kristan; Eisenhut, Robin; Sundaram, Vandana; McMahon, Donal; Olkin, Ingram; McDonald, Kathryn M.; Owens, Douglas K.; Stafford, Randall S.			Systematic Review: Benefits and Harms of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications	ANNALS OF INTERNAL MEDICINE			English	Review							ACTIVATED FACTOR-VII; ORTHOTOPIC LIVER-TRANSPLANTATION; CARDIAC-SURGERY; INTRACEREBRAL HEMORRHAGE; TRANSFUSION REQUIREMENTS; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE ANALYSIS; COAGULOPATHIC PATIENTS; ADJUNCTIVE THERAPY; RANDOMIZED-TRIALS	Background: Recombinant factor VIIa (rFVIIa), a hemostatic agent approved for hemophilia, is increasingly used for off-label indications. Purpose: To evaluate the benefits and harms of rFVIIa use for 5 off-label, in-hospital indications: intracranial hemorrhage, cardiac surgery, trauma, liver transplantation, and prostatectomy. Data Sources: Ten databases (including PubMed, EMBASE, and the Cochrane Library) queried from inception through December 2010. Articles published in English were analyzed. Study Selection: Two reviewers independently screened titles and abstracts to identify clinical use of rFVIIa for the selected indications and identified all randomized, controlled trials (RCTs) and observational studies for full-text review. Data Extraction: Two reviewers independently assessed study characteristics and rated study quality and indication-wide strength of evidence. Data Synthesis: 16 RCTs, 26 comparative observational studies, and 22 noncomparative observational studies met inclusion criteria. Identified comparators were limited to placebo (RCTs) or usual care (observational studies). For intracranial hemorrhage, mortality was not improved with rFVIIa use across a range of doses. Arterial thromboembolism was increased with medium-dose rFVIIa use (risk difference [RD], 0.03 [95% CI, 0.01 to 0.06]) and high-dose rFVIIa use (RD, 0.06 [CI, 0.01 to 0.11]). For adult cardiac surgery, there was no mortality difference, but there was an increased risk for thromboembolism (RD, 0.05 [CI, 0.01 to 0.10]) with rFVIIa. For body trauma, there were no differences in mortality or thromboembolism, but there was a reduced risk for the acute respiratory distress syndrome (RD, -0.05 [CI, -0.02 to -0.08]). Mortality was higher in observational studies than in RCTs. Limitations: The amount and strength of evidence were low for most outcomes and indications. Publication bias could not be excluded. Conclusion: Limited available evidence for 5 off-label indications suggests no mortality reduction with rFVIIa use. For some indications, it increases thromboembolism.	[Yank, Veronica] Stanford Univ, Stanford Prevent Res Ctr, Stanford, CA 94304 USA; Stanford Sch Med, Stanford, CA USA; Palo Alto Med Fdn Res Inst, Palo Alto, CA USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Castlight Hlth, San Francisco, CA USA	Stanford University; Stanford University; Palo Alto Medical Foundation Research Institute; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; University of Pennsylvania	Yank, V (corresponding author), Stanford Univ, Stanford Prevent Res Ctr, Med Sch Off Bldg X312,251 Campus Dr, Stanford, CA 94304 USA.	vyank@stanford.edu	Logan, Aaron C/ADJ-7526-2022; Stafford, Randall/F-3974-2017	Logan, Aaron C/0000-0002-1179-5879; Stafford, Randall/0000-0003-1805-1271	Agency for Healthcare Research and Quality, U. S. Department of Health and Human Services [290-02-0017]; U.S. Department of Veterans Affairs; National Heart, Lung, and Blood Institute [K24HL086703]; Palo Alto Medical Foundation Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL086703] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality, U. S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); U.S. Department of Veterans Affairs(US Department of Veterans Affairs); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Palo Alto Medical Foundation Research Institute; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Grant Support: By the Agency for Healthcare Research and Quality, U. S. Department of Health and Human Services, under contract 290-02-0017. Dr. Owens was supported by the U.S. Department of Veterans Affairs. This research also was supported by training grants from the National Heart, Lung, and Blood Institute (RSS, K24HL086703) and the Palo Alto Medical Foundation Research Institute.	*AG HEALTC RES QUL, 2011, METH REF GUID EFF CO; Aggarwal Anita, 2004, Thromb J, V2, P9, DOI 10.1186/1477-9560-2-9; Bartal C, 2007, J TRAUMA, V63, P725, DOI 10.1097/TA.0b013e318031ccca; Birchall J, 2008, TRANSFUS MED REV, V22, P177, DOI 10.1016/j.tmrv.2008.02.007; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bowman LJ, 2008, ANN THORAC SURG, V85, P1669, DOI 10.1016/j.athoracsur.2008.01.089; Brody DL, 2005, NEUROCRIT CARE, V2, P263, DOI 10.1385/NCC:2:3:263; Brown CVR, 2010, J TRAUMA, V68, P348, DOI 10.1097/TA.0b013e3181bbfb6b; Bruckner BA, 2009, J HEART LUNG TRANSPL, V28, P785, DOI 10.1016/j.healun.2009.04.028; Cameron P, 2007, INJURY, V38, P1030, DOI 10.1016/j.injury.2007.05.003; De Gasperi A, 2005, INTENS CARE MED, V31, P315, DOI 10.1007/s00134-004-2525-9; Deeks J J, 2003, Health Technol Assess, V7, piii; DEMENTEVA II, 2004, ANESTEZIOL REANIMAT, V5, P11; Dementyeva II, 2005, GEMATOL TRANSFUZIOL, V50, P12; Diprose P, 2005, BRIT J ANAESTH, V95, P596, DOI 10.1093/bja/aei244; Duchesne JC, 2008, AM SURGEON, V74, P1159; Dunning J, 2008, EUR J CARDIO-THORAC, V34, P73, DOI 10.1016/j.ejcts.2008.02.024; Dutton RP, 2004, J TRAUMA, V57, P709, DOI 10.1097/01.TA.0000140646.66852.AB; Felfernig M, 2007, J R Army Med Corps, V153, P32; Filsoufi F, 2006, ANN THORAC SURG, V82, P1779, DOI 10.1016/j.athoracsur.2006.05.076; Flower O, 2010, BLOOD COAGUL FIBRIN, V21, P207, DOI 10.1097/MBC.0b013e3283333589; Fox CJ, 2009, J TRAUMA, V66, pS112, DOI 10.1097/TA.0b013e31819ce240; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Friedrich JO, 2005, NEW ENGL J MED, V352, P2133; Gandhi MJ, 2007, J CARDIOTHORAC SURG, V2, DOI 10.1186/1749-8090-2-32; Garcia E, 2008, TRAFFIC, V9, P200, DOI 10.1111/j.1600-0854.2007.00678.x; Gelsomino S, 2008, EUR J CARDIO-THORAC, V33, P64, DOI 10.1016/j.ejcts.2007.10.004; Gill R, 2009, CIRCULATION, V120, P21, DOI 10.1161/CIRCULATIONAHA.108.834275; GLESER L. J., 2009, HDB RES SYNTHESIS ME, P357; Gong Zhi-yun, 2008, Zhonghua Wai Ke Za Zhi, V46, P1497; Grintescu Ioana, 2006, Chirurgia (Bucur), V101, P615; Hallevi H, 2008, STROKE, V39, P473, DOI 10.1161/STROKEAHA.107.497651; Harrison TD, 2005, J TRAUMA, V59, P150, DOI 10.1097/01.TA.0000171470.39742.8E; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; HEDGES L, 1985, STAT METHODS METAANA, P166; Hendriks HGD, 2001, TRANSPLANTATION, V71, P402, DOI 10.1097/00007890-200102150-00011; Howes Jeremy L, 2009, Am J Surg, V198, P895, DOI 10.1016/j.amjsurg.2009.05.026; Hsia CC, 2009, TRANSFUSION MED, V19, P43, DOI 10.1111/j.1365-3148.2009.00913.x; Hsia CC, 2008, ANN SURG, V248, P61, DOI 10.1097/SLA.0b013e318176c4ec; Hyllner M, 2005, EUR J CARDIO-THORAC, V28, P254, DOI 10.1016/j.ejcts.2005.04.021; Ityas C, 2008, J CLIN ANESTH, V20, P276, DOI 10.1016/j.jclinane.2007.12.012; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jarosz K, 2009, TRANSPL P, V41, P3088, DOI 10.1016/j.transproceed.2009.07.099; Johansson PI, 2008, VOX SANG, V95, P1, DOI 10.1111/j.1423-0410.2008.01063.x; Kalicinski P, 2005, PEDIATR TRANSPLANT, V9, P299, DOI 10.1111/j.1399-3046.2005.00309.x; Karkouti K, 2005, TRANSFUSION, V45, P26, DOI 10.1111/j.1537-2995.2005.04216.x; Karkouti K, 2008, CIRCULATION, V118, P331, DOI 10.1161/CIRCULATIONAHA.108.764308; Karkouti K, 2007, CAN J ANAESTH, V54, P573, DOI 10.1007/BF03022322; Kjaergard LL, 2001, ANN INTERN MED, V135, P982, DOI 10.7326/0003-4819-135-11-200112040-00010; Knudson MM, 2011, J AM COLL SURGEONS, V212, P87, DOI 10.1016/j.jamcollsurg.2010.08.020; Kranzler HR, 2001, ALCOHOL CLIN EXP RES, V25, P1335, DOI 10.1097/00000374-200109000-00014; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Lin YL, 2011, CAN MED ASSOC J, V183, pE9, DOI 10.1503/cmaj.100408; LIU J, 2009, TISSUE ENG RES, V13, P3580; Lodge JPA, 2005, LIVER TRANSPLANT, V11, P973, DOI 10.1002/lt.20470; Logan AC, 2011, ANN INTERN MED, V154, P516, DOI 10.7326/0003-4819-154-8-201104190-00002; MA B, 2006, DIER JUNYI DAXUE XUE, V27, P1110; Martinowitz U, 2005, J THROMB HAEMOST, V3, P640, DOI 10.1111/j.1538-7836.2005.01203.x; Masud F, 2009, J CARDIOTHOR VASC AN, V23, P28, DOI 10.1053/j.jvca.2008.08.003; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2005, STROKE, V36, P74, DOI 10.1161/01.STR.0000149628.80251.b8; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; Mayer SA, 2006, NEUROCRIT CARE, V4, P206, DOI 10.1385/NCC:4:3:206; McCall P, 2006, CAN J ANAESTH, V53, P926, DOI 10.1007/BF03022836; McQuay N, 2009, J NEUROSURG, V111, P666, DOI 10.3171/2009.4.JNS081611; *MED EC, 2009, PHYS DES REF; Millan C, 2009, REV ESP ANEST REANIM, V56, P485, DOI 10.1016/S0034-9356(09)70439-6; Mitra B, 2010, ANAESTH INTENS CARE, V38, P671, DOI 10.1177/0310057X1003800409; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Niemann CU, 2006, TRANSFUSION MED, V16, P93, DOI 10.1111/j.1365-3148.2006.00653.x; Nishijima DK, 2010, ACAD EMERG MED, V17, P244, DOI 10.1111/j.1553-2712.2010.00666.x; Nishijima DK, 2009, ANN EMERG MED, V54, P737, DOI 10.1016/j.annemergmed.2009.01.027; Novak V, 2008, SRP ARK CELOK LEK, V136, P193, DOI 10.2298/SARH08S3193N; Nussbaum ES, 2009, NEUROCRIT CARE, V10, P55, DOI 10.1007/s12028-008-9149-9; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Patanwala AE, 2008, AM J HEALTH-SYST PH, V65, P1616, DOI 10.2146/ajhp080008; Perel P, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007877.pub2; Pickard JD, 2000, BLOOD COAGUL FIBRIN, V11, pS117, DOI 10.1097/00001721-200004001-00022; Planinsic RM, 2005, LIVER TRANSPLANT, V11, P895, DOI 10.1002/lt.20458; POHAR S, 2009, RECOMBINANT ACTIVATE; Pugliese F, 2007, TRANSPL P, V39, P1883, DOI 10.1016/j.transproceed.2007.05.062; Raivio P, 2005, ANN THORAC SURG, V80, P66, DOI 10.1016/j.athoracsur.2005.02.044; Rizoli SB, 2006, J TRAUMA, V61, P1419, DOI 10.1097/01.ta.0000243045.56579.74; Robinson MT, 2010, STROKE, V41, P1459, DOI 10.1161/STROKEAHA.110.581538; Rucker G, 2009, STAT MED, V28, P721, DOI 10.1002/sim.3511; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Squizzato A, 2007, CURR DRUG SAF, V2, P155, DOI 10.2174/157488607780598278; Stanworth SJ, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005011.pub2; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Sutherland CS, 2008, CAN J NEUROL SCI, V35, P567, DOI 10.1017/S0317167100009343; Tatoulis James, 2009, Interact Cardiovasc Thorac Surg, V9, P459, DOI 10.1510/icvts.2009.204735; Tawil I, 2008, J TRAUMA, V64, P849, DOI 10.1097/TA.0b013e318160c08a; Tritapepe L, 2007, CRIT CARE MED, V35, P1685, DOI 10.1097/01.CCM.0000269033.89428.B3; Trowbridge Cody, 2008, J Extra Corpor Technol, V40, P89; Vandenbroucke JP, 2008, JAMA-J AM MED ASSOC, V300, P2417, DOI 10.1001/jama.2008.723; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; von Heymann C, 2005, CRIT CARE MED, V33, P2241, DOI 10.1097/01.CCM.0000181527.47749.57; Wade CE, 2010, J TRAUMA, V69, P353, DOI 10.1097/TA.0b013e3181e49059; Warren O, 2007, ANN THORAC SURG, V83, P707, DOI 10.1016/j.athoracsur.2006.10.033; Woodruff SI, 2010, EMERG MED J, V27, P121, DOI 10.1136/emj.2008.060657; YANK V, 2011, COMP EFFECTIVENESS R; You H, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005951.pub2; Yuan ZH, 2010, J CLIN NEUROSCI, V17, P685, DOI 10.1016/j.jocn.2009.11.020; Zangrillo A, 2009, J CARDIOTHOR VASC AN, V23, P34, DOI 10.1053/j.jvca.2008.09.017	108	168	173	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2011	154	8					529	540		10.7326/0003-4819-154-8-201104190-00004	http://dx.doi.org/10.7326/0003-4819-154-8-201104190-00004			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	751MK	21502651	Green Accepted			2023-01-03	WOS:000289622000016
J	Babigumira, JB; Castelnuovo, B; Stergachis, A; Kiragga, A; Shaefer, P; Lamorde, M; Kambugu, A; Muwanga, A; Garrison, LP				Babigumira, Joseph B.; Castelnuovo, Barbara; Stergachis, Andy; Kiragga, Agnes; Shaefer, Petra; Lamorde, Mohammed; Kambugu, Andrew; Muwanga, Alice; Garrison, Louis P.			Cost Effectiveness of a Pharmacy-Only Refill Program in a Large Urban HIV/AIDS Clinic in Uganda	PLOS ONE			English	Article							HUMAN-RESOURCES; HEALTH; CARE	Background: HIV/AIDS clinics in Uganda and other low-income countries face increasing numbers of patients and workforce shortages. We performed a cost-effectiveness analysis comparing a Pharmacy-only Refill Program (PRP), a form of task-shifting, to the Standard of Care (SOC) at a large HIV/AIDS clinic in Uganda, the Infectious Diseases Institute (IDI). The PRP was started to reduce workforce shortages and optimize patient care by substituting pharmacy visits for SOC involving monthly physician visits for accessing antiretroviral medicines. Methodology/Principal Findings: We used a retrospective cohort analysis to compare the effectiveness of the PRP compared to SOC. Effectiveness was defined as Favorable Immune Response (FIR), measured as having a CD4 lymphocyte count of over 500 cells/mu l at follow-up. We used multivariate logistic regression to assess the difference in FIR between patients in the PRP and SOC. We incorporated estimates of effectiveness into an incremental cost-effectiveness analysis performed from a limited societal perspective. We estimated costs from previous studies at IDI and conducted univariate and probabilistic sensitivity analyses. We identified 829 patients, 578 in the PRP and 251 in SOC. After 12.8 months (PRP) and 15.1 months (SOC) of follow-up, 18.9% of patients had a FIR, 18.6% in the PRP and 19.6% in SOC. There was a non-significant 9% decrease in the odds of having a FIR for PRP compared to SOC after adjusting for other variables (OR 0.93, 95% CI 0.55-1.58). The PRP was less costly than the SOC (US$ 520 vs. 655 annually, respectively). The incremental cost-effectiveness ratio comparing PRP to SOC was US$ 13,500 per FIR. PRP remained cost-effective at univariate and probabilistic sensitivity analysis. Conclusion/Significance: The PRP is more cost-effective than the standard of care. Similar task-shifting programs might help large HIV/AIDS clinics in Uganda and other low-income countries to cope with increasing numbers of patients seeking care.	[Babigumira, Joseph B.; Stergachis, Andy; Garrison, Louis P.] Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA; [Castelnuovo, Barbara; Kiragga, Agnes; Shaefer, Petra; Lamorde, Mohammed; Kambugu, Andrew; Muwanga, Alice] Makerere Univ, Infect Dis Inst, Kampala, Uganda; [Stergachis, Andy] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA; [Stergachis, Andy] Univ Washington, Sch Publ Hlth, Dept Global Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Makerere University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Babigumira, JB (corresponding author), Univ Washington, Sch Pharm, Pharmaceut Outcomes Res & Policy Program, Seattle, WA 98195 USA.	babijo@uw.edu	Babigumira, Joseph/T-4208-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER; NIAID NIH HHS [P30 AI027757] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anyangwe Stella C E, 2007, Int J Environ Res Public Health, V4, P93, DOI 10.3390/ijerph2007040002; Babigumira JB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-192; Bemelmans M, 2010, TROP MED INT HEALTH, V15, P1413, DOI 10.1111/j.1365-3156.2010.02649.x; Brentlinger PE, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-23; Callaghan M, 2010, HUM RESOUR HEALTH, V8, DOI 10.1186/1478-4491-8-8; Castelnuovo B, 2009, INT J STD AIDS, V20, P123, DOI 10.1258/ijsa.2008.008174; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; Garrison LP, 2010, VALUE HEALTH, V13, P8, DOI 10.1111/j.1524-4733.2009.00660.x; Jaffar S, 2009, LANCET, V374, P2080, DOI 10.1016/S0140-6736(09)61674-3; *JOINT UN PROGR HI, 2009, AIDS EP UPD; McCollum ED, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009626; Morris MB, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-5; Price J, 2010, DEV WORLD BIOETH, V10, P99, DOI 10.1111/j.1471-8847.2010.00281.x; Samb B, 2007, NEW ENGL J MED, V357, P2510, DOI 10.1056/NEJMsb071889; Sanne I, 2010, LANCET, V376, P33, DOI 10.1016/S0140-6736(10)60894-X; SCHRANTZ S, 2007, 45 ANN C INF DIS SOC; Selke HM, 2010, JAIDS-J ACQ IMM DEF, V55, P483, DOI 10.1097/QAI.0b013e3181eb5edb; Shumbusho F, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000163; TUGUME SB, 1995, CLIN DIAGN LAB IMMUN, V2, P233, DOI 10.1128/CDLI.2.2.233-235.1995; Weinstein MC., 1996, COST EFFECTIVENESS H; *WHOCHOICE, 2010, EST UN COSTS PAT SER; World Health Organization (WHO), 2009, WORLD HLTH STAT; Zachariah R, 2009, T ROY SOC TROP MED H, V103, P549, DOI 10.1016/j.trstmh.2008.09.019	23	40	40	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 28	2011	6	3							e18193	10.1371/journal.pone.0018193	http://dx.doi.org/10.1371/journal.pone.0018193			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	743XV	21464895	Green Submitted, Green Published, gold			2023-01-03	WOS:000289053800027
J	Nagler, J; Krauss, B				Nagler, Joshua; Krauss, Baruch			Intraosseous Catheter Placement in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ACCESS		[Nagler, Joshua; Krauss, Baruch] Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp Boston,Div Emergency Med, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School	Nagler, J (corresponding author), Harvard Univ, Sch Med, Dept Pediat, Childrens Hosp Boston,Div Emergency Med, Boston, MA 02115 USA.		Krauss, Baruch/U-6182-2019					Garcia CT, 1996, PEDIATR EMERG CARE, V12, P94, DOI 10.1097/00006565-199604000-00007; KANTER RK, 1986, AM J DIS CHILD, V140, P132, DOI 10.1001/archpedi.1986.02140160050030; Kleinman ME, 2010, CIRCULATION, V122, pS876, DOI 10.1161/CIRCULATIONAHA.110.971101; Levitan RM, 2009, ANN EMERG MED, V54, P692, DOI 10.1016/j.annemergmed.2009.06.012; Ong MEH, 2009, AM J EMERG MED, V27, P8, DOI 10.1016/j.ajem.2008.01.025; ORLOWSKI JP, 1989, ANN EMERG MED, V18, P1062, DOI 10.1016/S0196-0644(89)80932-1; ROSETTI VA, 1985, ANN EMERG MED, V14, P885, DOI 10.1016/S0196-0644(85)80639-9; SIMMONS CM, 1994, ANN EMERG MED, V23, P363, DOI 10.1016/S0196-0644(94)70053-2; Tsung JW, 2009, RESUSCITATION, V80, P665, DOI 10.1016/j.resuscitation.2009.03.009	9	6	6	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2011	364	8					E14	U76		10.1056/NEJMvcm0900916	http://dx.doi.org/10.1056/NEJMvcm0900916			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	725NP	21345096				2023-01-03	WOS:000287652500010
J	Burns, KEA; Adhikari, NKJ; Slutsky, AS; Guyatt, GH; Villar, J; Zhang, HB; Zhou, Q; Cook, DJ; Stewart, TE; Meade, MO				Burns, Karen E. A.; Adhikari, Neill K. J.; Slutsky, Arthur S.; Guyatt, Gordon H.; Villar, Jesus; Zhang, Haibo; Zhou, Qi; Cook, Deborah J.; Stewart, Thomas E.; Meade, Maureen O.			Pressure and Volume Limited Ventilation for the Ventilatory Management of Patients with Acute Lung Injury: A Systematic Review and Meta-Analysis	PLOS ONE			English	Review							RESPIRATORY-DISTRESS-SYNDROME; COMPUTERIZED DECISION-SUPPORT; END-EXPIRATORY PRESSURE; MECHANICAL VENTILATION; PERMISSIVE HYPERCAPNIA; CLINICAL-TRIALS; MORTALITY; STRATEGY; SCORE; SEVERITY	Background: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life threatening clinical conditions seen in critically ill patients with diverse underlying illnesses. Lung injury may be perpetuated by ventilation strategies that do not limit lung volumes and airway pressures. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) comparing pressure and volume-limited (PVL) ventilation strategies with more traditional mechanical ventilation in adults with ALI and ARDS. Methods and Findings: We searched Medline, EMBASE, HEALTHSTAR and CENTRAL, related articles on PubMed (TM), conference proceedings and bibliographies of identified articles for randomized trials comparing PVL ventilation with traditional approaches to ventilation in critically ill adults with ALI and ARDS. Two reviewers independently selected trials, assessed trial quality, and abstracted data. We identified ten trials (n = 1,749) meeting study inclusion criteria. Tidal volumes achieved in control groups were at the lower end of the traditional range of 10-15 mL/kg. We found a clinically important but borderline statistically significant reduction in hospital mortality with PVL [relative risk (RR) 0.84; 95% CI 0.70, 1.00; p = 0.05]. This reduction in risk was attenuated (RR 0.90; 95% CI 0.74, 1.09, p = 0.27) in a sensitivity analysis which excluded 2 trials that combined PVL with open-lung strategies and stopped early for benefit. We found no effect of PVL on barotrauma; however, use of paralytic agents increased significantly with PVL (RR 1.37; 95% CI, 1.04, 1.82; p = 0.03). Conclusions: This systematic review suggests that PVL strategies for mechanical ventilation in ALI and ARDS reduce mortality and are associated with increased use of paralytic agents.	[Burns, Karen E. A.; Adhikari, Neill K. J.; Slutsky, Arthur S.; Zhang, Haibo; Stewart, Thomas E.] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Burns, Karen E. A.; Slutsky, Arthur S.; Villar, Jesus; Zhang, Haibo] St Michaels Hosp, Keenan Res Ctr, Toronto, ON M5B 1W8, Canada; [Burns, Karen E. A.; Slutsky, Arthur S.; Villar, Jesus; Zhang, Haibo] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON M4N 3M5, Canada; [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON M4N 3M5, Canada; [Guyatt, Gordon H.; Zhou, Qi; Cook, Deborah J.; Meade, Maureen O.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Villar, Jesus] Inst Salud Carlos III, CIBER Enfermedades Resp, Madrid, Spain; [Villar, Jesus] Hosp Univ Dr Negrin, Res Unit, Las Palmas Gran Canaria, Spain	University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; McMaster University; CIBER - Centro de Investigacion Biomedica en Red; CIBERES; Instituto de Salud Carlos III	Burns, KEA (corresponding author), Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada.	burnsk@smh.ca	Slutsky, Arthur/M-3325-2019; Villar, Jesús/R-4526-2019; Zhou, Qi/GSM-9583-2022	Villar, Jesús/0000-0001-5687-3562; 	Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Dr. Burns holds a Clinician Scientist Award with the Canadian Institutes of Health Research. No funding was received to conduct the systematic review and meta-analysis.	AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; [Anonymous], COCHRANE DATABASE SY; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BALK R, 1983, MED CLIN N AM, V67, P685, DOI 10.1016/S0025-7125(16)31197-X; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; Carvalho CRR, 1997, AM J RESP CRIT CARE, V156, P1458, DOI 10.1164/ajrccm.156.5.9604081; COCHRAN WG, 1954, BIOMETRICS, V10, P101, DOI 10.2307/3001666; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; East TD, 1999, J AM MED INFORM ASSN, P251; Eichacker PQ, 2002, AM J RESP CRIT CARE, V166, P1510, DOI 10.1164/rccm.200208-956OC; Esteban A, 2000, CHEST, V117, P1690, DOI 10.1378/chest.117.6.1690; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; Gainnier M, 2004, CRIT CARE MED, V32, P113, DOI 10.1097/01.CCM.0000104114.72614.BC; GATTINONI L, 1987, AM REV RESPIR DIS, V136, P730, DOI 10.1164/ajrccm/136.3.730; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; GREENFIELD LJ, 1964, ANESTHESIOLOGY, V25, P312, DOI 10.1097/00000542-196405000-00009; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P995, DOI 10.1136/bmj.39490.551019.BE; HICKLING KG, 1994, CRIT CARE MED, V22, P1568, DOI 10.1097/00003246-199422100-00011; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HICKLING KG, 1988, INTENS CARE MED, V14, P617; Higgins J.P.T, 2011, COCHRANE HDB SYSTEMA, DOI [10.1002/9780470712184.ch1, DOI 10.1002/9780470712184.CH1]; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Kallet R H, 2001, Respir Care, V46, P1024; KLEINBAUM DG, 1988, APPL REGRESSION ANAL, P512; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOLOBOW T, 1987, AM REV RESPIR DIS, V135, P312; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; LEGALL JR, 1984, CRIT CARE MED, V12, P975; Long Yun, 2006, Zhonghua Jiehe He Huxi Zazhi, V29, P549; MARINI JJ, 1994, CHEST, V105, pS109, DOI 10.1378/chest.105.3_Supplement.109S; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; McKinley BA, 2001, J TRAUMA, V50, P415, DOI 10.1097/00005373-200103000-00004; Meade M O, 1995, Clin Intensive Care, V6, P166, DOI 10.1080/714028896; Montori VM, 2005, JAMA-J AM MED ASSOC, V294, P2203, DOI 10.1001/jama.294.17.2203; Moran JL, 2005, INTENS CARE MED, V31, P227, DOI 10.1007/s00134-004-2506-z; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NIU T, 2000, CHINESE CRIT CARE ME, V12, P36; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Phoenix SI, 2009, ANESTHESIOLOGY, V110, P1098, DOI 10.1097/ALN.0b013e31819fae06; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; Qin Zhi-qiang, 2003, Zhonghua Yi Xue Za Zhi, V83, P224; Ranieri VM, 1999, JAMA-J AM MED ASSOC, V282, P54, DOI 10.1001/jama.282.1.54; RAPPAPORT SH, 1994, CRIT CARE MED, V22, P22, DOI 10.1097/00003246-199401000-00009; SLUTSKY AS, 1993, CHEST, V104, P1833, DOI 10.1378/chest.104.6.1833; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; SUN JJ, 2009, CHIN CRIT CARE MED, V21, P209; Villar J, 2006, CRIT CARE MED, V34, P1311, DOI 10.1097/01.CCM.0000215598.84885.01; Wang Xiao-zhi, 2007, Zhonghua Jiehe He Huxi Zazhi, V30, P44; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; WU G, 1998, B HUNAN MED U, V23, P57	59	65	71	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 28	2011	6	1							e14623	10.1371/journal.pone.0014623	http://dx.doi.org/10.1371/journal.pone.0014623			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	712JX	21298026	Green Submitted, gold, Green Published			2023-01-03	WOS:000286664100008
J	Kawaguchi, N; Smith, AJ; Waring, CD; Hasan, MK; Miyamoto, S; Matsuoka, R; Ellison, GM				Kawaguchi, Nanako; Smith, Andrew J.; Waring, Cheryl D.; Hasan, Md Kamrul; Miyamoto, Shinka; Matsuoka, Rumiko; Ellison, Georgina M.			c-kit(pos) GATA-4 High Rat Cardiac Stem Cells Foster Adult Cardiomyocyte Survival through IGF-1 Paracrine Signalling	PLOS ONE			English	Article							GROWTH-FACTOR-I; REGENERATE INFARCTED MYOCARDIUM; BONE-MARROW-CELLS; PROGENITOR CELLS; HEART-FAILURE; MURINE HEART; APOPTOSIS; MECHANISMS; THERAPY; MULTIPOTENT	Background: Resident c-kit positive (c-kit(pos)) cardiac stem cells (CSCs) could be considered the most appropriate cell type for myocardial regeneration therapies. However, much is still unknown regarding their biological properties and potential. Methodology/Principal Findings: We produced clones of high and low expressing GATA-4 CSCs from long-term bulk-cultured c-kit(pos) CSCs isolated from adult rat hearts. When c-kit(pos) GATA-4 high expressing clonal CSCs (cCSCs) were co-cultured with adult rat ventricular cardiomyocytes, we observed increased survival and contractility of the cardiomyocytes, compared to cardiomyocytes cultured alone, co-cultured with fibroblasts or c-kit(pos) GATA-4 low expressing cCSCs. When analysed by ELISA, the concentration of IGF-1 was significantly increased in the c-kit(pos) GATA-4 high cCSC/cardiomyocyte co-cultures and there was a significant correlation between IGF-1 concentration and cardiomyocyte survival. We showed the activation of the IGF-1 receptor and its downstream molecular targets in cardiomyocytes co-cultured with c-kit(pos) GATA-4 high cCSCs but not in cardiomyocytes that were cultured alone, co-cultured with fibroblasts or c-kit(pos) GATA-4 low cCSCs. Addition of a blocking antibody specific to the IGF-1 receptor inhibited the survival of cardiomyocytes and prevented the activation of its signalling in cardiomyocytes in the c-kit(pos) GATA-4 high cCSC/cardiomyocyte co-culture system. IGF-1 supplementation or IGF-1 high conditioned medium taken from the co-culture of c-kit(pos) GATA-4 high cCSCs plus cardiomyocytes did extend the survival and contractility of cardiomyocytes cultured alone and cardiomyocytes co-cultured with c-kit(pos) GATA-4 low cCSCs. Conclusion/Significance: c-kit(pos) GATA-4 high cCSCs exert a paracrine survival effect on cardiomyocytes through induction of the IGF-1R and signalling pathway.	[Kawaguchi, Nanako; Hasan, Md Kamrul; Miyamoto, Shinka; Matsuoka, Rumiko] Tokyo Womens Med Univ, IREIIMS, Tokyo, Japan; [Smith, Andrew J.; Waring, Cheryl D.; Ellison, Georgina M.] Liverpool John Moores Univ, Res Inst Sport & Exercise Sci, Stem Cell & Mol Physiol Lab, Liverpool L3 5UX, Merseyside, England; [Miyamoto, Shinka] Tokyo Womens Med Univ, Heart Inst Japan, Dept Cardiovasc Surg, Tokyo, Japan	Tokyo Women's Medical University; Liverpool John Moores University; Tokyo Women's Medical University	Kawaguchi, N (corresponding author), Tokyo Womens Med Univ, IREIIMS, Tokyo, Japan.	g.m.ellison@ljmu.ac.uk	Ellison-Hughes, Georgina M./B-4597-2016	Ellison-Hughes, Georgina M./0000-0002-2733-3361; Smith, Andrew/0000-0001-7283-5611	Ministry of Education, Culture, Sports, Science and Technology, Japan; British Heart Foundation [PG/06/053, PG 08/085]; European Community [PIRG02-GA-2007-224853]	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); British Heart Foundation(British Heart Foundation); European Community(European Commission)	This work was supported by the encouraging Development of Strategic Research Centers, Special Co-ordination Funds for Promoting Science and Technology and a Grant-in Aid for Scientific Research (A), Ministry of Education, Culture, Sports, Science and Technology, Japan; grants to G. M. E from the British Heart Foundation (PG/06/053; PG 08/085) and a Marie Curie International Reintegration Grant within the 7th European Community Framework Programme (PIRG02-GA-2007-224853). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aoyama T, 2002, CARDIOVASC RES, V55, P787, DOI 10.1016/S0008-6363(02)00493-5; Balsam LB, 2004, NATURE, V428, P668, DOI 10.1038/nature02460; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Bernecker Oliver Y, 2003, Cardiovasc Toxicol, V3, P183, DOI 10.1385/CT:3:3:183; Braunwald E, 2000, CIRCULATION, V102, P14; BRAUNWALD E, 1991, AM J CARDIOL, V68, pD1; Chien KR, 2004, NATURE, V428, P607, DOI 10.1038/nature02500; Chimenti I, 2010, CIRC RES, V106, P971, DOI 10.1161/CIRCRESAHA.109.210682; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Ellison Georgina M, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS52, DOI 10.1038/ncpcardio0773; Ellison GM, 2007, J BIOL CHEM, V282, P11397, DOI 10.1074/jbc.M607391200; Fu YC, 2004, CARDIOVASC RES, V62, P558, DOI 10.1016/j.cardiores.2004.01.039; Fujio Y, 2000, CIRCULATION, V101, P660, DOI 10.1161/01.CIR.101.6.660; Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826; Gnecchi M, 2006, FASEB J, V20, P661, DOI 10.1096/fj.05-5211com; Heineke J, 2007, J CLIN INVEST, V117, P3198, DOI 10.1172/JCI32573; Janssens S, 2010, ANNU REV MED, V61, P287, DOI 10.1146/annurev.med.051508.215152; KELLEY C, 1993, DEVELOPMENT, V118, P817; Kinnaird T, 2004, CIRC RES, V94, P678, DOI 10.1161/01.RES.0000118601.37875.AC; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Kubal C, 2006, J THORAC CARDIOV SUR, V132, P1112, DOI 10.1016/j.jtcvs.2006.06.028; Lai VK, 2009, J THORAC CARDIOV SUR, V138, P1400, DOI 10.1016/j.jtcvs.2009.07.013; LaVoie HA, 2004, ENDOCRINOLOGY, V145, P3122, DOI 10.1210/en.2003-1719; Linke A, 2005, P NATL ACAD SCI USA, V102, P8966, DOI 10.1073/pnas.0502678102; Martin-Rendon E, 2008, EUR HEART J, V29, P1807, DOI 10.1093/eurheartj/ehn220; Matsuura K, 2004, J BIOL CHEM, V279, P11384, DOI 10.1074/jbc.M310822200; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Miyamoto S, 2010, STEM CELLS DEV, V19, P105, DOI 10.1089/scd.2009.0041; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Moore XL, 2007, ENDOCRINOLOGY, V148, P1582, DOI 10.1210/en.2006-1324; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Nadal-Ginard B, 2006, REV ESP CARDIOL, V59, P1175; Oka T, 2006, CIRC RES, V98, P837, DOI 10.1161/01.RES.0000215985.18538.c4; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Padin-Iruegas ME, 2009, CIRCULATION, V120, P876, DOI 10.1161/CIRCULATIONAHA.109.852285; Reffelmann T, 2009, J AM COLL CARDIOL, V53, P305, DOI 10.1016/j.jacc.2008.10.018; Rosenblatt-Velin N, 2005, J CLIN INVEST, V115, P1724, DOI 10.1172/JCI23418; Rota M, 2005, CIRC RES, V97, P1332, DOI 10.1161/01.RES.0000196568.11624.ae; Sadat S, 2007, BIOCHEM BIOPH RES CO, V363, P674, DOI 10.1016/j.bbrc.2007.09.058; Tang XL, 2010, CIRCULATION, V121, P293, DOI 10.1161/CIRCULATIONAHA.109.871905; Tomita Y, 2005, J CELL BIOL, V170, P1135, DOI 10.1083/jcb.200504061; Torella D, 2004, CIRC RES, V94, P514, DOI 10.1161/01.RES.0000117306.10142.50; Torella Daniele, 2007, Nat Clin Pract Cardiovasc Med, V4 Suppl 1, pS46, DOI 10.1038/ncpcardio0772; Wencker D, 2003, J CLIN INVEST, V111, P1497, DOI 10.1172/JCI200317664; Wu S, 2002, J MOL CELL CARDIOL, V34, P1595, DOI 10.1006/jmcc.2002.2110; Yamaoka M, 2000, J MOL CELL CARDIOL, V32, P881, DOI 10.1006/jmcc.2000.1132; Yang L, 2008, NATURE, V453, P524, DOI 10.1038/nature06894; Zaruba MM, 2010, CIRCULATION, V121, P1992, DOI 10.1161/CIRCULATIONAHA.109.909093; Zhou X, 2010, CARDIOLOGY, V115, P243, DOI 10.1159/000301278	49	68	73	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 13	2010	5	12							e14297	10.1371/journal.pone.0014297	http://dx.doi.org/10.1371/journal.pone.0014297			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	693SY	21179204	Green Published, Green Submitted, gold			2023-01-03	WOS:000285246900010
J	Ferrara, F				Ferrara, Felicetto			Treatment of older patients with acute myeloid leukaemia	LANCET			English	Editorial Material							ACUTE MYELOGENOUS LEUKEMIA; ADULTS; DIAGNOSIS; DECISION; SURVIVAL; AML; AGE		[Ferrara, Felicetto] Cardarelli Hosp, Div Haematol, I-80128 Naples, Italy; [Ferrara, Felicetto] Cardarelli Hosp, Stem Cell Transplantat Unit, I-80128 Naples, Italy	Antonio Cardarelli Hospital; Antonio Cardarelli Hospital	Ferrara, F (corresponding author), Cardarelli Hosp, Div Haematol, I-80128 Naples, Italy.	felicettoferrara@katamail.com						Dohner H, 2010, BLOOD, V115, P453, DOI 10.1182/blood-2009-07-235358; Estey E, 2009, BEST PRACT RES CL HA, V22, P529, DOI 10.1016/j.beha.2009.08.007; Ferrara F, 2004, LANCET ONCOL, V5, P443, DOI 10.1016/S1470-2045(04)01512-8; Ferrara F, 2008, CRIT REV ONCOL HEMAT, V66, P181, DOI 10.1016/j.critrevonc.2007.09.008; Juliusson G, 2009, BLOOD, V113, P4179, DOI 10.1182/blood-2008-07-172007; Kantarjian H, 2010, BLOOD, V116, P4422, DOI 10.1182/blood-2010-03-276485; Klepin HD, 2009, ONCOLOGIST, V14, P222, DOI 10.1634/theoncologist.2008-0224; Krug U, 2010, LANCET, V376, P2000, DOI 10.1016/S0140-6736(10)62105-8; Sekeres MA, 2004, LEUKEMIA, V18, P809, DOI 10.1038/sj.leu.2403289; Sekeres MA, 2009, BLOOD, V113, P28, DOI 10.1182/blood-2008-05-157065; Shipley JL, 2009, EXP HEMATOL, V37, P649, DOI 10.1016/j.exphem.2009.04.002; Wheatley K, 2009, BRIT J HAEMATOL, V145, P598, DOI 10.1111/j.1365-2141.2009.07663.x	12	9	10	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 11	2010	376	9757					1967	1968		10.1016/S0140-6736(10)62104-6	http://dx.doi.org/10.1016/S0140-6736(10)62104-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701GZ	21131041				2023-01-03	WOS:000285807700006
J	Kimberley, TJ; Di Fabio, RP				Kimberley, Teresa Jacobson; Di Fabio, Richard P.			Visualizing the Effects of rTMS in a Patient Sample: Small N vs. Group Level Analysis	PLOS ONE			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; INTERINDIVIDUAL VARIABILITY; HAND DYSTONIA; EXCITABILITY; RELIABILITY; MODULATION; RESPONSES; CURVES	The use of transcranial magnetic stimulation (TMS) to assess changes in cortical excitability is a tool used with increased prevalence in healthy and impaired populations. One factor of concern with this technique is how to achieve adequate statistical power given constraints of a small number of subjects and variability in responses. This paper compares a single pulse excitability measure using traditional group-level statistics vs single subject analyses in a patient population of subjects with focal hand dystonia, pre and post repetitive TMS (rTMS). Results show significant differences in cortical excitability for 4/5 subjects using a split middle line analysis on plots of individual subject data. Group level statistics (ANOVA), however, did not detect any significant findings. The consideration of single subject statistics for TMS excitability measures may assist researchers in describing the variably of rTMS outcome measures.	[Kimberley, Teresa Jacobson; Di Fabio, Richard P.] Univ Minnesota, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Kimberley, TJ (corresponding author), Univ Minnesota, Dept Phys Med & Rehabil, Minneapolis, MN 55455 USA.	tjk@umn.edu	Kimberley, Teresa/AAL-1893-2020	Kimberley, Teresa/0000-0001-6397-4054	Dystonia Medical Research Foundation; National Center for Research Resources (NCRR) in the National Institutes of Health [M01 RR00400]	Dystonia Medical Research Foundation; National Center for Research Resources (NCRR) in the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	Dystonia Medical Research Foundation (http://www.dystonia-foundation.org/pages/2010_solicitation_for_research_support_from_dod/364.php) and partial support from: National Center for Research Resources (NCRR) M01 RR00400 in the National Institutes of Health (http://www.ncrr.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Backman CL, 1997, ARCH PHYS MED REHAB, V78, P1145, DOI 10.1016/S0003-9993(97)90142-8; Berardelli A, 1998, EXP BRAIN RES, V122, P79, DOI 10.1007/s002210050493; Borich M, 2009, RESTOR NEUROL NEUROS, V27, P55, DOI 10.3233/RNN-2009-0461; Carey JR, 2010, NEUROSCI LETT, V469, P338, DOI 10.1016/j.neulet.2009.12.023; Devanne H, 1997, EXP BRAIN RES, V114, P329, DOI 10.1007/PL00005641; Duque J, 2008, CEREB CORTEX, V18, P1395, DOI 10.1093/cercor/bhm173; Fink GR, 1997, J NEUROPHYSIOL, V77, P2164, DOI 10.1152/jn.1997.77.4.2164; FITZGERALD PB, 2002, CLIN NEUROPHYSIOLOGY, V113; Gangitano M, 2002, CLIN NEUROPHYSIOL, V113, P1249, DOI 10.1016/S1388-2457(02)00109-8; HINZE J, 2007, NCSS HELP SYSTEM; Kimberley TJ, 2009, NEUROSCI LETT, V464, P84, DOI 10.1016/j.neulet.2009.08.029; KOH THHG, 1988, ARCH DIS CHILD, V63, P1347, DOI 10.1136/adc.63.11.1347; Maeda F, 2002, CLIN NEUROPHYSIOL, V113, P376, DOI 10.1016/S1388-2457(02)00008-1; Maeda F, 2000, EXP BRAIN RES, V133, P425, DOI 10.1007/s002210000432; Moll GH, 1999, EEG CL N SU, P243; Muellbacher W, 2000, CLIN NEUROPHYSIOL, V111, P1002, DOI 10.1016/S1388-2457(00)00284-4; Murase N, 2005, BRAIN, V128, P104, DOI 10.1093/brain/awh315; NOURBAKHSH MR, 1994, PHYS THER, V74, P768, DOI 10.1093/ptj/74.8.768; OTTENBACHER KJ, 1986, AM J OCCUP THER, V40, P464, DOI 10.5014/ajot.40.7.464; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; Portney LG., 2000, FDN CLIN RES APPL PR, V2, DOI DOI 10.1016/S0039-6257(02)00362-4; Quartarone A, 2006, TRENDS NEUROSCI, V29, P192, DOI 10.1016/j.tins.2006.02.007; Rossini P M, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P171; Schluter ND, 1998, BRAIN, V121, P785, DOI 10.1093/brain/121.5.785; Sommer M, 2002, CLIN NEUROPHYSIOL, V113, P265, DOI 10.1016/S1388-2457(01)00726-X; Stinear CM, 2004, HUM MOVEMENT SCI, V23, P527, DOI 10.1016/j.humov.2004.08.022; vanderKamp W, 1996, J CLIN NEUROPHYSIOL, V13, P164, DOI 10.1097/00004691-199603000-00007; Wassermann EM, 1998, NEUROSCI LETT, V250, P141, DOI 10.1016/S0304-3940(98)00437-6; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5	29	9	9	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	DEC 8	2010	5	12							e15155	10.1371/journal.pone.0015155	http://dx.doi.org/10.1371/journal.pone.0015155			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	691MJ	21151629	gold, Green Published, Green Submitted			2023-01-03	WOS:000285084100023
J	Marshall, J; Ashe, KM; Bangari, D; McEachern, K; Chuang, WL; Pacheco, J; Copeland, DP; Desnick, RJ; Shayman, JA; Scheule, RK; Cheng, SH				Marshall, John; Ashe, Karen M.; Bangari, Dinesh; McEachern, KerryAnne; Chuang, Wei-Lien; Pacheco, Joshua; Copeland, Diane P.; Desnick, Robert J.; Shayman, James A.; Scheule, Ronald K.; Cheng, Seng H.			Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry Disease	PLOS ONE			English	Article							AGALSIDASE-BETA THERAPY; GAUCHER-DISEASE; REPLACEMENT THERAPY; ALPHA-GALACTOSIDASE; RENAL-FUNCTION; MICE; GLOBOTRIAOSYLCERAMIDE; INVOLVEMENT; MIGLUSTAT; SAFETY	Fabry disease is an X-linked glycosphingolipid storage disorder caused by a deficiency in the activity of the lysosomal hydrolase a-galactosidase A (a-gal). This deficiency results in accumulation of the glycosphingolipid globotriaosylceramide (GL-3) in lysosomes. Endothelial cell storage of GL-3 frequently leads to kidney dysfunction, cardiac and cerebrovascular disease. The current treatment for Fabry disease is through infusions of recombinant a-gal (enzyme-replacement therapy; ERT). Although ERT can markedly reduce the lysosomal burden of GL-3 in endothelial cells, variability is seen in the clearance from several other cell types. This suggests that alternative and adjuvant therapies may be desirable. Use of glucosylceramide synthase inhibitors to abate the biosynthesis of glycosphingolipids (substrate reduction therapy, SRT) has been shown to be effective at reducing substrate levels in the related glycosphingolipidosis, Gaucher disease. Here, we show that such an inhibitor (eliglustat tartrate, Genz-112638) was effective at lowering GL-3 accumulation in a mouse model of Fabry disease. Relative efficacy of SRT and ERT at reducing GL-3 levels in Fabry mouse tissues differed with SRT being more effective in the kidney, and ERT more efficacious in the heart and liver. Combination therapy with ERT and SRT provided the most complete clearance of GL-3 from all the tissues. Furthermore, treatment normalized urine volume and uromodulin levels and significantly delayed the loss of a nociceptive response. The differential efficacies of SRT and ERT in the different tissues indicate that the combination approach is both additive and complementary suggesting the possibility of an improved therapeutic paradigm in the management of Fabry disease.	[Marshall, John; Ashe, Karen M.; Bangari, Dinesh; McEachern, KerryAnne; Chuang, Wei-Lien; Pacheco, Joshua; Copeland, Diane P.; Scheule, Ronald K.; Cheng, Seng H.] Genzyme Corp, Appl Discovery Res, Framingham, MA 01701 USA; [Desnick, Robert J.] Mt Sinai Sch Med, New York, NY USA; [Shayman, James A.] Univ Michigan, Genzyme Corp, Ann Arbor, MI 48109 USA	Sanofi-Aventis; Genzyme Corporation; Icahn School of Medicine at Mount Sinai; Sanofi-Aventis; Genzyme Corporation; University of Michigan System; University of Michigan	Marshall, J (corresponding author), Genzyme Corp, Appl Discovery Res, Framingham, MA 01701 USA.	john.marshall@genzyme.com	Cheng, Seng H/AAC-6564-2022	Marshall, John/0000-0003-1361-2869	NIDDK NIH HHS [R01 DK055823] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; [Anonymous], 2014, METABOLIC MOL BASES; Banikazemi M, 2007, ANN INTERN MED, V146, P77, DOI 10.7326/0003-4819-146-2-200701160-00148; Cox TM, 2003, J INHERIT METAB DIS, V26, P513, DOI 10.1023/A:1025902113005; Crosbie TW, 2009, J INHERIT METAB DIS, V32, P745, DOI 10.1007/s10545-009-1254-1; Dutsch M, 2002, J CLIN NEUROPHYSIOL, V19, P575; GADOTH N, 1983, J MED GENET, V20, P309, DOI 10.1136/jmg.20.4.309; Germain DP, 2007, J AM SOC NEPHROL, V18, P1547, DOI 10.1681/ASN.2006080816; Heare T, 2007, J INHERIT METAB DIS, V30, P79, DOI 10.1007/s10545-006-0473-y; Hoffmann B, 2007, CLIN GASTROENTEROL H, V5, P1447, DOI 10.1016/j.cgh.2007.08.012; Hollak CEM, 2009, PHARMACOEPIDEM DR S, V18, P770, DOI 10.1002/pds.1779; Kobayashi M, 2008, J Inherit Metab Dis, V31 Suppl 3, P483, DOI 10.1007/s10545-007-0740-6; Lidove O, 2007, INT J CLIN PRACT, V61, P293, DOI 10.1111/j.1742-1241.2006.01237.x; Luciano CA, 2002, MUSCLE NERVE, V26, P622, DOI 10.1002/mus.10236; Lukina E, 2010, BLOOD, V116, P893, DOI 10.1182/blood-2010-03-273151; Marshall J, 2010, J INHERIT METAB DIS, V33, P281, DOI 10.1007/s10545-010-9072-z; McEachern KA, 2007, MOL GENET METAB, V91, P259, DOI 10.1016/j.ymgme.2007.04.001; Moller AT, 2009, PAIN, V145, P237, DOI 10.1016/j.pain.2009.06.032; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moore DF, 2006, ACTA PAEDIATR, V95, P69, DOI 10.1080/08035320600618932; Ohshima T, 1999, P NATL ACAD SCI USA, V96, P6423, DOI 10.1073/pnas.96.11.6423; Ohshima T, 1997, P NATL ACAD SCI USA, V94, P2540, DOI 10.1073/pnas.94.6.2540; Pastores GM, 2005, CLIN THER, V27, P1215, DOI 10.1016/j.clinthera.2005.08.004; Platt FM, 2009, BBA-MOL CELL RES, V1793, P737, DOI 10.1016/j.bbamcr.2008.08.009; Rodrigues LG, 2009, NEUROBIOL DIS, V33, P48, DOI 10.1016/j.nbd.2008.09.001; Schiffmann R, 2002, ACTA PAEDIATR, V91, P48, DOI 10.1080/080352502762457923; Schiffmann R, 2006, NEPHROL DIAL TRANSPL, V21, P345, DOI 10.1093/ndt/gfi152; Schiffmann R, 2007, J AM SOC NEPHROL, V18, P1576, DOI 10.1681/ASN.2006111263; Sessa A, 2003, J NEPHROL, V16, P310; Shu L, 2007, J BIOL CHEM, V282, P20960, DOI 10.1074/jbc.M702436200; Shu LM, 2005, J AM SOC NEPHROL, V16, P2636, DOI 10.1681/ASN.2005040383; Thurberg BL, 2009, CIRCULATION, V119, P2561, DOI 10.1161/CIRCULATIONAHA.108.841494; Thurberg BL, 2002, KIDNEY INT, V62, P1933, DOI 10.1046/j.1523-1755.2002.00675.x; Vedder AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000598; Vylet'al P, 2008, J INHERIT METAB DIS, V31, P508, DOI 10.1007/s10545-008-0900-3; Waldek S, 2009, GENET MED, V11, P790, DOI 10.1097/GIM.0b013e3181bb05bb; Wang A. M., 1996, American Journal of Human Genetics, V59, pA208; Wilcox WR, 2008, MOL GENET METAB, V93, P112, DOI 10.1016/j.ymgme.2007.09.013; Wilcox WR, 2004, AM J HUM GENET, V75, P65, DOI 10.1086/422366; Ziegler RJ, 2007, MOL THER, V15, P492, DOI 10.1038/sj.mt.6300066	40	55	58	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	NOV 24	2010	5	11							e15033	10.1371/journal.pone.0015033	http://dx.doi.org/10.1371/journal.pone.0015033			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	684TK	21124789	Green Published, gold, Green Submitted			2023-01-03	WOS:000284572000020
J	Talaei, F; Bouma, H; Van der Graaf, A; Strijkstra, A; Schmidt, M; Henning, R				Talaei, Fatemeh; Bouma, Hjalmar; Van der Graaf, Adrianus; Strijkstra, Arjen; Schmidt, Martina; Henning, Robert			Serotonin and Dopamine Protect from Hypothermia/Rewarming Damage through the CBS/H2S Pathway	PLOS ONE			English	Article							CYSTATHIONINE-BETA-SYNTHASE; RAT VAS-DEFERENS; HYDROGEN-SULFIDE; ISCHEMIA-REPERFUSION; REDOX REGULATION; MICE; H2S; INJURY; INHIBITION; KIDNEY	Biogenic amines have been demonstrated to protect cells from apoptotic cell death. Herein we show for the first time that serotonin and dopamine increase H2S production by the endogenous enzyme cystathionine-beta-synthase (CBS) and protect cells against hypothermia/rewarming induced reactive oxygen species (ROS) formation and apoptosis. Treatment with both compounds doubled CBS expression through mammalian target of rapamycin (mTOR) and increased H2S production in cultured rat smooth muscle cells. In addition, serotonin and dopamine treatment significantly reduced ROS formation. The beneficial effect of both compounds was minimized by inhibition of their re-uptake and by pharmacological inhibition of CBS or its down-regulation by siRNA. Exogenous administration of H2S and activation of CBS by Prydoxal 5'-phosphate also protected cells from hypothermic damage. Finally, serotonin and dopamine pretreatment of rat lung, kidney, liver and heart prior to 24 h of hypothermia at 3 degrees C followed by 30 min of rewarming at 37 degrees C upregulated the expression of CBS, strongly reduced caspase activity and maintained the physiological pH compared to untreated tissues. Thus, dopamine and serotonin protect cells against hypothermia/rewarming induced damage by increasing H2S production mediated through CBS. Our data identify a novel molecular link between biogenic amines and the H2S pathway, which may profoundly affect our understanding of the biological effects of monoamine neurotransmitters.	[Talaei, Fatemeh; Bouma, Hjalmar; Strijkstra, Arjen; Henning, Robert] Univ Groningen, Dept Clin Pharmacol FB20, Univ Med Ctr Groningen, Groningen, Netherlands; [Van der Graaf, Adrianus] Angteq BV, Groningen, Netherlands; [Strijkstra, Arjen] Univ Groningen, Dept Chronobiol, Groningen, Netherlands; [Schmidt, Martina] Univ Groningen, Dept Mol Pharmacol, Fac Pharm, Groningen, Netherlands	University of Groningen; University of Groningen; University of Groningen	Talaei, F (corresponding author), Univ Groningen, Dept Clin Pharmacol FB20, Univ Med Ctr Groningen, Groningen, Netherlands.	F.Talaei@med.umcg.nl	Bouma, Hjalmar/F-9737-2015; Schmidt, Martina/C-5339-2018; Henning, Robert H/AAY-5222-2020	Bouma, Hjalmar/0000-0003-1032-321X; Schmidt, Martina/0000-0003-3075-0630; Henning, Robert/0000-0002-5135-4621	UMCG	UMCG	This work is supported by a PhD grant from UMCG to FT. AVdG was involved in designing the experiments, no additional financial contribution was received from Angteq B.V. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banerjee R, 2005, ARCH BIOCHEM BIOPHYS, V433, P144, DOI 10.1016/j.abb.2004.08.037; Becker LB, 2004, CARDIOVASC RES, V61, P461, DOI 10.1016/j.cardiores.2003.10.025; Betten A, 2001, J LEUKOCYTE BIOL, V70, P65; Bianchi P, 2005, FASEB J, V19, P641, DOI 10.1096/fj.04-2518fje; Boutilier RG, 2001, J EXP BIOL, V204, P3171; Brinkkoetter PT, 2008, CELL PHYSIOL BIOCHEM, V22, P195, DOI 10.1159/000149797; BUSZA AL, 1992, TRANSPLANTATION, V54, P562, DOI 10.1097/00007890-199209000-00037; Calvert JW, 2010, ANTIOXID REDOX SIGN, V12, P1203, DOI 10.1089/ars.2009.2882; CELUCH SM, 1988, NEUROCHEM RES, V13, P967, DOI 10.1007/BF00970770; Dorweiler B, 2007, EUR J TRAUMA EMERG S, V33, P600, DOI 10.1007/s00068-007-7152-z; Drabek T, 2011, SHOCK, V35, P67, DOI 10.1097/SHK.0b013e3181e86f49; Eisenhofer G, 2001, PHARMACOL THERAPEUT, V91, P35, DOI 10.1016/S0163-7258(01)00144-9; Finkelstein JD, 1998, EUR J PEDIATR, V157, pS40, DOI 10.1007/PL00014300; Frank N, 2008, ARCH BIOCHEM BIOPHYS, V470, P64, DOI 10.1016/j.abb.2007.11.006; FUENMAYORT L, 1976, NEUROSCIENCE, V1, P197; GREEN RGF, 1995, BR J ANAESTHESIOL, V74, P591; Hamelet J, 2007, EXP MOL PATHOL, V83, P249, DOI 10.1016/j.yexmp.2007.04.005; Haouzi P, 2008, RESP PHYSIOL NEUROBI, V160, P109, DOI 10.1016/j.resp.2007.09.001; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Janosik M, 2001, BIOCHEMISTRY-US, V40, P10625, DOI 10.1021/bi010711p; Kawabata A, 2007, PAIN, V132, P74, DOI 10.1016/j.pain.2007.01.026; LaBella FS, 2000, SEMIN CANCER BIOL, V10, P47, DOI 10.1006/scbi.2000.0307; Lin KH, 2002, NUCL MED BIOL, V29, P643, DOI 10.1016/S0969-8051(02)00323-2; Liu YL, 2006, AM J RESP CELL MOL, V34, P182, DOI 10.1165/rcmb.2005-0163OC; MUDD SH, 1985, AM J HUM GENET, V37, P1; Mustafa AK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000464; Osipov RM, 2009, J CARDIOVASC PHARM, V54, P287, DOI 10.1097/FJC.0b013e3181b2b72b; Ovechkin AV, 2006, AM J PHYSIOL-LUNG C, V291, pL905, DOI 10.1152/ajplung.00543.2005; Pena-Silva RA, 2009, AM J PHYSIOL-HEART C, V297, pH1354, DOI 10.1152/ajpheart.00570.2009; Peng YJ, 2010, P NATL ACAD SCI USA, V107, P10719, DOI 10.1073/pnas.1005866107; Qu K, 2008, NEUROCHEM INT, V52, P155, DOI 10.1016/j.neuint.2007.05.016; Racagni G, 2010, INT CLIN PSYCHOPHARM, V25, P117, DOI 10.1097/YIC.0b013e3283311acd; Rauen U, 2002, BIOL CHEM, V383, P477, DOI 10.1515/BC.2002.050; Robert K, 2003, J HISTOCHEM CYTOCHEM, V51, P363, DOI 10.1177/002215540305100311; Santini E, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000308; Schnuelle P, 2009, JAMA-J AM MED ASSOC, V302, P1067, DOI 10.1001/jama.2009.1310; SCHUFFWERNER P, 1995, EUR J CLIN INVEST, V25, P477, DOI 10.1111/j.1365-2362.1995.tb01733.x; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Sola A, 2003, TRANSPLANTATION, V75, P744, DOI 10.1097/01.TP.0000054683.72223.2D; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Tang GH, 2005, MOL PHARMACOL, V68, P1757, DOI 10.1124/mol.105.017467; Taoka S, 1998, J BIOL CHEM, V273, P25179, DOI 10.1074/jbc.273.39.25179; Wang XM, 2006, PHYSIOLOGY, V21, P362, DOI 10.1152/physiol.00024.2006; WARENYCIA MW, 1989, ARCH TOXICOL, V63, P131, DOI 10.1007/BF00316435; WATANABE M, 1995, P NATL ACAD SCI USA, V92, P1585, DOI 10.1073/pnas.92.5.1585; Wolf RFE, 1996, TRANSPLANTATION, V61, P66, DOI 10.1097/00007890-199601150-00014; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Yard B, 2004, AM J TRANSPLANT, V4, P22, DOI 10.1046/j.1600-6143.2003.00268.x; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	51	42	44	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2011	6	7							e22568	10.1371/journal.pone.0022568	http://dx.doi.org/10.1371/journal.pone.0022568			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799JJ	21829469	Green Submitted, gold, Green Published			2023-01-03	WOS:000293282700040
J	Montaner, JSG				Montaner, Julio S. G.			Treatment as prevention-a double hat-trick	LANCET			English	Editorial Material							ACTIVE ANTIRETROVIRAL THERAPY; HIV TRANSMISSION; ACCESS; EPIDEMIC; STRATEGY; GROWTH; CURB		[Montaner, Julio S. G.] Univ British Columbia, Fac Med, Div Aids, Vancouver, BC, Canada; [Montaner, Julio S. G.] St Pauls Hosp, BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; [Montaner, Julio S. G.] Providence Healthcare, Vancouver, BC, Canada	University of British Columbia; B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of Saskatchewan	Montaner, JSG (corresponding author), Univ British Columbia, Fac Med, Div Aids, Vancouver, BC, Canada.	jmontaner@cfenet.ubc.ca	Montaner, Julio/K-7621-2012		CIHR Funding Source: Medline; NIDA NIH HHS [1DP1DA026182-01, DP1 DA026182] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [DP1DA026182] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		[Anonymous], 2011, LANCET, V377, P1719, DOI 10.1016/S0140-6736(11)60713-7; Das M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011068; Dieffenbach CW, 2009, JAMA-J AM MED ASSOC, V301, P2380, DOI 10.1001/jama.2009.828; Donnell D, 2010, LANCET, V375, P2092, DOI 10.1016/S0140-6736(10)60705-2; Fang CT, 2004, J INFECT DIS, V190, P879, DOI 10.1086/422601; Granich RM, 2009, LANCET, V373, P48, DOI 10.1016/S0140-6736(08)61697-9; Kirk G, 2011, 18 C RETR OPP INF BO, P484; Lima VD, 2008, J INFECT DIS, V198, P59, DOI 10.1086/588673; Montaner JSG, 2006, LANCET, V368, P531, DOI 10.1016/S0140-6736(06)69162-9; Montaner JSG, 2010, LANCET, V376, P532, DOI 10.1016/S0140-6736(10)60936-1; *NAT I ALL INF DIS, 2011, TREAT HIV INF PEOPL; *NAT I ALL INF DIS, 2011, HPTN 052 STUD PREV S; Sturt AS, 2010, COCHRANE DB SYST REV, V3; Volkow ND, 2010, JAMA-J AM MED ASSOC, V303, P1423, DOI 10.1001/jama.2010.421; Wagner BG, 2010, AIDS, V24, P775, DOI 10.1097/QAD.0b013e3283366782; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649; 2011, INT TREATM PREV WORK	17	94	99	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 16	2011	378	9787					208	209		10.1016/S0140-6736(11)60821-0	http://dx.doi.org/10.1016/S0140-6736(11)60821-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	798JD	21763923				2023-01-03	WOS:000293201100008
J	Rao, MS				Rao, Mahendra S.			Funding Translational Work in Cell-Based Therapy	CELL STEM CELL			English	Editorial Material							STEM; PRODUCTS; MEDICINE	The cell therapy branch of the regenerative medicine field has been innovative in developing new models of delivery and development and identifying alternative sources of funding. We discuss the implications of these changes for pharmaceutical companies and the opportunities they offer to a new entrepreneur.	Life Technol, Frederick, MD 21704 USA	Thermo Fisher Scientific	Rao, MS (corresponding author), Life Technol, 7335 Execut Way, Frederick, MD 21704 USA.	mahendra.rao@lifetech.com			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041192] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Bergman K, 2007, NAT BIOTECHNOL, V25, P419, DOI 10.1038/nbt0407-419; Brown N, 2006, TECHNOL ANAL STRATEG, V18, P313, DOI 10.1080/09537320600777044; Caplan AI, 2011, CELL STEM CELL, V9, P11, DOI 10.1016/j.stem.2011.06.008; Enserink M, 2006, SCIENCE, V313, P160, DOI 10.1126/science.313.5784.160; Fink DW, 2009, SCIENCE, V324, P1662, DOI 10.1126/science.1173712; Freeman SN, 2010, CELL STEM CELL, V7, P283, DOI 10.1016/j.stem.2010.08.003; Harvey O, 2009, POLITICS POLICY, V37, P51, DOI 10.1111/j.1747-1346.2008.00161.x; Lau D, 2008, CELL STEM CELL, V3, P591, DOI 10.1016/j.stem.2008.11.001; Lysaght MJ, 2008, TISSUE ENG PT A, V14, P305, DOI 10.1089/tea.2007.0267; McKernan R, 2010, CELL STEM CELL, V6, P517, DOI 10.1016/j.stem.2010.05.012; Salter B, 2006, REGEN MED, V1, P671, DOI 10.2217/17460751.1.5.671; Salter B, 2007, REGEN MED, V2, P75, DOI 10.2217/17460751.2.1.75	12	22	22	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1934-5909			CELL STEM CELL	Cell Stem Cell	JUL 8	2011	9	1					7	10		10.1016/j.stem.2011.06.009	http://dx.doi.org/10.1016/j.stem.2011.06.009			4	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	797VA	21726828	Bronze			2023-01-03	WOS:000293157000004
J	Meijvis, SCA; Hardeman, H; Remmelts, HHF; Heijligenberg, R; Rijkers, GT; van Velzen-Blad, H; Voorn, GP; van de Garde, EMW; Endeman, H; Grutters, JC; Bos, WJW; Biesma, DH				Meijvis, Sabine C. A.; Hardeman, Hans; Remmelts, Hilde H. F.; Heijligenberg, Rik; Rijkers, Ger T.; van Velzen-Blad, Heleen; Voorn, G. Paul; van de Garde, Ewoudt M. W.; Endeman, Henrik; Grutters, Jan C.; Bos, Willem Jan W.; Biesma, Douwe H.			Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; GLUCOCORTICOIDS; INTERLEUKIN-10; HYDROCORTISONE; CORTICOSTEROIDS; GUIDELINES; INCREASES; SEVERITY; EFFICACY; RISK	Background Whether addition of corticosteroids to antibiotic treatment benefits patients with community-acquired pneumonia who are not in intensive care units is unclear. We aimed to assess effect of addition of dexamethasone on length of stay in this group, which might result in earlier resolution of pneumonia through dampening of systemic inflammation. Methods In our double-blind, placebo-controlled trial, we randomly assigned adults aged 18 years or older with confirmed community-acquired pneumonia who presented to emergency departments of two teaching hospitals in the Netherlands to receive intravenous dexamethasone (5 mg once a day) or placebo for 4 days from admission. Patients were ineligible if they were immunocompromised, needed immediate transfer to an intensive-care unit, or were already receiving corticosteroids or immunosuppressive drugs. We randomly allocated patients on a one-to-one basis to treatment groups with a computerised randomisation allocation sequence in blocks of 20. The primary outcome was length of hospital stay in all enrolled patients. This study is registered with ClinicalTrials.gov, number NCT00471640. Findings Between November, 2007, and September, 2010, we enrolled 304 patients and randomly allocated 153 to the placebo group and 151 to the dexamethasone group. 143 (47%) of 304 enrolled patients had pneumonia of pneumonia severity index class 4-5 (79 [52%] patients in the dexamethasone group and 64 [42%] controls). Median length of stay was 6.5 days (IQR 5.0-9.0) in the dexamethasone group compared with 7.5 days (5.3-11.5) in the placebo group (95% CI of difference in medians 0-2 days; p=0.0480). In-hospital mortality and severe adverse events were infrequent and rates did not differ between groups, although 67 (44%) of 151 patients in the dexamethasone group had hyperglycaemia compared with 35 (23%) of 153 controls (p<0.0001). Interpretation Dexamethasone can reduce length of hospital stay when added to antibiotic treatment in non-immunocompromised patients with community-acquired pneumonia.	[Meijvis, Sabine C. A.; Bos, Willem Jan W.; Biesma, Douwe H.] St Antonius Hosp, Dept Internal Med, NL-3430 EM Nieuwegein, Netherlands; [Hardeman, Hans; Grutters, Jan C.] St Antonius Hosp, Dept Pulmonol, NL-3430 EM Nieuwegein, Netherlands; [Rijkers, Ger T.; van Velzen-Blad, Heleen; Voorn, G. Paul] St Antonius Hosp, Dept Med Microbiol & Immunol, NL-3430 EM Nieuwegein, Netherlands; [van de Garde, Ewoudt M. W.] St Antonius Hosp, Dept Clin Pharm, NL-3430 EM Nieuwegein, Netherlands; [Remmelts, Hilde H. F.; Heijligenberg, Rik] Gelderse Vallei Hosp, Dept Internal Med, Ede, Netherlands; [van de Garde, Ewoudt M. W.] Univ Utrecht, Fac Sci, Div Pharmacoepidemiol & Clin Pharmacol, Utrecht, Netherlands; [Endeman, Henrik] Onze Lieve Vrouw Hosp, Dept Intens Care Med, Amsterdam, Netherlands; [Grutters, Jan C.] Univ Med Ctr Utrecht, Div Heart & Lungs, Utrecht, Netherlands; [Remmelts, Hilde H. F.; Biesma, Douwe H.] Univ Med Ctr Utrecht, Dept Internal Med, Utrecht, Netherlands	St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; St. Antonius Hospital Utrecht; Gelderse Vallei Hospital; Utrecht University; Onze Lieve Vrouwe Gasthuis Hospital; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Meijvis, SCA (corresponding author), St Antonius Hosp, Dept Internal Med, Koekoekslaan 1,POB 2500, NL-3430 EM Nieuwegein, Netherlands.	s.meijvis@antoniusziekenhuis.nl	Rijkers, Ger/AAW-6143-2020; Rijkers, Ger/R-7236-2019; Biesma, Douwe H./AAV-6343-2020	Rijkers, Ger/0000-0001-6948-6123; Biesma, Douwe H./0000-0001-8334-3057; Bos, Willem Jan W/0000-0002-5062-2567				American Diabetes Association, 2011, Diabetes Care, V34 Suppl 1, pS4, DOI 10.2337/dc11-S004; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; CAMPBELL MJ, 1988, BRIT MED J, V296, P1454, DOI 10.1136/bmj.296.6634.1454; Castellanos Mario R, 2010, Int Arch Med, V3, P16, DOI 10.1186/1755-7682-3-16; Christ-Crain M, 2007, AM J RESP CRIT CARE, V176, P913, DOI 10.1164/rccm.200702-307OC; Confalonieri M, 2005, AM J RESP CRIT CARE, V171, P242, DOI 10.1164/rccm.200406-808OC; Dellinger RP, 2004, CRIT CARE MED, V32, P858, DOI 10.1097/01.CCM.0000117317.18092.E4; Yandiola PPE, 2009, CHEST, V135, P1572, DOI 10.1378/chest.08-2179; FINE MJ, 1993, AM J MED, V94, P153, DOI 10.1016/0002-9343(93)90177-Q; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Franchimont D, 1999, J CLIN ENDOCR METAB, V84, P2834, DOI 10.1210/jc.84.8.2834; Fushimi T, 1997, INT ARCH ALLERGY IMM, V112, P13, DOI 10.1159/000237425; Garcia-Vidal C, 2007, EUR RESPIR J, V30, P951, DOI 10.1183/09031936.00027607; Garnacho-Montero J, 2010, SCAND J INFECT DIS, V42, P185, DOI 10.3109/00365540903418522; Gil-Prieto R, 2011, VACCINE, V29, P412, DOI 10.1016/j.vaccine.2010.11.025; Hays RD, 2001, ANN MED, V33, P350, DOI 10.3109/07853890109002089; Hotchkiss RS, 2003, NEW ENGL J MED, V348, P138, DOI 10.1056/NEJMra021333; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; MARIK P, 1993, CHEST, V104, P389, DOI 10.1378/chest.104.2.389; MELBY JC, 1977, ANNU REV PHARMACOL, V17, P511, DOI 10.1146/annurev.pa.17.040177.002455; Mikami K, 2007, LUNG, V185, P249, DOI 10.1007/s00408-007-9020-3; MIKE V, 1982, STAT MED RES METHODS; Monton C, 1999, EUR RESPIR J, V14, P218, DOI 10.1034/j.1399-3003.1999.14a37.x; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Salluh JIF, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2010.03.004; Schouten J A, 2005, Ned Tijdschr Geneeskd, V149, P2495; Snijders D, 2010, AM J RESP CRIT CARE, V181, P975, DOI 10.1164/rccm.200905-0808OC; vanderPoll T, 1996, J CLIN ENDOCR METAB, V81, P3604, DOI 10.1210/jc.81.10.3604; Visser J, 1998, BLOOD, V91, P4255, DOI 10.1182/blood.V91.11.4255.411a03_4255_4264; Voelker R, 2010, JAMA-J AM MED ASSOC, V303, P2345, DOI 10.1001/jama.2010.790	32	213	230	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 11	2011	377	9782					2023	2030		10.1016/S0140-6736(11)60607-7	http://dx.doi.org/10.1016/S0140-6736(11)60607-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	782LR	21636122				2023-01-03	WOS:000292011700037
J	Cho, SJ; Kim, YJ; Surh, YJ; Kim, BM; Lee, SK				Cho, Seung-Ju; Kim, Young-Jong; Surh, Young-Joon; Kim, B. Moon; Lee, Seung-Ki			Ibulocydine Is a Novel Prodrug Cdk Inhibitor That Effectively Induces Apoptosis in Hepatocellular Carcinoma Cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASE INHIBITOR; RNA-POLYMERASE-II; MULTIPLE-MYELOMA CELLS; RETINOBLASTOMA PROTEIN; DOWN-REGULATION; CYCLE; PHOSPHORYLATION; SURVIVAL; MCL-1; DEATH	Hepatocellular carcinoma (HCC) is frequently associated with abnormalities in cell cycle regulation, leading to increased activity of cyclin-dependent kinases (Cdks) due to the loss, or low expression of, Cdk inhibitors. In this study, we showed that ibulocydine (an isobutyrate prodrug of the specific Cdk inhibitor, BMK-Y101) is a candidate anti-cancer drug for HCC. Ibulocydine has high activity against Cdk7/cyclin H/Mat1 and Cdk9/cyclin T. Ibulocydine inhibited the growth of HCC cells more effectively than other Cdk inhibitors, including olomoucine and roscovitine, whereas ibulocydine as well as the other Cdk inhibitors and BMK-Y101 minimally influenced the growth of normal hepatocyte cells. Ibulocydine induced apoptosis in HCC cells, most likely by inhibiting Cdk7 and Cdk9. In vitro treatment of HCC cells with ibulocydine rapidly blocked phosphorylation of the carboxyl-terminal domain (CTD) of the large subunit of RNA polymerase II, a process mediated by Cdk7/9. Anti-apoptotic gene products such as Mcl-1, survivin, and X-linked IAP (XIAP) are crucial for the survival of many cell types, including HCC. Following the inhibition of RNA polymerase II phosphorylation, ibulocydine caused rapid down-regulation of Mcl-1, survivin, and XIAP, thus inducing apoptosis. Furthermore, ibulocydine effectively induced apoptosis in HCC xenografts with no toxic side effects. These results suggest that ibulocydine is a strong candidate anti-cancer drug for the treatment of HCC.	[Cho, Seung-Ju; Surh, Young-Joon; Lee, Seung-Ki] Seoul Natl Univ, Div Pharmaceut Biosci, Coll Pharm, Pharmaceut Sci Res Inst, Seoul 151742, South Korea; [Cho, Seung-Ju; Kim, Young-Jong; Kim, B. Moon] Seoul Natl Univ, Dept Chem, Seoul 151742, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Kim, BM (corresponding author), Seoul Natl Univ, Dept Chem, 599 Gwanakro, Seoul 151747, South Korea.	kimbm@snu.ac.kr; sklcrs@snu.ac.kr			Korea Science and Engineering Foundation [M108KB010025-08K0201-02510]	Korea Science and Engineering Foundation(Korea Science and Engineering Foundation)	This work was supported by Fund for Functional Analysis of the Human Genome Grant M108KB010025-08K0201-02510, managed by The Center for Functional Analysis of Human Genome, from the 21st Century Frontier Research and Development program of the National Research and Development programs of the Korea Science and Engineering Foundation.	Bolondi L, 2001, GUT, V48, P251, DOI 10.1136/gut.48.2.251; Bregman DB, 2000, FRONT BIOSCI, V5, pD244, DOI 10.2741/Bregman; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Chen R, 2009, BLOOD, V113, P4637, DOI 10.1182/blood-2008-12-190256; Cho SJ, 2010, CANCER LETT, V287, P196, DOI 10.1016/j.canlet.2009.06.011; Coultas L, 2003, SEMIN CANCER BIOL, V13, P115, DOI 10.1016/S1044-579X(02)00129-3; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; El-Serag H, 2003, ANN INTERN MED, V139, P817, DOI 10.7326/0003-4819-139-10-200311180-00009; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Gomez-Bougie P, 2004, EUR J IMMUNOL, V34, P3156, DOI 10.1002/eji.200424981; Hahntow IN, 2004, LEUKEMIA, V18, P747, DOI 10.1038/sj.leu.2403295; Hirose Y, 2000, GENE DEV, V14, P1415; HUANG CC, 1992, J NATL CANCER I, V84, P262, DOI 10.1093/jnci/84.4.262; Ito Y, 2000, ONCOLOGY-BASEL, V59, P68, DOI 10.1159/000012140; Kimura K, 1998, SCIENCE, V282, P487, DOI 10.1126/science.282.5388.487; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Lam LT, 2001, GENOME BIOL, V2; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Malumbres M, 2008, TRENDS PHARMACOL SCI, V29, P16, DOI 10.1016/j.tips.2007.10.012; Mendizabal M, 2009, MED CLIN N AM, V93, P885, DOI 10.1016/j.mcna.2009.03.004; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Nurse PM, 2002, BIOSCIENCE REP, V22, P487, DOI 10.1023/A:1022017701871; Oelgeschlager T, 2002, J CELL PHYSIOL, V190, P160, DOI 10.1002/JCP.10058; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peterlin BM, 2006, MOL CELL, V23, P297, DOI 10.1016/j.molcel.2006.06.014; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Senderowicz AM, 2004, CURR OPIN CELL BIOL, V16, P670, DOI 10.1016/j.ceb.2004.09.014; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Silverman R.B, 2004, ORGANIC CHEM DRUG DE, P497; Sinhababu AK, 1996, ADV DRUG DELIVER REV, V19, P241, DOI 10.1016/0169-409X(95)00109-K; Svendsen A, 2000, BBA-PROTEIN STRUCT M, V1543, P223, DOI 10.1016/S0167-4838(00)00239-9; Swanton C, 2004, LANCET ONCOL, V5, P27, DOI 10.1016/S1470-2045(03)01321-4; Wu KM, 2009, PHARMACEUTICALS, V2, P77, DOI 10.3390/ph2030077; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885	39	26	28	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 3	2011	286	22					19662	19671		10.1074/jbc.M110.209551	http://dx.doi.org/10.1074/jbc.M110.209551			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	769OZ	21478145	Green Published, hybrid			2023-01-03	WOS:000291027700049
J	Yang, Q; Kapoula, Z				Yang, Qing; Kapoula, Zoi			Distinct Control of Initiation and Metrics of Memory-Guided Saccades and Vergence by the FEF: A TMS Study	PLOS ONE			English	Article							FRONTAL EYE FIELD; TRANSCRANIAL MAGNETIC STIMULATION; POSTERIOR PARIETAL CORTEX; CORTICAL CONTROL; AREA; MOVEMENT; NEURONS; CHILDREN; FEEDBACK; LATENCY	Background: The initiation of memory guided saccades is known to be controlled by the frontal eye field (FEF). Recent physiological studies showed the existence of an area close to FEF that controls also vergence initiation and execution. This study is to explore the effect of transcranial magnetic simulation (TMS) over FEF on the control of memory-guided saccade-vergence eye movements. Methodology/Principal Findings: Subjects had to make an eye movement in dark towards a target flashed 1 sec earlier (memory delay); the location of the target relative to fixation point was such as to require either a vergence along the median plane, or a saccade, or a saccade with vergence; trials were interleaved. Single pulse TMS was applied on the left or right FEF; it was delivered at 100 ms after the end of memory delay, i.e. extinction of fixation LED that was the "go" signal. Twelve healthy subjects participated in the study. TMS of left or right FEF prolonged the latency of all types of eye movements; the increase varied from 21 to 56 ms and was particularly strong for the divergence movements. This indicates that FEF is involved in the initiation of all types of memory guided movement in the 3D space. TMS of the FEF also altered the accuracy but only for leftward saccades combined with either convergence or divergence; intrasaccadic vergence also increased after TMS of the FEF. Conclusions/Significance: The results suggest anisotropy in the quality of space memory and are discussed in the context of other known perceptual motor anisotropies.	[Yang, Qing; Kapoula, Zoi] Hop Europeen Georges Pompidou, CNRS, UMR 8194, IRIS Grp, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Yang, Q (corresponding author), Hop Europeen Georges Pompidou, CNRS, UMR 8194, IRIS Grp, Paris, France.	qing.yang@egp.aphp.fr						Baddeley A, 2010, CURR BIOL, V20, pR136, DOI 10.1016/j.cub.2009.12.014; Busettini C, 2005, J NEUROPHYSIOL, V94, P2312, DOI 10.1152/jn.01337.2004; Dias EC, 1999, J NEUROPHYSIOL, V81, P2191, DOI 10.1152/jn.1999.81.5.2191; ERKELENS CJ, 1989, PROC R SOC SER B-BIO, V236, P417, DOI 10.1098/rspb.1989.0030; Evdokimidis I, 2001, COGNITIVE BRAIN RES, V12, P89, DOI 10.1016/S0926-6410(01)00037-4; Ferraina S, 2000, J NEUROPHYSIOL, V83, P625, DOI 10.1152/jn.2000.83.1.625; Gamlin PD, 2000, NATURE, V407, P1003, DOI 10.1038/35039506; Gaymard B, 1999, EXP BRAIN RES, V129, P288, DOI 10.1007/s002210050899; GAYMARD B, 1990, ANN NEUROL, V28, P622, DOI 10.1002/ana.410280504; GNADT JW, 1995, J NEUROPHYSIOL, V73, P280, DOI 10.1152/jn.1995.73.1.280; Hausmann M, 2002, NEUROPSYCHOLOGIA, V40, P808, DOI 10.1016/S0028-3932(01)00179-8; JAMPEL RS, 1960, J COMP NEUROL, V115, P371, DOI 10.1002/cne.901150306; Kapoula Z, 2005, ANN NY ACAD SCI, V1039, P184, DOI 10.1196/annals.1325.018; Kapoula Z., 2008, J EYE MOVEMENT RES, V2, P1; Koch G, 2005, NEUROIMAGE, V24, P34, DOI 10.1016/j.neuroimage.2004.09.042; KROMMENHOEK KP, 1994, EXP BRAIN RES, V102, P95, DOI 10.1007/BF00232442; Kumar AN, 2005, ANN NY ACAD SCI, V1039, P466, DOI 10.1196/annals.1325.046; Kurkin S, 2003, ANN NY ACAD SCI, V1004, P262, DOI 10.1196/annals.1303.023; Leigh R. J., 2006, NEUROLOGY EYE MOVEME; Mays LE, 1995, CURR OPIN NEUROBIOL, V5, P763, DOI 10.1016/0959-4388(95)80104-9; MURI RM, 1991, EXP BRAIN RES, V86, P219; Naghavi HR, 2005, CONSCIOUS COGN, V14, P390, DOI 10.1016/j.concog.2004.10.003; Narayanan NS, 2005, NEUROPSYCHOLOGY, V19, P223, DOI 10.1037/0894-4105.19.2.223; Nyffeler T, 2004, EUR J NEUROSCI, V20, P2240, DOI 10.1111/j.1460-9568.2004.03667.x; OHTSUKA K, 1989, OPHTHALMOLOGICA, V198, P53, DOI 10.1159/000309959; OHTSUKA K, 1988, OPHTHALMOLOGICA, V197, P85, DOI 10.1159/000309925; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1993, EXP BRAIN RES, V95, P166; PIERROTDESEILLIGNY C, 1995, ANN NEUROL, V37, P557, DOI 10.1002/ana.410370504; RIVAUD S, 1994, EXP BRAIN RES, V102, P110; Ro T, 2002, J CLIN EXP NEUROPSYC, V24, P930, DOI 10.1076/jcen.24.7.930.8385; Ro T, 1999, NEUROPSYCHOLOGIA, V37, P225; SEGRAVES MA, 1987, J NEUROPHYSIOL, V58, P1387, DOI 10.1152/jn.1987.58.6.1387; TAKAGI M, 1995, VISION RES, V35, P3373, DOI 10.1016/0042-6989(95)00073-N; Umeno MM, 2001, J NEUROPHYSIOL, V86, P2344, DOI 10.1152/jn.2001.86.5.2344; Vernet M, 2008, INVEST OPHTH VIS SCI, V49, P230, DOI 10.1167/iovs.07-0854; Weiss PH, 2000, BRAIN, V123, P2531, DOI 10.1093/brain/123.12.2531; Yang Q, 2003, J VISION, V3, P554, DOI 10.1167/3.8.3; Yang Q, 2004, INVEST OPHTH VIS SCI, V45, P2231, DOI 10.1167/iovs.03-1291; Yang Q, 2002, INVEST OPHTH VIS SCI, V43, P2939; ZEE DS, 1992, J NEUROPHYSIOL, V68, P1624, DOI 10.1152/jn.1992.68.5.1624	41	11	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 26	2011	6	5							e20322	10.1371/journal.pone.0020322	http://dx.doi.org/10.1371/journal.pone.0020322			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	769XS	21637804	Green Published, gold, Green Submitted			2023-01-03	WOS:000291052200051
J	Sculier, JP; Meert, AP; Berghmans, T				Sculier, Jean-Paul; Meert, Anne-Pascal; Berghmans, Thieny			Salvage with erlotinib plus bevacizumab: not in NSCLC	LANCET			English	Editorial Material							CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; CHEMOTHERAPY; DOCETAXEL; BLOCKADE; THERAPY; TRIAL		[Sculier, Jean-Paul] Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Intens Care Serv, B-1000 Brussels, Belgium	Institut Jules Bordet; Universite Libre de Bruxelles	Sculier, JP (corresponding author), Univ Libre Bruxelles, Ctr Tumeurs, Inst Jules Bordet, Intens Care Serv, B-1000 Brussels, Belgium.	sculier@bordet.be						Hanna N, 2004, J CLIN ONCOL, V22, P1589, DOI 10.1200/JCO.2004.08.163; Herbst RS, 2011, LANCET, V377, P1846, DOI 10.1016/S0140-6736(11)60545-X; Naumov GN, 2009, CLIN CANCER RES, V15, P3484, DOI 10.1158/1078-0432.CCR-08-2904; Sculier JP, 2009, EUR RESPIR J, V33, P915, DOI 10.1183/09031936.00132008; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Wu WJ, 2007, MOL CANCER THER, V6, P471, DOI 10.1158/1535-7163.MCT-06-0416	7	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAY-JUN	2011	377	9780					1810	1812		10.1016/S0140-6736(11)60740-X	http://dx.doi.org/10.1016/S0140-6736(11)60740-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	774UI	21621709				2023-01-03	WOS:000291411700005
J	Roychoudhury, J; Sinha, R; Ali, N				Roychoudhury, Jayeeta; Sinha, Roma; Ali, Nahid			Therapy with Sodium Stibogluconate in Stearylamine-Bearing Liposomes Confers Cure against SSG-Resistant Leishmania donovani in BALB/c Mice	PLOS ONE			English	Article							EXPERIMENTAL VISCERAL LEISHMANIASIS; AZAR DERMAL LEISHMANIASIS; IN-VITRO SUSCEPTIBILITY; NITRIC-OXIDE SYNTHASE; AMPHOTERICIN-B; ANTIMONY GLUCONATE; CATIONIC LIPOSOMES; KALA-AZAR; INTRACELLULAR INFECTION; IMMUNE-RESPONSES	Background: Resistance of Leishmania donovani to pentavalent antimonials, the first-line treatment of visceral leishmaniasis (VL), has become a critical issue worldwide. Second-line and new drugs are also not devoid of limitations. Suitable drug-delivery systems can improve the mode of administration and action of the existing antimonials, thus increasing their clinical life. Methodology/Principal Findings: We investigated the efficacy of sodium stibogluconate (SSG) in phosphatidylcholine (PC)-stearylamine-bearing liposomes (PC-SA-SSG), PC-cholesterol liposomes (PC-Chol-SSG) and free amphotericin B (AmB) against SSG-resistant L. donovani strains in 8-wk infected BALB/c mice. Animals were sacrificed and parasites in liver, spleen and bone marrow were estimated 4-wk post-treatment by microscopic examination of stamp smears and limiting dilution assay. A set of PC-SA-SSG and AmB treated mice were further studied for protection against reinfection. Serum antibodies and cytokine profiles of ex-vivo cultured splenocytes were determined by ELISA. Uptake of free and liposomal SSG in intracellular amastigotes was determined by atomic absorption spectroscopy. Rhodamine 123 and 5-carboxyfluorescein, known substrates of Pgp and MRP transporter proteins, respectively, were used in free and liposomal forms for efflux studies to estimate intracellular drug retention. Unlike free and PC-Chol-SSG, PC-SA-SSG was effective in curing mice infected with two differentially originated SSG-unresponsive parasite strains at significantly higher levels than AmB. Successful therapy correlated with complete suppression of disease-promoting IL-10 and TGF-beta, upregulation of Th1 cytokines and expression of macrophage microbicidal NO. Cure due to elevated accumulation of SSG in intracellular parasites, irrespective of SSG-resistance, occurs as a result of increased drug retention and improved therapy when administered as PC-SA-SSG versus free SSG. Conclusions/Significance: The design of this single-dose combination therapy with PC-SA-SSG for VL, having reduced toxicity and long-term efficacy, irrespective of SSG-sensitivity may prove promising, not only to overcome SSG-resistance in Leishmania, but also for drugs with similar resistance-related problems in other diseases.	[Roychoudhury, Jayeeta; Sinha, Roma; Ali, Nahid] Indian Inst Chem Biol, Infect Dis & Immunol Div, Kolkata, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Roychoudhury, J (corresponding author), Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.	nali@iicb.res.in	bhattacharyya, Anirban/F-6067-2015; Sinha, Roma/B-3808-2010		Indian Council of Medical Research; University Grants Commission, Government of India	Indian Council of Medical Research(Indian Council of Medical Research (ICMR)); University Grants Commission, Government of India(University Grants Commission, India)	This study was supported by grants from the Indian Council of Medical Research, and University Grants Commission, Government of India. JR was a Senior Research Fellow of Council for Scientific and Industrial Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afrin F, 2002, INFECT IMMUN, V70, P6697, DOI 10.1128/IAI.70.12.6697-6706.2002; Afrin F, 2001, J PARASITOL, V87, P188, DOI 10.1645/0022-3395(2001)087[0188:LAOSBL]2.0.CO;2; Alexander J, 2000, EUR J IMMUNOL, V30, P2935, DOI 10.1002/1521-4141(200010)30:10&lt;2935::AID-IMMU2935&gt;3.0.CO;2-Q; ALVING CR, 1978, P NATL ACAD SCI USA, V75, P2959, DOI 10.1073/pnas.75.6.2959; ALVING CR, 1978, LIFE SCI, V22, P1021, DOI 10.1016/0024-3205(78)90270-9; Anderson CF, 2008, J IMMUNOL, V180, P4090, DOI 10.4049/jimmunol.180.6.4090; Ashutosh, 2007, J MED MICROBIOL, V56, P143, DOI 10.1099/jmm.0.46841-0; BAILLIE AJ, 1986, J PHARM PHARMACOL, V38, P502, DOI 10.1111/j.2042-7158.1986.tb04623.x; BANERJEE A, 2011, ANTIMICROB IN PRESS, DOI DOI 10.1128/AAC.00524-10); Banerjee A, 2008, J IMMUNOL, V181, P1386, DOI 10.4049/jimmunol.181.2.1386; Banerjee A, 2008, J ANTIMICROB CHEMOTH, V61, P103, DOI 10.1093/jac/dkm396; BARRALNETTO M, 1992, SCIENCE, V257, P545, DOI 10.1126/science.1636092; Basu JM, 2006, ANTIMICROB AGENTS CH, V50, P1788, DOI [10.1128/AAC.50.5.1788-1797.2006, 10.1128/AAC.50.5.1768-1797.2006]; Basu R, 2005, J IMMUNOL, V174, P7160, DOI 10.4049/jimmunol.174.11.7160; Bhattacharyya A, 2002, J BIOSCIENCES, V27, P503, DOI 10.1007/BF02705047; BLACK CDV, 1977, T ROY SOC TROP MED H, V71, P550, DOI 10.1016/0035-9203(77)90155-9; CARTER KC, 1989, J PHARM PHARMACOL, V41, P87, DOI 10.1111/j.2042-7158.1989.tb06399.x; Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003; Carter KC, 2001, ANTIMICROB AGENTS CH, V45, P3555, DOI 10.1128/AAC.45.12.3555-3559.2001; Chandra D, 2008, CLIN EXP IMMUNOL, V154, P224, DOI 10.1111/j.1365-2249.2008.03741.x; CHUNGE CN, 1990, T ROY SOC TROP MED H, V84, P221, DOI 10.1016/0035-9203(90)90263-E; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Croft SL, 2003, TRENDS PARASITOL, V19, P502, DOI 10.1016/j.pt.2003.09.008; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Dey T, 2000, ANTIMICROB AGENTS CH, V44, P1739, DOI 10.1128/AAC.44.6.1739-1742.2000; DING AH, 1988, J IMMUNOL, V141, P2407; Feng GJ, 1999, J IMMUNOL, V163, P6403; Frezard F, 2009, MOLECULES, V14, P2317, DOI 10.3390/molecules14072317; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; Haldar AK, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000907; HALDAR JP, 1983, INFECT IMMUN, V42, P702, DOI 10.1128/IAI.42.2.702-707.1983; HUNTER CA, 1988, J PHARM PHARMACOL, V40, P161, DOI 10.1111/j.2042-7158.1988.tb05210.x; Iwaoka S, 2006, J LEUKOCYTE BIOL, V79, P184, DOI 10.1189/jlb.0405181; Kang DI, 2009, DRUG DELIV, V16, P261, DOI 10.1080/10717540902937562; Kok JW, 2000, INT J CANCER, V87, P172, DOI 10.1002/1097-0215(20000715)87:2<172::AID-IJC3>3.0.CO;2-K; Kumar D, 2009, ANTIMICROB AGENTS CH, V53, P835, DOI 10.1128/AAC.01233-08; Lukes J, 2007, P NATL ACAD SCI USA, V104, P9375, DOI 10.1073/pnas.0703678104; Maltezou HC, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/617521; Mamot C, 2003, DRUG RESIST UPDATE, V6, P271, DOI 10.1016/S1368-7646(03)00082-7; Mandal G, 2009, INDIAN J BIOCHEM BIO, V46, P86; Mastroianni A, 2004, Infez Med, V12, P197; Mathur RK, 2004, NAT MED, V10, P540, DOI 10.1038/nm1045; Melaku Y, 2007, AM J TROP MED HYG, V77, P89, DOI 10.4269/ajtmh.2007.77.89; Mora M, 2002, PHARMACEUT RES, V19, P1430, DOI 10.1023/A:1020440229102; Mukherjee SB, 2002, J BIOL CHEM, V277, P24717, DOI 10.1074/jbc.M201961200; Murphy ML, 2001, EUR J IMMUNOL, V31, P2848, DOI 10.1002/1521-4141(2001010)31:10&lt;2848::AID-IMMU2848&gt;3.0.CO;2-T; MURRAY HW, 1989, J CLIN INVEST, V83, P1253, DOI 10.1172/JCI114009; Murray HW, 2005, J IMMUNOL, V174, P4916, DOI 10.4049/jimmunol.174.8.4916; Nakanishi T, 1997, BIOCHEM BIOPH RES CO, V240, P793, DOI 10.1006/bbrc.1997.7749; NEW RRC, 1978, NATURE, V272, P55, DOI 10.1038/272055a0; Olliaro PL, 2010, CURR OPIN INFECT DIS, V23, P595, DOI 10.1097/QCO.0b013e32833fca9d; Olliaro PL, 2005, LANCET INFECT DIS, V5, P763, DOI 10.1016/S1473-3099(05)70296-6; Owais M., 2005, Current Drug Delivery, V2, P311, DOI 10.2174/156720105774370177; Padigel UM, 2003, J IMMUNOL, V171, P3705, DOI 10.4049/jimmunol.171.7.3705; Pal S, 2004, ANTIMICROB AGENTS CH, V48, P3591, DOI 10.1128/AAC.48.9.3591-3593.2004; Ranatunga D, 2009, P NATL ACAD SCI USA, V106, P17123, DOI 10.1073/pnas.0904955106; ROBERTS WL, 1993, ANAL BIOCHEM, V211, P1, DOI 10.1006/abio.1993.1223; Saha S, 2007, J IMMUNOL, V179, P5592, DOI 10.4049/jimmunol.179.8.5592; Stauber AL, 1956, RICE I PAM, V45, P80; Sundar S, 2008, CLIN INFECT DIS, V47, P1000, DOI 10.1086/591972; Sundar S, 2006, INDIAN J MED RES, V123, P345; Teng S, 2003, DRUG METAB DISPOS, V31, P1296, DOI 10.1124/dmd.31.11.1296; Valiathan R, 2006, EXP PARASITOL, V114, P103, DOI 10.1016/j.exppara.2006.02.015; WEBB MS, 1995, BBA-BIOMEMBRANES, V1238, P147, DOI 10.1016/0005-2736(95)00121-I	65	34	35	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 10	2011	6	3							e17376	10.1371/journal.pone.0017376	http://dx.doi.org/10.1371/journal.pone.0017376			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	732VZ	21423750	Green Submitted, Green Published, gold			2023-01-03	WOS:000288219100007
J	Xu, XL; Xie, CZ; Edwards, H; Zhou, H; Buck, SA; Ge, YB				Xu, Xuelian; Xie, Chengzhi; Edwards, Holly; Zhou, Hui; Buck, Steven A.; Ge, Yubin			Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells	PLOS ONE			English	Article							REFRACTORY SOLID TUMORS; SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE MEGAKARYOCYTIC LEUKEMIA; PHASE-I; HEMATOLOGIC MALIGNANCIES; VALPROIC ACID; DOWN-SYNDROME; CHEMOTHERAPY SENSITIVITY; CYTOSINE-ARABINOSIDE; TARGETED THERAPY	Background: Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for treating AML. However, HDAC family members that are involved in chemotherapy sensitivities remain unknown. In this study, we sought to identify members of the HDAC family that are involved in cytarabine sensitivities, and to select the optimal HDACI that is most efficacious when combined with cytarabine for treating children with AML. Methodology: Expression profiles of classes I, II, and IV HDACs in 4 pediatric AML cell lines were determined by Western blotting. Inhibition of class I HDACs by different HDACIs was measured post immnunoprecipitation. Individual down-regulation of HDACs in pediatric AML cells was performed with lentiviral shRNA. The effects of cytarabine and HDACIs on apoptosis were determined by flow cytometry analysis. Results: Treatments with structurally diverse HDACIs and HDAC shRNA knockdown experiments revealed that down-regulation of both HDACs 1 and 6 is critical in enhancing cytarabine-induced apoptosis in pediatric AML, at least partly mediated by Bim. However, down-regulation of HDAC2 may negatively impact cytarabine sensitivities in the disease. At clinically achievable concentrations, HDACIs that simultaneously inhibited both HDACs 1 and 6 showed the best anti-leukemic activities and significantly enhanced cytarabine-induced apoptosis. Conclusion: Our results further confirm that HDACs are bona fide therapeutic targets for treating pediatric AML and suggest that pan-HDACIs may be more beneficial than isoform-specific drugs.	[Xu, Xuelian; Xie, Chengzhi; Edwards, Holly; Ge, Yubin] Wayne State Univ, Sch Med, Dev Therapeut Program, Barbara Ann Karmanos Canc Inst, Detroit, MI 48202 USA; [Xu, Xuelian; Xie, Chengzhi; Edwards, Holly; Ge, Yubin] Wayne State Univ, Sch Med, Dept Oncol, Detroit, MI USA; [Xu, Xuelian; Xie, Chengzhi; Zhou, Hui; Ge, Yubin] Jilin Univ, State Engn Lab AIDS Vaccine, Coll Life Sci, Changchun 130023, Peoples R China; [Buck, Steven A.] Childrens Hosp Michigan, Div Pediat Hematol Oncol, Detroit, MI 48201 USA; [Ge, Yubin] Wayne State Univ, Sch Med, Dept Pediat, Detroit, MI USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University; Jilin University; Children's Hospital of Michigan; Wayne State University	Xu, XL (corresponding author), Wayne State Univ, Sch Med, Dev Therapeut Program, Barbara Ann Karmanos Canc Inst, Detroit, MI 48202 USA.	gey@karmanos.org	xie, chengzhi/F-9615-2012; qiao, zhixin/I-3408-2012	Ge, Yubin/0000-0002-8748-716X; Zhou, Hui/0000-0001-5858-5636	Karmanos Cancer Institute; Children's Research Center of Michigan, Leukemia Research Life; Herrick Foundation; Children's Leukemia Foundation of Michigan	Karmanos Cancer Institute; Children's Research Center of Michigan, Leukemia Research Life; Herrick Foundation; Children's Leukemia Foundation of Michigan	Funding: This work was supported by the Karmanos Cancer Institute Start-up Fund, the Children's Research Center of Michigan, Leukemia Research Life, the Herrick Foundation, and the Children's Leukemia Foundation of Michigan.	Balasubramanian S, 2009, CANCER LETT, V280, P211, DOI 10.1016/j.canlet.2009.02.013; Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200; Bhalla KN, 2005, J CLIN ONCOL, V23, P3971, DOI 10.1200/JCO.2005.16.600; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037; Chen S, 2009, MOL CELL BIOL, V29, P6149, DOI 10.1128/MCB.01481-08; DAMON LE, 1991, CANCER RES, V51, P4141; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; DEANGELIS LM, 1992, CANCER CHEMOTH PHARM, V29, P173, DOI 10.1007/BF00686248; Edwards H, 2009, BLOOD, V114, P2744, DOI 10.1182/blood-2008-09-179812; Fujiwara Y, 2009, CANCER SCI, V100, P1728, DOI 10.1111/j.1349-7006.2009.01237.x; Garcia-Manero G, 2008, BLOOD, V112, P981, DOI 10.1182/blood-2007-10-115873; Garcia-Manero G, 2008, BLOOD, V111, P1060, DOI 10.1182/blood-2007-06-098061; Gaymes TJ, 2006, MOL CANCER RES, V4, P563, DOI 10.1158/1541-7786.MCR-06-0111; Ge YB, 2006, BLOOD, V107, P1570, DOI 10.1182/blood-2005-06-2219; Ge YB, 2005, JNCI-J NATL CANCER I, V97, P226, DOI 10.1093/jnci/dji026; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Glaser KB, 2003, BIOCHEM BIOPH RES CO, V310, P529, DOI 10.1016/j.bbrc.2003.09.043; Gojo I, 2007, BLOOD, V109, P2781, DOI 10.1182/blood-2006-05-021873; Gore L, 2008, CLIN CANCER RES, V14, P4517, DOI 10.1158/1078-0432.CCR-07-1461; Gregoretti IV, 2004, J MOL BIOL, V338, P17, DOI 10.1016/j.jmb.2004.02.006; Guardiola AR, 2002, J BIOL CHEM, V277, P3350, DOI 10.1074/jbc.M109861200; Huang BH, 2005, CELL DEATH DIFFER, V12, P395, DOI 10.1038/sj.cdd.4401567; Insinga A, 2005, NAT MED, V11, P71, DOI 10.1038/nm1160; Karagiannis TC, 2007, LEUKEMIA, V21, P61, DOI 10.1038/sj.leu.2404464; Kaspers GJL, 2007, HAEMATOLOGICA, V92, P1519, DOI 10.3324/haematol.11203; Kummar S, 2007, CLIN CANCER RES, V13, P5411, DOI 10.1158/1078-0432.CCR-07-0791; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Ledent V, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-24; Letai A, 2005, TRENDS MOL MED, V11, P442, DOI 10.1016/j.molmed.2005.08.007; LILIEMARK JO, 1985, CANCER RES, V45, P2373; Mariadason JM, 2000, CANCER RES, V60, P4561; Melnick A, 2002, CURR OPIN HEMATOL, V9, P322, DOI 10.1097/00062752-200207000-00010; Meshinchi S, 2007, ONCOLOGIST, V12, P341, DOI 10.1634/theoncologist.12-3-341; Ryan QC, 2005, J CLIN ONCOL, V23, P3912, DOI 10.1200/JCO.2005.02.188; Siu LL, 2008, J CLIN ONCOL, V26, P1940, DOI 10.1200/JCO.2007.14.5730; Soriano AO, 2007, BLOOD, V110, P2302, DOI 10.1182/blood-2007-03-078576; Steele NL, 2008, CLIN CANCER RES, V14, P804, DOI 10.1158/1078-0432.CCR-07-1786; Taub JW, 1999, BLOOD, V94, P1393; ten Cate B, 2007, LEUKEMIA, V21, P248, DOI 10.1038/sj.leu.2404477; Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8; Xie CZ, 2009, BLOOD, V114, P823; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102; Zwaan CM, 2004, BRIT J HAEMATOL, V127, P264, DOI 10.1111/j.1365-2141.2004.05167.x	45	4	10	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2011	6	2							e17138	10.1371/journal.pone.0017138	http://dx.doi.org/10.1371/journal.pone.0017138			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	721YC	21359182	Green Published, Green Submitted, gold			2023-01-03	WOS:000287392700054
J	Axon, RN; Williams, MV				Axon, R. Neal; Williams, Mark V.			Hospital Readmission as an Accountability Measure	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							INPATIENT CARE; QUALITY; ASSOCIATION		[Axon, R. Neal] Ralph H Johnson VAMC, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA; [Axon, R. Neal] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC USA; [Williams, Mark V.] Northwestern Univ, Feinberg Sch Med, Div Hosp Med, Chicago, IL 60611 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; Medical University of South Carolina; Northwestern University; Feinberg School of Medicine	Axon, RN (corresponding author), 135 Rutledge Ave,MSC 591, Charleston, SC 29425 USA.	axon@musc.edu		Williams, Mark V/0000-0001-6107-0457				[Anonymous], HOSP CAR OUTC EFF ME; ASHTON CM, 1995, ANN INTERN MED, V122, P415, DOI 10.7326/0003-4819-122-6-199503150-00003; Ashton CM, 1997, MED CARE, V35, P1044, DOI 10.1097/00005650-199710000-00006; Benbassat J, 2000, ARCH INTERN MED, V160, P1074, DOI 10.1001/archinte.160.8.1074; Chassin MR, 2010, NEW ENGL J MED, V363, P683, DOI 10.1056/NEJMsb1002320; Coleman EA, 2006, ARCH INTERN MED, V166, P1822, DOI 10.1001/archinte.166.17.1822; Gorodeski EZ, 2010, NEW ENGL J MED, V363, P297, DOI 10.1056/NEJMc1001882; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Keenan PS, 2008, CIRC-CARDIOVASC QUAL, V1, P29, DOI 10.1161/CIRCOUTCOMES.108.802686; *MED PAYM ADV COMM, 2007, MED PAYM POL	10	298	299	0	27	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	2011	305	5					504	505		10.1001/jama.2011.72	http://dx.doi.org/10.1001/jama.2011.72			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	714LI	21285430				2023-01-03	WOS:000286810700026
J	Bippes, CC; Feldmann, A; Stamova, S; Cartellieri, M; Schwarzer, A; Wehner, R; Schmitz, M; Rieber, EP; Zhao, SM; Schakel, K; Temme, A; Scofield, RH; Kurien, BT; Bartsch, H; Bachmann, M				Bippes, Claudia C.; Feldmann, Anja; Stamova, Slava; Cartellieri, Marc; Schwarzer, Adrian; Wehner, Rebekka; Schmitz, Marc; Rieber, E. Peter; Zhao, Senming; Schaekel, Knut; Temme, Achim; Scofield, R. Hal; Kurien, Biji T.; Bartsch, Holger; Bachmann, Michael			A Novel Modular Antigen Delivery System for Immuno Targeting of Human 6-sulfo LacNAc-Positive Blood Dendritic Cells (SlanDCs)	PLOS ONE			English	Article							CLASS-SWITCH RECOMBINATION; CD8(+) T-CELLS; IN-VIVO; SOMATIC HYPERMUTATION; DEC-205 RECEPTOR; PROTEIN; ACTIVATION; UNRESPONSIVENESS; AUTOIMMUNITY; AUTOANTIBODY	Background: Previously, we identified a major myeloid-derived proinflammatory subpopulation of human blood dendritic cells which we termed slanDCs (e.g. Schakel et al. (2006) Immunity 24, 767-777). The slan epitope is an O-linked sugar modification (6-sulfo LacNAc, slan) of P-selectin glycoprotein ligand-1 (PSGL-1). As slanDCs can induce neoantigen-specific CD4+ T cells and tumor-reactive CD8+ cytotoxic T cells, they appear as promising targets for an in vivo delivery of antigens for vaccination. However, tools for delivery of antigens to slanDCs were not available until now. Moreover, it is unknown whether or not antigens delivered via the slan epitope can be taken up, properly processed and presented by slanDCs to T cells. Methodology/Principal Findings: Single chain fragment variables were prepared from presently available decavalent monoclonal anti-slan IgM antibodies but failed to bind to slanDCs. Therefore, a novel multivalent anti-slanDC scaffold was developed which consists of two components: (i) a single chain bispecific recombinant diabody (scBsDb) that is directed on the one hand to the slan epitope and on the other hand to a novel peptide epitope tag, and (ii) modular (antigen-containing) linker peptides that are flanked at both their termini with at least one peptide epitope tag. Delivery of a Tetanus Toxin-derived antigen to slanDCs via such a scBsDb/antigen scaffold allowed us to recall autologous Tetanus-specific memory T cells. Conclusions/Significance: In summary our data show that (i) the slan epitope can be used for delivery of antigens to this class of human-specific DCs, and (ii) antigens bound to the slan epitope can be taken up by slanDCs, processed and presented to T cells. Consequently, our novel modular scaffold system may be useful for the development of human vaccines.	[Bippes, Claudia C.; Feldmann, Anja; Stamova, Slava; Cartellieri, Marc; Schwarzer, Adrian; Wehner, Rebekka; Schmitz, Marc; Rieber, E. Peter; Zhao, Senming; Schaekel, Knut; Temme, Achim; Bartsch, Holger; Bachmann, Michael] Tech Univ Dresden, Inst Immunol, Med Fac Carl Gustav Carus, Dresden, Germany; [Schmitz, Marc; Bachmann, Michael] Tech Univ Dresden, Ctr Regenerat Therapies Dresden, Dresden, Germany; [Zhao, Senming] Hebei Med Univ, Hosp 3, Shijiazhuang, Hebei, Peoples R China; [Scofield, R. Hal; Kurien, Biji T.] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Technische Universitat Dresden; Hebei Medical University; Oklahoma Medical Research Foundation	Bippes, CC (corresponding author), Tech Univ Dresden, Inst Immunol, Med Fac Carl Gustav Carus, Dresden, Germany.	michael.bachmann@tu-dresden.de	Kurien, Biji T/C-2392-2008; Cartellieri, Marc/AAL-8197-2020; Cartellieri, Marc/M-3281-2013; Bachmann, Michael P/E-8850-2010; Scofield, Robert Hal/AEJ-8314-2022; Feldmann, Anja/AAI-1809-2020; Schwarzer, Adrian/AAA-2571-2022; Feldmann, Anja/D-7843-2014; Bachmann, Michael/AAA-5153-2020	Kurien, Biji T/0000-0002-7877-6859; Cartellieri, Marc/0000-0002-4672-3963; Bachmann, Michael P/0000-0002-8029-5755; Feldmann, Anja/0000-0001-5099-2448; Feldmann, Anja/0000-0001-5099-2448; Bachmann, Michael/0000-0002-8029-5755; Stamova, Slava/0000-0002-2543-1523; Schwarzer, Adrian/0000-0001-5684-2280	Center for Regenerative Therapies Dresden (CRTD), Technical University Dresden, Germany; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR053483] Funding Source: NIH RePORTER	Center for Regenerative Therapies Dresden (CRTD), Technical University Dresden, Germany; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The work was supported by a seed grant given to MB by the Center for Regenerative Therapies Dresden (CRTD), Technical University Dresden, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; BIRKHOLZ K, 2010, BLOOD; Bonifaz L, 2002, J EXP MED, V196, P1627, DOI 10.1084/jem.20021598; Bonifaz LC, 2004, J EXP MED, V199, P815, DOI 10.1084/jem.20032220; Bozzacco L, 2007, P NATL ACAD SCI USA, V104, P1289, DOI 10.1073/pnas.0610383104; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Bruder D, 2005, DIABETES, V54, P3395, DOI 10.2337/diabetes.54.12.3395; CARMOFONSECA M, 1989, EXP CELL RES, V185, P73, DOI 10.1016/0014-4827(89)90038-4; Charalambous A, 2006, J IMMUNOL, V177, P8410, DOI 10.4049/jimmunol.177.12.8410; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Do Y, 2008, EUR J IMMUNOL, V38, P20, DOI 10.1002/eji.200737799; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; GAITHER KK, 1987, J CLIN INVEST, V79, P841, DOI 10.1172/JCI112892; Gurer C, 2008, BLOOD, V112, P1231, DOI 10.1182/blood-2008-03-148072; Hawiger D, 2004, IMMUNITY, V20, P695, DOI 10.1016/j.immuni.2004.05.002; Hawiger D, 2001, J EXP MED, V194, P769, DOI 10.1084/jem.194.6.769; Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Mahnke K, 2000, J CELL BIOL, V151, P673, DOI 10.1083/jcb.151.3.673; Malik S, 2007, LUPUS, V16, P863, DOI 10.1177/0961203307083365; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Mannering SI, 2003, J IMMUNOL METHODS, V283, P173, DOI 10.1016/j.jim.2003.09.004; Maugeri N, 2009, BLOOD, V113, P5254, DOI 10.1182/blood-2008-09-180794; Moll H, 2003, CELL MICROBIOL, V5, P493, DOI 10.1046/j.1462-5822.2003.00291.x; Morgenroth A, 2007, PROSTATE, V67, P1121, DOI 10.1002/pros.20608; Mukhopadhaya A, 2008, P NATL ACAD SCI USA, V105, P6374, DOI 10.1073/pnas.0802644105; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Proudfoot O, 2007, MOL PHARMACEUT, V4, P58, DOI 10.1021/mp0601087; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Schakel K, 2006, IMMUNITY, V24, P767, DOI 10.1016/j.immuni.2006.03.020; Schakel K, 1998, EUR J IMMUNOL, V28, P4084, DOI 10.1002/(SICI)1521-4141(199812)28:12<4084::AID-IMMU4084>3.0.CO;2-4; Schakel K, 1999, PATHOBIOLOGY, V67, P287, DOI 10.1159/000028081; Schakel K, 2002, IMMUNITY, V17, P289, DOI 10.1016/S1074-7613(02)00393-X; Schmitz M, 2005, J IMMUNOL, V174, P4127, DOI 10.4049/jimmunol.174.7.4127; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392, DOI 10.1016/S0952-7915(99)80066-1; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; Steinman RM, 2003, ANNU REV IMMUNOL, V21, P685, DOI 10.1146/annurev.immunol.21.120601.141040; Wang ZD, 2000, J IMMUNOL METHODS, V233, P167, DOI 10.1016/S0022-1759(99)00184-2; Wilson NS, 2005, ADV IMMUNOL, V86, P241, DOI 10.1016/S0065-2776(04)86007-3	39	25	28	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2011	6	1							e16315	10.1371/journal.pone.0016315	http://dx.doi.org/10.1371/journal.pone.0016315			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710OY	21283706	Green Published, gold, Green Submitted			2023-01-03	WOS:000286522300033
J	O'Shaughnessy, J; Osborne, C; Pippen, JE; Yoffe, M; Patt, D; Rocha, C; Koo, IC; Sherman, BM; Bradley, C				O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra; Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles			Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHASE-II TRIAL; GENE-EXPRESSION; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE; SPORADIC BREAST; SUBTYPES; TUMORS; GEMCITABINE/CARBOPLATIN; TRASTUZUMAB; CARCINOMAS	Background: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. Methods: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8 -- with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11 -- every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for greater/equal 6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. Results: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. Conclusions: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.) N Engl J Med 2011;364:205-14.	[O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.] Baylor Charles A Sammons Canc Ctr, Dallas, TX USA; [O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.; Yoffe, Mark; Patt, Debra] US Oncol, Dallas, TX USA; [O'Shaughnessy, Joyce; Osborne, Cynthia; Pippen, John E.] Texas Oncol, Dallas, TX USA; [Yoffe, Mark] Canc Ctr N Carolina, Raleigh, NC USA; [Patt, Debra] Texas Oncol Canc Ctr, Austin, TX USA; [Rocha, Christine; Koo, Ingrid Chou; Sherman, Barry M.; Bradley, Charles] BiPar Sci, San Francisco, CA USA	Baylor University Medical Center; Texas Oncology-Baylor Charles A Sammons Cancer Center; US Oncology Network; Texas Oncology	O'Shaughnessy, J (corresponding author), Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.	joyce.oshaughnessy@usoncology.com			BiPar Sciences; Sanofi-Aventis	BiPar Sciences; Sanofi-Aventis(Sanofi-Aventis)	Supported by BiPar Sciences (now owned by Sanofi-Aventis).; Dr. O'Shaughnessy reports receiving speaking fees and consulting fees from Sanofi-Aventis; Dr. Osborne, receiving travel support from Sanofi-Aventis; Dr. Yoffe, owning stock in Sanofi-Aventis; and Ms. Rocha and Drs. Koo, Sherman, and Bradley, being employees of and owning stock or stock options in BiPar Sciences. No other potential conflict of interest relevant to this article was reported.	Alli E, 2009, CANCER RES, V69, P3589, DOI 10.1158/0008-5472.CAN-08-4016; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Bartkova J, 2008, MOL ONCOL, V2, P296, DOI 10.1016/j.molonc.2008.09.007; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Chew HK, 2009, J CLIN ONCOL, V27, P2163, DOI 10.1200/JCO.2008.17.4839; Dent R, 2009, BREAST CANCER RES TR, V115, P423, DOI 10.1007/s10549-008-0086-2; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; HASTAK K, CANC RES IN PRESS; Heikkinen T, 2009, CLIN CANCER RES, V15, P3214, DOI 10.1158/1078-0432.CCR-08-3128; Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005; Loesch D, 2008, CLIN BREAST CANCER, V8, P178, DOI 10.3816/CBC.2008.n.019; MAHANY JJ, 2008, J CLIN ONCOL S, V26, pS172; Mok I., 2008, J CLIN ONCOL S, V26, p172S; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Osborne CR, 2005, SAN ANT BREAST CANC; OSSOVSKAYA V, 2009, AM ASS CANC RES ANN, P5552; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Rodriguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Swain SM, 2008, AM SOC CLIN ONC ANN; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tommiska J, 2008, ONCOGENE, V27, P2501, DOI 10.1038/sj.onc.1210885; Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Yardley DA, 2008, CLIN BREAST CANCER, V8, P425, DOI 10.3816/CBC.2008.n.051	30	638	664	2	78	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	2011	364	3					205	214		10.1056/NEJMoa1011418	http://dx.doi.org/10.1056/NEJMoa1011418			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	708SF	21208101	Bronze			2023-01-03	WOS:000286383900005
J	Brown, EN; Lydic, R; Schiff, ND				Brown, Emery N.; Lydic, Ralph; Schiff, Nicholas D.			Mechanisms of Disease: General Anesthesia, Sleep, and Coma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LESS-THAN-1 HZ OSCILLATION; ACETYLCHOLINE-RELEASE; EMERGENCE DELIRIUM; PROPOFOL; ELECTROENCEPHALOGRAM; MIDAZOLAM; CONSCIOUSNESS; KETAMINE; EEG; RECOVERY		[Brown, Emery N.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA; [Brown, Emery N.] Harvard Univ, Sch Med, Boston, MA USA; [Brown, Emery N.] MIT, Dept Brain & Cognit Sci, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; [Lydic, Ralph] Univ Michigan, Dept Anesthesiol, Ann Arbor, MI 48109 USA; [Schiff, Nicholas D.] Weill Cornell Med Coll, Dept Neurol & Neurosci, New York, NY USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); University of Michigan System; University of Michigan; Cornell University	Brown, EN (corresponding author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St,GRJ 4, Boston, MA 02114 USA.	enb@neurostat.mit.edu	Lydic, Ralph/O-9396-2014	Lydic, Ralph/0000-0002-2686-251X	Massachusetts General Hospital Department of Anesthesia, Critical Care, and Pain Medicine; National Institutes of Health (NIH) [DP1OD003646, HL40881, HL65272, HD51912]; University of Michigan, Department of Anesthesiology; James S. McDonnell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD051912] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065272, R01HL040881] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH [DP1OD003646] Funding Source: NIH RePORTER	Massachusetts General Hospital Department of Anesthesia, Critical Care, and Pain Medicine; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Michigan, Department of Anesthesiology(University of Michigan System); James S. McDonnell Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	Supported by the Massachusetts General Hospital Department of Anesthesia, Critical Care, and Pain Medicine and by the National Institutes of Health (NIH) Director's Pioneer Award (DP1OD003646, to Dr. Brown); by the University of Michigan, Department of Anesthesiology, and by NIH grants (HL40881 and HL65272, to Dr. Lydic); and by grants from the James S. McDonnell Foundation (to Dr. Schiff) and the NIH (HD51912, to Dr. Schiff).	ALDRETE JA, 1995, J CLIN ANESTH, V7, P89, DOI 10.1016/0952-8180(94)00001-K; Alkire MT, 2008, SCIENCE, V322, P876, DOI 10.1126/science.1149213; Alkire MT, 2007, ANESTHESIOLOGY, V107, P264, DOI 10.1097/01.anes.0000270741.33766.24; ALKIRE MT, 1995, ANESTHESIOLOGY, V82, pA27; ANGEL A, 1991, EXP PHYSIOL, V76, P1; [Anonymous], 1995, Neurology, V45, P1012; [Anonymous], 2006, PONT MED MED LAT RET; Bai DL, 1999, J NEUROSCI, V19, P10635, DOI 10.1523/JNEUROSCI.19-24-10635.1999; Bedford OH, 2008, PROP; Bergey Gregory K, 2006, Epilepsy Curr, V6, P119, DOI 10.1111/j.1535-7511.2006.00117.x; Bevan JC, 1997, ANESTH ANALG, V85, P50, DOI 10.1097/00000539-199707000-00009; Blumenfeld H, 2003, NEUROSCIENTIST, V9, P301, DOI 10.1177/1073858403255624; Brefel-Courbon C, 2007, ANN NEUROL, V62, P102, DOI 10.1002/ana.21110; CESSELIN F, 1999, OPIOIDS PAIN CONTROL, P70; Chase MH, 2008, SLEEP, V31, P1487, DOI 10.1093/sleep/31.11.1487; Chen L, 2004, EXP NEUROL, V186, P212, DOI 10.1016/j.expneurol.2003.11.003; Ching S, 2010, P NATL ACAD IN PRESS; Claassen J, 2002, EPILEPSIA, V43, P146, DOI 10.1046/j.1528-1157.2002.28501.x; CLARK DL, 1973, ANESTHESIOLOGY, V38, P564, DOI 10.1097/00000542-197306000-00011; CORREASALES C, 1992, ANESTHESIOLOGY, V76, P948, DOI 10.1097/00000542-199206000-00013; COTE CJ, 1981, ANESTHESIOLOGY, V55, P703, DOI 10.1097/00000542-198155060-00023; Davis MH, 2007, P NATL ACAD SCI USA, V104, P16032, DOI 10.1073/pnas.0701309104; Devor M, 2001, PAIN, V94, P101, DOI 10.1016/S0304-3959(01)00345-1; Doyle PW, 1999, BRIT J ANAESTH, V83, P580, DOI 10.1093/bja/83.4.580; DURRANI Z, 1991, ANESTH ANALG, V72, P249, DOI 10.1213/00000539-199102000-00020; DUTTON RP, 1994, ANESTHESIOLOGY, V80, P939, DOI 10.1097/00000542-199404000-00028; Evers A., 2006, CLIN ANESTH, P95; Feldman JL, 2006, NAT REV NEUROSCI, V7, P232, DOI 10.1038/nrn1871; Ferrarelli F, 2010, P NATL ACAD SCI USA, V107, P2681, DOI 10.1073/pnas.0913008107; Feshchenko VA, 2004, NEUROPSYCHOBIOLOGY, V50, P257, DOI 10.1159/000079981; Fiset P, 1999, J NEUROSCI, V19, P5506; Franks NP, 2008, NAT REV NEUROSCI, V9, P370, DOI 10.1038/nrn2372; Fulton SA, 2000, AM J GASTROENTEROL, V95, P809; Funk W, 2008, EUR J ANAESTH, V25, P37, DOI 10.1017/S0265021507001159; Gawande A, 2008, NEW ENGL J MED, V358, P448, DOI 10.1056/NEJMp0800378; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gibbs FA, 1937, ARCH INTERN MED, V60, P154, DOI 10.1001/archinte.1937.00180010159012; Gray AT, 1997, ARCH NEUROL-CHICAGO, V54, P579, DOI 10.1001/archneur.1997.00550170055014; HEINRICHER MM, 1999, OPIOIDS PAIN CONTROL, P46; Hemmings HC, 2005, TRENDS PHARMACOL SCI, V26, P503, DOI 10.1016/j.tips.2005.08.006; HILGENBERG JC, 1981, ANESTHESIOLOGY, V54, P341, DOI 10.1097/00000542-198104000-00018; HUG CC, 1990, ANESTHESIOLOGY, V73, P1, DOI 10.1097/00000542-199007000-00001; Huupponen E, 2008, ACTA ANAESTH SCAND, V52, P289, DOI 10.1111/j.1399-6576.2007.01537.x; JORM CM, 1993, BRIT J ANAESTH, V71, pP317; Kelz MB, 2008, P NATL ACAD SCI USA, V105, P1309, DOI 10.1073/pnas.0707146105; Kennedy D, 2005, SCIENCE, V309, P75, DOI 10.1126/science.309.5731.75; KIERSEY D K, 1951, Br J Anaesth, V23, P141, DOI 10.1093/bja/23.3.141; Koenig MA, 2006, NEUROL CLIN, V24, P89, DOI 10.1016/j.ncl.2005.11.003; Kryger M.H., 2010, PRINCIPLES PRACTICE, V5th ed., DOI [10.1016/B0-7216-0797-7/X5001-0, DOI 10.1016/B0-7216-0797-7/X5001-0]; Kungys G, 2009, ANESTH ANALG, V108, P1531, DOI 10.1213/ane.0b013e31819d9308; Lavigne G, 2007, SLEEP AND PAIN; Lepouse C, 2006, BRIT J ANAESTH, V96, P747, DOI 10.1093/bja/ael094; Lydic R, 2005, ANESTHESIOLOGY, V103, P1268; Lydic R, 2002, SLEEP, V25, P617; Maksimow A, 2006, CLIN NEUROPHYSIOL, V117, P1660, DOI 10.1016/j.clinph.2006.05.011; McCarley RW, 2007, SLEEP MED, V8, P302, DOI 10.1016/j.sleep.2007.03.005; McCarthy Michelle M, 2008, J Neurosci, V28, P13488, DOI 10.1523/JNEUROSCI.3536-08.2008; Meuret P, 2000, ANESTHESIOLOGY, V93, pU190; Mhuircheartaigh RN, 2010, J NEUROSCI, V30, P9095, DOI 10.1523/JNEUROSCI.5516-09.2010; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Morairty S, 2004, NEUROSCIENCE, V123, P451, DOI 10.1016/j.neuroscience.2003.08.066; Mourisse J, 2003, ACTA ANAESTH SCAND, V47, P593, DOI 10.1034/j.1399-6576.2003.00100.x; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Olney JW, 1999, J PSYCHIAT RES, V33, P523, DOI 10.1016/S0022-3956(99)00029-1; Osman NI, 2005, ANESTHESIOLOGY, V103, P779, DOI 10.1097/00000542-200510000-00016; OYE I, 1992, J PHARMACOL EXP THER, V260, P1209; Palanca BA, 2009, CURR OPIN ANESTHESIO, V22, P553, DOI 10.1097/ACO.0b013e3283304032; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; Posner JB, 2007, PLUM POSNERS DIAGNOS; PRYSROBERTS C, 1987, BRIT J ANAESTH, V59, P1341, DOI 10.1093/bja/59.11.1341; Purdon PL, 2009, ANN NY ACAD SCI, V1157, P61, DOI 10.1111/j.1749-6632.2008.04119.x; Rampil IJ, 1998, ANESTHESIOLOGY, V89, P980, DOI 10.1097/00000542-199810000-00023; Reboso Morales J A, 1999, Rev Esp Anestesiol Reanim, V46, P111; Ren J, 2009, ANESTHESIOLOGY, V110, P1364, DOI 10.1097/ALN.0b013e31819faa2a; Rudolph U, 2004, NAT REV NEUROSCI, V5, P709, DOI 10.1038/nrn1496; Saper CB, 2005, NATURE, V437, P1257, DOI 10.1038/nature04284; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Seamans J, 2008, NAT CHEM BIOL, V4, P91, DOI 10.1038/nchembio0208-91; Shepherd G. M., 1998, SYNAPTIC ORG BRAIN; Sinner B., 2008, V182, P313, DOI 10.1007/978-3-540-74806-9_15; Stecker MM, 2001, ANN THORAC SURG, V71, P14, DOI 10.1016/S0003-4975(00)01592-7; Stein C, 2001, Curr Opin Pharmacol, V1, P62, DOI 10.1016/S1471-4892(01)00005-4; Steriade M, 2003, NEURON, V37, P563, DOI 10.1016/S0896-6273(03)00065-5; STERIADE M, 1993, J NEUROSCI, V13, P3284; STERIADE M, 1994, ELECTROEN CLIN NEURO, V90, P1, DOI 10.1016/0013-4694(94)90108-2; STERIADE M, 1993, J NEUROSCI, V13, P3252, DOI 10.1523/jneurosci.13-08-03252.1993; The Joint Commission, 2004, SENT EV AL PREV MAN; TINKER JH, 1977, ANESTHESIOLOGY, V46, P252, DOI 10.1097/00000542-197704000-00005; Tsuda N, 2007, ACTA ANAESTH SCAND, V51, P472, DOI 10.1111/j.1399-6576.2006.01246.x; Tung A, 2001, J CLIN ANESTH, V13, P24, DOI 10.1016/S0952-8180(00)00237-3; Velly LJ, 2007, ANESTHESIOLOGY, V107, P202, DOI 10.1097/01.anes.0000270734.99298.b4; Velly LJ, 2007, ANESTHESIOLOGY, V107, p[202, 175]; Watson CJ, 2010, SUPPRESSING THE MIND: ANESTHETIC MODULATION OF MEMORY AND CONSCIOUSNESS, P33, DOI 10.1007/978-1-60761-462-3_3; Watson SL, 2010, J PAIN, V11, P535, DOI 10.1016/j.jpain.2009.09.010; Yamatogi Y, 2002, BRAIN DEV-JPN, V24, P13, DOI 10.1016/S0387-7604(01)00392-8; Young GB, 2000, J CLIN NEUROPHYSIOL, V17, P473, DOI 10.1097/00004691-200009000-00006	101	653	680	7	174	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	2010	363	27					2638	2650		10.1056/NEJMra0808281	http://dx.doi.org/10.1056/NEJMra0808281			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	700SD	21190458	Green Accepted, Green Published			2023-01-03	WOS:000285763700009
J	Barrett, B; Brown, R; Rakel, D; Mundt, M; Bone, K; Barlow, S; Ewers, T				Barrett, Bruce; Brown, Roger; Rakel, Dave; Mundt, Marlon; Bone, Kerry; Barlow, Shari; Ewers, Tola			Echinacea for Treating the Common Cold A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							SUFFICIENTLY IMPORTANT DIFFERENCE; EXPERIMENTAL RHINOVIRUS COLDS; RESPIRATORY-TRACT INFECTIONS; PLACEBO-CONTROLLED TRIAL; TUMOR-NECROSIS-FACTOR; DOUBLE-BLIND; PURPUREA PREPARATIONS; ALKAMIDES; PREVENTION; PHARMACOKINETICS	Background: Echinacea is widely used to treat the common cold. Objective: To assess the potential benefits of echinacea as a treatment of common cold. Design: Randomized, controlled trial. (ClinicalTrials.gov registration number: NCT00065715) Setting: Dane County, Wisconsin. Patients: 719 patients, aged 12 to 80 years, with new-onset common cold. Intervention: Patients were assigned to 1 of 4 parallel groups: no pills, placebo pills (blinded), echinacea pills (blinded), or echinacea pills (unblinded, open-label). Echinacea groups received the equivalent of 10.2 g of dried echinacea root during the first 24 hours and 5.1 g during each of the next 4 days. Indistinguishable placebo tablets contained only inert ingredients. Measurements: The primary outcome was the area under the curve for global severity, with severity assessed twice daily by self-report using the Wisconsin Upper Respiratory Symptom Survey, short version. Secondary outcomes included interleukin-8 levels and neutrophil counts from nasal wash, assessed at intake and 2 days later. Results: Of the 719 patients enrolled, 713 completed the protocol. Mean age was 33.7 years, 64% were female, and 88% were white. Mean global severity was 236 and 258 for the blinded and unblinded echinacea groups, respectively; 264 for the blinded placebo group; and 286 for the no-pill group. A comparison of the 2 blinded groups showed a 28-point trend (95% CI, -69 to 13 points) toward benefit for echinacea (P = 0.089). Mean illness duration in the blinded and unblinded echinacea groups was 6.34 and 6.76 days, respectively, compared with 6.87 days in the blinded placebo group and 7.03 days in the no-pill group. A comparison of the blinded groups showed a nonsignificant 0.53-day (CI, -1.25 to 0.19 days) benefit (P = 0.075). Median change in interleukin-8 levels and neutrophil counts were also not statistically significant (30 ng/L and 1 cell/high-power field [hpf] in the no-pill group, 39 ng/L and 1 cell/hpf in the blinded placebo group, 58 ng/L and 2 cells/hpf in the blinded echinacea group, and 70 ng/L and 1 cell/hpf in the open-label echinacea group). Limitation: Higher-than-expected variability limited power to detect small benefits. Conclusion: Illness duration and severity were not statistically significant with echinacea compared with placebo. These results do not support the ability of this dose of the echinacea formulation to substantively change the course of the common cold.	[Barrett, Bruce] Univ Wisconsin, Dept Family Med, Madison, WI 53715 USA; MediHerb, Warwick, Qld 4370, Australia; Univ New England, Armidale, NSW, Australia	University of Wisconsin System; University of Wisconsin Madison; University of New England	Barrett, B (corresponding author), Univ Wisconsin, Dept Family Med, 1100 Delaplaine Court, Madison, WI 53715 USA.				National Center for Complementary and Alternative Medicine, National Institutes of Health [R01AT001428, K23 AT00051]; Robert Wood Johnson Foundation; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [K23AT000051, F32AT000051, R01AT001428] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT000051] Funding Source: NIH RePORTER	National Center for Complementary and Alternative Medicine, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	National Center for Complementary and Alternative Medicine, National Institutes of Health.; By the National Center for Complementary and Alternative Medicine at the National Institutes of Health (grant R01AT001428 and a Patient-Oriented Career Development Grant [K23 AT00051] to Dr. Barrett) and the Robert Wood Johnson Foundation Generalist Physician Faculty Scholars Program (Dr. Barrett). MediHerb (Queensland, Australia) provided the placebo and echinacea tablets used in this trial and conducted the phytochemical assays, all free of charge. When the National Institutes of Health funds ran out before data collection had been completed, Deans Robert Golden and Paul DeLuca of the UW School of Medicine and Public Health facilitated financial support to allow the project to reach enrollment goals.	American Herbal Pharmacopoeia, 2004, ECH PURP ROOT STAND; American Herbal Pharmacopoeia, 2010, ECH ANG ROOT STAND A; Barrett B, 2005, J CLIN EPIDEMIOL, V58, P609, DOI 10.1016/j.jclinepi.2004.11.019; Barrett B, 2005, MED DECIS MAKING, V25, P47, DOI 10.1177/0272989X04273147; Barrett B, 1999, J FAM PRACTICE, V48, P628; Barrett B, 2003, PHYTOMEDICINE, V10, P66, DOI 10.1078/094471103321648692; Barrett B, 2006, PHARMACOLOGYONLINE, V3, P392; Barrett BP, 2002, ANN INTERN MED, V137, P939, DOI 10.7326/0003-4819-137-12-200212170-00006; Barrett B, 2008, QUAL LIFE RES, V17, P75, DOI 10.1007/s11136-007-9277-2; Barrett B, 2007, EXPLORE-NY, V3, P561, DOI 10.1016/j.explore.2007.08.001; Barrett B, 2007, ANN FAM MED, V5, P216, DOI 10.1370/afm.698; Barrett B, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-76; Bauer R., 1991, EC MED PLANT RES, V5, P253; Bauer R, 1999, IMMUNOMODULATORY AGE, P41, DOI DOI 10.1007/978-3-0348-8763-22; BECKER S, 1993, AM J RESP CELL MOL, V8, P20, DOI 10.1165/ajrcmb/8.1.20; Bernath J, 2001, FASEB J, V15, pA1228; Block Keith I, 2003, Integr Cancer Ther, V2, P247, DOI 10.1177/1534735403256419; Bukovsky Marian, 1995, Polish Journal of Pharmacology, V47, P175; Call SA, 2005, JAMA-J AM MED ASSOC, V293, P987, DOI 10.1001/jama.293.8.987; Carrat F, 2008, AM J EPIDEMIOL, V167, P775, DOI 10.1093/aje/kwm375; Caruso TJ, 2005, CLIN INFECT DIS, V40, P807, DOI 10.1086/428061; Cohen HA, 2004, ARCH PEDIAT ADOL MED, V158, P217, DOI 10.1001/archpedi.158.3.217; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037/0278-6133.17.3.214; Cohen S., 1988, SOCIAL PSYCHOL HLTH; Eccles R, 2005, LANCET INFECT DIS, V5, P718, DOI 10.1016/S1473-3099(05)70270-X; Fendrick AM, 2003, ARCH INTERN MED, V163, P487, DOI 10.1001/archinte.163.4.487; Flannery M A, 1999, Pharm Hist, V41, P52; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226, DOI 10.1164/ajrccm.162.6.2003019; Gertsch J, 2004, FEBS LETT, V577, P563, DOI 10.1016/j.febslet.2004.10.064; Giles JT, 2000, PHARMACOTHERAPY, V20, P690, DOI 10.1592/phco.20.7.690.35173; Goel V, 2002, INT IMMUNOPHARMACOL, V2, P381, DOI 10.1016/S1567-5769(01)00163-1; Goel V, 2004, J CLIN PHARM THER, V29, P75, DOI 10.1111/j.1365-2710.2003.00542.x; Gorski JC, 2004, CLIN PHARMACOL THER, V75, P89, DOI 10.1016/j.clpt.2003.09.013; Guiotto P, 2008, PHYTOMEDICINE, V15, P547, DOI 10.1016/j.phymed.2008.05.003; GWALTNEY J M JR, 1985, Rhinology (Utrecht), V23, P265; Hinz B, 2007, BIOCHEM BIOPH RES CO, V360, P441, DOI 10.1016/j.bbrc.2007.06.073; Huntley AL, 2005, DRUG SAFETY, V28, P387, DOI 10.2165/00002018-200528050-00003; JACKSON GG, 1962, AM J PUBLIC HEALTH N, V56, P940, DOI 10.2105/AJPH.52.6.940; Jager H, 2002, PLANTA MED, V68, P469, DOI 10.1055/s-2002-32076; Lalone CA, 2007, J AGR FOOD CHEM, V55, P7314, DOI 10.1021/jf063711a; Linde K, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000530.pub2; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Llach XB, 1999, MED CARE, V37, P671, DOI 10.1097/00005650-199907000-00007; Matthias A, 2005, LIFE SCI, V77, P2018, DOI 10.1016/j.lfs.2005.04.009; Matthias A, 2005, CHEM-BIOL INTERACT, V155, P62, DOI 10.1016/j.cbi.2005.04.003; McCullagh P., 1989, GEN LINEAR MODELS; Melchart D, 1994, Phytomedicine, V1, P245, DOI 10.1016/S0944-7113(11)80072-3; Monto AS, 1995, AM J MED, V99, pS24, DOI 10.1016/S0002-9343(99)80307-6; NOAH TL, 1995, J INFECT DIS, V171, P584, DOI 10.1093/infdis/171.3.584; Panel on antiretroviral guidelines for adults and adolescents, 2009, GUID US ANT AG HIV 1, P1; Ryff CD, 1996, PSYCHOTHER PSYCHOSOM, V65, P14, DOI 10.1159/000289026; Schafer J.L., 1997, ANAL INCOMPLETE MULT; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Schoop R, 2006, CLIN THER, V28, P174, DOI 10.1016/j.clinthera.2006.02.001; Senchina DS, 2005, CLIN CHIM ACTA, V355, P67, DOI 10.1016/j.cccn.2004.12.013; Shah SA, 2007, LANCET INFECT DIS, V7, P473, DOI 10.1016/S1473-3099(07)70160-3; Sperber SJ, 2004, CLIN INFECT DIS, V38, P1367, DOI 10.1086/386324; Taylor JA, 2003, JAMA-J AM MED ASSOC, V290, P2824, DOI 10.1001/jama.290.21.2824; Teran LM, 1997, AM J RESP CRIT CARE, V155, P1362, DOI 10.1164/ajrccm.155.4.9105080; Turner RB, 2005, NEW ENGL J MED, V353, P341, DOI 10.1056/NEJMoa044441; Turner RB, 2000, ANTIMICROB AGENTS CH, V44, P1708, DOI 10.1128/AAC.44.6.1708-1709.2000; Turner RB, 2005, PEDIATR ANN, V34, P53, DOI 10.3928/0090-4481-20050101-12; WAGNER H, 1988, PHYTOCHEMISTRY, V27, P119, DOI 10.1016/0031-9422(88)80601-0; Ware JE, 2001, CORE INTERPRET SINGL; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Woelkart K, 2006, INT J CLIN PHARM TH, V44, P401; Woelkart K, 2005, PLANTA MED, V71, P701, DOI 10.1055/s-2005-871290; Woelkart K, 2008, PLANTA MED, V74, P651, DOI 10.1055/s-2008-1034284; Woelkart K, 2007, PLANTA MED, V73, P615, DOI 10.1055/s-2007-981531; Yale SH, 2004, ARCH INTERN MED, V164, P1237, DOI 10.1001/archinte.164.11.1237; Zhai Z, 2007, FOOD AGR IMMUNOL, V18, P221, DOI 10.1080/09540100701797363	72	52	53	2	55	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 21	2010	153	12					769	+		10.7326/0003-4819-153-12-201012210-00003	http://dx.doi.org/10.7326/0003-4819-153-12-201012210-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	696PL	21173411	Green Accepted			2023-01-03	WOS:000285453700001
J	Krug, U; Rollig, C; Koschmieder, A; Heinecke, A; Sauerland, MC; Schaich, M; Thiede, C; Kramer, M; Braess, J; Spiekermann, K; Haferlach, T; Haferlach, C; Koschmieder, S; Rohde, C; Serve, H; Wormann, B; Hiddemann, W; Ehninger, G; Berdel, WE; Buchner, T; Muller-Tidow, C				Krug, Utz; Roellig, Christoph; Koschmieder, Anja; Heinecke, Achim; Sauerland, Maria Cristina; Schaich, Markus; Thiede, Christian; Kramer, Michael; Braess, Jan; Spiekermann, Karsten; Haferlach, Torsten; Haferlach, Claudia; Koschmieder, Steffen; Rohde, Christian; Serve, Hubert; Woermann, Bernhard; Hiddemann, Wolfgang; Ehninger, Gerhard; Berdel, Wolfgang E.; Buechner, Thomas; Mueller-Tidow, Carsten		German Acute Myeloid Leukaemia Coo	Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes	LANCET			English	Article							MICRORNA-EXPRESSION SIGNATURES; RISK MYELODYSPLASTIC SYNDROME; STEM-CELL TRANSPLANTATION; ELDERLY-PATIENTS; INDUCTION CHEMOTHERAPY; FAVORABLE PROGNOSIS; DOSE CYTARABINE; NPM1 MUTATIONS; SURVIVAL; CANCER	Background About 50% of patients (age >= 60 years) who have acute myeloid leukaemia and are otherwise medically healthy (ie, able to undergo intensive chemotherapy) achieve a complete remission (CR) after intensive chemotherapy, but with a substantially increased risk of early death (ED) compared with younger patients. We verified the association of standard clinical and laboratory variables with CR and ED and developed a web-based application for risk assessment of intensive chemotherapy in these patients. Methods Multivariate regression analysis was used to develop risk scores with or without knowledge of the cytogenetic and molecular risk profiles for a cohort of 1406 patients (aged >= 60 years) with acute myeloid leukaemia, but otherwise medically healthy, who were treated with two courses of intensive induction chemotherapy (tioguanine, standard-dose cytarabine, and daunorubicin followed by high-dose cytarabine and mitoxantrone; or with high-dose cytarabine and mitoxantrone in the first and second induction courses) in the German Acute Myeloid Leukaemia Cooperative Group 1999 study. Risk prediction was validated in an independent cohort of 801 patients (aged >60 years) with acute myeloid leukaemia who were given two courses of cytarabine and daunorubicin in the Acute Myeloid Leukaemia 1996 study. Findings Body temperature, age, de-novo leukaemia versus leukaemia secondary to cytotoxic treatment or an antecedent haematological disease, haemoglobin, platelet count, fibrinogen, and serum concentration of lactate dehydrogenase were significantly associated with CR or ED. The probability of CR with knowledge of cytogenetic and molecular risk (score 1) was from 12% to 91%, and without knowledge (score 2) from 21% to 80%. The predicted risk of ED was from 6% to 69% for score 1 and from 7% to 63% for score 2. The predictive power of the risk scores was confirmed in the independent patient cohort (CR score 1, from 10% to 91%; CR score 2, from 16% to 80%; ED score 1, from 6% to 69%; and ED score 2, from 7% to 61%). Interpretation The scores for acute myeloid leukaemia can be used to predict the probability of CR and the risk of ED in older patients with acute myeloid leukaemia, but otherwise medically healthy, for whom intensive induction chemotherapy is planned. This information can help physicians with difficult decisions for treatment of these patients.	[Koschmieder, Anja; Koschmieder, Steffen; Rohde, Christian; Berdel, Wolfgang E.; Buechner, Thomas; Mueller-Tidow, Carsten] Univ Munster, Dept Med Haematol & Oncol A, Munster, Germany; [Roellig, Christoph; Schaich, Markus; Thiede, Christian; Kramer, Michael; Ehninger, Gerhard] Tech Univ Dresden, Dept Med 1, Dresden, Germany; [Heinecke, Achim; Sauerland, Maria Cristina] Univ Munster, Inst Biostat & Clin Res, Munster, Germany; [Braess, Jan; Spiekermann, Karsten; Hiddemann, Wolfgang] Univ Munich, Dept Internal Med 3, Munich, Germany; [Haferlach, Torsten; Haferlach, Claudia] Munich Leukaemia Lab, Munich, Germany; [Serve, Hubert] Goethe Univ Frankfurt, Dept Med, Frankfurt, Germany; [Woermann, Bernhard] Municipal Hosp, Dept Haematol & Oncol, Braunschweig, Germany	University of Munster; Technische Universitat Dresden; University of Munster; University of Munich; MLL Munich Leukemia Laboratory; Goethe University Frankfurt	Krug, U (corresponding author), Univ Hosp Munster, Dept Med A, Albert Schweitzer Str 33, D-48149 Munster, Germany.	utz.krug@ukmuenster.de	Müller-Tidow, Carsten CMT/B-5257-2014; Müller-Tidow, Carsten/O-7207-2018; Sauerland, Maria Cristina/A-4154-2014; Gramatzki, Martin/A-9533-2010	Müller-Tidow, Carsten/0000-0002-7166-5232; Serve, Hubert/0000-0001-8472-5516; Kramer, Michael/0000-0002-0251-2726; Koschmieder, Steffen/0000-0002-1011-8171; Thiede, Christian/0000-0003-1241-2048	Amgen; Celgene; Bundesministerium fur Bildung und Forschung; Novartis; Bayer; Ambit; Bristol-Myers Sqibb; Mundipharma; Deutsche Forschungsgemeinschaft [Mu-1328/8-1]; Deutsche Krebshilfe; Sander-Foundation; Aicuris; Leverkusen; Deutsche Krebshilfe [70-2839-Bu4]	Amgen(Amgen); Celgene(Bristol-Myers SquibbCelgene Corporation); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Novartis(Novartis); Bayer(Bayer AG); Ambit; Bristol-Myers Sqibb; Mundipharma; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Sander-Foundation; Aicuris; Leverkusen; Deutsche Krebshilfe(Deutsche Krebshilfe)	UK has received expenses for travel, accommodation, and meetings from Amgen and Celgene. CT has received grants from Bundesministerium fur Bildung und Forschung; payment for lectures, including service on speakers' bureaus, from Novartis; payment for diagnostic services from Novartis and Ambit; and expenses for travel, accommodations, and meetings from Novartis, Bayer, and Ambit. TH has received payment for lectures including service on speakers' bureaus from Novartis, Bristol-Myers Sqibb, and Celgene; and has part ownership in Munich Leukemia Laboratory. CH has part ownership in Munich Leukemia Laboratory. SK has received grants from Novartis; and expenses for travel, accommodations, and meetings from Mundipharma, Novartis, and Bristol-Myers Sqibb. WEB has received grants from Deutsche Forschungsgemeinschaft, Deutsche Krebshilfe, and Sander-Foundation; payment for lectures, including service on speakers' bureaus, and development of educational presentations from Molecular and Targeted Therapy of Cancer; and expenses for travel, accommodations, and meetings from Amgen. CMT has received grants from Bundesministerium fur Bildung und Forschung; payment for lectures, including service on speakers' bureaus, from Novartis and Celgene; payment for manuscript preparation from Celgene; and expenses for travel, accommodations, and meetings from Celgene, Amgen, Novartis, and Bayer. GE has received payment for board membership from Rhon Klinikum; payment for consultancy from Aicuris, Leverkusen; and grants from Deutsche Forschungsgemeinschaft; payments for lectures, including service on speakers' bureaus, from Update Conference; has stock or stock options in Rhon Klinikum; and has received expenses for travel, accommodations, and meetings from Novartis. The other authors declare that they have no conflicts of interest.; This work was supported by a grant from the Deutsche Krebshilfe (70-2839-Bu4 to TB) and by a grant from the Deutsche Forschungsgemeinschaft (Mu-1328/8-1 to CMT and TB).	Anderson JE, 2002, BLOOD, V100, P3869, DOI 10.1182/blood-2001-12-0354; Appelbaum FR, 2006, BLOOD, V107, P3481, DOI 10.1182/blood-2005-09-3724; Becker H, 2010, J CLIN ONCOL, V28, P596, DOI 10.1200/JCO.2009.25.1496; Bertz H, 2003, J CLIN ONCOL, V21, P1480, DOI 10.1200/JCO.2003.09.110; Breccia M, 2009, HEMATOL ONCOL, V27, P148, DOI 10.1002/hon.889; Buchner T, 2006, J CLIN ONCOL, V24, P2480, DOI 10.1200/JCO.2005.04.5013; Buchner T, 2009, J CLIN ONCOL, V27, P61, DOI 10.1200/JCO.2007.15.4245; Burnett AK, 2007, CANCER, V109, P1114, DOI 10.1002/cncr.22496; Cashen AF, 2010, J CLIN ONCOL, V28, P556, DOI 10.1200/JCO.2009.23.9178; COMINGS DE, 1973, EXP CELL RES, V77, P469, DOI 10.1016/0014-4827(73)90601-0; Dohner K, 2005, BLOOD, V106, P3740, DOI 10.1182/blood-2005-05-2164; Etienne A, 2007, CANCER, V109, P1376, DOI 10.1002/cncr.22537; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Giles FJ, 2007, BRIT J HAEMATOL, V136, P624, DOI 10.1111/j.1365-2141.2006.06476.x; Goldstone AH, 2002, BLOOD, V100, p88A; Goldstone AH, 2001, BLOOD, V98, P1302, DOI 10.1182/blood.V98.5.1302; Grimwade D, 2001, BLOOD, V98, P1312, DOI 10.1182/blood.V98.5.1312; Itzykson R, 2011, BLOOD, V117, P403, DOI 10.1182/blood-2010-06-289280; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1090, DOI 10.1002/cncr.21723; Kantarjian H, 2010, BLOOD, V116, P4422, DOI 10.1182/blood-2010-03-276485; Kern W, 2003, BLOOD, V101, P64, DOI 10.1182/blood-2002-02-0532; LOWENBERG B, 1989, J CLIN ONCOL, V7, P1268; Lowenberg B, 2009, NEW ENGL J MED, V361, P1235, DOI 10.1056/NEJMoa0901409; Ohtake S, 2011, BLOOD, V117, P2358, DOI 10.1182/blood-2010-03-273243; Rollig C, 2010, BLOOD, V116, P971, DOI 10.1182/blood-2010-01-267302; Rollig C, 2009, BLOOD, V114, P139, DOI 10.1182/blood.V114.22.329.329; Rowe JM, 2004, BLOOD, V103, P479, DOI 10.1182/blood-2003-05-1686; Schnittger S, 2005, BLOOD, V106, p68A, DOI 10.1182/blood.V106.11.223.223; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Sekeres MA, 2009, BLOOD, V113, P28, DOI 10.1182/blood-2008-05-157065; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Walter RB, 2010, J CLIN ONCOL, V28, P1766, DOI 10.1200/JCO.2009.25.1066; Whitman SP, 2010, BLOOD, V116, P3622, DOI 10.1182/blood-2010-05-283648	34	216	226	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	2010	376	9757					2000	2008		10.1016/S0140-6736(10)62105-8	http://dx.doi.org/10.1016/S0140-6736(10)62105-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	701GZ	21131036				2023-01-03	WOS:000285807700029
J	Okie, S				Okie, Susan			A Flood of Opioids, a Rising Tide of Deaths	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							UNITED-STATES; OVERDOSE		Georgetown Univ, Sch Med, Washington, DC 20057 USA	Georgetown University	Okie, S (corresponding author), Georgetown Univ, Sch Med, Washington, DC 20057 USA.							[Anonymous], 2010, MMWR MORB MORTAL WKL, V59, P705; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Hall AJ, 2008, JAMA-J AM MED ASSOC, V300, P2613, DOI 10.1001/jama.2008.802; Paulozzi LJ, 2006, AM J PREV MED, V31, P506, DOI 10.1016/j.amepre.2006.08.017; *SUBST AB MENT HLT, SUBST AB TREATM ADM	5	635	645	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					1981	1985		10.1056/NEJMp1011512	http://dx.doi.org/10.1056/NEJMp1011512			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	681KC	21083382				2023-01-03	WOS:000284310000001
J	Bate, R; Attaran, A				Bate, Roger; Attaran, Amir			A counterfeit drug treaty: great idea, wrong implementation	LANCET			English	Editorial Material									[Attaran, Amir] Univ Ottawa, Fac Law, Ottawa, ON K1N 6N5, Canada; [Attaran, Amir] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada; [Bate, Roger] Amer Enterprise Inst Publ Policy Res, Washington, DC USA	University of Ottawa; University of Ottawa; American Enterprise Institute for Public Policy Research	Attaran, A (corresponding author), Univ Ottawa, Fac Law, Ottawa, ON K1N 6N5, Canada.	aattaran@uottawa.ca						ATTARAN A, WHY MAKE INT CRIME M; Cockburn R, 2005, PLOS MED, V2, P302, DOI 10.1371/journal.pmed.0020100; *COUNC EUR, 2010, MEDICRIME DRAFT COUN; Dondorp AM, 2004, TROP MED INT HEALTH, V9, P1241, DOI 10.1111/j.1365-3156.2004.01342.x; *ECCP COUNC EUR, 2008, 3 M APR 15; *EUR COMM CRIM PRO, 2009, DRAFT COUNC EUR CONV; Ludwig SP, 2005, DRUG DEV IND PHARM, V31, P215, DOI 10.1081/DDC-200047811; LYNN J, 2010, REUTERS         0512; Mullard A, 2010, LANCET, V375, P1335, DOI 10.1016/S0140-6736(10)60560-0; *US FDA, 2008, UPD QUEST ANSW HEP S; 1929, INT CONV SUPPR COUNT	11	13	13	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2010	376	9751					1446	1448		10.1016/S0140-6736(10)61416-X	http://dx.doi.org/10.1016/S0140-6736(10)61416-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	680QC	21036261				2023-01-03	WOS:000284248500008
J	Hoyle, E				Hoyle, Ewan			PERSONAL VIEW It's time for the UK government to fully review drug policy	BRITISH MEDICAL JOURNAL			English	Editorial Material												ewanhoyle@gmail.com							0	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 17	2011	343								d5235	10.1136/bmj.d5235	http://dx.doi.org/10.1136/bmj.d5235			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	811LB	21849391				2023-01-03	WOS:000294210500006
J	Kucirka, LM; Grams, ME; Lessler, J; Hall, EC; James, N; Massie, AB; Montgomery, RA; Segev, DL				Kucirka, Lauren M.; Grams, Morgan E.; Lessler, Justin; Hall, Erin Carlyle; James, Nathan; Massie, Allan B.; Montgomery, Robert A.; Segev, Dorry L.			Association of Race and Age With Survival Among Patients Undergoing Dialysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; QUALITY-OF-LIFE; RACIAL-DIFFERENCES; HEMODIALYSIS-PATIENTS; REPLACEMENT THERAPY; AFRICAN-AMERICANS; UNITED-STATES; PRACTICE PATTERNS; DISPARITIES	Context Many studies have reported that black individuals undergoing dialysis survive longer than those who are white. This observation is paradoxical given racial disparities in access to and quality of care, and is inconsistent with observed lower survival among black patients with chronic kidney disease. We hypothesized that age and the competing risk of transplantation modify survival differences by race. Objective To estimate death among dialysis patients by race, accounting for age as an effect modifier and kidney transplantation as a competing risk. Design, Setting, and Participants An observational cohort study of 1 330 007 incident end-stage renal disease patients as captured in the United States Renal Data System between January 1, 1995, and September 28, 2009 (median potential follow-up time, 6.7 years; range, 1 day-14.8 years). Multivariate age-stratified Cox proportional hazards and competing risk models were constructed to examine death in patients who receive dialysis. Main Outcome Measures Death in black vs white patients who receive dialysis. Results Similar to previous studies, black patients undergoing dialysis had a lower death rate compared with white patients (232 361 deaths [57.1% mortality] vs 585 792 deaths [63.5% mortality], respectively; adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.83-0.84; P<.001). However, when stratifying by age and treating kidney transplantation as a competing risk, black patients had significantly higher mortality than their white counterparts at ages 18 to 30 years (27.6% mortality vs 14.2%; aHR, 1.93; 95% CI, 1.84-2.03), 31 to 40 years (37.4% mortality vs 26.8%; aHR, 1.46; 95% CI, 1.41-1.50), and 41 to 50 years (44.8% mortality vs 38.0%; aHR, 1.12; 95% CI, 1.10-1.14; P<.001 for interaction terms between race and each aforementioned age category), as opposed to patients aged 51 to 60 years (51.5% vs 50.9%; aHR, 0.93; 95% CI, 0.92-0.94), 61 to 70 years (64.9% vs 67.2%; aHR, 0.87; 95% CI, 0.86-0.88), 71 to 80 years (76.1% vs 79.7%; aHR, 0.85; 95% CI, 0.84-0.86), and older than 80 years (82.4% vs 83.6%; aHR, 0.87; 95% CI, 0.85-0.88). Conclusions Overall, among dialysis patients in the United States, there was a lower risk of death for black patients compared with their white counterparts. However, the commonly cited survival advantage for black dialysis patients applies only to older adults, and those younger than 50 years have a higher risk of death. JAMA. 2011;306(6):620-626 www.jama.com	[Kucirka, Lauren M.; Hall, Erin Carlyle; James, Nathan; Massie, Allan B.; Montgomery, Robert A.; Segev, Dorry L.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Grams, Morgan E.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Grams, Morgan E.; Lessler, Justin; Segev, Dorry L.] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Segev, DL (corresponding author), Johns Hopkins Med Inst, 720 Rutland Ave,Ross 771B, Baltimore, MD 21205 USA.	dorry@jhmi.edu		Grams, Morgan/0000-0002-4430-6023; Lessler, Justin/0000-0002-9741-8109	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R21DK085409]; National Institute on Aging [K23AG032885]; American Federation for Aging Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK085409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K23AG032885] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); American Federation for Aging Research; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Dr Segev reports that this work was supported by grant number R21DK085409 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and by a Paul Beeson Career Development Award (cofunded by the National Institute on Aging K23AG032885 and American Federation for Aging Research).	Abbott KC, 2004, KIDNEY INT, V65, P597, DOI 10.1111/j.1523-1755.2004.00385.x; Agodoa L, 2002, AM J KIDNEY DIS, V40, P1337, DOI 10.1053/ajkd.2002.37395; Agodoa L, 2007, SEMIN DIALYSIS, V20, P577, DOI 10.1111/j.1525-139X.2007.00350.x; Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bleyer AJ, 1996, AM J KIDNEY DIS, V28, P72, DOI 10.1016/S0272-6386(96)90133-X; BLEYER AJ, 1992, ARCH INTERN MED, V152, P879, DOI 10.1001/archinte.152.4.879; BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; Buckalew VM, 2010, AM J KIDNEY DIS, V55, P1102, DOI 10.1053/j.ajkd.2009.10.062; COWIE CC, 1994, DIABETES CARE, V17, P681, DOI 10.2337/diacare.17.7.681; Eisenstein EL, 2009, AM J MED, V122, P170, DOI 10.1016/j.amjmed.2008.08.025; ELLISON MD, 1993, TRANSPLANT P, V25, P2462; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Frankenfield DL, 1999, AM J KIDNEY DIS, V34, P721, DOI 10.1016/S0272-6386(99)70399-9; Gadegbeku C, 2002, J NATL MED ASSOC, V94, p45S; Garg PP, 2001, AM J KIDNEY DIS, V37, P921, DOI 10.1016/S0272-6386(05)80007-1; Hata Y, 1998, TRANSPLANTATION, V65, P208; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; Hopson S, 2008, AM J KIDNEY DIS, V52, P753, DOI 10.1053/j.ajkd.2008.04.007; Kalantar-Zadeh K, 2007, NAT CLIN PRACT NEPHR, V3, P493, DOI 10.1038/ncpneph0570; Kalantar-Zadeh K, 2010, J BONE MINER RES, V25, P2448, DOI 10.1002/jbmr.177; KJELLSTRAND CM, 1987, NEPHRON, V45, P257, DOI 10.1159/000184160; Leonard MB, 2004, J AM SOC NEPHROL, V15, P2923, DOI 10.1097/01.ASN.0000143475.39388.DE; LOWRIE EG, 1992, KIDNEY INT, V42, pS22; Medina RA, 1996, AM J KIDNEY DIS, V28, P226, DOI 10.1016/S0272-6386(96)90306-6; Mehrotra R, 2008, J AM SOC NEPHROL, V19, P1403, DOI 10.1681/ASN.2007070747; Mesler DE, 1999, AM J MED, V106, P300, DOI 10.1016/S0002-9343(99)00020-0; Morris D, 2005, AM J MED, V118, P671, DOI 10.1016/j.amjmed.2005.02.023; Myers OB, 2010, J AM SOC NEPHROL, V21, P1970, DOI 10.1681/ASN.2010010125; Norris KC, 2005, KIDNEY INT, V68, P914, DOI 10.1111/j.1523-1755.2005.00485.x; Owen WF, 1996, BLOOD PURIFICAT, V14, P278; Owen WF, 1998, JAMA-J AM MED ASSOC, V280, P1764, DOI 10.1001/jama.280.20.1764; Ozminkowski RJ, 1997, AM J KIDNEY DIS, V30, P749, DOI 10.1016/S0272-6386(97)90078-0; Pei YPC, 2000, KIDNEY INT, V58, P1293, DOI 10.1046/j.1523-1755.2000.00285.x; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; Powe NR, 2005, MED CLIN N AM, V89, P475, DOI 10.1016/j.mcna.2004.11.004; Price D A, 1997, Adv Ren Replace Ther, V4, P3; PUGH JA, 1994, AM J KIDNEY DIS, V23, P803; Reddan D, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000022422.79790.A8; Reddan DN, 2000, SEMIN DIALYSIS, V13, P399, DOI 10.1046/j.1525-139x.2000.00109.x; Robinson BM, 2006, J AM SOC NEPHROL, V17, P2910, DOI 10.1681/ASN.2005101078; Roderick P, 2009, NEPHROL DIAL TRANSPL, V24, P3774, DOI 10.1093/ndt/gfp348; Salem M, 2002, AM J MED SCI, V323, P100, DOI 10.1097/00000441-200202000-00008; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; Schold JD, CLIN TRANSPLANT; Segev DL, 2009, J AM SOC NEPHROL, V20, P621, DOI 10.1681/ASN.2008060591; Sehgal AR, 2000, AM J KIDNEY DIS, V35, pS148, DOI 10.1016/S0272-6386(00)70242-3; Streja E, 2011, AM J KIDNEY DIS, V57, P883, DOI 10.1053/j.ajkd.2010.10.050; Tanna MM, 2000, AM J KIDNEY DIS, V36, P1175, DOI 10.1053/ajkd.2000.19832; Unruh M, 2004, KIDNEY INT, V65, P1482, DOI 10.1111/j.1523-1755.2004.00529.x; USRDS, 2010, US REN DAT SYST ANN; Waikar SS, 2007, J AM SOC NEPHROL, V18, P2740, DOI 10.1681/ASN.2006091060; Winkelmayer WC, 2001, KIDNEY INT, V60, P1547, DOI 10.1046/j.1523-1755.2001.00958.x; Young CJ, 2000, NEW ENGL J MED, V343, P1545, DOI 10.1056/NEJM200011233432107	55	180	184	3	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 10	2011	306	6					620	626		10.1001/jama.2011.1127	http://dx.doi.org/10.1001/jama.2011.1127			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	804XD	21828325	Bronze, Green Accepted			2023-01-03	WOS:000293687300023
J	Best, T; Li, DL; Skol, AD; Kirchhoff, T; Jackson, SA; Yasui, Y; Bhatia, S; Strong, LC; Domchek, SM; Nathanson, KL; Olopade, OI; Huang, RS; Mack, TM; Conti, DV; Offit, K; Cozen, W; Robison, LL; Onel, K				Best, Timothy; Li, Dalin; Skol, Andrew D.; Kirchhoff, Tomas; Jackson, Sarah A.; Yasui, Yutaka; Bhatia, Smita; Strong, Louise C.; Domchek, Susan M.; Nathanson, Katherine L.; Olopade, Olufunmilayo I.; Huang, R. Stephanie; Mack, Thomas M.; Conti, David V.; Offit, Kenneth; Cozen, Wendy; Robison, Leslie L.; Onel, Kenan			Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma	NATURE MEDICINE			English	Article							CHILDHOOD-CANCER SURVIVOR; WIDE ASSOCIATION; 5-YEAR SURVIVORS; CELL LYMPHOMA; NEOPLASMS; DISEASE; CHEMOTHERAPY; RADIATION; BLIMP1; RISK	Survivors of pediatric Hodgkin's lymphoma are at risk for radiation therapy-induced second malignant neoplasms (SMNs). We identified two variants at chromosome 6q21 associated with SMNs in survivors of Hodgkin's lymphoma treated with radiation therapy as children but not as adults. The variants comprise a risk locus associated with decreased basal expression of PRDM1 (encoding PR domain containing 1, with ZNF domain) and impaired induction of the PRDM1 protein after radiation exposure. These data suggest a new gene-exposure interaction that may implicate PRDM1 in the etiology of radiation therapy-induced SMNs.	[Best, Timothy; Onel, Kenan] Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA; [Li, Dalin; Mack, Thomas M.; Conti, David V.; Cozen, Wendy] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Li, Dalin; Mack, Thomas M.; Conti, David V.; Cozen, Wendy] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA; [Skol, Andrew D.; Jackson, Sarah A.; Olopade, Olufunmilayo I.; Huang, R. Stephanie] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Kirchhoff, Tomas; Offit, Kenneth] Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, New York, NY 10021 USA; [Yasui, Yutaka] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB, Canada; [Bhatia, Smita] City Hope Natl Med Ctr, Dept Populat Sci, Duarte, CA USA; [Strong, Louise C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA; [Domchek, Susan M.; Nathanson, Katherine L.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Mack, Thomas M.; Cozen, Wendy] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA; [Robison, Leslie L.] St Jude Childrens Hosp, Dept Epidemiol & Canc Control, Memphis, TN 38105 USA; [Onel, Kenan] Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Southern California; University of Southern California; University of Chicago; Memorial Sloan Kettering Cancer Center; University of Alberta; City of Hope; University of Texas System; UTMD Anderson Cancer Center; University of Pennsylvania; Pennsylvania Medicine; University of Southern California; St Jude Children's Research Hospital; University of Chicago	Onel, K (corresponding author), Univ Chicago, Comm Canc Biol, Chicago, IL 60637 USA.	konel@uchicago.edu	Li, Dalin/F-4266-2011; Robison, Leslie/N-8122-2018; Yasui, Yutaka/E-2564-2015	Yasui, Yutaka/0000-0002-7717-8638; Huang, R. Stephanie/0000-0002-9862-0368; Nathanson, Katherine/0000-0002-6740-0901; Kirchhoff, Tomas/0000-0002-9055-2364	US National Institutes of Health [HD0433871, CA129045, CA40046, CA55727, GM089941, CA139278, CA58839, CA110836]; US National Institutes of Health/National Institute of General Medical Sciences Pharmacogenomics of Anticancer Agents [U01GM61393, N01-PC-35139]; US Army Medical Research and Materiel Command (Department of Defense) [PR054600]; Department of Defense DAMD [17-097-1-7147]; American Cancer Society-Illinois Division; American Lebanese Syrian Associated Charities; Leukemia Lymphoma Society [TR 6137-07, TR 6202-09]; Breast Cancer Research Foundation; Lymphoma Foundation; Robert and Kate Niehaus Research Fund; University of Chicago Cancer Center [P30 CA14599]; Breast Cancer Specialized Program; Cancer Research Foundation; California Department of Health Services; NATIONAL CANCER INSTITUTE [P01CA040046, U01CA055727, U24CA055727, R01CA058839, R21CA129045, R03CA110836, P30CA014599, R21CA139278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U01GM061393, K08GM089941] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institutes of Health/National Institute of General Medical Sciences Pharmacogenomics of Anticancer Agents(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Army Medical Research and Materiel Command (Department of Defense)(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Department of Defense DAMD(United States Department of Defense); American Cancer Society-Illinois Division(American Cancer Society); American Lebanese Syrian Associated Charities(American Lebanese Syrian Associated Charities (ALSAC)); Leukemia Lymphoma Society(Leukemia and Lymphoma Society); Breast Cancer Research Foundation; Lymphoma Foundation; Robert and Kate Niehaus Research Fund; University of Chicago Cancer Center(University of Chicago); Breast Cancer Specialized Program; Cancer Research Foundation; California Department of Health Services; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the US National Institutes of Health (HD0433871, CA129045 and CA40046 to K. Onel, CA55727 to L. L. R., GM089941 and CA139278 to R. S. H., CA58839 to T. M. M. and CA110836 to W. C.); US National Institutes of Health/National Institute of General Medical Sciences Pharmacogenomics of Anticancer Agents grant U01GM61393 (R. S. H.); contract number N01-PC-35139 (W. C.); the US Army Medical Research and Materiel Command (Department of Defense PR054600 to W. C. and Department of Defense DAMD 17-097-1-7147 to K. Offit); the American Cancer Society-Illinois Division (K. Onel); the American Lebanese Syrian Associated Charities (L. L. R.); the Leukemia Lymphoma Society (TR 6137-07 to W. C. and TR 6202-09 to T. K.); the Breast Cancer Research Foundation (S. M. D., K.L.N. and K. Offit); the Lymphoma Foundation (K. Offit); the Robert and Kate Niehaus Research Fund (K. Offit); the University of Chicago Cancer Center Support Grant (#P30 CA14599) (R. S. H.); the Breast Cancer Specialized Program of Research Excellence Career Development Award (R. S. H.); and the Cancer Research Foundation (K. Onel). We thank the University of Chicago Pharmacogenomics of Anticancer Agents Research Group cell core for providing lymphoblastoid cell lines. The collection of some samples from individuals with Hodgkin's lymphoma used in this publication was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885. The ideas and opinions expressed herein are those of the authors, and no endorsement by the State of California Department of Health Services is intended or should be inferred. We thank N.A. Ellis for many productive discussions and thoughtful feedback. We are especially grateful for the contributions of the many participating subjects and their parents, without whom this work would not have been possible.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Behrens C, 2000, CANCER EPIDEM BIOMAR, V9, P1027; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Calado DP, 2010, CANCER CELL, V18, P580, DOI 10.1016/j.ccr.2010.11.024; Calame K, 2010, J IMMUNOL, V185, P3, DOI 10.4049/jimmunol.1090044; Constine LS, 2008, INT J RADIAT ONCOL, V72, P24, DOI 10.1016/j.ijrobp.2008.04.067; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Friedman DL, 2010, JNCI-J NATL CANCER I, V102, P1083, DOI 10.1093/jnci/djq238; Gateva V, 2009, NAT GENET, V41, P1228, DOI 10.1038/ng.468; Lin Y, 1997, SCIENCE, V276, P596, DOI 10.1126/science.276.5312.596; Mandelbaum J, 2010, CANCER CELL, V18, P568, DOI 10.1016/j.ccr.2010.10.030; Meadows AT, 2009, J CLIN ONCOL, V27, P2356, DOI 10.1200/JCO.2008.21.1920; Neglia JP, 2001, J NATL CANCER I, V93, P618, DOI 10.1093/jnci/93.8.618; Nicolae DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000888; O'Brien MM, 2010, J CLIN ONCOL, V28, P1232, DOI 10.1200/JCO.2009.24.8062; Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847; Raychaudhuri S, 2009, NAT GENET, V41, P1313, DOI 10.1038/ng.479; Robison LL, 2005, CANCER-AM CANCER SOC, V104, P2557, DOI 10.1002/cncr.21249; Thomas D, 2010, NAT REV GENET, V11, P259, DOI 10.1038/nrg2764; Travis LB, 2003, JAMA-J AM MED ASSOC, V290, P465, DOI 10.1001/jama.290.4.465	20	111	114	1	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	AUG	2011	17	8					941	943		10.1038/nm.2407	http://dx.doi.org/10.1038/nm.2407			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	802JW	21785431	Green Accepted			2023-01-03	WOS:000293507400026
J	Pournot, H; Bieuzen, F; Louis, J; Fillard, JR; Barbiche, E; Hausswirth, C				Pournot, Herve; Bieuzen, Francois; Louis, Julien; Fillard, Jean-Robert; Barbiche, Etienne; Hausswirth, Christophe			Time-Course of Changes in Inflammatory Response after Whole-Body Cryotherapy Multi Exposures following Severe Exercise	PLOS ONE			English	Article							INDUCED MUSCLE DAMAGE; COLD-WATER IMMERSION; SKELETAL-MUSCLE; IMMUNE FUNCTION; ENVIRONMENTAL EXTREMES; ECCENTRIC EXERCISE; BLOOD-FLOW; CYTOKINES; HUMANS; PERFORMANCE	The objectives of the present investigation was to analyze the effect of two different recovery modalities on classical markers of exercise-induced muscle damage (EIMD) and inflammation obtained after a simulated trail running race. Endurance trained males (n = 11) completed two experimental trials separated by 1 month in a randomized crossover design; one trial involved passive recovery (PAS), the other a specific whole body cryotherapy (WBC) for 96 h post-exercise (repeated each day). For each trial, subjects performed a 48 min running treadmill exercise followed by PAS or WBC. The Interleukin (IL)-1 (IL-1), IL-6, IL-10, tumor necrosis factor alpha (TNF-alpha), protein C-reactive (CRP) and white blood cells count were measured at rest, immediately post-exercise, and at 24, 48, 72, 96 h in post-exercise recovery. A significant time effect was observed to characterize an inflammatory state (Pre vs. Post) following the exercise bout in all conditions (p<0.05). Indeed, IL-1 beta (Post 1 h) and CRP (Post 24 h) levels decreased and IL-1ra (Post 1 h) increased following WBC when compared to PAS. In WBC condition (p<0.05), TNF-alpha, IL-10 and IL-6 remain unchanged compared to PAS condition. Overall, the results indicated that the WBC was effective in reducing the inflammatory process. These results may be explained by vasoconstriction at muscular level, and both the decrease in cytokines activity pro-inflammatory, and increase in cytokines anti-inflammatory.	[Pournot, Herve; Bieuzen, Francois; Hausswirth, Christophe] Natl Inst Sport Expertise & Performance INSEP, Res Dept, Paris, France; [Pournot, Herve; Louis, Julien] Fac Sport Sci Nice Sophia Antipolis, Lab Physiol Adaptat Motor Performance & Hlth, EA 3837, Nice, France; [Fillard, Jean-Robert] Natl Inst Sport Expertise & Performance INSEP, Dept Med, Paris, France	Sanofi-Aventis; Sanofi France	Pournot, H (corresponding author), Natl Inst Sport Expertise & Performance INSEP, Res Dept, Paris, France.	francois.bieuzen@insep.fr	Louis, Julien/AAI-4392-2021; Bieuzen, Francois/F-8162-2013	Louis, Julien/0000-0002-9109-0958; Bieuzen, Francois/0000-0002-9690-9168; BIEUZEN, Francois/0000-0002-8073-8421	French Ministry of Sports	French Ministry of Sports	This study was entirely supported by the French Ministry of Sports. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALKharfy KM, 2000, SHOCK, V13, P346, DOI 10.1097/00024382-200005000-00002; Banfi G, 2010, SPORTS MED, V40, P509, DOI 10.2165/11531940-000000000-00000; Banfi G, 2009, J THERM BIOL, V34, P55, DOI 10.1016/j.jtherbio.2008.10.003; Barnett A, 2006, SPORTS MED, V36, P781, DOI 10.2165/00007256-200636090-00005; BONDEPETERSEN F, 1992, AVIAT SPACE ENVIR MD, V63, P346; Brenner IKM, 1999, J APPL PHYSIOL, V87, P699, DOI 10.1152/jappl.1999.87.2.699; Castell LM, 1997, EUR J APPL PHYSIOL O, V75, P47; Castellani JW, 2002, MED SCI SPORT EXER, V34, P2002, DOI 10.1097/00005768-200212000-00021; Chatzinikolaou A, 2010, J STRENGTH COND RES, V24, P1389, DOI 10.1519/JSC.0b013e3181d1d318; CLARKSON PM, 1988, J APPL PHYSIOL, V65, P1, DOI 10.1152/jappl.1988.65.1.1; CONTALDO F, 1986, KLIN WOCHENSCHR, V64, P177, DOI 10.1007/BF01713459; COTE DJ, 1988, PHYS THER, V68, P1072, DOI 10.1093/ptj/68.7.1072; Easthope CS, 2010, EUR J APPL PHYSIOL, V110, P1107, DOI 10.1007/s00421-010-1597-1; Gong Y, 2010, CELL TISSUE RES, V339, P437, DOI 10.1007/s00441-009-0908-5; Gregson W, 2011, AM J SPORT MED, V39, P1316, DOI 10.1177/0363546510395497; Halson SL, 2008, INTJ SPORT PHYSIOL, V3, P331, DOI 10.1123/ijspp.3.3.331; Hausswirth C, 2010, SCI SPORT, V25, P121, DOI 10.1016/j.scispo.2009.12.001; Heggie TW, 2009, J TRAVEL MED, V16, P23, DOI 10.1111/j.1708-8305.2008.00269.x; HELLEBRANDT F A, 1956, Phys Ther Rev, V36, P371; Hing WA, 2008, PHYS THER SPORT, V9, P148, DOI 10.1016/j.ptsp.2008.06.001; Hirose L, 2004, EXERC IMMUNOL REV, V10, P75; Howatson G, 2008, SPORTS MED, V38, P483, DOI 10.2165/00007256-200838060-00004; HOWLEY ET, 1995, MED SCI SPORT EXER, V27, P1292; Jiang BB, 2010, J CARDIOVASC TRANSL, V3, P410, DOI 10.1007/s12265-010-9193-7; JUNIOR ECL, 2011, LASER MED SCI, V26, P493; King M, 2009, J STRENGTH COND RES, V23, P1795, DOI 10.1519/JSC.0b013e3181b3f81f; Klimek AT, 2010, INT J OCCUP MED ENV, V23, P181, DOI 10.2478/v10001-010-0019-2; Laursen B, 2000, APPL ERGON, V31, P159, DOI 10.1016/S0003-6870(99)00036-8; Leppaluoto J, 2008, SCAND J CLIN LAB INV, V68, P145, DOI 10.1080/00365510701516350; LUBKOWSKA A, 2011, SCANDINAVIAN J CLIN, P1; Lubkowska A, 2010, EUR J APPL PHYSIOL, V109, P67, DOI 10.1007/s00421-009-1207-2; Lum D, 2010, INT J SPORTS MED, V31, P26, DOI 10.1055/s-0029-1239498; Malm C, 2004, J PHYSIOL-LONDON, V556, P983, DOI 10.1113/jphysiol.2003.056598; Malm C, 1999, J APPL PHYSIOL, V86, P461, DOI 10.1152/jappl.1999.86.2.461; Matsumoto T, 1999, INT J OBESITY, V23, P793, DOI 10.1038/sj.ijo.0800928; MAZLAM MZ, 1994, GUT, V35, P77, DOI 10.1136/gut.35.1.77; McDermott BP, 2009, J ATHL TRAINING, V44, P84, DOI 10.4085/1062-6050-44.1.84; Montgomery PG, 2008, J SPORT SCI, V26, P1135, DOI 10.1080/02640410802104912; Nemet D, 2009, EUR J APPL PHYSIOL, V107, P411, DOI 10.1007/s00421-009-1138-y; Ostrowski K, 1999, J PHYSIOL-LONDON, V515, P287, DOI 10.1111/j.1469-7793.1999.287ad.x; PAPENFUSS W, 2006, POWER COLD WHOLE BOD; Pedersen BK, 2000, BRIT J SPORT MED, V34, P246, DOI 10.1136/bjsm.34.4.246; Platzer C, 2000, J NEUROIMMUNOL, V105, P31, DOI 10.1016/S0165-5728(00)00205-8; PRINGLE J, 2002, EUR J APPL PHYSL, V88, P1; Rhind SG, 2001, AM J PHYSIOL-REG I, V281, pR66; Rymaszewska J, 2008, ARCH IMMUNOL THER EX, V56, P63, DOI 10.1007/s00005-008-0006-5; Savalli L, 2006, SCI SPORT, V21, P36, DOI 10.1016/j.scispo.2006.01.005; Schwameder H, 1999, J SPORT SCI, V17, P969, DOI 10.1080/026404199365362; SHEPHERD JT, 1983, GEN PHARMACOL, V14, P61, DOI 10.1016/0306-3623(83)90064-2; Stacey DL, 2010, J ORTHOP SPORT PHYS, V40, P656, DOI 10.2519/jospt.2010.3224; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; Suzuki K, 2000, EUR J APPL PHYSIOL, V81, P281, DOI 10.1007/s004210050044; Suzuki K, 2006, EUR J APPL PHYSIOL, V98, P525, DOI 10.1007/s00421-006-0296-4; Swenson C, 1996, SCAND J MED SCI SPOR, V6, P193, DOI 10.1111/j.1600-0838.1996.tb00090.x; Tidball JG, 2005, AM J PHYSIOL-REG I, V288, pR345, DOI 10.1152/ajpregu.00454.2004; Walsh NP, 2006, SPORTS MED, V36, P941, DOI 10.2165/00007256-200636110-00003; Walsh NP, 2011, EXERC IMMUNOL REV, V17, P6; WASSERMAN K, 1973, J APPL PHYSIOL, V35, P236, DOI 10.1152/jappl.1973.35.2.236; Westerlund T, 2003, J THERM BIOL, V28, P601, DOI 10.1016/j.jtherbio.2003.08.006; Wozniak A, 2007, EUR J APPL PHYSIOL, V100, P137, DOI 10.1007/s00421-007-0404-0; Yan Z, 2011, J APPL PHYSIOL, V110, P264, DOI 10.1152/japplphysiol.00993.2010; Yanagisawa O, 2007, EUR J APPL PHYSIOL, V100, P737, DOI 10.1007/s00421-007-0470-3	62	109	114	0	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2011	6	7							e22748	10.1371/journal.pone.0022748	http://dx.doi.org/10.1371/journal.pone.0022748			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	799KC	21829501	gold, Green Published, Green Accepted			2023-01-03	WOS:000293284600039
J	Greene, JA				Greene, Jeremy A.			The art of medicine The substance of the brand	LANCET			English	Editorial Material									[Greene, Jeremy A.] Harvard Univ, Dept Hist Sci, Cambridge, MA 02139 USA; [Greene, Jeremy A.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Cambridge, MA 02139 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Greene, JA (corresponding author), Harvard Univ, Dept Hist Sci, Cambridge, MA 02139 USA.	jgreene2@partners.org	Mendoza, Elvia/A-9361-2012					*AMA, 1965, JAMA-J AM MED ASSOC, V194, P1311; Greene Jeremy A., 2007, PRESCRIBING NUMBERS; HEFFERREN JJ, 1962, JAMA-J AM MED ASSOC, V182, P1146; Stinson Nina, 1982, INDIANA LAW REV, V15, P733; SWEETNAM WP, 1964, PRACTITIONER, V192, P543	5	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 9	2011	378	9786					120	121		10.1016/S0140-6736(11)61077-5	http://dx.doi.org/10.1016/S0140-6736(11)61077-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	795CJ	21748873				2023-01-03	WOS:000292948800017
J	Fimognari, C; Lenzi, M; Ferruzzi, L; Turrini, E; Scartezzini, P; Poli, F; Gotti, R; Guerrini, A; Carulli, G; Ottaviano, V; Cantelli-Forti, G; Hrelia, P				Fimognari, Carmela; Lenzi, Monia; Ferruzzi, Lorenzo; Turrini, Eleonora; Scartezzini, Paolo; Poli, Ferruccio; Gotti, Roberto; Guerrini, Alessandra; Carulli, Giovanni; Ottaviano, Virginia; Cantelli-Forti, Giorgio; Hrelia, Patrizia			Mitochondrial Pathway Mediates the Antileukemic Effects of Hemidesmus Indicus, a Promising Botanical Drug	PLOS ONE			English	Article							CELL-CYCLE; S-PHASE; PERMEABILITY TRANSITION; OVARIAN-CANCER; APOPTOSIS; CALCIUM; THERAPEUTICS; TARGETS; ARREST; DEATH	Background: Although cancers are characterized by the deregulation of multiple signalling pathways, most current anticancer therapies involve the modulation of a single target. Because of the enormous biological diversity of cancer, strategic combination of agents targeted against the most critical of those alterations is needed. Due to their complex nature, plant products interact with numerous targets and influence several biochemical and molecular cascades. The interest in further development of botanical drugs has been increasing steadily and the FDA recently approved the first new botanical prescription drug. The present study is designed to explore the potential antileukemic properties of Hemidesmus indicus with a view to contributing to further development of botanical drugs. Hemidesmus was submitted to an extensive in vitro preclinical evaluation. Methodology/Principal Findings: A variety of cellular assays and flow cytometry, as well as a phytochemical screening, were performed on different leukemic cell lines. We have demonstrated that Hemidesmus modulated many components of intracellular signaling pathways involved in cell viability and proliferation and altered the protein expression, eventually leading to tumor cell death, mediated by a loss of mitochondrial transmembrane potential and increased Bax/Bcl-2 ratio. ADP, adenine nucleotide translocator and mitochondrial permeability transition pore inhibitors did not reverse Hemidesmus-induced mitochondrial depolarization. Hemidesmus induced a significant [Ca(2+)](i) raise through the mobilization of intracellular Ca(2+) stores. Moreover, Hemidesmus significantly enhanced the antitumor activity of three commonly used chemotherapeutic drugs (methotrexate, 6-thioguanine, cytarabine). A clinically relevant observation is that its cytotoxic activity was also recorded in primary cells from acute myeloid leukemic patients. Conclusions/Significance: These results indicate the molecular basis of the antileukemic effects of Hemidesmus and identify the mitochondrial pathways and [Ca(2+)](i) as crucial actors in its anticancer activity. On these bases, we conclude that Hemidesmus can represent a valuable tool in the anticancer pharmacology, and should be considered for further investigations.	[Fimognari, Carmela; Lenzi, Monia; Ferruzzi, Lorenzo; Turrini, Eleonora; Cantelli-Forti, Giorgio; Hrelia, Patrizia] Univ Bologna, Dept Pharmacol, Bologna, Italy; [Scartezzini, Paolo; Poli, Ferruccio] Univ Bologna, Dept Evolutionary & Expt Biol, Bologna, Italy; [Gotti, Roberto] Univ Bologna, Dept Pharmaceut Sci, I-40126 Bologna, Italy; [Guerrini, Alessandra] Univ Ferrara, Dept Biol & Evolut, I-44100 Ferrara, Italy; [Carulli, Giovanni; Ottaviano, Virginia] Univ Pisa, Div Hematol, Dept Oncol Transplants & New Technol Med, Pisa, Italy	University of Bologna; University of Bologna; University of Bologna; University of Ferrara; University of Pisa	Fimognari, C (corresponding author), Univ Bologna, Dept Pharmacol, Bologna, Italy.	carmela.fimognari@unibo.it	Hrelia, Patrizia/AAC-2071-2020; Guerrini, Alessandra/N-1419-2015; Turrini, Eleonora/I-3629-2019; Fimognari, Carmela/J-7678-2019	Guerrini, Alessandra/0000-0002-6553-3938; Turrini, Eleonora/0000-0003-4743-1126; Fimognari, Carmela/0000-0002-2461-8214; gotti, roberto/0000-0003-0622-2248; HRELIA, Patrizia/0000-0002-8415-3711	Ministero dell'Istruzione dell'Universita e della Ricerca [2007SSZMPK]; FIRB Piattaforme/Reti [RBPR05NWWC_002]	Ministero dell'Istruzione dell'Universita e della Ricerca(Ministry of Education, Universities and Research (MIUR)); FIRB Piattaforme/Reti	This work was supported by Ministero dell'Istruzione dell'Universita e della Ricerca (http://sitouniversitario.cineca.it; grant number: 2007SSZMPK) and FIRB Piattaforme/Reti 2006 (http://sitofirb.cineca.it; grant number: RBPR05NWWC_002). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Aggarwal BB, 2009, BIOCHEM PHARMACOL, V78, P1083, DOI 10.1016/j.bcp.2009.05.027; Anand P, 2008, CANCER LETT, V267, P133, DOI 10.1016/j.canlet.2008.03.025; Armstrong JS, 2006, MITOCHONDRION, V6, P225, DOI 10.1016/j.mito.2006.07.006; Austin A., 2008, BR J BIOL SCI, V8, P1, DOI DOI 10.3923/jbs.2008.1.12; Borel F, 2002, J CELL SCI, V115, P2829; Bosanquet AG, 2008, INNOVATIVE LEUKEMIA, P23; BOSANQUET AG, 1994, FORUM TRENDS EXP CLI, V4, P179; Bosanquet Andrew G, 2004, J Exp Ther Oncol, V4, P145; Chen ST, 2008, NAT BIOTECHNOL, V26, P1077, DOI 10.1038/nbt1008-1077; Choi JH, 2008, FOOD CHEM TOXICOL, V46, P3486, DOI 10.1016/j.fct.2008.08.026; Cree IA, 2009, CURR OPIN OBSTET GYN, V21, P39, DOI 10.1097/GCO.0b013e32832210ff; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Cuello M, 2001, GYNECOL ONCOL, V81, P380, DOI 10.1006/gyno.2001.6194; Das S, 2006, PHYTOTHER RES, V20, P784, DOI 10.1002/ptr.1963; de Kok TM, 2008, EUR J NUTR, V47, P51, DOI 10.1007/s00394-008-2006-y; Deepak D, 1997, PHYTOCHEMISTRY, V44, P145, DOI 10.1016/S0031-9422(96)00393-7; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; *GOV IND MIN HLTH, 1989, AYURV PHARM IND; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Harper JL, 2003, BIOCHEM PHARMACOL, V65, P329, DOI 10.1016/S0006-2952(02)01488-0; Hsin YH, 2006, APOPTOSIS, V11, P2167, DOI 10.1007/s10495-006-0289-0; Ichikawa H, 2007, CURR PHARM DESIGN, V13, P3400, DOI 10.2174/138161207782360492; Jiang N, 2006, WORLD J GASTROENTERO, V12, P4694, DOI 10.3748/wjg.v12.i29.4694; Keith CT, 2005, NAT REV DRUG DISCOV, V4, P71, DOI 10.1038/nrd1609; Khan N, 2007, CARCINOGENESIS, V28, P233, DOI 10.1093/carcin/bgl243; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koh DW, 2005, PHARMACOL RES, V52, P5, DOI 10.1016/j.phrs.2005.02.011; Kotnis MS, 2004, NEPHROLOGY, V9, P142, DOI 10.1111/j.1440-1797.2004.00247.x; Lampronti I, 2005, MED CHEM, V1, P327, DOI 10.2174/1573406054368684; Levi F, 2007, ADV DRUG DELIVER REV, V59, P1015, DOI 10.1016/j.addr.2006.11.001; Macho A, 1999, CELL DEATH DIFFER, V6, P155, DOI 10.1038/sj.cdd.4400465; Macho A, 2004, BIOCHEM PHARMACOL, V68, P875, DOI 10.1016/j.bcp.2004.05.016; Meshinchi S, 2009, CLIN CANCER RES, V15, P4263, DOI 10.1158/1078-0432.CCR-08-1123; Moncada S, 2010, BRIT J PHARMACOL, V160, P217, DOI 10.1111/j.1476-5381.2010.00706.x; Nagourney Robert A, 2006, Curr Treat Options Oncol, V7, P103, DOI 10.1007/s11864-006-0045-2; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; NYGREN P, 2008, EXP OPIN MED DIAGN, V2, P1, DOI DOI 10.1517/17530059.2.1.1; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Pedeux R, 1998, J INVEST DERMATOL, V111, P472, DOI 10.1046/j.1523-1747.1998.00324.x; Prabakan M, 2000, FITOTERAPIA, V71, P55, DOI 10.1016/S0367-326X(99)00120-3; Previati M, 2007, J CHEM NEUROANAT, V34, P128, DOI 10.1016/j.jchemneu.2007.05.009; Qanungo S, 2005, CARCINOGENESIS, V26, P958, DOI 10.1093/carcin/bgi040; Qureshi S, 1997, Hindustan Antibiot Bull, V39, P56; Radhakrishnan SK, 2004, ONCOGENE, V23, P4173, DOI 10.1038/sj.onc.1207571; Roy SK, 2001, PHARMAZIE, V56, P244; Salvioli S, 1997, FEBS LETT, V411, P77, DOI 10.1016/S0014-5793(97)00669-8; Shapiro GI, 1999, J CLIN INVEST, V104, P1645, DOI 10.1172/JCI9054; Sircar D, 2007, CHROMATOGRAPHIA, V65, P349, DOI 10.1365/s10337-006-0146-x; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Toogood PL, 2002, CURR OPIN CHEM BIOL, V6, P472, DOI 10.1016/S1367-5931(02)00342-3; Tsang WY, 2007, J CELL BIOL, V178, P621, DOI 10.1083/jcb.200701166; *US DEP HHS, 2004, GUID IND; Williams SN, 2000, CHEM-BIOL INTERACT, V128, P211, DOI 10.1016/S0009-2797(00)00204-0; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zhou JR, 2003, J NUTR, V133, P516, DOI 10.1093/jn/133.2.516; Zimmermann GR, 2007, DRUG DISCOV TODAY, V12, P34, DOI 10.1016/j.drudis.2006.11.008	59	27	27	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	JUN 28	2011	6	6							e21544	10.1371/journal.pone.0021544	http://dx.doi.org/10.1371/journal.pone.0021544			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	784FW	21738701	gold, Green Published, Green Submitted			2023-01-03	WOS:000292142800038
J	Gabbe, BJ; Lyons, RA; Lecky, FE; Bouamra, O; Woodford, M; Coats, TJ; Cameron, PA				Gabbe, Belinda J.; Lyons, Ronan A.; Lecky, Fiona E.; Bouamra, Omar; Woodford, Maralyn; Coats, Timothy J.; Cameron, Peter A.			Comparison of Mortality Following Hospitalisation for Isolated Head Injury in England and Wales, and Victoria, Australia	PLOS ONE			English	Article							TRAUMATIC BRAIN-INJURY; MAJOR TRAUMA; SYSTEM; CARE; REGISTRY; QUALITY; MANAGEMENT; SURVIVAL; OUTCOMES; TRENDS	Background: Traumatic brain injury (TBI) remains a leading cause of death and disability. The National Institute for Health and Clinical Excellence (NICE) guidelines recommend transfer of severe TBI cases to neurosurgical centres, irrespective of the need for neurosurgery. This observational study investigated the risk-adjusted mortality of isolated TBI admissions in England/Wales, and Victoria, Australia, and the impact of neurosurgical centre management on outcomes. Methods: Isolated TBI admissions (> 15 years, July 2005-June 2006) were extracted from the hospital discharge datasets for both jurisdictions. Severe isolated TBI (AIS severity >3) admissions were provided by the Trauma Audit and Research Network (TARN) and Victorian State Trauma Registry (VSTR) for England/Wales, and Victoria, respectively. Multivariable logistic regression was used to compare risk-adjusted mortality between jurisdictions. Findings: Mortality was 12% (749/6256) in England/Wales and 9% (91/1048) in Victoria for isolated TBI admissions. Adjusted odds of death in England/Wales were higher compared to Victoria overall (OR 2.0, 95% CI: 1.6, 2.5), and for cases <65 years (OR 2.36, 95% CI: 1.51, 3.69). For severe TBI, mortality was 23% (133/575) for TARN and 20% (68/346) for VSTR, with 72% of TARN and 86% of VSTR cases managed at a neurosurgical centre. The adjusted mortality odds for severe TBI cases in TARN were higher compared to the VSTR (OR 1.45, 95% CI: 0.96, 2.19), but particularly for cases <65 years (OR 2.04, 95% CI: 1.07, 3.90). Neurosurgical centre management modified the effect overall (OR 1.12, 95% CI: 0.73, 1.74) and for cases <65 years (OR 1.53, 95% CI: 0.77, 3.03). Conclusion: The risk-adjusted odds of mortality for all isolated TBI admissions, and severe TBI cases, were higher in England/Wales when compared to Victoria. The lower percentage of cases managed at neurosurgical centres in England and Wales was an explanatory factor, supporting the changes made to the NICE guidelines.	[Gabbe, Belinda J.; Cameron, Peter A.] Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia; [Gabbe, Belinda J.; Cameron, Peter A.] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Lyons, Ronan A.] Swansea Univ, Sch Med, Swansea, W Glam, Wales; [Lecky, Fiona E.; Bouamra, Omar; Woodford, Maralyn; Coats, Timothy J.] Univ Manchester, Salford Royal Hosp, Manchester Acad Hlth Sci Ctr,Sch Community Based, Trauma Audit & Res Network,Hlth Sci Res Grp, Salford, Lancs, England; [Lecky, Fiona E.] Salford Royal Hosp, Dept Emergency Med, Salford, Lancs, England; [Coats, Timothy J.] Leicester Royal Infirm, Dept Accid & Emergency, Leicester, Leics, England; [Cameron, Peter A.] Alfred Hosp, Emergency & Trauma Ctr, Melbourne, Vic, Australia	Florey Institute of Neuroscience & Mental Health; Monash University; Florey Institute of Neuroscience & Mental Health; Swansea University; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Manchester; Salford Royal NHS Foundation Trust; Salford Royal Hospital; University of Leicester; Florey Institute of Neuroscience & Mental Health	Gabbe, BJ (corresponding author), Monash Univ, Alfred Hosp, Dept Epidemiol & Prevent Med, Melbourne, Vic 3181, Australia.	belinda.gabbe@monash.edu	Coats, Timothy/AAW-1254-2021; Lyons, Ronan/G-7741-2012	Coats, Timothy/0000-0003-2736-2784; Lyons, Ronan/0000-0001-5225-000X; Gabbe, Belinda/0000-0001-7096-7688; Cameron, Peter/0000-0002-1443-557X	Department of Human Services (Victoria); Transport Accident Commission (TAC) Health Research; National Health and Medical Research Council of Australia	Department of Human Services (Victoria); Transport Accident Commission (TAC) Health Research; National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	The VSTR is a Department of Human Services (Victoria) and Transport Accident Commission (TAC) Health Research funded and approved initiative. Dr. Belinda Gabbe and Prof. Peter Cameron were supported by a Career Development Award and a Practitioner Fellowship, respectively, from the National Health and Medical Research Council of Australia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Cameron PA, 2005, J TRAUMA, V59, P1469, DOI 10.1097/01.ta.0000198350.15936.a1; Cameron PA, 2004, ANZ J SURG, V74, P424, DOI 10.1111/j.1445-1433.2004.03029.x; Cameron PA, 2006, INJURY, V37, P1178, DOI 10.1016/j.injury.2006.07.015; Cameron PA, 2008, MED J AUSTRALIA, V189, P546, DOI 10.5694/j.1326-5377.2008.tb02176.x; Celso B, 2006, J TRAUMA, V60, P371, DOI 10.1097/01.ta.0000197916.99629.eb; Coats TJ, 1999, J ACCID EMERG MED, V16, P182; Esposito Thomas J, 2006, Adv Surg, V40, P213, DOI 10.1016/j.yasu.2006.06.002; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Gabbe Belinda J, 2003, Emerg Med (Fremantle), V15, P353, DOI 10.1046/j.1442-2026.2003.00474.x; Gabbe BJ, 2011, ANN SURG, V253, P138, DOI 10.1097/SLA.0b013e3181f6685b; Gabbe BJ, 2010, J TRAUMA, V69, P532, DOI 10.1097/TA.0b013e3181e5125b; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lee A, 2003, INJURY, V34, P815, DOI 10.1016/S0020-1383(02)00395-9; MacLeod JBA, 2004, AM SURGEON, V70, P805; Mendelow AD, 2008, LANCET, V372, P685, DOI 10.1016/S0140-6736(08)61280-5; Moore L, 2005, J TRAUMA, V59, P698, DOI 10.1097/01.ta.0000177700.54943.ee; MULLINS RJ, 1994, JAMA-J AM MED ASSOC, V271, P1919, DOI 10.1001/jama.271.24.1919; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Nathens AB, 2004, LANCET, V363, P1794, DOI 10.1016/S0140-6736(04)16307-1; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; O'Reilly GM, 2010, ACAD EMERG MED, V17, P1122, DOI 10.1111/j.1553-2712.2010.00887.x; Papa L, 2006, J TRAUMA, V61, P261, DOI 10.1097/01.ta.0000221789.53864.ba; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Yeung JHH, 2008, INJURY, V39, P1034, DOI 10.1016/j.injury.2008.03.017	27	14	14	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAY 31	2011	6	5							e20545	10.1371/journal.pone.0020545	http://dx.doi.org/10.1371/journal.pone.0020545			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	770OP	21655237	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000291097600093
J	Gay, C; Dibben, O; Anderson, JA; Stacey, A; Mayo, AJ; Norris, PJ; Kuruc, JD; Salazar-Gonzalez, JF; Li, H; Keele, BF; Hicks, C; Margolis, D; Ferrari, G; Haynes, B; Swanstrom, R; Shaw, GM; Hahn, BH; Eron, JJ; Borrow, P; Cohen, MS				Gay, Cynthia; Dibben, Oliver; Anderson, Jeffrey A.; Stacey, Andrea; Mayo, Ashley J.; Norris, Philip J.; Kuruc, JoAnn D.; Salazar-Gonzalez, Jesus F.; Li, Hui; Keele, Brandon F.; Hicks, Charles; Margolis, David; Ferrari, Guido; Haynes, Barton; Swanstrom, Ronald; Shaw, George M.; Hahn, Beatrice H.; Eron, Joseph J.; Borrow, Persephone; Cohen, Myron S.			Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy	PLOS ONE			English	Article							PLASMA CYTOKINE LEVELS; CD4(+) T-CELLS; SEXUAL TRANSMISSION; VIRUS; VIREMIA; AMPLIFICATION; RESPONSES; MULTIPLE; REPLICATION; EFFICIENT	Background: Acute HIV infection (AHI) is a critical phase of infection when irreparable damage to the immune system occurs and subjects are very infectious. We studied subjects with AHI prospectively to develop better treatment and public health interventions. Methods: Cross-sectional screening was employed to detect HIV RNA positive, antibody negative subjects. Date of HIV acquisition was estimated from clinical history and correlated with sequence diversity assessed by single genome amplification (SGA). Twenty-two cytokines/chemokines were measured from enrollment through week 24. Results: Thirty-seven AHI subjects were studied. In 7 participants with limited exposure windows, the median exposure to HIV occurred 14 days before symptom onset. Lack of viral sequence diversification confirmed the short duration of infection. Transmission dates estimated by SGA/sequencing using molecular clock models correlated with transmission dates estimated by symptom onset in individuals infected with single HIV variants (mean of 28 versus 33 days). Only 10 of 22 cytokines/chemokines were significantly elevated among AHI participants at enrollment compared to uninfected controls, and only 4 participants remained seronegative at enrollment. Discussion: The results emphasize the difficulty in recruiting subjects early in AHI. Viral sequence diversity proved accurate in estimating time of infection. Regardless of aggressive screening, peak viremia and inflammation occurred before enrollment and potential intervention. Given the personal and public health importance, improved AHI detection is urgently needed.	[Gay, Cynthia; Anderson, Jeffrey A.; Mayo, Ashley J.; Kuruc, JoAnn D.; Margolis, David; Swanstrom, Ronald; Eron, Joseph J.; Cohen, Myron S.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA; [Dibben, Oliver; Stacey, Andrea; Borrow, Persephone] Univ Oxford, Nuffield Dept Clin Med, Weatherall Inst Mol Med, Oxford, England; [Norris, Philip J.] Blood Syst Res Inst, San Francisco, CA USA; [Norris, Philip J.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Salazar-Gonzalez, Jesus F.; Li, Hui; Keele, Brandon F.; Shaw, George M.; Hahn, Beatrice H.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Hicks, Charles; Ferrari, Guido; Haynes, Barton] Duke Univ, Durham, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Oxford; Vitalant; Vitalant Research Institute; University of California System; University of California San Francisco; University of Alabama System; University of Alabama Birmingham; Duke University	Gay, C (corresponding author), Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27515 USA.	cynthia_gay@med.unc.edu	Margolis, David M./Y-2468-2019; Ferrari, Guido/A-6088-2015; Ferrari, Guido/Z-2137-2019; Gay, Cynthia/AAG-2927-2019	Margolis, David M./0000-0001-5714-0002; Ferrari, Guido/0000-0001-7747-3349; Salazar-Gonzalez, Jesus F./0000-0003-4626-6448; Gay, Cynthia/0000-0002-3620-3059; Borrow, Persephone/0000-0002-3877-9780; Hahn, Beatrice/0000-0002-9400-9887	Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health [AI67854]; Division of Research Resources [RR025747]; UNC Center for AIDS Research (CFAR) National Institutes of Health [AI50410]; Bristol Myers Squibb; Gilead Sciences; GSK; Merck; Tibotec; Gilead; Myriad Pharmaceuticals; Pfizer; Abbott; Roche; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067854, U01AI067854, P30AI050410] Funding Source: NIH RePORTER	Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Division of Research Resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); UNC Center for AIDS Research (CFAR) National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bristol Myers Squibb(Bristol-Myers Squibb); Gilead Sciences(Gilead Sciences); GSK(GlaxoSmithKline); Merck(Merck & Company); Tibotec; Gilead(Gilead Sciences); Myriad Pharmaceuticals; Pfizer(Pfizer); Abbott(Abbott Laboratories); Roche(Roche Holding); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was supported by the Division of AIDS, U.S. National Institute of Allergy and Infectious Diseases, U.S. National Institutes of Health (grant AI67854), from a UNC Clinical and Translational Science Award (CTSA) of the Division of Research Resources (grant RR025747), and AI50410 UNC Center for AIDS Research (CFAR) National Institutes of Health. P.B. is a Jenner Institute Investigator. Bristol Myers Squibb and Gilead Sciences, Inc, provided antiretroviral medications for a treatment study in which participants of this study could co-enroll. These companies and all other funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; C.G. has received research support from Bristol Myers Squibb and Gilead Sciences for studies which participants in this study could co-enroll on, but not for the CHAVI 001 study. C.H. has received grant support and/or consulting/honoraria from BMS, GSK, Merck, Tibotec, Gilead, Myriad Pharmaceuticals, Pfizer, none of which is related to this study. D.M. has received research support from Bristol Myers Squibb, Gilead Sciences, Merck, Abbott, and Roche, but none for this study, and is a honoraria for professional services to Bristol Myers Squibb, Merck, Chimerix, and Tibotec Therapeutics. J.E. receives research support from Merck and GlaxoSmithKline which is not related to this study and is a consultant to Bristol Myers Squibb, Merck, and Tibotec Therapeutics. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The remaining authors have no competing interests to declare.	Abecasis AB, 2009, J VIROL, V83, P12917, DOI 10.1128/JVI.01022-09; Abel K, 2005, J VIROL, V79, P12164, DOI 10.1128/JVI.79.19.12164-12172.2005; Anderson JA, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001053; BORROW P, 1994, J VIROL, V68, P6103, DOI 10.1128/JVI.68.9.6103-6110.1994; Bowman MC, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409000970; Brenner BG, 2007, J INFECT DIS, V195, P951, DOI 10.1086/512088; de Oliveira T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009311; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Drummond AJ, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-214; EDMONSON PF, 1992, NUCLEIC ACIDS RES, V20, P4933, DOI 10.1093/nar/20.18.4933; FIDLER S, 2010, COMPARISON HIV VIRAL; Fidler S, 2008, CURR OPIN INFECT DIS, V21, P4, DOI 10.1097/QCO.0b013e3282f428bf; GAY C, 2008, EFFICACY NNRTI BASED; GIANELLA S, 2010, IMPACT EARLY ART PRO; Goonetilleke N, 2009, J EXP MED, V206, P1253, DOI 10.1084/jem.20090365; Haissman JM, 2009, JAIDS-J ACQ IMM DEF, V52, P493, DOI 10.1097/QAI.0b013e3181b627dc; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Keele BF, 2008, P NATL ACAD SCI USA, V105, P7552, DOI 10.1073/pnas.0802203105; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; Lee HY, 2009, J THEOR BIOL, V261, P341, DOI 10.1016/j.jtbi.2009.07.038; Lee HH, 2010, J INFECT DIS, V201, pS65, DOI 10.1086/650385; Li QS, 2005, NATURE, V434, P1148, DOI 10.1038/nature03513; Lindback S, 2000, AIDS, V14, P2333, DOI 10.1097/00002030-200010200-00014; Mattapallil JJ, 2005, NATURE, V434, P1093, DOI 10.1038/nature03501; Mehandru S, 2006, PLOS MED, V3, P2335, DOI 10.1371/journal.pmed.0030484; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Miller WC, 2010, CURR OPIN HIV AIDS, V5, P277, DOI 10.1097/COH.0b013e32833a0d3a; Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749; Palmer S, 2005, J CLIN MICROBIOL, V43, P406, DOI 10.1128/JCM.43.1.406-413.2005; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; Pilcher CD, 2005, NEW ENGL J MED, V352, P1873, DOI 10.1056/NEJMoa042291; Pilcher CD, 2004, J INFECT DIS, V189, P1785, DOI 10.1086/386333; Regidor DL, 2011, AIDS, V25, P303, DOI 10.1097/QAD.0b013e32834273ad; RIEDER P, 2010, STRONG EFFECT EARLY; Roberts L, 2010, AIDS, V24, P819, DOI 10.1097/QAD.0b013e3283367836; Sachdeva RK, 2010, J INTERF CYTOK RES, V30, P299, DOI 10.1089/jir.2009.0056; Salazar-Gonzalez JF, 2008, J VIROL, V82, P3952, DOI 10.1128/JVI.02660-07; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SIMMONDS P, 1990, J VIROL, V64, P5840, DOI 10.1128/JVI.64.12.5840-5850.1990; Stacey AR, 2009, J VIROL, V83, P3719, DOI 10.1128/JVI.01844-08; Tomaras GD, 2008, J VIROL, V82, P12449, DOI 10.1128/JVI.01708-08; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411	44	54	55	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAY 10	2011	6	5							e19617	10.1371/journal.pone.0019617	http://dx.doi.org/10.1371/journal.pone.0019617			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	761YU	21573003	Green Published, gold			2023-01-03	WOS:000290440200014
J	Shrank, WH				Shrank, William H.			Our Bulging Medicine Cabinets - The Other Side of Medication Nonadherence	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Shrank, William H.] Brigham & Womens Hosp, Dept Med, Div Pharmacoeidemiol & Pharmacoecon, Boston, MA 02115 USA; [Shrank, William H.] Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Shrank, WH (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoeidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.							Benotti MJ, 2009, ENVIRON SCI TECHNOL, V43, P597, DOI 10.1021/es801845a; Catalano RF, 2011, ADDICT BEHAV, V36, P79, DOI 10.1016/j.addbeh.2010.08.028; *FOOD DRUG ADM, DISP FLUSH CERT UN M; McCabe SE, 2009, ARCH PEDIAT ADOL MED, V163, P739, DOI 10.1001/archpediatrics.2009.120; Richman PB, 2001, AM J EMERG MED, V19, P57, DOI 10.1053/ajem.2001.20035	5	26	26	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 28	2011	364	17					1591	1593		10.1056/NEJMp1011624	http://dx.doi.org/10.1056/NEJMp1011624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755NW	21524212				2023-01-03	WOS:000289940400004
J	Marshall, BDL; Milloy, MJ; Wood, E; Montaner, JSG; Kerr, T				Marshall, Brandon D. L.; Milloy, M-J; Wood, Evan; Montaner, Julio S. G.; Kerr, Thomas			Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study	LANCET			English	Article							NEW-YORK-CITY; DRUG-USERS; COHORT; VANCOUVER; RISK; ATTENDANCE; PATTERNS; TRENDS; IMPACT; DEATH	Background Overdose from illicit drugs is a leading cause of premature mortality in North America. Internationally, more than 65 supervised injecting facilities (SIFs), where drug users can inject pre-obtained illicit drugs, have been opened as part of various strategies to reduce the harms associated with drug use. We sought to determine whether the opening of an SIF in Vancouver, BC, Canada, was associated with a reduction in overdose mortality. Methods We examined population-based overdose mortality rates for the period before (Jan 1, 2001, to Sept 20, 2003) and after (Sept 21, 2003, to Dec 31, 2005) the opening of the Vancouver SIF. The location of death was determined from provincial coroner records. We compared overdose fatality rates within an a priori specified 500 m radius of the SIF and for the rest of the city. Findings Of 290 decedents, 229 (79.0%) were male, and the median age at death was 40 years (IQR 32-48 years). A third (89, 30.7%) of deaths occurred in city blocks within 500 m of the SIF. The fatal overdose rate in this area decreased by 35.0% after the opening of the SIF, from 253.8 to 165.1 deaths per 100000 person-years (p=0.048). By contrast, during the same period, the fatal overdose rate in the rest of the city decreased by only 9.3%, from 7.6 to 6.9 deaths per 100 000 person-years (p=0.490). There was a significant interaction of rate differences across strata (p=0.049). Interpretation SIFs should be considered where injection drug use is prevalent, particularly in areas with high densities of overdose.	[Marshall, Brandon D. L.; Milloy, M-J; Wood, Evan; Montaner, Julio S. G.; Kerr, Thomas] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada; [Wood, Evan; Montaner, Julio S. G.; Kerr, Thomas] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Milloy, M-J] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Marshall, Brandon D. L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA	B.C. Centre for Excellence in HIV/AIDS; University of British Columbia; University of British Columbia; University of British Columbia; Columbia University	Kerr, T (corresponding author), St Pauls Hosp, BC Ctr Excellence HIV AIDS, Urban Hlth Res Initiat, 608-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	uhri-tk@cfenet.ubc.ca	Montaner, Julio/K-7621-2012; Marshall, Brandon/B-4895-2010; Milloy, M-J/AAY-3618-2020	Marshall, Brandon/0000-0002-0134-7052; 	Abbott Laboratories; Agouron Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Borean Pharma AS; Bristol-Myers Squibb; DuPont Pharma; Gilead Sciences; GlaxoSmithKline; Hoffmann-La Roche; Immune Response Corporation; Incyte; Janssen-Ortho Inc; Kucera Pharmaceutical Company; Merck Frosst Laboratories; Pfizer Canada; Sanofi Pasteur; Shire Biochem; Tibotec Pharmaceuticals; Trimeris; Health Canada; Canadian Institutes of Health Research (CIHR); Vancouver Coastal Health; Michael Smith Foundation for Health Research (MSFHR)	Abbott Laboratories(Abbott Laboratories); Agouron Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals(Boehringer Ingelheim); Borean Pharma AS; Bristol-Myers Squibb(Bristol-Myers Squibb); DuPont Pharma; Gilead Sciences(Gilead Sciences); GlaxoSmithKline(GlaxoSmithKline); Hoffmann-La Roche(Hoffmann-La Roche); Immune Response Corporation; Incyte; Janssen-Ortho Inc; Kucera Pharmaceutical Company; Merck Frosst Laboratories; Pfizer Canada(Pfizer); Sanofi Pasteur; Shire Biochem; Tibotec Pharmaceuticals; Trimeris; Health Canada; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Vancouver Coastal Health; Michael Smith Foundation for Health Research (MSFHR)(Michael Smith Foundation for Health Research)	JSGM has received educational grants from, serves as an ad hoc adviser to, or speaks at various events sponsored by Abbott Laboratories, Agouron Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Borean Pharma AS, Bristol-Myers Squibb, DuPont Pharma, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Immune Response Corporation, Incyte, Janssen-Ortho Inc, Kucera Pharmaceutical Company, Merck Frosst Laboratories, Pfizer Canada, Sanofi Pasteur, Shire Biochem, Tibotec Pharmaceuticals, and Trimeris. No other authors declared any conflicts of interest.; We gratefully acknowledge the invaluable assistance of the Chief Coroner and other officials of the British Columbia Coroners Service, in particular Sara Weinstein and Tej Sidhu. We thank Daniel Kane, Deborah Graham, and Tricia Collingham of the British Columbia Centre for Excellence in HIV/AIDS for their research and administrative assistance. The SIF assessment was originally funded by a contribution from Health Canada, although the views expressed in this analysis do not represent the official policies of Health Canada. The study is now supported by the Canadian Institutes of Health Research (CIHR) and Vancouver Coastal Health. TK is supported by a CIHR New Investigator Award and a Michael Smith Foundation for Health Research (MSFHR) Scholar Award. BDLM and MJM are supported by Canada Graduate Scholarships from CIHR; BDLM is supported by a Senior Graduate Trainee Award from Michael Smith Foundation for Health Research.	*ANG REID, CAN AR SUPP INS OPP; Apparicio P, 2008, INT J HEALTH GEOGR, V7, DOI 10.1186/1476-072X-7-7; Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Bohnert ASB, 2010, ADDICTION, V105, P1049, DOI 10.1111/j.1360-0443.2009.02887.x; Bohnert ASB, 2009, ANN EMERG MED, V54, P618, DOI 10.1016/j.annemergmed.2009.05.004; Bow C Jennifer D, 2004, Int J Health Geogr, V3, P5, DOI 10.1186/1476-072X-3-5; Brugal MT, 2005, ADDICTION, V100, P981, DOI 10.1111/j.1360-0443.2005.01089.x; BUXTON JA, VANCOUVER DRUG USE E; Cameron AC, 1997, J ECONOMETRICS, V77, P329; *CDCP, UN DRUG POIS US; Crandall CG, 2002, ANN INTERN MED, V136, P785, DOI 10.7326/0003-4819-136-11-200206040-00006; Darke S, 2003, J URBAN HEALTH, V80, P189, DOI 10.1093/jurban/jtg022; DeBeck K, 2008, SUBST ABUSE TREAT PR, V3, DOI 10.1186/1747-597X-3-11; Fairbairn N, 2008, SOC SCI MED, V67, P817, DOI 10.1016/j.socscimed.2008.05.012; Fielden Sarah J, 2007, Harm Reduct J, V4, P10, DOI 10.1186/1477-7517-4-10; Fischer B, 2006, CAN J PUBLIC HEALTH, V97, P384, DOI 10.1007/BF03405347; Galai N, 2003, AM J EPIDEMIOL, V158, P695, DOI 10.1093/aje/kwg209; Galea S, 2003, J URBAN HEALTH, V80, P201, DOI 10.1093/jurban/jtg023; Hall W, 2005, LANCET, V366, P271, DOI 10.1016/S0140-6736(05)66476-8; HEDRICH D, EUROPEAN REPORT DRUG; Hulse GK, 1999, ADDICTION, V94, P221, DOI 10.1046/j.1360-0443.1999.9422216.x; Kaye S, 2004, ADDICTION, V99, P1315, DOI 10.1111/j.1360-0443.2004.00875.x; Kerr T, 2006, BRIT MED J, V332, P220, DOI 10.1136/bmj.332.7535.220; Kerr T, 2005, LANCET, V366, P316, DOI 10.1016/S0140-6736(05)66475-6; Kerr T, 2008, LANCET, V372, P354, DOI 10.1016/S0140-6736(08)61138-1; Kerr T, 2007, AM J PUBLIC HEALTH, V97, P1228, DOI 10.2105/AJPH.2006.086256; Kerr T, 2006, INT J DRUG POLICY, V17, P436, DOI 10.1016/j.drugpo.2006.05.008; Kimber J, 2003, DRUG ALCOHOL REV, V22, P227, DOI 10.1080/095952301000116951; Lloyd-Smith E, 2009, DRUG ALCOHOL DEPEN, V99, P176, DOI 10.1016/j.drugalcdep.2008.07.003; Milloy MJ, 2010, ADDICTION, V105, P1962, DOI 10.1111/j.1360-0443.2010.03077.x; *MSIC EV COMM, FIN REP EV SYDN MED; Petrar S, 2007, ADDICT BEHAV, V32, P1088, DOI 10.1016/j.addbeh.2006.07.013; Rachlis BS, 2008, HEALTH PLACE, V14, P536, DOI 10.1016/j.healthplace.2007.10.006; Rothman KJ., 2008, MODERN EPIDEMIOLOGY; Small W, 2008, DRUG ALCOHOL DEPEN, V98, P159, DOI 10.1016/j.drugalcdep.2008.05.014; Small W, 2007, INT J DRUG POLICY, V18, P27, DOI 10.1016/j.drugpo.2006.11.019; Spittal PM, 2006, AIDS CARE, V18, P101, DOI 10.1080/09540120500159292; *STAT CAN, 2003, POP FAM EST METH STA; Statistics Canada, 2007, POST COD CONV FIL PC; Stoove MA, 2008, DRUG ALCOHOL DEPEN, V96, P281, DOI 10.1016/j.drugalcdep.2008.03.006; Strathdee SA, 1997, AIDS, V11, pF59, DOI 10.1097/00002030-199708000-00001; Tyndall MW, 2006, DRUG ALCOHOL DEPEN, V83, P193, DOI 10.1016/j.drugalcdep.2005.11.011; *VANC COAST HLTH, INJ DRUG US DTES; Werb D, 2010, DRUG ALCOHOL REV, V29, P271, DOI 10.1111/j.1465-3362.2009.00145.x; White JM, 1999, ADDICTION, V94, P961, DOI 10.1046/j.1360-0443.1999.9479612.x; Wood E, 2006, NEW ENGL J MED, V354, P2512, DOI 10.1056/NEJMc052939; Wood E, 2006, AM J PUBLIC HEALTH, V96, P770, DOI 10.2105/AJPH.2004.057828; Wood E, 2006, ADDICTION, V101, P689, DOI 10.1111/j.1360-0443.2006.01385.x; Wood E, 2005, AM J PREV MED, V29, P126, DOI 10.1016/j.amepre.2005.04.011; Wood E, 2004, LANCET INFECT DIS, V4, P301, DOI 10.1016/S1473-3099(04)01006-0; Wood E, 2008, INT J DRUG POLICY, V19, P220, DOI 10.1016/j.drugpo.2007.11.001; Wood E, 2008, AM J PUBLIC HEALTH, V98, P515, DOI 10.2105/AJPH.2007.114595; Wood E, 2006, CAN MED ASSOC J, V175, P1399, DOI 10.1503/cmaj.060863; Wood Evan, 2004, Harm Reduct J, V1, P9, DOI 10.1186/1477-7517-1-9; DOWNTOWN EASTSIDE CO	55	275	275	3	43	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 23	2011	377	9775					1429	1437		10.1016/S0140-6736(10)62353-7	http://dx.doi.org/10.1016/S0140-6736(10)62353-7			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	755UF	21497898				2023-01-03	WOS:000289963000032
J	Logan, AC; Yank, V; Stafford, RS				Logan, Aaron C.; Yank, Veronica; Stafford, Randall S.			Off-Label Use of Recombinant Factor VIIa in US Hospitals: Analysis of Hospital Records	ANNALS OF INTERNAL MEDICINE			English	Article							ACTIVATED FACTOR-VII; THROMBOEMBOLIC ADVERSE EVENTS; INTRACEREBRAL HEMORRHAGE; CONTROLLED-TRIALS; CARDIAC-SURGERY; CLINICAL-TRIALS; SAFETY; EFFICACY; HEMOPHILIA; TRANSFUSION	Background: Recombinant factor VIIa (rFVIIa) is approved for treatment of bleeding in patients who have hemophilia with inhibitors but has been applied to a wide range of off-label indications. Objective: To estimate patterns of off-label rFVIIa use in U. S. hospitals. Design: Retrospective database analysis. Setting: Data were extracted from the Premier Perspectives database (Premier, Charlotte, North Carolina), which contains discharge records from a sample of academic and nonacademic U. S. hospitals. Patients: 12 644 hospitalizations for patients who received rFVIIa during a hospital stay. Measurements: Hospital diagnoses and patient dispositions from 1 January 2000 to 31 December 2008. Statistical weights for each hospital were used to provide national estimates of rFVIIa use. Results: From 2000 to 2008, off-label use of rFVIIa in hospitals increased more than 140-fold, such that in 2008, 97% (95% CI, 96% to 98%) of 18 311 in-hospital uses were off-label. In contrast, in-hospital use for hemophilia increased less than 4-fold and accounted for 2.7% (CI, 1.9% to 3.5%) of use in 2008. Adult and pediatric cardiovascular surgery (29% [CI, 21% to 33%]), body and brain trauma (29% [CI, 19% to 38%]), and intracranial hemorrhage (11% [CI, 7.7% to 14%]) were the most common indications for rFVIIa use. Across all indications, in-hospital mortality was 27% (CI, 19% to 34%) and 43% (CI, 26% to 59%) of patients were discharged to home. Limitation: Accuracy and completeness of the discharge diagnoses and patient medication records in the database sample cannot be verified. Conclusion: Off-label use of rFVIIa in the hospital setting far exceeds use for approved indications. These patterns raise concern about the application of rFVIIa to conditions for which strong supporting evidence is lacking.	[Stafford, Randall S.] Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Palo Alto, CA 94304 USA	Stanford University	Stafford, RS (corresponding author), Stanford Univ, Sch Med, Stanford Prevent Res Ctr, Off Bldg X312,251 Campus Dr, Palo Alto, CA 94304 USA.	rstafford@stanford.edu	Logan, Aaron C/ADJ-7526-2022; Stafford, Randall/F-3974-2017	Logan, Aaron C/0000-0002-1179-5879; Stafford, Randall/0000-0003-1805-1271	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services [290-02-0017]; National Heart, Lung, and Blood Institute [K24HL086703]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL086703] Funding Source: NIH RePORTER	Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Grant Support: By the Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, under contract 290-02-0017. Dr. Stafford also was supported by a National Heart, Lung, and Blood Institute mentoring award (RSS, K24HL086703).	Aledort LM, 2004, J THROMB HAEMOST, V2, P1700, DOI 10.1111/j.1538-7836.2004.00944.x; Aledort LM, 2010, NEW ENGL J MED, V363, P1853, DOI 10.1056/NEJMe1008857; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Carcao MD, 2008, SEMIN HEMATOL, V45, pS68, DOI 10.1053/j.seminhematol.2008.03.003; Diprose P, 2005, BRIT J ANAESTH, V95, P596, DOI 10.1093/bja/aei244; Diringer MN, 2008, STROKE, V39, P850, DOI 10.1161/STROKEAHA.107.493601; Diringer MN, 2010, STROKE, V41, P48, DOI 10.1161/STROKEAHA.109.561712; Ganguly S, 2006, CLIN LAB HAEMATOL, V28, P309, DOI 10.1111/j.1365-2257.2006.00815.x; Gill R, 2009, CIRCULATION, V120, P21, DOI 10.1161/CIRCULATIONAHA.108.834275; Goodnough LT, 2004, TRANSFUSION, V44, P1325, DOI 10.1111/j.1537-2995.2004.04052.x; Goodnough LT, 2002, INTENS CARE MED, V28, pS221, DOI 10.1007/s00134-002-1468-2; Hardy JF, 2008, ANN THORAC SURG, V86, P1038, DOI 10.1016/j.athoracsur.2008.05.013; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Hedner U, 2008, THROMB HAEMOSTASIS, V100, P557, DOI 10.1160/TH08-07-0434; Heller M, 2008, PEDIATR BLOOD CANCER, V50, P1013, DOI 10.1002/pbc.21375; Howes Jeremy L, 2009, Am J Surg, V198, P895, DOI 10.1016/j.amjsurg.2009.05.026; Hsia CC, 2009, TRANSFUSION MED, V19, P43, DOI 10.1111/j.1365-3148.2009.00913.x; Hsia CC, 2008, ANN SURG, V248, P61, DOI 10.1097/SLA.0b013e318176c4ec; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; MacLaren R, 2005, TRANSFUSION, V45, P1434, DOI 10.1111/j.1537-2995.2005.00548.x; MAGNETTI S, 2007, P & T, V32, P218; Mayer SA, 2003, STROKE, V34, P224, DOI 10.1161/01.STR.0000046458.67968.E4; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; O'Connell KA, 2006, JAMA-J AM MED ASSOC, V295, P293, DOI 10.1001/jama.295.3.293; Roberts HR, 2004, BLOOD, V104, P3858, DOI 10.1182/blood-2004-06-2223; Roberts HR, 2004, SEMIN HEMATOL, V41, P101, DOI 10.1053/j.seminhematol.2003.11.019; Stafford RS, 2008, NEW ENGL J MED, V358, P1427, DOI 10.1056/NEJMp0802107; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Webert KE, 2007, HAEMOPHILIA, V13, P518, DOI 10.1111/j.1365-2516.2007.01490.x; YANK V, 2010, COMP EFFECTIVENESS R; Yank V, 2011, ANN INTERN MED, V154, P529, DOI 10.7326/0003-4819-154-8-201104190-00004	31	99	104	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 19	2011	154	8					516	522		10.7326/0003-4819-154-8-201104190-00002	http://dx.doi.org/10.7326/0003-4819-154-8-201104190-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	751MK	21502649	Green Accepted			2023-01-03	WOS:000289622000014
J	Villareal, DT; Chode, S; Parimi, N; Sinacore, DR; Hilton, T; Armamento-Villareal, R; Napoli, N; Qualls, C; Shah, K				Villareal, Dennis T.; Chode, Suresh; Parimi, Nehu; Sinacore, David R.; Hilton, Tiffany; Armamento-Villareal, Reina; Napoli, Nicola; Qualls, Clifford; Shah, Krupa			Weight Loss, Exercise, or Both and Physical Function in Obese Older Adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NURSING-HOME ADMISSION; CALORIC RESTRICTION; KNEE OSTEOARTHRITIS; CONTROLLED-TRIAL; US ADULTS; FRAILTY; WOMEN; PERFORMANCE; HEALTH; ASSOCIATION	BACKGROUND Obesity exacerbates the age-related decline in physical function and causes frailty in older adults; however, the appropriate treatment for obese older adults is controversial. METHODS In this 1-year, randomized, controlled trial, we evaluated the independent and combined effects of weight loss and exercise in 107 adults who were 65 years of age or older and obese. Participants were randomly assigned to a control group, a weight-management (diet) group, an exercise group, or a weight-management-plus-exercise (diet-exercise) group. The primary outcome was the change in score on the modified Physical Performance Test. Secondary outcomes included other measures of frailty, body composition, bone mineral density, specific physical functions, and quality of life. RESULTS A total of 93 participants (87%) completed the study. In the intention-to-treat analysis, the score on the Physical Performance Test, in which higher scores indicate better physical status, increased more in the diet-exercise group than in the diet group or the exercise group (increases from baseline of 21% vs. 12% and 15%, respectively); the scores in all three of those groups increased more than the scores in the control group (in which the score increased by 1%) (P<0.001 for the between-group differences). Moreover, the peak oxygen consumption improved more in the diet-exercise group than in the diet group or the exercise group (increases of 17% vs. 10% and 8%, respectively; P<0.001); the score on the Functional Status Questionnaire, in which higher scores indicate better physical function, increased more in the diet-exercise group than in the diet group (increase of 10% vs. 4%, P<0.001). Body weight decreased by 10% in the diet group and by 9% in the diet-exercise group, but did not decrease in the exercise group or the control group (P<0.001). Lean body mass and bone mineral density at the hip decreased less in the diet-exercise group than in the diet group (reductions of 3% and 1%, respectively, in the diet-exercise group vs. reductions of 5% and 3%, respectively, in the diet group; P<0.05 for both comparisons). Strength, balance, and gait improved consistently in the diet-exercise group (P<0.05 for all comparisons). Adverse events included a small number of exercise-associated musculoskeletal injuries. CONCLUSIONS These findings suggest that a combination of weight loss and exercise provides greater improvement in physical function than either intervention alone.	[Villareal, Dennis T.; Chode, Suresh; Parimi, Nehu; Sinacore, David R.; Shah, Krupa] Washington Univ, Sch Med, Div Geriatr & Nutr Sci, St Louis, MO USA; [Sinacore, David R.; Hilton, Tiffany] Washington Univ, Sch Med, Program Phys Therapy, St Louis, MO USA; [Armamento-Villareal, Reina; Napoli, Nicola] Washington Univ, Sch Med, Div Bone & Mineral Dis, St Louis, MO USA; [Villareal, Dennis T.] New Mexico VA Hlth Care Syst, Sect Geriatr, Albuquerque, NM 87108 USA; [Armamento-Villareal, Reina] New Mexico VA Hlth Care Syst, Endocrinol Sect, Albuquerque, NM 87108 USA; [Villareal, Dennis T.] Univ New Mexico, Sch Med, Div Geriatr, Albuquerque, NM 87131 USA; [Armamento-Villareal, Reina] Univ New Mexico, Sch Med, Div Endocrinol, Albuquerque, NM 87131 USA; [Qualls, Clifford] Univ New Mexico, Sch Med, Dept Math & Stat, Albuquerque, NM 87131 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of New Mexico; University of New Mexico; University of New Mexico	Villareal, DT (corresponding author), New Mexico VA Hlth Care Syst, Sect Geriatr, Geriatr 111K,1501 San Pedro Dr, Albuquerque, NM 87108 USA.	dennis.villareal@va.gov	Biguzzi, Felipe A/E-4724-2015; PT, David R. Sinacore/AAS-3377-2020; Villareal, Reina/AAH-6028-2019; Napoli, Nicola/K-8242-2016	PT, David R. Sinacore/0000-0002-7242-3585; Hilton, Tiffany/0000-0001-5869-201X; Napoli, Nicola/0000-0002-3091-8205	National Institutes of Health [RO1-AG025501, P30-DK56341, UL1-RR024992, DK20579]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [HD007434]; Foundation for Physical Therapy; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007434] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, P60DK020579, P30DK020579] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025501] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Foundation for Physical Therapy; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	Supported by grants (RO1-AG025501 and P30-DK56341 [Clinical Nutrition Research Unit], UL1-RR024992 [a Clinical and Translational Science Award], and DK20579 [Diabetes Research and Training Center]) from the National Institutes of Health. Dr. Hilton was supported by a postdoctoral fellowship (HD007434) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development and a New Investigator Fellowship Initiative grant from the Foundation for Physical Therapy.	Ahmed N, 2007, AM J MED, V120, P748, DOI 10.1016/j.amjmed.2006.10.018; Alley DE, 2008, J GERONTOL A-BIOL, V63, P1257, DOI 10.1093/gerona/63.11.1257; Apovian CM, 1996, J AM GERIATR SOC, V44, P1487, DOI 10.1111/j.1532-5415.1996.tb04082.x; Arterburn DE, 2004, J AM GERIATR SOC, V52, P1907, DOI 10.1111/j.1532-5415.2004.52517.x; Bales CW, 2008, J AM MED DIR ASSOC, V9, P302, DOI 10.1016/j.jamda.2008.01.006; Binder EF, 2002, J AM GERIATR SOC, V50, P1921, DOI 10.1046/j.1532-5415.2002.50601.x; Binder EF, 1999, J GERONTOL A-BIOL, V54, pM353, DOI 10.1093/gerona/54.7.M353; Blaum CS, 2005, J AM GERIATR SOC, V53, P927, DOI 10.1111/j.1532-5415.2005.53300.x; Bouchard DR, 2009, MENOPAUSE, V16, P66, DOI 10.1097/gme.0b013e31817dacf7; Brown M, 2000, ARCH PHYS MED REHAB, V81, P960, DOI 10.1053/apmr.2000.4425; Brown M, 2000, J GERONTOL A-BIOL, V55, pM350, DOI 10.1093/gerona/55.6.M350; Elia M, 2001, OBES RES, V9, p244S, DOI 10.1038/oby.2001.126; Elkins JS, 2006, OBESITY, V14, P1472, DOI 10.1038/oby.2006.167; Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014; GURALNIK JM, 1994, J GERONTOL, V49, pM85, DOI 10.1093/geronj/49.2.M85; Hamerman D, 1999, ANN INTERN MED, V130, P945, DOI 10.7326/0003-4819-130-11-199906010-00022; Host H., 1996, PHYS THER, V76; Jensen GL, 2010, CURR OPIN CLIN NUTR, V13, P46, DOI 10.1097/MCO.0b013e32833309cf; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; Kalantar-Zadeh K, 2001, J AM SOC NEPHROL, V12, P2797, DOI 10.1681/ASN.V12122797; Klein S, 2002, GASTROENTEROLOGY, V123, P882, DOI 10.1053/gast.2002.35514; Lapane KL, 2005, J AM GERIATR SOC, V53, P1386, DOI 10.1111/j.1532-5415.2005.53420.x; Li FZ, 2005, J AM GERIATR SOC, V53, P737, DOI 10.1111/j.1532-5415.2005.53228_10.x; LYONS RA, 1994, AGE AGEING, V23, P182, DOI 10.1093/ageing/23.3.182; MA V, 2006, Am J Clin Nutr, V84, P1257; Messier SP, 2004, ARTHRITIS RHEUM-US, V50, P1501, DOI 10.1002/art.20256; Miller GD, 2006, OBESITY, V14, P1219, DOI 10.1038/oby.2006.139; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Rejeski WJ, 2010, OBES REV, V11, P671, DOI 10.1111/j.1467-789X.2009.00679.x; REUBEN DB, 1992, J GERONTOL, V47, pM106, DOI 10.1093/geronj/47.4.M106; Roubenoff R, 2004, OBES RES, V12, P887, DOI 10.1038/oby.2004.107; Shah K, 2008, J AM GERIATR SOC, V56, pS183; Shea MK, 2010, J GERONTOL A-BIOL, V65, P519, DOI 10.1093/gerona/glp217; Villareal DT, 2006, ARCH INTERN MED, V166, P2502, DOI 10.1001/archinte.166.22.2502; Villareal DT, 2006, ARCH INTERN MED, V166, P860, DOI 10.1001/archinte.166.8.860; Villareal DT, 2004, OBES RES, V12, P913, DOI 10.1038/oby.2004.111; Villareal DT, 2005, AM J CLIN NUTR, V82, P923, DOI 10.1093/ajcn/82.5.923; VILLAREAL DT, 2007, ARCH INTERN MED, V167, P452; Weiss EP, 2007, J APPL PHYSIOL, V102, P634, DOI 10.1152/japplphysiol.00853.2006; Witham MD, 2010, AGE AGEING, V39, P176, DOI 10.1093/ageing/afp251; Zizza CA, 2002, OBES RES, V10, P816, DOI 10.1038/oby.2002.110	41	641	675	3	128	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	2011	364	13					1218	1229		10.1056/NEJMoa1008234	http://dx.doi.org/10.1056/NEJMoa1008234			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	742NO	21449785	Bronze, Green Published, Green Accepted			2023-01-03	WOS:000288951300006
J	Beebe, DW; Byars, KC				Beebe, Dean W.; Byars, Kelly C.			Adolescents with Obstructive Sleep Apnea Adhere Poorly to Positive Airway Pressure (PAP), but PAP Users Show Improved Attention and School Performance	PLOS ONE			English	Article							CHILDREN; THERAPY; METAANALYSIS; QUALITY; ADULTS	Background: Obstructive Sleep Apnea (OSA) is associated with medical and neurobehavioral morbidity across the lifespan. Positive airway pressure (PAP) treatment has demonstrated efficacy in treating OSA and has been shown to improve daytime functioning in adults, but treatment adherence can be problematic. There are nearly no published studies examining functional outcomes such as academic functioning in adolescents treated with PAP. This study was conducted as an initial step towards determining whether PAP treatment improves daytime functioning among adolescents with OSA. Methods: Self-reported academic grades, self-and parent-reported academic quality of life, and objectively-measured attention were assessed before and after PAP was clinically initiated in a sample of 13 obese adolescents with OSA, as well as 15 untreated obese Controls without OSA. Based on adherence data, the treated group was divided into PAP Users (n = 6) and Non-Adherent participants (n = 7). Results: Though demographically similar, the three groups significantly differed in how their academic performance and attention scores changed from baseline to follow-up. Non-Adherent participants showed worsening functioning over time, while PAP Users showed stable or improved functioning, similar to controls. Conclusion: Although many adolescents prescribed PAP for OSA are non-adherent to the treatment, those who adhere to treatment can display improved attention and academic functioning.	[Beebe, Dean W.; Byars, Kelly C.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Beebe, Dean W.; Byars, Kelly C.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Beebe, DW (corresponding author), Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.	dean.beebe@cchmc.org			United States National Institutes of Health (NIH) [K23 HL075369, R01 HL092149, UL1 RR026314]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR026314] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL092149, K23HL075369] Funding Source: NIH RePORTER	United States National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the United States National Institutes of Health (NIH) grants K23 HL075369, R01 HL092149, and UL1 RR026314. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Archbold KH, 2009, CURR OPIN PULM MED, V15, P585, DOI 10.1097/MCP.0b013e3283319b3f; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P69, DOI 10.1093/jpepsy/jsj104; Beebe DW, 2006, SLEEP, V29, P1115, DOI 10.1093/sleep/29.9.1115; Beebe DW, 2010, SLEEP, V33, P1447, DOI 10.1093/sleep/33.11.1447; Beebe DW, 2003, SLEEP, V26, P298, DOI 10.1093/sleep/26.3.298; Costa DJ, 2009, OTOLARYNG HEAD NECK, V140, P455, DOI 10.1016/j.otohns.2008.12.038; Dahl RE, 2004, ANN NY ACAD SCI, V1021, P1, DOI 10.1196/annals.1308.001; Gay P, 2006, SLEEP, V29, P381, DOI 10.1093/sleep/29.3.381; Gordon M, 1983, GORDON DIAGNOSTIC SY; Sanchez AI, 2009, SLEEP MED REV, V13, P223, DOI 10.1016/j.smrv.2008.07.002; Marcus CL, 2006, PEDIATRICS, V117, pE442, DOI 10.1542/peds.2005-1634; O'Donnell AR, 2006, SLEEP, V29, P651; Uong EC, 2007, PEDIATRICS, V120, pE1203, DOI 10.1542/peds.2006-2731; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Wolfson AR, 1998, CHILD DEV, V69, P875, DOI 10.1111/j.1467-8624.1998.tb06149.x	15	39	41	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 17	2011	6	3							e16924	10.1371/journal.pone.0016924	http://dx.doi.org/10.1371/journal.pone.0016924			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	736SO	21437285	Green Submitted, gold, Green Published			2023-01-03	WOS:000288514600001
J	Takigawa, I; Tsuda, K; Mamitsuka, H				Takigawa, Ichigaku; Tsuda, Koji; Mamitsuka, Hiroshi			Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network	PLOS ONE			English	Article							PROTEIN-COUPLED RECEPTORS; SELECTIVITY	A current key feature in drug-target network is that drugs often bind to multiple targets, known as polypharmacology or drug promiscuity. Recent literature has indicated that relatively small fragments in both drugs and targets are crucial in forming polypharmacology. We hypothesize that principles behind polypharmacology are embedded in paired fragments in molecular graphs and amino acid sequences of drug-target interactions. We developed a fast, scalable algorithm for mining significantly co-occurring subgraph-subsequence pairs from drug-target interactions. A noteworthy feature of our approach is to capture significant paired patterns of subgraph-subsequence, while patterns of either drugs or targets only have been considered in the literature so far. Significant substructure pairs allow the grouping of drug-target interactions into clusters, covering approximately 75% of interactions containing approved drugs. These clusters were highly exclusive to each other, being statistically significant and logically implying that each cluster corresponds to a distinguished type of polypharmacology. These exclusive clusters cannot be easily obtained by using either drug or target information only but are naturally found by highlighting significant substructure pairs in drug-target interactions. These results confirm the effectiveness of our method for interpreting polypharmacology in drug-target network.	[Takigawa, Ichigaku; Mamitsuka, Hiroshi] Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 606, Japan; [Tsuda, Koji] Natl Inst Adv Ind Sci & Technol, Computat Biol Res Ctr, Koto Ku, Tokyo, Japan; [Takigawa, Ichigaku; Tsuda, Koji; Mamitsuka, Hiroshi] Japan Sci & Technol Agcy, Inst Bioinformat Res & Dev, Chiyoda Ku, Tokyo, Japan; [Tsuda, Koji] Japan Sci & Technol Agcy, ERATO Minato Project, Sapporo, Hokkaido, Japan	Kyoto University; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST)	Takigawa, I (corresponding author), Kyoto Univ, Inst Chem Res, Bioinformat Ctr, Kyoto 606, Japan.	mami@kuicr.kyoto-u.ac.jp	Takigawa, Ichigaku/B-3823-2012; Mamitsuka, Hiroshi/R-1110-2016	Takigawa, Ichigaku/0000-0001-5633-995X; Mamitsuka, Hiroshi/0000-0002-6607-5617	Ministry of Education, Culture, Sports, Science and Technology (MEXT) [20700134, 21680025]; Japan Society for the Promotion of Science (JSPS)	Ministry of Education, Culture, Sports, Science and Technology (MEXT)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work has been supported by Grant-in-Aid for Scientific Research 20700134 and 21680025 from Ministry of Education, Culture, Sports, Science and Technology (MEXT), and "Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST Program)'' by the Japan Society for the Promotion of Science (JSPS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Aronov AM, 2004, J MED CHEM, V47, P5616, DOI 10.1021/jm049793g; Batagelj V, 2004, MATH VIS, P77; Beissbarth T, 2004, BIOINFORMATICS, V20, P1464, DOI 10.1093/bioinformatics/bth088; Campillos M, 2008, SCIENCE, V321, P263, DOI 10.1126/science.1158140; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Cordell HJ, 2002, HUM MOL GENET, V11, P2463, DOI 10.1093/hmg/11.20.2463; Frantz S, 2005, NATURE, V437, P942, DOI 10.1038/437942a; FRUCHTERMAN TMJ, 1991, SOFTWARE PRACT EXPER, V21, P1129, DOI 10.1002/spe.4380211102; Han JW, 2007, DATA MIN KNOWL DISC, V15, P55, DOI 10.1007/s10618-006-0059-1; Hopkins AL, 2002, NAT REV DRUG DISCOV, V1, P727, DOI 10.1038/nrd892; Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118; Metz JT, 2010, CURR OPIN CHEM BIOL, V14, P498, DOI 10.1016/j.cbpa.2010.06.166; Morphy R, 2007, DRUG DISCOV TODAY, V12, P156, DOI 10.1016/j.drudis.2006.12.006; Murray CW, 2009, NAT CHEM, V1, P187, DOI [10.1038/NCHEM.217, 10.1038/nchem.217]; Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228; PEARSON WR, 1991, GENOMICS, V11, P635, DOI 10.1016/0888-7543(91)90071-L; Rovati GE, 2007, MOL PHARMACOL, V71, P959, DOI 10.1124/mol.106.029470; Russ AP, 2005, DRUG DISCOV TODAY, V10, P1607, DOI 10.1016/S1359-6446(05)03666-4; Shi L, 2002, ANNU REV PHARMACOL, V42, P437, DOI 10.1146/annurev.pharmtox.42.091101.144224; Wang RX, 2004, J MED CHEM, V47, P2977, DOI 10.1021/jm030580l; Wess J, 1997, FASEB J, V11, P346, DOI 10.1096/fasebj.11.5.9141501; Yildirim MA, 2007, NAT BIOTECHNOL, V25, P1119, DOI 10.1038/nbt1338	24	28	31	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	FEB 23	2011	6	2							e16999	10.1371/journal.pone.0016999	http://dx.doi.org/10.1371/journal.pone.0016999			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	725PJ	21373195	Green Submitted, Green Published, gold			2023-01-03	WOS:000287657500026
J	Albrecht, E; Schoettker, P				Albrecht, Eric; Schoettker, Patrick			The Jaw-Thrust Maneuver	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Albrecht, Eric; Schoettker, Patrick] CHU Vaudois, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Albrecht, E (corresponding author), CHU Vaudois, CH-1011 Lausanne, Switzerland.		Schoettker, Patrick/AAE-4462-2020	Schoettker, Patrick/0000-0001-5370-048X; Albrecht, Prof. Dr. Eric/0000-0001-6432-1311					0	7	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	2010	363	21					E32	E32		10.1056/NEJMicm0910490	http://dx.doi.org/10.1056/NEJMicm0910490			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	681KC	21083381	Green Published			2023-01-03	WOS:000284310000010
J	Peters, KM; Brooks, BE; Schumacher, MA; Skurray, RA; Brennan, RG; Brown, MH				Peters, Kate M.; Brooks, Benjamin E.; Schumacher, Maria A.; Skurray, Ronald A.; Brennan, Richard G.; Brown, Melissa H.			A Single Acidic Residue Can Guide Binding Site Selection but Does Not Govern QacR Cationic-Drug Affinity	PLOS ONE			English	Article							MULTIDRUG-RESISTANCE; TRANSCRIPTIONAL REGULATOR; STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURES; CONFORMATIONAL-CHANGE; COMPLEXES REVEAL; STRUCTURAL BASIS; LIGAND-BINDING; TETR FAMILY; DNA-BINDING	Structures of the multidrug-binding repressor protein QacR with monovalent and bivalent cationic drugs revealed that the carboxylate side-chains of E90 and E120 were proximal to the positively charged nitrogens of the ligands ethidium, malachite green and rhodamine 6G, and therefore may contribute to drug neutralization and binding affinity. Here, we report structural, biochemical and in vivo effects of substituting these glutamate residues. Unexpectedly, substitutions had little impact on ligand affinity or in vivo induction capabilities. Structures of QacR(E90Q) and QacR(E120Q) with ethidium or malachite green took similar global conformations that differed significantly from all previously described QacR-drug complexes but still prohibited binding to cognate DNA. Strikingly, the QacR(E90Q)-rhodamine 6G complex revealed two mutually exclusive rhodamine 6G binding sites. Despite multiple structural changes, all drug binding was essentially isoenergetic. Thus, these data strongly suggest that rather than contributing significantly to ligand binding affinity, the role of acidic residues lining the QacR multidrug-binding pocket is primarily to attract and guide cationic drugs to the "best available'' positions within the pocket that elicit QacR induction.	[Peters, Kate M.; Skurray, Ronald A.; Brown, Melissa H.] Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia; [Brooks, Benjamin E.; Schumacher, Maria A.; Brennan, Richard G.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Brown, Melissa H.] Flinders Univ S Australia, Sch Biol Sci, Adelaide, SA 5001, Australia	University of Sydney; University of Texas System; UTMD Anderson Cancer Center; Flinders University South Australia	Peters, KM (corresponding author), Univ Sydney, Sch Biol Sci, Sydney, NSW 2006, Australia.	rgbrenna@mdanderson.org; melissa.brown@flinders.edu.au	Giampietro, Vincent P/D-1279-2011; Williams, Steve/D-6979-2011; Brown, Melissa/V-2296-2017; Uher, Rudolf/A-5477-2008	Giampietro, Vincent P/0000-0002-9381-8201; Williams, Steve/0000-0003-4299-1941; Treasure, Janet/0000-0003-0871-4596; Brown, Melissa/0000-0001-6461-7550; Uher, Rudolf/0000-0002-2998-0546; opoku, anita/0000-0001-7243-8157; Brennan, Richard/0000-0001-7647-485X; Brooks, Samantha/0000-0002-9146-6257	National Health and Medical Research Council (Australia) [301941]; National Institutes of Health [AI048593]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048593] Funding Source: NIH RePORTER	National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by Project Grant 301941 from the National Health and Medical Research Council (Australia) (to R.A.S. and M.H.B.) and by grant AI048593 from the National Institutes of Health Grant (to R.G.B.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adler J, 2004, BIOCHEMISTRY-US, V43, P518, DOI 10.1021/bi035485t; Alguel Y, 2007, J MOL BIOL, V369, P829, DOI 10.1016/j.jmb.2007.03.062; Aller SG, 2009, SCIENCE, V323, P1718, DOI 10.1126/science.1168750; Aramaki H, 1995, PROTEIN ENG, V8, P1259, DOI 10.1093/protein/8.12.1259; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brooks BE, 2007, J AM CHEM SOC, V129, P8389, DOI 10.1021/ja072576v; Davis IW, 2007, NUCLEIC ACIDS RES, V35, pW375, DOI 10.1093/nar/gkm216; DeLano W.L, 2006, PYMOL MOL GRAPHICS S; Edgar R, 1999, EMBO J, V18, P822, DOI 10.1093/emboj/18.4.822; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Frenois F, 2004, MOL CELL, V16, P301, DOI 10.1016/j.molcel.2004.09.020; Grkovic S, 2002, MICROBIOL MOL BIOL R, V66, P671, DOI 10.1128/MMBR.66.4.671-701.2002; Grkovic S, 2003, BIOCHEMISTRY-US, V42, P15226, DOI 10.1021/bi035447+; Grkovic S, 2003, MICROBIOL-SGM, V149, P785, DOI 10.1099/mic.0.25951-0; Grkovic S, 2001, J BACTERIOL, V183, P7102, DOI 10.1128/JB.183.24.7102-7109.2001; Gu RY, 2008, ACTA CRYSTALLOGR F, V64, P584, DOI 10.1107/S1744309108016035; Gu RY, 2007, J MOL BIOL, V372, P583, DOI 10.1016/j.jmb.2007.06.072; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; Higgins CF, 2007, NATURE, V446, P749, DOI 10.1038/nature05630; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAATZ GW, 1995, ANTIMICROB AGENTS CH, V39, P2650, DOI 10.1128/AAC.39.12.2650; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE AGW, 1992, NEWSL PROT CRYSTALL, V26; LYON BR, 1983, ANTIMICROB AGENTS CH, V23, P817, DOI 10.1128/AAC.23.6.817; Madoori PK, 2009, EMBO J, V28, P156, DOI 10.1038/emboj.2008.263; Mitchell BA, 1999, J BIOL CHEM, V274, P3541, DOI 10.1074/jbc.274.6.3541; Murakami S, 2006, NATURE, V443, P173, DOI 10.1038/nature05076; Murray DS, 2004, J BIOL CHEM, V279, P14365, DOI 10.1074/jbc.M313870200; Muth TR, 2000, EMBO J, V19, P234, DOI 10.1093/emboj/19.2.234; Natsume R, 2004, J MOL BIOL, V336, P409, DOI 10.1016/j.jmb.2003.12.040; Newberry KJ, 2008, J BIOL CHEM, V283, P26795, DOI 10.1074/jbc.M804191200; NEYFAKH AA, 1993, ANTIMICROB AGENTS CH, V37, P128, DOI 10.1128/AAC.37.1.128; Paulsen IT, 1996, P NATL ACAD SCI USA, V93, P3630, DOI 10.1073/pnas.93.8.3630; Peters KM, 2008, BIOCHEMISTRY-US, V47, P8122, DOI 10.1021/bi8008246; Peters KM, 2009, BIOCHEMISTRY-US, V48, P9794, DOI 10.1021/bi901102h; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Piddock LJV, 2006, CLIN MICROBIOL REV, V19, P382, DOI 10.1128/CMR.19.2.382-402.2006; Price CTD, 2002, INT J ANTIMICROB AG, V20, P206, DOI 10.1016/S0924-8579(02)00162-0; Ramos JL, 2005, MICROBIOL MOL BIOL R, V69, P326, DOI 10.1128/MMBR.69.2.326-356.2005; Rayment I, 1997, METHOD ENZYMOL, V276, P171, DOI 10.1016/S0076-6879(97)76058-0; Routh MD, 2009, BBA-PROTEINS PROTEOM, V1794, P844, DOI 10.1016/j.bbapap.2008.12.001; Sambrook Joseph, 1989, MOL CLONING LAB MANU; Schaedler TA, 2010, FASEB J, V24, P3653, DOI 10.1096/fj.10-156927; SCHENK S, 1992, FEMS MICROBIOL LETT, V94, P133; Schumacher MA, 2002, EMBO J, V21, P1210, DOI 10.1093/emboj/21.5.1210; Schumacher MA, 2001, SCIENCE, V294, P2158, DOI 10.1126/science.1066020; Schumacher MA, 2004, EMBO J, V23, P2923, DOI 10.1038/sj.emboj.7600288; Seeger MA, 2006, SCIENCE, V313, P1295, DOI 10.1126/science.1131542; Sigal N, 2009, J BIOL CHEM, V284, P6966, DOI 10.1074/jbc.M808877200; Vazquez-Laslop N, 1999, BIOCHEMISTRY-US, V38, P16925, DOI 10.1021/bi991988g; Vincent F, 2000, J MOL BIOL, V300, P127, DOI 10.1006/jmbi.2000.3820; Watkins RE, 2001, SCIENCE, V292, P2329, DOI 10.1126/science.1060762; YOON KP, 1991, J BACTERIOL, V173, P7643, DOI 10.1128/jb.173.23.7643-7649.1991	55	67	67	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 17	2011	6	1							e15974	10.1371/journal.pone.0015974	http://dx.doi.org/10.1371/journal.pone.0015974			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	710ND	21799807	Green Published, Green Submitted, gold			2023-01-03	WOS:000286517600015
J	Tanaka, Y; Taneichi, M; Kasai, M; Kakiuchi, T; Uchida, T				Tanaka, Yuriko; Taneichi, Maiko; Kasai, Michiyuki; Kakiuchi, Terutaka; Uchida, Tetsuya			Liposome-Coupled Antigens Are Internalized by Antigen-Presenting Cells via Pinocytosis and Cross-Presented to CD8(+) T Cells	PLOS ONE			English	Article							IN-VIVO; VACCINE; RECOGNITION; DIPHTHERIA; TRANSPORT; IMMUNITY; TETANUS; BOOSTER; CYTOSOL; WORLD	We have previously demonstrated that antigens chemically coupled to the surface of liposomes consisting of unsaturated fatty acids were cross-presented by antigen-presenting cells (APCs) to CD8(+) T cells, and that this process resulted in the induction of antigen-specific cytotoxic T lymphocytes. In the present study, the mechanism by which the liposome-coupled antigens were cross-presented to CD8(+) T cells by APCs was investigated. Confocal laser scanning microscopic analysis demonstrated that antigens coupled to the surface of unsaturated-fatty-acid-based liposomes received processing at both MHC class I and class II compartments, while most of the antigens coupled to the surface of saturated-fatty-acid-based liposomes received processing at the class II compartment. In addition, flow cytometric analysis demonstrated that antigens coupled to the surface of unsaturated-fatty-acid-liposomes were taken up by APCs even in a 4 degrees C environment; this was not true of saturated-fatty-acid-liposomes. When two kinds of inhibitors, dimethylamiloride (DMA) and cytochalasin B, which inhibit pinocytosis and phagocytosis by APCs, respectively, were added to the culture of APCs prior to the antigen pulse, DMA but not cytochalasin B significantly reduced uptake of liposome-coupled antigens. Further analysis of intracellular trafficking of liposomal antigens using confocal laser scanning microscopy revealed that a portion of liposome-coupled antigens taken up by APCs were delivered to the lysosome compartment. In agreement with the reduction of antigen uptake by APCs, antigen presentation by APCs was significantly inhibited by DMA, and resulted in the reduction of IFN-gamma production by antigen-specific CD8(+) T cells. These results suggest that antigens coupled to the surface of liposomes consisting of unsaturated fatty acids might be pinocytosed by APCs, loaded onto the class I MHC processing pathway, and presented to CD8(+) T cells. Thus, these liposome-coupled antigens are expected to be applicable for the development of vaccines that induce cellular immunity.	[Tanaka, Yuriko; Kakiuchi, Terutaka] Toho Univ, Sch Med, Dept Immunol, Tokyo, Japan; [Taneichi, Maiko; Kasai, Michiyuki; Uchida, Tetsuya] Natl Inst Infect Dis, Dept Safety Res Blood & Biol Prod, Tokyo, Japan	Toho University; National Institute of Infectious Diseases (NIID)	Tanaka, Y (corresponding author), Toho Univ, Sch Med, Dept Immunol, Tokyo, Japan.	taneichi@nih.go.jp			Ministry of Health, Labor and Welfare of Japan; Japan Society for the Promotion of Science [21790963]; Toho University Graduate School of Medicine [08-02]	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Toho University Graduate School of Medicine(Toho University)	This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan (to TU), grants-in-aid for young scientists from the Japan Society for the Promotion of Science (21790963 to YT) and the research promotion grant from Toho University Graduate School of Medicine (No. 08-02 to YT). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aggerbeck H, 1996, VACCINE, V14, P1265, DOI 10.1016/S0264-410X(96)00092-8; BANKOWSKI MK, 1995, SCIENCE, V267, P243; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; Bevan MJ, 2006, NAT IMMUNOL, V7, P363, DOI 10.1038/ni0406-363; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Chen M, 1999, GASTROENTEROLOGY, V116, P135, DOI 10.1016/S0016-5085(99)70237-4; Chen WS, 2004, EUR J IMMUNOL, V34, P194, DOI 10.1002/eji.200324257; Doherty PC, 2008, J CLIN INVEST, V118, P3273, DOI 10.1172/JCI37232; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; Gurnani K, 2004, J IMMUNOL, V173, P566, DOI 10.4049/jimmunol.173.1.566; HERMEL E, 1995, IMMUNOGENETICS, V42, P136, DOI 10.1007/BF00178588; Kasturi SP, 2008, NAT IMMUNOL, V9, P461, DOI 10.1038/ni0508-461; MARK A, 1995, VACCINE, V13, P669, DOI 10.1016/0264-410X(94)00017-H; Matsui M, 2010, BIOCHEM BIOPH RES CO, V391, P1494, DOI 10.1016/j.bbrc.2009.12.100; McMichael AJ, 2003, NAT MED, V9, P874, DOI 10.1038/nm0703-874; Naito S, 1996, INT ARCH ALLERGY IMM, V109, P223, DOI 10.1159/000237241; Nakano Y, 1999, INT ARCH ALLERGY IMM, V120, P199, DOI 10.1159/000024268; Nelson D, 2000, J IMMUNOL, V165, P6123, DOI 10.4049/jimmunol.165.11.6123; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; Nothdurft HD, 1996, J INFECTION, V32, P119, DOI 10.1016/S0163-4453(96)91281-5; Ohno S, 2009, VACCINE, V27, P3912, DOI 10.1016/j.vaccine.2009.04.001; Rock KL, 2006, IMMUNITY, V25, P523, DOI 10.1016/j.immuni.2006.09.003; Rock KL, 2003, NAT IMMUNOL, V4, P941, DOI 10.1038/ni1003-941; Rodriguez A, 1999, NAT CELL BIOL, V1, P362, DOI 10.1038/14058; Shen LJ, 2004, IMMUNITY, V21, P155, DOI 10.1016/j.immuni.2004.07.004; Taneichi M, 2006, J IMMUNOL, V177, P2324, DOI 10.4049/jimmunol.177.4.2324; UCHIDA T, 1985, J IMMUNOL, V134, P772; Vyas JM, 2008, NAT REV IMMUNOL, V8, P607, DOI 10.1038/nri2368; Yerly D, 2008, J VIROL, V82, P3147, DOI 10.1128/JVI.02252-07	31	51	51	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 17	2010	5	12							e15225	10.1371/journal.pone.0015225	http://dx.doi.org/10.1371/journal.pone.0015225			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	698DS	21179411	Green Submitted, Green Published, gold			2023-01-03	WOS:000285572900015
